PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Raja, MM; Tyagi, NK; Kinne, RKH				Raja, MM; Tyagi, NK; Kinne, RKH			Phlorizin recognition in a C-terminal fragment of SGLT1 studied by tryptophan scanning and affinity labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANES; NA+/GLUCOSE COTRANSPORTER; GLUCOSE-TRANSPORT; PROTEIN; BINDING; FLUORESCENCE; REGION; NA+; CONFORMATION; INHIBITION	SGLT1 as a sodium/glucose cotransporter is strongly inhibited by phlorizin, a phloretin 2'-glucoside that has strong interactions with the C-terminal loop 13. We have examined phlorizin recognition by the protein by site-directed single Trp scanning mutagenesis experiments. Six mutants (Q581W, E591W, R601W, D611W, E621W, and L630W) of truncated loop 13 (amino acids 564 - 638) were expressed in Escherichia coli and purified to homogeneity. Changes in Trp quenching and positions of the emission maxima were determined after addition of phlorizin. D611W displayed the largest quenching of 80%, followed by R601W (67%). It also exhibited the maximum red shift in Trp fluorescence (similar to14 nm), indicating an exposure of this region to a more hydrophilic environment. Titration experiments performed for each mutant showed a similar affinity for all mutants, except for D611W, which exhibited a significantly lower affinity (K-d approximate to 54 muM). Also the maximum change in the collisional quenching constant by acrylamide was noted for D611W (K-SV = 11 M-1 in the absence of phlorizin and 55 M-1 in its presence). Similar results were obtained with phloretin. CD measurements and computer modeling revealed that D611W is positioned in a random coil situated between two alpha-helical segments. By combining gel electrophoresis, enzymatic fragmentation, and matrix-assisted laser desorption ionization mass spectrometry, we also analyzed truncated loop 13 photolabeled with 3-azidophlorizin. The attachment site of the ortho-position of aromatic ring B of phlorizin was localized to Arg-602. Taken together, these data indicate that phlorizin binding elicits changes in conformation leading to a less ordered state of loop 13. Modeling suggests an interaction of the 4- and 6-OH groups of aromatic ring A of phlorizin with the region between amino acids 606 and 611 and an interaction of ring B at or around amino acid 602. Phloretin seems to interact with the same region of the protein.	Max Planck Inst Mol Physiol, Dept Epithelial Cell Physiol, D-44227 Dortmund, Germany	Max Planck Society	Kinne, RKH (corresponding author), Max Planck Inst Mol Physiol, Dept Epithelial Cell Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.							Callis PR, 2003, CHEM PHYS LETT, V369, P409, DOI 10.1016/S0009-2614(02)02046-8; DIEDRICH DF, 1966, ARCH BIOCHEM BIOPHYS, V117, P248, DOI 10.1016/0003-9861(66)90409-7; Diez-Sampedro A, 2001, J BIOL CHEM, V276, P49188, DOI 10.1074/jbc.M108286200; GIBBS EM, 1982, BIOCHIM BIOPHYS ACTA, V688, P547, DOI 10.1016/0005-2736(82)90366-2; Hirayama BA, 1997, J BIOL CHEM, V272, P2110; Hirayama BA, 2001, BRIT J PHARMACOL, V134, P484, DOI 10.1038/sj.bjp.0704274; LIN JT, 1982, BIOCHIM BIOPHYS ACTA, V693, P379, DOI 10.1016/0005-2736(82)90445-X; Lo B, 1998, J BIOL CHEM, V273, P29341, DOI 10.1074/jbc.273.45.29341; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; NEUHOFF V, 1985, ELECTROPHORESIS, V6, P427, DOI 10.1002/elps.1150060905; Novakova R, 2001, J MEMBRANE BIOL, V184, P55, DOI 10.1007/s00232-001-0073-6; Oulianova N, 2001, J MEMBRANE BIOL, V179, P223, DOI 10.1007/s002320010049; Oulianova N, 1996, J MEMBRANE BIOL, V153, P181, DOI 10.1007/s002329900121; PANAYOTOVAHEIERMANN M, 1994, J BIOL CHEM, V269, P21016; PanayotovaHeiermann M, 1997, J BIOL CHEM, V272, P20324, DOI 10.1074/jbc.272.33.20324; Vayro S, 1998, BIOCHEM J, V332, P119, DOI 10.1042/bj3320119; Vivian JT, 2001, BIOPHYS J, V80, P2093, DOI 10.1016/S0006-3495(01)76183-8; Wielert-Badt S, 2000, J MED CHEM, V43, P1692, DOI 10.1021/jm9905460; Wielert-Badt S, 2002, BIOPHYS J, V82, P2767, DOI 10.1016/S0006-3495(02)75617-8; Xia XB, 2003, BIOCHEMISTRY-US, V42, P6115, DOI 10.1021/bi020695b; Yova Dido, 1999, Proceedings of the SPIE - The International Society for Optical Engineering, V3565, P174, DOI 10.1117/12.335800; YOVA D, 2002, UV 98	23	57	57	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49154	49163		10.1074/jbc.M306881200	http://dx.doi.org/10.1074/jbc.M306881200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12954647	hybrid			2022-12-25	WOS:000186829000079
J	Fratti, RA; Chua, J; Deretic, V				Fratti, RA; Chua, J; Deretic, V			Induction of p38 mitogen-activated protein kinase reduces early endosome autoantigen 1 (EEA1) recruitment to phagosomal membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOBACTERIUM-TUBERCULOSIS PHAGOSOME; CONTAINING VACUOLES; EARLY ENDOSOMES; MATURATION; TRAFFICKING; FUSION; AVIUM; EXPRESSION; HOST; RAB5	Mycobacterium tuberculosis survives in the infected host by parasitizing macrophages in which the bacillus resides in a specialized phagosome sequestered from the phagolysosomal degradative pathway. Here we report a role of the stress-induced p38 mitogen-activated protein kinase (p38 MAPK) in the component of M. tuberculosis phagosome maturation arrest that has been linked previously to the reduced recruitment of the endosomal and phagosomal membrane-tethering molecule called early endosome autoantigen 1 (EEA1; Fratti, R. A., Backer, J.M., Gruenberg, J., Corvera, S., and Deretic, V. (2001) J. Cell Biol. 154, 631-644). A pharmacological inhibition of M. tuberculosis var. bovis Bacillus Calmette-Guerin-induced p38 MAPK activity caused a marked increase in EEA1 colocalization with mycobacterial phagosomes. Consistent with the increase in EEA1 association and its role in phagosomal maturation, the pharmacological block of p38 activity caused phagosomal acidification and enrichment of the late endocytic markers lysobisphosphatidic acid and CD63 (lysosomal integral membrane protein 1) on mycobacterial phagosomes. A negative regulatory role of p38 MAPK activation in phagosome maturation was further demonstrated by converse experiments with latex bead phagosomes. Artificial activation of p38 MAPK caused a decrease in EEA1 colocalization with model latex bead phagosomes, which normally acquire EEA1 and subsequently mature into the phagolysosome. These findings show that p38 MAPK activity contributes to the arrest of M. tuberculosis phagosome maturation and demonstrate a negative regulatory role of p38 in phagolysosome biogenesis.	Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Sch Med, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico	Deretic, V (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Sch Med, 915 Camino de Salud NE, Albuquerque, NM 87131 USA.	vderetic@salud.unm.edu		Chua, Jennifer/0000-0001-8156-5174; Deretic, Vojo/0000-0002-3624-5208	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045148] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 45148] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alvarez-Dominguez C, 1999, J BIOL CHEM, V274, P11459, DOI 10.1074/jbc.274.17.11459; ARMSTRONG JA, 1971, J EXP MED, V134, P713, DOI 10.1084/jem.134.3.713; Botelho RJ, 2000, J BIOL CHEM, V275, P15717, DOI 10.1074/jbc.M910068199; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Cavalli V, 2001, MOL CELL, V7, P421, DOI 10.1016/S1097-2765(01)00189-7; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; Clemens DL, 1996, J EXP MED, V184, P1349, DOI 10.1084/jem.184.4.1349; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823, DOI 10.1128/IAI.59.5.1823-1831.1991; DECHASTELLIER C, 1995, EUR J CELL BIOL, V68, P167; Deretic V, 1999, MOL MICROBIOL, V31, P1603, DOI 10.1046/j.1365-2958.1999.01279.x; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DHANDAYUTHAPANI S, 1995, MOL MICROBIOL, V17, P901, DOI 10.1111/j.1365-2958.1995.mmi_17050901.x; Fratti RA, 2001, J CELL BIOL, V154, P631, DOI 10.1083/jcb.200106049; Fratti RA, 2003, P NATL ACAD SCI USA, V100, P5437, DOI 10.1073/pnas.0737613100; Fratti RA, 2000, ELECTROPHORESIS, V21, P3378, DOI 10.1002/1522-2683(20001001)21:16<3378::AID-ELPS3378>3.0.CO;2-B; Hackam DJ, 1997, J BIOL CHEM, V272, P29810, DOI 10.1074/jbc.272.47.29810; Hackstadt T, 2000, TRAFFIC, V1, P93, DOI 10.1034/j.1600-0854.2000.010201.x; Juffermans NP, 2000, J INFECT DIS, V182, P888, DOI 10.1086/315750; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Malik ZA, 2001, J IMMUNOL, V166, P3392, DOI 10.4049/jimmunol.166.5.3392; Meresse S, 1999, NAT CELL BIOL, V1, pE183, DOI 10.1038/15620; Meresse S, 1999, EMBO J, V18, P4394, DOI 10.1093/emboj/18.16.4394; Moody DB, 2000, NATURE, V404, P884, DOI 10.1038/35009119; Mordue DG, 1997, J IMMUNOL, V159, P4452; Mott J, 1999, INFECT IMMUN, V67, P1368, DOI 10.1128/IAI.67.3.1368-1378.1999; Perskvist N, 2000, J IMMUNOL, V164, P959, DOI 10.4049/jimmunol.164.2.959; Pieters J, 2002, TRENDS MICROBIOL, V10, P142, DOI 10.1016/S0966-842X(02)02305-3; Russell DG, 2002, J CELL BIOL, V158, P421, DOI 10.1083/jcb.200205034; Russell DG, 1996, J IMMUNOL, V156, P4764; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; SturgillKoszycki S, 1996, EMBO J, V15, P6960, DOI 10.1002/j.1460-2075.1996.tb01088.x; Vergne I, 2003, J EXP MED, V198, P653, DOI 10.1084/jem.20030527; Vergne I, 2003, TRAFFIC, V4, P600, DOI 10.1034/j.1600-0854.2003.00120.x; Via LE, 1998, J CELL SCI, V111, P897; Via LE, 1997, J BIOL CHEM, V272, P13326, DOI 10.1074/jbc.272.20.13326; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; XU SM, 1994, J IMMUNOL, V153, P2568	40	89	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46961	46967		10.1074/jbc.M305225200	http://dx.doi.org/10.1074/jbc.M305225200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963735	hybrid			2022-12-25	WOS:000186569400090
J	Mohney, RP; Das, M; Bivona, TG; Hanes, R; Adams, AG; Philips, MR; O'Bryan, JP				Mohney, RP; Das, M; Bivona, TG; Hanes, R; Adams, AG; Philips, MR; O'Bryan, JP			Intersectin activates Ras but stimulates transcription through an independent pathway involving JNK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCYTIC PROTEIN INTERSECTIN; GROWTH-FACTOR RECEPTOR; PHOSPHOTYROSINE-BINDING DOMAINS; CLATHRIN-MEDIATED ENDOCYTOSIS; SRC HOMOLOGY 2; ADAPTER PROTEIN; EPS15 HOMOLOGY; DOWN-SYNDROME; KINASE; INHIBITOR	Intersectin (ITSN) is a molecular scaffold involved in regulating endocytosis and mitogenic signaling. We previously demonstrated that ITSN transformed rodent fibroblasts, accelerated hormone-induced maturation of Xenopus oocytes, and activated the Elk-1 transcription factor through an MEK- and Erk-independent mechanism. We now demonstrate that ITSN complexes with the Ras guanine nucleotide exchange factor Sos1 leading to increased RasGTP levels. Using fluorescence resonant energy transfer analysis, we demonstrate that ITSN complexes with Ras in living cells leading to Ras activation on intracellular vesicles. These vesicles contain epidermal growth factor receptor but are distinct from transferrin-positive vesicles. However, Ras is not required for ITSN stimulation of transcription. Rather, we demonstrate that ITSN signals through JNK to activate Elk-1. Although ITSN activation of Elk-1 was Ras-independent, ITSN cooperates with Ras to synergistically activate JNK. These findings indicate that ITSN activates multiple intracellular signaling pathways and suggest that this adaptor protein may coordinately regulate the activity of these pathways in vivo.	NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	New York University; New York University; New York University	O'Bryan, JP (corresponding author), NIEHS, Lab Signal Transduct, NIH, US Dept HHS, Bldg 101,Rm F336,MD F3-06,POB 12233, Res Triangle Pk, NC 27709 USA.			O'Bryan, John/0000-0001-5386-1080; Mark, Philips/0000-0002-1179-8156	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090091] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams A, 2000, J BIOL CHEM, V275, P27414; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; CorbalanGarcia S, 1996, ONCOGENE, V12, P1063; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Elion EA, 2001, J CELL SCI, V114, P3967; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Graf D, 2002, GASTROENTEROLOGY, V122, P1411, DOI 10.1053/gast.2002.32976; Guipponi M, 1998, GENOMICS, V53, P369, DOI 10.1006/geno.1998.5521; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Jenna S, 2002, J BIOL CHEM, V277, P6366, DOI 10.1074/jbc.M105516200; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Martin JH, 1996, MOL BRAIN RES, V35, P47, DOI 10.1016/0169-328X(95)00181-Q; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; O'Bryan JP, 1998, J BIOL CHEM, V273, P20431, DOI 10.1074/jbc.273.32.20431; O'Bryan JP, 2001, ONCOGENE, V20, P6300, DOI 10.1038/sj.onc.1204773; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; Pucharcos C, 1999, EUR J HUM GENET, V7, P704, DOI 10.1038/sj.ejhg.5200356; Pucharcos C, 2000, FEBS LETT, V478, P43, DOI 10.1016/S0014-5793(00)01793-2; Pucharcos C, 2001, BBA-GENE STRUCT EXPR, V1521, P1, DOI 10.1016/S0167-4781(01)00276-7; PUESCHEL SM, 1991, ARCH NEUROL-CHICAGO, V48, P318, DOI 10.1001/archneur.1991.00530150088024; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; Ramjaun AR, 2001, J BIOL CHEM, V276, P28913, DOI 10.1074/jbc.M103198200; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Tong XK, 2000, J BIOL CHEM, V275, P29894, DOI 10.1074/jbc.M004096200; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	47	54	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47038	47045		10.1074/jbc.M303895200	http://dx.doi.org/10.1074/jbc.M303895200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12970366	hybrid			2022-12-25	WOS:000186569400100
J	Roy, S; Khanna, S; Wallace, WA; Lappalainen, J; Rink, C; Cardounel, AJ; Zweier, JL; Sen, CK				Roy, S; Khanna, S; Wallace, WA; Lappalainen, J; Rink, C; Cardounel, AJ; Zweier, JL; Sen, CK			Characterization of perceived hyperoxia in isolated primary cardiac fibroblasts and in the reoxygenated heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGONUCLEOTIDE ARRAYS; OXYGEN-PRESSURE; GENE; EXPRESSION; RNA; HYPOXIA; GROWTH; CELLS; WIG-1; PIGS	Under normoxic conditions, pO(2) ranges from 90 to < 3 torr in mammalian organs with the heart at similar to 35 torr ( 5%) and arterial blood at similar to 100 torr. Thus, " normoxia" for cells is an adjustable variable. In response to chronic moderate hypoxia, cells adjust their normoxia set point such that reoxygenation- dependent relative elevation of pO(2) results in perceived hyperoxia. We hypothesized that O-2, even in marginal relative excess of the pO2 to which cells are adjusted, results in the activation of specific O-2- sensitive signal transduction pathways that alter cellular phenotype and function. Thus, reperfusion causes damage to the tissue at the focus of ischemia while triggering remodeling in the peri- infarct region by means of perceived hyperoxia. We reported first evidence demonstrating that perceived hyperoxia triggers the differentiation of cardiac fibroblasts ( CF) to myofibroblasts by a p21- dependent mechanism ( Roy, S., Khanna, S., Bickerstaff, A. A., Subramanian, S. V., Atalay, M., Bierl, M., Pendyala, S., Levy, D., Sharma, N., Venojarvi, M., Strauch, A., Orosz, C. G., and Sen, C. K. ( 2003) Circ. Res. 92, 264 - 271). Here, we sought to characterize the genomic response to perceived hyperoxia in CF using GeneChips(TM). Candidate genes were identified, confirmed and clustered. Cell cycle- and differentiation-associated genes represented a key target of perceived hyperoxia. Bioinformatics- assisted pathway reconstruction revealed the specific signaling processes that were sensitive to perceived hyperoxia. To test the significance of our in vitro findings, a survival model of rat heart focal ischemia- reperfusion ( I- R) was investigated. A significant induction in p21 mRNA expression was observed in I- R tissue. The current results provide a comprehensive molecular definition of perceived hyperoxia in cultured CF. Furthermore, the first evidence demonstrating activation of perceived hyperoxia sensitive genes in the cardiac I- R tissue is presented.	Ohio State Univ, Med Ctr, Davis Heart & Lung Res Inst 512, Dept Surg,Lab Mol Med, Columbus, OH 43210 USA; Ohio State Univ, Med Ctr, Davis Heart & Lung Res Inst 512, Dept Internal Med,Lab Mol Med, Columbus, OH 43210 USA	Ohio State University; Ohio State University	Sen, CK (corresponding author), Ohio State Univ, Med Ctr, Davis Heart & Lung Res Inst 512, Dept Surg,Lab Mol Med, 473 W 12th Ave, Columbus, OH 43210 USA.	sen-1@medctr.osu.edu	Khanna, Savita/E-3378-2011; Rink, Cameron/AAA-4484-2021; Rink, Cameron/E-3954-2011; Sen, Chandan K/A-8762-2013	Wallace, William Angus/0000-0003-0468-2611; Rink, Cameron/0000-0002-3149-3624				BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; Chen HJ, 2003, AM J PHYSIOL-HEART C, V284, pH1612, DOI 10.1152/ajpheart.00992.2002; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; DERRY JMJ, 1995, HUM MOL GENET, V4, P2307, DOI 10.1093/hmg/4.12.2307; EGHBALI M, 1988, J MOL CELL CARDIOL, V20, P267, DOI 10.1016/S0022-2828(88)80059-2; Frangogiannis NG, 2000, CARDIOVASC RES, V48, P89, DOI 10.1016/S0008-6363(00)00158-9; GONSCHIOR P, 1992, BASIC RES CARDIOL, V87, P27, DOI 10.1007/BF00795387; Grinnell F, 2003, MOL BIOL CELL, V14, P384, DOI 10.1091/mbc.E02-08-0493; Hellborg F, 2001, ONCOGENE, V20, P5466, DOI 10.1038/sj.onc.1204722; HERSKOWITZ A, 1995, AM J PATHOL, V146, P419; Jaubert J, 2003, DEVELOPMENT, V130, P2767, DOI 10.1242/dev.00477; Kuo ML, 2003, CANCER RES, V63, P1046; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li WEI, 2002, DEVELOPMENT, V129, P2031; Mendez-Vidal C, 2002, NUCLEIC ACIDS RES, V30, P1991, DOI 10.1093/nar/30.9.1991; Nabel EG, 2002, NAT REV DRUG DISCOV, V1, P587, DOI 10.1038/nrd869; Porwol T, 2001, RESP PHYSIOL, V128, P331, DOI 10.1016/S0034-5687(01)00310-3; Roy S, 2003, CIRC RES, V92, P264, DOI 10.1161/01.RES.0000056770.30922.E6; Roy S, 2002, METHOD ENZYMOL, V353, P487; Roy S, 2002, FEBS LETT, V530, P17, DOI 10.1016/S0014-5793(02)03309-4; RUMSEY WL, 1994, AM J PHYSIOL, V266, pH1676, DOI 10.1152/ajpheart.1994.266.4.H1676; Scott JN, 2000, SCI AM, V282, P72, DOI 10.1038/scientificamerican0600-72; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Siaghy EM, 2000, J MOL CELL CARDIOL, V32, P493, DOI 10.1006/jmcc.1999.1094; Staversky RJ, 2002, AM J PATHOL, V161, P1383, DOI 10.1016/S0002-9440(10)64414-8; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; Whalen W J, 1971, Physiologist, V14, P69; Winegrad S, 1999, CIRC RES, V85, P690, DOI 10.1161/01.RES.85.8.690; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yoshida Y, 2003, GENE DEV, V17, P1201, DOI 10.1101/gad.1088003	31	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47129	47135		10.1074/jbc.M308703200	http://dx.doi.org/10.1074/jbc.M308703200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12952964	hybrid			2022-12-25	WOS:000186569400111
J	Sass, E; Karniely, S; Pines, O				Sass, E; Karniely, S; Pines, O			Folding of fumarase during mitochondrial import determines its dual targeting in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE TRANSLATION PRODUCT; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; INTERMEMBRANE SPACE; PROTEIN IMPORT; FUM1 GENE; TRANSLOCATION; PREPROTEINS; BIOGENESIS; SEQUENCE	We have previously proposed that a single translation product of the FUM1 gene encoding fumarase is distributed between the cytosol and mitochondria of Saccharomyces cerevisiae and that all fumarase translation products are targeted and processed in mitochondria before distribution. Thus, fumarase processed in mitochondria returns to the cytosol. In the current work, we (i) generated mutations throughout the coding sequence which resulted in fumarases with altered conformations that are targeted to mitochondria but have lost their ability to be distributed; (ii) showed by mass spectrometry that mature cytosolic and mitochondrial fumarase isoenzymes are identical; and (iii) showed that hsp70 chaperones in the cytosol (Ssa) and mitochondria (Ssc1) can affect fumarase distribution. The results are discussed in light of our model of targeting and distribution, which suggests that rapid folding of fumarase into an import-incompetent state provides the driving force for retrograde movement of the processed protein back to the cytosol through the translocation pore.	Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Pines, O (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel.		Karniely, Sharon/AAY-5499-2020; Karniely, Sharon/AAN-7886-2021; pines, ophry/C-4086-2011	pines, ophry/0000-0001-7126-2575				Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; AKIBA T, 1984, J BIOCHEM-TOKYO, V96, P189, DOI 10.1093/oxfordjournals.jbchem.a134812; Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Bhagwat SV, 1999, J BIOL CHEM, V274, P24014, DOI 10.1074/jbc.274.34.24014; BLACHINSKI E, 2001, THESIS HEBREW U JERU; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; Haucke V, 1997, MOL CELL BIOL, V17, P4024, DOI 10.1128/MCB.17.7.4024; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KANAREK L, 1964, J BIOL CHEM, V5, P465; Knox C, 1998, J BIOL CHEM, V273, P25587, DOI 10.1074/jbc.273.40.25587; Lim JH, 2001, EMBO J, V20, P941, DOI 10.1093/emboj/20.5.941; Okamoto K, 2002, EMBO J, V21, P3659, DOI 10.1093/emboj/cdf358; ONO H, 1995, J BIOL CHEM, V270, P16932, DOI 10.1074/jbc.270.28.16932; Peeters N, 2001, BBA-MOL CELL RES, V1541, P54, DOI 10.1016/S0167-4889(01)00146-X; PELEG Y, 1990, APPL ENVIRON MICROB, V56, P2777, DOI 10.1128/AEM.56.9.2777-2783.1990; Sass E, 2001, J BIOL CHEM, V276, P46111, DOI 10.1074/jbc.M106061200; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; Strobel G, 2002, MOL BIOL CELL, V13, P1439, DOI 10.1091/mbc.01-08-0396; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; Voos W, 2002, BBA-MOL CELL RES, V1592, P51, DOI 10.1016/S0167-4889(02)00264-1; Weaver T, 1998, J MOL BIOL, V280, P431, DOI 10.1006/jmbi.1998.1862; WEIZMAN PDJ, 1969, METHOD ENZYMOL, V13, P22; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Worthington C.C., 1988, WORTHINGTON MANUAL, p[159, 294]; WU M, 1987, J BIOL CHEM, V262, P12275	32	66	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45109	45116		10.1074/jbc.M302344200	http://dx.doi.org/10.1074/jbc.M302344200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12960177	hybrid			2022-12-25	WOS:000186452300010
J	Fukuhara, H; Masvuda, M; Yageta, M; Fukami, T; Kuramochi, M; Maruyama, T; Kitamura, T; Murakami, Y				Fukuhara, H; Masvuda, M; Yageta, M; Fukami, T; Kuramochi, M; Maruyama, T; Kitamura, T; Murakami, Y			Association of a lung tumor suppressor TSLC1 with MPP3, a human homologue of Drosophila tumor suppressor Dlg	ONCOGENE			English	Article						tumor suppressor gene; lung cancer; TSLC1; MPP3; discs large	SEPTATE JUNCTIONS; BINDING INTERFACE; GLYCOPHORIN-C; PDZ DOMAINS; GENE; CANCER; PROTEIN; PROMOTER; FAMILY; HYPERMETHYLATION	We have previously identified the tumor suppressor in lung cancer 1 (TSLC1) gene as a novel tumor suppressor in human non-small cell lung cancer (NSCLC) by functional complementation. TSLC1 encodes a membrane glycoprotein belonging to an immunoglobulin superfamily and participates in cell adhesion. A truncating mutation of the TSLC1 corresponding to its cytoplasmic domain in a primary NSCLC tumor suggests that this domain is important for tumor suppressor activity. Here, we report that TSLC1 directly associates with MPP3, one of the human homologues of a Drosophila tumor suppressor gene, Discs large (Dlg). This interaction was dependent on the presence of a PDZ-binding motif at the carboxyl terminus of TSLC1. Furthermore, TSLC1 and MPP3 were colocalized at the cell - cell attachment sites in both a low and a high cell density. The MPP3 gene was expressed in normal lung as well as in many tissues examined except for peripheral blood lymphocytes but lost its expression in one of the nine NSCLC cell lines. These results suggest that TSLC1 and MPP3 are involved in the same cascade of cell - cell interaction, and that the disruption of this cascade might lead cells to malignant growth and tumor formation in lung cancer.	Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, Tokyo 1040045, Japan; Univ Tokyo, Sch Med, Dept Urol, Bunkyo Ku, Tokyo 1138655, Japan	National Cancer Center - Japan; University of Tokyo	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	ymurakam@gan2.res.ncc.go.jp	Sakurai-Yageta, Mika/U-1842-2019	Sakurai-Yageta, Mika/0000-0001-5606-3324				Allinen M, 2002, GENE CHROMOSOME CANC, V34, P384, DOI 10.1002/gcc.10079; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; Bellaiche Y, 2001, CELL, V106, P355, DOI 10.1016/S0092-8674(01)00444-5; BRYANT PJ, 1990, J CELL SCI, P169; FEHON RG, 1994, DEVELOPMENT, V120, P545; FONG KM, 1995, CANCER RES, V55, P4268; Fukami T, 2002, GENE, V295, P7, DOI 10.1016/S0378-1119(02)00835-1; Fukuhara H, 2002, JPN J CANCER RES, V93, P605, DOI 10.1111/j.1349-7006.2002.tb01297.x; Fukuhara H, 2001, ONCOGENE, V20, P5401, DOI 10.1038/sj.onc.1204696; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; Gomyo H, 1999, GENOMICS, V62, P139, DOI 10.1006/geno.1999.6001; Harris BZ, 2001, J CELL SCI, V114, P3219; Honda T, 2002, JPN J CANCER RES, V93, P857, DOI 10.1111/j.1349-7006.2002.tb01329.x; James P, 1996, GENETICS, V144, P1425; Jansen M, 2002, CANCER BIOL THER, V1, P293, DOI 10.4161/cbt.84; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Murakami Y, 2002, ONCOGENE, V21, P6936, DOI 10.1038/sj.onc.1205825; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Smith SA, 1996, GENOMICS, V31, P145, DOI 10.1006/geno.1996.0025; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yageta M, 2002, CANCER RES, V62, P5129	29	66	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6160	6165		10.1038/sj.onc.1206744	http://dx.doi.org/10.1038/sj.onc.1206744			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679854				2022-12-25	WOS:000185506200005
J	Chamulitrat, W; Schmidt, R; Tomakidi, P; Stremmel, W; Chunglok, W; Kawahara, T; Rokutan, K				Chamulitrat, W; Schmidt, R; Tomakidi, P; Stremmel, W; Chunglok, W; Kawahara, T; Rokutan, K			Association of gp91phox homolog Nox1 with anchorage-independent growth and MAP kinase-activation of transformed human keratinocytes	ONCOGENE			English	Article						redox-signaling; human gingival keratinocytes; anchorage-independent growth; gp91phox homologs; Nox1	SMOOTH-MUSCLE CELLS; NADPH OXIDASE; IN-VITRO; MALIGNANT TRANSFORMATION; SUPEROXIDE GENERATION; RAS TRANSFORMATION; EPITHELIAL-CELLS; FIBROBLASTS; EXPRESSION; LOCALIZATION	Among five members of the NADPH oxidase (Nox) family, Nox1 confers mitogenic properties and is implicated to participate in the process of cell transformation. We have established two phenotypes of carcinogenesis model by ethanol treatment of human gingival keratinocytes immortalized with E6/E7 oncogenes of human papillomavirus type16: immortalized (EPI) nontransformed cells with epithelium-like morphology and more advanced transformed (FIB) cells with spindle fibroblastic-shape morphology. FIB membranes possessed a 63-kDa Nox1 protein at higher levels and exhibited 2.8-fold higher capability for superoxide and hydroxyl radical generation, compared with EPI membranes. Both EPI and FIB cells expressed more abundant Nox1 protein at a proliferating stage than that at a quiescent confluent phase. Immunofluorescence staining with an anti-Nox1 antibody showed that immunoreactive materials were distributed in the whole interior of both types of cells, while they were preferentially localized in the nuclei of FIB cells. Nuclei isolated from EPI and FIB cells contained a 63 kDa-Nox1 protein. Compared with EPI cells, FIB cells expressed elevated levels of Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase proteins. Furthermore, JNK2 was constitutively phosphorylated in FIB cells. Together, our data strongly implicate Nox1 in redox-mediated signaling related to cellular activation of human keratinocytes at a more advanced stage of transformation.	Univ Heidelberg, Univ Clin Hosp, Dept Gastroenterol & Infect Dis, D-69115 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Dept Appl Tumorvirol, D-69120 Heidelberg, Germany; Univ Heidelberg, Sch Dent, Dept Orthodont, D-69120 Heidelberg, Germany; Mahidol Univ, Fac Med Technol, Bangkok 10700, Thailand; Univ Tokushima, Sch Med, Dept Nutr, Tokushima 770, Japan	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Mahidol University; Tokushima University	Chamulitrat, W (corresponding author), Univ Heidelberg, Univ Clin Hosp, Dept Gastroenterol & Infect Dis, Bergheimer Str 58, D-69115 Heidelberg, Germany.	Walee_Chamulitrat@med.uni-heidelberg.de		Stremmel, Wolfgang/0000-0002-8545-1753				Aplin AE, 2002, J CELL SCI, V115, P2781; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; BJERRUM OW, 1989, EUR J HAEMATOL, V43, P67; Chamulitrat W, 2003, EUR J CELL BIOL, V82, P313, DOI 10.1078/0171-9335-00317; Chamulitrat W, 1999, FREE RADICAL BIO MED, V27, P411, DOI 10.1016/S0891-5849(99)00088-X; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Chiu C, 2001, INT J MOL MED, V8, P251; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; FINKELSTEIN E, 1979, MOL PHARMACOL, V16, P676; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; Goldman R, 1999, BBA-MOL CELL BIOL L, V1438, P349, DOI 10.1016/S1388-1981(99)00066-9; Gupta A, 1999, CARCINOGENESIS, V20, P2063, DOI 10.1093/carcin/20.11.2063; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; Hei TK, 1997, ENVIRON HEALTH PERSP, V105, P1085, DOI 10.2307/3433513; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jones RD, 2000, FREE RADICAL BIO MED, V29, P416, DOI 10.1016/S0891-5849(00)00320-8; KUROKI T, 1993, JPN J CANCER RES, V84, P1091, DOI 10.1111/j.1349-7006.1993.tb02806.x; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Li JM, 2002, J BIOL CHEM, V277, P19952, DOI 10.1074/jbc.M110073200; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; NAKAMURA Y, 1988, CARCINOGENESIS, V9, P203, DOI 10.1093/carcin/9.2.203; PARK NH, 1995, ONCOGENE, V10, P2145; Plattner R, 1999, ONCOGENE, V18, P1807, DOI 10.1038/sj.onc.1202482; Rennefahrt UEE, 2002, J BIOL CHEM, V277, P29510, DOI 10.1074/jbc.M203010200; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Sashiyama H, 2002, CANCER LETT, V177, P21, DOI 10.1016/S0304-3835(01)00771-6; Schimmel M, 2002, ONCOGENE, V21, P5886, DOI 10.1038/sj.onc.1205740; Sen CK, 2002, J BIOL CHEM, V277, P33284, DOI 10.1074/jbc.M203391200; Sorescu D, 2001, FREE RADICAL BIO MED, V30, P603, DOI 10.1016/S0891-5849(00)00507-4; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Teshima S, 2000, AM J PHYSIOL-GASTR L, V279, pG1169, DOI 10.1152/ajpgi.2000.279.6.G1169; Yang JQ, 1999, MOL CARCINOGEN, V26, P180; Yang XL, 1998, MOL CARCINOGEN, V22, P95, DOI 10.1002/(SICI)1098-2744(199806)22:2<95::AID-MC4>3.3.CO;2-Y; Yoshida LS, 2002, BIOCHEM BIOPH RES CO, V296, P1322, DOI 10.1016/S0006-291X(02)02059-4	40	93	95	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6045	6053		10.1038/sj.onc.1206654	http://dx.doi.org/10.1038/sj.onc.1206654			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955083				2022-12-25	WOS:000185137800013
J	Shankar, K; Vaidya, VS; Corton, JC; Bucci, TJ; Liu, J; Waalkes, MP; Mehendale, HM				Shankar, K; Vaidya, VS; Corton, JC; Bucci, TJ; Liu, J; Waalkes, MP; Mehendale, HM			Activation of PPAR-alpha in streptozotocin-induced diabetes is essential for resistance against acetaminophen toxicity	FASEB JOURNAL			English	Article						cell proliferation; microarray; real-time PCR; tissue repair	HEAT-SHOCK-PROTEIN; PEROXISOME PROLIFERATOR CIPROFIBRATE; ANTIMITOTIC AGENT COLCHICINE; AMELIORATES LIVER-INJURY; CARBON-TETRACHLORIDE; RECEPTOR-ALPHA; COVALENT BINDING; N-ACETYLCYSTEINE; KAPPA-B; THIOACETAMIDE	Diabetic (DB) mice exhibit significant resistance to hepatotoxicants. The role of peroxisome proliferator receptor (PPAR)-alpha activation in diabetes, in protection against lethal acetaminophen (APAP) challenge, was investigated. Upon treatment with APAP (600 mg/kg, i.p., a LD100 dose in wild-type [WT] non-DB mice), WT-DB mice showed only 30% mortality and 40% less liver injury as measured by alanine aminotransferase and histopathology. In contrast, diabetes in PPAR knockout (PPAR-alpha(-/-)) mice failed to protect against APAP toxicity, suggesting the importance of PPAR-alpha in diabetes-induced protection. S-phase DNA synthesis and PCNA immunohistochemical staining after injury showed early and robust tissue repair in WT-DB mice, but not in the PPAR-alpha(-/-) DB mice. Microarray analyses were performed on livers from non-DB and DB (WT and PPAR-alpha(-/-)) mice at 0 and 12 h after APAP. Microarray data were confirmed via real-time polymerase chain reaction analysis of several genes, including stress response, immediate early genes, DNA damage, heat shock proteins, and cell cycle regulators, followed by Western analyses of selected proteins. Gel shift assays revealed higher activation of nuclear factor-kappaB in WT-DB mice after APAP treatment. These findings suggest PPAR-alpha activation as a hepatoprotective adaptive response mediating protection against APAP in diabetes.	Univ Louisiana Monroe, Dept Toxicol, Sch Pharm, Coll Hlth Sci, Monroe, LA 71209 USA; Toxicogenomics, Chapel Hill, NC USA; Natl Ctr Toxicol Res, Pathol Associates Int, Jefferson, AR 72079 USA; NIEHS, Inorgan Carcinogenesis Sect, NCI, Res Triangle Pk, NC 27709 USA	University of Louisiana System; University of Louisiana Monroe; US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Institute of Environmental Health Sciences (NIEHS)	Mehendale, HM (corresponding author), Univ Louisiana Monroe, Dept Toxicol, Sch Pharm, Coll Hlth Sci, 700 Univ Ave,Sugar Hall 306, Monroe, LA 71209 USA.	mehendale@ulm.edu		Shankar, Kartik/0000-0002-7964-9026				Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; Anderson SP, 2002, HEPATOLOGY, V36, P544, DOI 10.1053/jhep.2002.35276; Asayama K, 1999, MOL CELL BIOCHEM, V194, P227, DOI 10.1023/A:1006930513476; Awad MM, 2000, CELL GROWTH DIFFER, V11, P325; Awad MM, 2000, J BIOL CHEM, V275, P38716, DOI 10.1074/jbc.M008040200; BARTOLONE JB, 1988, BIOCHEM PHARMACOL, V37, P4763, DOI 10.1016/0006-2952(88)90350-4; Blazka ME, 1996, J INFLAMM, V47, P138; Calfee KG, 1998, FASEB J, V12, pA563; CHANDA S, 1995, HEPATOLOGY, V21, P477, DOI 10.1002/hep.1840210232; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; Cosulich S, 2000, CARCINOGENESIS, V21, P579, DOI 10.1093/carcin/21.4.579; Dalu A, 1998, ENVIRON HEALTH PERSP, V106, P597, DOI 10.2307/3434235; Dharaney S, 2002, HEPATOLOGY, V36, p264A; Engels W, 1999, MOL CELL BIOCHEM, V192, P53, DOI 10.1023/A:1006855214237; Fujimori S, 1997, DIGEST DIS SCI, V42, P1987, DOI 10.1023/A:1018892000606; GAYNES BI, 1989, COMP BIOCHEM PHYS B, V94, P213, DOI 10.1016/0305-0491(89)90036-9; GREENWELL A, 1991, CANCER LETT, V59, P251, DOI 10.1016/0304-3835(91)90149-C; HERBER B, 1994, ONCOGENE, V9, P1295; Holden PR, 2000, CELL MOL BIOL, V46, P29; JEFFERY EH, 1991, ADV EXP MED BIOL, V283, P249; Kirschner M W, 1978, Int Rev Cytol, V54, P1, DOI 10.1016/S0074-7696(08)60164-3; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; Kulkarni SG, 1997, TOXICOLOGY, V120, P79, DOI 10.1016/S0300-483X(97)03627-5; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Li YX, 2000, BIOCHEM PHARMACOL, V59, P427, DOI 10.1016/S0006-2952(99)00339-1; Manautou JE, 1998, TOXICOLOGY, V127, P1, DOI 10.1016/S0300-483X(98)00013-4; Manautou JE, 1996, FUND APPL TOXICOL, V29, P229, DOI 10.1006/faat.1996.0026; MANAUTOU JE, 1994, TOXICOL APPL PHARM, V129, P252, DOI 10.1006/taap.1994.1250; MANFREDI JJ, 1984, PHARMACOL THERAPEUT, V25, P83, DOI 10.1016/0163-7258(84)90025-1; MANGIPUDY RS, 1995, PHARMACOL TOXICOL, V77, P182, DOI 10.1111/j.1600-0773.1995.tb01010.x; Mangipudy RS, 1996, ENVIRON HEALTH PERSP, V104, P744, DOI 10.2307/3433220; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; Nicholls-Grzemski FA, 2000, TOXICOL SCI, V56, P220, DOI 10.1093/toxsci/56.1.220; NICHOLLSGRZEMSKI FA, 1992, BIOCHEM PHARMACOL, V43, P1395, DOI 10.1016/0006-2952(92)90193-M; Nilakantan V, 1998, FREE RADICAL BIO MED, V24, P1430, DOI 10.1016/S0891-5849(98)00007-0; O'Brien ML, 2002, TOXICOL SCI, V69, P139, DOI 10.1093/toxsci/69.1.139; Parrish AR, 1999, TOXICOL SCI, V50, P98, DOI 10.1093/toxsci/50.1.98; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; RAO CV, 1991, BIOCHEM PHARMACOL, V42, P2323, DOI 10.1016/0006-2952(91)90237-Y; Rao PS, 1996, TOXICOL APPL PHARM, V140, P235, DOI 10.1006/taap.1996.0218; RAO VC, 1993, ARCH TOXICOL, V67, P392, DOI 10.1007/BF01977400; RAO VC, 1991, TOXICOL PATHOL, V19, P597, DOI 10.1177/019262339101900405; Rauscher FM, 2001, J BIOCHEM MOL TOXIC, V15, P41, DOI 10.1002/1099-0461(2001)15:1<41::AID-JBT5>3.3.CO;2-Q; REINKE LA, 1985, DRUG METAB DISPOS, V13, P548; Roberts RA, 2002, TOXICOL SCI, V68, P270, DOI 10.1093/toxsci/68.2.270; Salminen WF, 1998, J PHARMACOL EXP THER, V286, P519; Salminen WF, 1997, TOXICOL APPL PHARM, V147, P247, DOI 10.1006/taap.1997.8290; Shankar K, 2003, TOXICOL SCI, V73, P220, DOI 10.1093/toxsci/kfg059; Shankar K, 2003, TOXICOL APPL PHARM, V188, P122, DOI 10.1016/S0041-008X(02)00037-6; TSUKAMOTO I, 1989, BIOCHIM BIOPHYS ACTA, V1009, P191, DOI 10.1016/0167-4781(89)90101-2; Vanden Heuvel JP, 1999, TOXICOL SCI, V47, P1, DOI 10.1093/toxsci/47.1.1; Walker NJ, 2002, SCIENCE, V296, P557, DOI 10.1126/science.296.5567.557; Walker NJ, 2001, J BIOCHEM MOL TOXIC, V15, P121, DOI 10.1002/jbt.8; Wang J, 2001, J CERAM PROCESS RES, V2, P27; Wang T, 2000, TOXICOL APPL PHARM, V166, P92, DOI 10.1006/taap.2000.8952; Wang T, 2000, J PHARMACOL EXP THER, V294, P473; Yamagami K, 1998, J SURG RES, V79, P47, DOI 10.1006/jsre.1998.5403; Yamagishi N, 2001, LIFE SCI, V69, P2603, DOI 10.1016/S0024-3205(01)01337-6; Yamamoto H, 2000, RES EXP MED, V199, P309, DOI 10.1007/s004339900040; Zaher H, 1998, TOXICOL APPL PHARM, V152, P193, DOI 10.1006/taap.1998.8501	61	48	48	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1748	+		10.1096/fj.02-1186fje	http://dx.doi.org/10.1096/fj.02-1186fje			33	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958197				2022-12-25	WOS:000184471600016
J	Blundell, CD; Mahoney, DJ; Almond, A; DeAngelis, PL; Kahmann, JD; Teriete, P; Pickford, AR; Campbell, ID; Day, AJ				Blundell, CD; Mahoney, DJ; Almond, A; DeAngelis, PL; Kahmann, JD; Teriete, P; Pickford, AR; Campbell, ID; Day, AJ			The link module from ovulation- and inflammation-associated protein TSG-6 changes conformation on hyaluronan binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-STIMULATED GENE-6; INTER-ALPHA-INHIBITOR; CRYSTAL-STRUCTURE; PASTEURELLA-MULTOCIDA; RHEUMATOID-ARTHRITIS; EXTRACELLULAR-MATRIX; MICE; EXPRESSION; COMPLEX; LYASE	The solution structure of the Link module from human TSG-6, a hyaladherin with important roles in inflammation and ovulation, has been determined in both its free and hyaluronan-bound conformations. This reveals a well defined hyaluronan-binding groove on one face of the Link module that is closed in the absence of ligand. The groove is lined with amino acids that have been implicated in mediating the interaction with hyaluronan, including two tyrosine residues that appear to form essential intermolecular hydrogen bonds and two basic residues capable of supporting ionic interactions. This is the first structure of a non-enzymic hyaladherin in its active state, and identifies a ligand-induced conformational change that is likely to be conserved across the Link module superfamily. NMR and isothermal titration calorimetry experiments with defined oligosaccharides have allowed us to infer the minimum length of hyaluronan that can be accommodated within the binding site and its polarity in the groove; these data have been used to generate a model of the complex formed between the Link module and a hyaluronan octasaccharide.	Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	University of Oxford; University of Oklahoma System; University of Oklahoma Health Sciences Center	Day, AJ (corresponding author), Univ Oxford, Dept Biochem, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.		Teriete, Peter/N-3331-2014; Pickford, Andy/AGB-6901-2022; Day, Anthony/O-1658-2015	Teriete, Peter/0000-0003-3692-9308; Day, Anthony/0000-0002-1415-3134; Almond, Andrew/0000-0001-7471-6333; Blundell, Charles/0000-0002-1439-9126; Pickford, Andy/0000-0002-7237-0030				Almond A, 2000, J PHYS CHEM B, V104, P5634, DOI 10.1021/jp000402t; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; Bayliss MT, 2001, OSTEOARTHR CARTILAGE, V9, P42, DOI 10.1053/joca.2000.0348; Blundell C. D., 2002, HYALURONAN, P161; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; Day AJ, 2001, CURR OPIN STRUC BIOL, V11, P617, DOI 10.1016/S0959-440X(00)00256-6; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; DeAngelis PL, 2002, CARBOHYD RES, V337, P1547, DOI 10.1016/S0008-6215(02)00219-7; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Getting SJ, 2002, J BIOL CHEM, V277, P51068, DOI 10.1074/jbc.M205121200; Glant TT, 2002, ARTHRITIS RHEUM-US, V46, P2207, DOI 10.1002/art.10555; Hamburger ZA, 1999, SCIENCE, V286, P291, DOI 10.1126/science.286.5438.291; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jedrzejas MJ, 2002, J BIOL CHEM, V277, P28287, DOI 10.1074/jbc.M112009200; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; Kida D, 1999, J RHEUMATOL, V26, P1230; Kogelberg H, 2001, CURR OPIN STRUC BIOL, V11, P635, DOI 10.1016/S0959-440X(00)00259-1; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; LUO Y, 2000, NATURE, V405, P1074; Mahoney DJ, 2001, GLYCOBIOLOGY, V11, P1025, DOI 10.1093/glycob/11.12.1025; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6; Mello LV, 2002, J BIOL CHEM, V277, P36678, DOI 10.1074/jbc.M205140200; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Mindrescu C, 2002, ARTHRITIS RHEUM, V46, P2453, DOI 10.1002/art.10503; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Nukui M, 2003, J BIOL CHEM, V278, P3079, DOI 10.1074/jbc.M204999200; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P1008, DOI 10.1210/en.2002-220435; Pickford AR, 2001, EMBO J, V20, P1519, DOI 10.1093/emboj/20.7.1519; Pure E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3; Quiocho FA, 1997, STRUCTURE, V5, P997, DOI 10.1016/S0969-2126(97)00253-0; Siegelman MH, 1999, J LEUKOCYTE BIOL, V66, P315, DOI 10.1002/jlb.66.2.315; Spicer AP, 2003, J BIOL CHEM, V278, P21083, DOI 10.1074/jbc.M213100200; Swaminathan GJ, 2001, J BIOL CHEM, V276, P26197, DOI 10.1074/jbc.M100848200; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	44	76	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49261	49270		10.1074/jbc.M309623200	http://dx.doi.org/10.1074/jbc.M309623200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12972412	hybrid			2022-12-25	WOS:000186829000092
J	Sela, M				Sela, M			From proteins and protein models to their use in immunology and immunotherapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; ALPHA-AMINO ACIDS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL LINES; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; REMITTING MULTIPLE-SCLEROSIS; HUMAN ACETYLCHOLINE-RECEPTOR; BUILT-IN ADJUVANTICITY; SYNTHETIC ANTIGEN		Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Sela, M (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.							ABOUDPIRAK E, 1988, J NATL CANCER I, V80, P1605, DOI 10.1093/jnci/80.20.1605; ACHER R, 1968, EUR J BIOCHEM, V3, P476, DOI 10.1111/j.1432-1033.1967.tb19555.x; Aharoni R, 1999, P NATL ACAD SCI USA, V96, P634, DOI 10.1073/pnas.96.2.634; Aharoni R, 1998, J NEUROIMMUNOL, V91, P135, DOI 10.1016/S0165-5728(98)00166-0; Aharoni R, 1997, P NATL ACAD SCI USA, V94, P10821, DOI 10.1073/pnas.94.20.10821; ANFINSEN CB, 1962, J BIOL CHEM, V237, P1825; ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; ARNON R, 1971, P NATL ACAD SCI USA, V68, P1450, DOI 10.1073/pnas.68.7.1450; ARNON R, 1960, SCIENCE, V132, P86, DOI 10.1126/science.132.3419.86; ARNON R, 1967, EUR J BIOCHEM, V2, P79, DOI 10.1111/j.1432-1033.1967.tb00109.x; ARNON R, 1976, P NATL ACAD SCI USA, V73, P2123, DOI 10.1073/pnas.73.6.2123; ARNON R, 1980, P NATL ACAD SCI-BIOL, V77, P6769, DOI 10.1073/pnas.77.11.6769; AUDIBERT F, 1982, P NATL ACAD SCI-BIOL, V79, P5042, DOI 10.1073/pnas.79.16.5042; BERGER A, 1953, ANAL CHEM, V25, P1554, DOI 10.1021/ac60082a040; BORNSTEIN MB, 1991, NEUROLOGY, V41, P533, DOI 10.1212/WNL.41.4.533; BORNSTEIN MB, 1987, NEW ENGL J MED, V317, P408, DOI 10.1056/NEJM198708133170703; CAHNMANN HJ, 1966, J BIOL CHEM, V241, P3247; CITRI N, 1960, J BIOL CHEM, V235, P3454; CONWAYJACOBS A, 1970, BIOCHEMISTRY-US, V9, P4870, DOI 10.1021/bi00827a007; EDELMAN IS, 1968, ARCH BIOCHEM BIOPHYS, V123, P211, DOI 10.1016/0003-9861(68)90126-4; EPSTEIN CJ, 1962, J BIOL CHEM, V237, P3458; FREEDMAN MH, 1966, J BIOL CHEM, V241, P2383; FREEDMAN MH, 1966, J BIOL CHEM, V241, P5225; FRIDKISHARALI M, 1997, INT IMMUNOL, V7, P925; FRIDKISHARELI M, 1994, P NATL ACAD SCI USA, V91, P4872, DOI 10.1073/pnas.91.11.4872; FUCHS S, 1968, BIOCHEM J, V87, P70; GIVOL D, 1962, BIOCHIM BIOPHYS ACTA, V63, P222, DOI 10.1016/0006-3002(62)90362-1; HURWITZ E, 1995, P NATL ACAD SCI USA, V92, P3353, DOI 10.1073/pnas.92.8.3353; HURWITZ E, 1978, EUR J CANCER, V14, P1213, DOI 10.1016/0014-2964(78)90227-X; JACOB CO, 1983, P NATL ACAD SCI-BIOL, V80, P7611, DOI 10.1073/pnas.80.24.7611; JACOB CO, 1986, IMMUNOL LETT, V14, P43, DOI 10.1016/0165-2478(86)90018-0; JAGENDORF AT, 1963, BIOCHIM BIOPHYS ACTA, V78, P516, DOI 10.1016/0006-3002(63)90913-2; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; KATCHALSKI E, 1958, ADV PROTEIN CHEM, V13, P243, DOI 10.1016/S0065-3233(08)60600-2; KATCHALSKI E, 1953, J AM CHEM SOC, V75, P5284, DOI 10.1021/ja01117a042; KatzLevy Y, 1997, P NATL ACAD SCI USA, V94, P3200, DOI 10.1073/pnas.94.7.3200; KATZLEVY Y, 1993, P NATL ACAD SCI USA, V90, P7000, DOI 10.1073/pnas.90.15.7000; Kipnis J, 2000, P NATL ACAD SCI USA, V97, P7446, DOI 10.1073/pnas.97.13.7446; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; LAHAV M, 1967, J EXP MED, V125, P787, DOI 10.1084/jem.125.5.787; LANGBEHEIM H, 1976, P NATL ACAD SCI USA, V73, P4636, DOI 10.1073/pnas.73.12.4636; LEVY R, 1975, CANCER RES, V35, P1182; MAOZ A, 1973, BIOCHEMISTRY-US, V9, P4246; MCDEVITT HO, 1965, J EXP MED, V122, P517, DOI 10.1084/jem.122.3.517; MCDEVITT HO, 1967, J EXP MED, V126, P969, DOI 10.1084/jem.126.5.969; McDevitt HO, 2000, ANNU REV IMMUNOL, V18, P1, DOI 10.1146/annurev.immunol.18.1.1; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; MOZES E, 1980, P NATL ACAD SCI-BIOL, V77, P4933, DOI 10.1073/pnas.77.8.4933; Neuhaus O, 2000, P NATL ACAD SCI USA, V97, P7452, DOI 10.1073/pnas.97.13.7452; Paas-Rozner M, 2000, P NATL ACAD SCI USA, V97, P2168, DOI 10.1073/pnas.040554597; PECHT I, 1972, J MOL BIOL, V68, P241, DOI 10.1016/0022-2836(72)90211-2; RIGBI M, 1964, BIOCHEMISTRY-US, V3, P629, DOI 10.1021/bi00893a006; ROBBINS JB, 1967, IMMUNOCHEMISTRY, V4, P11, DOI 10.1016/0019-2791(67)90192-9; SCHECHTE.B, 1971, EUR J BIOCHEM, V20, P321, DOI 10.1111/j.1432-1033.1971.tb01396.x; SCHECHTER B, 1991, INT J CANCER, V48, P167, DOI 10.1002/ijc.2910480203; SCHECHTER B, 1970, IMMUNOCHEMISTRY, V7, P587, DOI 10.1016/0019-2791(70)90279-X; SCHECHTER B, 1970, J BIOL CHEM, V245, P1438; Schori H, 2001, P NATL ACAD SCI USA, V98, P3398, DOI 10.1073/pnas.041609498; Sela M, 1997, FASEB J, V11, P449; SELA M, 1967, COLD SPRING HARB SYM, V32, P537, DOI 10.1101/SQB.1967.032.01.065; SELA M, 1962, BIOCHEM J, V85, P223, DOI 10.1042/bj0850223; SELA M, 1970, P NATL ACAD SCI USA, V67, P1288, DOI 10.1073/pnas.67.3.1288; SELA M, 1956, J AM CHEM SOC, V78, P746, DOI 10.1021/ja01585a015; SELA M, 1963, BIOCHEMISTRY-US, V2, P416, DOI 10.1021/bi00903a004; SELA M, 1956, NATURE, V178, P540, DOI 10.1038/178540a0; SELA M, 1962, BIOCHIM BIOPHYS ACTA, V62, P594, DOI 10.1016/0006-3002(62)90248-2; SELA M, 1955, J AM CHEM SOC, V77, P3662, DOI 10.1021/ja01618a079; SELA M, 1956, J AM CHEM SOC, V78, P3986, DOI 10.1021/ja01597a032; SELA M, 1960, BIOCHIM BIOPHYS ACTA, V40, P382, DOI 10.1016/0006-3002(60)91377-9; SELA M, 1959, BIOCHIM BIOPHYS ACTA, V31, P417, DOI 10.1016/0006-3002(59)90016-2; SELA M, 1966, P NATL ACAD SCI USA, V55, P445, DOI 10.1073/pnas.55.2.445; Sela M, 2001, Expert Opin Pharmacother, V2, P1149, DOI 10.1517/14656566.2.7.1149; SELA M, 1960, BIOCHEM J, V75, P91, DOI 10.1042/bj0750091; SELA M, 1969, SCIENCE, V166, P1365, DOI 10.1126/science.166.3911.1365; SELA M, 1959, ADV PROTEIN CHEM, V14, P391, DOI 10.1016/S0065-3233(08)60614-2; Sela M, 1996, ADV PROTEIN CHEM, V49, P289, DOI 10.1016/S0065-3233(08)60492-1; SELA M, 1990, B I PASTEUR, V88, P303; SELA M, 1955, J AM CHEM SOC, V77, P1893, DOI 10.1021/ja01612a054; SELA M, 1957, SCIENCE, V125, P691, DOI 10.1126/science.125.3250.691; Sela M, 1999, CR ACAD SCI III-VIE, V322, P933, DOI 10.1016/S0764-4469(00)87189-9; SELA M, 1962, J BIOL CHEM, V237, P418; SELA M, 1972, B I PASTEUR, V2, P73; SELA M, 1954, B RES COUNC ISRAEL, V4, P109; SELA MICHAEL, 1966, ADVANCE IMMUNOL, V5, P29, DOI 10.1016/S0065-2776(08)60272-2; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; TEITELBAUM D, 1988, P NATL ACAD SCI USA, V85, P9724, DOI 10.1073/pnas.85.24.9724; TEITELBAUM D, 1992, P NATL ACAD SCI USA, V89, P137, DOI 10.1073/pnas.89.1.137; TEITELBAUM D, 1973, IMMUNOCHEMISTRY, V10, P735, DOI 10.1016/0019-2791(73)90175-4; TEITELBAUM D, 1974, CLIN IMMUNOL IMMUNOP, V3, P256, DOI 10.1016/0090-1229(74)90012-9; TEITELBAUM D, 1973, EUR J IMMUNOL, V3, P273, DOI 10.1002/eji.1830030505; TEITELBAUM D, 1971, European Journal of Immunology, V1, P242, DOI 10.1002/eji.1830010406; TEITELBAUM D, 1991, P NATL ACAD SCI USA, V88, P9528, DOI 10.1073/pnas.88.21.9528; TSUKADA Y, 1982, P NATL ACAD SCI-BIOL, V79, P7896, DOI 10.1073/pnas.79.24.7896; WEBB C, 1976, IMMUNOCHEMISTRY, V13, P333, DOI 10.1016/0019-2791(76)90344-X; WEBB C, 1973, EUR J IMMUNOL, V3, P279, DOI 10.1002/eji.1830030506; WELLNER D, 1963, J BIOL CHEM, V238, P1324; Zisman E, 1996, P NATL ACAD SCI USA, V93, P4492, DOI 10.1073/pnas.93.9.4492	97	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48507	48519		10.1074/jbc.X300007200	http://dx.doi.org/10.1074/jbc.X300007200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	13679360	hybrid			2022-12-25	WOS:000186829000001
J	Shor, B; Calaycay, J; Rushbrook, J; McLeod, M				Shor, B; Calaycay, J; Rushbrook, J; McLeod, M			Cpc2/RACK1 is a ribosome-associated protein that promotes efficient translation in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED C-KINASE; SACCHAROMYCES-CEREVISIAE; BETA-SUBUNIT; SEXUAL DEVELOPMENT; MESSENGER-RNA; CELL-GROWTH; YEAST; RACK1; RECEPTOR; INITIATION	Cpc2/RACK1 is a highly conserved WD domain protein found in all eucaryotes. Cpc2/RACK1 functions on mammalian signal transduction pathways most notably as an adaptor protein for the betaII protein kinase C isozyme. In single cell eucaryotes, Cpc2/RACK1 regulates growth, differentiation, and entry into G(0) stationary phase. The exact biochemical function of Cpc2/RACK1 is unknown. Here, we provide evidence that Cpc2 is associated with the ribosome. Using immunoaffinity purification, we isolated ribosomal proteins in association with Cpc2/ RACK1. Polysome and ribosomal subunit analysis using velocity gradient centrifugation of cell lysates demonstrated that Cpc2 co-sediments with the 40 S ribosomal subunit and with polysomes. Conditions known to disrupt ribosome structure alter sedimentation of the ribosome and of Cpc2/ RACK1 coordinately. Loss of cpc2 does not dramatically alter the rate of cellular protein synthesis but causes a decrease in the steady state level of numerous proteins, some of which regulate methionine metabolism. Whereas real time PCR analysis demonstrated that transcriptional mechanisms are responsible for down-regulation of some of these proteins, one protein, ribosomal protein L25, is probably regulated at the level of translation.	SUNY Downstate Med Ctr, Morse Inst Mol Genet, Dept Microbiol & Immunol, Brooklyn, NY 11203 USA; SUNY Downstate Med Ctr, Dept Biochem, Brooklyn, NY 11203 USA; SUNY Downstate Med Ctr, Mol & Cellular Biol Program, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	McLeod, M (corresponding author), SUNY Downstate Med Ctr, Morse Inst Mol Genet, Dept Microbiol & Immunol, Brooklyn, NY 11203 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056875] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01GM56875] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitchison JD, 2000, J CELL BIOL, V151, pF23, DOI 10.1083/jcb.151.5.F23; Alfa C., 1993, EXPT FISSION YEAST; Angenstein F, 2002, J NEUROSCI, V22, P8827; Ashe MP, 2000, MOL BIOL CELL, V11, P833, DOI 10.1091/mbc.11.3.833; Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; BETTANY AJE, 1989, YEAST, V5, P187, DOI 10.1002/yea.320050308; CANCEDDA R, 1979, EUR J BIOCHEM, V94, P41, DOI 10.1111/j.1432-1033.1979.tb12869.x; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; Chantrel Y, 1998, GENETICS, V148, P559; Csukai M, 1999, PHARMACOL RES, V39, P253, DOI 10.1006/phrs.1998.0418; Daga RR, 1999, J CELL SCI, V112, P3137; Edskes HK, 1998, J BIOL CHEM, V273, P28912, DOI 10.1074/jbc.273.44.28912; Eisinger DP, 1997, MOL CELL BIOL, V17, P5136, DOI 10.1128/MCB.17.9.5136; Eisinger DP, 1997, MOL CELL BIOL, V17, P5146, DOI 10.1128/MCB.17.9.5146; ERICKSON FL, 1995, YEAST, V11, P157, DOI 10.1002/yea.320110207; Garrels JI, 1997, ELECTROPHORESIS, V18, P1347, DOI 10.1002/elps.1150180810; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; Grallert B, 2000, J CELL SCI, V113, P1447; Gross T, 1998, NUCLEIC ACIDS RES, V26, P3319, DOI 10.1093/nar/26.14.3319; Hoffmann B, 1999, MOL MICROBIOL, V31, P807, DOI 10.1046/j.1365-2958.1999.01219.x; Hoffmann B, 2000, MOL MICROBIOL, V37, P28, DOI 10.1046/j.1365-2958.2000.01954.x; IINO Y, 1985, MOL GEN GENET, V198, P416, DOI 10.1007/BF00332932; JIMENEZ A, 1975, EUR J BIOCHEM, V54, P483, DOI 10.1111/j.1432-1033.1975.tb04160.x; Kiely PA, 2002, J BIOL CHEM, V277, P22581, DOI 10.1074/jbc.M201758200; KRUGER D, 1990, CURR GENET, V18, P211, DOI 10.1007/BF00318383; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Maiti T, 1997, J BIOL CHEM, V272, P18333, DOI 10.1074/jbc.272.29.18333; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; McCarthy JEG, 1998, MICROBIOL MOL BIOL R, V62, P1492, DOI 10.1128/MMBR.62.4.1492-1553.1998; McLeod M, 2000, MOL CELL BIOL, V20, P4016, DOI 10.1128/MCB.20.11.4016-4027.2000; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; Mochly-Rosen D, 1998, FASEB J, V12, P35; Naora H, 1999, IMMUNOL CELL BIOL, V77, P197, DOI 10.1046/j.1440-1711.1999.00816.x; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; NURSE P, 1985, MOL GEN GENET, V198, P497, DOI 10.1007/BF00332946; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; PALMER E, 1979, J MOL BIOL, V128, P107, DOI 10.1016/0022-2836(79)90311-5; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Ron D, 2000, FASEB J, V14, P2303, DOI 10.1096/fj.00-0143com; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SAMBROOK J, 2000, MOL CLONING LAB MANU; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Scheer U, 1999, CURR OPIN CELL BIOL, V11, P385, DOI 10.1016/S0955-0674(99)80054-4; Schweingruber AM, 1998, J BACTERIOL, V180, P6338; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Stevens SW, 2002, MOL CELL, V9, P31, DOI 10.1016/S1097-2765(02)00436-7; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; Usacheva A, 2001, J BIOL CHEM, V276, P22948, DOI 10.1074/jbc.M100087200; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724	58	65	67	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49119	49128		10.1074/jbc.M303968200	http://dx.doi.org/10.1074/jbc.M303968200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12972434	hybrid			2022-12-25	WOS:000186829000075
J	Kiel, MC; Raj, VS; Kaji, H; Kaji, A				Kiel, MC; Raj, VS; Kaji, H; Kaji, A			Release of ribosome-bound ribosome recycling factor by elongation factor G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RIBONUCLEIC-ACID; RNA BINDING-SITES; EF-G; GUANOSINE TRIPHOSPHATE; SOLUBLE-RNA; 4TH STEP; TRANSLOCATION; PROTEIN; MECHANISM; SUBUNITS	Elongation factor G (EF-G) and ribosome recycling factor (RRF) disassemble post-termination complexes of ribosome, mRNA, and tRNA. RRF forms stable complexes with 70 S ribosomes and 50 S ribosomal subunits. Here, we show that EF-G releases RRF from 70 S ribosomal and model post-termination complexes but not from 50 S ribosomal subunit complexes. The release of bound RRF by EF-G is stimulated by GTP analogues. The EF-G-dependent release occurs in the presence of fusidic acid and viomycin. However, thiostrepton inhibits the release. RRF was shown to bind to EF-G-ribosome complexes in the presence of GTP with much weaker affinity, suggesting that EF-G may move RRF to this position during the release of RRF. On the other hand, RRF did not bind to EF-G-ribosome complexes with fusidic acid, suggesting that EF-G stabilized by fusidic acid does not represent the natural post-termination complex. In contrast, the complexes of ribosome, EF-G and thiostrepton could bind RRF, although with lower affinity. These results suggest that thiostrepton traps an intermediate complex having RRF on a position that clashes with the P/E site bound tRNA. Mutants of EF-G that are impaired for translocation fail to disassemble post-termination complexes and exhibit lower activity in releasing RRF. We propose that the release of ribosome-bound RRF by EF-G is required for post-termination complex disassembly. Before release from the ribosome, the position of RRF on the ribosome will change from the original A/P site to a new location that clashes with tRNA on the P/E site.	Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA	University of Pennsylvania; Jefferson University	Kaji, A (corresponding author), Univ Penn, Sch Med, Dept Microbiol, Rm 203B Johnson Pavil,3610 Hamilton Walk, Philadelphia, PA 19104 USA.	kaji@mail.med.upenn.edu			CGH CDC HHS [GH60429] Funding Source: Medline	CGH CDC HHS		Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Agrawal RK, 2001, J MOL BIOL, V311, P777, DOI 10.1006/jmbi.2001.4907; BODLEY JW, 1970, J BIOL CHEM, V245, P5656; BODLEY JW, 1969, BIOCHEM BIOPH RES CO, V37, P437, DOI 10.1016/0006-291X(69)90934-6; Borowski C, 1996, P NATL ACAD SCI USA, V93, P4202, DOI 10.1073/pnas.93.9.4202; CABANAS MJ, 1980, BIOCHEMISTRY-US, V19, P5411, DOI 10.1021/bi00564a040; Cameron DM, 2002, J MOL BIOL, V319, P27, DOI 10.1016/S0022-2836(02)00235-8; Frank J, 2003, BIOPOLYMERS, V68, P223, DOI 10.1002/bip.10210; Frank J, 2001, COLD SPRING HARB SYM, V66, P67, DOI 10.1101/sqb.2001.66.67; Gualerzi CO, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P477; HAUSNER TP, 1988, J BIOL CHEM, V263, P13103; HIRASHIM.A, 1970, BIOCHEM BIOPH RES CO, V41, P877, DOI 10.1016/0006-291X(70)90165-8; HIRASHIM.A, 1973, J BIOL CHEM, V248, P7580; HIRASHIMA A, 1972, BIOCHEMISTRY-US, V11, P4037, DOI 10.1021/bi00772a005; HIRASHIMA A, 1972, J MOL BIOL, V65, P43, DOI 10.1016/0022-2836(72)90490-1; Hirohawa G, 2002, J BIOL CHEM, V277, P35847, DOI 10.1074/jbc.M206295200; Hirokawa G, 2002, EMBO J, V21, P2272, DOI 10.1093/emboj/21.9.2272; HOU Y, 1994, J BACTERIOL, V176, P7038, DOI 10.1128/JB.176.22.7038-7044.1994; IGARASHI K, 1967, P NATL ACAD SCI USA, V58, P1971, DOI 10.1073/pnas.58.5.1971; IGARASHI K, 1969, BIOCHEM BIOPH RES CO, V37, P499, DOI 10.1016/0006-291X(69)90943-7; INOUEYOKOSAWA N, 1974, J BIOL CHEM, V249, P4321; ISHITSUKA H, 1970, J BIOL CHEM, V245, P3346; Janosi L, 1998, EMBO J, V17, P1141, DOI 10.1093/emboj/17.4.1141; Janosi L, 1996, ADV BIOPHYS, V32, P121, DOI 10.1016/0065-227X(96)84743-5; JANOSI L, 1994, P NATL ACAD SCI USA, V91, P4249, DOI 10.1073/pnas.91.10.4249; Kaji A, 2001, COLD SPRING HARB SYM, V66, P515, DOI 10.1101/sqb.2001.66.515; KAJI A, 1963, BIOCHEM BIOPH RES CO, V13, P186, DOI 10.1016/0006-291X(63)90279-1; KAJI H, 1966, J BIOL CHEM, V241, P1251; KAZIRO Y, 1968, J BIOCHEM-TOKYO, V64, P423, DOI 10.1093/oxfordjournals.jbchem.a128913; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KURIKI Y, 1970, Biochimica et Biophysica Acta, V224, P487, DOI 10.1016/0005-2787(70)90581-2; Lancaster L, 2002, CELL, V111, P129, DOI 10.1016/S0092-8674(02)00938-8; LILL R, 1986, BIOCHEMISTRY-US, V25, P3245, DOI 10.1021/bi00359a025; LILL R, 1984, BIOCHEMISTRY-US, V23, P6710, DOI 10.1021/bi00321a066; MARSH RC, 1977, BIOCHEMISTRY-US, V16, P1278, DOI 10.1021/bi00626a006; Nierhaus KH, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P319; Noller HF, 2002, FEBS LETT, V514, P11, DOI 10.1016/S0014-5793(02)02327-X; OGAWA K, 1975, EUR J BIOCHEM, V58, P411, DOI 10.1111/j.1432-1033.1975.tb02388.x; Pape T, 1998, EMBO J, V17, P7490, DOI 10.1093/emboj/17.24.7490; PESTKA S, 1970, BIOCHEM BIOPH RES CO, V40, P667, DOI 10.1016/0006-291X(70)90956-3; Ramakrishnan V, 2002, CELL, V108, P557, DOI 10.1016/S0092-8674(02)00619-0; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; Rodnina MV, 1999, P NATL ACAD SCI USA, V96, P9586, DOI 10.1073/pnas.96.17.9586; Rodnina PV, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P301; Savelsbergh A, 2000, J MOL BIOL, V300, P951, DOI 10.1006/jmbi.2000.3886; Selmer M, 1999, SCIENCE, V286, P2349, DOI 10.1126/science.286.5448.2349; SHIMIZU I, 1991, J BACTERIOL, V173, P5181, DOI 10.1128/jb.173.16.5181-5187.1991; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; SUZUKA I, 1966, P NATL ACAD SCI USA, V55, P1483, DOI 10.1073/pnas.55.6.1483; Wilson DN, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P495; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; Wintermeyer W, 2001, COLD SPRING HARB SYM, V66, P449, DOI 10.1101/sqb.2001.66.449	54	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48041	48050		10.1074/jbc.M304834200	http://dx.doi.org/10.1074/jbc.M304834200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12960150	hybrid			2022-12-25	WOS:000186731400083
J	Li, Q; Luo, X; Zeng, WH; Muallem, S				Li, Q; Luo, X; Zeng, WH; Muallem, S			Cell-specific behavior of P2X7 receptors in mouse parotid acinar and duct cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBMANDIBULAR-GLAND ACINAR; BRILLIANT BLUE-G; P2X(7) RECEPTOR; NUCLEOTIDE RECEPTORS; PURINERGIC RECEPTORS; POLARIZED EXPRESSION; EXTRACELLULAR ATP; LOCALIZATION; TRAFFICKING; INITIATION	P2X7 receptors (P2X7Rs) affect many epithelial cell functions including transcellular ion transport, secretion, and cell death. Here we used parotid acinar and duct cells to reveal the unique cell-specific assembly and gating of the P2X7R channels. Immunolocalization indicated expression of P2X7Rs in the luminal membrane of both cell types. Stimulation with 5 mM ATP raised [Ca2+](i) levels in a cell-specific manner and activated multiple currents. The current mediated by P2X7R was isolated by infusing the cells with high [ EGTA]. The initial activation of acinar cell P2X7Rs by ATP was slow requiring similar to 2.5 min. Subsequent removal and addition of ATP, however, resulted in rapid inhibition and activation ( gating) of the P2X7Rs. By contrast, P2X7Rs in duct cells displayed only rapid gating by ATP. Activation of P2X7Rs in both cell types was verified by ( a) low Km for ATP, (b) sensitivity to external divalent ions, ( c) lack of desensitization/inactivation, (d) permeability to Na+, and (e) inhibition by Brilliant Blue G, Cu2+, and pyridoxal phosphate-6-azophenyl-2', 4'-disulfonic acid tetrasodium. The slow P2X7R activation in acinar cells was not affected by manipulation of exo-/ endocytosis. Rather, disassembly or solidification of the actin cytoskeleton prior to incubation with ATP prevented channel assembly. Remarkably, after completion of the slow activation, manipulation of the actin cytoskeleton no longer affected gating by ATP. Accordingly, manipulation of the actin cytoskeleton had no effect on P2X7R gating by ATP in duct cells. We concluded that P2X7Rs are not active in resting acinar cells. On exposure to ATP, P2X7Rs are assembled into functional channels with the aid of the actin cytoskeleton. Once assembled, P2X7Rs are subject to rapid gating by ATP. Duct cell P2X7Rs are preassembled and therefore continually subject to rapid gating by ATP. This cell-specific behavior may reflect the specific function of P2X7Rs in the two cell types.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Zeng, WH (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK38938] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afework M, 2000, CELLS TISSUES ORGANS, V167, P297, DOI 10.1159/000016793; Bertrand CA, 2003, AM J PHYSIOL-CELL PH, V285, pC1, DOI 10.1152/ajpcell.00554.2002; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Burnstock G, 2002, CLIN MED, V2, P45, DOI 10.7861/clinmedicine.2-1-45; Chaib N, 2000, BRIT J PHARMACOL, V129, P703, DOI 10.1038/sj.bjp.0703124; Communi D, 2000, CELL SIGNAL, V12, P351, DOI 10.1016/S0898-6568(00)00083-8; COOK DI, 1994, TXB PHYSL GASTROINTE, P1061; Cressman VL, 1999, J BIOL CHEM, V274, P26461, DOI 10.1074/jbc.274.37.26461; Dubyak GR, 2003, MOL PHARMACOL, V63, P773, DOI 10.1124/mol.63.4.773; Gibbons SJ, 2001, J AUTON PHARMACOL, V21, P181, DOI 10.1046/j.1365-2680.2001.00224.x; Hede SE, 1999, J BIOL CHEM, V274, P31784, DOI 10.1074/jbc.274.45.31784; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jiang LH, 2000, MOL PHARMACOL, V58, P82, DOI 10.1124/mol.58.1.82; JORGENSEN TD, 1995, BIOCHEM J, V312, P457, DOI 10.1042/bj3120457; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Lee MG, 1997, J BIOL CHEM, V272, P32951, DOI 10.1074/jbc.272.52.32951; Leipziger J, 2003, AM J PHYSIOL-RENAL, V284, pF419, DOI 10.1152/ajprenal.00075.2002; Luo X, 1999, AM J PHYSIOL-CELL PH, V277, pC205, DOI 10.1152/ajpcell.1999.277.2.C205; Moe OW, 1999, J AM SOC NEPHROL, V10, P2412; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Rossier BC, 2002, J GEN PHYSIOL, V120, P67, DOI 10.1085/jgp.20028638; Sage CL, 2002, J MEMBRANE BIOL, V185, P103, DOI 10.1007/s00232-001-0116-z; Shin DM, 2001, J BIOL CHEM, V276, P44146, DOI 10.1074/jbc.M105203200; SOLTOFF SP, 1989, BIOCHEM BIOPH RES CO, V165, P1279, DOI 10.1016/0006-291X(89)92741-1; Sorensen CE, 2001, J BIOL CHEM, V276, P32925, DOI 10.1074/jbc.M103313200; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Tenneti L, 1998, J BIOL CHEM, V273, P26799, DOI 10.1074/jbc.273.41.26799; Turner JT, 1999, CRIT REV ORAL BIOL M, V10, P210, DOI 10.1177/10454411990100020701; Turner JT, 1998, EUR J MORPHOL, V36, P170; Virginio C, 1997, NEUROPHARMACOLOGY, V36, P1285, DOI 10.1016/S0028-3908(97)00141-X; Watano T, 2002, JPN J PHARMACOL, V89, P296, DOI 10.1254/jjp.89.296; Wilson HL, 2002, J BIOL CHEM, V277, P34017, DOI 10.1074/jbc.M205120200; Xiang ZH, 1998, NEUROSCI LETT, V256, P105, DOI 10.1016/S0304-3940(98)00774-5; Zeng WZ, 1997, J BIOL CHEM, V272, P32956, DOI 10.1074/jbc.272.52.32956; Zeng WZ, 1997, AM J PHYSIOL-CELL PH, V273, pC442, DOI 10.1152/ajpcell.1997.273.2.C442	36	47	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47554	47561		10.1074/jbc.M308306200	http://dx.doi.org/10.1074/jbc.M308306200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12968021	hybrid			2022-12-25	WOS:000186731400027
J	Takeuchi, K; Hatanaka, A; Kimura, M; Seki, N; Kimura, I; Yamada, S; Yamashita, S				Takeuchi, K; Hatanaka, A; Kimura, M; Seki, N; Kimura, I; Yamada, S; Yamashita, S			Aspolin, a novel extremely aspartic acid-rich protein in fish muscle, promotes iron-mediated demethylation of trimethylamine-N-oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; DETOXICATION MECHANISMS; CATALYZED DEALKYLATION; PARTIAL-PURIFICATION; MOLECULAR-CLONING; EXPRESSION; CALSEQUESTRINS; LOCALIZATION; BINDS	Trimethylamine-N-oxide (TMAO) is abundant in marine fish. Formaldehyde synthesis by TMAO demethylation during storage markedly deteriorates fish meat. In the present work, we cloned the extremely aspartic acid-rich proteins from skeletal muscle of a commercially important species, walleye pollack, in the course of molecular identification of trimethylamine-N-oxide demethylase (TMAOase). One of the cDNAs, designated as aspolin1, encodes an extremely aspartic acid-rich protein of 228 amino acids which is converted to the TMAOase after processing between Ala(42) and Asp(43). Mature aspolin1/TMAOase protein contains 179 Asp in 186 total amino acids. The other cDNA, designated as aspolin2, has a common nucleotide sequence with aspolin1 in the 5' part and encodes a protein which has an additional Asp polymer and a C-terminal cysteine-rich region. The amino acid sequence of the C-terminal cysteine-rich region of aspolin2 is highly homologous to the mammalian histidine-rich Ca2+-binding protein. Aspolin1/ TMAOase and aspolin2 mRNA was most abundant in the skeletal muscle. A lower level of the mRNA was also detected in kidney, heart, spleen, and brain. Synthetic Asp polymer showed marked TMAOase activity in the presence of Fe2+, whereas a monomer and oligomers did not. Purified TMAOase protein bound to Fe2+ with low affinity, which may be responsible for the catalytic activity. Poly aspartic acid-Fe2+ complex generated after death would be involved in formaldehyde synthesis by the demethylation of TMAO during the storage of fish meat.	Nippon Suisan Kaisha Ltd, Cent Res Lab, Tokyo 1920906, Japan; Hokkaido Univ, Grad Sch Fisheries Sci, Lab Food Biochem, Hakodate, Hokkaido 0418611, Japan	Nippon Suisan Kaisha, Ltd.; Hokkaido University	Takeuchi, K (corresponding author), Nippon Suisan Kaisha Ltd, Cent Res Lab, 559-6 Kitanomachi, Tokyo 1920906, Japan.	k-takeuchi@nissui.co.jp						Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; CASTELL CH, 1973, J FISH RES BOARD CAN, V30, P1246, DOI 10.1139/f73-199; CASTELL CH, 1973, J FISH RES BOARD CAN, V30, P1205, DOI 10.1139/f73-191; CHOI ESH, 1990, DEV BIOL, V142, P169, DOI 10.1016/0012-1606(90)90160-K; CRAIG JC, 1961, J AM CHEM SOC, V83, P1871, DOI 10.1021/ja01469a023; Dyer W. J., 1945, JOUR FISH RES BD CANADA, V6, P359; DYER W. J., 1952, JOUR FISH RES BD CANADA, V8, P314; FERRIS JP, 1967, J AM CHEM SOC, V89, P5270, DOI 10.1021/ja00996a033; FERRIS JP, 1968, J ORG CHEM, V33, P3493, DOI 10.1021/jo01273a028; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FUJII J, 1990, SOMAT CELL MOLEC GEN, V16, P185, DOI 10.1007/BF01233048; GILL TA, 1982, COMP BIOCHEM PHYS B, V71, P49, DOI 10.1016/0305-0491(82)90174-2; HEGENAUER J, 1977, ANAL BIOCHEM, V78, P308, DOI 10.1016/0003-2697(77)90038-0; HOFMANN SL, 1989, J BIOL CHEM, V264, P8260; HOFMANN SL, 1989, J BIOL CHEM, V264, P18083; JOLY A, 1992, J SCI FOOD AGR, V59, P261, DOI 10.1002/jsfa.2740590219; Kimura M, 2000, FISHERIES SCI, V66, P725, DOI 10.1046/j.1444-2906.2000.00118.x; Kimura M, 2000, FISHERIES SCI, V66, P967, DOI 10.1046/j.1444-2906.2000.00115.x; Kimura M, 2003, FISHERIES SCI, V69, P414, DOI 10.1046/j.1444-2906.2003.00637.x; MONKOVIC I, 1985, SYNTHESIS-STUTTGART, P770; Park KW, 1998, GENE, V217, P25, DOI 10.1016/S0378-1119(98)00372-2; PARKIN KL, 1986, J BIOCHEM-TOKYO, V100, P87, DOI 10.1093/oxfordjournals.jbchem.a121709; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; Shin DW, 2000, FEBS LETT, V486, P178, DOI 10.1016/S0014-5793(00)02246-8; Sotelo CG, 2000, FOOD SCI, V97, P167; Tokunaga T., 1970, Bull. Jap. Soc. scient. Fish., V36, P502; TOKUNAGA T, 1974, NIPPON SUISAN GAKK, V40, P167; TREVES S, 1992, BIOCHEM J, V283, P767, DOI 10.1042/bj2830767; YANO K, 1994, MOL CELL BIOCHEM, V135, P61, DOI 10.1007/BF00925961	29	19	22	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47416	47422		10.1074/jbc.M309415200	http://dx.doi.org/10.1074/jbc.M309415200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13129916	hybrid			2022-12-25	WOS:000186731400011
J	Goldberg, GS; Alexander, DB; Pellicena, P; Zhang, ZY; Tsuda, H; Miller, WT				Goldberg, GS; Alexander, DB; Pellicena, P; Zhang, ZY; Tsuda, H; Miller, WT			Src phosphorylates cas on tyrosine 253 to promote migration of transformed cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CRK-ASSOCIATED SUBSTRATE; ADAPTER PROTEIN CAS; SH3 DOMAINS; V-CRK; STABLE ASSOCIATION; P130(CAS); ACTIVATION; GROWTH; FAK	Cas is a member of the focal adhesion complex. Phosphorylation of Cas by Src is an important event leading to cell transformation. Using mass spectrometry, we have mapped 11 sites in Cas that are phosphorylated by Src. These sites are all located between residues 132 and 414 of Cas, in a region that is required for binding to a number of other proteins including Crk. We tested synthetic peptides modeled on Cas phosphorylation sites, and found that the sequence containing tyrosine 253 was phosphorylated by Src most efficiently. Using cells derived from Cas- deficient mice, we confirmed that Cas greatly enhanced the ability of Src to transform cells. Phosphorylation of Cas on tyrosine 253 was not required for Src to increase growth rate, suppress contact inhibition, or suppress anchorage dependence. Yet, in contrast to these growth characteristics, phosphorylation of Cas on tyrosine 253 was required for Src to promote cell migration. Thus, a single phosphorylation site on this focal adhesion adaptor protein can effectively separate cell migration from other transformed growth characteristics.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Natl Canc Ctr, Res Inst, Div Expt Pathol & Chemotherapy, Chuo Ku, Tokyo 1040045, Japan	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Yeshiva University; Albert Einstein College of Medicine; National Cancer Center - Japan	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Basic Sci Tower T6,Hlth Sci Complex, Stony Brook, NY 11794 USA.				NCI NIH HHS [CA 58530, R01 CA058530-10A1, CA 88805-01A2, R01 CA088805, R01 CA058530] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058530, R01CA088805, R29CA058530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Bruce-Staskal PJ, 2001, EXP CELL RES, V264, P296, DOI 10.1006/excr.2000.5137; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Burnham MR, 1996, ONCOGENE, V12, P2467; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; CZERNILOFSKY AP, 1983, NATURE, V301, P736, DOI 10.1038/301736b0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Goldberg GS, 2000, CANCER RES, V60, P6018; GOLDBERG GS, 1994, MOL CARCINOGEN, V11, P106, DOI 10.1002/mc.2940110208; Goldberg GS, 2001, CANCER RES, V61, P1334; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Huang JH, 2002, J BIOL CHEM, V277, P27265, DOI 10.1074/jbc.M203063200; Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; Khwaja A, 1996, ONCOGENE, V12, P2491; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kook S, 2000, MOL BIOL CELL, V11, P929, DOI 10.1091/mbc.11.3.929; Lamorte L, 2000, ONCOGENE, V19, P5973, DOI 10.1038/sj.onc.1203977; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Manie SN, 1997, J BIOL CHEM, V272, P15636, DOI 10.1074/jbc.272.25.15636; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; RESH MD, 1988, MOL CELL BIOL, V8, P1896, DOI 10.1128/MCB.8.5.1896; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; Sakai R, 1997, ONCOGENE, V14, P1419, DOI 10.1038/sj.onc.1200954; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sorokin A, 1998, BIOCHEM J, V334, P595, DOI 10.1042/bj3340595; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wei L, 2002, J CELL BIOCHEM, V87, P439, DOI 10.1002/jcb.10322; Yamakita Y, 1999, J CELL BIOL, V144, P315, DOI 10.1083/jcb.144.2.315	48	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46533	46540		10.1074/jbc.M307526200	http://dx.doi.org/10.1074/jbc.M307526200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12972425	Green Published, hybrid, Green Accepted			2022-12-25	WOS:000186569400038
J	Kaser, M; Kambacheld, M; Kisters-Woike, B; Langer, T				Kaser, M; Kambacheld, M; Kisters-Woike, B; Langer, T			Oma1, a novel membrane-bound metallopeptidase in mitochondria with activities overlapping with the m-AAA protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; CYTOCHROME-OXIDASE SUBUNIT-2; CHAPERONE-LIKE ACTIVITY; INNER MEMBRANE; SPASTIC PARAPLEGIA; PROTEINS; DEGRADATION; IMPORT; SITES; REQUIREMENT	The integrity of the inner membrane of mitochondria is maintained by a membrane-embedded quality control system that ensures the removal of misfolded membrane proteins. Two ATP-dependent AAA proteases with catalytic sites at opposite membrane surfaces are key components of this proteolytic system. Here we describe the identification of a novel conserved metallopeptidase that exerts activities overlapping with the m-AAA protease and was therefore termed Oma1. Both peptidases are integral parts of the inner membrane and mediate the proteolytic breakdown of a misfolded derivative of the polytopic inner membrane protein Oxa1. The m-AAA protease cleaves off the matrix-exposed C-terminal domain of Oxa1 and processively degrades its transmembrane domain. In the absence of the m-AAA protease, proteolysis of Oxa1 is mediated in an ATP-independent manner by Oma1 and a yet unknown peptidase resulting in the accumulation of N- and C-terminal proteolytic fragments. Oma1 exposes its proteolytic center to the matrix side; however, mapping of Oma1 cleavage sites reveals clipping of Oxa1 in loop regions at both membrane surfaces. These results identify Oma1 as a novel component of the quality control system in the inner membrane of mitochondria. Proteins homologous to Oma1 are present in higher eukaryotic cells, eubacteria and archaebacteria, suggesting that Oma1 is the founding member of a conserved family of membrane-embedded metallopeptidases.	Univ Cologne, Inst Genet, D-50674 Cologne, Germany	University of Cologne	Langer, T (corresponding author), Univ Cologne, Inst Genet, Zulpicher Str 47, D-50674 Cologne, Germany.	thomas.langer@uni-koeln.de		Kaser, Michael/0000-0001-8673-7238; Langer, Thomas/0000-0003-1250-1462				Arlt H, 1998, EMBO J, V17, P4837, DOI 10.1093/emboj/17.16.4837; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; ATORINO L, 2003, IN PRESS J CELL BIOL; BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, P989; BAUER M, 1994, MOL GEN GENET, V245, P272, DOI 10.1007/BF00290106; BUCHLER M, 1994, EUR J BIOCHEM, V219, P627, DOI 10.1111/j.1432-1033.1994.tb19978.x; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; DAUM G, 1982, J BIOL CHEM, V257, P3075; DESAUTELS M, 1982, P NATL ACAD SCI-BIOL, V79, P1869, DOI 10.1073/pnas.79.6.1869; Esser K, 2002, J MOL BIOL, V323, P835, DOI 10.1016/S0022-2836(02)01000-8; Gakh E, 2002, BBA-MOL CELL RES, V1592, P63, DOI 10.1016/S0167-4889(02)00265-3; Halperin T, 2001, PLANT MOL BIOL, V45, P461, DOI 10.1023/A:1010677220323; Hansen JJ, 2002, AM J HUM GENET, V70, P1328, DOI 10.1086/339935; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Herlan M, 2003, J BIOL CHEM, V278, P27781, DOI 10.1074/jbc.M211311200; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; Kang SG, 2002, J BIOL CHEM, V277, P21095, DOI 10.1074/jbc.M201642200; Kaser M, 2000, SEMIN CELL DEV BIOL, V11, P181, DOI 10.1006/scdb.2000.0166; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; KUZELA S, 1994, METHOD ENZYMOL, V244, P376; Langer T, 2001, BIOCHEM SOC T, V29, P431, DOI 10.1042/BST0290431; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Lemaire C, 2000, J BIOL CHEM, V275, P23471, DOI 10.1074/jbc.M002045200; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; Leonhard K, 2000, MOL CELL, V5, P629, DOI 10.1016/S1097-2765(00)80242-7; Leonhard K, 1999, NATURE, V398, P348, DOI 10.1038/18704; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Luirink J, 2001, FEBS LETT, V501, P1, DOI 10.1016/S0014-5793(01)02616-3; McQuibban GA, 2003, NATURE, V423, P537, DOI 10.1038/nature01633; Meyer W, 1997, CURR GENET, V31, P401, DOI 10.1007/s002940050222; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Rape M, 2002, NAT CELL BIOL, V4, pE113, DOI 10.1038/ncb0502-e113; SERIZAWA A, 1995, J BIOL CHEM, V270, P2092, DOI 10.1074/jbc.270.5.2092; Shah ZH, 2000, FEBS LETT, V478, P267, DOI 10.1016/S0014-5793(00)01859-7; Stahl A, 2002, J BIOL CHEM, V277, P41931, DOI 10.1074/jbc.M205500200; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; VANDYCK L, 1994, J BIOL CHEM, V269, P238; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; Weber ER, 1996, MOL BIOL CELL, V7, P307, DOI 10.1091/mbc.7.2.307; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; Wolfe MS, 2002, SCIENCE, V296, P2156, DOI 10.1126/science.1073844; Yen MR, 2001, FEMS MICROBIOL LETT, V204, P223, DOI 10.1111/j.1574-6968.2001.tb10889.x; Young L, 2001, SCIENCE, V291, P2135, DOI 10.1126/science.1056957	55	117	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46414	46423		10.1074/jbc.M305584200	http://dx.doi.org/10.1074/jbc.M305584200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963738	hybrid			2022-12-25	WOS:000186569400025
J	Moore, PL; Ong, S; Harrison, TJ				Moore, PL; Ong, S; Harrison, TJ			Squamous cell carcinoma antigen 1-mediated binding of hepatitis B virus to hepatocytes does not involve the hepatic serpin clearance system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; REACTIVE-SITE LOOP; ALPHA-2-MACROGLOBULIN RECEPTOR; PROTEIN; INHIBITOR; FAMILY; IDENTIFICATION; PENETRATION; ADSORPTION; INFECTION	The cellular receptor for hepatitis B virus (HBV) has not yet been identified. A recent candidate is a homologue of squamous cell carcinoma antigen 1 (SCCA1), a serpin. This study confirms that transfection of SCCA1 into mammalian cells ( both hepatocyte-derived and of non-hepatocyte origin) results in increased HBV binding. Furthermore, virus bound to transfected cells is protected significantly from degradation by trypsin (75% compared with 30% in untransfected cells). The possibility that HBV enters cells via the hepatic clearance system for serpin-enzyme complexes was investigated by analysis of the reactive site loop of SCCA1. Functional and deletion mutants of SCCA1 were constructed by site-directed mutagenesis and compared with the wild type construct. In no case was virus binding reduced by functional alterations or deletions within the reactive site loop. A possible role for the low density lipoprotein receptor-related protein (LRP) in binding virus was investigated. SCCA1 transfection of Huh7 cells was shown to result in up-regulation of LRP expression, reaching levels observed in total liver. However, the use of receptor-associated protein ( RAP), a competitive ligand for LRP, suggests than LRP up-regulation is not responsible for enhanced virus binding to SCCA1-transfected cells.	UCL Royal Free & Univ Coll Med Sch, Dept Med, Ctr Hepatol, London NW3 2PF, England	University of London; University College London; UCL Medical School	Harrison, TJ (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Med, Ctr Hepatol, Rowland Hill St, London NW3 2PF, England.	t.harrison@rfc.ucl.ac.uk	Harrison, Tim J/C-6550-2009	Moore, Penny/0000-0001-8719-4028				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Al-Khunaizi M, 2002, BIOCHEMISTRY-US, V41, P3189, DOI 10.1021/bi015999x; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; Cataltepe S, 2000, J HISTOCHEM CYTOCHEM, V48, P113, DOI 10.1177/002215540004800112; De Falco S, 2001, J BIOL CHEM, V276, P36613, DOI 10.1074/jbc.M102377200; DeMeyer S, 1997, J VIRAL HEPATITIS, V4, P145, DOI 10.1046/j.1365-2893.1997.00126.x; GRIPON P, 1993, VIROLOGY, V192, P534, DOI 10.1006/viro.1993.1069; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; HOOK VYH, 1993, J BIOL CHEM, V268, P20570; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Irving JA, 2002, BIOCHEMISTRY-US, V41, P4998, DOI 10.1021/bi0159985; Kock J, 1996, HEPATOLOGY, V23, P405; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Ling R, 1997, J GEN VIROL, V78, P1463, DOI 10.1099/0022-1317-78-6-1463; Luke C, 2000, BIOCHEMISTRY-US, V39, P7081, DOI 10.1021/bi000050g; Ma Z, 2002, J CELL BIOL, V159, P1061, DOI 10.1083/jcb.200207070; Marsh M, 2000, TRAFFIC, V1, P525, DOI 10.1034/j.1600-0854.2000.010701.x; Moore PL, 2003, BIOTECHNIQUES, V35, P379, DOI 10.2144/03352pt02; NEURATH AR, 1986, CELL, V46, P429, DOI 10.1016/0092-8674(86)90663-X; NEURATH AR, 1994, VIROLOGY, V204, P475, DOI 10.1006/viro.1994.1558; Nykjaer A, 2002, TRENDS CELL BIOL, V12, P273, DOI 10.1016/S0962-8924(02)02282-1; Perani P, 2000, BIOCHEM BIOPH RES CO, V274, P841, DOI 10.1006/bbrc.2000.3191; QIAO M, 1994, VIROLOGY, V201, P356, DOI 10.1006/viro.1994.1301; Salzet M, 1999, IMMUNOL TODAY, V20, P541, DOI 10.1016/S0167-5699(99)01495-4; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schick C, 1998, P NATL ACAD SCI USA, V95, P13465, DOI 10.1073/pnas.95.23.13465; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; Wells MJ, 1999, THROMB HAEMOSTASIS, V81, P325, DOI 10.1055/s-0037-1614472; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; Worrall DM, 1999, BIOCHEM SOC T, V27, P746, DOI 10.1042/bst0270746	33	11	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46709	46717		10.1074/jbc.M302842200	http://dx.doi.org/10.1074/jbc.M302842200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12975381	hybrid			2022-12-25	WOS:000186569400061
J	Petrat, F; Paluch, S; Dogruoz, E; Dorfler, P; Kirsch, M; Korth, HG; Sustmann, R; de Groot, H				Petrat, F; Paluch, S; Dogruoz, E; Dorfler, P; Kirsch, M; Korth, HG; Sustmann, R; de Groot, H			Reduction of Fe(III) ions complexed to physiological ligands by lipoyl dehydrogenase and other flavoenzymes in vitro - Implications for an enzymatic reduction of Fe(III) ions of the labile iron pool	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; INTRACELLULAR FREE IRON; OXIDATIVE CELL INJURY; MOLECULAR-WEIGHT IRON; CHELATABLE IRON; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; DT-DIAPHORASE; METAL-IONS; DISULFIDE OXIDOREDUCTASES	Enzymatic reduction of physiological Fe(III) complexes of the "labile iron pool" has not been studied so far. By use of spectrophotometric assays based on the oxidation of NAD(P)H and formation of [Fe(II) (1,10-phenanthroline)(3)](2+) as well as by utilizing electron paramagnetic resonance spectrometry, it was demonstrated that the NAD(P)H-dependent flavoenzyme lipoyl dehydrogenase (diaphorase, EC 1.8.1.4) effectively catalyzes the one-electron reduction of Fe(III) complexes of citrate, ATP, and ADP at the expense of the co-enzymes NAD(P) H. Deactivated or inhibited lipoyl dehydrogenase did not reduce the Fe(III) complexes. Likewise, in the absence of NAD(P) H or in the presence of NAD(P)(+), Fe(III) reduction could not be detected. The fact that reduction also occurred in the absence of molecular oxygen as well as in the presence of superoxide dismutase proved that the Fe(III) reduction was directly linked to the enzymatic activity of lipoyl dehydrogenase and not mediated by O-2.. Kinetic studies revealed different affinities of lipoyl dehydrogenase for the reduction of the low molecular weight Fe(III) complexes in the relative order Fe(III)-citrate>Fe(III)-ATP>Fe(III)-ADP (half- maximal velocities at 346-485 muM). These Fe(III) complexes were enzymatically reduced also by other flavoenzymes, namely glutathione reductase (EC 1.6.4.2), cytochrome c reductase (EC 1.6.99.3), and cytochrome P450 reductase (EC 1.6.2.4) with somewhat lower efficacy. The present data suggest a (patho) physiological role for lipoyl dehydrogenase and other flavoenzymes in intracellular iron metabolism.	Univ Klinikum, Inst Physiol Chem, D-45122 Essen, Germany; Univ Duisburg Essen, Inst Organ Chem, D-45117 Essen, Germany	University of Duisburg Essen; University of Duisburg Essen	de Groot, H (corresponding author), Univ Klinikum, Inst Physiol Chem, Hufelandstr 55, D-45122 Essen, Germany.	h.de.groot@uni-essen.de						ALBE KR, 1990, J THEOR BIOL, V143, P163, DOI 10.1016/S0022-5193(05)80266-8; BALIGA R, 1993, BIOCHEM J, V291, P901, DOI 10.1042/bj2910901; BALLA G, 1990, J LAB CLIN MED, V116, P546; BECKER K, 1995, METHOD ENZYMOL, V251, P173, DOI 10.1016/0076-6879(95)51120-2; BERGMEYER HU, 1983, METHOD ENZYMAT AN, V2, P180; BREUER W, 1995, AM J PHYSIOL-CELL PH, V268, pC1354, DOI 10.1152/ajpcell.1995.268.6.C1354; BREUER W, 1995, J BIOL CHEM, V270, P24209, DOI 10.1074/jbc.270.41.24209; Breuer W, 1997, FEBS LETT, V403, P213, DOI 10.1016/S0014-5793(97)00056-2; Browne P, 1998, FREE RADICAL BIO MED, V24, P1040, DOI 10.1016/S0891-5849(97)00391-2; Buettner GR, 1996, RADIAT RES, V145, P532, DOI 10.2307/3579271; CAROTHERS DJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P409, DOI 10.1016/0003-9861(89)90309-3; CEDERBAUM AI, 1989, FREE RADICAL BIO MED, V7, P559, DOI 10.1016/0891-5849(89)90033-6; Cheng IF, 2000, BIOMETALS, V13, P77, DOI 10.1023/A:1009229429250; CHER M, 1955, J AM CHEM SOC, V77, P793, DOI 10.1021/ja01608a086; Colman R, 1971, METHODS ENZYMOL B, V17, P500; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Cowart RE, 2002, ARCH BIOCHEM BIOPHYS, V400, P273, DOI 10.1016/S0003-9861(02)00012-7; CRICHTON R, 2001, INORGANIC BIOCH IRON, P241; Dinkova-Kostova LT, 2000, FREE RADICAL BIO MED, V29, P231, DOI 10.1016/S0891-5849(00)00300-2; EDELHOCH H, 1952, J BIOL CHEM, V197, P97; EVANS PJ, 1994, METHOD ENZYMOL, V233, P82; Fasman G.D., 1976, HDB BIOCH MOL BIOL, VI, P123; Fenton H., 1894, J CHEM SOC T, V65, P899, DOI [10.1039/CT8946500899, DOI 10.1039/CT8946500899]; FUNKHOUSER EA, 1976, EUR J BIOCHEM, V66, P225, DOI 10.1111/j.1432-1033.1976.tb10511.x; GREER S, 1986, BIOCHEMISTRY-US, V25, P2736, DOI 10.1021/bi00357a069; Gurgueira SA, 1996, J BIOL CHEM, V271, P13616, DOI 10.1074/jbc.271.23.13616; Haas E, 1940, J BIOL CHEM, V136, P747; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Haramaki N, 1997, FREE RADICAL BIO MED, V22, P535, DOI 10.1016/S0891-5849(96)00400-5; HARDWICK TJ, 1957, CAN J CHEM, V35, P428, DOI 10.1139/v57-062; HEALING G, 1990, BIOCHEM PHARMACOL, V39, P1239, DOI 10.1016/0006-2952(90)90269-Q; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; HORNIG D, 1975, ANN NY ACAD SCI, V258, P103, DOI 10.1111/j.1749-6632.1975.tb29271.x; Huang A, 2000, J BIOL CHEM, V275, P17399, DOI 10.1074/jbc.M002248200; IDE S, 1967, J BIOL CHEM, V242, P54; JONAS SK, 1991, CELL BIOCHEM FUNCT, V9, P245, DOI 10.1002/cbf.290090406; Kakhlon O, 2002, FREE RADICAL BIO MED, V33, P1037, DOI 10.1016/S0891-5849(02)01006-7; Kakhlon O, 2001, BLOOD, V97, P2863, DOI 10.1182/blood.V97.9.2863; Karczewski JM, 1999, BIOCHEM PHARMACOL, V57, P27, DOI 10.1016/S0006-2952(98)00288-3; KENNEY WC, 1972, EUR J BIOCHEM, V28, P253, DOI 10.1111/j.1432-1033.1972.tb01908.x; KOZLOV AV, 1992, FREE RADICAL BIO MED, V13, P9, DOI 10.1016/0891-5849(92)90159-E; Lehnen-Beyel I, 2002, BIOCHEM J, V368, P517, DOI 10.1042/BJ20020639; MAHLER HR, 1955, METHOD ENZYMOL, V2, P688, DOI 10.1016/S0076-6879(55)02284-2; MASSEY V, 1961, BIOCHIM BIOPHYS ACTA, V48, P33, DOI 10.1016/0006-3002(61)90512-1; MASSEY V, 1962, J BIOL CHEM, V237, P3820; MASSEY V, 1960, BIOCHIM BIOPHYS ACTA, V37, P314, DOI 10.1016/0006-3002(60)90239-0; MILLER DM, 1989, ARCH BIOCHEM BIOPHYS, V271, P113, DOI 10.1016/0003-9861(89)90261-0; Ollinger K, 1997, J BIOL CHEM, V272, P23707, DOI 10.1074/jbc.272.38.23707; Petrat F, 1999, HEPATOLOGY, V29, P1171, DOI 10.1002/hep.510290435; Petrat F, 2000, ARCH BIOCHEM BIOPHYS, V376, P74, DOI 10.1006/abbi.2000.1711; Petrat F, 2002, BIOCHEM J, V362, P137, DOI 10.1042/0264-6021:3620137; Petrat F, 2002, BIOL CHEM, V383, P489, DOI 10.1515/BC.2002.051; Petrat F, 2001, BIOCHEM J, V356, P61, DOI 10.1042/0264-6021:3560061; Pierre JL, 2000, BIOMETALS, V13, P91, DOI 10.1023/A:1009225701332; Pierre JL, 2002, BIOMETALS, V15, P341, DOI 10.1023/A:1020259021641; PILBROW JR, 1990, TRANSITION ION ELECT, P135; PREUSCH PC, 1991, FREE RADICAL BIO MED, V11, P77, DOI 10.1016/0891-5849(91)90191-5; Puskas F, 2000, FASEB J, V14, P1352, DOI 10.1096/fj.14.10.1352; Qian SY, 1999, FREE RADICAL BIO MED, V26, P1447, DOI 10.1016/S0891-5849(99)00002-7; Rauen U, 2000, FASEB J, V14, P1953, DOI 10.1096/fj.00-0071com; REED J, 1970, J BIOL CHEM, V245, P5297; REINKE LA, 1995, ARCH BIOCHEM BIOPHYS, V316, P758, DOI 10.1006/abbi.1995.1101; SCHIERBEEK AJ, 1983, J MOL BIOL, V165, P563, DOI 10.1016/S0022-2836(83)80221-6; SEARLS RL, 1961, J BIOL CHEM, V236, P2317; SERGENT O, 1995, BIOL TRACE ELEM RES, V47, P185, DOI 10.1007/BF02790116; SEVANIAN A, 1990, FREE RADICAL BIO MED, V8, P145, DOI 10.1016/0891-5849(90)90087-Y; SHI XL, 1990, FEBS LETT, V276, P189, DOI 10.1016/0014-5793(90)80539-U; Smith R. M., 1990, CRITICAL STABILITY C, V2, P251; SRERE PA, 1967, SCIENCE, V158, P936, DOI 10.1126/science.158.3803.936; Staubli A, 1998, AM J PHYSIOL-GASTR L, V274, pG1031, DOI 10.1152/ajpgi.1998.274.6.G1031; STEINMAN CR, 1967, J BIOL CHEM, V242, P5019; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; Straub FB, 1939, BIOCHEM J, V33, P787, DOI 10.1042/bj0330787; VANDOP C, 1977, J BIOL CHEM, V252, P1303; VOOGD A, 1992, J CLIN INVEST, V90, P2050, DOI 10.1172/JCI116086; WEAVER J, 1989, BIOCHEM J, V261, P787, DOI 10.1042/bj2610787; WEAVER J, 1993, BRIT J HAEMATOL, V83, P138, DOI 10.1111/j.1365-2141.1993.tb04644.x; Welch KD, 2002, ARCH BIOCHEM BIOPHYS, V397, P360, DOI 10.1006/abbi.2001.2694; Welch KD, 2002, FREE RADICAL BIO MED, V32, P577, DOI 10.1016/S0891-5849(02)00760-8; WILLIAMS CH, 1976, CHEM BIOCH FLAVOENZY, V3, P121; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182; Woodmansee AN, 2002, J BIOL CHEM, V277, P34055, DOI 10.1074/jbc.M203977200; YEGOROV DY, 1993, FREE RADICAL BIO MED, V15, P565, DOI 10.1016/0891-5849(93)90158-Q; Young Stephen P., 1994, P597; Zager RA, 1998, KIDNEY INT, V53, P1661, DOI 10.1046/j.1523-1755.1998.00919.x	86	59	61	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46403	46413		10.1074/jbc.M305291200	http://dx.doi.org/10.1074/jbc.M305291200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963736	hybrid			2022-12-25	WOS:000186569400024
J	Sanchez, T; Estrada-Hernandez, T; Paik, JH; Wu, MT; Venkataraman, K; Brinkmann, V; Claffey, K; Hla, T				Sanchez, T; Estrada-Hernandez, T; Paik, JH; Wu, MT; Venkataraman, K; Brinkmann, V; Claffey, K; Hla, T			Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SPHINGOSINE 1-PHOSPHATE; FUNCTIONAL-CHARACTERIZATION; SPHINGOLIPID METABOLISM; DIFFERENTIAL REGULATION; LYMPHOCYTE TRAFFICKING; SPHINGOSINE-1-PHOSPHATE; ACTIVATION; KINASE; EDG-1	FTY720, a potent immunosuppressive agent, is phosphorylated in vivo into FTY720-P, a high affinity agonist for sphingosine 1-phosphate (S1P) receptors. The effects of FTY720 on vascular cells, a major target of S1P action, have not been addressed. We now report the metabolic activation of FTY720 by sphingosine kinase-2 and potent activation of vascular endothelial cell functions in vitro and in vivo by phosphorylated FTY720 (FTY720-P). Incubation of endothelial cells with FTY720 resulted in phosphorylation by sphingosine kinase activity and formation of FTY720-P. Sphingosine kinase-2 effectively phosphorylated FTY720 in the human embryonic kidney 293T heterologous expression system. FTY720-P treatment of endothelial cells stimulated extracellular signal-activated kinase and Akt phosphorylation and adherens junction assembly and promoted cell survival. The effects of FTY720-P were inhibited by pertussis toxin, suggesting the requirement for G(i)-coupled S1P receptors. Indeed, transmonolayer permeability induced by vascular endothelial cell growth factor was potently reversed by FTY720-P. Furthermore, oral FTY720 administration in mice potently blocked VEGF-induced vascular permeability in vivo. These findings suggest that FTY720 or its analogs may find utility in the therapeutic regulation of vascular permeability, an important process in angiogenesis, inflammation, and pathological conditions such as sepsis, hypoxia, and solid tumor growth.	Univ Connecticut, Ctr Hlth, Dept Cell Biol, Ctr Vasc Biol, Farmington, CT 06030 USA; Novartis Inst Biomed Res, Dept Transplantat & Immunol, Basel, Switzerland	University of Connecticut; Novartis	Hla, T (corresponding author), Univ Connecticut, Ctr Hlth, Dept Cell Biol, Ctr Vasc Biol, 263 Farmington Ave, Farmington, CT 06030 USA.	hla@nso2.uchc.edu	Hla, Timothy/G-5873-2012; Venktaraman, Krishnan/U-5460-2019	Hla, Timothy/0000-0001-8355-4065; 	NCI NIH HHS [CA 64436] Funding Source: Medline; NHLBI NIH HHS [HL 70694, HL 67330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064436, R01CA064436] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070694, R37HL067330, R01HL067330] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Avirutnan P, 1998, J IMMUNOL, V161, P6338; Biedermann BC, 2002, LANCET, V359, P2078, DOI 10.1016/S0140-6736(02)08907-9; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2002, CURR OPIN IMMUNOL, V14, P569, DOI 10.1016/S0952-7915(02)00374-6; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Esser S, 1998, J CELL SCI, V111, P1853; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; GIMBRONE MA, 1969, NATURE, V222, P33, DOI 10.1038/222033a0; Heringdorf DM, 1999, FEBS LETT, V461, P217, DOI 10.1016/S0014-5793(99)01463-5; HLA T, 1990, J BIOL CHEM, V265, P9308; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hordijk PL, 1999, J CELL SCI, V112, P1915; Hotchkiss RS, 2002, CRIT CARE MED, V30, pS225, DOI 10.1097/00003246-200205001-00009; Huang MC, 2002, BBA-MOL CELL BIOL L, V1582, P161, DOI 10.1016/S1388-1981(02)00151-8; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Im DS, 2003, TRENDS PHARMACOL SCI, V24, P2, DOI 10.1016/S0165-6147(02)00012-3; Jenison S, 1995, Semin Respir Infect, V10, P259; Koshiba T, 2003, TRANSPLANTATION, V75, P945, DOI 10.1097/01.TP0000058469.38572.10; Koshiba T, 2002, TRANSPLANT P, V34, P748, DOI 10.1016/S0041-1345(01)02901-3; Le Stunff H, 2002, J BIOL CHEM, V277, P8920, DOI 10.1074/jbc.M109968200; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Lei HY, 2001, J BIOMED SCI, V8, P377, DOI 10.1007/BF02255946; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Liu WH, 2002, BIOCHEM BIOPH RES CO, V294, P347, DOI 10.1016/S0006-291X(02)00478-3; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; MCMILLAN DE, 1984, MICROCIRC ENDOTH LYM, V1, P3; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Sukocheva OA, 2003, MOL ENDOCRINOL, V17, P2002, DOI 10.1210/me.2003-0119; Van Brocklyn JR, 2000, BLOOD, V95, P2624; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wong ML, 2000, P NATL ACAD SCI USA, V97, P8681, DOI 10.1073/pnas.150098097; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Yanagawa Y, 1998, J IMMUNOL, V160, P5493; Yang LB, 1999, BRIT J HAEMATOL, V107, P282, DOI 10.1046/j.1365-2141.1999.01697.x; Yatomi Y, 1997, J BIOL CHEM, V272, P5291, DOI 10.1074/jbc.272.8.5291; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193	57	320	347	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47281	47290		10.1074/jbc.M306896200	http://dx.doi.org/10.1074/jbc.M306896200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12954648	hybrid			2022-12-25	WOS:000186569400130
J	Shieh, JJ; Pan, CJ; Mansfield, BC; Chou, JY				Shieh, JJ; Pan, CJ; Mansfield, BC; Chou, JY			A glucose-6-phosphate hydrolase, widely expressed outside the liver, can explain age-dependent resolution of hypoglycemia in glycogen storage disease type Ia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-PRODUCTION; IDENTIFICATION; TRANSPORTER; PROTEINS; 1B	A fine control of the blood glucose level is essential to avoid hyper- or hypo- glycemic shocks associated with many metabolic disorders, including diabetes mellitus and type I glycogen storage disease. Between meals, the primary source of blood glucose is gluconeogenesis and glycogenolysis. In the final step of both pathways, glucose-6- phosphate ( G6P) is hydrolyzed to glucose by the glucose- 6- phosphatase ( G6Pase) complex. Because G6Pase ( renamed G6Pase-alpha) is primarily expressed only in the liver, kidney, and intestine, it has implied that most other tissues cannot contribute to interprandial blood glucose homeostasis. We demonstrate that a novel, widely expressed G6Pase- related protein, PAP2.8/ UGRP, renamed here G6Pase-beta, is an acid- labile, vanadate-sensitive, endoplasmic reticulum- associated phosphohydrolase, like G6Pase-alpha. Both enzymes have the same active site structure, exhibit a similar Km toward G6P, but the V-max of G6Pase-alpha is similar to6- fold greater than that of G6Pase-beta. Most importantly, G6Pase-beta couples with the G6P transporter to form an active G6Pase complex that can hydrolyze G6P to glucose. Our findings challenge the current dogma that only liver, kidney, and intestine can contribute to blood glucose homeostasis and explain why type Ia glycogen storage disease patients, lacking a functional liver/ kidney/ intestine G6Pase complex, are still capable of endogenous glucose production.	NICHHD, Sect Cellular Differentiat, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Chou, JY (corresponding author), NICHHD, Sect Cellular Differentiat, Heritable Disorders Branch, NIH, Bldg 10,Room 9S241,9000 Rockville Pike, Bethesda, MD 20892 USA.		Shieh, Jeng-Jer/AAX-6903-2020	Shieh, Jeng-Jer/0000-0001-8412-3603; Mansfield, Brian/0000-0002-8533-2789	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000912] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000912] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAYNES J, 1999, MED BIOCH, P139; Chen LY, 2002, HUM MOL GENET, V11, P3199, DOI 10.1093/hmg/11.25.3199; Chen LY, 2003, HUM MOL GENET, V12, P2547, DOI 10.1093/hmg/ddg263; Chou Janice Yang, 2002, Current Molecular Medicine (Hilversum), V2, P121, DOI 10.2174/1566524024605798; COLLINS JE, 1990, J INHERIT METAB DIS, V13, P195, DOI 10.1007/BF01799686; Gallagher D., 1999, The role of protein and amino acids in sustaining and enhancing performance., P255; Ghosh A, 2002, J BIOL CHEM, V277, P32837, DOI 10.1074/jbc.M201853200; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hiraiwa H, 1999, J BIOL CHEM, V274, P5532, DOI 10.1074/jbc.274.9.5532; HOFFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Janssen I, 2000, J APPL PHYSIOL, V89, P465, DOI 10.1152/jappl.2000.89.2.465; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; Martin CC, 2002, J MOL ENDOCRINOL, V29, P205, DOI 10.1677/jme.0.0290205; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; Pan CJ, 1998, ARCH BIOCHEM BIOPHYS, V358, P17, DOI 10.1006/abbi.1998.0849; POWELL RC, 1981, METABOLISM, V30, P443, DOI 10.1016/0026-0495(81)90178-5; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Rebhan M., 1997, GENECARDS ENCY GENES; Scriver C.R., 2001, METABOLIC MOL BASIS, VEighth; Shieh JJ, 2002, J BIOL CHEM, V277, P5047, DOI 10.1074/jbc.M110486200; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; Snyder WS, 1975, REPORT TASK GROUP RE; TAYLOR SI, 2001, METABOLIC MOL BASES, P1433; TSALIKIAN E, 1984, AM J PHYSIOL, V247, pE513, DOI 10.1152/ajpendo.1984.247.4.E513	28	74	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47098	47103		10.1074/jbc.M309472200	http://dx.doi.org/10.1074/jbc.M309472200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	13129915	hybrid			2022-12-25	WOS:000186569400107
J	Yagi, M; Sakurai, K; Kalidas, C; Batt, CA; Goto, Y				Yagi, M; Sakurai, K; Kalidas, C; Batt, CA; Goto, Y			Reversible unfolding of bovine beta-lactoglobulin mutants without a free thiol group	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOMER-DIMER EQUILIBRIUM; CONFORMATIONAL STABILITY; INTERMEDIATE; SHEET; STABILIZATION; DISSOCIATION; TRANSITION; PH	Bovine beta-lactoglobulin (beta-lg) has been used extensively as a model for studying protein folding. One of the problems preventing clarification of the folding mechanism is the incomplete reversibility from the unfolded state, probably caused by the thiol-disulfide exchange between a free thiol at Cys-121 and two disulfide bonds. We constructed and expressed three beta-lg subtype A mutants in which Cys-121 was replaced by Ala, Ser, or Val (i.e. C121A, C121S, and C121V). We studied the reversibilities of these mutants from urea denaturation using circular dichroism, tryptophan fluorescence, reversed-phase and gel-filtration high performance liquid chromatographies, and SDS-PAGE. The folded structure of each mutant was similar to that of wild-type beta-lg. Urea-induced unfolding at pH 7.0 and 3.0 showed that although the C121S mutation notably decreases the stability, the destabilizing effects of the C121A and C121V mutations are less severe. For all of the mutants, complete refolding from the unfolded state in 8 M urea at both pH 7.0 and 3.0 was observed. Kinetics of the formation of the irreversibly unfolded species of wild-type beta-lg in 8 M urea at pH 7.0 indicated that, first, an intramolecular thiol-disulfide exchange occurs to produce a mixture of species with non-native disulfide bonds followed by the intermolecular thiol-disulfide exchange producing the oligomers. These results indicate that intramolecular and intermolecular thiol-disulfide exchange reactions cause the low reversibility of wild-type beta-lg especially at neutral pH and that the mutation of Cys-121 improves the reversibility, enabling us to study the folding of beta-lg more exactly under various conditions.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Japan Sci Corp, CREST, Suita, Osaka 5650871, Japan; Cornell Univ, Dept Food Sci, Ithaca, NY 14853 USA; Cornell Univ, Nanobiotechnol Ctr, Ithaca, NY 14853 USA	Osaka University; Japan Science & Technology Agency (JST); Cornell University; Cornell University	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp						Apenten RKO, 1998, INT J BIOL MACROMOL, V23, P19, DOI 10.1016/S0141-8130(98)00008-7; Brownlow S, 1997, STRUCTURE, V5, P481, DOI 10.1016/S0969-2126(97)00205-0; Burova TV, 1998, PROTEIN ENG, V11, P1065, DOI 10.1093/protein/11.11.1065; Carrotta R, 2001, PROTEIN SCI, V10, P1312, DOI 10.1110/ps.42501; CHO YJ, 1994, PROTEIN ENG, V7, P263, DOI 10.1093/protein/7.2.263; Cohen FE, 1999, J MOL BIOL, V293, P313, DOI 10.1006/jmbi.1999.2990; Croguennec T, 2003, BIOCHEM BIOPH RES CO, V301, P465, DOI 10.1016/S0006-291X(02)02997-2; CUPO JF, 1983, BIOCHEMISTRY-US, V22, P2654, DOI 10.1021/bi00280a010; Forge V, 2000, J MOL BIOL, V296, P1039, DOI 10.1006/jmbi.1999.3515; Fujiwara K, 1999, BIOCHEMISTRY-US, V38, P4455, DOI 10.1021/bi982683p; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRIKO YV, 1994, BIOPHYS J, V67, P356, DOI 10.1016/S0006-3495(94)80488-6; Hamada D, 1996, NAT STRUCT BIOL, V3, P868, DOI 10.1038/nsb1096-868; Hamada D, 1997, J MOL BIOL, V269, P479, DOI 10.1006/jmbi.1997.1055; HAMADA D, 1995, J MOL BIOL, V254, P737, DOI 10.1006/jmbi.1995.0651; Hambling S. G., 1992, ADV DAIRY CHEM, V1, P141; Kim TR, 1997, PROTEIN ENG, V10, P1339, DOI 10.1093/protein/10.11.1339; Kontopidis G, 2002, J MOL BIOL, V318, P1043, DOI 10.1016/S0022-2836(02)00017-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuroda Y, 1996, FOLD DES, V1, P255, DOI 10.1016/S1359-0278(96)00039-9; Kuwata K, 2001, NAT STRUCT BIOL, V8, P151, DOI 10.1038/84145; Kuwata K, 1999, PROTEIN SCI, V8, P2541; Kuwata K, 1998, J MOL BIOL, V283, P731, DOI 10.1006/jmbi.1998.2117; MILLS OE, 1975, BIOCHIM BIOPHYS ACTA, V379, P618, DOI 10.1016/0005-2795(75)90168-3; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; Qin BY, 1998, FEBS LETT, V438, P272, DOI 10.1016/S0014-5793(98)01199-5; Qin BY, 1998, BIOCHEMISTRY-US, V37, P14014, DOI 10.1021/bi981016t; Ragona L, 1999, J MOL BIOL, V293, P953, DOI 10.1006/jmbi.1999.3191; Ragona L, 2002, BIOCHEMISTRY-US, V41, P2786, DOI 10.1021/bi011615r; Renard D, 1998, INT J BIOL MACROMOL, V22, P41, DOI 10.1016/S0141-8130(97)00086-X; Sakai K, 2000, PROTEIN SCI, V9, P1719; Sakurai K, 2002, J BIOL CHEM, V277, P25735, DOI 10.1074/jbc.M203659200; Sakurai K, 2001, PROTEIN SCI, V10, P2325, DOI 10.1110/ps.17001; Sawyer L, 2000, BBA-PROTEIN STRUCT M, V1482, P136, DOI 10.1016/S0167-4838(00)00160-6; Schokker EP, 1999, INT DAIRY J, V9, P791, DOI 10.1016/S0958-6946(99)00148-X; SHIRAKI K, 1995, J MOL BIOL, V245, P180, DOI 10.1006/jmbi.1994.0015; Surroca Y, 2002, J CHROMATOGR A, V970, P275, DOI 10.1016/S0021-9673(02)00884-1; TELLER DC, 1969, ANN NY ACAD SCI, V164, P66, DOI 10.1111/j.1749-6632.1969.tb14033.x; Uhrinova S, 2000, BIOCHEMISTRY-US, V39, P3565, DOI 10.1021/bi992629o; Wal JM, 1998, ALLERGY, V53, P1013, DOI 10.1111/j.1398-9995.1998.tb03811.x; Yamasaki R, 1999, J MOL BIOL, V292, P965, DOI 10.1006/jmbi.1999.3129; ZIMMERMAN JK, 1970, ARCH BIOCHEM BIOPHYS, V138, P101, DOI 10.1016/0003-9861(70)90289-4	42	52	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47009	47015		10.1074/jbc.M308592200	http://dx.doi.org/10.1074/jbc.M308592200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963719	hybrid			2022-12-25	WOS:000186569400096
J	Hassa, PO; Buerki, C; Lombardi, C; Imhof, R; Hottiger, MO				Hassa, PO; Buerki, C; Lombardi, C; Imhof, R; Hottiger, MO			Transcriptional coactivation of nuclear factor-kappa B-dependent gene expression by p300 is regulated by poly(ADP)-ribose polymerase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSACTIVATION DOMAIN; RIBOSE POLYMERASE; IMMUNE-RESPONSES; BINDING PROTEIN; ENDOTOXIC-SHOCK; P50 SUBUNIT; ACTIVATION; MICE; PARP; P65	Nuclear factor kappaB (NF-kappaB) plays an important role in the transcriptional regulation of genes involved in inflammation and cell survival. In this study, we demonstrated that NF-kappaB-dependent gene expression was inhibited by E1A in poly(ADP)- ribose polymerase-1 knock out (PARP-1 (-/-)) cells complemented with wild type PARP-1 after tumor necrosis factor alpha (TNFalpha) or lipopolysaccharide (LPS) treatment. PARP-1 and p300 synergistically coactivated NF-kappaB-dependent gene expression in response to TNFalpha and LPS. Furthermore, PARP-1 interacted directly with p300 and enhanced the interaction of NF-kappaB1/p50 to p300. The C terminus, harboring the catalytic domain of PARP-1 but not its enzymatic activity, was required for complete transcriptional coactivation of NF-kappaB by p300 in response to TNFalpha and LPS. Together, these results indicate that PARP-1 acts synergistically with p300 and plays an essential regulatory role in NF-kappaB-dependent gene expression.	Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	University of Zurich	Hottiger, MO (corresponding author), Univ Zurich, Inst Vet Biochem & Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Hottiger, Michael O./J-7747-2013	Hottiger, Michael O./0000-0002-7323-2270				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bauer PI, 2001, FEBS LETT, V506, P239, DOI 10.1016/S0014-5793(01)02919-2; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Felzien LK, 1999, MOL CELL BIOL, V19, P4241; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Goodman RH, 2000, GENE DEV, V14, P1553; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; Hasan S, 2001, MOL CELL, V7, P1221, DOI 10.1016/S1097-2765(01)00272-6; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KARIN M, 1998, CANC J SCI AM S1, V4, P92; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Mabley JG, 2001, BRIT J PHARMACOL, V133, P909, DOI 10.1038/sj.bjp.0704156; Malik S, 2000, MOL CELL, V5, P753, DOI 10.1016/S1097-2765(00)80254-3; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Paal K, 1997, NUCLEIC ACIDS RES, V25, P1050, DOI 10.1093/nar/25.5.1050; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; Yamit-Hezi E, 2000, J BIOL CHEM, V275, P18180, DOI 10.1074/jbc.275.24.18180; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	47	193	198	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45145	45153		10.1074/jbc.M307957200	http://dx.doi.org/10.1074/jbc.M307957200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12960163	hybrid			2022-12-25	WOS:000186452300014
J	Hess, A; Wijayanti, N; Neuschafer-Rube, AP; Katz, N; Kietzmann, T; Immenschuh, S				Hess, A; Wijayanti, N; Neuschafer-Rube, AP; Katz, N; Kietzmann, T; Immenschuh, S			Phorbol ester-dependent activation of peroxiredoxin I gene expression via a protein kinase C, Ras, p38 mitogen-activated protein kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; THIOL-SPECIFIC ANTIOXIDANT; HEME OXYGENASE-1 GENE; OXIDATIVE STRESS; TRANSCRIPTIONAL REGULATION; MAMMALIAN PEROXIREDOXIN; THIOREDOXIN PEROXIDASE; TRANSDUCTION PATHWAY; HYDROGEN-PEROXIDE; CELLS	The antioxidant protein peroxiredoxin (Prx) I is a thioredoxin peroxidase that is involved in the regulation of proliferation and differentiation of mammalian cells. Here, it is shown that Prx I gene expression was induced transcriptionally by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) in cultured rat liver tissue macrophages and RAW264.7 monocytic cells. TPA-dependent induction of Prx I gene expression was mediated by two proximal activator protein-1 sites of the rat Prx I promoter region that were nuclear targets of c-Jun as determined by transfection studies with luciferase reporter gene constructs and electrophoretic mobility shift assays. The transcription factor Nrf2, however, was not involved in the regulation of Prx I promoter activity. Prx I gene induction by TPA was decreased by protein kinase C inhibitors and overexpressed dominant negative forms of Ras and MEKK1, but not Raf-1. The p38 MAPK inhibitor SB202190 and overexpression of dominant negative mutants of MAPK kinase 4 (MKK4), MKK6, and p38 inhibited the TPA-dependent induction of Prx I gene transcription. In contrast, inhibitors of the JNK, SP600125, and the NF-kappaB signaling pathway, caffeic acid phenethyl ester, respectively, as well as overexpressed dominant negative MKK7 and IkappaB, had no effect on the up-regulation of Prx I reporter gene activity by TPA. Cotransfection of wild-type p38alpha and p38beta, but not that of p38gamma and p38delta, increased Prx I promoter activity. The data indicate that a protein kinase C, Ras, MEKK1, p38 MAPK signaling pathway plays a major role for the transcriptional up-regulation of Prx I gene expression.	Univ Giessen, Inst Klin Chem & Pathobiochem, D-35392 Giessen, Germany; Univ Gottingen, Inst Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	Justus Liebig University Giessen; University of Gottingen	Immenschuh, S (corresponding author), Univ Giessen, Inst Klin Chem & Pathobiochem, Gaffkystr 11, D-35392 Giessen, Germany.		Immenschuh, Stephan/AAM-9181-2020	Immenschuh, Stephan/0000-0003-3722-5791; Kietzmann, Thomas/0000-0003-0242-8636; Wijayanti, Nastiti/0000-0001-6483-2816				Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; Carter AB, 2001, J BIOL CHEM, V276, P33826, DOI 10.1074/jbc.M100209200; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chang TS, 2002, J BIOL CHEM, V277, P25370, DOI 10.1074/jbc.M110432200; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Immenschuh S, 1999, HEPATOLOGY, V30, P118, DOI 10.1002/hep.510300142; IMMENSCHUH S, 1995, BIOCHEMISTRY-US, V34, P13407, DOI 10.1021/bi00041a018; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; ISHII T, 1993, J BIOL CHEM, V268, P18633; IWAHARA S, 1995, BIOCHEMISTRY-US, V34, P13398, DOI 10.1021/bi00041a017; JENNER P, 1994, LANCET, V344, P796, DOI 10.1016/S0140-6736(94)92347-7; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kietzmann T, 2003, J BIOL CHEM, V278, P17927, DOI 10.1074/jbc.M203929200; Kim H, 2000, J BIOL CHEM, V275, P18266, DOI 10.1074/jbc.275.24.18266; Kim HP, 1999, J BIOL CHEM, V274, P37455, DOI 10.1074/jbc.274.52.37455; KNOOK DL, 1976, EXP CELL RES, V99, P444, DOI 10.1016/0014-4827(76)90605-4; Koo KH, 2002, ARCH BIOCHEM BIOPHYS, V397, P312, DOI 10.1006/abbi.2001.2700; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee HW, 2002, J BIOL CHEM, V277, P32624, DOI 10.1074/jbc.M200353200; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Li BJ, 2002, J BIOL CHEM, V277, P12418, DOI 10.1074/jbc.M111443200; Majumdar S, 2002, J IMMUNOL, V168, P2644, DOI 10.4049/jimmunol.168.6.2644; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; Mu ZM, 2002, J BIOL CHEM, V277, P43175, DOI 10.1074/jbc.M206066200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oberley TD, 2002, AM J PATHOL, V160, P403, DOI 10.1016/S0002-9440(10)64857-2; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; PROSPERI MT, 1994, GENOMICS, V19, P236, DOI 10.1006/geno.1994.1053; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Rebollo A, 1999, BLOOD, V94, P2971, DOI 10.1182/blood.V94.9.2971.421k43_2971_2980; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Simon C, 2001, EXP CELL RES, V271, P344, DOI 10.1006/excr.2001.5374; SIOW RCM, 1995, FEBS LETT, V368, P239, DOI 10.1016/0014-5793(95)00650-X; Takahashi H, 1998, J BIOL CHEM, V273, P17375, DOI 10.1074/jbc.273.28.17375; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wong WK, 2002, J BIOL CHEM, V277, P22222, DOI 10.1074/jbc.M202844200; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8	51	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45419	45434		10.1074/jbc.M307871200	http://dx.doi.org/10.1074/jbc.M307871200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12960165	hybrid			2022-12-25	WOS:000186452300047
J	Zhang, DW; Gu, HM; Situ, D; Haimeur, A; Cole, SPC; Deeley, RG				Zhang, DW; Gu, HM; Situ, D; Haimeur, A; Cole, SPC; Deeley, RG			Functional importance of polar and charged amino acid residues in transmembrane helix 14 of multidrug resistance protein 1 (MRP1/ABCC1) - Identification of an aspartate residue critical for conversion from a high to low affinity substrate binding state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATE EXPORT PUMP; ATP-BINDING; LEUKOTRIENE C-4; P-GLYCOPROTEIN; PHARMACOLOGICAL CHARACTERIZATION; DRUG-RESISTANCE; LUNG-CANCER; TRANSPORTER SUPERFAMILY; VINCRISTINE TRANSPORT; MONOCLONAL-ANTIBODIES	Human multidrug resistance protein 1 (MRP1) confers resistance to many chemotherapeutic agents and transports diverse conjugated organic anions. We previously demonstrated that Glu(1089) in transmembrane (TM) 14 is critical for the protein to confer anthracycline resistance. We have now assessed the functional importance of all polar and charged amino acids in this TM helix. Asn(1100), Ser(1097), and Lys(1092), which are all predicted to be on the same face of the helix as to Glu1089, are involved in determining the substrate specificity of the protein. Notably, elimination of the positively charged side chain of Lys(1092), increased resistance to the cationic drugs vincristine and doxorubicin, but not the electroneutral drug etoposide (VP-16). In addition, mutations S1097A and N1100A selectively decreased transport of 17beta-estradiol 17-(beta-D-glucuronide) (E(2)17betaG) but not cysteinyl leukotriene 4 (LTC4), demonstrating the importance of multiple residues in this helix in determining substrate specificity. In contrast, mutations of Asp(1084) that eliminate the carboxylate side chain markedly decreased resistance to all drugs tested, as well as transport of both E(2)17betaG and LTC4, despite the fact that LTC4 binding was unaffected. We show that these mutations prevent the ATP-dependent transition of the protein from a high to low affinity substrate binding state and drastically diminish ADP trapping at nucleotide binding domain 2. Based on results presented here and crystal structures of prokaryotic ATP binding cassette transporters, Asp(1084) may be critical for interaction between the cytoplasmic loop connecting TM13 and TM14 and a region of nucleotide binding domain 2 between the conserved Walker A and ABC signature motifs.	Queens Univ, Canc Res Inst, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; McMaster University; Queens University - Canada; Queens University - Canada; Queens University - Canada	Deeley, RG (corresponding author), Queens Univ, Canc Res Inst, Div Canc Biol & Genet, Suite 300,10 Stuart St, Kingston, ON K7L 3N6, Canada.		Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017; Zhang, Dawei/ABD-8990-2022	Cole, Susan P.C./0000-0001-6571-6884; Zhang, Dawei/0000-0001-8279-8041				Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bera TK, 2001, MOL MED, V7, P509, DOI 10.1007/BF03401856; BREUNINGER LM, 1995, CANCER RES, V55, P5342; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Efferth T, 2001, INT J ONCOL, V19, P367; Filipits M, 1996, CLIN CANCER RES, V2, P1231; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; GRANT CE, 1994, CANCER RES, V54, P357; Hafkemeyer P, 1998, BIOCHEMISTRY-US, V37, P16400, DOI 10.1021/bi980871+; Haimeur A, 2002, J BIOL CHEM, V277, P41326, DOI 10.1074/jbc.M206228200; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Hopper E, 2001, CANCER LETT, V162, P181, DOI 10.1016/S0304-3835(00)00646-7; Hou YX, 2003, J BIOL CHEM, V278, P3599, DOI 10.1074/jbc.M210480200; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Jedlitschky G, 1996, CANCER RES, V56, P988; Kao HH, 2002, GENE, V286, P299, DOI 10.1016/S0378-1119(02)00461-4; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Koike K, 2002, J BIOL CHEM, V277, P49495, DOI 10.1074/jbc.M206896200; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Mao QC, 2000, J BIOL CHEM, V275, P34166, DOI 10.1074/jbc.M004584200; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Nooter K, 1997, BRIT J CANCER, V76, P486, DOI 10.1038/bjc.1997.414; Nunoya K, 2003, DRUG METAB DISPOS, V31, P1016, DOI 10.1124/dmd.31.8.1016; Oleschuk CJ, 2003, AM J PHYSIOL-GASTR L, V284, pG280, DOI 10.1152/ajpgi.00331.2002; Payen LF, 2003, J BIOL CHEM, V278, P38537, DOI 10.1074/jbc.M305786200; Qian YM, 2002, J BIOL CHEM, V277, P35225, DOI 10.1074/jbc.M206058200; Qian YM, 2001, J BIOL CHEM, V276, P38636, DOI 10.1074/jbc.M107025200; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Rappa G, 1997, CANCER RES, V57, P5232; Ren XQ, 2002, BIOCHEMISTRY-US, V41, P14132, DOI 10.1021/bi026443s; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Song JM, 2001, MOL PHARMACOL, V60, P254, DOI 10.1124/mol.60.2.254; Stride BD, 1999, J BIOL CHEM, V274, P22877, DOI 10.1074/jbc.274.32.22877; Stride BD, 1997, MOL PHARMACOL, V52, P344, DOI 10.1124/mol.52.3.344; Tada Y, 2002, INT J CANCER, V98, P630, DOI 10.1002/ijc.10246; Taguchi Y, 2002, FEBS LETT, V521, P211, DOI 10.1016/S0014-5793(02)02816-8; Tammur J, 2001, GENE, V273, P89, DOI 10.1016/S0378-1119(01)00572-8; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; van der Kolk DM, 2000, CLIN CANCER RES, V6, P3205; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; Yabuuchi H, 2001, BIOCHEM BIOPH RES CO, V288, P933, DOI 10.1006/bbrc.2001.5865; Yokoyama Y, 1999, J Obstet Gynaecol Res, V25, P387; Young LC, 2001, CLIN CANCER RES, V7, P1798; Young LC, 1999, CLIN CANCER RES, V5, P673; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; Zhang DW, 2003, BIOCHEMISTRY-US, V42, P9989, DOI 10.1021/bi034462b; Zhang DW, 2002, J BIOL CHEM, V277, P20934, DOI 10.1074/jbc.M201311200; Zhang DW, 2001, J BIOL CHEM, V276, P34966, DOI 10.1074/jbc.M105063200; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200	61	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46052	46063		10.1074/jbc.M308403200	http://dx.doi.org/10.1074/jbc.M308403200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954620	hybrid			2022-12-25	WOS:000186452300122
J	Lin, MI; Fulton, D; Babbitt, R; Fleming, I; Busse, R; Pritchard, KA; Sessa, WC				Lin, MI; Fulton, D; Babbitt, R; Fleming, I; Busse, R; Pritchard, KA; Sessa, WC			Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; HSP90; DEPHOSPHORYLATION; IDENTIFICATION; ASSOCIATION; GENERATION; SITES; GOLGI; CELLS	There is evidence that endothelial nitric-oxide synthase ( eNOS) is regulated by reciprocal dephosphorylation of Thr(497) and phosphorylation of Ser(1179). To examine the interrelationship between these sites, cells were transfected with wild-type (WT), T497A, T497D, S1179D, and T497A/S1179D eNOS and activity, NO release and eNOS localization were assessed. Although eNOS T497A, S1179D and T497A/S1179D eNOS had greater enzymatic activity than did WT eNOS in lysates, basal production of NO from cells was markedly reduced in cells transfected with T497A and T497A/S1179D eNOS but augmented in cells transfected with S1179D eNOS. Stimulating cells with ATP or ionophore normalized the loss of function seen with T497A and T497A/S1179D eNOS to levels observed with WT and S1179D eNOS, respectively. Despite these functional differences, the localization of eNOS mutants were similar to WT. Because both T497A and T497A/S1179D eNOS exhibited higher enzyme activity but reduced production of NO, we examined whether these mutations were "uncoupling" NO synthesis. T497A and T497A/S1179D eNOS generated 2 - 3 times more superoxide anion than WT eNOS, and both basal and stimulated interactions of T497A/S1179D eNOS with hsp90 were reduced in co- immunoprecipitation experiments. Thus, the phosphorylation/dephosphorylation of Thr497 may be an intrinsic switch mechanism that determines whether eNOS generates NO versus superoxide in cells.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Program Vasc Cell Signaling & Therapeut, New Haven, CT 06536 USA; Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Univ Frankfurt Klinikum, Inst Kardiovaskulaere Physiol, D-60590 Frankfurt, Germany; Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA	Yale University; Yale University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Medical College of Wisconsin	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 295 Congress Ave, New Haven, CT 06536 USA.	william.sessa@yale.edu	Sessa, William C/B-6844-2011; Fleming, Ingrid/L-1225-2014; Fleming, Ingrid/AAB-6123-2022	Sessa, William C/0000-0001-5759-1938; Fleming, Ingrid/0000-0003-1881-3635; Fleming, Ingrid/0000-0003-1881-3635	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057665, P01HL068769, R01HL071214, R01HL064793, R37HL061371, R01HL061371, R01HL061417] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL71214, HL68769, HL64793, R01 HL57665, HL 61417, HL61371] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; de Montellano PRO, 1998, DRUG METAB DISPOS, V26, P1185; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Fulton D, 2002, J BIOL CHEM, V277, P4277, DOI 10.1074/jbc.M106302200; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Greif DM, 2002, BIOCHEMISTRY-US, V41, P15845, DOI 10.1021/bi026732g; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Kou RQ, 2002, J BIOL CHEM, V277, P29669, DOI 10.1074/jbc.M204519200; Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Michell BJ, 2002, J BIOL CHEM, V277, P42344, DOI 10.1074/jbc.M205144200; Ou J, 2003, FREE RADICAL BIO MED, V34, P269, DOI 10.1016/S0891-5849(02)01299-6; Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200; PRITCHARD KA, 1995, CIRC RES, V77, P510, DOI 10.1161/01.RES.77.3.510; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shi Y, 2002, CIRC RES, V91, P300, DOI 10.1161/01.RES.0000031799.12850.1E; Song Y, 2001, BIOCHEM J, V355, P357, DOI 10.1042/0264-6021:3550357; Song Y, 2001, AM J PHYSIOL-CELL PH, V281, pC1819, DOI 10.1152/ajpcell.2001.281.6.C1819	24	197	200	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44719	44726		10.1074/jbc.M302836200	http://dx.doi.org/10.1074/jbc.M302836200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12952971	hybrid			2022-12-25	WOS:000186306700105
J	Shaw, N; Elholm, M; Noy, N				Shaw, N; Elholm, M; Noy, N			Retinoic acid is a high affinity selective ligand for the peroxisome proliferator-activated receptor beta/delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED GROWTH ARREST; BREAST-CANCER CELLS; BINDING-PROTEINS; X-RECEPTOR; ECTOPIC EXPRESSION; NUCLEAR RECEPTORS; INDUCED APOPTOSIS; EPITHELIAL-CELLS; FATTY-ACIDS; DIFFERENTIATION	Retinoic acid (RA) modulates transcription of numerous target genes, thereby regulating a myriad of biological processes. It is well established that RA functions by activating retinoic acid receptors (RARs), which, in turn, control cell differentiation, proliferation, and apoptosis. However, perplexing reports of diverse and sometime opposing actions of RA have been published. Hence, while RA induces apoptosis and inhibits cell growth in some settings, it potentiates proliferation and acts as an anti-apoptotic agent in others. These observations raise the possibility that signaling pathways other than RAR may be involved in mediating RA activities. Here we show that RA is a high affinity ligand for another nuclear receptor, namely the orphan receptor peroxisome proliferator-activated receptor (PPAR) beta/delta. We demonstrate that while RA does not activate PPARalpha and PPARgamma, it binds to PPARbeta/delta with nanomolar affinity, modulates the conformation of the receptor, promotes interaction with the coactivator SRC-1, and efficiently activates PPARbeta/delta-mediated transcription. Transcriptional signaling by RA is thus exerted by a dual pathway, providing a rationale for understanding divergent cellular responses to this hormone.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	Cornell University	Noy, N (corresponding author), Cornell Univ, Div Nutr Sci, 225 Savage Hall, Ithaca, NY 14853 USA.							Ahlemeyer B, 2000, J NEUROSCI RES, V60, P767, DOI 10.1002/1097-4547(20000615)60:6<767::AID-JNR9>3.3.CO;2-Y; ALLAN GF, 1992, J BIOL CHEM, V267, P19513; BREITMAN TR, 1981, BLOOD, V57, P1000; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; Dong D, 1999, J BIOL CHEM, V274, P23695, DOI 10.1074/jbc.274.34.23695; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; Evans TRJ, 1999, BRIT J CANCER, V80, P1, DOI 10.1038/sj.bjc.6690312; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Jinno H, 2002, INT J ONCOL, V21, P127; Jorgensen C, 2002, ANN NY ACAD SCI, V967, P431; KERSTEN S, 1995, BIOCHEMISTRY-US, V34, P14263, DOI 10.1021/bi00043a034; Kersten S, 1997, J BIOL CHEM, V272, P29759, DOI 10.1074/jbc.272.47.29759; KISTLER A, 1986, CARCINOGENESIS, V7, P1175, DOI 10.1093/carcin/7.7.1175; Kitamura M, 2002, NEPHROL DIAL TRANSPL, V17, P84, DOI 10.1093/ndt/17.suppl_9.84; KOMURA H, 1986, ENDOCRINOLOGY, V118, P1530, DOI 10.1210/endo-118-4-1530; Lee HY, 1996, CELL GROWTH DIFFER, V7, P997; Lin QO, 1999, BIOCHEMISTRY-US, V38, P185, DOI 10.1021/bi9816094; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Mangelsdorf David J., 1994, P319; Miller WH, 1998, CANCER, V83, P1471, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1471::AID-CNCR1>3.0.CO;2-6; Niu MY, 2001, ONCOGENE, V20, P3506, DOI 10.1038/sj.onc.1204453; NORRIS AW, 1994, BBA-PROTEIN STRUCT M, V1209, P10, DOI 10.1016/0167-4838(94)90130-9; Raffo P, 2000, ANTICANCER RES, V20, P1535; Rohwedel J, 1999, CELLS TISSUES ORGANS, V165, P190, DOI 10.1159/000016699; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Saluja I, 2001, GLIA, V33, P191, DOI 10.1002/1098-1136(200103)33:3<191::AID-GLIA1018>3.0.CO;2-M; Sapi E, 1999, CANCER RES, V59, P5578; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Tan NS, 2002, MOL CELL BIOL, V22, P5114, DOI 10.1128/MCB.22.14.5114-5127.2002; Tan NS, 2001, GENE DEV, V15, P3263, DOI 10.1101/gad.207501; Westin S, 2000, ADV PHARMACOL, V47, P89; Wightman J, 2002, MOL CANCER THER, V1, P493; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Yen A, 1998, CANCER RES, V58, P3163; Zhao Q, 2000, J MOL BIOL, V296, P509, DOI 10.1006/jmbi.1999.3457	39	184	189	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41589	41592		10.1074/jbc.C300368200	http://dx.doi.org/10.1074/jbc.C300368200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12963727	hybrid			2022-12-25	WOS:000185989500005
J	Copland, JA; Luxon, BA; Ajani, L; Maity, T; Campagnaro, E; Guo, HP; LeGrand, SN; Tamboli, P; Wood, CG				Copland, JA; Luxon, BA; Ajani, L; Maity, T; Campagnaro, E; Guo, HP; LeGrand, SN; Tamboli, P; Wood, CG			Genomic profiling identifies alterations in TGF beta signaling through loss of TGF beta receptor expression in human renal cell carcinogenesis and progression	ONCOGENE			English	Article						TGF beta, type III TGF beta receptor, type II TGF beta; receptor, renal cell carcinoma; carcinogenesis; metastasis	GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; II RECEPTOR; CARCINOMA; AUTOCRINE; PROLIFERATION; INACTIVATION; BETAGLYCAN; PATTERNS; CULTURE	Renal cell carcinoma (RCC) is a major health issue. Whereas localized disease can be cured surgically, there is no effective therapy for metastatic disease. The development of an effective therapy will require an understanding of the pathways that are important in RCC carcinogenesis and progression. Using genomic profiling of patient-matched tissue, we have identified aberrations in the transforming growth factor beta (TGFbeta) signaling pathway in RCC. We observed loss of type III TGFbeta receptor (TBR3) expression in all RCC samples. This suggests that TBR3 loss is an early event in RCC carcinogenesis and plays a sentinel role in the acquisition of a tumorigenic phenotype. We also observed subsequent loss of type II TGFbeta receptor (TBR2) expression in metastatic RCCs. We propose that loss of TBR3 is necessary for RCC carcinogenesis, and that loss of TBR2 leads to acquisition of a metastatic phenotype. To this end, we have identified a human renal cell carcinoma tine (UMRC6) that is representative of localized, nonmetastatic RCC, reflecting a loss of TBR3, but not TBR2 expression. Another cell line, UMRC3, is highly metastatic, having lost TBR3 and TBR2 expression. We demonstrate functional loss of TGFbeta responsiveness in these cell lines as observed through phenotypic and transcriptional responsiveness to exogenous TGFbeta. Restoring TBR2 and TBR3 expression in UMRC3 cells attenuates cell proliferation, completely restores TGFbeta-mediated transcriptional responses, and completely blocks anchorage independent-growth: while restoration of TBR2 partially restores TGFbeta-mediated signaling. Based on these data, we propose that dysregulation in TGFbeta signaling, through stepwise loss in receptor expression, plays a prominent role in RCC carcinogenesis and progression. In addition, these studies unequivocably demonstrate a link between loss of TBR3 and a human disease.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Urol & Canc Biol, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Internal Med, Div Endocrinol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Bioinformat Program, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Wood, CG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Urol, Box 446,1515 Holcombe Blvd, Houston, TX 77030 USA.	cgwood@mdanderson.org	Luxon, Bruce A/C-9140-2012	Campagnaro, Erica/0000-0003-3820-3260				Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Allander SV, 2001, CANCER RES, V61, P8624; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Bottinger EP, 2002, J AM SOC NEPHROL, V13, P2600, DOI 10.1097/01.ASN.0000033611.79556.AE; BOYD FT, 1989, J BIOL CHEM, V264, P2272; Boyer AS, 2001, DEV DYNAM, V221, P454, DOI 10.1002/dvdy.1154; Cardillo MR, 2001, ANAL QUANT CYTOL, V23, P109; Chen CG, 1997, J BIOL CHEM, V272, P12862, DOI 10.1074/jbc.272.19.12862; Copland JA, 2003, RECENT PROG HORM RES, V58, P25, DOI 10.1210/rp.58.1.25; DEDIR A, 1996, CLIN BIOCHEM, V29, P385; Deng XB, 1999, CELL GROWTH DIFFER, V10, P11; DeRisi J, 1996, NAT GENET, V14, P457; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Engel JD, 1999, UROLOGY, V54, P164, DOI 10.1016/S0090-4295(99)00093-X; Esparza-Lopez J, 2001, J BIOL CHEM, V276, P14588, DOI 10.1074/jbc.M008866200; Gilbert RE, 1998, DIABETES, V47, P414, DOI 10.2337/diabetes.47.3.414; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; GROSSMAN HB, 1985, J SURG ONCOL, V28, P237; Hegele A, 2003, UROL RES, V30, P363, DOI 10.1007/s00240-002-0280-3; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kundu SD, 1998, J UROLOGY, V160, P1883, DOI 10.1016/S0022-5347(01)62437-6; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moustakas A, 2001, J CELL SCI, V114, P4359; Ramp U, 1997, J UROLOGY, V157, P2345, DOI 10.1016/S0022-5347(01)64778-5; Ramp U, 1997, LAB INVEST, V76, P739; Sakharova OV, 2001, CURR OPIN NEPHROL HY, V10, P727, DOI 10.1097/00041552-200111000-00001; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schiemann WP, 2002, J BIOL CHEM, V277, P27367, DOI 10.1074/jbc.M200148200; Sens DA, 1999, EXP NEPHROL, V7, P344; Sun LZ, 1997, J BIOL CHEM, V272, P25367, DOI 10.1074/jbc.272.40.25367; Takahashi M, 2001, P NATL ACAD SCI USA, V98, P9754, DOI 10.1073/pnas.171209998; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Terzi F, 2000, J CLIN INVEST, V106, P225, DOI 10.1172/JCI8315; Trifillis AL, 1999, EXP NEPHROL, V7, P353; Wogensen L, 1999, DIABETES, V48, P182, DOI 10.2337/diabetes.48.1.182; Wunderlich H, 1998, UROL INT, V60, P205, DOI 10.1159/000030255; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	43	87	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					8053	8062		10.1038/sj.onc.1206835	http://dx.doi.org/10.1038/sj.onc.1206835			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970754				2022-12-25	WOS:000185388200021
J	Bublin, M; Radauer, C; Wilson, IBH; Kraft, D; Scheiner, O; Breiteneder, H; Hoffmann-Sommergruber, K				Bublin, M; Radauer, C; Wilson, IBH; Kraft, D; Scheiner, O; Breiteneder, H; Hoffmann-Sommergruber, K			Cross-reactive N-glycans of Api g 5, a high molecular weight glycoprotein allergen from celery, are required for immunoglobulin E binding and activation of effector cells from allergic patients	FASEB JOURNAL			English	Article						type I hypersensitivity; food allergy; pollen allergy; berberine bridge enzyme	CORE ALPHA-1,3-LINKED FUCOSE; CARBOHYDRATE DETERMINANTS; MAJOR ALLERGEN; LINKED OLIGOSACCHARIDES; APIUM-GRAVEOLENS; BIRCH POLLEN; IGE-BINDING; TREE POLLEN; MUGWORT; EPITOPE	Allergy diagnosis relying on the determination of specific IgE is frequently complicated by the presence of cross-reacting IgE of unclear clinical relevance. Particularly, the anaphylactogenic activity of IgE directed to cross-reactive carbohydrate moieties of glycoproteins from plants and invertebrates has been a matter of debate. In this study, we present the biochemical and immunological characterization of Api g 5, a glycoprotein allergen from celery with homology to FAD containing oxidases. Carbohydrate analysis of the allergen revealed the presence of glycans carrying fucosyl and xylosyl residues, structures previously shown to bind IgE. Chemical deglycosylation of the protein completely abolished binding of serum IgE from all 14 patients tested. Likewise, basophils from a patient allergic to mugwort pollen and celery were stimulated only by native Api g 5, whereas the deglycosylated allergen did not trigger release of histamine. IgE inhibition immunoblots showed that native Api g 5 other than the deglycosylated protein completely inhibited IgE binding to high molecular weight allergens in protein extracts from birch pollen, mugwort pollen, and celery. A similar inhibition was accomplished using the IgE binding oligosaccharide, MUXF, coupled to bovine serum albumin. All these observations taken together confer convincing evidence that IgE directed to cross-reactive carbohydrates is capable of eliciting allergic reactions in vivo.	Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Agr Univ Vienna, Inst Chem, A-1190 Vienna, Austria	University of Vienna; University of Natural Resources & Life Sciences, Vienna	Hoffmann-Sommergruber, K (corresponding author), AKH EBO, 3Q,Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	Karin.Hoffmann@akh-wien.ac.at	Wilson, Iain/B-3326-2009; Radauer, Christian/AAN-6260-2021	Wilson, Iain/0000-0001-8996-1518; Radauer, Christian/0000-0001-9920-4449; Bublin, Merima/0000-0002-7191-9431; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Aalberse RC, 1998, ALLERGY, V53, P54, DOI 10.1111/j.1398-9995.1998.tb04940.x; Aalberse RC, 1997, CLIN REV ALLERG IMMU, V15, P375, DOI 10.1007/BF02737733; Batanero E, 1999, J ALLERGY CLIN IMMUN, V103, P147, DOI 10.1016/S0091-6749(99)70538-5; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; Chardin H, 2001, INT ARCH ALLERGY IMM, V125, P128, DOI 10.1159/000053806; DITTRICH H, 1991, P NATL ACAD SCI USA, V88, P9969, DOI 10.1073/pnas.88.22.9969; FORSBECK M, 1979, CONTACT DERMATITIS, V5, P191, DOI 10.1111/j.1600-0536.1979.tb04839.x; Fotisch K, 1999, INT ARCH ALLERGY IMM, V120, P30, DOI 10.1159/000024217; Fotisch K, 2001, GLYCOCONJUGATE J, V18, P373, DOI 10.1023/A:1014860030380; Ganglberger E, 2000, CLIN EXP ALLERGY, V30, P566, DOI 10.1046/j.1365-2222.2000.00773.x; Hoffmann-Sommergruber K, 2000, INT ARCH ALLERGY IMM, V122, P155, DOI 10.1159/000024392; Iacovacci P., 2002, Clinical and Experimental Allergy, V32, P1620, DOI 10.1046/j.1365-2222.2002.01516.x; JANKIEWICZ A, 1998, ALLERGO J, V7, P87; Kolarich D, 2000, ANAL BIOCHEM, V285, P64, DOI 10.1006/abio.2000.4737; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; Lerouge P, 1998, PLANT MOL BIOL, V38, P31, DOI 10.1023/A:1006012005654; Liaw SH, 2001, BIOCHEM BIOPH RES CO, V280, P738, DOI 10.1006/bbrc.2000.4203; Luttkopf D, 2000, J ALLERGY CLIN IMMUN, V106, P390, DOI 10.1067/mai.2000.108711; Mari A, 1999, J ALLERGY CLIN IMMUN, V103, P1005, DOI 10.1016/S0091-6749(99)70171-5; PAULI G, 1985, CLIN ALLERGY, V15, P273, DOI 10.1111/j.1365-2222.1985.tb02285.x; RINK E, 1975, FEBS LETT, V49, P396, DOI 10.1016/0014-5793(75)80794-0; Scheurer S, 2000, CLIN EXP ALLERGY, V30, P962, DOI 10.1046/j.1365-2222.2000.00821.x; SOJAR HT, 1987, ARCH BIOCHEM BIOPHYS, V259, P52, DOI 10.1016/0003-9861(87)90469-3; Su SN, 1996, J ALLERGY CLIN IMMUN, V98, P486, DOI 10.1016/S0091-6749(96)70080-5; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; VALLIER P, 1988, CLIN ALLERGY, V18, P491, DOI 10.1111/j.1365-2222.1988.tb02899.x; van Ree R, 2002, INT ARCH ALLERGY IMM, V129, P189, DOI 10.1159/000066770; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; Vieths S, 2002, ALLERGY, V57, P100, DOI 10.1034/j.1398-9995.57.s72.20.x; VIETHS S, 1997, ARBEITEN P EHRLICH I, V91, P250; Wilson IBH, 2001, GLYCOBIOLOGY, V11, P261, DOI 10.1093/glycob/11.4.261; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651; Wilson IBH, 1998, GLYCOCONJUGATE J, V15, P1055, DOI 10.1023/A:1006960401562; WUTHRICH B, 1985, SCHWEIZ MED WSCHR, V115, P358; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x; WUTHRICH B, 1993, ALLERGOLOGIE, V16, P280	40	91	95	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1697	+		10.1096/fj.02-0872fje	http://dx.doi.org/10.1096/fj.02-0872fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958180				2022-12-25	WOS:000184471600009
J	Imagawa, S; Nakano, Y; Obara, N; Suzuki, N; Doi, T; Kodama, T; Nagasawa, T; Yamamoto, M				Imagawa, S; Nakano, Y; Obara, N; Suzuki, N; Doi, T; Kodama, T; Nagasawa, T; Yamamoto, M			A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1 beta, TNF-alpha, or L-NMMA	FASEB JOURNAL			English	Article						interleukin-1 beta; N-G-monomethyl-L-arginine; tumor necrosis factor-alpha; erythropoietin	TUMOR-NECROSIS-FACTOR; RECOMBINANT-HUMAN-ERYTHROPOIETIN; SERUM IMMUNOREACTIVE ERYTHROPOIETIN; MONOMETHYL-L-ARGININE; RHEUMATOID-ARTHRITIS; GENE-EXPRESSION; INFLAMMATORY CYTOKINES; CHRONIC DISORDERS; INTERLEUKIN-1; SUPPRESSION	Interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), or N-G-monomethyl-L-arginine (L-NMMA) are increased in patients with chronic disease-related anemia. They increase the binding activity of GATA and inhibit erythropoietin (Epo) promoter activity. In this study, we examined the ability of K-7174 (a GATA-specific inhibitor) to improve Epo production when inhibited by treatment with IL-1beta, TNF-alpha, or L-NMMA. Epo protein production and promoter activity were induced in Hep3B cells with 1% O-2. However, 15 U/ml IL-1beta, 220 U/ml TNF-alpha, or 10(-3) M L-NMMA inhibited Epo protein production and promoter activity, respectively. Addition of 10 muM K-7174 rescued these inhibitions of Epo protein production and promoter activity induced by IL-1beta, TNF-alpha, or L-NMMA, respectively. Electrophoretic mobility shift assays revealed that addition of K-7174 decreased GATA binding activity, which was increased with the addition of IL-1beta, TNF-alpha, or L-NMMA. Furthermore, intraperitoneal injection of mice with IL-1beta or TNF-alpha decreased the hemoglobin concentrations and reticulocyte counts. However, the addition of K-7174 reversed these effects. These results raise the possibility of using K-7174 as therapy to treat anemia.	Univ Tsukuba, Div Hematol, Inst Clin Med, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan; Kowa Co Ltd, Kowa Res Inst, Tokyo 1038433, Japan; Univ Tokyo, Lab Syst Biol, Tokyo 1538904, Japan; Univ Tokyo, Med Res Ctr Adv Sci & Technol, Tokyo 1538904, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; Kowa Company, Ltd.; University of Tokyo; University of Tokyo	Imagawa, S (corresponding author), Univ Tsukuba, Div Hematol, Inst Clin Med, Tsukuba, Ibaraki 3058575, Japan.	simagawa@md.tsukuba.ac.jp	Suzuki, Norio/AAZ-9458-2021; Yamamoto, Masayuki/A-4873-2010; Suzuki, Norio/F-3456-2010	Suzuki, Norio/0000-0001-6100-3350; Yamamoto, Masayuki/0000-0002-9073-9436; 				BAER AN, 1987, BRIT J HAEMATOL, V66, P559, DOI 10.1111/j.1365-2141.1987.tb01344.x; BENDTZEN K, 1988, IMMUNOL LETT, V19, P183, DOI 10.1016/0165-2478(88)90141-1; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; CLINBON U, 1990, EXP HEMATOL, V18, P438; DINARELLO CA, 1989, CYTOKINES, V1, P105; DOUGLAS SW, 1975, BLOOD, V45, P55; DOWTON SB, 1988, SEMIN HEMATOL, V25, P84; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; FAQUIN W C, 1992, Blood, V79, P1987; FISCHL M, 1990, NEW ENGL J MED, V322, P1488, DOI 10.1056/NEJM199005243222103; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; HOCHBERG MC, 1988, ARTHRITIS RHEUM, V31, P1318, DOI 10.1002/art.1780311016; IMAGAWA S, 1991, BLOOD, V77, P278; Imagawa S, 1997, BLOOD, V89, P1430, DOI 10.1182/blood.V89.4.1430; JELKMANN W, 1992, LIFE SCI, V50, P301, DOI 10.1016/0024-3205(92)90338-P; JOHANNSEN H, 1989, EUR J HAEMATOL, V43, P201; JOHNSON CS, 1990, EXP HEMATOL, V18, P109; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; La Ferla K, 2002, FASEB J, V16, P1811, DOI 10.1096/fj.02-0168fje; LEE GR, 1983, SEMIN HEMATOL, V20, P61; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; LUDWIG H, 1990, NEW ENGL J MED, V322, P1693, DOI 10.1056/NEJM199006143222402; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; MEANS RT, 1989, ARTHRITIS RHEUM-US, V32, P638, DOI 10.1002/anr.1780320519; MEANS RT, 1990, J CLIN INVEST, V86, P538, DOI 10.1172/JCI114741; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MILLER CB, 1990, NEW ENGL J MED, V322, P1689, DOI 10.1056/NEJM199006143222401; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Papadaki HA, 2002, BLOOD, V100, P474, DOI 10.1182/blood-2002-01-0136; PINCUS T, 1990, AM J MED, V89, P161, DOI 10.1016/0002-9343(90)90294-N; REIFF RH, 1958, AM J CLIN PATHOL, V30, P199, DOI 10.1093/ajcp/30.3.199; Ribeiro ACM, 1996, EXP PHYSIOL, V81, P475, DOI 10.1113/expphysiol.1996.sp003950; RUDNICK S, 1990, P AN M AM SOC CLIN, V9, P182; Sano Y, 2001, J BIOL CHEM, V276, P3674, DOI 10.1074/jbc.M006896200; SCHOOLEY JC, 1987, BRIT J HAEMATOL, V67, P11, DOI 10.1111/j.1365-2141.1987.tb02289.x; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Silva Maite, 1996, Blood, V88, P1576; SPIVAK JL, 1989, JAMA-J AM MED ASSOC, V261, P3104, DOI 10.1001/jama.261.21.3104; Tarumoto T, 2000, BLOOD, V96, P1716, DOI 10.1182/blood.V96.5.1716.h8001716_1716_1722; ULICH TR, 1990, EXP HEMATOL, V18, P311; Umetani M, 2000, BIOCHEM BIOPH RES CO, V272, P370, DOI 10.1006/bbrc.2000.2784; Whyatt D, 2000, NATURE, V406, P519, DOI 10.1038/35020086; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZARRABI MH, 1977, BRIT J HAEMATOL, V35, P647, DOI 10.1111/j.1365-2141.1977.tb00628.x	46	55	57	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1742	+		10.1096/fj.02-1134fje	http://dx.doi.org/10.1096/fj.02-1134fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958195				2022-12-25	WOS:000184471600012
J	Murphy, MP; Echtay, KS; Blaikie, FH; Asin-Cayuela, J; Cocheme, HM; Green, K; Buckingham, JA; Taylor, ER; Hurrell, F; Hughes, G; Miwa, S; Cooper, CE; Svistunenko, DA; Smith, RAJ; Brand, MD				Murphy, MP; Echtay, KS; Blaikie, FH; Asin-Cayuela, J; Cocheme, HM; Green, K; Buckingham, JA; Taylor, ER; Hurrell, F; Hughes, G; Miwa, S; Cooper, CE; Svistunenko, DA; Smith, RAJ; Brand, MD			Superoxide activates uncoupling proteins by generating carbon-centered radicals and initiating lipid peroxidation - Studies using a mitochondria-targeted spin trap derived from alpha-phenyl-N-tert-butylnitrone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; OXIDATIVE STRESS; HYDROXYL RADICALS; BUTYL NITRONE; IN-VIVO; ANTIOXIDANTS; ACONITASE; DEOXYRIBOSE; UBIQUINONE; ELECTRODE	Although the physiological role of uncoupling proteins (UCPs) 2 and 3 is uncertain, their activation by superoxide and by lipid peroxidation products suggest that UCPs are central to the mitochondrial response to reactive oxygen species. We examined whether superoxide and lipid peroxidation products such as 4-hydroxy-2- trans-nonenal act independently to activate UCPs, or if they share a common pathway, perhaps by superoxide exposure leading to the formation of lipid peroxidation products. This possibility can be tested by blocking the putative reactive oxygen species cascade with selective antioxidants and then reactivating UCPs with distal cascade components. We synthesized a mitochondria-targeted derivative of the spin trap alpha-phenyl-N-tert-butylnitrone, which reacts rapidly with carbon-centered radicals but is unreactive with superoxide and lipid peroxidation products. [4-[4-[[(1,1-Dimethylethyl)oxidoimino] methyl] phenoxy] butyl] triphenylphosphonium bromide (MitoPBN) prevented the activation of UCPs by superoxide but did not block activation by hydroxynonenal. This was not due to MitoPBN reacting with superoxide or the hydroxyl radical or by acting as a chain-breaking antioxidant. MitoPBN did react with carbon-centered radicals and also prevented lipid peroxidation by the carbon-centered radical generator 2,2'-azobis( 2-methyl propionamidine) dihydrochloride ( AAPH). Furthermore, AAPH activated UCPs, and this was blocked by MitoPBN. These data suggest that superoxide and lipid peroxidation products share a common pathway for the activation of UCPs. Superoxide releases iron from iron-sulfur center proteins, which then generates carbon-centered radicals that initiate lipid peroxidation, yielding breakdown products that activate UCPs.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Otago, Dept Chem, Dunedin, New Zealand; Univ Otago, Dept Biochem, Dunedin, New Zealand; Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Otago; University of Otago; University of Essex	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.		Cooper, Chris/AAK-9729-2020; Murphy, Michael P/C-2120-2009; Brand, Martin D/A-9423-2012	Cooper, Chris/0000-0003-0381-3990; Murphy, Michael P/0000-0003-1115-9618; Brand, Martin D/0000-0003-4418-6153; Miwa, Satomi/0000-0002-1239-1198; Svistunenko, Dimitri/0000-0001-8060-2738; Cocheme, Helena/0000-0001-8637-0042				AIKENS J, 1991, J BIOL CHEM, V266, P15091; Atamna H, 2000, J BIOL CHEM, V275, P6741, DOI 10.1074/jbc.275.10.6741; AZZONE GF, 1984, CURR TOP BIOENERG, V13, P1; Barclay LRC, 2000, FREE RADICAL BIO MED, V28, P1079, DOI 10.1016/S0891-5849(00)00197-0; Brand M. D., 1995, BIOENERGETICS, V154, P62; Brand MD, 2002, BIOCHEM J, V368, P597, DOI 10.1042/BJ20021077; BRAND MD, 2003, IN PRESS BIOCH SOC S; BROWN GC, 1985, BIOCHEM J, V225, P399, DOI 10.1042/bj2250399; Chappell J. B., 1972, SUBCELLULAR COMPONEN, P77; COOPER CE, 1994, FREE RADICAL RES, V20, P219, DOI 10.3109/10715769409147518; DAVEY GP, 1992, BIOCHEM J, V288, P439, DOI 10.1042/bj2880439; Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FIESER LF, 1967, REAGENTS ORGANIC SYN, V1, P1276; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076-6879(02)49317-2; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GREENSTOCK CL, 1982, CAN J CHEM, V60, P1560, DOI 10.1139/v82-503; GUTTERIDGE JMC, 1987, BIOCHEM J, V243, P709, DOI 10.1042/bj2430709; HAFNER RP, 1990, BIOCHEM J, V265, P731, DOI 10.1042/bj2650731; HAFNER RP, 1988, BIOCHEM J, V250, P477, DOI 10.1042/bj2500477; HALLIWELL B, 1987, ANAL BIOCHEM, V165, P215, DOI 10.1016/0003-2697(87)90222-3; HINTON RD, 1992, J ORG CHEM, V57, P2646, DOI 10.1021/jo00035a020; James AM, 2003, EUR J BIOCHEM, V270, P2827, DOI 10.1046/j.1432-1033.2003.03660.x; JANZEN EG, 1992, TETRAHEDRON LETT, V33, P1257, DOI 10.1016/S0040-4039(00)91595-8; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kotake Y, 1999, ANTIOXID REDOX SIGN, V1, P481, DOI 10.1089/ars.1999.1.4-481; LI ASW, 1988, J MAGN RESON, V79, P140, DOI 10.1016/0022-2364(88)90329-0; Lin TK, 2002, J BIOL CHEM, V277, P17048, DOI 10.1074/jbc.M110797200; Nedergaard J, 2003, EXP PHYSIOL, V88, P65, DOI 10.1113/eph8802502; OHTO N, 1977, J CHEM SOC P2, V13, P1770; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; POU S, 1994, ANAL BIOCHEM, V217, P76, DOI 10.1006/abio.1994.1085; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; ROSE IA, 1967, J BIOL CHEM, V242, P1870; ROSEN GM, 1999, FREE RADICALS BIOL D, P442; SAWYER DT, 1981, ACCOUNTS CHEM RES, V14, P393, DOI 10.1021/ar00072a005; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P19771; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x; Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100; SMITH RAJ, 2004, IN PRESS METHODS ENZ; SRIDHAR R, 1986, J RADIOAN NUCL CH AR, V101, P227, DOI 10.1007/BF02042423; TRIBBLE DL, 1994, P NATL ACAD SCI USA, V91, P1183, DOI 10.1073/pnas.91.3.1183; Vasquez-Vivar J, 2000, J BIOL CHEM, V275, P14064, DOI 10.1074/jbc.275.19.14064; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Welch KD, 2002, ARCH BIOCHEM BIOPHYS, V397, P360, DOI 10.1006/abbi.2001.2694; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	56	268	275	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48534	48545		10.1074/jbc.M308529200	http://dx.doi.org/10.1074/jbc.M308529200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12972420	hybrid			2022-12-25	WOS:000186829000005
J	Broos, J; Gabellieri, E; van Boxel, GI; Jackson, JB; Strambini, GB				Broos, J; Gabellieri, E; van Boxel, GI; Jackson, JB; Strambini, GB			Tryptophan phosphorescence spectroscopy reveals that a domain in the NAD(H)-binding component (dI) of transhydrogenase from Rhodospirillum rubrum has an extremely rigid and conformationally homogeneous protein core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING TRANSHYDROGENASE; NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; NADP(H)-BINDING COMPONENT; HYDRIDE TRANSFER; GLUTAMATE-DEHYDROGENASE; CRYSTAL-STRUCTURE; ALTERNATING-SITE; BINDING; LUMINESCENCE; RECOMBINANT	The characteristics of tryptophan phosphorescence from the NAD(H)-binding component (dI) component of Rhodospirillum rubrum transhydrogenase are described. This enzyme couples hydride transfer between NAD( H) and NADP( H) to proton translocation across a membrane and is only active as a dimer. Tryptophan phosphorescence spectroscopy is a sensitive technique for the detection of protein conformational changes and was used here to characterize dI under mechanistically relevant conditions. Our results indicate that the single tryptophan in dI, Trp-72, is embedded in a rigid, compact, and homogeneous protein matrix that efficiently suppresses collisional quenching processes and results in the longest triplet lifetime for Trp ever reported in a protein at ambient temperature (2.9 s). The protein matrix surrounding Trp-72 is extraordinarily rigid up to 50degreesC. In all previous studies on Trp-containing proteins, changes in structure were reflected in a different triplet lifetime. In dI, the lifetime of Trp-72 phosphorescence was barely affected by protein dimerization, cofactor binding, complexation with the NADP(H)-binding component (dIII), or by the introduction of two amino acid substitutions at the hydride-transfer site. It is suggested that the rigidity and structural invariance of the protein domain ( dI. 1) housing this Trp residue are important to the mechanism of transhydrogenase: movement of dI. 1 affects the width of a cleft which, in turn, regulates the positioning of bound nucleotides ready for hydride transfer. The unique protein core in dI may be a paradigm for the design of compact and stable de novo proteins.	Univ Birmingham, Sch Biochem, Birmingham B15 2TT, W Midlands, England; Univ Groningen, Dept Biochem, NL-9747 AG Groningen, Netherlands; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; CNRS, Inst Biofis, Area Ric Pisa, I-56010 Pisa, Italy	University of Birmingham; University of Groningen; University of Groningen	Jackson, JB (corresponding author), Univ Birmingham, Sch Biochem, POB 363, Birmingham B15 2TT, W Midlands, England.			Gabellieri, Edi/0000-0003-0750-4095				Buckley PA, 2000, STRUCTURE, V8, P809, DOI 10.1016/S0969-2126(00)00171-4; Cioni P, 1998, J AM CHEM SOC, V120, P11749, DOI 10.1021/ja9820543; CIONI P, 1994, J MOL BIOL, V242, P291, DOI 10.1006/jmbi.1994.1579; CIONI P, 1994, BIOPHYS CHEM, V52, P25, DOI 10.1016/0301-4622(94)00039-5; CIONI P, 1989, J MOL BIOL, V207, P237, DOI 10.1016/0022-2836(89)90453-1; Cotton NPJ, 2001, STRUCTURE, V9, P165, DOI 10.1016/S0969-2126(01)00571-8; DIGGLE C, 1995, EUR J BIOCHEM, V228, P719, DOI 10.1111/j.1432-1033.1995.0719m.x; Diggle C, 1996, EUR J BIOCHEM, V241, P162, DOI 10.1111/j.1432-1033.1996.0162t.x; Gabellieri E, 1996, BIOCHEMISTRY-US, V35, P12549, DOI 10.1021/bi960231b; GALLEY WC, 1976, BIOCH FLUORESCENCE C, P409; GONNELLI M, 1995, BIOCHEMISTRY-US, V34, P13847, DOI 10.1021/bi00042a017; HERSHBERGER MV, 1980, BIOCHEMISTRY-US, V19, P2204, DOI 10.1021/bi00551a032; Jackson JB, 2002, BIOCHEMISTRY-US, V41, P4173, DOI 10.1021/bi012078d; Kerwin BA, 2002, PROTEIN SCI, V11, P1825, DOI 10.1110/ps.0208102; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P4475, DOI 10.1021/bi00314a037; Prasad GS, 1999, NAT STRUCT BIOL, V6, P1126; Prasad GS, 2002, BIOCHEMISTRY-US, V41, P12745, DOI 10.1021/bi020251f; Quirk PG, 1999, FEBS LETT, V446, P127, DOI 10.1016/S0014-5793(99)00198-2; Quirk PG, 1999, BBA-BIOENERGETICS, V1412, P139, DOI 10.1016/S0005-2728(99)00057-2; Rodrigues DJ, 2001, EUR J BIOCHEM, V268, P1430, DOI 10.1046/j.1432-1327.2001.02008.x; Schauerte JA, 1997, METHOD ENZYMOL, V278, P49; STRAMBINI GB, 1995, J AM CHEM SOC, V117, P7646, DOI 10.1021/ja00134a008; Strambini GB, 1999, J AM CHEM SOC, V121, P8337, DOI 10.1021/ja9915596; STRAMBINI GB, 1992, BIOCHEMISTRY-US, V31, P7535, DOI 10.1021/bi00148a014; Strambini GB, 1996, BIOPHYS J, V70, P971, DOI 10.1016/S0006-3495(96)79640-6; STRAMBINI GB, 1991, J PHYS CHEM-US, V95, P4347, DOI 10.1021/j100164a033; STRAMBINI GB, 1989, BIOCHEMISTRY-US, V28, P3808, DOI 10.1021/bi00435a028; STRAMBINI GB, 1990, BIOCHEMISTRY-US, V29, P196, DOI 10.1021/bi00453a027; van Boxel GI, 2003, BIOCHEMISTRY-US, V42, P1217, DOI 10.1021/bi027032e; VANDERKOOI JM, 1992, TOPICS FLUORESCENCE, V3, P113; Venning JD, 2001, J BIOL CHEM, V276, P30678, DOI 10.1074/jbc.M104429200; White SA, 2000, STRUCT FOLD DES, V8, P1, DOI 10.1016/S0969-2126(00)00075-7	33	15	16	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47578	47584		10.1074/jbc.M309287200	http://dx.doi.org/10.1074/jbc.M309287200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12972415	hybrid, Green Published			2022-12-25	WOS:000186731400030
J	Kolker, S; Schwab, M; Horster, F; Sauer, S; Hinz, A; Wolf, NI; Mayatepek, E; Hoffmann, GF; Smeitink, JAM; Okun, JG				Kolker, S; Schwab, M; Horster, F; Sauer, S; Hinz, A; Wolf, NI; Mayatepek, E; Hoffmann, GF; Smeitink, JAM; Okun, JG			Methylmalonic acid, a biochemical hallmark of methylmalonic acidurias but no inhibitor of mitochondrial respiratory chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCCINATE-DEHYDROGENASE; CEREBRAL-CORTEX; METABOLISM; MUSCLE; BRAIN; MANAGEMENT; DISORDERS; BINDING; LESIONS; LIVER	Methylmalonic acidurias are biochemically characterized by an accumulation of methylmalonic acid and alternative metabolites. An impairment of energy metabolism plays a key role in the pathophysiology of this disease, resulting in neurodegeneration of the basal ganglia and renal failure. It has become the subject of intense debates whether methylmalonic acid is the major toxin, inhibiting respiratory chain complex II. To elucidate whether methylmalonic acid is a respiratory chain inhibitor, we used spectrophotometric analysis of complex II activity in submitochondrial particles from bovine heart, radiometric analysis of C-14-labeled substrates ( pyruvate, malate, succinate), and analysis of ATP production in muscle from mice. Methylmalonic acid revealed no direct effects on the respiratory chain function, i.e. on single electron transferring complexes I-IV, ATPase, and mitochondrial transporters. However, we identified a variety of variables that must be carefully controlled to avoid an artificial inhibition of complex II activity. In summary, the study verifies our hypothesis that methylmalonic acid is not the major toxic metabolite in methylmalonic acidurias. Inhibition of respiratory chain and tricarboxylic acid cycle is most likely induced by synergistically acting alternative metabolites, in particular 2-methylcitric acid, malonic acid, and propionyl-CoA.	Univ Childrens Hosp, Dept Gen Pediat, Div Metab & Endocrine Dis, D-69120 Heidelberg, Germany; Univ Childrens Hosp, Dept Pediat Neurol, D-69120 Heidelberg, Germany; Univ Childrens Hosp, Dept Gen Pediat, D-40225 Dusseldorf, Germany; Univ Med Ctr Nijmegen, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, NL-6500 HB Nijmegen, Netherlands	Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Radboud University Nijmegen	Kolker, S (corresponding author), Univ Childrens Hosp, Div Metab & Endocrine Dis, Neuenheimer Feld 150, D-69115 Heidelberg, Germany.	Stefan_Koelker@med.uni-heidelberg.de	Wolf, Nicole I/H-3943-2014; Smeitink, Jan A.M./D-6064-2011; Smeitink, Jan/C-1351-2013	Wolf, Nicole I/0000-0003-1721-0728; 				ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; BEAL MF, 1993, J NEUROSCI, V13, P4181; Brandt U, 1997, BIOCHEMISTRY-US, V36, P11234, DOI 10.1021/bi970968g; BRISMAR J, 1994, AM J NEURORADIOL, V15, P1459; Brusque AM, 2002, NEUROCHEM INT, V40, P593, DOI 10.1016/S0197-0186(01)00130-9; CHEEMADHADLI S, 1975, PEDIATR RES, V9, P905, DOI 10.1203/00006450-197512000-00008; deMello CF, 1996, BRAIN RES, V721, P120, DOI 10.1016/0006-8993(96)00117-5; DUTRA JC, 1993, J INHERIT METAB DIS, V16, P147, DOI 10.1007/BF00711328; Fenton WA, 2001, METABOLIC MOL BASES, P2165; Fighera MR, 1999, NEUROREPORT, V10, P2039, DOI 10.1097/00001756-199907130-00009; FISCHER JC, 1985, CLIN CHIM ACTA, V145, P89, DOI 10.1016/0009-8981(85)90022-1; GREENE JG, 1993, J NEUROCHEM, V61, P1151, DOI 10.1111/j.1471-4159.1993.tb03634.x; HALPERIN ML, 1971, J CLIN INVEST, V50, P2276, DOI 10.1172/JCI106725; HEIDENREICH R, 1988, J PEDIATR-US, V113, P1022, DOI 10.1016/S0022-3476(88)80574-2; HELENIUS A, 1972, J BIOL CHEM, V247, P3656; Kolker S, 2000, J INHERIT METAB DIS, V23, P355, DOI 10.1023/A:1005631230455; Kolker S, 2001, J NEUROSCI RES, V66, P666, DOI 10.1002/jnr.10012; Larnaout A, 1998, J INHERIT METAB DIS, V21, P639, DOI 10.1023/A:1005428432730; LEDLEY FD, 1988, AM J HUM GENET, V42, P839; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHONEY MJ, 1975, P NATL ACAD SCI USA, V72, P2799, DOI 10.1073/pnas.72.7.2799; MARTIN JJ, 1988, J NEUROL SCI, V84, P189, DOI 10.1016/0022-510X(88)90124-4; McLaughlin BA, 1998, NEUROSCIENCE, V86, P279, DOI 10.1016/S0306-4522(97)00594-0; Narasimhan P, 1996, J NEUROSCI, V16, P7336; OBERHOLZ.VG, 1967, ARCH DIS CHILD, V42, P492, DOI 10.1136/adc.42.225.492; Okun JG, 1999, J BIOL CHEM, V274, P2625, DOI 10.1074/jbc.274.5.2625; Okun JG, 2002, J BIOL CHEM, V277, P14674, DOI 10.1074/jbc.M200997200; RUITENBEEK W, 1981, J INHERIT METAB DIS, V4, P91, DOI 10.1007/BF02263606; SPERL W, 1993, ENZYME PROTEIN, V47, P37, DOI 10.1159/000468654; Srere PA., 1969, METHODS ENZYMOLOGY, P3, DOI DOI 10.1016/0076-6879(69)13005-0; TRIJBELS JMF, 1988, EUR J PEDIATR, V148, P92, DOI 10.1007/BF00445910; Trinh BC, 2001, AM J NEURORADIOL, V22, P831; VANDERMEER SB, 1994, J PEDIATR-US, V125, P903, DOI 10.1016/S0022-3476(05)82005-0; Wajner M, 1997, J INHERIT METAB DIS, V20, P761, DOI 10.1023/A:1005359416197; Wyse ATS, 2000, NEUROREPORT, V11, P2331, DOI 10.1097/00001756-200007140-00052	35	68	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47388	47393		10.1074/jbc.M308861200	http://dx.doi.org/10.1074/jbc.M308861200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12972416	hybrid, Green Published			2022-12-25	WOS:000186731400007
J	Leung, L; Kwong, M; Hou, S; Lee, C; Chan, JY				Leung, L; Kwong, M; Hou, S; Lee, C; Chan, JY			Deficiency of the Nrf1 and Nrf2 transcription factors results in early embryonic lethality and severe oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; GENE-EXPRESSION; TARGETED DISRUPTION; MOUSE DEVELOPMENT; CELL-SURVIVAL; SUBUNIT GENE; FACTOR NF-E2; MICE; INDUCTION; FAMILY	Nrf1 and Nrf2 are members of the CNC family of bZIP transcription factors that exhibit structural similarities, and they are co-expressed in a wide range of tissues during development. Nrf2 has been shown to be dispensable for growth and development in mice. Nrf2-deficient mice, however, are impaired in oxidative stress defense. We previously showed that loss of Nrf1 function in mice results late gestational embryonic lethality. To determine whether Nrf1 and Nrf2 have overlapping functions during early development and in the oxidative stress response, we generated mice that are deficient in both Nrf1 and Nrf2. In contrast to the late embryonic lethality in Nrf1 mutants, compound Nrf1, Nrf2 mutants die early between embryonic days 9 and 10 and exhibit extensive apoptosis that is not observed in the single mutants. Loss of Nrf1 and Nrf2 leads to marked oxidative stress in cells that is indicated by elevated intracellular reactive oxygen species levels and cell death that is reversed by culturing under reduced oxygen tension or the addition of antioxidants. Compound mutant cells also show increased levels of p53 and induction of Noxa, a death effector p53 target gene, suggesting that cell death is potentially mediated by reactive oxygen species activation of p53. Moreover, we show that expression of genes related to antioxidant defense is severely impaired in compound mutant cells compared with single mutant cells. Together, these findings indicate that the functions of Nrf1 and Nrf2 overlap during early development and to a large extent in regulating antioxidant gene expression in cells.	Univ Calif Irvine, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Opt Biol Core Ctr, Irvine, CA 92697 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Francisco	Chan, JY (corresponding author), Univ Calif Irvine, Dept Pathol, D440 Med Sci, Irvine, CA 92697 USA.							AKAZAWA S, 1994, METABOLISM, V43, P830, DOI 10.1016/0026-0495(94)90262-3; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531; Chan D, 2000, AUSTRALAS J AGEING, V19, P26; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1995, HUM GENET, V95, P265; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; CHASE JW, 1972, DEV BIOL, V27, P504, DOI 10.1016/0012-1606(72)90189-3; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; CIACCIO PJ, 1994, J BIOL CHEM, V269, P15558; CLOUGH JR, 1985, BIOCHEM SOC T, V13, P77, DOI 10.1042/bst0130077; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Farmer SC, 1997, GENE DEV, V11, P786, DOI 10.1101/gad.11.6.786; FAVREAU LV, 1993, J BIOL CHEM, V268, P19875; FAVREAU LV, 1995, J BIOL CHEM, V270, P24468, DOI 10.1074/jbc.270.41.24468; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Halliwell B, 1999, FREE RADICAL BIO MED, P105, DOI DOI 10.1093/ACPR0F:0S0/9780198717478.003.0005; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; HOGAN B, 1994, MANIPULATING MOUSE E, P260; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; JAISWAL AK, 1994, PHARMACOGENETICS, V4, P1, DOI 10.1097/00008571-199402000-00001; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Kwong M, 1999, J BIOL CHEM, V274, P37491, DOI 10.1074/jbc.274.52.37491; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Shi ZZ, 2000, P NATL ACAD SCI USA, V97, P5101, DOI 10.1073/pnas.97.10.5101; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wasserman WW, 1997, ARCH BIOCHEM BIOPHYS, V344, P387, DOI 10.1006/abbi.1997.0215; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; [No title captured]	55	232	243	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48021	48029		10.1074/jbc.M308439200	http://dx.doi.org/10.1074/jbc.M308439200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12968018	hybrid			2022-12-25	WOS:000186731400081
J	Godreau, D; Vranckx, R; Maguy, A; Goyenvalle, C; Hatem, SN				Godreau, D; Vranckx, R; Maguy, A; Goyenvalle, C; Hatem, SN			Different isoforms of synapse-associated protein, SAP97, are expressed in the heart and have distinct effects on the voltage-gated K+ channel Kv1.5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE KINASE DOMAINS; POTASSIUM CHANNEL; HUMAN HOMOLOG; DISCS LARGE; MEMBRANE; PSD-95; AGGRESOMES; HDLG; SH3; IDENTIFICATION	The SAP97 isoforms differ by alternatively spliced insertion domains that regulate protein localization and oligomerization. We used reverse transcription-PCR to identify SAP97 isoforms of human and rat myocardium. In Chinese hamster ovary cells, cloned protein expression was studied using Western blot, confocal imaging of green fluorescent protein-tagged proteins, and patch clamp technique. The two main cardiac SAP97 isoforms contained both I3 and I1B inserts and differed by the I1A insert. Both isoforms co-precipitated with hKv1.5 channels. Only the isoform lacking I1A increased the current (by 215+/-22%), whatever the level of channel expression. To examine the involvement of the proline-rich I1A insert in the effect of SAP97, a W623F mutation in the Src homology 3 domain was created, and that restored the effect of the SAP97 on current. SAP97 isoform containing an I1A and I2 domain instead of the I3 domain stimulated the current, whereas SAP97 after deletion of the Src homology 3 and guanylate kinase-like domains did not. In cells co-expressing I3(+I1A) or I3(+I1A), green fluorescent protein-tagged Kv1.5 channels were organized in plaque-like structures at the plasma membrane level, whereas intracellular aggregates of channels predominated with the I2 isoform. The two cardiac SAP97 isoforms have different effects on the hKv1.5 current, depending on their capacity to form channel clusters.	Med Hosp Xavier Bichat Claude Bernard, INSERM, U460, F-75018 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Hatem, SN (corresponding author), Med Hosp Xavier Bichat Claude Bernard, INSERM, U460, 46 Rue Henri Huchard, F-75018 Paris, France.		Maguy, Ange/ABG-9298-2021; Hatem, Stephane/D-1016-2017	hatem, stephane/0000-0002-9790-0755; Maguy, Ange/0000-0003-0170-7430				Bron P, 1999, J STRUCT BIOL, V128, P287, DOI 10.1006/jsbi.1999.4196; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; Eldstrom J, 2002, FEBS LETT, V531, P529, DOI 10.1016/S0014-5793(02)03572-X; Godreau D, 2002, CARDIOVASC RES, V56, P433, DOI 10.1016/S0008-6363(02)00602-8; Godreau D, 2002, J PHARMACOL EXP THER, V300, P612, DOI 10.1124/jpet.300.2.612; Hanada T, 2003, J BIOL CHEM, V278, P34445, DOI 10.1074/jbc.M305209200; Hibino H, 2000, EMBO J, V19, P78, DOI 10.1093/emboj/19.1.78; Horio Y, 1997, J BIOL CHEM, V272, P12885, DOI 10.1074/jbc.272.20.12885; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kohu K, 2002, GENES CELLS, V7, P707, DOI 10.1046/j.1365-2443.2002.00555.x; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Leonoudakis D, 2001, J CELL SCI, V114, P987; Li DQ, 2000, J BIOL CHEM, V275, P11597, DOI 10.1074/jbc.275.16.11597; Lu XY, 2000, BRAIN RES, V863, P143, DOI 10.1016/S0006-8993(00)02112-0; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 2000, J BIOL CHEM, V275, P13759, DOI 10.1074/jbc.275.18.13759; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; McLaughlin M, 2002, J BIOL CHEM, V277, P6406, DOI 10.1074/jbc.M108724200; Murata M, 2001, AM J PHYSIOL-HEART C, V281, pH2575, DOI 10.1152/ajpheart.2001.281.6.H2575; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; Paarmann I, 2002, J BIOL CHEM, V277, P40832, DOI 10.1074/jbc.M205618200; Reuver SM, 1998, J CELL SCI, V111, P1071; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; Wong W, 2002, J BIOL CHEM, V277, P20423, DOI 10.1074/jbc.M109412200; Wu HJ, 2000, EMBO J, V19, P5740, DOI 10.1093/emboj/19.21.5740; Wu HJ, 1998, J CELL SCI, V111, P2365; Zobel ATC, 2003, HUM MOL GENET, V12, P1609, DOI 10.1093/hmg/ddg173	32	35	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47046	47052		10.1074/jbc.M308463200	http://dx.doi.org/10.1074/jbc.M308463200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12970345	hybrid			2022-12-25	WOS:000186569400101
J	Lee, JH; Lau, KF; Perkinton, MS; Standen, CL; Shemilt, SJA; Mercken, L; Cooper, JD; McLoughlin, DM; Miller, CCJ				Lee, JH; Lau, KF; Perkinton, MS; Standen, CL; Shemilt, SJA; Mercken, L; Cooper, JD; McLoughlin, DM; Miller, CCJ			The neuronal adaptor protein X11 alpha reduces A beta levels in the brains of Alzheimer's APPswe Tg2576 transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-PRECURSOR-PROTEIN; PHOSPHOTYROSINE-BINDING DOMAIN; INTRACELLULAR DOMAIN; MUTANT PRESENILIN-1; CYTOPLASMIC DOMAIN; FE65 PROTEIN; MOUSE MODEL; SECRETASE; DISEASE; X11	Increased production and deposition of the 40-42-amino acid beta-amyloid peptide (Abeta) is believed to be central to the pathogenesis of Alzheimer's disease. Abeta is derived from the amyloid precursor protein (APP), but the mechanisms that regulate APP processing to produce Abeta are not fully understood. X11alpha (also known as munc-18-interacting protein-1 (Mint1)) is a neuronal adaptor protein that binds APP and modulates APP processing in transfected non-neuronal cells. To investigate the in vivo effect of X11alpha on Abeta production in the brain, we created transgenic mice that overexpress X11alpha and crossed these with transgenics harboring a familial Alzheimer's disease mutant APP that produces increased levels of Abeta (APPswe Tg2576 mice). Analyses of Abeta levels in the offspring generated from two separate X11alpha founder mice revealed a significant, approximate 20% decrease in Abeta(1-40) in double transgenic mice expressing APPswe/X11alpha compared with APPswe mice. At a key time point in Abeta plaque deposition (8 months old), the number of Abeta plaques was also deceased in APPswe/X11alpha mice. Thus, we report here the first demonstration that X11alpha inhibits Abeta production and deposition in vivo in the brain.	Kings Coll London, Inst Psychiat, Dept Neurosci, London SE5 8AF, England; Kings Coll London, Inst Psychiat, Old Age Psychiat Sect, London SE5 8AF, England; Aventis Pharma, F-94403 Paris, France	University of London; King's College London; University of London; King's College London; Sanofi-Aventis; Sanofi France	Miller, CCJ (corresponding author), Kings Coll London, Inst Psychiat, Dept Neurosci, POB P037De Crespigny Pk,Denmark Hill, London SE5 8AF, England.	chris.miller@iop.kcl.ac.uk	Cooper, Jonathan/V-9962-2019; Miller, Christopher/H-5733-2012; Cooper, Jonathan/C-8117-2009	Cooper, Jonathan/0000-0003-1339-4750; Cooper, Jonathan/0000-0003-1339-4750; Miller, Christopher/0000-0002-5130-1845; McLoughlin, Declan/0000-0003-4574-2799; Lau, Kwok-Fai/0000-0002-0193-1152	Medical Research Council [G0000749] Funding Source: Medline; MRC [G0000749] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Biederer T, 2000, J BIOL CHEM, V275, P39803, DOI 10.1074/jbc.C000656200; Biederer T, 2002, J NEUROSCI, V22, P7340; Bodendorf U, 2002, J NEUROCHEM, V80, P799, DOI 10.1046/j.0022-3042.2002.00770.x; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1999, J NEUROSCI, V19, P1307; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dineley KT, 2002, J BIOL CHEM, V277, P22768, DOI 10.1074/jbc.M200164200; Duff K, 2001, CURR OPIN NEUROL, V14, P441, DOI 10.1097/00019052-200108000-00003; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Ho CS, 2002, J BIOL CHEM, V277, P27021, DOI 10.1074/jbc.M201823200; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Ide N, 1998, BIOCHEM BIOPH RES CO, V244, P258, DOI 10.1006/bbrc.1998.8243; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kurt MA, 2001, EXP NEUROL, V171, P59, DOI 10.1006/exnr.2001.7717; Lau KF, 2002, MOL CELL NEUROSCI, V20, P13, DOI 10.1006/mcne.2002.1108; Lau KF, 2000, MOL CELL NEUROSCI, V16, P557, DOI 10.1006/mcne.2000.0898; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Matsuda S, 2001, J NEUROSCI, V21, P6597; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; McLoughlin DM, 1999, EUR J NEUROSCI, V11, P1988, DOI 10.1046/j.1460-9568.1999.00610.x; McLoughlin DM, 2001, J BIOL CHEM, V276, P9303, DOI 10.1074/jbc.M010023200; McLoughlin DM, 1996, FEBS LETT, V397, P197; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Mueller HT, 2000, J BIOL CHEM, V275, P39302, DOI 10.1074/jbc.M008453200; Nakajima Y, 2001, MOL BRAIN RES, V92, P27, DOI 10.1016/S0169-328X(01)00126-7; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Okamoto M, 1998, EUR J CELL BIOL, V77, P161, DOI 10.1016/S0171-9335(98)80103-9; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Tanahashi H, 1999, BIOCHEM BIOPH RES CO, V255, P663, DOI 10.1006/bbrc.1999.0265; Taru H, 2002, J BIOL CHEM, V277, P20070, DOI 10.1074/jbc.M108372200; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; Van Gassen G, 2000, NEUROBIOL DIS, V7, P135, DOI 10.1006/nbdi.2000.0306; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 2002, NAT NEUROSCI, V5, P633, DOI 10.1038/nn0702-633; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141	59	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47025	47029		10.1074/jbc.M300503200	http://dx.doi.org/10.1074/jbc.M300503200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12970358	hybrid			2022-12-25	WOS:000186569400098
J	Saito, N; Courtois, G; Chiba, A; Yamamoto, N; Nitta, T; Hironaka, N; Rowe, M; Yamamoto, N; Yamaoka, S				Saito, N; Courtois, G; Chiba, A; Yamamoto, N; Nitta, T; Hironaka, N; Rowe, M; Yamamoto, N; Yamaoka, S			Two carboxyl-terminal activation regions of Epstein-Barr virus latent membrane protein 1 activate NF-kappa B through distinct signaling pathways in fibroblast cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN 1; LYMPHOTOXIN-BETA-RECEPTOR; IKK-ALPHA; MICE LACKING; LYMPHOCYTE TRANSFORMATION; CONSTITUTIVE ACTIVATION; LIVER DEGENERATION; KINASE-ALPHA; JNK PATHWAY; C-TERMINUS	Latent membrane protein 1 ( LMP1), an Epstein- Barr virus transforming protein, is able to activate NF-kappaB through its carboxyl- terminal activation region 1 ( CTAR1) and 2 ( CTAR2), but the exact role of each domain is not fully understood. Here we show that LMP1 activates NF-kappaB in different NF-kappaB essential modulator ( NEMO)- defective cell lines, but not in cells lacking both IkappaB kinase 1 ( IKK1) and 2 ( IKK2). Mutational studies reveal that CTAR1, but not CTAR2, mediates NEMO-independent NF-kappaB activation and that this process largely depends on IKK1. Retroviral expression of LMP1 mutants in cells lacking either functional NF-kappaB inducing kinase ( NIK), NEMO, IKK1, or IKK2 further illustrates distinct signals from the two activation regions of LMP1 for persistent NF-kappaB activation. One originates in CTAR2, operates through the canonical NEMO- dependent pathway, and induces NFKB2 p100 production; the second signal originates in CTAR1, utilizes NIK and IKK1, and induces the processing of p100. Our results thus help clarify how two functional domains of LMP1 persistently activate NF-kappaB through distinct signaling pathways.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Virol, Bunkyo Ku, Tokyo 1138519, Japan; Inst Pasteur, Unite Biol Mol Express Gen, F-75724 Paris 15, France; Cardiff Univ, Sect Infect & Immun, Cardiff CF14 4XX, S Glam, Wales	Tokyo Medical & Dental University (TMDU); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Cardiff University	Yamaoka, S (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Virol, Bunkyo Ku, Yushima 1-5-45, Tokyo 1138519, Japan.	shojmmb@tmd.ac.jp	Rowe, Martin/B-2880-2009	Rowe, Martin/0000-0003-4139-7326; COURTOIS, Gilles/0000-0003-3117-9595				BAICHWAL VR, 1989, ONCOGENE, V4, P67; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chinanonwait N, 2002, FEBS LETT, V531, P553, DOI 10.1016/S0014-5793(02)03618-9; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 2002, J VIROL, V76, P4567, DOI 10.1128/JVI.76.9.4567-4579.2002; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; Hatzivassiliou E, 1998, J IMMUNOL, V160, P1116; He ZM, 2000, CANCER RES, V60, P1845; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Kaye KM, 1999, J VIROL, V73, P10525, DOI 10.1128/JVI.73.12.10525-10530.1999; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaykas A, 2001, EMBO J, V20, P2641, DOI 10.1093/emboj/20.11.2641; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lam N, 2003, CELL SIGNAL, V15, P9, DOI 10.1016/S0898-6568(02)00083-9; LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; LOMBARDI L, 1995, NUCLEIC ACIDS RES, V23, P2328, DOI 10.1093/nar/23.12.2328; Luftig MA, 2001, J BIOL CHEM, V276, P14602, DOI 10.1074/jbc.C100103200; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Mosialos G, 2001, CYTOKINE GROWTH F R, V12, P259, DOI 10.1016/S1359-6101(00)00035-6; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pai S, 2002, J VIROL, V76, P1914, DOI 10.1128/JVI.76.4.1914-1921.2002; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; Saitoh T, 2002, FEBS LETT, V532, P45, DOI 10.1016/S0014-5793(02)03622-0; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	73	58	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46565	46575		10.1074/jbc.M302549200	http://dx.doi.org/10.1074/jbc.M302549200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12968033	hybrid			2022-12-25	WOS:000186569400042
J	Jiang, JXS; Choi, RCY; Siow, NL; Lee, HHC; Wan, DCC; Tsim, KWK				Jiang, JXS; Choi, RCY; Siow, NL; Lee, HHC; Wan, DCC; Tsim, KWK			Muscle induces neuronal expression of acetylcholinesterase in neuron-muscle co-culture - Transcriptional regulation mediated by camp-dependent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; DEVELOPING NEUROMUSCULAR-JUNCTIONS; P2Y(1) NUCLEOTIDE RECEPTOR; TISSUE-SPECIFIC EXPRESSION; MESSENGER-RNA LEVELS; NEUREGULIN EXPRESSION; PROMOTER ELEMENTS; FORM; AGGREGATION; MYOTUBES	Presynaptic motor neuron synthesizes and secretes acetylcholinesterase (AChE) at vertebrate neuromuscular junctions. In order to determine the retrograde role of muscle in regulating the expression of AChE in motor neuron, a chimeric co-culture of NG108-15 cell, a cholinergic cell line that resembles motor neuron, with chick myotube was established to mimic the neuromuscular contact in vitro. A DNA construct of human AChE promoter tagged with luciferase (pAChE-Luc) was stably transfected into NG108-15 cells. The co-culture with myotubes robustly stimulated the promoter activity as well as the endogenous expression of AChE in pAChE-Luc stably transfected NG108-15 cells. Muscle extract derived from chick embryos when applied onto pAChE-Luc-expressing NG108-15 cells induced expressions of AChE promoter and endogenous AChE. The cAMP-responsive element mutation on human AChE promoter blocked the muscle-induced AChE transcriptional activity in cultured NG108-15 cells either in co-culturing with myotube or in applying muscle extract. The accumulation of intracellular cAMP and the phosphorylation of cAMP-responsive element-binding protein in cultured NG108-15 cells were stimulated by applied muscle extract. Part of the muscle-induced signaling was mimicked by application of calcitonin gene-related peptide in cultured NG108-15 cells. These results suggest the muscle-induced neuronal AChE expression in the co-culture is mediated by a cAMP-dependent signaling.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Kowloon, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Chinese University of Hong Kong	Tsim, KWK (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay Rd, Kowloon, Hong Kong, Peoples R China.	BOTSIM@UST.HK	Lee, Henry HC/S-6014-2016; Lee, Henry/GVS-2114-2022; Wan, David C/H-3335-2014	Lee, Henry HC/0000-0003-4975-7330; Tsim, Karl/0000-0003-4808-1674				ANGLISTER L, 1991, J CELL BIOL, V115, P755, DOI 10.1083/jcb.115.3.755; ANGLISTER L, 1994, NEURON, V12, P783, DOI 10.1016/0896-6273(94)90331-X; BENAZIZALOYA R, 1993, P NATL ACAD SCI USA, V90, P2471, DOI 10.1073/pnas.90.6.2471; Boudreau-Lariviere C, 1999, FEBS LETT, V444, P22, DOI 10.1016/S0014-5793(99)00015-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenner T, 2003, FASEB J, V17, P214, DOI 10.1096/fj.02-0609com; BRIMIJOIN S, 1978, J PHYSIOL-LONDON, V285, P143, DOI 10.1113/jphysiol.1978.sp012563; BUSIS NA, 1984, BRAIN RES, V324, P201, DOI 10.1016/0006-8993(84)90030-1; Chakravarty P, 2000, BRIT J PHARMACOL, V130, P189, DOI 10.1038/sj.bjp.0702975; Chan RYY, 1999, P NATL ACAD SCI USA, V96, P4627, DOI 10.1073/pnas.96.8.4627; Cheng AWM, 2003, NEUROREPORT, V14, P351, DOI 10.1097/01.wnr.0000058033.29600.a3; Choi RCY, 1997, NEUROSCI LETT, V236, P167, DOI 10.1016/S0304-3940(97)00789-1; Choi RCY, 2001, J NEUROSCI, V21, P9224, DOI 10.1523/JNEUROSCI.21-23-09224.2001; Choi RCY, 1998, NEUROSCI LETT, V248, P17, DOI 10.1016/S0304-3940(98)00320-6; Choi RCY, 2003, J NEUROSCI, V23, P4445; Choi RCY, 1998, J NEUROCHEM, V71, P152; Choi RCY, 2001, MOL CELL NEUROSCI, V17, P732, DOI 10.1006/mcne.2001.0968; CHRISTIAN CN, 1978, P NATL ACAD SCI USA, V75, P4011, DOI 10.1073/pnas.75.8.4011; Coleman BA, 1996, J BIOL CHEM, V271, P4410; Day T, 2002, NEUROSCIENCE, V111, P649, DOI 10.1016/S0306-4522(02)00031-3; Deschenes-Furry J, 2003, J BIOL CHEM, V278, P5710, DOI 10.1074/jbc.M209383200; Deuchars SA, 2001, J NEUROSCI, V21, P7143, DOI 10.1523/JNEUROSCI.21-18-07143.2001; EKSTROM TJ, 1993, DNA CELL BIOL, V12, P63, DOI 10.1089/dna.1993.12.63; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Farchi N, 2003, J PHYSIOL-LONDON, V546, P165, DOI 10.1113/jphysiol.2002.030841; Fernandes KJL, 1998, J NEUROSCI, V18, P9936; FERNANDEZVALLE C, 1989, J BIOL CHEM, V264, P14043; FONTAINE B, 1987, J CELL BIOL, V105, P1337, DOI 10.1083/jcb.105.3.1337; Fu AKY, 1997, NEUROREPORT, V8, P3895, DOI 10.1097/00001756-199712220-00011; FUNAKOSHI H, 1995, SCIENCE, V268, P1495, DOI 10.1126/science.7770776; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; GLANTZ SA, 1988, PRIMER BIOSTATISTICS; GOEMAEREVANNESTE J, 1988, J NEUROCHEM, V51, P1746, DOI 10.1111/j.1471-4159.1988.tb01154.x; LAYER PG, 1991, CELL MOL NEUROBIOL, V11, P7, DOI 10.1007/BF00712798; LI Y, 1993, J BIOL CHEM, V268, P5790; Loeb JA, 1997, J NEUROSCI, V17, P1416; Loeb JA, 2002, J NEUROSCI, V22, P2206, DOI 10.1523/JNEUROSCI.22-06-02206.2002; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MICHEL RN, 1994, J CELL BIOL, V127, P1061, DOI 10.1083/jcb.127.4.1061; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; Pun S, 1997, MOL CELL NEUROSCI, V10, P87, DOI 10.1006/mcne.1997.0637; Pun S, 1997, FEBS LETT, V418, P275, DOI 10.1016/S0014-5793(97)01369-0; Reiss Y, 1996, CELL TISSUE RES, V286, P13, DOI 10.1007/s004410050670; Rossi SG, 2003, J BIOL CHEM, V278, P24994, DOI 10.1074/jbc.M211379200; Rossi SG, 1996, J BIOL CHEM, V271, P1979, DOI 10.1074/jbc.271.4.1979; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SEIDMAN S, 1994, J NEUROCHEM, V62, P1670; Seybold VS, 2003, J NEUROSCI, V23, P1816; SHAPIRA M, 1994, P NATL ACAD SCI USA, V91, P9072, DOI 10.1073/pnas.91.19.9072; Siow NL, 2002, J BIOL CHEM, V277, P36129, DOI 10.1074/jbc.M206498200; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Sternfeld M, 1998, J NEUROSCI, V18, P1240; Stoop R, 1996, J NEUROSCI, V16, P3256; Tsim KWK, 1997, J NEUROCHEM, V68, P479; Tsim KWK, 2002, NEUROSIGNALS, V11, P58, DOI 10.1159/000057322; TSIM KWK, 1988, P NATL ACAD SCI USA, V85, P1262, DOI 10.1073/pnas.85.4.1262; VALLETTE FM, 1991, J NEUROCHEM, V56, P1518, DOI 10.1111/j.1471-4159.1991.tb02046.x; Wan DCC, 2000, NEUROSCI LETT, V288, P81, DOI 10.1016/S0304-3940(00)01200-3; Wan DCC, 1997, NEUROSCI LETT, V232, P83, DOI 10.1016/S0304-3940(97)00577-6	60	38	40	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45435	45444		10.1074/jbc.M306320200	http://dx.doi.org/10.1074/jbc.M306320200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12963741	hybrid			2022-12-25	WOS:000186452300048
J	Wallas, TR; Smith, MD; Sanchez-Nieto, S; Schnell, DJ				Wallas, TR; Smith, MD; Sanchez-Nieto, S; Schnell, DJ			The roles of Toc34 and Toc75 in targeting the Toc159 preprotein receptor to chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT APPARATUS; OUTER ENVELOPE; MEMBRANE; GTP; MACHINERY; COMPONENT; BINDING; DOMAIN; TRANSLOCATION; ATTOC159	The Toc complex at the outer envelope of chloroplasts initiates the import of nuclear-encoded preproteins from the cytosol into the organelle. The core of the Toc complex is composed of two receptor GTPases, Toc159 and Toc34, as well as Toc75, a beta-barrel membrane channel. Toc159 is equally distributed between a soluble cytoplasmic form and a membrane-inserted form, suggesting that assembly of the Toc complex is dynamic. In the present study, we used the Arabidopsis thaliana orthologs of Toc159 and Toc34, atToc159 and atToc33, respectively, to investigate the requirements for assembly of the trimeric Toc complex. In addition to its intrinsic GTPase activity, we demonstrate that integration of atToc159 into the Toc complex requires atToc33 GTPase activity. Additionally, we show that the interaction of the two GTPase domains stimulates association of the membrane anchor of atToc159 with the translocon. Finally, we employ reconstituted proteoliposomes to demonstrate that proper insertion of the receptor requires both Toc75 and Toc34. Collectively these data suggest that Toc34 and Toc75 act sequentially to mediate docking and insertion of Toc159 resulting in assembly of the functional translocon.	Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Schnell, DJ (corresponding author), Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA.		Smith, Matthew/M-4726-2014	Smith, Matthew/0000-0002-2855-5126; Sanchez-Nieto, Sobeida/0000-0002-2315-450X	NIGMS NIH HHS [GM61893] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061893] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bauer J, 2002, J CELL BIOL, V159, P845, DOI 10.1083/jcb.200208018; Bauer J, 2001, CELL MOL LIFE SCI, V58, P420, DOI 10.1007/PL00000867; Chen DD, 1997, J BIOL CHEM, V272, P6614, DOI 10.1074/jbc.272.10.6614; Chen KH, 2000, PLANT PHYSIOL, V122, P813, DOI 10.1104/pp.122.3.813; Clark PL, 1998, FOLD DES, V3, P401, DOI 10.1016/S1359-0278(98)00053-4; Fitzpatrick LM, 2001, PLANT J, V27, P59, DOI 10.1046/j.0960-7412.2001.01061.x; Gutensohn M, 2000, PLANT J, V23, P771, DOI 10.1046/j.1365-313x.2000.00849.x; Hiltbrunner A, 2001, J CELL BIOL, V154, P309, DOI 10.1083/jcb.200104022; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; Jarvis P, 1998, SCIENCE, V282, P100, DOI 10.1126/science.282.5386.100; Jelic M, 2003, BIOCHEMISTRY-US, V42, P5906, DOI 10.1021/bi034001q; Jelic M, 2002, BIOL CHEM, V383, P1875, DOI 10.1515/BC.2002.211; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; Ling MM, 1997, ANAL BIOCHEM, V254, P157, DOI 10.1006/abio.1997.2428; MA Y, 1996, J CELL BIOL, V134, P1; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; Schleiff E, 2003, J CELL BIOL, V160, P541, DOI 10.1083/jcb.200210060; Schleiff E, 2000, PLANTA, V211, P449, DOI 10.1007/s004250000357; Schleiff E, 2003, P NATL ACAD SCI USA, V100, P4604, DOI 10.1073/pnas.0730860100; Schleiff E, 2002, BIOCHEMISTRY-US, V41, P1934, DOI 10.1021/bi011361+; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; Smith MD, 2002, J CELL BIOL, V159, P833, DOI 10.1083/jcb.200208017; SMITH MD, 2002, CURRENT PROTOCOLS CE; Sveshnikova N, 2000, P NATL ACAD SCI USA, V97, P4973, DOI 10.1073/pnas.080491597	27	61	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44289	44297		10.1074/jbc.M307873200	http://dx.doi.org/10.1074/jbc.M307873200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12951325	hybrid			2022-12-25	WOS:000186306700050
J	Lui, VWY; Thomas, SM; Zhang, Q; Wentzel, AL; Siegfried, JM; Li, JY; Grandis, JR				Lui, VWY; Thomas, SM; Zhang, Q; Wentzel, AL; Siegfried, JM; Li, JY; Grandis, JR			Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor	ONCOGENE			English	Article						EGFR transactivation; GRPR; G-protein-coupled receptor; TGF-alpha; head and neck cancer	BOMBESIN ANTAGONIST RC-3095; LUNG-CARCINOMA CELLS; SMOOTH-MUSCLE-CELLS; PROSTATE-CANCER; MESSENGER-RNA; NEUROMEDIN-B; EGF RECEPTOR; AUTOCRINE GROWTH; EPITHELIAL-CELLS; PROTEIN-KINASE	Head and neck squamous cell carcinomas (HNSCC) are characterized by upregulation of the epidermal growth factor receptor ( EGFR), where EGFR serves as a potential therapeutic target. We previously reported that a gastrin-releasing peptide/gastrin-releasing peptide receptor (GRP/GRPR) autocrine growth pathway is activated early in HNSCC carcinogenesis. In the present study, we examined the mechanism of EGFR activation by GRP/GRPR in HNSCC proliferation. In HNSCC cells that express elevated levels of both GRPR and EGFR, we found that GRP induced rapid phosphorylation of EGFR as well as p44/42-MAPK activation. Using several EGFR-specific tyrosine kinase inhibitors and cells derived from EGFR knockout mice, we demonstrated that GRP-induced p44/42-MAPK activation was dependent upon EGFR activation. Further investigation demonstrated that cleavage of transforming growth factor-alpha (TGF-alpha) by matrix metalloproteinases mediated GRP-induced MAPK activation. In addition, HNSCC proliferation stimulated by GRP was eliminated upon specific inhibition of EGFR or MEK, and GRP failed to stimulate proliferation in EGFR- deficient cells. These results imply that the mitogenic effects of GRP in HNSCC are mediated by extracellular release of TGF-alpha and require the activation of an EGFR- dependent MEK/MAPK-dependent pathway.	Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Grandis, JR (corresponding author), Univ Pittsburgh, Sch Med, Dept Otolaryngol, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA.		Thomas, Sufi/O-1487-2018; Thomas, Sufi Mary/AFR-1642-2022; Lui, Vivian W. Y./I-5458-2016; ZHANG, QING/AGY-7972-2022	Thomas, Sufi/0000-0001-5370-0842; Thomas, Sufi Mary/0000-0001-5370-0842; Lui, Vivian W. Y./0000-0001-6918-1573; ZHANG, QING/0000-0002-6595-8995	NATIONAL CANCER INSTITUTE [P50CA090440, R01CA079882, U01CA084968] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA79882, P50CA90440, U01CA84968] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; Akeson M, 1997, J BIOL CHEM, V272, P17405, DOI 10.1074/jbc.272.28.17405; ALEXANDER RW, 1988, CANCER RES, V48, P1439; ANASTASI A, 1971, EXPERIENTIA, V27, P166, DOI 10.1007/BF02145873; Boerner JL, 2001, J BIOL CHEM, V276, P3691, DOI 10.1074/jbc.M003801200; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CARNEY DN, 1987, CANCER RES, V47, P821; Carroll RE, 2000, CELL GROWTH DIFFER, V11, P385; Castagliuolo I, 2000, J BIOL CHEM, V275, P26545, DOI 10.1074/jbc.M003990200; Charlesworth A, 1996, ONCOGENE, V12, P1337; Chaudhry A, 1999, CLIN CANCER RES, V5, P3385; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; FATHI Z, 1993, J BIOL CHEM, V268, P5979; Feldman RI, 1996, MOL PHARMACOL, V50, P1346; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Grandis JR, 1997, ONCOGENE, V15, P409, DOI 10.1038/sj.onc.1201188; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Halmos G, 1997, P NATL ACAD SCI USA, V94, P956, DOI 10.1073/pnas.94.3.956; HALMOS G, 1995, CANCER RES, V55, P280; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Kelley MJ, 1997, CHEST, V112, P256, DOI 10.1378/chest.112.1.256; Koppan M, 1998, CANCER, V83, P1335, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1335::AID-CNCR10>3.0.CO;2-5; LACH EB, 1995, CELL GROWTH DIFFER, V6, P1427; Lango MN, 2002, J NATL CANCER I, V94, P375; LEBACQVERHEYDEN AM, 1990, HDB EXPT PHARM, V95, P71; LIEBOW C, 1994, P NATL ACAD SCI USA, V91, P3804, DOI 10.1073/pnas.91.9.3804; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; Nagakawa O, 2001, INT J UROL, V8, P65, DOI 10.1046/j.1442-2042.2001.00250.x; Nagakawa O, 2000, CANCER LETT, V155, P173, DOI 10.1016/S0304-3835(00)00425-0; NAGALLA SR, 1995, P NATL ACAD SCI USA, V92, P6205, DOI 10.1073/pnas.92.13.6205; Pansky A, 2000, J AM SOC NEPHROL, V11, P1409, DOI 10.1681/ASN.V1181409; PINSKI J, 1994, BRIT J CANCER, V70, P886, DOI 10.1038/bjc.1994.415; Plonowski A, 2000, INT J CANCER, V88, P652, DOI 10.1002/1097-0215(20001115)88:4<652::AID-IJC21>3.0.CO;2-1; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Rounseville MP, 2000, J MOL ENDOCRINOL, V25, P121, DOI 10.1677/jme.0.0250121; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Santiskulvong C, 2001, AM J PHYSIOL-CELL PH, V281, pC886, DOI 10.1152/ajpcell.2001.281.3.C886; Sharif TR, 1997, MOL CELL ENDOCRINOL, V130, P119, DOI 10.1016/S0303-7207(97)00080-4; Shin DM, 2001, CLIN CANCER RES, V7, P1204; Siegfried JM, 1999, PULM PHARMACOL THER, V12, P291, DOI 10.1006/pupt.1999.0210; SIEGFRIED JM, 1998, BIOL LUNG CANC, P317; SORENSON GD, 1982, REGUL PEPTIDES, V4, P59, DOI 10.1016/0167-0115(82)90095-7; Sun BD, 2000, REGUL PEPTIDES, V90, P77, DOI 10.1016/S0167-0115(00)00114-2; Sun BD, 2000, PROSTATE, V42, P295; Szepeshazi K, 1997, P NATL ACAD SCI USA, V94, P10913, DOI 10.1073/pnas.94.20.10913; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4	54	75	78	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6183	6193		10.1038/sj.onc.1206720	http://dx.doi.org/10.1038/sj.onc.1206720			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679857				2022-12-25	WOS:000185506200008
J	Liu, GJ; Simpson, AM; Swan, MA; Tao, C; Tuch, BE; Crawford, RM; Jovanovic, A; Martin, DK				Liu, GJ; Simpson, AM; Swan, MA; Tao, C; Tuch, BE; Crawford, RM; Jovanovic, A; Martin, DK			ATP-sensitive potassium channels induced in liver cells after transfection with insulin cDNA and the GLUT2 transporter regulate glucose-stimulated insulin secretion	FASEB JOURNAL			English	Article						HEPG2ins/g; patch-clamp electrophysiology; Western blotting; confocal laser scanning microscopy; radioimmunoassay	FUNCTIONAL EXPRESSION; K+ CHANNELS; LINE; CALCIUM; CLONING; SINGLE; PATHWAYS; GENE	As part of our research into the liver-directed gene therapy of Type I diabetes, we have engineered a human hepatoma cell line (HEPG2ins/g cells) to store and secrete insulin to a glucose stimulus. The aim of the present study was to determine whether HEPG2ins/g cells respond to glucose via signaling pathways that depend on ATP-sensitive potassium channels (K-ATP). Using patch-clamp electrophysiology with symmetrical KCl solutions, the single-channel conductance of K-ATP was 61pS. K-ATP was inhibited by ATP (1 mM) or cAMP (50 muM) applied to the cytosolic side of the membrane. Single K-ATP channels and macroscopic whole-cell currents were inhibited by glucose (20 mM) and glibenclamide (20 muM) and were activated by diazoxide (150 muM). Immunoprecipitation and Western blot analysis confirmed the presence of Kir6.2 K-ATP channel subunit protein in HEPG2ins/g and HEPG2ins cells. Using radioimmunoassay techniques, we report that exposure of the cells to tolbutamide (100 muM) resulted in an increase in insulin secretion from 0.3 +/- 0.05 to 1.8 +/- 0.2 pmol insulin/10(6) cells and glibenclamide (20 muM) from 0.4 +/- 0.06 to 2.1 +/- 0.3 (n=4), similar to what is seen on glucose (20 mM) stimulation. Diazoxide (150 muM) completely inhibited glucose-stimulated insulin release. Glucose 20 mM and glibenclamide 100 muM increased intracellular Ca2+ level in the HEPG2ins/g cells. However, glucose 20 mM did not stimulate a rise in intracellular Ca2+ in the un-transfected parent cell-line HEPG2. We used confocal microscopy to confirm that glucose (20 mM) stimulated the release of insulin from the fluorescently labeled secretion granules in the cells. Furthermore, glibenclamide (20 muM) also stimulated the release of insulin from fluorescently labeled secretion granules, and diazoxide (150 muM) blocked that stimulated release of insulin. Our results suggest that HEPG2ins/g cells respond to glucose via signaling pathways that depend on K-ATP, similar to a normal pancreatic beta cell.	Univ Technol Sydney, Dept Hlth Sci, Broadway, NSW 2007, Australia; Univ Technol Sydney, Dept Cell & Mol Biol, Broadway, NSW 2007, Australia; Univ Sydney, Dept Anat & Histol, Sydney, NSW 2006, Australia; Univ Sydney, Inst Biomed Res, Sydney, NSW 2006, Australia; Prince Wales Hosp, Diabet Transplant Unit, Randwick, NSW 2031, Australia; Univ New S Wales, Randwick, NSW, Australia; Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland; Univ Technol Sydney, Inst Nanoscale Technol, Sydney, NSW, Australia	University of Technology Sydney; University of Technology Sydney; University of Sydney; University of Sydney; University of New South Wales Sydney; University of Dundee; University of Technology Sydney	Martin, DK (corresponding author), Univ Technol Sydney, Dept Hlth Sci, POB 123, Broadway, NSW 2007, Australia.	donm@uts.edu.au	Tuch, Bernard E/D-8041-2013; Jovanovic, Aleksandar/A-4482-2008	Jovanovic, Aleksandar/0000-0002-1214-9318; Liu, Guo-Jun/0000-0002-4278-8372; Martin, Donald/0000-0001-5913-2372	Biotechnology and Biological Sciences Research Council [C15048] Funding Source: Medline; British Heart Foundation [PG/02/091/14227] Funding Source: Medline; Wellcome Trust [059528/Z/99/Z/JMW/CP/JF] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome TrustEuropean Commission)		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; BABENKO AP, 1998, ANNU REV PHYSIOL, V60, P308; CAPIOD T, 1989, J PHYSIOL-LONDON, V409, P285, DOI 10.1113/jphysiol.1989.sp017497; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; HENDERSON RM, 1989, AM J PHYSIOL, V256, pG1028, DOI 10.1152/ajpgi.1989.256.6.G1028; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Lee K, 1998, J PHYSIOL-LONDON, V510, P441, DOI 10.1111/j.1469-7793.1998.441bk.x; LIDOFSKY SD, 1995, P NATL ACAD SCI USA, V92, P7115, DOI 10.1073/pnas.92.15.7115; Malhi H, 2000, J BIOL CHEM, V275, P26050, DOI 10.1074/jbc.M001576200; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; PERMUTT MA, 1989, P NATL ACAD SCI USA, V86, P8688, DOI 10.1073/pnas.86.22.8688; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; Ranki HJ, 2001, J AM COLL CARDIOL, V38, P906, DOI 10.1016/S0735-1097(01)01428-0; Reimann F, 2001, DIABETES, V50, P2253, DOI 10.2337/diabetes.50.10.2253; Russ U, 1999, J PHYSIOL-LONDON, V517, P781, DOI 10.1111/j.1469-7793.1999.0781s.x; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; SAKURADA M, 1993, ENDOCRINOLOGY, V132, P2659, DOI 10.1210/en.132.6.2659; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Simpson AM, 1999, TRANSPLANT P, V31, P812, DOI 10.1016/S0041-1345(98)01782-5; SIMPSON AM, 1995, GENE THER, V2, P223; Simpson AM, 1997, GENE THER, V4, P1202, DOI 10.1038/sj.gt.3300527; Soria B, 2000, DIABETES, V49, P157, DOI 10.2337/diabetes.49.2.157; SPRUCE AE, 1985, NATURE, V316, P736, DOI 10.1038/316736a0; Straub SG, 1998, DIABETES, V47, P758, DOI 10.2337/diabetes.47.5.758; Tuch BE, 2003, GENE THER, V10, P490, DOI 10.1038/sj.gt.3301911; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Weinhouse S, 1976, CURRENT TOPICS CELLU, P1; Wellman GC, 1999, BRIT J PHARMACOL, V128, P909, DOI 10.1038/sj.bjp.0702868; Yamada K, 2000, J BIOL CHEM, V275, P22278, DOI 10.1074/jbc.M908048199; ZALEWSKI PD, 1994, J HISTOCHEM CYTOCHEM, V42, P877, DOI 10.1177/42.7.8014471	34	12	12	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1682	+		10.1096/fj.02-0051fje	http://dx.doi.org/10.1096/fj.02-0051fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958175	Green Accepted			2022-12-25	WOS:000184471600002
J	Billich, A; Bornancin, F; Devay, P; Mechtcheriakova, D; Urtz, N; Baumruker, T				Billich, A; Bornancin, F; Devay, P; Mechtcheriakova, D; Urtz, N; Baumruker, T			Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; 1-PHOSPHATE; SPHINGOSINE-1-PHOSPHATE; PURIFICATION; ACTIVATION; RECEPTORS	The immunomodulatory drug FTY720 is phosphorylated in vivo, and the resulting FTY720 phosphate as a ligand for sphingosine-1-phosphate receptors is responsible for the unique biological effects of the compound. So far, phosphorylation of FTY720 by murine sphingosine kinase (SPHK) 1a had been documented. We found that, while FTY720 is also phosphorylated by human SPHK1, the human type 2 isoform phosphorylates the drug 30-fold more efficiently, because of a lower K-m of FTY720 for SPHK2. Similarly, murine SPHK2 was more efficient than SPHK1a. Among splice variants of the human SPHKs, an N-terminally extended SPHK2 isoform was even more active than SPHK2 itself. Further SPHK superfamily members, namely ceramide kinase and a "SPHK-like" protein, failed to phosphorylate sphingosine and FTY720. Thus, only SPHK1 and 2 appear to be capable of phosphorylating FTY720. Using selective assay conditions, SPHK1 and 2 activities in murine tissues were measured. While activity of SPHK2 toward sphingosine was generally lower than of SPHK1, FTY720 phosphorylation was higher under conditions favoring SPHK2. In human endothelial cells, while activity of SPHK1 toward sphingosine was 2-fold higher than of SPHK2, FTY720 phosphorylation was 7-fold faster under SPHK2 assay conditions. Finally, FTY720 was poorly phosphorylated in human blood as compared with rodent blood, in line with the low activity of SPHK1 and in particular of SPHK2 in human blood. To conclude, both SPHK1 and 2 are capable of phosphorylating FTY720, but SPHK2 is quantitatively more important than SPHK1.	Novartis Res Inst Vienna, A-1235 Vienna, Austria	Novartis	Billich, A (corresponding author), Novartis Res Inst Vienna, Brunnerstr 59, A-1235 Vienna, Austria.			Mechtcheriakova, Diana/0000-0002-8737-3592				Banno Y, 1998, BIOCHEM J, V335, P301, DOI 10.1042/bj3350301; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2002, CURR OPIN IMMUNOL, V14, P569, DOI 10.1016/S0952-7915(02)00374-6; Brinkmann V, 2001, TRANSPLANTATION, V72, P764, DOI 10.1097/00007890-200109150-00002; Chiba K, 1998, J IMMUNOL, V160, P5037; Gijsbers S, 2002, BBA-MOL CELL BIOL L, V1580, P1, DOI 10.1016/S1388-1981(01)00166-4; Gijsbers S, 2001, BBA-MOL CELL BIOL L, V1532, P37, DOI 10.1016/S1388-1981(01)00111-1; Hla T, 2003, PHARMACOL RES, V47, P401, DOI 10.1016/S1043-6618(03)00046-X; Honig SM, 2003, J CLIN INVEST, V111, P627, DOI 10.1172/JCI200316200; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Melendez AJ, 2000, GENE, V251, P19, DOI 10.1016/S0378-1119(00)00205-5; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; Olivera A, 2000, METHOD ENZYMOL, V311, P215; Pinschewer DD, 2000, J IMMUNOL, V164, P5761, DOI 10.4049/jimmunol.164.11.5761; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; Schenborn E T, 2000, Methods Mol Biol, V130, P135; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Stahl E, 1969, THIN LAYER CHROMATOG, P904; Sugiura M, 2002, J BIOL CHEM, V277, P23294, DOI 10.1074/jbc.M201535200	25	362	384	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47408	47415		10.1074/jbc.M307687200	http://dx.doi.org/10.1074/jbc.M307687200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13129923	hybrid			2022-12-25	WOS:000186731400010
J	Nayernia, K; Vauti, F; Meinhardt, A; Cadenas, C; Schweyer, S; Meyer, BI; Schwandt, I; Chowdhury, K; Engel, W; Arnold, HH				Nayernia, K; Vauti, F; Meinhardt, A; Cadenas, C; Schweyer, S; Meyer, BI; Schwandt, I; Chowdhury, K; Engel, W; Arnold, HH			Inactivation of a testis-specific Lis1 transcript in mice prevents spermatid differentiation and causes male infertility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; LISSENCEPHALY GENE-PRODUCT; NEURONAL MIGRATION; CYTOPLASMIC DYNEIN; NUCLEAR MIGRATION; ASPERGILLUS-NIDULANS; NERVOUS-SYSTEM; HEAVY-CHAIN; ACETYLHYDROLASE; PROTEIN	Lis1 protein is the non-catalytic component of platelet-activating factor acetylhydrolase 1b (PAF-AH 1B) and associated with microtubular structures. Hemizygous mutations of the LIS1 gene cause type I lissencephaly, a brain abnormality with developmental defects of neuronal migration. Lis1 is also expressed in testis, but its function there has not been determined. We have generated a mouse mutant (LIS1(GT/GT)) by gene trap integration leading to selective disruption of a Lis1 splicing variant in testis. Homozygous mutant males are infertile with no other apparent phenotype. We demonstrate that Lis1 is predominantly expressed in spermatids, and spermiogenesis is blocked when Lis1 is absent. Mutant spermatids fail to form correct acrosomes and nuclei appear distorted in size and shape. The tissue architecture in mutant testis appears severely disturbed displaying collapsed seminiferous tubules, mislocated germ cells, and increased apoptosis. These results provide evidence for an essential and hitherto uncharacterized role of the Lis1 protein in spermatogenesis, particularly in the differentiation of spermatids into spermatozoa.	Tech Univ Carolo Wilhelmina Braunschweig, Dept Cell & Mol Biol, D-38106 Braunschweig, Germany; Univ Gottingen, Inst Human Genet, D-37073 Gottingen, Germany; Univ Gottingen, Dept Pathol, D-37073 Gottingen, Germany; Univ Giessen, Dept Anat & Cell Biol, D-35378 Giessen, Germany; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany	Braunschweig University of Technology; University of Gottingen; University of Gottingen; Justus Liebig University Giessen; Max Planck Society	Arnold, HH (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Dept Cell & Mol Biol, Spielmannstr 7, D-38106 Braunschweig, Germany.		Meinhardt, Andreas/B-3688-2009	Vauti, Franz/0000-0003-0275-1433				Adham IM, 2001, MOL HUM REPROD, V7, P513, DOI 10.1093/molehr/7.6.513; Albrecht U, 1996, DEV BIOL, V180, P579, DOI 10.1006/dbio.1996.0330; Arai H, 2002, J BIOCHEM, V131, P635, DOI 10.1093/oxfordjournals.jbchem.a003145; Bazan NG, 1998, PROG BRAIN RES, V118, P281; Benoff S, 1998, MOL HUM REPROD, V4, P453, DOI 10.1093/molehr/4.5.453; BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; CEBRATHOMAS JA, 1990, GENETIC ASPECT SPERM, P29; Cheminade C, 2002, BIOL REPROD, V66, P421, DOI 10.1095/biolreprod66.2.421; Chowdhury K, 1997, NUCLEIC ACIDS RES, V25, P1531, DOI 10.1093/nar/25.8.1531; Dawe AL, 2001, DEV GENES EVOL, V211, P434, DOI 10.1007/s004270100176; DOBYNS WB, 1989, NEUROL CLIN, V7, P89, DOI 10.1016/S0733-8619(18)30830-2; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8; Geiser JR, 1997, MOL BIOL CELL, V8, P1035, DOI 10.1091/mbc.8.6.1035; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0; Kitagawa M, 2000, FEBS LETT, V479, P57, DOI 10.1016/S0014-5793(00)01856-1; Koizumi H, 2003, J BIOL CHEM, V278, P12489, DOI 10.1074/jbc.M211836200; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; KREMLING H, 1991, GENOMICS, V11, P828, DOI 10.1016/0888-7543(91)90005-Y; Lee WL, 2003, J CELL BIOL, V160, P355, DOI 10.1083/jcb.200209022; Levine AS, 2002, J ANDROL, V23, P471; Liu Z, 2000, NAT CELL BIOL, V2, P776, DOI 10.1038/35041011; Liu Z, 1999, DEVELOPMENT, V126, P4477; LO NC, 1997, HUM MOL GENET, V6, P157; Maclennan KM, 1996, PROG NEUROBIOL, V50, P585, DOI 10.1016/S0301-0082(96)00047-0; MARCHESELLI VL, 1994, J NEUROSCI RES, V37, P54, DOI 10.1002/jnr.490370108; Matzuk MM, 2002, NAT CELL BIOL, V4, pS41; Minhas BS, 1996, AM J REPROD IMMUNOL, V35, P267; MIZUGUCHI M, 1995, AM J PATHOL, V147, P1142; Morris SM, 1998, CURR BIOL, V8, P603, DOI 10.1016/S0960-9822(98)70232-5; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; OSMANI AH, 1990, J CELL BIOL, V111, P543, DOI 10.1083/jcb.111.2.543; Palmer JS, 1997, J UROLOGY, V158, P1186, DOI 10.1016/S0022-5347(01)64420-3; Peterfy M, 1998, GENOMICS, V47, P200, DOI 10.1006/geno.1997.5121; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; RAPP G, 1989, BIOL CHEM H-S, V370, P1071, DOI 10.1515/bchm3.1989.370.2.1071; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Roudebush WE, 2001, ASIAN J ANDROL, V3, P81; Sambrook J., 2002, MOL CLONING LAB MANU; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Schluter G, 1996, MOL REPROD DEV, V43, P1, DOI 10.1002/(SICI)1098-2795(199601)43:1&lt;1::AID-MRD1&gt;3.0.CO;2-W; Sheeman B, 2003, CURR BIOL, V13, P364, DOI 10.1016/S0960-9822(03)00013-7; Smith DS, 2000, NAT CELL BIOL, V2, P767, DOI 10.1038/35041000; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Sweeney KJ, 2001, MECH DEVELOP, V101, P21, DOI 10.1016/S0925-4773(00)00543-8; Tacken PJ, 2001, TRANSGENIC RES, V10, P211, DOI 10.1023/A:1016682520887; VENABLE ME, 1993, J LIPID RES, V34, P691; Willins DA, 1997, MOL GEN GENET, V255, P194, DOI 10.1007/s004380050489; XIANG X, 1995, MOL BIOL CELL, V6, P297, DOI 10.1091/mbc.6.3.297; Yan W, 2003, P NATL ACAD SCI USA, V100, P7189, DOI 10.1073/pnas.1236145100	55	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48377	48385		10.1074/jbc.M309583200	http://dx.doi.org/10.1074/jbc.M309583200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13129914	hybrid, Green Published			2022-12-25	WOS:000186731400123
J	Parker, AR; O'Meally, RN; Sahin, F; Su, GH; Racke, FK; Nelson, WG; DeWeese, TL; Eshleman, JR				Parker, AR; O'Meally, RN; Sahin, F; Su, GH; Racke, FK; Nelson, WG; DeWeese, TL; Eshleman, JR			Defective human MutY phosphorylation exists in colorectal cancer cell lines with wild-type MutY alleles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BASE EXCISION-REPAIR; OXIDATIVE DNA-DAMAGE; HUMAN-COLON; HUMAN HOMOLOG; EXPRESSION; GLYCOSYLASE; MUTATIONS; CLONING; TUMORS	Oxidative DNA damage can generate a variety of cytotoxic DNA lesions such as 8-oxoguanine (8-oxoG), which is one of the most mutagenic bases formed from oxidation of genomic DNA because 8-oxoG can readily mispair with either cytosine or adenine. If unrepaired, further replication of A . 8-oxoG mispairs results in C: G to A: T transversions, a form of genomic instability. We reported previously that repair of A . 8-oxoG mispairs was defective and that 8-oxoG levels were elevated in several microsatellite stable human colorectal cancer cell lines lacking MutY mutations ( human MutY homolog gene, hmyh, MYH MutY homolog protein). In this report, we provide biochemical evidence that the defective repair of A . 8- oxoG may be due, at least in part, to defective phosphorylation of the MutY protein in these cell lines. In MutY-defective cell extracts, but not extracts with functional MutY, A . 8-oxoG repair was increased by incubation with protein kinases A and C (PKA and PKC) and caesin kinase II. Treatment of these defective cells, but not cells with functional MutY, with phorbol-12-myristate-13- acetate also increased the cellular A . 8- oxoG repair activity and decreased the elevated 8- oxoG levels. We show that MutY is serine-phosphorylated in vitro by the action of PKC and in the MutY-defective cells by phorbol-12-myristate-13- acetate but that MutY is already phosphorylated at baseline in proficient cell lines. Finally, using antibody-isolated MutY protein, we show that MutY can be directly phosphorylated by PKC that directly increases the level of MutY catalyzed A . 8-oxoG repair.	Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med & Pharmacol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Eshleman, JR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, 720 Rutland Ave,632 Ross Bldg, Baltimore, MD 21205 USA.			Su, Gloria/0000-0002-5158-6019	NCI NIH HHS [R01CA81439] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081439] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; BAUM CL, 1990, CANCER RES, V50, P3915; CHENG KC, 1992, J BIOL CHEM, V267, P166; Christiansen M, 2003, NUCLEIC ACIDS RES, V31, P963, DOI 10.1093/nar/gkg164; Christmann M, 2002, NUCLEIC ACIDS RES, V30, P1959, DOI 10.1093/nar/30.9.1959; DOI S, 1994, MOL CARCINOGEN, V11, P197, DOI 10.1002/mc.2940110405; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; Gu YS, 2002, J BIOL CHEM, V277, P11135, DOI 10.1074/jbc.M108618200; Gu YS, 2001, NUCLEIC ACIDS RES, V29, P2666, DOI 10.1093/nar/29.12.2666; KAHLRAINER P, 1994, CARCINOGENESIS, V15, P779, DOI 10.1093/carcin/15.4.779; Klein IK, 2000, CANCER RES, V60, P2077; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; KUSUNOKI M, 1992, CANCER, V69, P24, DOI 10.1002/1097-0142(19920101)69:1<24::AID-CNCR2820690107>3.0.CO;2-1; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Olinski R, 2002, FREE RADICAL BIO MED, V33, P192, DOI 10.1016/S0891-5849(02)00878-X; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Parker AR, 2002, CANCER RES, V62, P7230; PARKER AR, 2003, IN PRESS CELL MOL LI; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Rossi R, 1999, EMBO J, V18, P5745, DOI 10.1093/emboj/18.20.5745; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Seidman MD, 1999, HEAD NECK-J SCI SPEC, V21, P467, DOI 10.1002/(SICI)1097-0347(199908)21:5<467::AID-HED14>3.0.CO;2-C; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; Verstovsek G, 1998, GASTROENTEROLOGY, V115, P75, DOI 10.1016/S0016-5085(98)70367-1; WALI RK, 1991, BIOCHIM BIOPHYS ACTA, V1092, P119, DOI 10.1016/0167-4889(91)90185-Z; WILLSON JKV, 1987, CANCER RES, V47, P2704; Yacoub A, 1997, CANCER RES, V57, P5457	30	38	40	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47937	47945		10.1074/jbc.M306598200	http://dx.doi.org/10.1074/jbc.M306598200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12966098	hybrid			2022-12-25	WOS:000186731400072
J	Han, BG; Dong, ZZ; Zhang, JT				Han, BG; Dong, ZZ; Zhang, JT			Tight control of platelet-derived growth factor B/c-sis expression by interplay between the 5 '-untranslated region sequence and the major upstream promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME ENTRY SITES; B-CHAIN EXPRESSION; MESSENGER-RNA; GENE-EXPRESSION; TRANSLATION INITIATION; INTERNAL TRANSLATION; REGULATORY ELEMENTS; FACTOR-II; CELLS; PROTEIN	The long and GC- rich 5'-untranslated region (5'-UTR) of the known 3.8-kb platelet-derived growth factor B (PDGF-B)/c-sis mRNA is highly conserved and inhibits its own translation. It has been thought that this 5'-UTR functions by regulating translation possibly using an internal ribosome entry site (IRES)-mediated mechanism. However, in the present study we found no evidence that the 5'-UTR sequence of PDGF-B mRNA contains any IRES activity. Instead, we found that the 5'-UTR sequence of PDGF-B functions as a promoter both constitutively and upon induction in a variety of cell lines. The 5'-UTR sequence contains two promoters (termed P1 and P2) when only the 5'-UTR sequence is analyzed. In the presence of the upstream TATA-box-containing promoter (P0), P1 and P0 promoters are integrated into one promoter, whereas the P2 promoter still functions. The full promoter with combined P0, P1, and P2 produced two transcripts, with the major one having the full-length 5'-UTR and the minor one the short 5'-UTR. The integrated P0/P1 promoter and P2 promoter are likely responsible for producing the endogenous 3.8- and 2.8-kb PDGF-B mRNAs that are detected in cultured human renal microvascular endothelial cells, a few tumor cells, and rat brain tissues. Furthermore, we detected the 2.8-kb PDGF-B mRNA in erythroleukemia K562 cells upon 12-O-tetradecanoylphorbol-13-acetate-induced differentiation. Considering that the 5'-UTR in the 3.8-kb mRNA contains no IRES activity and inhibits cap-dependent translation, we believe that the endogenous 2.8-kb mRNA produced from the 5'-UTR promoter is likely the major template responsible for protein production both constitutively and upon induction. We also found that the transcription from the 5'-UTR P2 promoter might be coordinated by the major upstream P0 promoter upon stimulation. Based on these observations, we propose that the TATA-containing P0 promoter and the 5'-UTR promoter work together to tightly control the expression of PDGF-B.	Indiana Univ, Sch Med, IUCC,Walther Oncol Ctr,Walther Canc Inst, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Zhang, JT (corresponding author), Indiana Univ, Sch Med, IUCC,Walther Oncol Ctr,Walther Canc Inst, Dept Pharmacol & Toxicol, 1044 W Walnut St,R4-166, Indianapolis, IN 46202 USA.		Zhang, Jian-Ting/L-8334-2015		NCI NIH HHS [CA 64539] Funding Source: Medline; NIGMS NIH HHS [GM 59475] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064539, R01CA064539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059475] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernstein J, 1997, J BIOL CHEM, V272, P9356; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; FEN Z, 1991, ONCOGENE, V6, P953; Gerlitz G, 2002, EUR J BIOCHEM, V269, P2810, DOI 10.1046/j.1432-1033.2002.02974.x; Han BG, 2003, ONCOGENE, V22, P5325, DOI 10.1038/sj.onc.1206783; Han BG, 2002, MOL CELL BIOL, V22, P7372, DOI 10.1128/MCB.22.21.7372-7384.2002; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Heller S, 2000, INT J CANCER, V85, P211; IGARASHI H, 1987, ONCOGENE, V1, P79; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JIN HM, 1994, J BIOL CHEM, V269, P28648; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; Kozak M, 2001, MOL CELL BIOL, V21, P1899, DOI 10.1128/MCB.21.6.1899-1907.2001; Kujoth GC, 1998, CELL GROWTH DIFFER, V9, P523; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; Mariani S, 2002, TRENDS ENDOCRIN MET, V13, P11, DOI 10.1016/S1043-2760(01)00518-5; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; RATNER L, 1987, NUCLEIC ACIDS RES, V15, P6017, DOI 10.1093/nar/15.15.6017; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; Sasahara M, 1998, ONCOGENE, V16, P1571, DOI 10.1038/sj.onc.1201679; Schneider R, 2001, MOL CELL BIOL, V21, P8238, DOI 10.1128/MCB.21.23.8238-8246.2001; Sella O, 1999, MOL CELL BIOL, V19, P5429; Taylor LM, 2000, J BIOL CHEM, V275, P16709, DOI 10.1074/jbc.275.22.16709; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; WANG J, 1994, CANCER RES, V54, P560; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232	35	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46983	46993		10.1074/jbc.M304976200	http://dx.doi.org/10.1074/jbc.M304976200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12960151	hybrid			2022-12-25	WOS:000186569400093
J	Swan, MK; Solomons, JTG; Beeson, CC; Hansen, T; Schonheit, P; Davies, C				Swan, MK; Solomons, JTG; Beeson, CC; Hansen, T; Schonheit, P; Davies, C			Structural evidence for a hydride transfer mechanism of catalysis in phosphoglucose isomerase from Pyrococcus furiosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGES; RABBIT; PROGRAM	In the Euryarchaeota species Pyrococcus furiosus and Thermococcus litoralis, phosphoglucose isomerase (PGI) activity is catalyzed by an enzyme unrelated to the well known family of PGI enzymes found in prokaryotes, eukaryotes, and some archaea. We have determined the crystal structure of PGI from Pyrococcus furiosus in native form and in complex with two active site ligands, 5-phosphoarabinonate and gluconate 6-phosphate. In these structures, the metal ion, which in vivo is presumed to be Fe2+, is located in the core of the cupin fold and is immediately adjacent to the C1-C2 region of the ligands, suggesting that Fe2+ is involved in catalysis rather than serving a structural role. The active site contains a glutamate residue that contacts the substrate, but, because it is also coordinated to the metal ion, it is highly unlikely to mediate proton transfer in a cis-enediol mechanism. Consequently, we propose a hydride shift mechanism of catalysis. In this mechanism, Fe2+ is responsible for proton transfer between O1 and O2, and the hydride shift between C1 and C2 is favored by a markedly hydrophobic environment in the active site. The absence of any obvious enzymatic machinery for catalyzing ring opening of the sugar substrates suggests that pyrococcal PGI has a preference for straight chain substrates and that metabolism in extreme thermophiles may use sugars in both ring and straight chain forms.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA; Univ Sussex, Sch Biol Sci, Grad Program, Brighton BN1 9QG, E Sussex, England; Univ Kiel, Inst Allgemeine Mikrobiol, D-24118 Kiel, Germany	Medical University of South Carolina; Medical University of South Carolina; University of Sussex; University of Kiel	Davies, C (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	davies@musc.edu						Anand R, 2002, BIOCHEMISTRY-US, V41, P7659, DOI 10.1021/bi0200965; Arsenieva D, 2002, J MOL BIOL, V323, P77, DOI 10.1016/S0022-2836(02)00892-6; Berrisford JM, 2003, J BIOL CHEM, V278, P33290, DOI 10.1074/jbc.M305170200; CHIRGWIN JM, 1975, J BIOL CHEM, V250, P7272; Davies C, 2003, ACTA CRYSTALLOGR D, V59, P453, DOI 10.1107/S0907444902023387; DELANO WL, 2002, PYMOL MOL MODELING S; Dunwell JM, 2000, MICROBIOL MOL BIOL R, V64, P153, DOI 10.1128/MMBR.64.1.153-179.2000; DYSON JED, 1968, J BIOL CHEM, V243, P1401; Hansen T, 2001, J BACTERIOL, V183, P3428, DOI 10.1128/JB.183.11.3428-3435.2001; Jeffery CJ, 2001, BIOCHEMISTRY-US, V40, P1560, DOI 10.1021/bi0018483; Jeong JJ, 2003, FEBS LETT, V535, P200, DOI 10.1016/S0014-5793(02)03900-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JH, 2001, BIOCHEMISTRY-US, V40, P7799, DOI 10.1021/bi002916o; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ostermeier M, 2001, ADV PROTEIN CHEM, V55, P29, DOI 10.1016/S0065-3233(01)55002-0; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; RAINES RT, 1986, BIOCHEMISTRY-US, V25, P7142, DOI 10.1021/bi00370a057; Read J, 2001, J MOL BIOL, V309, P447, DOI 10.1006/jmbi.2001.4680; ROSE IA, 1975, ADV ENZYMOL RAMB, V43, P491; Swan MK, 2003, PROTEIN PEPTIDE LETT, V10, P517, DOI 10.2174/0929866033478762; SWENSON CA, 1971, BIOCHEMISTRY-US, V10, P3151, DOI 10.1021/bi00792a026; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Verhees CH, 2001, J BIOL CHEM, V276, P40926, DOI 10.1074/jbc.M104603200; Watanabe H, 1996, CANCER RES, V56, P2960; WHITLOW M, 1991, PROTEINS, V9, P153, DOI 10.1002/prot.340090302; Xu W, 1996, BLOOD, V87, P4502, DOI 10.1182/blood.V87.11.4502.bloodjournal87114502	32	35	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47261	47268		10.1074/jbc.M308603200	http://dx.doi.org/10.1074/jbc.M308603200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12970347	hybrid			2022-12-25	WOS:000186569400127
J	Wang, P; Wang, CT; Bai, JH; Jackson, MB; Chapman, ER				Wang, P; Wang, CT; Bai, JH; Jackson, MB; Chapman, ER			Mutations in the effector binding loops in the C2A and C2B domains of synaptotagmin I disrupt exocytosis in a nonadditive manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE; CA2+ BINDING; C(2)A DOMAIN; 3-DIMENSIONAL STRUCTURE; PHOSPHOLIPID-BINDING; MEMBRANE-FUSION; SNARE COMPLEX; C-2 DOMAIN; PC12 CELLS; CALCIUM	The secretory vesicle protein synaptotagmin I (syt) plays a critical role in Ca2+-triggered exocytosis. Its cytoplasmic domain is composed of tandem C2 domains, C2A and C2B; each C2 domain binds Ca2+. Upon binding Ca2+, positively charged residues within the Ca2+-binding loops are thought to interact with negatively charged phospholipids in the target membrane to mediate docking of the cytoplasmic domain of syt onto lipid bilayers. The C2 domains of syt also interact with syntaxin and SNAP-25, two components of a conserved membrane fusion complex. Here, we have neutralized single positively charged residues at the membrane-binding interface of C2A (R233Q) and C2B (K366Q). Either of these mutations shifted the Ca2+ requirements for syt-liposome interactions from similar to20 to similar to40 muM Ca2+. Kinetic analysis revealed that the reduction in Ca2+-sensing activity was associated with a decrease in affinity for membranes. These mutations did not affect syt-syntaxin interactions but resulted in a similar to50% loss in SNAP-25 binding activity, suggesting that these residues lie at an interface between membranes and SNAP-25. Expression of full-length versions of syt that harbored these mutations reduced the rate of exocytosis in PC12 cells. In both biochemical and functional assays, effects of the R233Q and K366Q mutations were not additive, indicating that mutations in one domain affect the activity of the adjacent domain. These findings indicate that the tandem C2 domains of syt cooperate with one another to trigger release via loop-mediated electrostatic interactions with effector molecules.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Chapman, ER (corresponding author), Univ Wisconsin, Dept Physiol, 1300 Univ Ave,SMI 129, Madison, WI 53706 USA.		Wang, Chih-Tien/GRE-8232-2022	Wang, Chih-Tien/0000-0001-7639-7508; Chapman, Edwin/0000-0001-9787-8140	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061876] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044057] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 56827] Funding Source: Medline; NIMH NIH HHS [MH 61876] Funding Source: Medline; NINDS NIH HHS [NS 44057] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arac D, 2003, BIOCHEMISTRY-US, V42, P2774, DOI 10.1021/bi0272050; Bai JH, 2002, P NATL ACAD SCI USA, V99, P1665, DOI 10.1073/pnas.032541099; Bai JH, 2000, J BIOL CHEM, V275, P25427, DOI 10.1074/jbc.M906729199; BARK IC, 1994, GENE, V139, P291, DOI 10.1016/0378-1119(94)90773-0; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; CHAPMAN ER, 1992, BIOCHEMISTRY-US, V31, P12819, DOI 10.1021/bi00166a016; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Craxton M, 2001, GENOMICS, V77, P43, DOI 10.1006/geno.2001.6619; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Desai RC, 2000, J CELL BIOL, V150, P1125, DOI 10.1083/jcb.150.5.1125; Earles CA, 2001, J CELL BIOL, V154, P1117, DOI 10.1083/jcb.200105020; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fernandez I, 2001, NEURON, V32, P1057, DOI 10.1016/S0896-6273(01)00548-7; Fernandez-Chacon R, 2002, J NEUROSCI, V22, P8438; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fukuda M, 2002, J BIOL CHEM, V277, P4601, DOI 10.1074/jbc.C100588200; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; Littleton JT, 2001, J NEUROSCI, V21, P1421, DOI 10.1523/JNEUROSCI.21-05-01421.2001; Mackler JM, 2002, NATURE, V418, P340, DOI 10.1038/nature00846; Mackler JM, 2001, J COMP NEUROL, V436, P4, DOI 10.1002/cne.1049; Mahal LK, 2002, J CELL BIOL, V158, P273, DOI 10.1083/jcb.200203135; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; Matos MF, 2000, EUR J CELL BIOL, V79, P377, DOI 10.1078/0171-9335-00063; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Robinson IM, 2002, NATURE, V418, P336, DOI 10.1038/nature00915; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; Shao XG, 1998, BIOCHEMISTRY-US, V37, P16106, DOI 10.1021/bi981789h; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tucker WC, 2003, J CELL BIOL, V162, P199, DOI 10.1083/jcb.200302060; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Ubach J, 2001, BIOCHEMISTRY-US, V40, P5854, DOI 10.1021/bi010340c; Wang CT, 2001, SCIENCE, V294, P1111, DOI 10.1126/science.1064002; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wu Y, 2003, P NATL ACAD SCI USA, V100, P2082, DOI 10.1073/pnas.0435872100; Yoshihara M, 2002, NEURON, V36, P897, DOI 10.1016/S0896-6273(02)01065-6; Zhang XD, 2002, NEURON, V34, P599, DOI 10.1016/S0896-6273(02)00671-2	47	53	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47030	47037		10.1074/jbc.M306728200	http://dx.doi.org/10.1074/jbc.M306728200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963743	hybrid			2022-12-25	WOS:000186569400099
J	Prokop, Z; Monincova, M; Chaloupkova, R; Klvana, M; Nagata, Y; Janssen, DB; Damborsky, J				Prokop, Z; Monincova, M; Chaloupkova, R; Klvana, M; Nagata, Y; Janssen, DB; Damborsky, J			Catalytic mechanism of the haloalkane dehalogenase LinB from Sphingomonas paucimobilis UT26	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXACHLOROCYCLOHEXANE-DEGRADING BACTERIUM; SITE-DIRECTED MUTAGENESIS; X-RAY-STRUCTURE; KINETIC-ANALYSIS; SUBSTRATE CLASS; HALIDE-BINDING; STEADY-STATE; SPECIFICITY; EVOLUTION; MUTATIONS	Haloalkane dehalogenases are bacterial enzymes capable of carbon-halogen bond cleavage in halogenated compounds. To obtain insights into the mechanism of the haloalkane dehalogenase from Sphingomonas paucimobilis UT26 (LinB), we studied the steady-state and presteady-state kinetics of the conversion of the substrates 1-chlorohexane, chlorocyclohexane, and bromocyclohexane. The results lead to a proposal of a minimal kinetic mechanism consisting of three main steps: (i) substrate binding, (ii) cleavage of the carbon-halogen bond with simultaneous formation of an alkyl-enzyme intermediate, and (iii) hydrolysis of the alkyl-enzyme intermediate. Release of both products, halide and alcohol, is a fast process that was not included in the reaction mechanism as a distinct step. Comparison of the kinetic mechanism of LinB with that of haloalkane dehalogenase DhlA from Xantobacter autotrophicus GJ10 and the haloalkane dehalogenase DhaA from Rhodococcus rhodochrous NCIMB 13064 shows that the overall mechanisms are similar. The main difference is in the rate-limiting step, which is hydrolysis of the alkylenzyme intermediate in LinB, halide release in DhlA, and liberation of an alcohol in DhaA. The occurrence of different rate-limiting steps for three enzymes that belong to the same protein family indicates that extrapolation of this important catalytic property from one enzyme to another can be misleading even for evolutionary closely related proteins. The differences in the rate-limiting step were related to: (i) number and size of the entrance tunnels, (ii) protein flexibility, and (iii) composition of the halide-stabilizing active site residues based on comparison of protein structures.	Masaryk Univ, Natl Ctr Biomol Res, CS-61137 Brno, Czech Republic; Tohoku Univ, Grad Sch Life Sci, Dept Life Sci, Sendai, Miyagi 9808577, Japan; Univ Groningen, NL-9747 AG Groningen, Netherlands	Masaryk University Brno; Tohoku University; University of Groningen	Prokop, Z (corresponding author), Masaryk Univ, Natl Ctr Biomol Res, Kotlarska 2, CS-61137 Brno, Czech Republic.		Prokop, Zbynek/H-5707-2012; Chaloupkova, Radka/M-5565-2016; Damborsky, Jiri/H-3799-2012; Klvana, Martin/B-1299-2015	Prokop, Zbynek/0000-0001-9358-4081; Chaloupkova, Radka/0000-0002-3539-7445; Damborsky, Jiri/0000-0002-7848-8216; Klvana, Martin/0000-0002-5076-4936				Bohac M, 2002, BIOCHEMISTRY-US, V41, P14272, DOI 10.1021/bi026427v; Bosma T, 2003, BIOCHEMISTRY-US, V42, P8047, DOI 10.1021/bi026907m; Bosma T, 2002, APPL ENVIRON MICROB, V68, P3582, DOI 10.1128/AEM.68.7.3582-3587.2002; Damborsky J, 1999, PROTEIN ENG, V12, P989, DOI 10.1093/protein/12.11.989; Damborsky J, 1998, PURE APPL CHEM, V70, P1375, DOI 10.1351/pac199870071375; Gray KA, 2001, ADV SYNTH CATAL, V343, P607, DOI 10.1002/1615-4169(200108)343:6/7<607::AID-ADSC607>3.3.CO;2-D; Hynkova K, 1999, FEBS LETT, V446, P177, DOI 10.1016/S0014-5793(99)00199-4; JANSSEN DB, 1988, EUR J BIOCHEM, V171, P67, DOI 10.1111/j.1432-1033.1988.tb13759.x; KENNES C, 1995, EUR J BIOCHEM, V228, P403; Kmunicek J, 2001, BIOCHEMISTRY-US, V40, P8905, DOI 10.1021/bi010464p; Krooshof GH, 1998, BIOCHEMISTRY-US, V37, P15013, DOI 10.1021/bi9815187; Krooshof GH, 1997, BIOCHEMISTRY-US, V36, P9571, DOI 10.1021/bi971014t; Kulakova AN, 1997, MICROBIOL-SGM, V143, P109, DOI 10.1099/00221287-143-1-109; Lewandowicz A, 2001, J AM CHEM SOC, V123, P4550, DOI 10.1021/ja003503d; Marek J, 2000, BIOCHEMISTRY-US, V39, P14082, DOI 10.1021/bi001539c; Marvanova S, 2001, J MICROBIOL METH, V44, P149, DOI 10.1016/S0167-7012(00)00250-5; MENDES P, 1993, COMPUT APPL BIOSCI, V9, P563; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nagata Y, 1999, PROTEIN EXPRES PURIF, V17, P299, DOI 10.1006/prep.1999.1143; Nagata Y, 2003, APPL ENVIRON MICROB, V69, P2349, DOI 10.1128/AEM.69.4.2349-2355.2003; Nagata Y, 1997, APPL ENVIRON MICROB, V63, P3707, DOI 10.1128/AEM.63.9.3707-3710.1997; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otyepka M, 2002, PROTEIN SCI, V11, P1206, DOI 10.1110/ps.ps3830102; Paneth P, 2003, ACCOUNTS CHEM RES, V36, P120, DOI 10.1021/ar010101h; Pikkemaat MG, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.8.e35; PRIES F, 1994, J BIOL CHEM, V269, P17490; PRIES F, 1995, J BIOL CHEM, V270, P10405, DOI 10.1074/jbc.270.18.10405; PRIES F, 1994, BIOCHEMISTRY-US, V33, P1242, DOI 10.1021/bi00171a026; Schanstra JP, 1996, J BIOL CHEM, V271, P14747, DOI 10.1074/jbc.271.25.14747; Schanstra JP, 1996, BIOCHEMISTRY-US, V35, P5624, DOI 10.1021/bi952904g; Schanstra JP, 1997, PROTEIN ENG, V10, P53, DOI 10.1093/protein/10.1.53; Schanstra JP, 1996, BIOCHEMISTRY-US, V35, P13186, DOI 10.1021/bi961151a; Schindler JF, 1999, BIOCHEMISTRY-US, V38, P5772, DOI 10.1021/bi982853y; TERADA I, 1990, J BIOL CHEM, V265, P6576; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	36	70	72	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45094	45100		10.1074/jbc.M307056200	http://dx.doi.org/10.1074/jbc.M307056200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952988	hybrid, Green Published			2022-12-25	WOS:000186452300008
J	Ruone, S; Rhoades, AR; Formosa, T				Ruone, S; Rhoades, AR; Formosa, T			Multiple Nhp6 molecules are required to recruit Spt16-Pob3 to form yFACT complexes and to reorganize nucleosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; CATALYTIC SUBUNIT; PROTEINS NHP6A/B; HMG PROTEINS; DNA-BINDING; POB3; DETERMINANTS; ELONGATION; INTERACTS; GENES	Saccharomyces cerevisiae Nhp6 protein contains a DNA-binding motif that is similar to those found in the high mobility group B family of chromatin proteins. Nhp6 bound to nucleosomes and made at least two changes in them: the nucleosomal DNA became more sensitive to DNase I at specific sites, and the nucleosomes became competent to bind Spt16-Pob3 to form yFACT.nucleosome complexes. Both changes occurred at similar concentrations of Nhp6, suggesting that they reflect the same structural reorganization of the nucleosome. Nucleosomes have multiple binding sites for Nhp6, and structural reorganization was associated with a concentration of Nhp6 about 10-fold higher than that needed for simple binding. We propose that the coordinated action of multiple Nhp6 molecules is required to convert nucleosomes to an alternative form as the first step in a two-step reorganization of nucleosomes with the second step being dependent on Spt16-Pob3. The presence of linker DNA had only subtle effects on these processes, indicating that both Nhp6 and yFACT act on core nucleosome structure rather than on the interaction between nucleosomes and adjacent DNA. These results suggest that Nhp6 and the related high mobility group B proteins may have a general role in promoting rearrangements of chromatin by initiating the destabilization of core nucleosomal structure.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Formosa, T (corresponding author), Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA.	Tim@biochem.utah.edu		Formosa, Tim/0000-0002-8477-2483				Allain FHT, 1999, EMBO J, V18, P2563, DOI 10.1093/emboj/18.9.2563; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Brewster NK, 1998, J BIOL CHEM, V273, P21972, DOI 10.1074/jbc.273.34.21972; Brewster NK, 2001, MOL CELL BIOL, V21, P3491, DOI 10.1128/MCB.21.10.3491-3502.2001; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Bustin M, 1999, MOL CELL BIOL, V19, P5237; COSTIGAN C, 1994, MOL CELL BIOL, V14, P2391, DOI 10.1128/MCB.14.4.2391; Formosa T, 2001, EMBO J, V20, P3506, DOI 10.1093/emboj/20.13.3506; Formosa T, 2003, CURR TOP MICROBIOL, V274, P171; Formosa T, 2002, GENETICS, V162, P1557; GRAZIANO V, 1988, J MOL BIOL, V203, P997, DOI 10.1016/0022-2836(88)90124-6; John S, 2000, GENE DEV, V14, P1196; Kolodrubetz D, 2001, GENE, V272, P93, DOI 10.1016/S0378-1119(01)00568-6; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; Luger K, 1999, METHOD ENZYMOL, V304, P3; Okuhara K, 1999, CURR BIOL, V9, P341, DOI 10.1016/S0960-9822(99)80160-2; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Paull TT, 1996, GENE DEV, V10, P2769, DOI 10.1101/gad.10.21.2769; PAULL TT, 1995, J BIOL CHEM, V270, P8744, DOI 10.1074/jbc.270.15.8744; Ross ED, 2001, MOL CELL BIOL, V21, P6598, DOI 10.1128/MCB.21.19.6598-6605.2001; SAMBROOK J., 1989, MOL CLONING LAB MANU, pB23; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; van Holde K.E., 1988, CHROMATIN; Wittmeyer J, 1999, BIOCHEMISTRY-US, V38, P8961, DOI 10.1021/bi982851d; Wittmeyer J, 1997, MOL CELL BIOL, V17, P4178, DOI 10.1128/MCB.17.7.4178; Yen YM, 1998, J BIOL CHEM, V273, P4424, DOI 10.1074/jbc.273.8.4424; Yu YX, 2000, MOL CELL BIOL, V20, P2350, DOI 10.1128/MCB.20.7.2350-2357.2000	31	61	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45288	45295		10.1074/jbc.M307291200	http://dx.doi.org/10.1074/jbc.M307291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952948	hybrid			2022-12-25	WOS:000186452300030
J	Seibold, SA; Ball, T; Hsi, LC; Mills, DA; Abeysinghe, RD; Micielli, R; Rieke, CJ; Cukier, RI; Smith, WL				Seibold, SA; Ball, T; Hsi, LC; Mills, DA; Abeysinghe, RD; Micielli, R; Rieke, CJ; Cukier, RI; Smith, WL			Histidine 386 and its role in cyclooxygenase and peroxidase catalysis by prostaglandin-endoperoxide H synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER OXIDATION-STATE; MOLECULAR-DYNAMICS; ARACHIDONIC-ACID; NITRIC-OXIDE; SELECTIVE-INHIBITION; PROXIMAL LIGAND; FATTY-ACIDS; COMPOUND-I; HEME; BINDING	Prostaglandin-endoperoxide H synthases (PGHSs) have a cyclooxygenase that forms prostaglandin (PG) G(2) from arachidonic acid (AA) plus oxygen and a peroxidase that reduces the PGG(2) to PGH(2). The peroxidase activates the cyclooxygenase. This involves an initial oxidation of the peroxidase heme group by hydroperoxide, followed by oxidation of Tyr(385) to a tyrosyl radical within the cyclooxygenase site. His(386) of PGHS-1 is not formally part of either active site, but lies in an extended helix between Tyr(385), which protrudes into the cyclooxygenase site, and His(388), the proximal ligand of the peroxidase heme. When His(386) was substituted with alanine in PGHS-1, the mutant retained < 2.5% of the native peroxidase activity, but > 20% of the native cyclooxygenase activity. However, peroxidase activity could be restored (10-30%) by treating H386A PGHS-1 with cyclooxygenase inhibitors or AA, but not with linoleic acid; in contrast, mere occupancy of the cyclooxygenase site of native PGHS-1 had no effect on peroxidase activity. Heme titrations indicated that H386A PGHS-1 binds heme less tightly than does native PGHS-1. The low peroxidase activity and decreased affinity for heme of H386A PGHS-1 imply that His(386) helps optimize heme binding. Molecular dynamic simulations suggest that this is accomplished in part by a hydrogen bond between the heme D-ring propionate and the N-delta of Asn(382) of the extended helix. The structure of the extended helix is, in turn, strongly supported by stable hydrogen bonding between the N-delta of His(386) and the backbone carbonyl oxygens of Asn(382) and Gln(383). We speculate that the binding of cyclooxygenase inhibitors or AA to the cyclooxygenase site of ovine H386A PGHS-1 reopens the constriction in the cyclooxygenase site between the extended helix and a helix containing Gly(526) and Ser(530) and restores native-like structure to the extended helix. Being less bulky than AA, linoleic acid is apparently unable to reopen this constriction.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	University of Michigan System; University of Michigan; Michigan State University; Michigan State University	Smith, WL (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 5416 Med Sci I,1301 Catherine St, Ann Arbor, MI 48109 USA.	smithww@umich.edu			NIGMS NIH HHS [P01 GM57323, R01 GM68848] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057323, R01GM068848] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bakovic M, 1996, J BIOL CHEM, V271, P2048, DOI 10.1074/jbc.271.4.2048; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Blair-Johnson M, 2001, BIOCHEMISTRY-US, V40, P13990, DOI 10.1021/bi0111808; Case DA, 2002, AMBER SIMULATION SOF; Cukier RI, 2002, J PHYS CHEM B, V106, P12031, DOI 10.1021/jp021232i; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; DeWitt DL, 1999, MOL PHARMACOL, V55, P625; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Goodwin DC, 2000, BIOCHEMISTRY-US, V39, P5422, DOI 10.1021/bi992752f; Goodwin DC, 1998, J BIOL CHEM, V273, P8903, DOI 10.1074/jbc.273.15.8903; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; Hirst J, 2001, BIOCHEMISTRY-US, V40, P1274, DOI 10.1021/bi002090q; HSI LC, 1994, BIOCHEM BIOPH RES CO, V202, P1592, DOI 10.1006/bbrc.1994.2114; Hwang D, 2001, FASEB J, V15, P2556, DOI 10.1096/fj.01-0432com; Koljak R, 2001, J BIOL CHEM, V276, P7033, DOI 10.1074/jbc.M009803200; Kozak KR, 2001, J BIOL CHEM, V276, P30072, DOI 10.1074/jbc.M104467200; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; Loll PJ, 2001, MOL PHARMACOL, V60, P1407, DOI 10.1124/mol.60.6.1407; Lu GQ, 1999, J BIOL CHEM, V274, P16162, DOI 10.1074/jbc.274.23.16162; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; Malkowski MG, 2001, J BIOL CHEM, V276, P37547, DOI 10.1074/jbc.M105982200; MARNETT LJ, 1988, J BIOL CHEM, V263, P16532; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; Marnett LJ, 1999, TRENDS PHARMACOL SCI, V20, P465, DOI 10.1016/S0165-6147(99)01385-1; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; MUNOZ V, 1995, CURR OPIN BIOTECH, V6, P382, DOI 10.1016/0958-1669(95)80066-2; Newmyer SL, 1996, BIOCHEMISTRY-US, V35, P12788, DOI 10.1021/bi9609331; ODENWALLER R, 1992, J BIOL CHEM, V267, P13863; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Poulos TL, 1996, J BIOL INORG CHEM, V1, P356, DOI 10.1007/s007750050064; POULOS TL, 1997, BIOCHEMISTRY-US, V36, P1010; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SANCHO J, 1992, BIOCHEMISTRY-US, V31, P2253, DOI 10.1021/bi00123a006; SCHAFMEISTER CEA, 1995, LEAP SOFTWARE PACKAG; Schelvis JPM, 2000, J PHYS CHEM B, V104, P10844, DOI 10.1021/jp0016434; Schneider C, 2000, J BIOL CHEM, V275, P4743, DOI 10.1074/jbc.275.7.4743; Seibold SA, 2000, BIOCHEMISTRY-US, V39, P6616, DOI 10.1021/bi0002333; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; Smith T, 2000, ARCH BIOCHEM BIOPHYS, V375, P195, DOI 10.1006/abbi.1999.1659; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Smulevich G, 1998, BIOSPECTROSCOPY, V4, pS3, DOI 10.1002/(SICI)1520-6343(1998)4:5+<S3::AID-BSPY2>3.0.CO;2-R; Song I, 2001, BIOCHEM BIOPH RES CO, V289, P869, DOI 10.1006/bbrc.2001.6071; Spencer AG, 1999, J BIOL CHEM, V274, P32936, DOI 10.1074/jbc.274.46.32936; STRIEDER S, 1992, J BIOL CHEM, V267, P13870; Tamura K, 1996, J AM CHEM SOC, V118, P9434, DOI 10.1021/ja9543457; Taniura S, 2002, J BIOL CHEM, V277, P16823, DOI 10.1074/jbc.M200527200; Thuresson ED, 2001, J BIOL CHEM, V276, P10347, DOI 10.1074/jbc.M009377200; Tsai AL, 2002, J BIOL CHEM, V277, P38311, DOI 10.1074/jbc.M206961200; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; UENO R, 1982, J BIOL CHEM, V257, P5584; van der Donk WA, 2002, BIOCHEMISTRY-US, V41, P15451, DOI 10.1021/bi026938h; WEI CH, 1995, BIOCHEMISTRY-US, V34, P8499, DOI 10.1021/bi00026a034; Zou J, 1999, BIOCHEM J, V340, P153, DOI 10.1042/bj3400153	66	9	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46163	46170		10.1074/jbc.M306319200	http://dx.doi.org/10.1074/jbc.M306319200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952981	hybrid			2022-12-25	WOS:000186452300134
J	Shan, YX; Yang, TL; Mestril, R; Wang, PH				Shan, YX; Yang, TL; Mestril, R; Wang, PH			Hsp10 and Hsp60 suppress ubiquitination of insulin-like growth factor-1 receptor and augment insulin-like growth factor-1 receptor signaling in cardiac muscle - Implications on decreased myocardial protection in diabetic cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC HEAT-SHOCK-PROTEIN-60; PHOSPHATIDYLINOSITOL 3-KINASE; EXPRESSION; APOPTOSIS; OVEREXPRESSION; ACTIVATION; ISCHEMIA; STRESS; CELLS; RAT	We have investigated the effects of two heat shock proteins, Hsp10 and Hsp60, on insulin-like growth factor-1 receptor (IGF-1R) signaling in cardiac muscle cells. Neonatal cardiomyocytes were transduced with Hsp10 or Hsp60 via adenoviral vector. Compared with the cells transduced with a control vector, overexpression of Hsp10 or Hsp60 increased the abundance of IGF-1R and IGF-1-stimulated receptor autophosphorylation. Thus, Hsp10 and Hsp60 overexpression increased the number of functioning receptors and amplified activation of IGF-1R signaling. IGF-1 stimulation of MEK, Erk, p90Rsk, and Akt were accordingly augmented. Transducing cardiomyocytes with antisense Hsp60 oligonucleotides reduced Hsp60 expression, decreased the abundance of IGF-1R, attenuated IGF-1R autophosphorylation, and suppressed the pro-survival action of IGF-1 in cardiomyocytes. Using cycloheximide to inhibit protein synthesis did not alter the effect of Hsp60 on IGF-1R signaling, and IGF-1R mRNA levels were not up-regulated by Hsp10 or Hsp60. Additional experiments showed that Hsp10 and Hsp60 suppressed polyubiquitination of IGF-1 receptor. These data indicate that Hsp10 and Hsp60 can modulate IGF-1R signaling through post-translational modification. In animal models of diabetes, diabetic myocardium is associated with decreased abundance of Hsp60, increased ubiquitination of IGF-1R, and lower level of IGF-1R protein. Declined myocardial protection is a major feature of diabetic cardiomyopathy. These data suggest that decreased Hsp60 expression and subsequent decline of IGF-1R signaling may be a fundamental mechanism underlying the development of diabetic cardiomyopathy.	Univ Calif Irvine, Ctr Cardiovasc Hormone Res, Dept Med Biol Chem Physiol & Biophys, Irvine, CA 92697 USA; First Med Univ, Nanfang Hosp, Dept Med, Guangzhou 510515, Peoples R China; Loyola Univ, Dept Physiol, Maywood, IL 60153 USA	University of California System; University of California Irvine; Southern Medical University - China; Loyola University Chicago	Wang, PH (corresponding author), Univ Calif Irvine, Dept Med, C240, Irvine, CA 92697 USA.	phwang@uci.edu		Mestril, Ruben/0000-0003-3631-2236				Barazi HO, 2002, CANCER RES, V62, P1541; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; CONDORELLI G, 1994, J BIOL CHEM, V269, P8510; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; Dalle S, 2002, MOL CELL BIOL, V22, P6272, DOI 10.1128/MCB.22.17.6272-6285.2002; Gupta S, 2002, CIRCULATION, V106, P2727, DOI 10.1161/01.CIR.0000038112.64503.6E; Izaki K, 2001, MOL BRAIN RES, V88, P14, DOI 10.1016/S0169-328X(01)00012-2; Kajstura J, 2001, DIABETES, V50, P1414, DOI 10.2337/diabetes.50.6.1414; Kim JJ, 2002, GROWTH HORM IGF RES, V12, P84, DOI 10.1054/ghir.2002.0265; Kirchhoff SR, 2002, CIRCULATION, V105, P2899, DOI 10.1161/01.CIR.0000019403.35847.23; Latchman DS, 2001, CARDIOVASC RES, V51, P637, DOI 10.1016/S0008-6363(01)00354-6; Lau S, 1997, CIRCULATION, V96, P2287; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Li Q, 1997, J CLIN INVEST, V100, P1991, DOI 10.1172/JCI119730; Lin KM, 2001, CIRCULATION, V103, P1787, DOI 10.1161/01.CIR.103.13.1787; Parrizas M, 1997, J BIOL CHEM, V272, P154; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Schafler AE, 2002, BASIC RES CARDIOL, V97, P258, DOI 10.1007/s003950200019; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; Shah M, 2002, J BIOL CHEM, V277, P45662, DOI 10.1074/jbc.M205935200; Wang PH, 1999, ENDOCRINOLOGY, V140, P1141, DOI 10.1210/en.140.3.1141; Wang PH, 2001, CIRC RES, V88, P552, DOI 10.1161/01.RES.88.6.552; Wu WH, 2000, J BIOL CHEM, V275, P40113, DOI 10.1074/jbc.M004108200	25	67	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45492	45498		10.1074/jbc.M304498200	http://dx.doi.org/10.1074/jbc.M304498200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12970367	hybrid			2022-12-25	WOS:000186452300055
J	Srivastava, S; Matsuda, M; Hou, ZY; Bailey, JP; Kitazawa, R; Herbst, MP; Horseman, ND				Srivastava, S; Matsuda, M; Hou, ZY; Bailey, JP; Kitazawa, R; Herbst, MP; Horseman, ND			Receptor activator of NF-kappa B ligand induction via Jak2 and Stat5a in mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN D1 EXPRESSION; GLAND DEVELOPMENT; OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN-LIGAND; PROGESTERONE-RECEPTOR; SIGNAL TRANSDUCER; GENE-EXPRESSION; PROLACTIN; GROWTH; PROMOTER	Prolactin (PRL) is the primary hormone that, in conjunction with local factors, leads to lobuloalveolar development during pregnancy. Recently, receptor activator of NF-kappaB ligand (RANKL) has been identified as one of the effector molecules essential for lobuloalveolar development. The molecular mechanisms by which PRL may induce RANKL expression have not been carefully examined. Here we report that RANKL expression in the mammary gland is developmentally regulated and dependent on PRL and progesterone, whereas its receptor RANK (receptor activator of NF-kappaB) and decoy receptor osteoprotegerin (OPG) are constitutively expressed at all stages in both normal (PRL+/-) and prolactin knockout (PRL-/-) mice. In vitro, PRL markedly increased RANKL expression in primary mammary epithelial cells and RANKL-luciferase reporter activity in CHOD6 cells, which constitutively express the PRL receptor. We identified a gamma-interferon activation sequence (GAS) in the region between residues -965 to -725 of the RANKL promoter, which conferred a PRL response. Using dominant negative mutants of recombinant Jak2 and Stat5 in CHOD6 cells, and by reconstituting the Jak2/Stat5 pathway in COS7 cells, we determined that Jak2 and Stat5a are essential for the PRL-induced RANKL expression in mammary gland.	Univ Cincinnati, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 113003, Japan; Kobe Univ, Dept Pathol, Kobe, Hyogo 6500017, Japan	University System of Ohio; University of Cincinnati; University of Tokyo; Kobe University	Horseman, ND (corresponding author), Univ Cincinnati, Dept Cellular & Mol Physiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	nelson.horseman@uc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R43DK053124] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-53124] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Brisken C, 2002, DEV CELL, V3, P877, DOI 10.1016/S1534-5807(02)00365-9; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Brisken C, 2002, J MAMMARY GLAND BIOL, V7, P39, DOI 10.1023/A:1015718406329; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Clarkson RWE, 1999, J MAMMARY GLAND BIOL, V4, P165, DOI 10.1023/A:1018725207969; Fantl V, 1999, DEV BIOL, V212, P1, DOI 10.1006/dbio.1999.9329; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Gao J, 1996, MOL ENDOCRINOL, V10, P847, DOI 10.1210/me.10.7.847; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hinz M, 2002, J EXP MED, V196, P605, DOI 10.1084/jem.20020062; Horseman ND, 1999, J MAMMARY GLAND BIOL, V4, P79, DOI 10.1023/A:1018708704335; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; Hou ZY, 2003, MOL ENDOCRINOL, V17, P1910, DOI 10.1210/me.2003-0045; Hovey RC, 2003, MOL ENDOCRINOL, V17, P460, DOI 10.1210/me.2002-0214; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; IMAGAWA W, 1982, P NATL ACAD SCI-BIOL, V79, P4074, DOI 10.1073/pnas.79.13.4074; Kelly PA, 2002, MOL CELL ENDOCRINOL, V197, P127, DOI 10.1016/S0303-7207(02)00286-1; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Kim HJ, 2002, J BIOL CHEM, V277, P5339, DOI 10.1074/jbc.M108342200; Kitazawa R, 1999, BBA-GENE STRUCT EXPR, V1445, P134, DOI 10.1016/S0167-4781(99)00032-9; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Matsuda M, 2003, ENDOCRINE, V20, P91, DOI 10.1385/ENDO:20:1-2:91; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; NANDI S, 1958, J NATL CANCER I, V21, P1039; Neville MC, 2002, J MAMMARY GLAND BIOL, V7, P49, DOI 10.1023/A:1015770423167; Ormandy CJ, 1997, J MAMMARY GLAND BIOL, V2, P355, DOI 10.1023/A:1026395229025; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Shyamala G, 1999, J MAMMARY GLAND BIOL, V4, P89, DOI 10.1023/A:1018760721173; Silberstein GB, 1996, CELL GROWTH DIFFER, V7, P945; Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Vomachka AJ, 2000, ONCOGENE, V19, P1077, DOI 10.1038/sj.onc.1203348; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Watson CJ, 2001, J MAMMARY GLAND BIOL, V6, P115, DOI 10.1023/A:1009524817155; Xie J, 2002, J BIOL CHEM, V277, P14020, DOI 10.1074/jbc.M112399200	44	94	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46171	46178		10.1074/jbc.M308545200	http://dx.doi.org/10.1074/jbc.M308545200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952963	hybrid			2022-12-25	WOS:000186452300135
J	Cai, Y; Jin, JJ; Tomomori-Sato, C; Sato, S; Sorokina, I; Parmely, TJ; Conaway, RC; Conaway, JW				Cai, Y; Jin, JJ; Tomomori-Sato, C; Sato, S; Sorokina, I; Parmely, TJ; Conaway, RC; Conaway, JW			Identification of new subunits of the multiprotein mammalian TRRAP/TIP60-containing histone acetyltransferase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ACETYLASE COMPLEX; TRANSCRIPTIONAL ACTIVATION; NUCLEOSOME ACETYLATION; BINDING PROTEIN; YEAST; NUA4; CHROMATIN; MRG15; ENHANCER	The mammalian ATM/PI 3-kinase-related TRRAP protein was previously found to be a component of a multiprotein histone acetyltransferase ( HAT) complex containing the HAT TIP60. In this report, we identify a previously uncharacterized protein encoded by the FLJ10914 ORF, which we designate MRGBP, as a new component of the TRRAP/TIP60 HAT complex. In addition, through purification of MRGBP and its associated proteins from HeLa cell nuclear extracts, we identify the thyroid receptor coactivating protein (TRCp120), DMAP1, and the related MRG15 and MRGX proteins as MRGBP-associating proteins, and we present biochemical evidence that they are previously unrecognized components of the TRRAP/TIP60 HAT complex. Taken together, our findings shed new light on the structure and function of the mammalian TRRAP/TIP60 histone acetyltransferase complex.	Stowers Inst Med Res, Kansas City, MO 64110 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Stowers Institute for Medical Research; University of Kansas; University of Kansas Medical Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Conaway, JW (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.			Conaway, Joan/0000-0002-2786-0663; Sorokina, Irina/0000-0003-1531-1832; Tomomori-Sato, Chieri/0000-0002-2543-293X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Boudreault AA, 2003, GENE DEV, V17, P1415, DOI 10.1101/gad.1056603; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Brower CS, 2002, P NATL ACAD SCI USA, V99, P10353, DOI 10.1073/pnas.162424199; Cavusoglu N, 2003, PROTEOMICS, V3, P217, DOI 10.1002/pmic.200390030; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eisen A, 2001, J BIOL CHEM, V276, P3484, DOI 10.1074/jbc.M008159200; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Le Masson I, 2003, MOL CELL BIOL, V23, P6086, DOI 10.1128/MCB.23.17.6086-6102.2003; Leung JK, 2001, J BIOL CHEM, V276, P39171, DOI 10.1074/jbc.M103435200; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Matangkasombut O, 2003, MOL CELL, V11, P353, DOI 10.1016/S1097-2765(03)00033-9; Monden T, 1997, J BIOL CHEM, V272, P29834, DOI 10.1074/jbc.272.47.29834; Nourani A, 2001, MOL CELL BIOL, V21, P7629, DOI 10.1128/MCB.21.22.7629-7640.2001; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Pardo PS, 2002, J BIOL CHEM, V277, P50860, DOI 10.1074/jbc.M203839200; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sato S, 2003, J BIOL CHEM, V278, P15123, DOI 10.1074/jbc.C300054200; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Yochum GS, 2002, MOL CELL BIOL, V22, P7868, DOI 10.1128/MCB.22.22.7868-7876.2002	26	167	185	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42733	42736		10.1074/jbc.C300389200	http://dx.doi.org/10.1074/jbc.C300389200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12963728	hybrid			2022-12-25	WOS:000186157000002
J	Goueli, BS; Janknecht, R				Goueli, BS; Janknecht, R			Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor	ONCOGENE			English	Article						E-box; human telomerase reverse transcriptase (hTERT); Myc; transcription; upstream regulatory factor (USF)	FACTOR USF; C-MYC; MEDIATED REGULATION; CATALYTIC SUBUNIT; ACTIVATION; PROMOTER; HTERT; PROTEIN; KINASE; CELLS	Upregulation of human telomerase reverse transcriptase (hTERT) transcription accounts for the immortalization of greater than 85% of all human tumor cells. However, the mechanism whereby hTERT expression is activated remains unresolved. Specifically, recent data challenging the role of Myc/Max in E-box-dependent activation of hTERT expression suggests that other E-box-binding proteins regulate hTERT transcription. Indeed, we now demonstrate that two such proteins, upstream stimulatory factor (USF) 1 and 2, readily associate with two E-boxes in the hTERT promoter in vitro and in vivo primarily as heterodimers, whereas Myc/Max does not. The avid binding of USF1/2 heterodimers to these E-boxes occurs in both hTERT-positive and -negative cells. In contrast, USF1/2 activates the hTERT promoter exclusively in hTERT-positive cells in a manner that is enhanced by the coactivator p300 and attenuated upon inhibiting p38-MAP kinase, a known modulator of USF activity. Collectively, our data indicate that USF binding to the hTERT promoter may be transcriptionally neutral, or even repressive, in nonimmortalized hTERT-negative somatic cells, but stimulatory in hTERT-positive cells where USF1/2 contributes to the acquisition and maintenance of immortality.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Janknecht, R (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.			Janknecht, Ralf/0000-0003-1741-1562				Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; BredemeierErnst I, 1997, FEBS LETT, V408, P47, DOI 10.1016/S0014-5793(97)00387-6; Breen GAM, 1999, BBA-GEN SUBJECTS, V1428, P169, DOI 10.1016/S0304-4165(99)00061-6; Dhaene K, 2000, J PATHOL, V190, P80; Dillner NB, 2002, J BIOL CHEM, V277, P33890, DOI 10.1074/jbc.M204399200; Drissi R, 2001, J BIOL CHEM, V276, P29994, DOI 10.1074/jbc.M101899200; Ducrest AL, 2002, ONCOGENE, V21, P541, DOI 10.1038/sj.onc.1205081; Ducrest AL, 2001, CANCER RES, V61, P7594; Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022; Goodman RH, 2000, GENE DEV, V14, P1553; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Heckert LL, 2001, MOL ENDOCRINOL, V15, P704, DOI 10.1210/me.15.5.704; Hiyama E, 2002, ONCOGENE, V21, P643, DOI 10.1038/sj.onc.1205070; Horikawa I, 2002, MOL BIOL CELL, V13, P2585, DOI 10.1091/mbc.E01-11-0107; HORIUCHI K, 1981, CANCER RES, V41, P1488; Janknecht R, 2002, HISTOL HISTOPATHOL, V17, P657, DOI 10.14670/HH-17.657; Kumari D, 2001, J BIOL CHEM, V276, P4357, DOI 10.1074/jbc.M009629200; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Won JJ, 2002, FASEB J, V16, P1943, DOI 10.1096/fj.02-0311fje; Yago M, 2002, FEBS LETT, V520, P40, DOI 10.1016/S0014-5793(02)02757-6	32	95	98	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					8042	8047		10.1038/sj.onc.1206847	http://dx.doi.org/10.1038/sj.onc.1206847			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970752				2022-12-25	WOS:000185388200019
J	Li, YQ; Liu, D; Chen, DS; Kharbanda, S; Kufe, D				Li, YQ; Liu, D; Chen, DS; Kharbanda, S; Kufe, D			Human DF3/MUC1 carcinoma-associated protein functions as an oncogene	ONCOGENE			English	Article						DF3/MUC1; 3Y1 cells; anchorage-independent growth; cellular transformation	BETA-CATENIN; CELL-ADHESION; C-SRC; ANTIGEN; CANCER; DF3	The human DF3/MUC1 mucin-like glycoprotein is aberrantly overexpressed by most carcinomas of the breast and other epithelia. The contribution of MUC1 overexpression to the malignant phenotype is, however, not known. In the present studies, we have stably expressed MUC1 in rat 3Y1 fibroblasts. MUC1-positive cells were selected from independent transfections. The results demonstrate that, as found in human carcinomas, MUC1 is expressed on the cell surface and as a complex with P-catenin in the nucleus of the transfectants. Colony formation in soft agar demonstrates that cells expressing MUC1, but not the empty vector, exhibit anchorage-independent growth. The results also show that MUC1 expression confers tumor formation in nude mice. These findings provide the first evidence that MUC1 induces cellular transformation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; ILEX Prod Inc, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NCI NIH HHS [R01 CA097098, CA97098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; Kondo K, 1998, CANCER RES, V58, P2014; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGHTENBERG M, 1992, CANCER RES, V52, P223; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; VLERNINCKX K, 1991, CELL, V66, P107; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492	17	168	186	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6107	6110		10.1038/sj.onc.1206732	http://dx.doi.org/10.1038/sj.onc.1206732			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955090	Green Accepted			2022-12-25	WOS:000185137800020
J	Gingras, M; Bergeron, J; Dery, J; Durham, HD; Berthod, F				Gingras, M; Bergeron, J; Dery, J; Durham, HD; Berthod, F			In vitro development of a tissue-engineered model of peripheral nerve regeneration to study neurite growth	FASEB JOURNAL			English	Article						axon guidance; biomaterial; peripheral nervous system; keratinocytes; NGF	SCHWANN-CELL INVASION; LONG-TERM CULTURE; NEUROTROPHIC FACTOR; SENSORY NEURONS; COLLAGEN SPONGE; SKIN EQUIVALENT; AXONAL GROWTH; FIBROBLASTS; OUTGROWTH; EXPRESSION	A unique tissue-engineered model of peripheral nerve regeneration was developed in vitro to study neurite outgrowth. Mouse dorsal root ganglia neurons were seeded on a collagen sponge populated with human endothelial cells and/or human fibroblasts. Addition of nerve growth factor (NGF; 10 ng/ml) was not required for sensory neurons survival but was necessary to promote neurite outgrowth, as assessed by immunostaining of the 150 kDa neurofilament. A vigorous neurite elongation was detected inside the reconstructed tissue after 14 and 31 days of neurons culture, reaching up to 770 mum from day 14. Axons were often observed closely associated with the capillary-like tubes reconstructed in the model, in a similar pattern as in the human dermis. The presence of endothelial cells induced a significant increase of the neurite elongation after 14 days of culture. The addition of human keratinocytes totally avoided the twofold decrease in the amount of neurites observed between 14 and 31 days in controls. Besides the addition of NGF, axonal growth did not necessitate B27 supplement or glial cell coculture to be promoted and stabilized for long-term culture. Thus, this model might be a valuable tool to study the effect of various cells and/or attractive or repulsive molecules on neurite outgrowth in vitro.	Univ Laval, CHA, Hop St Sacrement, Lab Organogenese Expt, Quebec City, PQ G1S 4L8, Canada; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	Laval University; McGill University	Berthod, F (corresponding author), Univ Laval, CHA, Hop St Sacrement, Lab Organogenese Expt, 1050 Chemin St Foy, Quebec City, PQ G1S 4L8, Canada.	berthod@chg.ulaval.ca		Berthod, Francois/0000-0003-3580-0297				ACHESON A, 1991, NEURON, V7, P265, DOI 10.1016/0896-6273(91)90265-2; AUGER FA, 1995, IN VITRO CELL DEV-AN, V31, P432; Backstrom E, 2000, J IMMUNOL, V165, P4895, DOI 10.4049/jimmunol.165.9.4895; Balgude AP, 2001, BIOMATERIALS, V22, P1077, DOI 10.1016/S0142-9612(00)00350-1; Becq H, 1999, J NEUROSCI RES, V58, P553, DOI 10.1002/(SICI)1097-4547(19991115)58:4<553::AID-JNR8>3.0.CO;2-8; Berthod F, 1996, J BIOMED MATER RES, V32, P87, DOI 10.1002/(SICI)1097-4636(199609)32:1<87::AID-JBM10>3.0.CO;2-F; Berthod F, 1997, J INVEST DERMATOL, V108, P737, DOI 10.1111/1523-1747.ep12292122; BERTHOD F, 1993, BIOMATERIALS, V14, P749, DOI 10.1016/0142-9612(93)90039-5; BERTHOD F, 1994, CLIN MATER, V15, P259, DOI 10.1016/0267-6605(94)90055-8; Berthod F, 1997, SKIN SUBSTITUTE PROD, P23; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; Borkenhagen M, 1998, J BIOMED MATER RES, V40, P392, DOI 10.1002/(SICI)1097-4636(19980603)40:3<392::AID-JBM8>3.3.CO;2-4; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Byers MR, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008870; Cantarella G, 2002, FASEB J, V16, P1307, DOI 10.1096/fj.01-1000fje; Cao X, 2001, NEUROSCIENCE, V103, P831, DOI 10.1016/S0306-4522(01)00029-X; Cheng B, 2002, MICROSURG, V22, P133, DOI 10.1002/micr.21740; D'Arcangelo D, 2000, CIRC RES, V86, P312, DOI 10.1161/01.RES.86.3.312; DANIELSEN N, 1988, J NEUROSCI RES, V20, P320, DOI 10.1002/jnr.490200306; Doroudchi MM, 1996, J NEUROPATH EXP NEUR, V55, P246, DOI 10.1097/00005072-199602000-00013; Dubey N, 1999, EXP NEUROL, V158, P338, DOI 10.1006/exnr.1999.7095; Durham HD, 1997, J NEUROPATH EXP NEUR, V56, P523, DOI 10.1097/00005072-199705000-00008; Edoff K, 2002, J NEUROSCI RES, V67, P255, DOI 10.1002/jnr.10092; GERMAIN L, 1993, BURNS, V19, P99, DOI 10.1016/0305-4179(93)90028-7; Gotz ME, 2002, J NEURAL TRANSM, V109, P597, DOI 10.1007/s007020200049; Hudon V, 2003, BRIT J DERMATOL, V148, P1094, DOI 10.1046/j.1365-2133.2003.05298.x; Jerregard H, 2001, J NEUROCYTOL, V30, P327, DOI 10.1023/A:1014460413884; KNOOPS B, 1991, BRAIN RES, V540, P183, DOI 10.1016/0006-8993(91)90506-Q; Lee YS, 2002, J NEUROTRAUM, V19, P357, DOI 10.1089/089771502753594927; Lesuisse C, 2002, J NEUROBIOL, V51, P9, DOI 10.1002/neu.10037; Lillesaar C, 2001, NEUROSCI LETT, V308, P161, DOI 10.1016/S0304-3940(01)01997-8; Luo FR, 1999, CANCER CHEMOTH PHARM, V44, P29, DOI 10.1007/s002800050941; Ma MY, 2000, J NEUROCYTOL, V29, P249, DOI 10.1023/A:1026519720352; Miller C, 2001, TISSUE ENG, V7, P705, DOI 10.1089/107632701753337663; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Nakahashi T, 2000, FEBS LETT, V470, P113, DOI 10.1016/S0014-5793(00)01302-8; Padilla F, 1999, J NEUROSCI RES, V58, P270; Patel TD, 2000, NEURON, V25, P345, DOI 10.1016/S0896-6273(00)80899-5; Pincelli C, 1997, J INVEST DERMATOL, V109, P757, DOI 10.1111/1523-1747.ep12340768; Pinney E, 2000, J CELL PHYSIOL, V183, P74, DOI 10.1002/(SICI)1097-4652(200004)183:1<74::AID-JCP9>3.0.CO;2-G; Rangappa N, 2000, J BIOMED MATER RES, V51, P625, DOI 10.1002/1097-4636(20000915)51:4<625::AID-JBM10>3.0.CO;2-U; Ruscheweyh R, 2001, NEUROSCIENCE, V107, P275, DOI 10.1016/S0306-4522(01)00354-2; Snider WD, 1996, PHILOS T ROY SOC B, V351, P395, DOI 10.1098/rstb.1996.0034; Snow DM, 2002, J NEUROBIOL, V51, P285, DOI 10.1002/neu.10060; SODERSTROM S, 1995, TOXICOL LETT, V75, P133, DOI 10.1016/0378-4274(94)03176-8; Sondell M, 1999, BRAIN RES, V846, P219, DOI 10.1016/S0006-8993(99)02056-9; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Steinbrech DS, 1999, ANN PLAS SURG, V42, P514, DOI 10.1097/00000637-199905000-00009; Terman GW, 2001, J NEUROPHYSIOL, V85, P485, DOI 10.1152/jn.2001.85.2.485; Vikman KS, 2001, J NEUROSCI METH, V105, P175, DOI 10.1016/S0165-0270(00)00360-5; Yip PM, 1998, MOL BIOL CELL, V9, P277, DOI 10.1091/mbc.9.2.277; Young RC, 2002, BRIT J PLAST SURG, V55, P235, DOI 10.1054/bjps.2002.3798; Yu XJ, 2001, J NEUROSCI RES, V66, P303, DOI 10.1002/jnr.1225	53	40	41	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2124	+		10.1096/fj.02-1180fje	http://dx.doi.org/10.1096/fj.02-1180fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958159				2022-12-25	WOS:000185925100022
J	Wheeler, YRY; Kute, TE; Willingham, MC; Chen, SY; Sane, DC				Wheeler, YRY; Kute, TE; Willingham, MC; Chen, SY; Sane, DC			Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis	FASEB JOURNAL			English	Article						adenovirus; KDR; tube formation; HUVEC	PERMEABILITY FACTOR; TUMOR-GROWTH; FACTOR VEGF; TYROSINE KINASE; QUALITY-CONTROL; KDEL RECEPTOR; FACTOR GENE; EXPRESSION; PROTEINS; PROLIFERATION	VEGF, an endothelial-specific mitogen, is an important tumor angiogenesis growth factor. The major receptor for VEGF on endothelial cells is KDR. We hypothesized that an intrabody could bind newly synthesized KDR and block receptor transport to the cell surface, thereby inhibiting important VEGF effects. We expressed a single chain antibody (p3S5) to KDR with or without the endoplasmic reticulum ( ER) retention signal ( KDEL), using either a plasmid (p3S5-HAK) or a tet-off adenoviral system (Ad-HAK). Plasmid-mediated expression of the tethered intrabody significantly reduced KDR expression ( from 82.5 +/- 12.5% to 27.9 +/- 13.6% of cells; P< 0.01) and thymidine incorporation in successfully transfected cells. Ad-HAK infection resulted in intrabody expression in >90% of human umbilical vein endothelial cells ( HUVECs), producing marked (80%) apoptosis at 48 h postinfection. The intrabody was essential for these effects, as confirmed by inhibiting its expression with doxycycline or by expressing irrelevant genes (lacZ, GFP). Cell death was dependent on KDR, because Ad-HAK infection of cell lines with minimal or no KDR had little effect on cell viability. Infected HUVECs were unable to form tubes on Engelbreth Holm-Swarm (EHS) tumor gel matrix. These results demonstrate the potential for development of an intrabody-based strategy to block angiogenesis and prevent tumor growth.	Wake Forest Univ, Bowman Gray Sch Med, Cardiol Sect, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Baylor College of Medicine	Sane, DC (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Cardiol Sect, Dept Canc Biol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	dsane@wfubmc.edu						ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Alvarez RD, 2000, CLIN CANCER RES, V6, P3081; Anan K, 1996, SURGERY, V119, P333, DOI 10.1016/S0039-6060(96)80120-6; BEJAMIN LE, 1999, J CLIN INVEST, V103, P159; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; Brekken RA, 1998, CANCER RES, V58, P1952; BREM S, 1976, CANCER RES, V36, P2807; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; Bu GJ, 1997, J CELL SCI, V110, P65; Chen JD, 1997, NAT MED, V3, P1110, DOI 10.1038/nm1097-1110; Chen SY, 1999, GENE THERAPY OF CANCER, P389; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; Crew JP, 1997, CANCER RES, V57, P5281; Cunningham SA, 1999, J BIOL CHEM, V274, P18421, DOI 10.1074/jbc.274.26.18421; der Maur AA, 2001, FEBS LETT, V508, P407, DOI 10.1016/S0014-5793(01)03101-5; Deshane J, 1995, J CLIN INVEST, V96, P2980, DOI 10.1172/JCI118370; Engel BC, 2000, MOL THER, V1, P165, DOI 10.1006/mthe.2000.0026; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 2003, J MOL MED, V81, P20, DOI 10.1007/s00109-002-0397-4; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Hunt S, 2001, CURR OPIN MOL THER, V3, P418; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KONDO S, 1993, BIOCHEM BIOPH RES CO, V194, P1234, DOI 10.1006/bbrc.1993.1955; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1992, J MOL BIOL, V226, P913, DOI 10.1016/0022-2836(92)91039-R; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; Llewellyn DH, 1997, BIOCHEM BIOPH RES CO, V240, P36, DOI 10.1006/bbrc.1997.7607; Lu D, 1999, J IMMUNOL METHODS, V230, P159, DOI 10.1016/S0022-1759(99)00135-0; Marasco WA, 1997, GENE THER, V4, P11, DOI 10.1038/sj.gt.3300346; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; OLSON TA, 1994, CANCER RES, V54, P276; Orlando JS, 2002, J VIROL, V76, P1475, DOI 10.1128/JVI.76.3.1475-1487.2002; PARANGI S, 1995, CANCER RES, V55, P6071; Parry TJ, 1999, NUCLEIC ACIDS RES, V27, P2569, DOI 10.1093/nar/27.13.2569; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; Rajpal A, 2001, J BIOL CHEM, V276, P33139, DOI 10.1074/jbc.M101332200; Ramakrishnan S, 1996, CANCER RES, V56, P1324; RICHARDSON JH, 1995, P NATL ACAD SCI USA, V92, P3137, DOI 10.1073/pnas.92.8.3137; Robinson CJ, 2001, J CELL SCI, V114, P853; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; Saleh M, 1996, CANCER RES, V56, P393; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; Shaheen RM, 1999, CANCER RES, V59, P5412; Siemeister G, 1998, P NATL ACAD SCI USA, V95, P4625, DOI 10.1073/pnas.95.8.4625; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Steinberger P, 2000, P NATL ACAD SCI USA, V97, P805, DOI 10.1073/pnas.97.2.805; Sukbuntherng J, 2001, J PHARM PHARMACOL, V53, P1629, DOI 10.1211/0022357011778232; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213	69	27	46	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1733	+		10.1096/fj.02-0942fje	http://dx.doi.org/10.1096/fj.02-0942fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958192				2022-12-25	WOS:000184471600027
J	Hamada, K; Ago, H; Sugahara, M; Nodake, Y; Kuramitsu, S; Miyano, M				Hamada, K; Ago, H; Sugahara, M; Nodake, Y; Kuramitsu, S; Miyano, M			Oxyanion hole-stabilized stereospecific isomerization in ribose-5-phosphate isomerase (Rpi)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOGLUCOSE ISOMERASE; CRYSTAL-STRUCTURE; TRIOSEPHOSPHATE ISOMERASE; D-RIBOSE-5-PHOSPHATE ISOMERASE; ESCHERICHIA-COLI; PROTON-TRANSFER; CALVIN CYCLE; RESOLUTION; CATALYSIS; MECHANISM	Ribose-5-phosphate isomerase (Rpi) acts as a key enzyme in the oxidative and reductive pentose-phosphate pathways for the conversion of ribose-5-phosphate (R5P) to ribulose-5-phosphate and vice versa. We have determined the crystal structures of Rpi from Thermus thermophilus HB8 in complex with the open chain form of the substrate R5P and the open chain form of the C2 epimeric inhibitor arabinose-5-phosphate as well as the apo form at high resolution. The crystal structures of both complexes revealed that these ring-opened epimers are bound in the active site in a mirror symmetry binding mode. The O1 atoms are stabilized by an oxyanion hole composed of the backbone amide nitrogens in the conserved motif. In the structure of the Rpi . R5P complex, the conversion moiety O1-C1-C2-O2 in cis-configuration interacts with the carboxyl oxygens of Glu-108 in a water-excluded environment. Furthermore, the C2 hydroxyl group is presumed to be highly polarized by short hydrogen bonding with the side chain of Lys-99. R5P bound as the ring-opened reaction intermediate clarified the high stereoselectivity of the catalysis and is consistent with an aldose-ketose conversion by Rpi that proceeds via a cis-enediolate intermediate.	SPring 8, RIKEN Harima Inst, Struct Biophys Lab, Sayo, Hyogo 6795148, Japan; SPring 8, RIKEN Harima Inst, Highthroughput Factory, Sayo, Hyogo 6795148, Japan; SPring 8, RIKEN Harima Inst, Structurome Res Grp, Sayo, Hyogo 6795148, Japan	Japan Synchrotron Radiation Research Institute; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN	Miyano, M (corresponding author), SPring 8, RIKEN Harima Inst, Struct Biophys Lab, 1-1-1 Kouto, Sayo, Hyogo 6795148, Japan.		Miyano, Masashi/R-2785-2016	Miyano, Masashi/0000-0003-2253-6175; Ago, Hideo/0000-0002-9040-488X				Arsenieva D, 2002, P NATL ACAD SCI USA, V99, P5872, DOI 10.1073/pnas.052131799; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAYEN NE, 1990, J APPL CRYSTALLOGR, V23, P297, DOI 10.1107/S0021889890003260; Cui Q, 2002, J AM CHEM SOC, V124, P3093, DOI 10.1021/ja0118439; FERSHT A, 1999, STRUCTURE MECH PROTE, P251; HOVEJENSEN B, 1988, J BACTERIOL, V170, P1148, DOI 10.1128/jb.170.3.1148-1152.1988; Ishikawa K, 2002, STRUCTURE, V10, P877, DOI 10.1016/S0969-2126(02)00779-7; Jeffery CJ, 2001, BIOCHEMISTRY-US, V40, P1560, DOI 10.1021/bi0018483; Jogl G, 2003, P NATL ACAD SCI USA, V100, P50, DOI 10.1073/pnas.0233793100; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jung CH, 2000, ARCH BIOCHEM BIOPHYS, V373, P409, DOI 10.1006/abbi.1999.1554; KOMIVES EA, 1991, BIOCHEMISTRY-US, V30, P3011, DOI 10.1021/bi00226a005; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kursula I, 2001, EUR J BIOCHEM, V268, P5189, DOI 10.1046/j.0014-2956.2001.02452.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JH, 2001, BIOCHEMISTRY-US, V40, P7799, DOI 10.1021/bi002916o; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rangarajan ES, 2002, PROTEINS, V48, P737, DOI 10.1002/prot.10203; Read J, 2001, J MOL BIOL, V309, P447, DOI 10.1006/jmbi.2001.4680; ROSE IA, 1960, BIOCHIM BIOPHYS ACTA, V42, P159, DOI 10.1016/0006-3002(60)90765-4; SEEHOLZER SH, 1993, P NATL ACAD SCI USA, V90, P1237, DOI 10.1073/pnas.90.4.1237; Sugahara Mitsuaki, 2002, Tanpakushitsu Kakusan Koso, V47, P1026; SUSS KH, 1993, P NATL ACAD SCI USA, V90, P5514, DOI 10.1073/pnas.90.12.5514; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1872, DOI 10.1107/S090744499901029X; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; TOPPER YJ, 1957, J BIOL CHEM, V225, P419; VOLK R, 1991, J BIOL CHEM, V266, P20610; WOOD T, 1970, ANAL BIOCHEM, V33, P297, DOI 10.1016/0003-2697(70)90300-3; Yamamoto M, 1998, J SYNCHROTRON RADIAT, V5, P222, DOI 10.1107/S0909049597014738; Zhang RG, 2003, STRUCTURE, V11, P31, DOI 10.1016/S0969-2126(02)00933-4; ZHANG ZD, 1994, BIOCHEMISTRY-US, V33, P2830, DOI 10.1021/bi00176a012	36	26	28	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49183	49190		10.1074/jbc.M309272200	http://dx.doi.org/10.1074/jbc.M309272200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	13679361	hybrid			2022-12-25	WOS:000186829000082
J	Migliaccio, G; Tomassini, JE; Carroll, SS; Tomei, L; Altamura, S; Bhat, B; Bartholomew, L; Bosserman, MR; Ceccacci, A; Colwell, LF; Cortese, R; De Francesco, R; Eldrup, AB; Getty, KL; Hou, XS; LaFemina, RL; Ludmerer, SW; MacCoss, M; McMasters, DR; Stahlhut, MW; Olsen, DB; Hazuda, DJ; Flores, OA				Migliaccio, G; Tomassini, JE; Carroll, SS; Tomei, L; Altamura, S; Bhat, B; Bartholomew, L; Bosserman, MR; Ceccacci, A; Colwell, LF; Cortese, R; De Francesco, R; Eldrup, AB; Getty, KL; Hou, XS; LaFemina, RL; Ludmerer, SW; MacCoss, M; McMasters, DR; Stahlhut, MW; Olsen, DB; Hazuda, DJ; Flores, OA			Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; PHOSPHONIC ACID ANALOGS; REVERSE-TRANSCRIPTASE; IDENTIFICATION; GANCICLOVIR; ACYCLOVIR; MECHANISM; VIRAZOLE; SYSTEM; SITE	The urgent need for efficacious drugs to treat chronic hepatitis C virus (HCV) infection requires a concerted effort to develop inhibitors specific for virally encoded enzymes. We demonstrate that 2'-C-methyl ribonucleosides are efficient chain-terminating inhibitors of HCV genome replication. Characterization of drug-resistant HCV replicons defined a single S282T mutation within the active site of the viral polymerase that conferred loss of sensitivity to structurally related compounds in both replicon and isolated polymerase assays. Biochemical analyses demonstrated that resistance at the level of the enzyme results from a combination of reduced affinity of the mutant polymerase for the drug and an increased ability to extend the incorporated nucleoside analog. Importantly, the combination of these agents with interferon-alpha results in synergistic inhibition of HCV genome replication in cell culture. Furthermore, 2'-C-methyl-substituted ribonucleosides also inhibited replication of genetically related viruses such as bovine diarrhea virus, yellow fever, and West African Nile viruses. These observations, together with the finding that 2'-C-methyl-guanosine in particular has a favorable pharmacological profile, suggest that this class of compounds may have broad utility in the treatment of HCV and other flavivirus infections.	Merck Res Labs, Dept Biol Chem, West Point, PA 19486 USA; Ist Ric Biol Mol P Angeletti, Dept Biochem, I-00040 Pomezia, Italy; Isis Pharmaceut, Dept Med Chem, Carlsbad, CA 92008 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA; Merck Res Labs, Dept Biometr, West Point, PA 19486 USA; Merck Res Labs, Dept Med Chem, West Point, PA 19486 USA	Merck & Company; Merck & Company; Isis Pharmaceuticals Inc; Merck & Company; Merck & Company; Merck & Company	Flores, OA (corresponding author), Merck Res Labs, Dept Biol Chem, POB 4,WP26A-4000, West Point, PA 19486 USA.	osvaldo_flores@merck.com	De Francesco, Raffaele/J-6003-2012	De Francesco, Raffaele/0000-0001-8754-5123; olsen, david/0000-0001-5521-0206; McMasters, Daniel/0000-0003-3794-8666				Barnard DL, 2001, ANTIVIR CHEM CHEMOTH, V12, P241, DOI 10.1177/095632020101200405; BARTON CN, 1993, BIOMETRICS, V49, P95, DOI 10.2307/2532605; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Carroll SS, 2003, J BIOL CHEM, V278, P11979, DOI 10.1074/jbc.M210914200; Carroll SS, 2000, BIOCHEMISTRY-US, V39, P8243, DOI 10.1021/bi991992s; Dhanak D, 2002, J BIOL CHEM, V277, P38322, DOI 10.1074/jbc.M205566200; el Kouni MH, 2002, CURR PHARM DESIGN, V8, P581, DOI 10.2174/1381612024607171; GROB PM, 1992, AIDS RES HUM RETROV, V8, P145, DOI 10.1089/aid.1992.8.145; HUFFMAN JH, 1994, NUCLEOS NUCLEOT, V13, P607, DOI 10.1080/15257779408013266; HUFFMAN JH, 1973, ANTIMICROB AGENTS CH, V3, P235, DOI 10.1128/AAC.3.2.235; KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440; Liang J. T., 2000, HEPATITIS C BIOMEDIC, P185; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Murray EM, 2003, J VIROL, V77, P2928, DOI 10.1128/JVI.77.5.2928-2935.2003; SIDWELL RW, 1972, SCIENCE, V177, P705, DOI 10.1126/science.177.4050.705; SIDWELL RW, 1989, NUCLEOS NUCLEOT, V8, P833, DOI 10.1080/07328318908054224; SIDWELL RW, 1971, APPL MICROBIOL, V22, P797, DOI 10.1128/AEM.22.5.797-801.1971; Tomassini JE, 2003, VIROLOGY, V313, P274, DOI 10.1016/S0042-6822(03)00314-3; Trozzi C, 2003, J VIROL, V77, P3669, DOI 10.1128/JVI.77.6.3669-3679.2003; Tucker TJ, 1996, METHOD ENZYMOL, V275, P440; Wang MT, 2003, J BIOL CHEM, V278, P9489, DOI 10.1074/jbc.M209397200; Wang QM, 2002, J VIROL, V76, P3865, DOI 10.1128/JVI.76.8.3865-3872.2002; Wilson JE, 1996, METHOD ENZYMOL, V275, P398	27	272	311	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49164	49170		10.1074/jbc.M305041200	http://dx.doi.org/10.1074/jbc.M305041200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12966103	hybrid			2022-12-25	WOS:000186829000080
J	Saxowsky, TT; Choudhary, G; Klingbeil, MM; Englund, PT				Saxowsky, TT; Choudhary, G; Klingbeil, MM; Englund, PT			Trypanosoma brucei has two distinct mitochondrial DNA polymerase beta enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRITHIDIA-FASCICULATA; KINETOPLAST DNA; TOPOISOMERASE-II; REPLICATION; PROTEINS; IDENTIFICATION; LOCALIZATION; MINICIRCLES; EQUIPERDUM; REPAIR	In higher eukaryotes, DNA polymerase (pol) beta resides in the nucleus and participates primarily in DNA repair. The DNA polymerase beta from the trypanosomatid Crithidia fasciculata, however, was the first mitochondrial enzyme of this type described. Upon searching the nearly completed genome data base of the related parasite Trypanosoma brucei, we discovered genes for two pol beta-like proteins. One is similar to 70% identical to the C. fasciculata pol beta and is likely the homolog of this enzyme. The other, although similar to 30% identical within the polymerase region, has unusual structural features including a short C-terminal tail and a long N-terminal extension rich in prolines, alanines, and lysines. Both proteins, when expressed recombinantly, are active as DNA polymerases and deoxyribose phosphate lyases, but their polymerase activity optima differ with respect to pH and KCl and MgCl2 concentrations. Remarkably, green fluorescent protein fusion proteins and immunofluorescence demonstrate that both are mitochondrial, but their locations with respect to the mitochondrial DNA ( kinetoplast DNA network) in this organism are strikingly different.	Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Englund, PT (corresponding author), Johns Hopkins Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.			Klingbeil, Michele/0000-0002-7236-8424	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027608, R37GM027608] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27608] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Elneel K, 2001, J CELL BIOL, V153, P725, DOI 10.1083/jcb.153.4.725; BIRKENMEYER L, 1986, J BIOL CHEM, V261, P2362; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; CavalierSmith T, 1997, TRENDS GENET, V13, P6, DOI 10.1016/S0168-9525(96)30116-9; Drew ME, 2001, J CELL BIOL, V153, P735, DOI 10.1083/jcb.153.4.735; Engel ML, 1999, P NATL ACAD SCI USA, V96, P8455, DOI 10.1073/pnas.96.15.8455; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; Fuenmayor J, 1998, J EUKARYOT MICROBIOL, V45, P404, DOI 10.1111/j.1550-7408.1998.tb05091.x; Haltiwanger BM, 2000, BIOCHEMISTRY-US, V39, P763, DOI 10.1021/bi9923151; HARLOW E, 1988, ANTIBODIES LAB MANUA, P498; Hausler T, 1997, EUR J CELL BIOL, V73, P240; Hines JC, 1998, MOL BIOCHEM PARASIT, V94, P41, DOI 10.1016/S0166-6851(98)00048-6; Hines JC, 2001, MOL BIOCHEM PARASIT, V115, P63, DOI 10.1016/S0166-6851(01)00272-9; Johnson CE, 1998, J CELL BIOL, V143, P911, DOI 10.1083/jcb.143.4.911; KITCHIN PA, 1985, J BIOL CHEM, V260, P3844; Klingbeil MM, 2002, MOL CELL, V10, P175, DOI 10.1016/S1097-2765(02)00571-3; Klingbeil MM, 2001, PROTIST, V152, P255, DOI 10.1078/1434-4610-00066; Li CJ, 1997, J BIOL CHEM, V272, P20787, DOI 10.1074/jbc.272.33.20787; Marchetti MA, 2000, J CELL SCI, V113, P899; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; Morris JC, 2001, INT J PARASITOL, V31, P453, DOI 10.1016/S0020-7519(01)00156-4; RYAN KA, 1989, J BIOL CHEM, V264, P823; RYAN KA, 1989, MOL CELL BIOL, V9, P3212, DOI 10.1128/MCB.9.8.3212; Saxowsky TT, 2002, J BIOL CHEM, V277, P37201, DOI 10.1074/jbc.M206654200; SHAPIRO TA, 1995, ANNU REV MICROBIOL, V49, P117, DOI 10.1146/annurev.mi.49.100195.001001; Sogin ML, 1991, CURR OPIN GENET DEV, V1, P457, DOI 10.1016/S0959-437X(05)80192-3; Taladriz S, 2001, NUCLEIC ACIDS RES, V29, P3822, DOI 10.1093/nar/29.18.3822; TORRI AF, 1995, J BIOL CHEM, V270, P3495, DOI 10.1074/jbc.270.8.3495; TORRI AF, 1992, J BIOL CHEM, V267, P4786; TORRI AF, 1994, J BIOL CHEM, V269, P8165; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674	31	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49095	49101		10.1074/jbc.M308565200	http://dx.doi.org/10.1074/jbc.M308565200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12966090	hybrid			2022-12-25	WOS:000186829000072
J	Suzuki, M; Angata, K; Nakayama, J; Fukuda, M				Suzuki, M; Angata, K; Nakayama, J; Fukuda, M			Polysialic acid and mucin type O-glycans on the neural cell adhesion molecule differentially regulate myoblast fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH; N-CAM; 2 POLYSIALYLTRANSFERASES; EXPRESSION CLONING; NEURITE OUTGROWTH; NCAM; PROTEIN; STX; RHABDOMYOSARCOMA; POLYSIALYLATION	Polysialic acid attached to the neural cell adhesion molecule ( NCAM) is thought to play a critical role in development. NCAM in muscle tissue contains a muscle-specific domain (MSD) to which mucin type O-glycans are attached. In the present study, using the C2C12 myoblast system, we show that NCAM containing MSD is increasingly expressed on the cell surface as myotubes form. Polysialic acid is primarily attached to N-glycans of NCAM, and polysialylated NCAM is expressed on the outer surface of myotube bundles. By transfecting cDNAs encoding wild type and mutant forms of NCAM, we found that NCAM containing MSD facilitates myoblast fusion, and this effect is diminished by mutating O-glycosylation sites at MSD. By contrast, forced expression of polysialic acid in early differentiation stages reduces myotube formation and delays the expression of NCAM containing the MSD domain. Strikingly, inhibition of polysialic acid synthesis by antisense DNA approach induced differentiation in both human rhabdomyosarcoma cells, which overexpress polysialic acid, and C2C12 cells. These results indicate that polysialic acid and mucin type O-glycans on NCAM differentially regulate myoblast fusion, playing critical roles in muscle development.	Burnham Inst, Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA; Shinshu Univ, Sch Med, Dept Pathol, Matsumoto, Nagano 3908621, Japan	Sanford Burnham Prebys Medical Discovery Institute; Shinshu University	Fukuda, M (corresponding author), Burnham Inst, Canc Res Ctr, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	minoru@burnham.org	Angata, Kiyohiko/M-2749-2018	Angata, Kiyohiko/0000-0001-5561-1368	NATIONAL CANCER INSTITUTE [R01CA033000, R01CA033895, R37CA033000] Funding Source: NIH RePORTER; NCI NIH HHS [CA33000, CA33895] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angata K, 2003, BIOCHIMIE, V85, P195, DOI 10.1016/S0300-9084(03)00051-8; Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 2001, J BIOL CHEM, V276, P15369, DOI 10.1074/jbc.M100576200; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; Aravind L, 1999, CURR BIOL, V9, pR836, DOI 10.1016/S0960-9822(00)80039-1; Beltran-Valero de Bernabe D, 2002, AM J HUM GENET, V71, P1033, DOI 10.1086/342975; BIEGEL JA, 1995, GENE CHROMOSOME CANC, V12, P186, DOI 10.1002/gcc.2870120305; Cavallaro U, 2001, NAT CELL BIOL, V3, P650, DOI 10.1038/35083041; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; Close BE, 2003, J BIOL CHEM, V278, P30796, DOI 10.1074/jbc.M305390200; Coltart DM, 2002, J AM CHEM SOC, V124, P9833, DOI 10.1021/ja020208f; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; Daniel L, 2001, ONCOGENE, V20, P997, DOI 10.1038/sj.onc.1204176; DICKSON G, 1987, CELL, V50, P1119, DOI 10.1016/0092-8674(87)90178-4; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; Fazeli S, 1996, J CELL BIOL, V135, P241, DOI 10.1083/jcb.135.1.241; FINNE J, 1985, J BIOL CHEM, V260, P1265; Franceschini I, 2001, GLYCOBIOLOGY, V11, P231, DOI 10.1093/glycob/11.3.231; FREDETTE B, 1993, J CELL BIOL, V123, P1867, DOI 10.1083/jcb.123.6.1867; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; GAD AE, 1986, BIOCHIM BIOPHYS ACTA, V860, P314, DOI 10.1016/0005-2736(86)90528-6; Gluer S, 1998, PEDIATR RES, V43, P145, DOI 10.1203/00006450-199801000-00022; Grewal PK, 2001, NAT GENET, V28, P151, DOI 10.1038/88865; Jigami Y, 1999, BBA-GEN SUBJECTS, V1426, P335, DOI 10.1016/S0304-4165(98)00134-2; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; KNUDSEN KA, 1990, DEV BIOL, V138, P159, DOI 10.1016/0012-1606(90)90185-L; KNUDSEN KA, 1991, MEMBRANE FUSION, P601; Kobayashi K, 1998, NATURE, V394, P388, DOI 10.1038/28653; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kolkova K, 2000, J NEUROSCI, V20, P2238; Kunou M, 2000, BIOMACROMOLECULES, V1, P451, DOI 10.1021/bm000011k; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LOLLINI PL, 1991, INVAS METAST, V11, P116; Martersteck CM, 1996, GLYCOBIOLOGY, V6, P289, DOI 10.1093/glycob/6.3.289; Mayanil CSK, 2001, J BIOL CHEM, V276, P49299, DOI 10.1074/jbc.M107933200; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Moscoso LM, 1998, J NEUROSCI, V18, P1465; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; Ong E, 2002, J BIOL CHEM, V277, P18182, DOI 10.1074/jbc.M201312200; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; Schwander M, 2003, DEV CELL, V4, P673, DOI 10.1016/S1534-5807(03)00118-7; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; WALSH FS, 1989, DEVELOPMENT, V105, P803; Williams EJ, 2003, J CELL BIOL, V160, P481, DOI 10.1083/jcb.200210164; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Yoshida A, 1997, J BIOL CHEM, V272, P16884, DOI 10.1074/jbc.272.27.16884; YOSHIMI T, 1993, CELL STRUCT FUNCT, V18, P1, DOI 10.1247/csf.18.1	57	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49459	49468		10.1074/jbc.M308316200	http://dx.doi.org/10.1074/jbc.M308316200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	13679364	hybrid			2022-12-25	WOS:000186829000114
J	Adiseshaiah, P; Papaiahgari, SR; Vuong, H; Kalvakolanu, DV; Reddy, SP				Adiseshaiah, P; Papaiahgari, SR; Vuong, H; Kalvakolanu, DV; Reddy, SP			Multiple cis-elements mediate the transcriptional activation of human fra-1 by 12-O-tetradecanoylphorbol-13-acetate in bronchial epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; EXPRESSION; AP-1; FOS; GENE; PROLIFERATION; TRANSACTIVATION; IDENTIFICATION; PROTOONCOGENE; MECHANISMS	Recent studies indicate a potential role for Fra-1, a heterodimeric partner of activator protein 1 (AP1), in toxicant-induced epithelial injury, repair, and cellular transformation. Here, we have investigated the transcriptional regulation of fra-1 by 12-O-tetradecanoylphorbol-13- acetate (TPA) in human bronchial epithelial (HBE) cells, which are the direct targets of inhaled toxins/ carcinogens. In contrast to a transient induction by H2O2, TPA persistently activated fra-1 transcription, principally at the transcriptional level. A deletion analysis of the fra-1 promoter revealed that several cis-elements located between - 105/ + 32 and - 283/ - 105 bp mediate minimal and basal promoter activities, respectively. A region between - 379 and - 283 bp, which harbors a putative TPA response element, a GC box, and an Ets-like binding site, was required for high level TPA-inducible expression. Mutations in any of these cis-elements markedly reduced both basal and TPA-inducible expression. Thus, cooperative interactions between factors binding to multiple cis-elements of the - 379/ - 283 promoter region appear to regulate TPA-induced fra-1 transcription in HBE cells. Consistent with this finding, electrophoretic mobility shift assays indicated the formation of multiple complexes consisting of the AP1-, Sp-, and ETS-specific family of transcription factors with the - 379/ - 283 fragment. Members of the AP1 family distinctly regulated the fra-1 promoter. In particular, coexpression of c-Jun, Jun-D, and Fra-2 up-regulated fra-1 transcription. Chromatin immunoprecipitation assays revealed an enhanced recruitment of c-Jun, Jun-D, and Fra-2 to the endogenous fra-1 promoter upon TPA stimulation. These results underscore the regulatory role of c-Jun, Jun-D, and Fra-2 in TPA-inducible fra-1 expression in HBE cells in vivo.	Johns Hopkins Univ, Dept Environm Hlth Sci, Div Physiol, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; Johns Hopkins Univ, Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; Univ Maryland, Sch Med, Greenbaum Canc Ctr, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Reddy, SP (corresponding author), Johns Hopkins Univ, Dept Environm Hlth Sci, Div Physiol, Bloomberg Sch Publ Hlth, Rm W7006,615 N Wolfe St, Baltimore, MD 21205 USA.	sreddy@jhsph.edu		Papaiahgari, Srinivas/0000-0002-1110-7562	NHLBI NIH HHS [HL58122, HL66109] Funding Source: Medline; NIEHS NIH HHS [ES30819, ES011863] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058122, R01HL066109, R29HL058122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011863] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADISESHAIAH P, 2002, AM J RESP CRIT CARE, V165, P626; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; COFFER P, 1994, ONCOGENE, V9, P911; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; HEINTZ NH, 1993, P NATL ACAD SCI USA, V90, P3299, DOI 10.1073/pnas.90.8.3299; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Hu YC, 2001, CLIN CANCER RES, V7, P2213; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Maeda S, 2003, CANCER CELL, V3, P102, DOI 10.1016/S1535-6108(03)00025-4; MATSUI M, 1990, ONCOGENE, V5, P249; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; Patterson T, 2001, ONCOGENE, V20, P634, DOI 10.1038/sj.onc.1204134; Ramos-Nino ME, 2002, CANCER RES, V62, P6065; REDDY SP, 2002, AM J RESP CRIT CARE, V165, P828; Sandhu H, 2000, CARCINOGENESIS, V21, P1023, DOI 10.1093/carcin/21.5.1023; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber M, 1997, ONCOGENE, V15, P1171, DOI 10.1038/sj.onc.1201460; Schwenger GTF, 2002, J BIOL CHEM, V277, P47022, DOI 10.1074/jbc.M207414200; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shukla A, 2001, CANCER RES, V61, P1791; Timblin CR, 1998, TOXICOL APPL PHARM, V151, P88, DOI 10.1006/taap.1998.8450; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; Vuong H, 2002, AM J PHYSIOL-LUNG C, V282, pL215, DOI 10.1152/ajplung.00125.2001; Weitzman JB, 2002, NAT GENET, V30, P128, DOI 10.1038/ng0202-128; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Zajchowski DA, 2001, CANCER RES, V61, P5168	41	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47423	47433		10.1074/jbc.M303505200	http://dx.doi.org/10.1074/jbc.M303505200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13679379	hybrid			2022-12-25	WOS:000186731400012
J	Miele, C; Riboulet, A; Maitan, MA; Oriente, F; Romano, C; Formisano, P; Giudicelli, J; Beguinot, F; Van Obberghen, E				Miele, C; Riboulet, A; Maitan, MA; Oriente, F; Romano, C; Formisano, P; Giudicelli, J; Beguinot, F; Van Obberghen, E			Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C alpha-mediated mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; FACTOR-KAPPA-B; END-PRODUCTS; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; DIABETIC NEPHROPATHY; DEPENDENT PATHWAY; FACTOR EXPRESSION; OXIDATIVE STRESS; MESANGIAL CELLS	Nonenzymatic glycation is increased in diabetes and leads to increased levels of glycated proteins. Most studies have focused on the role of glycation products in vascular complications. Here, we have investigated the action of human glycated albumin (HGA) on insulin signaling in L6 skeletal muscle cells. Exposure of these cells to HGA inhibited insulin-stimulated glucose uptake and glycogen synthase activity by 95 and 80%, respectively. These effects were time- and dose-dependent, reaching a maximum after 12 h incubation with 0.1 mg/ml HGA. In contrast, exposure of the cells to HGA had no effect on thymidine incorporation. Further, HGA reduced insulin-stimulated serine phosphorylation of PKB and GSK3, but did not alter ERK1/2 activation. HGA did not affect either insulin receptor kinase activity or insulin-induced Shc phosphorylation on tyrosine. In contrast, insulin-dependent IRS-1 and IRS-2 tyrosine phosphorylation was severely reduced in cells preincubated with HGA for 24 h. Insulin-stimulated association of PI3K with IRS-1 and IRS-2, and PI3K activity were reduced by HGA in parallel with the changes in IRS tyrosine phosphorylation, while Grb2-IRS association was unchanged. In L6 myotubes, exposure to HGA increased PKC activity by 2-fold resulting in a similar increase in Ser/Thr phosphorylation of IRS-1 and IRS-2. These phosphorylations were blocked by the PKC inhibitor bisindolylmaleimide (BDM). BDM also blocked the action of HGA on insulin-stimulated PKB and GSK3alpha. Simultaneously, BDM rescued insulin-stimulation of glucose uptake and glycogen synthase activity in cells exposed to HGA. The use of antibodies specific to PKC isoforms shows that this effect appears to be mediated by activated PKCalpha, independent of reactive oxygen species production. In summary, in L6 skeletal muscle cells, exposure to HGA leads to insulin resistance selectively in glucose metabolism with no effect on growth-related pathways regulated by the hormone.	Fac Med, INSERM, U145, F-06107 Nice 2, France; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples Federico II, Ctr Endocrinol & Oncol Sperimentale, CNR, I-80131 Naples, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Van Obberghen, E (corresponding author), Fac Med, INSERM, U145, 28 Ave Valombrose, F-06107 Nice 2, France.		Formisano, Pietro/J-4237-2018; ORIENTE, Francesco/J-6652-2018	ORIENTE, Francesco/0000-0003-4375-4526; Formisano, Pietro/0000-0001-7020-6870				Aiello LP, 2002, SURV OPHTHALMOL, V47, pS263, DOI 10.1016/S0039-6257(02)00391-0; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Bossenmaier B, 1997, DIABETOLOGIA, V40, P863, DOI 10.1007/s001250050761; Brownlee M, 2000, METABOLISM, V49, P9, DOI 10.1016/S0026-0495(00)80078-5; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Cabrero A, 2002, J BIOL CHEM, V277, P10100, DOI 10.1074/jbc.M110321200; CHIN JE, 1994, MOL ENDOCRINOL, V8, P51, DOI 10.1210/me.8.1.51; Cohen MP, 1999, AM J PHYSIOL-RENAL, V276, pF684, DOI 10.1152/ajprenal.1999.276.5.F684; DAVIDSON MB, 1994, AM J PHYSIOL-ENDOC M, V267, pE808, DOI 10.1152/ajpendo.1994.267.6.E808; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Degenhardt TP, 1998, CELL MOL BIOL, V44, P1139; Farese RV, 2002, AM J PHYSIOL-ENDOC M, V283, pE1, DOI 10.1152/ajpendo.00045.2002; FIELDS R, 1971, BIOCHEM J, V124, P581, DOI 10.1042/bj1240581; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Flyvbjerg A, 2000, DIABETOLOGIA, V43, P1205, DOI 10.1007/s001250051515; FORMISANO P, 1993, J BIOL CHEM, V268, P5241; Formisano P, 2000, MOL CELL BIOL, V20, P6323, DOI 10.1128/MCB.20.17.6323-6333.2000; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; HAGER SR, 1991, AM J PHYSIOL, V260, pE353, DOI 10.1152/ajpendo.1991.260.3.E353; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hattori Y, 2002, HYPERTENSION, V39, P22, DOI 10.1161/hy1201.097300; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; Hoffmann S, 2002, GRAEF ARCH CLIN EXP, V240, P996, DOI 10.1007/s00417-002-0568-6; Hofmann SM, 2002, DIABETES, V51, P2082, DOI 10.2337/diabetes.51.7.2082; Ido Y, 2001, MICROCIRCULATION, V8, P251, DOI 10.1038/sj.mn.7800079; Idris I, 2002, ANN NY ACAD SCI, V967, P176; Jiang ZY, 1999, DIABETES, V48, P1120, DOI 10.2337/diabetes.48.5.1120; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kellerer M, 1998, DIABETOLOGIA, V41, P833, DOI 10.1007/s001250050995; Kim YB, 2000, DIABETES, V49, P847, DOI 10.2337/diabetes.49.5.847; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Kurowski TG, 1999, DIABETES, V48, P658, DOI 10.2337/diabetes.48.3.658; Makita Z, 1995, J DIABETES COMPLICAT, V9, P265, DOI 10.1016/1056-8727(95)80018-A; Mamputu JC, 2002, J DIABETES COMPLICAT, V16, P284, DOI 10.1016/S1056-8727(01)00229-X; Matsuoka T, 1997, J CLIN INVEST, V99, P144, DOI 10.1172/JCI119126; Maziere C, 2003, FREE RADICAL BIO MED, V34, P629, DOI 10.1016/S0891-5849(02)01329-1; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; Morcos M, 2002, DIABETES, V51, P3532, DOI 10.2337/diabetes.51.12.3532; Motley ED, 2001, CELL MOL BIOL, V47, P1059; Nagai R, 2000, DIABETES, V49, P1714, DOI 10.2337/diabetes.49.10.1714; Naitoh T, 2001, CELL SIGNAL, V13, P331, DOI 10.1016/S0898-6568(01)00152-8; Nakajima K, 2000, J BIOL CHEM, V275, P20880, DOI 10.1074/jbc.M905410199; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; PONGOR S, 1984, P NATL ACAD SCI-BIOL, V81, P2684, DOI 10.1073/pnas.81.9.2684; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; Rossetti L, 2000, ENDOCRINOLOGY, V141, P1922, DOI 10.1210/en.141.6.1922; RuggieroLopez D, 1997, DIABETES RES CLIN PR, V34, P135, DOI 10.1016/S0168-8227(96)01352-6; Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2; SCIMECA JC, 1991, BIOCHEMISTRY-US, V30, P9313, DOI 10.1021/bi00102a025; Scivittaro V, 2000, AM J PHYSIOL-RENAL, V278, pF676, DOI 10.1152/ajprenal.2000.278.4.F676; SMITH PR, 1992, EUR J BIOCHEM, V210, P729, DOI 10.1111/j.1432-1033.1992.tb17474.x; SMITH RE, 1978, ANAL BIOCHEM, V90, P246, DOI 10.1016/0003-2697(78)90029-5; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Strack V, 2000, DIABETOLOGIA, V43, P443, DOI 10.1007/s001250051327; THORNALLEY PJ, 1990, BIOCHEM J, V269, P1; Tomas E, 2002, ANN NY ACAD SCI, V967, P43; Treins C, 2001, J BIOL CHEM, V276, P43836, DOI 10.1074/jbc.M106534200; Valverde AM, 2000, FEBS LETT, V472, P153, DOI 10.1016/S0014-5793(00)01448-4; Van Obberghen E, 2001, EUR J CLIN INVEST, V31, P966, DOI 10.1046/j.1365-2362.2001.00896.x; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wu CH, 2002, MOL CELL ENDOCRINOL, V194, P9, DOI 10.1016/S0303-7207(02)00212-5; Wu VY, 2001, BIOCHEM BIOPH RES CO, V284, P602, DOI 10.1006/bbrc.2001.4982; Xu B, 2003, FASEB J, V17, P1289, DOI 10.1096/fj.02-0490fje; Yamagishi S, 2002, J BIOL CHEM, V277, P20309, DOI 10.1074/jbc.M202634200; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yeh CH, 2001, DIABETES, V50, P1495, DOI 10.2337/diabetes.50.6.1495; Yerneni KKV, 1999, DIABETES, V48, P855, DOI 10.2337/diabetes.48.4.855	72	114	120	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47376	47387		10.1074/jbc.M301088200	http://dx.doi.org/10.1074/jbc.M301088200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12970360	hybrid			2022-12-25	WOS:000186731400006
J	Wintz, H; Fox, T; Wu, YY; Feng, V; Chen, WQ; Chang, HS; Zhu, T; Vulpe, C				Wintz, H; Fox, T; Wu, YY; Feng, V; Chen, WQ; Chang, HS; Zhu, T; Vulpe, C			Expression profiles of Arabidopsis thaliana in mineral deficiencies reveal novel transporters involved in metal homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; IRON TRANSPORT; GENE FAMILY; MOLECULAR CHARACTERIZATION; SUBCELLULAR-LOCALIZATION; COPPER TRANSPORTER; ESCHERICHIA-COLI; NICOTIANAMINE; PROTEIN; ENCODES	Plants directly assimilate minerals from the environment and thus are key for acquisition of metals by all subsequent consumers. Limited bio-availability of copper, zinc and iron in soil decreases both the agronomic productivity and the nutrient quality of crops. Understanding the molecular mechanisms underlying metal homeostasis in plants is a prerequisite to optimizing plant yield and metal nutrient content. To absorb and maintain a balance of potentially toxic metal ions, plants utilize poorly understood mechanisms involving a large number of membrane transporters and metal-binding proteins with overlapping substrate specificities and complex regulation. To better understand the function and the integrated regulation, we analyzed in Arabidopsis the expression patterns in roots and in leaves of 53 genes coding for known or potential metal transporters, in response to copper, zinc, and iron deficiencies in Arabidopsis. Comparative analysis of gene expression profiles revealed specific transcriptional regulation by metals of the genes contrasting with the known wide substrate specificities of the encoded transporters. Our analysis suggested novel transport roles for several gene products and we used functional complementation of yeast mutants to correlate specific regulation by metals with transport activity. We demonstrate that two ZIP genes, ZIP2 and ZIP4, are involved in copper transport. We also present evidence that AtOPT3, a member of the oligopeptide transporter gene family with significant similarities to the maize iron-phytosiderophore transporter YS1, is regulated by metals and heterologous expression AtOPT3 can rescue yeast mutants deficient in metal transport.	Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; Torrey Mesa Res Inst Inc, San Diego, CA 92121 USA	University of California System; University of California Berkeley	Wintz, H (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, 119 Morgan Hall, Berkeley, CA 94720 USA.	wintz@uclink.berkeley.edu	Zhu, Tong/G-5202-2011; Vulpe, Chris/AAF-9170-2020	Zhu, Tong/0000-0002-8732-3499; Vulpe, Chris/0000-0001-5134-8929				Anderson GJ, 2002, CELL BIOCHEM BIOPHYS, V36, P137, DOI 10.1385/CBB:36:2-3:137; Baldet P, 1997, FEBS LETT, V419, P206, DOI 10.1016/S0014-5793(97)01458-0; BECKER R, 1995, PLANT PHYSIOL, V108, P269, DOI 10.1104/pp.108.1.269; BERTONCINI CRA, 1995, NUCLEIC ACIDS RES, V23, P2995, DOI 10.1093/nar/23.15.2995; Brueggemann Wolfgang, 1993, Planta (Heidelberg), V190, P151; Cazale AC, 2001, FEBS LETT, V507, P215, DOI 10.1016/S0014-5793(01)02976-3; Chen WQ, 2002, PLANT CELL, V14, P559, DOI 10.1105/tpc.010410; Clemens S, 2002, TRENDS PLANT SCI, V7, P309, DOI 10.1016/S1360-1385(02)02295-1; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Cobbett C, 2002, ANNU REV PLANT BIOL, V53, P159, DOI 10.1146/annurev.arplant.53.100301.135154; Connolly EL, 2002, PLANT CELL, V14, P1347, DOI 10.1105/tpc.001263; Curie C, 2000, BIOCHEM J, V347, P749, DOI 10.1042/0264-6021:3470749; Curie C, 2001, NATURE, V409, P346, DOI 10.1038/35053080; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; De Freitas J, 2003, BIOMETALS, V16, P185, DOI 10.1023/A:1020771000746; Dykema PE, 1999, PLANT MOL BIOL, V41, P139, DOI 10.1023/A:1006367609556; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; FONG ST, 1995, MOL MICROBIOL, V15, P1127, DOI 10.1111/j.1365-2958.1995.tb02286.x; FUJIWARA T, 1994, J CELL BIOCHEM, P93; Garcia-Hernandez M, 1998, PLANT PHYSIOL, V118, P387, DOI 10.1104/pp.118.2.387; Grotz N, 1998, P NATL ACAD SCI USA, V95, P7220, DOI 10.1073/pnas.95.12.7220; Guerinot ML, 2000, BBA-BIOMEMBRANES, V1465, P190, DOI 10.1016/S0005-2736(00)00138-3; Harris ZL, 1998, AM J CLIN NUTR, V67, p972S, DOI 10.1093/ajcn/67.5.972S; Higuchi K, 2001, PLANT J, V25, P159, DOI 10.1046/j.1365-313x.2001.00951.x; Hirayama T, 1999, CELL, V97, P383, DOI 10.1016/S0092-8674(00)80747-3; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; KAMPFENKEL K, 1995, J BIOL CHEM, V270, P28479, DOI 10.1074/jbc.270.47.28479; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Koh S, 2002, PLANT PHYSIOL, V128, P21, DOI 10.1104/pp.010332; Korshunova YO, 1999, PLANT MOL BIOL, V40, P37, DOI 10.1023/A:1026438615520; Kushnir S, 2001, PLANT CELL, V13, P89, DOI 10.1105/tpc.13.1.89; La Fontaine S, 2002, EUKARYOT CELL, V1, P736, DOI 10.1128/EC.1.5.736-757.2002; Lubkowitz MA, 1998, MOL MICROBIOL, V28, P729, DOI 10.1046/j.1365-2958.1998.00827.x; Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646; MINET M, 1992, PLANT J, V2, P417; Mira H, 2001, BIOCHEM J, V357, P545, DOI 10.1042/0264-6021:3570545; Mukhopadhyay CK, 1998, SCIENCE, V279, P714, DOI 10.1126/science.279.5351.714; NELSON H, 1990, J BIOL CHEM, V265, P20390; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Parker D. R., 1995, Chemical equilibrium and reaction models. Proceedings San Antonio, Texas, USA, 23 and 24 October, 1990., P163; Patzer SI, 1999, J BACTERIOL, V181, P3307, DOI 10.1128/JB.181.10.3307-3309.1999; Petit JM, 2001, BIOCHEM J, V359, P575, DOI 10.1042/0264-6021:3590575; PETRUKHIN K, 1994, HUM MOL GENET, V3, P1647, DOI 10.1093/hmg/3.9.1647; Pich A, 2001, PLANTA, V213, P967, DOI 10.1007/s004250100573; Quigley F, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2001-3-1-research0001; Robinson NJ, 1999, NATURE, V397, P694, DOI 10.1038/17800; ROGERS EE, 2002, MOL CELLULAR IRON TR; SALEEBA JA, 1995, BIOMETALS, V8, P297, DOI 10.1007/BF00141602; SCHOLZ G, 1992, J PLANT NUTR, V15, P1647, DOI 10.1080/01904169209364428; Stacey MG, 2002, PLANT CELL, V14, P2799, DOI 10.1105/tpc.005629; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; Suzuki K, 1999, SOIL SCI PLANT NUTR, V45, P993, DOI 10.1080/00380768.1999.10414350; Thomine S, 2000, P NATL ACAD SCI USA, V97, P4991, DOI 10.1073/pnas.97.9.4991; van der Zaal BJ, 1999, PLANT PHYSIOL, V119, P1047, DOI 10.1104/pp.119.3.1047; Vert G, 2001, PLANT J, V26, P181, DOI 10.1046/j.1365-313x.2001.01018.x; Vert G, 2002, PLANT CELL, V14, P1223, DOI 10.1105/tpc.001388; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; WINTZ H, 2002, BIOCHEM SOC T, V30, P235; Woeste KE, 2000, PLANT CELL, V12, P443, DOI 10.1105/tpc.12.3.443; Yen MR, 2001, MICROBIOL-SGM, V147, P2881, DOI 10.1099/00221287-147-11-2881; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; ZHOU JM, 1995, MOL GEN GENET, V248, P318, DOI 10.1007/BF02191599; Zhu T, 2001, PLANT PHYSIOL BIOCH, V39, P221, DOI 10.1016/S0981-9428(00)01234-1; Zhu T, 2000, PLANT PHYSIOL, V124, P1472, DOI 10.1104/pp.124.4.1472	66	265	300	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47644	47653		10.1074/jbc.M309338200	http://dx.doi.org/10.1074/jbc.M309338200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13129917	hybrid			2022-12-25	WOS:000186731400038
J	Yun, TH; Baglia, FA; Myles, T; Navaneetham, D; Lopez, JA; Walsh, PN; Leung, LLK				Yun, TH; Baglia, FA; Myles, T; Navaneetham, D; Lopez, JA; Walsh, PN; Leung, LLK			RETRACTED: Thrombin activation of factor XI on activated platelets requires the interaction of factor XI and platelet glycoprotein Ib alpha with thrombin anion-binding exosites I and II, respectively (Retracted Article. See vol 282, pg 29067, 2007)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							COAGULATION-FACTOR-XI; PRO-ARG CHLOROMETHYLKETONE; MOLECULAR-WEIGHT KININOGEN; BLOOD-COAGULATION; CRYSTAL-STRUCTURE; V COMPLEX; ANTITHROMBIN-III; HIGH-AFFINITY; FACTOR-VIII; FACTOR IXA	Activation of factor XI (FXI) by thrombin on stimulated platelets plays a physiological role in hemostasis, providing additional thrombin generation required in cases of severe hemostatic challenge. Using a collection of 53 thrombin mutants, we identified 16 mutants with < 50% of the wild-type thrombin FXI-activating activity in the presence of dextran sulfate. These mutants mapped to anion-binding exosite (ABE) I, ABE-II, the Na+-binding site, and the 50-insertion loop. Only the ABE-II mutants showed reduced binding to dextran sulfate-linked agarose. Selected thrombin mutants in ABE-I (R68A, R70A, and R73A), ABE-II (R98A, R245A, and K248A), the 50-insertion loop (W50A), and the Na+-binding site ( E229A and R233A) with < 10% of the wildtype activity also showed a markedly reduced ability to activate FXI in the presence of stimulated platelets. The ABE-I, 50-insertion loop, and Na+-binding site mutants had impaired binding to FXI, but normal binding to glycocalicin, the soluble form of glycoprotein Ibalpha (GPIbalpha). In contrast, the ABE-II mutants were defective in binding to glycocalicin, but displayed normal binding to FXI. Our data support a quaternary complex model of thrombin activation of FXI on stimulated platelets. Thrombin bound to one GPIbalpha molecule, via ABE-II on its posterior surface, is properly oriented for its activation of FXI bound to a neighboring GPIalpha molecule, via ABE-I on its anterior surface. GPIbalpha plays a critical role in the co-localization of thrombin and FXI and the resultant efficient activation of FXI.	Stanford Univ, Sch Med, Dept Med, Div Hematol, Stanford, CA 94305 USA; Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Baylor Coll Med, Dept Med, Thrombosis Res Sect, Houston, TX 77030 USA; Houston Vet Affairs Med Ctr, Houston, TX 77030 USA	Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center	Leung, LLK (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Hematol, 269 Campus Dr, Stanford, CA 94305 USA.	lawrence.leung@stanford.edu			NHLBI NIH HHS [HL69493, HL46213, HL57530, HL70683] Funding Source: Medline; PHS HHS [P5065967] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057530, R01HL046213, R01HL070683] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1994, BIOCHEMISTRY-US, V33, P12048, DOI 10.1021/bi00206a006; AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024; Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200; Baglia FA, 2002, J BIOL CHEM, V277, P1662, DOI 10.1074/jbc.M108319200; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; Baglia FA, 1996, J BIOL CHEM, V271, P3652; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; BERLINER LJ, 1985, BIOCHEMISTRY-US, V24, P7005, DOI 10.1021/bi00345a038; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; De Cristofaro R, 2000, J BIOL CHEM, V275, P3887, DOI 10.1074/jbc.275.6.3887; De Cristofaro R, 2003, BIOCHEM J, V373, P593, DOI 10.1042/BJ20030167; De Cristofaro R, 2001, BIOCHEMISTRY-US, V40, P13268, DOI 10.1021/bi010491f; DECRISTOFARO R, 1998, BIOCHEM J, V332, P6403; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; EDSON JR, 1967, THROMB DIATH HAEMOST, V18, P342, DOI 10.1055/s-0038-1655041; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; Furman MI, 2000, THROMB HAEMOSTASIS, V84, P897, DOI 10.1055/s-0037-1614134; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Gailani D, 2001, BLOOD, V97, P3117, DOI 10.1182/blood.V97.10.3117; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; GRALNICK HR, 1994, P NATL ACAD SCI USA, V91, P6334, DOI 10.1073/pnas.91.14.6334; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510; Hall SW, 2001, THROMB HAEMOSTASIS, V86, P1466, DOI 10.1055/s-0037-1616750; HENRIKSEN RA, 1988, BIOCHEMISTRY-US, V27, P9160, DOI 10.1021/bi00426a013; Ho DH, 2000, J BIOL CHEM, V275, P25139, DOI 10.1074/jbc.M001890200; Ho DH, 2000, BIOCHEMISTRY-US, V39, P316, DOI 10.1021/bi991851q; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; Huntington JA, 2003, STRUCTURE, V11, P469, DOI 10.1016/S0969-2126(03)00049-2; KITCHENS CS, 1991, SEMIN THROMB HEMOST, V17, P55, DOI 10.1055/s-2007-1002590; Krishnan R, 2000, ACTA CRYSTALLOGR D, V56, P406, DOI 10.1107/S0907444900001487; Leung LLK, 2000, TRENDS CARDIOVAS MED, V10, P89, DOI 10.1016/S1050-1738(00)00047-5; Li CQ, 2001, J BIOL CHEM, V276, P6161, DOI 10.1074/jbc.M004164200; LIU LW, 1991, J BIOL CHEM, V266, P16977; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; Myles T, 2002, BLOOD, V100, P2820, DOI 10.1182/blood-2002-03-0843; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; NAITO K, 1991, J BIOL CHEM, V266, P7353; RAGNI MV, 1985, BLOOD, V65, P719; Ramakrishnan V, 2001, P NATL ACAD SCI USA, V98, P1823, DOI 10.1073/pnas.98.4.1823; Richardson JL, 2000, EMBO J, V19, P5650, DOI 10.1093/emboj/19.21.5650; Romo GM, 1999, J EXP MED, V190, P803, DOI 10.1084/jem.190.6.803; ROSENTHAL RL, 1955, BLOOD, V10, P120, DOI 10.1182/blood.V10.2.120.120; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SEAMAN FS, 1994, BIOCHEM J, V304, P715, DOI 10.1042/bj3040715; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; SINHA D, 1984, J CLIN INVEST, V73, P1550, DOI 10.1172/JCI111361; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; Tsiang M, 1996, BIOCHEMISTRY-US, V35, P16449, DOI 10.1021/bi9616108; van Zanten GH, 1998, BLOOD, V91, P2353, DOI 10.1182/blood.V91.7.2353.2353_2353_2359	56	64	67	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48112	48119		10.1074/jbc.M306925200	http://dx.doi.org/10.1074/jbc.M306925200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12968031	hybrid			2022-12-25	WOS:000186731400092
J	Belting, M; Mani, K; Jonsson, M; Cheng, F; Sandgren, S; Jonsson, S; Ding, K; Delcros, JG; Fransson, LA				Belting, M; Mani, K; Jonsson, M; Cheng, F; Sandgren, S; Jonsson, S; Ding, K; Delcros, JG; Fransson, LA			Glypican-1 is a vehicle for polyamine uptake in mammalian cells - A pivotal role for nitrosothiol-derived nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; N-UNSUBSTITUTED GLUCOSAMINE; FIBROBLAST-GROWTH-FACTOR; ORNITHINE DECARBOXYLASE; ENDOTHELIAL-CELLS; S-NITROSYLATION; BINDING SITES; DEGRADATION; GLYCOSIDES; TRANSPORT	Polyamines ( putrescine, spermidine, and spermine) are essential for growth and survival of all cells. When polyamine biosynthesis is inhibited, there is up- regulation of import. The mammalian polyamine transport system is unknown. We have previously shown that the heparan sulfate ( HS) side chains of recycling glypican- 1 ( Gpc- 1) can sequester spermine, that intracellular polyamine depletion increases the number of NO- sensitive N- unsubstituted glucosamines in HS, and that NO- dependent cleavage of HS at these sites is required for spermine uptake. The NO is derived from S- nitroso groups in the Gpc- 1 protein. Using RNA interference technology as well as biochemical and microscopic techniques applied to both normal and uptake- deficient cells, we demonstrate that inhibition of Gpc- 1 expression abrogates spermine uptake and intracellular delivery. In unperturbed cells, spermine and recycling Gpc- 1 carrying HS chains rich in N-unsubstituted glucosamines were co- localized. By exposing cells to ascorbate, we induced release of NO from the S- nitroso groups, resulting in HS degradation and unloading of the sequestered polyamines as well as nuclear targeting of the deglycanated Gpc- 1 protein. Polyamine uptake-deficient cells appear to have a defect in the NO release mechanism. We have managed to restore spermine uptake partially in these cells by providing spermine NONOate and ascorbate. The former bound to the HS chains of recycling Gpc- 1 and S- nitrosylated the core protein. Ascorbate released NO, which degraded HS and liberated the bound spermine. Recycling HS proteoglycans of the glypican- type may be plasma membrane carriers for cargo taken up by caveolar endocytosis.	Lund Univ, Dept Cell & Mol Biol, SE-22184 Lund, Sweden; Univ Rennes 1, Fac Med, Grp Rech Therapeut Anticanc, CNRS FRE22 61, F-35043 Rennes, France	Lund University; Universite de Rennes	Fransson, LA (corresponding author), Lund Univ, Dept Cell & Mol Biol, BMC C13, SE-22184 Lund, Sweden.		delcros, jean-guy/N-5813-2017	delcros, jean-guy/0000-0002-9593-4046; Belting, Mattias/0000-0003-1585-5434				Bauer PM, 1999, BIOCHEM BIOPH RES CO, V262, P355, DOI 10.1006/bbrc.1999.1210; Belting M, 1999, BIOCHEM J, V338, P317, DOI 10.1042/0264-6021:3380317; Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; Belting M, 2002, P NATL ACAD SCI USA, V99, P371, DOI 10.1073/pnas.012346499; Belting M, 1996, GLYCOBIOLOGY, V6, P121, DOI 10.1093/glycob/6.2.121; BYERS TL, 1989, BIOCHEM J, V263, P745, DOI 10.1042/bj2630745; Cheng F, 2002, J BIOL CHEM, V277, P44431, DOI 10.1074/jbc.M205241200; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; Delcros JG, 1997, CYTOMETRY, V27, P255; Ding K, 2002, J BIOL CHEM, V277, P33353, DOI 10.1074/jbc.M203383200; Ding K, 2001, J BIOL CHEM, V276, P46779, DOI 10.1074/jbc.M105419200; Ding K, 2001, J BIOL CHEM, V276, P3885, DOI 10.1074/jbc.M005238200; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fransson LA, 2003, INT J BIOCHEM CELL B, V35, P125, DOI 10.1016/S1357-2725(02)00095-X; Fujise M, 2003, DEVELOPMENT, V130, P1515, DOI 10.1242/dev.00379; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HORTON D, 1973, CARBOHYD RES, V30, P367, DOI 10.1016/S0008-6215(00)81823-6; HSU SM, 1981, AM J CLIN PATHOL, V75, P816, DOI 10.1093/ajcp/75.6.816; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; Jones M, 2000, J BIOL CHEM, V275, P7964, DOI 10.1074/jbc.275.11.7964; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; Liu J, 2002, J BIOL CHEM, V277, P33456, DOI 10.1074/jbc.M202034200; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; Mani K, 2000, GLYCOBIOLOGY, V10, P577, DOI 10.1093/glycob/10.6.577; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; Murakami M, 2000, BBA-MOL CELL BIOL L, V1488, P159, DOI 10.1016/S1388-1981(00)00118-9; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, CANCER RES, V48, P759; PERSSON L, 1988, CANCER RES, V48, P4807; Sakata K, 2000, BIOCHEM J, V347, P297, DOI 10.1042/0264-6021:3470297; Sandback-Pikas D., 1998, J BIOL CHEM, V273, P18770; Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200; Seiler N, 1996, INT J BIOCHEM CELL B, V28, P843, DOI 10.1016/1357-2725(96)00021-0; SHIVELY JE, 1970, BIOCHEMISTRY-US, V9, P33, DOI 10.1021/bi00803a005; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; TOMITORI H, 1999, BIOCHEM J, V344, P633; Tumova S, 1999, BIOCHEM J, V337, P471, DOI 10.1042/0264-6021:3370471; Vilar RE, 1997, BIOCHEM J, V324, P473, DOI 10.1042/bj3240473; Vincent JP, 2003, CELL, V112, P745, DOI 10.1016/S0092-8674(03)00198-3; Westling C, 2002, J BIOL CHEM, V277, P49247, DOI 10.1074/jbc.M209139200; XIA H, 1996, METHOD ENZYMOL, V268, P434	45	122	128	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47181	47189		10.1074/jbc.M308325200	http://dx.doi.org/10.1074/jbc.M308325200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12972423	hybrid			2022-12-25	WOS:000186569400117
J	Bracci, L; Falciani, C; Lelli, B; Lozzi, L; Runci, Y; Pini, A; De Montis, MG; Tagliamonte, A; Neri, P				Bracci, L; Falciani, C; Lelli, B; Lozzi, L; Runci, Y; Pini, A; De Montis, MG; Tagliamonte, A; Neri, P			Synthetic peptides in the form of dendrimers become resistant to protease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BUNGAROTOXIN; HIGH-AFFINITY; RECEPTOR; NEUROTENSIN; DESIGN; PEPTIDOMIMETICS; ANALOGS; BINDING; DRUG	In previous papers, we observed that dendrimers of peptide mimotopes of the nicotinic receptor ligand site are strong antidotes against the lethality of the nicotinic receptor ligand alpha- bungarotoxin. Although their in vitro activity is identical to that of dendrimers, the corresponding monomeric peptide mimotopes are not effective in vivo. Because the higher in vivo efficiency of dendrimers could not in this case be related to polyvalent interaction, the stability to blood protease activity of monomeric versus tetrabranched dendrimeric mimotope peptides was compared here by incubating three different mimotopes with human plasma and serum. Unmodified peptides and cleaved sequences were followed by high pressure liquid chromatography and mass spectrometry. Tetrabranched peptides were shown to be much more stable in plasma and also in serum. To assess the notable stability of multimeric peptides, different bioactive neuropeptides, including enkephalins, neurotensin and nociceptin, were synthesized in monomeric and tetrabranched forms and incubated with human plasma and serum and with rat brain membrane extracts. All the tetrabranched neuropeptides fully retained biological activity and generally showed much greater stability to blood and brain protease activity. Some tetrabranched peptides were also resistant to trypsin and chymotrypsin. Our findings provide new insights into the possible therapeutic use of bioactive peptides.	Univ Siena, Dept Mol Biol, Biochem & Mol Biol Lab, I-53100 Siena, Italy; Univ Siena, Dept Neurosci, Pharmacol Unit, I-53100 Siena, Italy	University of Siena; University of Siena	Bracci, L (corresponding author), Univ Siena, Dept Mol Biol, Biochem & Mol Biol Lab, Via Fiorentina 1, I-53100 Siena, Italy.	braccil@unisi.it	Falciani, Chiara/R-1330-2018; Pini, Alessandro/R-1359-2018; Lozzi, Luisa/Q-8542-2018; Bracci, Luisa/V-9913-2018	Falciani, Chiara/0000-0002-1027-8482; Pini, Alessandro/0000-0002-3832-8349; Lozzi, Luisa/0000-0002-1603-8770; Bracci, Luisa/0000-0002-0738-5746; DE MONTIS, Maria Graziella/0000-0001-5835-1880				Adessi C, 2002, CURR MED CHEM, V9, P963, DOI 10.2174/0929867024606731; Binder EB, 2001, PHARMACOL REV, V53, P453; Bracci L, 2002, BIOCHEMISTRY-US, V41, P10194, DOI 10.1021/bi0256025; Bruehlmeier M, 2002, NUCL MED BIOL, V29, P321, DOI 10.1016/S0969-8051(01)00304-3; CARRAWAY R, 1973, J BIOL CHEM, V248, P6854; de Boisferon MH, 2002, BIOCONJUGATE CHEM, V13, P654, DOI 10.1021/bc015585g; Dooley CT, 1999, BIOPOLYMERS, V51, P379, DOI 10.1002/(SICI)1097-0282(1999)51:6<379::AID-BIP2>3.3.CO;2-5; Feng HJ, 2002, BIOORGAN MED CHEM, V10, P3849, DOI 10.1016/S0968-0896(02)00342-5; Garcia-Garayoa E, 2001, NUCL MED BIOL, V28, P75; Goodman M, 2001, BIOPOLYMERS, V60, P229, DOI 10.1002/1097-0282(2001)60:3<229::AID-BIP10034>3.0.CO;2-P; Gully D, 1997, J PHARMACOL EXP THER, V280, P802; Hruby VJ, 2002, NAT REV DRUG DISCOV, V1, P847, DOI 10.1038/nrd939; Lozzi L, 2003, CHEM BIOL, V10, P411, DOI 10.1016/S1074-5521(03)00094-2; Meloen RH, 2000, J MOL RECOGNIT, V13, P352, DOI 10.1002/1099-1352(200011/12)13:6<352::AID-JMR509>3.0.CO;2-C; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Mogil JS, 2001, PHARMACOL REV, V53, P381; Mourez M, 2001, NAT BIOTECHNOL, V19, P958, DOI 10.1038/nbt1001-958; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Sadler Kristen, 2002, J Biotechnol, V90, P195; Shrimpton CN, 2002, ENDOCR REV, V23, P647, DOI 10.1210/er.2001-0032; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Tam JP, 2002, EUR J BIOCHEM, V269, P923, DOI 10.1046/j.0014-2956.2001.02728.x	22	140	157	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46590	46595		10.1074/jbc.M308615200	http://dx.doi.org/10.1074/jbc.M308615200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12972419	hybrid			2022-12-25	WOS:000186569400045
J	Irvin, BJ; Wood, LD; Wang, LI; Fenrick, R; Sansam, CG; Packham, G; Kinch, M; Yang, E; Hiebert, SW				Irvin, BJ; Wood, LD; Wang, LI; Fenrick, R; Sansam, CG; Packham, G; Kinch, M; Yang, E; Hiebert, SW			TEL, a putative tumor suppressor, induces apoptosis and represses transcription of Bcl-X-L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOMONOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BETA-R FUSION; TYROSINE KINASE; ETS-FAMILY; TRANSFORMED-CELLS; FREQUENT LOSS; KAPPA-B; GENE; PROTEIN	The ETS family transcriptional repressor TEL is frequently disrupted by chromosomal translocations, including the t(12;21) in which the second allele of TEL is deleted in up to 90% of the cases. Consistent with its role as a putative tumor suppressor, TEL expression inhibits colony formation by Ras-transformed NIH 3T3 cells and hinders proliferation of a variety of cell types. Although we observed no alteration in the cell cycle of TEL-expressing cells, we did find a marked increase in apoptosis of serum-starved TEL-expressing NIH 3T3 cells. This decrease in cell survival required the DNA binding domain of TEL, suggesting that TEL repressed an antiapoptotic gene. These observations prompted us to search for genes regulated by ETS family proteins that regulate apoptosis. The anti-apoptotic molecule Bcl-X-L contains multiple ets-factor binding sites within its promoters, and TEL repressed a Bcl-X-L promoter-linked reporter gene. Moreover, the enforced expression of TEL decreased the endogenous expression of both Bcl-X-L mRNA and protein. TEL-mediated repression of Bcl-X-L likely affects cell survival via regulation of the apoptotic pathway.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pediat & Canc Biol, Nashville, TN 37232 USA; Univ Southampton, Sch Med, Southampton Gen Hosp, Canc Res UK Oncol Unit, Southampton SO16 6YD, Hants, England; Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Vanderbilt University; Vanderbilt University; University of Southampton; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Biochem, Preston Res Bldg,Rm 512,23rd & Pierce, Nashville, TN 37232 USA.	scott.hiebert@mcmail.vanderbilt.edu	Hiebert, Scott W/C-9979-2010	Sansam, Courtney/0000-0002-0253-8643; Packham, Graham/0000-0002-9232-5691; Kinch, Michael/0000-0003-3939-3756	NATIONAL CANCER INSTITUTE [R01CA064140, T32CA009385, R01CA087549, P30CA068485, R01CA078443, R01CA077274] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 09385, R01 CA 87549, R01 CA 77274, R01 CA 64140, CA 68485, 1R01 CA 78443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreasson P, 2001, CANCER GENET CYTOGEN, V130, P93, DOI 10.1016/S0165-4608(01)00518-0; BUIJS A, 1995, ONCOGENE, V10, P1511; Buijs A, 2000, MOL CELL BIOL, V20, P9281, DOI 10.1128/MCB.20.24.9281-9293.2000; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Cave H, 1997, LEUKEMIA, V11, P1459, DOI 10.1038/sj.leu.2400798; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; de Groot Rolf P., 2000, Molecular Cell Biology Research Communications, V3, P299, DOI 10.1006/mcbr.2000.0231; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Golub TR, 1996, CURR TOP MICROBIOL, V211, P279; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Gu XS, 2001, J BIOL CHEM, V276, P9421, DOI 10.1074/jbc.M010070200; Guidez F, 2000, BLOOD, V96, P2557; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kirito K, 2002, J BIOL CHEM, V277, P8329, DOI 10.1074/jbc.M109824200; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MacCarthy-Morrogh L, 2000, ONCOGENE, V19, P5534, DOI 10.1038/sj.onc.1203949; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Packham G, 1996, ONCOGENE, V13, P461; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Poirel H, 2000, ONCOGENE, V19, P4802, DOI 10.1038/sj.onc.1203830; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; SATO Y, 1995, BLOOD, V86, P1525, DOI 10.1182/blood.V86.4.1525.bloodjournal8641525; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Spiekermann K, 2002, EXP HEMATOL, V30, P262, DOI 10.1016/S0301-472X(01)00787-1; Spirin KS, 1996, CANCER RES, V56, P2400; STEGMAIER K, 1995, BLOOD, V86, P38, DOI 10.1182/blood.V86.1.38.bloodjournal86138; Szymczyna BR, 2000, J BIOL CHEM, V275, P28363, DOI 10.1074/jbc.M004294200; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; Van Rompaey L., 1999, Neoplasia (New York), V1, P526; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; Van Rompaey L, 2002, BIOCHEM BIOPH RES CO, V291, P820, DOI 10.1006/bbrc.2002.6513; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; Wilbanks AM, 2000, EXP HEMATOL, V28, P584, DOI 10.1016/S0301-472X(00)00138-7; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036	58	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46378	46386		10.1074/jbc.M305189200	http://dx.doi.org/10.1074/jbc.M305189200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12960174	hybrid			2022-12-25	WOS:000186569400021
J	Melo, EO; Dhalia, R; de Sa, CM; Standart, N; Neto, OPD				Melo, EO; Dhalia, R; de Sa, CM; Standart, N; Neto, OPD			Identification of a C-terminal poly(A)-binding protein (PABP)-PABP interaction domain - Role in cooperative binding to poly(A) and efficient cap distal translational repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSLATION; INITIATION; YEAST; REGION; MECHANISMS; POSITION; IRON; LOCALIZATION; ABUNDANCE; COMPLEX	The poly(A)-binding protein (PABP), bound to the 3' poly(A) tail of eukaryotic mRNAs, plays critical roles in mRNA translation and stability. PABP autoregulates its synthesis by binding to a conserved A-rich sequence present in the 5'-untranslated region of PABP mRNA and repressing its translation. PABP is composed of two parts: the highly conserved N terminus, containing 4 RNA recognition motifs (RRMs) responsible for poly(A) and eIF4G binding; and the more variable C terminus, which includes the recently described PABC domain, and promotes intermolecular interaction between PABP molecules as well as cooperative binding to poly(A). Here we show that, in vitro, GST-PABP represses the translation of reporter mRNAs containing 20 or more A residues in their 5'-untranslated regions and remains effective as a repressor when an A(61) tract is placed at different distances from the cap, up to 126 nucleotides. Deletion of the PABP C terminus, but not the PABC domain alone, significantly reduces its ability to inhibit translation when bound to sequences distal to the cap, but not to proximal ones. Moreover, cooperative binding by multiple PABP molecules to poly(A) requires the C terminus, but not the PABC domain. Further analysis using pull-down assays shows that the interaction between PABP molecules, mediated by the C terminus, does not require the PABC domain and is enhanced by the presence of RRM 4. In vivo, fusion proteins containing parts of the PABP C terminus fused to the viral coat protein MS2 have an enhanced ability to prevent the expression of chloramphenicol acetyltransferase reporter mRNAs containing the MS2 binding site at distal distances from the cap. Altogether, our results identify a proline- and glutamine-rich linker located between the RRMs and the PABC domain as being strictly required for PABP/PABP interaction, cooperative binding to poly(A) and enhanced translational repression of reporter mRNAs in vitro and in vivo.	Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, BR-50670420 Recife, PE, Brazil; Univ Brasilia, Dept Biol Celular, BR-70910900 Brasilia, DF, Brazil; Embrapa Recursos Genet & Biotecnol, BR-70770900 Brasilia, DF, Brazil; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	Fundacao Oswaldo Cruz; Universidade de Brasilia; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); University of Cambridge	Neto, OPD (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Campus Univ Fed Pernambuco,Ave Moraes Rego S-N, BR-50670420 Recife, PE, Brazil.	opmn@cpqam.fiocruz.br	de Melo Neto, Osvaldo P/B-1366-2015; Melo, Eduardo O/K-8305-2015; Dhalia, Rafael/AAD-5432-2020	de Melo Neto, Osvaldo P/0000-0001-5402-7346; Melo, Eduardo O/0000-0003-0797-920X; 				ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; Afonina E, 1998, J BIOL CHEM, V273, P13015, DOI 10.1074/jbc.273.21.13015; Bag J, 1996, EUR J BIOCHEM, V237, P143, DOI 10.1111/j.1432-1033.1996.0143n.x; Bag J, 2001, J BIOL CHEM, V276, P47352, DOI 10.1074/jbc.M107676200; Bates EJ, 2000, NUCLEIC ACIDS RES, V28, P1211, DOI 10.1093/nar/28.5.1211; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BIGNON C, 1993, BIOTECHNIQUES, V15, P243; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; Coller JM, 1998, GENE DEV, V12, P3226, DOI 10.1101/gad.12.20.3226; Cosson B, 2002, MOL CELL BIOL, V22, P3301, DOI 10.1128/MCB.22.10.3301-3315.2002; DE SA MFG, 1988, EUR J BIOCHEM, V176, P521; Deardorff JA, 1997, J MOL BIOL, V269, P67, DOI 10.1006/jmbi.1997.1013; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Deo RC, 2001, P NATL ACAD SCI USA, V98, P4414, DOI 10.1073/pnas.071552198; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; Gray NK, 2000, EMBO J, V19, P4723, DOI 10.1093/emboj/19.17.4723; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hornstein E, 1999, FEBS LETT, V457, P209, DOI 10.1016/S0014-5793(99)01039-X; Hornstein E, 1999, J BIOL CHEM, V274, P1708, DOI 10.1074/jbc.274.3.1708; Hoshino S, 1999, J BIOL CHEM, V274, P16677, DOI 10.1074/jbc.274.24.16677; Hotchkiss TL, 1999, MOL BIOCHEM PARASIT, V98, P117, DOI 10.1016/S0166-6851(98)00156-X; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; JOSHI B, 1994, J BIOL CHEM, V269, P2048; Kessler SH, 1998, MOL CELL BIOL, V18, P51, DOI 10.1128/MCB.18.1.51; Koloteva N, 1997, J BIOL CHEM, V272, P16531, DOI 10.1074/jbc.272.26.16531; Kozlov G, 2001, P NATL ACAD SCI USA, V98, P4409, DOI 10.1073/pnas.071024998; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; Le H, 2000, J BIOL CHEM, V275, P17452, DOI 10.1074/jbc.M001186200; Lee J, 2002, EMBO REP, V3, P268, DOI 10.1093/embo-reports/kvf052; Mangus DA, 1998, MOL CELL BIOL, V18, P7383, DOI 10.1128/MCB.18.12.7383; Melo EO, 2003, FEBS LETT, V546, P329, DOI 10.1016/S0014-5793(03)00620-3; Meyuhas O, 2000, COLD SPRING HARBOR M, V39, P671; Muckenthaler M, 1998, MOL CELL, V2, P383, DOI 10.1016/S1097-2765(00)80282-8; Neto OPD, 2000, NUCLEIC ACIDS RES, V28, P3346, DOI 10.1093/nar/28.17.3346; NETO OPD, 1995, NUCLEIC ACIDS RES, V23, P2198, DOI 10.1093/nar/23.12.2198; Otero LJ, 1999, EMBO J, V18, P3153, DOI 10.1093/emboj/18.11.3153; Paraskeva E, 1999, MOL CELL BIOL, V19, P807; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; Preiss T, 1999, CURR OPIN GENET DEV, V9, P515, DOI 10.1016/S0959-437X(99)00005-2; Rouault TA, 2000, COLD SPRING HARBOR M, V39, P655; Roy G, 2002, MOL CELL BIOL, V22, P3769, DOI 10.1128/MCB.22.11.3769-3782.2002; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; STRIPECKE R, 1992, NUCLEIC ACIDS RES, V20, P5555, DOI 10.1093/nar/20.21.5555; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; Walker James, 1998, V77, P365; Wang ZR, 2000, MOL CELL BIOL, V20, P6334, DOI 10.1128/MCB.20.17.6334-6341.2000; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Wormington M, 1996, EMBO J, V15, P900, DOI 10.1002/j.1460-2075.1996.tb00424.x; Wu J, 1998, J BIOL CHEM, V273, P34535, DOI 10.1074/jbc.273.51.34535	59	62	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46357	46368		10.1074/jbc.M307624200	http://dx.doi.org/10.1074/jbc.M307624200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12952955	hybrid			2022-12-25	WOS:000186569400019
J	Rao, US; Nuti, SL				Rao, US; Nuti, SL			Identification of two different states of P-glycoprotein in its catalytic cycle - Role of the linker region in the transition between these two states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; NUCLEOTIDE-BINDING SITES; DRUG-INTERACTION SITES; ATP HYDROLYSIS; INSECT CELLS; MDR1; VINBLASTINE; EXPRESSION; TRANSPORT; GENE	P- glycoprotein ( Pgp) is a drug- translocating ATPase responsible for multidrug resistance in cancer. Although it is well- established that Pgp exhibits drug- dependent ATPase and ATP- dependent drug transport functions, the mechanism by which these two reactions are coupled remains unclear. We have shown recently that proteolytic cleavage of the linker region, which joins the NH2 and COOH halves of the Pgp molecule, results in a Pgp form that exhibits drug- independent and - dependent ATPase activities ( Nuti et al., ( 2000) Biochemistry 39, 3424 - 3432; Nuti, S. L., and Rao, U. S. ( 2002) J. Biol. Chem. 277, 29417 - 29423). To understand the mechanism underlying this phenomenon, we used the procedure of vanadate- mediated trapping of the Pgp transport cycle intermediates to determine the steps in the catalytic cycle that are being regulated by the linker region. We show that vanadate stably traps Pgp under two different conditions, one in the presence of ATP alone and the other in the presence of ATP and drug, suggesting the existence of two Pgp conformations. These two conformations, one mediating basal and the other drug- stimulated ATPase reactions, represent different transport cycle intermediates of Pgp, because arresting Pgp in either conformation prevents the catalytic cycle from proceeding to completion. The results also show that these two conformations are uncoupled and appear simultaneously in Pgp that was cleaved in the linker region. These results together suggest that Pgp assumes at least two distinct conformational states, which catalyze two ATP hydrolysis events in the drug transport cycle, and the linker region mediates the transition between these two states of Pgp.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Rao, US (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Nebraska Med Ctr 984525, Omaha, NE 68198 USA.				NIDDK NIH HHS [DK 51529] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051529, R01DK051529] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HORIO M, 1991, BIOCHIM BIOPHYS ACTA, V1061, P106, DOI 10.1016/0005-2736(91)90274-C; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Hrycyna CA, 1998, BIOCHEMISTRY-US, V37, P13660, DOI 10.1021/bi9808823; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; MANTSCH HH, 1991, CHEM PHYS LIPIDS, V57, P213, DOI 10.1016/0009-3084(91)90077-O; Muller M, 1996, J BIOL CHEM, V271, P1877; Nuti SL, 2000, BIOCHEMISTRY-US, V39, P3424, DOI 10.1021/bi992392w; Nuti SL, 2002, J BIOL CHEM, V277, P29417, DOI 10.1074/jbc.M204054200; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; RAO US, 1995, J BIOL CHEM, V270, P6686; Rao US, 2002, J BIOL CHEM, V277, P4900, DOI 10.1074/jbc.M108258200; Rao US, 1998, BIOCHEMISTRY-US, V37, P14981, DOI 10.1021/bi980072r; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; Safa AR, 1998, METHOD ENZYMOL, V292, P289; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOL CHEM, V276, P21199, DOI 10.1074/jbc.M100886200; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Shepard RL, 1998, BIOCHEM PHARMACOL, V56, P719, DOI 10.1016/S0006-2952(98)00212-3; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956	37	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46576	46582		10.1074/jbc.M308078200	http://dx.doi.org/10.1074/jbc.M308078200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12968025	hybrid			2022-12-25	WOS:000186569400043
J	Yu, J; Leibiger, B; Yang, SN; Caffery, JJ; Shears, SB; Leibiger, IB; Barker, CJ; Berggren, PO				Yu, J; Leibiger, B; Yang, SN; Caffery, JJ; Shears, SB; Leibiger, IB; Barker, CJ; Berggren, PO			Cytosolic multiple inositol polyphosphate phosphatase in the regulation of cytoplasmic free Ca2+ concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; ENDOPLASMIC-RETICULUM; TRISPHOSPHATE RECEPTOR; RYANODINE RECEPTOR; CALCIUM-CHANNEL; ACTIVATION; 1,4,5-TRISPHOSPHATE; 5-PHOSPHATASE; INHIBITION; RELEASE	Multiple inositol polyphosphate phosphatase (MIPP) is an enzyme that, in vitro, has the interesting property of degrading higher inositol polyphosphates to the Ca2+ second messenger, inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3), independently of inositol lipid breakdown. We hypothesized that a truncated cytosolic form of the largely endoplasmic reticulum-confined MIPP (cyt-MIPP) could represent an important new tool in the investigation of Ins( 1,4,5)P-3-dependent intracellular Ca2+ homeostasis. To optimize our ability to judge the impact of cyt-MIPP on intracellular Ca2+ concentration ([Ca2+](i)) we chose a poorly responsive beta-cell line (HIT M2.2.2) with an abnormally low [Ca2+](i). Our results show for the first time in an intact mammalian cell that cyt-MIPP expression leads to a significant enhancement of Ins(1,4,5)P-3 concentration. This is achieved without a significant interference from other cyt-MIPP-derived inositol phosphates. Furthermore, the low basal [Ca2+](i) of these cells was raised to normal levels (35 to 115 nM) when they expressed cyt-MIPP. Noteworthy is that the normal feeble glucose-induced Ca2+ response of HIT M2.2.2 cells was enhanced dramatically by mechanisms related to this increase in basal [Ca2+](i). These data support the use of cyt-MIPP as an important tool in investigating Ins(1,4,5)P-3-dependent Ca2+ homeostasis and suggest a close link between Ins(1,4,5)P-3 concentration and basal [Ca2+](i), the latter being an important modulator of Ca2+ signaling in the pancreatic beta-cell.	Karolinska Hosp, Karolinska Inst, Rolf Luft Ctr Diabet Res, Dept Mol Med, SE-17176 Stockholm, Sweden; NIEHS, Inositide Signaling Sect, NIH, Res Triangle Pk, NC 27709 USA	Karolinska Institutet; Karolinska University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Barker, CJ (corresponding author), Karolinska Hosp, Karolinska Inst, Rolf Luft Ctr Diabet Res, Dept Mol Med, L3, SE-17176 Stockholm, Sweden.	chris.barker@molmed.ki.se	Tuluc, Petronel/C-2527-2011; Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916; Berggren, Per-Olof/0000-0001-8991-413X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080046] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 58508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI N, 1993, J BIOL CHEM, V268, P6161; BARKER CJ, 1995, BIOCHEM J, V306, P557, DOI 10.1042/bj3060557; BARKER CJ, 1994, BIOCHEM J, V297, P265, DOI 10.1042/bj2970265; Barker CJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE1113, DOI 10.1152/ajpendo.00088.2002; BERGGREN PO, 1994, BIOCHEM SOC T, V22, P12, DOI 10.1042/bst0220012; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Bruton JD, 2002, FASEB J, V16, P301, DOI 10.1096/fj.02-0481fje; Chi HB, 2000, MOL CELL BIOL, V20, P6496, DOI 10.1128/MCB.20.17.6496-6507.2000; Craxton A, 1997, BIOCHEM J, V328, P75, DOI 10.1042/bj3280075; DELISLE S, 1994, AM J PHYSIOL, V266, pC429, DOI 10.1152/ajpcell.1994.266.2.C429; ESTRADAGARCIA T, 1991, P ROY SOC B-BIOL SCI, V244, P63, DOI 10.1098/rspb.1991.0052; Hayashi M, 1999, J AM SOC NEPHROL, V10, P2094; Hermosura MC, 2000, NATURE, V408, P735, DOI 10.1038/35047115; Hirata M, 1997, BIOCHEM J, V328, P93, DOI 10.1042/bj3280093; Irvine R, 2001, CURR BIOL, V11, pR172, DOI 10.1016/S0960-9822(01)00086-0; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Islam MS, 2002, DIABETES, V51, P1299, DOI 10.2337/diabetes.51.5.1299; ISLAM MS, 1993, SCIENCE, V262, P1499, DOI 10.1126/science.8248793; Islam MS, 1997, BIOCHEM J, V321, P347, DOI 10.1042/bj3210347; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; Kavalali ET, 1997, J NEUROSCI, V17, P5334; Kermode H, 1998, FEBS LETT, V431, P59, DOI 10.1016/S0014-5793(98)00725-X; Larsson O, 1997, SCIENCE, V278, P471, DOI 10.1126/science.278.5337.471; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; LEIBIGER IB, 1994, FEBS LETT, V337, P161, DOI 10.1016/0014-5793(94)80265-3; Lemmens R, 2001, J BIOL CHEM, V276, P9971, DOI 10.1074/jbc.M009463200; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Ouzzine M, 1999, J BIOL CHEM, V274, P31401, DOI 10.1074/jbc.274.44.31401; Putney JW, 2001, J CELL SCI, V114, P2223; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; Speed CJ, 1999, J CELL SCI, V112, P669; Speed CJ, 1996, EMBO J, V15, P4852, DOI 10.1002/j.1460-2075.1996.tb00866.x; Speed CJ, 2000, J CELL SCI, V113, P2631; STEPHENS LR, 1989, BIOCHEM J, V262, P727, DOI 10.1042/bj2620727; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; STUART JA, 1994, BIOCHEM J, V303, P517, DOI 10.1042/bj3030517; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; VALVERDE I, 1979, SCIENCE, V206, P225, DOI 10.1126/science.225798; VANDIJKEN P, 1995, J BIOL CHEM, V270, P29724; Williams RSB, 1999, EMBO J, V18, P2734, DOI 10.1093/emboj/18.10.2734; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317; Zhang WJ, 2003, FREE RADICAL BIO MED, V34, P674, DOI 10.1016/S0891-5849(02)01375-8	44	24	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46210	46218		10.1074/jbc.M303743200	http://dx.doi.org/10.1074/jbc.M303743200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963730	hybrid			2022-12-25	WOS:000186569400004
J	Begg, M; Mo, FM; Offertaler, L; Batkai, S; Pacher, P; Razdan, RK; Lovinger, DM; Kunos, G				Begg, M; Mo, FM; Offertaler, L; Batkai, S; Pacher, P; Razdan, RK; Lovinger, DM; Kunos, G			G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; EPOXYEICOSATRIENOIC ACIDS; CA2+-INDUCED RELAXATION; MESENTERIC-ARTERY; GUANYLYL CYCLASE; HIGH-CONDUCTANCE; CELLS; ANANDAMIDE; CALCIUM; INHIBITION	The cannabinoid analog "abnormal cannabidiol" (abn-cbd) causes endothelium-dependent vasodilation in rat isolated mesenteric arteries through a G protein-coupled receptor distinct from CB1 or CB2. We examined the actions of abn-cbd on the electrophysiology of human umbilical vein endothelial cells (HUVEC), using the whole cell version of the patch clamp technique. Voltage steps produced noninactivating outward currents, which were abolished by iberiotoxin or by chelation of intracellular calcium. The presence of a BKCa channel in HUVEC was documented by reverse transcriptase-PCR. Abn-cbd concentration dependently potentiated the outward current produced by a single voltage step. This potentiation was abolished by the cannabidiol analog O-1918 or by pertussis toxin but was unaffected by CB1 or CB2 antagonists. HU-210, a CB1/CB2 receptor agonist, had no effect on the outward current. Clamping [Ca2+](i) did not prevent abn-cbd-induced increases in outward current. cGMP potentiated the outward current, and abn-cbd increased the cellular levels of cGMP. The increase in outward current produced by abn-cbd was blocked by KT-5823, an inhibitor of protein kinase G, or 1H-[1,2,4]oxadiazolo[4,3-a]quinoxaline-1-one (ODQ), an inhibitor of soluble guanylate cyclase. We conclude that a Ca2+-activated K+ current in HUVEC is potentiated by activation of a G(i)/G(o)-coupled receptor distinct from CB1 or CB2, which signals through cGMP and protein kinase G to increase channel availability or the sensitivity of the channel to voltage and/or Ca2+. Because iberiotoxin also inhibited abn-cbd-induced relaxation of intact, but not of endothelium-denuded, rat mesenteric artery segments, modulation of endothelial BKCa channels may underlie the mesenteric vasodilator action of abn-cbd.	NIAAA, Lab Integrat Neurosci, NIH, Bethesda, MD 20892 USA; NIAAA, Lab Physiol Studies, NIH, Bethesda, MD 20892 USA; Organix Inc, Woburn, MA 01801 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Lovinger, DM (corresponding author), NIAAA, Lab Integrat Neurosci, NIH, 12420 Parklawn Dr,MSC-8115, Bethesda, MD 20892 USA.		Batkai, Sandor/G-3889-2010; Pacher, Pal/B-6378-2008; Batkai, Sandor/H-7983-2014	Pacher, Pal/0000-0001-7036-8108; Begg, Malcolm/0000-0001-9508-3424	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000351, ZIAAA000407, Z01AA000407, Z01AA000351] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ADAMS DJ, 1989, FASEB J, V3, P2389, DOI 10.1096/fasebj.3.12.2477294; ADAMS MD, 1977, EXPERIENTIA, V33, P1204, DOI 10.1007/BF01922330; Alfonzo MJ, 1998, ARCH BIOCHEM BIOPHYS, V350, P19, DOI 10.1006/abbi.1997.0469; ANDRIANTSITOHAINA R, 1995, AM J PHYSIOL-HEART C, V268, pH1223, DOI 10.1152/ajpheart.1995.268.3.H1223; Bang L, 1999, CARDIOVASC RES, V43, P772, DOI 10.1016/S0008-6363(99)00116-9; Baron A, 1997, J PHYSIOL-LONDON, V504, P537, DOI 10.1111/j.1469-7793.1997.537bd.x; Bukoski RD, 2002, HYPERTENSION, V39, P251, DOI 10.1161/hy0202.102702; Busse R, 2002, TRENDS PHARMACOL SCI, V23, P374, DOI 10.1016/S0165-6147(02)02050-3; Bychkov R, 2002, BRIT J PHARMACOL, V137, P1346, DOI 10.1038/sj.bjp.0705057; Cui J, 1997, J GEN PHYSIOL, V109, P647, DOI 10.1085/jgp.109.5.647; DEWEY WL, 1986, PHARMACOL REV, V38, P151; ESGUERRA M, 1994, NATURE, V369, P563, DOI 10.1038/369563a0; Frieden M, 1999, J PHYSIOL-LONDON, V519, P361, DOI 10.1111/j.1469-7793.1999.0361m.x; Fukao M, 2001, MOL PHARMACOL, V59, P16, DOI 10.1124/mol.59.1.16; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; GARCIA ML, 1995, AM J PHYSIOL-CELL PH, V269, pC1, DOI 10.1152/ajpcell.1995.269.1.C1; GARCIA ML, 1991, J BIOENERG BIOMEMBR, V23, P615, DOI 10.1007/BF00785814; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; Gauthier KM, 2002, J PHYSIOL-LONDON, V545, P829, DOI 10.1113/jphysiol.2002.029843; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Ho WSV, 2003, BRIT J PHARMACOL, V138, P1320, DOI 10.1038/sj/bjp.0705160; HOYER J, 1994, P NATL ACAD SCI USA, V91, P2367, DOI 10.1073/pnas.91.6.2367; Ishac EJN, 1996, BRIT J PHARMACOL, V118, P2023, DOI 10.1111/j.1476-5381.1996.tb15639.x; Ishioka N, 1999, J PHARMACOL EXP THER, V289, P245; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; Jow F, 1999, J MEMBRANE BIOL, V171, P127, DOI 10.1007/s002329900565; Jow F, 2000, J MEMBRANE BIOL, V173, P107, DOI 10.1007/s002320001012; Kestler HA, 1998, RES EXP MED, V198, P133, DOI 10.1007/s004330050097; KO FN, 1994, BLOOD, V84, P4226, DOI 10.1182/blood.V84.12.4226.bloodjournal84124226; Kohler R, 2000, CIRC RES, V87, P496; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Liu J, 2000, BIOCHEM J, V346, P835, DOI 10.1042/0264-6021:3460835; LUCKHOFF A, 1990, PFLUG ARCH EUR J PHY, V416, P305, DOI 10.1007/BF00392067; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Mechoulam R, 1998, EUR J PHARMACOL, V359, P1, DOI 10.1016/S0014-2999(98)00649-9; Mukhopadhyay S, 2002, AM J PHYSIOL-HEART C, V282, pH2046, DOI 10.1152/ajpheart.00497.2001; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Offertaler L, 2003, MOL PHARMACOL, V63, P699, DOI 10.1124/mol.63.3.699; OLESEN SP, 1994, EUR J PHARMACOL, V251, P53, DOI 10.1016/0014-2999(94)90442-1; Price JM, 1997, LIFE SCI, V61, P1185, DOI 10.1016/S0024-3205(97)00660-7; Stefani E, 1997, P NATL ACAD SCI USA, V94, P5427, DOI 10.1073/pnas.94.10.5427; Sun D, 2001, MICROVASC RES, V61, P179, DOI 10.1006/mvre.2000.2291; TANIGUCHI J, 1993, PFLUG ARCH EUR J PHY, V423, P167, DOI 10.1007/BF00374390; VARGA K, 1995, EUR J PHARMACOL, V278, P279, DOI 10.1016/0014-2999(95)00181-J; VOLLMER RR, 1974, J PHARM PHARMACOL, V26, P186, DOI 10.1111/j.2042-7158.1974.tb09252.x; Wagner JA, 1999, HYPERTENSION, V33, P429, DOI 10.1161/01.HYP.33.1.429; Walter L, 2003, J NEUROSCI, V23, P1398, DOI 10.1523/JNEUROSCI.23-04-01398.2003; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	49	73	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46188	46194		10.1074/jbc.M307258200	http://dx.doi.org/10.1074/jbc.M307258200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952947	hybrid			2022-12-25	WOS:000186452300137
J	Lim, HK; Choi, YA; Park, W; Lee, T; Ryu, SH; Kim, SY; Kim, JR; Kim, JH; Baek, SH				Lim, HK; Choi, YA; Park, W; Lee, T; Ryu, SH; Kim, SY; Kim, JR; Kim, JH; Baek, SH			Phosphatidic acid regulates systemic inflammatory responses by modulating the Akt-mammalian target of rapamycin-p70 S6 kinase 1 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL EPITHELIAL-CELLS; NITRIC-OXIDE PRODUCTION; PHOSPHOLIPASE-D; INNATE IMMUNITY; INTERLEUKIN-8 SECRETION; MACROPHAGE ACTIVATION; PLASMA-MEMBRANE; ENDOTOXIC-SHOCK; HUMAN MONOCYTES; SEPTIC SHOCK	Macrophages are pivotal effector cells in the innate immune system. When microbial products bind to pathogen recognition receptors, macrophages are activated and release a broad array of mediators, such as cytokines, that orchestrate the inflammatory responses of the host. Phosphatidic acid (PA) has been implicated as an important metabolite of phospholipid biosynthesis and in membrane remodeling and has been further suggested to be a crucial second messenger in various cellular signaling events. Here we show that PA is an essential regulator of inflammatory response. Deleterious effects of PA are associated with the secretion of proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and the production of nitric oxide, prostaglandin E-2, which are predominantly released by macrophage Raw264.7 cells. Furthermore, the administration of PA to mice increased the serum cytokine level. Moreover, direct or lipopolysaccharide-induced PA accumulation by macrophages led to the Akt-dependent activation of the mammalian target of rapamycin-p70 S6 kinase 1, a process required for the induction of inflammatory mediators. These findings demonstrate the importance of the role of PA in systemic inflammatory responses, and provide a potential usefulness as specific targets for the development of therapies.	Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, Taegu 705717, South Korea; Kyungpook Natl Univ, Coll Nat Sci, Dept Microbiol, Taegu 702701, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea	Yeungnam University; Kyungpook National University; Pohang University of Science & Technology (POSTECH)	Baek, SH (corresponding author), Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, 317-1 Daemyung 5 Dong, Taegu 705717, South Korea.			Ryu, Sung Ho/0000-0003-0913-3048				ABRAHAM E, 1995, J EXP MED, V181, P569, DOI 10.1084/jem.181.2.569; Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Bandyopadhyay R, 2000, MOL CELL BIOCHEM, V203, P127, DOI 10.1023/A:1007055804978; Beutler B, 2000, CURR OPIN MICROBIOL, V3, P23, DOI 10.1016/S1369-5274(99)00046-6; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; Choi WS, 2002, ANN NY ACAD SCI, V968, P198, DOI 10.1111/j.1749-6632.2002.tb04336.x; Coutant A, 2002, HEPATOLOGY, V36, P1079, DOI 10.1053/jhep.2002.36160; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; Cummings RJ, 2002, J BIOL CHEM, V277, P30227, DOI 10.1074/jbc.M111078200; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; Gonzalez-Garcia A, 2002, J BIOL CHEM, V277, P1500, DOI 10.1074/jbc.M103808200; Guha M, 2002, J BIOL CHEM, V277, P32124, DOI 10.1074/jbc.M203298200; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hasegawa N, 1997, AM J RESP CRIT CARE, V155, P928, DOI 10.1164/ajrccm.155.3.9117028; HIGGINS GC, 1994, J EXP MED, V180, P607, DOI 10.1084/jem.180.2.607; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Kim Y, 2000, J BIOL CHEM, V275, P13621, DOI 10.1074/jbc.275.18.13621; Kusner DJ, 1999, J IMMUNOL, V162, P2266; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; MCPHAIL LC, 1995, P NATL ACAD SCI USA, V92, P7931, DOI 10.1073/pnas.92.17.7931; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; Monick MM, 2001, J IMMUNOL, V166, P4713, DOI 10.4049/jimmunol.166.7.4713; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; Olivera A, 1996, J CELL BIOCHEM, V60, P529, DOI 10.1002/(SICI)1097-4644(19960315)60:4<529::AID-JCB9>3.0.CO;2-U; Park DW, 2003, J IMMUNOL, V170, P2093, DOI 10.4049/jimmunol.170.4.2093; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Potter MW, 2001, J SURG RES, V97, P54, DOI 10.1006/jsre.2001.6111; PUGIN J, 1993, J EXP MED, V178, P2193, DOI 10.1084/jem.178.6.2193; Reeves HL, 2000, HEPATOLOGY, V31, P95, DOI 10.1002/hep.510310116; RICE GC, 1994, P NATL ACAD SCI USA, V91, P3857, DOI 10.1073/pnas.91.9.3857; RICE GC, 1994, SHOCK, V1, P254, DOI 10.1097/00024382-199404000-00003; Rizzo MA, 2002, PHARMACOL THERAPEUT, V94, P35, DOI 10.1016/S0163-7258(02)00170-5; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekulic A, 2000, CANCER RES, V60, P3504; Sergeant S, 2001, J BIOL CHEM, V276, P4737, DOI 10.1074/jbc.M006571200; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Szabo C, 1998, ANN NY ACAD SCI, V851, P422, DOI 10.1111/j.1749-6632.1998.tb09019.x; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; Wang LX, 2002, BIOCHEM J, V367, P751, DOI 10.1042/BJ20020586; Weinstein SL, 2000, J LEUKOCYTE BIOL, V67, P405, DOI 10.1002/jlb.67.3.405; Zhang FH, 2001, INT IMMUNOPHARMACOL, V1, P1375, DOI 10.1016/S1567-5769(01)00069-8; ZHANG XK, 1993, J EXP MED, V177, P511, DOI 10.1084/jem.177.2.511	60	107	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45117	45127		10.1074/jbc.M303789200	http://dx.doi.org/10.1074/jbc.M303789200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12960176	hybrid			2022-12-25	WOS:000186452300011
J	Sukumaran, SK; McNamara, G; Prasadarao, NV				Sukumaran, SK; McNamara, G; Prasadarao, NV			Escherichia coli K-1 interaction with human brain micro-vascular endothelial cells triggers phospholipase C-gamma 1 activation downstream of phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PROTEIN-A; FOCAL ADHESION KINASE; C-GAMMA; TYROSINE RESIDUES; K1 INVASION; PHOSPHORYLATION; CALCIUM; RECEPTOR; BINDING; IDENTIFICATION	Escherichia coli, the most common Gram-negative bacterium that causes meningitis in neonates, invades human brain microvascular endothelial cells (HBMEC) by rearranging host cell actin via the activation of phosphatidylinositol 3-kinase (PI3K) and PKC-alpha. Here, further, we show that phospholipase (PLC)-gamma1 is phosphorylated on tyrosine 783 and condenses at the HBMEC membrane beneath the E. coli entry site. Overexpression of a dominant negative (DN) form of PLC-gamma, the PLC-z fragment, in HBMEC inhibits PLC-gamma1 activation and significantly blocks E. coli invasion. PI3K activation is not affected in PLC-z/HBMEC upon infection, whereas PKC-alpha phosphorylation is completely abolished, indicating that PLC-gamma1 is downstream of PI3K. Concomitantly, the phosphorylation of PLC-gamma1 is blocked in HBMEC overexpressing a dominant negative form of the p85 subunit of PI3K but not in HBMEC overexpressing a dominant negative form of PKC-alpha. In addition, the recruitment of PLC-gamma1 to the cell membrane in both PLC-z/HBMEC and DN-p85/HBMEC is inhibited. Activation of PI3K is associated with the conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 1,4,5-trisphosphate (PIP3), which in turn recruits PLC-gamma1 to the cell membrane via its interaction with pleckstrin homology domain of PLC-gamma1. Utilizing the pleckstrin homology domains of PKC-delta and Btk proteins fused to green fluorescent protein (GFP), which specifically interact with PIP2 and PIP3, respectively, we show herein that E. coli invasion induces the break-down of PIP2 at the plasma membrane near the site of E. coli interaction. PIP3, on the other hand, recruits the GFP(Bkt) to the cell membrane beneath the sites of E. coli attachment. Our studies further show that E. coli invasion induces the release of Ca2+ from intracellular pools as well as the influx of Ca2+ from the extracellular medium. This elevation in Ca2+ levels is completely blocked both in PLC-z/HBMEC and DN-p85/HBMEC, but not in DN-PKC/HBMEC. Taken together, these results suggest that E. coli infection of HBMEC induces PLC-gamma1 activation in a PI3K-dependent manner to increase Ca2+ levels in HBMEC. This is the first report demonstrating the recruitment of activated PLC-gamma1 to the sites of bacterial entry.	Childrens Hosp Los Angeles, Div Infect Dis, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch Med, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California	Prasadarao, NV (corresponding author), Childrens Hosp Los Angeles, Div Infect Dis, MS 51,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	pnemani@chla.usc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040567, R29AI040567] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40567] Funding Source: Medline; NICHD NIH HHS [HD50325] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Bierne H, 2000, CELL MICROBIOL, V2, P465, DOI 10.1046/j.1462-5822.2000.00069.x; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FOUBISTER V, 1994, J EXP MED, V179, P993, DOI 10.1084/jem.179.3.993; HOMMA Y, 1992, J BIOL CHEM, V267, P21844; Kassis J, 1999, CLIN CANCER RES, V5, P2251; Kenny B, 1997, INFECT IMMUN, V65, P2528, DOI 10.1128/IAI.65.7.2528-2536.1997; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Prasadarao NV, 1999, INFECT IMMUN, V67, P5775, DOI 10.1128/IAI.67.11.5775-5783.1999; Prasadarao NV, 2003, INFECT IMMUN, V71, P1680, DOI 10.1128/IAI.71.4.1680-1688.2003; Prasadarao NV, 1996, INFECT IMMUN, V64, P146, DOI 10.1128/IAI.64.1.146-153.1996; Prasadarao NV, 2002, INFECT IMMUN, V70, P4556, DOI 10.1128/IAI.70.8.4556-4563.2002; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Reddy MA, 2000, INFECT IMMUN, V68, P6423, DOI 10.1128/IAI.68.11.6423-6430.2000; Reddy MA, 2000, J BIOL CHEM, V275, P36769, DOI 10.1074/jbc.M007382200; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rhinehart K, 2002, AM J PHYSIOL-RENAL, V283, pF852, DOI 10.1152/ajprenal.00065.2002; Rudrabhatla RS, 2003, INFECT IMMUN, V71, P2787, DOI 10.1128/IAI.71.5.2787-2797.2003; RUSCHKOWSKI S, 1992, FEMS MICROBIOL LETT, V95, P121; Stins MF, 1999, INFECT IMMUN, V67, P5522, DOI 10.1128/IAI.67.10.5522-5525.1999; STINS MF, 1994, AM J PATHOL, V145, P1228; Stoll BJ, 2002, NEW ENGL J MED, V347, P240, DOI 10.1056/NEJMoa012657; Sukumaran SK, 2002, J BIOL CHEM, V277, P50716, DOI 10.1074/jbc.M208830200; Sukumaran SK, 2002, J BIOL CHEM, V277, P12253, DOI 10.1074/jbc.M110740200; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Watanabe D, 2001, J BIOL CHEM, V276, P38595, DOI 10.1074/jbc.M103675200; Xie ZJ, 1999, J BIOL CHEM, V274, P20421, DOI 10.1074/jbc.274.29.20421	29	28	31	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45753	45762		10.1074/jbc.M307374200	http://dx.doi.org/10.1074/jbc.M307374200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952950	hybrid			2022-12-25	WOS:000186452300086
J	Uemura, S; Kihara, A; Inokuchi, J; Igarashi, Y				Uemura, S; Kihara, A; Inokuchi, J; Igarashi, Y			Csg1p and newly identified Csh1p function in mannosylinositol phosphorylceramide synthesis by interacting with Csg2p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL KINASE HOMOLOG; CELL-CYCLE ARREST; SACCHAROMYCES-CEREVISIAE; SERINE PALMITOYLTRANSFERASE; LIPID RAFTS; HEAT-STRESS; YEAST; PROTEIN; GENE; MEMBRANE	Csg1p and Csg2p have been shown to be involved in the synthesis of mannosylinositol phosphorylceramide (MIPC) from inositol phosphorylceramide. YBR161w, termed CSH1 here, encodes a protein that exhibits a strong similarity to Csg1p. To examine whether Csh1p also functions in MIPC synthesis, we performed a [H-3] dihydrosphingosine labeling experiment. Deltacsg1 cells exhibited only a reduction in the synthesis of mannosylated sphingolipids compared with wild-type cells, whereas the Deltacsg1 Deltacsh1 double deletion mutant exhibited a total loss. These results indicated that Csg1p and Csh1p have redundant functions in MIPC synthesis. Analyses using Deltacsg1 and Deltacsh1 cells in the Deltaipt1, Deltasur2, or Deltascs7 genetic background demonstrated that Csh1p has a different substrate specificity from Csg1p. We also revealed that Csg2p interacts with both Csg1p and Csh1p. Deletion of the CSG2 gene reduced the Csg1p activity and abolished the Csh1p activity. These results suggested that two distinct inositol phosphorylceramide mannosyltransferase complexes, Csg1p-Csg2p and Csh1p-Csg2p, exist.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University	Igarashi, Y (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Kita 12 Jo,Nishi 6 Choume, Sapporo, Hokkaido 0600812, Japan.		Inokuchi, Jin-ichi/AAW-9964-2020; KIHARA, AKIO/A-3802-2012	Inokuchi, Jin-ichi/0000-0002-0703-5746; KIHARA, AKIO/0000-0001-5889-0788				Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BEELER T, 1994, J BIOL CHEM, V269, P7279; Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; Birchwood CJ, 2001, J BIOL CHEM, V276, P11712, DOI 10.1074/jbc.M010221200; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dunn TM, 1998, YEAST, V14, P311, DOI 10.1002/(SICI)1097-0061(19980315)14:4<311::AID-YEA220>3.0.CO;2-B; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; Gable K, 2000, J BIOL CHEM, V275, P7597, DOI 10.1074/jbc.275.11.7597; Gottlieb D, 1999, Mol Cell Biol Res Commun, V1, P66, DOI 10.1006/mcbr.1999.0109; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; HANSON BA, 1980, J LIPID RES, V21, P309; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Kihara A, 2002, J BIOL CHEM, V277, P30048, DOI 10.1074/jbc.M203385200; Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; TAKITA Y, 1995, MOL GEN GENET, V246, P269, DOI 10.1007/BF00288599; Tanida I, 1996, FEBS LETT, V379, P38, DOI 10.1016/0014-5793(95)01478-0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; ZHAO C, 1994, J BIOL CHEM, V269, P21480	38	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45049	45055		10.1074/jbc.M305498200	http://dx.doi.org/10.1074/jbc.M305498200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954640	hybrid			2022-12-25	WOS:000186452300003
J	van Rossum, AGSH; de Graaf, JH; Schuuring-Scholtes, E; Kluin, PM; Fan, YX; Zhan, X; Moolenaar, WH; Schuuring, E				van Rossum, AGSH; de Graaf, JH; Schuuring-Scholtes, E; Kluin, PM; Fan, YX; Zhan, X; Moolenaar, WH; Schuuring, E			Alternative splicing of the actin binding domain of human cortactin affects cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT NETWORK FORMATION; CHROMOSOME 11Q13 REGION; TYROSINE PHOSPHORYLATION; ARP2/3 COMPLEX; BREAST-CANCER; EMS1 GENE; PROTEIN CORTACTIN; HUMAN CARCINOMAS; CONTACT SITES; CYCLIN D1	Cortactin is a filamentous actin (F-actin)-binding protein that regulates cytoskeletal dynamics by activating the Arp2/3 complex; it binds to F-actin by means of six N-terminal "cortactin repeats". Gene amplification of 11q13 and consequent overexpression of cortactin in several human cancers is associated with lymph node metastasis. Overexpression as well as tyrosine phosphorylation of cortactin has been reported to enhance cell migration, invasion, and metastasis. Here we report the identification of two alternative splice variants (SV1 and SV2) that affect the cortactin repeats: SV1-cortactin lacks the 6th repeat (exon 11), whereas SV2-cortactin lacks the 5th and 6th repeats (exons 10 and 11). SV-1 cortactin is found co-expressed with wild type (wt)-cortactin in all tissues and cell lines examined, whereas the SV2 isoform is much less abundant. SV1-cortactin binds F-actin and promotes Arp2/3-mediated actin polymerization equally well as wt-cortactin, whereas SV2-cortactin shows reduced F-actin binding and polymerization. Alternative splicing of cortactin does not affect its subcellular localization or growth factor-induced tyrosine phosphorylation. However, cells that overexpress SV1- or SV2-cortactin show significantly reduced cell migration when compared with wt-cortactin-overexpressing cells. Thus, in addition to overexpression and tyrosine phosphorylation, alternative splicing of the F-actin binding domain of cortactin is a new mechanism by which cortactin influences cell migration.	Univ Groningen, Univ Med Ctr Groningen, Dept Pathol, NL-9700 RB Groningen, Netherlands; Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Amer Red Cross, Holland Lab, Dept Expt Pathol, Rockville, MD 20855 USA	University of Groningen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Cancer Institute; American Red Cross	Schuuring, E (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pathol, POB 30001, NL-9700 RB Groningen, Netherlands.	e.schuuring@path.azg.nl						Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; Hermsen MAJA, 1996, GENE CHROMOSOME CANC, V15, P1; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Hui R, 1998, ONCOGENE, V17, P1053, DOI 10.1038/sj.onc.1202023; Kaksonen M, 2000, J CELL SCI, V113, P4421; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; Kranenburg O, 1997, J CELL SCI, V110, P2417; Li YS, 2001, CANCER RES, V61, P6906; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Mulder J, 2003, J BIOL CHEM, V278, P27216, DOI 10.1074/jbc.M302399200; Ohoka Y, 1998, GENES CELLS, V3, P603, DOI 10.1046/j.1365-2443.1998.00216.x; Patel AM, 1996, ONCOGENE, V12, P31; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Schuuring E, 1998, CELL ADHES COMMUN, V6, P185, DOI 10.3109/15419069809004475; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; Small JV, 1999, CURR OPIN CELL BIOL, V11, P54, DOI 10.1016/S0955-0674(99)80007-6; Uruno T, 2003, J BIOL CHEM, V278, P26086, DOI 10.1074/jbc.M301997200; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; vanHam SM, 1997, CURR BIOL, V7, P950, DOI 10.1016/S0960-9822(06)00414-3; Vidal C, 2002, BLOOD, V100, P4462, DOI 10.1182/blood.V100.13.4462; Weaver AM, 2002, CURR BIOL, V12, P1270, DOI 10.1016/S0960-9822(02)01035-7; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 1998, J CELL SCI, V111, P2433; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1994, J BIOL CHEM, V269, P20221; Zondag GCM, 1996, J CELL BIOL, V134, P1513, DOI 10.1083/jcb.134.6.1513	38	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45672	45679		10.1074/jbc.M306688200	http://dx.doi.org/10.1074/jbc.M306688200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952985	hybrid			2022-12-25	WOS:000186452300076
J	Bernat, A; Avvakumov, N; Mymryk, JS; Banks, L				Bernat, A; Avvakumov, N; Mymryk, JS; Banks, L			Interaction between the HPV E7 oneoprotein and the transcriptional coactivator p300	ONCOGENE			English	Article						HPV; E7; p300 transcriptional coactivation	HUMAN-PAPILLOMAVIRUS TYPE-16; CREB-BINDING-PROTEIN; RETINOBLASTOMA TUMOR-SUPPRESSOR; E6 ONCOPROTEIN; HISTONE ACETYLTRANSFERASES; HUMAN KERATINOCYTES; P53 DEGRADATION; ADENOVIRUS E1A; CELL-GROWTH; E2 PROTEIN	Infection with high-risk human papillomaviruses (HPV) can lead to the development of cervical cancer. This process depends on the interaction of the virus-encoded oncoproteins, E6 and E7, with a variety of host regulatory proteins. As E7 shares both functional and structural similarities with the Adenovirus E1a (Ad E1a) protein, we were interested in investigating the possible interactions between E7 and the transcriptional coactivator p300, since it was originally identified as a target of Ad E1a. Using a variety of assays, we show that E7s from both high- and low-risk HPV types interact with p300. Mutational analysis of E7 maps the site of the interaction to a region spanning the pRb-binding domain and the CKII phosphorylation site. We also map the site of interaction on p300 largely to the CH1 domain. In addition, we demonstrate that the binding between 16E7 and p300 is direct, and can be detected in vivo by coimmunoprecipitation and mammalian two-hybrid assays. Finally, we show that E7 can abolish the p300-mediated E2 transactivation function, suggesting that complex formation between E7 and p300 may contribute to the regulation of E2 transcriptional activity.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ Western Ontario, London Reg Canc Ctr, Dept Microbiol & Immunol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Oncol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Physiol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Pharmacol, London, ON N6A 4L6, Canada	International Center for Genetic Engineering & Biotechnology (ICGEB); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.			Bernat, Agnieszka/0000-0002-1232-4286				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avvakumov N, 2003, ONCOGENE, V22, P3833, DOI 10.1038/sj.onc.1206562; BANKS L, 1990, ONCOGENE, V5, P1383; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARBOSA MS, 1989, ONCOGENE, V4, P1529; Bernat A, 2002, J GEN VIROL, V83, P829, DOI 10.1099/0022-1317-83-4-829; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DAVIES RC, 1992, J GEN VIROL, V73, P2135, DOI 10.1099/0022-1317-73-8-2135; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Georges SA, 2002, MOL CELL BIOL, V22, P127, DOI 10.1128/MCB.22.1.127-137.2002; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guccione E, 2002, VIROLOGY, V293, P20, DOI 10.1006/viro.2001.1290; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Huang SM, 2002, J VIROL, V76, P8710, DOI 10.1128/JVI.76.17.8710-8721.2002; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kung AL, 2000, GENE DEV, V14, P272; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Marcello A, 2000, J VIROL, V74, P9090, DOI 10.1128/JVI.74.19.9090-9098.2000; Massimi P, 1996, ONCOGENE, V12, P2325; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; McIntyre MC, 1996, VIROLOGY, V215, P73, DOI 10.1006/viro.1996.0008; Muller A, 2002, J VIROL, V76, P11042, DOI 10.1128/JVI.76.21.11042-11053.2002; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1989, J VIROL, V63, P4417; Mymryk JS, 1998, NUCLEIC ACIDS RES, V26, P292, DOI 10.1093/nar/26.1.292; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1994, ONCOGENE, V9, P1869; PIM D, 2001, VIRUSES CELL TRANSFO, P145; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; Smith-McCune K, 1999, P NATL ACAD SCI USA, V96, P6999, DOI 10.1073/pnas.96.12.6999; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; Stubenrauch F, 1998, J VIROL, V72, P1071, DOI 10.1128/JVI.72.2.1071-1077.1998; Tanaka Y, 2000, MECH DEVELOP, V95, P133, DOI 10.1016/S0925-4773(00)00360-9; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Wong HK, 1996, J VIROL, V70, P332, DOI 10.1128/JVI.70.1.332-340.1996; Yan JP, 1998, J MOL BIOL, V281, P395, DOI 10.1006/jmbi.1998.1951; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zimmermann H, 2000, J GEN VIROL, V81, P2617, DOI 10.1099/0022-1317-81-11-2617; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291; Zwerschke W, 2000, J BIOL CHEM, V275, P9534, DOI 10.1074/jbc.275.13.9534	86	108	112	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7871	7881		10.1038/sj.onc.1206896	http://dx.doi.org/10.1038/sj.onc.1206896			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970734				2022-12-25	WOS:000185388200001
J	Domon-Dell, C; Schneider, A; Moucadel, V; Guerin, E; Guenot, D; Aguillon, S; Duluc, I; Martin, E; Iovanna, J; Launay, JF; Duclos, B; Chenard, MP; Meyer, C; Oudet, P; Kedinger, M; Gaub, MP; Freund, JN				Domon-Dell, C; Schneider, A; Moucadel, V; Guerin, E; Guenot, D; Aguillon, S; Duluc, I; Martin, E; Iovanna, J; Launay, JF; Duclos, B; Chenard, MP; Meyer, C; Oudet, P; Kedinger, M; Gaub, MP; Freund, JN			Cdx1 homeobox gene during human colon cancer progression	ONCOGENE			English	Article						allelic imbalance; genomic rearrangement; gene expression; xenografts	DOWN-REGULATION; COLORECTAL-CANCER; EXPRESSION; CELLS; PATHWAYS	The Cdx1 homeobox gene encodes an intestine-specific transcription factor with a pro-oncogenic function in vitro. Here we have analysed the pattern of Cdx1 in human colon cancer progression. Cdx1 expression remains at a high level in the majority of the polyps and it is even overexpressed in more than one-third of the specimens, consistent with the fact that the gene is an intestine-specific target of oncogenic pathways. However, Cdx1 decreases in one-fifth of the polyps, which is reminiscent of the loss of expression previously reported in the majority of carcinomas. Allelic imbalance analysis demonstrates that the Cdx1 locus located on chromosome 5q is a major site of genomic rearrangement in colorectal cancers, and that the frequency of the rearrangements increases during polyps to carcinoma progression. Allelic imbalance at the Cdx1 locus occurs in relation to, although not invariably in association with, the rearrangements at the APC locus on the same chromosomal arm. Xenografts of primary human colon carcinomas indicate that the level of Cdx1 mRNA correlates with the intensity of allelic imbalance. Together, these data show that Cdx1 exhibits a complex pattern during colorectal cancer progression. Given that Cdx1 has a pro-oncogenic function in vitro, the maintenance of a high level of expression in polyps, and even its overexpression in one-third of the specimens, suggest that this homeobox gene may be an important factor in the process toward malignant transformation during the first steps of tumorigenesis.	INSERM, U381, F-67200 Strasbourg, France; INSERM, Ctr Rech, EMI 0116, F-13009 Marseille, France; Univ Strasbourg, Hop Hautepierre, F-67200 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Freund, JN (corresponding author), INSERM, U381, 3 Ave Moliere, F-67200 Strasbourg, France.	jean-noel.freund@inserm.u-strasburg.fr	Freund, Jean-Noel/R-4383-2016; Domon-Dell, Claire/P-2368-2017; Duluc, Isabelle/O-1972-2017; DULUC, Isabelle/AAA-7062-2022; guenot, dominique/R-3355-2016; Guerin, Eric/R-3426-2016; Chenard, Marie-Pierre/O-2373-2016; Iovanna, Juan/M-9805-2017	Freund, Jean-Noel/0000-0002-0971-3774; Duluc, Isabelle/0000-0001-8396-6385; DULUC, Isabelle/0000-0001-8396-6385; guenot, dominique/0000-0003-2782-8425; Iovanna, Juan/0000-0003-1822-2237; GUERIN, ERIC/0000-0003-1388-2834; DOMON-DELL, Claire/0000-0002-8445-9593				BONNER CA, 1995, GENOMICS, V28, P206, DOI 10.1006/geno.1995.1132; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Domon-Dell C, 2002, FEBS LETT, V518, P83, DOI 10.1016/S0014-5793(02)02650-9; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; JAMES R, 1994, J BIOL CHEM, V269, P15229; Lickert H, 2000, DEVELOPMENT, V127, P3805; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; Moucadel V, 2002, BIOCHEM BIOPH RES CO, V297, P607, DOI 10.1016/S0006-291X(02)02250-7; Moucadel V, 2001, EUR J CELL BIOL, V80, P156, DOI 10.1078/0171-9335-00148; Oh EJ, 2002, INT J ONCOL, V20, P23; Ren P, 2000, AM J PATHOL, V156, P621, DOI 10.1016/S0002-9440(10)64766-9; Schneider A, 2000, CANCER RES, V60, P4617; Schneider A, 2000, AUST NZ J SURG, V70, P587, DOI 10.1046/j.1440-1622.2000.01904.x; Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Soubeyran P, 2001, ONCOGENE, V20, P4180, DOI 10.1038/sj.onc.1204551; Subramanian V, 1998, DIFFERENTIATION, V64, P11, DOI 10.1046/j.1432-0436.1998.6410011.x; Suh ER, 2002, J BIOL CHEM, V277, P35795, DOI 10.1074/jbc.M205567200; Vider BZ, 1997, BIOCHEM BIOPH RES CO, V232, P742, DOI 10.1006/bbrc.1997.6364; Weber JC, 2001, ANN SURG, V234, P795, DOI 10.1097/00000658-200112000-00011	26	25	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					7913	7921		10.1038/sj.onc.1206756	http://dx.doi.org/10.1038/sj.onc.1206756			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970739				2022-12-25	WOS:000185388200006
J	M'kacher, R; Bennaceur, A; Farace, F; Lauge, A; Plassa, LF; Wittmer, E; Dossou, J; Violot, D; Deutsch, E; Bourhis, J; Stoppa-Lyonnet, D; Ribrag, V; Carde, P; Parmentier, C; Bernheim, A; Turhan, AG				M'kacher, R; Bennaceur, A; Farace, F; Lauge, A; Plassa, LF; Wittmer, E; Dossou, J; Violot, D; Deutsch, E; Bourhis, J; Stoppa-Lyonnet, D; Ribrag, V; Carde, P; Parmentier, C; Bernheim, A; Turhan, AG			Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma	ONCOGENE			English	Article						DNA repair; ATM; P53; mantle cell lymphoma; irradiation	ATAXIA-TELANGIECTASIA GENE; IONIZING-RADIATION; MISSENSE MUTATIONS; C-ABL; ATM; PROTEIN; INACTIVATION; KINASE; PHOSPHORYLATION; P53	Mantle cell lymphomas (MCL) are characterized by their aggressive behavior and poor response to chemotherapy regimens. We report here evidence of increased in vitro radiation sensitivity in two cell lines that we have generated from two MCL patients (UPN1 and UPN2). However, despite their increased radiation sensitivity, UPN2 cells were totally resistant to apoptotic cell death, whereas UPN1 cells underwent massive apoptosis 6 h after irradiation. The frequency of induced chromosomal abnormalities was higher in UPN1 as compared to UPN2. Distinct mechanisms have been found to contribute to this phenotype: a major telomere shortening (UPN1 and UPN2), deletion of one ATM allele and a point mutation in the remaining allele in UPN2, mutation of p53 gene (UPN1 and UPN2) with absence of functional p53 as revealed by functional yeast assays. After irradiation, Ku70 levels in UPN1 increased and decreased in UPN2, whereas in the same conditions, DNA-PKcs protein levels decreased in UPN1 and remained unchanged in UPN2. Thus, irradiation-induced apoptotic cell death can occur despite the nonfunctional status of p53 (UPN1), suggesting activation of a unique pathway in MCL cells for the induction of this event. Overall, our study demonstrates that MCL cells show increased radiation sensitivity, which can be the result of distinct molecular events. These findings could clinically be exploited to increase the dismal response rates of MCL patients to the current chemotherapy regimens.	IGR, INSERM, U362, Translat Res Cell Therapy Lab, Villejuif, France; UPRES EA 27 10, Dept Med, Villejuif, France; UPRES EA 27 10, Dept Biol Clin, Villejuif, France; IGR, Cytogenet & Oncol Genet Lab, Villejuif, France; Inst Curie, Serv Genet Oncol, F-75231 Paris, France; Hop St Louis, Lab Biochim B, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Turhan, AG (corresponding author), IGR, INSERM, U362, Translat Res Cell Therapy Lab, Villejuif, France.	turali@igr.fr		deutsch, eric/0000-0002-8223-3697; Bourhis, Jean/0000-0001-5162-1171; bennaceur griscelli, annelise/0000-0002-3557-4499; TURHAN, Ali/0000-0002-4861-0137				Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Behr TM, 2002, CANCER-AM CANCER SOC, V94, P1363, DOI 10.1002/cncr.10307; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BOSCH F, 1994, BLOOD, V84, P2726; Brown KD, 1999, AM J HUM GENET, V64, P46, DOI 10.1086/302223; Camacho E, 2002, BLOOD, V99, P238, DOI 10.1182/blood.V99.1.238; Campo E, 1999, SEMIN HEMATOL, V36, P115; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; di Fagagna FD, 1999, NAT GENET, V23, P76; Dreyling MH, 1997, CANCER RES, V57, P4608; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Gatei M, 2000, CANCER RES, V60, P3299; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Gilley D, 2001, P NATL ACAD SCI USA, V98, P15084, DOI 10.1073/pnas.261574698; Gopal AK, 2002, BLOOD, V99, P3158, DOI 10.1182/blood.V99.9.3158; Hou M, 2001, CLIN CHEM, V47, P519; Iavarone A, 1997, NATURE, V387, P417; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; M'kacher R, 2003, CANCER GENET CYTOGEN, V143, P32, DOI 10.1016/S0165-4608(02)00823-3; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Meyer KM, 1999, ONCOGENE, V18, P5795, DOI 10.1038/sj.onc.1202977; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Pandita TK, 1999, MOL CELL BIOL, V19, P5096; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; TOLKSDORF G, 1980, BRIT J CANCER, V41, P168, DOI 10.1038/bjc.1980.27; VERPY E, 1994, P NATL ACAD SCI USA, V91, P1873, DOI 10.1073/pnas.91.5.1873; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Weisenburger DD, 1996, BLOOD, V87, P4483, DOI 10.1182/blood.V87.11.4483.bloodjournal87114483; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	38	33	35	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					7905	7912		10.1038/sj.onc.1206826	http://dx.doi.org/10.1038/sj.onc.1206826			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970738				2022-12-25	WOS:000185388200005
J	Henshall, SM; Afar, DEH; Rasiah, KK; Horvath, LG; Gish, K; Caras, I; Ramakrishnan, V; Wong, M; Jeffry, U; Kench, JG; Quinn, DI; Turner, JJ; Delprado, W; Lee, CS; Golovsky, D; Brenner, PC; O'Neill, GF; Kooner, R; Stricker, PD; Grygiel, JJ; Mack, DH; Sutherland, RL				Henshall, SM; Afar, DEH; Rasiah, KK; Horvath, LG; Gish, K; Caras, I; Ramakrishnan, V; Wong, M; Jeffry, U; Kench, JG; Quinn, DI; Turner, JJ; Delprado, W; Lee, CS; Golovsky, D; Brenner, PC; O'Neill, GF; Kooner, R; Stricker, PD; Grygiel, JJ; Mack, DH; Sutherland, RL			Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer	ONCOGENE			English	Article						ZnT4; prostate cancer; zinc transporter; oligonucleotide microarrray; hyperplasia	FUNCTIONAL-CHARACTERIZATION; MONOCLONAL-ANTIBODY; CONFERS RESISTANCE; GERMLINE MUTATIONS; EPITHELIAL-CELLS; GENE; CLONING; MICROARRAYS; THERAPY; TISSUE	We have utilized oligonucleotide microarrays to identify novel genes of potential clinical and biological importance in prostate cancer. RNA from 74 prostate cancers and 164 normal body samples representing 40 different tissues were analysed using a customized Affymetrix GeneChip(R) oligonucleotide microarray representative of over 90% of the expressed human genome. The gene for the zinc transporter ZnT4 was one of several genes that displayed significantly higher expression in prostate cancer compared to normal tissues from other organs. A polyclonal antipeptide antibody was used to demonstrate ZnT4 expression in the epithelium of all 165 elements of benign and 326 elements of localized prostate cancers examined and in nine of 10 advanced prostate cancer specimens by immunohistochemistry. Interestingly, decreased intensity of ZnT4 immunoreactivity occurred in the progression from benign to invasive localized prostate cancer and to metastatic disease. Immunofluorescence analysis and surface biotinylation studies of cells expressing ZnT4 localised the protein to intracellular vesicles and to the plasma membrane. These findings are consistent with a role for ZnT4 in vesicular transport of zinc to the cell membrane and potentially in efflux of zinc in the prostate.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; Eos Biotechnol, Genom Res, San Francisco, CA 94080 USA; St Vincents Hosp, Dept Anat Pathol, Darlinghurst, NSW 2010, Australia; Douglass Hanly Moir Pathol, N Ryde, NSW 2113, Australia; Royal Prince Alfred Hosp, Dept Anat Pathol, Camperdown, NSW 2050, Australia; Univ Sydney, Dept Pathol, Camperdown, NSW 2050, Australia; St Vincents Hosp, Dept Urol, Darlinghurst, NSW 2010, Australia; St Vincents Hosp, Dept Med Oncol, Darlinghurst, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; St Vincents Hospital Sydney; University of Sydney; University of Sydney; St Vincents Hospital Sydney; St Vincents Hospital Sydney	Sutherland, RL (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	r.sutherland@garvan.org.au	Quinn, David/N-3730-2019; Quinn, David I/F-4343-2015; Sutherland, Robert L/A-8378-2008	Quinn, David/0000-0002-1411-0417; Quinn, David I/0000-0002-1411-0417; Caras, Ingrid/0000-0002-8902-808X; Turner, Jennifer/0000-0001-5550-3375; Horvath, Lisa/0000-0001-6842-9223; Kench, James Geoffrey/0000-0001-8687-4988; Lee, C. Soon/0000-0003-1058-5826				Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; Cho YH, 2002, INT J ANTIMICROB AG, V19, P576, DOI 10.1016/S0924-8579(02)00115-2; Costello LC, 1999, J BIOL CHEM, V274, P17499, DOI 10.1074/jbc.274.25.17499; Costello LC, 1997, J BIOL CHEM, V272, P28875, DOI 10.1074/jbc.272.46.28875; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Feng P, 2000, MOL UROL, V4, P31; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; Huang LP, 2002, J BIOL CHEM, V277, P26389, DOI 10.1074/jbc.M200462200; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; Inoue K, 2002, HUM MOL GENET, V11, P1775, DOI 10.1093/hmg/11.15.1775; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Liang JY, 1999, PROSTATE, V40, P200; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; MCMAHON RJ, 1998, J NUTR, V128; MCNEAL JE, 1997, HISTOLOGY PATHOLOGIS; Michalczyk AA, 2002, BIOCHEM J, V364, P105, DOI 10.1042/bj3640105; Murgia C, 1999, AM J PHYSIOL-GASTR L, V277, pG1231, DOI 10.1152/ajpgi.1999.277.6.G1231; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Quinn DI, 2001, J CLIN ONCOL, V19, P3692, DOI 10.1200/JCO.2001.19.16.3692; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Uzzo RG, 2002, CLIN CANCER RES, V8, P3579; Xu JF, 2002, NAT GENET, V32, P321, DOI 10.1038/ng994; Zaichick V. Ye., 1997, International Urology and Nephrology, V29, P565, DOI 10.1007/BF02552202	28	85	87	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6005	6012		10.1038/sj.onc.1206797	http://dx.doi.org/10.1038/sj.onc.1206797			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955079				2022-12-25	WOS:000185137800009
J	Nistri, S; Chiappini, L; Sassoli, C; Bani, D				Nistri, S; Chiappini, L; Sassoli, C; Bani, D			Relaxin inhibits lipopolysaccharide-induced adhesion of neutrophils to coronary endothelial cells by a nitric oxide-mediated mechanism	FASEB JOURNAL			English	Article						P-selectin; VCAM-1; ICAM-1	LEUKOCYTE ADHESION; TISSUE-INJURY; EXPRESSION; DISEASE; INFLAMMATION; ACTIVATION; RECEPTORS; HORMONE; WOMEN; HEART	Neutrophil margination within blood vessels is an early finding during myocardial ischemia and can result in myocardial tissue injury. This phenomenon depends on the endothelial expression of adhesion molecules, which allow leukocyte extravasation. The hormone relaxin (RLX) was found to protect against experimental myocardial injury and to reduce neutrophil extravasation into the inflamed tissues. This study addresses the role of RLX in down-regulating endothelial adhesiveness to neutrophils and the possible involvement of NO, an anti-adhesive molecule, in the mechanism of action of RLX. Lipopolysaccharide (LPS)-primed rat coronary endothelial (RCE) cells and neutrophils were co-cultured and their adhesion was quantified in the absence and presence of RLX, alone or together with the NO-synthase inhibitor L-NMMA. Inactivated RLX was used as control for specificity of the RLX effect. A 24-h incubation of LPS-primed RCE cells with RLX (60 and 600 ng/ml) caused a significant reduction of adherent neutrophils and of endothelial expression of the adhesion molecules P-selectin and VCAM-1 protein and mRNA, evaluated by immunohistochemistry, Western blot, and RT-PCR. These effects of RLX were blunted by L-NMMA and were not reproduced by inactivated RLX. These findings suggest that RLX has anti-inflammatory properties that could be of benefit in ischemic heart disease.	Univ Florence, Sect Histol, Dept Anat Histol & Forens Med, I-50139 Florence, Italy; Univ Florence, Sect Anat, Dept Anat Histol & Forens Med, I-50139 Florence, Italy	University of Florence; University of Florence	Bani, D (corresponding author), Univ Florence, Sect Histol, Dept Anat Histol & Forens Med, Vle G Pieraccini 6, I-50139 Florence, Italy.	daniele.bani@unifi.it	SASSOLI, CHIARA/AAC-4023-2019	SASSOLI, CHIARA/0000-0002-1337-0938; Bani, Daniele/0000-0001-6302-901X				ANDERSON BO, 1991, J SURG RES, V51, P170, DOI 10.1016/0022-4804(91)90090-9; Bachschmid M, 2003, FASEB J, V17, P914, DOI 10.1096/fj.02-0530fje; Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; Bani D, 1997, ENDOCRINOLOGY, V138, P1909, DOI 10.1210/en.138.5.1909; Bani D, 1998, AM J PATHOL, V152, P1367; BULLESBACH EE, 1988, INT J PEPT PROT RES, V32, P361; DAVENPECK KL, 1994, GASTROENTEROLOGY, V107, P1050, DOI 10.1016/0016-5085(94)90229-1; DE CR, 1995, J CLIN INVEST, V96, P60; ENGLER RL, 1986, AM J PHYSIOL, V251, P314; FAILLI P, 1996, FASEB J         1214; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Hu FB, 2000, NEW ENGL J MED, V343, P530, DOI 10.1056/NEJM200008243430802; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; Laroux FS, 2000, ANTIOXID REDOX SIGN, V2, P391, DOI 10.1089/15230860050192161; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Nistri Silvia, 2002, Biological Procedures Online, V4, P32, DOI 10.1251/bpo31; OSHEROFF PL, 1993, J BIOL CHEM, V268, P15193; Peng HB, 1998, J IMMUNOL, V161, P1970; PIETERSMA A, 1994, AM J PHYSIOL, V267, pH874, DOI 10.1152/ajpheart.1994.267.3.H874; SLUITER W, 1993, J CARDIOVASC PHARM, V22, pS37, DOI 10.1097/00005344-199322004-00006; Spiecker M, 1999, METHOD ENZYMOL, V300, P374; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406	23	50	57	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2109	+		10.1096/fj.03-0216fje	http://dx.doi.org/10.1096/fj.03-0216fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500542	Green Submitted			2022-12-25	WOS:000185925100015
J	Anakk, S; Kalsotra, A; Shen, Q; Vu, MT; Staudinger, JL; Davies, PJA; Strobel, HW				Anakk, S; Kalsotra, A; Shen, Q; Vu, MT; Staudinger, JL; Davies, PJA; Strobel, HW			Genomic characterization and regulation of CYP3a13: role of xenobiotics and nuclear receptors	FASEB JOURNAL			English	Article						cytochrome P4503A; drug metabolism; sexual dimorphism; nuclear receptors	RETINOID-X-RECEPTOR; TATA-LESS; HUMAN HEPATOCYTES; CDNA CLONING; EXPRESSION; GENE; INDUCTION; LIVER; TRANSCRIPTION; DEXAMETHASONE	We report that CYP3a13 gene, located on mouse chromosome 5, spans 27.5 Kb and contains 13 exons. The transcription start site is 35 bp upstream of the coding region and results in a 109 bp 5' untranslated region. CYP3a13 promoter shows putative binding sites for retinoid X receptor, pregnane X receptor, and estrogen receptor. CYP3a13 shows a broad tissue distribution with predominant expression in liver. Although CYP3a13 shares 92% nucleotide identity with the female-specific rat CYP3A9, its expression does not exhibit sexual dimorphism. Ligand activation of peroxisomal proliferator-activated receptor-gamma and retinoid X receptor inhibit expression of CYP3a13 at the transcription level in a tissue-specific manner. Another novel finding is hepatic induction of CYP3a13 by dexamethasone occurring only in pregnane X receptor null mice. We also report that pregnane X receptor is essential to maintain robust in vivo basal levels of CYP3a13 in contrast to CYP3a11. CYP3a13 protein expressed in vitro can metabolize clinically active drugs ethylmorphine and erythromycin, as well as benzphetamine. We conclude that CYP3a13 is regulated differentially by various nuclear receptors. In humans this may lead to altered drug metabolism, as many of the newly synthesized ligands/drugs targeted toward these nuclear receptors could influence CYP3A gene expression.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Integrat Biol, Houston, TX 77225 USA; Univ Kansas, Med Ctr, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA	University of Texas System; University of Texas System; University of Kansas; University of Kansas Medical Center	Strobel, HW (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708, Houston, TX 77225 USA.	henry.w.strobel@uth.tmc.edu		Kalsotra, Auinash/0000-0002-1011-0006				Balthazart J, 1998, TRENDS NEUROSCI, V21, P243, DOI 10.1016/S0166-2236(97)01221-6; Bernard P, 1999, MOL PHARMACOL, V56, P526, DOI 10.1124/mol.56.3.526; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; BURGER HJ, 1992, P NATL ACAD SCI USA, V89, P2145, DOI 10.1073/pnas.89.6.2145; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Cui XM, 2002, GENE, V297, P179, DOI 10.1016/S0378-1119(02)00885-5; Dai D, 2001, J BIOCHEM MOL TOXIC, V15, P90, DOI 10.1002/jbt.4; Davies PJA, 2001, MOL PHARMACOL, V59, P170, DOI 10.1124/mol.59.2.170; Domanski TL, 2001, MOL PHARMACOL, V59, P386, DOI 10.1124/mol.59.2.386; El-Sankary W, 2002, DRUG METAB DISPOS, V30, P1029, DOI 10.1124/dmd.30.9.1029; Finta C, 2000, GENE, V260, P13, DOI 10.1016/S0378-1119(00)00470-4; Goodwin B, 2002, ANNU REV PHARMACOL, V42, P1, DOI 10.1146/annurev.pharmtox.42.111901.111051; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Howell SR, 1998, DRUG METAB DISPOS, V26, P234; Huber R, 1998, GENE, V214, P35, DOI 10.1016/S0378-1119(98)00233-9; ITOH S, 1994, EUR J BIOCHEM, V226, P877, DOI 10.1111/j.1432-1033.1994.t01-1-00877.x; JANIKAMJORN K, 2001, BIOCHEM PHARMACOL, V62, P161; JOUNAIDI Y, 1994, BIOCHEM BIOPH RES CO, V205, P1741, DOI 10.1006/bbrc.1994.2870; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; KATO R, 1993, HORMONAL REGULATION; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; LeCluyse EL, 2001, CHEM-BIOL INTERACT, V134, P283, DOI 10.1016/S0009-2797(01)00163-6; Lenhard JM, 1999, DIABETOLOGIA, V42, P545, DOI 10.1007/s001250051193; Mahnke Z, 1997, ARCH BIOCHEM BIOPHYS, V337, P62, DOI 10.1006/abbi.1996.9752; MOLOWA DT, 1986, P NATL ACAD SCI USA, V83, P5311, DOI 10.1073/pnas.83.14.5311; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Pascussi JM, 2000, MOL PHARMACOL, V58, P361, DOI 10.1124/mol.58.2.361; Pascussi JM, 2000, MOL PHARMACOL, V58, P1441, DOI 10.1124/mol.58.6.1441; Pereira TM, 1998, DNA CELL BIOL, V17, P39, DOI 10.1089/dna.1998.17.39; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Quattrochi LC, 2001, DRUG METAB DISPOS, V29, P615; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Robertson GR, 1998, BIOCHEM BIOPH RES CO, V242, P57, DOI 10.1006/bbrc.1997.7904; Rubin GL, 2002, ENDOCRINOLOGY, V143, P2863, DOI 10.1210/en.143.8.2863; Sakuma T, 2002, ARCH BIOCHEM BIOPHYS, V404, P234, DOI 10.1016/S0003-9861(02)00329-6; Sakuma T, 2000, ARCH BIOCHEM BIOPHYS, V377, P153, DOI 10.1006/abbi.2000.1747; Savas U, 1999, MOL PHARMACOL, V56, P851, DOI 10.1124/mol.56.5.851; Skak K, 1999, GENE, V236, P231, DOI 10.1016/S0378-1119(99)00286-3; Staudinger J, 2001, DRUG METAB DISPOS, V29, P1467; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Thummel KE, 2001, MOL PHARMACOL, V60, P1399, DOI 10.1124/mol.60.6.1399; Toide K, 1997, ARCH BIOCHEM BIOPHYS, V338, P43, DOI 10.1006/abbi.1996.9792; VandenBroek PJA, 1996, EXPERIENTIA, V52, P851; Wang HM, 2000, MOL CELL BIOCHEM, V213, P127, DOI 10.1023/A:1007124417566; Wang HM, 1997, ARCH BIOCHEM BIOPHYS, V344, P365, DOI 10.1006/abbi.1997.0230; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Yamada H, 2000, BIOCHEM BIOPH RES CO, V277, P66, DOI 10.1006/bbrc.2000.3620; YANAGIMOTO T, 1994, BBA-GEN SUBJECTS, V1201, P405, DOI 10.1016/0304-4165(94)90069-8; Yanagimoto T, 1997, ARCH BIOCHEM BIOPHYS, V340, P215, DOI 10.1006/abbi.1997.9900	53	27	27	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1736	+		10.1096/fj.02-1004fje	http://dx.doi.org/10.1096/fj.02-1004fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958193				2022-12-25	WOS:000184471600022
J	Portella, G; Laezza, C; Laccetti, P; De Petrocellis, L; Di Marzo, V; Bifulco, M				Portella, G; Laezza, C; Laccetti, P; De Petrocellis, L; Di Marzo, V; Bifulco, M			Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis	FASEB JOURNAL			English	Article						thyroid; cancer; endocannabinoid; p27; lung; VEGF	THYROID EPITHELIAL-CELLS; MURINE SARCOMA-VIRUS; IN-VIVO; UP-REGULATION; HUMAN BREAST; FRTL-5 CELLS; FACTOR VEGF; ANANDAMIDE; CANCER; PROLIFERATION	Stimulation of cannabinoid CB1 receptors by 2-methyl-arachidonyl-2'-fluoro-ethylamide (Met-F-AEA) inhibits the growth of a rat thyroid cancer cell-derived tumor in athymic mice by inhibiting the activity of the oncogene product p21(ras). Here we report that Met-F-AEA also blocks the growth of tumors previously induced in nude mice by the s.c. injection of the same rat thyroid carcinoma cells. Met-F-AEA significantly inhibited, in tumors as well as transformed cells, the expression of the vascular endothelial growth factor, an angiogenetic factor known to be up-regulated by p21ras, as well as of one of its receptors,flt-1/VEGFR-1. The levels of the cyclin-dependent kinase inhibitor p27(kip1),which is down-regulated by p21ras, were instead increased by Met-F-AEA. All these effects were antagonized by the selective CB1 receptor antagonist SR141716A. Met-F-AEA inhibited in vitro the growth of a metastasis-derived thyroid cancer cell line more potently than a primary cancer cell line. Therefore, the hypothesis that CB1 receptor stimulation interferes not only with angiogenesis but also with metastatic processes was tested in a widely used model of metastatic infiltration in vivo, the Lewis lung carcinoma(3LL) in C57Bl/6 mice. Three weeks from the paw injection of 3LL cells, Met-F-AEA reduced significantly the number of metastatic nodes, in away antagonized by SR141716A. Our findings indicate that CB1 receptor agonists might be used therapeutically to retard tumor growth in vivo by inhibiting at once tumor growth, angiogenesis, and metastasis.	Univ Naples Federico 2, Endocannabinoid Res Grp, Naples, Italy; Univ Naples Federico 2, Ist Endocrinol & Oncol Sperimentale, CNR, Naples, Italy; Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol L Calif, Naples, Italy; CNR, Ist Cibernet, I-80078 Pozzuoli, NA, Italy; CNR, Ist Chim Biomol, I-80078 Pozzuoli, NA, Italy; Univ Salerno, Dipartimento Sci Farmaceut, I-84084 Fisciano, SA, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR); University of Salerno	Di Marzo, V (corresponding author), Univ Naples Federico 2, Endocannabinoid Res Grp, Naples, Italy.	maubiful@unina.it	laez, chi/AAW-4437-2020; Portella, Giuseppe/AFU-6826-2022; Di Marzo, Vincenzo/AAD-7742-2019	Di Marzo, Vincenzo/0000-0002-1490-3070; Bifulco, Maurizio/0000-0002-1771-4531; PORTELLA, Giuseppe/0000-0001-8276-9769				ADAMS IB, 1995, J PHARMACOL EXP THER, V273, P1172; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Belletti B, 1999, ONCOGENE, V18, P4860, DOI 10.1038/sj.onc.1202869; Bifulco M, 2002, NAT MED, V8, P547, DOI 10.1038/nm0602-547; Bifulco M, 2001, FASEB J, V15, P2745, DOI 10.1096/fj.01-0320fje; Bisogno T, 2000, BIOCHEM J, V351, P817, DOI 10.1042/0264-6021:3510817; Blazquez C, 2003, FASEB J, V17, P529, DOI 10.1096/fj.02-0795fje; Casanova ML, 2003, J CLIN INVEST, V111, P43, DOI 10.1172/JCI200316116; De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2000, PROSTAG OTH LIPID M, V61, P43, DOI 10.1016/S0090-6980(00)00054-X; DIMARZO V, 2002, BIOL MARIJUANA, P125; FUSCO A, 1981, INT J CANCER, V28, P655, DOI 10.1002/ijc.2910280519; FUSCO A, 1982, CANCER RES, V42, P618; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Goukassian D, 2001, FASEB J, V15, P1877, DOI 10.1096/fj.01-0065com; Guzman M, 2001, J MOL MED-JMM, V78, P613, DOI 10.1007/s001090000177; Hanus L, 2001, P NATL ACAD SCI USA, V98, P3662, DOI 10.1073/pnas.061029898; Howlett AC, 2000, CHEM PHYS LIPIDS, V108, P53, DOI 10.1016/S0009-3084(00)00187-0; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; Khoo MLC, 2002, J CLIN ENDOCR METAB, V87, P1814, DOI 10.1210/jcem.87.4.8353; LACCETTI P, 1994, CANCER RES, V54, P4253; Laezza C, 1998, P NATL ACAD SCI USA, V95, P13646, DOI 10.1073/pnas.95.23.13646; Larcher F, 1996, CANCER RES, V56, P5391; Lei HT, 2002, J BIOL CHEM, V277, P43137, DOI 10.1074/jbc.M203103200; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Melck D, 2000, ENDOCRINOLOGY, V141, P118, DOI 10.1210/en.141.1.118; Melck D, 1999, FEBS LETT, V463, P235, DOI 10.1016/S0014-5793(99)01639-7; Miyagi E, 2001, THYROID, V11, P539, DOI 10.1089/105072501750302831; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; PORTELLA G, 1989, ONCOGENE, V4, P181; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 2000, CANCER RES, V60, P490; Rak J, 2001, METHOD ENZYMOL, V333, P267; Sanchez C, 2001, CANCER RES, V61, P5784; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; Viglietto G, 1997, ONCOGENE, V15, P2687, DOI 10.1038/sj.onc.1201456; Wang JF, 1998, J ENDOCRINOL, V157, P5, DOI 10.1677/joe.0.1570005	41	145	157	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1771	+		10.1096/fj.02-1129fje	http://dx.doi.org/10.1096/fj.02-1129fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958205				2022-12-25	WOS:000184471600021
J	Rivat, C; Le Floch, N; Sabbah, M; Teyrol, I; Redeuilh, G; Bruyneel, E; Mareel, M; Matrisian, LM; Crawford, HC; Gespach, C; Attoub, S				Rivat, C; Le Floch, N; Sabbah, M; Teyrol, I; Redeuilh, G; Bruyneel, E; Mareel, M; Matrisian, LM; Crawford, HC; Gespach, C; Attoub, S			Synergistic cooperation between the AP-1 and LEF-1 transcription factors in the activation of the matrilysin promoter by the src oncogene: implications in cellular invasion	FASEB JOURNAL			English	Article						kidney and colonic cancer cells; HGF/Met; metastasis; PKC; MAPK	HUMAN COLORECTAL-CANCER; MATRIX-METALLOPROTEINASE MATRILYSIN; ADENOMATOUS POLYPOSIS-COLI; KIDNEY EPITHELIAL-CELLS; MIDDLE T-ONCOGENES; GROWTH-FACTOR-BETA; V-SRC; SIGNALING PATHWAYS; C-JUN; NEOPLASTIC PROGRESSION	The matrix metalloprotease matrilysin is expressed in premalignant polyps and plays a key role in local invasion during the progression of digestive tumors. In the present work, we investigated the possible relationships between the activity of the mouse and human matrilysin promoters (Mp), endogenous matrilysin protein expression, and two early oncogenetic defects frequently observed in human colonic cancers, namely activation of the src oncogene and impairment of the Wnt/APC/beta-catenin pathway. Using transient transfection assays, we report here that src signaling and the HMG-box transcription factor LEF-1 act synergistically with the proximal (-61 to -67) AP-1 binding site to transactivate the Mp in premalignant and tumorigenic kidney and colonic epithelial cells, through beta-catenin- and axin-independent signaling pathways. This synergism involves the -109 and -194 Tcf/LEF-1 binding sites in the Mp and a physical interaction between LEF-1 and c-Jun. Furthermore, src coordinates accumulation of the c-Jun factor and matrilysin transcripts. Conversely, the c-Jun dominant negative mutant TAM67 and the src tyrosine kinase inhibitor M475271 impaired src-induced Mp activation, matrilysin protein cellular invasion during the early-stage adenoma/adenocarcinoma conversion and the metastatic process of digestive tumors.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Vanderbilt Univ, Dept Canc Biol, Sch Med, Nashville, TN 37232 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; Vanderbilt University	Attoub, S (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	attoub@st-antoine.inserm.fr	Crawford, Howard/A-2874-2008; Attoub, Samir/N-6852-2018; LE FLOCH, Nathalie/I-3415-2015	LE FLOCH, Nathalie/0000-0002-6411-7975; SABBAH, Michele/0000-0001-5368-9022				Abdel-Ghany M, 2001, J BIOL CHEM, V276, P25438, DOI 10.1074/jbc.M100478200; Adachi Y, 2001, INT J CANCER, V95, P290, DOI 10.1002/1097-0215(20010920)95:5<290::AID-IJC1050>3.0.CO;2-I; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; Batlle E, 1998, J BIOL CHEM, V273, P15091, DOI 10.1074/jbc.273.24.15091; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; Cho-Chung YS, 1999, CURR OPIN MOL THER, V1, P386; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; DECESARE D, 1995, ONCOGENE, V11, P365; Dehm S, 2001, FEBS LETT, V487, P367, DOI 10.1016/S0014-5793(00)02354-1; DELAGE S, 1993, CANCER RES, V53, P2762; Dong ZG, 1996, J BIOL CHEM, V271, P9942, DOI 10.1074/jbc.271.17.9942; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; GAIRE M, 1994, J BIOL CHEM, V269, P2032; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gumbiner BM, 1997, CURR BIOL, V7, pR443, DOI 10.1016/S0960-9822(06)00214-4; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Howe LR, 2001, J BIOL CHEM, V276, P20108, DOI 10.1074/jbc.M010692200; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Kadono Y, 1998, BIOCHEM BIOPH RES CO, V251, P681, DOI 10.1006/bbrc.1998.9531; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kataoka H, 2000, CANCER RES, V60, P6148; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Masaki T, 1998, HEPATOLOGY, V27, P1257, DOI 10.1002/hep.510270511; Masaki T, 2001, BRIT J CANCER, V84, P1317, DOI 10.1054/bjoc.2001.1790; MELLSTROM K, 1987, MOL CELL BIOL, V7, P4178, DOI 10.1128/MCB.7.12.4178; MORI M, 1995, CANCER, V75, P1516, DOI 10.1002/1097-0142(19950315)75:6+<1516::AID-CNCR2820751522>3.0.CO;2-7; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; NEWELL KJ, 1994, MOL CARCINOGEN, V10, P199, DOI 10.1002/mc.2940100404; Noe V, 2001, J CELL SCI, V114, P111; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Pacheco MM, 2002, HEAD NECK-J SCI SPEC, V24, P24, DOI 10.1002/hed.10009; Pasche B, 2001, J CELL PHYSIOL, V186, P153, DOI 10.1002/1097-4652(200002)186:2<153::AID-JCP1016>3.0.CO;2-J; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Prunier C, 1999, J BIOL CHEM, V274, P22919, DOI 10.1074/jbc.274.33.22919; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; SATO H, 1993, J BIOL CHEM, V268, P23460; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; Sparks AB, 1998, CANCER RES, V58, P1130; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Vider BZ, 1996, ONCOGENE, V12, P153; Visser CJT, 1996, LAB INVEST, V74, P2; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wilson CL, 1996, INT J BIOCHEM CELL B, V28, P123, DOI 10.1016/1357-2725(95)00121-2; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; YAMAMOTO H, 1995, J CLIN LAB ANAL, V9, P297, DOI 10.1002/jcla.1860090504; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367	73	66	67	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1721	+		10.1096/fj.03-0132fje	http://dx.doi.org/10.1096/fj.03-0132fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958188				2022-12-25	WOS:000184471600005
J	Yamada, M; Hirasawa, A; Shiojima, S; Tsujimoto, G				Yamada, M; Hirasawa, A; Shiojima, S; Tsujimoto, G			Granzyme A mediates glucocorticoid-induced apoptosis in leukemia cells	FASEB JOURNAL			English	Article						microarray; dexamethasone; caspase; Bcl-2	TOXIC LYMPHOCYTES-T; GENE-EXPRESSION; SERINE PROTEASES; OLIGONUCLEOTIDE ARRAYS; DNA FRAGMENTATION; MULTIPLE-MYELOMA; CARCINOMA-CELLS; DEATH; DEXAMETHASONE; PATHWAY	To identify the genes responsible for mediating apoptotic effects of glucocorticoid on leukemia cells, changes in gene expression were analyzed during dexamethasone-induced apoptosis of glucocorticoid-sensitive human acute lymphocytic leukemia 697 cells by using cDNA microarrays containing more than 4000 named genes. The microarray analysis showed that 26 genes had markedly differential expression after treatment with 100 nM dexamethasone; 17 genes were up-regulated, including granzyme A, glucocorticoid receptor, and suppressor of cytokine signaling-2; and nine genes were down-regulated, including early growth response 1 and acute myeloid leukemia 1. To circumvent the problem of recovering mRNA from dying cells, 697 cells that were stably transfected with the death inhibitor Bcl-2 were also used, and the expression of selected genes was examined by RT-PCR analysis, which confirmed the expression profile obtained by microarray analysis. The granzyme A protein accumulated in 697 cells and its enzymatic activity increased after dexamethasone treatment in a time-dependent manner, in accordance with the increase in caspase-3 activity. Furthermore, the granzyme inhibitor 3,4-dichloroisocoumarin inhibited the dexamethasone-induced apoptosis of 697 cells in a concentration-dependent manner. These results showed that granzyme A is critically involved in mediating the apoptotic effect of glucocorticoid on leukemia cells.	Natl Res Inst Child Hlth & Dev, Dept Mol Cell Pharmacol, Setagaya Ku, Tokyo 1548567, Japan; Teikyo Univ, Biotech Ctr, Genox Res Inc, Kawasaki, Kanagawa 2160001, Japan	National Center for Child Health & Development - Japan; Teikyo University	Tsujimoto, G (corresponding author), Natl Res Inst Child Hlth & Dev, Dept Mol Cell Pharmacol, Setagaya Ku, 3-35-31 Taishido, Tokyo 1548567, Japan.	gtsujimoto@nch.go.jp						AEBISCHER F, 1992, IMMUNOPHARMACOLOGY, V23, P181, DOI 10.1016/0162-3109(92)90024-7; ALEXANIAN R, 1994, NEW ENGL J MED, V330, P484; BANSAL N, 1991, FASEB J, V5, P211, DOI 10.1096/fasebj.5.2.2004665; BARKER PE, 1987, CANCER GENET CYTOGEN, V25, P379, DOI 10.1016/0165-4608(87)90204-4; Beresford PJ, 1997, P NATL ACAD SCI USA, V94, P9285, DOI 10.1073/pnas.94.17.9285; BLEACKLEY RC, 1988, IMMUNOL REV, V103, P5, DOI 10.1111/j.1600-065X.1988.tb00746.x; CARONLESLIE LAM, 1994, FASEB J, V8, P639, DOI 10.1096/fasebj.8.9.8005391; Chauhan D, 2002, ONCOGENE, V21, P1346, DOI 10.1038/sj.onc.1205205; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Dong G, 2001, CANCER RES, V61, P4797; El-Naghy M, 2001, EXP CELL RES, V270, P166, DOI 10.1006/excr.2001.5350; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; Gaynon PS, 1999, ADV EXP MED BIOL, V457, P593; GERSHENFELD HK, 1988, P NATL ACAD SCI USA, V85, P1184, DOI 10.1073/pnas.85.4.1184; Greenstein S, 2002, CLIN CANCER RES, V8, P1681; Hameed A, 1996, HUM IMMUNOL, V49, P13, DOI 10.1016/0198-8859(96)00052-3; IRMLER M, 1995, J EXP MED, V181, P1917, DOI 10.1084/jem.181.5.1917; Ishibashi T, 2002, INVEST OPHTH VIS SCI, V43, P3691; JENNE DE, 1988, IMMUNOL REV, V103, P53, DOI 10.1111/j.1600-065X.1988.tb00749.x; Katsuma S, 2002, METHOD ENZYMOL, V345, P585; MIYASHITA T, 1993, BLOOD, V81, P151; Miyashita T, 1997, J BIOL CHEM, V272, P29238, DOI 10.1074/jbc.272.46.29238; Mohamadzadeh M, 1996, J INVEST DERMATOL, V107, P738, DOI 10.1111/1523-1747.ep12365634; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; NAKAJIMA H, 1995, J EXP MED, V181, P1037, DOI 10.1084/jem.181.3.1037; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; Planey SL, 2003, CANCER RES, V63, P172; PODACK ER, 1985, P NATL ACAD SCI USA, V82, P8629, DOI 10.1073/pnas.82.24.8629; PODACK ER, 1991, ANNU REV IMMUNOL, V9, P129, DOI 10.1146/annurev.iy.09.040191.001021; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Riccardi C, 1999, CELL DEATH DIFFER, V6, P1182, DOI 10.1038/sj.cdd.4400609; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; Shresta S, 1999, IMMUNITY, V10, P595, DOI 10.1016/S1074-7613(00)80059-X; Smets LA, 1996, LEUKEMIA LYMPHOMA, V20, P199, DOI 10.3109/10428199609051608; Smets LA, 1999, ADV EXP MED BIOL, V457, P607; Smyth MJ, 1996, J LEUKOCYTE BIOL, V60, P555, DOI 10.1002/jlb.60.5.555; Sower LE, 1996, CELL IMMUNOL, V171, P159, DOI 10.1006/cimm.1996.0187; Spaeny-Dekking EHA, 1998, J IMMUNOL, V160, P3610; Tak PP, 1999, CLIN EXP IMMUNOL, V116, P366; TAKAYAMA H, 1987, J IMMUNOL, V138, P566; THOMPSON EB, 1994, MOL ENDOCRINOL, V8, P665, DOI 10.1210/me.8.6.665; Tonko M, 2001, FASEB J, V15, P693, DOI 10.1096/fj.00-0327com; TORIGOE T, 1994, CANCER RES, V54, P4851; VELOTTI F, 1989, EUR J IMMUNOL, V19, P575, DOI 10.1002/eji.1830190328; Vermijlen D, 1999, HEPATOLOGY, V29, P51, DOI 10.1002/hep.510290143; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; Yoshida NL, 2002, BIOCHEM BIOPH RES CO, V293, P1254; Zhang D, 2001, P NATL ACAD SCI USA, V98, P5746, DOI 10.1073/pnas.101329598; Zhou J, 1997, CELL IMMUNOL, V178, P108, DOI 10.1006/cimm.1997.1138	52	21	21	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1712	+		10.1096/fj.02-0116fje	http://dx.doi.org/10.1096/fj.02-0116fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958185				2022-12-25	WOS:000184471600026
J	Yet, SF; Layne, MD; Liu, XL; Chen, YH; Ith, B; Sibinga, NES; Perrella, MA				Yet, SF; Layne, MD; Liu, XL; Chen, YH; Ith, B; Sibinga, NES; Perrella, MA			Absence of heme oxygenase-1 exacerbates atherosclerotic lesion formation and vascular remodeling	FASEB JOURNAL			English	Article						atherosclerosis; vein graft; pressure overload; oxidative stress	SMOOTH-MUSCLE-CELLS; CORONARY-ARTERY DISEASE; APOE-DEFICIENT MICE; APOLIPOPROTEIN-E; CARBON-MONOXIDE; ACCELERATED ATHEROSCLEROSIS; MICROSATELLITE POLYMORPHISM; TRANSGENIC MICE; GRAFT FAILURE; VEIN GRAFTS	To examine the role of hemeoxygenase(HO)-1 in the pathophysiology of vascular diseases,we generated mice deficient in both HO-1 and apolipoprotein E( HO-1(-/-)apoE(-/-)). Despite similar total plasma cholesterol levels in response to hypercholesterolemia, HO-1-/-apoE-/-mice, in comparison with HO-1(+/+) apoE(-/-) mice, had an accelerated and more advanced atherosclerotic lesion formation. In addition to greater lipid accumulation, these advanced lesions from HO-1(-/-) apoE(-/-) mice contained macrophages and smooth muscle alpha-actin-positive cells. We further tested the role of HO-1 on neointimal formation in a mouse model of vein graft stenosis. Autologous vein grafts in HO-1(-/-) mice showed robust neointima consisting of alpha-actin-positive vascular smooth muscle cells(VSMC) 10 days after surgery in comparison to the smaller neointima formed in autologous vein grafts in HO-1(+/+) mice. However, at 14 days after surgery, the neointima from composite vessels of HO-1(-/-) mice was composed mainly of acellular material, indicative of substantial VSMC death. VSMC isolated from HO-1(-/-) mice were susceptible to oxidant stress, leading to cell death. Our data demonstrate that HO-1 plays an essential protective role in the pathophysiology of atherosclerosis and vein graft stenosis.	Brigham & Womens Hosp, Div Pulm & Crit Care, Dept Med, Boston, MA 02115 USA; Kaohsiung Med Univ, Dept Internal Med, Div Infect Dis, Kaohsiung, Taiwan; Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Cardiovasc, Bronx, NY 10467 USA	Harvard University; Brigham & Women's Hospital; Kaohsiung Medical University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Yet, SF (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care, Dept Med, 75 Francis St,Thorn 133, Boston, MA 02115 USA.	syet@rics.bwh.harvard.edu	Sibinga, Nicholas/GOJ-8544-2022; Liu, Xiaoli/HGE-7614-2022; Chen, Yen-Hsu/D-5484-2009; Yet, Shaw-Fang/B-1067-2010; Yet, Shaw-Fang/O-8583-2019	Sibinga, Nicholas/0000-0003-4838-910X; Yet, Shaw-Fang/0000-0001-9097-3962; Layne, Matthew/0000-0003-0007-4870; Chen, Yen-hsu/0000-0002-8667-4844; Liu, Xiaoli/0000-0003-2904-4413				Angelini GD, 2002, BIORHEOLOGY, V39, P491; Chen YH, 2002, HUM GENET, V111, P1, DOI 10.1007/s00439-002-0769-4; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Cyrus T, 2002, CIRCULATION, V106, P1282, DOI 10.1161/01.CIR.0000027816.54430.96; Dietrich H, 2000, AM J PATHOL, V157, P659, DOI 10.1016/S0002-9440(10)64576-2; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Exner M, 2001, J ENDOVASC THER, V8, P433, DOI 10.1583/1545-1550(2001)008<0433:HOGPMP>2.0.CO;2; Grundemar L, 1997, TRENDS PHARMACOL SCI, V18, P193, DOI 10.1016/S0165-6147(97)90622-2; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; Hishikawa K, 1997, CIRC RES, V81, P797; Hopkins PN, 1996, ARTERIOSCL THROM VAS, V16, P250, DOI 10.1161/01.ATV.16.2.250; Hunt SC, 2001, ATHEROSCLEROSIS, V154, P747, DOI 10.1016/S0021-9150(00)00420-2; Ishikawa K, 2001, CIRCULATION, V104, P1831, DOI 10.1161/hc3901.095897; Ishikawa K, 2001, CIRC RES, V88, P506, DOI 10.1161/01.RES.88.5.506; Ishikawa K, 1997, J CLIN INVEST, V100, P1209, DOI 10.1172/JCI119634; Johnson JL, 2001, ATHEROSCLEROSIS, V154, P399, DOI 10.1016/S0021-9150(00)00515-3; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; KEYSE SM, 1987, CARCINOGENESIS, V8, P1251, DOI 10.1093/carcin/8.9.1251; Kockx MM, 1996, CIRCULATION, V94, P1255, DOI 10.1161/01.CIR.94.6.1255; Lardenoye JHP, 2002, CIRC RES, V91, P577, DOI 10.1161/01.RES.0000036901.58329.D7; Layne MD, 1998, J BIOL CHEM, V273, P15654, DOI 10.1074/jbc.273.25.15654; Lee TS, 1999, CIRCULATION, V99, P1222, DOI 10.1161/01.CIR.99.9.1222; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Mehta D, 1997, INT J CARDIOL, V62, pS55, DOI 10.1016/S0167-5273(97)00214-3; Minamino T, 2001, P NATL ACAD SCI USA, V98, P8798, DOI 10.1073/pnas.161272598; Morita T, 1995, J CLIN INVEST, V96, P2676, DOI 10.1172/JCI118334; Morita T, 1997, J BIOL CHEM, V272, P32804, DOI 10.1074/jbc.272.52.32804; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; Nakayama M, 2001, ARTERIOSCL THROM VAS, V21, P1373, DOI 10.1161/hq0801.093592; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Patil CV, 2001, EUR HEART J, V22, P1183, DOI 10.1053/euhj.2000.2497; Perrella MA, 2001, FASEB J, V15, P1774, DOI 10.1096/fj.01-0017fje; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Serruys PW, 2001, NEW ENGL J MED, V344, P1117, DOI 10.1056/NEJM200104123441502; Shi CW, 1999, CIRC RES, V84, P883; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Wagner CT, 1997, J CLIN INVEST, V100, P589, DOI 10.1172/JCI119569; Wang A. Y., 1999, Journal of Submicroscopic Cytology and Pathology, V31, P423; Wang LJ, 1998, AM J PATHOL, V152, P711; Wiesel P, 2001, CIRC RES, V88, P1088, DOI 10.1161/hh1001.091521; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163; Yet SF, 2001, CIRC RES, V89, P168, DOI 10.1161/hh1401.093314; Yet SF, 1997, J BIOL CHEM, V272, P4295, DOI 10.1074/jbc.272.7.4295; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	51	249	259	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1759	+		10.1096/fj.03-0187fje	http://dx.doi.org/10.1096/fj.03-0187fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958201				2022-12-25	WOS:000184471600023
J	Aoki, K; Matsumoto, K; Tsujimoto, M				Aoki, K; Matsumoto, K; Tsujimoto, M			Xenopus cold-inducible RNA-binding protein 2 interacts with ElrA, the Xenopus homolog of HuR, and inhibits deadenylation of specific mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENT; CYTOPLASMIC POLYADENYLATION; OOCYTE MATURATION; MAMMALIAN EXOSOME; CIRP EXPRESSION; POLY(A) TAIL; SEQUENCE; STABILIZATION; NUCLEAR; LAEVIS	Xenopus cold-inducible RNA-binding protein 2 (xCIRP2) is a major cytoplasmic RNA-binding protein in oocytes. In this study, we identify another RNA-binding protein ElrA, the Xenopus homolog of HuR, as an interacting protein of xCIRP2 by yeast two-hybrid screening. As ElrA stabilizes the RNA body in the in vitro mRNA stability system, we examine the role of xCIRP2 in the stabilization of mRNA and find that xCIRP2 inhibits deadenylation of AU-rich element-containing mRNA. These results suggest that xCIRP2 and ElrA may be involved in the regulation of mRNA stability at different steps. By immunoprecipitation with anti-xCIRP2 antibody, we find that xCIRP2 interacts with several mRNAs including mRNA encoding the centrosomal kinase Nek2B in oocytes. xCIRP2 also inhibits deadenylation of the mRNA substrate containing the 3'-untranslated region of Nek2B mRNA in the in vitro system. Our results suggest that xCIRP2 associates with specific mRNAs and can regulate the length of poly(A) tail in Xenopus oocytes.	RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan; Tokyo Univ Agr & Technol, Dept Agr, Lab Appl Prot Chem, Tokyo 1830054, Japan	RIKEN; Tokyo University of Agriculture & Technology	Matsumoto, K (corresponding author), RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	matsumok@postman.riken.go.jp	Matsumoto, Ken/F-9083-2013	Matsumoto, Ken/0000-0002-7864-3394				Abe R, 1996, NUCLEIC ACIDS RES, V24, P4895, DOI 10.1093/nar/24.24.4895; Aoki K, 2002, NUCLEIC ACIDS RES, V30, P5182, DOI 10.1093/nar/gkf638; Baggs JE, 2003, CURR BIOL, V13, P189, DOI 10.1016/S0960-9822(03)00014-9; BOUVET P, 1994, MOL CELL BIOL, V14, P1893, DOI 10.1128/MCB.14.3.1893; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; Cao QP, 2002, EMBO J, V21, P3852, DOI 10.1093/emboj/cdf353; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CY, 2000, GENE DEV, V14, P1236; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Davidson E. H., 1986, GENE ACTIVITY EARLY; de Moor CH, 1999, EMBO J, V18, P2294, DOI 10.1093/emboj/18.8.2294; de Moor CH, 2001, INT REV CYTOL, V203, P567; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FOX CA, 1990, GENE DEV, V4, P2287, DOI 10.1101/gad.4.12b.2287; Furuno N, 2003, GENE EXPR PATTERNS, V3, P165, DOI 10.1016/S1567-133X(03)00037-1; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gao M, 2000, MOL CELL, V5, P479, DOI 10.1016/S1097-2765(00)80442-6; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Matsumoto K, 2000, NUCLEIC ACIDS RES, V28, P4689, DOI 10.1093/nar/28.23.4689; Matsumoto K, 2003, BIOCHEM BIOPH RES CO, V306, P53, DOI 10.1016/S0006-291X(03)00909-4; Matsumoto K, 1999, MOL CELL BIOL, V19, P6940; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Nishiyama H, 1998, BIOCHEM BIOPH RES CO, V245, P534, DOI 10.1006/bbrc.1998.8482; Nishiyama H, 1997, J CELL BIOL, V137, P899, DOI 10.1083/jcb.137.4.899; Nishiyama H, 1998, AM J PATHOL, V152, P289; Ovchinnikov L. P., 2001, Molekulyarnaya Biologiya (Moscow), V35, P548; Paillard L, 1998, EMBO J, V17, P278, DOI 10.1093/emboj/17.1.278; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Peng Y, 2000, FEBS LETT, V482, P37, DOI 10.1016/S0014-5793(00)02019-6; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; Saito T, 2000, COMP BIOCHEM PHYS B, V125, P237, DOI 10.1016/S0305-0491(99)00174-1; Simon R, 1996, DEV BIOL, V179, P239, DOI 10.1006/dbio.1996.0254; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; Spirin A. S., 1966, Current Topics in Developmental Biology, V1, P1; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Uochi T, 1998, GENE, V211, P245, DOI 10.1016/S0378-1119(98)00102-4; Uto K, 1999, DEV BIOL, V208, P456, DOI 10.1006/dbio.1999.9231; VARNUM SM, 1990, GENE DEV, V4, P2278, DOI 10.1101/gad.4.12b.2278; Voeltz GK, 2001, GENE DEV, V15, P774, DOI 10.1101/gad.872201; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X; Wu L, 1997, MOL CELL BIOL, V17, P6402, DOI 10.1128/MCB.17.11.6402; Xue JH, 1999, FREE RADICAL BIO MED, V27, P1238, DOI 10.1016/S0891-5849(99)00158-6; Yang CL, 2001, J BIOL CHEM, V276, P47277, DOI 10.1074/jbc.M105396200	57	32	34	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48491	48497		10.1074/jbc.M308328200	http://dx.doi.org/10.1074/jbc.M308328200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13679363	hybrid			2022-12-25	WOS:000186731400135
J	Cao, CY; Kwon, K; Jiang, YL; Drohat, AC; Stivers, JT				Cao, CY; Kwon, K; Jiang, YL; Drohat, AC; Stivers, JT			Solution structure and base perturbation studies reveal a novel mode of alkylated base recognition by 3-methyladenine DNA glycosylase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALKYLADENINE GLYCOSYLASE; REPAIR ENZYME; HYDROGEN-BOND; NMR; EXCISION; SUPERFAMILY; SPECIFICITY; MECHANISMS; CATALYSIS; SUBSTRATE	The specific recognition mechanisms of DNA repair glycosylases that remove cationic alkylpurine bases in DNA are not well understood partly due to the absence of structures of these enzymes with their cognate bases. Here we report the solution structure of 3-methyladenine DNA glycosylase I ( TAG) in complex with its 3-methyladenine (3-MeA) cognate base, and we have used chemical perturbation of the base in combination with mutagenesis of the enzyme to evaluate the role of hydrogen bonding and pi-cation interactions in alkylated base recognition by this DNA repair enzyme. We find that TAG uses hydrogen bonding with heteroatoms on the base, van der Waals interactions with the 3-Me group, and conventional pi-pi stacking with a conserved Trp side chain to selectively bind neutral 3-MeA over the cationic form of the base. Discrimination against binding of the normal base adenine is derived from direct sensing of the 3-methyl group, leading to an induced-fit conformational change that engulfs the base in a box defined by five aromatic side chains. These findings indicate that base specific recognition by TAG does not involve strong pi-cation interactions, and suggest a novel mechanism for alkylated base recognition and removal.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University	Stivers, JT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.			Drohat, Alex/0000-0002-7458-8770	NIGMS NIH HHS [R01 GM056834, GM56834] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056834] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asaeda A, 2000, BIOCHEMISTRY-US, V39, P1959, DOI 10.1021/bi9917075; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; BROWN DJ, 1955, J CHEM SOC, P4035, DOI 10.1039/jr9550004035; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bujnicki JM, 2002, DNA REPAIR, V1, P391, DOI 10.1016/S1568-7864(02)00017-4; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Drohat AC, 2000, BIOCHEMISTRY-US, V39, P11865, DOI 10.1021/bi000922e; Drohat AC, 2000, J AM CHEM SOC, V122, P1840, DOI 10.1021/ja993254x; Drohat AC, 2002, NAT STRUCT BIOL, V9, P659, DOI 10.1038/nsb829; FUJII T, 1989, CHEM PHARM BULL, V37, P1208; FUJII T, 1986, HETEROCYCLES, V24, P2449, DOI 10.3987/R-1986-09-2449; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; Hollis T, 2001, PROG NUCLEIC ACID RE, V68, P305; Hollis T, 2000, MUTAT RES-DNA REPAIR, V460, P201, DOI 10.1016/S0921-8777(00)00027-6; KAY LE, 1993, J AM CHEM SOC, V115, P2055, DOI 10.1021/ja00058a072; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Kuszewski J, 1996, PROTEIN SCI, V5, P1067; Kwon K, 2003, J BIOL CHEM, V278, P19442, DOI 10.1074/jbc.M300934200; LAM FL, 1978, HETEROCYCLES, V9, P287; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Lau AY, 2000, P NATL ACAD SCI USA, V97, P13573, DOI 10.1073/pnas.97.25.13573; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; Mol CD, 1999, ANNU REV BIOPH BIOM, V28, P101, DOI 10.1146/annurev.biophys.28.1.101; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; OGILVIE KK, 1978, TETRAHEDRON LETT, V35, P3203; Parikh SS, 2000, P NATL ACAD SCI USA, V97, P5083, DOI 10.1073/pnas.97.10.5083; SCHWEITZER BA, 1994, J ORG CHEM, V59, P7238, DOI 10.1021/jo00103a013; Shan SO, 1996, P NATL ACAD SCI USA, V93, P14474, DOI 10.1073/pnas.93.25.14474; Stivers JT, 2003, CHEM REV, V103, P2729, DOI 10.1021/cr010219b; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777	33	33	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48012	48020		10.1074/jbc.M307500200	http://dx.doi.org/10.1074/jbc.M307500200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13129925	hybrid			2022-12-25	WOS:000186731400080
J	Hiller, NL; Akompong, T; Morrow, JS; Holder, AA; Haldar, K				Hiller, NL; Akompong, T; Morrow, JS; Holder, AA; Haldar, K			Identification of a stomatin orthologue in vacuoles induced in human erythrocytes by malaria parasites - A role for microbial raft proteins in apicomplexan vacuole biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; RED-CELL INVASION; PLASMODIUM-FALCIPARUM; PARASITOPHOROUS VACUOLE; CAENORHABDITIS-ELEGANS; TOXOPLASMA-GONDII; SURFACE-ANTIGEN; BLOOD-CELLS; C-ELEGANS; IN-VITRO	When the human malaria parasite Plasmodium falciparum infects erythrocytes, proteins associated with host-derived detergent-resistant membrane (DRM) rafts are selectively recruited into the newly formed vacuole, but parasite proteins that contribute to raft-based vacuole development are unknown. In mammalian cells, DRM-associated integral membrane proteins such as caveolin-1 and flotillin-1 that form oligomers have been linked to the formation of DRM-based invaginations called caveolae. Here we show that the P. falciparum genome does not encode caveolins or flotillins but does contain an orthologue of human band 7 stomatin, a protein known to oligomerize, associate with non-caveolar DRMs and is distantly related to flotillins. Stomatins are members of a large protein family conserved in evolution and P. falciparum (Pf) stomatin appears to be a prokaryotic-like molecule. Evidence is presented that it associates with DRMs and may oligomerize, suggesting that these features are conserved in the stomatin family. Further, Pfstomatin is an integral membrane protein concentrated at the apical end of extracellular parasites, where it co-localizes with invasion-associated rhoptry organelles. A resident rhoptry protein, RhopH2 also resides in DRMs. This provides the first evidence that rhoptries of an apicomplexan parasite contain DRM rafts. Further, when the parasite invades erythrocytes, rhoptry Pfstomatin and RhopH2 are inserted into the newly formed vacuole. Thus, like caveolin-1 and flotillin-1, a stomatin may also associate with non-clathrin coated, DRM-enriched vacuoles. We propose a new model of invasion and vacuole formation involving DRM-based interactions of both host and parasite molecules.	Northwestern Univ, Dept Pathol & Microbiol Immunol, Chicago, IL 60611 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Natl Inst Med Res, Div Parasitol, London NW7 1AA, England	Northwestern University; Yale University; MRC National Institute for Medical Research	Haldar, K (corresponding author), Northwestern Univ, Dept Pathol & Microbiol Immunol, Chicago, IL 60611 USA.		Haldar, Kasturi/C-6685-2014; Hiller, N. Luisa/A-3739-2016; Holder, Anthony A/A-7554-2013	Hiller, N. Luisa/0000-0001-6572-1368; Holder, Anthony A/0000-0002-8490-6058	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039071] Funding Source: NIH RePORTER; MRC [MC_U117532067] Funding Source: UKRI; Medical Research Council [MC_U117532067] Funding Source: Medline; NHLBI NIH HHS [HL28560] Funding Source: Medline; NIAID NIH HHS [AI39071] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bahl A, 2002, NUCLEIC ACIDS RES, V30, P87, DOI 10.1093/nar/30.1.87; BANNISTER LH, 1989, J PROTOZOOL, V36, P362, DOI 10.1111/j.1550-7408.1989.tb05527.x; Barnes TM, 1996, J NEUROCHEM, V67, P46; Berzins K, 2002, CHEM IMMUNOL, V80, P125; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Blackman MJ, 2001, MOL BIOCHEM PARASIT, V117, P11, DOI 10.1016/S0166-6851(01)00328-0; BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; Cheresh P, 2002, J BIOL CHEM, V277, P16265, DOI 10.1074/jbc.M109331200; COOPER JA, 1988, MOL BIOCHEM PARASIT, V29, P251, DOI 10.1016/0166-6851(88)90080-1; DeRocher A, 2000, J CELL SCI, V113, P3969; Dluzewski AR, 1995, EUR J CELL BIOL, V68, P446; DLUZEWSKI AR, 1992, J CELL SCI, V102, P527; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; ELMENDORF HG, 1993, EMBO J, V12, P4763, DOI 10.1002/j.1460-2075.1993.tb06165.x; Fernandez I, 2002, P NATL ACAD SCI USA, V99, P11193, DOI 10.1073/pnas.172196599; FOUSSARD F, 1991, PARASITOLOGY, V102, P367, DOI 10.1017/S0031182000064313; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; GALLAGHER PG, 1995, J BIOL CHEM, V270, P26358, DOI 10.1074/jbc.270.44.26358; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; Goodman MB, 2002, NATURE, V415, P1039, DOI 10.1038/4151039a; Hakansson S, 2001, EMBO J, V20, P3132, DOI 10.1093/emboj/20.12.3132; HALDAR K, 1994, METHOD CELL BIOL, V45, P221; HALDAR K, 1985, J BIOL CHEM, V260, P4969; Haldar K, 2002, CELL MICROBIOL, V4, P383, DOI 10.1046/j.1462-5822.2002.00204.x; HALL SJ, 1991, MOL BIOCHEM PARASIT, V45, P317, DOI 10.1016/0166-6851(91)90100-K; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P123, DOI 10.1016/0167-4781(91)90047-P; Hoessli DC, 2003, EUR J BIOCHEM, V270, P366, DOI 10.1046/j.1432-1033.2003.03397.x; HUANG MX, 1995, NATURE, V378, P292, DOI 10.1038/378292a0; Huttner WB, 2001, CURR OPIN CELL BIOL, V13, P478, DOI 10.1016/S0955-0674(00)00239-8; Kadekoppala M, 2000, INFECT IMMUN, V68, P2328, DOI 10.1128/IAI.68.4.2328-2332.2000; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lauer S, 2000, EMBO J, V19, P3556, DOI 10.1093/emboj/19.14.3556; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; Ling IT, 2003, MOL BIOCHEM PARASIT, V127, P47, DOI 10.1016/S0166-6851(02)00302-X; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Nagao E, 2002, EXP PARASITOL, V102, P57, DOI 10.1016/S0014-4894(02)00143-1; Rajaram S, 1999, GENETICS, V153, P1673; Rajaram S, 1998, P NATL ACAD SCI USA, V95, P8761, DOI 10.1073/pnas.95.15.8761; Riese MJ, 2002, J BIOL CHEM, V277, P12082, DOI 10.1074/jbc.M109039200; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Salzer U, 2001, BLOOD, V97, P1141, DOI 10.1182/blood.V97.4.1141; SALZER U, 1993, BIOCHIM BIOPHYS ACTA, V1151, P149, DOI 10.1016/0005-2736(93)90098-K; Samuel BU, 2001, J BIOL CHEM, V276, P29319, DOI 10.1074/jbc.M101268200; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHRIER SL, 1987, METHOD ENZYMOL, V149, P260; Sedensky MM, 2001, AM J PHYSIOL-CELL PH, V280, pC1340, DOI 10.1152/ajpcell.2001.280.5.C1340; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Snyers L, 1998, J BIOL CHEM, V273, P17221, DOI 10.1074/jbc.273.27.17221; Stewart GW, 1997, INT J BIOCHEM CELL B, V29, P271, DOI 10.1016/S1357-2725(96)00072-6; Tavernarakis N, 1999, TRENDS BIOCHEM SCI, V24, P425, DOI 10.1016/S0968-0004(99)01467-X; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wang YJ, 2000, J BIOL CHEM, V275, P8062, DOI 10.1074/jbc.275.11.8062; WARD GE, 1993, J CELL SCI, V106, P237; Zhu YW, 1999, BLOOD, V93, P2404, DOI 10.1182/blood.V93.7.2404.407k13_2404_2410	61	76	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48413	48421		10.1074/jbc.M307266200	http://dx.doi.org/10.1074/jbc.M307266200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12968029	hybrid			2022-12-25	WOS:000186731400127
J	Meinhart, A; Blobel, J; Cramer, P				Meinhart, A; Blobel, J; Cramer, P			An extended winged helix domain in general transcription factor E/IIE alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; CO-CRYSTAL STRUCTURE; STRUCTURAL BASIS; DNA-BINDING; BASAL TRANSCRIPTION; PROTEIN-STRUCTURE; LARGE SUBUNIT; INITIATION; TFIIE	Initiation of eukaryotic mRNA transcription requires melting of promoter DNA with the help of the general transcription factors TFIIE and TFIIH. Here we define a conserved and functionally essential N-terminal domain in TFE, the archaeal homolog of the large TFIIE subunit alpha. X-ray crystallography shows that this TFE domain adopts a winged helix-turn-helix (winged helix) fold, extended by specific alpha-helices at the N and C termini. Although the winged helix fold is often found in DNA-binding proteins, we show that TFE is not a typical DNA-binding winged helix protein, because its putative DNA-binding face shows a negatively charged groove and an unusually long wing, and because the domain lacks DNA-binding activity in vitro. The groove and a conserved hydrophobic surface patch on the additional N-terminal alpha-helix may, however, allow for interactions with other general transcription factors and RNA polymerase. Homology modeling shows that the TFE domain is conserved in TFIIEalpha, including the potential functional surfaces.	Univ Munich, Gene Ctr, Inst Biochem, D-81377 Munich, Germany	University of Munich	Cramer, P (corresponding author), Univ Munich, Gene Ctr, Inst Biochem, Feodor Lynen Str 25, D-81377 Munich, Germany.	cramer@LMB.uni-muenchen.de	Meinhart, Anton/M-9647-2014	Blobel, Jascha/0000-0001-5512-6258				Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bashford D, 1997, LECT NOTES COMPUTER, P233, DOI [10.1007/3-540-63827-X, DOI 10.1007/3-540-63827-X_66]; Bell SD, 2001, BIOCHEM SOC T, V29, P392, DOI 10.1042/BST0290392; Bell SD, 2001, EMBO REP, V2, P133, DOI 10.1093/embo-reports/kve021; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Coin F, 1998, COLD SPRING HARB SYM, V63, P105, DOI 10.1101/sqb.1998.63.105; Conaway RC, 1997, PROG NUCLEIC ACID RE, V56, P327, DOI 10.1016/S0079-6603(08)61009-0; Cramer P, 2001, SCIENCE, V292, P1863, DOI 10.1126/science.1059493; Cramer P, 2002, CURR OPIN STRUC BIOL, V12, P89, DOI 10.1016/S0959-440X(02)00294-4; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gaiser F, 2000, J MOL BIOL, V302, P1119, DOI 10.1006/jmbi.2000.4110; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Groft CM, 1998, P NATL ACAD SCI USA, V95, P9117, DOI 10.1073/pnas.95.16.9117; Hanzelka BL, 2001, J BACTERIOL, V183, P1813, DOI 10.1128/JB.183.5.1813-1818.2001; Heldwein EEZ, 2001, NATURE, V409, P378, DOI 10.1038/35053138; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kamada K, 2003, P NATL ACAD SCI USA, V100, P2296, DOI 10.1073/pnas.262798199; Kamada K, 2001, P NATL ACAD SCI USA, V98, P3115, DOI 10.1073/pnas.051631098; Kenney LJ, 2002, CURR OPIN MICROBIOL, V5, P135, DOI 10.1016/S1369-5274(02)00310-7; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kornberg Roger D., 1999, Trends in Cell Biology, V9, pM46, DOI 10.1016/S0962-8924(99)01679-7; Kosa PF, 1997, P NATL ACAD SCI USA, V94, P6042, DOI 10.1073/pnas.94.12.6042; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuldell NH, 1997, MOL CELL BIOL, V17, P5288, DOI 10.1128/MCB.17.9.5288; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Littlefield O, 1999, P NATL ACAD SCI USA, V96, P13668, DOI 10.1073/pnas.96.24.13668; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MAXON ME, 1994, P NATL ACAD SCI USA, V91, P9529, DOI 10.1073/pnas.91.20.9529; Meinhart A, 2003, J BIOL CHEM, V278, P15917, DOI 10.1074/jbc.M301643200; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Nguyen BD, 2003, P NATL ACAD SCI USA, V100, P5688, DOI 10.1073/pnas.1031524100; Nguyen BD, 2003, BIOCHEMISTRY-US, V42, P1460, DOI 10.1021/bi0265473; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; OHKUMA Y, 1995, MOL CELL BIOL, V15, P4856; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; Ohkuma Y, 1997, J BIOCHEM-TOKYO, V122, P481; Okuda M, 2000, EMBO J, V19, P1346, DOI 10.1093/emboj/19.6.1346; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Reeve JN, 1997, CELL, V89, P999, DOI 10.1016/S0092-8674(00)80286-X; Robert F, 1996, J BIOL CHEM, V271, P8517, DOI 10.1074/jbc.271.15.8517; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; Wilson KS, 1999, J MOL BIOL, V289, P1179, DOI 10.1006/jmbi.1999.2814; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	75	73	74	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48267	48274		10.1074/jbc.M307874200	http://dx.doi.org/10.1074/jbc.M307874200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13679366	hybrid, Green Published			2022-12-25	WOS:000186731400111
J	Shea, ME; Hiasa, H				Shea, ME; Hiasa, H			The RuvAB branch migration complex can displace topoisomerase IV center dot quinolone center dot DNA ternary complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FORK ARREST; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; HELICASE ACTIVITY; STRAND CLEAVAGE; NALIDIXIC-ACID; CELL-DEATH; IN-VITRO; GYRASE; PURIFICATION	Quinolone antimicrobial drugs target both DNA gyrase and topoisomerase IV (Topo IV) and convert these essential enzymes into cellular poisons. Topoisomerase poisoning results in the inhibition of DNA replication and the generation of double-strand breaks. Double-strand breaks are repaired by homologous recombination. Here, we have investigated the interaction between the RuvAB branch migration complex and the Topo IV . quinolone . DNA ternary complex. A strand-displacement assay is employed to assess the helicase activity of the RuvAB complex in vitro. RuvAB-catalyzed strand displacement requires both RuvA and RuvB proteins, and it is stimulated by a 3'-non-hybridized tail. Interestingly, Topo IV . quinolone . DNA ternary complexes do not inhibit the translocation of the RuvAB complex. In fact, Topo IV . quinolone . DNA ternary complexes are reversed and displaced from the DNA upon their collisions with the RuvAB complex. These results suggest that the RuvAB branch migration complex can actively remove quinolone-induced covalent topoisomerase . DNA complexes from DNA and complete the homologous recombination process in vivo.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Hiasa, H (corresponding author), 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059465] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59465] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; Clark AJ, 1996, BIOESSAYS, V18, P767, DOI 10.1002/bies.950180912; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; Eggleston AK, 1996, TRENDS GENET, V12, P20, DOI 10.1016/0168-9525(96)81384-9; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Hiasa H, 2000, J BIOL CHEM, V275, P34780, DOI 10.1074/jbc.M001608200; Hiasa H, 2003, J BIOL CHEM, V278, P8861, DOI 10.1074/jbc.M209207200; Hiasa H, 1996, J BIOL CHEM, V271, P26424, DOI 10.1074/jbc.271.42.26424; Hong G, 2000, MOL CELL BIOL, V20, P594, DOI 10.1128/MCB.20.2.594-603.2000; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; Jones JM, 2000, MOL MICROBIOL, V36, P519, DOI 10.1046/j.1365-2958.2000.01888.x; KATO J, 1992, J BIOL CHEM, V267, P25676; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; Khodursky AB, 1998, J BIOL CHEM, V273, P27668, DOI 10.1074/jbc.273.42.27668; Kogoma T, 1996, CELL, V85, P625, DOI 10.1016/S0092-8674(00)81229-5; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Lloyd RG, 1992, CURR OPIN GENET DEV, V2, P683, DOI 10.1016/S0959-437X(05)80127-3; Marians KJ, 1997, J BIOL CHEM, V272, P9401; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; PENG H, 1993, J BIOL CHEM, V268, P24481; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; Rothstein R, 2000, GENE DEV, V14, P1; Shea ME, 2000, J BIOL CHEM, V275, P14649, DOI 10.1074/jbc.275.19.14649; Shea ME, 1999, J BIOL CHEM, V274, P22747, DOI 10.1074/jbc.274.32.22747; Smith GR, 2001, ANNU REV GENET, V35, P243, DOI 10.1146/annurev.genet.35.102401.090509; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1994, J BIOL CHEM, V269, P26552; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; TSAO YP, 1993, CANCER RES, V53, P5908; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wentzell LM, 2000, J MOL BIOL, V304, P779, DOI 10.1006/jmbi.2000.4266; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213	44	12	13	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48485	48490		10.1074/jbc.M304217200	http://dx.doi.org/10.1074/jbc.M304217200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13679378	hybrid			2022-12-25	WOS:000186731400134
J	Allouch, J; Jam, M; Helbert, W; Barbeyron, T; Kloareg, B; Henrissat, B; Czjzek, M				Allouch, J; Jam, M; Helbert, W; Barbeyron, T; Kloareg, B; Henrissat, B; Czjzek, M			The three-dimensional structures of two beta-agarases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LICHENIFORMIS 1,3-1,4-BETA-D-GLUCAN 4-GLUCANOHYDROLASE; SEQUENCE-BASED CLASSIFICATION; ACTIVE-SITE; PSEUDOMONAS-ATLANTICA; KAPPA-CARRAGEENASE; CRYSTAL-STRUCTURE; GLYCOSYL; MECHANISMS; EVOLUTION	Agars are important gelifying agents for biochemical use and the food industry. To cleave the beta- 1,4- linkages between beta- D- galactose and alpha- L- 3,6- anhydro- galactose residues in the red algal galactans known as agars, marine bacteria produce polysaccharide hydrolases called beta- agarases. beta- Agarases A and B from Zobellia galactanivorans Dsij have recently been biochemically characterized. Here we report the first crystal structure of these two beta- agarases. The two proteins were overproduced in Escherichia coli and crystallized, and the crystal structures were determined at 1.48 and 2.3 Angstrom for beta- agarases A and B, respectively. The structure of beta- agarase A was solved by the multiple anomalous diffraction method, whereas beta- agarase B was solved with molecular replacement using beta- agarase A as model. Their structures adopt a jelly roll fold with a deep active site channel harboring the catalytic machinery, namely the nucleophilic residues Glu- 147 and Glu- 184 and the acid/ base residues Glu- 152 and Glu- 189 for beta- agarases A and B, respectively. The structures of the agarases were compared with those of two lichenases and of a kappa- carrageenase, which all belong to family 16 of the glycoside hydrolases in order to pinpoint the residues responsible for their widely differing substrate specificity. The relationship between structure and enzymatic activity of the two beta- agarases from Z. galactanivorans Dsij was studied by analysis of the degradation products starting with different oligosaccharides. The combination of the structural and biochemical results allowed the determination of the number of subsites present in the catalytic cleft of the beta- agarases.	CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; CNRS, UMR 1931, F-29682 Roscoff, France; CNRS, Biol Stn, Labs Goemar, F-29682 Roscoff, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Czjzek, M (corresponding author), CNRS, UMR 6098, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	czjzek@afmb.cnrs-mrs.fr	Henrissat, Bernard/J-2475-2012	Henrissat, Bernard/0000-0002-3434-8588				ARNOTT S, 1974, J MOL BIOL, V90, P269, DOI 10.1016/0022-2836(74)90372-6; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barbeyron T, 1998, MOL BIOL EVOL, V15, P528, DOI 10.1093/oxfordjournals.molbev.a025952; BELAS R, 1989, J BACTERIOL, V171, P602, DOI 10.1128/jb.171.1.602-605.1989; BUTTNER MJ, 1987, MOL GEN GENET, V209, P101, DOI 10.1007/BF00329843; Czjzek M, 2000, P NATL ACAD SCI USA, V97, P13555, DOI 10.1073/pnas.97.25.13555; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; De Ruiter GA, 1997, TRENDS FOOD SCI TECH, V8, P389, DOI 10.1016/S0924-2244(97)01091-1; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; GEBLER J, 1992, J BIOL CHEM, V267, P12559; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HAHN M, 1995, J BIOL CHEM, V270, P3081, DOI 10.1074/jbc.270.7.3081; HAHN M, 1995, FEBS LETT, V374, P221, DOI 10.1016/0014-5793(95)01111-Q; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Johansson P, 2003, ACTA CRYSTALLOGR D, V59, P535, DOI 10.1107/S090744490202348X; JUNCOSA M, 1994, J BIOL CHEM, V269, P14530; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; KLOAREG B, 1988, OCEANOGR MAR BIOL, V26, P259; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LICHU T, 2003, J MOL BIOL, V330, P607; MALET C, 1993, BIOCHEM J, V296, P753, DOI 10.1042/bj2960753; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; Michel G, 2001, STRUCTURE, V9, P513, DOI 10.1016/S0969-2126(01)00612-8; MORRICE LM, 1983, EUR J BIOCHEM, V137, P149, DOI 10.1111/j.1432-1033.1983.tb07808.x; MORRICE LM, 1983, EUR J BIOCHEM, V135, P553, DOI 10.1111/j.1432-1033.1983.tb07688.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; ROCHAS C, 1986, CARBOHYD RES, V148, P199, DOI 10.1016/S0008-6215(00)90388-4; ROUSSEL A, 1991, SILICON GRAPHICS GEO; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SUGANO Y, 1993, APPL ENVIRON MICROB, V59, P1549; SUGANO Y, 1994, BBA-GENE STRUCT EXPR, V1218, P105, DOI 10.1016/0167-4781(94)90109-0; Sulzenbacher G, 1996, BIOCHEMISTRY-US, V35, P15280, DOI 10.1021/bi961946h; Terwilliger TC, 1997, ACTA CRYSTALLOGR D, V53, P571, DOI 10.1107/S0907444997005398; Weinberger F, 2001, J PHYCOL, V37, P418, DOI 10.1046/j.1529-8817.2001.037003418.x	46	106	117	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47171	47180		10.1074/jbc.M308313200	http://dx.doi.org/10.1074/jbc.M308313200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12970344	hybrid			2022-12-25	WOS:000186569400116
J	Bard, F; Mazelin, L; Pechoux-Longin, C; Malhotra, V; Jurdic, P				Bard, F; Mazelin, L; Pechoux-Longin, C; Malhotra, V; Jurdic, P			Src regulates Golgi structure and KDEL receptor-dependent retrograde transport to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC; FAMILY KINASES; SYNAPSIN I; PROTEIN; FRAGMENTATION; MITOSIS; COMPLEX; ACTIVATION; INTERACTS; MEMBRANE	The tyrosine kinase Src is present on the Golgi membranes. Its role, however, in the overall function and organization of the Golgi apparatus is unclear. We have found that in a cell line called SYF, which lacks the three ubiquitous Src- like kinases ( Src, Yes, and Fyn), the organization of the Golgi apparatus is perturbed. The Golgi apparatus is composed of collapsed stacks and bloated cisternae in these cells. Expression of an activated form of Src relocated the KDEL receptor ( KDEL- R) from the Golgi apparatus to the endoplasmic reticulum. Other Golgi- specific marker proteins were not affected under these conditions. Because of the specific effect of Src on the location of KDEL- R, we tested whether protein transport between ER and the Golgi apparatus involves Src. Transport of Pseudomonas exotoxin, which is transported to the ER by binding to the KDEL- R is accelerated by inhibition or genetic ablation of Src. Protein transport from ER to the Golgi apparatus however, is unaffected by Src deletion or inhibition. We propose that Src has an appreciable role in the organization of the Golgi apparatus, which may be linked to its involvement in protein transport from the Golgi apparatus to the endoplasmic reticulum.	Univ Calif San Diego, Dept Cell & Dev Biol, Div Biol Sci, La Jolla, CA 92093 USA; Univ Lyon 1, CNRS, Unite Mixte Rech 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France; INRA, Lab Genome & Physiol Lactat, F-78352 Jouy En Josas, France; Ecole Normale Super Lyon, INRA, ENS, CNRS,Unite Mixte Rech 5665,Lab Biol Mol Cellulair, F-69007 Lyon, France	University of California System; University of California San Diego; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE	Bard, F (corresponding author), Univ Calif San Diego, Dept Cell & Dev Biol, Div Biol Sci, La Jolla, CA 92093 USA.		Mazelin, Laetitia/AAD-9319-2020; BARD, Frederic/G-9914-2011; Malhotra, Vivek/O-9811-2014	Mazelin, Laetitia/0000-0002-4001-2132; BARD, Frederic/0000-0002-3783-4805; Malhotra, Vivek/0000-0001-6198-7943				Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; Bard F, 2002, EUR J CELL BIOL, V81, P26, DOI 10.1078/0171-9335-00217; BARNEKOW A, 1990, ONCOGENE, V5, P1019; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Colanzi A, 2000, J CELL BIOL, V149, P331, DOI 10.1083/jcb.149.2.331; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; Jackson ME, 1999, J CELL SCI, V112, P467; Jakymiw A, 2000, J BIOL CHEM, V275, P4137, DOI 10.1074/jbc.275.6.4137; Jamora C, 1997, CELL, V91, P617, DOI 10.1016/S0092-8674(00)80449-3; Janz R, 1998, J BIOL CHEM, V273, P2851, DOI 10.1074/jbc.273.5.2851; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Onofri F, 2000, J BIOL CHEM, V275, P29857, DOI 10.1074/jbc.M006018200; Onofri F, 1997, P NATL ACAD SCI USA, V94, P12168, DOI 10.1073/pnas.94.22.12168; Sandvig K, 2002, ANNU REV CELL DEV BI, V18, P1, DOI 10.1146/annurev.cellbio.18.011502.142107; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513	24	83	85	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46601	46606		10.1074/jbc.M302221200	http://dx.doi.org/10.1074/jbc.M302221200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12975382	hybrid, Green Published			2022-12-25	WOS:000186569400047
J	Fukusumi, S; Yoshida, H; Fujii, R; Maruyama, M; Komatsu, H; Habata, Y; Shintani, Y; Hinuma, S; Fujino, M				Fukusumi, S; Yoshida, H; Fujii, R; Maruyama, M; Komatsu, H; Habata, Y; Shintani, Y; Hinuma, S; Fujino, M			A new peptidic ligand and its receptor regulating adrenal function in rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; PROLACTIN-RELEASING PEPTIDE; NEUROMEDIN U; IDENTIFICATION; NEUROPEPTIDE; RFAMIDE; GENE; ASSAY; BRAIN; FF	We searched for peptidic ligands for orphan G protein-coupled receptors utilizing a human genome data base and identified a new gene encoding a preproprotein that could generate a peptide. This peptide consisted of 43 amino acid residues starting from N-terminal pyroglutamic acid and ending at C-terminal arginine-phenylalanine-amide. We therefore named it QRFP after pyroglutamylated arginine-phenylalanineamide peptide. We subsequently searched for its receptor and found that Chinese hamster ovary cells expressing an orphan G protein-coupled receptor, AQ27, specifically responded to QRFP. We analyzed tissue distributions of QRFP and its receptor mRNAs in rats utilizing quantitative reverse transcription-polymerase chain reaction and in situ hybridization. QRFP mRNA was highly expressed in the hypothalamus, whereas its receptor mRNA was highly expressed in the adrenal gland. The intravenous administration of QRFP caused the release of aldosterone, suggesting that QRFP and its receptor have a regulatory function in the rat adrenal gland.	Takeda Chem Ind Ltd, Div Pharmaceut Res, Discovery Res Labs, Tsukuba, Ibaraki 3004293, Japan	Takeda Chemical Industries	Hinuma, S (corresponding author), Takeda Chem Ind Ltd, Div Pharmaceut Res, Discovery Res Labs, Wadai 10, Tsukuba, Ibaraki 3004293, Japan.			Komatsu, Hidetoshi/0000-0003-1630-0537; Maruyama, Minoru/0000-0002-1478-9415				BUSBY WH, 1987, J BIOL CHEM, V262, P8532; CAMPBELL WB, 1974, SCIENCE, V184, P994, DOI 10.1126/science.184.4140.994; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; Durocher Y, 2000, ANAL BIOCHEM, V284, P316, DOI 10.1006/abio.2000.4698; Elshourbagy NA, 2000, J BIOL CHEM, V275, P25965, DOI 10.1074/jbc.M004515200; Fujii R, 2000, J BIOL CHEM, V275, P21068, DOI 10.1074/jbc.M001546200; Fujiwara K, 2003, NEUROSCI LETT, V338, P127, DOI 10.1016/S0304-3940(02)01395-2; Fukusumi S, 2001, BBA-MOL CELL RES, V1540, P221, DOI 10.1016/S0167-4889(01)00135-5; Fukusumi S, 1997, BIOCHEM BIOPH RES CO, V232, P157, DOI 10.1006/bbrc.1997.6252; Hinuma S, 1999, J MOL MED, V77, P495, DOI 10.1007/s001090050403; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; Hinuma S, 2000, NAT CELL BIOL, V2, P703, DOI 10.1038/35036326; HINUMA S, 1994, BBA-GENE STRUCT EXPR, V1219, P251, DOI 10.1016/0167-4781(94)90046-9; Hosoya M, 2000, J BIOL CHEM, V275, P29528, DOI 10.1074/jbc.M004261200; Jiang Y, 2003, J BIOL CHEM, V278, P27652, DOI 10.1074/jbc.M302945200; JOOST P, 2002, GENOME BIOL; JOPEZGIMENEZ JF, 2001, MOL PHARMACOL, V60, P690; Labrouche S, 1998, J NEUROENDOCRINOL, V10, P559, DOI 10.1046/j.1365-2826.1998.00241.x; Lee DK, 2001, GENE, V275, P83, DOI 10.1016/S0378-1119(01)00651-5; Li C, 1999, BRAIN RES, V848, P26, DOI 10.1016/S0006-8993(99)01972-1; MEKLER DJ, 1994, ENZYME MICROB TECHNO, V16, P450; Monti JM, 2000, LIFE SCI, V66, P1999, DOI 10.1016/S0024-3205(99)00649-9; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; PERRY SJ, 1997, FEBS LETT, V409, P420; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Yoshida H, 2003, BBA-MOL CELL RES, V1593, P151, DOI 10.1016/S0167-4889(02)00389-0	29	145	162	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46387	46395		10.1074/jbc.M305270200	http://dx.doi.org/10.1074/jbc.M305270200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12960173	hybrid			2022-12-25	WOS:000186569400022
J	Kim, E; Xie, SZ; Yeh, SD; Lee, YF; Collins, LL; Hu, YC; Shyr, CR; Mu, XM; Liu, NC; Chen, YT; Wang, PH; Chang, CS				Kim, E; Xie, SZ; Yeh, SD; Lee, YF; Collins, LL; Hu, YC; Shyr, CR; Mu, XM; Liu, NC; Chen, YT; Wang, PH; Chang, CS			Disruption of TR4 orphan nuclear receptor reduces the expression of liver apolipoprotein E/C-I/C-II gene cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC CONTROL REGION; RESPONSE ELEMENT; TRANSGENIC MICE; RXR HETERODIMERS; TRANSCRIPTION; SUPERFAMILY; TRANSACTIVATION; PROMOTER; MEMBER; HNF-4	Apolipoprotein E (apoE) is synthesized in many tissues, and the liver is the primary site from which apoE redistributes cholesterol and other lipids to peripheral tissues. Here we demonstrate that the TR4 orphan nuclear receptor (TR4) can induce apoE expression in HepG2 cells. This TR4-mediated regulation of apoE gene expression was further confirmed in vivo using TR4 knockout mice. Both serum apoE protein and liver apoE mRNA levels were significantly reduced in TR4 knockout mice. Gel shift and luciferase reporter gene assays further demonstrated that TR4 can induce apoE gene expression via a TR4 response element located in the hepatic control region that is 15 kb downstream of the apoE gene. Furthermore our in vivo data from TR4 knockout mice prove that TR4 can also regulate apolipoprotein C-I and C-II gene expression via the TR4 response element within the hepatic control region. Together our data show that loss of TR4 down-regulates expression of the apoE/C-I/C-II gene cluster in liver cells, demonstrating important roles of TR4 in the modulation of lipoprotein metabolism.	Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.		Hu, Yueh-Chiang/AAX-2370-2020	Chang, Chawnshang/0000-0001-8510-3516; Hu, Yueh-Chiang/0000-0002-7992-0525	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258, R01DK056984] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47258, DK 56984] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN CM, 1995, J BIOL CHEM, V270, P26278, DOI 10.1074/jbc.270.44.26278; Allan CM, 1997, J BIOL CHEM, V272, P29113, DOI 10.1074/jbc.272.46.29113; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; DANG Q, 1995, J BIOL CHEM, V270, P22577, DOI 10.1074/jbc.270.38.22577; DRISCOLL DM, 1984, J LIPID RES, V25, P1368; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Fraser JD, 1998, NUCLEIC ACIDS RES, V26, P2702, DOI 10.1093/nar/26.11.2702; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Kardassis D, 1998, J BIOL CHEM, V273, P17810, DOI 10.1074/jbc.273.28.17810; Kassam A, 2000, J BIOL CHEM, V275, P4345, DOI 10.1074/jbc.275.6.4345; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lee HJ, 2001, BIOCHEM BIOPH RES CO, V285, P1361, DOI 10.1006/bbrc.2001.5342; LEE HJ, 1995, J BIOL CHEM, V270, P30129; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Lee YF, 1998, J BIOL CHEM, V273, P13437, DOI 10.1074/jbc.273.22.13437; Lee YF, 1999, J BIOL CHEM, V274, P16198, DOI 10.1074/jbc.274.23.16198; Lee YF, 1997, J BIOL CHEM, V272, P12215, DOI 10.1074/jbc.272.18.12215; Lee YF, 1999, P NATL ACAD SCI USA, V96, P14724, DOI 10.1073/pnas.96.26.14724; LIN TM, 1995, J BIOL CHEM, V270, P30121; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mak PA, 2002, J BIOL CHEM, V277, P31900, DOI 10.1074/jbc.M202993200; Makita T, 2001, GENE DEV, V15, P889, DOI 10.1101/gad.871601; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mazzone T, 1996, CURR OPIN LIPIDOL, V7, P303, DOI 10.1097/00041433-199610000-00008; METZGER S, 1993, J BIOL CHEM, V268, P16831; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; Nakshatri H, 1998, NUCLEIC ACIDS RES, V26, P2491, DOI 10.1093/nar/26.10.2491; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Ribeiro A, 1999, J BIOL CHEM, V274, P1216, DOI 10.1074/jbc.274.3.1216; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Smirlis D, 2001, J BIOL CHEM, V276, P12822, DOI 10.1074/jbc.M005930200; SMITH JD, 1990, J BIOL CHEM, V265, P14709; Tsukamoto K, 1999, ARTERIOSCL THROM VAS, V19, P2162, DOI 10.1161/01.ATV.19.9.2162; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Yan ZH, 1998, J BIOL CHEM, V273, P10948, DOI 10.1074/jbc.273.18.10948; Young WJ, 1997, J BIOL CHEM, V272, P3109, DOI 10.1074/jbc.272.5.3109	46	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46919	46926		10.1074/jbc.M304088200	http://dx.doi.org/10.1074/jbc.M304088200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12954636	hybrid			2022-12-25	WOS:000186569400086
J	Suzuki, N; Khoo, KH; Chen, CM; Chen, HC; Lee, YC				Suzuki, N; Khoo, KH; Chen, CM; Chen, HC; Lee, YC			N-glycan structures of pigeon IgG - A major serum glycoprotein containing Gal alpha 1-4Gal termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED SUGAR CHAINS; IMMUNOGLOBULIN-G; FERTILIZED-EGGS; JAPANESE-QUAIL; BIOSYNTHETIC-PATHWAY; MAPPING TECHNIQUE; ESCHERICHIA-COLI; FANCIERS LUNG; CYST MEMBRANE; VH-GENE	We had shown previously that all major glycoproteins of pigeon egg white contain Galalpha1-4Gal epitopes (Suzuki, N., Khoo, K.H., Chen, H.C., Johnson, J.R., and Lee, Y.C. (2001) J. Biol. Chem. 276, 23221-23229). We now report that Galalpha1-4Gal-bearing glycoproteins are also present in pigeon serum, lymphocytes, and liver, as probed by Western blot with Griffonia simplicifolia-I lectin (specific for terminal alpha-Gal) and anti-P-1 (specific for Galalpha1-4Galbeta1-4GlcNAcbeta1-) monoclonal antibody. One of the major glycoproteins from pigeon plasma was identified as IgG (also known as IgY), which has Galalpha1-4Gal in its heavy chains. High pressure liquid chromatography, mass spectrometric (MS), and MS/MS analyses revealed that N-glycans of pigeon serum IgG included (i) high mannose-type (33.3%), (ii) disialylated biantennary complex-type (19.2%), and (iii) alpha-galactosylated complex-type N-glycans (47.5%). Bi- and tri-antennary oligosaccharides with bisecting GlcNAc and alpha1-6 Fuc on the Asn-linked GlcNAc were abundant among N-glycans possessing terminal Galalpha1-4Gal sequences. Moreover, MS/MS analysis identified Galalpha1-4Galbeta1-4Galbeta1-4GlcNAc branch terminals, which are not found in pigeon egg white glycoproteins. An additional interesting aspect is that about two-thirds of high mannose-type N-glycans from pigeon IgG were monoglucosylated. Comparison of the N-glycan structures with chicken and quail IgG indicated that the presence of high mannose-type oligosaccharides may be a characteristic of these avian IgG.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Academia Sinica - Taiwan; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Lee, YC (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.		Khoo, Kay-Hooi/E-1989-2019	Khoo, Kay-Hooi/0000-0003-2906-406X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009970, R37DK009970] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 09970] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baldwin CI, 1999, CLIN EXP IMMUNOL, V117, P230; Bengten E, 2000, CURR TOP MICROBIOL, V248, P189; Bouhours D, 2000, GLYCOBIOLOGY, V10, P857, DOI 10.1093/glycob/10.9.857; BROCTEUR J, 1975, Haematologia, V9, P43; BURLEY RW, 1989, AVIAN EGG CHEM BIOL, P129; Burton D. R, 1987, MOL GENETICS IMMUNOG, V17, P1; Calvert JE, 1999, CLIN EXP ALLERGY, V29, P166; COSSEY A, 1979, EUR J BIOCHEM, V98, P53, DOI 10.1111/j.1432-1033.1979.tb13159.x; DAHAN A, 1983, NUCLEIC ACIDS RES, V11, P5381, DOI 10.1093/nar/11.16.5381; DELL A, 1994, METHOD ENZYMOL, V230, P108; Delplace F, 2002, BIOCHEM J, V363, P457, DOI 10.1042/0264-6021:3630457; DORLAND L, 1984, BIOCHEM BIOPH RES CO, V122, P859, DOI 10.1016/S0006-291X(84)80113-8; ENDO T, 1995, MOL IMMUNOL, V32, P931, DOI 10.1016/0161-5890(95)00078-S; ENGBERG RM, 1992, AVIAN PATHOL, V21, P409, DOI 10.1080/03079459208418859; FRANCOISGERARD C, 1980, REV FR TRANSFUS IMMU, V23, P95, DOI 10.1016/S0338-4535(80)80050-X; FRANCOISGERARD C, 1980, VOX SANG, V39, P141, DOI 10.1111/j.1423-0410.1980.tb01849.x; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; GAHMBERG CG, 1975, J BIOL CHEM, V250, P2438; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1987, P NATL ACAD SCI USA, V84, P1369, DOI 10.1073/pnas.84.5.1369; Guerardel Y, 2000, BIOCHEM J, V352, P449, DOI 10.1042/0264-6021:3520449; HAMAKO J, 1993, COMP BIOCHEM PHYS B, V106, P949, DOI 10.1016/0305-0491(93)90056-B; Harris LJ, 1997, BIOCHEMISTRY-US, V36, P1581, DOI 10.1021/bi962514+; HASE S, 1986, J BIOCHEM-TOKYO, V99, P1725, DOI 10.1093/oxfordjournals.jbchem.a135649; HASE S, 1982, J BIOCHEM-TOKYO, V91, P735, DOI 10.1093/oxfordjournals.jbchem.a133748; Hooper LV, 2001, GLYCOBIOLOGY, V11, p1R, DOI 10.1093/glycob/11.2.1R; IWASAKI M, 1992, J BIOL CHEM, V267, P24287; JOHNSON JR, 1992, INFECT IMMUN, V60, P578, DOI 10.1128/IAI.60.2.578-583.1992; Khoo KH, 1997, MOL BIOCHEM PARASIT, V86, P237, DOI 10.1016/S0166-6851(97)00036-4; KOBATA A, 1990, Glycobiology, V1, P5, DOI 10.1093/glycob/1.1.5; KOTANI M, 1994, ARCH BIOCHEM BIOPHYS, V310, P89, DOI 10.1006/abbi.1994.1144; LESLIE GA, 1969, J EXP MED, V130, P1337, DOI 10.1084/jem.130.6.1337; Lopez M, 1998, J BIOL CHEM, V273, P33644, DOI 10.1074/jbc.273.50.33644; LYERLA T, 1986, J CELL PHYSIOL, V129, P390, DOI 10.1002/jcp.1041290318; MAGOR KE, 1992, J IMMUNOL, V149, P2627; MANSIKKA A, 1992, J IMMUNOL, V149, P855; MATSUURA F, 1993, GLYCOCONJUGATE J, V10, P202, DOI 10.1007/BF00702201; Mimura Y, 2000, MOL IMMUNOL, V37, P697, DOI 10.1016/S0161-5890(00)00105-X; NAKAGAWA H, 1995, ANAL BIOCHEM, V226, P130, DOI 10.1006/abio.1995.1200; NAKAMURA K, 1984, J BIOCHEM-TOKYO, V95, P1137, DOI 10.1093/oxfordjournals.jbchem.a134702; OHTA M, 1991, GLYCOCONJUGATE J, V8, P400, DOI 10.1007/BF00731292; PARVARI R, 1988, EMBO J, V7, P739, DOI 10.1002/j.1460-2075.1988.tb02870.x; Radaev S, 2001, J BIOL CHEM, V276, P16478, DOI 10.1074/jbc.M100351200; Raju TS, 2000, GLYCOBIOLOGY, V10, P477, DOI 10.1093/glycob/10.5.477; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; Rother RP, 1996, CELL, V86, P185, DOI 10.1016/S0092-8674(00)80090-2; RUSSI S, 1974, J IMMUNOL, V112, P1061; Schmidt H, 2000, APPL ENVIRON MICROB, V66, P1205, DOI 10.1128/AEM.66.3.1205-1208.2000; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRECKER G, 1992, EUR J BIOCHEM, V207, P995, DOI 10.1111/j.1432-1033.1992.tb17135.x; Suzuki N, 2001, J BIOL CHEM, V276, P23221, DOI 10.1074/jbc.M101379200; TAGUCHI T, 1995, GLYCOBIOLOGY, V5, P611, DOI 10.1093/glycob/5.6.611; TAGUCHI T, 1993, J BIOL CHEM, V268, P2353; TAGUCHI T, 1994, J BIOL CHEM, V269, P8762; TAKAHASHI N, 1993, GLYCOCONJUGATE J, V10, P425, DOI 10.1007/BF00737962; TAKAHASHI N, 1995, ANAL BIOCHEM, V226, P139, DOI 10.1006/abio.1995.1201; Takahashi N, 2001, J BIOL CHEM, V276, P23230, DOI 10.1074/jbc.M101380200; TAKAHASHI N, 1995, ANAL BIOCHEM, V230, P333, DOI 10.1006/abio.1995.1483; THALL A, 1990, BIOCHEMISTRY-US, V29, P3959, DOI 10.1021/bi00468a024; Tomiya N, 1998, ANAL BIOCHEM, V264, P204, DOI 10.1006/abio.1998.2849; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; Wan T, 2002, NAT IMMUNOL, V3, P681, DOI 10.1038/ni811; WARR GW, 1995, IMMUNOL TODAY, V16, P392, DOI 10.1016/0167-5699(95)80008-5; Welsh RM, 1998, J VIROL, V72, P4650, DOI 10.1128/JVI.72.6.4650-4656.1998; WIERUSZESKI JM, 1987, J BIOL CHEM, V262, P6650; YAMASHITA K, 1983, J BIOL CHEM, V258, P3099; YAMASHITA K, 1982, J BIOL CHEM, V257, P2809; YANG ZT, 1994, J BIOL CHEM, V269, P14620	68	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46293	46306		10.1074/jbc.M307132200	http://dx.doi.org/10.1074/jbc.M307132200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12966096	hybrid			2022-12-25	WOS:000186569400013
J	Winklhofer, KF; Henn, IH; Kay-Jackson, PC; Heller, U; Tatzelt, J				Winklhofer, KF; Henn, IH; Kay-Jackson, PC; Heller, U; Tatzelt, J			Inactivation of parkin by oxidative stress and C-terminal truncations - A protective role of molecular chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; HEAT-SHOCK PROTEINS; ALPHA-SYNUCLEIN; PRION PROTEIN; CELLULAR TOXICITY; IN-VIVO; DISEASE; GENE; HSP70; MUTATIONS	Loss of parkin function is linked to autosomal recessive juvenile parkinsonism. Here we show that proteotoxic stress and short C- terminal truncations induce misfolding of parkin. As a consequence, wild- type parkin was depleted from a high molecular weight complex and inactivated by aggregation. Similarly, the pathogenic parkin mutant W453Stop, characterized by a C-terminal deletion of 13 amino acids, spontaneously adopted a misfolded conformation. Mutational analysis indicated that C- terminal truncations exceeding 3 amino acids abolished formation of detergent- soluble parkin. In the cytosol scattered aggregates of misfolded parkin contained the molecular chaperone Hsp70. Moreover, increased expression of chaperones prevented aggregation of wild- type parkin and promoted folding of the W453Stop mutant. Analyzing parkin folding in vitro indicated that parkin is aggregation- prone and that its folding is dependent on chaperones. Our study demonstrates that C- terminal truncations impede parkin folding and reveal a new mechanism for inactivation of parkin.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany	Max Planck Society	Winklhofer, KF (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany.	winklhof@biochem.mpg.de; tatzelt@biochem.mpg.de		Tatzelt, Jorg/0000-0001-5017-5528; Winklhofer, Konstanze/0000-0002-7256-8231				Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; Bonini NM, 2002, P NATL ACAD SCI USA, V99, P16407, DOI 10.1073/pnas.152330499; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chai YH, 1999, J NEUROSCI, V19, P10338; Chan HYE, 2000, HUM MOL GENET, V9, P2811, DOI 10.1093/hmg/9.19.2811; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; Fallon L, 2002, J BIOL CHEM, V277, P486, DOI 10.1074/jbc.M109806200; FARGNOLI J, 1990, P NATL ACAD SCI USA, V87, P846, DOI 10.1073/pnas.87.2.846; Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hedrich K, 2001, HUM MOL GENET, V10, P1649, DOI 10.1093/hmg/10.16.1649; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIU AYC, 1989, J BIOL CHEM, V264, P12037; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Mattson MP, 1999, ANN NY ACAD SCI, V893, P154, DOI 10.1111/j.1749-6632.1999.tb07824.x; Mengesdorf T, 2002, P NATL ACAD SCI USA, V99, P15042, DOI 10.1073/pnas.232588799; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Periquet M, 2001, AM J HUM GENET, V68, P617, DOI 10.1086/318791; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; Schultz C, 2001, NEUROBIOL AGING, V22, P677, DOI 10.1016/S0197-4580(01)00229-9; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307; Soti C, 2000, BIOGERONTOLOGY, V1, P225, DOI 10.1023/A:1010082129022; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Stockel J, 2001, J MOL BIOL, V313, P861, DOI 10.1006/jmbi.2001.5085; TATZELT J, 1995, P NATL ACAD SCI USA, V92, P2944, DOI 10.1073/pnas.92.7.2944; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; Unno K, 2000, J GERONTOL A-BIOL, V55, pB329, DOI 10.1093/gerona/55.7.B329; Walters TJ, 2001, BRAIN RES BULL, V55, P367, DOI 10.1016/S0361-9230(01)00502-0; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; Welch WJ, 1998, NATURE, V392, P23, DOI 10.1038/32049; West A, 2002, AM J MED GENET, V114, P584, DOI 10.1002/ajmg.10525; Winklhofer KF, 2003, J BIOL CHEM, V278, P14961, DOI 10.1074/jbc.M209942200; Winklhofer KF, 2001, J BIOL CHEM, V276, P45160, DOI 10.1074/jbc.M104873200; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhou H, 2001, J BIOL CHEM, V276, P48417, DOI 10.1074/jbc.M104140200	59	113	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47199	47208		10.1074/jbc.M306769200	http://dx.doi.org/10.1074/jbc.M306769200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12972428	hybrid			2022-12-25	WOS:000186569400119
J	Illario, M; Cavallo, AL; Bayer, KU; Di Matola, T; Fenzi, G; Rossi, G; Vitale, M				Illario, M; Cavallo, AL; Bayer, KU; Di Matola, T; Fenzi, G; Rossi, G; Vitale, M			Calcium/calmodulin-dependent protein kinase II binds to Raf-1 and modulates integrin-stimulated ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; FOCAL ADHESION KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-ADHESION; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; HUMAN NEUTROPHILS; THYROID-CELLS; PATHWAY; CALMODULIN	Integrin activation generates different signalings in a cell type-dependent manner and stimulates cell proliferation through the Ras/Raf-1/Mek/Erk pathway. In this study, we demonstrate that integrin stimulation by fibronectin (FN), besides activating the Ras/Erk pathway, generates an auxiliary calcium signal that activates calmodulin and the Ca2+/calmodulin-dependent protein kinase II (CaMKII). This signal regulates Raf-1 activation by Ras and modulates the FN-stimulated extracellular signal-regulated kinase (Erk-1/2). The binding of soluble FN to integrins induced increase of intracellular calcium concentration associated with phosphorylation and activation of CaMKII. In two different cell lines, inhibition of CaMKII activity by specific inhibitors inhibited Erk-1/2 phosphorylation. Whereas CaMK inhibition affected neither integrin-stimulated Akt phosphorylation nor p21Ras or Mek-1 activity, it was necessary for Raf-1 activity. FN-induced Raf-1 activity was abrogated by the CaMKII specific inhibitory peptide antCaNtide. Integrin activation by FN induced the formation of a Raf-1/CaMKII complex, abrogated by inhibition of CaMKII. Active CaMKII phosphorylated Raf-1 in vitro. This is the first demonstration that CaMKII interplays with Raf-1 and regulates Erk activation induced by Ras-stimulated Raf-1. These findings also provide evidence supporting the possible existence of cross-talk between other intracellular pathways involving CaMKII and Raf-1.	Univ Naples Federico II, Dipartimento Endocrinol & Oncol Mol & Clin, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; CNR, Ist Endocrinol & Oncol Sperimentale G Salvatore, I-80131 Naples, Italy; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Naples Federico II; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Vitale, M (corresponding author), Univ Naples Federico II, Dipartimento Endocrinol & Oncol Mol & Clin, Via S Pansini 5, I-80131 Naples, Italy.			Illario, Maddalena/0000-0001-9834-6517				Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; Bilato C, 1997, J CLIN INVEST, V100, P693, DOI 10.1172/JCI119582; Blystone SD, 1999, J CELL BIOL, V145, P889, DOI 10.1083/jcb.145.4.889; Borgquist JD, 2002, J LEUKOCYTE BIOL, V71, P764; Bouvard D, 1998, BIOCHEM BIOPH RES CO, V252, P46, DOI 10.1006/bbrc.1998.9592; Chang BH, 1998, P NATL ACAD SCI USA, V95, P10890, DOI 10.1073/pnas.95.18.10890; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; Cheng JJ, 2001, J BIOL CHEM, V276, P31368, DOI 10.1074/jbc.M011317200; Colomer JM, 2000, MOL ENDOCRINOL, V14, P1125, DOI 10.1210/me.14.8.1125; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; Egea J, 2000, MOL CELL BIOL, V20, P1931, DOI 10.1128/MCB.20.6.1931-1946.2000; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Heemskerk JWM, 1997, BLOOD, V90, P2615, DOI 10.1182/blood.V90.7.2615.2615_2615_2625; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Illario M, 2003, J CLIN ENDOCR METAB, V88, P260, DOI 10.1210/jc.2002-020774; JACONI MEE, 1991, J CELL BIOL, V112, P1249, DOI 10.1083/jcb.112.6.1249; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; Kwon MS, 2000, MOL BIOL CELL, V11, P1433, DOI 10.1091/mbc.11.4.1433; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; Tebar F, 2002, FEBS LETT, V517, P206, DOI 10.1016/S0014-5793(02)02624-8; UEHARA T, 1995, BIOCHEM BIOPH RES CO, V210, P574, DOI 10.1006/bbrc.1995.1698; Villalonga P, 2002, J BIOL CHEM, V277, P37929, DOI 10.1074/jbc.M202245200; Villalonga P, 2001, MOL CELL BIOL, V21, P7345, DOI 10.1128/MCB.21.21.7345-7354.2001; Vitale M, 1997, ENDOCRINOLOGY, V138, P1642, DOI 10.1210/en.138.4.1642; Vitale M, 1998, J CLIN ENDOCR METAB, V83, P3673, DOI 10.1210/jc.83.10.3673; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; YANG SD, 1994, J BIOL CHEM, V269, P29855	44	122	124	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45101	45108		10.1074/jbc.M305355200	http://dx.doi.org/10.1074/jbc.M305355200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954639	hybrid			2022-12-25	WOS:000186452300009
J	Bai, YQ; Miyake, S; Iwai, T; Yuasa, Y				Bai, YQ; Miyake, S; Iwai, T; Yuasa, Y			CDX2, a homeobox transcription factor, upregulates transcription of the p21/WAF1/CIP1 gene	ONCOGENE			English	Article						CDX2; transcription; p21/WAF1/CIP1	HEPATOCYTE NUCLEAR FACTOR-1-ALPHA; HOMEODOMAIN PROTEIN CDX2; CYCLIN-DEPENDENT KINASES; INTESTINAL METAPLASIA; CELL-LINE; P21(WAF1/CIP1) GENE; ECTOPIC EXPRESSION; DNA-REPLICATION; TRANSGENIC MICE; DOWN-REGULATION	The CDX2 homeobox transcription factor plays key roles in intestinal development and homeostasis. CDX2 is downregulated during colorectal carcinogenesis, whereas overexpression of CDX2 results in growth inhibition and differentiation of colon carcinoma and intestinal cells. However, the means by which CDX2 functions remain poorly understood. p21/WAF1/CIP1 is one of the cyclin-dependent kinase inhibitors. In addition to its role in cell cycle control, p21 plays critical roles in differentiation and tumor suppression. The overlapping in both the expression and function of CDX2 and p21 in the small intestine and colon strongly suggests a link between these two genes. By means of luciferase reporter and electrophoretic mobility shift assays, we show here that CDX2 transactivated and physically interacted with the promoter of p21 in a p53-independent manner. Moreover, overexpression of CDX2 increased the mRNA expression of p21 in HT-29 colon carcinoma cells, as demonstrated by reverse transcription-polymerase chain reaction. These data suggest that p21 is a transcriptional target of CDX2. Our results may thus provide a new mechanism underlying the functions of CDX2.	Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Surg, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Yuasa, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Mol Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.							Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; Bai YQ, 2000, MOL CARCINOGEN, V28, P184, DOI 10.1002/1098-2744(200007)28:3<184::AID-MC7>3.0.CO;2-6; Bai YQ, 2002, CANCER LETT, V176, P47, DOI 10.1016/S0304-3835(01)00753-4; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bukholm IK, 2000, VIRCHOWS ARCH, V436, P224, DOI 10.1007/s004280050034; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; EE HC, 1995, AM J PATHOL, V147, P586; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 2000, ONCOGENE, V19, P5182, DOI 10.1038/sj.onc.1203900; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; HARPER JW, 1993, CELL, V75, P805; Hinoi T, 2002, GASTROENTEROLOGY, V123, P1565, DOI 10.1053/gast.2002.36598; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JAMES R, 1994, J BIOL CHEM, V269, P15229; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lickert H, 2000, DEVELOPMENT, V127, P3805; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Moucadel V, 2002, BIOCHEM BIOPH RES CO, V297, P607, DOI 10.1016/S0006-291X(02)02250-7; Mutoh H, 2002, BIOCHEM BIOPH RES CO, V294, P470, DOI 10.1016/S0006-291X(02)00480-1; Perlman H, 1998, J BIOL CHEM, V273, P13713, DOI 10.1074/jbc.273.22.13713; Polyak K, 1996, AM J PATHOL, V149, P381; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Subramanian V, 1998, DIFFERENTIATION, V64, P11, DOI 10.1046/j.1432-0436.1998.6410011.x; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; van Wering HM, 2002, J BIOL CHEM, V277, P27659, DOI 10.1074/jbc.M203645200; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	47	86	90	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7942	7949		10.1038/sj.onc.1206634	http://dx.doi.org/10.1038/sj.onc.1206634			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970742				2022-12-25	WOS:000185388200009
J	Johansson, EM; Kannius-Janson, M; Bjursell, G; Nilsson, J				Johansson, EM; Kannius-Janson, M; Bjursell, G; Nilsson, J			The p53 tumor suppressor gene is regulated in vivo by nuclear factor 1-C2 in the mouse mammary gland during pregnancy	ONCOGENE			English	Article						p53; NF1-C2; NF1-A1; mammary gland; development; transcriptional regulation	ESTER LIPASE GENE; HUMAN BREAST-TUMORS; CELL-LINE K562; TRANSCRIPTION FACTOR; WILD-TYPE; KAPPA-B; HA-RAS; EXPRESSION; DIFFERENTIATION; PROMOTER	The p53 tumor suppressor protein plays an important role in preventing cancer development by arresting or killing potential tumor cells. Downregulated p53 levels, or mutations within the p53 gene, leading to the loss of p53 activity, are found in many breast carcinomas. Here we demonstrate that the p53 gene is transcriptionally upregulated in the normal mouse mammary gland at midpregnancy. We show that the specific isoform nuclear factor 1-C2 (NF1-C2) plays an important role in this activation. Functional mutation of the NF1-binding site in the mouse p53 promoter resulted in a reduction of the gene expression to less than 30% in mammary epithelial cells. By the use of two powerful techniques, chromatin immunoprecipitation and oligonucleotide decoy, we verify the importance of NF1-C2 in p53 gene activation in vivo. These findings demonstrate a broader role for NF1-C2 in the mammary gland at midpregnancy, beyond its earlier reported activation of milk protein genes. We also demonstrate that NF1-A1 proteins are produced in the mouse mammary gland. However, due to their lower affinity to the NF1-binding site, these proteins are not involved in the transcriptional upregulation of p53 at midpregnancy. This paper constitutes the first report demonstrating the importance of NF1 proteins in the p53 gene activation in the mouse mammary gland. It is also the first time that p53 gene activation is coupled to a specific, endogenously expressed NF1 isoform.	Dept CMB Mol Biol, S-40530 Gothenburg, Sweden		Johansson, EM (corresponding author), Dept CMB Mol Biol, Box 462, S-40530 Gothenburg, Sweden.	Eva.Johansson@molbio.gu.se	Kannius Janson, Marie/M-3052-2015; Nilsson, Jeanette/M-3051-2015					Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Balint E, 1996, CANCER RES, V56, P1648; BANERJEE D, 1995, CELL GROWTH DIFFER, V6, P1405; Bengtsson SHM, 2002, BIOCHEM J, V365, P481, DOI 10.1042/BJ20020223; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P315; COLES C, 1992, CANCER RES, V52, P5291; EHINGER M, 1995, CELL GROWTH DIFFER, V6, P9; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Hale TK, 2000, J BIOL CHEM, V275, P17991, DOI 10.1074/jbc.M000921200; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; Kane R, 2000, ADV EXP MED BIOL, V480, P117; Kannius-Janson M, 1998, BIOCHEM J, V336, P577, DOI 10.1042/bj3360577; Kannius-Janson M, 2002, J BIOL CHEM, V277, P17589, DOI 10.1074/jbc.M105979200; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; Kuperwasser C, 2000, CANCER RES, V60, P2723; Lang D, 1998, ONCOGENE, V16, P1593, DOI 10.1038/sj.onc.1201665; Lidberg U, 1998, J BIOL CHEM, V273, P31417, DOI 10.1074/jbc.273.47.31417; LIDBERG U, 1992, GENOMICS, V13, P630, DOI 10.1016/0888-7543(92)90134-E; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; Mukhopadhyay SS, 2001, MOL CELL BIOL, V21, P6859, DOI 10.1128/MCB.21.20.6859-6869.2001; Nayak BK, 1999, MOL BIOL REP, V26, P223, DOI 10.1023/A:1007006011253; NEBL G, 1994, J BIOL CHEM, V269, P7371; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Osada S, 1999, BIOCHEM J, V342, P189, DOI 10.1042/0264-6021:3420189; Rafty LA, 2002, EMBO J, V21, P334, DOI 10.1093/emboj/21.3.334; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Saifudeen Z, 2002, J CLIN INVEST, V109, P1021, DOI 10.1172/JCI200213972; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; Sivaraman L, 2001, P NATL ACAD SCI USA, V98, P12379, DOI 10.1073/pnas.221459098; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SOINI Y, 1992, VIRCHOWS ARCH A, V421, P415, DOI 10.1007/BF01606914; STRANGE R, 1992, DEVELOPMENT, V115, P49; Stromqvist M, 1997, ARCH BIOCHEM BIOPHYS, V347, P30, DOI 10.1006/abbi.1997.0307; SUN XG, 1995, MOL CELL BIOL, V15, P4489; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	45	18	19	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6061	6070		10.1038/sj.onc.1206884	http://dx.doi.org/10.1038/sj.onc.1206884			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955085				2022-12-25	WOS:000185137800015
J	Baar, K; Song, Z; Semenkovich, CF; Jones, TE; Han, DH; Nolte, LA; Ojuka, EO; Chen, M; Holloszy, JO				Baar, K; Song, Z; Semenkovich, CF; Jones, TE; Han, DH; Nolte, LA; Ojuka, EO; Chen, M; Holloszy, JO			Skeletal muscle overexpression of nuclear respiratory factor 1 increases glucose transport capacity	FASEB JOURNAL			English	Article						delta-aminolevulinate synthase; cytochrome c; mitochondria; pyruvate oxidation; respiratory enzymes	TRANSCRIPTIONAL COACTIVATOR PGC-1; GLUT4 GENE-EXPRESSION; MITOCHONDRIAL BIOGENESIS; CYTOCHROME-C; BIOCHEMICAL ADAPTATIONS; GAMMA COACTIVATOR-1; ENDURANCE EXERCISE; ACTIVATION; INSULIN; CELLS	Nuclear respiratory factor 1 (NRF-1) is a transcriptional activator of nuclear genes that encode a range of mitochondrial proteins including cytochrome c, various other respiratory chain subunits, and delta-aminolevulinate synthase. Activation of NRF-1 in fibroblasts has been shown to induce increases in cytochrome c expression and mitochondrial respiratory capacity. To further evaluate the role of NRF-1 in the regulation of mitochondrial biogenesis and respiratory capacity, we generated transgenic mice overexpressing NRF-1 in skeletal muscle. Cytochrome c expression was increased similar to twofold and delta-aminolevulinate synthase was increased similar to 50% in NRF-1 transgenic muscle. The levels of some mitochondrial proteins were increased 50 - 60%, while others were unchanged. Muscle respiratory capacity was not increased in the NRF-1 transgenic mice. A finding that provides new insight regarding the role of NRF-1 was that expression of MEF2A and GLUT4 was increased in NRF-1 transgenic muscle. The increase in GLUT4 was associated with a proportional increase in insulin-stimulated glucose transport. These results show that an isolated increase in NRF-1 is not sufficient to bring about a coordinated increase in expression of all of the proteins necessary for assembly of functional mitochondria. They also provide the new information that NRF-1 overexpression results in increased expression of GLUT4.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Holloszy, JO (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8113,4566 Scott Ave, St Louis, MO 63110 USA.	jhollosz@im.wustl.edu		Semenkovich, Clay/0000-0003-1163-1871; Baar, Keith/0000-0001-9337-6186	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018986, P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R56AG000425, R37AG000425, R01AG020091, R01AG000425] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58427] Funding Source: Medline; NIA NIH HHS [AG20091, AG00425] Funding Source: Medline; NIDDK NIH HHS [DK18986, DK56341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Booth F, 1977, Ann N Y Acad Sci, V301, P431, DOI 10.1111/j.1749-6632.1977.tb38219.x; BOOTH FW, 1997, HDB PHYSL 12, P1075; BOUREY RE, 1990, J CLIN INVEST, V86, P542, DOI 10.1172/JCI114742; BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; Connor MK, 2001, J BIOL CHEM, V276, P15898, DOI 10.1074/jbc.M100272200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY GA, 1987, J BIOL CHEM, V262, P9109; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FRIEDMAN JE, 1990, FEBS LETT, V268, P13, DOI 10.1016/0014-5793(90)80960-Q; GOODYEAR LJ, 1992, DIABETES, V41, P1091, DOI 10.2337/diabetes.41.9.1091; GOPALAKRISHNAN L, 1994, J BIOL CHEM, V269, P105; GOPALAKRISHNAN L, 1995, J BIOL CHEM, V270, P18019, DOI 10.1074/jbc.270.30.18019; HANSEN PA, 1994, J APPL PHYSIOL, V76, P979, DOI 10.1152/jappl.1994.76.2.979; Herzig RP, 2000, J BIOL CHEM, V275, P13134, DOI 10.1074/jbc.275.17.13134; HOLLOSZY JO, 1976, ANNU REV PHYSIOL, V38, P273, DOI 10.1146/annurev.ph.38.030176.001421; Holloszy JO, 1996, REV PHYSIOL BIOCH P, V128, P99; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; Hood DA, 2001, J APPL PHYSIOL, V90, P1137, DOI 10.1152/jappl.2001.90.3.1137; KLIP A, 1990, BIOCHEM BIOPH RES CO, V172, P728, DOI 10.1016/0006-291X(90)90735-6; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Li B, 1999, J BIOL CHEM, V274, P17534, DOI 10.1074/jbc.274.25.17534; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; LIU ML, 1994, J BIOL CHEM, V269, P28514; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; MOLE PA, 1971, J CLIN INVEST, V50, P2323, DOI 10.1172/JCI106730; Mora S, 2000, J BIOL CHEM, V275, P16323, DOI 10.1074/jbc.M910259199; MURAKAMI S, 1998, J PLASMA FUSION RES, V1, P122; Ojuka EO, 2003, FASEB J, V17, P675, DOI 10.1096/fj.02-0951com; Ojuka EO, 2002, AM J PHYSIOL-ENDOC M, V283, pE1040, DOI 10.1152/ajpendo.00242.2002; Ojuka EO, 2002, AM J PHYSIOL-ENDOC M, V282, pE1008, DOI 10.1152/ajpendo.00512.2001; OSCAI LB, 1971, J BIOL CHEM, V246, P6968; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; REN JM, 1993, AM J PHYSIOL, V264, pC146, DOI 10.1152/ajpcell.1993.264.1.C146; REN JM, 1994, J BIOL CHEM, V269, P14396; Scarpulla RC, 2002, GENE, V286, P81, DOI 10.1016/S0378-1119(01)00809-5; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; WEINSTEIN SP, 1994, DIABETES, V43, P1185, DOI 10.2337/diabetes.43.10.1185; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; WINDER WW, 1975, AM J PHYSIOL, V228, P1341, DOI 10.1152/ajplegacy.1975.228.5.1341; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xia Y, 1997, P NATL ACAD SCI USA, V94, P11399, DOI 10.1073/pnas.94.21.11399; YOUNG DA, 1986, J BIOL CHEM, V261, P6049; Zheng DH, 2001, J APPL PHYSIOL, V91, P1073, DOI 10.1152/jappl.2001.91.3.1073	51	89	94	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1666	1673		10.1096/fj.03-0049com	http://dx.doi.org/10.1096/fj.03-0049com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958173				2022-12-25	WOS:000185925100041
J	Chen, CJ; Huang, HS; Chang, WC				Chen, CJ; Huang, HS; Chang, WC			Depletion of phospholipid hydroperoxide glutathione peroxidase up-regulates arachidonate metabolism by 12(S)-lipoxygenase and cyclooxygenase 1 in human epidermoid carcinoma A431 cells	FASEB JOURNAL			English	Article						PHGPx; peroxides; 12(S)-hydroxyeicosatetraenoic acid; prostaglandin E(2)	GROWTH-FACTOR; LIPOXYGENASE INHIBITOR; LIPID-PEROXIDATION; INDUCED APOPTOSIS; 12-LIPOXYGENASE; INVOLVEMENT; REDUCTION; PLATELETS; NECROSIS; SELENIUM	Phospholipid hydroperoxide glutathione peroxidase (PHGPx), a selenium-dependent glutathione peroxidase, can interact with lipophilic substrates, including the phospholipid hydroperoxides, fatty-acid hydroperoxides, and cholesteryl ester hydroperoxides, and reduce them to hydroxide compounds. We studied the functional role of endogenous PHGPx in regulation of 12(S)-lipoxygenase and cyclooxygenase 1 activities in human epidermoid carcinoma A431 cells by using a cell system overexpressing anti-PHGPx mRNA. A retroviral expression vector designated as L1-3, wherein cDNA of PHGPx was reversely inserted into pFB-ERV in antisense orientation, was constructed. A number of stable transfectants of A431 cells with PHGPx depletion were generated from virions containing plasmid L1-3. In an intact cell assay system, the metabolism of arachidonic acid to prostaglandin E(2) and 12(S)-hydroxyeicosatetraenoic acid was significantly enhanced in stable L1-3 transfectants compared with that in vector-control cells. Flow cytometric analysis revealed a significant elevated level of intracellular hydroperoxides in stable L1-3 transfectants. Treatment of stable L1-3 transfectants with 50 muM arsenite induced more significant formation of intracellular hydroperoxides than that of vector-control cells. Taken together, these results support the notion that the endogenous PHGPx plays a pivotal role in the regulation of 12(S)-lipoxygenase and cyclooxygenase 1 activities by reducing the level of intracellular lipid hydroperoxides in arachidonate metabolism in A431 cells.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 704, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Med Technol, Tainan 704, Taiwan	National Cheng Kung University; National Cheng Kung University	Chang, WC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, 138 Sheng Li Rd, Tainan 704, Taiwan.	wcchang@mail.ncku.edu.tw	Huang, Huei-Sheng/F-9945-2011					BASS DA, 1983, J IMMUNOL, V130, P1910; CHANG WC, 1993, J BIOL CHEM, V268, P18734; CHANG WC, 1992, J BIOL CHEM, V267, P3657; CHANG WC, 1982, BIOCHEM J, V202, P771, DOI 10.1042/bj2020771; Chen CJ, 2002, J BIOMED SCI, V9, P453, DOI 10.1007/BF02256540; Chen CJ, 2000, PROSTAG LEUKOTR ESS, V62, P261, DOI 10.1103/PhysRevD.62.094026; Chen CJ, 1997, BIOCHEM J, V327, P193, DOI 10.1042/bj3270193; CHU FF, 1993, J BIOL CHEM, V268, P2571; Degli Esposti M, 1998, FEBS LETT, V430, P338, DOI 10.1016/S0014-5793(98)00688-7; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; GHYSELINCK NB, 1990, NUCLEIC ACIDS RES, V18, P7144, DOI 10.1093/nar/18.23.7144; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; Huang HS, 2002, FREE RADICAL BIO MED, V33, P864, DOI 10.1016/S0891-5849(02)00983-8; Huang HS, 1999, PROSTAG OTH LIPID M, V58, P65, DOI 10.1016/S0090-6980(99)00017-9; Huang HS, 1998, FEBS LETT, V424, P22, DOI 10.1016/S0014-5793(98)00130-6; Imai H, 1998, J BIOL CHEM, V273, P1990, DOI 10.1074/jbc.273.4.1990; Jabs T, 1999, BIOCHEM PHARMACOL, V57, P231, DOI 10.1016/S0006-2952(98)00227-5; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADDIPATI KR, 1987, ARCH BIOCHEM BIOPHYS, V254, P9, DOI 10.1016/0003-9861(87)90075-0; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; NELSON MJ, 1995, BIOCHEMISTRY-US, V34, P6159, DOI 10.1021/bi00018a019; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; Sakamoto H, 2000, J BIOL CHEM, V275, P40028, DOI 10.1074/jbc.M003191200; Sato T, 1997, PROSTAGLANDINS, V53, P355, DOI 10.1016/0090-6980(97)00036-1; Schnurr K, 1996, J BIOL CHEM, V271, P4653; SHORNICK LP, 1993, J BIOL CHEM, V268, P371; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Sutherland M, 2001, BIOCHEM J, V353, P91, DOI 10.1042/bj3530091; THOMAS JP, 1990, J BIOL CHEM, V265, P454; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; YAMAMOTO S, 1991, FREE RADICAL BIO MED, V10, P149, DOI 10.1016/0891-5849(91)90008-Q	34	28	29	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1694	+		10.1096/fj.02-0847fje	http://dx.doi.org/10.1096/fj.02-0847fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958179				2022-12-25	WOS:000184471600020
J	Wang, XR; Zhang, Z; Louboutin, JP; Moser, C; Weiner, DJ; Wilson, JM				Wang, XR; Zhang, Z; Louboutin, JP; Moser, C; Weiner, DJ; Wilson, JM			Airway epithelia regulate expression of human beta-defensin 2 through toll-like receptor 2	FASEB JOURNAL			English	Article						TLR; defensin; lung	TOLL-LIKE RECEPTORS; NF-KAPPA-B; MEDIATED TRANSCRIPTIONAL REGULATION; DERMAL ENDOTHELIAL-CELLS; INNATE IMMUNE-RESPONSE; ANTIMICROBIAL PEPTIDE; HUMAN BETA-DEFENSIN-2; ADAPTIVE IMMUNITY; ESCHERICHIA-COLI; DROSOPHILA TOLL	The goal of this study is to investigate whether TLR2 mediates hBD2 induction through NF-kappaB in response to bacterial components in the human airway epithelia. We showed that hTLR2 is expressed in the airway epithelial cells by immunohistochemical staining and RT-PCR. The biology of hTLR2 in this context was studied initially in 293 cells transfected with a plasmid expressing hTLR2 together with an hBD2 promoter-driven luciferase reporter(hBD2-promoter-LUC). Upon incubation with lipoteichoic acid(LTA), the major cell wall component of gram positive bacteria,luciferase activity was greatly increased compared with mock stimulation. Analysis of mutation constructs of the hBD2 promoter revealed that NF-kappaB sites are important for hTLR2-mediated hBD2 up-regulation upon LTA stimulation. When hBD2-promoter-LUC was transfected into primary human airway epithelial cells(EC), the luciferase activity was greatly increased upon LTA stimulation compared with mock stimulation. The hBD2 promoter mutation constructs were also tested in EC, which confirmed the studies in 293 cells. When a plasmid expressing a dominant-negative mutant of hTLR2 was co-transfected with hBD2 promoter-LUC into EC,LTA could not stimulate hBD2 expression. These data provide convincing evidence that up-regulation of hBD2 can be induced through hTLR2-mediated NFkappaB/IkappaB pathway in the human airway epithelial cells.	Univ Penn, Sch Med, Dept Med, Div Med Genet, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; The Wistar Institute; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Wilson, JM (corresponding author), 204 Wistar Inst, 3601 Spruce St, Philadelphia, PA 19104 USA.	wilsonjm@mail.med.upenn.edu	Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131; Weiner, Daniel/0000-0001-8245-1961				Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Backhed F, 2001, CELL MICROBIOL, V3, P153, DOI 10.1046/j.1462-5822.2001.00101.x; Bals R, 1999, INFECT IMMUN, V67, P3542, DOI 10.1128/IAI.67.7.3542-3547.1999; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; Beauparlant P, 1996, J VIROL, V70, P5777, DOI 10.1128/JVI.70.9.5777-5785.1996; Becker MN, 2000, J BIOL CHEM, V275, P29731, DOI 10.1074/jbc.M000184200; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Birchler T, 2001, EUR J IMMUNOL, V31, P3131, DOI 10.1002/1521-4141(200111)31:11<3131::AID-IMMU3131>3.0.CO;2-G; Bulut Y, 2001, J IMMUNOL, V167, P987, DOI 10.4049/jimmunol.167.2.987; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; Fusunyan RD, 2001, PEDIATR RES, V49, P589, DOI 10.1203/00006450-200104000-00023; GANZ T, 1995, PHARMACOL THERAPEUT, V66, P191, DOI 10.1016/0163-7258(94)00076-F; Garcia JRC, 2001, FASEB J, V15, P1819, DOI 10.1096/fj.00-0865fje; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Harder J, 2000, AM J RESP CELL MOL, V22, P714, DOI 10.1165/ajrcmb.22.6.4023; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Huttner KM, 1997, FEBS LETT, V413, P45, DOI 10.1016/S0014-5793(97)00875-2; Janeway CA, 1998, SEMIN IMMUNOL, V10, P349, DOI 10.1006/smim.1998.0142; Jia HP, 2000, J BIOL CHEM, V275, P33314, DOI 10.1074/jbc.M006603200; Kaisho T, 2001, TRENDS IMMUNOL, V22, P78, DOI 10.1016/S1471-4906(00)01811-1; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Ma XJ, 2000, J IMMUNOL, V164, P1722, DOI 10.4049/jimmunol.164.4.1722; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200; Morrison GM, 1999, FEBS LETT, V442, P112, DOI 10.1016/S0014-5793(98)01630-5; Naik S, 2001, J PEDIATR GASTR NUTR, V32, P449, DOI 10.1097/00005176-200104000-00011; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Schilling JD, 2001, J IMMUNOL, V166, P1148, DOI 10.4049/jimmunol.166.2.1148; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Sebastiani G, 2000, GENOMICS, V64, P230, DOI 10.1006/geno.2000.6115; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Thoma-Uszynski S, 2000, J IMMUNOL, V165, P3804, DOI 10.4049/jimmunol.165.7.3804; Tsutsumi-Ishii Y, 2002, J LEUKOCYTE BIOL, V71, P154; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Wada A, 2001, CELL MICROBIOL, V3, P115, DOI 10.1046/j.1462-5822.2001.00096.x; Wolfs TGAM, 2002, J IMMUNOL, V168, P1286, DOI 10.4049/jimmunol.168.3.1286; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	51	73	85	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1727	+		10.1096/fj.02-0616fje	http://dx.doi.org/10.1096/fj.02-0616fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958190				2022-12-25	WOS:000184471600024
J	Heddle, J; Scott, DJ; Unzai, S; Park, SY; Tame, JRH				Heddle, J; Scott, DJ; Unzai, S; Park, SY; Tame, JRH			Crystal structures of the liganded and unliganded nickel-binding protein NikA from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TREPONEMA-PALLIDUM TROA; PERIPLASMIC RECEPTORS; TRANSPORT; AFFINITY; OPPA; METALLOCHAPERONE; SPECIFICITY; CHEMOTAXIS; MUTANTS; REVEALS	Bacteria have evolved a number of tightly controlled import and export systems to maintain intracellular levels of the essential but potentially toxic metal nickel. Nickel homeostasis systems include the dedicated nickel uptake system nik found in Escherichia coli, a member of the ABC family of transporters, that involves a periplasmic nickel-binding protein, NikA. This is the initial nickel receptor and mediator of the chemotactic response away from nickel. We have solved the crystal structure of NikA protein in the presence and absence of nickel, showing that it behaves as a "classical" periplasmic binding protein. In contrast to other binding proteins, however, the ligand remains accessible to the solvent and is not completely enclosed. No direct bonds are formed between the metal cation and the protein. The nickel binding site is apolar, quite unlike any previously characterized protein nickel binding site. Despite relatively weak binding, NikA is specific for nickel. Using isothermal titration calorimetry, the dissociation constant for nickel was found to be similar to 10 muM and that for cobalt was approximately 20 times higher.	Yokohama City Univ, Prot Design Lab, Yokohama, Kanagawa 2300045, Japan; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	Yokohama City University; University of Bristol	Tame, JRH (corresponding author), Yokohama City Univ, Prot Design Lab, Suehiro 1-7-29, Yokohama, Kanagawa 2300045, Japan.	jtame@tsurumi.yokohama-cu.ac.jp	Heddle, Jonathan/AAP-7167-2020; Heddle, Jonathan G/H-4586-2014	Scott, David/0000-0002-6726-2078				ANKE M, 1984, IARC SCI PUBL, P339; BABICH H, 1983, ADV APPL MICROBIOL, V29, P195, DOI 10.1016/S0065-2164(08)70358-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benini S, 1999, STRUCTURE, V7, P205, DOI 10.1016/S0969-2126(99)80026-4; Carrington PE, 2003, NAT STRUCT BIOL, V10, P126, DOI 10.1038/nsb890; Chivers PT, 2000, J BIOL CHEM, V275, P19735, DOI 10.1074/jbc.M002232200; Chivers PT, 2002, CHEM BIOL, V9, P1141, DOI 10.1016/S1074-5521(02)00241-7; Claverys JP, 2001, RES MICROBIOL, V152, P231, DOI 10.1016/S0923-2508(01)01195-0; Clugston SL, 1998, BIOCHEMISTRY-US, V37, P8754, DOI 10.1021/bi972791w; Davies TG, 1999, PROTEIN SCI, V8, P1432, DOI 10.1110/ps.8.7.1432; De Lorimier RM, 2002, PROTEIN SCI, V11, P2655, DOI 10.1110/ps.021860; De Pina K, 1999, J BACTERIOL, V181, P670, DOI 10.1128/JB.181.2.670-674.1999; Deng X, 2003, WATER RES, V37, P2505, DOI 10.1016/S0043-1354(03)00027-7; DEPINA K, 1995, EUR J BIOCHEM, V227, P857; Eitinger T, 1997, J BIOL CHEM, V272, P17139, DOI 10.1074/jbc.272.27.17139; Foote J, 2000, P NATL ACAD SCI USA, V97, P978, DOI 10.1073/pnas.97.3.978; Fukami-Kobayashi K, 1999, J MOL BIOL, V286, P279, DOI 10.1006/jmbi.1998.2454; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Grass G, 2001, J BACTERIOL, V183, P2803, DOI 10.1128/JB.183.9.2803-2807.2001; HAUSINGER RP, 1987, MICROBIOL REV, V51, P22, DOI 10.1128/MMBR.51.1.22-42.1987; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Kobayashi M, 1999, EUR J BIOCHEM, V261, P1, DOI 10.1046/j.1432-1327.1999.00186.x; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lawrence MC, 1998, STRUCTURE, V6, P1553, DOI 10.1016/S0969-2126(98)00153-1; Lawson DM, 1998, STRUCTURE, V6, P1529, DOI 10.1016/S0969-2126(98)00151-8; Ledvina PS, 1996, P NATL ACAD SCI USA, V93, P6786, DOI 10.1073/pnas.93.13.6786; Lee YH, 2002, J BACTERIOL, V184, P2300, DOI 10.1128/JB.184.8.2300-2304.2002; Lee YH, 1999, NAT STRUCT BIOL, V6, P628; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; MAIER T, 1993, J BACTERIOL, V175, P630, DOI 10.1128/JB.175.3.630-635.1993; Maroney MJ, 1999, CURR OPIN CHEM BIOL, V3, P188, DOI 10.1016/S1367-5931(99)80032-5; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVARRO C, 1993, MOL MICROBIOL, V9, P1181, DOI 10.1111/j.1365-2958.1993.tb01247.x; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Nickitenko AV, 1995, BIOCHEMISTRY-US, V34, P16585, DOI 10.1021/bi00051a006; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; Remaut H, 2001, J BIOL CHEM, V276, P49365, DOI 10.1074/jbc.M108304200; Roussel A., 1989, SILICON GRAPHICS GEO; Salins LLE, 2002, ANAL BIOANAL CHEM, V372, P174, DOI 10.1007/s00216-001-1169-7; SCHMIDT T, 1994, J BACTERIOL, V176, P7045, DOI 10.1128/JB.176.22.7045-7054.1994; Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X; Shilton BH, 1996, J MOL BIOL, V264, P350, DOI 10.1006/jmbi.1996.0645; SILHAVY TJ, 1975, P NATL ACAD SCI USA, V72, P2120, DOI 10.1073/pnas.72.6.2120; Sleigh SH, 1997, BIOCHEMISTRY-US, V36, P9747, DOI 10.1021/bi970457u; Song HK, 2001, J BIOL CHEM, V276, P49359, DOI 10.1074/jbc.M108619200; STOCK JB, 1977, J BIOL CHEM, V252, P7850; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; Tame JRH, 1995, STRUCTURE, V3, P1395, DOI 10.1016/S0969-2126(01)00276-3; Tame JRH, 1996, NAT STRUCT BIOL, V3, P998, DOI 10.1038/nsb1296-998; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Uthus EO, 1996, BIOL TRACE ELEM RES, V52, P23, DOI 10.1007/BF02784087; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; VANWIELINK JE, 1990, TRENDS BIOCHEM SCI, V15, P136, DOI 10.1016/0968-0004(90)90208-S; Watt RK, 1999, CELL MOL LIFE SCI, V56, P604, DOI 10.1007/s000180050456; Wolfram L, 2002, J BACTERIOL, V184, P1438, DOI 10.1128/JB.184.5.1438-1443.2002; WOLFRAM L, 1995, J BACTERIOL, V177, P1840, DOI 10.1128/jb.177.7.1840-1843.1995; WU LF, 1989, MOL MICROBIOL, V3, P1709, DOI 10.1111/j.1365-2958.1989.tb00156.x; WU LF, 1991, GENE, V107, P37; WU LF, 1986, BIOCHIMIE, V68, P167, DOI 10.1016/S0300-9084(86)81081-1	64	62	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50322	50329		10.1074/jbc.M307941200	http://dx.doi.org/10.1074/jbc.M307941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	12960164	hybrid			2022-12-25	WOS:000187068200081
J	Braybrooke, JP; Li, JL; Wu, L; Caple, F; Benson, FE; Hickson, ID				Braybrooke, JP; Li, JL; Wu, L; Caple, F; Benson, FE; Hickson, ID			Functional interaction between the Bloom's syndrome helicase and the RAD51 paralog, RAD51L3 (RAD51D)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; SYNDROME GENE-PRODUCT; DEFENDING GENOME INTEGRITY; RECQ FAMILY HELICASES; DOUBLE-STRAND BREAKS; DNA-REPAIR GENE; HOMOLOGOUS RECOMBINATION; TOPOISOMERASE-III; S-PHASE; SACCHAROMYCES-CEREVISIAE	Bloom's syndrome (BS) is a genetic disorder associated with short stature, fertility defects, and a predisposition to the development of cancer. BS cells are characterized by genomic instability; in particular, a high rate of reciprocal exchanges between sister-chromatids and homologous chromosomes. The BS gene product, BLM, is a helicase belonging to the highly conserved RecQ family. BLM is known to form a complex with the RAD51 recombinase, and to act upon DNA intermediates that form during homologous recombination, including D-loops and Holliday junctions. Here, we show that BLM also makes a direct physical association with the RAD51L3 protein ( also known as RAD51D), a so-called RAD51 paralog that shows limited sequence similarity to RAD51 itself. This interaction is mediated through the N-terminal domain of BLM. To analyze functional interactions between BLM and RAD51L3, we have purified a heteromeric complex comprising RAD51L3 and a second RAD51 paralog, XRCC2. We show that the RAD51L3-XRCC2 complex stimulates BLM to disrupt synthetic 4-way junctions that model the Holliday junction. We also show that a truncated form of BLM, which retains helicase activity but is unable to bind RAD51L3, is not stimulated by the RAD51L3-XRCC2 complex. Our data indicate that the activity of BLM is modulated through an interaction with the RAD51L3-XRCC2 complex, and that this stimulatory effect on BLM is dependent upon a direct physical association between the BLM and RAD51L3 proteins. We propose that BLM co-operates with RAD51 paralogs during the late stages of homologous recombination processes that serve to restore productive DNA replication at sites of damaged or stalled replication forks.	Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK, Oxford OX3 9DS, England; Univ Lancaster, Dept Biol Sci, Lancaster Environm Ctr, Lancaster LA1 4YQ, England	Cancer Research UK; University of Oxford; Lancaster University	Hickson, ID (corresponding author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK, Oxford OX3 9DS, England.		Hickson, Ian/AAJ-7548-2020	Benson, Fiona Elizabeth/0000-0002-3918-7015; Hickson, Ian/0000-0002-0583-566X; Braybrooke, Jeremy/0000-0003-1943-7360				Albala JS, 1997, GENOMICS, V46, P476, DOI 10.1006/geno.1997.5062; Beamish H, 2002, J BIOL CHEM, V277, P30515, DOI 10.1074/jbc.M203801200; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Braybrooke JP, 2000, J BIOL CHEM, V275, P29100, DOI 10.1074/jbc.M002075200; Brenneman MA, 2002, MOL CELL, V10, P387, DOI 10.1016/S1097-2765(02)00595-6; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P1653, DOI 10.1093/nar/26.7.1653; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cui S, 2003, J BIOL CHEM, V278, P1424, DOI 10.1074/jbc.M209407200; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Frei C, 2000, GENE DEV, V14, P81; French CA, 2002, J BIOL CHEM, V277, P19322, DOI 10.1074/jbc.M201402200; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; Gaymes TJ, 2002, ONCOGENE, V21, P2525, DOI 10.1038/sj.onc.1205331; GERMAN J, 1995, DERMATOL CLIN, V13, P7, DOI 10.1016/S0733-8635(18)30101-3; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Kawabata M, 1999, BIOCHEM BIOPH RES CO, V257, P156, DOI 10.1006/bbrc.1999.0413; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kurumizaka H, 2002, J BIOL CHEM, V277, P14315, DOI 10.1074/jbc.M105719200; Langland G, 2002, CANCER RES, V62, P2766; Liu N, 2002, NUCLEIC ACIDS RES, V30, P1009, DOI 10.1093/nar/30.4.1009; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Masson JY, 2001, P NATL ACAD SCI USA, V98, P8440, DOI 10.1073/pnas.111005698; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; O'Regan P, 2001, J BIOL CHEM, V276, P22148, DOI 10.1074/jbc.M102396200; Oakley TJ, 2002, DNA REPAIR, V1, P175, DOI 10.1016/S1568-7864(02)00002-2; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pittman DL, 1998, GENOMICS, V49, P103, DOI 10.1006/geno.1998.5226; Rafii S, 2002, HUM MOL GENET, V11, P1433, DOI 10.1093/hmg/11.12.1433; Rice MC, 1997, P NATL ACAD SCI USA, V94, P7417, DOI 10.1073/pnas.94.14.7417; Sigurdsson S, 2001, GENE DEV, V15, P3308, DOI 10.1101/gad.935501; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Sun H, 1999, NUCLEIC ACIDS RES, V27, P1978, DOI 10.1093/nar/27.9.1978; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; Thacker J, 2003, DNA REPAIR, V2, P655, DOI 10.1016/S1568-7864(03)00062-4; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Wu L, 2002, NUCLEIC ACIDS RES, V30, P4823, DOI 10.1093/nar/gkf611; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Wu X, 2001, NUCLEIC ACIDS RES, V29, P1765, DOI 10.1093/nar/29.8.1765; Yokoyama H, 2003, J BIOL CHEM, V278, P2767, DOI 10.1074/jbc.M210899200; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	67	67	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48357	48366		10.1074/jbc.M308838200	http://dx.doi.org/10.1074/jbc.M308838200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12975363	Green Published, hybrid			2022-12-25	WOS:000186731400121
J	Dietrich, A; Schnitzler, MMY; Emmel, J; Kalwa, H; Hofmann, T; Gudermann, T				Dietrich, A; Schnitzler, MMY; Emmel, J; Kalwa, H; Hofmann, T; Gudermann, T			N-linked protein glycosylation is a major determinant for basal TRPC3 and TRPC6 channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR POTENTIAL CHANNELS; CAPACITATIVE CA2+ ENTRY; CA2+-PERMEABLE CATION CHANNEL; MOUSE TRANSIENT RECEPTOR; CALCIUM-ENTRY; EXPRESSION; CELLS; ACTIVATION; CURRENTS; CLONING	The TRPC family of receptor-activated cation channels ( TRPC channels) can be subdivided into four subfamilies based on sequence homology as well as functional similarities. Members of the TRPC3/6/7 subfamily share common biophysical characteristics and are activated by diacylglycerol in a membrane-delimited manner. At present, it is only poorly understood whether members of the TRPC3/6/7 subfamily are functionally redundant or whether they serve distinct cellular roles. By electrophysiological and fluorescence imaging strategies we show that TRPC3 displays considerable constitutive activity, while TRPC6 is a tightly regulated channel. To identify potential molecular correlates accounting for the functional difference, we analyzed the glycosylation pattern of TRPC6 compared with TRPC3. Two NX(S/T) motifs in TRPC6 were mutated (Asn to Gln) by in vitro mutagenesis to delete one or both extracellular N-linked glycosylation sites. Immunoblotting analysis of HEK 293 cell lysates expressing TRPC6 wild type and mutants favors a model of TRPC6 that is dually glycosylated within the first (e1) and second extracelluar loop (e2) as opposed to the monoglycosylated TRPC3 channel (Vannier, B., Zhu, X., Brown, D., and Birnbaumer, L. (1998) J. Biol. Chem. 273, 8675 - 8679). Elimination of the e2 glycosylation site, missing in the monoglycosylated TRPC3, was sufficient to convert the tightly receptor-regulated TRPC6 into a constitutively active channel, displaying functional characteristics of TRPC3. Reciprocally, engineering of an additional second glycosylated site in TRPC3 to mimic the glycosylation status in TRPC6 markedly reduced TRPC3 basal activity. We conclude that the glycosylation pattern plays a pivotal role for the tight regulation of TRPC6 through phospholipase C-activating receptors.	Univ Marburg, Inst Pharmakol & Toxikol, D-35033 Marburg, Germany	Philipps University Marburg	Gudermann, T (corresponding author), Univ Marburg, Inst Pharmakol & Toxikol, Karl von Frisch Str 1, D-35033 Marburg, Germany.	guderman@staff.uni-marburg.de	Kalwa, Hermann/ABG-2323-2021; Dietrich, Alexander/G-8619-2013	Dietrich, Alexander/0000-0002-1168-8707				Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; FOZZARD HA, 2002, SCI STKE 2002, pE19; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Garcia RL, 1997, BIOCHEM BIOPH RES CO, V239, P279, DOI 10.1006/bbrc.1997.7458; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Hassock SR, 2002, BLOOD, V100, P2801, DOI 10.1182/blood-2002-03-0723; Hofmann T, 2000, BIOCHEM J, V351, P115, DOI 10.1042/0264-6021:3510115; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 2000, J MOL MED, V78, P14, DOI 10.1007/s001090050378; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Jung S, 2002, AM J PHYSIOL-CELL PH, V282, pC347, DOI 10.1152/ajpcell.00283.2001; Khanna R, 2001, J BIOL CHEM, V276, P34028, DOI 10.1074/jbc.M105248200; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.90.re1; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Putney JW, 2001, J CELL SCI, V114, P2223; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Trevino CL, 2001, FEBS LETT, V509, P119, DOI 10.1016/S0014-5793(01)03134-9; Vannier B, 1998, J BIOL CHEM, V273, P8675, DOI 10.1074/jbc.273.15.8675; Welsh DG, 2002, CIRC RES, V90, P248, DOI 10.1161/hh0302.105662; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Yu Y, 2003, AM J PHYSIOL-CELL PH, V284, pC316, DOI 10.1152/ajpcell.00125.2002; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	36	153	163	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47842	47852		10.1074/jbc.M302983200	http://dx.doi.org/10.1074/jbc.M302983200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12970363	hybrid			2022-12-25	WOS:000186731400061
J	Fleck, SL; Birdsall, B; Babon, J; Dluzewski, AR; Martin, SR; Morgan, WD; Angov, E; Kettleborough, CA; Feeney, J; Blackman, MJ; Holder, AA				Fleck, SL; Birdsall, B; Babon, J; Dluzewski, AR; Martin, SR; Morgan, WD; Angov, E; Kettleborough, CA; Feeney, J; Blackman, MJ; Holder, AA			Suramin and suramin analogues inhibit merozoite surface protein-1 secondary processing and erythrocyte invasion by the malaria parasite Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODY; SERINE-PROTEASE; CELL INVASION; BINDING; POLYANIONS; BLOCKING	Malarial merozoites invade erythrocytes; and as an essential step in this invasion process, the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 (MSP1(42)) is further cleaved to a 33-kDa N-terminal polypeptide (MSP1(33)) and an 19-kDa C-terminal fragment (MSP1(19)) in a secondary processing step. Suramin was shown to inhibit both merozoite invasion and MSP142 proteolytic cleavage. This polysulfonated naphthylurea bound directly to recombinant P. falciparum MSP1(42) (K-d = 0.2 muM) and to Plasmodium vivax MSP1(42) (K-d = 0.3 muM) as measured by fluorescence enhancement in the presence of the protein and by isothermal titration calorimetry. Suramin bound only slightly less tightly to the P. vivax MSP1(33) (K-d = 1.5 muM) secondary processing product ( fluorescence measurements), but very weakly to MSP1(19) (K-d similar to15 mM) (NMR measurements). Several residues in MSP1(19) were implicated in the interaction with suramin using NMR measurements. A series of symmetrical suramin analogues that differ in the number of aromatic rings and substitution patterns of the terminal naphthylamine groups was examined in invasion and processing assays. Two classes of analogue with either two or four bridging rings were found to be active in both assays, whereas two other classes without bridging rings were inactive. We propose that suramin and related compounds inhibit erythrocyte invasion by binding to MSP1 and by preventing its cleavage by the secondary processing protease. The results indicate that enzymatic events during invasion are suitable targets for drug development and validate the novel concept of an inhibitor binding to a macromolecular substrate to prevent its proteolysis by a protease.	Natl Inst Med Res, Div Parasitol, London NW7 1AA, England; Natl Inst Med Res, Div Mol Struct, London NW7 1AA, England; Natl Inst Med Res, Div Phys Biochem, London NW7 1AA, England; Med Res Council Technol, London NW7 1AD, England; Guys Hosp, Dept Immunol, Guys Kings & St Thomas Sch Med, London SE1 9RT, England; Walter Reed Army Inst Res, Dept Immunol, Silver Spring, MD 20910 USA	MRC National Institute for Medical Research; MRC National Institute for Medical Research; MRC National Institute for Medical Research; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Holder, AA (corresponding author), Natl Inst Med Res, Div Parasitol, London NW7 1AA, England.	aholder@nimr.mrc.ac.uk	Holder, Anthony A/A-7554-2013; babon, jeffrey j/B-9170-2013	Holder, Anthony A/0000-0002-8490-6058; babon, jeffrey j/0000-0002-5408-6239	MRC [MC_U117532067] Funding Source: UKRI; Medical Research Council [MC_U117532067] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Angov E, 2003, MOL BIOCHEM PARASIT, V128, P195, DOI 10.1016/S0166-6851(03)00077-X; Balaban IE, 1927, J CHEM SOC, P3068, DOI 10.1039/jr9270003068; Barale JC, 1999, P NATL ACAD SCI USA, V96, P6445, DOI 10.1073/pnas.96.11.6445; Blackman Michael J., 2000, Current Drug Targets, V1, P59, DOI 10.2174/1389450003349461; BLACKMAN MJ, 1992, MOL BIOCHEM PARASIT, V50, P307, DOI 10.1016/0166-6851(92)90228-C; BLACKMAN MJ, 1993, MOL BIOCHEM PARASIT, V62, P103, DOI 10.1016/0166-6851(93)90182-W; BLACKMAN MJ, 1994, METHOD CELL BIOL, V45, P213; BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; BLACKMAN MJ, 1994, J EXP MED, V180, P389, DOI 10.1084/jem.180.1.389; BRADDOCK PS, 1994, BRIT J CANCER, V69, P890, DOI 10.1038/bjc.1994.172; Cadene M, 1997, J BIOL CHEM, V272, P9950, DOI 10.1074/jbc.272.15.9950; CERAMI C, 1992, MOL BIOCHEM PARASIT, V54, P1, DOI 10.1016/0166-6851(92)90089-3; Clark DL, 1997, GLYCOCONJUGATE J, V14, P473, DOI 10.1023/A:1018551518610; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; COLLINS JM, 1986, J CLIN PHARMACOL, V26, P22; DALTON JP, 1991, EUR J BIOCHEM, V195, P789, DOI 10.1111/j.1432-1033.1991.tb15767.x; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; Fujiuchi S, 1997, ONCOLOGY, V54, P134; Gutteridge WE, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P449; Hackett F, 1999, MOL BIOCHEM PARASIT, V103, P183, DOI 10.1016/S0166-6851(99)00122-X; Hawking F, 1978, Adv Pharmacol Chemother, V15, P289, DOI 10.1016/S1054-3589(08)60486-X; HOLDER A, 2002, Patent No. 1180120; HOLDER AA, 1994, PARASITOLOGY, V108, pS5, DOI 10.1017/S0031182000075673; HOLDER AA, 1982, J EXP MED, V156, P1528, DOI 10.1084/jem.156.5.1528; KLEINE F. K., 1923, Deutsche Medizinische Wochenschrift, V49, P1039, DOI 10.1055/s-0028-1132332; KOPP R, 1990, CANCER RES, V50, P6490; MIDDAUGH CR, 1992, BIOCHEMISTRY-US, V31, P9016, DOI 10.1021/bi00152a044; Morgan WD, 1999, J MOL BIOL, V289, P113, DOI 10.1006/jmbi.1999.2753; MULLER HM, 1993, EMBO J, V12, P2881, DOI 10.1002/j.1460-2075.1993.tb05950.x; Olliaro PL, 1999, PHARMACOL THERAPEUT, V81, P91, DOI 10.1016/S0163-7258(98)00036-9; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; Polenova T, 1997, BIOCHEMISTRY-US, V36, P14202, DOI 10.1021/bi970297m; STEIN CA, 1993, CANCER RES, V53, P2239; Uthaipibull C, 2001, J MOL BIOL, V307, P1381, DOI 10.1006/jmbi.2001.4574; Winstanley PA, 2000, PARASITOL TODAY, V16, P146, DOI 10.1016/S0169-4758(99)01622-1; Xiao LH, 1996, INFECT IMMUN, V64, P1373, DOI 10.1128/IAI.64.4.1373-1378.1996	36	47	51	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47670	47677		10.1074/jbc.M306603200	http://dx.doi.org/10.1074/jbc.M306603200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13679371	hybrid			2022-12-25	WOS:000186731400041
J	Gusarova, V; Brodsky, JL; Fisher, EA				Gusarova, V; Brodsky, JL; Fisher, EA			Apolipoprotein B100 exit from the endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to very low density lipoprotein occurs post-ER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY SECRETORY PATHWAY; TRANSPORT VESICLES; MCA-RH7777 CELLS; TRANSFER PROTEIN; RAT HEPATOCYTES; B DEGRADATION; APO-B; MEMBRANE; TRANSLOCATION; APOPROTEIN	Hepatic apolipoprotein B100 (apoB100) associates with lipids to form dense lipoprotein particles in the endoplasmic reticulum (ER) and is further lipidated to very low density lipoproteins ( VLDL). Because the VLDL diameter can exceed 200 nm, classical ER-derived vesicles may be unable to accommodate VLDLs. Using hepatic membranes and cytosol to reconstitute ER budding, apoB100-containing vesicles sedimented distinct from those harboring more typical cargo but contained Sec23. Moreover, ER exit of apoB was inhibited by dominant-negative Sar1. Budding required Sar1 regardless of whether oleic acid (OA) was added to stimulate apoB lipidation; therefore, either large apoB100-lipoproteins reside in secretory vesicles, or full lipidation occurs post-ER. Using membranes from cells incubated in the presence or absence of OA, we determined that apoB100-lipoproteins in ER vesicles had not become lipidated to VLDLs. VLDL particles resided in the Golgi, but not the ER, after fractionation of OA-treated cells. We conclude that apoB100-lipoproteins exit the ER in COPII vesicles, but under conditions favorable for VLDL formation final lipid loading occurs post-ER.	CUNY Mt Sinai Sch Med, Dept Med & Biochem, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Mol Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Cardiovasc Inst, New York, NY 10029 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Fisher, EA (corresponding author), CUNY Mt Sinai Sch Med, Dept Med & Biochem, Box 1269,1 Gustave Levy Pl, New York, NY 10029 USA.	edward.fisher@mssm.edu	Fisher, Edward/ABE-7469-2020; Adiels, Martin/C-9278-2011		NHLBI NIH HHS [HL58541] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058541] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Asp L, 2000, J BIOL CHEM, V275, P26285, DOI 10.1074/jbc.M003520200; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BAMBERGER MJ, 1990, P NATL ACAD SCI USA, V87, P2390, DOI 10.1073/pnas.87.7.2390; Barlowe C, 2000, TRAFFIC, V1, P371, DOI 10.1034/j.1600-0854.2000.010501.x; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Barlowe C, 2002, CURR OPIN CELL BIOL, V14, P417, DOI 10.1016/S0955-0674(02)00348-4; Bonifacino J. S., 1998, CURRENT PROTOCOLS CE; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1994, J BIOL CHEM, V269, P25879; Cartwright IJ, 2001, J BIOL CHEM, V276, P48048, DOI 10.1074/jbc.M104229200; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; Du XB, 1998, J CELL BIOL, V141, P585, DOI 10.1083/jcb.141.3.585; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gusarova V, 2001, J BIOL CHEM, V276, P24891, DOI 10.1074/jbc.M100633200; HIGGINS JA, 1988, FEBS LETT, V232, P405, DOI 10.1016/0014-5793(88)80780-4; Ingram MF, 1996, J LIPID RES, V37, P2202; Jones B, 2003, NAT GENET, V34, P29, DOI 10.1038/ng1145; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; Kummrow E, 2002, J LIPID RES, V43, P2155, DOI 10.1194/jlr.M200249-JLR200; Liang JS, 2000, J BIOL CHEM, V275, P32003, DOI 10.1074/jbc.M004646200; LIN YG, 1995, BBA-LIPID LIPID MET, V1256, P88, DOI 10.1016/0005-2760(95)00006-X; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; Schekman R, 1997, CELL, V90, P197, DOI 10.1016/S0092-8674(00)80326-8; Shimoni Y, 2000, J CELL BIOL, V151, P973, DOI 10.1083/jcb.151.5.973; Siddiqi SA, 2003, J CELL SCI, V116, P415, DOI 10.1242/jcs.00215; Stephens DJ, 2002, J CELL SCI, V115, P1149; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Tran K, 2002, J BIOL CHEM, V277, P31187, DOI 10.1074/jbc.M200249200; Wendler F, 2001, TRAFFIC, V2, P606, DOI 10.1034/j.1600-0854.2001.20903.x; Xu Y, 1998, J BIOL CHEM, V273, P21783, DOI 10.1074/jbc.273.34.21783; Yoo JS, 2002, J BIOL CHEM, V277, P11401, DOI 10.1074/jbc.M110263200	42	104	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48051	48058		10.1074/jbc.M306898200	http://dx.doi.org/10.1074/jbc.M306898200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12960170	hybrid			2022-12-25	WOS:000186731400084
J	Jenkins-Kruchten, AE; Bennaars-Eiden, A; Ross, JR; Shen, WJ; Kraemer, FB; Bernlohr, DA				Jenkins-Kruchten, AE; Bennaars-Eiden, A; Ross, JR; Shen, WJ; Kraemer, FB; Bernlohr, DA			Fatty acid-binding protein-hormone-sensitive lipase interaction - Fatty acid dependence on binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; INSULIN-RESISTANCE; MURINE ADIPOCYTE; LIPOLYSIS; AP2; EXPRESSION; CELLS; PURIFICATION; MUTATION; OBESITY	Adipose lipolysis is mediated, in part, via interaction of fatty acid-binding protein ( FABP) with hormone-sensitive lipase (HSL). Mice with reduced FABP content in fat (adipocyte FABP null) exhibit diminished fat cell lipolysis, whereas transgenic mice with increased FABP content in fat (epithelial FABP transgenic) exhibit enhanced lipolysis. To examine the relationship between the binding of FABP to HSL and activation of catalytic activity, isothermal titration microcalorimetry as well as kinetic analysis using a variety of FABP isoforms have been employed. In the absence of fatty acids, no FABP-HSL association could be demonstrated for any FABP form. However, in the presence of 10 muM oleate, A-FABP and E-FABP each bound to HSL with high affinity (K-d of 0.5 and 3 nM, respectively) in a similar to1:1 molar stoichiometry, whereas liver FABP and intestinal FABP did not exhibit any association. To compare binding to catalysis, each FABP isoform was incubated with HSL in vitro, and enzymatic activity was assessed. Importantly, each FABP form stimulated HSL activity similar to2-fold using cholesteryl oleate as substrate but exhibited no activation using p-nitrophenyl butyrate. The activation by A-FABP was dependent upon its fatty acid binding properties because a non-fatty acid binding mutant, R126Q, failed to activate HSL. These results suggest that binding and activation of HSL by FABPs are separate and distinct functions and that HSL contains a site for fatty acid binding that allows for FABP association.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Stanford Univ, Dept Med, Div Endocrinol, Stanford, CA 94305 USA; Vet Adm Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	University of Minnesota System; University of Minnesota Twin Cities; Stanford University	Bernlohr, DA (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 321 Church St SE, Minneapolis, MN 55455 USA.		Kraemer, Fredric/AAC-3633-2019	Shen, Wen-Jun/0000-0001-5150-1698; Kraemer, Fredric/0000-0003-2468-7807	NHLBI NIH HHS [T32-HL07741] Funding Source: Medline; NIDDK NIH HHS [DK 46942, DK 53189] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK053189, R01DK053189, R01DK046942] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boord JB, 2002, ARTERIOSCL THROM VAS, V22, P1686, DOI 10.1161/01.ATV.0000033090.81345.E6; Coe NR, 1999, J LIPID RES, V40, P967; Contreras JA, 1996, J BIOL CHEM, V271, P31426, DOI 10.1074/jbc.271.49.31426; COOK KG, 1981, FEBS LETT, V132, P10, DOI 10.1016/0014-5793(81)80416-4; DEREWENDA U, 1994, J LIPID RES, V35, P524; FREDRIKSON G, 1986, BIOCHIM BIOPHYS ACTA, V876, P288, DOI 10.1016/0005-2760(86)90286-9; Grober J, 2003, J BIOL CHEM, V278, P6510, DOI 10.1074/jbc.M208513200; Hertzel AV, 2002, J LIPID RES, V43, P2105, DOI 10.1194/jlr.M200227-JLR200; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; Holm C, 1997, METHOD ENZYMOL, V286, P45; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Jenkins AE, 2002, BIOCHEMISTRY-US, V41, P2022, DOI 10.1021/bi015769i; Kane CD, 1996, ANAL BIOCHEM, V233, P197, DOI 10.1006/abio.1996.0028; KAWAMURA M, 1981, P NATL ACAD SCI-BIOL, V78, P732, DOI 10.1073/pnas.78.2.732; KRAEMER FB, 1993, J LIPID RES, V34, P663; Kraemer FB, 2002, J LIPID RES, V43, P1585, DOI 10.1194/jlr.R200009-JLR200; Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Maeda K, 2003, DIABETES, V52, P300, DOI 10.2337/diabetes.52.2.300; MATARESE V, 1988, J BIOL CHEM, V263, P14544; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; Richieri GV, 1998, J BIOL CHEM, V273, P7397, DOI 10.1074/jbc.273.13.7397; Scheja L, 1999, DIABETES, V48, P1987, DOI 10.2337/diabetes.48.10.1987; SHA RS, 1993, J BIOL CHEM, V268, P7885; Shen WJ, 1999, P NATL ACAD SCI USA, V96, P5528, DOI 10.1073/pnas.96.10.5528; Shen WJ, 2001, J BIOL CHEM, V276, P49443, DOI 10.1074/jbc.M104095200; Simpson MA, 1999, MOL CELL BIOCHEM, V192, P33, DOI 10.1023/A:1006819715146; TORNQVIST H, 1972, J LIPID RES, V13, P424; Uysal KT, 2000, ENDOCRINOLOGY, V141, P3388, DOI 10.1210/en.141.9.3388; Winzell MS, 2001, DIABETES, V50, P2225, DOI 10.2337/diabetes.50.10.2225; XU ZH, 1991, J BIOL CHEM, V266, P14367	32	81	87	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47636	47643		10.1074/jbc.M307680200	http://dx.doi.org/10.1074/jbc.M307680200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13129924	hybrid			2022-12-25	WOS:000186731400037
J	Kaneko, T; Kumasaka, T; Ganbe, T; Sato, T; Miyazawa, K; Kitamura, N; Tanaka, N				Kaneko, T; Kumasaka, T; Ganbe, T; Sato, T; Miyazawa, K; Kitamura, N; Tanaka, N			Structural insight into modest binding of a non-PXXP ligand to the signal transducing adaptor molecule-2 Src homology 3 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL SH3 DOMAIN; PROTEIN; RECOGNITION; PEPTIDE; MOTIF; IDENTIFICATION; UBIQUITIN; GRB2; HRS; ASSOCIATION	Although some exceptional motifs have been identified, it is well known that the PXXP motif is the motif of ligand proteins generally recognized by the Src homology 3 (SH3) domain. SH3-ligand interactions are usually weak, with ordinary K-D similar to 10 muM. The structural basis for a tight and specific association (K-D = 0.24 muM) between Gads SH3 and a novel motif, PX(V/I)(D/N) RXXKP, was revealed in a previous structural analysis of the complex formed between them. In this paper, we report the crystal structure of the signal transducing adaptor molecule-2 (STAM2) SH3 domain in complex with a peptide with a novel motif derived from a ligand protein, UBPY. The derived K-D value for this complex is 27 muM. The notable difference in affinity for these parallel complexes may be explained because the STAM2 SH3 structure does not provide a specificity pocket for binding, whereas the Gads SH3 structure does. Instead, the structure of STAM2 SH3 is analogous to that of Grb2 SH3 which, in addition to normal PXXP ligands, has also been shown to moderately recognize the novel motif discussed herein. Thus, the extremely tight interaction observed between Gads SH3 and the novel motif is caused not by an innate ability of the novel motif but rather by an evolutionary change in the Gads SH3 domain. Instead, SH3 domains of STAM2 and Grb2 retain the moderate characteristics of recognizing their ligand proteins like other SH3 domains for appropriate transient interactions between signaling molecules.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan	Tokyo Institute of Technology; Tokyo Institute of Technology; University of Tokyo	Kumasaka, T (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Life Sci, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.	tkumasak@bio.titech.ac.jp	Kaneko, Tomonori/H-4941-2011; Kumasaka, Takashi/D-7428-2018; MIYAZAWA, KEIJI/I-9713-2014	Kumasaka, Takashi/0000-0001-9289-1557; Kaneko, Tomonori/0000-0001-5448-9639				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berry DM, 2002, CURR BIOL, V12, P1336, DOI 10.1016/S0960-9822(02)01038-2; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen CL, 2000, J MOL CATAL B-ENZYM, V8, P213, DOI 10.1016/S1381-1177(99)00059-4; Endo K, 2000, FEBS LETT, V477, P55, DOI 10.1016/S0014-5793(00)01760-9; Inagaki F, 1999, Tanpakushitsu Kakusan Koso, V44, P355; Kami K, 2002, EMBO J, V21, P4268, DOI 10.1093/emboj/cdf428; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; Komada M, 2001, BIOCHEM BIOPH RES CO, V281, P1065, DOI 10.1006/bbrc.2001.4441; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larson SM, 2000, PROTEIN SCI, V9, P2170, DOI 10.1110/ps.9.11.2170; LIM WA, 1994, PROTEIN SCI, V3, P1261, DOI 10.1002/pro.5560030812; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Liu Q, 2003, MOL CELL, V11, P471, DOI 10.1016/S1097-2765(03)00046-7; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Lohi O, 2001, FEBS LETT, V508, P287, DOI 10.1016/S0014-5793(01)03079-4; Mayer BJ, 2001, J CELL SCI, V114, P1253; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mizuno E, 2003, MOL BIOL CELL, V14, P3675, DOI 10.1091/mbc.E02-12-0823; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishida M, 2001, EMBO J, V20, P2995, DOI 10.1093/emboj/20.12.2995; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; Tong AHY, 2002, SCIENCE, V295, P321, DOI 10.1126/science.1064987; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; Yamasaki S, 2003, MOL CELL BIOL, V23, P2515, DOI 10.1128/MCB.23.7.2515-2529.2003	36	42	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48162	48168		10.1074/jbc.M306677200	http://dx.doi.org/10.1074/jbc.M306677200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13129930	hybrid			2022-12-25	WOS:000186731400098
J	Kirchner, U; Westphal, AH; Muller, R; van Berkel, WJH				Kirchner, U; Westphal, AH; Muller, R; van Berkel, WJH			Phenol hydroxylase from Bacillus thermoglucosidasius A7, a two-protein component monooxygenase with a dual role for FAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-HYDROXYBENZOATE HYDROXYLASE; ARCHAEON ARCHAEOGLOBUS-FULGIDUS; NADPH-FMN OXIDOREDUCTASE; FLAVIN-REDUCTASE-P; ESCHERICHIA-COLI; NAD(P)H-FLAVIN OXIDOREDUCTASE; PSEUDOMONAS-FLUORESCENS; CRYSTAL-STRUCTURE; 4-HYDROXYPHENYLACETATE 3-MONOOXYGENASE; SUBSTRATE-SPECIFICITY	A novel phenol hydroxylase (PheA) that catalyzes the first step in the degradation of phenol in Bacillus thermoglucosidasius A7 is described. The two-protein system, encoded by the pheA1 and pheA2 genes, consists of an oxygenase (PheA1) and a flavin reductase (PheA2) and is optimally active at 55 degreesC. PheA1 and PheA2 were separately expressed in recombinant Escherichia coli BL21 (DE3) pLysS cells and purified to apparent homogeneity. The pheA1 gene codes for a protein of 504 amino acids with a predicted mass of 57.2 kDa. PheA1 exists as a homodimer in solution and has no enzyme activity on its own. PheA1 catalyzes the efficient ortho-hydroxylation of phenol to catechol when supplemented with PheA2 and FAD/NADH. The hydroxylase activity is strictly FAD-dependent, and neither FMN nor riboflavin can replace FAD in this reaction. The pheA2 gene codes for a protein of 161 amino acids with a predicted mass of 17.7kDa. PheA2 is also a homodimer, with each subunit containing a highly fluorescent FAD prosthetic group. PheA2 catalyzes the NADH-dependent reduction of free flavins according to a Ping Pong Bi Bi mechanism. PheA2 is structurally related to ferric reductase, an NAD(P) H-dependent reductase from the hyperthermophilic Archaea Archaeoglobus fulgidus that catalyzes the flavin-mediated reduction of iron complexes. However, PheA2 displays no ferric reductase activity and is the first member of a newly recognized family of short-chain flavin reductases that use FAD both as a substrate and as a prosthetic group.	Univ Wageningen & Res Ctr, Biochem Lab, NL-6703 HA Wageningen, Netherlands; Tech Univ Hamburg, Dept Tech Biochem, D-21071 Hamburg, Germany	Wageningen University & Research; Hamburg University of Technology	van Berkel, WJH (corresponding author), Univ Wageningen & Res Ctr, Biochem Lab, Dreijenlaan 3, NL-6703 HA Wageningen, Netherlands.	willem.vanberkel@wur.nl	van Berkel, Willem J.H./O-2431-2014; Westphal, Adrie Herman/L-3517-2019	van Berkel, Willem J.H./0000-0002-6551-2782; Westphal, Adrie Herman/0000-0003-4264-6267				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARUNACHALAM U, 1994, J BIOL CHEM, V269, P150; ARUNACHALAM U, 1994, J BIOL CHEM, V269, P11795; ARUNACHALAM U, 1992, J BIOL CHEM, V267, P25848; Beltrametti F, 1997, APPL ENVIRON MICROB, V63, P2232, DOI 10.1128/AEM.63.6.2232-2239.1997; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chaiyen P, 2001, EUR J BIOCHEM, V268, P5550, DOI 10.1046/j.1432-1033.2001.02490.x; Chiu HJ, 2001, STRUCTURE, V9, P311, DOI 10.1016/S0969-2126(01)00589-5; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; DEJONG E, 1992, EUR J BIOCHEM, V208, P651; DeLano W, 2002, PYMOL 0 99; Duffner FM, 2000, GENE, V256, P215, DOI 10.1016/S0378-1119(00)00352-8; Duffner FM, 1997, SYST APPL MICROBIOL, V20, P602, DOI 10.1016/S0723-2020(97)80032-X; Duffner FM, 1998, FEMS MICROBIOL LETT, V161, P37, DOI 10.1016/S0378-1097(98)00047-0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Enroth C, 1998, STRUCTURE, V6, P605, DOI 10.1016/S0969-2126(98)00062-8; ENTSCH B, 1995, FASEB J, V9, P476, DOI 10.1096/fasebj.9.7.7737455; Eppink MHM, 1999, J MOL BIOL, V292, P87, DOI 10.1006/jmbi.1999.3015; Eppink MHM, 1997, J BACTERIOL, V179, P6680, DOI 10.1128/jb.179.21.6680-6687.1997; ESCHENBRENNER M, 1995, J BIOL CHEM, V270, P20550, DOI 10.1074/jbc.270.35.20550; Fieschi F, 1995, J BIOL CHEM, V270, P30392, DOI 10.1074/jbc.270.51.30392; Filisetti L, 2003, J BIOL CHEM, V278, P296, DOI 10.1074/jbc.M209689200; Fromm H J, 1979, Methods Enzymol, V63, P467; Galan B, 2000, J BACTERIOL, V182, P627, DOI 10.1128/JB.182.3.627-636.2000; GATTI DL, 1994, SCIENCE, V266, P110, DOI 10.1126/science.7939628; Gray KA, 1996, NAT BIOTECHNOL, V14, P1705, DOI 10.1038/nbt1296-1705; GURUJEYALAKSHMI G, 1989, APPL ENVIRON MICROB, V55, P500, DOI 10.1128/AEM.55.2.500-502.1989; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; Hubner A, 1998, APPL ENVIRON MICROB, V64, P2086; Ingelman M, 1999, BIOCHEMISTRY-US, V38, P7040, DOI 10.1021/bi982849m; Jeffers CE, 2003, BIOCHEMISTRY-US, V42, P529, DOI 10.1021/bi026877n; Jeffers CE, 2001, BIOCHEMISTRY-US, V40, P1749, DOI 10.1021/bi0024310; KENDREW SG, 1995, J BIOL CHEM, V270, P17339, DOI 10.1074/jbc.270.29.17339; KIM IC, 1995, APPL ENVIRON MICROB, V61, P1252, DOI 10.1128/AEM.61.4.1252-1256.1995; Koike H, 1998, J MOL BIOL, V280, P259, DOI 10.1006/jmbi.1998.1871; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEI BF, 1994, J BACTERIOL, V176, P3552, DOI 10.1128/JB.176.12.3552-3558.1994; Lei BF, 1998, BIOCHEMISTRY-US, V37, P14623, DOI 10.1021/bi981841+; Liepinsh E, 1997, NAT STRUCT BIOL, V4, P975, DOI 10.1038/nsb1297-975; Louie TM, 2003, BIOCHEMISTRY-US, V42, P7509, DOI 10.1021/bi034092r; Louie TM, 2002, J BIOL CHEM, V277, P39450, DOI 10.1074/jbc.M206339200; Low JC, 2003, PHOTOCHEM PHOTOBIOL, V77, P446, DOI 10.1562/0031-8655(2003)077<0446:ETEFIV>2.0.CO;2; MASSEY V, 1994, J BIOL CHEM, V269, P22459; May BJ, 2001, P NATL ACAD SCI USA, V98, P3460, DOI 10.1073/pnas.051634598; Mayhew S G, 1980, Methods Enzymol, V66, P217; Medina M, 1998, BIOCHEMISTRY-US, V37, P2715, DOI 10.1021/bi971795y; Moiseeva OV, 2002, J BACTERIOL, V184, P5282, DOI 10.1128/JB.184.19.5282-5292.2002; Moonen MJH, 2002, ADV SYNTH CATAL, V344, P1023, DOI 10.1002/1615-4169(200212)344:10<1023::AID-ADSC1023>3.0.CO;2-T; Mutzel A, 1996, APPL MICROBIOL BIOT, V46, P593, DOI 10.1007/s002530050866; Niviere V, 1999, J BIOL CHEM, V274, P18252, DOI 10.1074/jbc.274.26.18252; Niviere V, 1998, BIOCHEMISTRY-US, V37, P11879, DOI 10.1021/bi980396f; Palfey BA, 1999, BIOCHEMISTRY-US, V38, P1153, DOI 10.1021/bi9826613; PALFEY BA, 1996, COMPREHENSIVE BIOCH, P83; Parry RJ, 1997, J BIOL CHEM, V272, P23303, DOI 10.1074/jbc.272.37.23303; Reinscheid UM, 1997, BIODEGRADATION, V7, P455, DOI 10.1007/BF00115292; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHREUDER HA, 1994, BIOCHEMISTRY-US, V33, P10161, DOI 10.1021/bi00199a044; Sen Gupta S, 2002, SCIENCE, V296, P326, DOI 10.1126/science.1069297; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Takami H, 2002, NUCLEIC ACIDS RES, V30, P3927, DOI 10.1093/nar/gkf526; TAKIZAWA N, 1995, J FERMENT BIOENG, V80, P318, DOI 10.1016/0922-338X(95)94198-Z; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P13531, DOI 10.1021/bi961400v; THIBAUT D, 1995, J BACTERIOL, V177, P5199, DOI 10.1128/jb.177.18.5199-5205.1995; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Timmis KN, 1999, TRENDS BIOTECHNOL, V17, P201, DOI 10.1016/S0167-7799(98)01295-5; UETZ T, 1992, J BACTERIOL, V174, P1179, DOI 10.1128/jb.174.4.1179-1188.1992; Vadas A, 1999, J BIOL CHEM, V274, P36715, DOI 10.1074/jbc.274.51.36715; van den Berg WAM, 2000, EUR J BIOCHEM, V267, P666, DOI 10.1046/j.1432-1327.2000.01032.x; VANBERKEL WJH, 1991, EUR J BIOCHEM, V197, P769; VANBERKEL WJH, 1989, EUR J BIOCHEM, V179, P307; vanderBolt FJT, 1997, BIOCHEMISTRY-US, V36, P14192, DOI 10.1021/bi971213c; Wang J, 2002, P NATL ACAD SCI USA, V99, P608, DOI 10.1073/pnas.022640199; Waterfield NR, 2001, TRENDS MICROBIOL, V9, P185, DOI 10.1016/S0966-842X(01)01978-3; Xi L, 1997, BIOCHEM BIOPH RES CO, V230, P73, DOI 10.1006/bbrc.1996.5878; Xu D, 2002, BIOCHEMISTRY-US, V41, P13627, DOI 10.1021/bi020446n; Xu YR, 1997, J BACTERIOL, V179, P1112, DOI 10.1128/jb.179.4.1112-1116.1997; Xun LY, 2000, APPL ENVIRON MICROB, V66, P481, DOI 10.1128/AEM.66.2.481-486.2000	80	115	119	3	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47545	47553		10.1074/jbc.M307397200	http://dx.doi.org/10.1074/jbc.M307397200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12968028	hybrid			2022-12-25	WOS:000186731400026
J	Wen, KK; Rubenstein, PA				Wen, KK; Rubenstein, PA			Biochemical consequences of the cardiofunk (R177H) mutation in yeast actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRYPTOPHAN FLUORESCENCE; PHOSPHATE RELEASE; BINDING SITE; BETA-ACTIN; POLYMERIZATION; FILAMENTS; RESIDUES; MUTANT; ASSAY	The zebrafish cardiofunk actin mutation, R177H, causes abnormal heart development. We have introduced this mutation into yeast actin to assess its biochemical consequences. R177H G-actin exhibited reduced thermal stability and an accelerated nucleotide exchange rate. R177H actin has an increased critical concentration and polymerizes with a greatly extended nucleation phase but a faster elongation process, suggesting that significant fragmentation accompanies filament formation. P-i release from R177H actin is tightly coupled to polymerization, as with wild type (WT) actin, suggesting that the R177H mutation does not affect ATPase activity and Pi release. R177H actin shows no polymerization-dependent decrease in intrinsic Trp fluorescence, and the fluorescence yield of a pyrene at Cys(374) is decreased. An equivalent amount of WT actin significantly but not completely rescues the mutant's polymerization defect. Tropomyosin greatly exacerbates the elongation of the nucleation phase of R177H actin but slightly decreases its critical concentration. It has only a slight effect on a 1: 1 WT/mutant mixture. The defects we observed with R177H actin in vitro indicate that Arg(177) is crucial for the control of the structural integrity of the actin monomer and the actin filament and provide insight into the defects caused by this mutation in zebrafish cardiogenesis.	Univ Iowa, Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Rubenstein, PA (corresponding author), Univ Iowa, Carver Coll Med, Dept Biochem, 51 Newton Rd, Iowa City, IA 52242 USA.			Rubenstein, Peter/0000-0003-1225-4414	NIAID NIH HHS [AI45728] Funding Source: Medline; NIGMS NIH HHS [GM33689] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Buzan JM, 1996, P NATL ACAD SCI USA, V93, P91, DOI 10.1073/pnas.93.1.91; COOK RK, 1992, J BIOL CHEM, V267, P9430; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Doyle TC, 2001, BIOPHYS J, V80, P427, DOI 10.1016/S0006-3495(01)76025-0; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; Du JY, 1998, BIOCHEMISTRY-US, V37, P13276, DOI 10.1021/bi981117r; HITCHCOCKDEGREGORI SE, 1988, BIOCHEMISTRY-US, V27, P9182, DOI 10.1021/bi00426a016; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Landis C, 1999, J BIOL CHEM, V274, P31279, DOI 10.1074/jbc.274.44.31279; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Schuler H, 2000, EUR J BIOCHEM, V267, P4054, DOI 10.1046/j.1432-1033.2000.01466.x; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SELDEN LA, 1994, ADV EXP MED BIOL, V358, P51; SIKORSKI RS, 1989, GENETICS, V122, P19; WANG YL, 1981, P NATL ACAD SCI-BIOL, V78, P5503, DOI 10.1073/pnas.78.9.5503; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; WEGNER A, 1988, J BIOL CHEM, V263, P13739; WEIGT C, 1989, FEBS LETT, V246, P181, DOI 10.1016/0014-5793(89)80279-0; Wen KK, 2002, J BIOL CHEM, V277, P41101, DOI 10.1074/jbc.M204025200; Wen KK, 2000, J BIOL CHEM, V275, P40594, DOI 10.1074/jbc.M007201200; Wong WNW, 2001, J MUSCLE RES CELL M, V22, P665, DOI 10.1023/A:1016354308436; Wriggers W, 1999, PROTEINS, V35, P262, DOI 10.1002/(SICI)1097-0134(19990501)35:2<262::AID-PROT11>3.0.CO;2-N; Yao XY, 2002, J BIOL CHEM, V277, P22875, DOI 10.1074/jbc.M201685200	25	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48386	48394		10.1074/jbc.M308980200	http://dx.doi.org/10.1074/jbc.M308980200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13129918	hybrid			2022-12-25	WOS:000186731400124
J	Liu, XQ; Yang, J; Meng, Q				Liu, XQ; Yang, J; Meng, Q			Four inteins and three group II introns encoded in a bacterial ribonucleotide reductase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; HOMING ENDONUCLEASES; PROTEIN; MULTIPLE; SEQUENCE; ELEMENTS; DNA; AUTOPROTEOLYSIS; INVASION; DATABASE	A bacterial ribonucleotide reductase gene was found to encode four inteins and three group II introns in the oceanic N-2-fixing cyanobacterium Trichodesmium erythraeum. The 13,650-bp ribonucleotide reductase gene is divided into eight extein- or exon-coding sequences that together encode a 768-amino acid mature ribonucleotide reductase protein, with 83% of the gene sequence encoding introns and inteins. The four inteins are encoded on the second half of the gene, and each has conserved sequence motifs for a protein-splicing domain and an endonuclease domain. These four inteins, together with known inteins, define five intein insertion sites in ribonucleotide reductase homologues. Two of the insertion sites are 10 amino acids apart and next to key catalytic residues of the enzyme. Protein-splicing activities of all four inteins were demonstrated in Escherichia coli. The four inteins coexist with three group II introns encoded on the first half of the same gene, which suggests a breakdown of the presumed barrier against intron insertion in this bacterial conserved protein-coding gene.	Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University	Liu, XQ (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada.	pxqliu@dal.ca						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amitai G, 2003, MOL MICROBIOL, V47, P61, DOI 10.1046/j.1365-2958.2003.03283.x; Belfort M, 1995, J BIOL CHEM, V270, P30237, DOI 10.1074/jbc.270.51.30237; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; Belfort Marlene, 2002, P761; Bonen L, 2001, TRENDS GENET, V17, P322, DOI 10.1016/S0168-9525(01)02324-1; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; Cho G, 1997, J MOL EVOL, V44, P573, DOI 10.1007/PL00006180; Cho Y, 1998, P NATL ACAD SCI USA, V95, P14244, DOI 10.1073/pnas.95.24.14244; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; Dai LX, 2003, NUCLEIC ACIDS RES, V31, P424, DOI 10.1093/nar/gkg049; Dai LX, 2002, NUCLEIC ACIDS RES, V30, P1091, DOI 10.1093/nar/30.5.1091; Derbyshire V, 1998, P NATL ACAD SCI USA, V95, P1356, DOI 10.1073/pnas.95.4.1356; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Edgell DR, 1996, CURR BIOL, V6, P385, DOI 10.1016/S0960-9822(02)00502-X; Edgell DR, 2000, J BACTERIOL, V182, P5281, DOI 10.1128/JB.182.19.5281-5289.2000; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; Gimble FS, 2000, FEMS MICROBIOL LETT, V185, P99; Gleason FK, 2002, J BACTERIOL, V184, P6544, DOI 10.1128/JB.184.23.6544-6550.2002; Gogarten JP, 2002, ANNU REV MICROBIOL, V56, P263, DOI 10.1146/annurev.micro.56.012302.160741; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Ichiyanagi K, 2000, J MOL BIOL, V300, P889, DOI 10.1006/jmbi.2000.3873; Ichiyanagi K, 2002, MOL MICROBIOL, V46, P1259, DOI 10.1046/j.1365-2958.2002.03226.x; Komori K, 1999, NUCLEIC ACIDS RES, V27, P4167, DOI 10.1093/nar/27.21.4167; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; Lambowitz AM., 1999, GROUP GROUP 2 RIBOZY, P451; Landthaler M, 1999, P NATL ACAD SCI USA, V96, P7005, DOI 10.1073/pnas.96.12.7005; Lazarevic V, 2001, NUCLEIC ACIDS RES, V29, P3212, DOI 10.1093/nar/29.15.3212; Lazarevic V, 1998, P NATL ACAD SCI USA, V95, P1692, DOI 10.1073/pnas.95.4.1692; Liu XQ, 2003, J BIOL CHEM, V278, P26315, DOI 10.1074/jbc.C300202200; Liu XQ, 2000, ANNU REV GENET, V34, P61, DOI 10.1146/annurev.genet.34.1.61; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; Nakamura Y, 2002, DNA RES, V9, P123, DOI 10.1093/dnares/9.4.123; OHMANHEDEN M, 1993, MOL MICROBIOL, V7, P975, DOI 10.1111/j.1365-2958.1993.tb01189.x; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Perler FB, 2002, NUCLEIC ACIDS RES, V30, P383, DOI 10.1093/nar/30.1.383; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; Pietrokovski S, 2001, TRENDS GENET, V17, P465, DOI 10.1016/S0168-9525(01)02365-4; Sintchak MD, 2002, NAT STRUCT BIOL, V9, P293, DOI 10.1038/nsb774; Stoltzfus A, 1997, P NATL ACAD SCI USA, V94, P10739, DOI 10.1073/pnas.94.20.10739; Toro N, 2003, ENVIRON MICROBIOL, V5, P143, DOI 10.1046/j.1462-2920.2003.00398.x; Wu H, 1998, BBA-PROTEIN STRUCT M, V1387, P422, DOI 10.1016/S0167-4838(98)00157-5; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x; Zimmerly S, 2001, NUCLEIC ACIDS RES, V29, P1238, DOI 10.1093/nar/29.5.1238; ZUKER M, 2003, NUCLEIC ACIDS RES, V31, P1	48	22	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46826	46831		10.1074/jbc.M309575200	http://dx.doi.org/10.1074/jbc.M309575200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12975359	hybrid			2022-12-25	WOS:000186569400074
J	Nair, VD; Sealfon, SC				Nair, VD; Sealfon, SC			Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D-2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; SRC-DEPENDENT PHOSPHORYLATION; BETA(2) ADRENERGIC-RECEPTOR; PARKINSONS-DISEASE; COUPLED RECEPTOR; TYROSINE KINASE; MAP KINASE; C-SRC; PHOSPHATIDYLINOSITOL 3-KINASE	Bromocriptine, acting through the dopamine D-2 receptor, provides robust protection against apoptosis induced by oxidative stress in PC12-D2R and immortalized nigral dopamine cells. We now report the characterization of the D-2 receptor signaling pathways mediating the cytoprotection. Bromocriptine caused protein kinase B (Akt) activation in PC12-D2R cells and the inhibition of either phosphoinositide (PI)3-kinase, epidermal growth factor receptor (EGFR), or c-Src eliminated the Akt activation and the cytoprotective effects of bromocriptine against oxidative stress. Co-immunoprecipitation studies showed that the D-2 receptor forms a complex with the EGFR and c-Src that was augmented by bromocriptine, suggesting a cross-talk between these proteins in mediating the activation of Akt. EGFR repression by inhibitor or by RNA interference eliminated the activation of Akt by bromocriptine. D-2 receptor stimulation by bromocriptine induced c-Src tyrosine 418 phosphorylation and EGFR phosphorylation specifically at tyrosine 845, a known substrate of Src kinase. Furthermore, Src tyrosine kinase inhibitor or dominant negative Src interfered with Akt translocation and phosphorylation. Thus, the predominant signaling cascade mediating cytoprotection by the D-2 receptor involves c-Src/EGFR transactivation by D-2 receptor, activating PI 3-kinase and Akt. We also found that the agonist pramipexole failed to stimulate activation of Akt in PC12-D2R cells, providing an explanation for our previous observations that, despite efficiently activating G-protein signaling, this agonist had little cytoprotective activity in this experimental system. These results support the hypothesis that specific dopamine agonists stabilize distinct conformations of the D-2 receptor that differ in their coupling to G-proteins and to a cytoprotective c-Src/EGFR-mediated PI-3 kinase/Akt pathway.	Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Sealfon, SC (corresponding author), Mt Sinai Sch Med, Dept Neurol, Box 1137,1 Gustave L Levy Pl, New York, NY 10029 USA.			Nair, Venugopalan/0000-0002-0299-0998; Nair, Venugopalan/0000-0002-8231-6230; SEALFON, Stuart/0000-0001-5791-1217				Ahlskog JE, 2003, NEUROLOGY, V60, P381, DOI 10.1212/01.WNL.0000044047.58984.2F; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Berg KA, 1998, MOL PHARMACOL, V54, P94, DOI 10.1124/mol.54.1.94; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Brami-Cherrier K, 2002, J NEUROSCI, V22, P8911; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172; Ching TT, 2001, J BIOL CHEM, V276, P43932, DOI 10.1074/jbc.M105159200; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Cordeaux Y, 2001, J BIOL CHEM, V276, P28667, DOI 10.1074/jbc.M008644200; Cussac D, 1999, MOL PHARMACOL, V56, P1025, DOI 10.1124/mol.56.5.1025; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Fahn S., 1988, CECILS TXB MED, P2143; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; Gao YL, 2001, J PHARMACOL EXP THER, V296, P426; Hartmann A, 2001, ADV NEUROL, V86, P143; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; HORNYKIEWICZ O, 1987, PARKINSONS DIS, P19; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Kihara T, 2002, J NEUROSCI RES, V70, P274, DOI 10.1002/jnr.10426; Kotecha SA, 2002, NEURON, V35, P1111, DOI 10.1016/S0896-6273(02)00859-0; Kurrasch-Orbaugh DM, 2003, J PHARMACOL EXP THER, V304, P229, DOI 10.1124/jpet.102.042184; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Lachowicz JE, 1997, PHARMACOL TOXICOL, V81, P105, DOI 10.1111/j.1600-0773.1997.tb00039.x; Le WD, 2001, DRUG AGING, V18, P389, DOI 10.2165/00002512-200118060-00001; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Marie J, 2001, J BIOL CHEM, V276, P41100, DOI 10.1074/jbc.M104875200; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Nair VD, 2003, BIOCHEM J, V373, P25, DOI 10.1042/BJ20030017; Oak JN, 2001, MOL PHARMACOL, V60, P92, DOI 10.1124/mol.60.1.92; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Oldenhof J, 2001, CELL SIGNAL, V13, P411, DOI 10.1016/S0898-6568(01)00157-7; Pauwels PJ, 2002, NEUROPHARMACOLOGY, V42, P855, DOI 10.1016/S0028-3908(01)00201-5; Peleg G, 2001, P NATL ACAD SCI USA, V98, P8469, DOI 10.1073/pnas.151239698; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Piiper A, 2002, J BIOL CHEM, V277, P43623, DOI 10.1074/jbc.M203926200; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Prioleau C, 2002, J BIOL CHEM, V277, P36577, DOI 10.1074/jbc.M206223200; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; Sealfon SC, 2000, ANN NEUROL, V47, pS12; Seifert R, 2001, J PHARMACOL EXP THER, V297, P1218; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Son JH, 1999, J NEUROSCI, V19, P10, DOI 10.1523/JNEUROSCI.19-01-00010.1999; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; Vogel R, 2002, BIOCHEMISTRY-US, V41, P3529, DOI 10.1021/bi016023n; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yan Z, 1999, P NATL ACAD SCI USA, V96, P11607, DOI 10.1073/pnas.96.20.11607	67	76	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47053	47061		10.1074/jbc.M303364200	http://dx.doi.org/10.1074/jbc.M303364200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12970364	hybrid			2022-12-25	WOS:000186569400102
J	Song, JJ; Lee, YJ				Song, JJ; Lee, YJ			Role of the ASK1-SEK1-JNK1-HIPK1 signal in Daxx trafficking and ASK1 oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLIC OXIDATIVE STRESS; ACTIVATED PROTEIN-KINASE; FAS-BINDING-PROTEIN; TRANSCRIPTION FACTOR; TRANSDUCTION PATHWAY; REGULATING KINASE-1; CELL-DEATH; APOPTOSIS; GLUTAREDOXIN; THIOREDOXIN	Overexpression of JNK binding domain inhibited glucose deprivation-induced JNK1 activation, relocalization of Daxx from the nucleus to the cytoplasm, and apoptosis signal-regulating kinase 1 (ASK1) oligomerization in human prostate adenocarcinoma DU-145 cells. However, SB203580, a p38 inhibitor, did not prevent relocalization of Daxx and oligomerization of ASK1 during glucose deprivation. Studies from in vivo labeling and immune complex kinase assay demonstrated that phosphorylation of Daxx occurred during glucose deprivation, and its phosphorylation was mediated through the ASK1-SEK1-JNK1-HIPK1 signal transduction pathway. Data from immunofluorescence staining and protein interaction assay suggest that phosphorylated Daxx may be translocated to the cytoplasm, bind to ASK1, and subsequently lead to ASK1 oligomerization. Mutation of Daxx Ser(667) to Ala results in suppression of Daxx relocalization during glucose deprivation, suggesting that Ser667 residue plays an important role in the relocalization of Daxx. Unlike wild-type Daxx, a Daxx deletion mutant ( amino acids 501 - 625) mainly localized to the cytoplasm, where it associated with ASK1, activated JNK1, and induced ASK1 oligomerization without glucose deprivation. Taken together, these results show that glucose deprivation activates the ASK1-SEK1-JNK1- HIPK1 pathway, and the activated HIPK1 is probably involved in the relocalization of Daxx from the nucleus to the cytoplasm. The relocalized Daxx may play an important role in glucose deprivation-induced ASK1 oligomerization.	Univ Pittsburgh, Dept Surg, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, YJ (corresponding author), Univ Pittsburgh, Dept Surg, Hillman Canc Ctr, 5117 Ctr Ave,Rm G-5A, Pittsburgh, PA 15213 USA.			Song, Jae/0000-0001-8183-9550	NATIONAL CANCER INSTITUTE [R01CA095191, R01CA048000, R01CA096989] Funding Source: NIH RePORTER; NCI NIH HHS [CA 48000, CA 95191, CA 96989] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; CHRESTENSEN CA, 1995, FEBS LETT, V374, P25, DOI 10.1016/0014-5793(95)01066-N; Chung KC, 2000, EUR J BIOCHEM, V267, P4676, DOI 10.1046/j.1432-1327.2000.01517.x; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Ecsedy JA, 2003, MOL CELL BIOL, V23, P950, DOI 10.1128/MCB.23.3.950-960.2003; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; Ko YG, 2001, J BIOL CHEM, V276, P39103, DOI 10.1074/jbc.M105928200; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; PADILLA CA, 1995, EUR J BIOCHEM, V227, P27, DOI 10.1111/j.1432-1033.1995.tb20356.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Ryu SW, 2000, BIOCHEM BIOPH RES CO, V279, P6, DOI 10.1006/bbrc.2000.3882; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Song JJ, 2003, J CELL BIOCHEM, V90, P304, DOI 10.1002/jcb.10619; Song JJ, 2003, BIOCHEM J, V373, P845, DOI 10.1042/BJ20030275; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Toone WM, 2001, ONCOGENE, V20, P2336, DOI 10.1038/sj.onc.1204384; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	28	68	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47245	47252		10.1074/jbc.M213201200	http://dx.doi.org/10.1074/jbc.M213201200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12968034	hybrid			2022-12-25	WOS:000186569400125
J	Antoine, M; Boschi-Muller, S; Branlant, G				Antoine, M; Boschi-Muller, S; Branlant, G			Kinetic characterization of the chemical steps involved in the catalytic mechanism of methionine sulfoxide reductase a from Neisseria meningitidis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; ENZYME; PILB; MUTAGENESIS; OXIDATION	Oxidation of methionine into methionine sulfoxide is associated with many pathologies and is described to exert regulatory effects on protein functions. Two classes of methionine sulfoxide reductases, called MsrA and MsrB, have been described to reduce the S and the R isomers of the sulfoxide of methionine sulfoxide back to methionine, respectively. Although MsrAs and MsrBs display quite different x-ray structures, they share a similar, new catalytic mechanism that proceeds via the sulfenic acid chemistry and that includes at least three chemical steps with 1) the formation of a sulfenic acid intermediate and the concomitant release of methionine; 2) the formation of an intra-disulfide bond; and 3) the reduction of the disulfide bond by thioredoxin. In the present study, it is shown that for the Neisseria meningitidis MsrA, 1) the rate-limiting step is associated with the reduction of the Cys-51/Cys-198 disulfide MsrA bond by thioredoxin; 2) the formation of the sulfenic acid intermediate is very efficient, thus suggesting catalytic assistance via amino acids of the active site; 3) the rate-determining step in the formation of the Cys-51/Cys-198 disulfide bond is that leading to the formation of the sulfenic intermediate on Cys-51; and 4) the apparent affinity constant for methionine sulfoxide in the methionine sulfoxide reductase step is 80-fold higher than the K-m value determined under steady-state conditions.	Fac Sci, CNRS, UMR 7567, UHP Maturat ARN & Enzymol Mol, F-54506 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Branlant, G (corresponding author), Fac Sci, CNRS, UMR 7567, UHP Maturat ARN & Enzymol Mol, Bld Aiguillettes,BP 239, F-54506 Vandoeuvre Les Nancy, France.			Boschi, Sandrine/0000-0001-8962-4749				Boschi-Muller S, 2000, J BIOL CHEM, V275, P35908, DOI 10.1074/jbc.M006137200; Boschi-Muller S, 2001, PROTEIN SCI, V10, P2272, DOI 10.1110/ps.10701; Grimaud R, 2001, J BIOL CHEM, V276, P48915, DOI 10.1074/jbc.M105509200; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; HOLMGREN A, 1981, BIOCHEMISTRY-US, V20, P3204, DOI 10.1021/bi00514a033; Kauffmann B, 2002, ACTA CRYSTALLOGR D, V58, P1467, DOI 10.1107/S0907444902010570; Lowther WT, 2000, BIOCHEMISTRY-US, V39, P13307, DOI 10.1021/bi0020269; Lowther WT, 2000, P NATL ACAD SCI USA, V97, P6463, DOI 10.1073/pnas.97.12.6463; Lowther WT, 2002, NAT STRUCT BIOL, V9, P348, DOI 10.1038/nsb783; Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998; Mossner E, 1998, PROTEIN SCI, V7, P1233; Mulrooney SB, 1997, PROTEIN EXPRES PURIF, V9, P372, DOI 10.1006/prep.1996.0698; Olry A, 2002, J BIOL CHEM, V277, P12016, DOI 10.1074/jbc.M112350200; Ruan H, 2002, P NATL ACAD SCI USA, V99, P2748, DOI 10.1073/pnas.032671199; Schoneich C, 1999, EXP GERONTOL, V34, P19, DOI 10.1016/S0531-5565(98)00066-7; Slaby I, 1996, J BIOL CHEM, V271, P3091, DOI 10.1074/jbc.271.6.3091; Taylor AB, 2003, J BACTERIOL, V185, P4119, DOI 10.1128/JB.185.14.4119-4126.2003; Tete-Favier F, 2000, STRUCTURE, V8, P1167, DOI 10.1016/S0969-2126(00)00526-8; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G	19	47	47	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45352	45357		10.1074/jbc.M307471200	http://dx.doi.org/10.1074/jbc.M307471200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954610	Green Published, hybrid			2022-12-25	WOS:000186452300038
J	Haurie, V; Boucherie, H; Sagliocco, F				Haurie, V; Boucherie, H; Sagliocco, F			The snf1 protein kinase controls the induction of genes of the iron uptake pathway at the diauxic shift in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE LIMITATION; CARBON SOURCE; HEAT-SHOCK; YEAST; EXPRESSION; AFT1; PHOSPHORYLATION; REPRESSOR; ACTIVATION	In Saccharomyces cerevisiae the transition between the fermentative and the oxidative metabolism, called the diauxic shift, is associated with major changes in gene expression. In this study, we characterized a novel family of five genes whose expression is induced during the diauxic shift. These genes, FET3, FTR1, TIS11, SIT1, and FIT2, are involved in the iron uptake pathway. We showed that their induction at the diauxic shift is positively controlled by the Snf1/Snf4 kinase pathway. The transcriptional factor Aft1p, which is known to control their induction in response to iron limitation, is also required for their induction during the diauxic shift. The increase of the extracellular iron concentration does not affect this induction, indicating that glucose exhaustion by itself would be the signal. The possibility that the Snf1/Snf4 pathway was also involved in the induction of the same set of genes in response to iron starvation was considered. We demonstrate here that this is not the case. Thus, the two signals, glucose exhaustion and iron starvation, use two independent pathways to activate the same set of genes through the Aft1p transcriptional factor.	Inst Biochim & Genet Cellulaires, UMR 5095, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Sagliocco, F (corresponding author), Inst Biochim & Genet Cellulaires, UMR 5095, F-33077 Bordeaux, France.	francis.sagliocco@ibgc.u-bordeaux2.fr						BATAILLE N, 1988, ELECTROPHORESIS, V9, P774, DOI 10.1002/elps.1150091113; BATAILLE N, 1991, YEAST, V7, P367, DOI 10.1002/yea.320070407; BOUCHERIE H, 1985, J BACTERIOL, V161, P385, DOI 10.1128/JB.161.1.385-392.1985; BoyMarcotte E, 1996, MICROBIOL-UK, V142, P459, DOI 10.1099/13500872-142-3-459; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hardie DG, 1999, BIOCHEM SOC SYMP, P13; Hassett RF, 1998, J BIOL CHEM, V273, P7628, DOI 10.1074/jbc.273.13.7628; Haurie V, 2001, J BIOL CHEM, V276, P76, DOI 10.1074/jbc.M008752200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LINDQUIST S, 1981, NATURE, V293, P311, DOI 10.1038/293311a0; McCartney RR, 2001, J BIOL CHEM, V276, P36460, DOI 10.1074/jbc.M104418200; Ostling J, 1998, EUR J BIOCHEM, V252, P162, DOI 10.1046/j.1432-1327.1998.2520162.x; Pinson B, 2000, NUCLEIC ACIDS RES, V28, P4665, DOI 10.1093/nar/28.23.4665; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; Rahner A, 1996, NUCLEIC ACIDS RES, V24, P2331, DOI 10.1093/nar/24.12.2331; Robertson LS, 2000, P NATL ACAD SCI USA, V97, P5984, DOI 10.1073/pnas.100113397; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Treitel MA, 1998, MOL CELL BIOL, V18, P6273, DOI 10.1128/MCB.18.11.6273; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709	31	64	67	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45391	45396		10.1074/jbc.M307447200	http://dx.doi.org/10.1074/jbc.M307447200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12960168	hybrid			2022-12-25	WOS:000186452300043
J	Zhang, WD; Mojsilovic-Petrovic, J; Andrade, MF; Zhang, H; Ball, M; Stanimirovic, DB				Zhang, WD; Mojsilovic-Petrovic, J; Andrade, MF; Zhang, H; Ball, M; Stanimirovic, DB			Expression and functional characterization of ABCG2 in brain endothelial cells and vessels	FASEB JOURNAL			English	Article						ABC transporters; brain endothelium; blood-brain barrier; drug resistance; glioblastoma	CANCER RESISTANCE PROTEIN; MULTIDRUG-RESISTANCE; BLOOD-BRAIN; P-GLYCOPROTEIN; DRUG-RESISTANCE; IN-VITRO; BARRIER; TRANSPORTER; GENE; OVEREXPRESSION	Delivery of drugs to the brain is impeded by the activity of efflux pumps expressed by endothelial cells of brain vasculature. The ATP binding cassette (ABC) transporters, among which ABCB1/MDR1 P-glycoprotein and ABCC1/multidrug resistance-associated protein 1 are expressed in brain endothelial cells, participate in drug efflux properties of the blood-brain barrier (BBB). Searches of the EST ( expressed sequence tags) database with the conserved ABC domain, conducted to identify other ABC transporters expressed in the BBB, recovered 15 ABC transporter sequences expressed in human brain cDNA libraries. One of these sequences, identical to ABCG2, was highly expressed in cultured human cerebromicrovascular endothelial cells and human brain tissue at both mRNA and protein levels. Overexpression of human ABCG2 in immortalized rat brain endothelial cells resulted in enhanced polarized abluminal to luminal transport of various substrates tested in the in vitro BBB model. Brain vessels extracted from tissue sections of nonmalignant human brain and glioblastoma tomors by laser capture microdissection microscopy and analyzed by real-time polymerase chain reaction showed higher expression of ABCG2 relative to ABCB1/MDR1 and ABCC1/MRP1. ABCG2 was up-regulated in both glioblastoma vessels and parenchymal tissue. These studies suggest a role for brain endothelial ABCG2 transporter in modulating drug delivery to the brain and in conferring drug resistance to glioblastomas.	Natl Res Council Canada, Inst Biol Sci, Cerebrovasc Res Grp, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Stanimirovic, DB (corresponding author), Natl Res Council Canada, Inst Biol Sci, Cerebrovasc Res Grp, NRC 1200,Montreal Rd Campus,Bldg M-54, Ottawa, ON K1A 0R6, Canada.	danica.stanimirovic@nrc-cnrc.gc.ca		Zhang, Wandong/0000-0001-6412-8124				Allen JD, 1999, CANCER RES, V59, P4237; Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; Cooray HC, 2002, NEUROREPORT, V13, P2059, DOI 10.1097/00001756-200211150-00014; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Decleves X, 2002, INT J CANCER, V98, P173, DOI 10.1002/ijc.10135; Demeule M, 2002, VASC PHARMACOL, V38, P339, DOI 10.1016/S1537-1891(02)00201-X; Demeule M, 2001, INT J CANCER, V93, P62, DOI 10.1002/ijc.1306; Dombrowski SM, 2001, EPILEPSIA, V42, P1501, DOI 10.1046/j.1528-1157.2001.12301.x; Doolittle ND, 2000, CANCER, V88, P637, DOI 10.1002/(SICI)1097-0142(20000201)88:3<637::AID-CNCR22>3.0.CO;2-Y; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Eisenblatter T, 2002, BIOCHEM BIOPH RES CO, V293, P1273, DOI 10.1016/S0006-291X(02)00376-5; Eisenblatter T, 2003, BRAIN RES, V971, P221, DOI 10.1016/S0006-8993(03)02401-6; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; Fromm MF, 2000, INT J CLIN PHARM TH, V38, P69; GERHART DZ, 1988, BRAIN RES BULL, V21, P785, DOI 10.1016/0361-9230(88)90047-0; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Han HY, 1998, BIOCHEM BIOPH RES CO, V243, P816, DOI 10.1006/bbrc.1997.8132; HEGMANN EJ, 1992, CANCER RES, V52, P6969; Honjo Y, 2001, CANCER RES, V61, P6635; Imai Y, 2002, MOL CANCER THER, V1, P611; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Lee G, 2001, PHARMACOL REV, V53, P569; Lee JS, 1997, J CELL BIOCHEM, V65, P513, DOI 10.1002/(SICI)1097-4644(19970615)65:4<513::AID-JCB7>3.3.CO;2-W; Lesniak M S, 2001, Curr Neurol Neurosci Rep, V1, P210, DOI 10.1007/s11910-001-0020-z; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mickley L, 2001, MAMM GENOME, V12, P86, DOI 10.1007/s003350010237; MITOMO H, 2003, IN PRESS BIOCH J; Miyake K, 1999, CANCER RES, V59, P8; Muruganandam A, 1997, FASEB J, V11, P1187, DOI 10.1096/fasebj.11.13.9367354; Muruganandam A, 2001, FASEB J, V15, P240, DOI 10.1096/fj.01-0343fje; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Plotkin SR, 2000, BRAIN RES, V881, P57, DOI 10.1016/S0006-8993(00)02772-4; Potschka H, 2001, NEUROREPORT, V12, P3557, DOI 10.1097/00001756-200111160-00037; Robey RW, 2001, BBA-BIOMEMBRANES, V1512, P171, DOI 10.1016/S0005-2736(01)00308-X; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699; Schinkel AH, 2001, ADV EXP MED BIOL, V500, P365; Seetharaman S, 1998, J NEUROCHEM, V70, P1151, DOI 10.1046/j.1471-4159.1998.70031151.x; Spiegl-Kreinecker S, 2002, J NEURO-ONCOL, V57, P27, DOI 10.1023/A:1015735815111; Stanimirovic D, 1996, J CELL PHYSIOL, V169, P455; Sun HY, 2003, ADV DRUG DELIVER REV, V55, P83, DOI 10.1016/S0169-409X(02)00172-2; Sun HY, 2001, BIOCHEM BIOPH RES CO, V284, P863, DOI 10.1006/bbrc.2001.5062; Tamai I, 2000, J PHARM SCI-US, V89, P1371, DOI 10.1002/1520-6017(200011)89:11<1371::AID-JPS1>3.0.CO;2-D; VANBREE JBMM, 1988, J PHARMACOL EXP THER, V247, P1233; VORBRODT AW, 1986, J HISTOCHEM CYTOCHEM, V34, P251, DOI 10.1177/34.2.3753715; YONG VW, 1992, GLIA, V6, P269, DOI 10.1002/glia.440060405; ZHANG W, 2000, HGM, V5, P67; ZHANG W, 2002, HGM, V7, P122; Zhang WD, 2000, J CEREBR BLOOD F MET, V20, P967, DOI 10.1097/00004647-200006000-00009	53	151	159	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2085	+		10.1096/fj.02-1131fje	http://dx.doi.org/10.1096/fj.02-1131fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958161				2022-12-25	WOS:000185925100026
J	Korhonen, JA; Gaspari, M; Falkenberg, M				Korhonen, JA; Gaspari, M; Falkenberg, M			TWINKLE has 5 '-> 3 ' DNA helicase activity and is specifically stimulated by mitochondrial single-stranded DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-GAMMA; ACCESSORY SUBUNIT; UL8 SUBUNIT; REPLICATION; INITIATION; PRIMASE	Mutations in TWINKLE cause autosomal dominant progressive external ophthalmoplegia, a human disorder associated with multiple deletions in the mitochondrial DNA. TWINKLE displays primary sequence similarity to the phage T7 gene 4 primase- helicase, but no specific enzyme activity has been assigned to the protein. We have purified recombinant TWINKLE to near homogeneity and demonstrate here that TWINKLE is a DNA helicase with 5' to 3' directionality and distinct substrate requirements. The protein needs a stretch of 10 nucleotides of single-stranded DNA on the 5'-side of the duplex to unwind duplex DNA. In addition, helicase activity is not observed unless a short single-stranded 3'-tail is present. The helicase activity has an absolute requirement for hydrolysis of a nucleoside 5'-triphosphate, with UTP being the optimal substrate. DNA unwinding by TWINKLE is specifically stimulated by the mitochondrial single-stranded DNA-binding protein. Our enzymatic characterization strongly supports the notion that TWINKLE is the helicase at the mitochondrial DNA replication fork and provides evidence for a close relationship of the DNA replication machinery in bacteriophages and mammalian mitochondria.	Karolinska Inst, Novum, Dept Med Nutr, SE-14186 Huddinge, Sweden	Karolinska Institutet	Falkenberg, M (corresponding author), Karolinska Inst, Novum, Dept Med Nutr, SE-14186 Huddinge, Sweden.							Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; Eyre-Walker A, 2001, J MOL EVOL, V53, P430, DOI 10.1007/s002390010232; Falkenberg M, 1997, J BIOL CHEM, V272, P22766, DOI 10.1074/jbc.272.36.22766; Farr CL, 1999, J BIOL CHEM, V274, P14779, DOI 10.1074/jbc.274.21.14779; Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; KASAMATSU H, 1971, P NATL ACAD SCI USA, V68, P2252, DOI 10.1073/pnas.68.9.2252; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LeGac NT, 1996, J BIOL CHEM, V271, P21645; Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MIGNOTTE B, 1988, EUR J BIOCHEM, V174, P479, DOI 10.1111/j.1432-1033.1988.tb14123.x; MONTOYA J, 1982, P NATL ACAD SCI-BIOL, V79, P7195, DOI 10.1073/pnas.79.23.7195; Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379; WONG TW, 1985, J BIOL CHEM, V260, P1530; WONG TW, 1985, CELL, V42, P951, DOI 10.1016/0092-8674(85)90291-0; Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9	25	208	210	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48627	48632		10.1074/jbc.M306981200	http://dx.doi.org/10.1074/jbc.M306981200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12975372	hybrid			2022-12-25	WOS:000186829000015
J	Reglier-Poupet, H; Frehel, C; Dubail, I; Beretti, JL; Berche, P; Charbit, A; Raynaud, C				Reglier-Poupet, H; Frehel, C; Dubail, I; Beretti, JL; Berche, P; Charbit, A; Raynaud, C			Maturation of lipoproteins by type II signal peptidase is required for phagosomal escape of Listeria monocytogenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; PROTEIN SECRETION; ESCHERICHIA-COLI; BACTERIAL LIPOPROTEINS; PYRUVATE-DEHYDROGENASE; LIPID MODIFICATION; VIRULENCE GENES; CELL-LINE; IDENTIFICATION; GROWTH	Lipoproteins of Gram-positive bacteria are involved in a broad range of functions such as substrate binding and transport, antibiotic resistance, cell signaling, or protein export and folding. Lipoproteins are also known to initiate both innate and adaptative immune responses. However, their role in the pathogenicity of intracellular microorganisms is yet poorly understood. In Listeria monocytogenes, a Gram-positive facultative intracellular human pathogen, surface proteins have important roles in the interactions of the microorganism with the host cells. Among the putative surface proteins of L. monocytogenes, lipoproteins constitute the largest family. Here, we addressed the role of the signal peptidase (SPase II), responsible for the maturation of lipoproteins in listerial pathogenesis. We identified a gene, lsp, encoding a SPase II in the genome of L. monocytogenes and constructed a Deltalsp chromosomal deletion mutant. The mutant strain fails to process several lipoproteins demonstrating that lsp encodes a genuine SPase II. This defect is accompanied by a reduced efficiency of phagosomal escape during infection of eucaryotic cells, and leads to an attenuated virulence. We show that lsp gene expression is strongly induced when bacteria are still entrapped inside phagosomes of infected macrophages. The data presented establish, thus, that maturation of lipoproteins is critical for efficient phagosomal escape of L. monocytogenes, a process temporally controlled by the regulation of Lsp production in infected cells.	Fac Med Necker Enfants Malad, INSERM, U570, F-75730 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Charbit, A (corresponding author), Fac Med Necker Enfants Malad, INSERM, U570, 156 Rue Vaugirard, F-75730 Paris 15, France.		poupet, helene/P-4360-2017	charbit, alain/0000-0001-5243-4861				Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; An FY, 2002, J BACTERIOL, V184, P1880, DOI 10.1128/JB.184.7.1880-1887.2002; Antelmann H, 2001, GENOME RES, V11, P1484, DOI 10.1101/gr.182801; Autret N, 2003, INFECT IMMUN, V71, P4463, DOI 10.1128/IAI.71.8.4463-4471.2003; Autret N, 2001, INFECT IMMUN, V69, P2054, DOI 10.1128/IAI.69.4.2054-2065.2001; Barbour AH, 1996, MICROB PATHOGENESIS, V20, P247, DOI 10.1006/mpat.1996.0023; Bolhuis A, 1999, APPL ENVIRON MICROB, V65, P2934; Borezee E, 2000, INFECT IMMUN, V68, P7069, DOI 10.1128/IAI.68.12.7069-7077.2000; Bubert A, 1999, MOL GEN GENET, V261, P323, DOI 10.1007/s004380050973; Cabanes D, 2002, TRENDS MICROBIOL, V10, P238, DOI 10.1016/S0966-842X(02)02342-9; CenturionLara A, 1997, INFECT IMMUN, V65, P1440, DOI 10.1128/IAI.65.4.1440-1444.1997; Cossart P, 2001, CURR OPIN IMMUNOL, V13, P96, DOI 10.1016/S0952-7915(00)00188-6; Coulter SN, 1998, MOL MICROBIOL, V30, P393, DOI 10.1046/j.1365-2958.1998.01075.x; de Greeff A, 2003, MICROBIOL-SGM, V149, P1399, DOI 10.1099/mic.0.26329-0; FARBER JM, 1991, MICROBIOL REV, V55, P476, DOI 10.1128/MMBR.55.3.476-511.1991; GAILLARD JL, 1987, INFECT IMMUN, V55, P2822, DOI 10.1128/IAI.55.11.2822-2829.1987; Gao HC, 2002, J BACTERIOL, V184, P2780, DOI 10.1128/JB.184.10.2780-2788.2002; GIAM CZ, 1984, J BIOL CHEM, V259, P5601; Glaser P, 2001, SCIENCE, V294, P849; KONTINEN VP, 1993, MOL MICROBIOL, V8, P727, DOI 10.1111/j.1365-2958.1993.tb01616.x; Leskela S, 1999, MOL MICROBIOL, V31, P1075, DOI 10.1046/j.1365-2958.1999.01247.x; Lety MA, 2003, MICROBIOL-SGM, V149, P1249, DOI 10.1099/mic.0.26072-0; Lety MA, 2002, MOL MICROBIOL, V46, P367, DOI 10.1046/j.1365-2958.2002.03176.x; Lety MA, 2001, MOL MICROBIOL, V39, P1124, DOI 10.1046/j.1365-2958.2001.02281.x; LINGNAU A, 1995, INFECT IMMUN, V63, P3896, DOI 10.1128/IAI.63.10.3896-3903.1995; MACKANESS GB, 1962, J EXP MED, V116, P381, DOI 10.1084/jem.116.3.381; Masuda K, 2002, P NATL ACAD SCI USA, V99, P7390, DOI 10.1073/pnas.112085599; Mei JM, 1997, MOL MICROBIOL, V26, P399, DOI 10.1046/j.1365-2958.1997.5911966.x; Reglier-Poupet H, 2003, INFECT IMMUN, V71, P474, DOI 10.1128/IAI.71.1.474-482.2003; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; Tjalsma H, 1999, J BIOL CHEM, V274, P1698, DOI 10.1074/jbc.274.3.1698; Tjalsma H, 1999, J BIOL CHEM, V274, P28191, DOI 10.1074/jbc.274.40.28191; TOKUNAGA M, 1985, J BIOL CHEM, V260, P5610; Vazquez-Boland JA, 2001, CLIN MICROBIOL REV, V14, P584, DOI 10.1128/CMR.14.3.584-640.2001; Venema R, 2003, J BIOL CHEM, V278, P14739, DOI 10.1074/jbc.M209857200; VONHEIJNE G, 1989, PROTEIN ENG, V2, P531, DOI 10.1093/protein/2.7.531; Walter T, 1999, J BIOL CHEM, V274, P7901, DOI 10.1074/jbc.274.12.7901; WOOD S, 1993, INFECT IMMUN, V61, P3068, DOI 10.1128/IAI.61.7.3068-3072.1993; YAMAGATA H, 1982, J BACTERIOL, V152, P1163	41	53	59	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49469	49477		10.1074/jbc.M307953200	http://dx.doi.org/10.1074/jbc.M307953200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12975369	hybrid			2022-12-25	WOS:000186829000115
J	Balboa, MA; Shirai, Y; Gaietta, G; Ellisman, MH; Balsinde, J; Dennis, EA				Balboa, MA; Shirai, Y; Gaietta, G; Ellisman, MH; Balsinde, J; Dennis, EA			Localization of Group V phospholipase A(2) in caveolin-enriched granules in activated P388D1 macrophage-like cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID MOBILIZATION; MAST-CELLS; PROSTAGLANDIN PRODUCTION; LEUKOTRIENE BIOSYNTHESIS; HUMAN NEUTROPHILS; ENZYMES; INHIBITION; EXPRESSION; GENERATION; SYNTHASE-2	In murine P388D(1) macrophages, the generation of prostaglandin E-2 in response to long term stimulation by lipopolysaccharide involves the action of Group V secreted phospholipase A(2) (PLA(2)), Group IV cytosolic PLA(2) (cPLA(2)), and cyclooxygenase-2 (COX-2). There is an initial activation of cPLA(2) that induces expression of Group V PLA(2), which in turn induces both the expression of COX-2 and most of the arachidonic acid substrate for COX-2-dependent prostaglandin E-2 generation. Because Group V PLA(2) is a secreted enzyme, it has been assumed that after cellular stimulation, it must be released to the extracellular medium and re-associates with the outer membrane to release arachidonic acid from phospholipids. In the present study, confocal laser scanning microscopy experiments utilizing both immunofluorescence and green fluorescent protein-labeled Group V PLA(2) shows that chronic exposure of the macrophages to lipopolysaccharide results in Group V PLA(2) being associated with caveolin-2-containing granules close to the perinuclear region. Heparin, a cell-impermeable complex carbohydrate with high affinity for Group V PLA(2), blocks that association, suggesting that the granules are formed by internalization of the Group V sPLA(2) previously associated with the outer cellular surface. Localization of Group V PLA(2) in perinuclear granules is not observed if the cells are treated with the Group IV PLA(2) inhibitor methyl arachidonyl fluorophosphonate, confirming the important role for Group IV PLA(2) in the activation process. Cellular staining with antibodies against COX-2 reveals the presence of COX-2-rich granules in close proximity to those containing Group V PLA(2). Collectively, these results suggest that encapsulation of Group V PLA(2) into granules brings the enzyme to the perinuclear envelope during cell activation where it may be closer to Group IV PLA(2) and COX-2 for efficient prostaglandin synthesis.	Univ Calif San Diego, Sch Med, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Valladolid, Sch Med, Inst Mol Biol & Genet, E-47005 Valladolid, Spain; Univ Calif San Diego, Sch Med, Natl Ctr Microscopy & Imaging Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; University of California System; University of California San Diego; University of California System; University of California San Diego	Dennis, EA (corresponding author), Univ Calif San Diego, Sch Med, Dept Chem & Biochem, La Jolla, CA 92093 USA.	edennis@ucsd.edu	Balboa, María A./V-9493-2018; Dennis, Edward A./M-5554-2019; Balsinde, Jesús/C-7833-2018; Shirai, Yasuhito/O-3255-2018	Balboa, María A./0000-0002-2130-5298; Dennis, Edward A./0000-0003-3738-3140; Balsinde, Jesús/0000-0002-4157-6714; 	NCRR NIH HHS [P41 RR04050] Funding Source: Medline; NICHD NIH HHS [HD26171] Funding Source: Medline; NIGMS NIH HHS [GM20501] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 2000, J BIOL CHEM, V275, P22544, DOI 10.1074/jbc.M910163199; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Balsinde J, 2002, FEBS LETT, V531, P2, DOI 10.1016/S0014-5793(02)03413-0; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; Bingham CO, 1999, J BIOL CHEM, V274, P31476, DOI 10.1074/jbc.274.44.31476; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; CHEN J, 1994, J BIOL CHEM, V269, P2365; Cho W, 2000, BBA-MOL CELL BIOL L, V1488, P48, DOI 10.1016/S1388-1981(00)00109-8; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Gargalovic P, 2003, J LIPID RES, V44, P11, DOI 10.1194/jlr.R200005-JLR200; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Munoz NM, 2003, J BIOL CHEM, V278, P38813, DOI 10.1074/jbc.M302476200; Murakami M, 2000, BBA-MOL CELL BIOL L, V1488, P159, DOI 10.1016/S1388-1981(00)00118-9; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; MURAKAMI M, 2002, PROSTAGLANDINS, V68, P3; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886	28	59	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48059	48065		10.1074/jbc.M305904200	http://dx.doi.org/10.1074/jbc.M305904200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12963740	hybrid, Green Published			2022-12-25	WOS:000186731400085
J	Koshizuka, Y; Yamada, T; Hoshi, K; Ogasawara, T; Chung, U; Kawano, H; Nakamura, Y; Nakamura, K; Ikegawa, S; Kawaguchi, H				Koshizuka, Y; Yamada, T; Hoshi, K; Ogasawara, T; Chung, U; Kawano, H; Nakamura, Y; Nakamura, K; Ikegawa, S; Kawaguchi, H			Cystatin 10, a novel chondrocyte-specific protein, may promote the last steps of the chondrocyte differentiation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PEPTIDE; PROGRESSIVE MYOCLONUS EPILEPSY; RADIATION-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; PERIPHERAL T-CELLS; B-DEFICIENT MICE; PARATHYROID-HORMONE; CATHEPSIN-B; MOUSE EMBRYO; CYTOCHROME-C	This study attempts to characterize cystatin 10 (Cst10), which we recently identified as a novel protein implicated in endochondral ossification. Expression of Cst10 was specific to cartilage, localized in the cytosol of prehypertrophic and hypertrophic chondrocytes of the mouse growth plate. In the mouse chondrogenic cell line ATDC5, Cst10 expression preceded type X collagen expression and increased in synchrony with maturation. When we compared ATDC5 cells transfected with Cst10 cDNA with cells transfected with a mock vector, hypertrophic maturation and mineralization of chondrocytes were promoted by Cst10 gene overexpression in that type X collagen expression was observed earlier, and alizarin red staining was stronger. On the other hand, type II collagen expression and Alcian blue staining, both of which are markers of the early stage of chondrocyte differentiation, were similar in both cells. Overexpression of the Cst10 gene also caused fragmentation of nuclei, the appearance of annexin V, a change in the mitochondrial membrane potential, and activation of caspases. These results strongly suggest that Cst10 may play an important role in the last steps of the chondrocyte differentiation pathway as an inducer of maturation, followed by apoptosis of chondrocytes.	Univ Tokyo, Fac Med, Dept Orthoped Surg, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Fac Med, Dept Tissue Engn, Tokyo 1138655, Japan; Univ Tokyo, Inst Med Sci, Mol Med Lab, Tokyo 1138655, Japan; Inst Phys & Chem Res, SNP Res Ctr, Lab Bone & Joint Dis, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo; University of Tokyo; RIKEN	Kawaguchi, H (corresponding author), Univ Tokyo, Fac Med, Dept Orthoped Surg, Bunkyo Ku, Hongo 7-3-1, Tokyo 1138655, Japan.		Ikegawa, Shiro/N-6895-2015; Ogasawara, Toru/I-1629-2014	Ikegawa, Shiro/0000-0003-0316-2147; Ogasawara, Toru/0000-0002-2996-081X				ABRAHAMSON M, 1988, SCAND J CLIN LAB INV, V48, P21; ABRAHAMSON M, 1992, HUM GENET, V89, P377; Afonso S, 1997, DEVELOPMENT, V124, P3415; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205; BARRETT AJ, 1986, BIOCHEM J, V236, P312, DOI 10.1042/bj2360312; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Brunk UT, 1997, FREE RADICAL BIO MED, V23, P616, DOI 10.1016/S0891-5849(97)00007-5; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chrysis D, 2003, J ENDOCRINOL, V176, P331, DOI 10.1677/joe.0.1760331; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; FADOK VA, 1992, J IMMUNOL, V148, P2207; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; FOSSEL ET, 1994, CANCER RES, V54, P1240; Grimsrud CD, 1999, J BONE MINER RES, V14, P475, DOI 10.1359/jbmr.1999.14.4.475; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Hoshi K, 2001, J BONE MINER RES, V16, P289, DOI 10.1359/jbmr.2001.16.2.289; Hosoda Y, 1981, Ryumachi, V21 Suppl, P157; Ikegawa S, 2000, CYTOGENET CELL GENET, V90, P291, DOI 10.1159/000056791; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; Isahara K, 1999, NEUROSCIENCE, V91, P233, DOI 10.1016/S0306-4522(98)00566-1; Ishisaka R, 1998, FEBS LETT, V435, P233, DOI 10.1016/S0014-5793(98)01080-1; Johansson L, 2000, BONE, V26, P451, DOI 10.1016/S8756-3282(00)00261-1; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Katunum N, 1999, ADV ENZYME REGUL, V39, P247, DOI 10.1016/S0065-2571(98)00028-4; Kawaguchi H, 1999, J CLIN INVEST, V104, P229, DOI 10.1172/JCI5705; Komoriya A, 2000, J EXP MED, V191, P1819, DOI 10.1084/jem.191.11.1819; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Koshizuka Y, 2001, CYTOGENET CELL GENET, V94, P163, DOI 10.1159/000048809; Koshizuka Y, 2001, GENOMICS, V72, P252, DOI 10.1006/geno.2000.6475; Lalioti MD, 1997, NATURE, V386, P847, DOI 10.1038/386847a0; Lerner UH, 1997, ACTA PHYSIOL SCAND, V161, P81, DOI 10.1046/j.1365-201X.1997.d01-1933.x; LERNER UH, 1992, J BONE MINER RES, V7, P433; Lieuallen K, 2001, HUM MOL GENET, V10, P1867, DOI 10.1093/hmg/10.18.1867; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Nishio C, 2000, BRAIN RES, V873, P252, DOI 10.1016/S0006-8993(00)02540-3; Ogawa Y, 2001, INT J MOL MED, V7, P603; Okawa A, 1998, NAT GENET, V19, P271, DOI 10.1038/956; PALSDOTTIR A, 1988, LANCET, V2, P603; Pennacchio LA, 1998, NAT GENET, V20, P251, DOI 10.1038/3059; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; Reinheckel T, 2001, BIOL CHEM, V382, P735, DOI 10.1515/BC.2001.089; Roberg K, 2001, LAB INVEST, V81, P149, DOI 10.1038/labinvest.3780222; SARIN A, 1994, J IMMUNOL, V153, P862; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; Shi GP, 1999, J CLIN INVEST, V104, P1191, DOI 10.1172/JCI7709; Shimoaka T, 2002, J BIOL CHEM, V277, P7493, DOI 10.1074/jbc.M108653200; Shukunami C, 1997, J BONE MINER RES, V12, P1174, DOI 10.1359/jbmr.1997.12.8.1174; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang DS, 2001, J BIOL CHEM, V276, P33995, DOI 10.1074/jbc.M007757200; Zang Y, 2001, CELL DEATH DIFFER, V8, P477, DOI 10.1038/sj.cdd.4400843; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	55	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48259	48266		10.1074/jbc.M211639200	http://dx.doi.org/10.1074/jbc.M211639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13679380	hybrid			2022-12-25	WOS:000186731400110
J	Gaboriaud, C; Juanhuix, J; Gruez, A; Lacroix, M; Darnault, C; Pignol, D; Verger, D; Fontecilla-Camps, JC; Arlaud, GJ				Gaboriaud, C; Juanhuix, J; Gruez, A; Lacroix, M; Darnault, C; Pignol, D; Verger, D; Fontecilla-Camps, JC; Arlaud, GJ			The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; TUMOR-NECROSIS-FACTOR; B-CHAIN; IMMUNOGLOBULIN-G; 1ST COMPONENT; BINDING-SITE; 3-DIMENSIONAL STRUCTURE; ARGININE RESIDUES; SUBCOMPONENT C1Q; INNATE IMMUNITY	C1q is a versatile recognition protein that binds to an amazing variety of immune and non-immune ligands and triggers activation of the classical pathway of complement. The crystal structure of the C1q globular domain responsible for its recognition properties has now been solved and refined to 1.9 Angstrom of resolution. The structure reveals a compact, almost spherical heterotrimeric assembly held together mainly by non-polar interactions, with a Ca2+ ion bound at the top. The heterotrimeric assembly of the C1q globular domain appears to be a key factor of the versatile recognition properties of this protein. Plausible three-dimensional models of the C1q globular domain in complex with two of its physiological ligands, C-reactive protein and IgG, are proposed, highlighting two of the possible recognition modes of C1q. The C1q/human IgG1 model suggests a critical role for the hinge region of IgG and for the relative orientation of its Fab domain in C1q binding.	Univ Grenoble 1, CNRS, CEA,Inst Biol Struct Jean Pierre Ebel, Lab Enzymol Mol, F-38027 Grenoble 1, France; Univ Grenoble 1, CNRS, CEA,Inst Biol Struct Jean Pierre Ebel, Lab Cristallog & Cristallog Prot, F-38027 Grenoble, France; Lab Llum Sincrotro, Barcelona 08193, Spain; CEA Cadarache, Dept Ecophysiol Vegetale & Microbiol, Lab Bioenerget Cellulaire, F-13108 St Paul Les Durance, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CEA	Arlaud, GJ (corresponding author), Univ Grenoble 1, CNRS, CEA,Inst Biol Struct Jean Pierre Ebel, Lab Enzymol Mol, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.		Juanhuix, Judith/AAS-5222-2020	Juanhuix, Judith/0000-0003-3728-8215; PIGNOL, David/0000-0002-8070-0319				Agrawal A, 2001, J IMMUNOL, V166, P3998, DOI 10.4049/jimmunol.166.6.3998; Arlaud GJ, 2002, MOL IMMUNOL, V39, P383, DOI 10.1016/S0161-5890(02)00143-8; ARLAUD GJ, 1979, MOL IMMUNOL, V16, P445, DOI 10.1016/0161-5890(79)90069-5; Bogin O, 2002, STRUCTURE, V10, P165, DOI 10.1016/S0969-2126(02)00697-4; BREDT W, 1977, INFECT IMMUN, V15, P7, DOI 10.1128/IAI.15.1.7-12.1977; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURTON DR, 1980, NATURE, V288, P338, DOI 10.1038/288338a0; COMIS A, 1985, BIOCHIM BIOPHYS ACTA, V842, P45, DOI 10.1016/0304-4165(85)90291-0; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Ferrer JL, 1998, J SYNCHROTRON RADIAT, V5, P1346, DOI 10.1107/S0909049598004257; GUDDAT LW, 1993, P NATL ACAD SCI USA, V90, P4271, DOI 10.1073/pnas.90.9.4271; Hezareh M, 2001, J VIROL, V75, P12161, DOI 10.1128/JVI.75.24.12161-12168.2001; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Idusogie EE, 2000, J IMMUNOL, V164, P4178, DOI 10.4049/jimmunol.164.8.4178; Idusogie EE, 2001, J IMMUNOL, V166, P2571, DOI 10.4049/jimmunol.166.4.2571; ISENMAN DE, 1975, J IMMUNOL, V114, P1726; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KILCHHERR E, 1985, J MOL BIOL, V186, P403, DOI 10.1016/0022-2836(85)90114-7; Kishore U, 2000, IMMUNOPHARMACOLOGY, V49, P159, DOI 10.1016/S0162-3109(00)80301-X; Kishore U, 2003, J IMMUNOL, V171, P812, DOI 10.4049/jimmunol.171.2.812; Kishore U, 1998, BIOCHEM J, V333, P27, DOI 10.1042/bj3330027; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; Kojouharova MS, 1998, J IMMUNOL, V161, P4325; Lacroix M, 1997, BIOCHEMISTRY-US, V36, P6270, DOI 10.1021/bi962719i; Mabbott NA, 2001, NAT MED, V7, P485, DOI 10.1038/86562; MARQUES G, 1993, J BIOL CHEM, V268, P10393; MCCALL MN, 1989, BIOCHEM J, V257, P845, DOI 10.1042/bj2570845; MIZUOCHI T, 1978, J BIOL CHEM, V253, P7404; MOY JP, 1994, NUCL INSTRUM METH A, V348, P641, DOI 10.1016/0168-9002(94)90815-X; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Navratil JS, 2001, J IMMUNOL, V166, P3231, DOI 10.4049/jimmunol.166.5.3231; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PETRY F, 1991, J IMMUNOL, V147, P3988; Pidcock E, 2001, J BIOL INORG CHEM, V6, P479, DOI 10.1007/s007750100214; Rainey JK, 2002, PROTEIN SCI, V11, P2748, DOI 10.1110/ps.0218502; REID KBM, 1982, BIOCHEM J, V203, P559, DOI 10.1042/bj2030559; Ritchie DW, 2003, PROTEINS, V52, P98, DOI 10.1002/prot.10379; Ritchie DW, 2000, PROTEINS, V39, P178, DOI 10.1002/(SICI)1097-0134(20000501)39:2<178::AID-PROT8>3.3.CO;2-Y; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; ROSSI V, 1995, BIOCHEMISTRY-US, V34, P7311, DOI 10.1021/bi00022a004; SANTORO F, 1980, J IMMUNOL, V124, P2886; Saphire EO, 2002, J MOL BIOL, V319, P9, DOI 10.1016/S0022-2836(02)00244-9; Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346; STORRS SB, 1981, J BIOL CHEM, V256, P924; Szalai AJ, 1999, CLIN CHEM LAB MED, V37, P265, DOI 10.1515/CCLM.1999.046; Tacnet-Delorme P, 2001, J IMMUNOL, V167, P6374, DOI 10.4049/jimmunol.167.11.6374; Thielens NM, 2002, IMMUNOBIOLOGY, V205, P563, DOI 10.1078/0171-2985-00155; Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9; VILLIERS CL, 1980, FEBS LETT, V117, P289, DOI 10.1016/0014-5793(80)80964-1; VUILLARD L, 1994, FEBS LETT, V353, P294, DOI 10.1016/0014-5793(94)01060-9	59	272	328	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46974	46982		10.1074/jbc.M307764200	http://dx.doi.org/10.1074/jbc.M307764200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12960167	hybrid			2022-12-25	WOS:000186569400092
J	Mutucumarana, VP; Acher, F; Straight, DL; Jin, DY; Stafford, DW				Mutucumarana, VP; Acher, F; Straight, DL; Jin, DY; Stafford, DW			A conserved region of human vitamin K-dependent carboxylase between residues 393 and 404 is important for its interaction with the glutamate substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; BLOOD-COAGULATION FACTORS; POSTTRANSLATIONAL MODIFICATION; COMBINED DEFICIENCY; PROPEPTIDE REGION; PEPTIDE-SUBSTRATE; RECOGNITION SITE; ENZYME-ACTIVITY; ACTIVE-SITE; FACTOR-IX	Certain individuals with combined deficiencies of vitamin K- dependent proteins have a mutation, L394R, in their gamma- glutamyl carboxylase causing impaired glutamate binding. The sequence surrounding Leu(394) is similar in all known carboxylases, suggesting that the region is functionally important. To test this hypothesis we made the following mutant enzymes: W390A, Y395A, S398A, W399A, and H404A. We purified the enzymes and corrected the activity measurements for active enzyme concentration. Carboxylases W390A, S398A, and H404A had activities similar to that of wild type; however, Y395A and W399A had lower activities than did wild type. In the following descriptions we include our previously reported results for L394R. Kinetic studies with the substrate FLEEL, revealed K-m values of 0.5 ( wild type), 6.5 ( L394R), 15 ( Y395A), and 24 ( W399A) mM. The k(cat) values relative to wild type were 51% ( L394R), 1% ( Y395A), and 2% ( W399A). The k(cat)/ K-m values were 24- fold ( L394R) and > 2000- fold lower for Y395A and W399A than for wild- type carboxylase. Inhibition of FLEEL carboxylation by the competitive inhibitor, Boc- mEEV, gave K-i values of 0.013 ( wild type), 1.4 ( L394R), 2.1 ( Y395A), and > 5 ( W399A) mM. The Y395A propeptide affinity was similar to that of wild type, but those of L394R and W399A were 16 - 22- fold less than that of wild type. Results of kinetic studies with a propeptide- containing substrate were consistent with results of propeptide binding and FLEEL kinetics. Although propeptide and vitamin K binding in some mutants were affected, our data provide compelling evidence that glutamate recognition is the primary function of the conserved region around Leu(394).	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ Paris 05, CNRS, UMR 8601, Chim & Biochim Pharmacol & Toxicol Lab, F-75270 Paris 06, France	University of North Carolina; University of North Carolina Chapel Hill; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Cite	Stafford, DW (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.				NHLBI NIH HHS [HL 48318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZERAD R, 1988, CURRENT ADV VITAMIN, P17; Bandyopadhyay PK, 2002, P NATL ACAD SCI USA, V99, P1264, DOI 10.1073/pnas.022637099; Begley GS, 2000, J BIOL CHEM, V275, P36245, DOI 10.1074/jbc.M003944200; BRENNER B, 1990, BRIT J HAEMATOL, V75, P537, DOI 10.1111/j.1365-2141.1990.tb07795.x; Brenner B, 1998, BLOOD, V92, P4554, DOI 10.1182/blood.V92.12.4554.424k42_4554_4559; CARLISLE TL, 1980, BIOCHEMISTRY-US, V19, P1161, DOI 10.1021/bi00547a019; CHEUNG A, 1989, ARCH BIOCHEM BIOPHYS, V274, P574, DOI 10.1016/0003-9861(89)90472-4; DOWD P, 1995, SCIENCE, V269, P1684, DOI 10.1126/science.7569894; ESMON CT, 1975, J BIOL CHEM, V250, P4744; Houben RJTJ, 2002, BIOCHEM J, V364, P323, DOI 10.1042/bj3640323; HUBBARD BR, 1989, J BIOL CHEM, V264, P14145; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; KULIOPULOS A, 1994, J BIOL CHEM, V269, P21364; Kulman JD, 1997, P NATL ACAD SCI USA, V94, P9058, DOI 10.1073/pnas.94.17.9058; Kulman JD, 2001, P NATL ACAD SCI USA, V98, P1370, DOI 10.1073/pnas.98.4.1370; Li T, 2000, J BIOL CHEM, V275, P18291, DOI 10.1074/jbc.M001790200; Maillet M, 1997, FEBS LETT, V413, P1, DOI 10.1016/S0014-5793(97)00831-4; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MORRIS DP, 1993, J BIOL CHEM, V268, P8735; Morris DP, 1995, J BIOL CHEM, V270, P30491, DOI 10.1074/jbc.270.51.30491; Mutucumarana VP, 2000, J BIOL CHEM, V275, P32572, DOI 10.1074/jbc.M006808200; Presnell SR, 2001, BIOCHEMISTRY-US, V40, P11723, DOI 10.1021/bi010332w; PRICE PA, 1988, ANNU REV NUTR, V8, P565, DOI 10.1146/annurev.nu.08.070188.003025; Pudota BN, 2000, P NATL ACAD SCI USA, V97, P13033, DOI 10.1073/pnas.97.24.13033; Pudota BN, 2001, J BIOL CHEM, V276, P46878, DOI 10.1074/jbc.M108696200; REHEMTULLA A, 1993, P NATL ACAD SCI USA, V90, P4611, DOI 10.1073/pnas.90.10.4611; RICH DH, 1981, J MED CHEM, V24, P706, DOI 10.1021/jm00138a013; Romero EE, 1998, BIOCHEM BIOPH RES CO, V248, P783, DOI 10.1006/bbrc.1998.8987; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V251, P22, DOI 10.1006/bbrc.1998.9410; SOUTE BAM, 1990, BIOCHIM BIOPHYS ACTA, V1034, P11, DOI 10.1016/0304-4165(90)90146-N; Spronk HMH, 2000, BLOOD, V96, P3650; Stanley TB, 1998, BIOCHEMISTRY-US, V37, P13262, DOI 10.1021/bi981031y; Stanley TB, 1999, J BIOL CHEM, V274, P16940, DOI 10.1074/jbc.274.24.16940; Stanley TB, 1999, BIOCHEMISTRY-US, V38, P15681, DOI 10.1021/bi991544k; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; Sugiura I, 1996, J BIOL CHEM, V271, P17837, DOI 10.1074/jbc.271.30.17837; Sugiura I, 1997, P NATL ACAD SCI USA, V94, P9069, DOI 10.1073/pnas.94.17.9069; SUTTIE JW, 1980, CRC CR REV BIOCH MOL, V8, P191, DOI 10.3109/10409238009105469; THIJSSEN HHW, 1986, BIOCHEM PHARMACOL, V35, P3277, DOI 10.1016/0006-2952(86)90424-7; Tie J, 2000, BLOOD, V96, P973, DOI 10.1182/blood.V96.3.973.015k55_973_978; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; UOTILA L, 1988, ARCH BIOCHEM BIOPHYS, V264, P135, DOI 10.1016/0003-9861(88)90578-4; Walker CS, 2001, J BIOL CHEM, V276, P7769, DOI 10.1074/jbc.M009576200; WALLIN R, 1982, ARCH BIOCHEM BIOPHYS, V214, P155, DOI 10.1016/0003-9861(82)90017-0; WOOD GM, 1988, J BIOL CHEM, V263, P3234; WU SM, 1990, J BIOL CHEM, V265, P13124; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; Xu JA, 1998, PROTEIN SCI, V7, P158, DOI 10.1002/pro.5560070117	48	27	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46488	46493		10.1074/jbc.M307707200	http://dx.doi.org/10.1074/jbc.M307707200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12968027	hybrid, Green Published			2022-12-25	WOS:000186569400034
J	Wang, YN; Chang, WC				Wang, YN; Chang, WC			Induction of disease-associated keratin 16 gene expression by epidermal growth factor is regulated through cooperation of transcription factors Sp1 and c-Jun	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FACTOR-ALPHA; IN-VIVO; HUMAN 12(S)-LIPOXYGENASE; FUNCTIONAL INTERACTION; 12-LIPOXYGENASE GENE; CELL-PROLIFERATION; PROMOTER ACTIVITY; DNA-BINDING; ACTIVATION	Overexpression of keratin 16 has been observed in keratinocytes in those skin diseases characterized by hyperproliferation such as psoriasis. Therefore, keratin 16 is usually referred to as a disease-associated keratin. In the present study, we found that epidermal growth factor (EGF) increased the expression of keratin 16 mRNA and protein synthesis in a time-dependent manner in HaCaT cells. Reporter assays revealed that the EGF response region was in the range of -162 to -114 bp. Disruption of the Sp1 site <LF>(-127 to -122 bp) and the AP1 site (-148 to -142 bp) of the keratin 16 promoter by site-directed mutagenesis significantly inhibited keratin 16 promoter activity induced by EGF. Furthermore, keratin 16 gene expression induced by Ras activation was also regulated in the same manner as the EGF response. By using the DNA affinity precipitation assay in HaCaT and SL2 cells, Sp1 directly interacted with the Sp1 site of the promoter, and c-Jun and c-Fos precipitated with the Sp1 oligonucleotide was attributable to the interaction between the Sp1 and AP1 proteins. Moreover, cotransfection assays revealed that Sp1 acted synergistically with c-Jun to activate keratin 16. The coactivators p300/CBP could collaborate with Sp1 and c-Jun in the activation of keratin 16 promoter, and EGF-induced promoter activation was blocked by the viral oncoprotein E1A. Taken together, these results suggest that Sp1 and AP1 sites in the essential promoter region are critical for EGF response, and Sp1 showed a functional cooperation with c-Jun and coactivators p300/CBP in driving the transcriptional regulation of EGF-induced keratin 16 gene expression.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan	National Cheng Kung University	Chang, WC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan.							Abate C, 1990, Semin Cancer Biol, V1, P19; ARAKAWA T, 1995, FEBS LETT, V363, P105, DOI 10.1016/0014-5793(95)00293-I; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; Bannister AJ, 1995, ONCOGENE, V11, P2509; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chen BK, 2002, J BIOMED SCI, V9, P156, DOI 10.1159/000048212; Chen BK, 2000, MOL PHARMACOL, V57, P153; Corden L D, 1996, Exp Dermatol, V5, P297, DOI 10.1111/j.1600-0625.1996.tb00133.x; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Freedberg IM, 2001, J INVEST DERMATOL, V116, P633, DOI 10.1046/j.1523-1747.2001.01327.x; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Hu PPC, 1999, MOL ENDOCRINOL, V13, P2039, DOI 10.1210/me.13.12.2039; JIANG CK, 1993, P NATL ACAD SCI USA, V90, P6786, DOI 10.1073/pnas.90.14.6786; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Komine M, 2001, J INVEST DERMATOL, V116, P330, DOI 10.1046/j.1523-1747.2001.01249.x; Komine M, 2000, J BIOL CHEM, V275, P32077, DOI 10.1074/jbc.M001253200; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEIGH IM, 1995, BRIT J DERMATOL, V133, P501, DOI 10.1111/j.1365-2133.1995.tb02696.x; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Liu YW, 1997, BIOCHEM J, V324, P133, DOI 10.1042/bj3240133; LLOYD C, 1995, J CELL BIOL, V129, P1329, DOI 10.1083/jcb.129.5.1329; Machesney M, 1998, AM J PATHOL, V152, P1133; MAGNALDO T, 1993, DNA CELL BIOL, V12, P911, DOI 10.1089/dna.1993.12.911; May GHW, 1998, J BIOL CHEM, V273, P33429, DOI 10.1074/jbc.273.50.33429; MCLEAN WHI, 1995, NAT GENET, V9, P273, DOI 10.1038/ng0395-273; NANNEY LB, 1986, J INVEST DERMATOL, V86, P260, DOI 10.1111/1523-1747.ep12285389; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; Sano Y, 1998, J BIOL CHEM, V273, P29098, DOI 10.1074/jbc.273.44.29098; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WETZELS RHW, 1991, AM J PATHOL, V138, P751; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	48	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45848	45857		10.1074/jbc.M302630200	http://dx.doi.org/10.1074/jbc.M302630200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954631	hybrid			2022-12-25	WOS:000186452300098
J	Joerges, C; Kuntze, I; Herzinge, T				Joerges, C; Kuntze, I; Herzinge, T			Induction of a caffeine-sensitive S-phase cell cycle checkpoint by psoralen plus ultraviolet A radiation	ONCOGENE			English	Article						cell cycle; keratinocytes; psoralens; replication checkpoint; ultraviolet radiation	DNA-DAMAGE CHECKPOINT; INTERSTRAND CROSS-LINKS; IRRADIATED HELA-CELLS; ATAXIA-TELANGIECTASIA; SACCHAROMYCES-CEREVISIAE; DEPENDENT KINASES; G(1)/S TRANSITION; MAMMALIAN-CELLS; G(2) CHECKPOINT; PROTEIN-KINASE	Induction of interstrand crosslinks (ICLs) in chromosomal DNA is considered a major reason for the antiproliferative effect of psoralen plus ultraviolet A ( PUVA). It is unclear as to whether PUVA-induced cell cycle arrest is caused by ICLs mechanically stalling replication forks or by triggering cell cycle checkpoints. Cell cycle checkpoints serve to maintain genomic stability by halting cell cycle progression to prevent replication of damaged DNA templates or segregation of broken chromosomes. Here, we show that HaCaT keratinocytes treated with PUVA arrest with S-phase DNA content. Cells that had completed DNA replication were not perturbed by PUVA and passed through mitosis. Cells treated with PUVA during G1-phase continued traversing G1 until arresting in early S-phase. PUVA induced rapid phosphorylation of the Chk1 checkpoint kinase at Ser345 and a concomitant decrease in Cdc25A levels. Chk1 phosphorylation, decrease of Cdc25 A levels and S-phase arrest were abolished by caffeine, demonstrating that active checkpoint signaling rather than passive mechanical blockage by ICLs causes the PUVA-induced replication arrest. Overexpression of Cdc25A only partially overrode the S-phase arrest, suggesting that additional signaling events implement PUVA-induced S-phase arrest.	Univ Munich, Klin & Poliklin Dermatol & Allergol, D-80337 Munich, Germany	University of Munich	Herzinge, T (corresponding author), Univ Munich, Klin & Poliklin Dermatol & Allergol, Frauenlobstr 9-11, D-80337 Munich, Germany.	Thomas.Herzinger@lrz.uni-muenchen.de						Akkari YMN, 2000, MOL CELL BIOL, V20, P8283, DOI 10.1128/MCB.20.21.8283-8289.2000; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BUSSE PM, 1977, RADIAT RES, V71, P666, DOI 10.2307/3574634; BUSSE PM, 1978, RADIAT RES, V76, P292, DOI 10.2307/3574780; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; COHEN SR, 1981, J INVEST DERMATOL, V76, P409, DOI 10.1111/1523-1747.ep12520956; DEANDRADE HHR, 1989, MOL GEN GENET, V217, P419; Diffley JFX, 1998, CURR BIOL, V8, pR771, DOI 10.1016/S0960-9822(07)00483-6; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Esashi F, 1999, MOL CELL, V4, P167, DOI 10.1016/S1097-2765(00)80364-0; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Gaspprro F. P., 1988, PSORALEN DNA PHOTOBI, V1, P5; GUNTHER EJ, 1995, CANCER RES, V55, P1283; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HAMLIN JL, 1992, BIOESSAYS, V14, P651, DOI 10.1002/bies.950141002; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Henzinger T, 1998, J BIOL CHEM, V273, P14958, DOI 10.1074/jbc.273.24.14958; HERZINGER T, 1995, ONCOGENE, V11, P2151; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JACHYMCZYK WJ, 1981, MOL GEN GENET, V182, P196, DOI 10.1007/BF00269658; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Liu QH, 2000, GENE DEV, V14, P1448; LJUNGGREN B, 1980, J INVEST DERMATOL, V74, P59, DOI 10.1111/1523-1747.ep12514621; Luftl M, 1998, J INVEST DERMATOL, V111, P399, DOI 10.1046/j.1523-1747.1998.00316.x; MAGANASCHWENCKE N, 1982, P NATL ACAD SCI-BIOL, V79, P1722, DOI 10.1073/pnas.79.6.1722; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MENIEL V, 1995, MUTAT RES-FUND MOL M, V329, P121, DOI 10.1016/0027-5107(95)00023-C; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; TOBEY RA, 1975, NATURE, V254, P245, DOI 10.1038/254245a0; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; VARGA JM, 1982, CANCER RES, V42, P2223; WANG YY, 1988, MOL CELL BIOL, V8, P196, DOI 10.1128/MCB.8.1.196; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	58	31	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6119	6128		10.1038/sj.onc.1206613	http://dx.doi.org/10.1038/sj.onc.1206613			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679850				2022-12-25	WOS:000185506200001
J	McJilton, MA; Van Sikes, C; Wescott, GG; Wu, DQ; Foreman, TL; Gregory, CW; Weidner, DA; Ford, OH; Lasater, AM; Mohler, JL; Terrian, DM				McJilton, MA; Van Sikes, C; Wescott, GG; Wu, DQ; Foreman, TL; Gregory, CW; Weidner, DA; Ford, OH; Lasater, AM; Mohler, JL; Terrian, DM			Protein kinase C epsilon interacts with Bax and promotes survival of human prostate cancer cells	ONCOGENE			English	Article						apoptosis; LNCaP; CWR22; recurrent prostate cancer; phorbol ester; Bcl-2	ESTER-INDUCED APOPTOSIS; N-TERMINAL KINASE; PHORBOL ESTER; 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED APOPTOSIS; SIGNALING COMPLEXES; EPITHELIAL-CELLS; LINE LNCAP; ANDROGEN; ACTIVATION; EXPRESSION	Prostatic glandular epithelial cells express protein kinase Cepsilon (PKCepsilon), an oncoprotein that coordinately disrupts the reactivation of the tumor suppressor Rb, derepressess transcriptional elongation of the c-myc oncogene, and propagates survival signals in LNCaP cells. Since the activation of such a program may contribute to the progression of human prostate cancer, a proteomic analysis was performed to gain a more global perspective on the signaling network that PKCepsilon might be capable of engaging in prostate cancer cells. Using CWR22 xenografts, we identified at least 18 different structural, signaling, and stress-related proteins that associated with PKCepsilon, including an interaction with the proapoptotic protein Bax that was novel to recurrent CWR22 tumors. An investigation into the biological significance of the PKCepsilon association with Bax provided the first evidence of an inverse relationship between endogenous levels of PKCepsilon and susceptibility of prostate cancer cells to the apoptotic effects of phorbol esters. Western blot and antisense experiments demonstrated that CWR-R1 cells expressed moderate levels of PKCepsilon and relied on this protein to survive in the presence of phorbol esters, while the apoptosis normally induced by phorbol esters in PKCepsilon-deficient LNCaP cells was dependent on the presence of Bax. Forced expression of PKCepsilon in LNCaP cells was sufficient to confer a significant resistance to phorbol esters and this resistance was associated with an inhibition of phorbol ester-induced Bax conformational rearrangements that are important for Bax oligomerization, mitochondrial integration, and cytochrome c release. Considered in their entirety, our data suggest that an association of PKCepsilon with Bax may neutralize apoptotic signals propagated through a mitochondrial death-signaling pathway.	E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Leo W Jenkins Canc Ctr, Greenville, NC 27858 USA; Univ N Carolina, Dept Lab Med & Pathol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Surg, Div Urol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Terrian, DM (corresponding author), E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, 600 Moye Blvd, Greenville, NC 27858 USA.			Weidner, Douglas/0000-0003-1397-1757	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD035041] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008397] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA77739] Funding Source: Medline; NICHD NIH HHS [U54 HD35041] Funding Source: Medline; NIEHS NIH HHS [ES8397] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antonsson B, 2001, CELL TISSUE RES, V306, P347, DOI 10.1007/s00441-001-0472-0; Basu A, 2002, J BIOL CHEM, V277, P41850, DOI 10.1074/jbc.M205997200; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; DAY ML, 1994, CELL GROWTH DIFFER, V5, P735; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Ding L, 2002, J BIOL CHEM, V277, P35305, DOI 10.1074/jbc.M201460200; Edmondson RD, 2002, MOL CELL PROTEOMICS, V1, P421, DOI 10.1074/mcp.M100036-MCP200; Engedal N, 2002, ONCOGENE, V21, P1017, DOI 10.1038/sj.onc.1205167; Engedal N, 2001, PROSTATE, V46, P289, DOI 10.1002/1097-0045(20010301)46:4<289::AID-PROS1035>3.0.CO;2-K; Fribourg AF, 2000, CELL GROWTH DIFFER, V11, P361; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Gao WH, 2001, J CELL SCI, V114, P2855; Garcia-Bermejo ML, 2002, J BIOL CHEM, V277, P645, DOI 10.1074/jbc.M107639200; Garzotto M, 1998, CANCER RES, V58, P2260; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gregory CW, 1999, ENDOCRINOLOGY, V140, P2372, DOI 10.1210/en.140.5.2372; Gregory CW, 2001, J ANDROL, V22, P537; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2001, CANCER RES, V61, P2892; Gschwend JE, 2000, MOL PHARMACOL, V57, P1224; Henttu P, 1998, BIOCHEM BIOPH RES CO, V244, P167, DOI 10.1006/bbrc.1998.8238; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Metcalfe AD, 1999, J CELL SCI, V112, P1771; Montalvo L, 2002, LIFE SCI, V71, P2257, DOI 10.1016/S0024-3205(02)02016-7; Mousses S, 2001, ONCOGENE, V20, P6718, DOI 10.1038/sj.onc.1204889; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Ochoa WF, 2001, J MOL BIOL, V311, P837, DOI 10.1006/jmbi.2001.4910; Ping PP, 2001, CIRC RES, V88, P59, DOI 10.1161/01.RES.88.1.59; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Qiao LX, 2001, BIOORG MED CHEM LETT, V11, P955, DOI 10.1016/S0960-894X(01)00097-X; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Song CX, 2002, AM J PHYSIOL-HEART C, V282, pH1166, DOI 10.1152/ajpheart.00830.2001; Sumitomo M, 2002, J CLIN INVEST, V109, P827, DOI 10.1172/JCI200214146; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Wu DQ, 2002, J BIOL CHEM, V277, P40449, DOI 10.1074/jbc.M206270200; Wu DQ, 2002, CANCER RES, V62, P2423; YOUNG CYF, 1994, ONCOL RES, V6, P203; Zhao X, 2001, UROLOGY, V57, P860, DOI 10.1016/S0090-4295(01)00946-3; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	46	96	112	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7958	7968		10.1038/sj.onc.1206795	http://dx.doi.org/10.1038/sj.onc.1206795			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970744				2022-12-25	WOS:000185388200011
J	Nishizawa, M; Fu, SL; Kataoka, K; Vogt, PK				Nishizawa, M; Fu, SL; Kataoka, K; Vogt, PK			Artificial oncoproteins: modified versions of the yeast bZip protein GCN4 induce cellular transformation	ONCOGENE			English	Article						regulatable transcription; chimeric protein; dimerization	AP-1 TRANSCRIPTION FACTORS; DNA-BINDING DOMAIN; V-JUN; C-JUN; GROWTH-FACTOR; ONCOGENIC TRANSFORMATION; EMBRYO FIBROBLASTS; ESTROGEN-RECEPTOR; DIRECT TARGET; IN-VIVO	We have constructed artificial AP-1 proteins containing elements derived from yeast GCN4 and from the herpes simplex virus activator VP16. These proteins can only homodimerize but do not heterodimerize, and lacking significant homology to Jun outside the DNA-binding domain, they are largely unaffected by proteins that modulate Jun. Constructs in which the transactivation domain of GCN4 is replaced by that of VP16 induce oncogenic transformation in cultures of chicken embryo fibroblasts. The availability of transforming VP16-GCN4 fusion proteins permits an evaluation of downstream target genes, based on the hypothesis that transformation-relevant targets should be common between Jun and the artificial AP-1 proteins. In a pilot study, we examined the expression of several Jun target genes in cells transformed by the VP16-GCN4 fusions and found that some of the Jun targets are not upregulated by the GCN4-derived transforming construct, suggesting that their upregulation in Jun-transformed cells is not essential for cell transformation. We have further constructed a regulatable GCN4-VP16 protein that will permit a kinetic characterization of target gene responses and will facilitate discrimination between direct and indirect targets.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Scripps Research Institute; Tokyo Institute of Technology	Vogt, PK (corresponding author), Natl Yang Ming Univ, Inst Tradit Med, 155 Sec 2,Li Nong St, Taipei 112, Taiwan.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R01CA079616, R35CA042564, R01CA078230] Funding Source: NIH RePORTER; NCI NIH HHS [CA79616, CA78230, CA42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BLACK EJ, 1994, ONCOGENE, V9, P2363; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BROWN PH, 1994, ONCOGENE, V9, P791; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; Hartl M, 1998, ONCOGENE, V17, P2901, DOI 10.1038/sj.onc.1202219; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Jackson BM, 1996, MOL CELL BIOL, V16, P5557; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kataoka K, 2001, J BIOL CHEM, V276, P36849, DOI 10.1074/jbc.M102234200; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; SCHUUR ER, 1993, CELL GROWTH DIFFER, V4, P761; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; STUDLER JM, 1993, EUR J NEUROSCI, V5, P614, DOI 10.1111/j.1460-9568.1993.tb00527.x; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; WAKABAYASHIITO N, 1994, J BIOL CHEM, V269, P29831; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	51	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7931	7941		10.1038/sj.onc.1206527	http://dx.doi.org/10.1038/sj.onc.1206527			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970741				2022-12-25	WOS:000185388200008
J	Bak, I; Szendrei, L; Turoczi, T; Papp, G; Joo, F; Das, DK; de Leiris, J; Der, P; Juhasz, B; Varga, E; Bacskay, I; Balla, J; Kovacs, P; Tosaki, A				Bak, I; Szendrei, L; Turoczi, T; Papp, G; Joo, F; Das, DK; de Leiris, J; Der, P; Juhasz, B; Varga, E; Bacskay, I; Balla, J; Kovacs, P; Tosaki, A			Heme oxygenase-1 related carbon monoxide production and ventricular fibrillation in isolated ischemic/reperfused mouse myocardium	FASEB JOURNAL			English	Article						heme oxygenase-1 expression ischemia/reperfusion; HO-1 knockout mouse hearts	ENDOGENOUS MODULATOR; REPERFUSION INJURY; NITRIC-OXIDE; GENE; INDUCTION; BILIRUBIN; PROTECTS; HEART; OVEREXPRESSION; DYSFUNCTION	Heme oxygenase-1 (HO-1)-dependent carbon monoxide (CO) production related to reperfusion-induced ventricular fibrillation (VF) was studied in HO-1 wild-type (+/+), heterozygous (+/-), and homozygous (-/-) isolated ischemic/reperfused mouse heart. In HO-1 homozygous myocardium, under aerobic conditions, HO-1 enzyme activity, HO-1 mRNA, and protein expression were not detected in comparison with aerobically perfused wild-type and heterozygous myocardium. In wild-type, HO-1 hetero- and homozygous hearts subjected to 20 min ischemia followed by 2 h of reperfusion, the expression of HO-1 mRNA, protein, and HO-1 enzyme activity was detected in various degrees. A reduction in the expression of HO-1 mRNA, protein, and enzyme activity in fibrillated wild-type and heterozygous myocardium was observed. In reperfused/nonfibrillated wild-type and heterozygous hearts, a reduction in HO-1 mRNA, protein expression, and HO-1 enzyme activity was not observed, indicating that changes in HO-1 mRNA, protein, and enzyme activity could be related to the development of VF. These changes were reflected in the HO-1-related endogenous CO production measured by gas chromatography. In HO-1 knockout ischemic/reperfused myocardium, all hearts showed VF, and no detection in HO-1 mRNA, protein, and enzyme activity was observed. Thus, interventions that are able to increase endogenous CO may prevent the development of VF.	Univ Debrecen, Hlth & Sci Ctr, Dept Pharmacol, H-4032 Debrecen, Hungary; Univ Debrecen, Hlth & Sci Ctr, Dept Internal Med 1, H-4032 Debrecen, Hungary; Univ Debrecen, Dept Phys Chem, H-4032 Debrecen, Hungary; Univ Debrecen, Hungarian Acad Sci, Res Grp Homogeneous Catalysis, H-4032 Debrecen, Hungary; Univ Connecticut, Ctr Hlth, Sch Med, Farmington, CT USA; Univ Grenoble 1, Dept Cardiovasc Pharmacol, Grenoble, France	University of Debrecen; University of Debrecen; University of Debrecen; Hungarian Academy of Sciences; University of Debrecen; University of Connecticut; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Tosaki, A (corresponding author), Univ Debrecen, Hlth & Sci Ctr, Dept Pharmacol, Nagyerdei Krt 98, H-4032 Debrecen, Hungary.	tosaki@king.pharmacol.dote.hu	Ferenc, Joo/B-3753-2011; Gábor, Papp/J-5534-2015	Balla, Jozsef/0000-0001-7923-2645				ALTO LE, 1979, AM J PHYSIOL, V237, pH713, DOI 10.1152/ajpheart.1979.237.6.H713; Birnbaum Y, 1997, J ELECTROCARDIOL, V30, P211, DOI 10.1016/S0022-0736(97)80006-4; Birnbaum Y, 1996, AM J CARDIOL, V78, P396, DOI 10.1016/S0002-9149(96)00326-8; Choi AMK, 2001, CIRC RES, V89, P105, DOI 10.1161/res.89.2.105; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTODOULIDES N, 1995, CIRCULATION, V91, P2306, DOI 10.1161/01.CIR.91.9.2306; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; COOK MN, 1995, CAN J PHYSIOL PHARM, V73, P515, DOI 10.1139/y95-065; CURTIS MJ, 1993, CARDIOVASC RES, V27, P703, DOI 10.1093/cvr/27.5.703; DEBIAS DA, 1976, ARCH ENVIRON HEALTH, V31, P42, DOI 10.1080/00039896.1976.10667188; Dickson EW, 2001, J MOL CELL CARDIOL, V33, P1751, DOI 10.1006/jmcc.2001.1436; DOROSHOW JH, 1980, J CLIN INVEST, V65, P128, DOI 10.1172/JCI109642; EWING JF, 1994, J PHARMACOL EXP THER, V271, P408; Gray RA, 1998, NATURE, V392, P75, DOI 10.1038/32164; HEWETT TE, 1994, CIRC RES, V74, P740, DOI 10.1161/01.RES.74.4.740; Hoenicka M, 1999, J MOL MED-JMM, V77, P14, DOI 10.1007/s001090050292; Hopkins PN, 1996, ARTERIOSCL THROM VAS, V16, P250, DOI 10.1161/01.ATV.16.2.250; Ingi T, 1996, NEURON, V16, P835, DOI 10.1016/S0896-6273(00)80103-8; Katori M, 2002, TRANSPLANTATION, V73, P287, DOI 10.1097/00007890-200201270-00023; Keating MT, 1996, SCIENCE, V272, P681, DOI 10.1126/science.272.5262.681; KLONER RA, 1989, CIRCULATION, V80, P1115, DOI 10.1161/01.CIR.80.5.1115; Lakkisto P, 2002, J MOL CELL CARDIOL, V34, P1357, DOI 10.1006/jmcc.2002.2094; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; LI Y, 1995, MAT SCI ENG C-BIOMIM, V2, P221, DOI 10.1016/0928-4931(95)00075-5; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Melo LG, 2002, CIRCULATION, V105, P602, DOI 10.1161/hc0502.103363; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 1999, CHEST, V116, p61S, DOI 10.1378/chest.116.suppl_1.61S-a; Pannen BHJ, 1998, J CLIN INVEST, V102, P1220, DOI 10.1172/JCI3428; Pataki T, 2001, ANTIOXID REDOX SIGN, V3, P125, DOI 10.1089/152308601750100623; Pellacani A, 1998, CIRC RES, V83, P396, DOI 10.1161/01.RES.83.4.396; PRIDJIAN AK, 1987, J THORAC CARDIOV SUR, V93, P428; Reeve VE, 1999, P NATL ACAD SCI USA, V96, P9317, DOI 10.1073/pnas.96.16.9317; ROSEN MR, 1995, CIRCULATION, V92, P3373, DOI 10.1161/01.CIR.92.12.3373; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Schultz JEJ, 1997, AM J PHYSIOL-HEART C, V272, pH2607, DOI 10.1152/ajpheart.1997.272.6.H2607; Sharma VS, 1999, METHODS, V19, P494, DOI 10.1006/meth.1999.0892; Simkhovich Boris Z, 2002, Heart Dis, V4, P63; SUEMATSU M, 1995, J CLIN INVEST, V96, P2431, DOI 10.1172/JCI118300; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Tyrrell R, 1999, FREE RADICAL RES, V31, P335, DOI 10.1080/10715769900300901; TZIVONI D, 1983, AM HEART J, V105, P323, DOI 10.1016/0002-8703(83)90534-3; Vulapalli SR, 2002, AM J PHYSIOL-HEART C, V283, pH688, DOI 10.1152/ajpheart.00133.2002; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163; Yet SF, 2001, CIRC RES, V89, P168, DOI 10.1161/hh1401.093314	49	54	57	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2133	+		10.1096/fj.03-0032fje	http://dx.doi.org/10.1096/fj.03-0032fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958158				2022-12-25	WOS:000185925100021
J	Borlak, J; Thum, T				Borlak, J; Thum, T			Hallmarks of ion channel gene expression in end-stage heart failure	FASEB JOURNAL			English	Article						ion channels; gene expression; repressors; heart failure; assist device	HUMAN ATRIAL-FIBRILLATION; CURRENT DOWN-REGULATION; FAILING HUMAN HEART; CARDIAC TROPONIN-T; MESSENGER-RNA; DIFFERENTIAL REGULATION; DILATED CARDIOMYOPATHY; NATRIURETIC PEPTIDES; VENTRICULAR MYOCYTES; PRESSURE-OVERLOAD	Electrical conductance is greatly altered in end-stage heart failure, but little is known about the underlying events. We therefore investigated the expression of genes coding for major inward and outward ion channels, calcium binding proteins, ion receptors, ion exchangers, calcium ATPases, and calcium/calmodulin-dependent protein kinases in explanted hearts (n = 13) of patients diagnosed with end-stage heart failure. With the exception of Kv11.1 and Kir3.1 and when compared with healthy controls, major sodium, potassium, and calcium ion channels, ion transporters, and exchangers were significantly repressed, but expression of Kv7.1, HCN4, troponin C and I, SERCA1, and phospholamban was elevated. Hierarchical gene cluster analysis provided novel insight into regulated gene networks. Significant induction of the transcriptional repressor m-Bop and the translational repressor NAT1 coincided with repressed cardiac gene expression. The statistically significant negative correlation between repressors and ion channels points to a mechanism of disease. We observed coregulation of ion channels and the androgen receptor and propose a role for this receptor in ion channel regulation. Overall, the reversal of repressed ion channel gene expression in patients with implanted assist devices exemplifies the complex interactions between pressure load/stretch force and heart-specific gene expression.	Fraunhofer Inst Toxicol & Expt Med, Ctr Drug Res & Med Biotechnol, D-30625 Hannover, Germany	Fraunhofer Gesellschaft	Borlak, J (corresponding author), Fraunhofer Inst Toxicol & Expt Med, Ctr Drug Res & Med Biotechnol, Nicolai Fuchs Str 1, D-30659 Hannover, Germany.	Borlak@item.fraunhofer.de		Thum, Thomas/0000-0003-4360-1511				Akao M, 1997, J CLIN INVEST, V100, P3053, DOI 10.1172/JCI119860; Anger M, 1998, CIRCULATION, V98, P2477, DOI 10.1161/01.CIR.98.22.2477; Barrans JD, 2002, AM J PATHOL, V160, P2035, DOI 10.1016/S0002-9440(10)61153-4; Baumer AT, 2002, J APPL PHYSIOL, V92, P1058, DOI 10.1152/japplphysiol.00794.2001; BEUCKELMANN DJ, 1993, CIRC RES, V73, P379, DOI 10.1161/01.RES.73.2.379; Boixel C, 2001, CIRC RES, V89, P607, DOI 10.1161/hh1901.096702; Boknik P, 1999, CARDIOVASC RES, V43, P67, DOI 10.1016/S0008-6363(99)00053-X; Brown DW, 2000, AM HEART J, V140, P848, DOI 10.1067/mhj.2000.111112; BRUGADA P, 1992, J AM COLL CARDIOL, V20, P1391, DOI 10.1016/0735-1097(92)90253-J; Brundel BJJM, 2001, J AM COLL CARDIOL, V37, P926, DOI 10.1016/S0735-1097(00)01195-5; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; CATTERALL WA, 2002, IUPHAR COMPENDIUM VO; de Boer RA, 2001, INT J CARDIOL, V78, P5, DOI 10.1016/S0167-5273(00)00440-X; Dobrev D, 2001, CIRCULATION, V104, P2551, DOI 10.1161/hc4601.099466; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; F'entzke RC, 1999, J PHYSIOL-LONDON, V517, P143, DOI 10.1111/j.1469-7793.1999.0143z.x; Fan QI, 2000, J MOL CELL CARDIOL, V32, P1841, DOI 10.1006/jmcc.2000.1217; Fraysse B, 2001, AM J PHYSIOL-CELL PH, V280, pC146, DOI 10.1152/ajpcell.2001.280.1.C146; GO LO, 1995, J CLIN INVEST, V95, P888, DOI 10.1172/JCI117739; Gottlieb PD, 2002, NAT GENET, V31, P25, DOI 10.1038/ng866; Hammes A, 1998, CIRC RES, V83, P877; Harding JD, 2001, CIRCULATION, V104, P1241, DOI 10.1161/hc3601.095718; Heerdt PM, 2000, CIRCULATION, V102, P2713, DOI 10.1161/01.CIR.102.22.2713; Hoch B, 1999, CIRC RES, V84, P713, DOI 10.1161/01.RES.84.6.713; Hoppe UC, 2000, J CLIN INVEST, V105, P1077, DOI 10.1172/JCI8757; Huang BY, 2000, CARDIOVASC RES, V46, P442, DOI 10.1016/S0008-6363(00)00017-1; Jiang MT, 2002, CIRC RES, V91, P1015, DOI 10.1161/01.RES.0000043663.08689.05; Kaab S, 1998, CIRCULATION, V98, P1383, DOI 10.1161/01.CIR.98.14.1383; KAMITANI T, 1992, CIRC RES, V71, P1457, DOI 10.1161/01.RES.71.6.1457; Lai LP, 1999, J AM COLL CARDIOL, V33, P1231, DOI 10.1016/S0735-1097(99)00008-X; Lowes BD, 1997, J CLIN INVEST, V100, P2315, DOI 10.1172/JCI119770; Luss I, 1999, J MOL CELL CARDIOL, V31, P1299, DOI 10.1006/jmcc.1999.0962; Magnino Fabrice, 2000, Molecular Cell Biology Research Communications, V3, P374, DOI 10.1006/mcbr.2000.0242; Maier LS, 1998, AM J PHYSIOL-HEART C, V274, pH1361, DOI 10.1152/ajpheart.1998.274.4.H1361; Miki T, 2002, NAT MED, V8, P466, DOI 10.1038/nm0502-466; Miura H, 2003, CIRC RES, V92, P151, DOI 10.1161/01.RES.0000052671.53256.49; Munch G, 2001, CIRCULATION, V103, P2739; Nabauer M, 1998, CARDIOVASC RES, V37, P324, DOI 10.1016/S0008-6363(97)00274-5; Nakamura K, 2001, J CLIN INVEST, V107, P1245, DOI 10.1172/JCI12412; NGHIEM P, 1994, NATURE, V371, P347, DOI 10.1038/371347a0; Pak BJ, 1999, J MOL CELL CARDIOL, V31, P1717, DOI 10.1006/jmcc.1999.1008; Periasamy M, 2001, J MOL CELL CARDIOL, V33, P1053, DOI 10.1006/jmcc.2001.1366; Prestle L, 1999, CARDIOVASC RES, V43, P323, DOI 10.1016/S0008-6363(99)00119-4; Qu JH, 2001, CIRC RES, V89, pE8, DOI 10.1161/hh1301.094395; Ranki HJ, 2002, J AM COLL CARDIOL, V40, P367, DOI 10.1016/S0735-1097(02)01947-2; Reinecke H, 1997, CARDIOVASC RES, V36, P216, DOI 10.1016/S0008-6363(97)00180-6; Reiter MJ, 1998, AM J CARDIOL, V82, p9I, DOI 10.1016/S0002-9149(98)00468-8; Ricchiuti V, 1999, CLIN CHEM, V45, P2129; Rieder CV, 2002, AM J PHYSIOL-HEART C, V283, pH273, DOI 10.1152/ajpheart.00042.2002; Rozanski GJ, 2002, CLIN EXP PHARMACOL P, V29, P132, DOI 10.1046/j.1440-1681.2002.03618.x; SASSE S, 1993, CIRC RES, V72, P932, DOI 10.1161/01.RES.72.5.932; Sato Y, 1998, J BIOL CHEM, V273, P28470, DOI 10.1074/jbc.273.43.28470; Scherf M, 2000, J MOL BIOL, V297, P599, DOI 10.1006/jmbi.2000.3589; Schwinger RHG, 1999, CIRCULATION, V99, P2105, DOI 10.1161/01.CIR.99.16.2105; SCHWORER CM, 1993, J BIOL CHEM, V268, P14443; Sehnert AJ, 2002, NAT GENET, V31, P106, DOI 10.1038/ng875; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; Takimoto E, 2002, FASEB J, V16, DOI 10.1096/fj.01-0735com; Tan FL, 2002, P NATL ACAD SCI USA, V99, P11387, DOI 10.1073/pnas.162370099; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Thum T, 2002, FASEB J, V16, P1537, DOI 10.1096/fj.02-0138com; Trepanier-Boulay W, 2001, CIRC RES, V89, P437, DOI 10.1161/hh1701.095644; Viswanathan PC, 2003, J CLIN INVEST, V111, P341, DOI 10.1172/JCI200316879; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236; Wang ZG, 1998, CIRCULATION, V98, P2422, DOI 10.1161/01.CIR.98.22.2422; Wang ZY, 2001, J BIOL CHEM, V276, P17706, DOI 10.1074/jbc.M100544200; Wu AH, 1999, CLIN CARDIOL, V22, P267, DOI 10.1002/clc.4960220404; Yalcin Y, 1999, THYROID, V9, P53, DOI 10.1089/thy.1999.9.53; Yasui K, 2001, CIRC RES, V88, P536, DOI 10.1161/01.RES.88.5.536; Yue LX, 1999, CIRC RES, V84, P776; Zhu N, 1998, ENDOCRINOLOGY, V139, P4337, DOI 10.1210/en.139.10.4337; Zhu WD, 2000, J BIOL CHEM, V275, P15239, DOI 10.1074/jbc.275.20.15239	73	124	130	2	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1592	1608		10.1096/fj.02-0889com	http://dx.doi.org/10.1096/fj.02-0889com			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958166				2022-12-25	WOS:000185925100034
J	Gardner, B; Zhu, LX; Sharma, S; Tashkin, DP; Dubinett, SM				Gardner, B; Zhu, LX; Sharma, S; Tashkin, DP; Dubinett, SM			Methanandamide increases COX-2 expression and tumor growth in murine lung cancer	FASEB JOURNAL			English	Article						cannabinoid; PGE(2); MAPK	MESSENGER-RNA EXPRESSION; CYCLOOXYGENASE-2 EXPRESSION; CANNABINOID RECEPTOR; ENDOGENOUS CANNABINOIDS; IN-VIVO; PROGNOSTIC-SIGNIFICANCE; SIGNALING PATHWAYS; ANTITUMOR IMMUNITY; EPITHELIAL-CELLS; GASTRIC-CANCER	Increased COX-2 expression and elevated PGE(2) have been associated with a poor prognosis in lung cancer. Cannabinoids have been known to exert some of their biological effects via modulation of prostaglandin production. We evaluated the impact of methanandamide on COX-2 expression, PGE(2) production, and tumor growth in murine lung cancer. Methanandamide administration (5 mg/kg, four times/wk i.p.) resulted in an increased rate of tumor growth (P<0.01 compared with diluent treated controls). The CB1 and CB2 receptor antagonists, SR141716 and SR144528, did not block the methanandamide-mediated increase in tumor growth. In vivo, methanandamide treatment increased the production of PGE(2) at the tumor site as well as in splenocytes. Consistent with these results, methanandamide increased PGE(2) and COX-2 levels in murine lung cancer cells in vitro via a cannabinoid receptor-independent mechanism. The COX-2-specific inhibitor, SC58236, abrogated methanandamide induction of PGE2 production in vitro and blocked methanandamide-enhanced tumor growth in vivo. Furthermore, the p38/MAPK inhibitor, SB203528, and the p42/44 inhibitor, PD98059, blocked methanandamide-mediated induction of PGE(2) and COX-2. These results suggest that methanandamide augments tumor growth by a cannabinoid receptor-independent pathway that is associated with the up-regulation of COX-2.	Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Lung Canc Res Program,Ctr Hlth Sci 37 131, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Dubinett, SM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Lung Canc Res Program,Ctr Hlth Sci 37 131, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	sdubinett@mednet.ucla.edu						ABADJI V, 1994, J MED CHEM, V37, P1889, DOI 10.1021/jm00038a020; Achiwa H, 1999, CLIN CANCER RES, V5, P1001; Akhmedkhanov A, 2002, BRIT J CANCER, V87, P49, DOI 10.1038/sj.bjc.6600370; Brabender J, 2002, ANN SURG, V235, P440, DOI 10.1097/00000658-200203000-00017; Calignano A, 2000, NATURE, V408, P96, DOI 10.1038/35040576; Casanova ML, 2003, J CLIN INVEST, V111, P43, DOI 10.1172/JCI200316116; Chan G, 1999, CANCER RES, V59, P991; De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375; DEROCQ JM, 1995, FEBS LETT, V369, P177, DOI 10.1016/0014-5793(95)00746-V; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO TBV, 2002, 2002 S CANN INT CANN; DOHADWALA M, 2002, J BIOL CHEM, V21, P21; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Fan XM, 2001, J GASTROEN HEPATOL, V16, P1098, DOI 10.1046/j.1440-1746.2001.02593.x; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; Gately S, 2000, CANCER METAST REV, V19, P19, DOI 10.1023/A:1026575610124; Harris RE, 2002, ONCOL REP, V9, P693; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Hida T, 1998, CANCER RES, V58, P3761; Hosomi Y, 2000, LUNG CANCER, V30, P73, DOI 10.1016/S0169-5002(00)00132-X; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Huang M, 1998, CANCER RES, V58, P1208; Khuri FR, 2001, CLIN CANCER RES, V7, P861; LaPointe MC, 1999, HYPERTENSION, V33, P276, DOI 10.1161/01.HYP.33.1.276; Leahy KM, 2000, CURR MED CHEM, V7, P1163, DOI 10.2174/0929867003374336; Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1; Liu XJ, 1998, CANCER RES, V58, P4752; Martin BR, 1999, LIFE SCI, V65, P573, DOI 10.1016/S0024-3205(99)00281-7; Masferrer JL, 2000, CANCER RES, V60, P1306; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Miller PW, 2000, HUM GENE THER, V11, P53, DOI 10.1089/10430340050016157; Nong L, 2002, J NEUROIMMUNOL, V127, P169, DOI 10.1016/S0165-5728(02)00113-3; Pagotto U, 2001, J CLIN ENDOCR METAB, V86, P2687, DOI 10.1210/jc.86.6.2687; Parolaro D, 1999, LIFE SCI, V65, P637, DOI 10.1016/S0024-3205(99)00286-6; Ramer R, 2001, BIOCHEM BIOPH RES CO, V286, P1144, DOI 10.1006/bbrc.2001.5518; Recht LD, 2001, BIOCHEM PHARMACOL, V62, P755, DOI 10.1016/S0006-2952(01)00700-6; Salzet M, 2000, EUR J BIOCHEM, V267, P4917, DOI 10.1046/j.1432-1327.2000.01550.x; Sanchez C, 2001, CANCER RES, V61, P5784; Schmid PC, 2002, LIPIDS, V37, P907, DOI 10.1007/s11745-002-0978-z; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; Shamma A, 2000, CLIN CANCER RES, V6, P1229; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Shivachar AC, 1996, BIOCHEM PHARMACOL, V51, P669, DOI 10.1016/S0006-2952(95)02248-1; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Someya A, 2002, EUR J PHARMACOL, V450, P131, DOI 10.1016/S0014-2999(02)02122-2; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Stolina M, 2000, J IMMUNOL, V164, P361, DOI 10.4049/jimmunol.164.1.361; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Uefuji K, 2000, CLIN CANCER RES, V6, P135; Valk P, 1997, BLOOD, V90, P1448, DOI 10.1182/blood.V90.4.1448.1448_1448_1457; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wolff H, 1998, CANCER RES, V58, P4997; Yip-Schneider MT, 2000, CARCINOGENESIS, V21, P139, DOI 10.1093/carcin/21.2.139; Zhu LX, 2000, J IMMUNOL, V165, P373, DOI 10.4049/jimmunol.165.1.373	56	33	35	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2157	+		10.1096/fj.03-0254fje	http://dx.doi.org/10.1096/fj.03-0254fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958151				2022-12-25	WOS:000185925100017
J	Shi, XL; Stoj, C; Romeo, A; Kosman, DJ; Zhu, ZW				Shi, XL; Stoj, C; Romeo, A; Kosman, DJ; Zhu, ZW			Fre1p Cu2+ reduction and fet3p Cu1+ oxidation modulate copper toxicity in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED FORM; AFFINITY IRON TRANSPORT; ESCHERICHIA-COLI; MOLECULAR CHARACTERIZATION; TRANSCRIPTION FACTOR; YEAST; CERULOPLASMIN; GENE; PROTEIN; EXPRESSION	Fre1p is a metalloreductase in the yeast plasma membrane that is essential to uptake of environmental Cu2+ and Fe3+. Fet3p is a multicopper oxidase in this membrane essential for high affinity iron uptake. In the uptake of Fe3+, Fre1p produces Fe2+ that is a substrate for Fet3p; the Fe3+ produced by Fet3p is a ligand for the iron permease, Ftr1p. Deletion of FET3 leads to iron deficiency; this deletion also causes a copper sensitivity not seen in wild type. Deletion of FTR1 leads to copper sensitivity also. Production in the ftr1Delta strain of an iron-uptake negative Ftr1p mutant, Ftr1p(RAGLA), suppressed this copper sensitivity. This Ftr1p mutant supported the plasma membrane targeting of active Fet3p that is blocked in the parental ftr1Delta strain. A ferroxidase-negative Fet3p did not suppress the copper sensitivity in a fet3Delta strain, although it supported the plasma membrane localization of the Fet3p . Ftr1p complex. Thus, loss of membrane-associated Fet3p oxidase activity correlated with copper sensitivity. Furthermore, in vitro Cu1+ was shown to be an excellent substrate for Fet3p. Last, the copper sensitivity of the fet3Delta strain was suppressed by co-deletion of FRE1, suggesting that the cytotoxic species was Cu1+. In contrast, deletion of CTR1 or of FET4 did not suppress the copper sensitivity in the fet3Delta strain; these genes encode the two major copper transporters in laboratory yeast strains. This result indicated that the apparent cuprous ion toxicity was not due to excess intracellular copper. These biochemical and physiologic results indicate that at least with respect to cuprous and ferrous ions, Fet3p can be considered a metallo-oxidase and appears to play an essential role in both iron and copper homeostasis in yeast. Its functional homologs, e. g. ceruloplasmin and hephaestin, could play a similar role in mammals.	Univ Calif Santa Cruz, Dept Environm Toxicol, Santa Cruz, CA 95064 USA; SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	University of California System; University of California Santa Cruz; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Zhu, ZW (corresponding author), Univ Calif Santa Cruz, Dept Environm Toxicol, Santa Cruz, CA 95064 USA.		Shi, Xianglin/B-8588-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053820] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53820] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANG TP, 2003, IN PRESS J BIOL INOR, V8; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BESWICK PH, 1976, CHEM-BIOL INTERACT, V14, P347, DOI 10.1016/0009-2797(76)90113-7; Buettner G R, 1986, Free Radic Res Commun, V1, P349, DOI 10.3109/10715768609051638; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; Fortna RR, 1999, BIOL REPROD, V61, P1042, DOI 10.1095/biolreprod61.4.1042; Georgatsou E, 1999, YEAST, V15, P573, DOI 10.1002/(SICI)1097-0061(199905)15:7<573::AID-YEA404>3.3.CO;2-Z; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; Grass G, 2001, J BACTERIOL, V183, P2145, DOI 10.1128/JB.183.6.2145-2147.2001; Gross C, 2000, J BIOL CHEM, V275, P32310, DOI 10.1074/jbc.M005946200; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Hassett R, 2000, BIOCHEM J, V351, P477, DOI 10.1042/0264-6021:3510477; Hassett RF, 1998, J BIOL CHEM, V273, P23274, DOI 10.1074/jbc.273.36.23274; Hellman NE, 2002, ANNU REV NUTR, V22, P439, DOI 10.1146/annurev.nutr.22.012502.114457; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Kim C, 2001, J BACTERIOL, V183, P4866, DOI 10.1128/JB.183.16.4866-4875.2001; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Machonkin TE, 2001, J AM CHEM SOC, V123, P5507, DOI 10.1021/ja003975s; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; McKie A. T., 2001, Redox Report, V6, P133; Outten FW, 2001, J BIOL CHEM, V276, P30670, DOI 10.1074/jbc.M104122200; Patel BN, 2000, J BIOL CHEM, V275, P4305, DOI 10.1074/jbc.275.6.4305; Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Szczypka MS, 1997, YEAST, V13, P1423, DOI 10.1002/(SICI)1097-0061(199712)13:15<1423::AID-YEA190>3.3.CO;2-3; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	37	62	68	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50309	50315		10.1074/jbc.M307019200	http://dx.doi.org/10.1074/jbc.M307019200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	12954629	hybrid			2022-12-25	WOS:000187068200079
J	Brasch, F; Ochs, M; Kahne, T; Guttentag, S; Schauer-Vukasinovic, V; Derrick, M; Johnen, G; Kapp, N; Muller, KM; Richter, J; Giller, T; Hawgood, S; Buhling, F				Brasch, F; Ochs, M; Kahne, T; Guttentag, S; Schauer-Vukasinovic, V; Derrick, M; Johnen, G; Kapp, N; Muller, KM; Richter, J; Giller, T; Hawgood, S; Buhling, F			Involvement of napsin A in the C- and N-terminal processing of surfactant protein B in type-II pneumocytes of the human lung	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FETAL LUNG; PULMONARY SURFACTANT; ASPARTIC PROTEINASES; ELECTRON-MICROSCOPY; LAMELLAR BODIES; LOCALIZATION; TISSUE; CELLS; PH	Surfactant protein B (SP-B) is a critical component of pulmonary surfactant, and a deficiency of active SP-B results in fatal respiratory failure. SP-B is synthesized by type-II pneumocytes as a 42-kDa propeptide (proSPB), which is posttranslationally processed to an 8-kDa surface-active protein. Napsin A is an aspartic protease expressed in type-II pneumocytes. To characterize the role of napsin A in the processing of proSP-B, we colocalized napsin A and precursors of SP-B as well as SP-B in the Golgi complex, multivesicular, composite, and lamellar bodies of type-II pneumocytes in human lungs using immunogold labeling. Furthermore, we measured aspartic protease activity in isolated lamellar bodies as well as isolated human type-II pneumocytes and studied the cleavage of proSP-B by napsin A and isolated lamellar bodies in vitro. Both, napsin A and isolated lamellar bodies cleaved proSP-B and generated three identical processing products. Processing of proSP-B by isolated lamellar bodies was completely inhibited by an aspartic protease inhibitor. Sequence analysis of proSP-B processing products revealed several cleavage sites in the Nand C-terminal propeptides as well as one in the mature peptide. Two of the four processing products generated in vitro were also detected in type-II pneumocytes. In conclusion, our results show that napsin A is involved in the N- and C-terminal processing of proSP-B in type-II pneumocytes.	Univ Hosp Bergmannsheil, Inst Pathol, D-44789 Bochum, Germany; Univ Gottingen, Dept Anat, Div Electron Microscopy, D-37075 Gottingen, Germany; Univ Magdeburg, Inst Expt Internal Med, Immunol Res Ctr, D-39120 Magdeburg, Germany; F Hoffmann La Roche & Co Ltd, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Konstanz, Dept Biol, Fac Sci, D-78457 Constance, Germany; Univ Magdeburg, Inst Immunol, D-39120 Magdeburg, Germany	Ruhr University Bochum; University of Gottingen; Otto von Guericke University; Roche Holding; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Konstanz; Otto von Guericke University	Brasch, F (corresponding author), Univ Hosp Bergmannsheil, Inst Pathol, Burkle Camp Pl 1, D-44789 Bochum, Germany.		Guttentag, Susan/ABE-7405-2020; Kaehne, Thilo/E-4858-2012; Johnen, Georg/AFG-8027-2022; Guttentag, Susan H/D-8705-2013	Guttentag, Susan/0000-0003-4420-5879; Johnen, Georg/0000-0002-3773-5946; Guttentag, Susan H/0000-0003-4420-5879				ARBUSTINI E, 1994, AM J PATHOL, V145, P310; Beers MF, 2000, AM J RESP CELL MOL, V22, P380, DOI 10.1165/ajrcmb.22.3.3645; Brasch F, 2002, AM J RESP CELL MOL, V26, P659, DOI 10.1165/ajrcmb.26.6.4744; CHANDER A, 1986, J BIOL CHEM, V261, P6126; CHEVALIER G, 1972, ANAT RECORD, V174, P289, DOI 10.1002/ar.1091740303; Chuman Y, 1999, FEBS LETT, V462, P129, DOI 10.1016/S0014-5793(99)01493-3; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; DIAUGUSTINE RP, 1974, J BIOL CHEM, V249, P584; DUCKCHONG CG, 1978, LIFE SCI, V22, P2025, DOI 10.1016/0024-3205(78)90549-0; FEHRENBACH H, 1994, J HEART LUNG TRANSPL, V13, P1; Fehrenbach H, 1998, VIRCHOWS ARCH, V432, P229, DOI 10.1007/s004280050160; Fehrenbach H, 1998, METHODS PULMONARY RE, P429, DOI DOI 10.1007/978-3-0348-8855-4_17; Gonzales LW, 2001, PEDIATR PATHOL MOL M, V20, P387, DOI 10.1080/15513810109168622; GREEN DW, 1990, BIOCHEMISTRY-US, V29, P3126, DOI 10.1021/bi00464a032; Griese M, 1999, EUR RESPIR J, V13, P1455, DOI 10.1183/09031936.99.13614779; Guttentag S, 2003, AM J RESP CELL MOL, V28, P69, DOI 10.1165/rcmb.2002-0111OC; Guttentag SH, 1998, AM J PHYSIOL-LUNG C, V275, pL559, DOI 10.1152/ajplung.1998.275.3.L559; Hawgood S, 1998, BBA-MOL BASIS DIS, V1408, P150, DOI 10.1016/S0925-4439(98)00064-7; HAWGOOD S, 1993, AM J PHYSIOL, V264, pL290, DOI 10.1152/ajplung.1993.264.3.L290; JACOBS KA, 1987, J BIOL CHEM, V262, P9808; JUPP RA, 1988, BIOCHEM J, V254, P895, DOI 10.1042/bj2540895; Korimilli A, 2000, J BIOL CHEM, V275, P8672, DOI 10.1074/jbc.275.12.8672; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; Peterson JJ, 1998, BIOCONJUGATE CHEM, V9, P618, DOI 10.1021/bc980059j; Schauer-Vukasinovic V, 1999, FEBS LETT, V462, P135, DOI 10.1016/S0014-5793(99)01458-1; Schauer-Vukasinovic V, 2000, EUR J BIOCHEM, V267, P2573, DOI 10.1046/j.1432-1327.2000.01268.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Tatnell PJ, 1998, FEBS LETT, V441, P43, DOI 10.1016/S0014-5793(98)01522-1; VOORHOUT WF, 1992, AM J PHYSIOL, V263, pL479, DOI 10.1152/ajplung.1992.263.4.L479; VOORHOUT WF, 1993, MICROSC RES TECHNIQ, V26, P366, DOI 10.1002/jemt.1070260504; VORBROKER DK, 1995, AM J PHYSIOL, V268, P647; WEAVER TE, 1992, AM J PHYSIOL, V263, pL95, DOI 10.1152/ajplung.1992.263.1.L95	33	83	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49006	49014		10.1074/jbc.M306844200	http://dx.doi.org/10.1074/jbc.M306844200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	13129928	hybrid			2022-12-25	WOS:000186829000062
J	Gendron, S; Couture, J; Aoudjit, F				Gendron, S; Couture, J; Aoudjit, F			Integrin alpha(2)beta(1) inhibits Fas-mediated apoptosis in T lymphocytes by protein phosphatase 2A-dependent activation of the MAPK/ERK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; INDUCED CELL-DEATH; EXTRACELLULAR-MATRIX; FOCAL ADHESION; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; POSITIVE REGULATOR; KINASE-ACTIVITY; OKADAIC ACID; IN-VIVO	The mechanisms by which T lymphocytes escape apoptosis during their activation are still poorly defined. In this study, we elucidated the intracellular signaling pathways through which beta(1) integrins modulate Fas-mediated apoptosis in T lymphocytes. In experiments done in Jurkat T cells and activated peripheral blood T lymphocytes, engagement of alpha(2)beta(1) integrin with collagen type I ( Coll I) was found to significantly reduce Fas-induced apoptosis and caspase-8 activation; Annexin V binding and DNA fragmentation were reduced by similar to42 and 38%, respectively. We demonstrated that the protective action of Coll I does not require new protein synthesis but was dependent on the activation of the MAPK/ Erk pathway. Furthermore, we found that activation of protein phosphatase 2A (PP2A) by Coll I was required for both Coll I-mediated activation of Erk, and inhibition of Fas-induced caspase-8 activation and apoptosis. Other ligands of beta(1) integrins, fibronectin (Fbn), and laminin ( Lam), did not sustain significant Erk activation and had no effect on Fas-induced apoptosis. Taken together, these results provide the first evidence of a PP2A-dependent activation of the MAPK/ Erk pathway downstream of alpha(2)beta(1) integrin, which has a functional role in regulating Fas-mediated apoptosis in T lymphocytes. As such, this study emphasizes the potential importance that Coll I interactions may have on the control of T lymphocyte homeostasis and their persistence in chronic inflammatory diseases.	Ctr Hosp Univ Quebec, Ctr Rech Immunol & Rhumatol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Aoudjit, F (corresponding author), Ctr Hosp Univ Quebec, Ctr Rech Immunol & Rhumatol, Pavillon CHUL, Quebec City, PQ G1V 4G2, Canada.	fawzi.aoudjit@crchul.ulaval.ca						Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; AMARAL MC, 1993, IMMUNOLOGY, V79, P24; Aoudjit F, 2000, BLOOD, V95, P2044, DOI 10.1182/blood.V95.6.2044; Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Caricchio R, 2002, CELL DEATH DIFFER, V9, P574, DOI 10.1038/sj.cdd.4400996; CHAN BMC, 1991, J IMMUNOL, V147, P398; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; Coppolino MG, 2000, INT J BIOCHEM CELL B, V32, P171, DOI 10.1016/S1357-2725(99)00043-6; DAMLE NK, 1993, J IMMUNOL, V151, P2368; Damsky CH, 2002, CURR OPIN CELL BIOL, V14, P594, DOI 10.1016/S0955-0674(02)00368-X; de Fougerolles AR, 2000, J CLIN INVEST, V105, P721, DOI 10.1172/JCI7911; DEANA AD, 1990, BIOCHIM BIOPHYS ACTA, V1051, P199, DOI 10.1016/0167-4889(90)90194-I; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; HEMLER ME, 1986, J CLIN INVEST, V78, P696, DOI 10.1172/JCI112629; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Hyduk SJ, 2002, J IMMUNOL, V168, P696, DOI 10.4049/jimmunol.168.2.696; Ilic D, 1998, J CELL BIOL, V143, P547; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Iwata S, 2000, J DERMATOL SCI, V23, P75, DOI 10.1016/S0923-1811(99)00096-1; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; Laakko T, 2003, J BIOL CHEM, V278, P31621, DOI 10.1074/jbc.M304700200; MAGUIRE JE, 1995, J EXP MED, V182, P2079, DOI 10.1084/jem.182.6.2079; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Mitsuhashi S, 2003, J BIOL CHEM, V278, P82, DOI 10.1074/jbc.M208888200; MOBLEY JL, 1994, BLOOD, V83, P1039, DOI 10.1182/blood.V83.4.1039.bloodjournal8341039; Nishioka K, 1998, ARTHRITIS RHEUM, V41, P1; Parameswaran N, 2000, EUR J PHARMACOL, V388, P133, DOI 10.1016/S0014-2999(99)00848-1; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Rao WH, 2000, J IMMUNOL, V165, P4935, DOI 10.4049/jimmunol.165.9.4935; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; SHIMIZU Y, 1991, FASEB J, V5, P2292, DOI 10.1096/fasebj.5.9.1860621; Sieburth DS, 1999, GENE DEV, V13, P2562, DOI 10.1101/gad.13.19.2562; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Sonoda Y, 1997, J BIOL CHEM, V272, P15366, DOI 10.1074/jbc.272.24.15366; Stallmach A, 2001, EUR J IMMUNOL, V31, P1228, DOI 10.1002/1521-4141(200104)31:4<1228::AID-IMMU1228>3.0.CO;2-K; Strack S, 2002, J BIOL CHEM, V277, P41525, DOI 10.1074/jbc.M203767200; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; Weismann M, 1997, J IMMUNOL, V158, P1618; Xu Z, 2002, CELL GROWTH DIFFER, V13, P285; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	56	75	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48633	48643		10.1074/jbc.M305169200	http://dx.doi.org/10.1074/jbc.M305169200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	13679375	hybrid			2022-12-25	WOS:000186829000016
J	Kainov, DE; Pirttimaa, M; Tuma, R; Butcher, SJ; Thomas, GJ; Bamford, DH; Makeyev, EV				Kainov, DE; Pirttimaa, M; Tuma, R; Butcher, SJ; Thomas, GJ; Bamford, DH; Makeyev, EV			RNA packaging device of double-stranded RNA bacteriophages, possibly as simple as hexamer of P4 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3 GENOMIC SEGMENTS; POLYMERASE COMPLEX; RAMAN-SPECTROSCOPY; ASSEMBLY PATHWAY; PURIFIED PROTEIN; DNA TRANSPORT; VIRUS; PHI-6; BINDING; PARTICLES	Genomes of complex viruses have been demonstrated, in many cases, to be packaged into preformed empty capsids (procapsids). This reaction is performed by molecular motors translocating nucleic acid against the concentration gradient at the expense of NTP hydrolysis. At present, the molecular mechanisms of packaging remain elusive due to the complex nature of packaging motors. In the case of the double-stranded RNA bacteriophage phi6 from the Cystoviridae family, packaging of single-stranded genomic precursors requires a hexameric NTPase, P4. In the present study, the purified P4 proteins from two other cystoviruses, phi8 and phi13, were characterized and compared with phi6 P4. All three proteins are hexameric, single-stranded RNA-stimulated NTPases with alpha/beta folds. Using a direct motor assay, we found that phi8 and phi13 P4 hexamers translocate 5' to 3' along ssRNA, whereas the analogous activity of phi6 P4 requires association with the procapsid. This difference is explained by the intrinsically high affinity of phi8 and phi13 P4s for nucleic acids. The unidirectional translocation results in RNA helicase activity. Thus, P4 proteins of Cystoviridae exhibit extensive similarity to hexameric helicases and are simple models for studying viral packaging motor mechanisms.	Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA	University of Helsinki; University of Helsinki; University of Missouri System; University of Missouri Kansas City	Bamford, DH (corresponding author), Univ Helsinki, Dept Biosci, POB 56,Viikinkaari 5, FIN-00014 Helsinki, Finland.	dbamford@mappi.helsinki.fi	Tuma, Roman/AAL-4436-2020; kainov, denis/I-5526-2019; Butcher, Sarah J/H-5579-2012	Tuma, Roman/0000-0003-0047-0013; kainov, denis/0000-0001-7716-6955; Butcher, Sarah/0000-0001-7060-5871; Makeyev, Eugene/0000-0001-6034-6896; Bamford, Dennis/0000-0002-6438-8118	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050776] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50776] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANDEKAR J, 1992, BIOCHIM BIOPHYS ACTA, V1120, P123, DOI 10.1016/0167-4838(92)90261-B; Baumann RG, 2003, J BIOL CHEM, V278, P4618, DOI 10.1074/jbc.M208574200; Benevides JM, 2002, BIOCHEMISTRY-US, V41, P11946, DOI 10.1021/bi0201623; Butcher SJ, 1997, EMBO J, V16, P4477, DOI 10.1093/emboj/16.14.4477; Catalano CE, 2000, CELL MOL LIFE SCI, V57, P128, DOI 10.1007/s000180050503; de Haas F, 1999, J MOL BIOL, V294, P357, DOI 10.1006/jmbi.1999.3260; Errington J, 2001, NAT REV MOL CELL BIO, V2, P538, DOI 10.1038/35080005; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRILANDER M, 1995, J MOL BIOL, V246, P418, DOI 10.1006/jmbi.1994.0096; GOTTLIEB P, 1992, J VIROL, V66, P2611, DOI 10.1128/JVI.66.5.2611-2616.1992; GOTTLIEB P, 1992, J VIROL, V66, P6220, DOI 10.1128/JVI.66.10.6220-6222.1992; Grimes S, 2002, ADV VIRUS RES, V58, P255, DOI 10.1016/S0065-3527(02)58007-6; Guo PX, 2002, PROG NUCLEIC ACID RE, V72, P415, DOI 10.1016/S0079-6603(02)72076-X; Hendrix RW, 1998, CELL, V94, P147, DOI 10.1016/S0092-8674(00)81413-0; Hoogstraten D, 2000, VIROLOGY, V272, P218, DOI 10.1006/viro.2000.0374; Ibarra B, 2001, NUCLEIC ACIDS RES, V29, P4264, DOI 10.1093/nar/29.21.4264; Ikonen T, 2003, J APPL CRYSTALLOGR, V36, P525, DOI 10.1107/S0021889803001857; JUUTI JT, 1995, J MOL BIOL, V249, P545, DOI 10.1006/jmbi.1995.0317; Juuti JT, 1998, J MOL BIOL, V279, P347, DOI 10.1006/jmbi.1998.1772; Juuti JT, 1997, J MOL BIOL, V266, P891, DOI 10.1006/jmbi.1996.0817; Kadare G, 1997, J VIROL, V71, P2583; Kainov DE, 2003, J MOL BIOL, V328, P791, DOI 10.1016/S0022-2836(03)00322-X; King JA, 2001, EMBO J, V20, P3282, DOI 10.1093/emboj/20.12.3282; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Makeyev EV, 2000, EMBO J, V19, P6275, DOI 10.1093/emboj/19.22.6275; Makeyev EV, 2000, EMBO J, V19, P124, DOI 10.1093/emboj/19.1.124; Meijer WJJ, 2001, MICROBIOL MOL BIOL R, V65, P261, DOI 10.1128/MMBR.65.2.261-287.2001; Mindich L, 1999, MICROBIOL MOL BIOL R, V63, P149, DOI 10.1128/MMBR.63.1.149-160.1999; Moore SD, 2002, CURR BIOL, V12, pR96, DOI 10.1016/S0960-9822(02)00670-X; PAATERO AO, 1995, J VIROL, V69, P6729, DOI 10.1128/JVI.69.11.6729-6734.1995; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; Pirttimaa MJ, 2002, J VIROL, V76, P10122, DOI 10.1128/JVI.76.20.10122-10127.2002; Pirttimaa MJT, 2000, RNA, V6, P880, DOI 10.1017/S1355838200992598; Poranen MM, 2001, MOL CELL, V7, P845, DOI 10.1016/S1097-2765(01)00228-3; Qiao XY, 2000, VIROLOGY, V275, P218, DOI 10.1006/viro.2000.0501; Qiao XY, 1997, P NATL ACAD SCI USA, V94, P4074, DOI 10.1073/pnas.94.8.4074; SAMBROOK J, 2001, MOL CLONING LAB MANU, P1017; Schmid S I, 1995, Curr Top Microbiol Immunol, V199 ( Pt 1), P67; Simpson AA, 2000, NATURE, V408, P745, DOI 10.1038/35047129; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Smith DE, 2001, NATURE, V413, P748, DOI 10.1038/35099581; STEVEN AC, 1997, STRUCTURAL BIOL VIRU, P312; Sun Y, 2003, VIROLOGY, V308, P354, DOI 10.1016/S0042-6822(03)00013-8; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; TABOR S, 1990, CURRENT PROTOCOLS MO, P8322; Thomas GJ, 1999, ANNU REV BIOPH BIOM, V28, P1, DOI 10.1146/annurev.biophys.28.1.1; Thomas GJ, 2002, BIOPOLYMERS, V67, P214, DOI 10.1002/bip.10105; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yang HY, 2003, J VIROL, V77, P1195, DOI 10.1128/JVI.77.2.1195-1203.2003	51	52	57	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48084	48091		10.1074/jbc.M306928200	http://dx.doi.org/10.1074/jbc.M306928200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12966097	hybrid			2022-12-25	WOS:000186731400088
J	Most, P; Boerries, M; Eicher, C; Schweda, C; Ehlermann, P; Pleger, ST; Loeffler, E; Koch, WJ; Katus, HA; Schoenenberger, CA; Remppis, A				Most, P; Boerries, M; Eicher, C; Schweda, C; Ehlermann, P; Pleger, ST; Loeffler, E; Koch, WJ; Katus, HA; Schoenenberger, CA; Remppis, A			Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular signal-regulated protein kinase 1/2 (ERK1/2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PATHWAY; NEURITE OUTGROWTH; KINASE; CELL; CA2+; MYOCYTES; GROWTH; FAMILY; RAS; CONTRACTILITY	S100A1 is a Ca2+-binding protein of the EF-hand type that belongs to the S100 protein family. It is specifically expressed in the myocardium at high levels and is considered to be an important regulator of cardiac contractility. Because the S100A1 protein is released into the extracellular space during ischemic myocardial injury, we examined the cardioprotective potential of the extracellular S100A1 protein on ventricular cardiomyocytes in vitro. In this report we show that extracellularly added S100A1 protein is endocytosed into the endosomal compartment of neonatal ventricular cardiomyocytes via a Ca2+-dependent clathrin-mediated process. S100A1 uptake protects neonatal ventricular cardiomyocytes from 2-deoxyglucose and oxidative stress-induced apoptosis in vitro. S100A1-mediated antiapoptotic effects involve specific activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) prosurvival pathway, including activation of phospholipase C, protein kinase C, mitogen-activated protein kinase kinase 1, and ERK1/2. In contrast, neither transsarcolemmal Ca2+ influx via the L-type channel nor protein kinase A activity seems to take part in the S100A1-mediated signaling pathway. In conclusion, this study provides evidence for the S100A1 protein serving as a novel cardioprotective factor in vitro. These findings warrant speculation that injury-dependent release of the S100A1 protein from cardiomyocytes may serve as an intrinsic mechanism to promote survival of the myocardium in vivo.	Univ Heidelberg, D-69115 Heidelberg, Germany; Univ Basel, Biozentrum, Maurice E Muller Inst, CH-4056 Basel, Switzerland; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA	Ruprecht Karls University Heidelberg; University of Basel; Duke University	Most, P (corresponding author), Univ Heidelberg, Bergheimer Str 58, D-69115 Heidelberg, Germany.		Boerries, Melanie/AAM-2602-2021					Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Alexanian AR, 1999, FASEB J, V13, P1611, DOI 10.1096/fasebj.13.12.1611; Bianchi R, 1996, BBA-MOL CELL RES, V1313, P258, DOI 10.1016/0167-4889(96)00098-5; Braz JC, 2002, J CELL BIOL, V156, P905, DOI 10.1083/jcb.200108062; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Convery MK, 1998, PFLUG ARCH EUR J PHY, V436, P581, DOI 10.1007/s004240050675; Davey GE, 2001, J BIOL CHEM, V276, P30819, DOI 10.1074/jbc.M103541200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Du XJ, 2002, MOL CELL BIOL, V22, P2821, DOI 10.1128/MCB.22.8.2821-2829.2002; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Hobai IA, 1997, PFLUG ARCH EUR J PHY, V433, P455, DOI 10.1007/s004240050300; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Kiewitz R, 2000, BIOCHEM BIOPH RES CO, V274, P865, DOI 10.1006/bbrc.2000.3229; Mehrhof FB, 2001, CIRCULATION, V104, P2088, DOI 10.1161/hc4201.097133; Mikkelsen SE, 2001, J NEUROCHEM, V79, P767, DOI 10.1046/j.1471-4159.2001.00605.x; Most P, 2003, J BIOL CHEM, V278, P33809, DOI 10.1074/jbc.M301788200; Most P, 2003, J BIOL CHEM, V278, P26356, DOI 10.1074/jbc.M303338200; Most P, 2001, P NATL ACAD SCI USA, V98, P13889, DOI 10.1073/pnas.241393598; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; Parrizas M, 1997, J BIOL CHEM, V272, P154; Pinson A., 1990, CELL CULTURE TECHNIQ, P20; Pol A, 1998, FEBS LETT, V441, P34, DOI 10.1016/S0014-5793(98)01517-8; Rammes A, 1997, J BIOL CHEM, V272, P9496; Remppis A, 1996, BBA-MOL CELL RES, V1313, P253, DOI 10.1016/0167-4889(96)00097-3; Remppis Andrew, 2002, Basic Research in Cardiology, V97; Reppel M, 2002, EUR HEART J, V23, P41; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	36	62	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48404	48412		10.1074/jbc.M308587200	http://dx.doi.org/10.1074/jbc.M308587200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12960148	hybrid			2022-12-25	WOS:000186731400126
J	Pawlyk, AC; Giasson, BI; Sampathu, DM; Perez, FA; Lim, KL; Dawson, VL; Dawson, TM; Palmiter, RD; Trojanowski, JQ; Lee, VMY				Pawlyk, AC; Giasson, BI; Sampathu, DM; Perez, FA; Lim, KL; Dawson, VL; Dawson, TM; Palmiter, RD; Trojanowski, JQ; Lee, VMY			Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; RECESSIVE JUVENILE PARKINSONISM; UBIQUITIN-PROTEIN LIGASE; ALPHA-SYNUCLEIN; LEWY BODIES; DISEASE; MUTATIONS; DEMENTIA; GENE; EXPRESSION	Autosomal recessive juvenile parkinsonism is a movement disorder associated with the degeneration of dopaminergic neurons in substantia nigra pars compacta. The loss of functional parkin caused by parkin gene mutations is the most common single cause of juvenile parkinsonism. Parkin has been shown to aid in protecting cells from endoplasmic reticulum and oxidative stressors presumably due to ubiquitin ligase activity of parkin that targets proteins for proteasomal degradation. However, studies on parkin have been impeded because of limited reagents specific for this protein. Here we report the generation and characterization of a panel of parkin-specific monoclonal antibodies. Biochemical analyses indicate that parkin is present only in the high salt-extractable fraction of mouse brain, whereas it is present in both the high salt-extractable and RIPA-resistant, SDS-extractable fraction in young human brain. Parkin is present at decreased levels in the high salt-extractable fraction and at increased levels in the SDS-extractable fraction from aged human brain. This shift in the extractability of parkin upon aging is seen in humans but not in mice, demonstrating species-specific differences in the biochemical characteristics of murine versus human parkin. Finally, by using these highly specific anti-parkin monoclonal antibodies, it was not possible to detect parkin in alpha-synuclein-containing lesions in alpha-synucleinopathies, thereby challenging prior inferences about the role of parkin in movement disorders other than autosomal recessive juvenile parkinsonism.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Natl Inst Neurosci, Neurodegenerat Res Lab, Singapore 308433, Singapore; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21287 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Washington; University of Washington Seattle; National Neuroscience Institute (NNI); Johns Hopkins University; Johns Hopkins University	Lee, VMY (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA.	vmylee@mail.med.upenn.edu	Dawson, Valina/Y-9757-2019; Lim, Kah-Leong/AAY-3308-2020; Lim, Kah/L-5426-2019	Lim, Kah-Leong/0000-0002-5440-2588; Dawson, Valina/0000-0002-2915-3970				Baba M, 1998, AM J PATHOL, V152, P879; Choi P, 2001, NEUROREPORT, V12, P2839, DOI 10.1097/00001756-200109170-00017; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; D'Agata V, 2000, EUR J NEUROSCI, V12, P3583, DOI 10.1046/j.1460-9568.2000.00244.x; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Duda JE, 2000, AM J PATHOL, V157, P1439, DOI 10.1016/S0002-9440(10)64781-5; Duda JE, 2000, J NEUROPATH EXP NEUR, V59, P830, DOI 10.1093/jnen/59.9.830; Duda JE, 2002, ANN NEUROL, V52, P205, DOI 10.1002/ana.10279; Forman MS, 2002, AM J PATHOL, V160, P1725, DOI 10.1016/S0002-9440(10)61119-4; Galvin JE, 2000, AM J PATHOL, V157, P361, DOI 10.1016/S0002-9440(10)64548-8; Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0; Gilman S, 1999, J NEUROL SCI, V163, P94, DOI 10.1016/S0022-510X(98)00304-9; Gu WJ, 2000, J NEUROCHEM, V74, P1773, DOI 10.1046/j.1471-4159.2000.0741773.x; Hase A, 2002, BRAIN RES, V930, P143, DOI 10.1016/S0006-8993(02)02241-2; Hilker R, 2002, NEUROSCI LETT, V323, P50, DOI 10.1016/S0304-3940(01)02529-0; Horowitz JM, 2001, DEV BRAIN RES, V126, P31, DOI 10.1016/S0165-3806(00)00133-4; Horowitz JM, 2001, J CHEM NEUROANAT, V21, P75, DOI 10.1016/S0891-0618(00)00111-3; Huynh DP, 2001, DEV BRAIN RES, V130, P173, DOI 10.1016/S0165-3806(01)00234-6; Huynh DP, 2000, ANN NEUROL, V48, P737, DOI 10.1002/1531-8249(200011)48:5<737::AID-ANA7>3.3.CO;2-4; Hyun DH, 2002, J BIOL CHEM, V277, P28572, DOI 10.1074/jbc.M200666200; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kubo S, 2001, J NEUROCHEM, V78, P42, DOI 10.1046/j.1471-4159.2001.00364.x; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; SCHMIDT ML, 1991, AM J PATHOL, V139, P53; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Stichel CC, 2000, EUR J NEUROSCI, V12, P4181, DOI 10.1111/j.1460-9568.2000.01314.x; Van der Reijden BA, 1999, PROTEIN SCI, V8, P1557, DOI 10.1110/ps.8.7.1557; West A, 2002, AM J MED GENET, V114, P584, DOI 10.1002/ajmg.10525; Zarate-Lagunes M, 2001, J COMP NEUROL, V432, P184, DOI 10.1002/cne.1096; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	38	119	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48120	48128		10.1074/jbc.M306889200	http://dx.doi.org/10.1074/jbc.M306889200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12972409	hybrid			2022-12-25	WOS:000186731400093
J	Uetani, T; Matsubara, T; Nomura, H; Murohara, T; Nakayama, S				Uetani, T; Matsubara, T; Nomura, H; Murohara, T; Nakayama, S			Ca2+-dependent modulation of intracellular Mg2+ concentration with amiloride and KB-R7943 in pig carotid artery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE MAGNESIUM CONCENTRATION; ACTIVATED POTASSIUM CHANNELS; PROTEIN-KINASE-C; SMOOTH-MUSCLE; TAENIA-CECI; NA+/CA2+ EXCHANGER; REVERSE-MODE; RAT HEARTS; RED-CELLS; PH	It has long been recognized that magnesium is associated with several important diseases, including diabetes, hypertension, cardiovascular, and cerebrovascular diseases. In the present study, we measured the intracellular free Mg2+ concentration ([Mg2+](i)) using P-31 nuclear magnetic resonance (NMR) in pig carotid artery smooth muscle. In normal solution, application of amiloride (1 mM) decreased [Mg2+](i) by similar to12% after 100 min. Subsequent washout tended to further decrease [Mg2+](i). In contrast, application of amiloride significantly increased [Mg2+](i) (by similar to 13% after 100 min) under Ca2+-free conditions, where passive Mg2+ influx is facilitated. The treatments had little effect on intracellular ATP and pH (pH(i)). Essentially the same Ca2+-dependent changes in [Mg2+](i) were produced with KB-R7943, a selective blocker of reverse mode Na+-Ca2+ exchange. Application of dimethyl amiloride (0.1 mM) in the presence of Ca2+ did not significantly change [Mg2+](i), although it inhibited Na+-H+ exchange at the same concentration. Removal of extracellular Na+ caused a marginal increase in [Mg2+](i) after 100 - 200 min, as seen in intestinal smooth muscle in which Na+- Mg2+ exchange is known to be the primary mechanism of maintaining a low [Mg2+](i) against electrochemical equilibrium. In Na+-free solution (containing Ca2+), neither amiloride nor KB-R7943 decreased [Mg2+](i), but they rather increased it. The results suggest that these inhibitory drugs for Na+-Ca2+ exchange directly modulate Na+- Mg2+ exchange in a Ca2+-dependent manner, and consequently produce the paradoxical decrease in [Mg2+](i) in the presence of Ca2+.	Nagoya Univ, Grad Sch Med, Dept Cell Physiol, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Cardiol, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Geriatr, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University; Nagoya University	Nakayama, S (corresponding author), Nagoya Univ, Grad Sch Med, Dept Cell Physiol, Nagoya, Aichi 4668550, Japan.	h44673a@nucc.cc.nagoya-u.ac.jp	Murohara, Toyoaki/M-4958-2014	Matsubara, Tatsuaki/0000-0002-0647-5475				AICKEN CC, 1989, SODIUM CALCIUM EXCHA, P233; AICKIN CC, 1988, CIBA F SYMP, V139, P3; ALMULLA HA, 2003, J PHYSIOL-LONDON, V547, pC19; Amano T, 2000, BRIT J PHARMACOL, V130, P731, DOI 10.1038/sj.bjp.0703361; BLAUSTEIN MP, 1989, SODIUM CALCIUM EXCHA, P208; BOEHM EA, 1995, AM J PHYSIOL-CELL PH, V268, pC628, DOI 10.1152/ajpcell.1995.268.3.C628; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; BRIGGMAN JV, 1983, HISTOCHEM J, V15, P239, DOI 10.1007/BF01006239; CLARK JF, 1995, J VASC RES, V32, P24, DOI 10.1159/000159074; DILLON PF, 1996, BIOCH SMOOTH MUSCLE, P393; FELDMAN GM, 1992, AMILORIDE ITS ANALOG, P265; FERAY JC, 1988, N-S ARCH PHARMACOL, V338, P332; FLATMAN PW, 1991, J PHYSIOL-LONDON, V443, P217, DOI 10.1113/jphysiol.1991.sp018831; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.ph.53.030191.001355; FREUDENRICH CC, 1992, AM J PHYSIOL, V262, pC1024, DOI 10.1152/ajpcell.1992.262.4.C1024; HADDY FJ, 1992, AMILORIDE ITS ANALOG, P279; HEADRICK JP, 1989, MAGNET RESON MED, V12, P328, DOI 10.1002/mrm.1910120305; Hisamitsu T, 2001, LIFE SCI, V69, P2775, DOI 10.1016/S0024-3205(01)01351-0; Iwamoto T, 1996, J BIOL CHEM, V271, P22391, DOI 10.1074/jbc.271.37.22391; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; Kao WHL, 1999, ARCH INTERN MED, V159, P2151, DOI 10.1001/archinte.159.18.2151; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; Ladilov Y, 1999, AM J PHYSIOL-HEART C, V276, pH1868, DOI 10.1152/ajpheart.1999.276.6.H1868; LUDI H, 1987, J PHYSIOL-LONDON, V390, P367; MCGUIGAN JAS, 2002, J CLIN BASIC CARDIOL, V5, P5; Mottet I, 1997, CAN J PHYSIOL PHARM, V75, P1015, DOI 10.1139/cjpp-75-8-1015; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; NAKAYAMA S, 1991, J PHYSIOL-LONDON, V435, P559, DOI 10.1113/jphysiol.1991.sp018525; NAKAYAMA S, 1995, J PHYSIOL-LONDON, V488, P1; NAKAYAMA S, 1995, JPN J PHYSIOL, V45, P411, DOI 10.2170/jjphysiol.45.411; NAKAYAMA S, 1994, J GEN PHYSIOL, V103, P833, DOI 10.1085/jgp.103.5.833; NAKAYAMA S, 1990, J PHYSIOL-LONDON, V421, P363, DOI 10.1113/jphysiol.1990.sp017949; NISHIMURA H, 1993, BRIT J PHARMACOL, V109, P443, DOI 10.1111/j.1476-5381.1993.tb13589.x; Paolisso G, 1997, AM J HYPERTENS, V10, P346, DOI 10.1016/S0895-7061(96)00342-1; Paul Richard J., 1996, P315; Satoh H, 2000, CIRCULATION, V101, P1441, DOI 10.1161/01.CIR.101.12.1441; SHATTOCK MJ, 1987, J AM COLL NUTR, V6, P27; Shi JY, 2002, NATURE, V418, P876, DOI 10.1038/nature00941; Simchowitz L., 1992, AMILORIDE ITS ANALOG, P9; Tashiro M, 1997, BIOPHYS J, V73, P3358, DOI 10.1016/S0006-3495(97)78360-7; TASHIRO M, 2002, PFLUGERS ARCH, V440, P819; VAUGHANJONES RD, 1983, NATURE, V301, P522, DOI 10.1038/301522a0; Watanabe J, 1998, J MOL CELL CARDIOL, V30, P2307, DOI 10.1006/jmcc.1998.0791; Watano T, 1996, BRIT J PHARMACOL, V119, P555, DOI 10.1111/j.1476-5381.1996.tb15708.x; WEISS RG, 1990, CIRC RES, V66, P1012, DOI 10.1161/01.RES.66.4.1012; WHITE JR, 1993, ANN PHARMACOTHER, V27, P775, DOI 10.1177/106002809302700619; WRAY S, 1988, AM J PHYSIOL, V254, pC213; Xia XM, 2002, NATURE, V418, P880, DOI 10.1038/nature00956; Yang CY, 1998, STROKE, V29, P411, DOI 10.1161/01.STR.29.2.411; Zeitz O, 2002, CIRC RES, V90, P988, DOI 10.1161/01.RES.0000018625.25212.1E; Zhang WQ, 1997, ANAL BIOCHEM, V251, P246, DOI 10.1006/abio.1997.2238; [No title captured]	52	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47491	47497		10.1074/jbc.M307898200	http://dx.doi.org/10.1074/jbc.M307898200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12958315	hybrid			2022-12-25	WOS:000186731400020
J	Wolucka, BA; Van Montagu, M				Wolucka, BA; Van Montagu, M			GDP-mannose 3 ',5 '-epimerase forms GDP-L-gulose, a putative intermediate for the de novo biosynthesis of vitamin C in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-LACTONE DEHYDROGENASE; L-ASCORBIC-ACID; PERFORMANCE LIQUID-CHROMATOGRAPHY; SHOCK COGNATE PROTEIN; ARABIDOPSIS-THALIANA; CATALYTIC MECHANISM; L-GALACTOSE; D-GLUCOSE; FUCOSE SYNTHETASE; ESCHERICHIA-COLI	Despite its importance for agriculture, bioindustry, and nutrition, the fundamental process of L-ascorbic acid ( vitamin C) biosynthesis in plants is not completely elucidated, and little is known about its regulation. The recently identified GDP-Man 3', 5'-epimerase catalyzes a reversible epimerization of GDP-D-mannose that precedes the committed step in the biosynthesis of vitamin C, resulting in the hydrolysis of the highly energetic glycosyl-pyrophosphoryl linkage. Here, we characterize the native and recombinant GDP-Man 3', 5'-epimerase of Arabidopsis thaliana. GDP and GDP-D-glucose are potent competitive inhibitors of the enzyme, whereas GDP-L-fucose gives a complex type of inhibition. The epimerase contains a modified version of the NAD binding motif and is inhibited by NAD(P) H and stimulated by NAD(P)(+). A feedback inhibition of vitamin C biosynthesis is observed apparently at the level of GDP-Man 3', 5'-epimerase. The epimerase catalyzes at least two distinct epimerization reactions and releases, besides the well known GDP-L-galactose, a novel intermediate: GDP- L-gulose. The yield of the epimerization varies and seems to depend on the molecular form of the enzyme. Both recombinant and native enzymes co-purified with a Hsp70 heat-shock protein ( Escherichia coli DnaK and A. thaliana Hsc70.3, respectively). We speculate, therefore, that the Hsp70 molecular chaperones might be involved in folding and/or regulation of the epimerase. In summary, the plant epimerase undergoes a complex regulation and could control the carbon flux into the vitamin C pathway in response to the redox state of the cell, stress conditions, and GDP- sugar demand for the cell wall/glycoprotein biosynthesis. Exogenous L-gulose and L-gulono-1,4-lactone serve as direct precursors of L-ascorbic acid in plant cells. We propose an L-gulose pathway for the de novo biosynthesis of vitamin C in plants.	VIB, Dept Mol Microbiol, B-3001 Louvain, Belgium; State Univ Ghent VIB, Dept Plant Syst Biol, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Flanders Institute for Biotechnology (VIB); Ghent University	Wolucka, BA (corresponding author), VIB, Dept Mol Microbiol, Kasteelpk Arenberg 31, B-3001 Louvain, Belgium.	beata.wolucka@bio.kuleuven.ac.be						Agius F, 2003, NAT BIOTECHNOL, V21, P177, DOI 10.1038/nbt777; Allard STM, 2001, CELL MOL LIFE SCI, V58, P1650, DOI 10.1007/PL00000803; Blankenfeldt W, 2000, EMBO J, V19, P6652, DOI 10.1093/emboj/19.24.6652; Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKHARD B, 1998, J PHYCOL, V34, P779; DAVIES MB, 1991, VITAMIN C ITS CHEM B, P81; Du LC, 2000, CHEM BIOL, V7, P623, DOI 10.1016/S1074-5521(00)00011-9; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; GABRIEL O, 1978, TRENDS BIOCHEM SCI, V3, P193, DOI 10.1016/S0968-0004(78)91666-3; Gatzek S, 2002, PLANT J, V30, P541, DOI 10.1046/j.1365-313X.2002.01315.x; Hancock RD, 2002, TRENDS BIOTECHNOL, V20, P299, DOI 10.1016/S0167-7799(02)01991-1; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HAUS U, 1993, EMBO J, V12, P3763, DOI 10.1002/j.1460-2075.1993.tb06054.x; He XM, 1996, BIOCHEMISTRY-US, V35, P4721, DOI 10.1021/bi952706p; HEBDA PA, 1979, ARCH BIOCHEM BIOPHYS, V194, P496, DOI 10.1016/0003-9861(79)90644-1; HONDA S, 1989, ANAL BIOCHEM, V180, P351, DOI 10.1016/0003-2697(89)90444-2; Imai T, 1998, PLANT CELL PHYSIOL, V39, P1350, DOI 10.1093/oxfordjournals.pcp.a029341; ISHERWOOD FA, 1954, BIOCHEM J, V56, P1; ISHERWOOD FA, 1953, NATURE, V171, P348, DOI 10.1038/171348a0; Jain AK, 2000, MOL BREEDING, V6, P73, DOI 10.1023/A:1009680818138; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KORNFELD RH, 1966, BIOCHIM BIOPHYS ACTA, V117, P79, DOI 10.1016/0304-4165(66)90154-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEWUS FA, 1961, NATURE, V191, P1059, DOI 10.1038/1911059a0; Lutz W, 2001, BIOCHEM BIOPH RES CO, V282, P1211, DOI 10.1006/bbrc.2001.4711; MELO A, 1965, J BIOL CHEM, V240, P398; MENGELE R, 1992, FEBS LETT, V298, P14, DOI 10.1016/0014-5793(92)80011-5; Menon S, 1999, J BIOL CHEM, V274, P26743, DOI 10.1074/jbc.274.38.26743; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; OBA K, 1994, PLANT CELL PHYSIOL, V35, P473; Ono K, 2001, PLANT SCI, V160, P455, DOI 10.1016/S0168-9452(00)00412-X; Ostergaard J, 1997, J BIOL CHEM, V272, P30009, DOI 10.1074/jbc.272.48.30009; Pallanca JE, 2000, J EXP BOT, V51, P669, DOI 10.1093/jexbot/51.345.669; Panchuk II, 2002, PLANT PHYSIOL, V129, P838, DOI 10.1104/pp.001362; Rayon C, 1999, PLANT PHYSIOL, V119, P725, DOI 10.1104/pp.119.2.725; Rosano C, 2000, J MOL BIOL, V303, P77, DOI 10.1006/jmbi.2000.4106; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SHIGEOKA S, 1979, AGR BIOL CHEM TOKYO, V43, P2187, DOI 10.1080/00021369.1979.10863782; Smirnoff N, 2000, CRIT REV PLANT SCI, V19, P267, DOI 10.1016/S0735-2689(00)80005-2; Somers WS, 1998, STRUCTURE, V6, P1601, DOI 10.1016/S0969-2126(98)00157-9; Somoza JR, 2000, STRUCTURE, V8, P123, DOI 10.1016/S0969-2126(00)00088-5; Sturla L, 1997, FEBS LETT, V412, P126, DOI 10.1016/S0014-5793(97)00762-X; Sugino M, 1999, PLANT SCI, V146, P81, DOI 10.1016/S0168-9452(99)00086-2; Swain M, 1997, BBA-LIPID LIPID MET, V1345, P56, DOI 10.1016/S0005-2760(96)00163-4; Wagner C, 2003, PHYTOCHEMISTRY, V62, P887, DOI 10.1016/S0031-9422(02)00703-3; Wheeler GL, 1998, NATURE, V393, P365, DOI 10.1038/30728; Wolucka BA, 2001, P NATL ACAD SCI USA, V98, P14843, DOI 10.1073/pnas.011578198; Wolucka BA, 2001, ANAL BIOCHEM, V294, P161, DOI 10.1006/abio.2001.5165; WU SH, 1994, PLANT MOL BIOL, V25, P577, DOI 10.1007/BF00043887; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Zablackis E, 1996, SCIENCE, V272, P1808, DOI 10.1126/science.272.5269.1808	52	277	312	3	49	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47483	47490		10.1074/jbc.M309135200	http://dx.doi.org/10.1074/jbc.M309135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12954627	hybrid			2022-12-25	WOS:000186731400019
J	Ananthanarayanan, B; Stahelin, RV; Digman, MA; Cho, WH				Ananthanarayanan, B; Stahelin, RV; Digman, MA; Cho, WH			Activation mechanisms of conventional protein kinase C isoforms are determined by the ligand affinity and conformational flexibility of their C1 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; PHORBOL ESTER BINDING; CYTOSOLIC PHOSPHOLIPASE A(2); MEMBRANE-BINDING; MOLECULAR-BASIS; PKC-GAMMA; ALPHA; MONOLAYERS; CALCIUM; DELTA	The regulatory domains of conventional and novel protein kinases C (PKC) have two C1 domains (C1A and C1B) that have been identified as the interaction site for diacylglycerol (DAG) and phorbol ester. It has been reported that C1A and C1B domains of individual PKC isoforms play different roles in their membrane binding and activation; however, DAG affinity of individual C1 domains has not been quantitatively determined. In this study, we measured the affinity of isolated C1A and C1B domains of two conventional PKCs, PKCalpha and PKCgamma, for soluble and membrane-incorporated DAG and phorbol ester by isothermal calorimetry and surface plasmon resonance. The C1A and C1B domains of PKCalpha have opposite affinities for DAG and phorbol ester; i.e. the C1A domain with high affinity for DAG and the C1B domain with high affinity for phorbol ester. In contrast, the C1A and C1b domains of PKCgamma have comparably high affinities for both DAG and phorbol ester. Consistent with these results, mutational studies of full-length proteins showed that the C1A domain is critical for the DAG-induced activation of PKCalpha, whereas both C1A and C1B domains are involved in the DAG-induced activation of PKCgamma. Further mutational studies in conjunction with in vitro activity assay and monolayer penetration analysis indicated that, unlike the C1A domain of PKCalpha, neither the C1A nor the C1B domain of PKCgamma is conformationally restricted. Cell studies with enhanced green fluorescent protein-tagged PKCs showed that PKCalpha did not translocate to the plasma membrane in response to DAG at a basal intracellular calcium concentration due to the inaccessibility of its C1A domain, whereas PKCgamma rapidly translocated to the plasma membrane under the same conditions. These data suggest that differential activation mechanisms of PKC isoforms are determined by the DAG affinity and conformational flexibility of their C1 domains.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, WH (corresponding author), Univ Illinois, Dept Chem MC 111, 845 W Taylor St, Chicago, IL 60607 USA.		Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863; , Michelle/0000-0003-4611-7100	NIGMS NIH HHS [GM 53987, GM 52598] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598, R01GM053987] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P6776, DOI 10.1021/bi00418a020; BERS DM, 1982, AM J PHYSIOL, V242, P404; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7; Bogi K, 1998, CANCER RES, V58, P1423; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cho Wonhwa, 2003, Methods Mol Biol, V233, P291; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Geiges D, 1997, BIOCHEM PHARMACOL, V53, P865, DOI 10.1016/S0006-2952(96)00885-4; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; Kohout SC, 2002, BIOCHEMISTRY-US, V41, P11411, DOI 10.1021/bi026041k; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Mozsolits H, 2003, J PEPT SCI, V9, P77, DOI 10.1002/psc.439; Mozsolits H, 2002, BIOPOLYMERS, V66, P3, DOI 10.1002/bip.10200; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Saito N, 2002, J BIOCHEM, V132, P683, DOI 10.1093/oxfordjournals.jbchem.a003274; SLATER SJ, 1994, J BIOL CHEM, V269, P17160; Slater SJ, 2002, J BIOL CHEM, V277, P15277, DOI 10.1074/jbc.M112207200; Slater SJ, 1996, J BIOL CHEM, V271, P4627; SLATER SJ, 1994, J BIOL CHEM, V269, P4866; SOUVIGNET C, 1991, J BIOL CHEM, V266, P40; Stahelin RV, 2003, J BIOL CHEM, V278, P12452, DOI 10.1074/jbc.M212864200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Szallasi Z, 1996, J BIOL CHEM, V271, P18299, DOI 10.1074/jbc.271.31.18299; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	44	115	116	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46886	46894		10.1074/jbc.M307853200	http://dx.doi.org/10.1074/jbc.M307853200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12954613	Green Published, hybrid			2022-12-25	WOS:000186569400082
J	Chew, O; Whelan, J; Millar, AH				Chew, O; Whelan, J; Millar, AH			Molecular definition of the ascorbate-glutathione cycle in Arabidopsis mitochondria reveals dual targeting of antioxidant defenses in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL REDUCTASE; OXIDATIVE STRESS; DEHYDROASCORBATE REDUCTASE; ELECTRON-TRANSPORT; SUBCELLULAR-LOCALIZATION; SACCHAROMYCES-CEREVISIAE; PEROXIDASE; PROTEIN; IMPORT; EXPRESSION	Key components of the ascorbate-glutathione cycle in Arabidopsis cell organelles are encoded by single organellar targeted isoforms that are dual localized in the chloroplast stroma and the mitochondrion. We demonstrate the presence of the ascorbate-glutathione cycle in purified Arabidopsis mitochondria using enzymatic activity, proteomic and in vitro and in vivo subcellular targeting data that identify the gene products responsible. In vitro experiments using a dual import assay assessing mitochondrial and chloroplast imports simultaneously show dual targeting of ascorbate peroxidase, monodehydroascorbate reductase, and glutathione reductase gene products to mitochondria and chloroplasts, while a putative dehydroascorbate reductase protein is only imported into mitochondria. In vivo subcellular localization using green fluorescent protein fusion proteins show clear targeting of all gene products to mitochondria. Transcript levels show these genes are induced by oxidative chemical stresses targeted to chloroplasts and/or mitochondria and are elevated during photosynthetic operation in the light. Together these data present a model of an integrated ascorbate-glutathione antioxidant defense common to plastids and mitochondria that is linked at the level of the genome in Arabidopsis.	Univ Western Australia, Fac Life & Phys Sci, Sch Biomed & Chem Sci, Plant Mol Biol Grp, Crawley, WA 6009, Australia	University of Western Australia	Millar, AH (corresponding author), Univ Western Australia, Fac Life & Phys Sci, Sch Biomed & Chem Sci, Plant Mol Biol Grp, Crawley, WA 6009, Australia.	hmillar@cyllene.uwa.edu.au	Millar, A. Harvey/A-5452-2008; Whelan, James/F-6402-2011	Millar, A. Harvey/0000-0001-9679-1473; Whelan, James/0000-0001-5754-025X				ANDERSON S, 1986, BIOCHEM J, V240, P709, DOI 10.1042/bj2400709; ARRIGONI O, 1981, FEBS LETT, V125, P242, DOI 10.1016/0014-5793(81)80729-6; Asada K, 1999, ANNU REV PLANT PHYS, V50, P601, DOI 10.1146/annurev.arplant.50.1.601; Asada K., 1987, PHOTOINHIBITION, P227; Babiychuk E, 2003, PLANT J, V33, P899, DOI 10.1046/j.1365-313X.2003.01680.x; Bartoli CG, 2000, PLANT PHYSIOL, V123, P335, DOI 10.1104/pp.123.1.335; Beardslee TA, 2002, PLANT J, V31, P199, DOI 10.1046/j.1365-313X.2002.01344.x; Berthold DA, 2000, BBA-BIOENERGETICS, V1460, P241, DOI 10.1016/S0005-2728(00)00149-3; BRUCE BD, 1994, PLANT MOL BIOL MANUA, pJ1; Chabregas SM, 2003, J CELL SCI, V116, P285, DOI 10.1242/jcs.00228; Charizanis C, 1999, MOL GEN GENET, V262, P437, DOI 10.1007/s004380051103; CHEN GX, 1989, PLANT CELL PHYSIOL, V30, P987; Chew O, 2003, FUNCT PLANT BIOL, V30, P805, DOI 10.1071/FP03077; CREISSEN G, 1995, PLANT J, V8, P167, DOI 10.1046/j.1365-313X.1995.08020167.x; DAHLIN C, 1991, PLANT CELL, V3, P1131, DOI 10.1105/tpc.3.10.1131; DALTON DA, 1993, PLANT PHYSIOL, V102, P481, DOI 10.1104/pp.102.2.481; DALTON DA, 1986, P NATL ACAD SCI USA, V83, P3811, DOI 10.1073/pnas.83.11.3811; DAY DA, 1985, AUST J PLANT PHYSIOL, V12, P219, DOI 10.1071/PP9850219; De Leonardis S, 2000, PLANT PHYSIOL BIOCH, V38, P773, DOI 10.1016/S0981-9428(00)01188-8; DELEONARDIS S, 1995, PLANT PHYSIOL, V109, P847, DOI 10.1104/pp.109.3.847; Dutilleul C, 2003, PLANT CELL, V15, P1212, DOI 10.1105/tpc.009464; EDWARDS EA, 1990, PLANTA, V180, P278, DOI 10.1007/BF00194008; Elo A, 2003, PLANT CELL, V15, P1619, DOI 10.1105/tpc.010009; FOYER CH, 1976, PLANTA, V133, P21, DOI 10.1007/BF00386001; Fryer MJ, 2003, PLANT J, V33, P691, DOI 10.1046/j.1365-313X.2003.01656.x; Giglione C, 2000, EMBO J, V19, P5916, DOI 10.1093/emboj/19.21.5916; Goggin DE, 2003, PLANT PHYSIOL, V131, P1033, DOI 10.1104/pp.102.015081; Gomez JM, 1999, FREE RADICAL RES, V31, pS11, DOI 10.1080/10715769900301261; HOSSAIN MA, 1984, PLANT CELL PHYSIOL, V25, P85; Ishikawa T, 1997, BIOCHEM J, V328, P795, DOI 10.1042/bj3280795; Iturbe-Ormaetxe I, 2001, MOL PLANT MICROBE IN, V14, P1189, DOI 10.1094/MPMI.2001.14.10.1189; Jespersen HM, 1997, BIOCHEM J, V326, P305, DOI 10.1042/bj3260305; Jimenez A, 1997, PLANT PHYSIOL, V114, P275, DOI 10.1104/pp.114.1.275; Jimenez A, 1998, PHYSIOL PLANTARUM, V104, P687, DOI 10.1034/j.1399-3054.1998.1040424.x; Karpinski S, 1997, PLANT CELL, V9, P627, DOI 10.1105/tpc.9.4.627; Kobayashi Y, 2001, BIOCHEM BIOPH RES CO, V289, P1106, DOI 10.1006/bbrc.2001.6130; Kubis S, 2003, PLANT CELL, V15, P1859, DOI 10.1105/tpc.012955; KUBO A, 1993, PLANT CELL PHYSIOL, V34, P1259; Larkin RM, 2003, SCIENCE, V299, P902, DOI 10.1126/science.1079978; Lister R, 2002, PLANT J, V30, P555, DOI 10.1046/j.1365-313X.2002.01316.x; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; Madhusudhan R, 2003, PHYSIOL PLANTARUM, V117, P550, DOI 10.1034/j.1399-3054.2003.00066.x; MAELLARO E, 1994, BIOCHEM J, V301, P471, DOI 10.1042/bj3010471; Millar AH, 2001, PLANT PHYSIOL, V127, P1711, DOI 10.1104/pp.010387; Millar AH, 2001, METHOD CELL BIOL, V65, P53, DOI 10.1016/S0091-679X(01)65004-0; Millar H, 2001, IUBMB LIFE, V51, P201, DOI 10.1080/152165401753311735; Miranda-Vizuete A, 2000, ANTIOXID REDOX SIGN, V2, P801, DOI 10.1089/ars.2000.2.4-801; Moller IM, 2001, ANNU REV PLANT PHYS, V52, P561, DOI 10.1146/annurev.arplant.52.1.561; Murcha MW, 2003, PLANT PHYSIOL, V131, P1737, DOI 10.1104/pp.102.016808; Netto LES, 2002, METHOD ENZYMOL, V348, P260, DOI 10.1016/S0076-6879(02)48644-2; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; Noctor G, 1998, ANNU REV PLANT PHYS, V49, P249, DOI 10.1146/annurev.arplant.49.1.249; Obara K, 2002, PLANT CELL PHYSIOL, V43, P697, DOI 10.1093/pcp/pcf103; Pedrajas JR, 2000, J BIOL CHEM, V275, P16296, DOI 10.1074/jbc.275.21.16296; Peeters N, 2001, BBA-MOL CELL RES, V1541, P54, DOI 10.1016/S0167-4889(01)00146-X; PRASAD TK, 1995, PLANT PHYSIOL, V108, P1597, DOI 10.1104/pp.108.4.1597; Rial DV, 2002, EUR J BIOCHEM, V269, P5431, DOI 10.1046/j.1432-1033.2002.03233.x; Rudhe C, 2002, PLANT J, V30, P213, DOI 10.1046/j.1365-313X.2002.01280.x; Shigeoka S, 2002, J EXP BOT, V53, P1305, DOI 10.1093/jexbot/53.372.1305; Strand A, 2003, NATURE, V421, P79, DOI 10.1038/nature01204; Sweetlove LJ, 2001, FEBS LETT, V508, P272, DOI 10.1016/S0014-5793(01)03069-1; Sweetlove LJ, 2002, PLANT J, V32, P891, DOI 10.1046/j.1365-313X.2002.01474.x; Szederkenyi J, 1997, PLANTA, V202, P349, DOI 10.1007/s004250050137; Taylor NL, 2002, J BIOL CHEM, V277, P42663, DOI 10.1074/jbc.M204761200; Waegemann K, 1995, METHOD CELL BIOL, V50, P255, DOI 10.1016/S0091-679X(08)61035-3; Watanabe N, 2001, J BIOL CHEM, V276, P20474, DOI 10.1074/jbc.M101140200; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WHELAN J, 1993, PLANT PHYSIOL, V103, P1481, DOI 10.1104/pp.103.4.1481	68	329	366	6	54	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46869	46877		10.1074/jbc.M307525200	http://dx.doi.org/10.1074/jbc.M307525200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12954611	hybrid			2022-12-25	WOS:000186569400080
J	Foster, CE; Colonna, M; Sun, PD				Foster, CE; Colonna, M; Sun, PD			Crystal structure of the human natural killer (NK) cell activating receptor NKp46 reveals structural relationship to other leukocyte receptor complex immunoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-2-DEFICIENT LYMPHOMA VARIANTS; IMMUNOGLOBULIN-LIKE RECEPTOR; HEAVY-ATOM DERIVATIVES; QUICK-SOAK METHOD; FC-ALPHA-RI; INHIBITORY RECEPTOR; CYTOTOXICITY RECEPTORS; SURFACE-MOLECULE; LIGAND-BINDING; T-CELLS	Natural cytotoxicity receptors (NCR) mediate lysis of a variety of tumor and virus-infected cells by natural killer (NK) cells. Upon engagement, NCR trigger the cytolytic activity and cytokine release of NK cells through association with ITAM-containing signaling molecules. To further understand the function of these receptors in activation of natural cytotoxicity, we determined the crystal structure of the extracellular ligand binding domain of human NKp46, one of three known NCR, at 2.2-Angstrom resolution. The overall fold and disposition of the two C2-set immunoglobulin domains are similar to the D1D2 domains of inhibitory killer cell Ig-like receptor (KIR) and Ig-like transcript (ILT) receptors. As the cellular ligands of NKp46 have not yet been defined, the known ligand binding sites of KIR and ILT were compared with the corresponding structural regions of NKp46 in an effort to identify potential areas suitable for molecular recognition. A potential binding site for influenza hemagglutinin is located near the interdomain hinge, a region that mediates ligand binding in KIR. The structural similarity of NKp46 to inhibitory KIR receptors may have implications for how NK cells balance activating and inhibitory signals.	NIAID, Struct Immunol Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Washington University (WUSTL)	Sun, PD (corresponding author), NIAID, Struct Immunol Sect, Immunogenet Lab, NIH, 12441 Parklawn Dr, Rockville, MD 20852 USA.	psun@niaid.nih.gov		Colonna, Marco/0000-0001-5222-4987	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000697, Z01AI000697] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Augugliaro R, 2003, EUR J IMMUNOL, V33, P1235, DOI 10.1002/eji.200323896; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Biassoni R, 1999, EUR J IMMUNOL, V29, P1014, DOI 10.1002/(SICI)1521-4141(199903)29:03<1014::AID-IMMU1014>3.0.CO;2-O; Boyington JC, 2000, NATURE, V405, P537, DOI 10.1038/35014520; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cantoni C, 2003, STRUCTURE, V11, P725, DOI 10.1016/S0969-2126(03)00095-9; Cantoni C, 1999, J EXP MED, V189, P787, DOI 10.1084/jem.189.5.787; Chapman TL, 1999, IMMUNITY, V11, P603, DOI 10.1016/S1074-7613(00)80135-1; Chapman TL, 2000, IMMUNITY, V13, P727, DOI 10.1016/S1074-7613(00)00071-6; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(09)00098-3; Davis DM, 1999, P NATL ACAD SCI USA, V96, P15062, DOI 10.1073/pnas.96.26.15062; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Ding Y, 2003, J BIOL CHEM, V278, P27966, DOI 10.1074/jbc.C300223200; Dustin ML, 2002, ARTHRITIS RES THER, V4, pS119, DOI 10.1186/ar559; Falco M, 1999, IMMUNOL LETT, V68, P411, DOI 10.1016/S0165-2478(99)00052-8; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; Fan QR, 2001, NAT IMMUNOL, V2, P452, DOI 10.1038/87766; Freiberg BA, 2002, NAT IMMUNOL, V3, P911, DOI 10.1038/ni836; Garman SC, 1999, ANNU REV IMMUNOL, V17, P973, DOI 10.1146/annurev.immunol.17.1.973; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Herr AB, 2003, NATURE, V423, P614, DOI 10.1038/nature01685; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Karre K, 2002, SCAND J IMMUNOL, V55, P221, DOI 10.1046/j.1365-3083.2002.01053.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Maenaka K, 1999, STRUCTURE, V7, P391, DOI 10.1016/S0969-2126(99)80052-5; Mandelboim O, 2001, NATURE, V409, P1055, DOI 10.1038/35059110; Martin AM, 2002, TRENDS IMMUNOL, V23, P81, DOI 10.1016/S1471-4906(01)02155-X; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Moretta A, 1999, CURR TOP MICROBIOL, V244, P69; Moretta A, 2000, IMMUNOL TODAY, V21, P228, DOI 10.1016/S0167-5699(00)01596-6; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pende D, 1999, J EXP MED, V190, P1505, DOI 10.1084/jem.190.10.1505; Pessino A, 1998, J EXP MED, V188, P953, DOI 10.1084/jem.188.5.953; Potter TA, 2001, P NATL ACAD SCI USA, V98, P12624, DOI 10.1073/pnas.221458898; Sivori S, 1997, J EXP MED, V186, P1129, DOI 10.1084/jem.186.7.1129; Sivori S, 1999, EUR J IMMUNOL, V29, P1656, DOI 10.1002/(SICI)1521-4141(199905)29:05<1656::AID-IMMU1656>3.0.CO;2-1; Snyder GA, 1999, P NATL ACAD SCI USA, V96, P3864, DOI 10.1073/pnas.96.7.3864; Storset AK, 2003, EUR J IMMUNOL, V33, P980, DOI 10.1002/eji.200323710; Sun PD, 2000, ACTA CRYSTALLOGR D, V56, P161, DOI 10.1107/S0907444999015188; Sun PD, 2002, ACTA CRYSTALLOGR D, V58, P1099, DOI 10.1107/S0907444902006522; Sun PD, 2002, ACTA CRYSTALLOGR D, V58, P1092, DOI 10.1107/S0907444902006510; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Vankayalapati R, 2002, J IMMUNOL, V168, P3451, DOI 10.4049/jimmunol.168.7.3451; Vitale M, 1998, J EXP MED, V187, P2065, DOI 10.1084/jem.187.12.2065; Wagtmann N, 1997, CURR BIOL, V7, P615, DOI 10.1016/S0960-9822(06)00263-6; Willcox BE, 2003, NAT IMMUNOL, V4, P913, DOI 10.1038/ni961; WILLCOX BE, 2002, BMC STRUCTURE BIOL; Wines BD, 1999, J IMMUNOL, V162, P2146; Wines BD, 2001, J IMMUNOL, V166, P1781, DOI 10.4049/jimmunol.166.3.1781; Zhang YH, 2000, IMMUNITY, V13, P387, DOI 10.1016/S1074-7613(00)00038-8	57	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46081	46086		10.1074/jbc.M308491200	http://dx.doi.org/10.1074/jbc.M308491200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12960161	hybrid			2022-12-25	WOS:000186452300125
J	Ott, C; Iwanciw, D; Graness, A; Giehl, K; Goppelt-Struebe, M				Ott, C; Iwanciw, D; Graness, A; Giehl, K; Goppelt-Struebe, M			Modulation of the expression of connective tissue growth factor by alterations of the cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SERUM RESPONSE FACTOR; RAT MESANGIAL CELLS; BINDING PROTEIN-RHO; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; AGENTS STIMULATE; FOCAL ADHESIONS; STRESS FIBERS; TGF-BETA	Modulation of the cytoskeletal architecture was shown to regulate the expression of CTGF ( connective tissue growth factor, CCN2). The microtubule disrupting agents nocodazole and colchicine strongly up-regulated CTGF expression, which was prevented upon stabilization of the microtubules by paclitaxel. As a consequence of microtubule disruption, RhoA was activated and the actin stress fibers were stabilized. Both effects were related to CTGF induction. Overexpression of constitutively active RhoA induced CTGF synthesis. Interference with RhoA signaling by simvastatin, toxinB, C3 toxin, and Y27632 prevented up-regulation of CTGF. Likewise, direct disintegration of the actin cytoskeleton by latrunculin B interfered with nocodazole-mediated up-regulation of CTGF expression. Disassembly of actin fibers by cytochalasin D, however, unexpectedly increased CTGF expression indicating that the content of F-actin per se was not the major determinant for CTGF gene expression. Given the fact that cytochalasin D sequesters G-actin, a decrease in G-actin increased CTGF, while increased levels of G-actin corresponded to reduced CTGF expression. These data link alterations in the microtubule and actin cytoskeleton to the expression of CTGF and provide a molecular basis for the observation that CTGF is up-regulated in cells exposed to mechanical stress.	Univ Erlangen Nurnberg, Med Klin 4, D-91054 Erlangen, Germany; Univ Ulm, Inst Pharmakol & Toxikol, D-89081 Ulm, Germany	University of Erlangen Nuremberg; Ulm University	Goppelt-Struebe, M (corresponding author), Univ Erlangen Nurnberg, Med Klin 4, Loschgestr 8, D-91054 Erlangen, Germany.							Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; Cipolla MJ, 2002, FASEB J, V16, P72, DOI 10.1096/cj.01-0104hyp; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Eberlein M, 2001, BRIT J PHARMACOL, V133, P1172, DOI 10.1038/sj.bjp.0704173; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Galle J, 2003, J AM SOC NEPHROL, V14, P1471, DOI 10.1097/01.ASN.0000067412.18899.9B; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; GOPPELTSTRUEBE M, 2001, MOL PATHOL, V3, P176; Grinnell F, 1999, J BIOL CHEM, V274, P918, DOI 10.1074/jbc.274.2.918; Hahn A, 2000, J BIOL CHEM, V275, P37429, DOI 10.1074/jbc.M000976200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Heusinger-Ribeiro J, 2001, J AM SOC NEPHROL, V12, P1853, DOI 10.1681/ASN.V1291853; Hishikawa K, 2001, J BIOL CHEM, V276, P16797, DOI 10.1074/jbc.M010722200; Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009; IWANCIW D, 2003, IN PRESS ARTERIOSCLE; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kessler D, 2001, J BIOL CHEM, V276, P36575, DOI 10.1074/jbc.M101602200; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; MANIE S, 1993, J BIOL CHEM, V268, P13675; MULLER GA, 1995, EXP NEPHROL, V3, P127; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Riser BL, 2000, J AM SOC NEPHROL, V11, P25, DOI 10.1681/ASN.V11125; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; Schild C, 2002, EXP CELL RES, V274, P83, DOI 10.1006/excr.2001.5458; Small JV, 1999, FEBS LETT, V452, P96, DOI 10.1016/S0014-5793(99)00530-X; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; STROEBEL M, 1994, J BIOL CHEM, V269, P22952; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Wahab NA, 2001, BIOCHEM J, V359, P77, DOI 10.1042/0264-6021:3590077; Wei L, 2001, FASEB J, V15, P785, DOI 10.1096/fj.00-026com; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415	42	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44305	44311		10.1074/jbc.M309140200	http://dx.doi.org/10.1074/jbc.M309140200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12951326	hybrid			2022-12-25	WOS:000186306700052
J	Van Komen, S; Reddy, MS; Krejci, L; Klein, H; Sung, P				Van Komen, S; Reddy, MS; Krejci, L; Klein, H; Sung, P			ATPase and DNA helicase activities of the Saccharomyces cerevisiae anti-recombinase Srs2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; REPLICATION PROTEIN-A; ESCHERICHIA-COLI; STRAND EXCHANGE; YEAST RAD51; MUTATIONS; GENE; FILAMENT; REQUIRES; ALLELE	Saccharomyces cerevisiae SRS2 encodes an ATP-dependent DNA helicase that is needed for DNA damage checkpoint responses and that modulates the efficiency of homologous recombination. Interestingly, strains simultaneously mutated for SRS2 and a variety of DNA repair genes show low viability that can be overcome by inactivating homologous recombination, thus implicating inappropriate recombination as the cause of growth impairment in these mutants. Here, we report on our biochemical characterization of the ATPase and DNA helicase activities of Srs2. ATP hydrolysis by Srs2 occurs efficiently only in the presence of DNA, with ssDNA being considerably more effective than dsDNA in this regard. Using homopolymeric substrates, the minimal DNA length for activating ATP hydrolysis is found to be 5 nucleotides, but a length of 10 nucleotides is needed for maximal activation. In its helicase action, Srs2 prefers substrates with a 3' ss overhang, and similar to10 bases of 3' overhanging DNA is needed for efficient targeting of Srs2 to the substrate. Even though a 3' overhang serves to target Srs2, under optimized conditions blunt-end DNA substrates are also dissociated by this protein. The ability of Srs2 to unwind helicase substrates with a long duplex region is enhanced by the inclusion of the single-strand DNA-binding factor replication protein A.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; New York University; New York University	Sung, P (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St,C130 Sterling Hall Med, New Haven, CT 06520 USA.	Patrick.Sung@yale.edu	Krejci, Lumir/B-7842-2009	Krejci, Lumir/0000-0002-4732-1405; Klein, Hannah/0000-0003-4228-8535	NCI NIH HHS [CA96593] Funding Source: Medline; NIEHS NIH HHS [ES07061] Funding Source: Medline; NIGMS NIH HHS [GM57814, GM53738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1989, NUCLEIC ACIDS RES, V17, P7211, DOI 10.1093/nar/17.18.7211; AGUILERA A, 1988, GENETICS, V119, P779; Aylon Y, 2003, MOL CELL BIOL, V23, P1403, DOI 10.1128/MCB.23.4.1403-1417.2003; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; Klein H, 2001, GENETICS, V157, P557; Klein HL, 2000, NAT GENET, V25, P132, DOI 10.1038/75957; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; LAWRENCE CW, 1979, J BACTERIOL, V139, P866, DOI 10.1128/JB.139.3.866-876.1979; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; Liberi G, 2000, EMBO J, V19, P5027, DOI 10.1093/emboj/19.18.5027; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Nakagawa T, 2001, J BIOL CHEM, V276, P31487, DOI 10.1074/jbc.M104003200; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PALLADINO F, 1992, GENETICS, V132, P23; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Petukhova G, 2000, GENE DEV, V14, P2206, DOI 10.1101/gad.826100; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; RONG L, 1991, GENETICS, V127, P75; RONG L, 1993, J BIOL CHEM, V268, P1252; SCHIESTL RH, 1990, GENETICS, V124, P817; SCHILD D, 1995, GENETICS, V140, P115; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wu L, 2002, MUTAT RES-FUND MOL M, V509, P35, DOI 10.1016/S0027-5107(02)00225-7	32	42	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44331	44337		10.1074/jbc.M307256200	http://dx.doi.org/10.1074/jbc.M307256200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12966095	hybrid			2022-12-25	WOS:000186306700056
J	Evans, JR; Mitchell, SA; Spriggs, KA; Ostrowski, J; Bomsztyk, K; Ostarek, D; Willis, AE				Evans, JR; Mitchell, SA; Spriggs, KA; Ostrowski, J; Bomsztyk, K; Ostarek, D; Willis, AE			Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo	ONCOGENE			English	Article						c-myc; translation; internal ribosome entry; IRES; poly (rC) binding proteins	NUCLEAR RIBONUCLEOPROTEIN-K; SITE-MEDIATED TRANSLATION; DOMAIN PROTEINS; HNRNP K; INITIATION; IRES; REGION; ONCOGENE; LEADS; GENE	The 5' untranslated region of the proto-oncogene c-myc contains an internal ribosome entry segment and c-Myc translation can be initiated by cap-independent as well as cap-dependent mechanisms. In contrast to the process of cap-dependent initiation, the trans-acting factor requirements for cellular internal ribosome entry are poorly understood. Here, we show that members of the poly (rC) binding protein family, poly (rC) binding protein 1 (PCBP1), poly (rC) binding protein 2 (PCBP2) and hnRNPK were able to activate the IRES in vitro up to threefold when added in combination with upstream of N-ras and unr-interacting protein. The interactions of PCBP1, PCBP2 and hnRNPK with c-myc-IRES-RNA were shown to be specific by ultraviolet crosslinking analysis and electrophoretic mobility shift assays, while immunoprecipitation of the three proteins using specific antibodies followed by reverse transcriptase-polymerase chain reaction showed that they were able to bind c-myc mRNA. c-myc-IRES-mediated translation from the reporter vector was stimulated by cotransfection of plasmids encoding PCBP1, PCBP2 and hnRNPK. Interestingly, the mutated version of the c-myc IRES that is prevalent in patients with multiple myeloma bound hnRNPK more efficiently in vitro and was stimulated by hnRNPK to a greater extent in vivo.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Washington, Seattle, WA 98195 USA; Univ Halle Wittenberg, Dept Biochem, D-06210 Halle An Der Saale, Germany	University of Leicester; University of Washington; University of Washington Seattle; Martin Luther University Halle Wittenberg	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	aew5@le.ac.uk		Ostareck, Dirk/0000-0001-9406-7190; Ostrowski, Jerzy/0000-0003-1363-3766; Willis, Anne/0000-0002-1470-8531				Andino R, 1999, TRENDS MICROBIOL, V7, P76, DOI 10.1016/S0966-842X(98)01446-2; BLACK DL, 1998, ELECTROPHORETIC MOBI; Chappell SA, 2000, ONCOGENE, V19, P4437, DOI 10.1038/sj.onc.1203791; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Gamarnik AV, 1997, RNA, V3, P882; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Henis-Korenblit S, 2002, P NATL ACAD SCI USA, V99, P5400, DOI 10.1073/pnas.082102499; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Holcik M, 1997, P NATL ACAD SCI USA, V94, P2410, DOI 10.1073/pnas.94.6.2410; Hunt SL, 1999, GENE DEV, V13, P437, DOI 10.1101/gad.13.4.437; Jopling CL, 2001, ONCOGENE, V20, P2664, DOI 10.1038/sj.onc.1204404; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kim JH, 2000, J MOL BIOL, V298, P395, DOI 10.1006/jmbi.2000.3687; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; Lomakin IB, 2000, MOL CELL BIOL, V20, P6019, DOI 10.1128/MCB.20.16.6019-6029.2000; Makeyev AV, 2002, RNA, V8, P265, DOI 10.1017/S1355838202024627; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; NIESVIZKY R, 1993, BLOOD REV, V7, P24, DOI 10.1016/0268-960X(93)90021-U; Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; Ostrowski J, 2002, J BIOL CHEM, V277, P6303, DOI 10.1074/jbc.M110267200; Paulin FEM, 1996, ONCOGENE, V13, P505; Paulin FEM, 1998, NUCLEIC ACIDS RES, V26, P3097, DOI 10.1093/nar/26.13.3097; Pilipenko EV, 2000, GENE DEV, V14, P2028; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; STONELEY M, 1998, THESIS U LEICESTER; Thisted T, 2001, J BIOL CHEM, V276, P17484, DOI 10.1074/jbc.M010594200; VANSEUNINGEN I, 1995, BIOCHEMISTRY-US, V34, P5644, DOI 10.1021/bi00016a040; Walter BL, 1999, RNA, V5, P1570, DOI 10.1017/S1355838299991483; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; West MJ, 1995, ONCOGENE, V11, P2515	43	177	187	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					8012	8020		10.1038/sj.onc.1206645	http://dx.doi.org/10.1038/sj.onc.1206645			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970749				2022-12-25	WOS:000185388200016
J	Kim, YK; Han, JW; Woo, YN; Chun, JK; Yoo, JY; Cho, EJ; Hong, SY; Lee, HY; Lee, YW; Lee, HW				Kim, YK; Han, JW; Woo, YN; Chun, JK; Yoo, JY; Cho, EJ; Hong, SY; Lee, HY; Lee, YW; Lee, HW			Expression of p21WAF1/Cip1 through Sp1 sites by histone deacetylase inhibitor apicidin requires PI 3-kinasePKC epsilon signaling pathway	ONCOGENE			English	Article						historic deacetylase inhibitor; apicidin; p21(WAF1/Cip1); PI 3-kinase; PKC epsilon	KINASE-C-EPSILON; HUMAN P21(WAF1/CIP1) GENE; GROWTH-FACTOR-BETA; TRANSCRIPTIONAL ACTIVATION; PHOSPHOINOSITIDE 3-KINASE; TRICHOSTATIN-A; INDUCTION; PROMOTER; P53; CHROMATIN	We previously reported that the activation of p21(WAF1/Cip1) transcription by histone deacetylase inhibitor apicidin was mediated through Sp1 sites and pointed to the possible participation of protein kinase C (PKC). In this study, we investigated the role and identity of the specific isoforms of PKC involved and identified phosphatidylinositol 3-kinase (PI 3-kinase) as an upstream effector in HeLa cells. Using an isoform-specific pharmacological inhibitor of PKC, a PKCepsilon dominant-negative mutant, and antisense oligonucleotide to inhibit PKCepsilon specifically, we found that among PKC isoforms, PKCepsilon was required for the p21(WAF1/Cip1) expression by apicidin. In addition to PKCepsilon, PI 3-kinase appeared to participate in the activation of p21(WAF1/Cip1) promoter by apicidin, since inactivation of PI 3-kinase either by transient expression of dominant-negative mutant of PI 3-kinase or its specific inhibitors, LY294002 and wortmannin, attenuated the activation of p21(WAF1/Cip1) promoter and p21(WAF1/Cip1) protein expression by apicidin. Furthermore, membrane translocation of PKCepsilon in response to apicidin was blocked by the PI 3-kinase inhibitor, indicating the role of PI 3-kinase as an upstream molecule of PRO: in the p21(WAF1/Cip1) promoter activation by apicidin. However, the p21(WAF1/Cip1) expression by apicidin appeared to be independent of the histone hyperacetylation, since apicidin-induced histone hyperacetylation of p21(WAF1/Cip1) promoter region was not affected by inhibition of PI 3-kinase and PKC, suggesting that the chromatin remodeling through the histone hyperacetylation alone might not be sufficient for the expression of p21(WAF1/Cip1) by apicidin. Taken together, these results suggest that the PI 3-kinase-PKCepsilon signaling pathway plays a pivotal role in the expression of the p21(WAF1/Cip1) by apicidin.	Sungkyunkwan Univ, Coll Pharm, Dept Biochem & Mol Biol, Suwon 440746, South Korea; Sungkyunkwan Univ, Dept Genet Engn, Suwon 440746, South Korea; Konyang Univ, Coll Med, Dept Pharmacol, Nonsan 320711, South Korea; Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea	Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Konyang University; Konyang University Hospital; Seoul National University (SNU)	Lee, HW (corresponding author), Sungkyunkwan Univ, Coll Pharm, Dept Biochem & Mol Biol, Suwon 440746, South Korea.	hylee@skku.ac.kr	Cho, Eun-Jung/AAR-1785-2020	Cho, Eun-Jung/0000-0002-6610-5329				Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; CHEDID M, 1994, ONCOGENE, V9, P3021; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; COUSENS LS, 1979, J BIOL CHEM, V254, P1716; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Espinos E, 1998, MOL BRAIN RES, V56, P118, DOI 10.1016/S0169-328X(98)00036-9; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Han JW, 2000, CANCER RES, V60, P6068; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Kwon SH, 2002, J BIOL CHEM, V277, P2073, DOI 10.1074/jbc.M106699200; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee TH, 2000, ONCOGENE, V19, P3766, DOI 10.1038/sj.onc.1203715; LI YJ, 1995, ONCOGENE, V10, P599; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Park JS, 1999, APPL ENVIRON MICROB, V65, P126; Petersohn D, 1996, EUR J BIOCHEM, V239, P827, DOI 10.1111/j.1432-1033.1996.0827u.x; Petrovics G, 2002, ARCH BIOCHEM BIOPHYS, V397, P217, DOI 10.1006/abbi.2001.2640; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rivero JA, 1998, BIOCHEM BIOPH RES CO, V248, P664, DOI 10.1006/bbrc.1998.9041; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sowa Y, 1999, CANCER RES, V59, P4266; Sternglanz R, 1996, TRENDS BIOCHEM SCI, V21, P357, DOI 10.1016/S0968-0004(96)90120-6; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TOKER A, 1994, J BIOL CHEM, V269, P32358; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YANO H, 1993, J BIOL CHEM, V268, P25846; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	63	48	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6023	6031		10.1038/sj.onc.1206875	http://dx.doi.org/10.1038/sj.onc.1206875			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955081				2022-12-25	WOS:000185137800011
J	Krause, DR; Jonnalagadda, JC; Gatei, MH; Sillje, HHW; Zhou, BB; Nigg, EA; Khanna, K				Krause, DR; Jonnalagadda, JC; Gatei, MH; Sillje, HHW; Zhou, BB; Nigg, EA; Khanna, K			Suppression of Tousled-like kinase activity after DNA damage or replication block requires ATM, NBS1 and Chk1	ONCOGENE			English	Article						ATM; NBS1; checkpoints; DNA damage; Chk1; TLK	S-PHASE CHECKPOINT; CELL-CYCLE CHECKPOINTS; ATAXIA-TELANGIECTASIA; INDUCED PHOSPHORYLATION; PROTEIN-KINASE; HUMAN ASF1; GENE; ACTIVATION; PATHWAYS; REPAIR	The human Tousled-like kinases 1 and 2 (TLK) have been shown to be active during S phase of the cell cycle. TLK activity is rapidly suppressed by DNA damage and by inhibitors of replication. Here we report that the signal transduction pathway, which leads to transient suppression of TLK activity after the induction of double-strand breaks (DSBs) in the DNA, is dependent on the presence of a functional ataxia-telangiectasia-mutated kinase (ATM). Interestingly, we have discovered that rapid suppression of TLK activity after low doses of ultraviolet (UV) irradiation or aphidicolin-induced replication block is also ATM-dependent. The nature of the signal that triggers ATM-dependent downregulation of TLK activity after UVC and replication block remains unknown, but it is not due exclusively to DSBs in the DNA. We also demonstrate that TLK suppression is dependent on the presence of a functional Nijmegan Breakage Syndrome protein (NBS1). ATM-dependent phosphorylation of NBS1 is required for the suppression of TLK activity, indicating a role for NBS1 as an adaptor or scaffold in the ATM/TLK pathway. ATM does not phosphorylate TLK directly to regulate its activity, but Chk1 does phosphorylate TLK1 GST-fusion proteins in vitro. Using Chk1 siRNAs, we show that Chk1 is essential for the suppression of TLK activity after replication block, but that ATR, Chk2 and BRCA1 are dispensable for TLK suppression. Overall, we propose that ATM activation is not linked solely to DSBs and that ATM participates in initiating signaling pathways in response to replication block and UV-induced DNA damage.	Queensland Inst Med Res, Canc & Cell Biol Div, Signal Transduct Lab, 300 Herston Rd, Herston, Qld 4029, Australia; Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany; Incyte Genom Inc, Newark, DE 19714 USA	QIMR Berghofer Medical Research Institute; Max Planck Society; DuPont; Incyte	Krause, DR (corresponding author), Queensland Inst Med Res, Canc & Cell Biol Div, Signal Transduct Lab, 300 Herston Rd, Herston, Qld 4029, Australia.	darrenk@qimr.edu.au		Khanna, Kum Kum/0000-0001-8650-5381; nigg, erich/0000-0003-4835-5719				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; GATEI M, 2003, J BIOL CHEM; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Jackson JR, 2000, CANCER RES, V60, P566; KAUFMANN WK, 1995, CANCER METAST REV, V14, P31, DOI 10.1007/BF00690209; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Li Y, 2001, ONCOGENE, V20, P726, DOI 10.1038/sj.onc.1204147; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Mello JA, 2002, EMBO REP, V3, P329, DOI 10.1093/embo-reports/kvf068; Nakanishi K, 2002, NAT CELL BIOL, V4, P913, DOI 10.1038/ncb879; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Oakley GG, 2001, MOL BIOL CELL, V12, P1199, DOI 10.1091/mbc.12.5.1199; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; ROE JL, 1993, CELL, V75, P939, DOI 10.1016/0092-8674(93)90537-Z; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Schar P, 2001, CELL, V104, P329, DOI 10.1016/S0092-8674(01)00220-3; Shiloh Y, 1996, J CLIN IMMUNOL, V16, P254, DOI 10.1007/BF01541389; Sillje HHW, 2001, CURR BIOL, V11, P1068, DOI 10.1016/S0960-9822(01)00298-6; Sillje HHW, 1999, EMBO J, V18, P5691, DOI 10.1093/emboj/18.20.5691; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang Y, 2000, GENE DEV, V14, P927; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Xu B, 2002, CANCER RES, V62, P4588; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; ZDZIENICKA MZ, 1989, CANCER RES, V49, P1481; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zhou XY, 2002, CANCER RES, V62, P1598	48	58	63	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5927	5937		10.1038/sj.onc.1206691	http://dx.doi.org/10.1038/sj.onc.1206691			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955071				2022-12-25	WOS:000185137800001
J	Rippe, V; Drieschner, N; Meiboom, M; Escobar, HM; Bonk, U; Belge, G; Bullerdiek, J				Rippe, V; Drieschner, N; Meiboom, M; Escobar, HM; Bonk, U; Belge, G; Bullerdiek, J			Identification of a gene rearranged by 2p21 aberrations in thyroid adenomas	ONCOGENE			English	Article						2p21 aberrations; thyroid adenomas; THADA; fusion gene	CYTOGENETIC FINDINGS; TUMORS; TRANSLOCATION; 19Q13	Thyroid adenomas belong to the cytogenetically best investigated human epithelial tumors. Cytogenetic studies of about 450 benign lesions allow one to distinguish between different cytogenetic subgroups. Two chromosomal regions, that is, 19q13 and 2p21, are frequently rearranged in these tumors. Although 2p21 aberrations only account for about 10% of the benign thyroid tumors with clonal cytogenetic deviations, 2p21 rearrangements belong to the most common cytogenetic rearrangements in epithelial tumors due to the high frequency of these benign lesions. The 2p21 breakpoint region recently has been delineated to a region of 450 kbp, but the gene affected by the cytogenetic rearrangements still has escaped detection. Positional cloning and 3' RACE-PCR allowed us to clone that gene which we will refer to as thyroid adenoma associated (THADA) gene. In cells from two thyroid adenomas characterized by translocations t(2;20;3) (p21;q11.2;p25) and t(2;7)(p21;p15), respectively, we performed 3'-RACE-PCRs and found two fusions of THADA with a sequence derived from chromosome band 3p25 or with a sequence derived from chromosome band 7p15. The THADA gene spans roughly 365 kbp and, based on preliminary results, encodes a death receptor-interacting protein.	Univ Bremen, Ctr Human Genet, D-28359 Bremen, Germany; Cent Hosp Bremen Nord, Inst Pathol, Bremen, Germany	University of Bremen	Bullerdiek, J (corresponding author), Univ Bremen, Ctr Human Genet, Leobener Str ZHG, D-28359 Bremen, Germany.	bullerdiek@uni-breinen.de	Murua Escobar, Hugo/A-1294-2012; Rippe, Volkhard/I-1927-2013	Rippe, Volkhard/0000-0001-8758-6013				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARTNITZKE S, 1989, CANCER GENET CYTOGEN, V39, P65, DOI 10.1016/0165-4608(89)90230-6; BELGE G, 1992, CELL BIOL INT REP, V16, P339, DOI 10.1016/S0309-1651(06)80139-6; Belge G, 1998, CANCER GENET CYTOGEN, V101, P42, DOI 10.1016/S0165-4608(97)00057-5; Belge G, 2001, CYTOGENET CELL GENET, V93, P48, DOI 10.1159/000056947; Berner JM, 1997, ONCOGENE, V14, P2935, DOI 10.1038/sj.onc.1201135; Bol S, 2001, CYTOGENET CELL GENET, V95, P189, DOI 10.1159/000059344; Bol S, 1999, CANCER GENET CYTOGEN, V114, P75, DOI 10.1016/S0165-4608(99)00028-X; BONDESON L, 1989, CANCER, V64, P680, DOI 10.1002/1097-0142(19890801)64:3<680::AID-CNCR2820640319>3.0.CO;2-I; BULLERDIEK J, 1987, CANCER GENET CYTOGEN, V24, P205, DOI 10.1016/0165-4608(87)90100-2; DALCIN P, 1992, CANCER GENET CYTOGEN, V60, P99, DOI 10.1016/0165-4608(92)90244-3; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; KIEVITS T, 1990, CYTOGENET CELL GENET, V53, P134, DOI 10.1159/000132913; Rippe V, 1999, GENE CHROMOSOME CANC, V26, P229, DOI 10.1002/(SICI)1098-2264(199911)26:3<229::AID-GCC7>3.0.CO;2-J; TEYSSIER JR, 1990, CANCER GENET CYTOGEN, V50, P249, DOI 10.1016/0165-4608(90)90184-C	16	49	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6111	6114		10.1038/sj.onc.1206867	http://dx.doi.org/10.1038/sj.onc.1206867			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955091				2022-12-25	WOS:000185137800021
J	Goglia, F; Skulachev, VP				Goglia, F; Skulachev, VP			A function for novel uncoupling proteins: antioxidant defense of mitochondrial matrix by translocating fatty acid peroxides from the inner to the outer membrane leaflet	FASEB JOURNAL			English	Article						uncoupling protein; mitochondria; lipid peroxide; anion carrier	OXIDATIVE STRESS; SKELETAL-MUSCLE; SUPEROXIDE-DISMUTASE; CYTOCHROME-C; DIFFERENTIAL REGULATION; PROTON TRANSPORT; THYROID-HORMONE; MAMMALIAN-CELLS; ANION CARRIERS; COLD-EXPOSURE	It is hypothesized that mitochondrial uncoupling proteins operate as carriers of fatty acid peroxide anions. This is assumed to result in electrophoretic extrusion of such anions from the inner to the outer leaflet of the inner mitochondrial membrane, being driven by membrane potential ( mitochondrial interior negative). In this way, the inner leaflet is ridded of fatty acid peroxides that otherwise can form very aggressive oxidants damaging mitochondrial DNA, aconitase, and other mitochondrial matrix-localized components of vital importance. The steady-state concentration the fatty acid peroxides is known to be low. This explains why UCP2, 3, 4, and 5 are present in small amounts usually insufficient to make a large contribution to the H+ conductance of the mitochondrial membrane. -	Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Dept Bioenerget, Moscow 119992, Russia; Dipartimento Sci Biol & Ambientali, I-082100 Benevento, Italy	Lomonosov Moscow State University	Skulachev, VP (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Dept Bioenerget, GSP-2, Moscow 119992, Russia.	skulach@belozersky.msu.ru	Skulachev, Vladimir P/J-4164-2012	Skulachev, Vladimir P/0000-0003-4886-2243; GOGLIA, Fernando/0000-0003-0468-9645; Skulachev, Vladimir/0000-0001-5141-7517				ANDREYEV AY, 1989, EUR J BIOCHEM, V182, P585, DOI 10.1111/j.1432-1033.1989.tb14867.x; Argiles JM, 2002, BIOCHEM BIOPH RES CO, V293, P1145, DOI 10.1016/S0006-291X(02)00355-8; Argyropoulos G, 2002, J APPL PHYSIOL, V92, P2187, DOI 10.1152/japplphysiol.00994.2001; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Barja G, 2002, FREE RADICAL BIO MED, V33, P1167, DOI 10.1016/S0891-5849(02)00910-3; Bechmann I, 2002, BIOCHEM PHARMACOL, V64, P363, DOI 10.1016/S0006-2952(02)01166-8; Boss O, 1997, FEBS LETT, V412, P111, DOI 10.1016/S0014-5793(97)00755-2; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Brand MD, 2002, BIOCHEM J, V368, P597, DOI 10.1042/BJ20021077; CARLSSON LM, 1995, P NATL ACAD SCI USA, V92, P6264, DOI 10.1073/pnas.92.14.6264; Carmona MC, 1998, BIOCHEM BIOPH RES CO, V243, P224, DOI 10.1006/bbrc.1998.8088; Cortez-Pinto H, 1999, GASTROENTEROLOGY, V116, P1184, DOI 10.1016/S0016-5085(99)70022-3; Cortez-Pinto H, 1998, BIOCHEM BIOPH RES CO, V251, P313, DOI 10.1006/bbrc.1998.9473; de Lange P, 2001, ENDOCRINOLOGY, V142, P3414, DOI 10.1210/en.142.8.3414; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gardner PR, 1997, BIOSCIENCE REP, V17, P33, DOI 10.1023/A:1027383100936; Garlid KD, 1998, FEBS LETT, V438, P10, DOI 10.1016/S0014-5793(98)01246-0; Garlid KD, 2001, BIOCHEM SOC T, V29, P803, DOI 10.1042/BST0290803; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Graziewicz MA, 2002, NUCLEIC ACIDS RES, V30, P2817, DOI 10.1093/nar/gkf392; Harper ME, 2001, BBA-BIOENERGETICS, V1504, P159, DOI 10.1016/S0005-2728(00)00244-9; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; Horvath B, 2002, BIOCHEM PHARMACOL, V64, P369, DOI 10.1016/S0006-2952(02)01167-X; Imai H, 2003, FREE RADICAL BIO MED, V34, P145, DOI 10.1016/S0891-5849(02)01197-8; Iwahashi H, 2002, BIOCHEM J, V361, P57, DOI 10.1042/0264-6021:3610057; Jarmuszkiewicz W, 2000, FEBS LETT, V467, P145, DOI 10.1016/S0014-5793(00)01138-8; Jezek P, 2003, FEBS LETT, V534, P15, DOI 10.1016/S0014-5793(02)03779-1; JEZEK P, 1994, J BIOL CHEM, V269, P26184; Jucker BM, 2000, P NATL ACAD SCI USA, V97, P6880, DOI 10.1073/pnas.120131997; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Klingenberg M, 2001, BBA-BIOENERGETICS, V1504, P128, DOI 10.1016/S0005-2728(00)00242-5; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Laloi M, 1997, NATURE, V389, P135, DOI 10.1038/38156; Lanni A, 2002, FEBS LETT, V525, P7, DOI 10.1016/S0014-5793(02)02828-4; Li LX, 2001, BIOCHEM BIOPH RES CO, V282, P273, DOI 10.1006/bbrc.2001.4577; Lin BZ, 1998, AM J PHYSIOL-ENDOC M, V275, pE386, DOI 10.1152/ajpendo.1998.275.3.E386; Liu SS, 1997, BIOSCIENCE REP, V17, P259, DOI 10.1023/A:1027328510931; Lombardi A, 2002, FEBS LETT, V532, P12, DOI 10.1016/S0014-5793(02)03690-6; Maia IG, 1998, FEBS LETT, V429, P403, DOI 10.1016/S0014-5793(98)00634-6; Mao WG, 1999, FEBS LETT, V443, P326, DOI 10.1016/S0014-5793(98)01713-X; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Melov S, 2000, ANN NY ACAD SCI, V908, P219; Mizuno T, 2000, BIOCHEM BIOPH RES CO, V278, P691, DOI 10.1006/bbrc.2000.3859; Murphy MP, 1997, TRENDS BIOTECHNOL, V15, P326, DOI 10.1016/S0167-7799(97)01068-8; Nedergaard J, 2001, BBA-BIOENERGETICS, V1504, P82, DOI 10.1016/S0005-2728(00)00247-4; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NEUBERT D, 1962, P NATL ACAD SCI USA, V48, P1651, DOI 10.1073/pnas.48.9.1651; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Pecqueur C, 2001, J MOL MED, V79, P48, DOI 10.1007/s001090000150; Raimbault S, 2001, BIOCHEM J, V353, P441, DOI 10.1042/0264-6021:3530441; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Santos JH, 2003, J BIOL CHEM, V278, P1728, DOI 10.1074/jbc.M208752200; Simonyan RA, 2001, BBA-BIOENERGETICS, V1505, P271, DOI 10.1016/S0005-2728(01)00168-2; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Skulachev VP, 1997, BIOSCIENCE REP, V17, P347, DOI 10.1023/A:1027344914565; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Skulachev VP, 1999, J BIOENERG BIOMEMBR, V31, P431, DOI 10.1023/A:1005492205984; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; SKULACHEV VP, 1988, MEMBRANE BIOENERGETI, P234; Sluse FE, 2002, FEBS LETT, V510, P117, DOI 10.1016/S0014-5793(01)03229-X; Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x; Stuart JA, 2001, BBA-BIOENERGETICS, V1504, P144, DOI 10.1016/S0005-2728(00)00243-7; Tomas P, 2002, FEBS LETT, V526, P63, DOI 10.1016/S0014-5793(02)03116-2; Toyomizu M, 2002, FEBS LETT, V529, P313, DOI 10.1016/S0014-5793(02)03395-1; VERCESI AE, 1995, NATURE, V375, P24, DOI 10.1038/375024a0; Vianna CR, 2001, PHYSIOL GENOMICS, V5, P137, DOI 10.1152/physiolgenomics.2001.5.3.137; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; WINKLER E, 1994, J BIOL CHEM, V269, P2508; Wojtczak L, 1998, ARCH BIOCHEM BIOPHYS, V357, P76, DOI 10.1006/abbi.1998.0777; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5; Yu XX, 2000, FASEB J, V14, P1611, DOI 10.1096/fj.14.11.1611; ZACKOVA M, 2003, J BIOL CHEM, V218, P20771; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	81	198	212	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1585	1591		10.1096/fj.03-0159hyp	http://dx.doi.org/10.1096/fj.03-0159hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958165				2022-12-25	WOS:000185925100033
J	Lemieux, K; Konrad, D; Klip, A; Marette, A				Lemieux, K; Konrad, D; Klip, A; Marette, A			The AMP-activated protein kinase activator AICAR does not induce GLUT4 translocation to transverse tubules but stimulates glucose uptake and p38 mitogen-activated protein kinases alpha and beta in skeletal muscle	FASEB JOURNAL			English	Article						glucose transport; exercise; contraction; insulin; plasma membrane	ACETYL-COA CARBOXYLASE; N-TERMINAL KINASE; IN-VIVO; SIGNALING PATHWAYS; POTENTIAL ROLE; MALONYL-COA; T TUBULES; TRANSPORT; INSULIN; CONTRACTION	The AMP-activated protein kinase ( AMPK) pathway participates in the metabolic effects of contraction on muscle glucose uptake. We have shown that contraction increases both GLUT4 translocation to the cell surface and p38 mitogen-activated protein kinase ( p38 MAPK) activity. The latter pathway may be involved in the activation of GLUT4. Here we investigated whether the AMPK activator AICAR increases glucose uptake by inducing translocation of GLUT4 and/or by activating the p38 MAPK pathway. AICAR infusion into glucose-clamped rats increased muscle glucose uptake and GLUT4 translocation from an intracellular fraction to the plasma membrane but not to T-tubules. AICAR also caused recruitment of the transferrin receptor to the plasma membrane and increased [I-125]-transferrin uptake in isolated muscle. AICAR treatment in vivo or in vitro activated both p38 MAPKalpha and beta (1.6- to 2.8-fold) in EDL muscles with a time course identical to that of stimulation of AMPK and glucose transport. The p38 MAPK inhibitor SB203580 abrogated the stimulatory effect of AICAR on glucose uptake. These results suggest that AICAR increases muscle glucose uptake by two mechanisms: 1) inducing selective recruitment of GLUT4 to the plasma membrane, and 2) activating p38 MAPKalpha and beta, which may be involved in the activation of GLUT4.	Laval Univ Hosp, Res Ctr, Dept Anat & Physiol, Lipid Res Unit, St Foy, PQ G1V 4G2, Canada; Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada	Laval University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Marette, A (corresponding author), Laval Univ Hosp, Res Ctr, Dept Physiol, 2705 Laurier Bld, St Foy, PQ G1V 4G2, Canada.	andre.marette@crchul.ulaval.ca	Marette, Andre/E-9342-2013	Konrad, Daniel/0000-0001-9067-4356				Abbud W, 2000, ARCH BIOCHEM BIOPHYS, V380, P347, DOI 10.1006/abbi.2000.1935; Bergeron R, 1999, AM J PHYSIOL-ENDOC M, V276, pE938, DOI 10.1152/ajpendo.1999.276.5.E938; Boppart MD, 2000, J PHYSIOL-LONDON, V526, P663, DOI 10.1111/j.1469-7793.2000.00663.x; CULLEN MJ, 1984, J ANAT, V138, P297; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; Dombrowski L, 1996, AM J PHYSIOL-ENDOC M, V270, pE667, DOI 10.1152/ajpendo.1996.270.4.E667; Eisenberg B. R., 2010, COMPREHENSIVE PHYSL, P73; Fryer LGD, 2002, FEBS LETT, V531, P189, DOI 10.1016/S0014-5793(02)03501-9; Goodyear LJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE403, DOI 10.1152/ajpendo.1996.271.2.E403; Guo JH, 1998, J BIOL CHEM, V273, P16487, DOI 10.1074/jbc.273.26.16487; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Huang M, 2002, J BIOL CHEM, V277, P28364, DOI 10.1074/jbc.C200321200; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Konrad D, 2001, DIABETES, V50, P1464, DOI 10.2337/diabetes.50.6.1464; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Lemieux K, 2000, DIABETES, V49, P183, DOI 10.2337/diabetes.49.2.183; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Musi N, 2001, AM J PHYSIOL-ENDOC M, V280, pE677, DOI 10.1152/ajpendo.2001.280.5.E677; Park SH, 2002, J APPL PHYSIOL, V92, P2475, DOI 10.1152/japplphysiol.00071.2002; Ploug T, 1998, J CELL BIOL, V142, P1429, DOI 10.1083/jcb.142.6.1429; Rasmussen BB, 1998, J APPL PHYSIOL, V85, P1629, DOI 10.1152/jappl.1998.85.5.1629; Rasmussen BB, 1997, J APPL PHYSIOL, V83, P1104, DOI 10.1152/jappl.1997.83.4.1104; Roy D, 1997, AM J PHYSIOL-ENDOC M, V273, pE688, DOI 10.1152/ajpendo.1997.273.4.E688; Roy D, 1996, BIOCHEM BIOPH RES CO, V223, P147, DOI 10.1006/bbrc.1996.0860; Roy D, 1998, AM J PHYSIOL-ENDOC M, V274, pE692, DOI 10.1152/ajpendo.1998.274.4.E692; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; Somwar R, 2000, DIABETES, V49, P1794, DOI 10.2337/diabetes.49.11.1794; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Widegren U, 1998, FASEB J, V12, P1379, DOI 10.1096/fasebj.12.13.1379; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Xi X, 2001, J BIOL CHEM, V276, P41029, DOI 10.1074/jbc.M102824200	37	100	106	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1658	1665		10.1096/fj.02-1125com	http://dx.doi.org/10.1096/fj.02-1125com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958172				2022-12-25	WOS:000185925100040
J	Zhang, SXL; Gozal, D; Sachleben, LR; Rane, M; Klein, JB; Gozal, E				Zhang, SXL; Gozal, D; Sachleben, LR; Rane, M; Klein, JB; Gozal, E			Hypoxia induces an autocrine-paracrine survival pathway via platelet-derived growth factor (PDGF)-B/PDGF-beta receptor/phosphatidylinositol 3-kinase/Akt signaling in RN46A neuronal cells	FASEB JOURNAL			English	Article						signal transduction; protein kinase B; growth factors	INDUCIBLE FACTOR 1-ALPHA; FACTOR-B-CHAIN; BETA RECEPTOR EXPRESSION; DORSOCAUDAL BRAIN-STEM; FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; OXYGEN-TENSION; CANCER CELLS; RAT	In neurons, hypoxia activates intracellular death-related pathways, yet the antiapoptotic mechanisms triggered by hypoxiaremainunclear.InRN46Aneuronalcells,minimum media growth conditions induced cell death as early as 12 h after the cells were placed in these conditions(i.e.,after removal of B-27 supplement). However, apoptosis occurred in hypoxia(1% O-2) only after 48 h,and in fact hypoxia reduced the apoptosis associated with trophic factor withdrawal. Furthermore, hypoxia induced time-dependent increases in expression of platelet-derived growth factor(PDGF) B mRNA and protein, as well as PDGF-beta receptor phosphorylation. Although exogenous PDGF-BB-induced only transient Akt activation,hypoxia triggered persistent activation of Akt for up to 2 4 h. Inhibition of phosphatidylinositol 3-kinase(PI3K)or of PDGF-beta receptor phosphorylation abrogated both hypoxia-induced and exogenous PDGF-BB-induced Akt phosphorylation, and it completely abolished hypoxia-induced protection from media supplement deprivation, which suggests that the long-lasting activation of Akt during hypoxia and the prosurvival induction were due to endogenously generated PDGF-BB. Furthermore,these inhibitors decreased hypoxia-inducible factor 1alpha(HIF-1alpha) DNA binding, which suggests that the PDGF/PDGF-beta receptor/Akt pathway induces downstream HIF-1alpha gene transcription. We conclude that in RN46A neuronal cells, hypoxia activates an autocrine-paracrine antiapoptotic mechanism that involves up-regulation of PDGF-B and PDGF-beta receptor-dependent activation of the PI3K/Akt signaling pathway to induce downstream transcription of survival genes.	Univ Louisville, KCHRI, Dept Pediat, Louisville, KY 40202 USA; Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA; Univ Louisville, Dept Med, Kidney Dis Program, Louisville, KY 40202 USA	University of Louisville; University of Louisville; University of Louisville	Gozal, E (corresponding author), Univ Louisville, KCHRI, Dept Pediat, 570 S Preston St, Louisville, KY 40202 USA.	Evelyne.gozal@louisville.edu	Gozal, David/ABH-3805-2020; Gozal, David/M-9492-2017; Klein, Jon/B-9833-2013					Alea OA, 2000, AM J PHYSIOL-REG I, V279, pR1625, DOI 10.1152/ajpregu.2000.279.5.R1625; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; Blancher C, 2001, CANCER RES, V61, P7349; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHENG B, 1995, J NEUROSCI, V15, P7095; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Faller DV, 1999, CLIN EXP PHARMACOL P, V26, P74, DOI 10.1046/j.1440-1681.1999.02992.x; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Gozal D, 2000, J NEUROCHEM, V74, P310, DOI 10.1046/j.1471-4159.2000.0740310.x; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; IIHARA K, 1994, J CEREBR BLOOD F MET, V14, P818, DOI 10.1038/jcbfm.1994.102; Iihara K, 1996, J CEREBR BLOOD F MET, V16, P941, DOI 10.1097/00004647-199609000-00018; Iihara K, 1997, J CEREBR BLOOD F MET, V17, P1097, DOI 10.1097/00004647-199710000-00012; Irving EA, 2000, MOL BRAIN RES, V77, P65, DOI 10.1016/S0169-328X(00)00043-7; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Minet E, 2001, FREE RADICAL BIO MED, V31, P847, DOI 10.1016/S0891-5849(01)00657-8; NIKKHAH G, 1993, EXP BRAIN RES, V92, P516; Ohno M, 1999, NEUROSCIENCE, V90, P643, DOI 10.1016/S0306-4522(98)00593-4; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Sharp FR, 2001, ADV EXP MED BIOL, V502, P273; Shimizu S, 1996, CANCER RES, V56, P2161; Simakajornboon N, 2001, BRAIN RES, V895, P111, DOI 10.1016/S0006-8993(01)02054-6; SMITS A, 1991, P NATL ACAD SCI USA, V88, P8159, DOI 10.1073/pnas.88.18.8159; Sodhi A, 2001, BIOCHEM BIOPH RES CO, V287, P292, DOI 10.1006/bbrc.2001.5532; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Ulleras E, 2001, GROWTH FACTORS, V19, P233, DOI 10.3109/08977190109001089; Vlasic V, 2001, PEDIATR RES, V50, P236, DOI 10.1203/00006450-200108000-00012; WHITE LA, 1994, J NEUROSCI, V14, P6744; Zhong H, 2000, CANCER RES, V60, P1541; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	42	82	86	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1709	+		10.1096/fj.02-1111fje	http://dx.doi.org/10.1096/fj.02-1111fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958184				2022-12-25	WOS:000184471600030
J	Ziegler, J; Sticht, H; Marx, UC; Muller, W; Rosch, P; Schwarzinger, S				Ziegler, J; Sticht, H; Marx, UC; Muller, W; Rosch, P; Schwarzinger, S			CD and NMR studies of prion protein (PrP) helix 1 - Novel implications for its role in the PrPC -> PrPSc conversion process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICAL PEPTIDES; EMPIRICAL PARAMETERS; SECONDARY STRUCTURE; CHEMICAL-SHIFTS; FOLDING PROBLEM; ALPHA-HELICES; DYNAMIC CHARACTERIZATION; CIRCULAR-DICHROISM; COHERENCE-TRANSFER; WATER SUPPRESSION	The conversion of prion helix 1 from an alpha-helical into an extended conformation is generally assumed to be an essential step in the conversion of the cellular isoform PrPC of the prion protein to the pathogenic isoform PrPSc. Peptides encompassing helix 1 and flanking sequences were analyzed by nuclear magnetic resonance and circular dichroism. Our results indicate a remarkably high instrinsic helix propensity of the helix 1 region. In particular, these peptides retain significant helicity under a wide range of conditions, such as high salt, pH variation, and presence of organic co-solvents. As evidenced by a data base search, the pattern of charged residues present in helix 1 generally favors helical structures over alternative conformations. Because of its high stability against environmental changes, helix 1 is unlikely to be involved in the initial steps of the pathogenic conformational change. Our results implicate that interconversion of helix 1 is rather representing a barrier than a nucleus for the PrPC-->PrPSc conversion.	Univ Bayreuth, Lehrstuhl Biopolymere, D-95440 Bayreuth, Germany; Univ Erlangen Nurnberg, Inst Biochem, Abt Bioinformat, D-91054 Erlangen, Germany	University of Bayreuth; University of Erlangen Nuremberg	Schwarzinger, S (corresponding author), Univ Bayreuth, Lehrstuhl Biopolymere, POB 101251, D-95440 Bayreuth, Germany.	stephan.schwarzinger@uni-bayreuth.de	Schwarzinger, Stephan/GWV-5819-2022; Rösch, Paul/I-5445-2014; Schwarzinger, Stephan/O-4318-2014	Rösch, Paul/0000-0003-3330-2446; Schwarzinger, Stephan/0000-0002-0894-5290; Sticht, Heinrich/0000-0001-5644-045X; Marx, Ute C./0000-0002-7077-9940				ARMSTRONG KM, 1993, J MOL BIOL, V230, P284, DOI 10.1006/jmbi.1993.1142; Bai YW, 2001, PROTEIN SCI, V10, P1056, DOI 10.1110/ps.00601; Baskakov IV, 2000, BIOCHEMISTRY-US, V39, P2792, DOI 10.1021/bi9923353; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brown DR, 2001, BRAIN RES BULL, V55, P165, DOI 10.1016/S0361-9230(01)00453-1; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; Butterfield SM, 2002, J AM CHEM SOC, V124, P9751, DOI 10.1021/ja026668q; CHAKRABARTTY A, 1993, BIOCHEMISTRY-US, V32, P5560, DOI 10.1021/bi00072a010; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Eberl H, 2002, BIOPHYS CHEM, V96, P293, DOI 10.1016/S0301-4622(02)00015-7; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Eigen M, 1996, BIOPHYS CHEM, V63, pA1, DOI 10.1016/S0301-4622(96)02250-8; Fernandez A, 2002, EUR J BIOCHEM, V269, P4165, DOI 10.1046/j.1432-1033.2002.03116.x; FRIEDRICHS MS, 1995, J BIOMOL NMR, V5, P147, DOI 10.1007/BF00208805; Garcia FL, 2000, P NATL ACAD SCI USA, V97, P8334, DOI 10.1073/pnas.97.15.8334; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; Hornemann S, 1997, FEBS LETT, V413, P277, DOI 10.1016/S0014-5793(97)00921-6; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; Jamin N, 2002, FEBS LETT, V529, P256, DOI 10.1016/S0014-5793(02)03353-7; Jobling MF, 1999, J NEUROCHEM, V73, P1557, DOI 10.1046/j.1471-4159.1999.0731557.x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Korth C, 2001, P NATL ACAD SCI USA, V98, P9836, DOI 10.1073/pnas.161274798; Liu ML, 1998, J MAGN RESON, V132, P125, DOI 10.1006/jmre.1998.1405; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; Martins VR, 2002, FEBS LETT, V512, P25, DOI 10.1016/S0014-5793(02)02291-3; Morrissey MP, 1999, P NATL ACAD SCI USA, V96, P11293, DOI 10.1073/pnas.96.20.11293; MUNOZ V, 1995, J MOL BIOL, V245, P297, DOI 10.1006/jmbi.1994.0024; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; MUNOZ V, 1995, J MOL BIOL, V245, P275, DOI 10.1006/jmbi.1994.0023; Pace CN, 1998, BIOPHYS J, V75, P422, DOI 10.1016/S0006-3495(98)77529-0; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; SCHOLTZ JM, 1991, J AM CHEM SOC, V113, P5102, DOI 10.1021/ja00013a079; Schwarzinger S, 2000, J BIOMOL NMR, V18, P43, DOI 10.1023/A:1008386816521; Schwarzinger S, 2002, BIOCHEMISTRY-US, V41, P12681, DOI 10.1021/bi020381o; Schwarzinger S, 2001, J AM CHEM SOC, V123, P2970, DOI 10.1021/ja003760i; SHOEMAKER KR, 1990, BIOPOLYMERS, V29, P1, DOI 10.1002/bip.360290104; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Speare JO, 2003, J BIOL CHEM, V278, P12522, DOI 10.1074/jbc.M211599200; Suzuki T, 2002, BIOCHEM BIOPH RES CO, V294, P912, DOI 10.1016/S0006-291X(02)00546-6; VANGEET AL, 1970, ANAL CHEM, V42, P679, DOI 10.1021/ac60288a022; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yao J, 2001, BIOCHEMISTRY-US, V40, P3561, DOI 10.1021/bi002776i; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	55	73	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50175	50181		10.1074/jbc.M305234200	http://dx.doi.org/10.1074/jbc.M305234200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	12952977	hybrid			2022-12-25	WOS:000187068200063
J	Araki, Y; Tomita, S; Yamaguchi, H; Miyagi, N; Sumioka, A; Kirino, Y; Suzuki, T				Araki, Y; Tomita, S; Yamaguchi, H; Miyagi, N; Sumioka, A; Kirino, Y; Suzuki, T			Novel cadherin-related membrane proteins, alcadeins, enhance the X11-like protein-mediated stabilization of amyloid beta-protein precursor metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; CYTOPLASMIC DOMAIN; INTRACELLULAR DOMAIN; SCAFFOLD PROTEINS; AXONAL-TRANSPORT; DIRECT BINDING; FE65 PROTEIN; PHOSPHORYLATION; CLEAVAGE; FAMILY	Previously we found that X11-like protein (X11L) associates with amyloid beta-protein precursor (APP). X11L stabilizes APP metabolism and suppresses the secretion of the amyloid beta-protein (Abeta) that are the pathogenic agents of Alzheimer's disease (AD). Here we found that Alcadein (Alc), a novel membrane protein family that contains cadherin motifs and originally reported as calsyntenins, also interacted with X11L. Alc was abundant in the brain and occurred in the same areas of the brain as X11L. X11L could simultaneously associate with APP and Alc, resulting in the formation of a tripartite complex in brain. The tripartite complex stabilized intracellular APP metabolism and enhanced the X11L-mediated suppression of Abeta secretion that is due to the retardation of intracellular APP maturation. X11L and Alc also formed another complex with C99, a carboxyl-terminal fragment of APP cleaved at the beta-site (CTFbeta). The formation of the Alc . X11L . C99 complex inhibited the interaction of C99 with presenilin, which strongly suppressed the gamma-cleavage of C99. In AD patient brains, Alc and APP were particularly colocalized in dystrophic neurites in senile plaques. Deficiencies in the X11L-mediated interaction between Alc and APP and/or CTFbeta enhanced the production of Abeta, which may be related to the development or progression of AD.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Univ Tokyo, Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, Tokyo 1130033, Japan; Gunma Univ, Sch Med, Coll Med Care & Technol, Maebashi, Gumma 3718514, Japan	Hokkaido University; University of Tokyo; Gunma University	Suzuki, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tsuzuki@pharm.hokudai.ac.jp	Suzuki, Toshiharu/B-5342-2013					Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Ando K, 1999, J NEUROSCI, V19, P4421; Biederer T, 2000, J BIOL CHEM, V275, P39803, DOI 10.1074/jbc.C000656200; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; CRAS P, 1991, P NATL ACAD SCI USA, V88, P7552, DOI 10.1073/pnas.88.17.7552; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; GRAHAM JM, 1997, SUBCELLULAR FRACTION, P205; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; Hase M, 2002, J NEUROCHEM, V81, P1223, DOI 10.1046/j.1471-4159.2002.00911.x; Hintsch G, 2002, MOL CELL NEUROSCI, V21, P393, DOI 10.1006/mcne.2002.1181; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; Kikuno R, 2000, NUCLEIC ACIDS RES, V28, P331, DOI 10.1093/nar/28.1.331; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; Lichtenthaler SF, 1999, FEBS LETT, V453, P288, DOI 10.1016/S0014-5793(99)00730-9; Margolis B, 1999, KIDNEY INT, V56, P1230, DOI 10.1046/j.1523-1755.1999.00700.x; McLoughlin DM, 1999, EUR J NEUROSCI, V11, P1988, DOI 10.1046/j.1460-9568.1999.00610.x; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Price DL, 1998, SCIENCE, V282, P1079, DOI 10.1126/science.282.5391.1079; Ramelot TA, 2001, J MOL BIOL, V307, P871, DOI 10.1006/jmbi.2001.4535; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Sawamura N, 2000, J BIOL CHEM, V275, P27901; Schnell SA, 1999, J HISTOCHEM CYTOCHEM, V47, P719, DOI 10.1177/002215549904700601; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHOJI M, 1990, BRAIN RES, V512, P164, DOI 10.1016/0006-8993(90)91187-L; Sisodia SS, 2002, SCIENCE, V295, P805, DOI 10.1126/science.1069661; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Taru H, 2002, J BIOL CHEM, V277, P20070, DOI 10.1074/jbc.M108372200; Taru H, 2002, J BIOL CHEM, V277, P27567, DOI 10.1074/jbc.M203713200; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Tomita S, 1998, J BIOL CHEM, V273, P19304, DOI 10.1074/jbc.273.30.19304; Tomita S, 2000, J BIOL CHEM, V275, P13056, DOI 10.1074/jbc.C000019200; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Verdile G, 2000, J BIOL CHEM, V275, P20794, DOI 10.1074/jbc.C000208200; Vogt L, 2001, MOL CELL NEUROSCI, V17, P151, DOI 10.1006/mcne.2000.0937; Yanagisawa K, 2002, J NEUROSCI RES, V70, P361, DOI 10.1002/jnr.10348; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062	54	110	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49448	49458		10.1074/jbc.M306024200	http://dx.doi.org/10.1074/jbc.M306024200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12972431	hybrid			2022-12-25	WOS:000186829000113
J	Radons, JR; Dove, S; Neumann, D; Altmann, R; Botzki, A; Martin, MU; Falk, W				Radons, JR; Dove, S; Neumann, D; Altmann, R; Botzki, A; Martin, MU; Falk, W			The interleukin 1 (IL-1) receptor accessory protein Toll/IL-1 receptor domain - Analysis of putative interaction sites by in vitro mutagenesis and molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TOLL-LIKE RECEPTOR-3; DOUBLE-STRANDED-RNA; SIGNAL-TRANSDUCTION PATHWAY; PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTER PROTEIN; IRAK FAMILY; KINASE IRAK; MAP KINASE; ACTIVATION	The Toll/interleukin 1 (IL-1) receptor family plays an important role in both innate and adaptive immunity. These receptors are characterized by a C-terminal homology motif called the Toll/IL-1 receptor (TIR) domain. A principal function of the TIR domain is mediating homotypic protein-protein interactions in the signal transduction pathway. To suggest interaction sites of TIR domains in the IL-1 receptor complex, we modeled the putative three-dimensional structure of the TIR domain within the co-receptor chain, IL-1 receptor accessory protein. The model was based on homology with the crystal structures of human TLR1 and TLR2. The final structure of the IL-1 receptor accessory protein TIR domain suggests the conserved regions box 1 and 2, including Pro-446, as well as box 3 within the C-terminal alpha-helix as possible protein-protein interaction sites due to their exposure and their electrostatic potential. Pro-446, corresponding to the Pro/His mutation in dominant negative TLR4, is located in the third loop at the outmost edge of the TIR domain and does not play any structural role. Inhibition of IL-1 responsiveness seen after substitution of Pro-446 by charged amino acids is due to the loss of an interaction site for other TIR domains. Amino acids 527 - 534 as part of the loop close to the conserved box 3 are critical for recruitment of myeloid differentiation factor 88 and to a lesser extent for IL-1 responsiveness. Modeling suggests that native folding of the TIR domain may be approached by the responsive deletion mutants Delta528 - 534 and Delta527 - 533, whereas the C-terminal beta-strand and/or alpha-helix is displaced in the nonresponsive mutant Delta527 - 534.	Univ Regensburg, Inst Pharm, Abt Pharmazeut Chem 2, D-93053 Regensburg, Germany; Univ Regensburg, Klin & Poliklin Innere Med 1, D-93042 Regensburg, Germany; Hannover Med Sch, Inst Pharmakol, D-30623 Hannover, Germany	University of Regensburg; University of Regensburg; Hannover Medical School	Radons, JR (corresponding author), Univ Regensburg, Abt Hamatol & Onkol, D-93053 Regensburg, Germany.	juergen.radons@klinik.uni-regensburg.de	Neumann, Detlef/F-6182-2011	Neumann, Detlef/0000-0003-0145-7507; Botzki, Alexander/0000-0001-6691-4233				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; BLUNDELL T, 1988, EUR J BIOCHEM, V172, P513, DOI 10.1111/j.1432-1033.1988.tb13917.x; Boch JA, 2003, BIOCHEM BIOPH RES CO, V303, P525, DOI 10.1016/S0006-291X(03)00385-1; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DUNNE A, 2003, SCI STKE; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; Guo FK, 2000, INFLAMMATION, V24, P305, DOI 10.1023/A:1007040813331; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; Hofmeister R, 1997, J BIOL CHEM, V272, P27730, DOI 10.1074/jbc.272.44.27730; Hoshino K, 1999, J IMMUNOL, V162, P3749; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Marmiroli S, 1998, FEBS LETT, V438, P49, DOI 10.1016/S0014-5793(98)01270-8; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; Matsumoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1364, DOI 10.1016/S0006-291X(02)00380-7; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; ONEILL LA, 2000, SCI STKE, V44, P1; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Radons J, 2002, J BIOL CHEM, V277, P16456, DOI 10.1074/jbc.M201000200; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Ridley SH, 1997, J IMMUNOL, V158, P3165; Rosati O, 2002, BIOCHEM BIOPH RES CO, V293, P1472, DOI 10.1016/S0006-291X(02)00411-4; Rosati O, 2002, BIOCHEM BIOPH RES CO, V297, P52, DOI 10.1016/S0006-291X(02)02130-7; Sarkar SN, 2003, J BIOL CHEM, V278, P4393, DOI 10.1074/jbc.C200655200; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SIMS JE, 1996, EUR CYTOKINE NETW, V7, P480; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; STRICKER K, 1993, EUR J IMMUNOL, V23, P1475, DOI 10.1002/eji.1830230712; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Trofimova M, 1996, J BIOL CHEM, V271, P17609, DOI 10.1074/jbc.271.30.17609; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540	58	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49145	49153		10.1074/jbc.M306077200	http://dx.doi.org/10.1074/jbc.M306077200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	13679373	hybrid			2022-12-25	WOS:000186829000078
J	Dode, L; Andersen, JP; Leslie, N; Dhitavat, J; Vilsen, B; Hovnanian, A				Dode, L; Andersen, JP; Leslie, N; Dhitavat, J; Vilsen, B; Hovnanian, A			Dissection of the functional differences between sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) 1 and 2 isoforms and characterization of Darier disease (SERCA2) mutants by steady-state and transient kinetic analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAIN; HAILEY-HAILEY-DISEASE; P-TYPE ATPASE; SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; AMINO-ACIDS; ATP2A2 MUTATIONS; CALCIUM-PUMP; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE	Steady-state and rapid kinetic studies were conducted to functionally characterize the overall and partial reactions of the Ca2+ transport cycle mediated by the human sarco(endo) plasmic reticulum Ca2+-ATPase 2 (SERCA2) isoforms, SERCA2a and SERCA2b, and 10 Darier disease ( DD) mutants upon heterologous expression in HEK-293 cells. SERCA2b displayed a 10-fold decrease in the rate of Ca2+ dissociation from E1Ca2 relative to SERCA2a (i.e. SERCA2b enzyme manifests true high affinity at cytosolic Ca2+ sites) and a lower rate of dephosphorylation. These fundamental kinetic differences explain the increased apparent affinity for activation by cytosolic Ca2+ and the reduced catalytic turnover rate in SERCA2b. Relative to SERCA1a, both SERCA2 isoforms displayed a 2-fold decrease of the rate of E-2 to E1Ca2 transition. Furthermore, seven DD mutants were expressed at similar levels as wild type. The expression level was 2-fold reduced for Gly(23) --> Glu and Ser(920) --> Tyr and 10-fold reduced for Gly(749) --> Arg. Uncoupling between Ca2+ translocation and ATP hydrolysis and/or changes in the rates of partial reactions account for lack of function for 7 of 10 mutants: Gly(23) --> Glu (uncoupling), Ser(186) --> Phe, Pro(602) --> Leu, and Asp(702) --> Asn (block of E-1 similar to P(Ca-2) to E-2-P transition), Cys(318) --> Arg (uncoupling and 3-fold reduction of E-2-P to E-2 transition rate), and Thr(357) --> Lys and Gly(769) --> Arg (lack of phosphorylation). A 2-fold decrease in the E-1 similar to P(Ca-2) to E-2-P transition rate is responsible for the 2-fold decrease in activity for Pro(895)-->Leu. Ser(920)-->Tyr is a unique DD mutant showing an enhanced molecular Ca2+ transport activity relative to wild-type SERCA2b. In this case, the disease may be a consequence of the low expression level and/or reduction of Ca2+ affinity and sensitivity to inhibition by lumenal Ca2+.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Aarhus Univ, Dept Physiol, DK-8000 Aarhus, Denmark; Hop Purpan, INSERM, U563, F-31059 Toulouse 3, France	University of Oxford; Wellcome Centre for Human Genetics; Aarhus University; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Andersen, JP (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.	jpa@fi.au.dk	Hovnanian, Alain/I-4711-2017	Hovnanian, Alain/0000-0003-3412-7512; Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300				Ahn W, 2003, J BIOL CHEM, V278, P20795, DOI 10.1074/jbc.M301638200; ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; ANDERSEN JP, 1994, FEBS LETT, V354, P93, DOI 10.1016/0014-5793(94)01100-1; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; CAMPBELL AM, 1992, J BIOL CHEM, V267, P9321; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Clausen JD, 2003, J BIOL CHEM, V278, P20245, DOI 10.1074/jbc.M301122200; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; Dhitavat J, 2003, J INVEST DERMATOL, V120, P229, DOI 10.1046/j.1523-1747.2003.t01-1-12045.x; Dode L, 2002, J BIOL CHEM, V277, P45579, DOI 10.1074/jbc.M207778200; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; Fairclough RJ, 2003, J BIOL CHEM, V278, P24721, DOI 10.1074/jbc.M300509200; Gelebart P, 2003, BIOCHEM BIOPH RES CO, V303, P676, DOI 10.1016/S0006-291X(03)00405-4; Hu ZL, 2000, NAT GENET, V24, P61, DOI 10.1038/71701; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; Jacobsen NJO, 1999, HUM MOL GENET, V8, P1631, DOI 10.1093/hmg/8.9.1631; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; Lee AG, 2001, BIOCHEM J, V356, P665, DOI 10.1042/0264-6021:3560665; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Martin V, 2002, J BIOL CHEM, V277, P24442, DOI 10.1074/jbc.M202011200; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; McIntosh DB, 1999, J BIOL CHEM, V274, P25227, DOI 10.1074/jbc.274.36.25227; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Odermatt A, 1996, NAT GENET, V14, P191, DOI 10.1038/ng1096-191; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; Ringpfeil F, 2001, EXP DERMATOL, V10, P19, DOI 10.1034/j.1600-0625.2001.100103.x; Roderick HL, 2000, J CELL BIOL, V149, P1235, DOI 10.1083/jcb.149.6.1235; Ruiz-Perez VL, 1999, HUM MOL GENET, V8, P1621, DOI 10.1093/hmg/8.9.1621; Sakuntabhai A, 2000, J INVEST DERMATOL, V115, P1144, DOI 10.1046/j.1523-1747.2000.00182.x; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Sakuntabhai A, 1999, HUM MOL GENET, V8, P1611, DOI 10.1093/hmg/8.9.1611; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; SORENSEN TLM, 2000, J BIOL CHEM, V275, P28594; Takahashi H, 2001, J DERMATOL SCI, V26, P169, DOI 10.1016/S0923-1811(00)00173-0; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Varadi A, 1999, DIABETOLOGIA, V42, P1240, DOI 10.1007/s001250051298; VERBOOMEN H, 1994, BIOCHEM J, V303, P979, DOI 10.1042/bj3030979; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1991, J BIOL CHEM, V266, P18839; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; WUYTACK F, 1989, BIOCHEM J, V264, P756; XHANG Y, 1995, GENOMICS, V30, P415; Yang Y, 2001, J INVEST DERMATOL, V116, P482, DOI 10.1046/j.1523-1747.2001.127910.x	65	98	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47877	47889		10.1074/jbc.M306784200	http://dx.doi.org/10.1074/jbc.M306784200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12975374	hybrid			2022-12-25	WOS:000186731400065
J	Poppenberger, B; Berthiller, F; Lucyshyn, D; Sieberer, T; Schuhmacher, R; Krska, R; Kuchler, K; Glossl, J; Luschnig, C; Adam, G				Poppenberger, B; Berthiller, F; Lucyshyn, D; Sieberer, T; Schuhmacher, R; Krska, R; Kuchler, K; Glossl, J; Luschnig, C; Adam, G			Detoxification of the Fusarium mycotoxin deoxynivalenol by a UDP-glucosyltransferase from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HEAD-BLIGHT; MULTIGENE FAMILY; GENE DISRUPTION; STRESS-RESPONSE; SALICYLIC-ACID; TOBACCO GENES; WHEAT SPIKES; EXPRESSION; GRAMINEARUM	Plant pathogenic fungi of the genus Fusarium cause agriculturally important diseases of small grain cereals and maize. Trichothecenes are a class of mycotoxins produced by different Fusarium species that inhibit eukaryotic protein biosynthesis and presumably interfere with the expression of genes induced during the defense response of the plants. One of its members, deoxynivalenol, most likely acts as a virulence factor during fungal pathogenesis and frequently accumulates in grain to levels posing a threat to human and animal health. We report the isolation and characterization of a gene from Arabidopsis thaliana encoding a UDP-glycosyltransferase that is able to detoxify deoxynivalenol. The enzyme, previously assigned the identifier UGT73C5, catalyzes the transfer of glucose from UDP-glucose to the hydroxyl group at carbon 3 of deoxynivalenol. Using a wheat germ extract-coupled transcription/ translation system we have shown that this enzymatic reaction inactivates the mycotoxin. This deoxynivalenol-glucosyltransferase (DOGT1) was also found to detoxify the acetylated derivative 15-acetyl-deoxynivalenol, whereas no protective activity was observed against the structurally similar nivalenol. Expression of the glucosyltransferase is developmentally regulated and induced by deoxynivalenol as well as salicylic acid, ethylene, and jasmonic acid. Constitutive overexpression in Arabidopsis leads to enhanced tolerance against deoxynivalenol.	BOKU Univ Nat Resources & Appl Life Sci, Ctr Appl Genet, A-1190 Vienna, Austria; Inst Agrobiotechnol IFA Tullin, Ctr Analyt Chem, A-3430 Tulln, Austria; Univ Vienna, Dept Biochem Med, Div Mol Genet, Max F Perutz Labs, A-1030 Vienna, Austria; Bioctr Vienna, A-1030 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Vienna Biocenter (VBC)	Adam, G (corresponding author), BOKU Univ Nat Resources & Appl Life Sci, Ctr Appl Genet, Muthgasse 18, A-1190 Vienna, Austria.		Glössl, Josef/H-8208-2013; kuchler, karl/AAL-6937-2020; Schuhmacher, Rainer/U-5174-2019	Glössl, Josef/0000-0002-5042-8828; kuchler, karl/0000-0003-2719-5955; Schuhmacher, Rainer/0000-0002-7520-4943; Luschnig, Christian/0000-0003-2099-9280; Lucyshyn, Doris/0000-0001-8558-1219; Krska, Rudolf/0000-0001-6843-9755; Berthiller, Franz/0000-0001-5883-2879; Adam, Gerhard/0000-0002-3008-3797				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Bai GH, 2002, MYCOPATHOLOGIA, V153, P91, DOI 10.1023/A:1014419323550; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; Betina V, 1989, MYCOTOXINS, P192; Canady C.R., 2001, WHO FOOD ADDITIVES S, P419; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; *COD COMM FOOD ADD, 2003, JOINT FAO WHO FOOD S; Coleman JOD, 1997, TRENDS PLANT SCI, V2, P144, DOI 10.1016/S1360-1385(97)01019-4; CUNDLIFFE E, 1977, ANTIMICROB AGENTS CH, V11, P491, DOI 10.1128/AAC.11.3.491; Desjardins AE, 1996, MOL PLANT MICROBE IN, V9, P775, DOI 10.1094/MPMI-9-0775; Diener AC, 2000, PLANT CELL, V12, P853, DOI 10.1105/tpc.12.6.853; EGNER R, 1995, MOL CELL BIOL, V15, P5879; Engelhardt Gabriele, 1999, Advances in Food Sciences, V21, P71; Eudes F, 2000, CAN J PLANT PATHOL, V22, P286, DOI 10.1080/07060660009500477; FARRAND SK, 1989, J BACTERIOL, V171, P5314, DOI 10.1128/jb.171.10.5314-5321.1989; Fraissinet-Tachet L, 1998, FEBS LETT, V437, P319, DOI 10.1016/S0014-5793(98)01257-5; GROVE JF, 1996, PROGR CHEM ORGANIC N, P1; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Horvath DM, 1996, PLANT MOL BIOL, V31, P1061, DOI 10.1007/BF00040724; Horvath DM, 1998, MOL PLANT MICROBE IN, V11, P895, DOI 10.1094/MPMI.1998.11.9.895; Hou ZM, 2002, MOL PLANT MICROBE IN, V15, P1119, DOI 10.1094/MPMI.2002.15.11.1119; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; Jenczmionka NJ, 2003, CURR GENET, V43, P87, DOI 10.1007/s00294-003-0379-2; Jones P, 2001, PLANTA, V213, P164, DOI 10.1007/s004250000492; Kang Z, 1999, PHYSIOL MOL PLANT P, V55, P275, DOI 10.1006/pmpp.1999.0233; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; Laskin JD, 2002, TOXICOL SCI, V69, P289, DOI 10.1093/toxsci/69.2.289; LEAH JM, 1992, PESTIC SCI, V34, P81, DOI 10.1002/ps.2780340112; Li Y, 2001, J BIOL CHEM, V276, P4338, DOI 10.1074/jbc.M007447200; Lim EK, 2003, GLYCOBIOLOGY, V13, P139, DOI 10.1093/glycob/cwg017; Lu SW, 2003, P NATL ACAD SCI USA, V100, P5980, DOI 10.1073/pnas.0931375100; McCormick S, 2003, FUSARIUM HEAD BLIGHT OF WHEAT & BARLEY, P165; McMullen M, 1997, PLANT DIS, V81, P1340, DOI 10.1094/PDIS.1997.81.12.1340; Messner B, 2003, PLANTA, V217, P138, DOI 10.1007/s00425-002-0969-0; Mesterhazy A, 2003, FUSARIUM HEAD BLIGHT OF WHEAT & BARLEY, P363; MILLER JD, 1986, CAN J PLANT PATHOL, V8, P147; MINET M, 1992, PLANT J, V2, P417; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NGANJE WE, 2001, AGRIBUS APPL EC REP, V464; O'Donnell K, 2000, P NATL ACAD SCI USA, V97, P7905, DOI 10.1073/pnas.130193297; Okubara PA, 2002, THEOR APPL GENET, V106, P74, DOI 10.1007/s00122-002-1066-2; Reymond P, 1998, CURR OPIN PLANT BIOL, V1, P404, DOI 10.1016/S1369-5266(98)80264-1; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; SAVARD ME, 1991, J AGR FOOD CHEM, V39, P570, DOI 10.1021/jf00003a027; SCOTT PM, 1984, APPL ENVIRON MICROB, V48, P884, DOI 10.1128/AEM.48.4.884-886.1984; SEWALD N, 1992, TETRAHEDRON-ASYMMETR, V3, P953, DOI 10.1016/S0957-4166(00)82193-X; SIKORSKI RS, 1989, GENETICS, V122, P19; TOPFER R, 1987, NUCLEIC ACIDS RES, V15, P5890, DOI 10.1093/nar/15.14.5890; Truesdale M. R., 1996, PLANT PHYSIOL, V112, P446; Vogt T, 1999, PLANT J, V19, P509, DOI 10.1046/j.1365-313X.1999.00540.x; WETZEL A, 1994, ARCH BIOCHEM BIOPHYS, V314, P323, DOI 10.1006/abbi.1994.1449; Wolfger H, 2001, RES MICROBIOL, V152, P375, DOI 10.1016/S0923-2508(01)01209-8	53	396	443	5	138	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47905	47914		10.1074/jbc.M307552200	http://dx.doi.org/10.1074/jbc.M307552200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12970342	hybrid			2022-12-25	WOS:000186731400068
J	Ruan, H; Zarnowski, MJ; Cushman, SW; Lodish, HF				Ruan, H; Zarnowski, MJ; Cushman, SW; Lodish, HF			Standard isolation of primary adipose cells from mouse epididymal fat pads induces inflammatory mediators and down-regulates adipocyte genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TYPE-2 DIABETES-MELLITUS; NF-KAPPA-B; INSULIN-RESISTANCE; TRANSCRIPTION FACTORS; GLUT4 TRANSLOCATION; TNF-ALPHA; KINASE; PATHOGENESIS; EXPRESSION	Isolation and subsequent in vitro culture of primary adipose cells are associated with down-regulation of GLUT4 mRNA and simultaneous induction of GLUT1 gene expression. Progressive loss of insulin-responsive GLUT4 contributes to the decrease in insulin-mediated glucose uptake in these cells when cultured in vitro. The mechanisms underlying these alterations are unknown. Here, we report that the standard procedure for isolating primary adipose cells from mouse adipose tissue triggers induction of many genes encoding inflammatory mediators including TNF-alpha, interleukin (IL)-1alpha, IL-6, multiple chemokines, cell adhesion molecules, acute-phase proteins, type I IL-1 receptor, and multiple transcription factors implicated in the cellular inflammatory response. Secretion of TNF-alpha protein was also significantly induced during the 2-h collagenase digestion of adipose tissue. Isolated primary adipose cells exhibit dramatic changes in expression of multiple mRNAs that are characteristic of TNF-alpha-treated 3T3-L1 adipocytes including down-regulation of many genes important for insulin action and triglyceride synthesis. Addition of TNF-alpha to primary adipose cells in culture did not change the kinetics or the extent of the repression of adipose cell- abundant genes. Moreover, TNF-alpha-neutralizing antibody failed to block the changes in gene transcription in isolated primary adipose cells. Also, the standard isolation procedure induced the expression of NF-kappaB family members and their target genes in primary adipose cells prepared from TNF-alpha-/- mice to the same extent as in cells isolated from wild-type mice and resulted in almost identical changes in global gene expression when these cells were cultured in vitro. Thus, these data suggest that the standard isolation procedure-triggered reprogramming of gene expression in primary adipose cells that results in decreased insulin sensitivity does not require TNF-alpha, at least in this in vitro model system, but may be dependent on other inflammatory cytokines produced by these cells.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; NIDDK, Expt Diabet Metab & Nutr Sect, Diabet Branch, NIH, Bethesda, MD 20892 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Lodish, HF (corresponding author), MIT, Whitehead Inst Biomed Res, 9 Cambridge Ctr,Rm 601, Cambridge, MA 02142 USA.							Boden G, 2001, ENDOCRIN METAB CLIN, V30, P801, DOI 10.1016/S0889-8529(05)70216-4; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DUNNE A, 2003, SCIENCE STKE; FERRANNINI E, 1995, METABOLISM, V44, P15, DOI 10.1016/0026-0495(95)90313-5; GERRITS PM, 1993, J BIOL CHEM, V268, P640; GODAMBE SA, 1994, J IMMUNOL, V153, P143; Goldstein BJ, 2002, AM J CARDIOL, V90, p3G; Hill MM, 1999, MOL CELL BIOL, V19, P7771; KOHONEN T, 1990, P IEEE, V78, P1464, DOI 10.1109/5.58325; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LeRoith D, 2002, AM J MED, V113, p3S; Maggs DG, 1998, ANN INTERN MED, V128, P176, DOI 10.7326/0003-4819-128-3-199802010-00002; Malide D, 2000, J CELL SCI, V113, P4203; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Moller DE, 2000, TRENDS ENDOCRIN MET, V11, P212, DOI 10.1016/S1043-2760(00)00272-1; Olefsky JM, 2000, TRENDS ENDOCRIN MET, V11, P362, DOI 10.1016/S1043-2760(00)00306-4; OLEFSKY JM, 1985, AM J MED, V79, P12, DOI 10.1016/S0002-9343(85)80003-6; POPE RM, 1994, J CLIN INVEST, V94, P1449, DOI 10.1172/JCI117482; Ruan H, 2003, J BIOL CHEM, V278, P28181, DOI 10.1074/jbc.M303141200; Ruan H, 2002, DIABETES, V51, P3176, DOI 10.2337/diabetes.51.11.3176; Ruan H, 2002, DIABETES, V51, P1319, DOI 10.2337/diabetes.51.5.1319; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; SIMPSON IA, 1984, DIABETES, V33, P13, DOI 10.2337/diabetes.33.1.13; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194; WALKER M, 1995, METABOLISM, V44, P18, DOI 10.1016/0026-0495(95)90314-3; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3	31	125	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47585	47593		10.1074/jbc.M305257200	http://dx.doi.org/10.1074/jbc.M305257200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12975378	hybrid			2022-12-25	WOS:000186731400031
J	Shah, S; Hecht, A; Pestell, R; Byers, SW				Shah, S; Hecht, A; Pestell, R; Byers, SW			Trans-repression of beta-catenin activity by nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN RECEPTOR; E-CADHERIN; ACTIVATION; CANCER; ACID; TRANSACTIVATION; RETINOIDS; BINDING; DOMAIN; CELLS	The signaling/oncogenic activity of beta-catenin can be repressed by the activation of nuclear receptors such as the vitamin A, vitamin D, and androgen receptors. Although these receptors directly interact with beta-catenin and can sequester it away from its transcription factor partner T-cell factor, it is not known if this is the mechanism of trans-repression. Using several different promoter constructs and nuclear receptors and mammalian two-hybrid and mutation analyses we now show that interaction with the co-activator, p300, underlies the trans-repression of beta-catenin signaling by nuclear receptors and their ligands.	Georgetown Univ, Sch Med, Vincent T Lombardi Canc Res Ctr, Washington, DC 20057 USA; Georgetown Univ, Sch Med, Dept Oncol, Washington, DC 20057 USA; Georgetown Univ, Sch Med, Dept Cell Biol, Washington, DC 20057 USA; Univ Freiburg, Inst Mol Med & Cell Sci, D-79106 Freiburg, Germany	Georgetown University; Georgetown University; Georgetown University; University of Freiburg	Byers, SW (corresponding author), Georgetown Univ, Med Ctr, E415 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.	byerss@georgetown.edu		Hecht, Andreas/0000-0003-2262-2575	NATIONAL CANCER INSTITUTE [P30CA051008] Funding Source: NIH RePORTER; NCI NIH HHS [1P30-CA-51008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benkoussa M, 2002, MOL CELL BIOL, V22, P4522, DOI 10.1128/MCB.22.13.4522-4534.2002; Bommer M, 2002, J BIOL CHEM, V277, P37961, DOI 10.1074/jbc.M206001200; Bright-Thomas RM, 2003, EUR J SURG ONCOL, V29, P107, DOI 10.1053/ejso.2002.1331; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Gottardi CJ, 2001, CURR BIOL, V11, pR792, DOI 10.1016/S0960-9822(01)00473-0; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Guberman AS, 2003, J BIOL CHEM, V278, P2317, DOI 10.1074/jbc.M205057200; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Kim SW, 2001, ONCOGENE, V20, P6638, DOI 10.1038/sj.onc.1204695; Lee SK, 2001, MOL ENDOCRINOL, V15, P241, DOI 10.1210/me.15.2.241; Lipkin M, 1999, J AM COLL NUTR, V18, p392S, DOI 10.1080/07315724.1999.10718903; Liu YY, 2000, MOL ENDOCRINOL, V14, P1776, DOI 10.1210/me.14.11.1776; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NEWMARK HL, 1994, ADV EXP MED BIOL, V364, P109; Nicke B, 1999, BIOCHEM BIOPH RES CO, V261, P572, DOI 10.1006/bbrc.1999.1086; ODWYER PJ, 1987, J SURG RES, V43, P550, DOI 10.1016/0022-4804(87)90130-2; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Shah S, 2002, J BIOL CHEM, V277, P25313, DOI 10.1074/jbc.M203158200; Sicinski P, 1997, J MAMMARY GLAND BIOL, V2, P335, DOI 10.1023/A:1026391128117; Slagsvold T, 2000, MOL ENDOCRINOL, V14, P1603, DOI 10.1210/me.14.10.1603; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Sporn MB, 2002, NAT REV CANCER, V2, P537, DOI 10.1038/nrc844; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Truica CI, 2000, CANCER RES, V60, P4709; van Wely KHM, 2003, ONCOGENE, V22, P699, DOI 10.1038/sj.onc.1206124; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Waliszewski P, 1997, J SURG ONCOL, V66, P156, DOI 10.1002/(SICI)1096-9098(199711)66:3<156::AID-JSO2>3.0.CO;2-B; Yang LM, 1997, CANCER RES, V57, P4652; Zhou XF, 1999, MOL ENDOCRINOL, V13, P276, DOI 10.1210/me.13.2.276	38	100	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48137	48145		10.1074/jbc.M307154200	http://dx.doi.org/10.1074/jbc.M307154200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12972427	hybrid			2022-12-25	WOS:000186731400095
J	Tarling, CA; He, SM; Sulzenbacher, G; Bignon, C; Bourne, Y; Henrissat, B; Withers, SG				Tarling, CA; He, SM; Sulzenbacher, G; Bignon, C; Bourne, Y; Henrissat, B; Withers, SG			Identification of the catalytic nucleophile of the family 29 alpha-L-fucosidase from Thermotoga maritima through trapping of a covalent glycosyl-enzyme intermediate and mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; MECHANISM; GLUCOSIDASE; INVOLVEMENT; INHIBITORS; MUTATIONS; AMYLASE	Fucose-containing glycoconjugates are key antigenic determinants in many biological processes. A change in expression levels of the enzymes responsible for tailoring these glycoconjugates has been associated with many pathological conditions and it is therefore surprising that little information is known regarding the mechanism of action of these important catabolic enzymes. Thermotoga maritima, a thermophilic bacterium, produces a wide range of carbohydrate-processing enzymes including a 52-kDa alpha-L-fucosidase that has 38% sequence identity and 56% similarity to human fucosidases. The catalytic nucleophile of this enzyme was identified to be Asp-224 within the peptide sequence (222)WNDMGWPE-KGKEDL(235) using the mechanism-based covalent inactivator 2-deoxy-2-fluoro-alpha-L-fucosyl fluoride. The 10(4)-fold lower activity (k(cat)/K-m) of the site-directed mutant D224A, and the subsequent rescue of activity upon addition of exogenous nucleophiles, conclusively confirms this assignment. This article presents the first direct identification of the catalytic nucleophile of an alpha-L-fucosidase, a key step in the understanding of these important enzymes.	Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France	University of British Columbia; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Withers, SG (corresponding author), Univ British Columbia, Dept Chem, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.	withers@chem.ubc.ca	Henrissat, Bernard/J-2475-2012; Bourne, Yves/AAC-4635-2022; Sulzenbacher, Gerlind/A-6801-2018	Henrissat, Bernard/0000-0002-3434-8588; Bourne, Yves/0000-0003-3850-0548; Sulzenbacher, Gerlind/0000-0003-4844-2820				Berteau O, 2002, GLYCOBIOLOGY, V12, P273, DOI 10.1093/glycob/12.4.273; BRAUN C, 1995, J BIOL CHEM, V270, P26778, DOI 10.1074/jbc.270.45.26778; Cobucci-Ponzano B, 2003, BIOCHEMISTRY-US, V42, P9525, DOI 10.1021/bi035036t; Cobucci-Ponzano B, 2003, J BIOL CHEM, V278, P14622, DOI 10.1074/jbc.M211834200; FEIZI T, 1991, TRENDS BIOCHEM SCI, V16, P84, DOI 10.1016/0968-0004(91)90038-W; Fersht A., 1985, ENZYME STRUCTURE MEC; Fox JD, 2003, FEBS LETT, V537, P53, DOI 10.1016/S0014-5793(03)00070-X; FUKUDA M, 1995, BIOORGAN MED CHEM, V3, P207, DOI 10.1016/0968-0896(95)00014-8; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Hosono J, 1998, J SURG ONCOL, V67, P77, DOI 10.1002/(SICI)1096-9098(199802)67:2<77::AID-JSO2>3.0.CO;2-I; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; KNEGTEL RMK, 1995, J BIOL CHEM, V270, P29256, DOI 10.1074/jbc.270.49.29256; KORYTNYK W, 1982, TETRAHEDRON, V38, P2547, DOI 10.1016/0040-4020(82)85090-4; LEATHERBARROW RJ, 1998, GRAFIT 4 0; Lee SS, 2001, BIOCHEM J, V359, P381, DOI 10.1042/0264-6021:3590381; LOWRY TH, 1985, PHYSICAL ORGANIC CHE; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; MacLeod AM, 1996, BIOCHEMISTRY-US, V35, P13165, DOI 10.1021/bi9610616; MCCARTER JD, 1993, CARBOHYD RES, V249, P77, DOI 10.1016/0008-6215(93)84061-A; McCarter JD, 1996, J AM CHEM SOC, V118, P241, DOI 10.1021/ja952732a; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; Michalski JC, 1999, BBA-MOL BASIS DIS, V1455, P69, DOI 10.1016/S0925-4439(99)00077-0; Mosi RM, 2002, METHOD ENZYMOL, V354, P64; Nieman CE, 2003, BIOCHEMISTRY-US, V42, P8054, DOI 10.1021/bi034293v; Numao S, 2000, FEBS LETT, V484, P175, DOI 10.1016/S0014-5793(00)02148-7; Rapoport E, 1999, GLYCOBIOLOGY, V9, P1337, DOI 10.1093/glycob/9.12.1337; Rydberg EH, 2002, BIOCHEMISTRY-US, V41, P4492, DOI 10.1021/bi011821z; SINNOTT ML, 1987, ENZYME MECH; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TULL D, 1991, J BIOL CHEM, V266, P15621; Vallmitjana M, 2001, BIOCHEMISTRY-US, V40, P5975, DOI 10.1021/bi002947j; WANG QP, 1994, J AM CHEM SOC, V116, P11594, DOI 10.1021/ja00104a060; Wicki J, 2002, METHOD ENZYMOL, V354, P84; Willems PJ, 1999, EUR J HUM GENET, V7, P60, DOI 10.1038/sj.ejhg.5200272; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+; Zechel DL, 2001, CURR OPIN CHEM BIOL, V5, P643, DOI 10.1016/S1367-5931(01)00260-5	39	67	70	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47394	47399		10.1074/jbc.M306610200	http://dx.doi.org/10.1074/jbc.M306610200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12975375	Green Published, hybrid			2022-12-25	WOS:000186731400008
J	De Felice, M; Esposito, L; Pucci, B; Carpentieri, F; De Falco, M; Rossi, M; Pisani, FM				De Felice, M; Esposito, L; Pucci, B; Carpentieri, F; De Falco, M; Rossi, M; Pisani, FM			Biochemical characterization of a CDC6-like protein from the crenarchaeon Sulfolobus solfataricus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; MCM PROTEINS; GENE-PRODUCT; HELICASE; ORIGIN; CDC6P; SITE; RECOGNITION; INITIATION; BACTERIA	Cdc6 proteins play an essential role in the initiation of chromosomal DNA replication in Eukarya. Genes coding for putative homologs of Cdc6 have been also identified in the genomic sequence of Archaea, but the properties of the corresponding proteins have been poorly investigated so far. Herein, we report the biochemical characterization of one of the three putative Cdc6-like factors from the hyperthermophilic crenarchaeon Sulfolobus solfataricus (SsoCdc6-1). SsoCdc6-1 was overproduced in Escherichia coli as a His-tagged protein and purified to homogeneity. Gel filtration and glycerol gradient ultracentrifugation experiments indicated that this protein behaves as a monomer in solution (molecular mass of about 45 kDa). We demonstrated that SsoCdc6-1 binds single- and double-stranded DNA molecules by electrophoretic mobility shift assays. SsoCdc6-1 undergoes autophosphorylation in vitro and possesses a weak ATPase activity, whereas the protein with a mutation in the Walker A motif (Lys-59-->Ala) is completely unable to hydrolyze ATP and does not autophosphorylate. We found that SsoCdc6-1 strongly inhibits the ATPase and DNA helicase activity of the S. solfataricus MCM protein. These findings provide the first in vitro biochemical evidence of a functional interaction between a MCM complex and a Cdc6 factor and have important implications for the understanding of the Cdc6 biological function.	CNR, Ist Biochim Prot, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Pisani, FM (corresponding author), CNR, Ist Biochim Prot, Via P Castellino 111, I-80131 Naples, Italy.	pisani@dafne.ibpe.na.cnr.it	Pucci, Biagio/AAS-7502-2021; pucci, biagio/AAA-9268-2020; Pisani, Francesca M./AAX-4025-2020	pucci, biagio/0000-0003-4502-1748; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BROCK TD, 1972, ARCH MIKROBIOL, V84, P54, DOI 10.1007/BF00408082; Carpentieri F, 2002, J BIOL CHEM, V277, P12118, DOI 10.1074/jbc.M200091200; Carr KM, 2002, J BIOL CHEM, V277, P39815, DOI 10.1074/jbc.M205031200; Davey MJ, 2002, EMBO J, V21, P3148, DOI 10.1093/emboj/cdf308; Davey MJ, 2002, NAT REV MOL CELL BIO, V3, P826, DOI 10.1038/nrm949; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Erzberger JP, 2002, EMBO J, V21, P4763, DOI 10.1093/emboj/cdf496; Feng L, 2000, MOL BIOL CELL, V11, P1673, DOI 10.1091/mbc.11.5.1673; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GABROWSKI B, 2001, J BACTERIOL, V183, P5459; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; Giraldo R, 2003, FEMS MICROBIOL REV, V26, P533, DOI 10.1111/j.1574-6976.2003.tb00629.x; Herbig U, 1999, MOL BIOL CELL, V10, P2631, DOI 10.1091/mbc.10.8.2631; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Kelman LM, 2003, MOL MICROBIOL, V48, P605, DOI 10.1046/j.1365-2958.2003.03369.x; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; Kornberg A, 1992, DNA REPLICATION, P471; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lee DG, 2000, CURR OPIN CELL BIOL, V12, P280, DOI 10.1016/S0955-0674(00)00089-2; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Liu JY, 2000, MOL CELL, V6, P637, DOI 10.1016/S1097-2765(00)00062-9; Manco G, 2001, J BIOL CHEM, V276, P37482, DOI 10.1074/jbc.M103017200; Neuwald AF, 1999, GENOME RES, V9, P27; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Tye BK, 2000, P NATL ACAD SCI USA, V97, P2399, DOI 10.1073/pnas.97.6.2399; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; Zhang R, 2003, BIOCHEM BIOPH RES CO, V302, P728, DOI 10.1016/S0006-291X(03)00252-3	36	40	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46424	46431		10.1074/jbc.M306075200	http://dx.doi.org/10.1074/jbc.M306075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12966100	hybrid			2022-12-25	WOS:000186569400026
J	Maira, M; Couture, C; Le Martelot, G; Pulichino, AM; Bilodeau, S; Drouin, J				Maira, M; Couture, C; Le Martelot, G; Pulichino, AM; Bilodeau, S; Drouin, J			The T-box factor Tpit recruits SRC/p 160Co-activators and mediates hormone action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICOTROPIN-RELEASING HORMONE; ORPHAN NUCLEAR RECEPTORS; GENE-EXPRESSION; PROTEIN-KINASE; GLUCOCORTICOID-RECEPTOR; DNA-BINDING; TRANSCRIPTION; PHOSPHORYLATION; NUR77; ACTIVATION	Tpit ( Tbx19) is a transcription factor belonging to the T- box family, and it is essential for late differentiation of pituitary pro- opiomelanocortin ( POMC)- expressing corticotroph and melanotroph cells. Tpit is also required, both in humans and mice, for cell- specific expression of the POMC gene in cooperation with the homeoprotein Pitx1. Despite their important roles as developmental regulators, the molecular mechanisms underpinning the functions of T- box factors in general, and of Tpit in particular, are still poorly defined. We now report that Tpit functions as an activator of transcription by recruiting SRC/ p160 co- activators to its cognate DNA target in the POMC promoter, the Tpit/ Pitx- RE. We also show that Tpit is a mediator of hormone signaling and that the Tpit/ Pitx- RE is responsive to signals elicited by hypothalamic corticotropin- releasing hormone. These signals are mediated by the cAMP- dependent protein kinase and mitogen- activated protein kinase pathways, and activation of cAMP- dependent protein kinase also enhances Tpit and SRC- dependent transcription. We have previously shown that corticotropin- releasing hormone action is also exerted at the POMC promoter through the orphan nuclear receptor NGFI- B and its recruitment of SRC co- activators. Given that Tpit exhibits transcriptional synergy with NGFI- B, our results suggest that Tpit, along with NGFI- B and SRC- 2, is part of a transcription regulatory complex assembled on the POMC promoter in response to hormonal stimulation.	Inst Rech Clin Montreal, Genet Mol Lab, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal	Drouin, J (corresponding author), Inst Rech Clin Montreal, Genet Mol Lab, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada.	drouinj@ircm.qc.ca		Bilodeau, Steve/0000-0002-9799-3832; Pulichino, Anne-Marie/0000-0002-2419-8344; Drouin, Jacques/0000-0001-8226-5691				Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; BOUTILLIER AL, 1995, MOL ENDOCRINOL, V9, P745, DOI 10.1210/me.9.6.745; Chen SL, 2000, GENE DEV, V14, P1209; Chen SL, 2001, MOL ENDOCRINOL, V15, P783, DOI 10.1210/me.15.5.783; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; DAVIS IJ, 1994, MOL CELL BIOL, V14, P3469, DOI 10.1128/MCB.14.5.3469; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; GAGNER JP, 1987, MOL ENDOCRINOL, V1, P677, DOI 10.1210/mend-1-10-677; GAGNER JP, 1985, MOL CELL ENDOCRINOL, V40, P25, DOI 10.1016/0303-7207(85)90154-6; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; Kovalovsky D, 2002, MOL ENDOCRINOL, V16, P1638, DOI 10.1210/me.16.7.1638; Kuryshev YA, 1996, ENDOCRINOLOGY, V137, P2269, DOI 10.1210/en.137.6.2269; LABRIE F, 1982, SCIENCE, V216, P1007, DOI 10.1126/science.6281886; Lamolet B, 2001, CELL, V104, P849, DOI 10.1016/S0092-8674(01)00282-3; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Lazaro JB, 2002, GENE DEV, V16, P1792, DOI 10.1101/gad.U-9988R; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li YZ, 1997, ENDOCRINOLOGY, V138, P4138, DOI 10.1210/en.138.10.4138; Lugo DI, 1996, DEV BIOL, V173, P95, DOI 10.1006/dbio.1996.0009; Maira M, 2003, MOL CELL BIOL, V23, P763, DOI 10.1128/MCB.23.3.763-776.2003; Maira M, 1999, MOL CELL BIOL, V19, P7549; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Muller CW, 1997, NATURE, V389, P884, DOI 10.1038/39929; Papaioannou VE, 2001, INT REV CYTOL, V207, P1; Papaioannou VE, 1998, BIOESSAYS, V20, P9, DOI 10.1002/(SICI)1521-1878(199801)20:1<9::AID-BIES4>3.0.CO;2-Q; Parker KL, 2002, RECENT PROG HORM RES, V57, P19, DOI 10.1210/rp.57.1.19; Phillips A, 1997, MOL CELL BIOL, V17, P5952, DOI 10.1128/MCB.17.10.5952; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Pulichino AM, 2003, GENE DEV, V17, P738, DOI 10.1101/gad.1065703; Pulichino AM, 2003, GENE DEV, V17, P711, DOI 10.1101/gad.1065603; Qutob MS, 2002, MOL CELL BIOL, V22, P6611, DOI 10.1128/MCB.22.18.6611-6626.2002; REISINE T, 1985, P NATL ACAD SCI USA, V82, P8261, DOI 10.1073/pnas.82.23.8261; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sinha S, 2000, GENE, V258, P15, DOI 10.1016/S0378-1119(00)00417-0; Smith J, 1999, TRENDS GENET, V15, P154, DOI 10.1016/S0168-9525(99)01693-5; Teyssier C, 2001, J BIOL CHEM, V276, P36361, DOI 10.1074/jbc.M101806200; THERRIEN M, 1991, MOL CELL BIOL, V11, P3492, DOI 10.1128/MCB.11.7.3492; Zanger K, 1999, MOL ENDOCRINOL, V13, P268, DOI 10.1210/me.13.2.268	46	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46523	46532		10.1074/jbc.M305626200	http://dx.doi.org/10.1074/jbc.M305626200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12970370	hybrid			2022-12-25	WOS:000186569400037
J	Pei, ZT; Oey, NA; Zuidervaart, MM; Jia, ZZ; Li, YY; Steinberg, SJ; Smith, KD; Watkins, PA				Pei, ZT; Oey, NA; Zuidervaart, MM; Jia, ZZ; Li, YY; Steinberg, SJ; Smith, KD; Watkins, PA			The acyl-CoA synthetase "bubblegum" (lipidosin) - Further characterization and role in neuronal fatty acid beta-oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED ADRENOLEUKODYSTROPHY; RAT-LIVER; MEMBRANE-FRACTION; ADRENO-LEUKODYSTROPHY; CDNA CLONING; EXPRESSION; MITOCHONDRIA; PROTEIN; PEROXISOMES; TRANSPORT	Acyl-CoA synthetases play a pivotal role in fatty acid metabolism, providing activated substrates for fatty acid catabolic and anabolic pathways. Acyl-CoA synthetases comprise numerous proteins with diverse substrate specificities, tissue expression patterns, and subcellular localizations, suggesting that each enzyme directs fatty acids toward a specific metabolic fate. We reported that hBG1, the human homolog of the acyl-CoA synthetase mutated in the Drosophila mutant "bubblegum," belongs to a previously unidentified enzyme family and is capable of activating both long- and very long-chain fatty acid substrates. We now report that when overexpressed, hBG1 can activate diverse saturated, monosaturated, and polyunsaturated fatty acids. Using in situ hybridization and immunohistochemistry, we detected expression of mBG1, the mouse homolog of hBG1, in cerebral cortical and cerebellar neurons and in steroidogenic cells of the adrenal gland, testis, and ovary. The expression pattern and ability of BG1 to activate very long- chain fatty acids implicates this enzyme in the pathogenesis of X-linked adrenoleukodystrophy. In neuron-derived Neuro2a cells, mBG1 co-sedimented with mitochondria and was found in small vesicular structures located in close proximity to mitochondria. RNA interference was used to decrease mBG1 expression in Neuro2a cells and led to a 30-35% decrease in activation and beta-oxidation of the long- chain fatty acid, palmitate. These results suggest that in Neuro2a cells, mBG1-activated long- chain fatty acids are directed toward mitochondrial degradation. mBG1 appears to play a minor role in very long- chain fatty acid activation in these cells, indicating that other acyl-CoA synthetases are necessary for very long- chain fatty acid metabolism in Neuro2a cells.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Watkins, PA (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.	watkins@kennedykrieger.org		Watkins, Paul A./0000-0002-3246-1405	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037355] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 10982, HD 24061] Funding Source: Medline; NINDS NIH HHS [NS 37355] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Berger J, 1998, FEBS LETT, V425, P305, DOI 10.1016/S0014-5793(98)00255-5; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; CUI Z, 1993, J BIOL CHEM, V268, P16655; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; GUILBAULT GG, 1968, ANAL CHEM, V40, P1256, DOI 10.1021/ac60264a027; Heinzer AK, 2003, HUM MOL GENET, V12, P1145, DOI 10.1093/hmg/ddg126; Heinzer AK, 2002, J BIOL CHEM, V277, P28765, DOI 10.1074/jbc.M203053200; Herrmann T, 2001, GENE, V270, P31, DOI 10.1016/S0378-1119(01)00489-9; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; IGARASHI M, 1976, J NEUROCHEM, V26, P851, DOI 10.1111/j.1471-4159.1976.tb04462.x; JOHNSON AB, 1976, J HISTOCHEM CYTOCHEM, V24, P725, DOI 10.1177/24.6.59773; Kang MJ, 1997, P NATL ACAD SCI USA, V94, P2880, DOI 10.1073/pnas.94.7.2880; LAZO O, 1989, ARCH BIOCHEM BIOPHYS, V270, P722, DOI 10.1016/0003-9861(89)90555-9; LEI ZM, 1994, MOL ENDOCRINOL, V8, P1111, DOI 10.1210/me.8.8.1111; LEI ZM, 1993, ENDOCRINOLOGY, V132, P2262, DOI 10.1210/en.132.5.2262; Lewin TM, 2002, ARCH BIOCHEM BIOPHYS, V404, P263, DOI 10.1016/S0003-9861(02)00247-3; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McGuinness MC, 2003, MOL CELL BIOL, V23, P744, DOI 10.1128/MCB.23.2.744-753.2003; Mihalik SJ, 2002, J BIOL CHEM, V277, P24771, DOI 10.1074/jbc.M203295200; Min KT, 1999, SCIENCE, V284, P1985, DOI 10.1126/science.284.5422.1985; Moriya-Sato A, 2000, BIOCHEM BIOPH RES CO, V279, P62, DOI 10.1006/bbrc.2000.3897; Moser H., 2001, METABOLIC MOL BASES, VII, P3257; OGINO T, 1981, J NEUROCHEM, V36, P776, DOI 10.1111/j.1471-4159.1981.tb01657.x; POWERS JM, 1973, ARCH PATHOL, V96, P305; POWERS JM, 1974, AM J PATHOL, V76, P481; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; Steinberg SJ, 2000, J BIOL CHEM, V275, P35162, DOI 10.1074/jbc.M006403200; Steinberg SJ, 1999, MOL GENET METAB, V68, P32, DOI 10.1006/mgme.1999.2883; Steinberg SJ, 1999, BIOCHEM BIOPH RES CO, V257, P615, DOI 10.1006/bbrc.1999.0510; Stone SJ, 2000, J BIOL CHEM, V275, P34534, DOI 10.1074/jbc.M002865200; Tang PZ, 2001, P NATL ACAD SCI USA, V98, P6581, DOI 10.1073/pnas.121046998; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; VANCE JE, 1990, J BIOL CHEM, V265, P7248; WANDERS RJA, 1988, BIOCHEM BIOPH RES CO, V153, P618, DOI 10.1016/S0006-291X(88)81140-9; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; Watkins PA, 1997, PROG LIPID RES, V36, P55, DOI 10.1016/S0163-7827(97)00004-0; Watkins PA, 1999, PROSTAG LEUKOTR ESS, V60, P323, DOI 10.1016/S0952-3278(99)80007-6; WATKINS PA, 1995, AM J HUM GENET, V57, P292; WATKINS PA, 1994, BBA-LIPID LIPID MET, V1214, P288, DOI 10.1016/0005-2760(94)90075-2	46	58	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47070	47078		10.1074/jbc.M310075200	http://dx.doi.org/10.1074/jbc.M310075200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12975357	hybrid			2022-12-25	WOS:000186569400104
J	Wu, GY; Zhao, GQ; He, Y				Wu, GY; Zhao, GQ; He, Y			Distinct pathways for the trafficking of angiotensin II and adrenergic receptors from the endoplasmic reticulum to the cell surface - Rab1-independent transport of a G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; BETA(2)-ADRENERGIC RECEPTOR; VESICULAR TRANSPORT; INTRACELLULAR-TRANSPORT; GOLGI COMPARTMENTS; SECRETORY PATHWAY; PLASMA-MEMBRANE; DOWN-REGULATION; RAB PROTEINS; EXPRESSION	The molecular mechanism underlying the transport of G protein-coupled receptors from the endoplasmic reticulum (ER) to the cell surface is poorly understood. This issue was addressed by determining the role of Rab1, a Ras-related small GTPase that coordinates vesicular protein transport in the early secretory pathway, in the subcellular distribution and function of the angiotensin II type 1A receptor (AT1R), beta(2)-adrenergic receptor (AR), and alpha(2B)-AR in HEK293T cells. Inhibition of endogenous Rab1 function by transient expression of dominant-negative Rab1 mutants or Rab1 small interfering RNA (siRNA) induced a marked perinuclear accumulation and a significant reduction in cell-surface expression of AT1R and beta(2)-AR. The accumulated receptors were colocalized with calregulin (an ER marker) and GM130 (a Golgi marker), consistent with Rab1 function in regulating protein transport from the ER to the Golgi. In contrast, dominant-negative Rab1 mutants and siRNA had no effect on the subcellular distribution of alpha(2B)-AR. Similarly, expression of dominant-negative Rab1 mutants and siRNA depletion of Rab1 significantly attenuated AT1R-mediated inositol phosphate accumulation and ERK1/2 activation and beta(2)-AR- mediated ERK1/2 activation, but not alpha(2B)-AR-stimulated ERK1/2 activation. These data indicate that Rab1 GTPase selectively regulates intracellular trafficking and signaling of G protein-coupled receptors and suggest a novel, as yet undefined pathway for movement of G protein-coupled receptors from the ER to the cell surface.	Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Wu, GY (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, 1901 Perdido St, New Orleans, LA 70112 USA.	gwu@lsuhsc.edu						Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Blumer JB, 2002, J BIOL CHEM, V277, P15897, DOI 10.1074/jbc.M112185200; Castellano F, 1995, J RECEPT SIGNAL TR R, V15, P847, DOI 10.3109/10799899509049861; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; DUGAN JM, 1995, J BIOL CHEM, V270, P10982, DOI 10.1074/jbc.270.18.10982; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; Hughes RJ, 1997, BBA-MOL CELL RES, V1356, P281, DOI 10.1016/S0167-4889(97)00005-0; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Jayadev S, 1999, ENDOCRINOLOGY, V140, P2010, DOI 10.1210/en.140.5.2010; Jin MJ, 1996, J BIOL CHEM, V271, P30105, DOI 10.1074/jbc.271.47.30105; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Lanctot PM, 1999, BIOCHEMISTRY-US, V38, P8621, DOI 10.1021/bi9830516; Li JG, 2000, MOL PHARMACOL, V58, P795, DOI 10.1124/mol.58.4.795; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; Montiel M, 1998, J MOL ENDOCRINOL, V20, P299, DOI 10.1677/jme.0.0200299; MOORE RH, 1995, J CELL SCI, V108, P2983; Moyer BD, 2001, TRAFFIC, V2, P268, DOI 10.1034/j.1600-0854.2001.1o007.x; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; Olkkonen VM, 2000, NEW ENGL J MED, V343, P1095, DOI 10.1056/NEJM200010123431507; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; Rosenfeld JL, 2002, RECEPTOR CHANNEL, V8, P87, DOI 10.1080/10606820212398; Satoh AK, 1997, J CELL SCI, V110, P2943; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; Seachrist JL, 2000, J BIOL CHEM, V275, P27221; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; Tisdale EJ, 1996, J BIOL CHEM, V271, P29372, DOI 10.1074/jbc.271.46.29372; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Volpicelli LA, 2001, J BIOL CHEM, V276, P47590, DOI 10.1074/jbc.M106535200; Waters MG, 2000, TRAFFIC, V1, P588, DOI 10.1034/j.1600-0854.2000.010802.x; WILSON BS, 1994, J CELL BIOL, V125, P557, DOI 10.1083/jcb.125.3.557; Wu GY, 2000, J BIOL CHEM, V275, P29927, DOI 10.1074/jbc.C000380200; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026; Wu GY, 2001, CIRC RES, V89, P1130, DOI 10.1161/hh2401.100427; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197; Yoo JS, 2002, J BIOL CHEM, V277, P11401, DOI 10.1074/jbc.M110263200; Zhang XY, 2002, MOL THER, V5, P555, DOI 10.1006/mthe.2002.0585	51	88	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47062	47069		10.1074/jbc.M305707200	http://dx.doi.org/10.1074/jbc.M305707200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12970354	hybrid			2022-12-25	WOS:000186569400103
J	Zimmer, G; Rohn, M; McGregor, GP; Schemann, M; Conzelmann, KK; Herrler, G				Zimmer, G; Rohn, M; McGregor, GP; Schemann, M; Conzelmann, KK; Herrler, G			Virokinin, a bioactive peptide of the tachykinin family, is released from the fusion protein of bovine respiratory syncytial virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; AIRWAY EPITHELIAL-CELLS; SUBSTANCE-P; NEUROGENIC INFLAMMATION; GENE-EXPRESSION; T-CELLS; RECEPTOR; INFECTION; ACTIVATION; CLEAVAGE	Tachykinins, an evolutionary conserved family of peptide hormones in both invertebrates and vertebrates, are produced by neuronal cells as inactive preprotachykinins that are post-translationally processed into different neuropeptides such as substance P, neurokinin A, and neurokinin B. We show here that furin-mediated cleavage of the bovine respiratory syncytial virus fusion protein results in the release of a peptide that is converted into a biologically active tachykinin ( virokinin) by additional posttranslational modifications. An antibody directed to substance P cross-reacted with the C terminus of mature virokinin that contains a classical tachykinin motif. The cellular enzymes involved in the C-terminal maturation of virokinin were found to be present in many established cell lines. Virokinin is secreted by virus-infected cells and was found to act on the tachykinin receptor 1 (TACR1), leading to rapid desensitization of this G protein-coupled receptor as shown by TACR1-green fluorescent protein conjugate translocation from the cell surface to endosomes and by co-internalization of the receptor with beta-arrestin 1-green fluorescent protein conjugates. In vitro experiments with isolated circular muscle from guinea pig stomach indicated that virokinin is capable of inducing smooth muscle contraction by acting on the tachykinin receptor 3. Tachykinins and their cognate receptors are present in the mammalian respiratory tract, where they have potent effects on local inflammatory and immune processes. The viral tachykinin-like peptide represents a novel form of molecular mimicry, which may benefit the virus by affecting the host immune response.	Tierarztl Hsch Hanover, Inst Virol, D-30559 Hannover, Germany; Tech Univ Munich, Lehrstuhl Humanbiol, D-85350 Freising Weihenstephan, Germany; Univ Marburg, Inst Normale & Pathol Physiol, D-35037 Marburg, Germany; Univ Munich, Max von Pettenkofer Inst, D-81377 Munich, Germany; Univ Munich, Genzentrum, D-81377 Munich, Germany	Technical University of Munich; Philipps University Marburg; University of Munich; University of Munich	Herrler, G (corresponding author), Tierarztl Hsch Hanover, Inst Virol, Bunteweg 17, D-30559 Hannover, Germany.	Georg.Herrler@tiho-hannover.de	Conzelmann, Karl-Klaus/L-7239-2013	Conzelmann, Karl-Klaus/0000-0002-8614-3656; mcgregor, gerard/0000-0003-3087-0018; Schemann, Michael/0000-0003-1007-9843; Zimmer, Gert/0000-0002-2708-2507				Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Becker S, 1999, IMMUNOBIOLOGY, V201, P88, DOI 10.1016/S0171-2985(99)80049-7; Bolt G, 2000, VIRUS RES, V68, P25, DOI 10.1016/S0168-1702(00)00149-0; BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; Bramley AM, 1999, EUR RESPIR J, V14, P1061, DOI 10.1183/09031936.99.14510619; Casola A, 2000, J IMMUNOL, V164, P5944, DOI 10.4049/jimmunol.164.11.5944; Castagliuolo I, 2000, J BIOL CHEM, V275, P26545, DOI 10.1074/jbc.M003990200; Chang J, 2002, NAT MED, V8, P54, DOI 10.1038/nm0102-54; COLLINS PL, 1996, VIROLOGY, P1313; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; Di Maria GU, 1998, EUR RESPIR J, V12, P1454, DOI 10.1183/09031936.98.12061454; Domachowske JB, 1999, CLIN MICROBIOL REV, V12, P298, DOI 10.1128/CMR.12.2.298; Domachowske JB, 2001, RESPIR RES, V2, P225, DOI 10.1186/rr61; Emonds-Alt X, 2002, CAN J PHYSIOL PHARM, V80, P482, DOI 10.1139/y02-041; Feldman SA, 2000, J VIROL, V74, P6442, DOI 10.1128/JVI.74.14.6442-6447.2000; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fiebich BL, 2000, J IMMUNOL, V165, P5606, DOI 10.4049/jimmunol.165.10.5606; Garofalo RP, 2001, J INFECT DIS, V184, P393, DOI 10.1086/322788; GARTEN W, 1983, J GEN VIROL, V64, P2127, DOI 10.1099/0022-1317-64-10-2127; GOETZL EJ, 1992, FASEB J, V6, P2646, DOI 10.1096/fasebj.6.9.1612288; Gonzalez-Reyes L, 2001, P NATL ACAD SCI USA, V98, P9859, DOI 10.1073/pnas.151098198; GOODING LR, 1992, CELL, V71, P5; Guo CJ, 2002, J NEUROIMMUNOL, V131, P160, DOI 10.1016/S0165-5728(02)00277-1; HALL CB, 1991, J INFECT DIS, V163, P693, DOI 10.1093/infdis/163.4.693; Haynes LM, 2002, J VIROL, V76, P6873, DOI 10.1128/JVI.76.14.6873-6881.2002; Heaney LG, 1998, THORAX, V53, P357, DOI 10.1136/thx.53.5.357; HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004; Jaovisidha P, 1999, J IMMUNOL, V163, P2816; Joos GF, 2001, EUR J PHARMACOL, V429, P239, DOI 10.1016/S0014-2999(01)01323-1; Kahn JS, 1999, VIROLOGY, V254, P81, DOI 10.1006/viro.1998.9535; Keles I, 1998, J COMP PATHOL, V118, P337, DOI 10.1016/S0021-9975(07)80009-0; Khawaja AM, 1996, INT J BIOCHEM CELL B, V28, P721, DOI 10.1016/1357-2725(96)00017-9; KincyCain T, 1997, J IMMUNOL, V158, P2334; King KA, 2001, AM J RESP CELL MOL, V24, P101, DOI 10.1165/ajrcmb.24.2.4264; Klenk Hans-Dieter, 1994, Trends in Microbiology, V2, P39, DOI 10.1016/0966-842X(94)90123-6; Lambrecht BN, 2001, RESP RES, V2, P133, DOI 10.1186/rr49; LAMPRECHT CL, 1976, J INFECT DIS, V134, P211, DOI 10.1093/infdis/134.3.211; Lecci A, 2000, NEUROPEPTIDES, V34, P303, DOI 10.1054/npep.2000.0825; Levite M, 1998, P NATL ACAD SCI USA, V95, P12544, DOI 10.1073/pnas.95.21.12544; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; Lukacs NW, 2001, J IMMUNOL, V167, P1060, DOI 10.4049/jimmunol.167.2.1060; MACLEOD AM, 1993, J MED CHEM, V36, P2044, DOI 10.1021/jm00066a015; Maggi CA, 1997, REGUL PEPTIDES, V70, P75, DOI 10.1016/S0167-0115(97)00029-3; Matsuse H, 2000, J IMMUNOL, V164, P6583, DOI 10.4049/jimmunol.164.12.6583; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; MCGILLIS JP, 1990, ANN NY ACAD SCI, V594, P85; MCGREGOR GP, 1983, LIFE SCI, V32, P655, DOI 10.1016/0024-3205(83)90211-4; Olszewska-Pazdrak B, 1998, J VIROL, V72, P4756, DOI 10.1128/JVI.72.6.4756-4764.1998; PASCUAL DW, 1999, MUCOSAL IMMUNOLOGY, P631; Patacchini R, 2001, EUR J PHARMACOL, V429, P13, DOI 10.1016/S0014-2999(01)01301-2; Payne CM, 2001, J VIROL, V75, P10467, DOI 10.1128/JVI.75.21.10467-10471.2001; Piedimonte G, 1999, AM J PHYSIOL-LUNG C, V277, pL831, DOI 10.1152/ajplung.1999.277.4.L831; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; Quartara L, 1997, NEUROPEPTIDES, V31, P537, DOI 10.1016/S0143-4179(97)90001-9; SCHEMANN M, 1991, PFLUG ARCH EUR J PHY, V419, P566, DOI 10.1007/BF00370296; Schlender J, 2002, J VIROL, V76, P1163, DOI 10.1128/JVI.76.3.1163-1170.2002; Schmidlin F, 2002, P NATL ACAD SCI USA, V99, P3324, DOI 10.1073/pnas.052161299; Schwarze J, 2002, EUR RESPIR J, V19, P341, DOI 10.1183/09031936.02.00254302; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SHARMA R, 1990, J COMP PATHOL, V103, P411, DOI 10.1016/S0021-9975(08)80029-1; SHARMA R, 1991, RES VET SCI, V50, P152, DOI 10.1016/0034-5288(91)90098-9; Small BA, 2001, J EXP MED, V194, P1835, DOI 10.1084/jem.194.12.1835; Techaarpornkul S, 2002, VIROLOGY, V294, P296, DOI 10.1006/viro.2001.1340; Tripp RA, 2000, J VIROL, V74, P1614, DOI 10.1128/JVI.74.4.1614-1622.2000; Valarcher JF, 2001, VIROLOGY, V291, P55, DOI 10.1006/viro.2001.1083; Vanden Broeck J, 1999, ANN NY ACAD SCI, V897, P374, DOI 10.1111/j.1749-6632.1999.tb07907.x; WOLDEHIWET Z, 1992, SCAND J IMMUNOL, V36, P75, DOI 10.1111/j.1365-3083.1992.tb01624.x; Zhang LQ, 2002, J VIROL, V76, P5654, DOI 10.1128/JVI.76.11.5654-5666.2002; Zimmer G, 2002, J VIROL, V76, P9218, DOI 10.1128/JVI.76.18.9218-9224.2002; Zimmer G, 2001, J BIOL CHEM, V276, P31642, DOI 10.1074/jbc.M102633200	71	41	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46854	46861		10.1074/jbc.M306949200	http://dx.doi.org/10.1074/jbc.M306949200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12952986	hybrid			2022-12-25	WOS:000186569400078
J	Dowell, P; Otto, TC; Adi, S; Lane, MD				Dowell, P; Otto, TC; Adi, S; Lane, MD			Convergence of peroxisome proliferator-activated receptor gamma and Foxo1 signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; PROTEIN-KINASE-B; GENE-EXPRESSION; PPAR-GAMMA; FACTOR FKHR; CAENORHABDITIS-ELEGANS; ADIPOSE-TISSUE; ADIPOCYTE DIFFERENTIATION; NUCLEAR RECEPTORS; PROMOTER ACTIVITY	The forkhead factor Foxo1 (or FKHR) was identified in a yeast two-hybrid screen as a peroxisome proliferator-activated receptor (PPAR) gamma-interacting protein. Foxo1 antagonized PPARgamma activity and vice versa indicating that these transcription factors functionally interact in a reciprocal antagonistic manner. One mechanism by which Foxo1 antagonizes PPARgamma activity is through disruption of DNA binding as Foxo1 inhibited the DNA binding activity of a PPARgamma/retinoid X receptor alpha heterodimeric complex. The Caenorhabditis elegans nuclear hormone receptor, DAF-12, interacted with the C. elegans forkhead factor, DAF-16, paralleling the interaction between PPARgamma and Foxo1. daf-12 and daf-16 have been implicated in C. elegans insulin-like signaling pathways, and PPARgamma and Foxo1 likewise have been linked to mammalian insulin signaling pathways. These results suggest a convergence of PPARgamma and Foxo1 signaling that may play a role in insulin action and the insulinomimetic properties of PPARgamma ligands. A more general convergence of nuclear hormone receptor and forkhead factor pathways may be important for multiple biological processes and this convergence may be evolutionarily conserved.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, WBSB 509, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Dowell, P (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, WBSB 509, 725 N Wolfe St, Baltimore, MD 21205 USA.				NIDDK NIH HHS [DK64934, DK38418, DK09894] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009894, R01DK038418, K01DK064934] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adi S, 2000, J CELL BIOCHEM, V78, P617, DOI 10.1002/1097-4644(20000915)78:4<617::AID-JCB11>3.3.CO;2-0; Altomonte J, 2003, AM J PHYSIOL-ENDOC M, V285, pE718, DOI 10.1152/ajpendo.00156.2003; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Cederberg A, 2001, CELL, V106, P563, DOI 10.1016/S0092-8674(01)00474-3; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Dowell P, 2002, J BIOL CHEM, V277, P1712, DOI 10.1074/jbc.M108589200; Dowell P, 2000, J BIOL CHEM, V275, P41325, DOI 10.1074/jbc.M006474200; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; IKEDA H, 1990, ARZNEIMITTEL-FORSCH, V40-1, P156; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lee CH, 2003, ENDOCRINOLOGY, V144, P2201, DOI 10.1210/en.2003-0288; Lee RYN, 2001, CURR BIOL, V11, P1950, DOI 10.1016/S0960-9822(01)00595-4; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; Murakami S, 2000, ANN NY ACAD SCI, V908, P40; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; ONATE SA, 1995, SCIENCE, V270, P1354; Perrot V, 2003, J BIOL CHEM, V278, P26111, DOI 10.1074/jbc.M212750200; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; TRAN H, 2003, SCI STKE; Wolfrum C, 2003, J CLIN INVEST, V112, P345, DOI 10.1172/JCI18698; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Zhao HH, 2001, J BIOL CHEM, V276, P27907, DOI 10.1074/jbc.M104278200	54	176	185	4	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45485	45491		10.1074/jbc.M309069200	http://dx.doi.org/10.1074/jbc.M309069200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12966085	hybrid			2022-12-25	WOS:000186452300054
J	McDearmon, EL; Combs, AC; Ervasti, JM				McDearmon, EL; Combs, AC; Ervasti, JM			Core 1 glycans on alpha-dystroglycan mediate laminin-induced acetylcholine receptor clustering but not laminin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-GLYCOPROTEIN COMPLEX; SYNAPSE-SPECIFIC CARBOHYDRATE; SKELETAL-MUSCLE; NEUROMUSCULAR-JUNCTION; ALPHA-7-BETA-1 INTEGRIN; MUSK; ACTIVATION; PROTEINS; PATHWAY; GLYCOSYLATION	Although unique O-linked oligosaccharides on alpha-dystroglycan are important for binding to a variety of extracellular ligands, the function(s) of more generic carbohydrate structures on alpha-dystroglycan remain unclear. Recent studies suggest a role for glycoconjugates bearing the core 1 disaccharide Galbeta(1-3) GalNAc in acetylcholine receptor (AChR) clustering on the surface of muscle cells. Here, we report experiments demonstrating that the core 1-specific lectin jacalin almost completely abrogated laminin-induced AChR clustering in C2C12 myotubes and that alpha-dystroglycan was the predominant jacalin-binding protein detected in C2C12 myotube lysates. Although jacalin likely inhibited laminin-induced AChR clustering by directly binding to alpha-dystroglycan, jacalin had no effect on laminin binding to the myotube surface or to alpha-dystroglycan. Like jacalin, peanut agglutinin lectin also binds the core 1 disaccharide but not when it is terminally sialylated as expressed on alpha-dystroglycan. We show that C2C12 alpha-dystroglycan bound to peanut agglutinin only after digestion with neuraminidase. Simultaneous treatment of myotubes with neuraminidase and endo-O-glycosidase diminished alpha-dystroglycan binding to peanut agglutinin and inhibited neuraminidase-induced AChR clustering. We conclude that sialylated core 1 oligosaccharides of alpha-dystroglycan are important for laminin-induced AChR clustering and that their function in this process is distinct from the established role of alpha-dystroglycan oligosaccharides in laminin binding.	Univ Wisconsin, Sch Med, Dept Physiol, Serv Mem Inst 127, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Grad Program Mol & Cellular Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ervasti, JM (corresponding author), Univ Wisconsin, Sch Med, Dept Physiol, Serv Mem Inst 127, 1300 Univ Ave, Madison, WI 53706 USA.		Ervasti, James/AAZ-4786-2020		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR001985] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR01985] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arikawa-Hirasawa E, 2002, NAT NEUROSCI, V5, P119, DOI 10.1038/nn801; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BRANCACCIO A, 1995, FEBS LETT, V368, P139, DOI 10.1016/0014-5793(95)00628-M; Burkin DJ, 1998, J CELL BIOL, V143, P1067, DOI 10.1083/jcb.143.4.1067; Burkin DJ, 2000, J CELL SCI, V113, P2877; Cohn RD, 2002, CELL, V110, P639, DOI 10.1016/S0092-8674(02)00907-8; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; Cote PD, 1999, NAT GENET, V23, P338, DOI 10.1038/15519; Ervasti JM, 1997, J BIOL CHEM, V272, P22315, DOI 10.1074/jbc.272.35.22315; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Ervasti JM, 2003, J BIOL CHEM, V278, P13591, DOI 10.1074/jbc.R200021200; GEE SH, 1993, J BIOL CHEM, V268, P14972; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; Grow WA, 1999, J NEUROBIOL, V40, P356, DOI 10.1002/(SICI)1097-4695(19990905)40:3<356::AID-NEU7>3.3.CO;2-6; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; HORTIN GL, 1990, ANAL BIOCHEM, V188, P271, DOI 10.1016/0003-2697(90)90605-9; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; Jacobson C, 1998, J NEUROSCI, V18, P6340; Marangi PA, 2002, J CELL BIOL, V157, P883, DOI 10.1083/jcb.200202110; Martin PT, 1999, MOL CELL NEUROSCI, V13, P105, DOI 10.1006/mcne.1999.0737; MARTIN PT, 1995, NEURON, V14, P743, DOI 10.1016/0896-6273(95)90218-X; McDearmon EL, 1998, J BIOL CHEM, V273, P24139, DOI 10.1074/jbc.273.37.24139; McDearmon EL, 2001, J BIOL CHEM, V276, P35078, DOI 10.1074/jbc.M103843200; Michele DE, 2003, J BIOL CHEM, V278, P15457, DOI 10.1074/jbc.R200031200; Montanaro F, 1998, J NEUROSCI, V18, P1250; Pall EA, 1996, J BIOL CHEM, V271, P3817; Parkhomovskiy N, 2000, MOL CELL NEUROSCI, V15, P380, DOI 10.1006/mcne.2000.0835; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; SANES JR, 1982, NATURE, V300, P646, DOI 10.1038/300646a0; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; SCOTT LJC, 1988, J NEUROSCI, V8, P932; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; Sugiyama JE, 1997, J CELL BIOL, V139, P181, DOI 10.1083/jcb.139.1.181; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Watty A, 2002, J BIOL CHEM, V277, P50457, DOI 10.1074/jbc.M208664200; Xia B, 2002, MOL CELL NEUROSCI, V19, P539, DOI 10.1006/mcne.2001.1095	38	28	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44868	44873		10.1074/jbc.M307026200	http://dx.doi.org/10.1074/jbc.M307026200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12952987	hybrid			2022-12-25	WOS:000186306700122
J	Ji, P; Diederichs, S; Wang, WB; Boing, S; Metzger, R; Schneider, PM; Tidow, N; Brandt, B; Buerger, H; Bulk, E; Thomas, M; Berdel, WE; Serve, H; Muller-Tidow, C				Ji, P; Diederichs, S; Wang, WB; Boing, S; Metzger, R; Schneider, PM; Tidow, N; Brandt, B; Buerger, H; Bulk, E; Thomas, M; Berdel, WE; Serve, H; Muller-Tidow, C			MALAT-1, a novel noncoding RNA, and thymosin beta 4 predict metastasis and survival in early-stage non-small cell lung cancer	ONCOGENE			English	Article						metastasis; non-small cell lung cancer; subtractive hybridization; prognostic parameter; thymosin beta 4; MALAT-1	GENE-EXPRESSION; IDENTIFICATION; CHEMOTHERAPY; CARCINOMA; GROWTH; MAP; ADENOCARCINOMA; INVASION; MOTILITY; REVEALS	Early-stage non-small cell lung cancer (NSCLC) can be cured by surgical resection, but a substantial fraction of patients ultimately dies due to distant metastasis. In this study, we used subtractive hybridization to identify gene expression differences in stage I NSCLC tumors that either did or did not metastasize in the course of disease. Individual clones (n = 225) were sequenced and quantitative RT-PCR verified overexpression in metastasizing samples. Several of the identified genes (eIF4A1, thymosin beta4 and a novel transcript named MALAT-1) were demonstrated to be significantly associated with metastasis in NSCLC patients (n = 70). The genes' association with metastasis was stage- and histology specific. The Kaplan-Meier analyses identified MALAT-1 and thymosin beta4 as prognostic parameters for patient survival in stage I NSCLC. The novel MALAT-1 transcript is a noncoding RNA of more than 8000 nt expressed from chromosome 11q13. It is highly expressed in lung, pancreas and other healthy organs as well as in NSCLC. MALAT-1 expressed sequences are conserved across several species indicating its potentially important function. Taken together, these data contribute to the identification of early-stage NSCLC patients that are at high risk to develop metastasis. The identification of MALAT-1 emphasizes the potential role of noncoding RNAs in human cancer.	Univ Munster, Dept Med Hematol Oncol, D-48129 Munster, Germany; Univ Cologne, Dept Visceral & Vasc Surg, D-5000 Cologne 41, Germany; Univ Munster, Inst Lab Med & Clin Chem, D-48129 Munster, Germany; Univ Munster, Gerhard Domagk Inst Pathol, D-48129 Munster, Germany	University of Munster; University of Cologne; University of Munster; University of Munster	Muller-Tidow, C (corresponding author), Univ Munster, Dept Med Hematol Oncol, Domagkstr 3, D-48129 Munster, Germany.		Müller-Tidow, Carsten/O-7207-2018; Müller-Tidow, Carsten CMT/B-5257-2014; Diederichs, Sven/J-6237-2012	Müller-Tidow, Carsten/0000-0002-7166-5232; Brandt, Burkhard/0000-0003-3681-3049; Diederichs, Sven/0000-0001-7901-4752				Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Brem R, 2001, ANTICANCER RES, V21, P1731; Chakrabarti R, 1998, GENE CHROMOSOME CANC, V22, P130, DOI 10.1002/(SICI)1098-2264(199806)22:2<130::AID-GCC7>3.0.CO;2-Y; CHENCHIK A, 1998, GENE CLONING ANAL RT, P305; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; FIDLER IJ, 1990, CANCER RES, V50, P6130; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Guru SC, 1997, GENOME RES, V7, P725, DOI 10.1101/gr.7.7.725; HESKETH R, 1997, ONCOGENE TUMOUR SUPR; Hibi K, 1998, CANCER RES, V58, P5690; HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; Keller SM, 2000, NEW ENGL J MED, V343, P1217, DOI 10.1056/NEJM200010263431703; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Kobayashi T, 2002, AM J PATHOL, V160, P869, DOI 10.1016/S0002-9440(10)64910-3; Li X, 1996, GENOMICS, V32, P388, DOI 10.1006/geno.1996.0133; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; McDoniels-Silvers AL, 2002, CLIN CANCER RES, V8, P1127; Muller-Tidow C, 2001, CANCER RES, V61, P647; Nagamachi Y, 1998, CANCER LETT, V127, P203, DOI 10.1016/S0304-3835(98)00039-1; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; RASIO D, 1995, CANCER RES, V55, P3988; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; Shieh DB, 1999, CANCER-AM CANCER SOC, V85, P47, DOI 10.1002/(SICI)1097-0142(19990101)85:1<47::AID-CNCR7>3.0.CO;2-L; Shimizu K, 2000, GENOMICS, V65, P113, DOI 10.1006/geno.2000.6154; Sorenson S, 2001, ACTA ONCOL, V40, P327; Souquet PJ, 2001, LUNG CANCER-J IASLC, V34, pS155, DOI 10.1016/S0169-5002(01)00361-0; Ukena D, 2001, LUNG CANCER-J IASLC, V33, pS25, DOI 10.1016/S0169-5002(01)00299-9; URA H, 1989, CANCER RES, V49, P4615; van Asseldonk M, 2000, GENOMICS, V66, P35, DOI 10.1006/geno.2000.6194; Weston WM, 1999, J BIOL CHEM, V274, P13698, DOI 10.1074/jbc.274.19.13698; Xu GC, 2000, CHINESE MED J-PEKING, V113, P617; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	36	1673	1827	2	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					8031	8041		10.1038/sj.onc.1206928	http://dx.doi.org/10.1038/sj.onc.1206928			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970751				2022-12-25	WOS:000185388200018
J	Lee, SO; Lou, W; Hou, M; Onate, SA; Gao, AC				Lee, SO; Lou, W; Hou, M; Onate, SA; Gao, AC			Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway	ONCOGENE			English	Article						IL-4; androgen receptor; PSA; prostate cancer	STIMULATORY FACTOR-I; JAK-3 JANUS KINASE; CANCER CELLS; GENE-EXPRESSION; IL-4 RECEPTOR; PROTEIN; PHOSPHORYLATION; INSULIN; IGE; ACQUISITION	Androgen receptor (AR) plays an important role in the development and progression of prostate cancer upon the action of androgen through the binding of the androgen-responsive elements (AREs) on the target genes. Abnormal activation of the AR by nonandrogen has been implicated in the progression of androgen-independent prostate cancer. The levels of interleukin-4 (IL-4) are significantly elevated in sera of patients with hormone refractory prostate cancer. The potential role of IL-4 on the activation of AR was investigated in prostate cancer cells. IL-4 enhances AR-mediated prostate-specific antigen (PSA) expression and ARE-containing gene activity through activation of the AR in the androgen ablation condition in human prostate cancer cells. The AR can also be sensitized by IL-4 and activated by significantly lower levels of androgen (10 pm of R1881) in prostate cancer cells. IL-4 enhances nuclear translocation of AR and increases binding of the AR to the ARE in LNCaP prostate cancer cells. Blocking of the Akt pathway by an Akt-specific inhibitor LY294002 abrogates IL-4-induced PSA expression and AR signaling. These results demonstrate that IL-4 enhances PSA expression through activation of the AR and Akt signaling pathways in LNCaP prostate cancer cells. Understanding IL-4-induced signaling leading to abnormal activation of AR will provide insights into the molecular mechanisms of androgen-independent progression of prostate cancer cells.	Roswell Pk Canc Inst, Dept Med Pharmacol & Therapeut, Grace Canc Drug Ctr, Buffalo, NY 14263 USA; Univ Pittsburgh, Med Ctr, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA	Roswell Park Cancer Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gao, AC (corresponding author), Roswell Pk Canc Inst, Dept Med Pharmacol & Therapeut, Grace Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.				NCI NIH HHS [CA90271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrack ER, 1996, MT SINAI J MED, V63, P403; Chen TS, 2000, CANCER RES, V60, P2132; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; Godoy-Tundidor S, 2002, CLIN CANCER RES, V8, P2356; Hobisch A, 1998, CANCER RES, V58, P4640; HOBISCH A, 1995, CANCER RES, V55, P3068; ISAACS JT, 1994, VITAM HORM, V49, P433; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Lin DL, 2001, CLIN CANCER RES, V7, P1773; Linja MJ, 2001, CANCER RES, V61, P3550; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Murata T, 1996, J IMMUNOL, V156, P2972; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Pang S, 1997, CANCER RES, V57, P495; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Trapman J, 1997, SEMIN CANCER BIOL, V8, P29, DOI 10.1006/scbi.1997.0050; UEDA T, 2001, J BIOL CHEM, V19, P19; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VITETTA ES, 1985, J EXP MED, V162, P1726, DOI 10.1084/jem.162.5.1726; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; Wen Y, 2000, CANCER RES, V60, P6841; Wise GJ, 2000, J UROLOGY, V164, P722, DOI 10.1016/S0022-5347(05)67289-8; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388	36	61	63	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7981	7988		10.1038/sj.onc.1206735	http://dx.doi.org/10.1038/sj.onc.1206735			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970746				2022-12-25	WOS:000185388200013
J	Li, CH; Wernig, F; Leitges, M; Hu, YH; Xu, QB				Li, CH; Wernig, F; Leitges, M; Hu, YH; Xu, QB			Mechanical stress-activated PKC delta regulates smooth muscle cell migration	FASEB JOURNAL			English	Article						mechanical stress; smooth muscle cells; cell migration; cytoskeleton	PROTEIN-KINASE-C; MATRIX-METALLOPROTEINASE; ATHEROSCLEROSIS; EXPRESSION; APOPTOSIS; INTEGRINS; PATHWAYS; P53; PHOSPHORYLATION; TRANSLOCATION	Vascular smooth muscle cells (SMCs) are exposed to altered mechanical stress that may contribute to SMC migration in the development of atherosclerosis. Signal transduction pathways in SMCs activated by mechanical stress that instigate cell migration are undefined. Herein, we provide evidence that mechanical stress enhances SMC migration, which is mediated, at least in part, by protein kinase C (PKC) delta. When rat SMCs cultivated on a flexible membrane were subjected to cyclic strain stress (60 cycles/min, 5, 15, or 20% elongation), PKCdelta was translocated to the Triton-insoluble fraction, whereas PKCalpha was translocated to the membrane, which was confirmed by PKC kinase assays. Immunofluorescence and actin staining revealed a cytoskeleton translocation of PKCdelta in SMCs stimulated by cyclic strain. PKCdelta-deficient SMCs cultivated from PKCdelta-/- mice showed an abnormal cytoskeleton structure, which was related to a diminished phosphorylation of paxillin, focal adhesion kinase, and vinculin in response to mechanical stress. Mechanical stress enhanced SMC migration, which was diminished in PKCdelta-/- SMCs. Taken together, our data demonstrated that mechanical stress activates PKCdelta translocation to the cytoskeleton, which is related to decreased SMC migration and indicates that PKCdelta is a key signal transducer between mechanical stress and cell migration.	St George Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England; Austrian Acad Sci, Inst Biomed Aging Res, Innsbruck, Austria; Max Planck Inst Expt Endocrinol, Hannover, Germany	St Georges University London; Austrian Academy of Sciences; Max Planck Society	Xu, QB (corresponding author), St George Hosp, Sch Med, Dept Cardiol Sci, Granmer Terrance, London SW17 0RE, England.	q.xu@sghms.ac.uk	Leitges, Michael/AAN-1953-2021	Li, Chaohong/0000-0002-7979-1639				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; BHAGYALAKSHMI A, 1989, BIOCHEM BIOPH RES CO, V158, P31, DOI 10.1016/S0006-291X(89)80172-X; Blobe GC, 1996, CANCER SURV, V27, P213; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Cheng JJ, 2001, J BIOL CHEM, V276, P31368, DOI 10.1074/jbc.M011317200; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Defilippi P, 1997, J BIOL CHEM, V272, P21726, DOI 10.1074/jbc.272.35.21726; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hai CM, 2000, ARCH PHARM RES, V23, P535, DOI 10.1007/BF02975237; Hansen RS, 1996, ONCOGENE, V13, P995; Hu YH, 1999, CIRCULATION, V100, P861, DOI 10.1161/01.CIR.100.8.861; Hu YH, 1998, FASEB J, V12, P1135, DOI 10.1096/fasebj.12.12.1135; Hu YH, 1997, J BIOL CHEM, V272, P9113; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Lee RT, 1996, ARTERIOSCL THROM VAS, V16, P1070, DOI 10.1161/01.ATV.16.8.1070; Leitges M, 2001, J CLIN INVEST, V108, P1505; Li, 2000, Arterioscler Thromb Vasc Biol, V20, pE1; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; Li S, 2002, P NATL ACAD SCI USA, V99, P3546, DOI 10.1073/pnas.052018099; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Mayr M, 2002, FASEB J, V16, P1423, DOI 10.1096/fj.02-0042fje; Mayr U, 2002, CIRC RES, V90, P197, DOI 10.1161/hh0202.103715; Meininger GA, 1999, BIOPHYS J, V77, P973, DOI 10.1016/S0006-3495(99)76948-1; Metzler B, 1998, J BIOL CHEM, V273, P33320, DOI 10.1074/jbc.273.50.33320; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; Okada Y, 1998, JPN J OPHTHALMOL, V42, P90, DOI 10.1016/S0021-5155(97)00129-9; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; Perez-Moreno M, 1998, J CELL SCI, V111, P3563; Pomerantz KB, 1997, BIOCHEMISTRY-US, V36, P9532, DOI 10.1021/bi963070k; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; Shay-Salit A, 2002, P NATL ACAD SCI USA, V99, P9462, DOI 10.1073/pnas.142224299; Smith PG, 1997, EXP CELL RES, V232, P127, DOI 10.1006/excr.1997.3492; Suzuma I, 2002, J BIOL CHEM, V277, P1047, DOI 10.1074/jbc.M105336200; Takei T, 1997, J CELL BIOCHEM, V67, P327, DOI 10.1002/(SICI)1097-4644(19971201)67:3<327::AID-JCB5>3.0.CO;2-Y; Tanabe Y, 2000, MOL CELL BIOCHEM, V215, P103, DOI 10.1023/A:1026506801659; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; Tyagi SC, 1998, J CELL PHYSIOL, V176, P374, DOI 10.1002/(SICI)1097-4652(199808)176:2<374::AID-JCP16>3.0.CO;2-3; VINTERS HV, 1987, DIABETES METAB, V13, P294; VUORI K, 1993, J BIOL CHEM, V268, P21459; Wernig F, 2003, HYPERTENSION, V41, P903, DOI 10.1161/01.HYP.0000062882.42265.88; Xu QB, 2000, TRENDS CARDIOVAS MED, V10, P35, DOI 10.1016/S1050-1738(00)00042-6; Xu QB, 1996, J CLIN INVEST, V97, P508, DOI 10.1172/JCI118442; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Ziegler WH, 2002, J BIOL CHEM, V277, P7396, DOI 10.1074/jbc.M110008200	51	98	107	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2106	+		10.1096/fj.03-0150fje	http://dx.doi.org/10.1096/fj.03-0150fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958154				2022-12-25	WOS:000185925100025
J	Goldstein, S; Russo, A; Samuni, A				Goldstein, S; Russo, A; Samuni, A			Reactions of PTIO and carboxy-PTIO with (NO)-N-center dot, (NO2)-N-center dot, and O-2(center dot)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; NITRONYL NITROXIDES; SUPEROXIDE-DISMUTASE; PULSE-RADIOLYSIS; NITROGEN-DIOXIDE; AQUEOUS-SOLUTION; HUMAN-CELLS; CENTER-DOT; NO; PEROXYNITRITE	Nitronyl nitroxides, such as derivatives of 2- phenyl-4,4,5,5,- tetramethylimidazoline- 1- oxyl 3- oxide ( PTIOs), react with (.) NO to form the corresponding imino nitroxides ( PTIs) and (.) NO2. PTIOs are considered as monitors of (NO)-N-., stoichiometric sources of (NO2)-N-., biochemical and physiological effectors, specific tools for the elimination of (NO)-N-., and potential therapeutic agents. However, a better understanding of the chemical properties of PTIOs, especially following their reaction with (NO)-N-., is necessary to resolve many of the reported discrepancies surrounding the effects of PTIOs and to better characterize their potential therapeutic activity. We have generated electrochemically the oxidized and reduced forms of PTIO and carboxy- PTIO ( C- PTIO), characterized their absorption spectra, and determined the reduction potentials for the oxoammonium/ nitroxide and nitroxide/ hydroxylamine couples. The rate constants for the reaction of (NO2)-N-. with PTIO and C- PTIO to form the corresponding oxoammonium cations ( PTIO (+) s) and nitrite were determined to be ( 1.5 - 2) x 10(7) M-1 s(-1). We have also shown that the reactions of PTIO(+)s with (NO)-N-. form PTIOs and NO2-. The rate constants for these reactions are approximately 30- fold higher than those for the reactions of PTIOs with (NO)-N-. or O-2. The present results show that ( i) the reaction of PTIOs with (NO)-N-. forms solely PTIs and NO2- where [NO2-]/[ PTI] varies between 1 and 2 depending on the steady- state concentrations of (NO)-N-.. Consequently, quantitation of (NO)-N-. is valid only at sufficiently low fluxes of (NO)-N-.; ( ii) the reaction of PTIOs with (NO)-N-. can be used as a valid source of (NO2)-N-. only when the latter is effectively scavenged by an appropriate reductant; and ( iii) the formation of peroxynitrite cannot be efficiently inhibited by PTIOs even under relatively low fluxes of (NO)-N-. and O-2. and millimolar levels of PTIOs.	Hebrew Univ Jerusalem, Dept Phys Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel; NCI, Radiat Biol Branch, NIH, Bethesda, MD 20892 USA	Hebrew University of Jerusalem; Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Goldstein, S (corresponding author), Hebrew Univ Jerusalem, Dept Phys Chem, IL-91904 Jerusalem, Israel.							AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; [Anonymous], 1998, NIST STANDARD REFERE; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BISSOT TC, 1957, J AM CHEM SOC, V79, P796, DOI 10.1021/ja01561a005; Eiserich Jason P., 1998, Molecular Aspects of Medicine, V19, P221, DOI 10.1016/S0098-2997(99)00002-3; Espey MG, 2002, P NATL ACAD SCI USA, V99, P3481, DOI 10.1073/pnas.062604199; Espey MG, 2001, J BIOL CHEM, V276, P30085, DOI 10.1074/jbc.M101723200; Espey MG, 2002, P NATL ACAD SCI USA, V99, P11127, DOI 10.1073/pnas.152157599; Ford E, 2002, FREE RADICAL BIO MED, V32, P1314, DOI 10.1016/S0891-5849(02)00850-X; GOLDSTEIN S, 1995, J AM CHEM SOC, V117, P12078, DOI 10.1021/ja00154a007; Goldstein S, 1996, J AM CHEM SOC, V118, P3419, DOI 10.1021/ja9536680; GOLDSTEIN S, 1995, FREE RADICAL BIO MED, V19, P505, DOI 10.1016/0891-5849(95)00034-U; GOLDSTEIN S, 2003, CHEM RES TOXICOL, V125, P836; GOLDSTEIN S, 2003, IN PRESS J AM CHEM S; GRATZEL M, 1970, BERICH BUNSEN GESELL, V74, P488; Haseloff RF, 1997, FREE RADICAL RES, V26, P7, DOI 10.3109/10715769709097780; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HOGG N, 1995, FREE RADICAL RES, V22, P47, DOI 10.3109/10715769509147527; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Janssen YMW, 1998, AM J PHYSIOL-LUNG C, V275, pL1100, DOI 10.1152/ajplung.1998.275.6.L1100; JOSEPH J, 1993, BIOCHEM BIOPH RES CO, V192, P926, DOI 10.1006/bbrc.1993.1504; Jourd'heuil D, 2003, J BIOL CHEM, V278, P15720, DOI 10.1074/jbc.M300203200; KUTHAN H, 1982, BIOCHEM J, V203, P551, DOI 10.1042/bj2030551; LEWIS RS, 1994, CHEM RES TOXICOL, V7, P568, DOI 10.1021/tx00040a013; Lymar SV, 2002, J PHYS CHEM A, V106, P7245, DOI 10.1021/jp026107l; MCCORD JM, 1970, J BIOL CHEM, V245, P1374; MONCADA S, 1991, PHARMACOL REV, V43, P109; Noble DR, 2002, J CHEM SOC PERK T 2, P1834, DOI 10.1039/b206854k; Noda Y, 1997, RES COMMUN MOL PATH, V96, P115; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; Pfeiffer S, 1997, FREE RADICAL BIO MED, V22, P787, DOI 10.1016/S0891-5849(96)00407-8; PIRES M, 1994, INT J CHEM KINET, V26, P1207, DOI 10.1002/kin.550261208; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; Rosen GM, 2003, MACROMOLECULES, V36, P1021, DOI 10.1021/ma021292m; Rubbo H, 1996, CHEM RES TOXICOL, V9, P809, DOI 10.1021/tx960037q; SAMUNI A, 1988, J BIOL CHEM, V263, P17921; SAMUNI A, 1990, FREE RADICAL RES COM, V9, P241, DOI 10.3109/10715769009145682; Sarti P, 2000, BIOCHEM BIOPH RES CO, V274, P183, DOI 10.1006/bbrc.2000.3117; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; TREININ A, 1970, J AM CHEM SOC, V92, P5821, DOI 10.1021/ja00723a001; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; WOLDMAN YY, 1994, BIOCHEM BIOPH RES CO, V202, P195, DOI 10.1006/bbrc.1994.1912; YOSHIDA M, 1994, BIOCHEM BIOPH RES CO, V202, P923, DOI 10.1006/bbrc.1994.2018; Yoshioka T, 1996, J AM SOC NEPHROL, V7, P961	44	151	157	6	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50949	50955		10.1074/jbc.M308317200	http://dx.doi.org/10.1074/jbc.M308317200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	12954619	hybrid			2022-12-25	WOS:000187206300016
J	Fraser, JA; Kansagra, P; Kotecki, C; Saunders, RDC; McLellan, LI				Fraser, JA; Kansagra, P; Kotecki, C; Saunders, RDC; McLellan, LI			The modifier subunit of Drosophila glutamate-cysteine ligase regulates catalytic activity by covalent and noncovalent interactions and influences glutathione homeostasis in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; OXIDATIVE STRESS; MECHANISM; ENZYMES	Glutamate-cysteine ligase (GCL) has a key influence on glutathione homeostasis. It has been proposed that mammalian GCL is regulated by the redox environment, and we show here that cysteine residues in the Drosophila melanogaster GCL modifier subunit (DmGCLM) can form covalent interactions with the catalytic subunit (DmGCLC) and modify its activity. Candidate components of intersubunit disulfides (Cys(213), Cys(214), and Cys(267)) were identified using matrix-assisted laser desorption ionization time-of-flight spectroscopy of iodoacetamide-modified DmGCLM as well as examination of the evolutionary conservation of cysteines. Mutation of the 3 cysteine residues allowed DmGCLM to associate with DmGCLC, but inhibited the formation of intersubunit disulfides. This caused a 2-fold reduction in the catalytic efficiency of Drosophila GCL, although activity remained significantly higher than the catalytic subunit alone. The cysteine mutant was also more sensitive to inhibition by glutathione than the unmodified holoenzyme. Notably, human GCLM could substitute for DmGCLM in modification of DmGCLC activity. The role of DmGCLM in vivo was examined by analysis of a Drosophila mutant (l(3)L0580) containing a P-element insertion in Gclm. We found that the P-element is not responsible for the lethal phenotype and separated the recessive lethal mutation from the P-element by recombination. This yielded two fully viable and fertile recombinants bearing the P-element insertion, which Western and Northern blotting indicated is a severely hypomorphic allele of Gclm. Glutathione levels were similar to2-fold lower in the Gclm(L0580) mutants than in control strains, demonstrating the importance of DmGCLM in the regulation of glutathione homeostasis in vivo.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Open Univ, Dept Biol Sci, Milton Keynes MK7 6AA, Bucks, England	University of Dundee; Open University - UK	McLellan, LI (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.		Kotecki, Claire/ABA-3677-2020	Fraser, Jennifer/0000-0001-5546-3916				Brekken DL, 1998, J BIOL CHEM, V273, P26317, DOI 10.1074/jbc.273.41.26317; Dickinson DA, 2002, BIOCHEM PHARMACOL, V64, P1019, DOI 10.1016/S0006-2952(02)01172-3; EASTERBY JS, 1996, HYPER VERSION 1 1S; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fraser JA, 2002, J BIOL CHEM, V277, P1158, DOI 10.1074/jbc.M106683200; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Lueder DV, 1996, J BIOL CHEM, V271, P17485, DOI 10.1074/jbc.271.29.17485; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; Saunders RDC, 2000, FEBS LETT, V467, P337, DOI 10.1016/S0014-5793(00)01148-0; SEELIG GF, 1984, J BIOL CHEM, V259, P3534; Soltaninassab SR, 2000, J CELL PHYSIOL, V182, P163, DOI 10.1002/(SICI)1097-4652(200002)182:2<163::AID-JCP4>3.0.CO;2-1; Spradling AC, 1999, GENETICS, V153, P135; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tipnis SR, 1999, BIOCHEM J, V337, P559, DOI 10.1042/0264-6021:3370559; Tu ZH, 1998, BIOCHEM J, V336, P675, DOI 10.1042/bj3360675; Walsh EP, 2002, BIOCHEMISTRY-US, V41, P2409, DOI 10.1021/bi015815e; Yang Y, 2002, J BIOL CHEM, V277, P49446, DOI 10.1074/jbc.M209372200	25	44	44	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46369	46377		10.1074/jbc.M308035200	http://dx.doi.org/10.1074/jbc.M308035200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12954617	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000186569400020
J	Klampfer, L; Huang, J; Corner, G; Mariadason, J; Arango, D; Sasazuki, T; Shirasawa, S; Augenlicht, L				Klampfer, L; Huang, J; Corner, G; Mariadason, J; Arango, D; Sasazuki, T; Shirasawa, S; Augenlicht, L			Oncogenic Ki-ras inhibits the expression of interferon-responsive genes through inhibition of STAT1 and STAT2 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CANCER CELLS; CLASS-I; DOWN-REGULATION; IFN-GAMMA; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCER; REGULATORY FACTOR; ALPHA-INTERFERON; PATHWAYS; SUPPRESSION	Endogenous interferon gamma (IFNgamma) promotes the host response to primary tumors, and IFNgamma-insensitive tumors display increased tumorigenicity and can evade tumor surveillance mechanisms. Here we demonstrate that activating mutations of Ki-ras are sufficient to inhibit the expression of STAT1 and STAT2, transcription factors required for signaling by IFNs, providing a potential mechanism for the insensitivity of tumors to IFNs. We demonstrated that colon cancer cell lines with Ki-ras mutations display reduced expression of IFN-responsive genes compared with the cell lines that have retained wild type Ras and that inactivation of the mutant Ki-ras allele in the HCT116 colon cancer cell line is sufficient to restore the expression of STAT1, STAT2, and IRF-9. Accordingly, the expression of 27 interferon-inducible genes was reduced in HCT116 cells compared with the isogenic clones with targeted deletion of the mutant Ki-ras allele, Hkh2 and Hke-3. The expression of IFNgamma receptors did not differ among the isogenic cell lines. IFNgamma stimulated transcription of a STAT1-dependent reporter gene was impaired by RasV12, demonstrating a transmodulation of IFN/STAT signaling by activated Ras. Finally, we demonstrated that the expression of RasV12 in 293T cells is sufficient to inhibit the endogenous expression of STAT1 and STAT2, confirming the negative regulation of IFN signaling by oncogenic Ras. Our data demonstrate that the signaling initiated by activated Ki-ras interferes with the IFN/STAT signaling pathway and modulates the responsiveness of cancer cells to interferons. Furthermore, the data suggest that tumors harboring activating Ki-ras mutations may escape tumor surveillance mechanisms due to reduced responsiveness to IFNgamma.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA; Int Med Ctr Japan, Res Inst, Shinjuku Ku, Tokyo 1628655, Japan	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; National Center for Global Health & Medicine - Japan	Klampfer, L (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.	lklampf@aecom.yu.edu	Mariadason, John/N-2003-2013; Arango, Diego/AFW-0125-2022; Arango, Diego/M-5667-2016	Arango, Diego/0000-0003-2953-3284; Arango, Diego/0000-0003-2953-3284; Mariadason, John/0000-0001-9123-7684	NCI NIH HHS [P30 CA 13330, U01 CA 88104] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330, U01CA088104] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; ANWAR K, 1992, CANCER RES, V52, P5991; BILLARD C, 1986, BLOOD, V67, P821; Bluyssen Hans A. R., 1996, Cytokine and Growth Factor Reviews, V7, P11, DOI 10.1016/1359-6101(96)00005-6; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chang YJE, 2000, J VIROL, V74, P4174, DOI 10.1128/JVI.74.9.4174-4182.2000; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Clifford JL, 2002, CLIN CANCER RES, V8, P2067; COLAMONICI OR, 1992, BLOOD, V80, P744; DAbaco GM, 1996, MOL CELL BIOL, V16, P884; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Farassati F, 2001, NAT CELL BIOL, V3, P745, DOI 10.1038/35087061; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Hata N, 2001, BIOCHEM BIOPH RES CO, V285, P518, DOI 10.1006/bbrc.2001.5159; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Huang SY, 2002, ONCOGENE, V21, P2504, DOI 10.1038/sj.onc.1205341; Huang YC, 2000, CANCER RES, V60, P3200; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Janssen KP, 2002, GASTROENTEROLOGY, V123, P492, DOI 10.1053/gast.2002.34786; Jove R, 2000, ONCOGENE, V19, P2466, DOI 10.1038/sj.onc.1203549; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Klampfer L, 2003, MOL CANCER RES, V1, P855; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kroger A, 2003, ONCOGENE, V22, P1045, DOI 10.1038/sj.onc.1206260; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Landolfo S, 2000, Hematol J, V1, P7, DOI 10.1038/sj.thj.6200004; Leonard GT, 1996, VIROLOGY, V224, P25, DOI 10.1006/viro.1996.0503; Leonard GT, 1997, J VIROL, V71, P5095, DOI 10.1128/JVI.71.7.5095-5101.1997; Lohmann S, 1996, SCAND J IMMUNOL, V43, P537, DOI 10.1046/j.1365-3083.1996.d01-73.x; Long IS, 2003, MOL CANCER RES, V1, P393; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; Luker KE, 2001, CANCER RES, V61, P6540; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Mariadason JM, 2000, CANCER RES, V60, P4561; MARIADASON JM, 2003, IN PRESS CANC RES; MARX JL, 1979, SCIENCE, V204, P1183, DOI 10.1126/science.451564; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; MCDOUGALL CJ, 1990, CANCER RES, V50, P8023; MOMBURG F, 1989, J EXP MED, V169, P309, DOI 10.1084/jem.169.1.309; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; PANTEL K, 1991, CANCER RES, V51, P4712; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Ramana CV, 2000, ONCOGENE, V19, P2619, DOI 10.1038/sj.onc.1203525; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; Rebollo A, 1999, BLOOD, V94, P2971, DOI 10.1182/blood.V94.9.2971.421k43_2971_2980; Seliger B, 1996, EXP HEMATOL, V24, P1275; Sen GC, 2000, SEMIN CANCER BIOL, V10, P93, DOI 10.1006/scbi.2000.0312; SEONG RH, 1988, J EXP MED, V167, P288, DOI 10.1084/jem.167.2.288; Sevignani C, 1998, J CLIN INVEST, V101, P1572, DOI 10.1172/JCI919; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shir A, 2002, NAT BIOTECHNOL, V20, P895, DOI 10.1038/nbt730; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; SUN M, 1981, SCIENCE, V212, P141, DOI 10.1126/science.6163213; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Taniguchi T, 2001, NAT REV MOL CELL BIO, V2, P378, DOI 10.1038/35073080; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VILCEK J, 1970, SCIENCE, V168, P398, DOI 10.1126/science.168.3929.398; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Wong LH, 2002, J BIOL CHEM, V277, P19408, DOI 10.1074/jbc.M111302200; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	80	55	55	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46278	46287		10.1074/jbc.M304721200	http://dx.doi.org/10.1074/jbc.M304721200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12972432	hybrid			2022-12-25	WOS:000186569400011
J	Martynov, VI; Maksimov, BI; Martynova, NY; Pakhomov, AA; Gurskaya, NG; Lukyanov, SA				Martynov, VI; Maksimov, BI; Martynova, NY; Pakhomov, AA; Gurskaya, NG; Lukyanov, SA			A purple-blue chromoprotein from Goniopora tenuidens belongs to the DsRed subfamily of GFP-like proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN-FLUORESCENT PROTEIN; CRYSTAL-STRUCTURE; CHROMOPHORE; ANTHOZOA; HOMOLOG; FAMILY; CORAL	A number of recently cloned chromoproteins homologous to the green fluorescent protein show a substantial bathochromic shift in absorption spectra. Compared with red fluorescent protein from Discosoma sp. (DsRed), mutants of these so-called far-red proteins exhibit a clear red shift in emission spectra as well. Here we report that a far-red chromoprotein from Goniopora tenuidens (gtCP) contains a chromophore of the same chemical structure as DsRed. Denaturation kinetics of both DsRed and gtCP under acidic conditions indicates that the red form of the chromophore (absorption maximum at 436 nm) converts to the GFP-like form (384 nm) by a one-stage reaction. Upon neutralization, the 436-nm form of gtCP, but not the 384-nm form, renaturates instantly, implying that the former includes a chromophore in its intact state. gtCP represents a single-chain protein and, upon harsh denaturing conditions, shows three major bands in SDS/PAGE, two of which apparently result from hydrolysis of an acylimine C=N bond. Instead of having absorption maxima at 384 nm and 450 nm, which are characteristic for a GFP-like chromophore, fragmented gtCP shows a different spectrum, which presumably corresponds to a 2-keto derivative of imidazolidinone. Mass spectra of the chromophore-containing peptide from gtCP reveal an additional loss of 2 Da relative to the GFP-like chromophore. Tandem mass spectrometry of the chromopeptide shows that an additional bond is dehydrogenated in gtCP at the same position as in DsRed. Altogether, these data suggest that gtCP belongs to the same subfamily as DsRed (in the classification of GFP-like proteins based on the chromophore structure type).	Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; Russian Acad Med Sci, Orekhovich Inst Biomed Chem, Moscow 119121, Russia	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy of Medical Sciences; Institute of Biomedical Chemistry	Martynov, VI (corresponding author), Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Miklukho Maklaya 16-10, Moscow 117997, Russia.		Martynov, Vladimir I./S-3483-2016; Pakhomov, Alexey A/D-7199-2012; Martynova, Natalia Y/U-4520-2018; Gurskaya, Nadya G/Q-1750-2016; Lukyanov, Sergey/F-9140-2014	Martynov, Vladimir I./0000-0003-4923-6842; Pakhomov, Alexey A/0000-0001-7757-6452; Gurskaya, Nadya G/0000-0002-8028-8176; 				Ando R, 2002, P NATL ACAD SCI USA, V99, P12651, DOI 10.1073/pnas.202320599; Chudakov DM, 2003, NAT BIOTECHNOL, V21, P191, DOI 10.1038/nbt778; Chudakov DM, 2003, J BIOL CHEM, V278, P7215, DOI 10.1074/jbc.M211988200; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; Garcia-Parajo MF, 2001, P NATL ACAD SCI USA, V98, P14392, DOI 10.1073/pnas.251525598; Gross LA, 2000, P NATL ACAD SCI USA, V97, P11990, DOI 10.1073/pnas.97.22.11990; Gurskaya NG, 2001, FEBS LETT, V507, P16, DOI 10.1016/S0014-5793(01)02930-1; Labas YA, 2002, P NATL ACAD SCI USA, V99, P4256, DOI 10.1073/pnas.062552299; Lukyanov KA, 2000, J BIOL CHEM, V275, P25879, DOI 10.1074/jbc.C000338200; Martynov VI, 2001, J BIOL CHEM, V276, P21012, DOI 10.1074/jbc.M100500200; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PETERSEN J, 2003, J BIOL CHEM; Prescott M, 2003, STRUCTURE, V11, P275, DOI 10.1016/S0969-2126(03)00028-5; Remington SJ, 2002, NAT BIOTECHNOL, V20, P28, DOI 10.1038/nbt0102-28; SHIMOMURA O, 1979, FEBS LETT, V104, P220, DOI 10.1016/0014-5793(79)80818-2; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Wall MA, 2000, NAT STRUCT BIOL, V7, P1133; Wiedenmann J, 2002, P NATL ACAD SCI USA, V99, P11646, DOI 10.1073/pnas.182157199; Yarbrough D, 2001, P NATL ACAD SCI USA, V98, P462, DOI 10.1073/pnas.98.2.462	20	36	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46288	46292		10.1074/jbc.M306810200	http://dx.doi.org/10.1074/jbc.M306810200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12975373	hybrid			2022-12-25	WOS:000186569400012
J	Sesma, L; Alvarez, IA; Marcilla, M; Paradela, A; de Castro, JAL				Sesma, L; Alvarez, IA; Marcilla, M; Paradela, A; de Castro, JAL			Species-specific differences in proteasomal processing and tapasin-mediated loading influence peptide presentation by HLA-B27 in murine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; CYTOTOXIC T-CELLS; TRANSGENIC MICE; ANTIGEN PRESENTATION; ANKYLOSING-SPONDYLITIS; INFLAMMATORY DISEASE; REVEALS POLYMORPHISM; NATURAL LIGAND; HLA; IDENTIFICATION	Expression of HLA- B27 in murine cells has been used to establish animal models for human spondyloarthritis and for antigen presentation studies, but the effects of xenogeneic HLA- B27 expression on peptide presentation are little known. The issue was addressed in this study. HLA- B27- bound peptide repertoires from human and murine cells overlapped by 75 - 85%, indicating that many endogenous HLA- B27 ligands are generated and presented in both species. Of 20 differentially presented peptides that were sequenced, only 40% arose from obvious inter- species protein polymorphism, suggesting that differences in antigen processing- loading accounted for many species- specific ligands. Digestion of synthetic substrates with human and murine 20 S proteasomes revealed cleavage differences that accounted for or correlated with differential expression of particular peptides. One HLA- B27 ligand found only in human cells was similarly generated in vitro by human and murine proteasomes. Differential presentation correlated with significantly decreased amounts of this ligand in human tapasin- deficient cells reconstituted with murine tapasin, indicating that species- specific interactions between HLA- B27, tapasin, and/ or other proteins in the peptide- loading complex influenced presentation of this peptide. Our results indicate that differences in proteasomal specificity and in interactions involving tapasin determine differential processing and presentation of a significant number of HLA- B27 ligands in human and murine cells.	Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	de Castro, JAL (corresponding author), Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	aldecastro@cbm.uam.es	Alvarez, Iñaki/A-6684-2011; Marcilla, Miguel/B-8430-2013; Paradela, Alberto/H-2113-2015	Alvarez, Iñaki/0000-0001-9484-0868; Marcilla, Miguel/0000-0001-9171-5076; Paradela, Alberto/0000-0001-6837-7056				Alvarez I, 2001, J BIOL CHEM, V276, P48740, DOI 10.1074/jbc.M108882200; Alvarez I, 2001, J BIOL CHEM, V276, P32729, DOI 10.1074/jbc.M104663200; Barnden MJ, 2000, J IMMUNOL, V165, P322, DOI 10.4049/jimmunol.165.1.322; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BERNHARD EJ, 1987, J IMMUNOL, V139, P3614; Boisgerault F, 1998, INFECT IMMUN, V66, P4484; Braud VM, 1998, EUR J IMMUNOL, V28, P625, DOI 10.1002/(SICI)1521-4141(199802)28:02<625::AID-IMMU625>3.0.CO;2-I; BREWERTON DA, 1973, LANCET, V2, P996, DOI 10.1016/S0140-6736(73)91091-X; BREWERTON DA, 1973, LANCET, V1, P904; CALVO V, 1990, J IMMUNOL, V144, P4038; Cheuk E, 2002, J IMMUNOL, V169, P5571, DOI 10.4049/jimmunol.169.10.5571; Copeman J, 1998, EUR J IMMUNOL, V28, P3783, DOI 10.1002/(SICI)1521-4141(199811)28:11<3783::AID-IMMU3783>3.0.CO;2-9; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; GALOCHA B, 1993, J IMMUNOL, V150, P1653; Garcia F, 1997, TISSUE ANTIGENS, V49, P23, DOI 10.1111/j.1399-0039.1997.tb02705.x; GREENWOOD R, 1994, J IMMUNOL, V153, P5525; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; Huarte E, 2002, INT J CANCER, V97, P58, DOI 10.1002/ijc.1579; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KALINKE U, 1990, NATURE, V348, P642, DOI 10.1038/348642a0; KHARE SD, 1995, J EXP MED, V182, P1153, DOI 10.1084/jem.182.4.1153; KIEVITS F, 1987, NATURE, V329, P447, DOI 10.1038/329447a0; Kingsbury DJ, 2000, ARTHRITIS RHEUM, V43, P2290, DOI 10.1002/1529-0131(200010)43:10<2290::AID-ANR17>3.0.CO;2-6; KOLLER TD, 1987, J IMMUNOL, V138, P2044; Komlosh A, 2001, J BIOL CHEM, V276, P30050, DOI 10.1074/jbc.M103177200; Kuon W, 1997, ARTHRITIS RHEUM-US, V40, P945, DOI 10.1002/art.1780400524; Kuon W, 2001, J IMMUNOL, V167, P4738, DOI 10.4049/jimmunol.167.8.4738; Lamas JR, 1999, ARTHRITIS RHEUM-US, V42, P1975, DOI 10.1002/1529-0131(199909)42:9<1975::AID-ANR25>3.0.CO;2-V; Lankat-Buttgereit B, 2002, PHYSIOL REV, V82, P187, DOI 10.1152/physrev.00025.2001; Li SL, 2000, J BIOL CHEM, V275, P1581, DOI 10.1074/jbc.275.3.1581; Luckey CJ, 2001, J IMMUNOL, V167, P1212, DOI 10.4049/jimmunol.167.3.1212; Marina A, 1999, J MASS SPECTROM, V34, P17, DOI 10.1002/(SICI)1096-9888(199901)34:1<17::AID-JMS746>3.3.CO;2-Y; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; Paradela A, 2000, J IMMUNOL, V164, P329, DOI 10.4049/jimmunol.164.1.329; Paradela A, 1998, J IMMUNOL, V161, P5481; Peh CA, 2000, J IMMUNOL, V164, P292, DOI 10.4049/jimmunol.164.1.292; Peh CA, 1998, IMMUNITY, V8, P531, DOI 10.1016/S1074-7613(00)80558-0; Purcell AW, 2001, J IMMUNOL, V166, P1016, DOI 10.4049/jimmunol.166.2.1016; Ramos M, 2002, J BIOL CHEM, V277, P28749, DOI 10.1074/jbc.M204155200; Ramos M, 2002, J BIOL CHEM, V277, P37573, DOI 10.1074/jbc.M205470200; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; ROJO S, 1991, J IMMUNOL, V146, P634; ROTZSCHKE O, 1994, IMMUNOGENETICS, V39, P74; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Saric T, 2002, NAT IMMUNOL, V3, P1169, DOI 10.1038/ni859; Schmitt L, 2000, CHEMBIOCHEM, V1, P17; Seifert U, 2003, NAT IMMUNOL, V4, P375, DOI 10.1038/ni905; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Sesma L, 2002, J BIOL CHEM, V277, P16744, DOI 10.1074/jbc.M200371200; Solheim JC, 1997, J IMMUNOL, V158, P2236; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; Tanioka T, 2003, J BIOL CHEM, V278, P32275, DOI 10.1074/jbc.M305076200; TAUROG JD, 1993, J IMMUNOL, V150, P4168; Tishon A, 2000, VIROLOGY, V275, P286, DOI 10.1006/viro.2000.0517; Uebel S, 1997, P NATL ACAD SCI USA, V94, P8976, DOI 10.1073/pnas.94.17.8976; WEINREICH S, 1995, HUM IMMUNOL, V42, P103, DOI 10.1016/0198-8859(94)00034-N; Weinreich SS, 1997, IMMUNOGENETICS, V46, P35, DOI 10.1007/s002510050239; WEISDORF DJ, 1990, POSTGRAD MED, V87, P91; Yague J, 2000, J EXP MED, V191, P2083, DOI 10.1084/jem.191.12.2083; Yague J, 1998, TISSUE ANTIGENS, V52, P416, DOI 10.1111/j.1399-0039.1998.tb03067.x; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941; Zhou M, 1998, J EXP MED, V188, P877, DOI 10.1084/jem.188.5.877	63	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46461	46472		10.1074/jbc.M308816200	http://dx.doi.org/10.1074/jbc.M308816200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963723	hybrid			2022-12-25	WOS:000186569400031
J	Viatour, P; Legrand-Poels, S; van Lint, C; Warnier, M; Merville, MP; Gielen, J; Piette, J; Bours, V; Chariot, A				Viatour, P; Legrand-Poels, S; van Lint, C; Warnier, M; Merville, MP; Gielen, J; Piette, J; Bours, V; Chariot, A			Cytoplasmic I kappa B alpha increases NF-kappa B-independent transcription through binding to histone deacetylase (HDAC) 1 and HDAC3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; ACTIVATION; PROTEIN; TRANSACTIVATION; ASSOCIATION; EXPRESSION; INHIBITOR; COMPLEXES; BASAL	IkappaBalpha is an inhibitory molecule that sequesters NF-kappaB dimers in the cytoplasm of unstimulated cells. Upon stimulation, NF-kappaB moves to the nucleus and induces the expression of a variety of genes including IkappaBalpha. This newly synthesized IkappaBalpha also translocates to the nucleus, removes activated NF-kappaB from its target genes, and brings it back to the cytoplasm to terminate the phase of NF-kappaB activation. We show here that IkappaBalpha enhances the transactivation potential of several homeodomain- containing proteins such as HOXB7 and Pit- 1 through a NF-kappaB- independent association with histone deacetylase ( HDAC) 1 and HDAC3 but not with HDAC2, - 4, - 5, and - 6. IkappaBalpha bound both HDAC proteins through its ankyrin repeats, and this interaction was disrupted by p65. Immunofluorescence experiments demonstrated further that IkappaBalpha acts by partially redirecting HDAC3 to the cytoplasm. At the same time, an IkappaBalpha mutant, which lacked a functional nuclear localization sequence, interacted very efficiently with HDAC1 and - 3 and intensively enhanced the transactivation potential of Pit- 1. Our results support the hypothesis that the NF-kappaB inhibitor IkappaBalpha regulates the transcriptional activity of homeodomain- containing proteins positively through cytoplasmic sequestration of HDAC1 and HDAC3, a mechanism that would assign a new and unexpected role to IkappaBalpha.	Univ Liege, Lab Med Chem & Human Genet, B-4000 Liege, Belgium; Univ Liege, Ctr Cellular & Mol Therapy, Lab Virol & Immunol, B-4000 Liege, Belgium; Free Univ Brussels, Inst Biol & Mol Med, Dept Biol Chem, Mol Virol Lab, B-6041 Gosselies, Belgium	University of Liege; University of Liege	Chariot, A (corresponding author), Univ Liege, CHU Sart Tilman, Lab Med Chem CTCM, 3 B23, B-4000 Liege, Belgium.			Chariot, Alain/0000-0002-1691-4347				Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Caccavelli L, 1998, MOL ENDOCRINOL, V12, P1215, DOI 10.1210/me.12.8.1215; Chariot A, 2002, J BIOL CHEM, V277, P37029, DOI 10.1074/jbc.M205069200; Chariot A, 1999, J BIOL CHEM, V274, P5318, DOI 10.1074/jbc.274.9.5318; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hewitt SM, 1997, ANTICANCER RES, V17, P3211; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Huang TT, 2001, MOL CELL BIOL, V21, P4737, DOI 10.1128/MCB.21.14.4737-4747.2001; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; PEERS B, 1990, MOL CELL BIOL, V10, P4690, DOI 10.1128/MCB.10.9.4690; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732	24	84	86	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46541	46548		10.1074/jbc.M306381200	http://dx.doi.org/10.1074/jbc.M306381200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12972430	Green Published, hybrid			2022-12-25	WOS:000186569400039
J	Yang, ES; Burnstein, KL				Yang, ES; Burnstein, KL			Vitamin D inhibits G(1) to S progression in LNCaP prostate cancer cells through p27(Kip1) stabilization and Cdk2 mislocalization to the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P27 EXPRESSION; DEPENDENT DEGRADATION; LINE LNCAP; GROWTH; PROTEIN; PROLIFERATION; ACTIVATION; PHOSPHORYLATION; UBIQUITINATION; ACCUMULATION	1,25-(OH)(2) vitamin D-3 (1,25-(OH)(2)D-3) exerts antiproliferative effects via cell cycle regulation in a variety of tumor cells, including prostate. We have previously shown that in the human prostate cancer cell line LNCaP, 1,25-(OH)(2)D-3 mediates an increase in cyclin-dependent kinase inhibitor p27(Kip1) levels, inhibition of cyclin-dependent kinase 2 (Cdk2) activity, hypophosphorylation of retinoblastoma protein, and accumulation of cells in G(1). In this study, we investigated the mechanism whereby 1,25-(OH)(2)D-3 increases p27 levels. 1,25-( OH) 2D3 had no effect on p27 mRNA levels or on the regulation of a 3.5-kb fragment of the p27 promoter. The rate of p27 protein synthesis was not affected by 1,25( OH) 2D3 as measured by luciferase activity driven by the 5'- and 3'-untranslated regions of p27 that regulate p27 protein synthesis. Pulse-chase analysis of S-35-labeled p27 revealed an increased p27 protein half-life with 1,25( OH)(2)D-3 treatment. Because Cdk2- mediated phosphorylation of p27 at Thr(187) targets p27 for Skp2-mediated degradation, we examined the phosphorylation status of p27 in 1,25-(OH)(2)D-3-treated cells. 1,25-(OH)(2)D-3 decreased levels of Thr(187) phosphorylated p27, consistent with inhibition of Thr(187) phosphorylation-dependent p27 degradation. In addition, 1,25-(OH)(2)D-3 reduced Skp2 protein levels in LNCaP cells. Cdk2 is activated in the nucleus by Cdk-activating kinase through Thr(160) phosphorylation and by cdc25A phosphatase via Thr(14) and Tyr(15) dephosphorylation. Interestingly, 1,25-(OH)(2)D-3 decreased nuclear Cdk2 levels as assessed by subcellular fractionation and confocal microscopy. Inhibition of Cdk2 by 1,25-(OH)(2)D-3 may thus involve two mechanisms: 1) reduced nuclear Cdk2 available for cyclin binding and activation and 2) impairment of cyclin E-Cdk2-dependent p27 degradation through cytoplasmic mislocalization of Cdk2. These data suggest that Cdk2 mislocalization is central to the antiproliferative effects of 1,25-(OH)(2)D-3.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA	University of Miami	Burnstein, KL (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol R189, POB 016189 R-189, Miami, FL 33136 USA.	kburnste@miami.edu			NIDDK NIH HHS [DK 45478, R01 DK045478] Funding Source: Medline; NIEHS NIH HHS [F30 ES005910-02, F30 ES 05910-02, F30 ES005910, F30 ES005910-06, F30 ES005910-03, F30 ES005910-05, F30 ES005910-01, F30 ES005910-04] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045478, R29DK045478] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F30ES005910] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BIKLE DD, 1992, ENDOCR REV, V13, P765, DOI 10.1210/er.13.4.765; Blanchard DA, 2000, ONCOGENE, V19, P4184, DOI 10.1038/sj.onc.1203761; Blutt SE, 2000, ENDOCRINOLOGY, V141, P10, DOI 10.1210/en.141.1.10; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; Campbell MJ, 1997, J MOL ENDOCRINOL, V19, P15, DOI 10.1677/jme.0.0190015; Cheng L, 2000, CLIN CANCER RES, V6, P1896; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Cote RJ, 1998, J NATL CANCER I, V90, P916, DOI 10.1093/jnci/90.12.916; Davies MA, 1999, CANCER RES, V59, P2551; Donovan JCH, 2001, J BIOL CHEM, V276, P40888, DOI 10.1074/jbc.M106448200; FELDMAN D, 1997, VITAMIN D, P1089; Fernandez PL, 1999, J PATHOL, V187, P563, DOI 10.1002/(SICI)1096-9896(199904)187:5<563::AID-PATH292>3.0.CO;2-3; Ferrando AA, 1996, HUM GENET, V97, P91; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Gopfert U, 2003, HUM MOL GENET, V12, P1767, DOI 10.1093/hmg/ddg177; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Guo YP, 1997, CLIN CANCER RES, V3, P2269; Halvorsen OJ, 2003, CLIN CANCER RES, V9, P1474; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; KAWAMATA N, 1995, CANCER RES, V55, P2266; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; Lin R, 2003, ENDOCRINOLOGY, V144, P749, DOI 10.1210/en.2002-0026; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; MILLER GJ, 1992, CANCER RES, V52, P515; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Miskimins WK, 2001, MOL CELL BIOL, V21, P4960, DOI 10.1128/MCB.21.15.4960-4967.2001; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLS HAP, 1990, J STEROID BIOCHEM, V37, P873, DOI 10.1016/0960-0760(90)90435-N; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; SCHWARTZ GG, 1994, ANTICANCER RES, V14, P1077; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SKOWRONSKI RJ, 1993, ENDOCRINOLOGY, V132, P1952, DOI 10.1210/en.132.5.1952; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Tsihlias J, 1998, CANCER RES, V58, P542; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wagner M, 2001, EXP GERONTOL, V37, P41, DOI 10.1016/S0531-5565(01)00165-6; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Yang ES, 2002, MOL CELL ENDOCRINOL, V186, P69, DOI 10.1016/S0303-7207(01)00671-2; Yang G, 2002, CLIN CANCER RES, V8, P3419; Yang RM, 1998, J UROLOGY, V159, P941, DOI 10.1016/S0022-5347(01)63776-5; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197; Zhuang SH, 1997, MOL CELL ENDOCRINOL, V126, P83, DOI 10.1016/S0303-7207(96)03974-3	57	118	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46862	46868		10.1074/jbc.M306340200	http://dx.doi.org/10.1074/jbc.M306340200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12954644	hybrid			2022-12-25	WOS:000186569400079
J	Huang, J; Valluzzi, R; Bini, E; Vernaglia, B; Kaplan, DL				Huang, J; Valluzzi, R; Bini, E; Vernaglia, B; Kaplan, DL			Cloning, expression, and assembly of sericin-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID FIBRIL FORMATION; BOMBYX-MORI; CONGO RED; ROTATORY PROPERTIES; SECONDARY STRUCTURE; GLUTAMINE REPEATS; ESCHERICHIA-COLI; FORMING PEPTIDE; SILK PROTEINS; IN-VITRO	Recombinant sericin proteins of different molecular masses (17.4, 31.9, and 46.5 kDa), based on the 38-amino acid repetitive motif of native sericin, were cloned, expressed, and purified. The recombinant sericin self-assembled during dialysis (starting concentration of 2.5 mg/ml) forming twisted fibers. Circular dichroism and Fourier transform infrared spectroscopy studies demonstrated protein conformational transitions occurred from random coil to beta-sheets during the dialysis. Congo red-stained recombinant sericin fibrils exhibited apple-green birefringence, indicating long-range order in the array of beta-sheets. Biosynthetic sericin has a high content of polar amino acids (e.g. > 40 mol % serine), leading to a beta-sheet conformation formed by hydrogen bonding via polar zipper interactions. Analysis of recombinant sericin sequence using Mandel-Gutfreund's (Mandel-Gutfreund, Y., and Gregoret, L. M. (2002) J. Mol. Biol. 323, 453-461) definition of polar and non-polar amino acids showed that the hydrophobicity pattern resembles the most frequent pattern of amyloidogenic proteins, polar amino acid aggregates (PPPPP). Many beta-proteins and peptides are designed to study amyloidogenesis using a polar/non-polar alternating pattern (PNPNPN). Sericin-like proteins or peptides provide an alternative model in terms of hydrophobicity pattern with which to explore questions related to beta-sheet formation and amyloidogenesis. The glue-like property of sericin is attributed to the hydrogen bonding between serine residues of sericin with serine residues in the fibroin structural components of silk fiber.	Tufts Univ, Ctr Bioengn, Dept Biomed Engn, Medford, MA 02155 USA; Tufts Univ, Ctr Bioengn, Dept Chem Engn, Medford, MA 02155 USA; Tufts Univ, Ctr Bioengn, Dept Biol Engn, Medford, MA 02155 USA	Tufts University; Tufts University; Tufts University	Kaplan, DL (corresponding author), 4 Colby St, Medford, MA 02155 USA.	david.kaplan@tufts.edu	Ceriello, Antonio/J-9575-2016					Adamian L, 2002, PROTEINS, V47, P209, DOI 10.1002/prot.10071; Aggeli A, 2001, P NATL ACAD SCI USA, V98, P11857, DOI 10.1073/pnas.191250198; Asakura T., 1994, ENCY AGR SCI, V4, P1; Balbirnie M, 2001, P NATL ACAD SCI USA, V98, P2375, DOI 10.1073/pnas.041617698; BAUER HH, 1995, J STRUCT BIOL, V115, P1, DOI 10.1006/jsbi.1995.1024; BLOUT ER, 1960, J AM CHEM SOC, V82, P3787, DOI 10.1021/ja01499a080; Carter DB, 1998, NEUROBIOL AGING, V19, P37, DOI 10.1016/S0197-4580(97)00164-4; COUBLE P, 1987, DEV BIOL, V124, P431, DOI 10.1016/0012-1606(87)90496-9; de la Paz ML, 2002, P NATL ACAD SCI USA, V99, P16052, DOI 10.1073/pnas.252340199; Fahnestock SR, 1997, APPL MICROBIOL BIOT, V47, P23, DOI 10.1007/s002530050883; FASMAN GD, 1960, J AM CHEM SOC, V82, P2262, DOI 10.1021/ja01494a041; Fukushima Y, 1998, BIOPOLYMERS, V45, P269, DOI 10.1002/(SICI)1097-0282(19980405)45:4<269::AID-BIP1>3.0.CO;2-J; GAMO T, 1977, INSECT BIOCHEM, V7, P285, DOI 10.1016/0020-1790(77)90026-9; Garel A, 1997, INSECT BIOCHEM MOLEC, V27, P469, DOI 10.1016/S0965-1748(97)00022-2; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; Goldsbury CS, 1997, J STRUCT BIOL, V119, P17, DOI 10.1006/jsbi.1997.3858; HAMES BD, 1981, GEL ELECTROPHORESIS, P19; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; Jones DH, 2000, BIOCHEMISTRY-US, V39, P1870, DOI 10.1021/bi992495e; Kallijarvi J, 2001, BIOCHEMISTRY-US, V40, P10032, DOI 10.1021/bi002095n; Kameda T, 1999, MACROMOLECULES, V32, P7166, DOI 10.1021/ma990554q; Kaplan D, 1994, SILK POLYM MAT SCI B, P10; KAUFMANN E, 1984, FEBS LETT, V170, P81, DOI 10.1016/0014-5793(84)81373-3; Kim YC, 1998, BIOTECHNOL LETT, V20, P799, DOI 10.1023/B:BILE.0000015926.97548.cf; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Lashuel HA, 2000, J AM CHEM SOC, V122, P5262, DOI 10.1021/ja9937831; Lewis RV, 1996, PROTEIN EXPRES PURIF, V7, P400, DOI 10.1006/prep.1996.0060; Lucas F., 1968, Comprehensive Biochem, V26, P475; Mandel-Gutfreund Y, 2002, J MOL BIOL, V323, P453, DOI 10.1016/S0022-2836(02)00973-7; MATAGNE A, 1991, BIOCHEM J, V280, P553, DOI 10.1042/bj2800553; MCGRATH KP, 1992, J AM CHEM SOC, V114, P727, DOI 10.1021/ja00028a048; MICHAILLE JJ, 1990, GENE, V86, P177, DOI 10.1016/0378-1119(90)90277-X; Michelitsch MD, 2000, P NATL ACAD SCI USA, V97, P11910, DOI 10.1073/pnas.97.22.11910; Mira H, 2001, BIOCHEM J, V357, P545, DOI 10.1042/0264-6021:3570545; MITA K, 1994, J MOL EVOL, V38, P583; Nyrkova IA, 2000, EUR PHYS J B, V17, P481, DOI 10.1007/s100510070127; Okabayashi H, 2002, BIOPOLYMERS, V65, P129, DOI 10.1002/bip.10186; OKAMOTO H, 1982, J BIOL CHEM, V257, P5192; Patel H, 1996, BIOCHEM J, V318, P1041, DOI 10.1042/bj3181041; Perutz M F, 1995, Pharm Acta Helv, V69, P213, DOI 10.1016/0031-6865(95)00003-R; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5596, DOI 10.1073/pnas.042681599; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; PRINCE JT, 1995, BIOCHEMISTRY-US, V34, P10879, DOI 10.1021/bi00034a022; Qu Y, 2000, J AM CHEM SOC, V122, P5014, DOI 10.1021/ja9935761; QUADRIFO.F, 1968, J AM CHEM SOC, V90, P2760, DOI 10.1021/ja01013a005; Roterman I, 2001, Med Sci Monit, V7, P771; Saeger W, 1998, PATHOLOGE, V19, P345, DOI 10.1007/s002920050296; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; Szela S, 2000, BIOMACROMOLECULES, V1, P534, DOI 10.1021/bm0055697; TOONEY NM, 1968, BIOPOLYMERS, V6, P81, DOI 10.1002/bip.1968.360060107; TOONEY NM, 1968, J MOL BIOL, V36, P355, DOI 10.1016/0022-2836(68)90161-7; TSUKADA M, 1979, POLYM J, V11, P503, DOI 10.1295/polymj.11.503; TSUKADA M, 1985, P 7 INT WOOL TEXT RE, V1, P383; TURNELL WG, 1992, J MOL BIOL, V227, P1205, DOI 10.1016/0022-2836(92)90532-O; URUSHIZAKI S, 1976, NIPPON SANSHIGAKU ZA, V45, P469; Valluzzi R, 1999, J PHYS CHEM B, V103, P11382, DOI 10.1021/jp991363s; West MW, 1999, P NATL ACAD SCI USA, V96, P11211, DOI 10.1073/pnas.96.20.11211; Wilson D, 2000, BIOPHYS J, V78, P2690, DOI 10.1016/S0006-3495(00)76813-5; Winkler S, 2000, BIOCHEMISTRY-US, V39, P12739, DOI 10.1021/bi001335w; Winkler S, 1999, INT J BIOL MACROMOL, V24, P265, DOI 10.1016/S0141-8130(98)00088-9; WOODY RW, 1977, MACROMOL REV, V12, P181, DOI 10.1002/pol.1977.230120104; Woody RW, 1974, PEPTIDES POLYPEPTIDE, P338; Wurth C, 2002, J MOL BIOL, V319, P1279, DOI 10.1016/S0022-2836(02)00399-6; Xing YM, 2002, MECH AGEING DEV, V123, P1625, DOI 10.1016/S0047-6374(02)00098-2; XIONG HY, 1995, P NATL ACAD SCI USA, V92, P6349, DOI 10.1073/pnas.92.14.6349; Xu GF, 2001, P NATL ACAD SCI USA, V98, P3652, DOI 10.1073/pnas.071400098; Yan SZ, 2001, J BIOL CHEM, V276, P8500, DOI 10.1074/jbc.M010361200; Zhou YT, 2001, BIOMACROMOLECULES, V2, P111, DOI 10.1021/bm005598h; Zhu L. J., 1996, NIPPON SANSHIGAKU ZA, V65, P270	70	62	63	2	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46117	46123		10.1074/jbc.M307792200	http://dx.doi.org/10.1074/jbc.M307792200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12963711	hybrid			2022-12-25	WOS:000186452300129
J	Jurado, J; Prieto-Alamo, MJ; Madrid-Risquez, J; Pueyo, C				Jurado, J; Prieto-Alamo, MJ; Madrid-Risquez, J; Pueyo, C			Absolute gene expression patterns of thioredoxin and glutaredoxin redox systems in mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; OXIDATIVE STRESS; GLUTATHIONE-REDUCTASE; THIOLTRANSFERASE GLUTAREDOXIN; MAMMALIAN THIOREDOXIN; CLONING; CELLS; MITOCHONDRIAL; SELENOCYSTEINE; INDUCTION	This work provides the first absolute expression patterns of genes coding for all known components of both thioredoxin (Trx) and glutaredoxin (Grx) systems in mouse: Trx1, Trx2, Grx1, Grx2, TrxR1, TrxR2, thioredoxin/glutathione reductase, and glutathione reductase. We devised a novel assay that, combining the advantages of multiplex and real-time PCR, streamlines the quantitation of the actual mRNA copy numbers in whole-animal experiments. Quantitations reported establish differences among adult organs and embryonic stages, compare mRNA decay rates, explore the significance of alternative mRNA isoforms derived from TrxR1 and Grx2 genes, and examine the time-course expression upon superoxide stress promoted by paraquat. Collectively, these quantitations show: i) unique expression profiles for each transcript and mouse organ examined, yet with some general trends like the higher amounts of mRNA species coding for thioredoxins than those coding for the reductases that control their redox states and activities; ii) continuous expression during embryogenesis with outstanding up-regulations of Trx1 and TrxR1 mRNAs in specific temporal sequences; iii) drastic differences in mRNA stability, liver decay rates range from 2.8 h (thioredoxin/glutathione reductase) to greater than or equal to35 h (Trx1 and Trx2), and directly correlate with mRNA steady-state values; iv) testis-specific differences in the amounts (relative to total isoforms) of transcripts yielding the mitochondrial Grx2a and 67-kDa TrxR1 variants; and v) coordinated up-regulation of TrxR1 and glutathione reductase mRNAs in response to superoxide stress in an organ-specific manner. Further insights into in vivo roles of these redox systems should be gained from more focused studies of the mechanisms underlying the vast differences reported here at the transcript level.	Univ Cordoba, Dept Bioquim & Biol Mol, E-14071 Cordoba, Spain	Universidad de Cordoba	Pueyo, C (corresponding author), Univ Cordoba, Dept Bioquim & Biol Mol, Campus Rabanales,Edificio Severo Ochoa,Planta 2A, E-14071 Cordoba, Spain.		Prieto-Alamo, Maria Jose/K-6141-2014; Pueyo, Carmen/B-4509-2016; Carpio, Juan Jurado/K-7808-2014	Prieto-Alamo, Maria Jose/0000-0002-8164-032X; Pueyo, Carmen/0000-0002-2624-2011; Carpio, Juan Jurado/0000-0003-1701-8496				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Bhuyan KC, 2002, METHOD ENZYMOL, V347, P421; CAREY M, 1999, TRANSCRIPTIONAL REGU, P65; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; DREW R, 1979, TOXICOL APPL PHARM, V48, P479, DOI 10.1016/0041-008X(79)90431-9; Gallardo-Madueno R, 1998, J BIOL CHEM, V273, P18382, DOI 10.1074/jbc.273.29.18382; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; Gasdaska PY, 1999, FEBS LETT, V442, P105, DOI 10.1016/S0014-5793(98)01638-X; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Higashikubo A, 1999, BIOL PHARM BULL, V22, P900; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; JOHNSON MT, 2003, J BIOL CHEM; Kawai H, 2000, GENE, V242, P321, DOI 10.1016/S0378-1119(99)00498-9; Kelner MJ, 2000, BIOCHEM BIOPH RES CO, V269, P366, DOI 10.1006/bbrc.2000.2267; Koishi R, 1997, J BIOL CHEM, V272, P2570; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Miranda-Vizuete A, 1999, BBA-GENE STRUCT EXPR, V1447, P113, DOI 10.1016/S0167-4781(99)00129-3; Osborne S A, 2001, BMC Genomics, V2, P10, DOI 10.1186/1471-2164-2-10; Park YS, 2002, BIOL CHEM, V383, P683, DOI 10.1515/BC.2002.070; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Prieto-Alamo MJ, 2003, GENE EXPRESSION, V11, P23, DOI 10.3727/000000003783992315; Pueyo C, 2002, METHOD ENZYMOL, V347, P441; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; ROSSANT J, 2002, MOUSE DEV PATTERNING; Rundlof AK, 2001, J BIOL CHEM, V276, P30542, DOI 10.1074/jbc.M101452200; SACHI Y, 1995, IMMUNOL LETT, V44, P189, DOI 10.1016/0165-2478(95)00213-O; Sadek CM, 2001, GENES CELLS, V6, P1077, DOI 10.1046/j.1365-2443.2001.00484.x; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Sun QA, 2001, J BIOL CHEM, V276, P3106, DOI 10.1074/jbc.M004750200; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Takashima Y, 1999, IMMUNOL LETT, V68, P397, DOI 10.1016/S0165-2478(99)00087-5; Tamura T, 1997, BIOCHEM BIOPH RES CO, V237, P419, DOI 10.1006/bbrc.1997.7153; Taniguchi Y, 1996, NUCLEIC ACIDS RES, V24, P2746, DOI 10.1093/nar/24.14.2746; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581	44	78	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45546	45554		10.1074/jbc.M307866200	http://dx.doi.org/10.1074/jbc.M307866200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954614	hybrid			2022-12-25	WOS:000186452300062
J	Litterst, CM; Kliem, S; Marilley, D; Pfitzner, E				Litterst, CM; Kliem, S; Marilley, D; Pfitzner, E			NCoA-1/SRC-1 is an essential coactivator of STAT5 that binds to the FDL motif in the alpha-helical region of the STAT5 transactivation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; BETA-CASEIN GENE; LIGAND-INDEPENDENT ACTIVATION; FACTOR-KAPPA-B; SIGNAL TRANSDUCER; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-FACTOR; HISTONE ACETYLTRANSFERASE; GLUCOCORTICOID RECEPTOR; DNA-BINDING	Signal transducer and activator of transcription 5 (STAT5) is a transcription factor that activates prolactin (PRL)-dependent gene expression in the mammary gland. For the activation of its target genes, STAT5 recruits coactivators like p300 and the CREB-binding protein (CBP). In this study we analyzed the function of p300/CBP-associated members of the p160/SRC/NCoA-family in STAT5-mediated transactivation of beta-casein expression. We found that only one of them, NCoA-1, acts as a coactivator for both STAT5a and STAT5b. The two coactivators p300/CBP and NCoA-1 cooperatively enhance STAT5a-mediated transactivation. For NCoA-1-dependent coactivation of STAT5, both the activation domain 1 and the amino-terminal bHLH/PAS domain are required. The amino-terminal region mediates the interaction with STAT5a in cells. A motif of three amino acids in an alpha-helical region of the STAT5a-transactivation domain is essential for the binding of NCoA-1 and for the transcriptional activity of STAT5a. Moreover we observed that NCoA-1 is involved in the synergistic action of the glucocorticoid receptor and STAT5a on the beta-casein promoter. These findings support a model in which STAT5, in concert with the glucocorticoid receptor, recruits a multifunctional coactivator complex to initiate the PRL-dependent transcription.	Georg Speyer Haus, Inst Biomed Res, D-60596 Frankfurt, Germany	Octapharma	Pfitzner, E (corresponding author), Georg Speyer Haus, Inst Biomed Res, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.		Pfitzner, Edith/AAU-7927-2021	Pfitzner, Edith/0000-0002-3484-9649				ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Barre B, 2003, J BIOL CHEM, V278, P2990, DOI 10.1074/jbc.M210422200; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Callus BA, 2000, J BIOL CHEM, V275, P16954, DOI 10.1074/jbc.M909976199; Carsol JL, 2002, MOL ENDOCRINOL, V16, P1696, DOI 10.1210/me.16.7.1696; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; DOPPLER W, 1990, MOL ENDOCRINOL, V4, P912, DOI 10.1210/mend-4-6-912; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; Faulds MH, 2001, MOL ENDOCRINOL, V15, P1929, DOI 10.1210/me.15.11.1929; Favre-Young H, 2000, MOL ENDOCRINOL, V14, P1411, DOI 10.1210/me.14.9.1411; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; Han YL, 1997, MOL ENDOCRINOL, V11, P1180, DOI 10.1210/me.11.8.1180; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Lee SK, 2000, MOL ENDOCRINOL, V14, P915, DOI 10.1210/me.14.6.915; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; LI S, 1995, MOL CELL BIOL, V15, P2063; Litterst CM, 2001, J BIOL CHEM, V276, P45713, DOI 10.1074/jbc.M108132200; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Rascle A, 2003, MOL CELL BIOL, V23, P4162, DOI 10.1128/MCB.23.12.4162-4173.2003; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Stoecklin E, 1999, J STEROID BIOCHEM, V69, P195, DOI 10.1016/S0960-0760(99)00052-7; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WAKAO H, 1995, EMBO J, V14, P854, DOI 10.1002/j.1460-2075.1995.tb07064.x; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Weiss RE, 1999, EMBO J, V18, P1900, DOI 10.1093/emboj/18.7.1900; Wyszomierski SL, 1999, MOL ENDOCRINOL, V13, P330, DOI 10.1210/me.13.2.330; Wyszomierski SL, 2001, MOL ENDOCRINOL, V15, P228, DOI 10.1210/me.15.2.228; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Xu Y, 2000, MOL CELL BIOL, V20, P2138, DOI 10.1128/MCB.20.6.2138-2146.2000; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhou YC, 1999, J BIOL CHEM, V274, P29874, DOI 10.1074/jbc.274.42.29874	69	64	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45340	45351		10.1074/jbc.M303644200	http://dx.doi.org/10.1074/jbc.M303644200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954634	hybrid			2022-12-25	WOS:000186452300037
J	Peyruchaud, O; Serre, CM; NicAmhlaoibh, R; Fournier, P; Clezardin, P				Peyruchaud, O; Serre, CM; NicAmhlaoibh, R; Fournier, P; Clezardin, P			Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; ANGIOGENESIS INHIBITOR; GROWTH; MODEL; BISPHOSPHONATES; RESORPTION; MECHANISMS; MIGRATION; CELLS	Bone is a very common metastatic site for breast cancer. In bone metastasis, there is a vicious circle wherein bone-residing metastatic cells stimulate osteoclast-mediated bone resorption, and bone-derived growth factors released from resorbed bone promote tumor growth. The contribution of tumor angiogenesis in the growth of bone metastases is, however, unknown. By using an experimental model of bone metastasis caused by MDA-MB-231/B02 breast cancer cells that quite closely mimics the conditions likely to occur in naturally arising metastatic human breast cancers, we demonstrate here that when MDA-MB-231/B02 cells were engineered to produce at the bone metastatic site an angiogenesis inhibitor, angiostatin, there was a marked inhibition in the extent of skeletal lesions. Inhibition of skeletal lesions came with a pronounced reduction in tumor burden in bone. However, although angiostatin produced by MDA-MB-231/B02 cells was effective at inhibiting in vitro endothelial cell proliferation and in vivo angiogenesis in a Matrigel implant model, we have shown that it inhibited cancer-induced bone destruction through a direct inhibition of osteoclast activity and generation. Overall, these results indicate that, besides its well known anti-angiogenic activity, angiostatin must also be considered as a very effective inhibitor of bone resorption, broadening its potential clinical use in cancer therapy.	Fac Med Laennec, INSERM, Res Unit 403, F-69372 Lyon 08, France; OSTEOPRO AS, DK-2730 Herlev, Denmark	Institut National de la Sante et de la Recherche Medicale (Inserm)	Peyruchaud, O (corresponding author), Fac Med Laennec, INSERM, Res Unit 403, Rue Guillaume Paradin, F-69372 Lyon 08, France.	peyruchaud@lyon.inserm.fr	Fournier, Pierrick/B-6560-2015; Clezardin, Philippe/M-8071-2014	Fournier, Pierrick/0000-0001-7633-8129; Clezardin, Philippe/0000-0003-0149-4463; Peyruchaud, Olivier/0000-0002-5393-4945				Barou O, 2002, BONE, V30, P604, DOI 10.1016/S8756-3282(02)00677-4; BODY JJ, 1992, BONE, V13, pS57, DOI 10.1016/S8756-3282(09)80011-2; Cao YH, 1998, J CLIN INVEST, V101, P1055, DOI 10.1172/JCI1558; Carron CP, 2000, J ENDOCRINOL, V165, P587, DOI 10.1677/joe.0.1650587; Duivenvoorden WCM, 2002, CANCER RES, V62, P1588; Duong L, 2000, MATRIX BIOL, V19, P97, DOI 10.1016/S0945-053X(00)00051-2; Fournier P, 2002, CANCER RES, V62, P6538; Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18; Gyorffy S, 2001, AM J PATHOL, V159, P1137, DOI 10.1016/S0002-9440(10)61790-7; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hillner BE, 2000, J CLIN ONCOL, V18, P1378, DOI 10.1200/JCO.2000.18.6.1378; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Maeshima Y, 2001, J BIOL CHEM, V276, P31959, DOI 10.1074/jbc.M103024200; Moser TL, 2001, P NATL ACAD SCI USA, V98, P6656, DOI 10.1073/pnas.131067798; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01-0911fje; Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027; Sasaki A, 1998, CANCER RES, V58, P462; Tarui T, 2002, J BIOL CHEM, V277, P33564, DOI 10.1074/jbc.M205514200; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; van der Pluijm G, 2000, CANCER TREAT REV, V26, P11, DOI 10.1053/ctrv.1999.0143; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; Yokoyama Y, 2000, CANCER RES, V60, P2190	23	72	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45826	45832		10.1074/jbc.M309024200	http://dx.doi.org/10.1074/jbc.M309024200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954626	hybrid			2022-12-25	WOS:000186452300095
J	Mallory, MJ; Strich, R				Mallory, MJ; Strich, R			Ume1p represses meiotic gene transcription in Saccharomyces cerevisiae through interaction with the histone deacetylase Rpd3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; NEGATIVE REGULATOR; YEAST; COMPLEX; IDENTIFICATION; RECRUITMENT; SEQUENCE; ENCODES; KINASE; INDUCTION	Ume1p is a member of a conserved protein family including RbAp48 that associates with histone deacetylases. Consistent with this finding, Ume1p is required for the full repression of a subset of meiotic genes during vegetative growth in budding yeast. In addition to mitotic cell division, this report describes a new role for Ume1p in meiotic gene repression in precommitment sporulating cultures returning to vegetative growth. However, Ume1p is not required to re-establish repression as part of the meiotic transient transcription program. Mutational analysis revealed that two conserved domains (NEE box and a WD repeat motif) are required for Ume1p-dependent repression. Co-immunoprecipitation studies revealed that both the NEE box and the WD repeat motif are essential for normal Rpd3p binding. Finally, Ume1p-Rpd3p association is dependent on the global co-repressor Sin3p. Moreover, this activity was localized to one of the four paired amphipathic-helix domains of Sin3p shown previously to be required for transcriptional repression. These findings support a model that Ume1p binding to Rpd3p is required for its repression activity. In addition, these results suggest that Rpd3-Ume1p-Sin3p comprises an interdependent complex required for mediating transcriptional repression.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Strich, R (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 333 Cottman Ave, Philadelphia, PA 19111 USA.	r_strich@fccc.edu			NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927] Funding Source: Medline; NIGMS NIH HHS [GM57842] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; BAKER HV, 1991, P NATL ACAD SCI USA, V88, P9443, DOI 10.1073/pnas.88.21.9443; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOWDISH KS, 1993, MOL CELL BIOL, V13, P2172, DOI 10.1128/MCB.13.4.2172; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; BUCKINGHAM LE, 1990, P NATL ACAD SCI USA, V87, P9406, DOI 10.1073/pnas.87.23.9406; CAPIEAUX E, 1989, J BIOL CHEM, V264, P7437; CHAMBERS A, 1989, MOL CELL BIOL, V9, P5516, DOI 10.1128/MCB.9.12.5516; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Cooper KF, 2002, EUKARYOT CELL, V1, P66, DOI 10.1128/EC.01.1.66-74.2002; Cooper KF, 1997, EMBO J, V16, P4665, DOI 10.1093/emboj/16.15.4665; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; Fazzio TG, 2001, MOL CELL BIOL, V21, P6450, DOI 10.1128/MCB.21.19.6450-6460.2001; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; Goldmark JP, 2000, CELL, V103, P423, DOI 10.1016/S0092-8674(00)00134-3; HOLLAND MJ, 1987, MOL CELL BIOL, V7, P813, DOI 10.1128/MCB.7.2.813; Honigberg SM, 1993, CURR OPIN CELL BIOL, V5, P219, DOI 10.1016/0955-0674(93)90106-Z; HUDAK KA, 1994, GENETICS, V136, P475; Jackson JC, 1996, NUCLEIC ACIDS RES, V24, P1322, DOI 10.1093/nar/24.7.1322; Johnson PR, 1998, CELL, V94, P217, DOI 10.1016/S0092-8674(00)81421-X; JOHNSTON M, 1993, MOL CELLULAR BIOL YE, V2, P193; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KASSIR Y, 1991, METHOD ENZYMOL, V194, P94; KLAPHOLZ S, 1980, GENETICS, V96, P567; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Miller JH., 1972, EXPT MOL GENETICS; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Primig M, 2000, NAT GENET, V26, P415, DOI 10.1038/82539; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW P E, 1990, New Biologist, V2, P111; SIKORSKI RS, 1989, GENETICS, V122, P19; STERNBERG PW, 1987, CELL, V32, P409; STRICH R, 1989, P NATL ACAD SCI USA, V86, P10018, DOI 10.1073/pnas.86.24.10018; STRICH R, 1994, GENE DEV, V8, P796, DOI 10.1101/gad.8.7.796; SUROSKY RT, 1992, MOL CELL BIOL, V12, P3948, DOI 10.1128/MCB.12.9.3948; SUROSKY RT, 1994, MOL CELL BIOL, V14, P3446, DOI 10.1128/MCB.14.5.3446; SZENTGYORGYI C, 1995, MOL CELL BIOL, V15, P6754; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; VERSHON AK, 1992, MOL CELL BIOL, V12, P3706, DOI 10.1128/MCB.12.9.3706; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; WANG HM, 1990, MOL CELL BIOL, V10, P1743, DOI 10.1128/MCB.10.4.1743; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; Washburn BK, 2001, MOL CELL BIOL, V21, P2057, DOI 10.1128/MCB.21.6.2057-2069.2001	56	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44727	44734		10.1074/jbc.M308632200	http://dx.doi.org/10.1074/jbc.M308632200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12954623	hybrid			2022-12-25	WOS:000186306700106
J	Jung, YJ; Isaacs, JS; Lee, SM; Trepel, J; Neckers, L				Jung, YJ; Isaacs, JS; Lee, SM; Trepel, J; Neckers, L			IL-1 beta mediated up-regulation of HIF-1 alpha via an NFkB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis	FASEB JOURNAL			English	Article						hypoxia-inducible factor-1 alpha; inflammation-induced cancer	NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; DNA-BINDING; PHOSPHATIDYLINOSITOL 3-KINASE; STABILIZE HIF-1-ALPHA; PROLYL HYDROXYLATION; SYNOVIAL FIBROBLASTS; SIGNAL-TRANSDUCTION	Growing evidence indicates that inflammation is a contributing factor leading to cancer development. However, pathways involved in this progression are not well understood. To examine whether HIF-1alpha is a factor linking inflammation and tumorigenesis, we investigated whether the HIF-1 signaling pathway was stimulated by the pro-inflammatory cytokine interleukin-1beta (IL- 1beta) in A549 cells. We find that IL-1beta up-regulated HIF-1alpha protein under normoxia and activated the HIF-1-responsive gene vascular endothelial growth factor ( VEGF) via a pathway dependent on nuclear factor kappaB (NFkB). Interestingly, although this pathway is stimulated by upstream signaling via AKT and mTOR and requires new transcription, IL- 1 mediated HIF-1alpha induction also utilizes a post-transcriptional mechanism that involves antagonism of VHL-dependent HIF-1alpha degradation, which results in increased HIF-1alpha protein stability. IL-1 mediated NFkB-dependent cyclooxygenases-2 (COX-2) expression served as a positive effector for HIF-1alpha induction. Although COX-2 inhibitors attenuated IL-1 mediated HIF-1alpha induction, prostaglandin E-2 (PGE(2)), a physiological product of COX-2, induced HIF-1alpha protein in a dose-dependent manner. Our data, therefore, demonstrate that IL-1beta up-regulates functional HIF-1alpha protein through a classical inflammatory signaling pathway involving NFkB and COX-2, culminating in up-regulation of VEGF, a potent angiogenic factor required for tumor growth and metastasis. Thus, HIF- 1 is identified as a pivotal transcription factor linking the inflammatory and oncogenic pathways.	NCI, Cell & Canc Biol Branch, CCR, Rockville, MD 20850 USA; NCI, Med Oncol Clin Res Unit, CCR, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Neckers, L (corresponding author), NCI, Cell & Canc Biol Branch, CCR, 9610 Med Ctr Dr,Suite 300, Rockville, MD 20850 USA.	len@helix.nih.gov			NATIONAL CANCER INSTITUTE [Z01SC010074, Z01SC006743, ZIASC010074, ZICSC006743] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albina JE, 2001, AM J PHYSIOL-CELL PH, V281, pC1971, DOI 10.1152/ajpcell.2001.281.6.C1971; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Apte RN, 2000, ADV EXP MED BIOL, V479, P277; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Coxon A, 2002, ARTHRITIS RHEUM, V46, P2604, DOI 10.1002/art.10546; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; Ding Min, 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P129; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Fang HY, 2003, EUR J SURG ONCOL, V29, P171, DOI 10.1053/ejso.2002.1316; Farrow B, 2002, SURG ONCOL, V10, P153, DOI 10.1016/S0960-7404(02)00015-4; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Gately S, 2000, CANCER METAST REV, V19, P19, DOI 10.1023/A:1026575610124; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Haefner B, 2002, DRUG DISCOV TODAY, V7, P653, DOI 10.1016/S1359-6446(02)02309-7; Hanada T, 2002, CYTOKINE GROWTH F R, V13, P413, DOI 10.1016/S1359-6101(02)00026-6; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jackson JR, 1997, J RHEUMATOL, V24, P1253; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Jung YJ, 2003, J BIOL CHEM, V278, P7445, DOI 10.1074/jbc.M209804200; Jung YJ, 2003, BIOCHEM J, V370, P1011, DOI 10.1042/BJ20021279; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kojima H, 2002, P NATL ACAD SCI USA, V99, P2170, DOI 10.1073/pnas.052706699; Koyama S, 2002, EUR RESPIR J, V20, P1449, DOI 10.1183/09031936.02.00089802; Kudryavtsev IA, 2002, BIOCHEMISTRY-MOSCOW+, V67, P1021, DOI 10.1023/A:1020526119866; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; Lind DS, 2001, SURGERY, V130, P363, DOI 10.1067/msy.2001.116672; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lukashev D, 2001, J BIOL CHEM, V276, P48754, DOI 10.1074/jbc.M104782200; Malkinson AM, 2002, CARCINOGENESIS, V23, P411, DOI 10.1093/carcin/23.3.411; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mecklenburgh KI, 2002, BLOOD, V100, P3008, DOI 10.1182/blood-2002-02-0454; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Mitchell JA, 1998, INFLAMM RES, V47, pS88; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; O'Neill L A, 2000, Sci STKE, V2000, pre1; PRESCOTT SM, 2000, BIOCHIM BIOPHYS ACTA, V1470, P69, DOI [10.1016/s0304-419x(00)00006-8), DOI 10.1016/S0304-419X(00)00006-8]; Rapisarda A, 2002, CANCER RES, V62, P4316; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Saijo Y, 2002, J IMMUNOL, V169, P469, DOI 10.4049/jimmunol.169.1.469; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salven P, 2002, FASEB J, V16, P1471, DOI 10.1096/fj.02-0134fje; Sandau KB, 2001, BLOOD, V97, P1009, DOI 10.1182/blood.V97.4.1009; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Shattuck-Brandt RL, 2000, GASTROENTEROLOGY, V118, P337, DOI 10.1016/S0016-5085(00)70216-2; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Spencer W, 1999, ONCOGENE, V18, P495, DOI 10.1038/sj.onc.1202335; Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Williams C, 1999, ANN NY ACAD SCI, V889, P72, DOI 10.1111/j.1749-6632.1999.tb08725.x; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Xu XC, 2002, ANTI-CANCER DRUG, V13, P127, DOI 10.1097/00001813-200202000-00003; Zhong H, 2000, CANCER RES, V60, P1541; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhou J, 2003, AM J PHYSIOL-CELL PH, V284, pC439, DOI 10.1152/ajpcell.00294.2002	76	548	584	4	51	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2115	+		10.1096/fj.03-0329fje	http://dx.doi.org/10.1096/fj.03-0329fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958148				2022-12-25	WOS:000185925100023
J	Riu, E; Ferre, T; Hidalgo, A; Mas, A; Franckhauser, S; Otaegui, P; Bosch, F				Riu, E; Ferre, T; Hidalgo, A; Mas, A; Franckhauser, S; Otaegui, P; Bosch, F			Overexpression of c-myc in the liver prevents obesity and insulin resistance	FASEB JOURNAL			English	Article						transgenic mice; type 2 diabetes; glucose metabolism	PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; PROLIFERATOR-ACTIVATED RECEPTORS; ELEMENT-BINDING PROTEIN-1C; TRANSGENIC MICE; GENE-EXPRESSION; UNCOUPLING PROTEIN-2; DIABETIC ALTERATIONS; RIBONUCLEIC-ACID; PPAR-ALPHA; GLUCOKINASE	Alterations in hepatic glucose metabolism play a key role in the development of the hyperglycemia observed in type 2 diabetes. Because the transcription factor c-Myc induces hepatic glucose uptake and utilization and blocks gluconeogenesis, we examined whether hepatic overexpression of c-myc counteracts the insulin resistance induced by a high-fat diet. After 3 months on this diet, control mice became obese, hyperglycemic, and hyperinsulinemic, indicating that they had developed insulin resistance. In contrast, transgenic mice remained lean and showed improved glucose disposal and normal levels of blood glucose and insulin, indicating that they had developed neither obesity nor insulin resistance. These findings were concomitant with normalization of hepatic glucokinase and pyruvate kinase gene expression and enzyme activity, which led to normalization of intrahepatic glucose-6-phosphate and glycogen content. In the liver of control mice fed a high-fat diet, the expression of genes encoding proteins that control energy metabolism, such as sterol receptor element binding protein 1-c, peroxisome proliferator activated receptor a, and uncoupling protein-2, was altered. In contrast, in the liver of transgenic mice fed a high-fat diet, the expression of these genes was normal. These results suggest that c-myc overexpression counteracted the obesity and insulin resistance induced by a high-fat diet by modulating the expression of genes that regulate hepatic metabolism.	Univ Autonoma Barcelona, Sch Vet Med, Dept Biochem & Mol Biol, E-08193 Bellaterra, Spain; Univ Autonoma Barcelona, Ctr Anim Biotechnol & Gene Therapy, E-08193 Bellaterra, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona	Bosch, F (corresponding author), Univ Autonoma Barcelona, Sch Vet Med, Dept Biochem & Mol Biol, E-08193 Bellaterra, Spain.	fatima.bosch@uab.es		BOSCH, FATIMA/0000-0002-7705-5515; Ferre, Tura/0000-0001-9713-0829; Riu, Efren/0000-0002-2574-3578; Franckhauser, Sylvie/0000-0001-5255-1224				Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; Chakravarty K, 2001, J BIOL CHEM, V276, P34816, DOI 10.1074/jbc.M103310200; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIS SN, 1994, DIABETES ANN, V8, P119; DeFronzo RA, 1997, DIABETES REV, V5, P177; Desai UJ, 2001, DIABETES, V50, P2287, DOI 10.2337/diabetes.50.10.2287; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; Ferre T, 1996, FASEB J, V10, P1213, DOI 10.1096/fasebj.10.10.8751724; Ferre T, 1996, P NATL ACAD SCI USA, V93, P7225, DOI 10.1073/pnas.93.14.7225; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; Guerre-Millo M, 2001, DIABETES, V50, P2809, DOI 10.2337/diabetes.50.12.2809; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hariharan N, 1997, DIABETES, V46, P11, DOI 10.2337/diabetes.46.1.11; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Iynedjian PB, 1998, BIOCHEM J, V333, P705, DOI 10.1042/bj3330705; IYNEDJIAN PB, 1987, J BIOL CHEM, V262, P6032; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kim H, 2000, DIABETES, V49, P1517, DOI 10.2337/diabetes.49.9.1517; Koyama K, 1997, AM J PHYSIOL-ENDOC M, V273, pE708, DOI 10.1152/ajpendo.1997.273.4.E708; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Memon RA, 2000, ENDOCRINOLOGY, V141, P4021, DOI 10.1210/en.141.11.4021; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; MITRAKOU A, 1990, DIABETES, V39, P1381, DOI 10.2337/diabetes.39.11.1381; Montagne CT, 2000, DIABETES, V49, P883, DOI 10.2337/diabetes.49.6.883; Narravula S, 2001, J IMMUNOL, V166, P7543, DOI 10.4049/jimmunol.166.12.7543; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; Oakes ND, 1997, DIABETES, V46, P1768, DOI 10.2337/diabetes.46.11.1768; Okamoto Y, 2002, HEPATOL RES, V23, P138, DOI 10.1016/S1386-6346(01)00172-3; Pagliassotti M, 1994, ROLE LIVER MAINTAINI, P45; Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207; Riu E, 2002, BIOCHEM J, V368, P931, DOI 10.1042/BJ20020605; Riu E, 1996, P NATL ACAD SCI USA, V93, P2198, DOI 10.1073/pnas.93.5.2198; ROSELLA G, 1995, MOL ENDOCRINOL, V9, P1396, DOI 10.1210/me.9.10.1396; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; Shiota M, 2001, DIABETES, V50, P622, DOI 10.2337/diabetes.50.3.622; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; VALERA A, 1995, FASEB J, V9, P1067, DOI 10.1096/fasebj.9.11.7649406; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; YAMAMOTO T, 1991, BIOCHEM BIOPH RES CO, V175, P995, DOI 10.1016/0006-291X(91)91663-W; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	58	30	31	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1715	+		10.1096/fj.02-1163fje	http://dx.doi.org/10.1096/fj.02-1163fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958186				2022-12-25	WOS:000184471600008
J	Ishikita, H; Knapp, EW				Ishikita, H; Knapp, EW			Redox potential of quinones in both electron transfer branches of photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION-CENTER; IRON-SULFUR CENTERS; BIOSYNTHETIC-PATHWAY MUTANTS; NUCLEAR DOUBLE-RESONANCE; SPECIAL TRIPLE-RESONANCE; RHODOBACTER-SPHAEROIDES; F-X; TRANSIENT EPR; ACCEPTOR A(1); PRIMARY DONOR	The redox potentials of the two electron transfer ( ET) active quinones in the central part of photosystem I ( PSI) were determined by evaluating the electrostatic energies from the solution of the Poisson-Boltzmann equation based on the crystal structure. The calculated redox potentials are - 531 mV for A(1A) and - 686 mV for A(1B). From these results we conclude the following. (i) Both branches are active with a much faster ET in the B-branch than in the A-branch. (ii) The measured lifetime of 200 - 290 ns of reduced quinones agrees with the estimate for the A-branch and corroborates with an uphill ET from this quinone to the iron-sulfur cluster as observed in recent kinetic measurements. (iii) The electron paramagnetic resonance spectroscopic data refer to the A-branch quinone where the corresponding ET is uphill in energy. The negative redox potential of A(1) in PSI is primarily because of the influence from the negatively charged F-X, in contrast to the positive shift on the quinone redox potential in bacterial reaction center and PSII that is attributed to the positively charged non-heme iron atom. The conserved residue Asp-B575 changes its protonation state after quinone reduction. The difference of 155 mV in the quinone redox potentials of the two branches were attributed to the conformation of the backbone with a large contribution from Ser-A692 and Ser-B672 and to the side chain of Asp-B575, whose protonation state couples differently with the formation of the quinone radicals.	Free Univ Berlin, Inst Chem, Dept Biol Chem & Pharm, D-14195 Berlin, Germany	Free University of Berlin	Knapp, EW (corresponding author), Free Univ Berlin, Inst Chem, Dept Biol Chem & Pharm, Takustr 6, D-14195 Berlin, Germany.	knapp@chemie.fu-berlin.de	Knapp, Ernst-Walter/E-4493-2010; Knapp, Ernst-Walter/AAH-6720-2021; Ishikita, Hiroshi/G-9864-2018	Knapp, Ernst-Walter/0000-0002-2858-0460; Knapp, Ernst-Walter/0000-0002-2858-0460; Ishikita, Hiroshi/0000-0002-5849-8150				Agalarov R, 2003, BBA-BIOENERGETICS, V1604, P7, DOI 10.1016/S0005-2728(03)00024-0; Alexov EG, 1999, BIOCHEMISTRY-US, V38, P8253, DOI 10.1021/bi982700a; ARATA H, 1983, BIOCHIM BIOPHYS ACTA, V725, P394, DOI 10.1016/0005-2728(83)90214-1; ARATA H, 1981, BIOCHIM BIOPHYS ACTA, V638, P201, DOI 10.1016/0005-2728(81)90228-0; BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; BEROZA P, 1991, P NATL ACAD SCI USA, V88, P5804, DOI 10.1073/pnas.88.13.5804; Bittl R, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P509; Bittl R, 1997, BIOCHEMISTRY-US, V36, P12001, DOI 10.1021/bi971645n; BOCK CH, 1989, FEBS LETT, V247, P91, DOI 10.1016/0014-5793(89)81247-5; Boudreaux B, 2001, J BIOL CHEM, V276, P37299, DOI 10.1074/jbc.M102327200; BRETTEL K, 1988, FEBS LETT, V239, P93, DOI 10.1016/0014-5793(88)80552-0; Brettel K, 2001, BBA-BIOENERGETICS, V1507, P100, DOI 10.1016/S0005-2728(01)00202-X; Brettel K, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P611; Brettel K, 1995, PHOTOSYNTH RES, V45, P183, DOI 10.1007/BF00015559; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brzezinski P, 1997, BBA-BIOENERGETICS, V1321, P149, DOI 10.1016/S0005-2728(97)00052-2; CHAMOROVSKY SK, 1982, PHOTOBIOCH PHOTOBIOP, V4, P195; DAVIS IH, 1993, BIOCHIM BIOPHYS ACTA, V1143, P183, DOI 10.1016/0005-2728(93)90141-2; Evans MCW, 1999, PHOTOSYNTH RES, V61, P33, DOI 10.1023/A:1006205811407; Evans MCW, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P183; Fromme P, 2001, BBA-BIOENERGETICS, V1507, P5, DOI 10.1016/S0005-2728(01)00195-5; Gibas CJ, 1996, BIOPHYS J, V71, P138, DOI 10.1016/S0006-3495(96)79209-3; Grafton AK, 1999, J PHYS CHEM B, V103, P5380, DOI 10.1021/jp9901139; Guergova-Kuras M, 2001, P NATL ACAD SCI USA, V98, P4437, DOI 10.1073/pnas.081078898; Hagio M, 2000, PLANT PHYSIOL, V124, P795, DOI 10.1104/pp.124.2.795; Hanley J, 1997, BIOCHEMISTRY-US, V36, P11543, DOI 10.1021/bi971360a; Hastings G, 2001, BIOCHEMISTRY-US, V40, P3681, DOI 10.1021/bi0023100; Hastings SF, 2000, EUR J BIOCHEM, V267, P5638, DOI 10.1046/j.1432-1327.2000.01643.x; HIENERWADEL R, 1995, BIOCHEMISTRY-US, V34, P2832, DOI 10.1021/bi00009a013; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Ishikita H, 2003, BIOCHEMISTRY-US, V42, P3882, DOI 10.1021/bi026781t; IWAKI M, 1991, BIOCHEMISTRY-US, V30, P5347, DOI 10.1021/bi00236a004; IWAKI M, 1994, PLANT CELL PHYSIOL, V35, P983; Joliot P, 1999, BIOCHEMISTRY-US, V38, P11130, DOI 10.1021/bi990857c; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kamlowski A, 1998, J PHYS CHEM B, V102, P8278, DOI 10.1021/jp9824611; Kass H, 1996, CHEM PHYS LETT, V251, P193, DOI 10.1016/0009-2614(96)00129-7; Kass H, 1996, CHEM PHYS LETT, V257, P197, DOI 10.1016/0009-2614(96)00533-7; Kaupp M, 2002, BIOCHEMISTRY-US, V41, P2895, DOI 10.1021/bi0159783; Klukas O, 1999, J BIOL CHEM, V274, P7361, DOI 10.1074/jbc.274.11.7361; Krabben L, 2000, BIOCHEMISTRY-US, V39, P13012, DOI 10.1021/bi001200q; KRIEGER A, 1995, BBA-BIOENERGETICS, V1229, P193, DOI 10.1016/0005-2728(95)00002-Z; Krieger-Liszkay A, 1998, BIOCHEMISTRY-US, V37, P17339, DOI 10.1021/bi9822628; LEIBL W, 1995, BIOCHEMISTRY-US, V34, P10237, DOI 10.1021/bi00032a018; Mac M, 1998, J AM CHEM SOC, V120, P13215, DOI 10.1021/ja982662i; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; MAROTI P, 1988, BIOCHIM BIOPHYS ACTA, V934, P329, DOI 10.1016/0005-2728(88)90092-8; MOUESCA JM, 1994, J AM CHEM SOC, V116, P11898, DOI 10.1021/ja00105a033; Muhiuddin IP, 2001, FEBS LETT, V503, P56, DOI 10.1016/S0014-5793(01)02696-5; NABEDRYK E, 1995, BIOCHEMISTRY-US, V34, P14722, DOI 10.1021/bi00045a013; Nabedryk E, 1998, BIOCHEMISTRY-US, V37, P14457, DOI 10.1021/bi981139d; O'Malley PJ, 1999, BBA-BIOENERGETICS, V1411, P101, DOI 10.1016/S0005-2728(99)00036-5; O'Malley PJ, 1998, CHEM PHYS LETT, V285, P99, DOI 10.1016/S0009-2614(97)01456-5; OMalley PJ, 1997, CHEM PHYS LETT, V274, P251, DOI 10.1016/S0009-2614(97)00643-X; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PARRETT KG, 1989, BIOCHIM BIOPHYS ACTA, V973, P324, DOI 10.1016/S0005-2728(89)80439-6; Popovic DM, 2002, J AM CHEM SOC, V124, P3775, DOI 10.1021/ja016249d; Popovic DM, 2001, J AM CHEM SOC, V123, P6040, DOI 10.1021/ja003878z; PRINCE RC, 1986, METHOD ENZYMOL, V125, P109; PRINCE RC, 1983, FEBS LETT, V160, P273, DOI 10.1016/0014-5793(83)80981-8; PRINCE RC, 1976, ARCH BIOCHEM BIOPHYS, V172, P329, DOI 10.1016/0003-9861(76)90084-9; Purton S, 2001, BIOCHEMISTRY-US, V40, P2167, DOI 10.1021/bi0019489; Rabenstein B, 1998, BIOCHEMISTRY-US, V37, P2488, DOI 10.1021/bi971921y; Rabenstein B, 2001, BIOPHYS J, V80, P1141, DOI 10.1016/S0006-3495(01)76091-2; Rabenstein B, 2000, BIOCHEMISTRY-US, V39, P10487, DOI 10.1021/bi000413c; RABENSTEIN B, 1998, EUR BOPHYS J, P626; Rabenstein B, 1999, KARLSBERG ONLINE MAN; RABENSTEIN B, 2003, IN PRESS BIOENERGETI; RIGBY SEJ, 1994, BIOCHEMISTRY-US, V33, P10043, DOI 10.1021/bi00199a031; Rigby SEJ, 1996, BIOCHEMISTRY-US, V35, P6651, DOI 10.1021/bi952619x; Sakuragi Y, 2002, BIOCHEMISTRY-US, V41, P394, DOI 10.1021/bi011297w; Schlodder E, 1998, BIOCHEMISTRY-US, V37, P9466, DOI 10.1021/bi973182r; Semenov AY, 2000, J BIOL CHEM, V275, P23429, DOI 10.1074/jbc.M000508200; SETIF P, 1990, CURRENT RES PHOTOSYN, V2, P539; Shinkarev VP, 2000, BIOPHYS J, V78, P363, DOI 10.1016/S0006-3495(00)76599-4; SMITH JC, 1992, J AM CHEM SOC, V114, P801, DOI 10.1021/ja00029a001; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; Torres RA, 2003, J AM CHEM SOC, V125, P1923, DOI 10.1021/ja0211104; ULLMANN GM, 1996, REACTION CTR PHOTOSY, P143; VANDENBRINK JS, 1994, FEBS LETT, V353, P273, DOI 10.1016/0014-5793(94)01047-1; VANDEREST A, 1995, CHEM PHYS, V194, P349, DOI 10.1016/0301-0104(95)00046-Q; VANDEREST A, 1994, BIOCHEMISTRY-US, V33, P11789, DOI 10.1021/bi00205a015; vanderEst A, 1997, J PHYS CHEM B, V101, P1437, DOI 10.1021/jp9622086; vanderEst A, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P143; Vassiliev IR, 1999, J BIOL CHEM, V274, P9993, DOI 10.1074/jbc.274.15.9993; Vassiliev IR, 2001, BBA-BIOENERGETICS, V1507, P139, DOI 10.1016/S0005-2728(01)00197-9; Veselov AV, 2000, BIOCHEMISTRY-US, V39, P3169, DOI 10.1021/bi9926835; Warshel A, 1997, J BIOL INORG CHEM, V2, P143, DOI 10.1007/s007750050119; WARSHEL A, 1984, Q REV BIOPHYS, V17, P283, DOI 10.1017/S0033583500005333; WARSHEL A, 1991, ANNU REV BIOPHYS BIO, V20, P267, DOI 10.1146/annurev.biophys.20.1.267; Webber AN, 2001, BBA-BIOENERGETICS, V1507, P61, DOI 10.1016/S0005-2728(01)00198-0; Xu W, 2003, J BIOL CHEM, V278, P27864, DOI 10.1074/jbc.M302962200; Yang F, 1998, J PHYS CHEM B, V102, P8288, DOI 10.1021/jp981952i; Zech SG, 2000, J PHYS CHEM B, V104, P9728, DOI 10.1021/jp002125w; Zybailov B, 2000, J BIOL CHEM, V275, P8531, DOI 10.1074/jbc.275.12.8531	96	85	94	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52002	52011		10.1074/jbc.M306434200	http://dx.doi.org/10.1074/jbc.M306434200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	12972408	hybrid			2022-12-25	WOS:000187480700006
J	Cascone, I; Giraudo, E; Caccavari, F; Napione, L; Bertotti, E; Collard, JG; Serini, G; Bussolino, F				Cascone, I; Giraudo, E; Caccavari, F; Napione, L; Bertotti, E; Collard, JG; Serini, G; Bussolino, F			Temporal and spatial modulation of Rho GTPases during in vitro formation of capillary vascular network - Adherens junctions and myosin light chain as targets of Rac1 and RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; FAMILY GTPASES; ANGIOGENESIS; KINASE; CDC42; LOCALIZATION; ACTIVATION; PHOSPHORYLATION; MIGRATION; ADHESION	Endothelial cells (ECs) self-organize into capillary networks when plated on extracellular matrix. In this process, Rho GTPases-mediated cytoskeletal dynamics control cell movement and organization of cell-to-matrix and cell-to-cell contacts. Time course analysis of RhoA and Rac1 activation matches specific morphological aspects of nascent pattern. RhoA-GTP increases early during EC adhesion and accumulates at sites of membrane ruffling. Rac1 is activated later and localizes in lamellipodia and at cell-to-cell contacts of organized cell chains. When ECs stretch and remodel to form capillary structures, RhoA-GTP increases again and associates with stress fibers running along the major cell axis. N17Rac1 and N19RhoA mutants impair pattern formation. Cell-to-cell contacts and myosin light chains (MLC) are targets of Rac1 and RhoA, respectively. N17Rac1 reduces the shift of beta-catenin and vascular endothelial cadherin to Triton X-100-insoluble fraction and impairs beta-catenin distribution at adherens junctions, suggesting that Rac1 controls the dynamics of cadherin-catenin complex with F-actin. During the remodeling phase of network formation, ECs show an intense staining for phosphorylated MLC along the plasma membrane; in contrast, MLC is less phosphorylated and widely diffused in N19RhoA ECs. Both N17Rac1 and N19RhoA have been used to investigate the role of wild type molecules in the main steps characterizing in vitro angiogenesis: (i) cell adhesion to the substrate, (ii) cell movement, and (iii) mechanical remodeling of matrix. N17Rac1 has a striking inhibitory effect on haptotaxis, whereas N19RhoA slightly inhibits EC adhesion and motility but more markedly Matrigel contraction. We conclude that different Rho GTPases control distinct morphogenetic aspects of vascular morphogenesis.	IRCC, Div Mol Angiogenesis, I-10060 Turin, Italy; Univ Turin, Sch Med, Dept Oncol Sci, I-10060 Candiolo, Italy; Netherlands Canc Inst, NL-1066 Amsterdam, Netherlands	University of Turin; Netherlands Cancer Institute	Bussolino, F (corresponding author), IRCC, Div Mol Angiogenesis, Strada Prov 142,Km 3-95, I-10060 Turin, Italy.	federico.bussolino@ircc.it	Cascone, Ilaria/Q-7844-2018; Napione, Lucia/K-3927-2016; Giraudo, Enrico/K-6441-2019; Serini, Guido/AAF-2873-2021; Giraudo, Enrico/K-3192-2016; Bussolino, Federico/AES-3951-2022; Bussolino, Federico/K-2500-2016	Cascone, Ilaria/0000-0003-4903-8926; Napione, Lucia/0000-0003-2648-1466; Giraudo, Enrico/0000-0003-4128-4786; Serini, Guido/0000-0002-3502-8367; Giraudo, Enrico/0000-0003-4128-4786; Bussolino, Federico/0000-0002-5348-1341				Bayless KJ, 2002, J CELL SCI, V115, P1123; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; Cascone I, 2003, BLOOD, V102, P2482, DOI 10.1182/blood-2003-03-0670; Connolly JO, 2002, MOL BIOL CELL, V13, P2474, DOI 10.1091/mbc.E02-01-0006; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; Djonov V, 2000, CIRC RES, V86, P286, DOI 10.1161/01.RES.86.3.286; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Guyton AC., 2006, TXB MED PHYSL; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hannah MJ, 1998, METHODS, V16, P170, DOI 10.1006/meth.1998.0664; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; Katoh K, 2001, J CELL BIOL, V153, P569, DOI 10.1083/jcb.153.3.569; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Lampugnani MG, 1997, J CELL SCI, V110, P2065; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Li Z, 2002, NEURON, V33, P741, DOI 10.1016/S0896-6273(02)00621-9; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; MADRI JA, 1992, LAB INVEST, V66, P519; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; MCNEILL H, 1993, J CELL BIOL, V120, P1217, DOI 10.1083/jcb.120.5.1217; Menager C, 1999, EXP CELL RES, V249, P221, DOI 10.1006/excr.1999.4481; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Miyazaki K, 2002, J BIOL CHEM, V277, P725, DOI 10.1074/jbc.M108568200; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Primo L, 2000, ONCOGENE, V19, P3632, DOI 10.1038/sj.onc.1203708; Ranta V, 1998, J CELL PHYSIOL, V176, P92, DOI 10.1002/(SICI)1097-4652(199807)176:1<92::AID-JCP11>3.0.CO;2-Q; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Roca C, 2003, CANCER RES, V63, P1500; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Sakurada K, 1998, AM J PHYSIOL-CELL PH, V274, pC1563, DOI 10.1152/ajpcell.1998.274.6.C1563; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Segura I, 2002, FASEB J, V16, DOI 10.1096/fj.01-0819com; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Serini G, 2003, EMBO J, V22, P1771, DOI 10.1093/emboj/cdg176; Soga N, 2001, EXP CELL RES, V269, P73, DOI 10.1006/excr.2001.5295; Strasly M, 2001, J IMMUNOL, V166, P3890, DOI 10.4049/jimmunol.166.6.3890; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; van Wetering S, 2002, J CELL SCI, V115, P1837; VERNON RB, 1995, AM J PATHOL, V147, P873; Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Yamada O, 1995, ARCH HISTOL CYTOL, V58, P567, DOI 10.1679/aohc.58.567	67	61	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50702	50713		10.1074/jbc.M307234200	http://dx.doi.org/10.1074/jbc.M307234200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	12972426	hybrid			2022-12-25	WOS:000187068200126
J	Labro, AJ; Raes, AL; Bellens, I; Ottschytsch, N; Snyders, DJ				Labro, AJ; Raes, AL; Bellens, I; Ottschytsch, N; Snyders, DJ			Gating of Shaker-type channels requires the flexibility of S6 caused by prolines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT K+ CHANNEL; POTASSIUM CHANNEL; CRYSTAL-STRUCTURE; ACTIVATION GATE; PORE; CONFORMATION; SELECTIVITY; CONDUCTION; MECHANISM; PROTEINS	The recent crystallization of a voltage-gated K+ channel has given insight into the structure of these channels but has not resolved the issues of the location and the operation of the gate. The conserved PXP motif in the S6 segment of Shaker channels has been proposed to contribute to the intracellular gating structure. To investigate the role of this motif in the destabilization of the alpha-helix, both prolines were replaced to promote an alpha-helix (alanine) or to allow a flexible configuration (glycine). These substitutions were nonfunctional or resulted in drastically altered channel gating, highlighting an important role of these prolines. Combining these mutations with a proline substitution scan demonstrated that proline residues in the midsection of S6 are required for functionality, but not necessarily at the positions conserved throughout evolution. These results indicate that the destabilization or bending of the S6 alpha-helix caused by the PXP motif apparently creates a flexible "hinge" that allows movement of the lower S6 segment during channel gating and opening.	Univ Instelling Antwerp, Dept Biomed Sci, Lab Mol Biophys Physiol & Pharmacol, B-2610 Wilrijk, Belgium	University of Antwerp	Snyders, DJ (corresponding author), Univ Instelling Antwerp, Dept Biomed Sci, Lab Mol Biophys Physiol & Pharmacol, Univ Pl 1, B-2610 Wilrijk, Belgium.		Snyders, Dirk/A-2713-2013	Snyders, Dirk/0000-0001-7142-6672; Labro, Alain J/0000-0002-0871-7511	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059689] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59689] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; Bright JN, 2002, BIOPOLYMERS, V64, P303, DOI 10.1002/bip.10197; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; del Camino D, 2001, NEURON, V32, P649, DOI 10.1016/S0896-6273(01)00487-1; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Hackos DH, 2002, J GEN PHYSIOL, V119, P521, DOI 10.1085/jgp.20028569; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Holmgren M, 1997, J GEN PHYSIOL, V109, P527, DOI 10.1085/jgp.109.5.527; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Jin TH, 2002, MOL CELL, V10, P469, DOI 10.1016/S1097-2765(02)00659-7; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; Morais-Cabral JH, 2001, NATURE, V414, P37, DOI 10.1038/35102000; NEHER E, 1992, METHOD ENZYMOL, V207, P123; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; SNYDERS DJ, 1993, J GEN PHYSIOL, V101, P513, DOI 10.1085/jgp.101.4.513; Tieleman DP, 2001, PROTEINS, V44, P63, DOI 10.1002/prot.1073; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	27	72	75	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50724	50731		10.1074/jbc.M306097200	http://dx.doi.org/10.1074/jbc.M306097200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	13679372	hybrid			2022-12-25	WOS:000187068200128
J	Peng, LY; Mirshahi, T; Zhang, HL; Hirsch, JP; Logothetis, DE				Peng, LY; Mirshahi, T; Zhang, HL; Hirsch, JP; Logothetis, DE			Critical determinants of the G protein gamma subunits in the G beta gamma stimulation of G protein-activated inwardly rectifying potassium (GIRK) channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC K+ CHANNEL; SACCHAROMYCES-CEREVISIAE; ALPHA-SUBUNIT; I-KACH; RECTIFIER; BINDING; IDENTIFICATION; G(BETA-GAMMA); REQUIRES; MEMBRANE	The betagamma subunits of G proteins modulate inwardly rectifying potassium (GIRK) channels through direct interactions. Although GIRK currents are stimulated by mammalian Gbetagamma subunits, we show that they were inhibited by the yeast Gbetagamma (Ste4/Ste18) subunits. A chimera between the yeast and the mammalian Gbeta(1) subunits (ymbeta) stimulated or inhibited GIRK currents, depending on whether it was co-expressed with mammalian or yeast Ggamma subunits, respectively. This result underscores the critical functional influence of the Ggamma subunits on the effectiveness of the Gbetagamma complex. A series of chimeras between Ggamma(2) and the yeast Ggamma revealed that the C-terminal half of the Ggamma(2) subunit is required for channel activation by the Gbeta(gamma) complex. Point mutations of Ggamma(2) to the corresponding yeast Ggamma residues identified several amino acids that reduced significantly the ability of Gbeta(gamma) to stimulate channel activity, an effect that was not due to improper association with Gbeta. Most of the identified critical Ggamma residues clustered together, forming an intricate network of interactions with the Gbeta subunit, defining an interaction surface of the Gbetagamma complex with GIRK channels. These results show for the first time a functional role for Ggamma in the effector role of Gbetagamma.	NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Dept Mol Cell & Dev Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University	Logothetis, DE (corresponding author), NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA.				NHLBI NIH HHS [HL10307, HL54185] Funding Source: Medline; NIGMS NIH HHS [GM61119] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054185, F32HL010307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061119] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albsoul-Younes AM, 2001, J BIOL CHEM, V276, P12712, DOI 10.1074/jbc.M011231200; Cohen NA, 1996, J BIOL CHEM, V271, P32301, DOI 10.1074/jbc.271.50.32301; Cook LA, 1998, BIOCHEMISTRY-US, V37, P12280, DOI 10.1021/bi980230e; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; GRISHIN AV, 1994, MOL CELL BIOL, V14, P4571, DOI 10.1128/MCB.14.7.4571; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; He C, 2002, J BIOL CHEM, V277, P6088, DOI 10.1074/jbc.M104851200; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Huang LQ, 1999, NAT NEUROSCI, V2, P1055, DOI 10.1038/15981; Hurowitz EH, 2000, DNA RES, V7, P111, DOI 10.1093/dnares/7.2.111; INANOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022, DOI 10.1006/bbrc.1995.2072; Kawano T, 1999, FEBS LETT, V463, P355, DOI 10.1016/S0014-5793(99)01656-7; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; Kubo Y, 1996, BIOCHEM BIOPH RES CO, V227, P240, DOI 10.1006/bbrc.1996.1496; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; LEE CH, 1995, J BIOL CHEM, V270, P8779, DOI 10.1074/jbc.270.15.8779; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; Lei QB, 2000, P NATL ACAD SCI USA, V97, P9771, DOI 10.1073/pnas.97.17.9771; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; Lim WK, 2001, BIOCHEMISTRY-US, V40, P10532, DOI 10.1021/bi010950c; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Mirshahi T, 2002, J BIOL CHEM, V277, P36345, DOI 10.1074/jbc.M205359200; Mirshahi T, 2002, J BIOL CHEM, V277, P7348, DOI 10.1074/jbc.M109999200; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; NAKAFUKU M, 1987, P NATL ACAD SCI USA, V84, P2140, DOI 10.1073/pnas.84.8.2140; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; Nakajima Y, 1996, FEBS LETT, V390, P217, DOI 10.1016/0014-5793(96)00661-8; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Roychowdhury S, 1997, J BIOL CHEM, V272, P31576, DOI 10.1074/jbc.272.50.31576; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Wall MA, 1998, STRUCTURE, V6, P1169, DOI 10.1016/S0969-2126(98)00117-8; Yamada M, 1998, PHARMACOL REV, V50, P723; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597	50	14	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50203	50211		10.1074/jbc.M308299200	http://dx.doi.org/10.1074/jbc.M308299200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	12975366	hybrid			2022-12-25	WOS:000187068200067
J	Missirlis, F; Hu, JG; Kirby, K; Hilliker, AJ; Rouault, TA; Phillips, JP				Missirlis, F; Hu, JG; Kirby, K; Hilliker, AJ; Rouault, TA; Phillips, JP			Compartment-specific protection of iron-sulfur proteins by superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; DROSOPHILA-MELANOGASTER; SACCHAROMYCES-CEREVISIAE; REGULATORY PROTEIN; RESPONSIVE ELEMENT; MOTOR-NEURONS; CU,ZN-SUPEROXIDE DISMUTASE; CAENORHABDITIS-ELEGANS; ACONITASE ACTIVITY; MESSENGER-RNA	Iron and oxygen are essential but potentially toxic constituents of most organisms, and their transport is meticulously regulated both at the cellular and systemic levels. Compartmentalization may be a homeostatic mechanism for isolating these biological reactants in cells. To investigate this hypothesis, we have undertaken a genetic analysis of the interaction between iron and oxygen metabolism in Drosophila. We show that Drosophila iron regulatory protein-1 (IRP1) registers cytosolic iron and oxidative stress through its labile iron sulfur cluster by switching between cytosolic aconitase and RNA-binding functions. IRP1 is strongly activated by silencing and genetic mutation of the cytosolic superoxide dismutase (Sod1), but is unaffected by silencing of mitochondrial Sod2. Conversely, mitochondrial aconitase activity is relatively insensitive to loss of Sod1 function, but drops dramatically if Sod2 activity is impaired. This strongly suggests that the mitochondrial boundary limits the range of superoxide reactivity in vivo. We also find that exposure of adults to paraquat converts cytosolic aconitase to IRP1 but has no affect on mitochondrial aconitase, indicating that paraquat generates superoxide in the cytosol but not in mitochondria. Accordingly, we find that transgene-mediated overexpression of Sod2 neither enhances paraquat resistance in Sod1(+) flies nor compensates for lack of SOD1 activity in Sod1-null mutants. We conclude that in vivo, superoxide is confined to the subcellular compartment in which it is formed, and that the mitochondrial and cytosolic SODs provide independent protection to compartment-specific protein iron-sulfur clusters against attack by superoxide generated under oxidative stress within those compartments.	Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada; NICHHD, Cell Biol & Metab Branch, Bethesda, MD 20892 USA; York Univ, Dept Biol, N York, ON M3J 1P3, Canada	University of Guelph; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); York University - Canada	Phillips, JP (corresponding author), Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada.		Missirlis, Fanis/C-1137-2011	Missirlis, Fanis/0000-0003-0467-8444	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001602] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001602] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BALZAN R, 1995, P NATL ACAD SCI USA, V92, P4219, DOI 10.1073/pnas.92.10.4219; Balzan R, 1999, BIOCHEM BIOPH RES CO, V256, P63, DOI 10.1006/bbrc.1999.0285; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Bouton C, 1996, J BIOL CHEM, V271, P2300, DOI 10.1074/jbc.271.4.2300; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cairo G, 1996, FASEB J, V10, P1326, DOI 10.1096/fasebj.10.11.8836047; Corson LB, 1999, J BIOL CHEM, V274, P27590, DOI 10.1074/jbc.274.39.27590; De Freitas JM, 2000, J BIOL CHEM, V275, P11645, DOI 10.1074/jbc.275.16.11645; Dussmann H, 2003, J BIOL CHEM, V278, P12645, DOI 10.1074/jbc.M210826200; Duttaroy A, 1997, DNA CELL BIOL, V16, P391, DOI 10.1089/dna.1997.16.391; Elia AJ, 1999, FREE RADICAL BIO MED, V26, P1332, DOI 10.1016/S0891-5849(98)00333-5; Fillebeen C, 2002, REDOX REP, V7, P15, DOI 10.1179/135100002125000136; FLINT DH, 1993, J BIOL CHEM, V268, P22369; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; Gourley BL, 2003, J BIOL CHEM, V278, P3227, DOI 10.1074/jbc.M210333200; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; HEIKKILA RE, 1976, ANAL BIOCHEM, V75, P356, DOI 10.1016/0003-2697(76)90089-0; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Kirby K, 2002, P NATL ACAD SCI USA, V99, P16162, DOI 10.1073/pnas.252342899; Kohler SA, 1995, J BIOL CHEM, V270, P30781, DOI 10.1074/jbc.270.51.30781; Li QY, 2001, J NEUROCHEM, V78, P746, DOI 10.1046/j.1471-4159.2001.00457.x; Lind MI, 1998, FEBS LETT, V436, P476, DOI 10.1016/S0014-5793(98)01186-7; Missirlis F, 2003, BIOL CHEM, V384, P463, DOI 10.1515/BC.2003.052; Missirlis F, 2002, J BIOL CHEM, V277, P11521, DOI 10.1074/jbc.M111692200; Mockett RJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P260, DOI 10.1006/abbi.1999.1460; Muckenthaler M, 1998, EUR J BIOCHEM, V254, P230, DOI 10.1046/j.1432-1327.1998.2540230.x; Pani G, 2001, IUBMB LIFE, V52, P7, DOI 10.1080/15216540252774702; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Park JI, 1998, J BIOL CHEM, V273, P22921, DOI 10.1074/jbc.273.36.22921; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; PHILLIPS JP, 1995, P NATL ACAD SCI USA, V92, P8574, DOI 10.1073/pnas.92.19.8574; PHILLIPS JP, 1989, P NATL ACAD SCI USA, V86, P2761, DOI 10.1073/pnas.86.8.2761; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; REVEILLAUD I, 1991, MOL CELL BIOL, V11, P632, DOI 10.1128/MCB.11.2.632; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Srinivasan C, 2000, J BIOL CHEM, V275, P29187, DOI 10.1074/jbc.M004239200; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Tabuchi A, 2003, J NEUROSCI RES, V71, P504, DOI 10.1002/jnr.10505	44	89	91	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47365	47369		10.1074/jbc.M307700200	http://dx.doi.org/10.1074/jbc.M307700200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12972424	hybrid			2022-12-25	WOS:000186731400004
J	Gotte, G; Libonati, M; Laurents, DV				Gotte, G; Libonati, M; Laurents, DV			Glycosylation and specific deamidation of ribonuclease B affect the formation of three-dimensional domain-swapped oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PANCREATIC RIBONUCLEASE; DOUBLE-STRANDED-RNA; CRYSTAL-STRUCTURE; AMYLOID FORMATION; SEMINAL RIBONUCLEASE; ISOASPARTYL RESIDUE; MASS-SPECTROMETRY; PROTEIN; AGGREGATION; RESOLUTION	RNase A oligomerizes via the three-dimensional domain-swapping mechanism to form a variety of oligomers, including two dimers. One, called the N-dimer, forms by swapping of the N termini of the protein; the other, called the C-dimer, forms by swapping of the C termini. RNase B is identical in protein sequence and conformation to RNase A, but its Asn(34) bears an oligosaccharide chain that might affect oligomerization. The ability of RNase B to oligomerize under two sets of conditions has been examined. The amount of oligomers formed via lyophilization was somewhat lower for RNase B than RNase A, and RNase B oligomerized more rapidly in 40% ethanol solution at high temperature than RNase A. The ratio of the N-dimer to C-dimer formed increased with the size of the carbohydrate chain under both sets of conditions. These results suggest that the oligosaccharide chain either favors productive collisions or stabilizes the oligomers, especially the N-dimer. Endoglycosidase H treatment of RNase B partially restored RNase A-like oligomerization. Derivatives of RNase A conjugated at the amine groups to polyethylene glycol chains showed a greatly reduced capacity for oligomerization, suggesting that oligomerization can be impeded sterically. Commercial preparations of RNase B eluted as two main peaks by cation exchange chromatography. Using chromatography, mass spectroscopy, and two-dimensional NMR, the major peak was identified as RNase B selectively deamidated at Asn(67). This deamidated protein showed a >4degreesC drop in thermal stability, disruption of the native structure of residues 67-69, and a decreased ability to oligomerize compared with unmodified RNase B.	CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; Univ Verona, Fac Med & Chirurg, Sez Chim Biol, Dipartimento Sci Neurol & Vis, I-37134 Verona, Italy	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); University of Verona	Laurents, DV (corresponding author), CSIC, Inst Quim Fis Rocasolano, Serrano 119, E-28006 Madrid, Spain.		Laurents, Douglas V/E-7527-2015	Laurents, Douglas V/0000-0002-4187-165X; Gotte, Giovanni/0000-0003-3179-7158				Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; Arnold U, 1997, BIOCHEMISTRY-US, V36, P2166, DOI 10.1021/bi962723u; Beintema J.J., 1982, P43; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; BENNETT MJ, 1994, PROTEIN SCI, V3, P1444, DOI 10.1002/pro.5560030911; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Bornstein P, 1977, Methods Enzymol, V47, P132; BROWN LR, 1975, EUR J BIOCHEM, V54, P219, DOI 10.1111/j.1432-1033.1975.tb04131.x; CAPASSO S, 1989, Peptide Research, V2, P195; Capasso S, 1996, J MOL BIOL, V257, P492, DOI 10.1006/jmbi.1996.0179; Capasso S, 1999, J PEPT RES, V54, P377, DOI 10.1034/j.1399-3011.1999.00111.x; CARSANA A, 1981, BIOCHIM BIOPHYS ACTA, V654, P77, DOI 10.1016/0005-2787(81)90138-6; Catanzano F, 1997, PROTEIN SCI, V6, P1682, DOI 10.1002/pro.5560060808; Chakrabartty A, 2001, P NATL ACAD SCI USA, V98, P14757, DOI 10.1073/pnas.261596398; Chen PY, 2002, P NATL ACAD SCI USA, V99, P12633, DOI 10.1073/pnas.192137799; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; COOK KH, 1979, P NATL ACAD SCI USA, V76, P6157, DOI 10.1073/pnas.76.12.6157; CRESTFIELD A M, 1962, Arch Biochem Biophys, VSuppl 1, P217; DIDONATO A, 1993, J BIOL CHEM, V268, P4745; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EAKER DL, 1965, BIOCHEMISTRY-US, V4, P1479, DOI 10.1021/bi00884a003; Esposito L, 2000, J MOL BIOL, V297, P713, DOI 10.1006/jmbi.2000.3597; FU DT, 1994, CARBOHYD RES, V261, P173, DOI 10.1016/0008-6215(94)84015-6; Gonzalez L, 2000, ARCH BIOCHEM BIOPHYS, V383, P17, DOI 10.1006/abbi.2000.2031; Gorman PM, 2003, J MOL BIOL, V325, P743, DOI 10.1016/S0022-2836(02)01279-2; Gotte G, 2003, J BIOL CHEM, V278, P10763, DOI 10.1074/jbc.M213146200; Gotte G, 1999, EUR J BIOCHEM, V265, P680, DOI 10.1046/j.1432-1327.1999.00761.x; Hatters DM, 2002, J BIOL CHEM, V277, P7824, DOI 10.1074/jbc.M110429200; Hou LM, 2002, J BIOL CHEM, V277, P40173, DOI 10.1074/jbc.C200338200; Janowski R, 2001, NAT STRUCT BIOL, V8, P316, DOI 10.1038/86188; JOAO HC, 1992, FEBS LETT, V307, P343, DOI 10.1016/0014-5793(92)80709-P; JOAO J, 1993, EUR J BIOCHEM, V21, P239; Kawasaki N, 1999, ANAL BIOCHEM, V269, P297, DOI 10.1006/abio.1999.4026; KIEFHABER T, 1992, J MOL BIOL, V224, P231, DOI 10.1016/0022-2836(92)90586-9; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; KUNITZ M, 1946, J BIOL CHEM, V164, P563; Libonati M, 2001, METHOD ENZYMOL, V341, P234, DOI 10.1016/S0076-6879(01)41155-4; Libonati M, 1996, BIOCHEM J, V318, P287, DOI 10.1042/bj3180287; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Liu YS, 1998, P NATL ACAD SCI USA, V95, P3437, DOI 10.1073/pnas.95.7.3437; Liu YS, 2002, PROTEIN SCI, V11, P371, DOI 10.1110/ps.36602; Liu YS, 2001, NAT STRUCT BIOL, V8, P211, DOI 10.1038/84941; MARZOTTO A, 1970, ARCH BIOCHEM BIOPHYS, V137, P373, DOI 10.1016/0003-9861(70)90451-0; Matousek J, 2002, J CONTROL RELEASE, V82, P29, DOI 10.1016/S0168-3659(02)00082-2; MAZZARELLA L, 1993, ACTA CRYSTALLOGR D, V49, P389, DOI 10.1107/S0907444993003403; Narhi LO, 2001, PROTEIN ENG, V14, P135, DOI 10.1093/protein/14.2.135; Nenci A, 2001, PROTEIN SCI, V10, P2017, DOI 10.1110/ps.14101; Nilsson MR, 2002, PROTEIN SCI, V11, P342, DOI 10.1110/ps.48702; PACE CN, 1989, BIOCHEMISTRY-US, V28, P2520, DOI 10.1021/bi00432a026; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; Park C, 2000, PROTEIN SCI, V9, P2026, DOI 10.1110/ps.9.10.2026; PLUMMER TH, 1963, J BIOL CHEM, V238, P1396; PUETT D, 1973, J BIOL CHEM, V248, P3566; RICO M, 1993, APPL MAGN RESON, V4, P385, DOI 10.1007/BF03162456; Solis D, 2001, GLYCOBIOLOGY, V11, P31, DOI 10.1093/glycob/11.1.31; SORRENTINO S, 1985, BIOCHIM BIOPHYS ACTA, V827, P135, DOI 10.1016/0167-4838(85)90081-0; TERZI E, 1994, BIOCHEMISTRY-US, V33, P1345, DOI 10.1021/bi00172a009; THANNHAUSER TW, 1985, BIOCHEMISTRY-US, V24, P7681, DOI 10.1021/bi00347a027; Uversky VN, 2002, FEBS LETT, V517, P239, DOI 10.1016/S0014-5793(02)02638-8; Wang CQ, 1996, BIOCHEMISTRY-US, V35, P7299, DOI 10.1021/bi9517704; WANG FFC, 1977, J BIOL CHEM, V252, P8358; WEICKMANN JL, 1981, BIOCHEMISTRY-US, V20, P1272, DOI 10.1021/bi00508a035; WILLIAMS RL, 1987, J BIOL CHEM, V262, P16020; Zou WQ, 2001, EUR J BIOCHEM, V268, P4885, DOI 10.1046/j.1432-1327.2001.02415.x	65	35	35	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46241	46251		10.1074/jbc.M308470200	http://dx.doi.org/10.1074/jbc.M308470200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12966091	hybrid			2022-12-25	WOS:000186569400007
J	Sathyamurthy, A; Allen, MD; Murzin, AG; Bycroft, M				Sathyamurthy, A; Allen, MD; Murzin, AG; Bycroft, M			Crystal structure of the malignant brain tumor (MBT) repeats in Sex Comb on Midleg-like 2 (SCML2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCOMB-GROUP PROTEINS; SMN TUDOR DOMAIN; X-RAY; DROSOPHILA; CHROMATIN; EXPRESSION; REPRESSOR; INTERACTS; FAMILY; PWWP	Sex Comb on Midleg (SCM) belongs to the Polycomb group of proteins, which are involved in transcriptional regulation in Drosophila. It is one of the components of Polycomb repressive complex 1, a multiprotein complex of Polycomb group proteins involved in the maintenance of repression and the blocking of chromatin remodeling. SCM contains two similar to100-residue malignant brain tumor (MBT) repeats at the N terminus. These repeats are also found in other proteins involved in transcriptional repression. Here, we report the 1.78-Angstrom crystal structure of the two MBT repeats of SCM-like 2 (SCML2), a human homologue of SCM. Each repeat consists of an extended arm and a beta-barrel core. There are significant structural similarities to the Tudor, PWWP, and chromo domains, suggesting probable evolutionary relationships and functional similarities between the MBT repeats and these domains.	MRC, Ctr Prot Engn, Cambridge CB2 2QH, England	University of Cambridge	Bycroft, M (corresponding author), MRC, Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.	mb10031@cus.cam.ac.uk	Bycroft, Mark/D-9446-2017	Bycroft, Mark/0000-0002-0673-2216				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boccuni P, 2003, J BIOL CHEM, V278, P15412, DOI 10.1074/jbc.M300592200; Bornemann D, 1996, DEVELOPMENT, V122, P1621; Bornemann D, 1998, GENETICS, V150, P675; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Francis NJ, 2001, MOL CELL, V8, P545, DOI 10.1016/S1097-2765(01)00316-1; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; JONES RS, 1990, GENETICS, V126, P185; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; King IFG, 2002, MOL CELL BIOL, V22, P7919, DOI 10.1128/MCB.22.22.7919-7928.2002; Koga H, 1999, ONCOGENE, V18, P3799, DOI 10.1038/sj.onc.1202732; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1991, RECENT CHANGES MOSFL; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Qiu C, 2002, NAT STRUCT BIOL, V9, P217, DOI 10.1038/nsb759; Rousseau F, 2003, STRUCTURE, V11, P243, DOI 10.1016/S0969-2126(03)00029-7; Satijn DPE, 1999, MOL CELL BIOL, V19, P57; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; SEWALT RG, 1993, MOL CELL BIOL, V18, P3586; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; SLATER LM, 2003, J MOL BIOL; Sprangers R, 2003, J MOL BIOL, V327, P507, DOI 10.1016/S0022-2836(03)00148-7; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; TURK D, 1992, THESIS TU MUNCHEN MU; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; Wang WK, 2003, STRUCTURE, V11, P775, DOI 10.1016/S0969-2126(03)00127-8	37	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46968	46973		10.1074/jbc.M306469200	http://dx.doi.org/10.1074/jbc.M306469200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12952983	hybrid			2022-12-25	WOS:000186569400091
J	Tellez, C; McCarty, M; Ruiz, M; Bar-Eli, M				Tellez, C; McCarty, M; Ruiz, M; Bar-Eli, M			Loss of activator protein-2 alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; ENDOTHELIAL GROWTH-FACTOR; HUMAN-BREAST-CARCINOMA; THROMBIN-RECEPTOR; PLASMINOGEN-ACTIVATOR; EPITHELIAL-CELLS; GENE-EXPRESSION; TUMOR-GROWTH; C-KIT; DOWN-REGULATION	Increasing evidence implicates the protease- activated receptor- 1 ( PAR- 1) as a contributor to tumor invasion and metastasis of human melanoma. Here we demonstrate that the metastatic potential of human melanoma cells correlates with overexpression of PAR- 1. We also provide evidence that an inverse correlation exists between the expression of activator protein- 2alpha ( AP- 2) and the expression of PAR- 1 in human melanoma cells. Re-expression of AP- 2 in WM266- 4 melanoma cells, which are AP- 2- negative, resulted in decreased mRNA and protein expression of PAR- 1. The promoter of the PAR- 1 gene contains multiple putative consensus elements for the transcription factors AP- 2 and specificity protein 1 ( Sp1). Chromatin immunoprecipitation analysis of the PAR- 1 promoter regions bp -365 to -329 ( complex 1) and bp - 206 to - 180 ( complex 2) demonstrated that Sp1 was predominantly bound to the PAR- 1 promoter in metastatic cells, whereas AP- 2 was bound to the PAR- 1 promoter in nonmetastatic cells. In vitro analysis of complex 1 demonstrated that AP- 2 and Sp1 bound to this region in a mutually exclusive manner. Transfection experiments with full- length and progressive deletions of the PAR- 1 promoter luciferase constructs demonstrated that metastatic melanoma cells had increased PAR- 1 promoter activity compared with low and nonmetastatic melanoma cells. Our data show that exogenous AP- 2 expression decreased promoter activity, whereas transient expression of Sp1 further increased expression of the reporter gene. Mutational analysis of complex 1 within PAR- 1 luciferase constructs further demonstrated that the regulation of PAR- 1 was mediated through interactions with AP- 2 and Sp1. Our data suggest that loss of AP- 2 in metastatic cells alters the AP- 2/ Sp1 ratio, resulting in overexpression of PAR- 1. Taken together, our results provide strong evidence that loss of AP- 2 correlates with overexpression of PAR- 1, which in turn contributes to the acquisition of the malignant phenotype of human melanoma.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Bar-Eli, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 173,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA076098] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldi A, 2001, J CELL BIOCHEM, V83, P364, DOI 10.1002/jcb.1235; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Bar-Eli M, 1999, CANCER METAST REV, V18, P377, DOI 10.1023/A:1006377309524; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Braun H, 1998, J BIOL CHEM, V273, P9821, DOI 10.1074/jbc.273.16.9821; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; Cucina A, 1999, J SURG RES, V82, P61, DOI 10.1006/jsre.1998.5514; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; FISCHER EG, 1995, CANCER RES, V55, P1629; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Gille J, 2000, J INVEST DERMATOL, V115, P30, DOI 10.1046/j.1523-1747.2000.00020.x; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; Hao H, 2003, BLOOD, V101, P4551, DOI 10.1182/blood-2002-10-3174; HEARING VJ, 1988, CANCER RES, V48, P1270; Henrikson KP, 1999, BRIT J CANCER, V79, P401, DOI 10.1038/sj.bjc.6690063; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang SY, 1996, ONCOGENE, V13, P2339; Huang YQ, 2001, THROMB HAEMOSTASIS, V86, P1094; ISHIKAWA M, 1988, CANCER RES, V48, P665; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Jiang JG, 2000, BIOCHEM BIOPH RES CO, V272, P882, DOI 10.1006/bbrc.2000.2848; Johnson JP, 1997, INT J CANCER, V73, P769; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kaufmann R, 1997, CANCER, V80, P2068, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2068::AID-CNCR5>3.0.CO;2-T; Kelley KMM, 2003, GENE, V307, P87, DOI 10.1016/S0378-1119(03)00445-1; Li FZ, 1996, J BIOL CHEM, V271, P26320, DOI 10.1074/jbc.271.42.26320; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; Liu YN, 2001, CANCER LETT, V169, P173, DOI 10.1016/S0304-3835(01)00504-3; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; LUCA M, 1995, ONCOGENE, V11, P1399; Luca MR, 1998, HISTOL HISTOPATHOL, V13, P1225, DOI 10.14670/HH-13.1225; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Nierodzik ML, 1998, BLOOD, V92, P3694, DOI 10.1182/blood.V92.10.3694.422k40_3694_3700; PRICE JE, 1990, CANCER RES, V50, P717; Rudroff C, 1998, PANCREAS, V16, P189, DOI 10.1097/00006676-199803000-00013; Schmidt VA, 1996, J BIOL CHEM, V271, P9307, DOI 10.1074/jbc.271.16.9307; Senger DR, 1996, AM J PATHOL, V149, P293; Shimizu S, 2000, AM J PHYSIOL-LUNG C, V279, pL503, DOI 10.1152/ajplung.2000.279.3.L503; Strom AC, 1996, NUCLEIC ACIDS RES, V24, P1981, DOI 10.1093/nar/24.11.1981; Turner BC, 1998, CANCER RES, V58, P5466; Ueno A, 1996, IMMUNOLOGY, V88, P76, DOI 10.1046/j.1365-2567.1996.d01-635.x; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; WHITE AC, 1982, CANCER RES, V42, P906; WOJTUKIEWICZ MZ, 1992, THROMB RES, V68, P233, DOI 10.1016/0049-3848(92)90081-K; WOJTUKIEWICZ MZ, 1995, CANCER RES, V55, P698; Wu YX, 1998, BIOCHEM J, V330, P1469, DOI 10.1042/bj3301469; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200; YOSHIDA E, 1994, CANCER RES, V54, P3300; YU H, 1990, CANCER RES, V50, P7623; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	62	93	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46632	46642		10.1074/jbc.M309159200	http://dx.doi.org/10.1074/jbc.M309159200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12975361	hybrid			2022-12-25	WOS:000186569400051
J	Ozawa, M				Ozawa, M			p120-independent modulation of E-cadherin adhesion activity by the membrane-proximal region of the cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; CATENIN COMPLEX; ALPHA-CATENIN; N-CADHERIN; JUXTAMEMBRANE REGION; MOLECULE UVOMORULIN; IN-VIVO; PROTEIN; BINDING; ACTIN	Cadherins are transmembrane glycoproteins that function as Ca2+-dependent cell-cell adhesion molecules and are linked to the actin cytoskeleton via catenins. Previously, we showed that, although E-cadherin lacking its cytoplasmic tail is active in aggregation assays, partially truncated E-cadherin lacking the carboxyl-terminal catenin-binding site is not. Contrary to this observation, a similar N-cadherin construct is found to be functional. Chimeric constructs, in which the membrane-proximal region of the partially truncated E-cadherin was replaced by that of N-cadherin, are active in aggregation assays. N-cadherin constructs in the opposite manner are nonfunctional. Although deletion of the membrane-proximal region, which eliminates the binding site for p120, results in activation of the nonfunctional E-cadherin mutant polypeptides, amino acid substitutions in the membrane-proximal region, which uncouple p120 binding, do not. The p120 uncoupling could not activate a full-length E-cadherin construct, which was beta-catenin-uncoupled by amino acid substitutions in the catenin-binding site. These results indicate that the membrane-proximal region determines the activity of these cadherin constructs but that p120 does not seem directly involved in the modulation of E-cadherin activity.	Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Biochem & Mol Biol, Kagoshima 8908544, Japan	Kagoshima University	Ozawa, M (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Biochem & Mol Biol, Kagoshima 8908544, Japan.			Ozawa, Masayuki/0000-0002-7887-8441				ABERLE H, 1994, J CELL SCI, V107, P3655; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Calkins CC, 2003, J BIOL CHEM, V278, P1774, DOI 10.1074/jbc.M205693200; Chen HY, 1997, J CELL SCI, V110, P345; Chitaev NA, 1998, J CELL BIOL, V142, P837, DOI 10.1083/jcb.142.3.837; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marie H, 2003, J BIOL CHEM, V278, P1220, DOI 10.1074/jbc.M205391200; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; Myster SH, 2003, J CELL BIOL, V160, P433, DOI 10.1083/jcb.200211083; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; Nieset JE, 1997, J CELL SCI, V110, P1013; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Ozawa M, 2002, J BIOL CHEM, V277, P19600, DOI 10.1074/jbc.M202029200; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; Pacquelet A, 2003, J CELL BIOL, V160, P313, DOI 10.1083/jcb.200207160; Paulson AF, 2000, J BIOL CHEM, V275, P30124, DOI 10.1074/jbc.M003048200; REID RA, 1990, NUCLEIC ACIDS RES, V18, P5896, DOI 10.1093/nar/18.19.5896; Riehl R, 1996, NEURON, V17, P837, DOI 10.1016/S0896-6273(00)80216-0; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; SALOMON D, 1992, J CELL SCI, V102, P7; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	42	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46014	46020		10.1074/jbc.M307778200	http://dx.doi.org/10.1074/jbc.M307778200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952959	hybrid			2022-12-25	WOS:000186452300117
J	Rotter, V; Nagaev, I; Smith, U				Rotter, V; Nagaev, I; Smith, U			Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-ALPHA; GLUCOSE-TRANSPORT; ADIPOSE-TISSUE; IRS 1; EXPRESSION; PROTEIN; RECEPTOR; LIPOLYSIS; SENSITIVITY; RELEASE	Several studies have shown a relationship between interleukin (IL) 6 levels and insulin resistance. We here show that human subcutaneous adipose cells, like 3T3-L1 cells, are target cells for IL-6. To examine putative mechanisms and cross-talk with insulin, 3T3-L1 adipocytes were cultured for different times with IL-6 and tumor necrosis factor alpha (TNF-alpha). IL-6, in contrast to TNF-alpha, did not increase pS-307 of insulin-receptor substrate (IRS)-1 or JNK activation. However, IL-6, like TNF-alpha exerted long term inhibitory effects on the gene transcription of IRS-1, GLUT-4, and peroxisome proliferator-activated receptor gamma. This effect of IL-6 was accompanied by a marked reduction in IRS-1, but not IRS-2, protein expression, and insulin-stimulated tyrosine phosphorylation, whereas no inhibitory effect was seen on the insulin receptor tyrosine phosphorylation. Consistent with the reduced GLUT-4 mRNA, insulin-stimulated glucose transport was also significantly reduced by IL-6. An important interaction with TNF-alpha was found because TNF-alpha markedly increased IL-6 mRNA and protein secretion. These results show that IL-6, through effects on gene transcription, is capable of impairing insulin signaling and action but, in contrast to TNF-alpha, IL-6 does not increase pS-307 (or pS-612) of IRS-1. The link between IL-6 and insulin resistance in man was further corroborated by the finding that the expression of IL-6, like that of TNF-alpha and IL-8, was markedly increased (similar to15-fold) in human fat cells from insulin-resistant individuals. We conclude that IL-6 can play an important role in insulin resistance in man and, furthermore, that it may act in concert with other cytokines that also are up-regulated in adipose cells in insulin resistance.	Univ Gothenburg, Sahlgrenska Acad, Lundberg Lab Diabet Res, Dept Internal Med, SE-41345 Gothenburg, Sweden	University of Gothenburg	Smith, U (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Lundberg Lab Diabet Res, Dept Internal Med, SE-41345 Gothenburg, Sweden.	ulf.smith@medic.gu.se	Nagaev, Ivan/B-7269-2008					BRADLEY DC, 1989, ANAL BIOCHEM, V180, P11, DOI 10.1016/0003-2697(89)90081-X; Bruun JM, 2002, OBES RES, V10, P499, DOI 10.1038/oby.2002.68; Carvalho E, 1999, FASEB J, V13, P2173, DOI 10.1096/fasebj.13.15.2173; Carvalho Eugenia, 2001, FASEB Journal, V15, P1101; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FEINGOLD KR, 1992, ENDOCRINOLOGY, V130, P10, DOI 10.1210/en.130.1.10; Fernandez-Real JM, 2001, J CLIN ENDOCR METAB, V86, P1154, DOI 10.1210/jc.86.3.1154; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Gasic S, 1999, J BIOL CHEM, V274, P6770, DOI 10.1074/jbc.274.10.6770; GREEN A, 1994, ENDOCRINOLOGY, V134, P2581, DOI 10.1210/en.134.6.2581; HAUNER H, 1995, DIABETOLOGIA, V38, P764, DOI 10.1007/s001250050350; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Huppertz C, 1996, DIABETOLOGIA, V39, P1432, DOI 10.1007/s001250050595; Jansson PA, 2003, FASEB J, V17, P1434, DOI 10.1096/fj.02-1132com; Kado S, 1999, ACTA DIABETOL, V36, P67, DOI 10.1007/s005920050147; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; Kubaszek A, 2003, DIABETES, V52, P558, DOI 10.2337/diabetes.52.2.558; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Muller S, 2002, DIABETOLOGIA, V45, P805, DOI 10.1007/s00125-002-0829-2; Ohshima S, 1998, P NATL ACAD SCI USA, V95, P8222, DOI 10.1073/pnas.95.14.8222; Paquot N, 2000, J CLIN ENDOCR METAB, V85, P1316, DOI 10.1210/jc.85.3.1316; Path G, 2001, J CLIN ENDOCR METAB, V86, P2281, DOI 10.1210/jc.86.5.2281; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; Peters M, 1997, J IMMUNOL, V159, P1474; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; Rosenstock M, 2001, DIABETOLOGIA, V44, P55, DOI 10.1007/s001250051580; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Senn JJ, 2002, DIABETES, V51, P3391, DOI 10.2337/diabetes.51.12.3391; Senn JJ, 2003, J BIOL CHEM, V278, P13740, DOI 10.1074/jbc.M210689200; SMITH U, 1972, J LIPID RES, V13, P822; Smith U, 2001, FASEB J, V15, P215, DOI 10.1096/fj.00-0020com; Steensberg A, 2003, J PHYSIOL-LONDON, V548, P631, DOI 10.1113/jphysiol.2002.032938; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; Stouthard JML, 1996, BIOCHEM BIOPH RES CO, V220, P241, DOI 10.1006/bbrc.1996.0389; Straub RH, 2000, J CLIN ENDOCR METAB, V85, P1340, DOI 10.1210/jc.85.3.1340; TILG H, 1994, BLOOD, V83, P113; Trujillo ME, 2001, DIABETES, V50, pA12; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; Xu HY, 2002, DIABETES, V51, P1876, DOI 10.2337/diabetes.51.6.1876; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yu ZW, 1997, DIABETOLOGIA, V40, P1197, DOI 10.1007/s001250050807	50	759	833	0	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45777	45784		10.1074/jbc.M301977200	http://dx.doi.org/10.1074/jbc.M301977200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952969	hybrid			2022-12-25	WOS:000186452300089
J	Yan, B; Zemskova, M; Holder, S; Chin, V; Kraft, A; Koskinen, PJ; Lilly, M				Yan, B; Zemskova, M; Holder, S; Chin, V; Kraft, A; Koskinen, PJ; Lilly, M			The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; C-MYC; INHIBITS APOPTOSIS; MYELOID CELLS; PROTEIN; SURVIVAL; ACTIVATION; EXPRESSION; ONCOGENE; LYMPHOMAGENESIS	Hematopoietic growth factors mediate the survival and proliferation of blood-forming cells, but the mechanisms through which these proteins produce their effects are incompletely known. Recent studies have identified the pim family of kinases as mediators of cytokine-dependent survival signals. Several studies have identified substrates for the pim-1 kinase, but little is known about the other family members, pim-2 and pim-3. We have investigated potential functions for the pim-2 kinase in factor-dependent murine hematopoietic cells. We find that pim-2 mRNA and protein expression are regulated by cytokines similarly to pim-1. Three PIM-2 protein isoforms are produced in cytokine-treated cells. All three forms are active kinases, and the short (PIM-2(34 kDa)) form is the most active at enhancing survival of FDCP1 cells after cytokine withdrawal. This pro-survival function involves inhibition of apoptosis and caspase activation. Enforced expression of PIM-2 (34 kDa) kinase does not appear to regulate expression of BCL-2, BCL-xL, BIM, or BAX proteins. However, the kinase can phosphorylate the pro-apoptotic protein BAD on serine 112, which accounts in part for its ability to reverse Bad-induced cell death. Our results indicate that pim-2 functions similarly to pim-1 as a pro-survival kinase and suggest that BAD is a legitimate PIM-2 substrate.	Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene therapy, Loma Linda, CA 92354 USA; Loma Linda Univ, Sch Med, Dept Microbiol, Loma Linda, CA 92354 USA; Loma Linda Univ, Sch Med, Dept Med, Loma Linda, CA 92354 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA; Univ Turku, Abo Akad, Turku Ctr Biotechnol, Turku 20521, Finland	Loma Linda University; Loma Linda University; Loma Linda University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Abo Akademi University; University of Turku	Lilly, M (corresponding author), Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene therapy, 11085 Campus St, Loma Linda, CA 92354 USA.		Koskinen, Päivi J/G-8939-2014	Zemskova, Marina/0000-0002-1454-3714	NATIONAL CANCER INSTITUTE [R01CA045672] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA45672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; BREUER M, 1991, CANCER RES, V51, P958; Chen XP, 2002, P NATL ACAD SCI USA, V99, P2175, DOI 10.1073/pnas.042035699; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; Eichmann A, 2000, ONCOGENE, V19, P1215, DOI 10.1038/sj.onc.1203355; Feldman JD, 1998, J BIOL CHEM, V273, P16535, DOI 10.1074/jbc.273.26.16535; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Lilly M, 1997, CANCER RES, V57, P5348; LILLY M, 1992, ONCOGENE, V7, P727; Maita H, 2000, EUR J BIOCHEM, V267, P5168, DOI 10.1046/j.1432-1327.2000.01585.x; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Pircher TJ, 2000, ONCOGENE, V19, P3684, DOI 10.1038/sj.onc.1203684; Rainio EM, 2002, J IMMUNOL, V168, P1524, DOI 10.4049/jimmunol.168.4.1524; Salomoni P, 2000, BLOOD, V96, P676; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; She QB, 2002, J BIOL CHEM, V277, P24039, DOI 10.1074/jbc.M109907200; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Wang ZP, 2001, ARCH BIOCHEM BIOPHYS, V390, P9, DOI 10.1006/abbi.2001.2370	30	215	229	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45358	45367		10.1074/jbc.M307933200	http://dx.doi.org/10.1074/jbc.M307933200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954615	hybrid			2022-12-25	WOS:000186452300039
J	Wang, J; Galgoci, A; Kodali, S; Herath, KB; Jayasuriya, H; Dorso, K; Vicente, F; Gonzalez, A; Cully, D; Bramhill, D; Singh, S				Wang, J; Galgoci, A; Kodali, S; Herath, KB; Jayasuriya, H; Dorso, K; Vicente, F; Gonzalez, A; Cully, D; Bramhill, D; Singh, S			Discovery of a small molecule that inhibits cell division by blocking FtsZ, a novel therapeutic target of antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; LOCALIZATION; PROTEIN; POLYMERIZATION; TUBULIN; SEPTUM; GENES; VIRIDITOXIN; HOMOLOG; ZIPA	The emergence of bacterial resistance to antibiotics is a major health problem and, therefore, it is critical to develop new antibiotics with novel modes of action. FtsZ, a tubulin-like GTPase, plays an essential role in bacterial cell division, and its homologs are present in almost all eubacteria and archaea. During cell division, FtsZ forms polymers in the presence of GTP that recruit other division proteins to make the cell division apparatus. Therefore, inhibition of FtsZ polymerization will prevent cells from dividing, leading to cell death. Using a fluorescent FtsZ polymerization assay, the screening of >100,000 extracts of microbial fermentation broths and plants followed by fractionation led to the identification of viriditoxin, which blocked FtsZ polymerization with an IC50 of 8.2 mug/ml and concomitant GTPase inhibition with an IC50 of 7.0 mug/ml. That the mode of antibacterial action of viriditoxin is via inhibition of FtsZ was confirmed by the observation of its effects on cell morphology, macromolecular synthesis, DNA-damage response, and increased minimum inhibitory concentration as a result of an increase in the expression of the FtsZ protein. Viriditoxin exhibited broad-spectrum antibacterial activity against clinically relevant Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci, without affecting the viability of eukaryotic cells.	Merck Res Labs, Dept Human & Anim Infect Dis, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Wang, J (corresponding author), Merck & Co Inc, POB 2000,R80Y-205, Rahway, NJ 07065 USA.	jun_wang2@merck.com	vicente, francisca/N-5126-2014	vicente, francisca/0000-0003-3198-9205				Addinall SG, 1997, MOL MICROBIOL, V25, P303, DOI 10.1046/j.1365-2958.1997.4641833.x; Addinall SG, 1996, J BACTERIOL, V178, P7167, DOI 10.1128/jb.178.24.7167-7172.1996; Akerley BJ, 2002, P NATL ACAD SCI USA, V99, P966, DOI 10.1073/pnas.012602299; BARONDESS JJ, 1991, RES MICROBIOL, V142, P295, DOI 10.1016/0923-2508(91)90044-B; BEGG KJ, 1995, J BACTERIOL, V177, P6211, DOI 10.1128/jb.177.21.6211-6222.1995; BI E, 1991, RES MICROBIOL, V142, P249, DOI 10.1016/0923-2508(91)90037-B; Bramhill D, 1997, ANNU REV CELL DEV BI, V13, P395, DOI 10.1146/annurev.cellbio.13.1.395; Buddelmeijer N, 1998, J BACTERIOL, V180, P6107; Chen JC, 1999, J BACTERIOL, V181, P521, DOI 10.1128/JB.181.2.521-530.1999; DAI K, 1991, J BACTERIOL, V173, P3500, DOI 10.1128/jb.173.11.3500-3506.1991; DEWAR SJ, 1993, J BACTERIOL, V175, P7097, DOI 10.1128/jb.175.21.7097-7101.1993; Erickson HP, 1997, TRENDS CELL BIOL, V7, P362, DOI 10.1016/S0962-8924(97)01108-2; Forsyth RA, 2002, MOL MICROBIOL, V43, P1387, DOI 10.1046/j.1365-2958.2002.02832.x; Ghigo JM, 1999, MOL MICROBIOL, V31, P725, DOI 10.1046/j.1365-2958.1999.01213.x; Hale CA, 1997, CELL, V88, P175, DOI 10.1016/S0092-8674(00)81838-3; HOOD RD, 1976, FOOD COSMET TOXICOL, V14, P175, DOI 10.1016/S0015-6264(76)80419-1; HUISMAN O, 1983, J BACTERIOL, V153, P169, DOI 10.1128/JB.153.1.169-175.1983; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Ji YD, 2001, SCIENCE, V293, P2266, DOI 10.1126/science.1063566; KHATTAR MM, 1994, J BACTERIOL, V176, P7140, DOI 10.1128/JB.176.23.7140-7147.1994; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; Liu Z, 1999, MOL MICROBIOL, V31, P1853, DOI 10.1046/j.1365-2958.1999.01322.x; Miller JH, 1972, EXPT MOL GENETICS, P201; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Romberg L, 2001, J BIOL CHEM, V276, P11743, DOI 10.1074/jbc.M009033200; Ross EM, 1999, CRC METH SIG TRANS, P123; Rothfield L, 1999, ANNU REV GENET, V33, P423, DOI 10.1146/annurev.genet.33.1.423; Sossong TM, 1999, BIOCHEMISTRY-US, V38, P14843, DOI 10.1021/bi990917e; SUZUKI K, 1990, CHEM PHARM BULL, V38, P3180, DOI 10.1248/cpb.38.3180; Trusca D, 1998, J BACTERIOL, V180, P3946, DOI 10.1128/JB.180.15.3946-3953.1998; Trusca D, 2002, ANAL BIOCHEM, V307, P322, DOI 10.1016/S0003-2697(02)00036-2; Wang L, 1998, J BACTERIOL, V180, P2810, DOI 10.1128/JB.180.11.2810-2816.1998; WEISLEDER D, 1971, TETRAHEDRON LETT, P4705; Weiss DS, 1999, J BACTERIOL, V181, P508, DOI 10.1128/JB.181.2.508-520.1999; YOUNG K, 1991, J BACTERIOL, V173, P3609, DOI 10.1128/JB.173.12.3609-3614.1991	36	156	165	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44424	44428		10.1074/jbc.M307625200	http://dx.doi.org/10.1074/jbc.M307625200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12952956	hybrid			2022-12-25	WOS:000186306700069
J	Kopitz, J; Andre, S; von Reitzenstein, C; Versluis, K; Kaltner, H; Pieters, RJ; Wasano, K; Kuwabara, I; Liu, FT; Cantz, M; Heck, AJR; Gabius, HJ				Kopitz, J; Andre, S; von Reitzenstein, C; Versluis, K; Kaltner, H; Pieters, RJ; Wasano, K; Kuwabara, I; Liu, FT; Cantz, M; Heck, AJR; Gabius, HJ			Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells	ONCOGENE			English	Article						apoptosis; cell growth; galectin; ganglioside; mass spectrometry; neuroblastoma	CARBOHYDRATE-BINDING PROTEINS; TOXIN B-SUBUNIT; MEMBRANE GANGLIOSIDE SIALIDASE; ADHERENS JUNCTION PROTEIN; ANIMAL LECTINS; ENDOGENOUS LECTINS; MASS-SPECTROMETRY; PLASMA-MEMBRANE; TUMOR BIOLOGY; HUMAN GLIOMAS	The extracellular functions of galectin-7 (p53-induced gene 1) are largely unknown. On the surface of neuroblastoma cells (SK-N-MC), the increased GM(1) density, a result of upregulated ganglioside sialidase activity, is a key factor for the switch from proliferation to differentiation. We show by solid-phase and cell assays that the sugar chain of this ganglioside is a ligand for galectin-7. In serum-supplemented proliferation assays, galectin-7 reduced neuroblastoma cell growth without the appearance of features characteristic for classical apoptosis. The presence of galectin-3 blocked this effect, which mechanistically resembles that of galectin-1. By virtue of carbohydrate binding, galectin-7 thus exerts neuroblastoma growth control similar to galectin-1 despite their structural differences. In addition to p53-linked proapoptotic activity intracellularly, galectin-7, acting as a lectin on the cell surface, appears to be capable of reducing cancer cell proliferation in susceptible systems.	Univ Heidelberg Klinikum, Inst Mol Pathol, D-69120 Heidelberg, Germany; Univ Munich, Tierarztliche Fak, Inst Physiol Chem, D-80539 Munich, Germany; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Biomol Mass Spectrometry, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Med Chem, NL-3508 TB Utrecht, Netherlands; Kyushu Univ, Fac Med, Dept Anat & Cell Biol, Fukuoka 8120054, Japan; Univ Calif Davis, Sch Med, Dept Dermatol, Sacramento, CA 95817 USA	Ruprecht Karls University Heidelberg; University of Munich; Utrecht University; Utrecht University; Utrecht University; Kyushu University; University of California System; University of California Davis	Kopitz, J (corresponding author), Univ Heidelberg Klinikum, Inst Mol Pathol, Neuenheimer Feld 220, D-69120 Heidelberg, Germany.	juergen_kopitz@med.uni-heidelberg.de	Heck, Albert/D-7098-2011; Pieters, Roland J/A-9254-2008; Liu, FU-TONG/A-5749-2019	Heck, Albert/0000-0002-2405-4404; Pieters, Roland J/0000-0003-4723-3584; Liu, FU-TONG/0000-0002-3354-1001; Kaltner, Herbert/0000-0003-4680-8411; Andre, Sabine/0000-0003-0850-0432; Gabius, Hans-Joachim/0000-0003-3467-3900				AGRWAL N, 1993, J BIOL CHEM, V268, P14932; Ahmad N, 2002, CAN J CHEM, V80, P1096, DOI 10.1139/V02-162; Aman AT, 2001, P NATL ACAD SCI USA, V98, P8536, DOI 10.1073/pnas.161273098; Andre S, 2000, PHARMACEUT RES, V17, P985, DOI 10.1023/A:1007535506705; Andre S, 1999, J CANCER RES CLIN, V125, P461, DOI 10.1007/s004320050303; Andre S, 2001, CHEMBIOCHEM, V2, P822, DOI 10.1002/1439-7633(20011105)2:11<822::AID-CBIC822>3.0.CO;2-W; Andre S, 1997, BIOCONJUGATE CHEM, V8, P845, DOI 10.1021/bc970164d; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Bernerd F, 1999, P NATL ACAD SCI USA, V96, P11329, DOI 10.1073/pnas.96.20.11329; Borriello A, 2002, HAEMATOLOGICA, V87, P196; Brewer CF, 2002, BBA-GEN SUBJECTS, V1572, P255, DOI 10.1016/S0304-4165(02)00312-4; Camby I, 2002, J NEUROPATH EXP NEUR, V61, P585, DOI 10.1093/jnen/61.7.585; Camby I, 2001, BRAIN PATHOL, V11, P12; CHIU ML, 1992, J CELL BIOL, V119, P1689, DOI 10.1083/jcb.119.6.1689; CHIU ML, 1994, J BIOL CHEM, V269, P31770; Cooper DNW, 2002, BBA-GEN SUBJECTS, V1572, P209, DOI 10.1016/S0304-4165(02)00310-0; Danguy A, 2002, BBA-GEN SUBJECTS, V1572, P285, DOI 10.1016/S0304-4165(02)00315-X; Dobo A, 2001, ANAL CHEM, V73, P4763, DOI 10.1021/ac010713f; Elad-Sfadia G, 2002, J BIOL CHEM, V277, P37169, DOI 10.1074/jbc.M205698200; FRIGERI LG, 1990, J BIOL CHEM, V265, P20763; Gabius HJ, 2000, NATURWISSENSCHAFTEN, V87, P108, DOI 10.1007/s001140050687; GABIUS HJ, 1990, ANAL BIOCHEM, V189, P91, DOI 10.1016/0003-2697(90)90050-J; GABIUS HJ, 1987, CANCER INVEST, V5, P39, DOI 10.3109/07357908709020305; Gabius HJ, 2002, BBA-GEN SUBJECTS, V1572, P165, DOI 10.1016/S0304-4165(02)00306-9; Gabius HJ, 2001, BIOCHIMIE, V83, P659, DOI 10.1016/S0300-9084(01)01311-6; Gabius HJ, 2001, ANAT HISTOL EMBRYOL, V30, P3, DOI 10.1046/j.1439-0264.2001.00305.x; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; GABIUS S, 1990, BIOCHEM BIOPH RES CO, V169, P239, DOI 10.1016/0006-291X(90)91459-6; Gauthier L, 2002, P NATL ACAD SCI USA, V99, P13014, DOI 10.1073/pnas.202323999; Giudicelli V, 1997, GLYCOBIOLOGY, V7, pR8; Gunnersen JM, 2000, GLIA, V32, P146, DOI 10.1002/1098-1136(200011)32:2<146::AID-GLIA40>3.3.CO;2-V; Hadari YR, 2000, J CELL SCI, V113, P2385; Hakamori S, 1998, ACTA ANAT, V161, P79; Hippo Y, 2001, CANCER RES, V61, P889; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P23648; Hirabayashi J, 1997, TRENDS GLYCOSCI GLYC, V9, P1; Horie H, 2000, NEUROSCI RES, V38, P131, DOI 10.1016/S0168-0102(00)00142-5; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Itzkowitz SH, 1997, GASTROENTEROLOGY, V113, P2003; Kaltner H, 1998, ACTA ANAT, V161, P162; Kayser K, 2001, J PATHOL, V193, P175, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH772>3.0.CO;2-T; Kilpatrick DC, 2002, BBA-GEN SUBJECTS, V1572, P187, DOI 10.1016/S0304-4165(02)00308-2; Kitanaka C, 2002, J NATL CANCER I, V94, P358; KOHNKEGODT B, 1989, BIOCHEMISTRY-US, V28, P6531, DOI 10.1021/bi00442a001; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; Kopitz J, 1997, EUR J CELL BIOL, V73, P1; Kopitz J, 1996, GLYCOBIOLOGY, V6, P367, DOI 10.1093/glycob/6.3.367; KOPITZ J, 1994, BIOCHEM BIOPH RES CO, V199, P1188, DOI 10.1006/bbrc.1994.1356; Kopitz J, 2001, J BIOL CHEM, V276, P35917, DOI 10.1074/jbc.M105135200; Kuwabara I, 2002, J BIOL CHEM, V277, P3487, DOI 10.1074/jbc.M109360200; Lahm H, 2001, J CANCER RES CLIN, V127, P375, DOI 10.1007/s004320000207; Leonidas DD, 1998, BIOCHEMISTRY-US, V37, P13930, DOI 10.1021/bi981056x; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; LIU FT, 2000, LECTINS PATHOLOGY, P51; Lu JX, 1997, MOL CARCINOGEN, V20, P204, DOI 10.1002/(SICI)1098-2744(199710)20:2<204::AID-MC7>3.0.CO;2-M; Lutomski D, 1997, GLYCOBIOLOGY, V7, P1193, DOI 10.1093/glycob/7.8.1193; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; Magnaldo T, 1998, DIFFERENTIATION, V63, P159, DOI 10.1046/j.1432-0436.1998.6330159.x; MAGNALDO T, 1995, DEV BIOL, V168, P259, DOI 10.1006/dbio.1995.1078; Matsushita N, 2000, J BIOL CHEM, V275, P8355, DOI 10.1074/jbc.275.12.8355; Nagy N, 2002, GUT, V50, P392, DOI 10.1136/gut.50.3.392; Nangia-Makker P, 2000, CANCER METAST REV, V19, P51, DOI 10.1023/A:1026540129688; OCHIENG J, 1993, BIOCHEMISTRY-US, V32, P4455, DOI 10.1021/bi00067a038; OHANNESIAN DW, 1997, GLYCOSCIENCES STATUS, P459; OUTENREATH RL, 1992, J NEUROCYTOL, V21, P788, DOI 10.1007/BF01237904; Park JW, 2001, NUCLEIC ACIDS RES, V29, P3595, DOI 10.1093/nar/29.17.3595; Paz A, 2001, ONCOGENE, V20, P7486, DOI 10.1038/sj.onc.1204950; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; POWELL JT, 1984, BIOCHEM J, V223, P769, DOI 10.1042/bj2230769; Puche AC, 1996, DEV BIOL, V179, P274, DOI 10.1006/dbio.1996.0257; Rabinovich GA, 2002, BBA-GEN SUBJECTS, V1572, P274, DOI 10.1016/S0304-4165(02)00314-8; Rappl G, 2002, LEUKEMIA, V16, P840, DOI 10.1038/sj.leu.2402438; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; Reuter G, 1999, CELL MOL LIFE SCI, V55, P368, DOI 10.1007/s000180050298; Rodighiero C, 2001, J BIOL CHEM, V276, P36939, DOI 10.1074/jbc.M104245200; Rodriguez JA, 2001, J NEUROSCI, V21, P8387, DOI 10.1523/JNEUROSCI.21-21-08387.2001; ROFF CF, 1983, J BIOL CHEM, V258, P657; Rorive S, 2001, GLIA, V33, P241, DOI 10.1002/1098-1136(200103)33:3<241::AID-GLIA1023>3.0.CO;2-1; Sato M, 2002, J BIOCHEM, V131, P255, DOI 10.1093/oxfordjournals.jbchem.a003096; SHAPER NL, 2000, CARBOHYDRATES CHEM 2, P175; Simmons DA, 2002, BIOCHEMISTRY-US, V41, P1906, DOI 10.1021/bi011697j; Solis D, 2001, CELLS TISSUES ORGANS, V168, P5, DOI 10.1159/000016802; Timmons PM, 1999, INT J DEV BIOL, V43, P229; van den Bremer ETJ, 2002, PROTEIN SCI, V11, P1738, DOI 10.1110/ps.0200502; van Dongen WD, 2000, ANALYST, V125, P583, DOI 10.1039/a907957b; Varela PF, 1999, J MOL BIOL, V294, P537, DOI 10.1006/jmbi.1999.3273; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Vrasidas I, 2001, EUR J ORG CHEM, V2001, P4685; Wasano K, 1999, J HISTOCHEM CYTOCHEM, V47, P75, DOI 10.1177/002215549904700108; Wollina U, 2002, J CANCER RES CLIN, V128, P103, DOI 10.1007/s00432-001-0304-3; WOO HJ, 1991, J BIOL CHEM, V266, P18419; Wu AM, 2002, BIOCHEM J, V367, P653, DOI 10.1042/BJ20020600; Yamaoka K, 2000, J NEUROSCI RES, V59, P722, DOI 10.1002/(SICI)1097-4547(20000315)59:6<722::AID-JNR4>3.0.CO;2-H; Yamaoka K., 1993, LECTINS GLYCOBIOLOGY, P492	95	131	136	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6277	6288		10.1038/sj.onc.1206631	http://dx.doi.org/10.1038/sj.onc.1206631			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679866				2022-12-25	WOS:000185506200017
J	Yin, XY; Giap, C; Lazo, JS; Prochownik, EV				Yin, XY; Giap, C; Lazo, JS; Prochownik, EV			Low molecular weight inhibitors of Myc-Max interaction and function	ONCOGENE			English	Article						mad; bHLH proteins; leucine zipper proteins; yeast two-hybrid assay	C-MYC; ORNITHINE-DECARBOXYLASE; DNA-BINDING; ID PROTEINS; GENE; EXPRESSION; GROWTH; APOPTOSIS; TARGET; CELLS	c-Myc is helix - loop - helix - leucine zipper (HLH-ZIP) oncoprotein that is frequently deregulated in human cancers. In order to bind DNA, regulate target gene expression, and function in a biological context, c-Myc must dimerize with another HLH - ZIP protein, Max. A large number of c-Myc target genes have been identified, and many of the encoded proteins are transforming. Such functional redundancy, however, complicates therapeutic strategies aimed at inhibiting any single target gene product. Given this consideration, we have instead attempted to identify ways by which c-Myc itself could be effectively disabled. We have used a yeast two-hybrid approach to identify low-molecular-weight compounds that inhibit c-Myc - Max association. All of the compounds prevented transactivation by c-Myc - Max heterodimers,inhibited cell cycle progression, and prevented the in vitro growth of fibroblasts in a c-Myc-dependent manner. Several of the compounds also inhibited tumor growth in vivo. These results show that the yeast two-hybrid screen is useful for identifying compounds that can be exploited in mammalian cells. More specifically, they provide a means by which structural analogs, based upon these first-generation Myc-Max inhibitors, can be developed to enhance antitumor efficacy.	Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Pittsburgh, PA 15213 USA; Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Room 2100,3460 5th Ave, Pittsburgh, PA 15213 USA.	edward_prochownik@poplar.chp.edu			NATIONAL CANCER INSTITUTE [U01CA052995, U19CA052995] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NCI NIH HHS [P12 CA52995] Funding Source: Medline; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bai C, 1996, METHOD ENZYMOL, V273, P331; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENGAL E, 1994, P NATL ACAD SCI USA, V91, P6221, DOI 10.1073/pnas.91.13.6221; Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 1999, MOL CELL BIOL, V19, P1; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Ebinuma H, 2001, J CELL PHYSIOL, V188, P56, DOI 10.1002/jcp.1195; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Guo QM, 2000, CANCER RES, V60, P5922; Hasskarl J, 2002, CANCER BIOL THER, V1, P91, DOI 10.4161/cbt.50; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; KIMURA S, 1995, CANCER RES, V55, P1379; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANANTWERP ME, 1992, P NATL ACAD SCI USA, V89, P9010, DOI 10.1073/pnas.89.19.9010; VanWardenburg RCAM, 1997, INT J CANCER, V73, P544, DOI 10.1002/(SICI)1097-0215(19971114)73:4<544::AID-IJC15>3.3.CO;2-C; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wechsler DS, 1997, CANCER RES, V57, P4905; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Yin XY, 2002, J BIOL CHEM, V277, P19998, DOI 10.1074/jbc.M200860200; Yin XY, 2001, CANCER RES, V61, P6487; Yin XY, 1999, ONCOGENE, V18, P6621, DOI 10.1038/sj.onc.1203097; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	47	330	351	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6151	6159		10.1038/sj.onc.1206641	http://dx.doi.org/10.1038/sj.onc.1206641			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679853				2022-12-25	WOS:000185506200004
J	Gales, C; Sanchez, D; Poirot, M; Pyronnet, S; Buscail, L; Cussac, D; Pradayrol, L; Fourmy, D; Silvente-Poirot, S				Gales, C; Sanchez, D; Poirot, M; Pyronnet, S; Buscail, L; Cussac, D; Pradayrol, L; Fourmy, D; Silvente-Poirot, S			High tumorigenic potential of a constitutively active mutant of the cholecystokinin 2 receptor	ONCOGENE			English	Article						CCK2R; constitutively active mutant; gastrin; cancer; nude mice	PROTEIN-COUPLED RECEPTOR; SARCOMA-ASSOCIATED HERPESVIRUS; ORNITHINE DECARBOXYLASE; KAPOSIS-SARCOMA; B RECEPTOR; STRUCTURAL INSTABILITY; CELL-TRANSFORMATION; B/GASTRIN RECEPTOR; ASPARTIC-ACID; ACTIVATION	The cholecystokinin 2 receptor (CCK2R) increases proliferation of normal and neoplastic gastrointestinal cells and activates various mitogenic signaling pathways when stimulated by gastrin. To study the incidence of permanent activation of this receptor in tumorigenicity, a constitutively active mutant was generated by replacing residue Glu151 in the conserved E/DRY motif by Ala. Expression of the E151A-CCK2R mutant in NIH-3T3 cells causes ligand-independent activation of phospholipase C and ornithine decarboxylase, two enzymes critical for mitogenesis. Strikingly, the constitutive activity of this mutant was associated with dramatic alteration of NIH-3T3 cell morphology, enhanced cell proliferation and invasion. Moreover, injection of cells expressing E151A-CCK2R in nude mice resulted in the development of large and rapidly growing tumors. By contrast, none of these effects was observed with cells expressing the wildtype CCK2R, indicating that the tumorigenic properties of the E151A-CCK2R mutant is the result of its constitutive activation. To date, this is the first report that provides evidence for the high tumorigenic effect of a constitutively active CCK2R mutant, thus raising a potential role of the CCK2R in human cancer.	Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, F-31052 Toulouse, France; CHU Rangueil, Inst Louis Bugnard, INSERM, U531, F-31403 Toulouse, France; CHU Rangueil, Inst Louis Bugnard, INSERM, U388, F-31403 Toulouse, France	UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Silvente-Poirot, S (corresponding author), Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, 20-24 Rue Pont St Pierre, F-31052 Toulouse, France.	poirot_s@icr.fnclcc.fr	Fourmy, Daniel/AAE-3703-2019; Cussac, Daniel/AAP-1544-2020; Pyronnet, Stéphane/P-2419-2014; Poirot, Sandrine/D-5448-2017; Poirot, Marc/C-7613-2009; Poirot, Marc/K-3551-2012	Fourmy, Daniel/0000-0001-9910-4827; Poirot, Marc/0000-0002-5711-6624; Poirot, Marc/0000-0002-5711-6624; GALES, Celine/0000-0002-4938-1583; Cussac, Daniel/0000-0002-7227-898X; Silvente-Poirot, Sandrine/0000-0003-2245-9069				ALBINI A, 1987, CANCER RES, V47, P3239; Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Auvinen M, 1997, CANCER RES, V57, P3016; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Burger M, 1999, J IMMUNOL, V163, P2017; Caplin M, 2000, BRIT J SURG, V87, P1035, DOI 10.1046/j.1365-2168.2000.01488.x; Clerc P, 2002, GASTROENTEROLOGY, V122, P428, DOI 10.1053/gast.2002.30984; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Ding WQ, 2002, CANCER RES, V62, P947; Estep RD, 2003, J VIROL, V77, P1738, DOI 10.1128/JVI.77.3.1738-1746.2003; FOURMY D, 1989, EUR J BIOCHEM, V185, P397, DOI 10.1111/j.1432-1033.1989.tb15128.x; Gales C, 2000, J BIOL CHEM, V275, P17321, DOI 10.1074/jbc.M909801199; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Hellmich MR, 2000, J BIOL CHEM, V275, P32122, DOI 10.1074/jbc.M005754200; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; Hunyady L, 2003, TRENDS PHARMACOL SCI, V24, P81, DOI 10.1016/S0165-6147(02)00050-0; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; MELCHIORI A, 1990, ANTICANCER RES, V10, P37; Morin D, 1998, FEBS LETT, V441, P470, DOI 10.1016/S0014-5793(98)01585-3; MORODER L, 1981, H-S Z PHYSIOL CHEM, V362, P929, DOI 10.1515/bchm2.1981.362.2.929; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Pagliocca A, 2002, AM J PHYSIOL-GASTR L, V283, pG292, DOI 10.1152/ajpgi.00056.2002; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Parnot C, 2002, TRENDS ENDOCRIN MET, V13, P336, DOI 10.1016/S1043-2760(02)00628-8; Pohl M, 1997, J BIOL CHEM, V272, P18179, DOI 10.1074/jbc.272.29.18179; Pyronnet S, 1998, ONCOGENE, V16, P2219, DOI 10.1038/sj.onc.1201748; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Reubi JC, 1997, CANCER RES, V57, P1377; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Samama P, 1997, P NATL ACAD SCI USA, V94, P137, DOI 10.1073/pnas.94.1.137; SCEMAMA JL, 1989, AM J PHYSIOL, V256, pG846, DOI 10.1152/ajpgi.1989.256.5.G846; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Schmitz F, 2001, EUR J CLIN INVEST, V31, P812, DOI 10.1046/j.1365-2362.2001.00870.x; Silvente-Poirot S, 1999, J BIOL CHEM, V274, P23191, DOI 10.1074/jbc.274.33.23191; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; Smith AM, 2000, GUT, V47, P820, DOI 10.1136/gut.47.6.820; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG1363, DOI 10.1152/ajpgi.1999.276.6.G1363; TODISCO A, 1995, J BIOL CHEM, V270, P28337; WANG SA, 1998, AM J PHYSIOL, V274, pG607; Whitehead IP, 2001, ONCOGENE, V20, P1547, DOI 10.1038/sj.onc.1204188; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	50	27	27	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6081	6089		10.1038/sj.onc.1206823	http://dx.doi.org/10.1038/sj.onc.1206823			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955087				2022-12-25	WOS:000185137800017
J	Hickery, MS; Bayliss, MT; Dudhia, J; Lewthwaite, JC; Edwards, JCW; Pitsillides, AA				Hickery, MS; Bayliss, MT; Dudhia, J; Lewthwaite, JC; Edwards, JCW; Pitsillides, AA			Age-related changes in the response of human articular cartilage to IL-1 alpha and transforming growth factor-beta (TGF-beta) - Chondrocytes exhibit a diminished sensitivity to TGF-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHOGLUCOSE DEHYDROGENASE-ACTIVITY; CHONDROITIN SULFATE; PROTEOGLYCAN METABOLISM; KERATAN SULFATES; INTERLEUKIN-1; BIOSYNTHESIS; OSTEOARTHRITIS; EXPRESSION; AGGRECAN; PROTEIN	Cartilage glycosaminoglycan (GAG) synthesis and composition, upon which its structural integrity depends, varies with age, is modified by anabolic and catabolic stimuli, and is regulated by UDP-glucuronate availability. However, how such stimuli, prototypically represented by transforming growth factor-beta1 (TGF-beta1) and IL-1alpha, modify GAG synthesis during aging of normal human articular cartilage is not known. Using explants, we show that chondroitin sulfate (CS): total GAG ratios decrease, whereas C6S:C4S ratios increase with cartilage maturation, and that chondrocytes in the cartilage mid-zone, but not the superficial or deep zones, exhibit uridine 5'-diphosphoglucose dehydrogenase (UDPGD) activity, which is also increased in mature cartilage. We also show that IL-1alpha treatment reduces both total GAG and CS synthesis, decreases C6S: C4S ratios (less C6S), but fails to modify chondrocyte UDPGD activity at all ages. On the other hand, TGF-beta1 increases total GAG synthesis in immature, but not mature, cartilage (stimulates CS but not non-CS), age-independently decreases C6S:C4S (more C4S), and increases chondrocyte UDPGD activity in a manner inversely correlated with age. Our findings show that TGF-beta1, but not IL-1alpha, modifies matrix synthesis such that its composition more closely resembles "less mature" articular cartilage. These effects of TGF-beta1, which appear to be restricted to periods of skeletal immaturity, are closely associated although not necessarily mechanistically linked with increases in chondrocyte UDPGD activity. The antianabolic effects of IL-1alpha are, on the other hand, likely to be independent of any direct modification in UDPGD activity and manifest equally in human cartilage of all ages.	Univ London Royal Vet Coll, Dept Vet Basic Sci, London NW1 0TU, England; Dept Cell & Mol Biol, Sect Connect Tissue Res, S-22184 Lund, Sweden; UCL, Sch Med, Dept Rheumatol, London W1P 9PG, England	University of London; University of London Royal Veterinary College; University of London; University College London; UCL Medical School	Bayliss, MT (corresponding author), Univ London Royal Vet Coll, Dept Vet Basic Sci, 32 Belgrave Sq, London NW1 0TU, England.	apitsill@rvc.ac.uk		Dudhia, Jayesh/0000-0002-2503-697X				ALTMANN FP, 1965, NATURE, V207, P1205, DOI 10.1038/2071205a0; Archer CW, 1996, J ANAT, V189, P23; BALDUINI C, 1989, KERATAN SULPHATE CHE, P53; Bayliss MT, 1999, J BIOL CHEM, V274, P15892, DOI 10.1074/jbc.274.22.15892; BAYLISS MT, BIOCH J, V176, P683; Bolton MC, 1996, BIOCHEM J, V319, P489, DOI 10.1042/bj3190489; BROCKLEHURST R, 1984, J BONE JOINT SURG AM, V66A, P95, DOI 10.2106/00004623-198466010-00013; Brown MP, 1998, AM J VET RES, V59, P786; BUSCHMANN MD, 1995, J BIOMECH ENG-T ASME, V117, P179, DOI 10.1115/1.2796000; CALABRO A, 2000, PROTEOGLYCANS STRUCT, P5; CASTELLANI AA, 1984, ITAL J BIOCHEM, V33, pA240; CASTELLANI AA, 1986, ITAL J BIOCHEM, V35, P296; CHAYEN J, 1984, BIOCHEM SOC T, V12, P887, DOI 10.1042/bst0120887; COMPER WD, 1978, PHYSIOL REV, V58, P255, DOI 10.1152/physrev.1978.58.1.255; CSSZABO G, 1995, ARTHRITIS RHEUM, V38, P660, DOI 10.1002/art.1780380514; DELUCA G, 1984, ACTA BIOL HUNG, V35, P109; Doege KJ, 1997, J BIOL CHEM, V272, P13974, DOI 10.1074/jbc.272.21.13974; Goldring MB, 2000, ARTHRITIS RHEUM-US, V43, P1916, DOI 10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I; Hacker U, 1997, DEVELOPMENT, V124, P3565; HANDLEY CJ, 1972, BIOCHEM J, V126, P417, DOI 10.1042/bj1260417; HANDLEY CJ, 1990, METHODS CARTILAGE RE, P105; HARDINGHAM T, 1990, SEMIN ARTHRITIS RHEU, V20, P12, DOI 10.1016/0049-0172(90)90044-G; HARDINGHAM TE, 1995, J RHEUMATOL, V22, P86; Hickery MS, 1998, BBA-GEN SUBJECTS, V1425, P282, DOI 10.1016/S0304-4165(98)00080-4; Hirose J, 2000, ARTHRITIS RHEUM, V43, P2703, DOI 10.1002/1529-0131(200012)43:12<2703::AID-ANR10>3.0.CO;2-Y; Kavanagh E, 2002, J HISTOCHEM CYTOCHEM, V50, P1039, DOI 10.1177/002215540205000806; Loeser RF, 2000, ARTHRITIS RHEUM, V43, P2110, DOI 10.1002/1529-0131(200009)43:9<2110::AID-ANR23>3.0.CO;2-U; Maroudas, 1979, ADULT ARTICULAR CART, P219; MEHDIZADEH S, 1991, CELL BIOCHEM FUNCT, V9, P103, DOI 10.1002/cbf.290090207; MOLZ RJ, 1971, BIOCHIM BIOPHYS ACTA, V250, P6, DOI 10.1016/0005-2744(71)90114-8; MORALES TI, 1989, ARTHRITIS RHEUM-US, V32, P1197, DOI 10.1002/anr.1780321003; MORALES TI, 1994, ARCH BIOCHEM BIOPHYS, V315, P190, DOI 10.1006/abbi.1994.1489; MORALES TI, 1989, CONNECT TISSUE RES, V19, P255, DOI 10.3109/03008208909043900; MUIR H, 1986, COPEMANS TXB RHEUMAT, P177; NIEDUSZYNSKI IA, 1990, BIOCHEM J, V271, P243, DOI 10.1042/bj2710243; Okazaki R, 1996, ANN RHEUM DIS, V55, P181, DOI 10.1136/ard.55.3.181; PATAKI A, 1980, EXP CELL BIOL, V48, P329; PITSILLIDES AA, 1995, J HISTOCHEM CYTOCHEM, V43, P263, DOI 10.1177/43.3.7868856; PITSILLIDES AA, 1992, ANN RHEUM DIS, V51, P992, DOI 10.1136/ard.51.8.992; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; REDINI F, 1991, BIOCHIM BIOPHYS ACTA, V1093, P196, DOI 10.1016/0167-4889(91)90123-F; REDINI F, 1993, ARTHRITIS RHEUM, V36, P44; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROUGHLEY PJ, 1980, J BIOL CHEM, V255, P217; Smith P, 2000, ARTHRITIS RHEUM-US, V43, P1156, DOI 10.1002/1529-0131(200005)43:5<1156::AID-ANR26>3.0.CO;2-M; SORRELL JM, 1989, DEVELOPMENT, V106, P657; SPICER AP, 1989, J BIOL CHEM, V73, P25117; Toma L, 1996, J BIOL CHEM, V271, P3897; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; TYLER JA, 1985, BIOCHEM J, V227, P869, DOI 10.1042/bj2270869; VANBEUNINGEN HM, 1994, ANN RHEUM DIS, V53, P593, DOI 10.1136/ard.53.9.593; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; Wegrowski Y, 1998, BIOCHEM BIOPH RES CO, V250, P206, DOI 10.1006/bbrc.1998.9262; YSART GE, 1994, BIOCHEM J, V303, P713, DOI 10.1042/bj3030713; ZEBROWER M, 1991, Glycobiology, V1, P271, DOI 10.1093/glycob/1.3.271; ZEMEL E, 1989, J RHEUMATOL, V16, P825	56	53	53	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					53063	53071		10.1074/jbc.M209632200	http://dx.doi.org/10.1074/jbc.M209632200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	13679381	hybrid			2022-12-25	WOS:000187480700130
J	Cieslak, M; Szymanski, J; Adamiak, RW; Cierniewski, CS				Cieslak, M; Szymanski, J; Adamiak, RW; Cierniewski, CS			Structural Rearrangements of the 10-23 DNAzyme to beta 3 integrin subunit mRNA induced by cations and their relations to the catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; RESONANCE ENERGY-TRANSFER; CLEAVING DNA ENZYME; HAMMERHEAD RIBOZYME; CLEAVAGE REACTION; METAL-IONS; MECHANISM; DNAZYMES; BINDING; INHIBITION	The intracellular ability of the "10-23" DNAzyme to efficiently inhibit expression of targeted proteins has been evidenced by in vitro and in vivo studies. However, standard conditions for kinetic measurements of the DNAzyme catalytic activity in vitro include 25 mM Mg2+, a concentration that is very unlikely to be achieved intracellularly. To study this discrepancy, we analyzed the folding transitions of the 10 - 23 DNAzyme induced by Mg2+. For this purpose, spectroscopic analyzes such as fluorescence resonance energy transfer, fluorescence anisotropy, circular dichroism, and surface plasmon resonance measurements were performed. The global geometry of the DNAzyme in the absence of added Mg2+ seems to be essentially extended, has no catalytic activity, and shows a very low binding affinity to its RNA substrate. The folding of the DNAzyme induced by binding of Mg2+ may occur in several distinct stages. The first stage, observed at 0.5 mM Mg2+, corresponds to the formation of a compact structure with limited binding properties and without catalytic activity. Then, at 5 mM Mg2+, flanking arms are projected at right position and angles to bind RNA. In such a state, DNAzyme shows substantial binding to its substrate and significant catalytic activity. Finally, the transition occurring at 15 mM Mg2+ leads to the formation of the catalytic domain, and DNAzyme shows high binding affinity toward substrate and efficient catalytic activity. Under conditions simulating intracellular conditions, the DNAzyme was only partially folded, did not bind to its substrate, and showed only residual catalytic activity, suggesting that it may be inactive in the transfected cells and behave like antisense oligodeoxynucleotide.	Med Univ Lodz, Dept Mol & Med Biophys, PL-92215 Lodz, Poland; Polish Acad Sci, Ctr Mol & Macromol Studies, PL-92215 Lodz, Poland; Polish Acad Sci, Dept Med Biol & Microbiol, PL-92215 Lodz, Poland; Polish Acad Sci, Inst Bioorgan Chem, PL-61704 Poznan, Poland	Medical University Lodz; Polish Academy of Sciences; Centre of Molecular & Macromolecular Studies of the Polish Academy of Sciences; Polish Academy of Sciences; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences	Cierniewski, CS (corresponding author), Med Univ Lodz, Dept Mol & Med Biophys, 6-8 Mazowiecka St, PL-92215 Lodz, Poland.		Adamiak, Ryszard W/W-5089-2018; Cieslak, Marcin/ABF-2494-2020	Adamiak, Ryszard W/0000-0001-8914-9618; Cieslak, Marcin/0000-0002-9628-214X				Bassi GS, 1997, EMBO J, V16, P7481, DOI 10.1093/emboj/16.24.7481; BONDESON K, 1993, ANAL BIOCHEM, V214, P245, DOI 10.1006/abio.1993.1484; BREAKER RR, 1995, CHEM BIOL, V2, P655, DOI 10.1016/1074-5521(95)90028-4; BRUKNER I, 1994, J MOL BIOL, V236, P26, DOI 10.1006/jmbi.1994.1115; Chiu TK, 2000, J MOL BIOL, V301, P915, DOI 10.1006/jmbi.2000.4012; CIERNIEWSKI CS, 1995, EUR J BIOCHEM, V227, P494, DOI 10.1111/j.1432-1033.1995.tb20415.x; Cieslak M, 2002, J BIOL CHEM, V277, P6779, DOI 10.1074/jbc.M102325200; Clark CL, 1997, NUCLEIC ACIDS RES, V25, P4098, DOI 10.1093/nar/25.20.4098; CLEGG RM, 1993, P NATL ACAD SCI USA, V90, P2994, DOI 10.1073/pnas.90.7.2994; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; Dahlgren PR, 2002, BIOCHEMISTRY-US, V41, P11372, DOI 10.1021/bi026102e; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; Dass CR, 2002, ANTISENSE NUCLEIC A, V12, P289, DOI 10.1089/108729002761381276; FAIRALL L, 1989, EMBO J, V8, P1809, DOI 10.1002/j.1460-2075.1989.tb03575.x; He QC, 2002, BIOMACROMOLECULES, V3, P69, DOI 10.1021/bm010095c; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAFFE EA, 1976, J EXP MED, V144, P209, DOI 10.1084/jem.144.1.209; Khachigian LM, 2002, CURR OPIN MOL THER, V4, P119; KUMAR PKR, 1996, NUCL ACIDS MOL BIOL, V10, P217; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Liu CH, 2001, BIOCHEM BIOPH RES CO, V284, P1077, DOI 10.1006/bbrc.2001.5077; McKay DB, 1996, RNA, V2, P395; MOORE DS, 1974, BIOPOLYMERS, V13, P977, DOI 10.1002/bip.1974.360130512; Okumoto Y, 2000, J INORG BIOCHEM, V82, P189, DOI 10.1016/S0162-0134(00)00159-8; Ota N, 1998, NUCLEIC ACIDS RES, V26, P3385, DOI 10.1093/nar/26.14.3385; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; Santoro SW, 1998, BIOCHEMISTRY-US, V37, P13330, DOI 10.1021/bi9812221; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; Scott WG, 1996, SCIENCE, V274, P2065, DOI 10.1126/science.274.5295.2065; Scott WG, 1996, TRENDS BIOCHEM SCI, V21, P220; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SOYFER VN, 1966, TRIPLE HELICAL NUCL, P360; WELCH JB, 1993, NUCLEIC ACIDS RES, V21, P4548, DOI 10.1093/nar/21.19.4548; Zhang L, 2002, CANCER RES, V62, P5463; Zhou DM, 1996, J AM CHEM SOC, V118, P5862, DOI 10.1021/ja9606790; ZUKER M, 2003, NUCLEIC ACIDS RES, V31, P1	38	61	62	6	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47987	47996		10.1074/jbc.M300504200	http://dx.doi.org/10.1074/jbc.M300504200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12952967	hybrid			2022-12-25	WOS:000186731400077
J	Robu, VG; Pfeiffer, ES; Robia, SL; Balijepalli, RC; Pi, YQ; Kamp, TJ; Walker, JW				Robu, VG; Pfeiffer, ES; Robia, SL; Balijepalli, RC; Pi, YQ; Kamp, TJ; Walker, JW			Localization of functional endothelin receptor signaling complexes in cardiac transverse tubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; VENTRICULAR MYOCYTES; CALCIUM-RELEASE; K+ CHANNEL; EXPRESSION; DIACYLGLYCEROL; ACTIVATION; EPSILON; INCREASE; SYSTEM	Endothelin-1 (ET-1) is an autocrine factor in the mammalian heart important in enhancing cardiac performance, protecting against myocardial ischemia, and initiating the development of cardiac hypertrophy. The ETA receptor is a seven-transmembrane G-protein-coupled receptor whose precise subcellular localization in cardiac muscle is unknown. Here we used fluorescein ET-1 and I-125-ET-1 to provide evidence for ET-1 receptors in cardiac transverse tubules (T-tubules). Moreover, the ETA receptor and downstream effector phospholipase C-beta(1) were co- localized within T-tubules using standard immunofluorescence techniques, and protein kinase C (PKC)-epsilon-enhanced green fluorescent protein bound reversibly to T-tubules upon activation. Localized photorelease of diacylglycerol further suggested compartmentation of PKC signaling, with release at the myocyte "surface" mimicking the negative inotropic effects of bath-applied PKC activators and "deep" release mimicking the positive inotropic effect of ET-1. The functional significance of T-tubular ET-1 receptors was further tested by rendering the T-tubule lumen inaccessible to bath-applied ET-1. Such "detubulated" cardiac myocytes showed no positive inotropic response to 20 nM ET-1, despite retaining both a nearly normal twitch response to field stimulation and a robust positive inotropic response to 20 nM isoproterenol. We propose that ET-1 enhances myocyte contractility by activating ETA receptor-phospholipase C-beta(1)-PKC-epsilon signaling complexes preferentially localized in cardiac T-tubules. Compartmentation of ET-1 signaling complexes may explain the discordant effects of ET-1 versus bath applied PKC activators and may contribute to both the specificity and diversity of the cardiac actions of ET-1.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Univ Wisconsin, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Walker, JW (corresponding author), Univ Wisconsin, Dept Physiol, 1300 Univ Ave, Madison, WI 53706 USA.	jwalker@physiology.wisc.edu	Kamp, Timothy/ABD-1343-2020	Kamp, Timothy/0000-0003-2103-7876	PHS HHS [P01 04573] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allen BG, 2003, CAN J PHYSIOL PHARM, V81, P95, DOI 10.1139/Y02-155; ASOTRA K, 1991, BIOCHIM BIOPHYS ACTA, V1081, P229, DOI 10.1016/0005-2760(91)90030-L; Balijepalli RC, 2003, CARDIOVASC RES, V59, P67, DOI 10.1016/S0008-6363(03)00325-0; Boivin B, 2003, J BIOL CHEM, V278, P29153, DOI 10.1074/jbc.M301738200; Brette F, 2002, AM J PHYSIOL-HEART C, V283, pH1720, DOI 10.1152/ajpheart.00347.2002; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CLERK A, 1994, J BIOL CHEM, V269, P32848; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DAVENPORT AP, 2002, CLIN SCI LOND S48, V103, P1; Dobrzynski H, 2001, J HISTOCHEM CYTOCHEM, V49, P1221, DOI 10.1177/002215540104901004; ENDOH M, 1995, GEN PHARMACOL, V26, P1, DOI 10.1016/0306-3623(94)00144-C; Furuta T, 1999, P NATL ACAD SCI USA, V96, P1193, DOI 10.1073/pnas.96.4.1193; He JQ, 2000, J PHYSIOL-LONDON, V524, P807, DOI 10.1111/j.1469-7793.2000.00807.x; He JQ, 2001, CARDIOVASC RES, V49, P298, DOI 10.1016/S0008-6363(00)00256-X; HILALDANDAN R, 1994, MOL PHARMACOL, V45, P1183; Huang XP, 1996, BIOPHYS J, V70, P2448, DOI 10.1016/S0006-3495(96)79816-8; Huang XP, 1997, J CELL SCI, V110, P1625; Jones SA, 2002, AM J PHYSIOL-HEART C, V283, pH181, DOI 10.1152/ajpheart.00963.2001; Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095; Kedzierski RM, 2001, ANNU REV PHARMACOL, V41, P851, DOI 10.1146/annurev.pharmtox.41.1.851; Kobayashi T, 1999, AM J PHYSIOL-HEART C, V276, pH1197, DOI 10.1152/ajpheart.1999.276.4.H1197; Kostin S, 1998, CELL TISSUE RES, V294, P449, DOI 10.1007/s004410051196; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; Maier SKG, 2002, P NATL ACAD SCI USA, V99, P4073, DOI 10.1073/pnas.261705699; McDonald RL, 2000, EUR J BIOCHEM, V267, P5142, DOI 10.1046/j.1432-1327.2000.01579.x; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Oksche A, 2000, MOL PHARMACOL, V57, P1104; Ozcelik C, 2002, P NATL ACAD SCI USA, V99, P8880, DOI 10.1073/pnas.122249299; Parker I, 1996, J PHYSIOL-LONDON, V497, P31, DOI 10.1113/jphysiol.1996.sp021747; Pass JM, 2001, AM J PHYSIOL-HEART C, V280, pH946, DOI 10.1152/ajpheart.2001.280.3.H946; Pi YQ, 2000, AM J PHYSIOL-HEART C, V279, pH26, DOI 10.1152/ajpheart.2000.279.1.H26; Pi YQ, 1997, CIRC RES, V81, P92, DOI 10.1161/01.RES.81.1.92; Protasi F, 1996, DEV BIOL, V173, P265, DOI 10.1006/dbio.1996.0022; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; Puri TS, 1997, BIOCHEMISTRY-US, V36, P9605, DOI 10.1021/bi970500d; Robia SL, 2001, BIOPHYS J, V80, P2140, DOI 10.1016/S0006-3495(01)76187-5; Robu VG, 2002, BIOPHYS J, V82, p348A; Serneri GGN, 2000, CIRC RES, V86, P377, DOI 10.1161/01.RES.86.4.377; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Voldstedlund M, 2001, CELL TISSUE RES, V306, P265, DOI 10.1007/s004410100439; Wokosin DL, 2003, REV SCI INSTRUM, V74, P193, DOI 10.1063/1.1524716; Xiang Y, 2003, SCIENCE, V300, P1530, DOI 10.1126/science.1079206; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982	46	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48154	48161		10.1074/jbc.M304396200	http://dx.doi.org/10.1074/jbc.M304396200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12972433	hybrid			2022-12-25	WOS:000186731400097
J	Temel, RE; Gebre, AK; Parks, JS; Rudel, LL				Temel, RE; Gebre, AK; Parks, JS; Rudel, LL			Compared with Acyl-CoA : cholesterol O-acyltransferase (ACAT) 1 and lecithin : cholesterol acyltransferase, ACAT2 displays the greatest capacity to differentiate cholesterol from sitosterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SITOSTEROL; PLANT STEROLS; SUBSTRATE-SPECIFICITY; DIETARY-CHOLESTEROL; SHELLFISH STEROLS; ESTERIFICATION; ABSORPTION; METABOLISM; CELLS; TRANSPORT	The capacity of acyl-CoA:cholesterol O-acyltransferase (ACAT) 2 to differentiate cholesterol from the plant sterol, sitosterol, was compared with that of the sterol esterifying enzymes, ACAT1 and lecithin: cholesterol acyltransferase (LCAT). Cholesterol-loaded microsomes from transfected cells containing either ACAT1 or ACAT2 exhibited significantly more ACAT activity than their sitosterol-loaded counterparts. In sitosterol-loaded microsomes, both ACAT1 and ACAT2 were able to esterify sitosterol albeit with lower efficiencies than cholesterol. The mass ratios of cholesterol ester to sitosterol ester formed by ACAT1 and ACAT2 were 1.6 and 7.2, respectively. Compared with ACAT1, ACAT2 selectively esterified cholesterol even when sitosterol was loaded into the microsomes. To further characterize the difference in sterol specificity, ACAT1 and ACAT2 were compared in intact cells loaded with either cholesterol or sitosterol. Despite a lower level of ACAT activity, the ACAT1-expressing cells esterified 4-fold more sitosterol than the ACAT2 cells. The data showed that compared with ACAT1, ACAT2 displayed significantly greater selectively for cholesterol compared with sitosterol. The plasma cholesterol esterification enzyme lecithin: cholesterol acyltransferase was also compared. With recombinant high density lipoprotein particles, the esterification rate of cholesterol by LCAT was only 15% greater than for sitosterol. Thus, LCAT was able to efficiently esterify both cholesterol and sitosterol. In contrast, ACAT2 demonstrated a strong preference for cholesterol rather than sitosterol. This sterol selectivity by ACAT2 may reflect a role in the sorting of dietary sterols during their absorption by the intestine in vivo.	Wake Forest Univ, Sch Med, Dept Pathol, Comparat Med Sect, Winston Salem, NC 27157 USA	Wake Forest University	Rudel, LL (corresponding author), Wake Forest Univ, Sch Med, Dept Pathol, Comparat Med Sect, Hanes Bldg,6th Floor, Winston Salem, NC 27157 USA.	lrudel@wfubmc.edu			NHLBI NIH HHS [HL-07115, HL 49373, HL 54176, R01 HL054176, HL 24736] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024736, R01HL054176, P01HL049373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BHATTACHARYYA AK, 1981, AM J PHYSIOL, V240, pG50, DOI 10.1152/ajpgi.1981.240.1.G50; BHATTACHARYYA AK, 1979, BIOCHIM BIOPHYS ACTA, V574, P146, DOI 10.1016/0005-2760(79)90093-6; Buhman KK, 2000, NAT MED, V6, P1341, DOI 10.1038/82153; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; Chang CCY, 1998, J BIOL CHEM, V273, P35132, DOI 10.1074/jbc.273.52.35132; Chisholm JW, 1999, J LIPID RES, V40, P1512; CONNOR WE, 1981, GASTROENTEROLOGY, V81, P276; DOOLITTLE GM, 1982, BIOCHIM BIOPHYS ACTA, V713, P529, DOI 10.1016/0005-2760(82)90313-7; Field FJ, 1997, J LIPID RES, V38, P348; FIELD FJ, 1987, J LIPID RES, V28, P1057; FIELD FJ, 1983, J LIPID RES, V24, P409; GOLDSTEIN JL, 1974, P NATL ACAD SCI USA, V71, P4288, DOI 10.1073/pnas.71.11.4288; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; GREGG RE, 1986, J CLIN INVEST, V77, P1864, DOI 10.1172/JCI112513; HEINEMANN T, 1993, EUR J CLIN INVEST, V23, P827, DOI 10.1111/j.1365-2362.1993.tb00737.x; IKEDA I, 1988, J LIPID RES, V29, P1583; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Lee RG, 2000, J LIPID RES, V41, P1991; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MIETTINEN TA, 1980, EUR J CLIN INVEST, V10, P27, DOI 10.1111/j.1365-2362.1980.tb00006.x; NORDBY G, 1975, SCAND J CLIN LAB INV, V35, P677, DOI 10.3109/00365517509095797; Parks JS, 1999, METH MOL B, V109, P123; PIRAN U, 1979, LIPIDS, V14, P478, DOI 10.1007/BF02533465; SALEN G, 1970, J CLIN INVEST, V49, P952, DOI 10.1172/JCI106315; SALEN G, 1985, J LIPID RES, V26, P203; SWELL L, 1959, P SOC EXP BIOL MED, V100, P140, DOI 10.3181/00379727-100-24552; TAVANI DM, 1982, J LIPID RES, V23, P774; WILSON MD, 1994, J LIPID RES, V35, P943	30	78	83	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47594	47601		10.1074/jbc.M308235200	http://dx.doi.org/10.1074/jbc.M308235200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12975367	hybrid			2022-12-25	WOS:000186731400032
J	Tkaczyk, C; Beaven, MA; Brachman, SM; Metcalfe, DD; Gilfillan, AM				Tkaczyk, C; Beaven, MA; Brachman, SM; Metcalfe, DD; Gilfillan, AM			The phospholipase C gamma(1)-dependent pathway of Fc epsilon RI-mediated mast cell activation is regulated independently of phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; PROTEIN-KINASE-C; INCREASED INSULIN SENSITIVITY; ANTIGEN RECEPTOR; B-CELL; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; RBL-2H3 CELLS; MICE LACKING; C-GAMMA-2	Mast cell degranulation following FcepsilonRI aggregation is generally believed to be dependent on phosphatidylinositide 3-kinase (PI 3-kinase)-mediated phospholipase C (PLC) gamma activation. Here we report evidence that the PLCgamma(1)-dependent pathway of FcepsilonRI-mediated activation of mast cells is independent of PI 3-kinase activation. In primary cultures of human mast cells, FcepsilonRI aggregation induced a rapid translocation and phosphorylation of PLCgamma(1), and subsequent inositol trisphosphate (IP3) production, which preceded PI 3-kinase-related signals. In addition, although PI 3-kinase-mediated responses were completely inhibited by wortmannin, even at high concentrations, this PI 3-kinase inhibitor had no effect on parameters of FcepsilonRI-mediated PLCgamma activation, and had little effect on the initial increase in intracellular calcium levels that correlated with PLCgamma activation. Wortmannin, however, did produce a partial ( similar to 50%) concentration-dependent inhibition of FcepsilonRI-mediated degranulation in human mast cells and a partial inhibition of the later calcium response at higher concentrations. Further studies, conducted in mast cells derived from the bone marrow of mice deficient in the p85alpha and p85beta subunits of PI 3-kinase, also revealed no defects in FcepsilonRI-mediated PLCgamma(1) activation. These data are consistent with the conclusion that the PLCgamma-dependent component of FcepsilonRI-mediated calcium flux leading to degranulation of mast cells is independent of PI 3-kinase. However, PI 3-kinase may contribute to the later phase of FcepsilonRI-mediated degranulation in human mast cells.	NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Free Univ Berlin, Inst Biochem, D-1000 Berlin, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Free University of Berlin	Gilfillan, AM (corresponding author), NIAID, Lab Allerg Dis, NIH, Bldg 10,Rm 11C206,10 Ctr Dr,MSC 1881, Bethesda, MD 20892 USA.	agilfillan@niaid.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000993, ZIAHL000993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000850] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINSON TP, 1993, J IMMUNOL, V151, P1448; Barker SA, 1999, J LEUKOCYTE BIOL, V65, P321, DOI 10.1002/jlb.65.3.321; BARKER SA, 1995, MOL BIOL CELL, V6, P1145, DOI 10.1091/mbc.6.9.1145; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; Chaves-Dias C, 2001, J IMMUNOL, V166, P6647, DOI 10.4049/jimmunol.166.11.6647; Choi OH, 1996, NATURE, V380, P634; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Hiller G, 2002, CELL SIGNAL, V14, P169, DOI 10.1016/S0898-6568(01)00252-2; Hirasawa N, 2000, BBA-BIOENERGETICS, V1456, P45, DOI 10.1016/S0005-2728(99)00104-8; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Ishizuka T, 1999, J IMMUNOL, V162, P2087; Ishizuka T, 1996, J BIOL CHEM, V271, P12762, DOI 10.1074/jbc.271.22.12762; Kawakami Y, 2000, J IMMUNOL, V165, P1210, DOI 10.4049/jimmunol.165.3.1210; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Li HL, 1999, J BIOL CHEM, V274, P9812, DOI 10.1074/jbc.274.14.9812; LIN PY, 1994, BIOCHEM J, V299, P109, DOI 10.1042/bj2990109; LIN PY, 1991, J IMMUNOL, V146, P1609; LIN PY, 1992, BIOCHEM J, V287, P325, DOI 10.1042/bj2870325; Lu-Kuo JM, 2000, J BIOL CHEM, V275, P6022, DOI 10.1074/jbc.275.8.6022; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; Marquardt DL, 1996, J IMMUNOL, V156, P1942; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Okada T, 2000, IMMUNITY, V13, P817, DOI 10.1016/S1074-7613(00)00079-0; Okayama Y, 2003, EUR J IMMUNOL, V33, P1450, DOI 10.1002/eji.200323563; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Pelletier C, 1998, INFLAMM RES, V47, P493, DOI 10.1007/s000110050364; Pivniouk VI, 1999, J CLIN INVEST, V103, P1737; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Suzuki H, 1997, J IMMUNOL, V159, P5881; Suzuki H, 2003, NAT IMMUNOL, V4, P280, DOI 10.1038/ni890; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Tkaczyk C, 2002, J IMMUNOL METHODS, V268, P239, DOI 10.1016/S0022-1759(02)00210-7; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Ueki K, 2002, P NATL ACAD SCI USA, V99, P419, DOI 10.1073/pnas.012581799; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898-6568(01)00191-7; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251	47	92	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48474	48484		10.1074/jbc.M301350200	http://dx.doi.org/10.1074/jbc.M301350200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13129935	hybrid			2022-12-25	WOS:000186731400133
J	Bretscher, LE; Li, HY; Poulos, TL; Griffith, OW				Bretscher, LE; Li, HY; Poulos, TL; Griffith, OW			Structural characterization and kinetics of nitric-oxide synthase inhibition by novel N-5-(iminoalkyl)- and N-5-(iminoalkenyl)-ornithines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHLY SELECTIVE INHIBITOR; METHYL-L-ARGININE; NG-METHYLARGININE; ESCHERICHIA-COLI; MECHANISM; INACTIVATION; MACROPHAGE; BINDING; ISOFORMS; POTENT	Isoform-specific nitric-oxide synthase (NOS) inhibitors may prove clinically useful in reducing the pathophysiological effects associated with increased neuronal NOS ( nNOS) or inducible NOS (iNOS) activity in a variety of neurological and inflammatory disorders. Analogs of the NOS substrate L-arginine are pharmacologically attractive inhibitors because of their stability, reliable cell uptake, and good selectivity for NOS over other heme proteins. Some inhibitory arginine analogs show significant isoform selectivity although the structural or mechanistic basis of such selectivity is generally poorly understood. In the present studies, we determined by x-ray crystallography the binding interactions between rat nNOS and N-5-(1-imino-3-butenyl)-L-ornithine (L-VNIO), a previously identified mechanism-based, irreversible inactivator with moderate nNOS selectivity. We have also synthesized and mechanistically characterized several L-VNIO analogs and find, surprisingly, that even relatively minor structural changes produce inhibitors that are either iNOS-selective or nonselective. Furthermore, derivatives having a methyl group added to the butenyl moiety of L-VNIO and L-VNIO derivatives that are analogs of homoarginine rather than arginine display slow-on, slow-off kinetics rather than irreversible inactivation. These results elucidate some of the structural requirements for isoform-selective inhibition by L-VNIO and its related alkyl- and alkenylimino ornithine and lysine derivatives and may provide information useful in the ongoing rational design of isoform-selective inhibitors.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA	Medical College of Wisconsin; University of California System; University of California Irvine; University of California System; University of California Irvine	Griffith, OW (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.				NIDDK NIH HHS [DK 48423] Funding Source: Medline; NIGMS NIH HHS [GM 57353] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057353] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AISAKA K, 1989, BIOCHEM BIOPH RES CO, V160, P881, DOI 10.1016/0006-291X(89)92517-5; Babu BR, 1998, CURR OPIN CHEM BIOL, V2, P491, DOI 10.1016/S1367-5931(98)80125-7; Babu BR, 1998, J BIOL CHEM, V273, P8882, DOI 10.1074/jbc.273.15.8882; Babu BR, 1999, J BIOL CHEM, V274, P25218, DOI 10.1074/jbc.274.36.25218; Bredt DS, 1999, FREE RADICAL RES, V31, P577, DOI 10.1080/10715769900301161; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bryk R, 1999, PHARMACOL THERAPEUT, V84, P157, DOI 10.1016/S0163-7258(99)00030-3; Chabrier PE, 1999, CELL MOL LIFE SCI, V55, P1029, DOI 10.1007/s000180050353; Cooper GR, 2000, ARCH BIOCHEM BIOPHYS, V375, P183, DOI 10.1006/abbi.1999.1658; Cotter G, 2000, CIRCULATION, V101, P1358, DOI 10.1161/01.CIR.101.12.1358; Fast W, 1997, BIOORGAN MED CHEM, V5, P1601, DOI 10.1016/S0968-0896(97)00109-0; Feelisch M., 1996, METHODS NITRIC OXIDE, P455; FELDMAN PL, 1993, J MED CHEM, V36, P491, DOI 10.1021/jm00056a009; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FURFINE ES, 1994, J BIOL CHEM, V269, P26677; FURFINE ES, 1993, BIOCHEMISTRY-US, V32, P8512, DOI 10.1021/bi00084a017; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Garvey EP, 1996, METHOD ENZYMOL, V268, P339; Gerber NC, 1997, ARCH BIOCHEM BIOPHYS, V343, P249, DOI 10.1006/abbi.1997.0187; Griffith OW, 1996, METHOD ENZYMOL, V268, P375; Griffith OW, 1997, ADV ENZYME REGUL, V37, P171, DOI 10.1016/S0065-2571(96)00008-8; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Hallinan EA, 1998, J MED CHEM, V41, P775, DOI 10.1021/jm9706675; Hobbs AJ, 1999, ANNU REV PHARMACOL, V39, P191, DOI 10.1146/annurev.pharmtox.39.1.191; Huang PL, 1998, PROG BRAIN RES, V118, P13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; Lassen LH, 1997, LANCET, V349, P401, DOI 10.1016/S0140-6736(97)80021-9; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; Li HY, 2002, BIOCHEMISTRY-US, V41, P13868, DOI 10.1021/bi020417c; Li HY, 2001, BIOCHEMISTRY-US, V40, P5399, DOI 10.1021/bi002658v; MASTERS BSS, 1996, METH NEUROSCI, V31, P140; Matsui T, 1999, CELL MOL NEUROBIOL, V19, P177, DOI 10.1023/A:1006966012266; MCCALL TB, 1991, BRIT J PHARMACOL, V102, P234, DOI 10.1111/j.1476-5381.1991.tb12159.x; Moali C, 1998, BIOCHEMISTRY-US, V37, P10453, DOI 10.1021/bi980742t; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; OLKEN NM, 1994, BIOCHEMISTRY-US, V33, P14784, DOI 10.1021/bi00253a017; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAND MJ, 1995, ANNU REV PHYSIOL, V57, P659; RodriguezCrespo I, 1996, ARCH BIOCHEM BIOPHYS, V336, P151, DOI 10.1006/abbi.1996.0543; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Symeonides S, 1999, INFECT DIS CLIN N AM, V13, P449, DOI 10.1016/S0891-5520(05)70085-4; Thomsen LL, 1997, ANN NY ACAD SCI, V835, P363, DOI 10.1111/j.1749-6632.1997.tb48642.x; Thomsen LL, 2001, CURR OPIN NEUROL, V14, P315, DOI 10.1097/00019052-200106000-00009; Wolff DJ, 1996, ARCH BIOCHEM BIOPHYS, V325, P227, DOI 10.1006/abbi.1996.0028; Zhang HQ, 1997, J MED CHEM, V40, P3869, DOI 10.1021/jm970550g; Zhang HQ, 1997, J AM CHEM SOC, V119, P10888, DOI 10.1021/ja964160f	51	35	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46789	46797		10.1074/jbc.M306787200	http://dx.doi.org/10.1074/jbc.M306787200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12960153	hybrid			2022-12-25	WOS:000186569400070
J	DeYoung, RA; Baker, JC; Cado, D; Winoto, A				DeYoung, RA; Baker, JC; Cado, D; Winoto, A			The orphan steroid receptor Nur77 family member Nor-1 is essential for early mouse embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NGFI-B; TRANSCRIPTION FACTOR; GENE ENCODES; GASTRULATION; EXPRESSION; EMBRYO; CELLS; BRACHYURY; ENDODERM; PROTEIN	Nur77 and its family members, Nor- 1 and Nurr1, are orphan steroid receptors implicated in a wide variety of biological processes, including apoptosis and dopamine neuron agenesis. Expression of these family members can be detected at low levels in many tissues but they are expressed at very high levels when cells are stimulated by outside signals, including serum, nerve growth factor, and receptor engagement. Introduction of a dominant negative Nur77 protein that blocks the activities of all family members led to inhibition of apoptosis in T cells. Nur77- deficient mice, however, exhibit no phenotype, and a line of Nor- 1 mutant mice was reported to exhibit a mild ear development phenotype but no other gross abnormalities. Here, we report the generation of Nor- 1- deficient mice with a block in early embryonic development. Nor- 1 is expressed early during embryogenesis, and its loss leads to embryonic lethality around embryonic day 8.5 of gestation. The mutant embryos fail to complete gastrulation and display distinct morphological abnormalities, including a decrease in overall size, developmental delay and an accumulation of mesoderm in the primitive streak during gastrulation. Abnormal expression of a number of early developmental markers and defects in growth or distribution of emerging mesoderm cells were also detected. These data suggest that Nor- 1 plays a crucial role in gastrulation.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA; Stanford Univ, Dept Genet, Palo Alto, CA 94305 USA	University of California System; University of California Berkeley; Stanford University	Winoto, A (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA.				NATIONAL CANCER INSTITUTE [R01CA066236] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 66236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; Beddington RSP, 1998, TRENDS GENET, V14, P277, DOI 10.1016/S0168-9525(98)01499-1; BEDDINGTON RSP, 1982, J EMBRYOL EXP MORPH, V69, P265; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; BEDDINGTON RSP, 1992, DEVELOPMENT, P157; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; CALNAN BJ, 1995, IMMUNITY, V3, P273; Chapman DL, 1998, NATURE, V391, P695, DOI 10.1038/35624; Chapman DL, 1996, DEV BIOL, V180, P534, DOI 10.1006/dbio.1996.0326; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; FAUST C, 1995, DEVELOPMENT, V121, P273; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; KISPERT A, 1995, EMBO J, V14, P4763, DOI 10.1002/j.1460-2075.1995.tb00158.x; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; Labelle Y, 1999, ONCOGENE, V18, P3303, DOI 10.1038/sj.onc.1202675; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LEE SL, 1995, SCIENCE, V269, P532, DOI 10.1126/science.7624775; Maltais A, 2000, DNA CELL BIOL, V19, P121, DOI 10.1089/104454900314636; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; Perea-Gomez A, 2001, DEVELOPMENT, V128, P753; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Ponnio T, 2002, MOL CELL BIOL, V22, P935, DOI 10.1128/MCB.22.3.935-945.2002; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SASAKI H, 1993, DEVELOPMENT, V118, P47; Shawlot W, 1999, DEVELOPMENT, V126, P4925; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; Sun X, 1999, GENE DEV, V13, P1834, DOI 10.1101/gad.13.14.1834; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; TAM PPL, 1992, CIBA F SYMP, V165, P27; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WILSON V, 1995, DEVELOPMENT, V121, P877; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhou T, 1996, J EXP MED, V183, P1879, DOI 10.1084/jem.183.4.1879	46	57	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47104	47109		10.1074/jbc.M307496200	http://dx.doi.org/10.1074/jbc.M307496200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	13129926	hybrid			2022-12-25	WOS:000186569400108
J	Fisette, PL; Ram, S; Andersen, JM; Guo, W; Ingalls, RR				Fisette, PL; Ram, S; Andersen, JM; Guo, W; Ingalls, RR			The Lip lipoprotein from Neisseria gonorrhoeae stimulates cytokine release and NF-kappa B activation in epithelial cells in a toll-like receptor 2-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE-DEFICIENT MUTANT; OUTER-MEMBRANE PROTEIN; INNATE IMMUNE-SYSTEM; CUTTING EDGE; PATHOGENIC NEISSERIA; MICROBIAL LIPOPROTEINS; BACTERIAL LIPOPROTEINS; MODIFIED AZURIN; H.8 ANTIGEN; TLR 2	The human pathogen Neisseria gonorrhoeae produces an array of diseases ranging from urethritis to disseminated gonococcal infections. Early events in the establishment of infection involve interactions between N. gonorrhoeae and the mucosal epithelium, which leads to the local release of inflammatory mediators. Because of this, it is important to identify the bacterial virulence factors and host cell components that contribute to inflammation. Using a series of column chromatography steps, we purified a lipoprotein from N. gonorrhoeae strain F62 called Lip. This outer membrane antigen expresses a conserved epitope known as H. 8, which is common to all pathogenic Neisseria species. We found the purified preparation of Lip to be a potent inflammatory mediator capable of inducing the release of the chemokine interleukin ( IL)-8 and the cytokine IL-6 by immortalized human endocervical epithelial cells and the production of IL-8 and the activation of the transcription factor NF-kappaB by human embryonic kidney 293 (HEK) cells transfected with toll-like receptor (TLR) 2. Upon removal of Lip by immunoprecipitation, the ability of the H.8/Lip preparation to stimulate NF-kappaB activation was abolished. In addition to TLR2, the activation of NF-kappaB by H.8/Lip in HEK cells was enhanced upon coexpression of TLR1 but not TLR6. These observations provide evidence that Lip is capable of inducing the release of inflammatory mediators from epithelial cells in a TLR2-dependent manner.	Boston Univ, Sch Med, Div Infect Dis, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Physiol & Biophys, Obes Res Unit, Boston, MA 02118 USA; Norwegian Univ Sci & Technol, N-7489 Trondheim, Norway	Boston University; Boston University; Norwegian University of Science & Technology (NTNU)	Ingalls, RR (corresponding author), Boston Univ, Sch Med, Div Infect Dis, EBRC Bldg,Rm 615,650 Albany St, Boston, MA 02118 USA.			Guo, Wen/0000-0002-4474-2837; Ingalls, Robin/0000-0003-2197-7198	NHLBI NIH HHS [T32 HL 07501] Funding Source: Medline; NIAID NIH HHS [AI 38515, AI 46613, T32 AI 52070, AI 32725] Funding Source: Medline; NIDDK NIH HHS [DK 59261] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032725, R37AI032725, U19AI038515, R01AI046613, T32AI052070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059261] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; APICELLA MA, 1990, J INFECT DIS, V162, P506, DOI 10.1093/infdis/162.2.506; BAEHR W, 1989, MOL MICROBIOL, V2, P49; BHATTACHARJEE AK, 1988, INFECT IMMUN, V56, P773, DOI 10.1128/IAI.56.4.773-778.1988; BISWAS GD, 1977, J BACTERIOL, V129, P983, DOI 10.1128/JB.129.2.983-992.1977; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; CANNON JG, 1989, CLIN MICROBIOL REV, V2, pS1, DOI 10.1128/CMR.2.Suppl.S1-S4.1989; CANNON JG, 1984, INFECT IMMUN, V43, P994, DOI 10.1128/IAI.43.3.994-999.1984; CARBONETTI N, 1990, MOL MICROBIOL, V4, P1009, DOI 10.1111/j.1365-2958.1990.tb00673.x; CHEN CY, 1984, PATHOGENIC NEISSERIA, P360; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; DENSEN P, 1987, J CLIN INVEST, V80, P78, DOI 10.1172/JCI113067; Fichorova RN, 2001, INFECT IMMUN, V69, P5840, DOI 10.1128/IAI.69.9.5840-5848.2001; Fichorova RN, 2002, J IMMUNOL, V168, P2424, DOI 10.4049/jimmunol.168.5.2424; GNEHM HE, 1985, J CLIN INVEST, V75, P1645, DOI 10.1172/JCI111872; GOTSCHLICH EC, 1987, FEMS MICROBIOL LETT, V43, P253; Hajjar AM, 2001, J IMMUNOL, V166, P15, DOI 10.4049/jimmunol.166.1.15; HANTKE K, 1973, EUR J BIOCHEM, V34, P284, DOI 10.1111/j.1432-1033.1973.tb02757.x; Harvey HA, 2002, INFECT IMMUN, V70, P5808, DOI 10.1128/IAI.70.10.5808-5815.2002; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; HITCHCOCK PJ, 1985, J EXP MED, V162, P2017, DOI 10.1084/jem.162.6.2017; Hobbs MM, 1999, J INFECT DIS, V179, P371, DOI 10.1086/314608; HOEHN GT, 1992, INFECT IMMUN, V60, P4704, DOI 10.1128/IAI.60.11.4704-4708.1992; Hoshino K, 1999, J IMMUNOL, V162, P3749; Ingalls RR, 2001, INFECT IMMUN, V69, P2230, DOI 10.1128/IAI.69.4.2230-2236.2001; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; KAWULA TH, 1987, MOL MICROBIOL, V1, P179, DOI 10.1111/j.1365-2958.1987.tb00510.x; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; MANTHEY CL, 1994, J IMMUNOL, V153, P2653; Massari P, 2002, J IMMUNOL, V168, P1533, DOI 10.4049/jimmunol.168.4.1533; Means TK, 1999, J IMMUNOL, V163, P3920; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; Naumann M, 1997, J EXP MED, V186, P247, DOI 10.1084/jem.186.2.247; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pridmore AC, 2001, J INFECT DIS, V183, P89, DOI 10.1086/317647; SCHNEIDER H, 1982, J GEN MICROBIOL, V128, P13; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; STRITTMATTER W, 1986, J EXP MED, V164, P2038, DOI 10.1084/jem.164.6.2038; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Trees DL, 2000, J CLIN MICROBIOL, V38, P2914, DOI 10.1128/JCM.38.8.2914-2916.2000; WAGNER DA, 1983, P NATL ACAD SCI-BIOL, V80, P4518, DOI 10.1073/pnas.80.14.4518; WESTPHAL O, 1952, Z NATURFORSCH B, V7, P148, DOI 10.1515/znb-1952-0303; WOODS JP, 1989, MOL MICROBIOL, V3, P43, DOI 10.1111/j.1365-2958.1989.tb00102.x; WOODS JP, 1989, MOL MICROBIOL, V3, P583, DOI 10.1111/j.1365-2958.1989.tb00205.x; Wyllie DH, 2000, J IMMUNOL, V165, P7125, DOI 10.4049/jimmunol.165.12.7125; Yoshimura A, 1999, J IMMUNOL, V163, P1; ZOLLINGER W, 1984, PATHOGENIC NEISSERIA, P579	52	85	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46252	46260		10.1074/jbc.M306587200	http://dx.doi.org/10.1074/jbc.M306587200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12966099	hybrid			2022-12-25	WOS:000186569400008
J	Marinissen, MJ; Servitja, JM; Offermanns, S; Simon, MI; Gutkind, JS				Marinissen, MJ; Servitja, JM; Offermanns, S; Simon, MI; Gutkind, JS			Thrombin protease-activated receptor-1 signals through G(q)- and G(13)-initiated MAPK cascades regulating c-Jun expression to induce cell transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; EARLY GENE-EXPRESSION; SMOOTH-MUSCLE-CELLS; NIH 3T3 CELLS; COUPLED RECEPTORS; ALPHA-SUBUNIT; BINDING PROTEINS; KINASE PATHWAY; MALIGNANT TRANSFORMATION; TYROSINE PHOSPHORYLATION	Although the ability of G protein-coupled receptors to stimulate normal and aberrant cell growth has been intensely investigated, the precise nature of the molecular mechanisms underlying their transforming potential are still not fully understood. In this study, we have taken advantage of the potent mitogenic effect of thrombin and the focus-forming activity of one of its receptors, protease-activated receptor-1, to dissect how this receptor coupled to Galpha(i), Galpha(q/11), and Galpha(12/13) transduces signals from the membrane to the nucleus to initiate transcriptional events involved in cell transformation. Using endogenous and transfected thrombin receptors in NIH 3T3 cells, ectopic expression of muscarinic receptors coupled to Galpha(q) and Galpha(i), and chimeric G protein alpha subunits and murine fibroblasts deficient in Galpha(q/11), and Galpha(12/13), we show here that, although coupling to Galpha(i) is sufficient to induce ERK activation, the ability to couple to Galpha(q) and/or Galpha(13) is necessary to induce c-jun expression and cell transformation. Furthermore, we show that Galpha(q) and Galpha(13) can initiate the activation of MAPK cascades, including JNK, p38, and ERK5, which in turn regulate the activity of transcription factors controlling expression from the c-jun promoter. We also present evidence that c-Jun and the kinases regulating its expression are integral components of the transforming pathway initiated by protease-activated receptor-1.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; CALTECH, Dept Biol, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; Univ Heidelberg, Inst Pharmacol, Dept Mol Pharmacol, D-69120 Heidelberg, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; Ruprecht Karls University Heidelberg	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bldg 30,Rm 211,9000 Rockville Pike, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009; Offermanns, Stefan/L-3313-2017	Gutkind, J. Silvio/0000-0002-5150-4482; SERVITJA, JOAN-MARC/0000-0002-1241-8004; Offermanns, Stefan/0000-0001-8676-6805	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; BROWN PH, 1993, ONCOGENE, V8, P877; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coso OA, 1997, J BIOL CHEM, V272, P20691, DOI 10.1074/jbc.272.33.20691; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 2000, J BIOL CHEM, V275, P21730, DOI 10.1074/jbc.M002410200; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Han JH, 1997, FEBS LETT, V403, P19, DOI 10.1016/S0014-5793(97)00021-5; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; O'Brien PJ, 2001, ONCOGENE, V20, P1570, DOI 10.1038/sj.onc.1204194; Offermanns S, 2001, ONCOGENE, V20, P1635, DOI 10.1038/sj.onc.1204189; Offermanns S, 1998, ONCOGENE, V17, P1375, DOI 10.1038/sj.onc.1202173; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Rao GN, 1996, J BIOL CHEM, V271, P20805, DOI 10.1074/jbc.271.34.20805; ROTHMAN A, 1994, J BIOL CHEM, V269, P6399; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITH SE, 1993, NUCLEIC ACIDS RES, V21, P1581, DOI 10.1093/nar/21.7.1581; STEPHENS EV, 1993, ONCOGENE, V8, P19; Teramoto H, 1997, J BIOL CHEM, V272, P10751; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; VanObberghenSchilling E, 1995, ANN NY ACAD SCI, V766, P431, DOI 10.1111/j.1749-6632.1995.tb26692.x; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1998, MOL CELL BIOL, V18, P4689, DOI 10.1128/MCB.18.8.4689; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	63	79	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46814	46825		10.1074/jbc.M305709200	http://dx.doi.org/10.1074/jbc.M305709200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12954641	Green Accepted, hybrid			2022-12-25	WOS:000186569400073
J	Takahashi, K; Mizuarai, S; Araki, H; Mashiko, S; Ishihara, A; Kanatani, A; Itadani, H; Kotani, H				Takahashi, K; Mizuarai, S; Araki, H; Mashiko, S; Ishihara, A; Kanatani, A; Itadani, H; Kotani, H			Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOATTRACTANT PROTEIN-1; INSULIN-RESISTANCE; OBESITY; EXPRESSION; ATHEROSCLEROSIS; CHEMOKINES; CELLS	Obesity is currently considered as an epidemic in the western world, and it represents a major risk factor for life-threatening diseases such as heart attack, stroke, diabetes, and cancer. Taking advantage of DNA microarray technology, we tried to identify the molecules explaining the relationship between obesity and vascular disorders, comparing mRNA expression of about 12,000 genes in white adipose tissue between normal, high fat diet-induced obesity (DIO) and D-Trp(34) neuropeptide Y-induced obesity in mice. Expression of monocyte chemoattractant protein-1 (MCP-1) mRNA displayed a 7.2-fold increase in obese mice as compared with normal mice, leading to substantially elevated MCP-1 protein levels in adipocytes. MCP-1 levels in plasma were also increased in DIO mice, and a strong correlation between plasma MCP-1 levels and body weight was identified. We also showed that elevated MCP-1 protein levels in plasma increased the CD11b-positive monocyte/macrophage population in DIO mice. Furthermore, infusion of MCP-1 into lean mice increased the CD11b-positive monocyte population without inducing changes in body weight. Given the importance of MCP-1 in activation of monocytes and subsequent atherosclerotic development, these results suggest a novel role of adiposity in the development of vascular disorders.	Merck Res Labs, Banyu Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan	Merck & Company	Kotani, H (corresponding author), Merck Res Labs, Banyu Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan.	kotanihh@banyu.co.jp						Ahren B, 1997, AM J PHYSIOL-REG I, V273, pR113, DOI 10.1152/ajpregu.1997.273.1.R113; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Boring L, 1996, J BIOL CHEM, V271, P7551, DOI 10.1074/jbc.271.13.7551; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; GERRITY RG, 1981, AM J PATHOL, V103, P181; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Hansen BC, 1999, ANN NY ACAD SCI, V892, P1, DOI 10.1111/j.1749-6632.1999.tb07782.x; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Juhan-Vague I, 1999, THROMB HAEMOSTASIS, V82, P832; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Kullo IJ, 2002, AM J CARDIOL, V89, P1441, DOI 10.1016/S0002-9149(02)02366-4; LEENEN PJM, 1994, J IMMUNOL METHODS, V174, P5, DOI 10.1016/0022-1759(94)90005-1; Loskutoff DJ, 1998, ARTERIOSCL THROM VAS, V18, P1, DOI 10.1161/01.ATV.18.1.1; Mashiko S, 2003, ENDOCRINOLOGY, V144, P1793, DOI 10.1210/en.2002-0119; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; STRIETER RM, 1989, BIOCHEM BIOPH RES CO, V162, P694, DOI 10.1016/0006-291X(89)92366-8; VADDI K, 1994, J IMMUNOL, V153, P4721; van Royen N, 2003, CIRC RES, V92, P218, DOI 10.1161/01.RES.0000052313.23087.3F; WASSERMANN F., 1965, HANDBOOK PHYSIOL, V5, P87; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	32	240	268	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46654	46660		10.1074/jbc.M309895200	http://dx.doi.org/10.1074/jbc.M309895200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	13129912	hybrid			2022-12-25	WOS:000186569400054
J	Zhu, YF; Wang, Y; Gorman, MJ; Jiang, HB; Kanost, MR				Zhu, YF; Wang, Y; Gorman, MJ; Jiang, HB; Kanost, MR			Manduca sexta serpin-3 regulates prophenoloxidase activation in response to infection by inhibiting prophenoloxidase-activating proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-PHENOL-OXIDASE; PLASMINOGEN-ACTIVATOR; SERINE PROTEINASES; MOLECULAR-CLONING; TOBACCO HORNWORM; BOMBYX-MORI; INSECT; PURIFICATION; HEMOLYMPH; ENZYME	Many serine proteinase inhibitors of the serpin superfamily have evolved in vertebrates and invertebrates to regulate serine proteinase cascades that mediate the host defense responses. We have isolated an immune-responsive serpin from the tobacco hornworm, Manduca sexta. This inhibitor, M. sexta serpin- 3, contains a reactive site loop strikingly similar to the proteolytic activation site in prophenoloxidase ( pro- PO). Molecular cloning and sequence comparison indicate that serpin- 3 is orthologous to Drosophila melanogaster serpin 27A, a regulator of melanization. M. sexta serpin-3 is constitutively present in hemolymph at a low concentration of 5 - 12 mug/ml and increases to 30 - 75 mug/ml after a microbial challenge. Recombinant serpin- 3 efficiently blocks pro- PO activation in the hemolymph, and it forms SDS- stable acyl- enzyme complexes with purified pro- PO- activating proteinases ( PAPs) from M. sexta. PAP- serpin- 3 complexes were isolated by immunoaffinity chromatography from hemolymph activated by treatment with Micrococcus luteus. Kinetic analysis of PAP- serpin- 3 association strongly suggests that serpin- 3 is a physiological regulator of the pro- PO activation reaction.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Kanost, MR (corresponding author), Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA.	kanost@ksu.edu	Jiang, Haobo/A-6519-2008	Jiang, Haobo/0000-0003-1357-1315; Kanost, Michael/0000-0002-6827-0061	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058634, R37GM041247, R29GM041247, R01GM041247] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 41247, GM 58634, R37 GM041247] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ashida Masaaki, 1998, P135; ASPAN A, 1990, INSECT BIOCHEM, V20, P709, DOI 10.1016/0020-1790(90)90085-9; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BOIGEGRAIN RA, 1992, BIOCHEM BIOPH RES CO, V189, P790, DOI 10.1016/0006-291X(92)92271-X; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; Djie MZ, 1997, J BIOL CHEM, V272, P16268, DOI 10.1074/jbc.272.26.16268; DOHKE K, 1973, ARCH BIOCHEM BIOPHYS, V157, P210, DOI 10.1016/0003-9861(73)90407-4; DUNN PE, 1983, J INVERTEBR PATHOL, V41, P77, DOI 10.1016/0022-2011(83)90238-0; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; Gan H, 2001, INSECT BIOCHEM MOLEC, V31, P887, DOI 10.1016/S0965-1748(01)00034-0; *GEN COMP GROUP, 1991, PROGR MAN GCG PACK V; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; HALL M, 1995, P NATL ACAD SCI USA, V92, P7764, DOI 10.1073/pnas.92.17.7764; HARLOW E, 1999, USING ANTIBODIES LAB, P311; HERMANS JM, 1994, BIOCHEMISTRY-US, V33, P5440, DOI 10.1021/bi00184a012; JIANG HB, 1994, J BIOL CHEM, V269, P55; Jiang HB, 2003, INSECT BIOCHEM MOLEC, V33, P1049, DOI 10.1016/S0965-1748(03)00123-1; Jiang HB, 2003, J BIOL CHEM, V278, P3552, DOI 10.1074/jbc.M205743200; Jiang HB, 1996, J BIOL CHEM, V271, P28017, DOI 10.1074/jbc.271.45.28017; Jiang HB, 2000, INSECT BIOCHEM MOLEC, V30, P95, DOI 10.1016/S0965-1748(99)00113-7; Jiang HB, 1997, INSECT BIOCHEM MOLEC, V27, P835, DOI 10.1016/S0965-1748(97)00066-0; Jiang HB, 1997, J BIOL CHEM, V272, P1082, DOI 10.1074/jbc.272.2.1082; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Kanost MR, 2001, ADV EXP MED BIOL, V484, P319; Kanost MR, 1999, DEV COMP IMMUNOL, V23, P291, DOI 10.1016/S0145-305X(99)00012-9; KANOST MR, 1995, INSECT BIOCHEM MOLEC, V25, P285, DOI 10.1016/0965-1748(94)00067-R; Kawabata Shun-ichiro, 1996, P255; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; Molnar K, 2001, J INSECT PHYSIOL, V47, P675, DOI 10.1016/S0022-1910(00)00130-X; Nappi AJ, 2000, BIOESSAYS, V22, P469, DOI 10.1002/(SICI)1521-1878(200005)22:5<469::AID-BIES9>3.3.CO;2-W; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; Park DS, 2000, MOL CELLS, V10, P186, DOI 10.1007/s10059-000-0186-2; Sambrook J, 2001, MOL CLONING LAB MANU; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; SAUL SJ, 1986, FEBS LETT, V208, P113, DOI 10.1016/0014-5793(86)81543-5; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Wang RG, 2001, EUR J BIOCHEM, V268, P895, DOI 10.1046/j.1432-1327.2001.01945.x; WANG Y, 1995, INSECT MOL BIOL, V4, P113, DOI 10.1111/j.1365-2583.1995.tb00015.x; Wang Y, 2001, PROTEIN EXPRES PURIF, V23, P328, DOI 10.1006/prep.2001.1517; Yu XQ, 2003, INSECT BIOCHEM MOLEC, V33, P197, DOI 10.1016/S0965-1748(02)00191-1; Zhu Y, 2003, INSECT BIOCHEM MOLEC, V33, P541, DOI 10.1016/S0965-1748(03)00028-6	48	150	163	6	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46556	46564		10.1074/jbc.M309682200	http://dx.doi.org/10.1074/jbc.M309682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12966082	hybrid			2022-12-25	WOS:000186569400041
J	Reddy, MN; Tang, LY; Lee, TL; Shen, CKJ				Reddy, MN; Tang, LY; Lee, TL; Shen, CKJ			A candidate gene for Drosophila genome methylation	ONCOGENE			English	Article						DNA methylation; Drosophila cells; enzyme	DNA METHYLATION; DE-NOVO; METHYLTRANSFERASES; MELANOGASTER; DNMT3A	Like vertebrates, the genome of Drosophila melanogaster also contains methylated cytosines. However, the enzyme( s) responsible for this methylation has been elusive. By DNA transfection and sodium bisulfite sequencing, we show here that overexpression of dDnmt2, which is the only expressed and cloned Drosophila protein consisting of motifs conserved among the DNA cytosine methyltransferases, results in genomic DNA methylation of Drosophila S2 cells. The data provide the first evidence for dDnmt2 being one candidate gene encoding the Drosophila DNA methyltransferase(s).	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan	Academia Sinica - Taiwan	Shen, CKJ (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.		shen, Che-Kun James/L-1343-2015					Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Dong AP, 2001, NUCLEIC ACIDS RES, V29, P439, DOI 10.1093/nar/29.2.439; Gowher H, 2000, EMBO J, V19, P6918, DOI 10.1093/emboj/19.24.6918; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; Hsu DW, 1999, P NATL ACAD SCI USA, V96, P9751, DOI 10.1073/pnas.96.17.9751; Hung MS, 1999, P NATL ACAD SCI USA, V96, P11940, DOI 10.1073/pnas.96.21.11940; Lyko F, 2000, NATURE, V408, P538, DOI 10.1038/35046205; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Tweedie S, 1999, NAT GENET, V23, P389, DOI 10.1038/70490; Warnecke PM, 2002, METHODS, V27, P101, DOI 10.1016/S1046-2023(02)00060-9; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279	15	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6301	6303		10.1038/sj.onc.1206650	http://dx.doi.org/10.1038/sj.onc.1206650			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679869				2022-12-25	WOS:000185506200020
J	Arnould, T; Mercy, L; Houbion, A; Vankoningsloo, S; Renard, P; Pascal, T; Ninane, N; Demazy, C; Raes, M				Arnould, T; Mercy, L; Houbion, A; Vankoningsloo, S; Renard, P; Pascal, T; Ninane, N; Demazy, C; Raes, M			MtCLIC is up-regulated and maintains a mitochondrial membrane potential in mtDNA-depleted L929 cells	FASEB JOURNAL			English	Article						mitochondrial dysfunction; chloride flux; CREB; p53; differential gene expression	CHLORIDE CHANNEL PROTEIN; RHO-DEGREES CELLS; OXIDATIVE-PHOSPHORYLATION; DIFFERENTIAL EXPRESSION; SIGNALING PATHWAY; MOLECULAR-CLONING; GENE-EXPRESSION; DNA; MUTATION; P64H1	To explain why mitochondrial DNA ( mtDNA)-depleted or rho0 cells still keep a mitochondrial membrane potential (Deltapsim) in the absence of respiration, several hypotheses have been proposed. The principal and well accepted one involves a reverse of action for ANT combined to F1-ATPase activity. However, the existence of other putative electrogenic channels has been speculated. Here, using mRNA differential display reverse transcriptase-polymerase chain reaction on L929 mtDNA-depleted cells, we identified mtCLIC as a differentially expressed gene in cells deprived from mitochondrial ATP production. Mitochondrial chloride intracellular channel ( mtCLIC), a member of a recently discovered and expanding family of chloride intracellular channels, is up-regulated in mtDNA-depleted and rho0 cells. We showed that its expression is dependent on CREB and p53 and is sensitive to calcium and tumor necrosis factor alpha. Interestingly, up- or down-regulation of mtCLIC protein expression changes Deltapsim whereas the chloride channel inhibitor NPPB reduces the Deltapsim in mtDNA-depleted L929 cells, measured with the fluorescent probe rhodamine 123. Finally, we demonstrated that purified mitochondria from mtDNA-depleted cells incorporate, in a NPPB-sensitive manner, more (36)chloride than parental mitochondria. These findings suggest that mtCLIC could be involved in mitochondrial membrane potential generation in mtDNA-depleted cells, a feature required to prevent apoptosis and to drive continous protein import into mitochondria.	Univ Namur, FUNDP, Lab Biochim & Biol Cellulaire, B-5000 Namur, Belgium	University of Namur	Arnould, T (corresponding author), Univ Namur, FUNDP, Lab Biochim & Biol Cellulaire, 61 Rue Bruxelles, B-5000 Namur, Belgium.	thierry.arnould@fundp.ac.be						Appleby RD, 1999, EUR J BIOCHEM, V262, P108, DOI 10.1046/j.1432-1327.1999.00350.x; Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53; Berryman M, 2000, MOL BIOL CELL, V11, P1509, DOI 10.1091/mbc.11.5.1509; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; CHEN LB, 1989, METHOD CELL BIOL, V29, P103; Chuang JZ, 1999, J NEUROSCI, V19, P2919; DUAN JM, 1989, CAN J PHYSIOL PHARM, V67, P704, DOI 10.1139/y89-114; DUEE ED, 1969, J BIOL CHEM, V244, P3920; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; Fernandez-Salas E, 2002, MOL CELL BIOL, V22, P3610, DOI 10.1128/MCB.22.11.3610-3620.2002; Fernandez-Salas E, 1999, J BIOL CHEM, V274, P36488, DOI 10.1074/jbc.274.51.36488; Geissler A, 2001, MOL CELL BIOL, V21, P7097, DOI 10.1128/MCB.21.20.7097-7104.2001; Giebler HA, 2000, MOL CELL BIOL, V20, P4849, DOI 10.1128/MCB.20.13.4849-4858.2000; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; Heiss NS, 1997, GENOMICS, V45, P224, DOI 10.1006/geno.1997.4922; HERZBERG NH, 1993, EUR J CELL BIOL, V61, P400; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kitamura A, 2001, BIOCHEM BIOPH RES CO, V287, P435, DOI 10.1006/bbrc.2001.5577; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; Miranda S, 1999, BIOCHEM BIOPH RES CO, V258, P44, DOI 10.1006/bbrc.1999.0580; MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509; Morin C, 2000, FUND CLIN PHARMACOL, V14, P493, DOI 10.1111/j.1472-8206.2000.tb00432.x; Naviaux RK, 2000, EUR J PEDIATR, V159, pS219, DOI 10.1007/PL00014407; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; Park KS, 2001, AM J PHYSIOL-ENDOC M, V280, pE1007, DOI 10.1152/ajpendo.2001.280.6.E1007; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; REMACLE JA, 1980, BIOCHIM BIOPHYS ACTA, V630, P57, DOI 10.1016/0304-4165(80)90137-3; Ronnov-Jessen L, 2002, AM J PATHOL, V161, P471, DOI 10.1016/S0002-9440(10)64203-4; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sherer TB, 2000, BBA-MOL CELL RES, V1496, P341, DOI 10.1016/S0167-4889(00)00027-6; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; Suginta W, 2001, BIOCHEM J, V359, P55, DOI 10.1042/0264-6021:3590055; Thomas AW, 1999, CLIN SCI, V97, P207, DOI 10.1042/CS19980400; Tulk BM, 2000, J BIOL CHEM, V275, P26986; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; Wang H, 1997, BBA-GENE STRUCT EXPR, V1352, P325, DOI 10.1016/S0167-4781(97)00035-3; Zhang H, 1996, NUCLEIC ACIDS RES, V24, P2454, DOI 10.1093/nar/24.12.2454	46	35	36	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2145	+		10.1096/fj.03-0075fje	http://dx.doi.org/10.1096/fj.03-0075fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958156				2022-12-25	WOS:000185925100027
J	Kondo-Okamoto, N; Shaw, JM; Okamoto, K				Kondo-Okamoto, N; Shaw, JM; Okamoto, K			Mmm1p spans both the outer and inner mitochondrial membranes and contains distinct domains for targeting and foci formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED GTPASE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; NEUROSPORA-CRASSA; RHOMBOID PROTEASE; FUSION; DNA; INHERITANCE; MAINTENANCE; MORPHOLOGY	In the yeast Saccharomyces cerevisiae, the integral membrane protein Mmm1p is required for maintenance of mitochondrial morphology and retention of mitochondrial DNA ( mtDNA). Mmm1p localizes to discrete foci on mitochondria that are adjacent to mtDNA nucleoids in the matrix, raising the possibility that this protein plays a direct role in organizing, replicating, or segregating mtDNA. Although Mmm1p has been shown to cross the outer membrane with its C terminus facing the cytoplasm, the location of the N terminus has not been resolved. Here we show that Mmm1p spans both the outer and inner mitochondrial membranes, exposing its N terminus to the matrix. Surprisingly, deletion of the N-terminal extension decreased steady-state levels of the Mmm1 protein but did not affect mitochondrial morphology or mtDNA maintenance. Moreover, expression of Neurospora crassa MMM1, which naturally lacks a long N-terminal extension, substituted for loss of Mmm1p in budding yeast. These results indicate that the matrix-exposed portion of Mmm1p is not essential for mtDNA nucleoid maintenance. Additional studies revealed that the transmembrane segment and C-terminal domain of Mmm1p are required for foci formation and mitochondrial targeting, respectively. Our data suggest that the double membrane-spanning topology of Mmm1p at the membrane contact site is critical for formation of tubular mitochondria.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Okamoto, K (corresponding author), Univ Utah, Dept Biol, 257 S 1400 E, Salt Lake City, UT 84112 USA.				NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053466] Funding Source: NIH RePORTER; NCI NIH HHS [CA42014] Funding Source: Medline; NIGMS NIH HHS [GM-53466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beilharz T, 2003, J BIOL CHEM, V278, P8219, DOI 10.1074/jbc.M212725200; Berger KH, 1997, J CELL BIOL, V136, P545, DOI 10.1083/jcb.136.3.545; Berger KH, 2000, TRENDS MICROBIOL, V8, P508, DOI 10.1016/S0966-842X(00)01862-X; Boldogh I, 1998, J CELL BIOL, V141, P1371, DOI 10.1083/jcb.141.6.1371; Boldogh IR, 2003, MOL BIOL CELL, V14, P4618, DOI 10.1091/mbc.E03-04-0225; Boldogh IR, 2001, TRAFFIC, V2, P368, DOI 10.1034/j.1600-0854.2001.002006368.x; BURGESS SM, 1994, J CELL BIOL, V126, P1375, DOI 10.1083/jcb.126.6.1375; Burke D., 2000, METHODS YEAST GENETI; CARRINGTON JC, 1988, P NATL ACAD SCI USA, V85, P3391, DOI 10.1073/pnas.85.10.3391; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Contamine V, 2000, MICROBIOL MOL BIOL R, V64, P281, DOI 10.1128/MMBR.64.2.281-315.2000; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; Esaki M, 1999, P NATL ACAD SCI USA, V96, P11770, DOI 10.1073/pnas.96.21.11770; Esser K, 2002, J MOL BIOL, V323, P835, DOI 10.1016/S0022-2836(02)01000-8; Faber KN, 2001, J BIOL CHEM, V276, P36501, DOI 10.1074/jbc.M105828200; Fuchs F, 2002, J CELL SCI, V115, P1931; Griparic L, 2001, TRAFFIC, V2, P235, DOI 10.1034/j.1600-0854.2001.1r008.x; GUAN KL, 1993, CURR GENET, V24, P141, DOI 10.1007/BF00324678; Herlan M, 2003, J BIOL CHEM, V278, P27781, DOI 10.1074/jbc.M211311200; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; Hermann GJ, 1998, ANNU REV CELL DEV BI, V14, P265, DOI 10.1146/annurev.cellbio.14.1.265; Hobbs AEA, 2001, J CELL BIOL, V152, P401, DOI 10.1083/jcb.152.2.401; Itoh T, 2002, MOL CELL BIOL, V22, P7744, DOI 10.1128/MCB.22.22.7744-7757.2002; Jensen RE, 2000, MICROSC RES TECHNIQ, V51, P573, DOI 10.1002/1097-0029(20001215)51:6<573::AID-JEMT7>3.0.CO;2-2; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; Kanaji S, 2000, J CELL BIOL, V151, P277, DOI 10.1083/jcb.151.2.277; McQuibban GA, 2003, NATURE, V423, P537, DOI 10.1038/nature01633; Mozdy AD, 2003, NAT REV MOL CELL BIO, V4, P468, DOI 10.1038/nrm1125; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; Prinz WA, 2000, J CELL BIOL, V150, P461, DOI 10.1083/jcb.150.3.461; Prokisch H, 2000, MOL BIOL CELL, V11, P2961, DOI 10.1091/mbc.11.9.2961; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Reichert AS, 2002, BBA-MOL CELL RES, V1592, P41, DOI 10.1016/S0167-4889(02)00263-X; Sambrook J., 2001, MOL CLONING; Scott SV, 2003, CURR OPIN CELL BIOL, V15, P482, DOI 10.1016/S0955-0674(03)00070-X; Sesaki H, 2001, J CELL BIOL, V152, P1123, DOI 10.1083/jcb.152.6.1123; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; SOGO LF, 1994, J CELL BIOL, V126, P1361, DOI 10.1083/jcb.126.6.1361; STEINBERG G, 1993, J CELL SCI, V106, P555; Westermann B, 2000, YEAST, V16, P1421, DOI 10.1002/1097-0061(200011)16:15<1421::AID-YEA624>3.3.CO;2-L; Westermann B, 2002, EMBO REP, V3, P527, DOI 10.1093/embo-reports/kvf113; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wong ED, 2003, J CELL BIOL, V160, P303, DOI 10.1083/jcb.200209015; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493; Yang HC, 1999, CURR BIOL, V9, P1111, DOI 10.1016/S0960-9822(99)80480-1; Yoon Y, 2001, CURR BIOL, V11, pR67, DOI 10.1016/S0960-9822(01)00011-2	52	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48997	49005		10.1074/jbc.M308436200	http://dx.doi.org/10.1074/jbc.M308436200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12972421	hybrid			2022-12-25	WOS:000186829000061
J	Llompart, B; Castells, E; Rio, A; Roca, R; Ferrando, A; Stiefel, V; Nech, PP; Casacuberta, JM				Llompart, B; Castells, E; Rio, A; Roca, R; Ferrando, A; Stiefel, V; Nech, PP; Casacuberta, JM			The direct activation of MIK, a germinal center kinase (GCK)-like kinase, by MARK, a maize atypical receptor kinase, suggests a new mechanism for signaling through kinase-dead receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STE20-LIKE PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE; ARABIDOPSIS; DOMAIN; PLANT; RYK; PHOSPHORYLATION; EMBRYOGENESIS; BINDING	Signaling by receptor protein kinases (RPKs) involves their dimerization and transphosphorylation. However, atypical RPKs with kinase-defective domains have been described recently. Some of them are essential for proper signaling in animal systems, although the precise mechanism involved is unknown in most cases. Here we describe the cloning and characterization of an atypical plant receptor kinase from maize, MARK, which does not phosphorylate in vitro. A yeast two-hybrid approach has allowed us to identify a new germinal center kinase (GCK)-related protein, MIK, that interacts with MARK. Interestingly, the interaction of the intracellular domain of MARK with the regulator domain of MIK strongly induces MIK kinase activity. As some GCK-related proteins connect cell-surface receptors to the intracellular MAPK cascades, the activation of MIK by direct interaction with MARK could illustrate a new mechanism for signaling through atypical RPKs.	CSIC, IBMB, Dept Mol Genet, ES-08034 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Casacuberta, JM (corresponding author), CSIC, IBMB, Dept Mol Genet, Jordi Girona 18, ES-08034 Barcelona, Spain.	jcsgmp@cid.csic.es	Ferrando, Alejandro/F-2346-2014	Ferrando, Alejandro/0000-0002-1903-9111; Casacuberta, josep/0000-0002-5609-4152				Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Braun DM, 1997, PLANT J, V12, P83, DOI 10.1046/j.1365-313X.1997.12010083.x; Cabrillac D, 2001, NATURE, V410, P220, DOI 10.1038/35065626; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Eichinger L, 1998, J BIOL CHEM, V273, P12952, DOI 10.1074/jbc.273.21.12952; Espinas ML, 2000, EMBO REP, V1, P253, DOI 10.1093/embo-reports/kvd046; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Glantschnig H, 2002, J BIOL CHEM, V277, P42987, DOI 10.1074/jbc.M208538200; Gomez-Gomez L, 2001, PLANT CELL, V13, P1155, DOI 10.1105/tpc.13.5.1155; Graves JD, 2001, J BIOL CHEM, V276, P14909, DOI 10.1074/jbc.M010905200; Guertin DA, 2001, J BIOL CHEM, V276, P28185, DOI 10.1074/jbc.M103802200; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Halford MM, 2000, NAT GENET, V25, P414, DOI 10.1038/78099; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jonak C, 2002, CURR OPIN PLANT BIOL, V5, P415, DOI 10.1016/S1369-5266(02)00285-6; Katso RM, 1999, MOL CELL BIOL, V19, P6427; Kim HH, 1998, BIOCHEM J, V334, P189, DOI 10.1042/bj3340189; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; Kroiher M, 2001, BIOESSAYS, V23, P69, DOI 10.1002/1521-1878(200101)23:1<69::AID-BIES1009>3.3.CO;2-B; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Leprince AS, 1999, BBA-GENE STRUCT EXPR, V1444, P1, DOI 10.1016/S0167-4781(98)00246-2; MORAN MF, 1988, ONCOGENE, V3, P665; MOSSIE K, 1995, ONCOGENE, V11, P2179; Nakashima M, 1998, PLANT CELL PHYSIOL, V39, P690, DOI 10.1093/oxfordjournals.pcp.a029423; Nishihama R, 2001, GENE DEV, V15, P352, DOI 10.1101/gad.863701; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Pawson T, 2000, GENE DEV, V14, P1027; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; Roca R, 1998, GENE, V208, P67, DOI 10.1016/S0378-1119(97)00654-9; Savant-Bhonsale S, 1999, GENE, V231, P155, DOI 10.1016/S0378-1119(99)00061-X; Shah K, 2002, GENE DEV, V16, P1707, DOI 10.1101/gad.220402; Shah K, 2001, J BIOL CHEM, V276, P41263, DOI 10.1074/jbc.M102381200; Sierke SL, 1997, BIOCHEM J, V322, P757, DOI 10.1042/bj3220757; Stein RA, 2000, J MOL EVOL, V50, P397, DOI 10.1007/s002390010043; Stone JM, 1998, PLANT PHYSIOL, V117, P1217, DOI 10.1104/pp.117.4.1217; Stone SL, 1999, SCIENCE, V286, P1729, DOI 10.1126/science.286.5445.1729; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tichtinsky G, 2003, TRENDS PLANT SCI, V8, P231, DOI 10.1016/S1360-1385(03)00062-1; Trivier E, 2002, J BIOL CHEM, V277, P23037, DOI 10.1074/jbc.M202486200; Trotochaud AE, 1999, PLANT CELL, V11, P393, DOI 10.1105/tpc.11.3.393; VALON C, 1993, PLANT MOL BIOL, V23, P415, DOI 10.1007/BF00029017	45	35	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48105	48111		10.1074/jbc.M307482200	http://dx.doi.org/10.1074/jbc.M307482200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12966093	hybrid			2022-12-25	WOS:000186731400091
J	Gardner, OS; Dewar, BJ; Earp, HS; Samet, JM; Graves, LM				Gardner, OS; Dewar, BJ; Earp, HS; Samet, JM; Graves, LM			Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; IMPROVED INSULIN-SENSITIVITY; RICH TYROSINE KINASE-2; ANGIOTENSIN-II; EGF RECEPTOR; PPAR-GAMMA; C-SRC; COUPLED RECEPTORS; REGULATED KINASE; MEDIATED PHOSPHORYLATION	Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that function as ligand-activated transcription factors regulating lipid metabolism and homeostasis. In addition to their ability to regulate PPAR-mediated gene transcription, PPARalpha and gamma ligands have recently been shown to induce activation of mitogen-activated protein kinases (MAPKs), which in turn phosphorylate PPARs, thereby affecting transcriptional activity. However, the mechanism for PPAR ligand-dependent MAPK activation is unclear. In the current study, we demonstrate that various PPARalpha (nafenopin) and gamma (ciglitazone and troglitazone) agonists rapidly induced extracellular signal-regulated kinase (Erk) and/or p38 phosphorylation in rat liver epithelial cells (GN4). The selective epidermal growth factor receptor (EGFR) kinase inhibitors, PD153035 and ZD1839 (Iressa), abolished PPARalpha and gamma agonist-dependent Erk activation. Consistent with this, PPAR agonists increased tyrosine autophosphorylation of the EGFR as well as phosphorylation at a putative Src-specific site, Tyr(845). Experiments with the Src inhibitor, PP2, and the antioxidant N-acetyl-L-cysteine revealed critical roles for Src and reactive oxygen species as upstream mediators of EGFR transactivation in response to PPAR ligands. Moreover, PPARalpha and gamma ligands increased Src autophosphorylation as well as kinase activity. EGFR phosphorylation, in turn, led to Ras-dependent Erk activation. In contrast, p38 activation by PPARalpha and gamma ligands occurred independently of Src, oxidative stress, the EGFR, and Ras. Interestingly, PPARalpha and gamma agonists caused rapid activation of proline-rich tyrosine kinase or Pyk2; Pyk2 as well as p38 phosphorylation was reduced by intracellular Ca2+ chelation without an observable effect on EGFR and Erk activation, suggesting a possible role for Pyk2 as an upstream activator of p38. In summary, PPARalpha and gamma ligands activate two distinct signaling cascades in GN4 cells leading to MAPK activation.	Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; US EPA, Human Studies Div, Natl Hlth Effects & Environm Res Lab, Res Triangle Pk, NC 27711 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; United States Environmental Protection Agency	Graves, LM (corresponding author), Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC 27599 USA.		Graves, Lee/AAG-5470-2021		NCI NIH HHS [CA 81503] Funding Source: Medline; NIEHS NIH HHS [ES 04325] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004325] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baek SJ, 2003, J BIOL CHEM, V278, P5845, DOI 10.1074/jbc.M208394200; Bandyopadhyay G, 2001, J BIOL CHEM, V276, P35537, DOI 10.1074/jbc.M106042200; Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; EARP HS, 1995, J BIOL CHEM, V270, P28440; Edwards Dean P, 2003, Mol Interv, V3, P12, DOI 10.1124/mi.3.1.12; Graves Lee M, 2002, Mol Interv, V2, P208, DOI 10.1124/mi.2.4.208; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hopkinson G. K., 1998, U.S. patent, Patent No. 5770599; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; HUANG W, 2002, EXP CELL RES, V277; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; JAMES NH, 1994, CARCINOGENESIS, V15, P2687, DOI 10.1093/carcin/15.12.2687; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Juge-Aubry CE, 1999, J BIOL CHEM, V274, P10505, DOI 10.1074/jbc.274.15.10505; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lennon AM, 2002, J BIOL CHEM, V277, P29681, DOI 10.1074/jbc.M201517200; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Masugi J, 1999, BIOCHEM BIOPH RES CO, V264, P93, DOI 10.1006/bbrc.1999.1488; Meves A, 2001, TOXICOL LETT, V122, P205, DOI 10.1016/S0378-4274(01)00359-9; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Mounho BJ, 1999, TOXICOL APPL PHARM, V159, P125, DOI 10.1006/taap.1999.8740; Nugent C, 2001, MOL ENDOCRINOL, V15, P1729, DOI 10.1210/me.15.10.1729; ORELLANA A, 1993, EUR J BIOCHEM, V215, P903, DOI 10.1111/j.1432-1033.1993.tb18108.x; Palakurthi SS, 2001, CANCER RES, V61, P6213; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Park JG, 2001, J BIOL CHEM, V276, P47751, DOI 10.1074/jbc.C100524200; Passilly P, 1999, BIOCHEM PHARMACOL, V58, P1001, DOI 10.1016/S0006-2952(99)00182-3; Pauley CJ, 2002, CELL SIGNAL, V14, P351, DOI 10.1016/S0898-6568(01)00260-1; Peters JM, 1997, CARCINOGENESIS, V18, P2029, DOI 10.1093/carcin/18.11.2029; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Ristow M, 1998, NEW ENGL J MED, V339, P953, DOI 10.1056/NEJM199810013391403; Rokos CL, 1997, J BIOL CHEM, V272, P13452, DOI 10.1074/jbc.272.20.13452; Rose ML, 1999, CARCINOGENESIS, V20, P27, DOI 10.1093/carcin/20.1.27; Sajan MP, 2002, BIOCHEM J, V362, P665, DOI 10.1042/0264-6021:3620665; Shah BH, 2003, J BIOL CHEM, V278, P2866, DOI 10.1074/jbc.m208783200; Shintani M, 2001, DIABETES, V50, P2296, DOI 10.2337/diabetes.50.10.2296; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; Sorokin A, 2001, J BIOL CHEM, V276, P21521, DOI 10.1074/jbc.M008869200; Suzaki Y, 2002, J BIOL CHEM, V277, P9614, DOI 10.1074/jbc.M111790200; Teruel T, 2003, J BIOL CHEM, V278, P263, DOI 10.1074/jbc.M207200200; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VANDENHEUVEL JP, 1999, J NUTR, V129, P575; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Wong CW, 2002, P NATL ACAD SCI USA, V99, P14783, DOI 10.1073/pnas.192569699; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yonemitsu S, 2001, DIABETES, V50, P1093, DOI 10.2337/diabetes.50.5.1093; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	66	93	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46261	46269		10.1074/jbc.M307827200	http://dx.doi.org/10.1074/jbc.M307827200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12966092	Green Published, hybrid			2022-12-25	WOS:000186569400009
J	Hellmark, T; Chen, LL; Ohlsson, S; Wieslander, R; Bolton, WK				Hellmark, T; Chen, LL; Ohlsson, S; Wieslander, R; Bolton, WK			Point mutations of single amino acids abolish ability of alpha(3) NC1 domain to elicit experimental autoimmune glomerulonephritis in rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	33rd Annual Meeting of the American-Society-of-Nephrology	OCT 10-16, 2000	TORONTO, CANADA	Amer Soc Nephrol			GLOMERULAR-BASEMENT-MEMBRANE; ANTI-GBM GLOMERULONEPHRITIS; IV COLLAGEN; GOODPASTURE AUTOANTIGEN; T-CELLS; MONOCLONAL-ANTIBODIES; NEPHRITOGENIC ANTIGEN; ALPHA-3(IV) COLLAGEN; SYNTHETIC PEPTIDES; INBRED RATS	We previously showed concordance between Goodpasture syndrome antibody binding and production of experimental glomerulonephritis using human chimeric proteins. We now examine a more limited aminoterminal region of alpha(3)( IV) non- collagenous domain ( NC1) and the impact of single amino acid ( AA) mutations of this region on glomerulonephritis induction. Rats were immunized with collagenase- solubilized glomerular basement membrane ( csGBM), D3, an alpha(1)( IV) NC1 chimeric protein with 69 AA of alpha(3)( IV) NC1 ( binds Goodpasture sera), D4, the D3 construct shortened by 4 AA ( nonbinding), P9, P10, single AA mutants ( non- binding), and S2, alpha(1)( IV) NC1 with 9 AA of alpha(3)( IV) NC1 ( binding). All rats immunized with csGBM and S2 and 50% of D3 rats developed glomerulonephritis. csGBM rats had intense GBM- bound IgG deposits, but S2 and D3 rats had minimal deposits. None of the D4, P9, or P10 rats developed glomerulonephritis. Lymphocytes from nephritic rats proliferated with csGBM, S2, and D3, but not with D4, P9, or P10. Discrete segments of alpha(3)( IV) NC1 within the alpha(1)( IV) NC1 backbone can induce glomerulonephritis. Single AA mutations within that epitope render the antigen unresponsive to Goodpasture sera and incapable of inducing glomerulonephritis. These studies support the concordance of glomerulonephritis inductivity and Goodpasture serum binding. Further, they define a critical limited AA sequence within alpha(3)( IV) NC1 of nine or fewer AA, which confers nephritogenicity to the non-nephritogenic alpha(1)( IV) NC1 without in vivo antibody binding. This region may be a T- cell epitope responsible for induction of glomerulonephritis in this model in rats and Goodpasture syndrome in man.	Univ Virginia, Hlth Sci Ctr, Dept Med, Div Nephrol, Charlottesville, VA 22908 USA; Univ Lund Hosp, Dept Nephrol, S-22185 Lund, Sweden	University of Virginia; Lund University; Skane University Hospital	Bolton, WK (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Med, Div Nephrol, POB 800133, Charlottesville, VA 22908 USA.		Hellmark, Thomas/U-6289-2017; Ohlsson, Sophie/W-9495-2019	Hellmark, Thomas/0000-0002-2952-1155; Ohlsson, Sophie/0000-0002-5253-1650	NIDDK NIH HHS [DK 55801] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055801] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOLTON WK, 1976, AM J PATHOL, V85, P277; BOLTON WK, 1984, J CLIN INVEST, V73, P1263, DOI 10.1172/JCI111328; BOLTON WK, 1988, KIDNEY INT, V34, P598, DOI 10.1038/ki.1988.224; BOLTON WK, 1993, KIDNEY INT, V44, P294, DOI 10.1038/ki.1993.244; BOLTON WK, 1995, KIDNEY INT, V47, P404, DOI 10.1038/ki.1995.53; BOLTON WK, 1978, CLIN EXP IMMUNOL, V33, P474; Bolton WK, 2002, J CLIN INVEST, V109, P713, DOI 10.1172/JCI200215285; Bolton WK, 1996, KIDNEY INT, V50, P1753, DOI 10.1038/ki.1996.495; Bolton WK, 1996, KIDNEY INT, V49, P327, DOI 10.1038/ki.1996.49; BOLTON WK, 2003, 36 ANN M AM SOC NEPH; Borza DB, 2000, J BIOL CHEM, V275, P6030, DOI 10.1074/jbc.275.8.6030; CHEN L, 2003, KIDNEY INT, V64, P1; Gunnarsson A, 2000, J BIOL CHEM, V275, P30844, DOI 10.1074/jbc.M004717200; Hellmark T, 1999, J BIOL CHEM, V274, P25862, DOI 10.1074/jbc.274.36.25862; Hellmark T, 1999, KIDNEY INT, V55, P936, DOI 10.1046/j.1523-1755.1999.055003936.x; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JANEWAY CA, 1996, IMMUNO BIOL IMMUNE S; JOHANSSON C, 1991, CONNECT TISSUE RES, V25, P229, DOI 10.3109/03008209109029159; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; Kalluri R, 1997, J CLIN INVEST, V100, P2263, DOI 10.1172/JCI119764; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER RA, 1966, J EXP MED, V124, P431, DOI 10.1084/jem.124.3.431; LERNER RA, 1967, J EXP MED, V126, P989, DOI 10.1084/jem.126.6.989; LUO AM, 1993, J CLIN INVEST, V92, P2117, DOI 10.1172/JCI116812; Luo AM, 2002, J LAB CLIN MED, V139, P303, DOI 10.1067/mlc.2002.123623; Merkel F, 1996, KIDNEY INT, V49, P1127, DOI 10.1038/ki.1996.163; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; NISHIKAWA K, 1993, J EXP MED, V177, P667, DOI 10.1084/jem.177.3.667; Phelps RG, 1998, J BIOL CHEM, V273, P11440, DOI 10.1074/jbc.273.19.11440; QUERIN S, 1986, CLIN NEPHROL, V25, P134; QUINONES S, 1992, J BIOL CHEM, V267, P19780; Reynolds J, 1998, NEPHROL DIAL TRANSPL, V13, P44, DOI 10.1093/ndt/13.1.44; REYNOLDS J, 1993, J AUTOIMMUN, V6, P571, DOI 10.1006/jaut.1993.1047; REYNOLDS J, 1991, CLIN EXP IMMUNOL, V85, P28; Reynolds J, 2000, J CLIN INVEST, V105, P643, DOI 10.1172/JCI6710; Reynolds J, 2001, J AM SOC NEPHROL, V12, P61, DOI 10.1681/ASN.V12161; RHIM SH, 1992, J CLIN INVEST, V89, P28, DOI 10.1172/JCI115572; Ryan JJ, 1998, CLIN EXP IMMUNOL, V113, P17, DOI 10.1046/j.1365-2249.1998.00623.x; Ryan JJ, 1998, NEPHROL DIAL TRANSPL, V13, P602, DOI 10.1093/ndt/13.3.602; SADO Y, 1991, VIRCHOWS ARCH B, V60, P345, DOI 10.1007/BF02899566; SADO Y, 1989, J PATHOL, V158, P325, DOI 10.1002/path.1711580410; SADO Y, 1984, J CLIN LAB IMMUNOL, V15, P199; SADO Y, 1992, J PATHOL, V168, P221, DOI 10.1002/path.1711680211; Sado Y, 1998, KIDNEY INT, V53, P664, DOI 10.1046/j.1523-1755.1998.00795.x; SADO Y, 1986, J CLIN LAB IMMUNOL, V19, P193; SHIBATA S, 1971, J IMMUNOL, V106, P1284; Sugihara K, 1996, J PATHOL, V178, P352; Wu J, 2002, J CLIN INVEST, V109, P517, DOI 10.1172/JCI200213876; Wu J, 2001, J IMMUNOL, V167, P2388, DOI 10.4049/jimmunol.167.4.2388	49	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46516	46522		10.1074/jbc.M211951200	http://dx.doi.org/10.1074/jbc.M211951200			7	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12970356	hybrid			2022-12-25	WOS:000186569400036
J	Jo, MJ; Thomas, KS; Wu, LH; Gonias, SL				Jo, MJ; Thomas, KS; Wu, LH; Gonias, SL			Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY BREAST-CANCER; REGULATED KINASE 1; OVARIAN-CANCER; HUMAN CARCINOMA; PROGNOSTIC-SIGNIFICANCE; DOWN-REGULATION; LIGAND-BINDING; TUMOR-GROWTH; CYCLIN D1; IN-VITRO	The urokinase-type plasminogen activator receptor ( uPAR) is released from human cancers and is readily detected in blood. In animal models, soluble uPAR (SuPAR) antagonizes cancer progression; however, the mechanism by which SuPAR functions in vivo remains unclear. It is generally thought that SuPAR scavenges uPA and prevents its interaction with membrane-anchored uPAR. In this study, we demonstrate a novel molecular mechanism by which SuPAR may inhibit cancer progression. We show that SuPAR has the potential to directly and in a uPA-independent manner block the signaling activity of membrane-anchored uPAR. Whether SuPAR inhibits signaling is cell type-specific, depending on the state of the endogenous uPA-uPAR signaling system. In uPAR-deficient cells that lack endogenous uPAR signaling, including uPAR -/- murine embryonic fibroblasts and human embryonal kidney 293 cells, SuPAR functions as a partial signaling agonist that activates ERK/mitogen-activated protein kinase. By contrast, in cells with potent autocrine uPA-uPAR signaling systems, including MDA-MB 231 breast cancer cells and low density lipoprotein receptor-related protein-1-deficient murine embryonic fibroblasts, SuPAR substantially decreases ERK activation. The mechanism probably involves competitive displacement of membrane-anchored uPAR-uPA complex from signaling adaptor proteins. As a result of its effects on cell signaling, SuPAR blocks cell growth and inhibits cellular invasion of Matrigel(TM). Cleavage of SuPAR by proteinases increases its signaling agonist activity and reverses its inhibitory effects on growth and invasion. Thus, proteolytic cleavage represents a molecular switch that neutralizes the anticancer activity of SuPAR.	Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Gonias, SL (corresponding author), Univ Virginia, Sch Med, Dept Pathol, POB 800214, Charlottesville, VA 22908 USA.	slg2t@virginia.edu			NCI NIH HHS [R01 CA 94900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Carriero MV, 1999, CANCER RES, V59, P5307; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; Duffy MJ, 2002, CLIN CHEM, V48, P1194; Duffy MJ, 1999, J SURG ONCOL, V71, P130, DOI 10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO;2-9; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Filardo EJ, 1996, J CELL SCI, V109, P1615; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; GYETKO MR, 1993, J LEUKOCYTE BIOL, V53, P598, DOI 10.1002/jlb.53.5.598; Higazi AAR, 1997, J BIOL CHEM, V272, P5348, DOI 10.1074/jbc.272.8.5348; Hildenbrand R, 1998, LAB INVEST, V78, P59; Holst-Hansen C, 1999, BRIT J CANCER, V81, P203, DOI 10.1038/sj.bjc.6690678; Hoyer-Hansen G, 1997, FEBS LETT, V420, P79, DOI 10.1016/S0014-5793(97)01491-9; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; Jo M, 2002, J BIOL CHEM, V277, P12479, DOI 10.1074/jbc.M111147200; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Knoop A, 1998, BRIT J CANCER, V77, P932, DOI 10.1038/bjc.1998.154; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; Kruger A, 2000, CANCER GENE THER, V7, P292, DOI 10.1038/sj.cgt.7700144; Lakka SS, 2002, ONCOGENE, V21, P5601, DOI 10.1038/sj.onc.1205646; Li Y, 2003, J BIOL CHEM, V278, P29925, DOI 10.1074/jbc.M300751200; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Lutz V, 2001, BIOL CHEM, V382, P789, DOI 10.1515/BC.2001.095; Ma Z, 2002, J CELL BIOL, V159, P1061, DOI 10.1083/jcb.200207070; Ma Z, 2001, J CELL SCI, V114, P3387; Mizukami IF, 1998, J LEUKOCYTE BIOL, V64, P203, DOI 10.1002/jlb.64.2.203; Montuori N, 2002, J BIOL CHEM, V277, P46932, DOI 10.1074/jbc.M207494200; Mustjoki S, 2000, CANCER RES, V60, P7126; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; Pappot H, 1997, EUR J CANCER, V33, P867, DOI 10.1016/S0959-8049(96)00523-0; Pedersen AN, 1997, J IMMUNOL METHODS, V203, P55, DOI 10.1016/S0022-1759(97)00008-2; PEDERSEN N, 1993, J CLIN INVEST, V92, P2160, DOI 10.1172/JCI116817; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; PLOUG M, 1993, J BIOL CHEM, V268, P17539; PYKE C, 1993, FEBS LETT, V326, P69, DOI 10.1016/0014-5793(93)81763-P; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Riisbro R, 2002, CLIN CANCER RES, V8, P1132; Schmitt M, 1997, THROMB HAEMOSTASIS, V78, P285; Sidenius N, 2000, FEBS LETT, V470, P40, DOI 10.1016/S0014-5793(00)01282-5; Sier CFM, 1998, CANCER RES, V58, P1843; Stephens RW, 1997, CLIN CHEM, V43, P1868; Stephens RW, 1999, JNCI-J NATL CANCER I, V91, P869, DOI 10.1093/jnci/91.10.869; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Webb DJ, 2000, J CELL SCI, V113, P123; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; WILHELM O, 1994, FEBS LETT, V337, P131, DOI 10.1016/0014-5793(94)80259-9; Wilhelm OG, 1999, J CELL PHYSIOL, V180, P225, DOI 10.1002/(SICI)1097-4652(199908)180:2<225::AID-JCP10>3.0.CO;2-2; WILLNOW TE, 1994, J CELL SCI, V107, P719; Xue W, 1997, CANCER RES, V57, P1682; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393	68	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46692	46698		10.1074/jbc.M308808200	http://dx.doi.org/10.1074/jbc.M308808200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963722	hybrid			2022-12-25	WOS:000186569400059
J	Kotturi, MF; Carlow, DA; Lee, JC; Ziltener, HJ; Jefferies, WA				Kotturi, MF; Carlow, DA; Lee, JC; Ziltener, HJ; Jefferies, WA			Identification and functional characterization of voltage-dependent calcium channels in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; STATIONARY NIGHT BLINDNESS; INDUCED ERK ACTIVATION; CA2+ INFLUX; ANTIGEN-RECEPTOR; CYCLOSPORINE-A; CELLS; NIFEDIPINE; GENE; SIGNALS	In T lymphocytes, sustained calcium (Ca2+) influx through Ca2+ channels localized in the plasma membrane is critical for T cell activation and proliferation. Previous studies indicated that voltage-dependent Ca2+ channels (VDCCs) play a role in Ca2+ mobilization during T lymphocyte activation. However, the role of VDCCs in otherwise nonexcitable cells is still poorly understood. We used RT-PCR to identify a transcript encoding the pore-forming alpha(1F)-subunit of an L-type Ca2+ channel in T lymphocytes. Its identity was confirmed by DNA sequencing. To further investigate the contribution of Ca2+ influx through VDCCs, we assessed the effects of the 1,4-dihydropyridine L-type Ca2(+) channel agonist, (+/-) Bay K 8644, and antagonist, nifedipine, on the human Jurkat T cell leukemia line, human peripheral blood T lymphocytes and mouse splenocytes. We found that treatment of T lymphocytes with (+/-) Bay K 8644 increased intracellular Ca2+ and induced the activation of phosphoextracellular-regulated kinase 1/2 (Erk1/2), whereas nifedipine blocked Ca2+ influx, the activity of Erk1/2 and nuclear factor of activated T cells ( NFAT), interleukin-2 (IL-2) production, and IL-2 receptor expression. Nifedipine also significantly suppressed splenocyte proliferation in an in vitro mixed lymphocyte reaction and the proliferation of male antigen (H-Y)-specific T cell receptor-transgenic CD8(+) T cells in transplanted male mice in vivo. Taken together these novel findings indicate that an L-type Ca2+ channel plays a significant role in the Ca2+ influx pathways mediating T lymphocyte activation and proliferation in vitro and in vivo.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Jefferies, WA (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.							Atherfold PA, 1999, MOL IMMUNOL, V36, P543, DOI 10.1016/S0161-5890(99)00076-0; Barger SW, 1999, NEUROSCIENCE, V89, P101, DOI 10.1016/S0306-4522(98)00312-1; Bech-Hansen NT, 1998, NAT GENET, V19, P264, DOI 10.1038/947; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BIRX DL, 1984, J IMMUNOL, V133, P2904; Brereton HM, 1997, CELL CALCIUM, V22, P39, DOI 10.1016/S0143-4160(97)90088-9; Carlow DA, 2001, J IMMUNOL, V166, P256, DOI 10.4049/jimmunol.166.1.256; Claussen D W, 1995, Gastroenterol Nurs, V18, P71, DOI 10.1097/00001610-199503000-00008; Cui J, 2002, J BIOL CHEM, V277, P47175, DOI 10.1074/jbc.M205870200; Densmore JJ, 1996, AM J PHYSIOL-CELL PH, V271, pC1494, DOI 10.1152/ajpcell.1996.271.5.C1494; DENSMORE JJ, 1992, FEBS LETT, V312, P161, DOI 10.1016/0014-5793(92)80926-8; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; FAGNI L, 1994, PFLUG ARCH EUR J PHY, V429, P176, DOI 10.1007/BF00374310; Fomina AF, 2000, J CELL BIOL, V150, P1435, DOI 10.1083/jcb.150.6.1435; Franklin RA, 2000, MOL IMMUNOL, V37, P675, DOI 10.1016/S0161-5890(00)00087-0; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; Gamberucci A, 2002, BIOCHEM J, V364, P245, DOI 10.1042/bj3640245; GELFAND EW, 1986, EUR J IMMUNOL, V16, P907, DOI 10.1002/eji.1830160806; Guse AH, 1998, CRIT REV IMMUNOL, V18, P419, DOI 10.1615/CritRevImmunol.v18.i5.20; HAVERSTICK DM, 1991, J IMMUNOL, V146, P3306; Hirota J, 1998, BIOCHEM J, V333, P615, DOI 10.1042/bj3330615; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; KAJI DM, 1990, AM J PHYSIOL, V259, pC332, DOI 10.1152/ajpcell.1990.259.2.C332; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; KITAGAWA M, 1991, FEBS LETT, V283, P210, DOI 10.1016/0014-5793(91)80590-Y; LARKIN JG, 1992, EPILEPSIA, V33, P760, DOI 10.1111/j.1528-1157.1992.tb02358.x; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; MARX M, 1990, NEPHROL DIAL TRANSPL, V5, P1038, DOI 10.1093/ndt/5.12.1038; Medema JP, 1999, HUM IMMUNOL, V60, P403, DOI 10.1016/S0198-8859(99)00008-7; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; Mitterdorfer J, 1998, J BIOENERG BIOMEMBR, V30, P319, DOI 10.1023/A:1021933504909; MORGANO A, 1990, EUR J CLIN PHARMACOL, V39, P545, DOI 10.1007/BF00316092; PADBERG WM, 1990, TRANSPLANT P, V22, P2337; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; PORCHET HC, 1992, EUR J CLIN PHARMACOL, V43, P551, DOI 10.1007/BF02285101; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Savignac M, 2001, FASEB J, V15, P1577, DOI 10.1096/fj.00-0733fje; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Strom TM, 1998, NAT GENET, V19, P260, DOI 10.1038/940; Tanimura A, 2000, J BIOL CHEM, V275, P27488; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; Willmott NJ, 1996, FEBS LETT, V394, P159, DOI 10.1016/0014-5793(96)00939-8; YOUNG W, 1988, MOL PHARMACOL, V34, P239; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zhang X, 1997, J PHARMACOL EXP THER, V281, P1247	49	90	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46949	46960		10.1074/jbc.M309268200	http://dx.doi.org/10.1074/jbc.M309268200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12954628	hybrid			2022-12-25	WOS:000186569400089
J	Majors, AK; Austin, RC; de la Motte, CA; Pyeritz, RE; Hascall, VC; Kessler, SP; Sen, G; Strong, SA				Majors, AK; Austin, RC; de la Motte, CA; Pyeritz, RE; Hascall, VC; Kessler, SP; Sen, G; Strong, SA			Endoplasmic reticulum stress induces hyaluronan deposition and leukocyte adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL PROPEPTIDE; T-CELL EXTRAVASATION; SMOOTH-MUSCLE-CELLS; PRO-ALPHA-1(I) CHAIN; CHONDROITIN SULFATE; COLLAGEN PRODUCTION; CD44; EXPRESSION; HOMOCYSTEINE; ACTIVATION	There is mounting evidence that perturbations in endoplasmic reticulum ( ER) function play a key role in the pathogenesis of a broad range of diseases. We have examined the ability of ER stress to modulate leukocyte binding to colonic and aortic smooth muscle cells. In vitro, control smooth muscle cells bind few leukocytes, but treatment with compounds that induce ER stress, including tunicamycin, A23187, and thapsigargin, promotes leukocyte binding. Likewise, dextran sulfate, another agent capable of inducing ER stress and promoting inflammation in vivo, strongly induces leukocyte adhesion. The bound leukocytes are released by hyaluronidase treatment, indicating a critical role for hyaluronan-containing structures in mediating leukocyte binding. Affinity histochemistry demonstrated that hyaluronan accumulates and is present in cable-like structures in the treated, but not the untreated, cultures and that these structures serve as attachment sites for leukocytes. Hyaluronan-rich regions of both murine and human inflamed colon contain numerous cells that stain intensely for ER-resident chaperones containing the KDEL sequence, demonstrating a relationship between ER stress and hyaluronan deposition in vivo. These results indicate that ER stress may contribute to chronic inflammation by forming a hyaluronan-rich extracellular matrix that is conducive to leukocyte binding.	Cleveland Clin Fdn, Dept Immunol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Colorectal Surg, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Biomed Engn, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Mol Biol, Cleveland, OH 44195 USA; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8V 1C3, Canada; Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada; Univ Penn, Sch Med, Dept Med, Div Med Genet, Philadelphia, PA 19104 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; McMaster University; University of Pennsylvania	Majors, AK (corresponding author), Cleveland Clin Fdn, Dept Immunol, NB30,9500 Euclid Ave, Cleveland, OH 44195 USA.	majorsa@ccf.org			NIDDK NIH HHS [DK 58867] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058867] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Bertolotti A, 2001, J CLIN INVEST, V107, P585, DOI 10.1172/JCI11476; BYERS PH, 2001, METABOLIC MOL BASES, P5241; CHESSLER SD, 1993, J BIOL CHEM, V268, P18218; CHESSLER SD, 1993, J BIOL CHEM, V268, P18226; de Fougerolles AR, 2000, IMMUNITY, V13, P749, DOI 10.1016/S1074-7613(00)00073-X; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; de la Motte CA, 1999, J BIOL CHEM, V274, P30747, DOI 10.1074/jbc.274.43.30747; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; DELAMOTTE CA, 2003, HYALURONAN CHEM BIOC, P381; Estess P, 1999, J EXP MED, V190, P9, DOI 10.1084/jem.190.1.9; FEDARKO NS, 1995, J BONE MINER RES, V10, P1122; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Gerdin B, 1997, J INTERN MED, V242, P49, DOI 10.1046/j.1365-2796.1997.00173.x; Goodstone NJ, 1998, ARCH BIOCHEM BIOPHYS, V350, P26, DOI 10.1006/abbi.1997.0472; Guo JJ, 2000, EMBO J, V19, P6891, DOI 10.1093/emboj/19.24.6891; HOBDEN AN, 1978, BIOCHEM J, V170, P57, DOI 10.1042/bj1700057; HOLBROOK KA, 1981, LAB INVEST, V44, P342; Johnson PRA, 2001, CLIN EXP PHARMACOL P, V28, P233, DOI 10.1046/j.1440-1681.2001.03426.x; Johnsson C, 2000, SURGERY, V127, P650, DOI 10.1067/msy.2000.106587; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; LAMANDE SR, 1995, J BIOL CHEM, V270, P8642, DOI 10.1074/jbc.270.15.8642; Laurent TC, 1996, ANN MED, V28, P241, DOI 10.3109/07853899609033126; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Lesley J, 1997, GLYCOCONJUGATE J, V14, P611, DOI 10.1023/A:1018540610858; Majors A, 1997, ARTERIOSCL THROM VAS, V17, P2074, DOI 10.1161/01.ATV.17.10.2074; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; Nandi A, 2000, J BIOL CHEM, V275, P14939, DOI 10.1074/jbc.275.20.14939; OOHIRA A, 1989, BONE, V10, P409, DOI 10.1016/8756-3282(89)90071-9; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Pereira L, 1999, P NATL ACAD SCI USA, V96, P3819, DOI 10.1073/pnas.96.7.3819; Pyeritz RE, 2000, ANNU REV MED, V51, P481, DOI 10.1146/annurev.med.51.1.481; Pyeritz RE, 1993, MCKUSICKS HERITABLE, P137; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; SHIMIZU Y, 1991, FASEB J, V5, P2292, DOI 10.1096/fasebj.5.9.1860621; Siegelman MH, 1999, J LEUKOCYTE BIOL, V66, P315, DOI 10.1002/jlb.66.2.315; Strong SA, 1998, GASTROENTEROLOGY, V114, P1244, DOI 10.1016/S0016-5085(98)70431-7; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; TURAKAINEN H, 1980, BIOCHIM BIOPHYS ACTA, V628, P388, DOI 10.1016/0304-4165(80)90388-8; UNDERHILL C, 1992, J CELL SCI, V103, P293; Vaday GG, 2001, J LEUKOCYTE BIOL, V69, P885; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Yang R, 2002, SCAND J IMMUNOL, V55, P2, DOI 10.1046/j.0300-9475.2001.01033.x	50	132	136	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47223	47231		10.1074/jbc.M304871200	http://dx.doi.org/10.1074/jbc.M304871200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12954638	hybrid			2022-12-25	WOS:000186569400122
J	Yu, G; Luo, HY; Wu, YL; Wu, JP				Yu, G; Luo, HY; Wu, YL; Wu, JP			Mouse EphrinB3 augments T-cell signaling and responses to T-cell receptor ligation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; EPH-FAMILY; IMMUNOLOGICAL SYNAPSE; CYCLOSPORINE-A; CROSS-LINKING; EXPRESSION; LIGANDS; ACTIVATION; RAPAMYCIN; PATHWAY	Ephrins ( EFN) are cell- surface ligands of Ephs, the largest family of cell- surface receptor tyrosine kinases. The function of EFNs in the immune system has not been well studied, although some EFNs and Ephs are expressed at high levels on certain leukocytes. We report here that EFNB3 and its receptors ( collectively called EFNB3Rs, as EFNB3 binds to multiple EphBs) were expressed in peripheral T cells and monocytes/ macrophages, with T cells being the dominant EFNB3 (+) and EFNB3R(+) cell type. Solid- phase EFNB3- Fc in the presence of suboptimal anti- CD3 crosslinking enhanced T- cell responses in terms of proliferation, activation marker expression, interferon-gamma but not interleukin- 2 production, and cytotoxic T- cell activity. EFNB3R co-stimulation in the presence of phorbol 12- myristate 13-acetate was insensitive to cyclosporin A, similar to CD28 costimulation, suggesting they might share a part of the signaling pathway. After crosslinking, T- cell receptor and EFNB3R congregated into aggregated rafts, and this provided a morphological basis for signaling pathways of T- cell receptor and EFNB3R to interact. Solid-phase EFNB3- Fc augmented p38 and p44/ 42 MAPK activation further downstream of the signaling pathway. These data suggest that EFNB3 is important in T- cell/ T-cell and T- cell/ antigen- presenting cell collaboration to enhance T- cell activation and function.	Univ Montreal, Notre Dame Hosp, CHUM, Res Ctr,Lab Immunol, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Notre Dame Hosp, CHUM, Serv Nephrol, Montreal, PQ H2L 4M1, Canada; Zhejiang Univ, Zhejiang Med Coll, Affiliated Hosp 2, Dept Surg, Hangzhou 310009, Peoples R China	Universite de Montreal; Universite de Montreal; Zhejiang University	Wu, JP (corresponding author), Univ Montreal, Notre Dame Hosp, CHUM, Res Ctr,Lab Immunol, Pavil DeSeve,Room Y-5616,1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.							Aasheim HC, 1997, BLOOD, V90, P3613, DOI 10.1182/blood.V90.9.3613; Almawi WY, 1999, EUR J PHARMACOL, V381, P51, DOI 10.1016/S0014-2999(99)00558-0; ANDRES AC, 1994, ONCOGENE, V9, P1461; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Brambilla R, 1996, MOL CELL NEUROSCI, V8, P199, DOI 10.1006/mcne.1996.0057; Carreno BM, 2002, ANNU REV IMMUNOL, V20, P29, DOI 10.1146/annurev.immunol.20.091101.091806; Chen HF, 1996, J IMMUNOL, V157, P4297; CIOSSEK T, 1995, ONCOGENE, V11, P2085; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; FOX GM, 1995, ONCOGENE, V10, P897; Freywald A, 2002, J BIOL CHEM, V277, P3823, DOI 10.1074/jbc.M108011200; Freywald A, 2003, J BIOL CHEM, V278, P10150, DOI 10.1074/jbc.M208179200; Gale NW, 1996, ONCOGENE, V13, P1343; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Ghosh P, 2002, BLOOD, V99, P4517, DOI 10.1182/blood-2001-11-0062; Gurniak CB, 1996, ONCOGENE, V13, P777; HATHCOCK KS, 1994, J EXP MED, V180, P631, DOI 10.1084/jem.180.2.631; Helbling PM, 1999, DEV DYNAM, V216, P361, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<361::AID-DVDY5>3.0.CO;2-W; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kullander K, 2001, GENE DEV, V15, P877, DOI 10.1101/gad.868901; Lickliter JD, 1996, P NATL ACAD SCI USA, V93, P145, DOI 10.1073/pnas.93.1.145; LUO HY, 1992, TRANSPLANTATION, V53, P1071, DOI 10.1097/00007890-199205000-00019; Luo HY, 2001, J IMMUNOL, V167, P1362, DOI 10.4049/jimmunol.167.3.1362; Luo HY, 2002, J CLIN INVEST, V110, P1141, DOI 10.1172/JCI200215883; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Munoz JJ, 2002, J IMMUNOL, V169, P177, DOI 10.4049/jimmunol.169.1.177; Rissoan MC, 2002, BLOOD, V100, P3295, DOI 10.1182/blood-2002-02-0638; Salojin KV, 1999, J IMMUNOL, V163, P844; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; Shimoyama M, 2000, GROWTH FACTORS, V18, P63, DOI 10.3109/08977190009003234; Sims TN, 2002, IMMUNOL REV, V186, P100, DOI 10.1034/j.1600-065X.2002.18610.x; Steube KG, 1999, LEUKEMIA LYMPHOMA, V33, P371, DOI 10.3109/10428199909058438; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang J, 2001, J CLIN INVEST, V108, P1771, DOI 10.1172/JCI200113827; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; Wilkinson DG, 2000, INT REV CYTOL, V196, P177; Xavier R, 1999, CURR OPIN IMMUNOL, V11, P265, DOI 10.1016/S0952-7915(99)80043-0; Zhang J, 2001, J CLIN INVEST, V107, P1459, DOI 10.1172/JCI12159	45	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47209	47216		10.1074/jbc.M306659200	http://dx.doi.org/10.1074/jbc.M306659200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	13679370	hybrid			2022-12-25	WOS:000186569400120
J	Abhyankar, MM; Zzaman, S; Bastia, D				Abhyankar, MM; Zzaman, S; Bastia, D			Reconstitution of R6K DNA replication in vitro using 22 purified proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; ESCHERICHIA-COLI CHROMOSOME; R-PLASMID RSF1040; INITIATOR PROTEIN; POLYMERASE-III; BINDING-SITES; ORIGIN-GAMMA; ENZYMATIC REPLICATION; NUCLEOTIDE-SEQUENCE; COPY NUMBER	We have reconstituted a multiprotein system consisting of 22 purified proteins that catalyzed the initiation of replication specifically at ori gamma of R6K, elongation of the forks, and their termination at specific replication terminators. The initiation was strictly dependent on the plasmid-encoded initiator protein pi and on the host-encoded initiator DnaA. The wild type pi was almost inert, whereas a mutant form containing 3 amino acid substitutions that tended to monomerize the protein was effective in initiating replication. The replication in vitro was primed by DnaG primase, whereas in a crude extract system that had not been fractionated, it was dependent on RNA polymerase. The DNA-bending protein IHF was needed for optimal replication and its substitution by HU, unlike in the oriC system, was less effective in promoting optimal replication. In contrast, wild type pi-mediated replication in vivo requires IHF. Using a template that contained ori gamma flanked by two asymmetrically placed Ter sites in the blocking orientation, replication proceeded in the Cairns type mode and generated the expected types of termination products. A majority of the molecules progressed counterclockwise from the ori, in the same direction that has been observed in vivo. Many features of replication in the reconstituted system appeared to mimic those of in vivo replication. The system developed here is an important milestone in continuing biochemical analysis of this interesting replicon.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Bastia, D (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.							ABLES AL, 1991, P NATL ACAD SCI USA, V88, P9011; BASTIA D, 1981, P NATL ACAD SCI-BIOL, V78, P2095, DOI 10.1073/pnas.78.4.2095; Bastia D., 1996, DNA REPLICATION EUKA, P177; BIEK DP, 1989, J BACTERIOL, V171, P2066, DOI 10.1128/jb.171.4.2066-2074.1989; BIEK DP, 1989, J BACTERIOL, V171, P2056, DOI 10.1128/jb.171.4.2056-2065.1989; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; Bussiere DE, 1999, MOL MICROBIOL, V31, P1611, DOI 10.1046/j.1365-2958.1999.01287.x; Chattoraj D K, 1995, Genet Eng (N Y), V17, P81; Chattoraj D K, 1985, Basic Life Sci, V30, P355; CHATTORAJ DK, 1988, CELL, V52, P551, DOI 10.1016/0092-8674(88)90468-0; Crooke E, 1995, METHOD ENZYMOL, V262, P500; CROSA JH, 1978, J MOL BIOL, V124, P443, DOI 10.1016/0022-2836(78)90181-X; CROSA JH, 1980, J BIOL CHEM, V255, P1075; CROSA JH, 1976, J BACTERIOL, V126, P454, DOI 10.1128/JB.126.1.454-466.1976; Datta HJ, 1999, P NATL ACAD SCI USA, V96, P73, DOI 10.1073/pnas.96.1.73; Fang LH, 1999, MOL CELL, V4, P541, DOI 10.1016/S1097-2765(00)80205-1; FILUTOWICZ M, 1985, NUCLEIC ACIDS RES, V13, P103, DOI 10.1093/nar/13.1.103; FILUTOWICZ M, 1988, NUCLEIC ACIDS RES, V16, P3829, DOI 10.1093/nar/16.9.3829; GERMINO J, 1983, CELL, V34, P125, DOI 10.1016/0092-8674(83)90142-3; GERMINO J, 1983, CELL, V32, P131, DOI 10.1016/0092-8674(83)90503-2; INUZUKA M, 1978, P NATL ACAD SCI USA, V75, P5381, DOI 10.1073/pnas.75.11.5381; INUZUKA M, 1975, BIOCHEMISTRY-US, V17, P2567; INUZUKA N, 1980, J BIOL CHEM, V255, P1071; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KELLEY W, 1985, P NATL ACAD SCI USA, V82, P2574, DOI 10.1073/pnas.82.9.2574; KELLEY WL, 1991, J BIOL CHEM, V266, P15924; KELLEY WL, 1992, NEW BIOL, V4, P569; KELLEY WL, 1992, P NATL ACAD SCI USA, V89, P5078, DOI 10.1073/pnas.89.11.5078; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; Kim DR, 1996, J BIOL CHEM, V271, P20681, DOI 10.1074/jbc.271.34.20681; KITTELL BL, 1991, P NATL ACAD SCI USA, V88, P1389, DOI 10.1073/pnas.88.4.1389; KOLTER R, 1978, CELL, V15, P1199, DOI 10.1016/0092-8674(78)90046-6; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; Konieczny I, 1997, P NATL ACAD SCI USA, V94, P14378, DOI 10.1073/pnas.94.26.14378; LEARN B, 1993, COLD SPRING HARB SYM, V58, P389, DOI 10.1101/SQB.1993.058.01.046; LOVETT MA, 1975, P NATL ACAD SCI USA, V72, P2905, DOI 10.1073/pnas.72.8.2905; Lu YB, 1998, EMBO J, V17, P5192, DOI 10.1093/emboj/17.17.5192; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; MACALLISTER TW, 1991, J BIOL CHEM, V266, P16056; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MCEACHERN MJ, 1985, P NATL ACAD SCI USA, V82, P1480, DOI 10.1073/pnas.82.5.1480; MCEACHERN MJ, 1989, P NATL ACAD SCI USA, V86, P7942, DOI 10.1073/pnas.86.20.7942; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; MIRON A, 1994, P NATL ACAD SCI USA, V91, P6438, DOI 10.1073/pnas.91.14.6438; MIRON A, 1992, EMBO J, V11, P1205, DOI 10.1002/j.1460-2075.1992.tb05161.x; MUKHERJEE S, 1988, P NATL ACAD SCI USA, V85, P6287, DOI 10.1073/pnas.85.17.6287; MUKHERJEE S, 1988, CELL, V52, P375, DOI 10.1016/S0092-8674(88)80030-8; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; OGAWA T, 1985, P NATL ACAD SCI USA, V82, P3562, DOI 10.1073/pnas.82.11.3562; PAL SK, 1988, J BACTERIOL, V170, P3554, DOI 10.1128/jb.170.8.3554-3560.1988; Pellegrini O, 2000, BIOCHIMIE, V82, P693, DOI 10.1016/S0300-9084(00)01151-2; Pritchard AE, 1996, J BIOL CHEM, V271, P10291, DOI 10.1074/jbc.271.17.10291; SHON M, 1982, J BIOL CHEM, V257, P13823; STALKER DM, 1979, P NATL ACAD SCI USA, V76, P1648; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; Weigel C, 1997, EMBO J, V16, P6574, DOI 10.1093/emboj/16.21.6574; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WU F, 1995, J BACTERIOL, V177, P6338, DOI 10.1128/jb.177.22.6338-6345.1995; WU F, 1992, NUCLEIC ACIDS RES, V20, P811, DOI 10.1093/nar/20.4.811	61	21	23	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45476	45484		10.1074/jbc.M308516200	http://dx.doi.org/10.1074/jbc.M308516200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12970346	hybrid			2022-12-25	WOS:000186452300053
J	Kwon, YH; Smerdon, MJ				Kwon, YH; Smerdon, MJ			Binding of zinc finger protein transcription factor IIIA to its cognate DNA sequence with single UV photoproducts at specific sites and its effect on DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; RNA GENE; DAMAGED DNA; IN-VITRO; 5S RNA; CHROMATIN; TFIIIA; MECHANISMS; INITIATION; REPLICATION	The relationship between DNA repair efficiency at specific locations in the binding site of the nine-zinc finger protein transcription factor IIIA (TFIIIA) and binding of its individual zinc fingers was studied. Homogeneously damaged oligonucleotides, which contained a single cis-syn cyclobutane thymine dimer (CTD) at one of six different sites in the internal control region (ICR) of the 5 S rRNA gene to generate a series of damaged DNA substrates, were prepared by chemical synthesis. Binding of TFIIIA to the substrates was assayed by measurement of dissociation constants (K-d), dissociation rates (k(off)), and protein-DNA contacts. The results indicated that a single CTD in the ICR does not significantly affect the K-d of TFIIIA. In contrast, CTDs at positions +55 and +72 (from the transcription start site) in the ICR markedly enhanced k(off) of TFIIIA from the complex. In addition, CTDs in these two sites increased methylation of the N-7 of guanines (by dimethyl sulfate) in the zinc finger contacts of the ICR-TFIIIA complex. Furthermore CTDs at +55 and +72 were more efficiently removed from the complex than CTDs at other sites in the ICR by Xenopus oocyte nuclear extracts. This suggests that repair of CTDs closely correlates with changes in the binding of individual zinc fingers of the ICR-TFIIIA complex. These results have implications for the mechanism of DNA damage recognition and repair in protein-DNA complexes.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Smerdon, MJ (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.	smerdon@mail.wsu.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002614, R37ES002614] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES02614] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Batty DP, 2000, GENE, V241, P193, DOI 10.1016/S0378-1119(99)00489-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown ML, 1996, J MOL BIOL, V262, P600, DOI 10.1006/jmbi.1996.0539; CADET J, 1992, J PHOTOCH PHOTOBIO B, V15, P277, DOI 10.1016/1011-1344(92)85135-H; CHEN YH, 1991, P NATL ACAD SCI USA, V88, P9583, DOI 10.1073/pnas.88.21.9583; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; CLEMENS KR, 1994, J MOL BIOL, V244, P23, DOI 10.1006/jmbi.1994.1701; Conconi A, 1999, EMBO J, V18, P1387, DOI 10.1093/emboj/18.5.1387; Conconi A, 2002, P NATL ACAD SCI USA, V99, P649, DOI 10.1073/pnas.022373099; Cordonnier AM, 1999, MUTAT RES-DNA REPAIR, V435, P111, DOI 10.1016/S0921-8777(99)00047-6; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DELRIO S, 1991, NUCLEIC ACIDS RES, V19, P6197; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; Gaillard H, 2003, J BIOL CHEM, V278, P17655, DOI 10.1074/jbc.M300770200; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; HANAS JS, 1984, NUCLEIC ACIDS RES, V12, P2745, DOI 10.1093/nar/12.6.2745; Hara R, 2002, MOL CELL BIOL, V22, P6779, DOI 10.1128/MCB.22.19.6779-6787.2002; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; Hess MT, 1997, P NATL ACAD SCI USA, V94, P6664, DOI 10.1073/pnas.94.13.6664; KIM JK, 1995, PHOTOCHEM PHOTOBIOL, V62, P44, DOI 10.1111/j.1751-1097.1995.tb05236.x; Kosmoski JV, 2001, P NATL ACAD SCI USA, V98, P10113, DOI 10.1073/pnas.181073398; Kosmoski JV, 1999, BIOCHEMISTRY-US, V38, P9485, DOI 10.1021/bi990297h; KOSMOSKI JV, 1999, THESIS WASHINGTON ST; Li SS, 2000, METHODS, V22, P170, DOI 10.1006/meth.2000.1058; Liu XQ, 1997, BIOCHEMISTRY-US, V36, P13710, DOI 10.1021/bi9716736; McBryant SJ, 1996, NUCLEIC ACIDS RES, V24, P2567, DOI 10.1093/nar/24.13.2567; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; Meijer M, 1999, BIOESSAYS, V21, P596, DOI 10.1002/(SICI)1521-1878(199907)21:7<596::AID-BIES8>3.0.CO;2-5; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; Nolte RT, 1998, P NATL ACAD SCI USA, V95, P2938, DOI 10.1073/pnas.95.6.2938; Oda N, 1996, J BIOL CHEM, V271, P13816, DOI 10.1074/jbc.271.23.13816; Park H, 2002, P NATL ACAD SCI USA, V99, P15965, DOI 10.1073/pnas.242422699; Patrick MH., 1976, PHOTOCHEM PHOTOBIOL, V2, P35, DOI [10.1016/B978-0-12-734602-1.50008-3, DOI 10.1016/B978-0-12-734602-1.50008-3]; PIELER T, 1987, CELL, V48, P91, DOI 10.1016/0092-8674(87)90359-X; Reid KJ, 2001, BIOTECHNIQUES, V30, P20, DOI 10.2144/01301bm01; ROMANIUK PJ, 1990, J BIOL CHEM, V265, P17593; SCHROTH GP, 1989, NATURE, V340, P487, DOI 10.1038/340487a0; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; SELBY CP, 1994, MICROBIOL REV, V58, P317, DOI 10.1128/MMBR.58.3.317-329.1994; Shaw PE, 2000, NUCLEIC ACID PROTOCOLS HANDBOOK, P737; Singer B., 1983, MOL BIOL MUTAGENS CA, P45; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; Tang J, 2002, DNA REPAIR, V1, P601, DOI 10.1016/S1568-7864(02)00052-6; Tommasi S, 2000, NUCLEIC ACIDS RES, V28, P3991, DOI 10.1093/nar/28.20.3991; Tommasi S, 1996, BIOCHEMISTRY-US, V35, P15693, DOI 10.1021/bi962117z; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; Ura K, 2001, EMBO J, V20, P2004, DOI 10.1093/emboj/20.8.2004; VELDHOEN N, 1994, BIOCHEMISTRY-US, V33, P7568, DOI 10.1021/bi00190a009; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; WOLFFE AP, 1994, J CELL SCI, V107, P2055; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028	54	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45451	45459		10.1074/jbc.M308645200	http://dx.doi.org/10.1074/jbc.M308645200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12963720	hybrid			2022-12-25	WOS:000186452300050
J	Shimizu, T; Ihara, K; Maesaki, R; Amano, M; Kaibuchi, K; Hakoshima, T				Shimizu, T; Ihara, K; Maesaki, R; Amano, M; Kaibuchi, K; Hakoshima, T			Parallel coiled-coil association of the RhoA-binding domain in Rho-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY KINASE; SERINE-THREONINE KINASE; SMALL GTPASE RHO; PROTEIN-KINASE; PUTATIVE TARGET; SERINE/THREONINE KINASE; ACTIN CYTOSKELETON; MYOSIN PHOSPHATASE; CATALYTIC-ACTIVITY; FOCAL ADHESIONS	Rho-kinase is a serine/threonine protein kinase that regulates cytoskeletal events in cells. The enzyme activity of Rho-kinase is auto-inhibited in the free state but is activated through direct binding to the small GTPase Rho in the GTP-bound form. The crystal structure of the Rho-binding domain (RhoBD) of Rho-kinase has been determined at 1.8-Angstrom resolution by the multi-wavelength anomalous dispersion technique. The structure shows that RhoBD dimerizes to form a parallel coiled-coil with long consecutive alpha-helices extended to similar to97 Angstrom and suggests that free Rho-kinase can also form a dimer through parallel self-association. At the middle region of the coiled-coil, the polypeptide chains are flexible and display loose "knobs-into-holes" packing of the side chains from both chains. RhoBD residues that have been shown to be critical for Rho-binding are spread in the positively charged C-terminal region. The parallel coiled-coil structure of our Rho-kinase RhoBD in the free form is different from the anti-parallel coiled-coil structure of RhoBD of protein kinase N when complexed with RhoA. Implications derived from these structural studies in relation to the mechanism of Rho-kinase activation will be addressed with previously reported experimental data.	Nara Inst Sci & Technol, Struct Biol Lab, Nara 6300192, Japan; Japan Sci & Technol Corp, CREST, Nara 6300192, Japan; Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Nagoya, Aichi 4668550, Japan	Nara Institute of Science & Technology; Japan Science & Technology Agency (JST); Nagoya University	Hakoshima, T (corresponding author), Nara Inst Sci & Technol, Struct Biol Lab, 8916-5 Takayama, Nara 6300192, Japan.		Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bush EW, 2000, BIOCHEMISTRY-US, V39, P8480, DOI 10.1021/bi992142f; Chen XQ, 2002, J BIOL CHEM, V277, P12680, DOI 10.1074/jbc.M109839200; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Hotta K, 1996, BIOCHEM BIOPH RES CO, V225, P69, DOI 10.1006/bbrc.1996.1132; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Ihara K, 2000, ACTA CRYSTALLOGR D, V56, P1042, DOI 10.1107/S0907444900007174; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Kosako H, 1997, J BIOL CHEM, V272, P10333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumar J, 1998, J BIOL CHEM, V273, P31738, DOI 10.1074/jbc.273.48.31738; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; Tan I, 2001, MOL CELL BIOL, V21, P2767, DOI 10.1128/MCB.21.8.2767-2778.2001; VAN AL, 1997, GENE DEV, V11, P2295; Walshaw J, 2001, J MOL BIOL, V307, P1427, DOI 10.1006/jmbi.2001.4545; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606	52	46	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46046	46051		10.1074/jbc.M306458200	http://dx.doi.org/10.1074/jbc.M306458200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954645	hybrid			2022-12-25	WOS:000186452300121
J	Tie, JK; Mutucumarana, VP; Straight, DL; Carrick, KL; Pope, RM; Stafford, DW				Tie, JK; Mutucumarana, VP; Straight, DL; Carrick, KL; Pope, RM; Stafford, DW			Determination of disulfide bond assignment of human vitamin K-dependent gamma-glutamyl carboxylase by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYGLUTAMIC ACID PROTEINS; INTEGRAL MEMBRANE-PROTEINS; LINKED PEPTIDES; IDENTIFICATION; DESORPTION; ENZYME; SITE; MS; BIOSYNTHESIS; EPOXIDATION	Vitamin K-dependent gamma-glutamyl carboxylase is a 758 amino acid integral membrane glycoprotein that catalyzes the post-translational conversion of certain protein glutamate residues to gamma-carboxyglutamate. Carboxylase has ten cysteine residues, but their form (sulfhydryl or disulfide) is largely unknown. Pudota et al. in Pudota, B.N., Miyagi, M., Hallgren, K.W., West, K.A., Crabb, J.W., Misono, K.S., and Berkner, K.L. (2000) Proc. Natl. Acad. Sci. U.S.A. 97, 13033-13038 reported that Cys-99 and Cys-450 are the carboxylase active site residues. We determined the form of all cysteines in carboxylase using in-gel protease digestion and matrix-assisted laser desorption/ionization mass spectrometry. The spectrum of non-reduced, trypsin-digested carboxylase revealed a peak at m/z 1991.9. Only this peak disappeared in the spectrum of the reduced sample. This peak's m/z is consistent with the mass of peptide 92-100 (Cys-99) disulfide-linked with peptide 446 453 (Cys-450). To confirm its identity, the m/z 1991.9 peak was isolated by a timed ion selector as the precursor ion for further MS analysis. The fragmentation pattern exhibited two groups of triplet ions characteristic of the symmetric and asymmetric cleavage of disulfide-linked tryptic peptides containing Cys-99 and Cys-450. Mutation of either Cys-99 or Cys-450 caused loss of enzymatic activity. We created a carboxylase variant with both C598A and C700A, leaving Cys-450 as the only remaining cysteine residue in the 60-kDa fragment created by limited trypsin digestion. Analysis of this fully active mutant enzyme showed a 30- and the 60-kDa fragment were joined under non-reducing conditions, thus confirming Cys-450 participates in a disulfide bond. Our results indicate that Cys-99 and Cys-450 form the only disulfide bond in carboxylase.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Stafford, DW (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.			Tie, Jian-Ke/0000-0002-8447-3408	NHLBI NIH HHS [HL48318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bartlett GJ, 2002, J MOL BIOL, V324, P105, DOI 10.1016/S0022-2836(02)01036-7; Berkner KL, 2000, J NUTR, V130, P1877, DOI 10.1093/jn/130.8.1877; Bouchard BA, 1999, BIOCHEMISTRY-US, V38, P9517, DOI 10.1021/bi9907375; Bristol JA, 1996, BLOOD, V88, P2585, DOI 10.1182/blood.V88.7.2585.bloodjournal8872585; CANFIELD LM, 1987, BIOCHEM BIOPH RES CO, V148, P184, DOI 10.1016/0006-291X(87)91093-X; CANFIELD LM, 1980, ARCH BIOCHEM BIOPHYS, V202, P515, DOI 10.1016/0003-9861(80)90457-9; CARLISLE TL, 1980, BIOCHEMISTRY-US, V19, P1161, DOI 10.1021/bi00547a019; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; CRIMMINS DL, 1995, ANAL BIOCHEM, V226, P355, DOI 10.1006/abio.1995.1236; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; DOWD P, 1995, SCIENCE, V269, P1684, DOI 10.1126/science.7569894; Furie B, 1999, BLOOD, V93, P1798, DOI 10.1182/blood.V93.6.1798.406k22_1798_1808; Garavito RM, 2001, J BIOL CHEM, V276, P32403, DOI 10.1074/jbc.R100031200; Giles NM, 2003, BIOCHEM BIOPH RES CO, V300, P1, DOI 10.1016/S0006-291X(02)02770-5; Happersberger HP, 2000, METH MOL B, V146, P167, DOI 10.1385/1-59259-045-4:167; Hiniker A, 2003, BIOCHEMISTRY-US, V42, P1179, DOI 10.1021/bi027141t; Jones MD, 1998, ANAL CHEM, V70, P136, DOI 10.1021/ac9707693; Kaneko R, 1999, J AGR FOOD CHEM, V47, P4950, DOI 10.1021/jf990267l; Kim JS, 2001, RAPID COMMUN MASS SP, V15, P2296, DOI 10.1002/rcm.509; Kulman JD, 1997, P NATL ACAD SCI USA, V94, P9058, DOI 10.1073/pnas.94.17.9058; Kulman JD, 2001, P NATL ACAD SCI USA, V98, P1370, DOI 10.1073/pnas.98.4.1370; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; MORRIS DP, 1993, J BIOL CHEM, V268, P8735; NASHEF AS, 1977, J AGR FOOD CHEM, V25, P245, DOI 10.1021/jf60210a020; PATTERSON SD, 1994, ANAL CHEM, V66, P3727, DOI 10.1021/ac00093a030; Presnell SR, 2002, THROMB HAEMOSTASIS, V87, P937, DOI 10.1055/s-0037-1613115; Presnell SR, 2001, BIOCHEMISTRY-US, V40, P11723, DOI 10.1021/bi010332w; PRICE PA, 1988, ANNU REV NUTR, V8, P565, DOI 10.1146/annurev.nu.08.070188.003025; Pudota BN, 2000, P NATL ACAD SCI USA, V97, P13033, DOI 10.1073/pnas.97.24.13033; Pudota BN, 2001, J BIOL CHEM, V276, P46878, DOI 10.1074/jbc.M108696200; RUDD PM, 1994, BIOCHEMISTRY-US, V33, P17, DOI 10.1021/bi00167a003; Santoni V, 2000, ELECTROPHORESIS, V21, P1054, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1054::AID-ELPS1054>3.3.CO;2-#; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schnaible V, 2002, ANAL CHEM, V74, P4980, DOI 10.1021/ac025807j; Stanley TB, 1999, J BIOL CHEM, V274, P16940, DOI 10.1074/jbc.274.24.16940; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; Stevens TJ, 2000, PROTEINS, V39, P417, DOI 10.1002/(SICI)1097-0134(20000601)39:4<417::AID-PROT140>3.0.CO;2-Y; Tie J, 2000, BLOOD, V96, P973, DOI 10.1182/blood.V96.3.973.015k55_973_978; van Montfort BA, 2002, J MASS SPECTROM, V37, P322, DOI 10.1002/jms.288; VERMEER C, 1990, BIOCHEM J, V266, P625, DOI 10.1042/bj2660625; Wallin E, 1998, PROTEIN SCI, V7, P1029, DOI 10.1002/pro.5560070420; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P4207, DOI 10.1021/bi992922o; Wu CC, 2003, NAT BIOTECHNOL, V21, P262, DOI 10.1038/nbt0303-262; Wu CC, 2003, NAT BIOTECHNOL, V21, P532, DOI 10.1038/nbt819; Wu SM, 1997, J BIOL CHEM, V272, P11718, DOI 10.1074/jbc.272.18.11718; ZHOU J, 1993, INT J MASS SPECTROM, V126, P115, DOI 10.1016/0168-1176(93)80076-Q	47	33	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45468	45475		10.1074/jbc.M309164200	http://dx.doi.org/10.1074/jbc.M309164200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12963724	hybrid			2022-12-25	WOS:000186452300052
J	Wu, KP; Wu, CW; Tsao, YP; Kuo, TW; Lou, YC; Lin, CW; Wu, SC; Cheng, JW				Wu, KP; Wu, CW; Tsao, YP; Kuo, TW; Lou, YC; Lin, CW; Wu, SC; Cheng, JW			Structural basis of a flavivirus recognized by its neutralizing antibody - Solution structure of the domain III of the Japanese encephalitis virus envelope protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE ANTIGEN OSPA; CHEMICAL-SHIFT; RESISTANT MUTANTS; NMR-SPECTROSCOPY; ESCHERICHIA-COLI; DENGUE VIRUS; EPITOPE; RELAXATION; NEUROINVASIVENESS; NEUROVIRULENCE	The flavivirus envelope protein is the dominant antigen in eliciting neutralizing antibodies and plays an important role in inducing immunologic responses in the infected host. We have determined the solution structure of the major antigenic domain (domain III) of the Japanese encephalitis virus (JEV) envelope protein. The JEV domain III forms a beta-barrel type structure composed of six antiparallel beta-strands resembling the immunoglobulin constant domain. We have also identified epitopes of the JEV domain III to its neutralizing antibody by chemical shift perturbation measurements. Site-directed mutagenesis experiments are performed to confirm the NMR results. Our study provides a structural basis for understanding the mechanism of immunologic protection and for rational design of vaccines effective against flaviviruses.	Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu 300, Taiwan; Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 300, Taiwan	National Tsing Hua University; National Tsing Hua University	Cheng, JW (corresponding author), Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu 300, Taiwan.		Wu, Kuen-Phon/B-7983-2009; Wu, Kuen-Phon/I-1789-2019; Wu, Suh-Chin/AAV-6233-2021	Wu, Kuen-Phon/0000-0002-1525-6004; Wu, Kuen-Phon/0000-0002-1525-6004; 				BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; Burke DS, 2001, FIELDS VIROLOGY, P1043, DOI 10.1093/emboj/cdg270; CECILIA D, 1991, VIROLOGY, V181, P70, DOI 10.1016/0042-6822(91)90471-M; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Ding W, 2000, J MOL BIOL, V302, P1153, DOI 10.1006/jmbi.2000.4119; FARROW NA, 1995, J BIOMOL NMR, V6, P153, DOI 10.1007/BF00211779; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; Fiaux J, 2002, NATURE, V418, P207, DOI 10.1038/nature00860; Hiramatsu K, 1996, VIROLOGY, V224, P437, DOI 10.1006/viro.1996.0550; Holzmann H, 1997, J GEN VIROL, V78, P31, DOI 10.1099/0022-1317-78-1-31; HOLZMANN H, 1990, J VIROL, V64, P5156, DOI 10.1128/JVI.64.10.5156-5159.1990; Huang XL, 1998, J MOL BIOL, V281, P61, DOI 10.1006/jmbi.1998.1930; JIANG WR, 1993, J GEN VIROL, V74, P931, DOI 10.1099/0022-1317-74-5-931; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lefevre JF, 1996, BIOCHEMISTRY-US, V35, P2674, DOI 10.1021/bi9526802; Leiting B, 1998, ANAL BIOCHEM, V265, P351, DOI 10.1006/abio.1998.2904; LIN B, 1994, VIROLOGY, V202, P885, DOI 10.1006/viro.1994.1410; Lin CW, 2003, J VIROL, V77, P2600, DOI 10.1128/JVI.77.4.2600-2606.2003; Markley JL, 1998, J BIOMOL NMR, V12, P1, DOI 10.1023/A:1008290618449; MARKUS MA, 1994, J MAGN RESON SER B, V105, P192, DOI 10.1006/jmrb.1994.1122; McMinn PC, 1997, J GEN VIROL, V78, P2711, DOI 10.1099/0022-1317-78-11-2711; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Roehrig JT, 1998, VIROLOGY, V246, P317, DOI 10.1006/viro.1998.9200; Saito Naoyuki G., 1996, Methods (Orlando), V9, P516, DOI 10.1006/meth.1996.0059; Schlesinger JJ, 1996, J GEN VIROL, V77, P1277, DOI 10.1099/0022-1317-77-6-1277; SEIF SA, 1995, VACCINE, V13, P1515, DOI 10.1016/0264-410X(95)00097-K; TASHIRO M, 1995, CURR OPIN STRUC BIOL, V5, P471, DOI 10.1016/0959-440X(95)80031-X; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Wu SC, 1998, VIRUS RES, V55, P83, DOI 10.1016/S0168-1702(98)00037-9; Wu SC, 2001, VIRUS RES, V76, P59, DOI 10.1016/S0168-1702(01)00246-5; Wu SC, 1997, VIRUS RES, V51, P173, DOI 10.1016/S0168-1702(97)00098-1	35	101	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46007	46013		10.1074/jbc.M307776200	http://dx.doi.org/10.1074/jbc.M307776200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952958	hybrid			2022-12-25	WOS:000186452300116
J	Sarkar, J; Seshadri, V; Tripoulas, NA; Ketterer, ME; Fox, PL				Sarkar, J; Seshadri, V; Tripoulas, NA; Ketterer, ME; Fox, PL			Role of ceruloplasmin in macrophage iron efflux during hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; MOUSE PERITONEAL-MACROPHAGES; TRANSCRIPTIONAL ACTIVATION; FERROXIDASE ACTIVITY; REGULATORY PROTEIN-1; TRANSFERRIN; CELLS; METABOLISM; RELEASE; SERUM	The reticuloendothelial system has a central role in erythropoiesis and iron homeostasis. An important function of reticuloendothelial macrophages is phagocytosis of senescent red blood cells. The iron liberated from heme is recycled for delivery to erythrocyte precursors for a new round of hemoglobin synthesis. The molecular mechanism by which recycled iron is released from macrophages remains unresolved. We have investigated the mechanism of macrophage iron efflux, focusing on the role of ceruloplasmin (Cp), a copper protein with a potent ferroxidase activity that converts Fe2+ to Fe3+ in the presence of molecular oxygen. As shown by others, Cp markedly increased iron binding to apotransferrin at acidic pH; however, the physiological significance of this finding is uncertain because little stimulation was observed at neutral pH. Introduction of a hypoxic atmosphere resulted in marked Cp-stimulated binding of iron to apotransferrin at physiological pH. The role of Cp in cellular iron release was examined in U937 monocytic cells induced to differentiate to the macrophage lineage. Cp added at its normal plasma concentration increased the rate of Fe-55 release from U937 cells by about 250%. The stimulation was absolutely dependent on the presence of apotransferrin and hypoxia. Cp-stimulated iron release was confirmed in mouse peritoneal macrophages. Stimulation of iron release required an intracellular "labile iron pool" that was rapidly depleted in the presence of Cp and apotransferrin. Ferroxidase-mediated loading of iron into apotransferrin was critical for iron release because ferroxidase-deficient Cp was inactive and because holotransferrin could not substitute for apotransferrin. The extracellular iron concentration was critical as shown by inhibition of iron release by exogenous free iron, and marked enhancement of release by an iron chelator. Together these data show that Cp stimulates iron release from macrophages under hypoxic conditions by a ferroxidase-dependent mechanism, possibly involving generation of a negative iron gradient.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA; No Arizona Univ, Dept Chem, Flagstaff, AZ 86011 USA; Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Northern Arizona University; Case Western Reserve University	Fox, PL (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	foxp@ccf.org			NHLBI NIH HHS [HL67725, HL29582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582, R01HL067725] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; AISEN P, 1967, J BIOL CHEM, V242, P2484; ALFORD CE, 1991, J EXP MED, V174, P459, DOI 10.1084/jem.174.2.459; Anderson GJ, 2002, BLOOD CELL MOL DIS, V29, P367, DOI 10.1006/bcmd.2002.0576; Attieh ZK, 1999, J BIOL CHEM, V274, P1116, DOI 10.1074/jbc.274.2.1116; BATES GW, 1973, BIOCHEM BIOPH RES CO, V50, P84, DOI 10.1016/0006-291X(73)91067-X; BEAUMIER DL, 1984, INFECT IMMUN, V46, P489, DOI 10.1128/IAI.46.2.489-494.1984; Brittenham GM, 2000, HEMATOLOGY BASIC PRI, P397; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Danzeisen R, 2000, PLACENTA, V21, P805, DOI 10.1053/plac.2000.0582; DINI L, 1990, EUR J CELL BIOL, V52, P207; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; EHRENWALD E, 1994, J CLIN INVEST, V93, P1493, DOI 10.1172/JCI117127; Epsztejn S, 1997, ANAL BIOCHEM, V248, P31, DOI 10.1006/abio.1997.2126; Erel O, 1998, CLIN CHEM, V44, P2313; ESPARZA I, 1981, BRIT J HAEMATOL, V49, P603, DOI 10.1111/j.1365-2141.1981.tb07270.x; Freshney RI., 2010, CULTURE ANIMAL CELLS, VSixth; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; HUFF RL, 1951, MEDICINE, V30, P197, DOI 10.1097/00005792-195109000-00001; Jeong SY, 2003, J BIOL CHEM, V278, P27144, DOI 10.1074/jbc.M301988200; JOHNSON DA, 1967, CLIN CHEM, V13, P142; Jurrus E R, 1977, Adv Vet Sci Comp Med, V21, P309; Kakhlon O, 2002, FREE RADICAL BIO MED, V33, P1037, DOI 10.1016/S0891-5849(02)01006-7; KATAOKA M, 1985, EXP HEMATOL, V13, P806; Knutson M, 2003, CRIT REV BIOCHEM MOL, V38, P61, DOI 10.1080/713609210; Kuriyama-Matsumura K, 1998, BIOCHEM BIOPH RES CO, V249, P241, DOI 10.1006/bbrc.1998.9046; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; LINDER MC, 1981, JNCI-J NATL CANCER I, V67, P263; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; MARESCHAL JC, 1980, FEBS LETT, V110, P268, DOI 10.1016/0014-5793(80)80089-5; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; Mukhopadhyay CK, 2000, J BIOL CHEM, V275, P21048, DOI 10.1074/jbc.M000636200; Mukhopadhyay CK, 1998, SCIENCE, V279, P714, DOI 10.1126/science.279.5351.714; Musci G, 1996, J BIOL CHEM, V271, P1972, DOI 10.1074/jbc.271.4.1972; NOYES WD, 1960, BRIT J HAEMATOL, V6, P43, DOI 10.1111/j.1365-2141.1960.tb06216.x; OSAKI S, 1969, J BIOL CHEM, V244, P5757; OSAKI S, 1971, J BIOL CHEM, V246, P3018; OSAKI S, 1966, J BIOL CHEM, V241, P2746; PEDERSEN JZ, 1987, EUR J RESPIR DIS, V70, P140; Qian ZM, 2001, EXP BRAIN RES, V140, P369, DOI 10.1007/s002210100831; RAGAN HA, 1969, AM J PHYSIOL, V217, P1320, DOI 10.1152/ajplegacy.1969.217.5.1320; RAMA R, 1988, BIOCHIM BIOPHYS ACTA, V968, P51, DOI 10.1016/0167-4889(88)90043-2; Richardson DR, 1999, J LAB CLIN MED, V134, P454, DOI 10.1016/S0022-2143(99)90166-X; ROESER HP, 1973, P SOC EXP BIOL MED, V142, P1155; ROESER HP, 1970, J CLIN INVEST, V49, P2408, DOI 10.1172/JCI106460; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Ryden L., 1984, COPP PROTEINS COPP E, V3, P37; SAITO K, 1986, BRIT J HAEMATOL, V62, P275, DOI 10.1111/j.1365-2141.1986.tb02930.x; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Seshadri V, 2002, J BIOL CHEM, V277, P27903, DOI 10.1074/jbc.M203610200; SHOKEIR MHK, 1972, CLIN BIOCHEM, V5, P115, DOI 10.1016/S0009-9120(72)80018-3; SURKS MI, 1966, J APPL PHYSIOL, V21, P1185; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; Toth I, 1999, J BIOL CHEM, V274, P4467, DOI 10.1074/jbc.274.7.4467; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; Yang FM, 2002, J BIOL CHEM, V277, P39786, DOI 10.1074/jbc.M201485200; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; Young SP, 1997, FEBS LETT, V411, P93, DOI 10.1016/S0014-5793(97)00478-X	60	70	73	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44018	44024		10.1074/jbc.M304926200	http://dx.doi.org/10.1074/jbc.M304926200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12952974	hybrid			2022-12-25	WOS:000186306700017
J	Rimoldi, V; Reversi, A; Taverna, E; Rosa, P; Francolini, M; Cassoni, P; Parenti, M; Chini, B				Rimoldi, V; Reversi, A; Taverna, E; Rosa, P; Francolini, M; Cassoni, P; Parenti, M; Chini, B			Oxytocin receptor elicits different EGFR/MAPK activation patterns depending on its localization in caveolin-1 enriched domains	ONCOGENE			English	Article						caveolin; oxytocin receptor; MAPK; EGFR; p21	GROWTH-FACTOR RECEPTOR; SIGNAL-TRANSDUCTION; LIPID RAFTS; PROTEIN-KINASE; CELL-GROWTH; TYROSINE KINASE; EGF RECEPTOR; INHIBITION; PATHWAY; ENDOCYTOSIS	We have recently shown that oxytocin inhibits cell proliferation when the vast majority of oxytocin receptors are excluded from caveolin-1-enriched microdomains, and that, on the contrary, it has a mitogenic effect when the receptors are targeted to these plasma membrane domains. In this study, we investigated whether the receptors located inside and outside caveolar microdomains initiate different signalling pathways and how this may lead to opposite effects on cell proliferation. Our data indicate that, depending on their localization, oxytocin receptors transactivate EGFR and activate ERK1/2 using different signalling intermediates. The final outcome is a different temporal pattern of EGFR and ERK1/2 phosphorylation, which is more persistent when the receptors are located outside caveolar microdomains and inhibit cell growth, and very transient when they are located in caveolar microdomains and stimulate cell growth. Finally, only the activation of receptors located outside caveolar microdomains correlates with the activation of the cell cycle inhibitor p21(WAF1/CIP1), thus suggesting that the antiproliferative OTR effects may, in this case, be achieved by a sustained activation of EGFR and MAPK leading to the induction of this cell cycle regulator.	CNR, Inst Neurosci, Cellular & Mol Pharmacol Sect, I-20129 Milan, Italy; Univ Milan, Dept Pharmacol, I-20122 Milan, Italy; Univ Turin, Dept Biomed Sci & Human Oncol, I-10124 Turin, Italy; Univ Milano Bicocca, Dept Expt & Environm Med & Med Biotechnol, Monza, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Turin; University of Milano-Bicocca	Chini, B (corresponding author), CNR, Inst Neurosci, Cellular & Mol Pharmacol Sect, Via Vanvitelli 32, I-20129 Milan, Italy.	B.Chini@csfic.mi.cnr.it	Cassoni, Paola/I-8544-2018; taverna, elena/O-8180-2014; Rimoldi, Valeria/AAB-4865-2020; Taverna, Elena/AFW-4935-2022	taverna, elena/0000-0002-2430-4725; Rimoldi, Valeria/0000-0002-5598-3986; Chini, Bice/0000-0002-1686-284X; FRANCOLINI, MAURA/0000-0002-3126-1575; Rosa, Patrizia/0000-0002-2590-6955; Reversi, Alessandra/0000-0002-9934-5636				Adachi T, 2002, J CELL PHYSIOL, V192, P151, DOI 10.1002/jcp.10124; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Breton C, 2002, J CLIN ENDOCR METAB, V87, P1415, DOI 10.1210/jc.87.3.1415; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Cassoni P, 2001, ENDOCRINOLOGY, V142, P1130, DOI 10.1210/en.142.3.1130; Copland JA, 1999, ENDOCRINOLOGY, V140, P4371, DOI 10.1210/en.140.9.4371; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dessy C, 2000, EMBO J, V19, P4272, DOI 10.1093/emboj/19.16.4272; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Guzzi F, 2002, ONCOGENE, V21, P1658, DOI 10.1038/sj.onc.1205219; Jakus J, 1996, ONCOGENE, V12, P2369; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Johannessen LE, 1999, BIOCHEM J, V337, P599, DOI 10.1042/0264-6021:3370599; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; MOORE JJ, 1988, ENDOCRINOLOGY, V123, P1771, DOI 10.1210/endo-123-4-1771; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Paquin J, 2002, P NATL ACAD SCI USA, V99, P9550, DOI 10.1073/pnas.152302499; PHANEUF S, 1993, J ENDOCRINOL, V136, P497, DOI 10.1677/joe.0.1360497; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sanborn BM, 2001, EXP PHYSIOL, V86, P223, DOI 10.1113/eph8602179; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Strakova Z, 1997, AM J PHYSIOL-ENDOC M, V272, pE870, DOI 10.1152/ajpendo.1997.272.5.E870; Thibonnier M, 1999, ENDOCRINOLOGY, V140, P1301, DOI 10.1210/en.140.3.1301; USHIOFUKAI M, 2001, J BIOL CHEM, V3, P3; Volmat V, 2001, BIOL CELL, V93, P71, DOI 10.1016/S0248-4900(01)01129-7; Xie W, 1997, ANTICANCER RES, V17, P2627	44	97	100	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6054	6060		10.1038/sj.onc.1206612	http://dx.doi.org/10.1038/sj.onc.1206612			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955084				2022-12-25	WOS:000185137800014
J	Xing, KY; Lou, MF				Xing, KY; Lou, MF			Possible physiological function of thioltransferase in cells	FASEB JOURNAL			English	Article; Proceedings Paper	United States-Japan Cooperative Research Conference	NOV 03-07, 2001	KONA, HI			over-expression; cadmium; repair function; oxidative stress; dethiolation	THIOL MIXED DISULFIDES; LENS EPITHELIAL-CELLS; HIGH-LEVEL EXPRESSION; EARLY EMBRYONIC LETHALITY; ACTIVATED PROTEIN-KINASE; ESCHERICHIA-COLI; OXIDATIVE STRESS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; INDUCED CATARACT; IN-VITRO	We sought to study the possible physiological function of thioltransferase (TTase) in combating oxidative damage in the lens epithelial cells. The cells transfected with either TTase-containing plasmid or vector only were compared for their resistance to oxidative stress in the presence of a bolus of H2O2 (0.1 mM) for 3 h. Cells depleted of TTase activity upon cadmium treatment were also examined for the resistance to oxidative stress under the same conditions. TTase activity assay, Western blot, and Northern blot analyses confirmed that hTTase gene was successfully transfected into the HLE B3 cells and was overexpressed. The TTase-transfected cells detoxified H2O2 as efficiently as the control cells but displayed a faster and more complete recovery of oxidatively inactivated glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and glutathione peroxidase (GPx) activities and suppressed protein thiolation (PSSG formation). With TTase activity being inhibited by cadmium, the spontaneous reactivation of GAPDH under bolus H2O2 treatment was not accomplished in cadmium-pretreated cells. These data indicate a new physiological function of TTase, which involves in the reactivation of the oxidatively inactivated enzymes through dethiolation; thus this redox-regulating enzyme can protect the human lens epithelial cells and maybe other cell types by preventing them from permanent oxidative damage.	Univ Nebraska, Dept Vet & Biomed Sci, VBS 134, Lincoln, NE 68583 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68583 USA; Univ Nebraska, Med Ctr, Dept Ophthalmol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Medical Center	Lou, MF (corresponding author), Univ Nebraska, Dept Vet & Biomed Sci, VBS 134, Lincoln, NE 68583 USA.	mlou1@unl.edu						Adams James D. Jr., 2001, Current Topics in Medicinal Chemistry, V1, P473, DOI 10.2174/1568026013394778; ANDLEY U, 2000, PRINCIPLE PRACTICES; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Bergmeyer HU, 1974, METHOD ENZYMAT AN, P466; Bhuyan DK, 1996, BBA-BIOMEMBRANES, V1285, P21, DOI 10.1016/S0005-2736(96)00142-3; BRODIE AE, 1987, BIOCHEM BIOPH RES CO, V148, P120, DOI 10.1016/0006-291X(87)91084-9; Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9; Cho YW, 2000, BBA-GENE STRUCT EXPR, V1517, P171, DOI 10.1016/S0167-4781(00)00242-6; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; CU XL, 1993, EXP EYE RES, V57, P157, DOI 10.1006/exer.1993.1111; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; Davis A, 1997, HEALTH TECHNOL ASSES, V1, P1; Draculic T, 2000, MOL MICROBIOL, V36, P1167, DOI 10.1046/j.1365-2958.2000.01948.x; FERNANDO MR, 2003, ANN M ABSTR PROGR PL; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; GIBLIN FJ, 1995, EXP EYE RES, V60, P219, DOI 10.1016/S0014-4835(05)80105-8; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Harrison J., 1976, P1; Hildebrandt A G, 1978, Methods Enzymol, V52, P342; HIRATO K, 2000, BIOCHEM BIOPH RES CO, V274, P177; Hirose S, 2000, DEVELOPMENT, V127, P3263; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOU MF, 1995, CURR EYE RES, V14, P951, DOI 10.3109/02713689508995135; Lou MF, 1997, ADVANCES IN OCULAR TOXICOLOGY, P27; Lou MF, 1998, EXP EYE RES, V66, P477, DOI 10.1006/exer.1997.0464; LOU MF, 1990, EXP EYE RES, V50, P819, DOI 10.1016/0014-4835(90)90133-F; LOU MF, 1992, EXP EYE RES, V55, P889, DOI 10.1016/0014-4835(92)90015-K; Lou MF, 2000, J OCUL PHARMACOL TH, V16, P137, DOI 10.1089/jop.2000.16.137; LOU MF, 2002, ANN M ABSTR PROGR PL; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Meyer EB, 1999, FREE RADICAL BIO MED, V26, P770, DOI 10.1016/S0891-5849(98)00247-0; MIEYAL JJ, 1995, GLUTATHIONYL SPECIFI, P305; Nakamura T, 1999, FREE RADICAL RES, V31, P357, DOI 10.1080/10715769900300931; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Padilla CA, 1996, FEBS LETT, V378, P69; Park SU, 2002, PLANT PHYSIOL, V128, P696, DOI 10.1104/pp.010741; Patzel V, 2000, NUCLEIC ACIDS RES, V28, P2462, DOI 10.1093/nar/28.13.2462; Powis G, 2001, ANNU REV BIOPH BIOM, V30, P421, DOI 10.1146/annurev.biophys.30.1.421; Qiao FY, 2000, EXP EYE RES, V70, P745, DOI 10.1006/exer.2000.0836; Qiao FY, 2001, INVEST OPHTH VIS SCI, V42, P743; Raghavachari N, 2001, INVEST OPHTH VIS SCI, V42, P1002; Raghavachari N, 1996, EXP EYE RES, V63, P433, DOI 10.1006/exer.1996.0133; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; SCHUPPEKOISTINEN I, 1994, EUR J BIOCHEM, V221, P1033, DOI 10.1111/j.1432-1033.1994.tb18821.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; SPECTOR A, 1993, CURR EYE RES, V12, P163, DOI 10.3109/02713689308999484; SPECTOR A, 1985, OCULAR LENS STRUCTUR, P405; STEFFENSEN IL, 1994, GEN PHARMACOL-VASC S, V25, P1621, DOI 10.1016/0306-3623(94)90364-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsangaris GT, 1998, TOXICOLOGY, V128, P143, DOI 10.1016/S0300-483X(98)00032-8; Wang GM, 1997, EXP EYE RES, V64, P693, DOI 10.1006/exer.1996.0251; Wells W W, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P149; WELLS WW, 1994, J BIOENERG BIOMEMBR, V26, P369, DOI 10.1007/BF00762777; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Xing KY, 2002, EXP EYE RES, V74, P113, DOI 10.1006/exer.2001.1103; XU GT, 1992, EXP EYE RES, V54, P63, DOI 10.1016/0014-4835(92)90070-9; YANG Y, 1990, J BIOL CHEM, V265, P589; YEGOROVA S, 2003, ANN M ABSTR PROGR PL; YEGOROVA S, 2003, IN PRESS INVEST OPHT; YOSHITAKE S, 1994, J BIOCHEM-TOKYO, V116, P42, DOI 10.1093/oxfordjournals.jbchem.a124500; Zatechka DS, 2002, EXP EYE RES, V74, P703, DOI 10.1006/exer.2002.1168; ZIGMAN S, 1991, INVEST OPHTH VIS SCI, V32, P1723	65	25	26	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2088	+		10.1096/fj.02-1164fje	http://dx.doi.org/10.1096/fj.02-1164fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958160				2022-12-25	WOS:000185925100020
J	Zhu, SY; Darbon, H; Dyason, K; Verdonck, F; Tytgat, J				Zhu, SY; Darbon, H; Dyason, K; Verdonck, F; Tytgat, J			Evolutionary origin of inhibitor cystine knot peptides	FASEB JOURNAL			English	Article						gene structure; evolution; exon shuffling; viruses	PATHOGEN CLADOSPORIUM-FULVUM; CONVERGENT EVOLUTION; POTASSIUM CHANNEL; SCORPION TOXINS; DRUG DESIGN; VENOM PEPTIDES; ANIMAL TOXINS; CDNA SEQUENCE; PROTEIN; FAMILY	The inhibitor cystine knot (ICK) fold is an evolutionarily conserved structural motif shared by a large group of polypeptides with diverse sequences and bioactivities. Although found in different phyla (animal, plant, and fungus), ICK peptides appear to be most prominent in venoms of cone snail and spider. Recently, two scorpion toxins activating a calcium release channel have been found to adopt an ICK fold. We have isolated and identified both cDNA and genomic clones for this family of ICK peptides from the scorpion Opistophthalmus carinatus. The gene characterized by three well-delineated exons respectively coding for three structural and functional domains in the toxin precursors illustrates the correlation between exon and module as suggested by the "exon theory of genes." Based on the analysis of precursor organization and gene structure combined with the 3-D fold and functional data, our results highlight a common evolutionary origin for ICK peptides from animals. In contrast, ICK peptides from plant and fungus might be independently evolved from another ancestor.	Univ Leuven, Toxicol Lab, B-3000 Louvain, Belgium; Univ Aix Marseille 1, AFMB, CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 2, AFMB, CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Potchefstroom, Dept Physiol, ZA-2520 Potchefstroom, South Africa; Univ Leuven, Interdisciplinary Res Ctr, B-8500 Kortrijk, Belgium	KU Leuven; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; North West University - South Africa; KU Leuven	Tytgat, J (corresponding author), Univ Leuven, Toxicol Lab, E Van Evenstr 4, B-3000 Louvain, Belgium.	Jan.Tytgat@pharm.kuleuven.ac.be	Tytgat, Jan/F-1560-2010	Tytgat, Jan/0000-0003-1778-6022				Anderluh G, 1999, TOXICON, V37, P1391, DOI 10.1016/S0041-0101(99)00082-3; Baldo AM, 1999, J VIROL, V73, P7710, DOI 10.1128/JVI.73.9.7710-7721.1999; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Bernard C, 2000, PROTEIN SCI, V9, P2059; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; DOOLITTLE RF, 1994, TRENDS BIOCHEM SCI, V19, P15, DOI 10.1016/0968-0004(94)90167-8; Duda TF, 1999, P NATL ACAD SCI USA, V96, P6820, DOI 10.1073/pnas.96.12.6820; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Froy O, 1998, FASEB J, V12, P1793, DOI 10.1096/fasebj.12.15.1793; Froy O, 1999, J MOL EVOL, V48, P187, DOI 10.1007/PL00006457; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilbert W, 1997, P NATL ACAD SCI USA, V94, P7698, DOI 10.1073/pnas.94.15.7698; Gilquin B, 2002, J BIOL CHEM, V277, P37406, DOI 10.1074/jbc.M206205200; Gurrola GB, 1999, J BIOL CHEM, V274, P7879, DOI 10.1074/jbc.274.12.7879; Holm L, 1997, TRENDS BIOCHEM SCI, V22, P116, DOI 10.1016/S0968-0004(97)01021-9; Hu ZH, 1998, VIRUS RES, V55, P71, DOI 10.1016/S0168-1702(98)00029-X; Kalapothakis E, 1998, TOXICON, V36, P1971, DOI 10.1016/S0041-0101(98)00127-5; Kuzio J, 1999, VIROLOGY, V253, P17, DOI 10.1006/viro.1998.9469; LEWIN B, 1997, GENES, V6, P243; Li LL, 2002, VIROLOGY, V297, P226, DOI 10.1006/viro.2002.1411; LING MH, 1993, J BIOL CHEM, V268, P810; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; Long MY, 1996, P NATL ACAD SCI USA, V93, P7727, DOI 10.1073/pnas.93.15.7727; Menez A, 1998, TOXICON, V36, P1557, DOI 10.1016/S0041-0101(98)00148-2; Mosbah A, 2000, PROTEINS, V40, P436, DOI 10.1002/1097-0134(20000815)40:3&lt;436::AID-PROT90&gt;3.0.CO;2-9; Murzin AG, 1998, NAT STRUCT BIOL, V5, P101, DOI 10.1038/nsb0298-101; NARASIMHAN L, 1994, NAT STRUCT BIOL, V1, P850, DOI 10.1038/nsb1294-850; Norton RS, 2002, PERSPECTIVES IN MOLECULAR TOXINOLOGY, P159; Ohno M, 1998, PROG NUCLEIC ACID RE, V59, P307; Olivera BM, 2001, TOXICON, V39, P7, DOI 10.1016/S0041-0101(00)00157-4; Olivera BM, 1999, ANN NY ACAD SCI, V870, P223, DOI 10.1111/j.1749-6632.1999.tb08883.x; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; PEAR JR, 1989, PLANT MOL BIOL, V13, P639, DOI 10.1007/BF00016019; Ponting CP, 2002, ANNU REV BIOPH BIOM, V31, P45, DOI 10.1146/annurev.biophys.31.082901.134314; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Srinivasan KN, 2002, J BIOL CHEM, V277, P30040, DOI 10.1074/jbc.M111258200; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; VANDENACKERVEKEN GFJM, 1992, PLANT J, V2, P359, DOI 10.1111/j.1365-313X.1992.00359.x; Vervoort J, 1997, FEBS LETT, V404, P153, DOI 10.1016/S0014-5793(97)00117-8; Villanueva J, 1998, FEBS LETT, V440, P175, DOI 10.1016/S0014-5793(98)01447-1; Wang XH, 2000, NAT STRUCT BIOL, V7, P505, DOI 10.1038/75921; Zhu SY, 2001, TOXICON, V39, P1291, DOI 10.1016/S0041-0101(01)00078-2	46	126	137	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1765	+		10.1096/fj.02-1044fje	http://dx.doi.org/10.1096/fj.02-1044fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958203				2022-12-25	WOS:000184471600019
J	Xiong, SQ; Zhao, QH; Rong, ZL; Huang, GR; Huang, YL; Chen, PL; Zhang, SP; Liu, L; Chang, ZJ				Xiong, SQ; Zhao, QH; Rong, ZL; Huang, GR; Huang, YL; Chen, PL; Zhang, SP; Liu, L; Chang, ZJ			hSef inhibits PC-12 cell differentiation by interfering with Ras-mitogen-activated protein kinase MAPK signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA EGF RECEPTOR; MOLECULAR CHARACTERIZATION; FEEDBACK LOOP; SPROUTY; EXPRESSION; SEF; PATHWAY; INTERLEUKIN-17; IDENTIFICATION; SPECIFICITY	Growth factor signaling by receptor tyrosine kinases regulates several cell fates, such as proliferation and differentiation. Sef was genetically identified as a negative regulator of fibroblast growth factor (FGF) signaling. Using bioinformatic methods and rapid amplification of cDNA ends-PCR, we isolated both the mouse and the human Sef genes, which encoded the Sef protein and Sef-S isoform that was generated through alternative splicing. We provide evidence that the Sef gene products were located mainly on the cell membrane. Co-immunoprecipitation and immunostaining experiments indicate that hSef interacts with FGFR1 and FGFR2 but not FGFR3. Our results demonstrated that stably expressed hSef strongly inhibits FGF2- or nerve growth factor-induced PC-12 cell differentiation. The intracellular domain of hSef is necessary for the inhibitory effect on FGF2- induced PC-12 cell differentiation. Furthermore, our data suggested Sef exerted the negative effect on FGF2- induced PC-12 cell differentiation through the prevention of Ras-mitogen-activated protein kinase signaling, possibly functioning upstream of the Ras molecule. These findings suggest that Sef may play an important role in the regulation of PC-12 cell differentiation.	Tsing Hua Univ, Tsinghua Inst Genome Res, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China	Tsinghua University	Chang, ZJ (corresponding author), Tsing Hua Univ, Tsinghua Inst Genome Res, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China.		Rong, Zhili/H-7561-2014; Chang, Zhijie/AAH-8109-2019	Rong, Zhili/0000-0002-1699-7074; Chang, Zhijie/0000-0003-1567-3227				Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cancilla B, 2001, KIDNEY INT, V60, P147, DOI 10.1046/j.1523-1755.2001.00781.x; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chambers D, 2000, MECH DEVELOP, V91, P361, DOI 10.1016/S0925-4773(99)00288-9; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Golembo M, 1996, DEVELOPMENT, V122, P223; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Haudenschild D, 2002, J BIOL CHEM, V277, P4309, DOI 10.1074/jbc.M109372200; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092-8674(00)00112-4; Kovalenko D, 2003, J BIOL CHEM, V278, P14087, DOI 10.1074/jbc.C200606200; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; Lee J, 2001, J BIOL CHEM, V276, P1660, DOI 10.1074/jbc.M008289200; Lin W, 2002, MECH DEVELOP, V113, P163, DOI 10.1016/S0925-4773(02)00018-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Minowada G, 1999, DEVELOPMENT, V126, P4465; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; O'Neill L, 2000, BIOCHEM SOC T, V28, P557, DOI 10.1042/bst0280557; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Reich A, 1999, DEVELOPMENT, V126, P4139; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Shi YG, 2000, J BIOL CHEM, V275, P19167, DOI 10.1074/jbc.M910228199; Spriggs MK, 1997, J CLIN IMMUNOL, V17, P366, DOI 10.1023/A:1027360106635; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; YANG RB, 2003, J BIOL CHEM; Yao ZB, 1997, CYTOKINE, V9, P794, DOI 10.1006/cyto.1997.0240; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	39	69	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50273	50282		10.1074/jbc.M306936200	http://dx.doi.org/10.1074/jbc.M306936200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	12958313	hybrid			2022-12-25	WOS:000187068200075
J	Wang, D; Pascual, JM; Iserovich, P; Yang, H; Ma, L; Kuang, KY; Zuniga, FA; Sun, RP; Swaroop, KM; Fischbarg, J; De Vivo, DC				Wang, D; Pascual, JM; Iserovich, P; Yang, H; Ma, L; Kuang, KY; Zuniga, FA; Sun, RP; Swaroop, KM; Fischbarg, J; De Vivo, DC			Functional studies of threonine 310 mutations in Glut1 - T310I is pathogenic, causing Glut1 deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; CYSTEINE-SCANNING MUTAGENESIS; DEFECTIVE GLUCOSE-TRANSPORT; ULTRASTRUCTURAL-LOCALIZATION; WATER CHANNEL; MESSENGER-RNA; ASCORBIC-ACID; EXPRESSION; MEMBRANE; MULTIPLE	We have previously reported on a patient with the Glut1 deficiency syndrome ( Online Mendelian Inheritance in Man number 606777) carrying a heterozygous T310I missense mutation in the GLUT1 gene (Klepper, J., Wang, D., Fischbarg, J., Vera, J. C., Jarjour, I. T., O'Driscoll, K. R., and De Vivo, D. C. ( 1999) Neurochem. Res. 24, 587 - 594). To investigate the molecular basis for the associated functional deficit, we constructed T310A, T310S, and T310I human GLUT1 mutants for expression in Xenopus laevis oocytes via cRNA injection. For all mutants, glucose transport was decreased, and osmotic water permeability (P-f) was increased. K-m values for 3-O-methylglucose (3-OMG) uptake under zero-trans influx and equilibrium exchange influx conditions were, respectively, 13 +/- 1 and 68 +/- 5 mM for wild-type Glut1, 5 +/- 1 and 25 +/- 6 mM for T310A, 6 +/- 3 and 30 +/- 6 mM for T310I, and 5 +/- 1 and 48 +/- 5 mM for T310S. Compared with wild- type Glut1, we determined the following. (a) Zero-trans and equilibrium exchange influx values of 3-OMG were significantly decreased, respectively, 15 and 5% in T310A, 8 and 3% in T310I, and 40 and 34% in T310S mutants. (b) Zero-trans efflux of 3-OMG and dehydroascorbic acid uptake were significantly decreased in mutants. ( c) The relative Pf values for T310A, T310I, and T310S were increased 3-, 4.8-, and 3.5- fold compared with wild- type values. We found a very high negative correlation between the rate of glucose uptake and P-f (- 0.93), and between hydropathy and uptake (- 0.92), a moderate correlation between hydropathy and P-f (0.73), and a minimal correlation between uptake, P-f, and molecular weight. These findings are consistent with a central role for hydropathy rather than size at position 310 of this mutation.	Columbia Univ, Neurol Inst, Dept Neurol, Colleen Giblin Labs Pediat Neurol Res, New York, NY 10032 USA; Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA; Qilu Hosp, Dept Pediat, Shandong 250012, Peoples R China	Columbia University; Columbia University; Columbia University; Shandong University	De Vivo, DC (corresponding author), Columbia Univ, Neurol Inst, Dept Neurol, Colleen Giblin Labs Pediat Neurol Res, 7100 W 168th St, New York, NY 10032 USA.	dcd1@columbia.edu	Zuniga, Felipe/Q-8035-2019; Zuniga, Felipe A/L-7885-2013	Pascual, Juan/0000-0002-0843-8221; Zuniga, Felipe A./0000-0003-0286-565X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY008918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K12NS001698, R01NS037949] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00645] Funding Source: Medline; NEI NIH HHS [EY08918] Funding Source: Medline; NINDS NIH HHS [NS01698, NS37949] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agus DB, 1997, J CLIN INVEST, V100, P2842, DOI 10.1172/JCI119832; BARNETT JEG, 1973, BIOCHEM J, V131, P211, DOI 10.1042/bj1310211; BELL GI, 1993, J BIOL CHEM, V268, P19161; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; Brockmann K, 2001, ANN NEUROL, V50, P476, DOI 10.1002/ana.1222; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; Cloherty EK, 2001, BIOCHEMISTRY-US, V40, P15549, DOI 10.1021/bi015586w; CORNFORD EM, 1994, J CEREBR BLOOD F MET, V14, P106, DOI 10.1038/jcbfm.1994.15; DEVIVO DC, 1991, NEW ENGL J MED, V325, P703, DOI 10.1056/NEJM199109053251006; DUE AD, 1995, BIOCHEMISTRY-US, V34, P5462, DOI 10.1021/bi00016a017; ECHEVARRIA M, 1993, J GEN PHYSIOL, V101, P827, DOI 10.1085/jgp.101.6.827; ENGLARD S, 1986, ANNU REV NUTR, V6, P365, DOI 10.1146/annurev.nu.06.070186.002053; FARRELL CL, 1991, J NEUROSCI METH, V37, P103, DOI 10.1016/0165-0270(91)90120-O; FARRELL CL, 1991, P NATL ACAD SCI USA, V88, P5779, DOI 10.1073/pnas.88.13.5779; FINIDORILEPICARD J, 1981, NATURE, V292, P255, DOI 10.1038/292255a0; FISCHBARG J, 1990, P NATL ACAD SCI USA, V87, P3244, DOI 10.1073/pnas.87.8.3244; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; HEBERT DN, 1991, BIOCHEMISTRY-US, V30, P4654, DOI 10.1021/bi00233a003; HORNIG D, 1975, ANN NY ACAD SCI, V258, P103, DOI 10.1111/j.1749-6632.1975.tb29271.x; Hruz PW, 2000, BIOCHEMISTRY-US, V39, P9367, DOI 10.1021/bi000821g; Hruz PW, 2001, MOL MEMBR BIOL, V18, P183; Iserovich P, 2002, J BIOL CHEM, V277, P30991, DOI 10.1074/jbc.M202763200; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; Klepper J, 1999, NEUROCHEM RES, V24, P587, DOI 10.1023/A:1022544131826; Klepper J, 1998, ANN NEUROL, V44, P286, DOI 10.1002/ana.410440225; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MCGOWAN KM, 1995, PHARMACOL THERAPEUT, V66, P465, DOI 10.1016/0163-7258(95)00007-4; Monden I, 2001, BIOL CHEM, V382, P1551, DOI 10.1515/BC.2001.189; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; Mueckler M, 2002, J BIOL CHEM, V277, P3498, DOI 10.1074/jbc.M109157200; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Naftalin RJ, 2002, J MEMBRANE BIOL, V186, P113, DOI 10.1007/s00232-001-0140-z; Olsowski A, 2000, BIOCHEMISTRY-US, V39, P2469, DOI 10.1021/bi992160x; Olsowski A, 1998, BIOCHEMISTRY-US, V37, P10738, DOI 10.1021/bi980440r; PADH H, 1990, BIOCHEM CELL BIOL, V68, P1166, DOI 10.1139/o90-173; Pardridge W M, 1991, Semin Cell Biol, V2, P419; Pardridge William M., 1993, P395; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; Seidner G, 1998, NAT GENET, V18, P188, DOI 10.1038/ng0298-188; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; VERA JC, 1989, MOL CELL BIOL, V9, P4187, DOI 10.1128/MCB.9.10.4187; Wang D, 2000, HUM MUTAT, V16, P224, DOI 10.1002/1098-1004(200009)16:3<224::AID-HUMU5>3.0.CO;2-P; Wang YX, 2000, BIOCHEM BIOPH RES CO, V267, P488, DOI 10.1006/bbrc.1999.1929; Widdas W. F., 1992, Cytobios, V72, P139; Widdas WF, 1998, EXP PHYSIOL, V83, P187; Zeng H, 1996, BIOPHYS J, V70, P14, DOI 10.1016/S0006-3495(96)79560-7; ZHANG R, 1991, J CLIN INVEST, V88, P1553, DOI 10.1172/JCI115466; Zuniga FA, 2001, J BIOL CHEM, V276, P44970, DOI 10.1074/jbc.M107350200	50	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49015	49021		10.1074/jbc.M308765200	http://dx.doi.org/10.1074/jbc.M308765200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	13129919	hybrid			2022-12-25	WOS:000186829000063
J	Forrest, JC; Campbell, JA; Schelling, P; Stehle, T; Dermody, TS				Forrest, JC; Campbell, JA; Schelling, P; Stehle, T; Dermody, TS			Structure-function analysis of reovirus binding to junctional adhesion molecule 1 - Implications for the mechanism of reovirus attachment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; CRYSTAL-STRUCTURE; ADENOVIRUS RECEPTOR; CELLULAR RECEPTOR; PROTEIN SIGMA-1; COXSACKIEVIRUS; FIBER; RESOLUTION; ANTIBODY; TYPE-3	Mammalian reoviruses are nonenveloped viruses with a long, filamentous attachment protein that dictates disease phenotypes following infection of newborn mice and is a structural homologue of the adenovirus attachment protein. Reoviruses use junctional adhesion molecule 1 (JAM1) as a serotype-independent cellular receptor. JAM1 is a broadly expressed immunoglobulin superfamily protein that forms stable homodimers and regulates tight-junction permeability and lymphocyte trafficking. We employed a series of structure-guided binding and infection experiments to define residues in human JAM1 (hJAM1) important for reovirus-receptor interactions and to gain insight into mechanisms of reovirus attachment. Binding and infection experiments using chimeric and domain deletion mutant receptor molecules indicate that the amino-terminal D1 domain of hJAM1 is required for reovirus attachment, infection, and replication. Reovirus binding to hJAM1 occurs more rapidly than homotypic hJAM1 association and is competed by excess hJAM1 in vitro and on cells. Crosslinking hJAM1 diminishes the capacity of reovirus to bind hJAM1 in vitro and on cells and negates the competitive effects of soluble hJAM1 on reovirus attachment. Finally, mutagenesis studies demonstrate that residues intimately associated with the hJAM1 dimer interface are critical for reovirus interactions with hJAM1. These results suggest that reovirus attachment disrupts hJAM1 dimers and highlight similarities between the attachment strategies of reovirus and adenovirus.	Vanderbilt Univ, Elizabeth B Lamb Ctr Pediat Res, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Microbiol & Immunol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pediat, Sch Med, Nashville, TN 37232 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Lab Dev Immunol, Boston, MA 02114 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Dermody, TS (corresponding author), Vanderbilt Univ, Elizabeth B Lamb Ctr Pediat Res, Sch Med, D7235 MCN, Nashville, TN 37232 USA.				NCI NIH HHS [CA68485, T32 CA09385] Funding Source: Medline; NIAID NIH HHS [R01 AI38296] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NIGMS NIH HHS [R01 GM67853] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, T32CA009385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067853] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEA AC, 1988, VIROLOGY, V167, P601, DOI 10.1016/0042-6822(88)90123-7; Barton ES, 2001, J BIOL CHEM, V276, P2200, DOI 10.1074/jbc.M004680200; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; Bazzoni G, 2000, J BIOL CHEM, V275, P30970, DOI 10.1074/jbc.M003946200; Becker MM, 2001, J VIROL, V75, P1459, DOI 10.1128/JVI.75.3.1459-1475.2001; Belnap DM, 2000, P NATL ACAD SCI USA, V97, P73, DOI 10.1073/pnas.97.1.73; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bewley MC, 1999, SCIENCE, V286, P1579, DOI 10.1126/science.286.5444.1579; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Chappell JD, 2000, J VIROL, V74, P8472, DOI 10.1128/JVI.74.18.8472-8479.2000; Chappell JD, 2002, EMBO J, V21, P1, DOI 10.1093/emboj/21.1.1; Cohen CJ, 2001, P NATL ACAD SCI USA, V98, P15191, DOI 10.1073/pnas.261452898; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; FERNANDES J, 1994, J BIOL CHEM, V269, P17043; FRASER RDB, 1990, J VIROL, V64, P2990, DOI 10.1128/JVI.64.6.2990-3000.1990; Freimuth P, 1999, J VIROL, V73, P1392, DOI 10.1128/JVI.73.2.1392-1398.1999; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; He YN, 2001, NAT STRUCT BIOL, V8, P874, DOI 10.1038/nsb1001-874; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; Kolatkar PR, 1999, EMBO J, V18, P6249, DOI 10.1093/emboj/18.22.6249; Kostrewa D, 2001, EMBO J, V20, P4391, DOI 10.1093/emboj/20.16.4391; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LEE PWK, 1981, VIROLOGY, V108, P156, DOI 10.1016/0042-6822(81)90535-3; LIMBIRD LE, 1996, CELL SURFACE RECEPTO; LIU Y, 2000, J CELL SCI, V113, P1; Lortat-Jacob H, 2001, J BIOL CHEM, V276, P9009, DOI 10.1074/jbc.M009304200; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; MORRISON LA, 1991, P NATL ACAD SCI USA, V88, P3852, DOI 10.1073/pnas.88.9.3852; Nemerow GR, 1999, MICROBIOL MOL BIOL R, V63, P725, DOI 10.1128/MMBR.63.3.725-734.1999; Nibert ML., 2001, FIELDS VIROLOGY, P1679; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ono N, 2001, J VIROL, V75, P1594, DOI 10.1128/JVI.75.4.1594-1600.2001; Ozaki H, 1999, J IMMUNOL, V163, P553; Prota AE, 2003, P NATL ACAD SCI USA, V100, P5366, DOI 10.1073/pnas.0937718100; SCHMID SL, 1990, J CELL BIOL, V111, P2307, DOI 10.1083/jcb.111.6.2307; Spear PG, 2002, DEV CELL, V3, P462, DOI 10.1016/S1534-5807(02)00298-8; Stehle T, 2003, REV MED VIROL, V13, P123, DOI 10.1002/rmv.379; STRONG JE, 1991, VIROLOGY, V184, P23, DOI 10.1016/0042-6822(91)90818-V; Tyler K.L., 2001, FIELDS VIROLOGY, P1729; TYLER KL, 1986, SCIENCE, V233, P770, DOI 10.1126/science.3016895; van Raaij MJ, 2000, STRUCTURE, V8, P1147, DOI 10.1016/S0969-2126(00)00528-1; VIRGIN HW, 1988, J VIROL, V62, P4594, DOI 10.1128/JVI.62.12.4594-4604.1988; Walters RW, 2002, CELL, V110, P789, DOI 10.1016/S0092-8674(02)00912-1; WEINER HL, 1977, P NATL ACAD SCI USA, V74, P5744, DOI 10.1073/pnas.74.12.5744; WEINER HL, 1980, J INFECT DIS, V141, P609, DOI 10.1093/infdis/141.5.609; WEINER HL, 1980, J IMMUNOL, V124, P2143	47	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48434	48444		10.1074/jbc.M305649200	http://dx.doi.org/10.1074/jbc.M305649200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12966102	hybrid			2022-12-25	WOS:000186731400129
J	Mogi, M; Togari, A				Mogi, M; Togari, A			Activation of caspases is required for osteoblastic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC CELL-DEATH; MATURATION; PROTEASES; MC3T3-E1; PATHWAYS	Previous studies have shown that mouse osteoblastic MC3T3-E1 cells undergo apoptosis when exposed to a mixture of proinflammatory cytokines. Bone morphogenetic protein (BMP) s are important regulators of osteoblast differentiation. Because regulation of osteoblastic differentiation is poorly understood, we sought to determine if BMP-4-induced differentiation of osteoblastic cells depends on the activity of the key apoptotic proteases, i.e. the caspases. BMP-4 induced the growth arrest and differentiation of osteoblastic cell line MC3T3-E1, as evidenced by the appearance of osteoblastic phenotypes such as alkaline phosphatase ( ALP) activation and parathyroid hormone (PTH)-dependent production of cAMP. Surprisingly, BMP-4 induced transient and potent activation of caspase-8, caspase-2, and caspase-3, in this order. However, no apoptosis or necrosis in BMP-4-treated cells could be detected by FACS using annexin-V/propodium iodine double staining. Peptide inhibition of caspase activity led to a dramatic reduction in ALP activation and PTH-induced production of cAMP in BMP-4-treated cells. Although BMP-4 treatment resulted in cell-cycle G(0)/G(1) arrest as detected by FACS cell-cycle analysis, caspase inhibitors (caspase-8, caspase-2, and caspase-3 inhibitors) could block the G(0)/G(1) arrest in MC3T3-E1 cells. Taken together, these results confirm a unique and unanticipated role for the caspase-mediated signal cascade in the differentiation of osteoblasts.	Aichi Gakuin Univ, Sch Dent, Dept Pharmacol, Nagoya, Aichi 4648650, Japan	Aichi Gakuin University	Mogi, M (corresponding author), Aichi Gakuin Univ, Sch Dent, Dept Pharmacol, Nagoya, Aichi 4648650, Japan.							Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chua CC, 2002, BBA-MOL CELL RES, V1593, P1, DOI 10.1016/S0167-4889(02)00257-4; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hay E, 2001, J BIOL CHEM, V276, P29028, DOI 10.1074/jbc.M011265200; Hoffmann A, 2001, CRIT REV EUKAR GENE, V11, P23; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Metkar SS, 2003, J CELL BIOL, V160, P875, DOI 10.1083/jcb.200210158; Mogi M, 1999, BIOCHEM PHARMACOL, V58, P649, DOI 10.1016/S0006-2952(99)00131-8; Morimoto Y, 1999, J DENT RES, V78, P735, DOI 10.1177/00220345990780030501; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Ritter SJ, 1998, J BIOL CHEM, V273, P12798, DOI 10.1074/jbc.273.21.12798; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411; Zamzami N, 1999, NATURE, V401, P127, DOI 10.1038/43591; ZELMATI Y, 2001, J EXP MED, V193, P247	25	114	121	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47477	47482		10.1074/jbc.M307055200	http://dx.doi.org/10.1074/jbc.M307055200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12954609	hybrid			2022-12-25	WOS:000186731400018
J	Takenaka, M; Brennicke, A				Takenaka, M; Brennicke, A			In vitro RNA editing in pea mitochondria requires NTP or dNTP, suggesting involvement of an RNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PLANT-MITOCHONDRIA; ARABIDOPSIS-THALIANA; CYTIDINE DEAMINASE; GENE-EXPRESSION; CHLOROPLASTS; SITE; ELEMENTS; SYSTEM; TRANSCRIPTION	To analyze the biochemical parameters of RNA editing in plant mitochondria and to eventually characterize the enzymes involved we developed a novel in vitro system. The high sensitivity of the mismatch-specific thymine glycosylase is exploited to facilitate reliable quantitative evaluation of the in vitro RNA editing products. A pea mitochondrial lysate correctly processes a C to U editing site in the cognate atp9 template. Reaction conditions were determined for a number of parameters, which allow first conclusions on the proteins involved. The apparent tolerance against specific Zn2+ chelators argues against the involvement of a cytidine deaminase enzyme, the theoretically most straightforward catalysator of the deamination reaction. Participation of a transaminase was investigated by testing potential amino group receptors, but none of these increased the RNA editing reaction. Most notable is the requirement of the RNA editing activity for NTPs. Any NTP or dNTP can substitute for ATP to the optimal concentration of 15 mM. This observation suggests the participation of an RNA helicase in the predicted RNA editing protein complex of plant mitochondria.	Univ Ulm, D-89069 Ulm, Germany	Ulm University	Takenaka, M (corresponding author), Univ Ulm, D-89069 Ulm, Germany.		Takenaka, Mizuki/AAK-9884-2020; Takenaka, Mizuki/B-2636-2013	Takenaka, Mizuki/0000-0002-3242-5092; Takenaka, Mizuki/0000-0002-3242-5092				ARAYA A, 1992, P NATL ACAD SCI USA, V89, P1040, DOI 10.1073/pnas.89.3.1040; Aubourg S, 1999, NUCLEIC ACIDS RES, V27, P628, DOI 10.1093/nar/27.2.628; BINDER S, 1995, J BIOL CHEM, V270, P22182, DOI 10.1074/jbc.270.38.22182; BLANC V, 1995, FEBS LETT, V373, P56, DOI 10.1016/0014-5793(95)00991-H; Bock R, 2000, BIOCHIMIE, V82, P549, DOI 10.1016/S0300-9084(00)00610-6; BONNARD G, 1992, CRIT REV PLANT SCI, V10, P503, DOI 10.1080/07352689209382325; Chateigner-Boutin AL, 2002, MOL CELL BIOL, V22, P8448, DOI 10.1128/MCB.22.24.8448-8456.2002; Chaudhuri S, 1996, EMBO J, V15, P5958, DOI 10.1002/j.1460-2075.1996.tb00982.x; Faivre-Nitschke SE, 1999, EUR J BIOCHEM, V263, P896, DOI 10.1046/j.1432-1327.1999.00591.x; Farre JC, 2001, MOL CELL BIOL, V21, P6731, DOI 10.1128/MCB.21.20.6731-6737.2001; Farre JC, 2001, NUCLEIC ACIDS RES, V29, P2484, DOI 10.1093/nar/29.12.2484; FLORESROZAS H, 1993, J BIOL CHEM, V268, P21372; Gagliardi D, 1999, FEBS LETT, V458, P337, DOI 10.1016/S0014-5793(99)01168-0; Giege P, 1999, P NATL ACAD SCI USA, V96, P15324, DOI 10.1073/pnas.96.26.15324; Grosjean H., 1998, MODIFICATION EDITING, DOI [10.1128/9781555818296, DOI 10.1128/9781555818296]; Hirose T, 2001, EMBO J, V20, P1144, DOI 10.1093/emboj/20.5.1144; HODGES P, 1992, TRENDS BIOCHEM SCI, V17, P77, DOI 10.1016/0968-0004(92)90506-5; Hoffmann M, 2002, J MOL BIOL, V320, P943, DOI 10.1016/S0022-2836(02)00552-1; Kuhn J, 2001, MOL CELL BIOL, V21, P731, DOI 10.1128/MCB.21.3.731-742.2001; LIPPOK B, 1994, MOL GEN GENET, V243, P39, DOI 10.1007/BF00283874; Malek O, 1996, EMBO J, V15, P1403, DOI 10.1002/j.1460-2075.1996.tb00482.x; Miyamoto T, 2002, MOL CELL BIOL, V22, P6726, DOI 10.1128/MCB.22.19.6726-6734.2002; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; Okanami M, 1998, NUCLEIC ACIDS RES, V26, P2638, DOI 10.1093/nar/26.11.2638; PRING D, 1993, PLANT MOL BIOL, V21, P1163, DOI 10.1007/BF00023611; RAJASEKHAR VK, 1993, PLANT CELL, V5, P1843, DOI 10.2307/3869699; Taylor GR, 1999, ELECTROPHORESIS, V20, P1125, DOI 10.1002/(SICI)1522-2683(19990101)20:6<1125::AID-ELPS1125>3.0.CO;2-O; YU W, 1995, J BIOL CHEM, V270, P18227, DOI 10.1074/jbc.270.31.18227	29	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47526	47533		10.1074/jbc.M305341200	http://dx.doi.org/10.1074/jbc.M305341200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12970369	hybrid			2022-12-25	WOS:000186731400024
J	Visintin, A; Latz, E; Monks, BG; Espevik, T; Golenbock, DT				Visintin, A; Latz, E; Monks, BG; Espevik, T; Golenbock, DT			Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUTTING EDGE; KAPPA-B; LPS; ENDOTOXIN; TLR4; ACTIVATION; COMPLEX; CONFERS; CD14; RESPONSIVENESS	Three cell-surface proteins have been recognized as components of the mammalian signaling receptor for bacterial lipopolysaccharide (LPS): CD14, Toll-like receptor-4 (TLR4), and MD-2. Biochemical and visual studies shown here demonstrate that the role of CD14 in signal transduction is to enhance LPS binding to MD-2, although its expression is not essential for cellular activation. These studies clarify how MD-2 functions: we found that MD-2 enables TLR4 binding to LPS and allows the formation of stable receptor complexes. MD-2 must be bound to TLR4 on the cell surface before binding can occur. Consequently, TLR4 clusters into receptosomes ( many of which are massive) that recruit intracellular toll/IL-1/resistance domain-containing adapter proteins within minutes, thus initiating signal transduction. TLR4 activation correlates with the ability of MD-2 to bind LPS, as MD-2 mutants that still bind TLR4, but are impaired in the ability to bind LPS, conferred a greatly blunted LPS response. These findings help clarify the earliest events of TLR4 triggering by LPS and identify MD-2 as an attractive target for pharmacological intervention in endotoxin-mediated diseases.	Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA; Norwegian Univ Sci & Technol, N-7489 Trondheim, Norway	University of Massachusetts System; University of Massachusetts Worcester; Norwegian University of Science & Technology (NTNU)	Golenbock, DT (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis & Immunol, LRB 309,364 Plantat St, Worcester, MA 01605 USA.	douglas.golenbock@umassmed.edu	Monks, Brian/B-8362-2015; Latz, Eicke/H-3951-2014	Monks, Brian/0000-0003-4008-3093; Latz, Eicke/0000-0003-1488-5666	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054060, R37GM054060, R01GM063244] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50305] Funding Source: Medline; NIGMS NIH HHS [GM63244, GM54060] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akashi S, 2001, INT IMMUNOL, V13, P1595, DOI 10.1093/intimm/13.12.1595; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; DELUDE RL, 1995, P NATL ACAD SCI USA, V92, P9288, DOI 10.1073/pnas.92.20.9288; Ferguson AD, 2000, STRUCTURE, V8, P585; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hoshino K, 1999, J IMMUNOL, V162, P3749; Ingalls RR, 1999, INFECT DIS CLIN N AM, V13, P341, DOI 10.1016/S0891-5520(05)70078-7; Kawasaki K, 2003, J IMMUNOL, V170, P413, DOI 10.4049/jimmunol.170.1.413; Kawasaki K, 2001, J ENDOTOXIN RES, V7, P232, DOI 10.1177/09680519010070030701; Lamping N, 1996, J IMMUNOL, V157, P4648; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Lien E, 2002, CRIT CARE MED, V30, pS1, DOI 10.1097/00003246-200201001-00001; Mancek M, 2002, BIOCHEM BIOPH RES CO, V292, P880, DOI 10.1006/bbrc.2002.6748; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mullen GED, 2003, P NATL ACAD SCI USA, V100, P3919, DOI 10.1073/pnas.0630495100; Muroi M, 2002, J BIOL CHEM, V277, P42372, DOI 10.1074/jbc.M205966200; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; ROBARDS AW, 1999, PROCEDURES ELECT MIC; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Schumann RR, 1997, J IMMUNOL, V159, P5599; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Vasselon T, 1999, J EXP MED, V190, P509, DOI 10.1084/jem.190.4.509; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Visintin A, 2001, P NATL ACAD SCI USA, V98, P12156, DOI 10.1073/pnas.211445098; Zarember KA, 2002, J IMMUNOL, V168, P554, DOI 10.4049/jimmunol.168.2.554	40	187	200	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48313	48320		10.1074/jbc.M306802200	http://dx.doi.org/10.1074/jbc.M306802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12960171	hybrid			2022-12-25	WOS:000186731400116
J	Breckau, D; Mahlitz, E; Sauerwald, A; Layer, G; Jahn, D				Breckau, D; Mahlitz, E; Sauerwald, A; Layer, G; Jahn, D			Oxygen-dependent coproporphyrinogen III oxidase (HemF) from Escherichia coli is stimulated by manganese	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; CONTAINING ENZYME; OXALATE OXIDASE; PURIFICATION; YEAST; EXPRESSION; MECHANISM; PROTEIN; GERMIN; BARLEY	During heme biosynthesis in Escherichia coli two structurally unrelated enzymes, one oxygen- dependent ( HemF) and one oxygen- independent ( HemN), are able to catalyze the oxidative decarboxylation of coproporphyrinogen III to form protoporphyrinogen IX. Oxygen-dependent coproporphyrinogen III oxidase was produced by overexpression of the E. coli hemF in E. coli and purified to apparent homogeneity. The dimeric enzyme showed a K-m value of 2.6 muM for coproporphyrinogen III with a k(cat) value of 0.17 min(-1) at its optimal pH of 6. HemF does not utilize protoporphyrinogen IX or coproporphyrin III as substrates and is inhibited by protoporphyrin IX. Molecular oxygen is essential for the enzymatic reaction. Single turnover experiments with oxygen- loaded HemF under anaerobic conditions demonstrated electron acceptor function for oxygen during the oxidative decarboxylation reaction with the concomitant formation of H2O2. Metal chelator treatment inactivated E. coli HemF. Only the addition of manganese fully restored coproporphyrinogen III oxidase activity. Evidence for the involvement of four highly conserved histidine residues ( His- 96, His- 106, His- 145, and His- 175) in manganese coordination was obtained. One catalytically important tryptophan residue was localized in position 274. None of the tested highly conserved cysteine ( Cys- 167), tyrosine ( Tyr- 135, Tyr- 160, Tyr- 170, Tyr- 213, Tyr- 240, and Tyr- 276), and tryptophan residues ( Trp- 36, Trp- 123, Trp- 166, and Trp- 298) were found important for HemF activity. Moreover, mutation of a potential nucleotide binding motif ( GGGXXTP) did not affect HemF activity. Two alternative routes for HemF-mediated catalysis, one metal- dependent, the other metal- independent, are proposed.	Tech Univ Carolo Wilhelmina Braunschweig, Inst Microbiol, D-38106 Braunschweig, Germany	Braunschweig University of Technology	Jahn, D (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Microbiol, Spielmannstr 7, D-38106 Braunschweig, Germany.			Jahn, Dieter/0000-0002-4064-9205				AKHTAR M, 1994, BIOSYNTHESIS TETRAPY, P131; Colloc'h N, 2002, FEBS LETT, V526, P5, DOI 10.1016/S0014-5793(02)03123-X; Frankenberg N, 1999, BIOCHEMISTRY-US, V38, P13968, DOI 10.1021/bi9906468; JACKSON AH, 1980, INT J BIOCHEM, V12, P681, DOI 10.1016/0020-711X(80)90144-5; Jones MA, 2002, J BIOCHEM, V131, P201, DOI 10.1093/oxfordjournals.jbchem.a003088; Kohno H, 1996, BBA-PROTEIN STRUCT M, V1292, P156, DOI 10.1016/0167-4838(95)00188-3; KRUSE E, 1995, PLANTA, V196, P796, DOI 10.1007/BF01106776; Labbe P, 1997, METHOD ENZYMOL, V281, P367; LABBE P, 1985, ANAL BIOCHEM, V149, P248, DOI 10.1016/0003-2697(85)90502-0; LANE BG, 1994, FASEB J, V8, P294, DOI 10.1096/fasebj.8.3.8143935; Layer G, 2002, J BIOL CHEM, V277, P34136, DOI 10.1074/jbc.M205247200; MAMET R, 1994, J MICROBIOL METH, V19, P173, DOI 10.1016/0167-7012(94)90067-1; Medlock AE, 1996, J BIOL CHEM, V271, P32507, DOI 10.1074/jbc.271.51.32507; Narita S, 1999, MOL GEN GENET, V261, P1012, DOI 10.1007/s004380051050; Reichard P, 2002, ARCH BIOCHEM BIOPHYS, V397, P149, DOI 10.1006/abbi.2001.2637; Requena L, 1999, BIOCHEM J, V343, P185, DOI 10.1042/0264-6021:3430185; Rompf A, 1998, MOL MICROBIOL, V29, P985, DOI 10.1046/j.1365-2958.1998.00980.x; Sambrook J., 2002, MOL CLONING LAB MANU; SEEHRA JS, 1983, BIOCHEM J, V209, P709, DOI 10.1042/bj2090709; Smith K.M., 1976, PORPHYRINS METALLOPO; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Tanner A, 2001, J BIOL CHEM, V276, P43627, DOI 10.1074/jbc.M107202200; TROUP B, 1994, J BACTERIOL, V176, P673, DOI 10.1128/jb.176.3.673-680.1994; TROUP B, 1995, J BACTERIOL, V177, P3326, DOI 10.1128/jb.177.11.3326-3331.1995; Woo EJ, 2000, NAT STRUCT BIOL, V7, P1036; Yoshinaga T, 1997, METHOD ENZYMOL, V281, P355; YOSHINAGA T, 1980, J BIOL CHEM, V255, P4727; ZAGOREC M, 1986, J BIOL CHEM, V261, P2506	28	53	56	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46625	46631		10.1074/jbc.M308553200	http://dx.doi.org/10.1074/jbc.M308553200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12975365	hybrid			2022-12-25	WOS:000186569400050
J	Jeong, SY; Kumagai, A; Lee, J; Dunphy, WG				Jeong, SY; Kumagai, A; Lee, J; Dunphy, WG			Phosphorylated claspin interacts with a phosphate-binding site in the kinase domain of Chk1 during ATR-mediated activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION STRESS; XENOPUS EGG EXTRACTS; CHECKPOINT CONTROL; DAMAGE CHECKPOINT; CRYSTAL-STRUCTURE; PROTEIN-KINASES; MRC1; PATHWAY; RAD53; FORK	Claspin is essential for the ATR-dependent activation of Chk1 in Xenopus egg extracts containing incompletely replicated or UV-damaged DNA. The activated form of Claspin contains two repeated phosphopeptide motifs that mediate its binding to Chk1. We show that these phosphopeptide motifs bind to Chk1 by means of its N-terminal kinase domain. The binding site on Chk1 involves a positively charged cluster of amino acids that contains lysine 54, arginine 129, threonine 153, and arginine 162. Mutagenesis of these residues strongly compromises the ability of Chk1 to interact with Claspin. These amino acids lie within regions of Chk1 that are involved in various aspects of its catalytic function. The predicted position on Chk1 of the phosphate group from Claspin corresponds to the location of activation-loop phosphorylation in various kinases. In addition, we have obtained evidence that the C-terminal regulatory domain of Chk1, which does not form a stable complex with Claspin under our assay conditions, nonetheless has some role in Claspin-dependent activation. Overall, these results indicate that Claspin docks with a phosphate-binding site in the catalytic domain of Chk1 during activation by ATR. Phosphorylated Claspin may mimic an activating phosphorylation of Chk1 during this process.	CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA	California Institute of Technology	Dunphy, WG (corresponding author), CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043974, R01GM043974] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43974] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Liu QH, 2000, GENE DEV, V14, P1448; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Wang SX, 2000, FEBS LETT, V487, P277, DOI 10.1016/S0014-5793(00)02370-X; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	23	60	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46782	46788		10.1074/jbc.M304551200	http://dx.doi.org/10.1074/jbc.M304551200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963733	Green Accepted, hybrid			2022-12-25	WOS:000186569400069
J	Lin, JY; DeCaprio, JA				Lin, JY; DeCaprio, JA			SV40 large T antigen promotes dephosphorylation of p130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN-VIRUS-40 LARGE-T; RETINOBLASTOMA SUSCEPTIBILITY GENE; PROTEIN PHOSPHATASE 2A; PRB-RELATED PROTEINS; SMALL TUMOR-ANTIGEN; HEAT-SHOCK PROTEIN; DNA-REPLICATION; CELL-CYCLE; OKADAIC ACID; J-DOMAIN	SV40 large T antigen ( Ag) binds to all members of the retinoblastoma ( RB) tumor suppressor family including pRb, p107, and p130. Although the LXCXE motif of T Ag binds directly to the RB proteins, it is not sufficient to fully inactivate their function. The N- terminal DNA J domain of T Ag cooperates with the LXCXE motif to override RB- mediated repression of E2F- dependent transcription. In addition, T Ag can reduce the overall phosphorylation state of p107 and p130 that is dependent on an intact J domain and LXCXE motif. However, the mechanism of this activity has not been described. Here we describe the use of a cell- free system to characterize the effect of T Ag on p130 phosphorylation. When incubated in extracts prepared from S phase cells, p130 undergoes specific phosphorylation. Addition of T Ag to S phase extracts leads to a reduction of p130 phosphorylation in vitro. The ability of T Ag to reduce the phosphorylation of p130 in vitro is dependent on an intact DNA J domain and can be inhibited by okadaic acid and PP2A- specific inhibitors. These results suggest that T Ag recruits a phosphatase activity in a DNA J domain- dependent manner to reduce the phosphorylation of p130.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	DeCaprio, JA (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Mayer 457,44 Binney St, Boston, MA 02115 USA.	james_decaprio@dfci.harvard.edu			NCI NIH HHS [CA 063113] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063113] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bastians H, 1999, MOL BIOL CELL, V10, P3927, DOI 10.1091/mbc.10.11.3927; Bastians H, 1998, P NATL ACAD SCI USA, V95, P15374, DOI 10.1073/pnas.95.26.15374; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; Chao HHA, 2000, MOL CELL BIOL, V20, P7624, DOI 10.1128/MCB.20.20.7624-7633.2000; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; KELLEY WL, 1994, TRENDS BIOCHEM SCI, V19, P277, DOI 10.1016/0968-0004(94)90003-5; Krtolica A, 1998, ONCOGENE, V17, P2295, DOI 10.1038/sj.onc.1202159; LAWSON R, 1990, J VIROL, V64, P2380, DOI 10.1128/JVI.64.5.2380-2383.1990; LUDLOW JW, 1992, ONCOGENE, V7, P1011; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Mateer SC, 1998, J BIOL CHEM, V273, P35339, DOI 10.1074/jbc.273.52.35339; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Parreno M, 2000, J VIROL, V74, P3166, DOI 10.1128/JVI.74.7.3166-3176.2000; Parreno M, 2001, ONCOGENE, V20, P4793, DOI 10.1038/sj.onc.1204644; PEDEN KWC, 1992, VIRUS GENES, V6, P107, DOI 10.1007/BF01703060; SAWAI ET, 1994, VIRUS RES, V31, P367, DOI 10.1016/0168-1702(94)90029-9; SAWAI ET, 1989, J VIROL, V63, P3961, DOI 10.1128/JVI.63.9.3961-3973.1989; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHEIDTMANN KH, 1991, J VIROL, V65, P2098, DOI 10.1128/JVI.65.4.2098-2101.1991; SCHONTHAL A, 1993, ONCOGENE, V8, P433; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; TAKAI A, 1995, BIOCHEM J, V306, P657, DOI 10.1042/bj3060657; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P4883, DOI 10.1128/MCB.12.11.4883; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; Voorhoeve PM, 1999, ONCOGENE, V18, P679, DOI 10.1038/sj.onc.1202289; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408	62	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46482	46487		10.1074/jbc.M307044200	http://dx.doi.org/10.1074/jbc.M307044200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12968030	hybrid			2022-12-25	WOS:000186569400033
J	Lundmark, R; Carlsson, SR				Lundmark, R; Carlsson, SR			Sorting nexin 9 participates in clathrin-mediated endocytosis through interactions with the core components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY PROTEIN; AXONAL GUIDANCE; DYNAMIN; DOMAINS; RECEPTOR; IDENTIFICATION; DSH3PX1; COMPLEX; SH3PX1; CELLS	Sorting nexin 9 (SNX9) belongs to a family of proteins, the sorting nexins, that are characterized by the presence of a subclass of the phosphoinositide-binding phox domain. SNX9 has in its amino terminus a Src homology 3 domain and a region with predicted low complexity followed by a carboxyl-terminal part containing the phox domain. We previously found that SNX9 is one of the major proteins in hematopoietic cells that binds to the alpha- and beta2-appendages of adaptor protein complex 2 (AP-2), a protein with a critical role in the formation of clathrin-coated vesicles at the plasma membrane. In the present study we show that clathrin and dynamin-2, two other essential molecules in the endocytic process, also interact with SNX9. We found that both AP-2 and clathrin bind to the low complexity region in SNX9 in a cooperative manner, whereas dynamin-2 binds to the Src homology 3 domain. In the cytosol, SNX9 is present in a 14.5 S complex containing dynamin-2 and an unidentified 41-kDa protein. In HeLa cells, SNX9 co-localized with both AP-2 and dynamin-2 at the plasma membrane or on vesicular structures derived from it but not with the early endosomal marker EEA1 or with AP-1. The results suggest that SNX9 may be recruited together with dynamin-2 and become co-assembled with AP-2 and clathrin at the plasma membrane. Overexpression in both K562 and HeLa cells of truncated forms of SNX9 interfered with the uptake of transferrin, consistent with a role of SNX9 in endocytosis.	Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden	Umea University	Carlsson, SR (corresponding author), Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden.			Carlsson, Sven R/0000-0001-5123-135X				Brett TJ, 2002, STRUCTURE, V10, P797, DOI 10.1016/S0969-2126(02)00784-0; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; D'Hondt K, 2000, ANNU REV GENET, V34, P255, DOI 10.1146/annurev.genet.34.1.255; Dell'Angelica EC, 2001, TRENDS CELL BIOL, V11, P315, DOI 10.1016/S0962-8924(01)02043-8; Dong JX, 2000, PROTEIN EXPRES PURIF, V20, P314, DOI 10.1006/prep.2000.1305; Fountoulakis M, 1997, ANAL BIOCHEM, V250, P153, DOI 10.1006/abio.1997.2213; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Hirst J, 2003, MOL BIOL CELL, V14, P625, DOI 10.1091/mbc.E02-09-0552; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; Lundmark R, 2002, BIOCHEM J, V362, P597, DOI 10.1042/0264-6021:3620597; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; Mayer BJ, 2001, J CELL SCI, V114, P1253; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Owen DJ, 2000, CURR OPIN CELL BIOL, V12, P467, DOI 10.1016/S0955-0674(00)00118-6; Qualmann B, 2002, INT REV CYTOL, V220, P93; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Sever S, 2000, J CELL BIOL, V150, P1137, DOI 10.1083/jcb.150.5.1137; Slepnev VI, 2000, J BIOL CHEM, V275, P17583, DOI 10.1074/jbc.M910430199; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; SMYTHE E, 1992, METHOD ENZYMOL, V219, P223; Song BD, 2003, BIOCHEMISTRY-US, V42, P1369, DOI 10.1021/bi027062h; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Worby CA, 2002, J BIOL CHEM, V277, P9422, DOI 10.1074/jbc.M110172200; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Worby CA, 2001, J BIOL CHEM, V276, P41782, DOI 10.1074/jbc.M107080200; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Zhong Q, 2002, P NATL ACAD SCI USA, V99, P6767, DOI 10.1073/pnas.092142699	33	118	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46772	46781		10.1074/jbc.M307334200	http://dx.doi.org/10.1074/jbc.M307334200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12952949	hybrid			2022-12-25	WOS:000186569400068
J	Makise, M; Takenaka, H; Kuwae, W; Takahashi, N; Tsuchiya, T; Mizushima, T				Makise, M; Takenaka, H; Kuwae, W; Takahashi, N; Tsuchiya, T; Mizushima, T			Kinetics of ATP binding to the origin recognition complex of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTATIONAL ANALYSIS; DNA-REPLICATION; ESCHERICHIA-COLI; AMINO-ACIDS; FUNCTIONAL INTERACTION; YEAST ORIGIN; IN-VITRO; MEMBRANE-BINDING; PROTEIN; INITIATOR	Origin recognition complex ( ORC), a candidate initiator of chromosomal DNA replication in eukaryotes, binds specifically to ATP through two of its subunits ( Orc1p and Orc5p). In this study, we investigated the kinetics of ATP binding to ORC by a filter binding assay. The K-d values for the ATP of wild- type ORC and ORC- 1A ( mutant ORC containing Orc1p with a defective Walker A motif) were less than 10 nM, suggesting that the affinity of Orc5p for ATP is very high. On the other hand, the K-d values for the ATP of ORC- 5A ( mutant ORC containing Orc5p with a defective Walker A motif) was much higher ( about 1.5 muM), suggesting that the affinity of Orc1p for ATP is relatively low in the absence of origin DNA. ATP dissociated more rapidly from its complex with ORC- 5A than from its complex with ORC- 1A, suggesting that the ATP- Orc5p complex is more stable than ATP- Orc1p complex. Origin DNA fragments decreased the K-d value of ORC- 5A for ATP and stabilized the complex of ATP with ORC- 5A. Wild- type ORC, ORC- 1A, and ORC- 5A required different concentrations of ATP for specific binding to origin DNA. All of these results imply that ATP binding to Orc5p, ATP binding to Orc1p, and origin DNA binding to ORC are co- operatively regulated, which may be important for the initiation of DNA replication.	Okayama Univ, Fac Pharmaceut Sci, Okayama 7008530, Japan	Okayama University	Mizushima, T (corresponding author), Okayama Univ, Fac Pharmaceut Sci, 1-1-1 Tsushima Naka, Okayama 7008530, Japan.	mizushima@pharm.okayama-u.ac.jp						BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CURR OPIN GENET DEV, V5, P162, DOI 10.1016/0959-437X(95)80003-4; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; Hase M, 1998, J BIOL CHEM, V273, P28651, DOI 10.1074/jbc.273.44.28651; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; Makise M, 2000, J BIOL CHEM, V275, P4513, DOI 10.1074/jbc.275.6.4513; Makise M, 2001, J BIOL CHEM, V276, P7450, DOI 10.1074/jbc.M009643200; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Mizushima T, 2000, GENE DEV, V14, P1631; Mizushima T, 1997, EMBO J, V16, P3724, DOI 10.1093/emboj/16.12.3724; Mizushima T, 1998, J BIOL CHEM, V273, P20847, DOI 10.1074/jbc.273.33.20847; Mizushima T, 1996, J BIOL CHEM, V271, P25178, DOI 10.1074/jbc.271.41.25178; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Takahara K, 1996, GENOMICS, V31, P119, DOI 10.1006/geno.1996.0018	29	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46440	46445		10.1074/jbc.M307392200	http://dx.doi.org/10.1074/jbc.M307392200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12966094	hybrid			2022-12-25	WOS:000186569400028
J	Shen, JC; Loeb, LA				Shen, JC; Loeb, LA			Mutations in the alpha 8 loop of human APE1 alter binding and cleavage of DNA containing an abasic site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE; BASE EXCISION-REPAIR; ESCHERICHIA-COLI; COORDINATION; RECOGNITION; SUBSTRATE; ANALOGS; MUTANT; HAP1; ENDS	Recent crystallographic studies reveal loops in human AP endonuclease 1 (APE1) that interact with the major and minor grooves of DNA containing apurinic/apyrimidinic ( AP) sites. These loops are postulated to stabilize the DNA helix and the flipped out AP residue. The loop alpha8 interacts with the major groove on the 3' side of the AP site. To determine the essentiality of the amino acids that constitute the alpha8 loop, we created a mutant library containing random nucleotides at codons 222-229 that, in wild-type APE1, specify the sequence NPKGNKKN. Upon expression of the library (2x10(6) different clones) in Escherichia coli and multiple rounds of selection with the alkylating agent methylmethane sulfonate (MMS), we obtained similar to2x10(5) active mutants that complemented the MMS sensitivity of AP endonuclease-deficient E. coli. DNA sequencing showed that active mutants tolerated amino acid substitutions at all eight randomized positions. Basic and uncharged polar amino acids together comprised the majority of substitutions, reflecting the positively charged, polar character of the wild-type loop. Asn-222, Asn-226, and Asn-229 exhibited the least mutability, consistent with x-ray data showing that each asparagine contacts a DNA phosphate. Substitutions at residues 226-229, located nearer to the AP site, that reduced basicity or hydrogen bonding potential, increased K-m 2- to 6-fold and decreased AP site binding; substitutions at residues 222-225 exhibited lesser effects. This initial mutational analysis of the alpha8 loop supports and extends the conclusion of crystallographic studies that the loop is important for binding of AP.DNA and AP site incision.	Univ Washington, Dept Pathol, HSB, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Univ Washington, Dept Pathol, HSB, Box 357705,K-072,1959 NE Pacific Ave, Seattle, WA 98195 USA.				NCI NIH HHS [CA 77852, CA 80993] Funding Source: Medline; NIA NIH HHS [AG 07151] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077852, R01CA080993] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Cal S, 1998, EMBO J, V17, P7128, DOI 10.1093/emboj/17.23.7128; Chou KM, 2000, J BIOL CHEM, V275, P31009, DOI 10.1074/jbc.M004082200; Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; DEMPLE B, 1986, P NATL ACAD SCI USA, V83, P7731, DOI 10.1073/pnas.83.20.7731; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Hill JW, 2001, NUCLEIC ACIDS RES, V29, P430, DOI 10.1093/nar/29.2.430; Izumi T, 2000, CARCINOGENESIS, V21, P1329, DOI 10.1093/carcin/21.7.1329; Lucas JA, 1999, BIOCHEMISTRY-US, V38, P4958, DOI 10.1021/bi982052v; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Mol CD, 2000, MUTAT RES-DNA REPAIR, V460, P211, DOI 10.1016/S0921-8777(00)00028-8; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Rothwell DG, 1996, NUCLEIC ACIDS RES, V24, P4217, DOI 10.1093/nar/24.21.4217; Rothwell DG, 2000, NUCLEIC ACIDS RES, V28, P2207, DOI 10.1093/nar/28.11.2207; Suh D, 1997, NUCLEIC ACIDS RES, V25, P2495, DOI 10.1093/nar/25.12.2495; Wilson DM, 2001, MUTAT RES-DNA REPAIR, V485, P283, DOI 10.1016/S0921-8777(01)00063-5; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002	19	11	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46994	47001		10.1074/jbc.M309362200	http://dx.doi.org/10.1074/jbc.M309362200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12966083	hybrid			2022-12-25	WOS:000186569400094
J	Greene, TA; Powell, P; Nzerem, C; Shapiro, MJ; Shapiro, VS				Greene, TA; Powell, P; Nzerem, C; Shapiro, MJ; Shapiro, VS			Cloning and characterization of ALX, an adaptor downstream of CD28	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL DEVELOPMENT; SH2 DOMAIN; IL-2 GENE; PROTEIN; LCK; ACTIVATION; RECEPTOR; TSAD	T cell activation requires two signals: specific recognition of antigen through the T cell receptor (TCR) and a costimulatory signal provided primarily by CD28 in naive T cells. We cloned a novel gene with considerable homology to RIBP/TSAd/Lad, an adaptor involved in T cell activation and interleukin-2 (IL-2) promoter activation. Expression of this gene is limited to the spleen and thymus. We have named this gene ALX, (a) under bar daptor in (l) under bar ymphocytes of unknown function (X) under bar. Because the related adaptor RIBP is involved in IL-2 regulation, we investigated whether ALX had a similar function. ALX overexpression in Jurkat T cells results in inhibition of IL-2 promoter activation after stimulation with superantigen. The IL-2 promoter contains several binding sites for transcription factors including the composite element RE/AP, which is the primary site of CD28 transcriptional activation. ALX overexpression had the greatest effect on the activation of a RE/AP reporter as opposed to an AP-1 reporter. Interestingly, ALX overexpression strongly inhibited RE/AP activation in response to anti-CD28/phorbol 12-myristate 13-acetate (PMA) stimulation but had minimal effect when anti-TCR/PMA was used. Therefore, it appears that ALX may function downstream of CD28 costimulation during T cell activation. In addition, the mobility of ALX shifts upon TCR/CD28 costimulation to a greater extent than what is observed with either stimulus alone demonstrating that ALX is a target of both TCR and CD28 costimulatory signaling pathways.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Shapiro, VS (corresponding author), Univ Penn, Dept Pathol & Lab Med, 288 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	shapirov@mail.med.upenn.edu						Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; Choi YB, 1999, J IMMUNOL, V163, P5242; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Holdorf AD, 1999, J EXP MED, V190, P375, DOI 10.1084/jem.190.3.375; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Marengere LEM, 1997, J IMMUNOL, V159, P3220; Marti F, 2001, J EXP MED, V193, P1425, DOI 10.1084/jem.193.12.1425; Mustelin T, 2002, FRONT BIOSCI-LANDMRK, V7, pD918, DOI 10.2741/musteli1; Oda T, 2001, BIOCHEM BIOPH RES CO, V288, P1078, DOI 10.1006/bbrc.2001.5890; Rajagopal K, 1999, J EXP MED, V190, P1657, DOI 10.1084/jem.190.11.1657; Schaeffer EM, 2000, J EXP MED, V192, P987, DOI 10.1084/jem.192.7.987; Shapiro VS, 1998, J IMMUNOL, V161, P6455; Shapiro VS, 1997, MOL CELL BIOL, V17, P4051, DOI 10.1128/MCB.17.7.4051; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; Spurkland A, 1998, J BIOL CHEM, V273, P4539, DOI 10.1074/jbc.273.8.4539; SUN W, J BIOL CHEM, V276, P5093; Sundvold V, 2000, J IMMUNOL, V165, P2927, DOI 10.4049/jimmunol.165.6.2927; UMLAUF SW, 1993, IMMUNOL REV, V133, P177, DOI 10.1111/j.1600-065X.1993.tb01516.x; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Yamada M, 2002, MOL CELL BIOL, V22, P8648, DOI 10.1128/MCB.22.24.8648-8658.2002	21	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45128	45134		10.1074/jbc.M306283200	http://dx.doi.org/10.1074/jbc.M306283200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12960172	hybrid			2022-12-25	WOS:000186452300012
J	Zhong, WM; Reche, PA; Lai, CC; Reinhold, B; Reinherz, EL				Zhong, WM; Reche, PA; Lai, CC; Reinhold, B; Reinherz, EL			Genome-wide characterization of a viral cytotoxic T lymphocyte epitope repertoire	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; SENDAI-VIRUS-INFECTION; CELL RESPONSE; CTL RESPONSES; MHC MOLECULES; PEPTIDES; ANTIGEN; IMMUNODOMINANCE; MOTIFS; VIVO	A genome-wide search using major histocompatibility complex (MHC) class I binding and proteosome cleavage site algorithms identified 101 influenza A PR8 virus-derived peptides as potential epitopes for CD8(+) T cell recognition in the H-2(b) mouse. Cytokine-based flow cytometry, ELISPOT, and cytotoxic T lymphocyte assays reveal that 16 are recognized by CD8(+) T cells recovered directly ex vivo from infected animals, accounting for greater than 70% of CD8(+) T cells recruited to lung after primary infection. Only six of the 22 highest affinity MHC class I binding peptides comprise cytotoxic T lymphocyte epitopes. The remaining non-immunogenic peptides have equivalent MHC affinity and MHC-peptide complex half-lives, eliciting T cell responses when given in adjuvant and with T cell receptor-ligand avidity comparable with their immunogenic counterparts. As revealed by a novel high sensitivity nanospray tandem mass spectrometry methodology, failure to process those predicted epitopes may contribute significantly to the absent response. These results have important implications for rationale design of CD8(+) T cell vaccines.	Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Reinherz, EL (corresponding author), Dana Farber Canc Inst, Immunobiol Lab, 44 Binney St, Boston, MA 02115 USA.	ellis_reinherz@dfci.harvard.edu	Reche, Pedro A/B-1881-2013	Reche, Pedro A/0000-0003-3966-5838	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050900] Funding Source: NIH RePORTER; NIAID NIH HHS [AI50900] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Belz GT, 2000, J IMMUNOL, V165, P2404, DOI 10.4049/jimmunol.165.5.2404; Belz GT, 2000, J VIROL, V74, P3486, DOI 10.1128/JVI.74.8.3486-3493.2000; Belz GT, 2001, J IMMUNOL, V166, P4627, DOI 10.4049/jimmunol.166.7.4627; Busch DH, 1998, J IMMUNOL, V160, P4441; Cole GA, 1997, J IMMUNOL, V158, P4301; DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123; Emmerich NPN, 2000, J BIOL CHEM, V275, P21140, DOI 10.1074/jbc.M000740200; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Flynn KJ, 1998, IMMUNITY, V8, P683, DOI 10.1016/S1074-7613(00)80573-7; Fu TM, 1997, J VIROL, V71, P2715, DOI 10.1128/JVI.71.4.2715-2721.1997; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; Hogan RJ, 2001, J IMMUNOL, V166, P1813, DOI 10.4049/jimmunol.166.3.1813; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; Kuon W, 2001, J IMMUNOL, V167, P4738, DOI 10.4049/jimmunol.167.8.4738; Lamb R.A., 1996, FIELDS VIROLOGY, V2, P1353; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; OUKKA M, 1994, J IMMUNOL, V152, P4843; Oukka M, 1996, J IMMUNOL, V157, P3039; Preckel T, 1997, J EXP MED, V185, P1803, DOI 10.1084/jem.185.10.1803; Price GE, 2000, J EXP MED, V191, P1853, DOI 10.1084/jem.191.11.1853; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Reche PA, 2002, HUM IMMUNOL, V63, P701, DOI 10.1016/S0198-8859(02)00432-9; RESTIFO NP, 1995, J IMMUNOL, V154, P4414; SASTRY KJ, 1994, VACCINE, V12, P1281; Schaible U E, 1999, Adv Immunol, V71, P267; SCHULZ M, 1991, P NATL ACAD SCI USA, V88, P991, DOI 10.1073/pnas.88.3.991; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; SETTE A, 1994, J IMMUNOL, V153, P5586; SHAPIRO GI, 1987, J VIROL, V61, P764, DOI 10.1128/JVI.61.3.764-773.1987; Sijts AJAM, 1996, J IMMUNOL, V156, P1497; Stolcke A., 2002, P INT C SPOK LANG PR, V2, P901; Toes REM, 2001, J EXP MED, V194, P1, DOI 10.1084/jem.194.1.1; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; vanderBurg SH, 1996, J IMMUNOL, V156, P3308; Vijh S, 1998, J IMMUNOL, V160, P3971; Vitiello A, 1996, J IMMUNOL, V157, P5555; Wang JH, 2002, MOL IMMUNOL, V38, P1039, DOI 10.1016/S0161-5890(02)00033-0; Wilson IA, 1997, CURR OPIN STRUC BIOL, V7, P839, DOI 10.1016/S0959-440X(97)80156-X; Yewdell JTW, 1999, ANNU REV IMMUNOL, V17, P51, DOI 10.1146/annurev.immunol.17.1.51; Zhong WM, 2001, J IMMUNOL, V167, P1379, DOI 10.4049/jimmunol.167.3.1379; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173	44	77	84	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45135	45144		10.1074/jbc.M307417200	http://dx.doi.org/10.1074/jbc.M307417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12960169	hybrid, Green Accepted			2022-12-25	WOS:000186452300013
J	Miller, CT; Chen, G; Gharib, TG; Wang, H; Thomas, DG; Misek, DE; Giordano, TJ; Yee, J; Orringer, MB; Hanash, SM; Beer, DG				Miller, CT; Chen, G; Gharib, TG; Wang, H; Thomas, DG; Misek, DE; Giordano, TJ; Yee, J; Orringer, MB; Hanash, SM; Beer, DG			Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas	ONCOGENE			English	Article						CRK; lung adenocarcinomas; differentiation; quantitative 2-D protein	ADAPTER PROTEIN CRK; CELL-MIGRATION; PROTEOMIC ANALYSIS; SIGNALING PATHWAY; KINASE ACTIVATION; GROWTH-FACTOR; SURVIVAL; CANCER; PHOSPHORYLATION; MEMBRANE	The C-CRK gene, cellular homolog of the avian v-crk oncogene, encodes two alternatively spliced adaptor signaling proteins, CRKI (28kDa) and CRKII (40kDa). Both CRKI and CRKII have been shown to activate kinase signaling and anchorage-independent growth in vitro and CRKI transformed cells readily form tumors in nude mice. Affymetrix oligonucleotide arrays were used to analyse 86 lung adenocarcinomas and 10 uninvolved lung tissues. C-CRK mRNA expression was increased in more advanced (stage III versus stage I), larger (T2-4 versus T-1), and poorly differentiated tumors and in tumors from patients demonstrating poor survival (P = 0.00034). An overlapping series of 93 lung adenocarcinomas (64 stage I and 29 stage III) and 10 uninvolved lung specimens were measured for quantitative differences in CRKI and CRKII protein levels using 2-D PAGE. CRK protein spots were identified using mass spectrometry and 2-D Western blotting. A significant increase in levels of the CRKI oncoprotein and the phosphorylated isoform of CRKII was observed in tumors (P < 0.05). No difference in protein level was evident between stages. Concordant with mRNA expression, CRKI and CRKII were increased in poorly differentiated tumors (P < 0.05). CRK immunohistochemical analysis of tumor tissue arrays using the same tumor series also demonstrated increased abundance of nuclear and cytoplasmic CRK in more proliferative tumors (P < 0.05). This study provides the first quantitative analysis of discrete CRKI and CRKII protein isoforms in human lung tumors and provides evidence that the C-CRK proto-oncogene may foment a more aggressive phenotype in lung cancers.	Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Beer, DG (corresponding author), Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA.		Chen, Guoan/J-9140-2018	Chen, Guoan/0000-0001-5608-6761; Giordano, Thomas/0000-0003-0641-8873	NATIONAL CANCER INSTITUTE [R01CA085953] Funding Source: NIH RePORTER; NCI NIH HHS [U19 CA-85953] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Chen GA, 2002, CLIN CANCER RES, V8, P2298; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; Colby TV, 1995, AFIP ATLAS TUMOR PAT, V13; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; EDELMAN GM, 1983, P NATL ACAD SCI-BIOL, V80, P4384, DOI 10.1073/pnas.80.14.4384; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fry WA, 1999, CANCER, V86, P1867, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1867::AID-CNCR31>3.0.CO;2-9; Gharib TG, 2002, NEOPLASIA, V4, P440, DOI 10.1038/sj.neo.7900257; Giordano TJ, 2001, AM J PATHOL, V159, P1231, DOI 10.1016/S0002-9440(10)62509-6; Girardin SE, 2001, EMBO J, V20, P3437, DOI 10.1093/emboj/20.13.3437; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; Hughes SJ, 1997, CANCER RES, V57, P5571; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; KUICK RD, 1987, ELECTROPHORESIS, V8, P199, DOI 10.1002/elps.1150080405; KUICK RD, 1991, ELECTROPHORESIS, V12, P736, DOI 10.1002/elps.1150121007; Lamorte L, 2002, MOL BIOL CELL, V13, P1449, DOI 10.1091/mbc.01-10-0477; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Miller JR, 1997, DEV BIOL, V192, P310, DOI 10.1006/dbio.1997.8739; Morali OG, 2000, DEV BIOL, V227, P133, DOI 10.1006/dbio.2000.9875; NARUKE T, 1988, J THORAC CARDIOV SUR, V96, P440; Nishihara H, 2002, CANCER LETT, V180, P55, DOI 10.1016/S0304-3835(01)00763-7; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; WILLIAMS DE, 1981, J THORAC CARDIOV SUR, V82, P70; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	37	65	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7950	7957		10.1038/sj.onc.1206529	http://dx.doi.org/10.1038/sj.onc.1206529			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970743				2022-12-25	WOS:000185388200010
J	Evans, JP; Ahn, K; Klinman, JP				Evans, JP; Ahn, K; Klinman, JP			Evidence that dioxygen and substrate activation are tightly coupled in dopamine beta-monooxygenase - Implications for the reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-HYDROXYLATING MONOOXYGENASE; ELECTRON-PARAMAGNETIC RESONANCE; ENZYME-BOUND COPPER; AMIDATING ENZYME; PEPTIDYLGLYCINE MONOOXYGENASE; CHEMICAL MECHANISM; PEPTIDE AMIDATION; ACTIVE-SITE; ATOMS; 3,4-DIHYDROXYPHENYLETHYLAMINE	Oxygen activation occurs at a wide variety of enzyme active sites. Mechanisms previously proposed for the copper monooxygenase, dopamine beta-monooxygenase (DbetaM), involve the accumulation of an activated oxygen intermediate with the properties of a copper-peroxo or copper-oxo species before substrate activation. These are reminiscent of the mechanism of cytochrome P-450, where a heme iron stabilizes the activated O-2 species. Herein, we report two experimental probes of the activated oxygen species in DbetaM. First, we have synthesized the substrate analog, beta,beta-difluorophenethylamine, and examined its capacity to induce reoxidation of the prereduced copper sites of DbetaM upon mixing with O-2 under rapid freeze-quench conditions. This experiment fails to give rise to an EPR-detectable copper species, in contrast to a substrate with a C-H active bond. This indicates either that the reoxidation of the enzyme-bound copper sites in the presence of O-2 is tightly linked to C-H activation or that a diamagnetic species Cu(II) - O-2(.) has been formed. In the context of the open and fully solvent-accessible active site for the homologous peptidyl-glycine-alpha-hydroxylating monooxygenase and by analogy to cytochrome P-450, the accumulation of a reduced and activated oxygen species in DbetaM before C-H cleavage would be expected to give some uncoupling of oxygen and substrate consumption. We have, therefore, examined the degree to which O-2 and substrate consumption are coupled in DbetaM using both end point and initial rate experimental protocols. With substrates that differ by more than three orders of magnitude in rate, we fail to detect any uncoupling of O-2 uptake from product formation. We conclude that there is no accumulation of an activated form of O-2 before C-H abstraction in the DbetaM and peptidylglycine-alpha-hydroxylating monooxygenase class of copper monooxygenases, presenting a mechanism in which a diamagnetic Cu( II)- superoxo complex, formed initially at very low levels, abstracts a hydrogen atom from substrate to generate Cu( II)- hydroperoxo and substrate-free radical as intermediates. Subsequent participation of the second copper site per subunit completes the reaction cycle, generating hydroxylated product and water.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Klinman, JP (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025765, R37GM025765] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 25765] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aboelella NW, 2002, J AM CHEM SOC, V124, P10660, DOI 10.1021/ja027164v; AHN N, 1983, BIOCHEMISTRY-US, V22, P3096, DOI 10.1021/bi00282a012; ASH DE, 1984, J BIOL CHEM, V259, P3395; Bakac A, 2000, J AM CHEM SOC, V122, P1092, DOI 10.1021/ja993371s; Bell J, 2003, BIOCHEMISTRY-US, V42, P7133, DOI 10.1021/bi034247v; Blackburn NJ, 2000, J BIOL INORG CHEM, V5, P341, DOI 10.1007/PL00010663; BLACKBURN NJ, 1991, J BIOL CHEM, V266, P23120; BLACKBURN NJ, 1988, BIOCHEMISTRY-US, V27, P6001, DOI 10.1021/bi00416a026; BRENNER MC, 1989, BIOCHEMISTRY-US, V28, P4664, DOI 10.1021/bi00437a023; BRENNER MC, 1989, BIOCHEMISTRY-US, V28, P4656, DOI 10.1021/bi00437a022; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P125; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; FITZPATRICK PF, 1985, BIOCHEMISTRY-US, V24, P2108, DOI 10.1021/bi00330a003; Francisco WA, 2002, J AM CHEM SOC, V124, P8194, DOI 10.1021/ja025758s; Francisco WA, 1998, BIOCHEMISTRY-US, V37, P8244, DOI 10.1021/bi973004y; Francisco WA, 2003, BIOCHEMISTRY-US, V42, P1813, DOI 10.1021/bi020592t; FREEMAN JC, 1993, J AM CHEM SOC, V115, P4923, DOI 10.1021/ja00064a077; FRIEDMAN S, 1965, J BIOL CHEM, V240, P4763; FUJISAWA K, 1994, J AM CHEM SOC, V116, P12079, DOI 10.1021/ja00105a069; HORTMANN AG, 1972, J ORG CHEM, V37, P322, DOI 10.1021/jo00967a033; Jaron S, 1999, BIOCHEMISTRY-US, V38, P15086, DOI 10.1021/bi991341w; KADKHODAYAN S, 1995, J BIOL CHEM, V270, P28042; KLINMAN JP, 1984, J BIOL CHEM, V259, P3399; KULATHILA R, 1994, ARCH BIOCHEM BIOPHYS, V311, P191, DOI 10.1006/abbi.1994.1225; Lee DH, 1995, J AM CHEM SOC, V117, P12498, DOI 10.1021/ja00155a014; LEVIN EY, 1960, J BIOL CHEM, V235, P2080; LEVINE J, 1948, J AM CHEM SOC, V60, P1930; LJONES T, 1978, FEBS LETT, V92, P81, DOI 10.1016/0014-5793(78)80726-1; MERKLER DJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P594, DOI 10.1016/0003-9861(92)90730-K; MILLER SM, 1985, BIOCHEMISTRY-US, V24, P2114, DOI 10.1021/bi00330a004; MURTHY ASN, 1986, J BIOL CHEM, V261, P1815; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; Ponce A, 2000, J AM CHEM SOC, V122, P8187, DOI 10.1021/ja000017h; POOS GI, 1963, J MED CHEM, V6, P266, DOI 10.1021/jm00339a011; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; Prigge ST, 1999, NAT STRUCT BIOL, V6, P976; Prigge ST, 1997, SCIENCE, V278, P1300, DOI 10.1126/science.278.5341.1300; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; SCOTT RA, 1988, BIOCHEMISTRY-US, V27, P5411, DOI 10.1021/bi00415a005; SKOTLAND T, 1980, ARCH BIOCHEM BIOPHYS, V201, P81, DOI 10.1016/0003-9861(80)90489-0; SOUTHAN C, 1989, FEBS LETT, V255, P116, DOI 10.1016/0014-5793(89)81072-5; STEWART LC, 1987, BIOCHEMISTRY-US, V26, P5302, DOI 10.1021/bi00391a013; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; TIAN GC, 1994, BIOCHEMISTRY-US, V33, P226, DOI 10.1021/bi00167a030; WADE TN, 1980, J ORG CHEM, V45, P5333, DOI 10.1021/jo01314a024; WALKER GA, 1977, BIOCHIM BIOPHYS ACTA, V482, P309, DOI 10.1016/0005-2744(77)90244-3; WITTAKER JW, 1990, METHOD ENZYMOL, V188, P82	47	160	162	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49691	49698		10.1074/jbc.M300797200	http://dx.doi.org/10.1074/jbc.M300797200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	12966104	hybrid			2022-12-25	WOS:000187068200008
J	Futaki, S; Hayashi, Y; Yamashita, M; Yagi, K; Bono, H; Hayashizaki, Y; Okazaki, Y; Sekiguchi, K				Futaki, S; Hayashi, Y; Yamashita, M; Yagi, K; Bono, H; Hayashizaki, Y; Okazaki, Y; Sekiguchi, K			Molecular basis of constitutive production of basement membrane components - Gene expression profiles of Engelbreth-Holm-Swarm tumor and F9 embryonal carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY MOUSE EMBRYO; RETINOIC ACID; TRANSCRIPTION FACTOR; FUNCTIONAL ANNOTATION; STEM-CELLS; PROTEOGLYCAN SYNTHESIS; EXTRACELLULAR-MATRIX; PARIETAL ENDODERM; IV COLLAGEN; IN-VIVO	Engelbreth-Holm-Swarm (EHS) tumors produce large amounts of basement membrane ( BM) components that are widely used as cell culture substrates mimicking BM functions. To delineate the tissue/organ origin of the tumor and the mechanisms operating in the BM overproduction, a genome-wide expression profile of EHS tumor was analyzed using RIKEN cDNA microarrays containing similar to40,000 mouse cDNA clones. Expression profiles of F9 embryonal carcinoma cells that produce laminin-1 and other BM components upon differentiation into parietal endoderm-like cells ( designated F9-PE) were also analyzed. Hierarchical clustering analysis showed that the gene expression profiles of EHS and F9-PE were the most similar among 49 mouse tissues/organs in the RIKEN Expression Array Database, suggesting that EHS tumor is parietal endoderm-derived. Quantitative PCR analysis confirmed that not only BM components but also the machineries required for efficient production of BM components, such as enzymes involved in post-translational modification and molecular chaperones, were highly expressed in both EHS and F9-PE. Pairs of similar transcription factor isoforms, such as Gata4/Gata6, Sox7/Sox17, and Cited1/Cited2, were also highly expressed in both EHS tumor and F9-PE. Time course analysis of F9 differentiation showed that up-regulation of the transcription factors was associated with those of BM components, suggesting their involvement in parietal endoderm specification and overproduction of the BM components.	Aichi Med Univ, Japanese Sci & Technol Agcy, ERATO, Sekiguchi Biomatrix Signaling Project, Aichi 4801195, Japan; RIKEN, Yokohama Inst, Gen Sci Ctr, Genome Explorat Res Grp, Yokohama, Kanagawa 2300045, Japan; RIKEN, Genome Sci Lab, Discovery & Res Inst, Wako, Saitama 3510198, Japan; Osaka Univ, Inst Prot Res, Osaka 5650871, Japan	Aichi Medical University; Japan Science & Technology Agency (JST); RIKEN; RIKEN; Osaka University	Hayashi, Y (corresponding author), Aichi Med Univ, Japanese Sci & Technol Agcy, ERATO, Sekiguchi Biomatrix Signaling Project, 21 Karimata, Aichi 4801195, Japan.		Hayashizaki, Yoshihide/N-6590-2015; Hayashi, Yoshitaka/I-6168-2014; Bono, Hidemasa/AAF-3649-2020	Hayashi, Yoshitaka/0000-0002-7557-4303; Bono, Hidemasa/0000-0003-4413-0651; Okazaki, Yasushi/0000-0003-3241-5502				ALLIEL PM, 1993, EUR J BIOCHEM, V214, P347, DOI 10.1111/j.1432-1033.1993.tb17930.x; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BALDWIN CT, 1989, MATRIX, V9, P389, DOI 10.1016/S0934-8832(89)80044-7; Bamforth SD, 2001, NAT GENET, V29, P469, DOI 10.1038/ng768; Barbacci E, 1999, DEVELOPMENT, V126, P4795; Becker S, 1997, DEV BIOL, V187, P298, DOI 10.1006/dbio.1997.8616; Bono H, 2003, GENOME RES, V13, P1318, DOI 10.1101/gr.1075103; Bono H, 2002, NUCLEIC ACIDS RES, V30, P211, DOI 10.1093/nar/30.1.211; Bono H, 2002, NUCLEIC ACIDS RES, V30, P116, DOI 10.1093/nar/30.1.116; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; Byrd N, 2002, DEVELOPMENT, V129, P361; Contos JJA, 2001, GENE, V267, P243, DOI 10.1016/S0378-1119(01)00410-3; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Erickson AC, 2000, J HISTOCHEM CYTOCHEM, V48, P1291, DOI 10.1177/002215540004801001; FOWLER KJ, 1990, EXP CELL RES, V191, P194, DOI 10.1016/0014-4827(90)90005-U; Fujikura J, 2002, GENE DEV, V16, P784, DOI 10.1101/gad.968802; Futaki S, 2000, MAMM GENOME, V11, P649, DOI 10.1007/s003350010121; Hagedorn HG, 2001, INT J ONCOL, V18, P669; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; HELAAKOSKI T, 1990, J BIOL CHEM, V265, P11413; Heller LC, 1999, J BIOL CHEM, V274, P1394, DOI 10.1074/jbc.274.3.1394; Ho HCK, 2001, BIOL REPROD, V64, P1667, DOI 10.1095/biolreprod64.6.1667; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Kadota K, 2001, PHYSIOL GENOMICS, V4, P183, DOI 10.1152/physiolgenomics.2001.4.3.183; Kanai-Azuma M, 2002, DEVELOPMENT, V129, P2367; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; Kemppainen RJ, 1998, J BIOL CHEM, V273, P3129, DOI 10.1074/jbc.273.6.3129; KLEINMAN HK, 1987, DEV BIOL, V122, P373, DOI 10.1016/0012-1606(87)90302-2; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kragh M, 2003, INT J ONCOL, V22, P305; KUDO H, 1994, EXP CELL RES, V212, P219, DOI 10.1006/excr.1994.1137; Laitusis AL, 1999, J BIOL CHEM, V274, P486, DOI 10.1074/jbc.274.1.486; Lang SH, 2001, CELL GROWTH DIFFER, V12, P631; LANKATBUTTGEREIT B, 1988, FEBS LETT, V236, P352, DOI 10.1016/0014-5793(88)80054-1; Levenberg S, 2002, P NATL ACAD SCI USA, V99, P4391, DOI 10.1073/pnas.032074999; Lu QX, 2001, SCIENCE, V293, P306, DOI 10.1126/science.1061663; MATSUBARA S, 1994, J BIOCHEM-TOKYO, V115, P1088, DOI 10.1093/oxfordjournals.jbchem.a124462; Miki R, 2001, P NATL ACAD SCI USA, V98, P2199, DOI 10.1073/pnas.041605498; Miyaishi O, 1998, J CELL BIOCHEM, V68, P436, DOI 10.1002/(SICI)1097-4644(19980315)68:4<436::AID-JCB4>3.0.CO;2-R; Murakami A, 1999, J BIOL CHEM, V274, P17242, DOI 10.1074/jbc.274.24.17242; Murray P, 2001, MECH DEVELOP, V101, P213, DOI 10.1016/S0925-4773(00)00554-2; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; ORKIN RW, 1977, J EXP MED, V145, P204, DOI 10.1084/jem.145.1.204; Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; PIHLAJANIEMI T, 1982, J BIOL CHEM, V257, P4914; Power SC, 1996, MOL CELL BIOL, V16, P778; REICHEL RR, 1994, EXP CELL RES, V214, P634, DOI 10.1006/excr.1994.1301; SALAMAT M, 1995, ANAT EMBRYOL, V192, P275; Smith ER, 2001, J BIOL CHEM, V276, P47303, DOI 10.1074/jbc.M106158200; Smith ER, 2001, J BIOL CHEM, V276, P32094, DOI 10.1074/jbc.M105009200; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; SWARM RL, 1963, J NATL CANCER I, V31, P953; Verheijen MHG, 1999, INT J DEV BIOL, V43, P711; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; WEWER UM, 1985, DIFFERENTIATION, V30, P61, DOI 10.1111/j.1432-0436.1985.tb00514.x; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301; Zhang LJ, 1998, J BIOL CHEM, V273, P27998, DOI 10.1074/jbc.273.43.27998	62	44	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50691	50701		10.1074/jbc.M304985200	http://dx.doi.org/10.1074/jbc.M304985200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	12968032	Green Published, hybrid			2022-12-25	WOS:000187068200125
J	Ritter, M; Ravasio, A; Jakab, M; Chwatal, S; Furst, J; Laich, A; Gschwentner, M; Signorelli, S; Burtscher, C; Eichmuller, S; Paulmichl, M				Ritter, M; Ravasio, A; Jakab, M; Chwatal, S; Furst, J; Laich, A; Gschwentner, M; Signorelli, S; Burtscher, C; Eichmuller, S; Paulmichl, M			Cell swelling stimulates cytosol to membrane transposition of ICln	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; REGULATORY VOLUME DECREASE; RESONANCE ENERGY-TRANSFER; CANINE KIDNEY-CELLS; SM PROTEINS; CHLORIDE CONDUCTANCE; ESCHERICHIA-COLI; HYPOTONIC STRESS; EPITHELIAL-CELLS; I-CLN	ICln is a multifunctional protein that is essential for cell volume regulation. It can be found in the cytosol and is associated with the cell membrane. Besides its role in the splicing process, ICln is critically involved in the generation of ion currents activated during regulatory volume decrease after cell swelling (RVDC). If reconstituted in artificial bilayers, ICln can form ion channels with biophysical properties related to RVDC. We investigated (i) the cytosol versus cell membrane distribution of ICln in rat kidney tubules, NIH 3T3 fibroblasts, Madin-Darby canine kidney (MDCK) cells, and LLC-PK1 epithelial cells, (ii) fluorescence resonance energy transfer ( FRET) in living fibroblasts between fluorescently tagged ICln and fluorochromes in the cell membrane, and (iii) possible functional consequences of an enhanced ICln presence at the cell membrane. We demonstrate that ICln distribution in rat kidneys depends on the parenchymal localization and functional state of the tubules and that cell swelling causes ICln redistribution from the cytosol to the cell membrane in NIH 3T3 fibroblasts and LLC-PK1 cells. The addition of purified ICln protein to the extracellular solution or overexpression of farnesylated ICln leads to an increased anion permeability in NIH 3T3 fibroblasts. The swelling-induced redistribution of ICln correlates to altered kinetics of RVDC in NIH 3T3 fibroblasts, LLC-PK1 cells, and MDCK cells. In these cells, RVDC develops more rapidly, and in MDCK cells the rate of swelling-induced depolarization is accelerated if cells are swollen for a second time. This coincides with an enhanced ICln association with the cell membrane.	Univ Innsbruck, Dept Physiol, A-6020 Innsbruck, Austria; Univ Milan, Dept Biomol Sci & Biotechnol, I-20133 Milan, Italy	University of Innsbruck; University of Milan	Ritter, M (corresponding author), Univ Innsbruck, Dept Physiol, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	markus.ritter@uibk.ac.at; markus.paulmichl@uibk.ac.at	Ravasio, Andrea/G-6167-2011; Ravasio, Andrea/H-6722-2012; Ritter, Markus/AAG-4987-2020	Ravasio, Andrea/0000-0001-7835-5133; Ritter, Markus/0000-0001-7346-7750				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen LX, 1999, AM J PHYSIOL-CELL PH, V276, pC182, DOI 10.1152/ajpcell.1999.276.1.C182; Cromer BA, 2002, EUR BIOPHYS J BIOPHY, V31, P356, DOI 10.1007/s00249-002-0219-1; Emma F, 1998, BBA-MOL CELL RES, V1404, P321, DOI 10.1016/S0167-4889(98)00073-1; Emma F, 1998, AM J PHYSIOL-CELL PH, V274, pC1545, DOI 10.1152/ajpcell.1998.274.6.C1545; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Friesen WJ, 2002, J BIOL CHEM, V277, P8243, DOI 10.1074/jbc.M109984200; Furst J, 2002, PFLUG ARCH EUR J PHY, V444, P1, DOI 10.1007/s00424-002-0805-1; Furst J, 2002, CELL PHYSIOL BIOCHEM, V12, P19, DOI 10.1159/000047823; Furst J, 2002, J BIOL CHEM, V277, P4435, DOI 10.1074/jbc.M107372200; Furst J, 2000, CELL PHYSIOL BIOCHEM, V10, P329, DOI 10.1159/000016374; Furst J, 2000, PFLUG ARCH EUR J PHY, V440, P100; Gadella TWJ, 1999, TRENDS PLANT SCI, V4, P287, DOI 10.1016/S1360-1385(99)01426-0; Garavaglia ML, 2002, PFLUG ARCH EUR J PHY, V443, P748, DOI 10.1007/s00424-001-0772-y; GSCHWENTNER M, 1995, PFLUG ARCH EUR J PHY, V430, P464, DOI 10.1007/BF00373882; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HUANG WM, 1983, HISTOCHEMISTRY, V77, P275, DOI 10.1007/BF00506570; Hubert MD, 2000, BBA-BIOMEMBRANES, V1466, P105, DOI 10.1016/S0005-2736(00)00177-2; Jakab M, 2002, CELL PHYSIOL BIOCHEM, V12, P235, DOI 10.1159/000067895; Krapivinsky G, 1998, J BIOL CHEM, V273, P10811, DOI 10.1074/jbc.273.18.10811; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laich A, 1997, KIDNEY INT, V51, P477, DOI 10.1038/ki.1997.65; LAKEY JH, 1992, FEBS LETT, V307, P26, DOI 10.1016/0014-5793(92)80895-N; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; LANG F, 1986, PFLUG ARCH EUR J PHY, V407, P158, DOI 10.1007/BF00580668; Li CH, 1998, J GEN PHYSIOL, V112, P727, DOI 10.1085/jgp.112.6.727; Li YY, 1999, J BIOCHEM-TOKYO, V126, P643, DOI 10.1093/oxfordjournals.jbchem.a022497; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Musch MW, 1997, J EXP ZOOL, V277, P460, DOI 10.1002/(SICI)1097-010X(19970415)277:6<460::AID-JEZ6>3.0.CO;2-M; Musch MW, 1998, PFLUG ARCH EUR J PHY, V436, P415, DOI 10.1007/s004240050651; PAULMICHL M, 1989, PFLUG ARCH EUR J PHY, V413, P456, DOI 10.1007/BF00594173; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Pu WT, 1999, MOL CELL BIOL, V19, P4113; Pu WT, 2000, J BIOL CHEM, V275, P12363, DOI 10.1074/jbc.275.17.12363; Reeves RE, 1998, CURR EYE RES, V17, P861, DOI 10.1076/ceyr.17.9.861.5140; Ritter M, 2001, CELL PHYSIOL BIOCHEM, V11, P1, DOI 10.1159/000047787; RITTER M, 1991, PFLUG ARCH EUR J PHY, V418, P35, DOI 10.1007/BF00370449; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanchez-Olea R, 1998, BBA-GEN SUBJECTS, V1381, P49, DOI 10.1016/S0304-4165(98)00009-9; Sanchez-Torres J, 1999, CURR EYE RES, V18, P408, DOI 10.1076/ceyr.18.6.408.5266; Scandella E, 2000, J BIOL CHEM, V275, P15613, DOI 10.1074/jbc.275.21.15613; Schmarda A, 2001, CELL PHYSIOL BIOCHEM, V11, P55, DOI 10.1159/000047792; Schwartz RS, 1997, BIOCHEM J, V327, P609; STUARTTILLEY A, 1994, AM J PHYSIOL, V266, pC559, DOI 10.1152/ajpcell.1994.266.2.C559; Tang CJC, 1998, BLOOD, V92, P1442, DOI 10.1182/blood.V92.4.1442.416k14_1442_1447; Tao GZ, 1998, BIOCHEM BIOPH RES CO, V247, P668, DOI 10.1006/bbrc.1998.8837; Tao GZ, 2000, PEPTIDES, V21, P485, DOI 10.1016/S0196-9781(00)00176-5; Tao GZ, 1998, FEBS LETT, V434, P28, DOI 10.1016/S0014-5793(98)00946-6; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200; Woll E, 1996, PFLUG ARCH EUR J PHY, V432, P486, DOI 10.1007/s004240050160; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9	54	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50163	50174		10.1074/jbc.M300374200	http://dx.doi.org/10.1074/jbc.M300374200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	12970357	hybrid			2022-12-25	WOS:000187068200062
J	Nguyen, HP; Seto, NOL; Cai, Y; Leinala, EK; Borisova, SN; Palcic, MM; Evans, SV				Nguyen, HP; Seto, NOL; Cai, Y; Leinala, EK; Borisova, SN; Palcic, MM; Evans, SV			The influence of an intramolecular hydrogen bond in differential recognition of inhibitory acceptor analogs by human ABO(H) blood group A and B glycosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIFICITY	Human ABO( H) blood group glycosyltransferases GTA and GTB catalyze the final monosaccharide addition in the biosynthesis of the human A and B blood group antigens. GTA and GTB utilize a common acceptor, the H antigen disaccharide alpha-L-Fucp-(1-->2)-beta-D-Galp-OR, but different donors, where GTA transfers GalNAc from UDP-GalNAc and GTB transfers Gal from UDP-Gal. GTA and GTB are two of the most homologous enzymes known to transfer different donors and differ in only 4 amino acid residues, but one in particular (Leu/Met-266) has been shown to dominate the selection between donor sugars. The structures of the A and B glycosyltransferases have been determined to high resolution in complex with two inhibitory acceptor analogs alpha-L-Fucp( 1-->2)-beta-D-(3-deoxy)-Galp-OR and alpha-L-Fucp-(1-->2)-beta-D-(3-amino)- Galp-OR, in which the 3-hydroxyl moiety of the Gal ring has been replaced by hydrogen or an amino group, respectively. Remarkably, although the 3-deoxy inhibitor occupies the same conformation and position observed for the native H antigen in GTA and GTB, the 3-amino analog is recognized differently by the two enzymes. The 3-amino substitution introduces a novel intramolecular hydrogen bond between O-2' on Fuc and N-3' on Gal, which alters the minimum-energy conformation of the inhibitor. In the absence of UDP, the 3-amino analog can be accommodated by either GTA or GTB with the L-Fuc residue partially occupying the vacant UDP binding site. However, in the presence of UDP, the analog is forced to abandon the intramolecular hydrogen bond, and the L-Fuc residue is shifted to a less ordered conformation. Further, the residue Leu/Met-266 that was thought important only in distinguishing between donor substrates is observed to interact differently with the 3-amino acceptor analog in GTA and GTB. These observations explain why the 3-deoxy analog acts as a competitive inhibitor of the glycosyltransferase reaction, whereas the 3-amino analog displays complex modes of inhibition.	Univ Victoria, Dept Biochem & Microbiol, STN CSC, Victoria, BC V8W 3P6, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Univ Alberta, Dept Chem, Edmonton, AB T6G 2V4, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Victoria; University of Ottawa; University of Alberta; National Research Council Canada	Evans, SV (corresponding author), Univ Victoria, Dept Biochem & Microbiol, STN CSC, POB 3800, Victoria, BC V8W 3P6, Canada.	svevans@uvic.ca		Evans, Stephen/0000-0002-0366-4027				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; EVANS SV, 1993, J MOL GRAPHICS, V11, P127; Greenwell P, 1997, GLYCOCONJUGATE J, V14, P159, DOI 10.1023/A:1018581503164; Laferte S, 2000, EUR J BIOCHEM, V267, P4840, DOI 10.1046/j.1432-1327.2000.01544.x; LOWARY TL, 1993, CARBOHYD RES, V249, P163, DOI 10.1016/0008-6215(93)84068-H; LOWARY TL, 1994, CARBOHYD RES, V251, P33, DOI 10.1016/0008-6215(94)84275-2; Marcus SL, 2003, J BIOL CHEM, V278, P12403, DOI 10.1074/jbc.M212002200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patenaude SI, 2002, NAT STRUCT BIOL, V9, P685, DOI 10.1038/nsb832; Watkins W M, 1980, Adv Hum Genet, V10, P1; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0	12	31	32	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49191	49195		10.1074/jbc.M308770200	http://dx.doi.org/10.1074/jbc.M308770200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12972418	hybrid			2022-12-25	WOS:000186829000083
J	Sengenes, C; Bouloumie, A; Hauner, H; Berlan, M; Busse, R; Lafontan, M; Galitzky, J				Sengenes, C; Bouloumie, A; Hauner, H; Berlan, M; Busse, R; Lafontan, M; Galitzky, J			Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FAT-CELLS; PROTEIN-KINASE; CYCLIC-GMP; CYTOPLASMIC DOMAIN; ADENYLYL-CYCLASE; ADIPOSE-TISSUE; LIPOLYSIS; RECEPTOR; MECHANISMS; ACTIVATION	Our previous studies have demonstrated that natriuretic peptides (NPs), peptide hormones with natriuretic, diuretic, and vasodilating properties, exert a potent control on the lipolysis in human adipocytes via the activation of the type A guanylyl cyclase receptor ( 1, 2). In the current study we investigated the intracellular mechanisms involved in the NP-stimulated lipolytic effect in human preadipocytes and adipocytes. We demonstrate that the atrial NP (ANP)-induced lipolysis in human adipocytes was associated with an enhanced serine phosphorylation of the hormone-sensitive lipase (HSL). Both ANP-mediated lipolysis and HSL phosphorylation were inhibited in the presence of increasing concentrations of the guanylyl cyclase inhibitor LY-83583. ANP did not modulate the activity of the cAMP-dependent protein kinase (PKA). Moreover, H-89, a PKA inhibitor, did not affect the ANP-induced lipolysis. On primary cultures of human preadipocytes, the ANP-mediated lipolytic effect was dependent on the differentiation process. On differentiated human preadipocytes, ANP-mediated lipolysis, associated with an increased phosphorylation of HSL and of perilipin A, was strongly decreased by treatment with the inhibitor of the cGMP-dependent protein kinase I ( cGKI), Rp-8-pCPT-cGMPS. Thus, ANP-induced lipolysis in human adipocytes is a cGMP-dependent pathway that induces the phosphorylation of HSL and perilipin A via the activation of cGKI. The present study shows that lipolysis in human adipocytes can be controlled by an independent cGKI-mediated signaling as well as by the classical cAMP/PKA pathway.	Univ Toulouse 3, Ctr Hosp Univ Rangueil, Inst Louis Bugnard, INSERM,U586,Obes Res Unit, F-31062 Toulouse, France; Univ Dusseldorf, Diabet Res Inst, D-4000 Dusseldorf, Germany; Univ Frankfurt Klinikum, Inst Cardiovasc Physiol, D-60590 Frankfurt, Germany	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Heinrich Heine University Dusseldorf; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Sengenes, C (corresponding author), Univ Toulouse 3, Ctr Hosp Univ Rangueil, Inst Louis Bugnard, INSERM,U586,Obes Res Unit, F-31062 Toulouse, France.		Bouloumie-Diehl, Anne/M-4446-2017; Galitzky, Jean/R-6599-2017; Sengenes, Coralie/GSN-0709-2022	Bouloumie-Diehl, Anne/0000-0001-5496-8891; Sengenes, Coralie/0000-0002-4820-6660				ALLEN DO, 1986, BIOCHEM PHARMACOL, V35, P767, DOI 10.1016/0006-2952(86)90244-3; AnandSrivastava MB, 1996, J BIOL CHEM, V271, P19324, DOI 10.1074/jbc.271.32.19324; Arner P, 2001, ANN MED, V33, P542, DOI 10.3109/07853890108995964; BRADLEY DC, 1989, ANAL BIOCHEM, V180, P11, DOI 10.1016/0003-2697(89)90081-X; Burkhardt M, 2000, J BIOL CHEM, V275, P33536, DOI 10.1074/jbc.M005670200; BUTT E, 1993, NEUROCHEM RES, V18, P17; Carey GB, 1998, ADV EXP MED BIOL, V441, P157; Degerman E, 1998, METHODS, V14, P43, DOI 10.1006/meth.1997.0564; EFENDIC S, 1970, Hormone and Metabolic Research, V2, P287; Galitzky J, 2001, J LIPID RES, V42, P536; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; HAUNER H, 1995, DIABETOLOGIA, V38, P764, DOI 10.1007/s001250050350; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; Kalra PR, 2001, EUR HEART J, V22, P997, DOI 10.1053/euhj.2000.2395; KHOO JC, 1977, P NATL ACAD SCI USA, V74, P4843, DOI 10.1073/pnas.74.11.4843; Klein G, 2000, CARDIOVASC RES, V48, P367, DOI 10.1016/S0008-6363(00)00194-2; Kone BC, 2001, CARDIOVASC RES, V51, P429, DOI 10.1016/S0008-6363(01)00327-3; LAFONTAN M, 1993, J LIPID RES, V34, P1057; LAFONTAN M, 2000, INT J OBES RELAT S4, V24, P47; Langin D, 2000, HORM METAB RES, V32, P443, DOI 10.1055/s-2007-978670; Ledoux S, 1997, AM J PHYSIOL-CELL PH, V272, pC82, DOI 10.1152/ajpcell.1997.272.1.C82; Levin ER, 1998, NEW ENGL J MED, V339, P321; LEVIN ER, 1993, AM J PHYSIOL, V264, pE483, DOI 10.1152/ajpendo.1993.264.4.E483; LINCOLN TM, 1976, P NATL ACAD SCI USA, V73, P2559, DOI 10.1073/pnas.73.8.2559; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Orstavik S, 1997, GENOMICS, V42, P311, DOI 10.1006/geno.1997.4743; Orstavik S, 1996, BIOCHEM BIOPH RES CO, V220, P759, DOI 10.1006/bbrc.1996.0477; Pagano M, 2001, J BIOL CHEM, V276, P22064, DOI 10.1074/jbc.M101587200; Potter LR, 2001, J BIOL CHEM, V276, P6057, DOI 10.1074/jbc.R000033200; RODBELL M, 1964, J BIOL CHEM, V239, P375; Ruth P, 1999, PHARMACOL THERAPEUT, V82, P355, DOI 10.1016/S0163-7258(98)00067-9; Ryden M, 2002, J BIOL CHEM, V277, P1085, DOI 10.1074/jbc.M109498200; SCHIMMEL RJ, 1975, BIOCHIM BIOPHYS ACTA, V399, P181, DOI 10.1016/0304-4165(75)90224-X; Sengenes C, 2002, INT J OBESITY, V26, P24, DOI 10.1038/sj.ijo.0801845; Sengenes C, 2002, AM J PHYSIOL-REG I, V283, pR257, DOI 10.1152/ajpregu.00453.2001; Sengenes C, 2000, FASEB J, V14, P1345, DOI 10.1096/fj.14.10.1345; Silberbach M, 2001, CELL SIGNAL, V13, P221, DOI 10.1016/S0898-6568(01)00139-5; Smolenski A, 1998, N-S ARCH PHARMACOL, V358, P134, DOI 10.1007/PL00005234; Sperelakis N, 1994, Adv Pharmacol, V26, P217, DOI 10.1016/S1054-3589(08)60056-3; STRALFORS P, 1983, J BIOL CHEM, V258, P5146; STRALFORS P, 1985, FEBS LETT, V180, P280, DOI 10.1016/0014-5793(85)81086-3; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; Tebar F, 1996, ENDOCRINOLOGY, V137, P4181, DOI 10.1210/en.137.10.4181; van den Akker F, 2001, J MOL BIOL, V311, P923, DOI 10.1006/jmbi.2001.4922; White RE, 1999, ADV SEC MESS PHOSPH, V33, P251; Xue BZ, 1998, FASEB J, V12, P1391, DOI 10.1096/fasebj.12.13.1391; Zhang HH, 2002, DIABETES, V51, P2929, DOI 10.2337/diabetes.51.10.2929	48	203	207	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48617	48626		10.1074/jbc.M303713200	http://dx.doi.org/10.1074/jbc.M303713200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12970365	hybrid			2022-12-25	WOS:000186829000014
J	Yamauchi, Y; Hayashi, M; Abe-Dohmae, S; Yokoyama, S				Yamauchi, Y; Hayashi, M; Abe-Dohmae, S; Yokoyama, S			Apolipoprotein A-I activates protein kinase C alpha signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CHOLESTEROL EFFLUX; CELLULAR LIPID RELEASE; TANGIER-DISEASE; SELECTIVE-INHIBITION; EXTRACELLULAR DOMAIN; DEPENDENT EFFLUX; PHOSPHOLIPASE-C; DOWN-REGULATION; PEST SEQUENCE; ABCA1	ATP-binding cassette transporter A1 (ABCA1) plays an essential role in the helical apolipoprotein-mediated assembly of high density lipoprotein, and the apolipoporteins stabilize ABCA1 against calpain-mediated degradation during the reaction ((2002) J. Biol. Chem. 277, 22426 - 22429). Protein kinase C (PKC) inhibitors suppressed both ABCA1 stabilization and cellular lipid release mediated by apolipoprotein A-I (apoA-I) but not ABCA1 increase by calpain inhibitors. The increase of ABCA1 and the cellular lipid release by apoA-I were both suppressed by a phosphatidylcholine phospholipase C (PC-PLC) inhibitor but not by the inhibitors of phosphatidylinositol- PLC and phosphatidylinositol 3-kinase. A protein phosphatase inhibitor further enhanced the ABCA1 increase by apoA-I. Biochemical and microscopic evidence indicated that apoA-I activated PKCalpha, and phosphorylation of ABCA1 was directly demonstrated by apoA-I via PKC. Finally, digestion of sphingomyelin increased ABCA1, and a PC-PLC inhibitor suppressed it. We conclude that apoA-I activates PKCalpha by PC-PLC-mediated generation of diacylglycerol initiated by the removal of cellular sphingomyelin (( 2002) J. Biol. Chem. 277, 44709 - 44714), and subsequently phosphorylates and stabilizes ABCA1.	Nagoya City Univ, Grad Sch Med Sci, Dept Biochem Cell Biol & Metab, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Yokoyama, S (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Biochem Cell Biol & Metab, Mizuho Ku, Kawasumi 1,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	syokoyam@med.nagoya-cu.ac.jp	Yamauchi, Yoshio/I-7539-2014	Yamauchi, Yoshio/0000-0001-5559-4596				Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Attie AD, 2002, J LIPID RES, V43, P1610, DOI 10.1194/jlr.M200223-JLR200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Buechler C, 2002, J BIOL CHEM, V277, P41307, DOI 10.1074/jbc.C200436200; Buechler C, 2002, BIOCHEM BIOPH RES CO, V293, P759, DOI 10.1016/S0006-291X(02)00303-0; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; Costet P, 2000, J BIOL CHEM, V275, P28240; de Thonel A, 2001, BLOOD, V98, P3770, DOI 10.1182/blood.V98.13.3770; Deeg MA, 1997, ARTERIOSCL THROM VAS, V17, P1667, DOI 10.1161/01.ATV.17.9.1667; Feng B, 2002, J BIOL CHEM, V277, P43271, DOI 10.1074/jbc.M207532200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Grewal T, 2003, J BIOL CHEM, V278, P16478, DOI 10.1074/jbc.C300085200; Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200; Haidar B, 2001, J LIPID RES, V42, P249; Hegedus T, 2003, BIOCHEM BIOPH RES CO, V302, P454, DOI 10.1016/S0006-291X(03)00196-7; Ito J, 2002, J BIOL CHEM, V277, P44709, DOI 10.1074/jbc.M208379200; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; Kojima K, 2001, BBA-MOL CELL BIOL L, V1532, P173, DOI 10.1016/S1388-1981(01)00124-X; Li QQ, 1997, BIOCHEMISTRY-US, V36, P12045, DOI 10.1021/bi970079t; LI QQ, 1995, J BIOL CHEM, V270, P26216, DOI 10.1074/jbc.270.44.26216; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; NazihSanderson F, 1997, BBA-LIPID LIPID MET, V1346, P45, DOI 10.1016/S0005-2760(97)00017-9; NazihSanderson F, 1997, BBA-MOL CELL RES, V1358, P103, DOI 10.1016/S0167-4889(97)00055-4; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; Nofer JR, 2000, BIOCHEMISTRY-US, V39, P15199, DOI 10.1021/bi001162a; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Ort T, 2001, EMBO J, V20, P4013, DOI 10.1093/emboj/20.15.4013; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; Prevostel C, 2000, J CELL SCI, V113, P2575; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; Slater SJ, 2001, BIOCHEMISTRY-US, V40, P4437, DOI 10.1021/bi001654n; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; Tanaka AR, 2001, BIOCHEM BIOPH RES CO, V283, P1019, DOI 10.1006/bbrc.2001.4891; Tanaka AR, 2003, J BIOL CHEM, V278, P8815, DOI 10.1074/jbc.M206885200; THERET N, 1990, BIOCHEM BIOPH RES CO, V173, P1361, DOI 10.1016/S0006-291X(05)80938-6; Tsujita M, 1996, BIOCHEMISTRY-US, V35, P13011, DOI 10.1021/bi960734h; Tsujita M, 2000, BBA-MOL CELL BIOL L, V1485, P199, DOI 10.1016/S1388-1981(00)00061-5; Tsukamoto K, 2001, BIOCHEM BIOPH RES CO, V287, P757, DOI 10.1006/bbrc.2001.5575; Vanoye CG, 1999, AM J PHYSIOL-CELL PH, V276, pC370, DOI 10.1152/ajpcell.1999.276.2.C370; Wagner S, 2000, EXP CELL RES, V258, P204, DOI 10.1006/excr.2000.4925; WALTER M, 1995, ARTERIOSCL THROM VAS, V15, P1975, DOI 10.1161/01.ATV.15.11.1975; Walter M, 1996, J CLIN INVEST, V98, P2315, DOI 10.1172/JCI119043; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Xia P, 1999, J BIOL CHEM, V274, P33143, DOI 10.1074/jbc.274.46.33143; Yamauchi Y, 2002, BBA-MOL CELL BIOL L, V1585, P1, DOI 10.1016/S1388-1981(02)00304-9; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9	61	118	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47890	47897		10.1074/jbc.M306258200	http://dx.doi.org/10.1074/jbc.M306258200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12952980	hybrid			2022-12-25	WOS:000186731400066
J	Frank, NY; Pendse, SS; Lapchak, PH; Margaryan, A; Shlain, D; Doeing, C; Sayegh, MH; Frank, MH				Frank, NY; Pendse, SS; Lapchak, PH; Margaryan, A; Shlain, D; Doeing, C; Sayegh, MH; Frank, MH			Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC STEM-CELLS; MULTIDRUG-RESISTANCE; IN-VITRO; MONOCLONAL-ANTIBODIES; GENE; EXPRESSION; VIVO; LYMPHOCYTES; EFFLUX; LIVER	Cell fusion involving progenitor cells is a newly recognized phenomenon thought to contribute to tissue differentiation. The molecular mechanisms governing cell fusion are unknown. P- glycoprotein and related ATP- binding cassette transporters are expressed by progenitor cells, but their physiological role in these cell types has not been defined. Here, we have cloned ABCB5, a rhodamine efflux transporter and novel member of the human P- glycoprotein family, which marks CD133- expressing progenitor cells among human epidermal melanocytes and determines as a regulator of membrane potential the propensity of this subpopulation to undergo cell fusion. Our findings show that polyploid ABCB5 (+) cells are generated by cell fusion and that this process is specifically enhanced by ABCB5 P-glycoprotein blockade. Remarkably, multinucleated cell hybrids gave rise to mononucleated progeny, demonstrating that fusion contributes to culture growth and differentiation. Thus, our findings define a molecular mechanism for cell fusion involving progenitor cells and show that fusion and resultant growth and differentiation are not merely spontaneous events, but phenomena regulated by ABCB5 P- glycoprotein.	Brigham & Womens Hosp, Dept Med, Div Renal, Lab Immunogenet & Transplantat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Partners Ctr Human Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Nephrol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Frank, MH (corresponding author), Brigham & Womens Hosp, Dept Med, Div Renal, Lab Immunogenet & Transplantat, 75 Francis St, Boston, MA 02115 USA.		Lapchak, Peter H./B-3559-2009; Frank, Markus/O-1625-2014	Frank, Markus/0000-0002-1312-0488; Lapchak, Peter/0000-0001-8597-088X; Sayegh, Mohamed/0000-0002-2847-588X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050783] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI 50151, K08 AI050783, K08 AI050783-03] Funding Source: Medline; PHS HHS [K08 1I 50783] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aleman C, 2003, CANCER RES, V63, P3084; Allikmets R, 1998, CANCER RES, V58, P5337; Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Bosch I, 1997, BIOCHEMISTRY-US, V36, P5685, DOI 10.1021/bi962728r; Bunting KD, 1999, ANN NY ACAD SCI, V872, P125, DOI 10.1111/j.1749-6632.1999.tb08459.x; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Drach J, 1996, BLOOD, V88, P1747, DOI 10.1182/blood.V88.5.1747.bloodjournal8851747; Frank MH, 2001, J IMMUNOL, V166, P2451, DOI 10.4049/jimmunol.166.4.2451; FREI E, 1993, CANCER CHEMOTH PHARM, V33, P113, DOI 10.1007/BF00685328; Gollapudi S, 2001, J CLIN IMMUNOL, V21, P420, DOI 10.1023/A:1013177710941; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; GRIMLEY PM, 1987, BIOCHEM BIOPH RES CO, V146, P300, DOI 10.1016/0006-291X(87)90725-X; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; Johnstone RW, 2000, TRENDS BIOCHEM SCI, V25, P1, DOI 10.1016/S0968-0004(99)01493-0; Leemhuis T, 1996, EXP HEMATOL, V24, P1215; Liu JH, 2003, DEVELOPMENT, V130, P3437, DOI 10.1242/dev.00562; Morandini R, 1998, J CELL PHYSIOL, V175, P276, DOI 10.1002/(SICI)1097-4652(199806)175:3<276::AID-JCP5>3.0.CO;2-L; Nishimura EK, 2002, NATURE, V416, P854, DOI 10.1038/416854a; Occhiodoro T, 1998, FEBS LETT, V434, P177, DOI 10.1016/S0014-5793(98)00973-9; Pendse S, 2003, CURR DRUG TARGETS, V4, P469, DOI 10.2174/1389450033490894; Raghu G, 1996, EXP HEMATOL, V24, P1258; Randolph GJ, 1998, P NATL ACAD SCI USA, V95, P6924, DOI 10.1073/pnas.95.12.6924; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; Romsicki Y, 2001, BIOCHEMISTRY-US, V40, P6937, DOI 10.1021/bi0024456; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; SCHINKEL AH, 1993, INT J CANCER, V55, P478, DOI 10.1002/ijc.2910550326; SCHUT TCB, 1993, BIOPHYS J, V65, P568, DOI 10.1016/S0006-3495(93)81128-7; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SPANGRUDE GJ, 1995, BLOOD, V85, P1006, DOI 10.1182/blood.V85.4.1006.bloodjournal8541006; SPANGRUDE GJ, 1990, P NATL ACAD SCI USA, V87, P7433, DOI 10.1073/pnas.87.19.7433; Spees JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI 10.1073/pnas.0437997100; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; UEDA K, 1986, BIOCHEM BIOPH RES CO, V141, P956, DOI 10.1016/S0006-291X(86)80136-X; Valverde MA, 1996, EMBO J, V15, P4460, DOI 10.1002/j.1460-2075.1996.tb00823.x; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDERBLIEK AM, 1987, EMBO J, V6, P3325, DOI 10.1002/j.1460-2075.1987.tb02653.x; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; WOLF NS, 1993, EXP HEMATOL, V21, P614; Wulf GG, 2001, BLOOD, V98, P1166, DOI 10.1182/blood.V98.4.1166; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Yu Y, 2002, J BIOL CHEM, V277, P20711, DOI 10.1074/jbc.M202349200; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028; ZIJLMANS JMJM, 1995, P NATL ACAD SCI USA, V92, P8901, DOI 10.1073/pnas.92.19.8901	54	180	202	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47156	47165		10.1074/jbc.M308700200	http://dx.doi.org/10.1074/jbc.M308700200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12960149	hybrid			2022-12-25	WOS:000186569400114
J	He, ML; Gonzales-Iglesias, AE; Stojilkovic, SS				He, ML; Gonzales-Iglesias, AE; Stojilkovic, SS			Role of nucleotide P2 receptors in calcium signaling and prolactin release in pituitary lactotrophs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM; ATP RECEPTORS; EXTRACELLULAR NUCLEOTIDES; PRIMARY CULTURES; ACTIVATION; CHANNELS; MOBILIZATION; INHIBITION; PURINES; LIGAND	Anterior pituitary cells express nucleotide-gated G protein-coupled P2 receptors (P2YRs) and cation-conducting channels (P2XRs). However, the identification of P2 receptors subtypes and their native ligands, and the distribution and function of these receptors within the secretory and non-secretory pituitary cells has been incompletely characterized. The focus in this study was on lactotroph subpopulation of cells. ATP and ADP, but not UTP and UDP, triggered calcium signaling in a majority (85%) of lactotrophs and prolactin release in mixed pituitary cells. Consistent with the role of P2 receptors in signaling and secretion, the actions of ATP and ADP were abolished in the presence of apyrase, an ectonucleotidase. Transcripts for G(q)-coupled calcium-mobilizing P2Y(1)R, P2Y(2)R, P2Y(4)R, and P2Y(6)R, as well as G(i)-coupled P2Y(12)R, were identified in mixed anterior pituitary cells. The ligand-selectivity profile of calcium mobilization-dependent signaling and prolactin secretion and the blockade of these responses by pyridoxal 5-phosphate 6-azophenyl-2', 4'-disulphonic acid indicated that P2Y(1)R mediates the stimulatory action of ATP and ADP. Within the channels expressed in anterior pituitary (P2X(2)R, P2X(3)R, P2X(4)R, and P2X(7)R), the P2X(4)R subtype provides a major pathway for calcium influx-dependent signaling and prolactin secretion. This conclusion was based on comparison of native to recombinant channels with respect to their ligand preference, sensitivity to pyridoxal 5-phosphate 6-azophenyl-2', 4'-disulphonic acid, and the rates of calcium signal desensitization.	NICHHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Stojilkovic, SS (corresponding author), NICHD, Sect Cellular Signaling, ERRB, NIH, Bldg 49,Room 6A-36,49 Convent Dr, Bethesda, MD 20892 USA.	stankos@helix.nih.gov	He, Mulan/C-4140-2009		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000195] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000195] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEUKERS MW, 1995, N-S ARCH PHARMACOL, V351, P523, DOI 10.1007/BF00171044; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; CAREW MA, 1994, CELL CALCIUM, V16, P227, DOI 10.1016/0143-4160(94)90025-6; Chen ZP, 1996, ENDOCRINOLOGY, V137, P248, DOI 10.1210/en.137.1.248; CHEN ZP, 1994, ENDOCRINOLOGY, V135, P1280, DOI 10.1210/en.135.3.1280; CHEN ZP, 1995, P NATL ACAD SCI USA, V92, P5219, DOI 10.1073/pnas.92.11.5219; Chen ZP, 1996, ENDOCRINOLOGY, V137, P1833, DOI 10.1210/en.137.5.1833; Chung HS, 2000, BRIT J PHARMACOL, V130, P1843, DOI 10.1038/sj.bjp.0703253; DAVIDSON JS, 1990, ENDOCRINOLOGY, V126, P80, DOI 10.1210/endo-126-1-80; He ML, 2003, AM J PHYSIOL-CELL PH, V285, pC467, DOI 10.1152/ajpcell.00042.2003; KANYICSKA B, 1995, ENDOCRINOLOGY, V136, P990, DOI 10.1210/en.136.3.990; Kapoor JR, 2000, J NEUROSCI, V20, P8868; Khakh BS, 2001, PHARMACOL REV, V53, P107; Koshimizu T, 2000, ENDOCRINOLOGY, V141, P4091, DOI 10.1210/en.141.11.4091; Koshimizu T, 2002, J BIOL CHEM, V277, P46891, DOI 10.1074/jbc.M205274200; Koshimizu T, 1998, MOL ENDOCRINOL, V12, P901, DOI 10.1210/me.12.7.901; Koshimizu T, 1998, J BIOL CHEM, V273, P12853, DOI 10.1074/jbc.273.21.12853; MOLLARD P, 1991, EUR J PHARM-MOLEC PH, V206, P271, DOI 10.1016/0922-4106(91)90109-U; Muller CE, 2002, CURR PHARM DESIGN, V8, P2353, DOI 10.2174/1381612023392937; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Nunez L, 1997, AM J PHYSIOL-ENDOC M, V272, pE1117, DOI 10.1152/ajpendo.1997.272.6.E1117; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rees DA, 2003, J ENDOCRINOL, V177, P357, DOI 10.1677/joe.0.1770357; Rees DA, 2003, CLIN SCI, V104, P467, DOI 10.1042/CS20030053; SAMSON WK, 1990, BIOCHEM BIOPH RES CO, V169, P737, DOI 10.1016/0006-291X(90)90393-2; Stojilkovic SS, 2001, TRENDS ENDOCRIN MET, V12, P218, DOI 10.1016/S1043-2760(01)00387-3; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; Tomic M, 1996, J BIOL CHEM, V271, P21200, DOI 10.1074/jbc.271.35.21200; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Troadec JD, 1999, PFLUG ARCH EUR J PHY, V437, P745, DOI 10.1007/s004240050841; Uchiyama M, 2001, J NEUROENDOCRINOL, V13, P378, DOI 10.1046/j.1365-2826.2001.00639.x; Van Goor F, 1999, MOL ENDOCRINOL, V13, P587, DOI 10.1210/me.13.4.587; VANDERMERWE PA, 1989, FEBS LETT, V243, P333, DOI 10.1016/0014-5793(89)80156-5; Villalobos C, 1997, AM J PHYSIOL-CELL PH, V273, pC1963, DOI 10.1152/ajpcell.1997.273.6.C1963; von Kugelgen I, 2000, N-S ARCH PHARMACOL, V362, P310, DOI 10.1007/s002100000310; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	36	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46270	46277		10.1074/jbc.M309005200	http://dx.doi.org/10.1074/jbc.M309005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12970352	hybrid			2022-12-25	WOS:000186569400010
J	Yokota, H; Goldring, MB; Sun, HB				Yokota, H; Goldring, MB; Sun, HB			CITED2-mediated regulation of MMP-1 and MMP-13 in human chondrocytes under flow shear	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMORTALIZED HUMAN CHONDROCYTES; MESSENGER-RNA EXPRESSION; MATRIX METALLOPROTEINASES; RHEUMATOID-ARTHRITIS; TRANSCRIPTION FACTORS; SYNOVIAL-MEMBRANE; TISSUE INHIBITORS; GENE-EXPRESSION; TGF-BETA; COLLAGEN	CITED2 (CBP/p300-interacting transactivator with ED-rich tail 2) is a member of the Cited family of nuclear regulators, previously known as mrg1 (melanocyte-specific gene-related gene 1). CITED2 is inducible by varying stimuli including lipopolysaccharide, hypoxia, and cytokines such as interleukin 9 and interferon gamma. Using the immortalized human chondrocyte cell line, C-28/I2, we investigated whether CITED2 could be responsive to mechanical stimuli, and if so, whether CITED2 could mediate shear-driven regulation of matrix metalloproteinase (MMP) genes. The C-28/I2 cells were cultured under flow shear at 1 - 20 dyn/cm(2), and the role of CIT-ED2 in regulation of MMPs was examined using the plasmids encoding sense and antisense CITED2 DNA sequences. The results showed that flow shear at 5 dyn/ cm(2) increased CITED2 mRNA and protein levels and down-regulated MMP-1 and MMP-13 mRNA and protein levels as well as enzyme activities. Consistent with the coordinated expression patterns of CITED2 and MMPs, overexpression of CITED2 repressed MMP-1 and MMP-13 mRNA levels and activities, whereas antisense CITED2 plasmids prevented the shear-induced downregulation of MMP expression. Interleukin-1beta induced the formation of p300-Ets-1 complexes without affecting expression of CITED2. Transforming growth factor-beta as well as flow shear at 5 dyn/ cm2 stimulated not only the expression of CITED2 but also the association of CITED2 with p300 by dissociating Ets-1 from p300. These results indicate that CITED2 plays a major role in shear-induced down-regulation of MMP-1 and MMP-13 via a transforming growth factor-beta-dependent pathway.	Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA; Indiana Univ Purdue Univ, Biomed Engn Program, Indianapolis, IN 46202 USA; Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Harvard University; Beth Israel Deaconess Medical Center	Sun, HB (corresponding author), Indiana Univ, Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS-504, Indianapolis, IN 46202 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR047628, R01AR045378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB001019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022021, R56AG022021] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 45378, AR 47628] Funding Source: Medline; NIA NIH HHS [AG 22021] Funding Source: Medline; NIBIB NIH HHS [EB 01019] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Agarwal S, 2001, ARTHRITIS RHEUM-US, V44, P608, DOI 10.1002/1529-0131(200103)44:3<608::AID-ANR109>3.3.CO;2-U; Bamforth SD, 2001, NAT GENET, V29, P469, DOI 10.1038/ng768; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; Burr DB, 2002, BONE, V30, P781, DOI 10.1016/S8756-3282(02)00707-X; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Ding GJF, 1998, J BIOL CHEM, V273, P28897, DOI 10.1074/jbc.273.44.28897; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Goldring MB, 1999, CONNECT TISSUE RES, V40, P1, DOI 10.3109/03008209909005273; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; Goldring MB, 2001, EXPERT OPIN BIOL TH, V1, P817, DOI 10.1517/14712598.1.5.817; Goodman RH, 2000, GENE DEV, V14, P1553; Heegaard JH, 1999, J ORTHOPAED RES, V17, P509, DOI 10.1002/jor.1100170408; Honda K, 2000, EUR J CELL BIOL, V79, P601, DOI 10.1078/0171-9335-00089; Huiskes R, 2000, NATURE, V405, P704, DOI 10.1038/35015116; Konttinen YT, 1999, ANN RHEUM DIS, V58, P691, DOI 10.1136/ard.58.11.691; Leung MK, 1999, GENOMICS, V61, P307, DOI 10.1006/geno.1999.5970; Loeser RF, 2000, OSTEOARTHR CARTILAGE, V8, P96, DOI 10.1053/joca.1999.0277; Long P, 2001, J DENT RES, V80, P1416, DOI 10.1177/00220345010800050601; Maini RN, 2000, ANNU REV MED, V51, P207, DOI 10.1146/annurev.med.51.1.207; Osaki M, 2003, BIOCHEM J, V369, P103, DOI 10.1042/BJ20020928; Qian L, 2002, FRONT BIOSCI-LANDMRK, V7, pA126, DOI 10.2741/qian; Redlich K, 2001, ARTHRITIS RHEUM, V44, P266, DOI 10.1002/1529-0131(200102)44:2<266::AID-ANR43>3.3.CO;2-7; Robling AG, 2000, J BONE MINER RES, V15, P1596, DOI 10.1359/jbmr.2000.15.8.1596; Shingleton WD, 1996, BIOCHEM CELL BIOL, V74, P759, DOI 10.1139/o96-083; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Smith RL, 2000, BIORHEOLOGY, V37, P95; Suh JK, 1999, OSTEOARTHR CARTILAGE, V7, P71, DOI 10.1053/joca.1998.0163; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; Sun HB, 2002, MATRIX BIOL, V21, P263, DOI 10.1016/S0945-053X(02)00003-3; Sun HB, 2001, BONE, V28, P303, DOI 10.1016/S8756-3282(00)00454-3; Tan LJ, 2003, J BIOL CHEM, V278, P17688, DOI 10.1074/jbc.M301676200; Tetlow LC, 2001, ARTHRITIS RHEUM-US, V44, P585, DOI 10.1002/1529-0131(200103)44:3<585::AID-ANR107>3.0.CO;2-C; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; Xu ZF, 2000, J IMMUNOL, V165, P453, DOI 10.4049/jimmunol.165.1.453; Yahata T, 2000, J BIOL CHEM, V275, P8825, DOI 10.1074/jbc.275.12.8825; Yang JH, 1998, J BIOL CHEM, V273, P6550, DOI 10.1074/jbc.273.11.6550; Yin Z, 2002, P NATL ACAD SCI USA, V99, P10488, DOI 10.1073/pnas.162371799; Zwicky R, 2002, BIOCHEM J, V367, P209, DOI 10.1042/BJ20020210	40	105	108	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47275	47280		10.1074/jbc.M304652200	http://dx.doi.org/10.1074/jbc.M304652200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12960175	hybrid			2022-12-25	WOS:000186569400129
J	Mori, S; Tanaka, M; Nanba, D; Nishiwaki, E; Ishiguro, H; Higashiyama, S; Matsuura, N				Mori, S; Tanaka, M; Nanba, D; Nishiwaki, E; Ishiguro, H; Higashiyama, S; Matsuura, N			PACSIN3 binds ADAM12/meltrin alpha and up-regulates ectodomain shedding of heparin-binding epidermal growth factor-like growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; METALLOPROTEASE-DISINTEGRIN; MELTRIN-ALPHA; EGF RECEPTOR; EPITHELIAL-CELLS; C2C12 CELLS; SH3 DOMAIN; PROTEIN; TRANSACTIVATION; SRC	A disintegrin and metalloprotease 12 (ADAM12/meltrin alpha) is a key enzyme implicated in the ectodomain shedding of membrane-anchored heparin-binding epidermal growth factor (EGF)-like growth factor (proHB-EGF)-dependent epidermal growth factor receptor (EGFR) transactivation. However, the activation mechanisms of ADAM12 are obscure. To determine how ADAM12 is activated, we screened proteins that bind to the cytoplasmic domain of ADAM12 using a yeast two-hybrid system and identified a protein called PACSIN3 that contains a Src homology 3 domain. An analysis of interactions between ADAM12 and PACSIN3 using glutathione S-transferase fusion protein revealed that a proline-rich region (amino acid residues 829-840) of ADAM12 was required to bind PACSIN3. Furthermore, co-immunoprecipitation and co-localization analyses of ADAM12 and PACSIN3 proteins also revealed their interaction in mammalian cells expressing both of them. The overexpression of PACSIN3 in HT1080 cells enhanced 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced proHB-EGF shedding. Furthermore, knockdown of endogenous PACSIN3 by small interfering RNA in HT1080 cells significantly attenuated the shedding of proHB-EGF induced by TPA and angiotensin II. Our data indicate that PACSIN3 has a novel function as an up-regulator in the signaling of proHB-EGF shedding induced by TPA and angiotensin II.	Ehime Univ, Sch Med, Dept Med Biochem, Shigenobu, Ehime 7910295, Japan; Osaka Univ, Fac Med, Sch Allied Hlth Sci, Dept Mol Pathol, Suita, Osaka 5650871, Japan; Carna Biosci Inc, Kobe, Hyogo 6508543, Japan	Ehime University; Osaka University	Higashiyama, S (corresponding author), Ehime Univ, Sch Med, Dept Med Biochem, Shigenobu, Ehime 7910295, Japan.							Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Cousin H, 2000, DEV BIOL, V227, P197, DOI 10.1006/dbio.2000.9871; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Fujiyama S, 2001, CIRC RES, V88, P22, DOI 10.1161/01.RES.88.1.22; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; Hougaard S, 2000, BIOCHEM BIOPH RES CO, V275, P261, DOI 10.1006/bbrc.2000.3295; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kadota N, 2000, J BIOCHEM-TOKYO, V128, P941, DOI 10.1093/oxfordjournals.jbchem.a022845; Kang Q, 2001, J BIOL CHEM, V276, P24466, DOI 10.1074/jbc.M101162200; Kang Q, 2000, BIOCHEM J, V352, P883, DOI 10.1042/0264-6021:3520883; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Keates S, 2001, J BIOL CHEM, V276, P48127, DOI 10.1074/jbc.M107630200; Kurisaki T, 2003, MOL CELL BIOL, V23, P55, DOI 10.1128/MCB.23.1.55-61.2003; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Modregger J, 2000, J CELL SCI, V113, P4511; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Sumoy L, 2001, GENE, V262, P199, DOI 10.1016/S0378-1119(00)00531-X; Suzuki A, 2000, ONCOGENE, V19, P5842, DOI 10.1038/sj.onc.1203986; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026	22	72	74	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46029	46034		10.1074/jbc.M306393200	http://dx.doi.org/10.1074/jbc.M306393200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952982	hybrid			2022-12-25	WOS:000186452300119
J	Zavala-Ruiz, Z; Sundberg, EJ; Stone, JD; DeOliveira, DB; Chan, IC; Svendsen, J; Mariuzza, RA; Stern, LJ				Zavala-Ruiz, Z; Sundberg, EJ; Stone, JD; DeOliveira, DB; Chan, IC; Svendsen, J; Mariuzza, RA; Stern, LJ			Exploration of the P6/P7 region of the peptide-binding site of the human class II major histocompatability complex protein HLA-DR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; STRUCTURAL BASIS; WATER-MOLECULES; ANTIGEN; AFFINITY; TCR; LIGANDS; DESIGN; IDENTIFICATION; INTERMEDIATE	Crystal structures of the class II major histocompatibilty complex (MHC) protein, HLA-DR1, generally show a tight fit between MHC and bound peptide except in the P6/P7 region of the peptide-binding site. In this region, there is a shallow water-filled pocket underneath the peptide and between the pockets that accommodate the P6 and P7 side chains. We investigated the properties of this pocket with the idea of engineering substitutions into the corresponding region of peptide antigens to increase their binding affinity for HLA-DR1. We investigated D-amino acids and N-alkyl modifications at both the P6 and P7 positions of the peptide and found that binding of peptides to HLA-DR1 could be increased by incorporating an N-methyl substitution at position 7 of the peptide. The crystal structure of HLA-DR1 bound to a peptide containing a P7 N-methyl alanine was determined. The N-methyl group orients in the P6/P7 pocket, displacing one of the waters usually bound in this pocket. The structure shows that the substitution does not alter the conformation of the bound peptide, which adopts the usual polyproline type II helix. An antigenic peptide carrying the N-methyl modification is taken up by antigen-presenting cells and loaded onto endogenous class II MHC molecules for presentation, and the resultant MHC-peptide complexes activate antigen-specific T-cells. These results suggest a possible strategy for increasing the affinity of weakly immunogenic peptides that might be applicable to the development of vaccines and diagnostic reagents.	Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA	University of Massachusetts System; University of Massachusetts Worcester; Massachusetts Institute of Technology (MIT); University System of Maryland; University of Maryland Baltimore	Stern, LJ (corresponding author), Univ Massachusetts, Sch Med, Dept Pathol, Rm S2-127,55 Lake Ave N, Worcester, MA 01655 USA.	lawrence.stern@umassmed.edu		Zavala-Ruiz, Zarixia/0000-0003-1513-5840; Sundberg, Eric/0000-0003-0478-3033	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM064859] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI38996, R01-AI369000] Funding Source: Medline; NIGMS NIH HHS [F31-GM64859] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen PS, 1999, IMMUNITY, V10, P473, DOI 10.1016/S1074-7613(00)80047-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balaban N, 2000, INT J FOOD MICROBIOL, V61, P1, DOI 10.1016/S0168-1605(00)00377-9; BEESON C, 1994, P NATL ACAD SCI USA, V91, P8842, DOI 10.1073/pnas.91.19.8842; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BOEHNCKE WH, 1993, J IMMUNOL, V150, P331; Boen E, 2000, J IMMUNOL, V165, P2040, DOI 10.4049/jimmunol.165.4.2040; Bolin DR, 2000, J MED CHEM, V43, P2135, DOI 10.1021/jm000034h; Brand DD, 2001, AUTOIMMUNITY, V34, P133, DOI 10.3109/08916930109001961; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; Chung E, 1998, STRUCTURE, V6, P1141, DOI 10.1016/S0969-2126(98)00115-4; CONNELLY PR, 1994, P NATL ACAD SCI USA, V91, P1964, DOI 10.1073/pnas.91.5.1964; Cotton J, 1998, INT IMMUNOL, V10, P159, DOI 10.1093/intimm/10.2.159; de Haan EC, 2002, BIOORGAN MED CHEM, V10, P1939, DOI 10.1016/S0968-0896(01)00434-5; Delano W.L., 2002, DELANO SCI; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; Dullweber F, 2001, J MOL BIOL, V313, P593, DOI 10.1006/jmbi.2001.5062; Fan EK, 2001, ACTA CRYSTALLOGR D, V57, P201, DOI 10.1107/S0907444900016814; Figliozzi GM, 1996, METHOD ENZYMOL, V267, P437; Frayser M, 1999, PROTEIN EXPRES PURIF, V15, P105, DOI 10.1006/prep.1998.0987; Fremont DH, 2002, J EXP MED, V195, P1043, DOI 10.1084/jem.20011971; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; Gregoriou M, 1998, PROTEIN SCI, V7, P915; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; Hart M, 2001, J MED CHEM, V44, P3700, DOI 10.1021/jm0101895; Hennecke J, 2002, J EXP MED, V195, P571, DOI 10.1084/jem.20011194; HILL CM, 1994, J IMMUNOL, V152, P2890; Howard SC, 1997, PROTEIN PEPTIDE LETT, V4, P63; Jardetzky TS, 1996, P NATL ACAD SCI USA, V93, P734, DOI 10.1073/pnas.93.2.734; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joshi RV, 2000, BIOCHEMISTRY-US, V39, P3751, DOI 10.1021/bi9923656; Kjellen P, 1998, EUR J IMMUNOL, V28, P755, DOI 10.1002/(SICI)1521-4141(199802)28:02<755::AID-IMMU755>3.0.CO;2-2; KRIEGER JI, 1991, J IMMUNOL, V146, P2331; LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812; LAMB JR, 1982, NATURE, V300, P456, DOI 10.1038/300456a0; Lang HLE, 2002, NAT IMMUNOL, V3, P940, DOI 10.1038/ni835; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee KH, 2001, NAT IMMUNOL, V2, P501, DOI 10.1038/88694; Li YL, 2000, J MOL BIOL, V304, P177, DOI 10.1006/jmbi.2000.4198; Li Z, 2003, J AM CHEM SOC, V125, P6636, DOI 10.1021/ja0299203; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8820, DOI 10.1073/pnas.132272099; Luque I, 2002, PROTEINS, V49, P181, DOI 10.1002/prot.10208; Maillere B, 1995, MOL IMMUNOL, V32, P1073, DOI 10.1016/0161-5890(95)00073-9; McFarland BJ, 2001, P NATL ACAD SCI USA, V98, P9231, DOI 10.1073/pnas.151131498; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mullen MM, 2002, MOL CELL, V9, P375, DOI 10.1016/S1097-2765(02)00465-3; Murthy VL, 1997, STRUCTURE, V5, P1385, DOI 10.1016/S0969-2126(97)00288-8; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rabinowitz JD, 1998, IMMUNITY, V9, P699, DOI 10.1016/S1074-7613(00)80667-6; Redpath S, 1999, J IMMUNOL, V163, P6; ROCHE PA, 1990, J IMMUNOL, V144, P1849; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1989, NATURE, V337, P274, DOI 10.1038/337274a0; Schmitt L, 1999, J MOL BIOL, V286, P207, DOI 10.1006/jmbi.1998.2463; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; Stratmann T, 2000, J IMMUNOL, V165, P3214, DOI 10.4049/jimmunol.165.6.3214; Sundberg EJ, 2002, J MOL BIOL, V319, P449, DOI 10.1016/S0022-2836(02)00370-4; TOMPKINS SM, 1993, J IMMUNOL METHODS, V163, P209; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; VARGAS LE, 2003, IN PRESS BBRC; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; Wu SH, 1996, J IMMUNOL, V156, P3815; Zarutskie JA, 1999, BIOCHEMISTRY-US, V38, P5878, DOI 10.1021/bi983048m	68	27	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44904	44912		10.1074/jbc.M307652200	http://dx.doi.org/10.1074/jbc.M307652200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12952957	hybrid			2022-12-25	WOS:000186306700126
J	Matsuzawa-Watanabe, Y; Inoue, J; Semba, K				Matsuzawa-Watanabe, Y; Inoue, J; Semba, K			Transcriptional activity of testis-determining factor SRY is modulated by the Wilms' tumor 1 gene product, WT1	ONCOGENE			English	Article						tumor-suppressor gene; transcription factor; gonad; sex determination	SEX-DETERMINING REGION; DNA-BINDING; SUPPRESSOR GENE; EXPRESSION; PROTEIN; CHROMOSOME; VARIANTS; SEQUENCE; SOX9	The Wilms' tumor 1 (WT1) and sex-determining region of the Y chromosome (SRY) genes are essential for development of the mammalian gonads and mutations in these genes are associated with gonadal dysgenesis in humans. The SRY gene encodes a transcription factor with one high-mobility group (HMG) box as a DNA-binding domain. WT1 encodes a transcription factor that contains four contiguous C2H2-type zinc-finger motifs as a DNA/RNA binding or protein-protein interaction domain. Here we report that WT1 binds to and acts synergistically with SRY to activate transcription from a promoter containing SRY-binding sites. This interaction is mediated by the WT1 zinc-finger domain and the SRY HMG box. WT1 mutants associated with Denys-Drash syndrome (DDS), which is characterized by Wilms' tumor, pseudohermaphroditism, and nephropathy, fail to interact with SRY. Wildtype WT1 is recruited to SRY-binding sites in an SRY-dependent manner, whereas DDS mutants are not recruited as efficiently. These results suggest that WT1 forms a complex with SRY to regulate transcription and that this WT1-SRY interaction is important in testis development.	Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Semba, K (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	ksemba@ims.u-tokyo.ac.jp						ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HACKER A, 1995, DEVELOPMENT, V121, P1603; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Hanley NA, 2000, MECH DEVELOP, V91, P403, DOI 10.1016/S0925-4773(99)00307-X; Hanley NA, 1999, MECH DEVELOP, V87, P175, DOI 10.1016/S0925-4773(99)00123-9; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Hossain A, 2001, J BIOL CHEM, V276, P16817, DOI 10.1074/jbc.M009056200; KENT J, 1995, ONCOGENE, V11, P1781; Kim J, 1999, MOL CELL BIOL, V19, P2289; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; Koopman P, 1999, CELL MOL LIFE SCI, V55, P839; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; McElreavey K, 1999, AM J MED GENET, V89, P176, DOI 10.1002/(SICI)1096-8628(19991229)89:4<176::AID-AJMG2>3.0.CO;2-B; Moore AW, 1999, DEVELOPMENT, V126, P1845; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Osaki E, 1999, NUCLEIC ACIDS RES, V27, P2503, DOI 10.1093/nar/27.12.2503; Patek CE, 1999, P NATL ACAD SCI USA, V96, P2931, DOI 10.1073/pnas.96.6.2931; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Sakamoto Y, 1997, ONCOGENE, V15, P2001, DOI 10.1038/sj.onc.1201391; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; Semba K, 1996, GENE, V175, P167, DOI 10.1016/0378-1119(96)00143-6; Shimamura R, 1997, CLIN CANCER RES, V3, P2571; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Wagner KD, 2002, FASEB J, V16, P1117, DOI 10.1096/fj.01-0986fje; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398	38	38	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					7900	7904		10.1038/sj.onc.1206717	http://dx.doi.org/10.1038/sj.onc.1206717			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970737				2022-12-25	WOS:000185388200004
J	Nath, N; Wang, S; Betts, V; Knudsen, E; Chellappan, S				Nath, N; Wang, S; Betts, V; Knudsen, E; Chellappan, S			Apoptotic and mitogenic stimuli inactivate Rb by differential utilization of p38 and cyclin-dependent kinases	ONCOGENE			English	Article						Fas; p38; E2F1; cyclins; cdk	S-PHASE ENTRY; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; HISTONE DEACETYLASE; CELL-PROLIFERATION; RB/E2F PATHWAY; E2F PROTEINS; EXPRESSION; ACTIVATION; BINDING	Inactivation of the retinoblastoma (Rb) tumor suppressor protein is essential for the G1/S transition during mammalian cell cycle progression. Although Rb is inactivated by phosphorylation by cyclins D and E and their associated kinases during cell cycle progression, we find that Rb is inactivated upon apoptotic stimulation by Fas through the mediation of p38 kinase, independent of cyclins and cyclin-dependent kinases (cdks). Inactivation by p38 kinase coincided with increased phosphorylation of Rb leading to dissociation of E2F and increased transcriptional activity; such p38-mediated changes in Rb function occurred only during Fas stimulation but not mitogenic progression. p38 kinase targets Rb preferentially and had minimal effects on p107 and had no effect on p130 function. We also find that phosphorylation site mutants of Rb (PSM7LP and PSM9-Rb) that cannot be inactivated by cdks can be targeted by Fas and p38 kinase, suggesting that Rb inactivation by these kinases is biochemically and functionally distinct. It appears that Rb inactivation is achieved by different kinase cascades in response to mitogenic and apoptotic signals.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Chellappan, S (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Chellasp@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [R01CA063136] Funding Source: NIH RePORTER; NCI NIH HHS [CA63136] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dou QP, 1997, J CELL BIOCHEM, V64, P586; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hou ST, 2000, J NEUROCHEM, V75, P91, DOI 10.1046/j.1471-4159.2000.0750091.x; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nath N, 1999, J IMMUNOL, V162, P5351; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEVINS JR, 1992, SCIENCE, V258, P424; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; Takahashi Y, 2000, GENE DEV, V14, P804; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang HL, 2000, CLIN CANCER RES, V6, P1579	50	32	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5986	5994		10.1038/sj.onc.1206843	http://dx.doi.org/10.1038/sj.onc.1206843			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955077				2022-12-25	WOS:000185137800007
J	Kim, HH; Shin, HS; Kwak, HJ; Ahn, KY; Kim, JH; Lee, HJ; Lee, MS; Lee, ZH; Koh, GY				Kim, HH; Shin, HS; Kwak, HJ; Ahn, KY; Kim, JH; Lee, HJ; Lee, MS; Lee, ZH; Koh, GY			RANKL regulates endothelial cell survival through the phosphatidylinositol 3 '-kinase/Akt signal transduction pathway	FASEB JOURNAL			English	Article						RANK; RANKL; endothelial cells; apoptosis	NF-KAPPA-B; OSTEOPROTEGERIN-LIGAND; OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR; EXPRESSION; APOPTOSIS; AKT; ANGIOGENESIS; CYTOKINE	The maintenance of endothelial integrity is important for prevention of vascular diseases. Several growth factors, such as bFGF and angiopoietin-1, have been shown to suppress endothelial cell apoptosis and thus help to maintain endothelial integrity. Several studies suggested that receptor activator of NF-kappaB (RANK) and its ligand (RANKL) could be involved in endothelial physiology. Using immunofluorescence and reverse transcriptase-polymerse chain reaction, we found that RANK was expressed by endothelial cells, and RANKL was expressed by arterial smooth muscle cells. Furthermore, RANKL suppressed apoptosis of primary cultured endothelial cells. The RANKL-induced survival appeared to be dependent on PI 3'-kinase activity, because wortmannin and LY294002, PI 3'-kinase-specific inhibitors, blocked the RANKL-induced survival effect. RANKL elicited the phosphorylation of the serine-threonine kinase Akt at Ser473 in a PI 3'-kinase-dependent manner. The expression of a dominant-negative form of Akt or pretreatment of Akt-specific inhibitor in endothelial cells reversed the RANKL-induced survival effect. Tumor necrosis factor-alpha, which causes endothelial cell apoptosis, induced endothelial cells to express osteoprotegerin, a decoy receptor that inhibits RANK-RANKL signaling. These findings indicate that RANK, in response to the paracrine stimulus of RANKL, may play an important role in maintaining endothelial cell integrity through the PI 3'-kinase/Akt signal transduction pathway.	Chosun Univ, Natl Res Lab Bone Metab, Kwangju 501759, South Korea; Seoul Natl Univ, Sch Dent, Dept Cell & Dev Biol, Seoul 110749, South Korea; Pohang Univ Sci & Technol, Natl Creat Res Initiat Ctr Endothelial Cells, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Chonnam Natl Univ, Res Inst Med Sci, Kwangju 501190, South Korea; Chosun Univ, Sch Dent, Kwangju 501759, South Korea	Chosun University; Seoul National University (SNU); Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Chonnam National University; Chosun University	Lee, ZH (corresponding author), Chosun Univ, Natl Res Lab Bone Metab, Kwangju 501759, South Korea.	jhblee@mail.chosun.ac.kr; gykoh@postech.ac.kr	Kim, Juhyun/AAD-6817-2019; Koh, Gou Young/C-1615-2011	Kim, Juhyun/0000-0002-3098-5010; 				BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Cines DB, 1998, BLOOD, V91, P3527; Collin-Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; Ishida A, 2002, J BIOL CHEM, V277, P26217, DOI 10.1074/jbc.M111093200; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim I, 2001, FASEB J, V15, P126, DOI 10.1096/fj.01-0556fje; Kim I, 2001, CARDIOVASC RES, V49, P872, DOI 10.1016/S0008-6363(00)00295-9; Kim YM, 2002, J BIOL CHEM, V277, P6799, DOI 10.1074/jbc.M109434200; Kwak HJ, 2000, CIRCULATION, V101, P2317, DOI 10.1161/01.CIR.101.19.2317; Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002-9440(10)64556-7; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee S, 2003, FASEB J, V17, pA326, DOI 10.1096/fj.02-0570fje; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Stefanec T, 2000, CHEST, V117, P841, DOI 10.1378/chest.117.3.841; Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; Warren JB, 1990, ENDOTHELIUM INTRO CU; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567	29	63	68	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2163	+		10.1096/fj.03-0215fje	http://dx.doi.org/10.1096/fj.03-0215fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500543				2022-12-25	WOS:000185925100006
J	Ishii, H; Zanesi, N; Vecchione, A; Trapasso, F; Yendamuri, S; Sarti, M; Baffa, R; During, MJ; Huebner, K; Fong, LYY; Croce, CM				Ishii, H; Zanesi, N; Vecchione, A; Trapasso, F; Yendamuri, S; Sarti, M; Baffa, R; During, MJ; Huebner, K; Fong, LYY; Croce, CM			Regression of upper gastric cancer in mice by FHIT gene delivery	FASEB JOURNAL			English	Article						NMBA; FHIT viruses; forestomach; tumor reversal; Bcl2-Bax	TUMOR-DEVELOPMENT; LUNG-CANCER; APOPTOSIS; EXPRESSION; THERAPY	Fhit expression is reduced in most cancers, and Fhit replacement by FHIT expression viruses in lung, esophageal, pancreatic, and cervical cancers induces apoptosis in the cancer cells. Mice carrying one or two inactivated Fhit alleles are hypersensitive to development of N-nitrosomethylbenzylamine (NMBA)-induced forestomach tumors. In the present study, we investigated the kinetics and mechanism of tumor reversal and intervention by oral delivery of FHIT expression viruses. Tumor analysis showed that: a) by 37 days post-NMBA, control mice showed similar to7 tumors and by 84 days similar to10 tumors/forestomach; b) mice receiving FHIT virus at 2 or 42 days post-NMBA showed significantly reduced tumor burdens; c) Fhit was still expressed at 82 days postinfection; d) control viral infection had no effect on tumor development; and e) reduced Bcl2, increased Bax expression, and increased TUNEL-positive apoptotic nuclei characterized the restored epithelia of FHIT transduced forestomachs. Thus, FHIT viral gene delivery prevents or retards development of carcinogen-induced forestomach tumors and reverses development of established tumors by 60 - 70% through an apoptotic pathway. This dramatic reduction in tumor burden emphasizes the efficacy of targeting the FHIT apoptotic pathway for tumor eradication.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, CNS, Gene Therapy Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Croce, CM (corresponding author), BLSB, Room 1050,233 S 10th St, Philadelphia, PA 19107 USA.	C_Croce@lacjci.tju.edu	Young, Richard A/F-6495-2012; During, Matthew/AAC-1388-2020	Young, Richard A/0000-0001-8855-8647; Vecchione, Andrea/0000-0002-5497-6856; Yendamuri, Sai/0000-0001-6654-3487; Fong, Louise/0000-0001-7654-7035				Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Dumon KR, 2001, CANCER RES, V61, P4827; During MJ, 2000, SCIENCE, V287, P1453, DOI 10.1126/science.287.5457.1453; During MJ, 1998, NAT MED, V4, P1131, DOI 10.1038/2625; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Grimm D, 1998, HUM GENE THER, V9, P2745, DOI 10.1089/hum.1998.9.18-2745; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Ishii H, 2001, CANCER RES, V61, P1578; Ji L, 1999, CANCER RES, V59, P3333; Mori M, 2000, CANCER RES, V60, P1177; Ramesh R, 2001, MOL THER, V3, P337, DOI 10.1006/mthe.2001.0266; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1998, CANCER RES, V58, P5032; Tseng JE, 1999, CANCER RES, V59, P4798; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898	16	47	55	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1768	+		10.1096/fj.03-0241fje	http://dx.doi.org/10.1096/fj.03-0241fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958204				2022-12-25	WOS:000184471600031
J	Miyanari, Y; Hijikata, M; Yamaji, M; Hosaka, M; Takahashi, H; Shimotohno, K				Miyanari, Y; Hijikata, M; Yamaji, M; Hosaka, M; Takahashi, H; Shimotohno, K			Hepatitis C virus non-structural proteins in the probable membranous compartment function in viral genome replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; HEPATOCELLULAR-CARCINOMA; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; ION-CHANNEL; P7 PROTEIN; NON-A; IDENTIFICATION; ASSOCIATION; EXPRESSION	The molecular mechanism of hepatitis C virus(HCV) RNA replication is still unknown. Recently, a cell culture system in which the HCV subgenomic replicon is efficiently replicated and maintained for a long period in Huh-7 cells has been established. Taking advantage of this replicon system, we detected the activity to synthesize the subgenomic RNA in the digitonin-permeabilized replicon cells. To elucidate how and where this viral RNA replicates in the cells, we monitored the activity for HCV RNA synthesis in the permeabilized replicon cells under several conditions. We obtained results suggesting that HCV replication complexes functioning to synthesize the replicon RNA are protected from access of nuclease and proteinase by possible cellular lipid membranes. We also found that a large part of the replicon RNA, including newly synthesized RNA, was present in such a membranous structure but a large part of each NS protein was not. A small part of each NS protein that was resistant to the proteinase action was shown to contribute sufficiently to the synthesis of HCV subgenomic RNA in the permeabilized replicon cells. These results suggested that a major subcellular site of HCV genome replication is probably compartmentalized by lipid membranes and that only a part of each NS protein forms the active replication complex in the replicon cells.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Kyoto 6068507, Japan	Kyoto University	Hijikata, M (corresponding author), 53 Kawahara Cho,Sakyo Ku, Kyoto 6068507, Japan.	mhijikat@virus.kyoto-u.ac.jp	Yamaji, Masashi/ABA-5267-2020	Yamaji, Masashi/0000-0002-8215-2184				Ali N, 2002, J VIROL, V76, P12001, DOI 10.1128/JVI.76.23.12001-12007.2002; Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Blight KJ, 2003, J VIROL, V77, P3181, DOI 10.1128/JVI.77.5.3181-3190.2003; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; Chen JB, 2003, J VIROL, V77, P2568, DOI 10.1128/JVI.77.4.2568-2577.2003; Chung KM, 2000, J VIROL, V74, P5233, DOI 10.1128/JVI.74.11.5233-5241.2000; Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002; Friebe P, 2001, J VIROL, V75, P12047, DOI 10.1128/JVI.75.24.12047-12057.2001; FRIED MW, 1995, SEMIN LIVER DIS, V15, P82, DOI 10.1055/s-2007-1007265; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Gosert R, 2003, J VIROL, V77, P5487, DOI 10.1128/JVI.77.9.5487-5492.2003; Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Griffin SDC, 2003, FEBS LETT, V535, P34, DOI 10.1016/S0014-5793(02)03851-6; Hagiwara Y, 2003, EMBO J, V22, P344, DOI 10.1093/emboj/cdg033; Hardy RW, 2003, J VIROL, V77, P2029, DOI 10.1128/JVI.77.3.2029-2037.2003; HIJIKATA M, 1990, J VIROL, V64, P4632, DOI 10.1128/JVI.64.10.4632-4639.1990; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Ikeda M, 2002, J VIROL, V76, P2997, DOI 10.1128/JVI.76.6.2997-3006.2002; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Kishine H, 2002, BIOCHEM BIOPH RES CO, V293, P993, DOI 10.1016/S0006-291X(02)00342-X; Krieger N, 2001, J VIROL, V75, P4614, DOI 10.1128/JVI.75.10.4614-4624.2001; Lai VCH, 2003, J VIROL, V77, P2295, DOI 10.1128/JVI.77.3.2295-2300.2003; LIANG TJ, 1993, HEPATOLOGY, V18, P1326, DOI 10.1016/0270-9139(93)90219-D; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 2003, J VIROL, V77, P3007, DOI 10.1128/JVI.77.5.3007-3019.2003; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; MIZUSHIMA H, 1994, J VIROL, V68, P2731, DOI 10.1128/JVI.68.4.2731-2734.1994; Oh JW, 1999, J VIROL, V73, P7694, DOI 10.1128/JVI.73.9.7694-7702.1999; Pavlovic D, 2003, P NATL ACAD SCI USA, V100, P6104, DOI 10.1073/pnas.1031527100; Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999; PFEIFER U, 1980, VIRCHOWS ARCH B, V33, P233, DOI 10.1007/BF02899184; Reinisch KM, 2000, NATURE, V404, P960, DOI 10.1038/35010041; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmidt-Mende J, 2001, J BIOL CHEM, V276, P44052, DOI 10.1074/jbc.M103358200; Schwartz M, 2002, MOL CELL, V9, P505, DOI 10.1016/S1097-2765(02)00474-4; Shi ST, 2003, J VIROL, V77, P4160, DOI 10.1128/JVI.77.7.4160-4168.2003; Shimotohno K, 1995, INTERVIROLOGY, V38, P162, DOI 10.1159/000150427; Shirota Y, 2002, J BIOL CHEM, V277, P11149, DOI 10.1074/jbc.M111392200; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; TANAKA K, 1991, CANCER RES, V51, P2842; Tanaka T, 1996, J VIROL, V70, P3307, DOI 10.1128/JVI.70.5.3307-3312.1996; TANJI Y, 1995, J VIROL, V69, P1575, DOI 10.1128/JVI.69.3.1575-1581.1995; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; Westaway EG, 1997, J VIROL, V71, P6650, DOI 10.1128/JVI.71.9.6650-6661.1997; Yi MK, 2003, J VIROL, V77, P3557, DOI 10.1128/JVI.77.6.3557-3568.2003; Yuan ZH, 1997, BIOCHEM BIOPH RES CO, V232, P231, DOI 10.1006/bbrc.1997.6249	54	121	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50301	50308		10.1074/jbc.M305684200	http://dx.doi.org/10.1074/jbc.M305684200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	12963739	hybrid			2022-12-25	WOS:000187068200078
J	Fakruddin, JM; Laurence, J				Fakruddin, JM; Laurence, J			HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-INDUCED ARTHRITIS; TUMOR-NECROSIS-FACTOR; BONE-MINERAL DENSITY; DIFFERENTIATION FACTOR; PERIPHERAL-BLOOD; INFECTED PATIENTS; CELL-FORMATION; IN-VIVO; GAMMA; OSTEOPROTEGERIN	Accelerated bone resorption leading to osteopenia and osteoporosis has been noted in human immunodeficiency virus (HIV) seropositive, treatment-naive patients, but it may be greatly increased in incidence in those receiving highly active anti-retroviral therapies that incorporate certain protease inhibitors ( PI). The pathophysiology of these processes is unclear. We have documented the induction of the primary cytokine responsible for osteoclast differentiation and bone resorption, the receptor activator of nuclear factor kappaB ligand ( RANKL), in T cells exposed to soluble HIV-1 envelope glycoprotein gp120. Using a murine osteoclast precursor cell line as well as primary human osteoclast precursors, we demonstrate that pharmacologic levels of two PIs that are linked clinically to osteopenia, ritonavir and saquinavir, abrogate a physiological block to RANKL activity, interferon-gamma-mediated degradation of the RANKL signaling adapter protein, TRAF6 ( tumor necrosis factor receptor-associated protein 6) in proteasomes. In contrast, indinavir and nelfinavir, PIs that may promote or stabilize bone formation in vivo, had no impact on this system. These findings offer a molecular basis for the acceleration of bone resorption by certain PIs and provide the first example of clinically useful drugs that can interfere with the cross-talk between RANKL and interferon-gamma via the proteasome. They also suggest a novel therapeutic approach to HIV osteopenia through modulation of these two molecules.	Cornell Univ, Weill Med Coll, Lab AIDS Virus Res, Dept Med, New York, NY 10021 USA	Cornell University	Laurence, J (corresponding author), Cornell Univ, Weill Med Coll, Lab AIDS Virus Res, Dept Med, 411 E 69th St, New York, NY 10021 USA.	jlaurenc@med.cornell.edu						AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; Andre P, 1998, P NATL ACAD SCI USA, V95, P13120, DOI 10.1073/pnas.95.22.13120; Bailer RT, 1999, J IMMUNOL, V162, P7534; Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348; Bello I, 1998, BIOTHERAPY, V11, P53, DOI 10.1023/A:1008087100315; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; CHEN SA, 1990, J INTERFERON RES S1, V10, P116; Chikatsu N, 2000, BIOCHEM BIOPH RES CO, V267, P632, DOI 10.1006/bbrc.1999.2008; CLOUSE KA, 1991, J IMMUNOL, V147, P2892; Crombie R, 1998, J EXP MED, V187, P25, DOI 10.1084/jem.187.1.25; Faust J, 1999, J CELL BIOCHEM, V72, P67, DOI 10.1002/(SICI)1097-4644(19990101)72:1<67::AID-JCB8>3.0.CO;2-A; Gaedicke S, 2002, CANCER RES, V62, P6901; HOY J, 2000, 7 C RETR OPP INF SAN; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; Jain RG, 2002, J BIOL CHEM, V277, P19247, DOI 10.1074/jbc.C200069200; Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574; Knobel H, 2001, AIDS, V15, P807, DOI 10.1097/00002030-200104130-00022; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; LAU AS, 1988, J CLIN INVEST, V82, P1415, DOI 10.1172/JCI113746; Lawal A, 2001, AIDS, V15, P278, DOI 10.1097/00002030-200101260-00022; Ledru E, 2000, BLOOD, V95, P3191, DOI 10.1182/blood.V95.10.3191.010k10_3191_3198; Madyastha PR, 2000, J INTERF CYTOK RES, V20, P645, DOI 10.1089/107999000414826; MANN GN, 1994, ENDOCRINOLOGY, V135, P1077, DOI 10.1210/en.135.3.1077; ManourySchwartz B, 1997, J IMMUNOL, V158, P5501; Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586; MCGOWAN I, 2001, 8 C RETR OPP INF CHI; Mondy K, 2003, CLIN INFECT DIS, V36, P482, DOI 10.1086/367569; Mora S, 2001, AIDS, V15, P1823, DOI 10.1097/00002030-200109280-00011; MURRAY HW, 1988, NEW ENGL J MED, V318, P1538, DOI 10.1056/NEJM198806093182312; NEGREDO E, 2001, 8 C RETR OPP INF CHI; Nolan D, 2001, AIDS, V15, P1275, DOI 10.1097/00002030-200107060-00009; Pajonk F, 2002, CANCER RES, V62, P5230; Popik W, 1998, J VIROL, V72, P6406, DOI 10.1128/JVI.72.8.6406-6413.1998; Reuben JM, 2002, J ALLERGY CLIN IMMUN, V110, P255, DOI 10.1067/mai.2002.125979; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; ROSSOL S, 1989, J INFECT DIS, V159, P815, DOI 10.1093/infdis/159.5.815; SATO K, 1992, CANCER RES, V52, P444; Schmidtke G, 1999, J BIOL CHEM, V274, P35734, DOI 10.1074/jbc.274.50.35734; Sereti I, 2001, AIDS, V15, P1765, DOI 10.1097/00002030-200109280-00004; SERRANO S, 1995, BONE, V16, P185, DOI 10.1016/8756-3282(94)00028-X; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030-200003100-00005; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Thomas J, 2003, JAIDS-J ACQ IMM DEF, V33, P281, DOI 10.1097/00126334-200307010-00001; Vermeire K, 1997, J IMMUNOL, V158, P5507; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	51	126	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48251	48258		10.1074/jbc.M304676200	http://dx.doi.org/10.1074/jbc.M304676200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12975380	hybrid			2022-12-25	WOS:000186731400109
J	Guo, J; Lemire, BD				Guo, J; Lemire, BD			The ubiquinone-binding site of the Saccharomyces cerevisiae succinate-ubiquinone oxidoreductase is a source of superoxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL RESPIRATORY-CHAIN; QUINOL-FUMARATE REDUCTASE; OXYGEN-FREE RADICALS; CYTOCHROME BC(1) COMPLEX; ESCHERICHIA-COLI; WOLINELLA-SUCCINOGENES; SPECIES GENERATION; ANCHOR SUBUNIT; DEHYDROGENASE; DOMAIN	The mitochondrial succinate dehydrogenase (SDH) is a tetrameric iron-sulfur flavoprotein of the Krebs cycle and of the respiratory chain. A number of mutations in human SDH genes are responsible for the development of paragangliomas, cancers of the head and neck region. The mev-1 mutation in the Caenorhabditis elegans gene encoding the homolog of the SDHC subunit results in premature aging and hypersensitivity to oxidative stress. It also increases the production of superoxide radicals by the enzyme. In this work, we used the yeast succinate dehydrogenase to investigate the molecular and catalytic effects of paraganglioma- and mev-1-like mutations. We mutated Pro-190 of the yeast Sdh2p subunit to Gln (P190Q) and recreated the C. elegans mev-1 mutation by converting Ser-94 in the Sdh3p subunit into a glutamate residue (S94E). The P190Q and S94E mutants have reduced succinate-ubiquinone oxidoreductase activities and are hypersensitive to oxygen and paraquat. Although the mutant enzymes have lower turnover numbers for ubiquinol reduction, larger fractions of the remaining activities are diverted toward superoxide production. The P190Q and S94E mutations are located near the proximal ubiquinone-binding site, suggesting that the superoxide radicals may originate from a ubisemiquinone intermediate formed at this site during the catalytic cycle. We suggest that certain mutations in SDH can make it a significant source of superoxide production in mitochondria, which may contribute directly to disease progression. Our data also challenge the dogma that superoxide production by SDH is a flavin-mediated event rather than a quinone-mediated one.	Univ Alberta, Dept Biochem, Canadian Inst Hlth, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada	University of Alberta	Lemire, BD (corresponding author), Univ Alberta, Dept Biochem, Canadian Inst Hlth, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada.							Ackrell B A, 1978, Methods Enzymol, V53, P466; Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; Ackrell BAC, 2002, MOL ASPECTS MED, V23, P369, DOI 10.1016/S0098-2997(02)00012-2; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Bakker BM, 2001, FEMS MICROBIOL REV, V25, P15, DOI 10.1016/S0168-6445(00)00039-5; Baysal BE, 2002, J MED GENET, V39, P178, DOI 10.1136/jmg.39.3.178; Baysal BE, 2002, J MED GENET, V39, P617, DOI 10.1136/jmg.39.9.617; Betarbet R, 2002, BIOESSAYS, V24, P308, DOI 10.1002/bies.10067; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; Brasseur G, 1997, EUR J BIOCHEM, V246, P103, DOI 10.1111/j.1432-1033.1997.t01-1-00103.x; Bruel C, 1996, J BIOENERG BIOMEMBR, V28, P59; BULLIS BL, 1994, J BIOL CHEM, V269, P6543; CECCHINI G, 1995, J BACTERIOL, V177, P4587, DOI 10.1128/jb.177.16.4587-4592.1995; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Hagerhall C, 1999, J BIOL CHEM, V274, P26157, DOI 10.1074/jbc.274.37.26157; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Iverson TM, 2002, J BIOL CHEM, V277, P16124, DOI 10.1074/jbc.M200815200; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Lancaster CRD, 2001, EUR J BIOCHEM, V268, P1820, DOI 10.1046/j.1432-1327.2001.02053.x; Lemire BD, 2002, BBA-BIOENERGETICS, V1553, P102, DOI 10.1016/S0005-2728(01)00229-8; Meeusen S, 1999, J CELL BIOL, V145, P291, DOI 10.1083/jcb.145.2.291; Messner KR, 2002, J BIOL CHEM, V277, P42563, DOI 10.1074/jbc.M204958200; Oyedotun KS, 1999, FEBS LETT, V442, P203, DOI 10.1016/S0014-5793(98)01657-3; Oyedotun KS, 1999, BBA-BIOENERGETICS, V1411, P170, DOI 10.1016/S0005-2728(99)00040-7; Oyedotun KS, 2001, J BIOL CHEM, V276, P16936, DOI 10.1074/jbc.M100184200; Oyedotun KS, 1999, J BIOL CHEM, V274, P23956, DOI 10.1074/jbc.274.34.23956; Oyedotun KS, 1997, J BIOL CHEM, V272, P31382, DOI 10.1074/jbc.272.50.31382; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Rich P, 1999, BIOCHEM SOC T, V27, P561, DOI 10.1042/bst0270561; RICKWOOD D, 1988, YEAST PRACTICAL APPR, P185; Robinson BH, 1998, BBA-BIOENERGETICS, V1364, P271, DOI 10.1016/S0005-2728(98)00033-4; Robinson KM, 1995, METHOD ENZYMOL, V260, P34, DOI 10.1016/0076-6879(95)60128-7; Rustin P, 2002, EUR J HUM GENET, V10, P289, DOI 10.1038/sj.ejhg.5200793; Rustin P, 2002, BBA-BIOENERGETICS, V1553, P117, DOI 10.1016/S0005-2728(01)00228-6; RUZICKA FJ, 1975, P NATL ACAD SCI USA, V72, P2886, DOI 10.1073/pnas.72.8.2886; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Senoo-Matsuda N, 2001, J BIOL CHEM, V276, P41553, DOI 10.1074/jbc.M104718200; Seo BB, 2002, MOL THER, V6, P336, DOI 10.1006/mthe.2002.0674; SINGER TP, 1965, FLAVINS FLAVOPROTEIN, V1, P391; Yanase S, 2002, MECH AGEING DEV, V123, P1579, DOI 10.1016/S0047-6374(02)00093-3; Yang XD, 1998, J BIOL CHEM, V273, P31916, DOI 10.1074/jbc.273.48.31916; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605	50	82	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47629	47635		10.1074/jbc.M306312200	http://dx.doi.org/10.1074/jbc.M306312200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13129931	hybrid			2022-12-25	WOS:000186731400036
J	Kasparkova, J; Novakova, O; Marini, V; Najajreh, Y; Gibson, D; Perez, JM; Brabec, V				Kasparkova, J; Novakova, O; Marini, V; Najajreh, Y; Gibson, D; Perez, JM; Brabec, V			Activation of trans geometry in bifunctional mononuclear platinum complexes by a piperidine ligand - Mechanistic studies on antitumor action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; INTERSTRAND CROSS-LINKS; CISPLATIN-DNA ADDUCTS; GROUP DOMAIN PROTEINS; ISOMERIZATION REACTION; RECOGNITION; BINDING; CIS-DIAMMINEDICHLOROPLATINUM(II); TRANS-DIAMMINEDICHLOROPLATINUM(II); CONFORMATION	A paradigm for the structure-pharmacological activity relationship of bifunctional platinum antitumor drugs is that the trans isomer of antitumor cisplatin ( transplatin) is clinically ineffective. To this end, however, several new complexes of the trans structure have been identified that exhibit cytotoxicity in tumor cells that is even better than that of the analogous cis isomers. We reported recently ( Kasparkova, J., Marini, V., Najajreh, Y., Gibson, D., and Brabec, V. (2003) Biochemistry 42, 6321 - 6332) that the replacement of one ammine ligand by the heterocyclic ligand, such as piperidine, piperazine, or 4-picoline in the molecule of transplatin resulted in a radical enhancement of its cytotoxicity. We examined oligodeoxyribonucleotide duplexes bearing a site-specific cross- link of the transplatin analogue containing the piperidine ligand by biochemical methods. The results indicate that in contrast to transplatin, trans-(PtCl2(NH3)(piperidine)) forms stable 1,3-intrastrand cross- links in double-helical DNA that distort DNA and are not readily removed from DNA by nucleotide excision repair system. Hence, the intrastrand cross-links of trans-(PtCl2(NH3)(piperidine)) could persist for a sufficiently long time, potentiating its toxicity toward tumor cells. trans-(PtCl2(NH3)(piperidine)) also forms in DNA minor interstrand cross-links that are similar to those of transplatin so that these adducts appear less likely candidates for genotoxic lesion responsible for antitumor effects of trans-(PtCl2(NH3)( piperidine)). Hence, the role of structurally unique intrastrand cross- links in the antitumor effects of transplatin analogues in which one ammine group is replaced by a heterocyclic ligand may predominate.	Acad Sci Czech Republ, Inst Biophys, CZ-61265 Brno, Czech Republic; Hebrew Univ Jerusalem, Sch Pharm, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, David R Bloom Ctr Pharm, IL-91120 Jerusalem, Israel; Univ Autonoma Madrid, Fac Ciencias, Dept Quim Inorgan, E-28049 Madrid, Spain	Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Autonomous University of Madrid	Kasparkova, J (corresponding author), Acad Sci Czech Republ, Inst Biophys, CZ-61265 Brno, Czech Republic.	jana@ibp.cz	Palomeque, María Victoria Marini/L-7480-2017; novakova, olga/H-1938-2014; Najajreh, Yousef/AAC-7498-2019; Brabec, Viktor/H-1946-2014	Najajreh, Yousef/0000-0002-0075-2726; Brabec, Viktor/0000-0002-8233-1393; Novakova, Olga/0000-0001-8653-4836				Alvarez-Valdes A, 2002, J MED CHEM, V45, P1835, DOI 10.1021/jm010968l; ANIN MF, 1990, NUCLEIC ACIDS RES, V18, P4395, DOI 10.1093/nar/18.15.4395; BANCROFT DP, 1990, J AM CHEM SOC, V112, P6860, DOI 10.1021/ja00175a020; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BOUDVILLAIN M, 1995, NUCLEIC ACIDS RES, V23, P2381, DOI 10.1093/nar/23.13.2381; BRABEC V, 1993, P NATL ACAD SCI USA, V90, P5345, DOI 10.1073/pnas.90.11.5345; BRABEC V, 1993, BIOCHEMISTRY-US, V32, P11676, DOI 10.1021/bi00094a025; Brabec V, 2000, J BIOL INORG CHEM, V5, P364, DOI 10.1007/PL00010665; BRABEC V, 1992, BIOCHEMISTRY-US, V31, P12397, DOI 10.1021/bi00164a014; Brabec V, 2002, PROG NUCLEIC ACID RE, V71, P1, DOI 10.1016/S0079-6603(02)71040-4; Buschta-Hedayat N, 1999, P NATL ACAD SCI USA, V96, P6090, DOI 10.1073/pnas.96.11.6090; COMESS KM, 1992, BIOCHEMISTRY-US, V31, P3975, DOI 10.1021/bi00131a013; Coste F, 1999, NUCLEIC ACIDS RES, V27, P1837, DOI 10.1093/nar/27.8.1837; DALBIES R, 1995, NUCLEIC ACIDS RES, V23, P949, DOI 10.1093/nar/23.6.949; DALBIES R, 1994, P NATL ACAD SCI USA, V91, P8147, DOI 10.1073/pnas.91.17.8147; Dunham SU, 1997, BIOCHEMISTRY-US, V36, P11428, DOI 10.1021/bi9709452; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; Farrell N, 1996, MET IONS BIOL SYST, V32, P603; FARRELL N, 1992, CANCER RES, V52, P5065; He Q, 2000, P NATL ACAD SCI USA, V97, P5768, DOI 10.1073/pnas.100108697; He Q, 2000, BIOCHEMISTRY-US, V39, P14426, DOI 10.1021/bi001700j; Hermanson-Miller IL, 2002, BIOCHEMISTRY-US, V41, P2402, DOI 10.1021/bi0112863; Highley MS, 2000, CANC DRUG DISC DEV, V7, P171; HUANG HF, 1995, SCIENCE, V270, P1842, DOI 10.1126/science.270.5243.1842; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Johnson N.P., 1989, PROG CLIN BIOCH MED, V10, P1, DOI [DOI 10.1007/978-3-642-74760-1, 10.1007/978-3-642-74760-1_1, DOI 10.1007/978-3-642-74760-1_1]; JONES SL, 1994, INT J CANCER, V59, P388, DOI 10.1002/ijc.2910590317; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P1, DOI 10.1016/s0027-5107(01)00142-7; KASPARKOVA J, 1995, BIOCHEMISTRY-US, V34, P12379, DOI 10.1021/bi00038a035; Kasparkova J, 1996, BIOCHEMISTRY-US, V35, P16705, DOI 10.1021/bi961160j; Kasparkova J, 2003, BIOCHEMISTRY-US, V42, P6321, DOI 10.1021/bi0342315; Kasparkova J, 2003, BIOCHEMISTRY-US, V42, P792, DOI 10.1021/bi026614t; Kasparkova J, 2002, J BIOL CHEM, V277, P48076, DOI 10.1074/jbc.M208016200; Kasparkova J, 2000, J BIOL CHEM, V275, P15789, DOI 10.1074/jbc.M000777200; KASPARKOVA J, 2003, IN PRESS CHEM RES TO; Khazanov E, 2002, J MED CHEM, V45, P5196, DOI 10.1021/jm020817y; Koberle B, 1999, CURR BIOL, V9, P273, DOI 10.1016/S0960-9822(99)80118-3; Kostrhunova H, 2000, BIOCHEMISTRY-US, V39, P12639, DOI 10.1021/bi000710h; Lam WC, 1999, BIOCHEMISTRY-US, V38, P2661, DOI 10.1021/bi9820762; LEMAIRE MA, 1991, P NATL ACAD SCI USA, V88, P1982, DOI 10.1073/pnas.88.5.1982; Leng M, 2000, MOL PHARMACOL, V58, P1525, DOI 10.1124/mol.58.6.1525; Leng M, 2000, CANC DRUG DISC DEV, V7, P63; Li MJ, 1999, INT J ONCOL, V15, P1177; Lokich J, 1998, ANN ONCOL, V9, P13, DOI 10.1023/A:1008215213739; Lone S, 2003, BIOCHEMISTRY-US, V42, P3826, DOI 10.1021/bi027297t; Loskotova H, 1999, EUR J BIOCHEM, V266, P392, DOI 10.1046/j.1432-1327.1999.00866.x; Malina J, 2000, BIOPHYS J, V78, P2008, DOI 10.1016/S0006-3495(00)76748-8; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; Missura M, 2001, EMBO J, V20, P3554, DOI 10.1093/emboj/20.13.3554; Moggs JG, 1997, NUCLEIC ACIDS RES, V25, P480, DOI 10.1093/nar/25.3.480; Najajreh Y, 2002, J MED CHEM, V45, P5189, DOI 10.1021/jm0201969; Nielsen P E, 1990, J Mol Recognit, V3, P1, DOI 10.1002/jmr.300030102; O'Dwyer P. J., 1999, CISPLATIN CHEM BIOCH, P31; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Paquet F, 1999, NUCLEIC ACIDS RES, V27, P4261, DOI 10.1093/nar/27.21.4261; Patrick SM, 1999, J BIOL CHEM, V274, P14972, DOI 10.1074/jbc.274.21.14972; Perez JM, 2000, CRIT REV ONCOL HEMAT, V35, P109, DOI 10.1016/S1040-8428(00)00053-6; Reardon JT, 1999, CANCER RES, V59, P3968; REARDON JT, 1998, ADV DNA DAMAGE REPAI, P377; RICE JA, 1988, P NATL ACAD SCI USA, V85, P4158, DOI 10.1073/pnas.85.12.4158; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Suo ZC, 1999, BIOCHEMISTRY-US, V38, P715, DOI 10.1021/bi981854n; Suo ZC, 1998, J BIOL CHEM, V273, P27259, DOI 10.1074/jbc.273.42.27259; Wakasugi M, 1999, J BIOL CHEM, V274, P18759, DOI 10.1074/jbc.274.26.18759; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Zakovska A, 1998, EUR J BIOCHEM, V254, P547, DOI 10.1046/j.1432-1327.1998.2540547.x; Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+; ZAMBLE DB, 1999, CISPLATIN CHEM BIOCH, P73; Zehnulova J, 2001, J BIOL CHEM, V276, P22191, DOI 10.1074/jbc.M103118200	76	60	61	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47516	47525		10.1074/jbc.M304720200	http://dx.doi.org/10.1074/jbc.M304720200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12970368	hybrid			2022-12-25	WOS:000186731400023
J	Willhite, DC; Cover, TL; Blanke, SR				Willhite, DC; Cover, TL; Blanke, SR			Cellular vacuolation and mitochondrial cytochrome c release are independent outcomes of Helicobacter pylori vacuolating cytotoxin activity that are each dependent on membrane channel formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC EPITHELIAL APOPTOSIS; TOXIN VACA; MAMMALIAN-CELLS; PLASMA-MEMBRANE; MOUSE MODEL; INFECTION; DISEASE; ACID; PROTEIN; BINDING	Helicobacter pylori vacuolating toxin (VacA) is a secreted toxin that is reported to produce multiple effects on mammalian cells. In this study, we explored the relationship between VacA-induced cellular vacuolation and VacA-induced cytochrome c release from mitochondria. Within intoxicated cells, vacuolation precedes cytochrome c release and occurs at lower VacA concentrations, indicating that cellular vacuolation is not a downstream consequence of cytochrome c release. Conversely, bafilomycin A1 blocks VacA-induced vacuolation but not VacA-induced cytochrome c release, which indicates that cytochrome c release is not a downstream consequence of cellular vacuolation. Acid activation of purified VacA is required for entry of VacA into cells, and correspondingly, acid activation of the toxin is required for both vacuolation and cytochrome c release, which suggests that VacA must enter cells to produce these two effects. Single amino acid substitutions (P9A and G14A) that ablate vacuolating activity and membrane channel-forming activity render VacA unable to induce cytochrome c release. Channel blockers known to inhibit cellular vacuolation and VacA membrane channel activity also inhibit cytochrome c release. These data indicate that cellular vacuolation and mitochondrial cytochrome c release are two independent outcomes of VacA intoxication and that both effects are dependent on the formation of anion-selective membrane channels.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vet Adm Med Ctr, Nashville, TN 37232 USA	University of Houston System; University of Houston; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Blanke, SR (corresponding author), Univ Houston, Dept Biol & Biochem, 369 Sci & Res Bldg 2, Houston, TX 77204 USA.	sblanke@uh.edu	Cover, Timothy/I-3814-2015	Cover, Timothy/0000-0001-8503-002X	NIAID NIH HHS [R01 AI39657, R01 AI45928] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045928, R01AI039657] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blaser M J, 1993, Trends Microbiol, V1, P255, DOI 10.1016/0966-842X(93)90047-U; Bossy-Wetzel E, 2000, METHOD ENZYMOL, V322, P235; CATRENICH CE, 1992, J MED MICROBIOL, V37, P389, DOI 10.1099/00222615-37-6-389; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; COVER TL, 1993, INFECT IMMUN, V61, P1427, DOI 10.1128/IAI.61.4.1427-1431.1993; COVER TL, 1992, J INFECT DIS, V166, P1073, DOI 10.1093/infdis/166.5.1073; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; Cover TL, 2003, CANCER RES, V63, P951; COVER TL, 1992, HUM PATHOL, V23, P1004, DOI 10.1016/0046-8177(92)90261-Z; Cover TL, 1997, J CELL BIOL, V138, P759, DOI 10.1083/jcb.138.4.759; Cover TL, 1996, ADV INTERNAL MED, V41, P85; deBernard M, 1997, MOL MICROBIOL, V26, P665, DOI 10.1046/j.1365-2958.1997.5881952.x; DEBERNARD M, 1995, J BIOL CHEM, V270, P23937, DOI 10.1074/jbc.270.41.23937; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; GHIRA P, 1995, INFECT IMMUN, V63, P4154, DOI 10.1128/IAI.63.10.4154-4160.1995; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Goldstein JC, 2000, ANN NY ACAD SCI, V926, P132; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Houghton J, 2000, J INFECT DIS, V182, P856, DOI 10.1086/315788; Israel DA, 2001, J CLIN INVEST, V107, P611, DOI 10.1172/JCI11450; Jones AD, 2003, J GASTROINTEST SURG, V7, P68, DOI 10.1016/S1091-255X(02)00129-4; Jones NL, 2002, INFECT IMMUN, V70, P2591, DOI 10.1128/IAI.70.5.2591-2597.2002; Jones NL, 1997, AM J PATHOL, V151, P1695; Kuck D, 2001, INFECT IMMUN, V69, P5080, DOI 10.1128/IAI.69.8.5080-5087.2001; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; Mannick EE, 1996, CANCER RES, V56, P3238; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MARSHALL BJ, 1984, LANCET, V1, P1311; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; McClain MS, 2000, MOL MICROBIOL, V37, P433, DOI 10.1046/j.1365-2958.2000.02013.x; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; McClain MS, 2001, J BACTERIOL, V183, P6499, DOI 10.1128/JB.183.22.6499-6508.2001; Molinari M, 1998, BIOCHEM BIOPH RES CO, V248, P334, DOI 10.1006/bbrc.1998.8808; Moss SF, 1996, GUT, V38, P498, DOI 10.1136/gut.38.4.498; Neu B, 2002, AM J PHYSIOL-GASTR L, V283, pG309, DOI 10.1152/ajpgi.00546.2001; Nguyen VQ, 2001, INFECT IMMUN, V69, P543, DOI 10.1128/IAI.69.1.543-546.2001; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; Papini E, 1996, J MED MICROBIOL, V45, P84, DOI 10.1099/00222615-45-2-84; Papini E, 2001, TOXICON, V39, P1757, DOI 10.1016/S0041-0101(01)00162-3; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; Patel HK, 2002, INFECT IMMUN, V70, P4112, DOI 10.1128/IAI.70.8.4112-4123.2002; Peek RM, 1999, CANCER RES, V59, P6124; Peek RM, 2000, GASTROENTEROLOGY, V118, P48, DOI 10.1016/S0016-5085(00)70413-6; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Rudi J, 1998, J CLIN INVEST, V102, P1506, DOI 10.1172/JCI2808; Rudi J, 1998, J CLIN MICROBIOL, V36, P944, DOI 10.1128/JCM.36.4.944-948.1998; Salama NR, 2001, INFECT IMMUN, V69, P730, DOI 10.1128/IAI.69.2.730-736.2001; Shibayama K, 2003, MOL MICROBIOL, V47, P443, DOI 10.1046/j.1365-2958.2003.03305.x; Shirin H, 2003, HELICOBACTER, V8, P66, DOI 10.1046/j.1523-5378.2003.00125.x; Sommi P, 1998, AM J PHYSIOL-GASTR L, V275, pG681, DOI 10.1152/ajpgi.1998.275.4.G681; Szabo I, 1999, EMBO J, V18, P5517, DOI 10.1093/emboj/18.20.5517; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Tombola F, 1999, FEBS LETT, V460, P221, DOI 10.1016/S0014-5793(99)01348-4; Vinion-Dubiel AD, 1999, J BIOL CHEM, V274, P37736, DOI 10.1074/jbc.274.53.37736; Wang TC, 1998, GASTROENTEROLOGY, V114, P675, DOI 10.1016/S0016-5085(98)70581-5; Waterhouse NJ, 2001, METHOD CELL BIOL, V66, P365; Willhite DC, 2002, INFECT IMMUN, V70, P3824, DOI 10.1128/IAI.70.7.3824-3832.2002; WILLHITE DC, 2000, SAAS B BIOCH BIOTECH, V13, P35; Yahiro K, 1999, J BIOL CHEM, V274, P36693, DOI 10.1074/jbc.274.51.36693; Ye D, 2000, INFECT IMMUN, V68, P4354, DOI 10.1128/IAI.68.7.4354-4357.2000; Ye D, 2002, MOL MICROBIOL, V43, P1243, DOI 10.1046/j.1365-2958.2002.02818.x; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277	63	79	83	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48204	48209		10.1074/jbc.M304131200	http://dx.doi.org/10.1074/jbc.M304131200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13129933	hybrid			2022-12-25	WOS:000186731400103
J	El-Mousawi, M; Tchistiakova, L; Yurchenko, L; Pietrzynski, G; Moreno, M; Stanimirovic, D; Ahmad, D; Alakhov, V				El-Mousawi, M; Tchistiakova, L; Yurchenko, L; Pietrzynski, G; Moreno, M; Stanimirovic, D; Ahmad, D; Alakhov, V			A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-INDUCED ANGIOGENESIS; FACTOR VEGF; TYROSINE KINASE; ANGSTROM RESOLUTION; SIGNAL-TRANSDUCTION; TUMOR ANGIOGENESIS; CRYSTAL-STRUCTURE; EXPRESSION; BINDING; CELLS	Vascular endothelial growth factor ( VEGF) is known to play a predominant role in tumor angiogenesis and metastasis formation that is mediated by its interactions with two tyrosine kinase receptors, VEGFRI (Flt-1) and VEGFRII (KDR). Inhibition of VEGF-dependent events in tumor tissues is known to enhance apoptosis and to suppress tumor growth. A novel peptide, SP5.2, which selectively binds Flt-1 and inhibits a broad range of VEGF-mediated events, was identified using a phage-display library screening. The fluorescein-labeled SP5.2 specifically bound to VEGF-stimulated primary human cerebral endothelial cells (HCECs), whereas non-stimulated HCECs, as well as human neuroblastoma cells (ShyY) did not show any interaction with the peptide. SP5.2 prevented proliferation of cultured primary human umbilical vein endothelial cells induced by recombinant human VEGF(165) with an IC50 of 5 muM. SP5.2 was also shown to antagonize VEGF- and PLGF-induced, but not basic fibroblast growth factor-induced proliferation of HCECs. In contrast to "scrambled" peptide, SP5.2 was also found to selectively inhibit VEGF- stimulated migration of HCECs. The in vitro analysis of antiangiogenic activity of SP5.2 using a capillary-like tube formation assay showed that VEGF- induced angiogenesis of HCECs grown on Matrigel(TM) was completely inhibited in the presence of 10 muM SP5.2. Further studies demonstrated that SP5.2 prevented VEGF- induced permeability increase in HCECs monolayers. To explore whether SP5.2 can be used as a targeting agent, chemical and recombinant conjugates of SP5.2 with reporter proteins ( peroxidase and beta-galactosidase) were produced. The resulting products showed significant increases (200-fold for SP5.2-beta-gal and 400-fold for SP5.2-peroxidase) in binding affinity to recombinant Flt-1 compared with the original synthetic SP5.2, suggesting that conjugate with therapeutic activity in nanomolar range could potentially be developed based on SP5.2 structure.	Supratek Pharma Inc, Dorval, PQ H9S 1A9, Canada; Wyeth Res, Cambridge, MA 02140 USA; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Inst Natl Rech Sci, Laval, PQ H7V 1B7, Canada	Pfizer; National Research Council Canada; University of Quebec; Institut national de la recherche scientifique (INRS)	Alakhov, V (corresponding author), Supratek Pharma Inc, 215 Bouchard St, Dorval, PQ H9S 1A9, Canada.	valery.alakhov@supratek.com						Achen MG, 1998, INT J EXP PATHOL, V79, P255, DOI 10.1046/j.1365-2613.1998.700404.x; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; BALASS M, 1993, P NATL ACAD SCI USA, V90, P10638, DOI 10.1073/pnas.90.22.10638; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Bisacchi D, 2003, CANCER DETECT PREV, V27, P229, DOI 10.1016/S0361-090X(03)00030-8; Broggini M, 2003, LEUKEMIA, V17, P52, DOI 10.1038/sj.leu.2402788; Cheng N, 2002, MOL CANCER RES, V1, P2; Drevs J, 2000, CANCER RES, V60, P4819; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Ferrara N, 1996, Curr Opin Nephrol Hypertens, V5, P35, DOI 10.1097/00041552-199601000-00008; Ferrieres G, 2000, EUR J BIOCHEM, V267, P1819, DOI 10.1046/j.1432-1327.2000.01184.x; Fischer S, 2002, MICROVASC RES, V63, P70, DOI 10.1006/mvre.2001.2367; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gehlbach P, 2003, HUM GENE THER, V14, P129, DOI 10.1089/104303403321070829; He YL, 1999, MOL ENDOCRINOL, V13, P537, DOI 10.1210/me.13.4.537; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; HOESS R, 1993, GENE, V128, P43, DOI 10.1016/0378-1119(93)90151-R; Hong Deng-Li, 2001, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V9, P268; JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028; JUNGER WG, 1993, J IMMUNOL METHODS, V160, P73, DOI 10.1016/0022-1759(93)90010-5; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kuehne J, 2001, BIOCONJUGATE CHEM, V12, P742, DOI 10.1021/bc010001w; Lee H, 2003, J PHARM SCI-US, V92, P97, DOI 10.1002/jps.10270; Li SW, 2003, CHEM BIOL, V10, P233, DOI 10.1016/S1074-5521(03)00047-4; Matsumoto Y, 2002, J IMMUNOL, V168, P5824, DOI 10.4049/jimmunol.168.11.5824; Mayr-Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756-3282(01)00690-1; Melnyk O, 1996, CANCER RES, V56, P921; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6; Muruganandam A, 1997, FASEB J, V11, P1187, DOI 10.1096/fasebj.11.13.9367354; Partanen TA, 1999, CIRCULATION, V100, P583, DOI 10.1161/01.CIR.100.6.583; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLATE KH, 1994, BRAIN PATHOL, V4, P207, DOI 10.1111/j.1750-3639.1994.tb00835.x; Popkov M, 1998, EUR J BIOCHEM, V251, P155, DOI 10.1046/j.1432-1327.1998.2510155.x; Puduvalli VK, 2000, J NEURO-ONCOL, V50, P189, DOI 10.1023/A:1006469830739; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Schoch HJ, 2002, BRAIN, V125, P2549, DOI 10.1093/brain/awf257; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Sheng Ming, 2003, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V11, P74; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; Shinkaruk S., 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P95, DOI 10.2174/1568011033353452; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; Stanimirovic D, 1996, J CELL PHYSIOL, V169, P455; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; Turetschek K, 2003, EUR J NUCL MED MOL I, V30, P448, DOI 10.1007/s00259-002-1000-5; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang DF, 2000, J BIOL CHEM, V275, P15905, DOI 10.1074/jbc.M001847200; Wang W, 2001, AM J PHYSIOL-HEART C, V280, pH434, DOI 10.1152/ajpheart.2001.280.1.H434; Wedge SR, 2000, ADV EXP MED BIOL, V476, P307; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427; Zachary I, 1998, INT J BIOCHEM CELL B, V30, P1169, DOI 10.1016/S1357-2725(98)00082-X	58	62	66	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46681	46691		10.1074/jbc.M308681200	http://dx.doi.org/10.1074/jbc.M308681200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12954624	hybrid			2022-12-25	WOS:000186569400058
J	Voziyan, PA; Khalifah, RG; Thibaudeau, C; Yildiz, A; Jacob, J; Serianni, AS; Hudson, BG				Voziyan, PA; Khalifah, RG; Thibaudeau, C; Yildiz, A; Jacob, J; Serianni, AS; Hudson, BG			Modification of proteins in vitro by physiological levels of glucose - Pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION REACTIONS; MAILLARD REACTION-PRODUCTS; LOW-DENSITY-LIPOPROTEIN; NONENZYMATIC GLYCATION; DIABETIC-NEPHROPATHY; POST-AMADORI; AGE INHIBITOR; CHEMICAL-MODIFICATION; OXIDATIVE DAMAGE; VASCULAR-DISEASE	Hyperglycemic conditions of diabetes accelerate protein modifications by glucose leading to the accumulation of advanced glycation end- products ( AGEs). We have investigated the conversion of protein- Amadori intermediate to protein- AGE and the mechanism of its inhibition by pyridoxamine ( PM), a potent AGE inhibitor that has been shown to prevent diabetic complications in animal models. During incubation of proteins with physiological diabetic concentrations of glucose, PM prevented the degradation of the protein glycation intermediate identified as fructosyllysine ( Amadori) by C-13 NMR using [ 2-C-13]- enriched glucose. Subsequent removal of glucose and PM led to conversion of protein-Amadori to AGE N-epsilon- carboxymethyllysine ( CML). We utilized this inhibition of post- Amadori reactions by PM to isolate protein- Amadori intermediate and to study the inhibitory effect of PM on its degradation to protein-CML. We first tested the hypothesis that PM blocks Amadori-to- CML conversion by interfering with the catalytic role of redox metal ions that are required for this glycoxidative reaction. Support for this hypothesis was obtained by examining structural analogs of PM in which its known bidentate metal ion binding sites were modified and by determining the effect of endogenous metal ions on PM inhibition. We also tested the alternative hypothesis that the inhibitory mechanism involves formation of covalent adducts between PM and protein-Amadori. However, our C-13 NMR studies demonstrated that PM does not react with the Amadori. Because the mechanism of interference with redox metal catalysis is operative under the conditions closely mimicking the diabetic state, it may contribute significantly to PM efficacy in preventing diabetic complications in vivo. Inhibition of protein- Amadori degradation by PM also provides a simple procedure for the isolation of protein-Amadori intermediate, prepared at physiological levels of glucose for relevancy, to study both the biological effects and the chemistry of post- Amadori pathways of AGE formation.	Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; BioStratum Inc, Durham, NC 27703 USA	Vanderbilt University; Vanderbilt University; University of Notre Dame	Voziyan, PA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol, S-3223 MCN,1161 21st Ave S, Nashville, TN 37232 USA.		Yıldız, Alaattin/AAY-6102-2020	YILDIZ, ALAATTIN/0000-0002-4066-929X; Hudson, Billy/0000-0002-5420-4100	NIDDK NIH HHS [P60 DK 20593, DK 065138] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R01DK065138] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acosta J, 2000, P NATL ACAD SCI USA, V97, P5450, DOI 10.1073/pnas.97.10.5450; AHMED MU, 1986, J BIOL CHEM, V261, P4889; Alderson NL, 2003, KIDNEY INT, V63, P2123, DOI 10.1046/j.1523-1755.2003.00027.x; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Booth AA, 1996, BIOCHEM BIOPH RES CO, V220, P113, DOI 10.1006/bbrc.1996.0366; Booth AA, 1997, J BIOL CHEM, V272, P5430, DOI 10.1074/jbc.272.9.5430; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; BUNN HF, 1978, SCIENCE, V200, P21, DOI 10.1126/science.635569; BUTLER WL, 1979, METHOD ENZYMOL, V56, P505; Castellani RJ, 2001, FREE RADICAL BIO MED, V31, P175, DOI 10.1016/S0891-5849(01)00570-6; CHEN HJC, 1993, J CARBOHYD CHEM, V12, P731; Chen S, 2000, KIDNEY INT, V58, pS40, DOI 10.1046/j.1523-1755.2000.07707.x; COLACO CALS, 1994, NEUROREPORT, V5, P859, DOI 10.1097/00001756-199404000-00001; Cussimanio BL, 2003, BIOPHYS CHEM, V105, P743, DOI 10.1016/S0301-4622(03)00100-5; DAWSON RMC, 1986, DATA BIOMEDICAL RES, P412; Degenhardt TP, 2002, KIDNEY INT, V61, P939, DOI 10.1046/j.1523-1755.2002.00207.x; Degenhardt TR, 2002, J AM SOC NEPHROL, V13, p652A; DUNN JA, 1990, BIOCHEMISTRY-US, V29, P10964, DOI 10.1021/bi00501a014; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; EVANS PJ, 1989, FREE RADICAL RES COM, V7, P55, DOI 10.3109/10715768909088162; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; GUSTAFSON RL, 1957, ARCH BIOCHEM BIOPHYS, V68, P485, DOI 10.1016/0003-9861(57)90379-X; Hawkins CL, 1997, BBA-MOL BASIS DIS, V1360, P84, DOI 10.1016/S0925-4439(96)00069-5; HAYASE F, 1989, J BIOL CHEM, V264, P3758; HAYASHI T, 1986, AMINO CARBONYL REACT, P29; IBERG N, 1986, J BIOL CHEM, V261, P3542; IENAGA K, 1995, CONTRIB NEPHROL, V112, P42; Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550; Imanaga Y, 2000, ATHEROSCLEROSIS, V150, P343, DOI 10.1016/S0021-9150(99)00396-2; ISLAM KN, 1995, J BIOCHEM-TOKYO, V118, P1054, DOI 10.1093/jb/118.5.1054; Khalifah RG, 1996, BIOCHEMISTRY-US, V35, P4645, DOI 10.1021/bi9525942; Khalifah RG, 1999, BIOCHEM BIOPH RES CO, V257, P251, DOI 10.1006/bbrc.1999.0371; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; MARX G, 1986, BIOCHEM J, V236, P397, DOI 10.1042/bj2360397; MCFARLAND KF, 1979, DIABETES, V28, P1011, DOI 10.2337/diabetes.28.11.1011; Metz TO, 2003, J BIOL CHEM, V278, P42012, DOI 10.1074/jbc.M304292200; Misselwitz J, 2002, PEDIATR NEPHROL, V17, P316, DOI 10.1007/s00467-001-0815-9; Monnier VM, 1999, DIABETES, V48, P870, DOI 10.2337/diabetes.48.4.870; Monnier VM, 2001, J CLIN INVEST, V107, P799, DOI 10.1172/JCI12635; Mott JD, 1997, KIDNEY INT, V52, P1302, DOI 10.1038/ki.1997.455; Mukhopadhyay CK, 1996, J BIOL CHEM, V271, P14773, DOI 10.1074/jbc.271.25.14773; Nakamura K, 1997, BIOCHEM BIOPH RES CO, V232, P227, DOI 10.1006/bbrc.1997.6262; NEGLIA CI, 1985, J BIOL CHEM, V260, P5406; Onorato JM, 2000, J BIOL CHEM, V275, P21177, DOI 10.1074/jbc.M003263200; Price DL, 2001, J BIOL CHEM, V276, P48967, DOI 10.1074/jbc.M108196200; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; Requena JR, 1996, NEPHROL DIAL TRANSPL, V11, P48; Saxena AK, 1999, BIOCHEM BIOPH RES CO, V260, P332, DOI 10.1006/bbrc.1999.0898; SELL DR, 1989, J BIOL CHEM, V264, P21597; SMITH PR, 1992, EUR J BIOCHEM, V210, P729, DOI 10.1111/j.1432-1033.1992.tb17474.x; Stitt A, 2002, DIABETES, V51, P2826, DOI 10.2337/diabetes.51.9.2826; Takata I, 1996, BIOCHEM BIOPH RES CO, V219, P243, DOI 10.1006/bbrc.1996.0212; THOMPSON DM, 1980, INORG CHIM A-BIOINOR, V46, P199, DOI 10.1016/S0020-1693(00)84191-2; THORNALLEY P, 1984, BIOCHIM BIOPHYS ACTA, V797, P276, DOI 10.1016/0304-4165(84)90131-4; Thorpe SR, 1996, DRUG AGING, V9, P69, DOI 10.2165/00002512-199609020-00001; Uesugi N, 2001, AM J KIDNEY DIS, V38, P1016, DOI 10.1053/ajkd.2001.28591; Verzijl N, 2000, BIOCHEM J, V350, P381, DOI 10.1042/0264-6021:3500381; Voziyan PA, 2002, J BIOL CHEM, V277, P3397, DOI 10.1074/jbc.M109935200; Wendt T, 2003, J AM SOC NEPHROL, V14, P1383, DOI 10.1097/01.ASN.0000065100.17349.CA; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; Zheng F, 2002, J AM SOC NEPHROL, V13, p534A	64	110	114	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46616	46624		10.1074/jbc.M307155200	http://dx.doi.org/10.1074/jbc.M307155200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12975371	hybrid			2022-12-25	WOS:000186569400049
J	Boulant, S; Becchi, M; Penin, F; Lavergne, JP				Boulant, S; Becchi, M; Penin, F; Lavergne, JP			Unusual multiple recoding events leading to alternative forms of hepatitis C virus core protein from genotype 1b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CODING REGION; EXPRESSION; GENE; RNA; IDENTIFICATION; SUBSTITUTIONS; NOMENCLATURE; TRANSLATION; CLEAVAGE; BINDING	In addition to its involvement in the formation of the capsid shell of the virus particles, the core protein of hepatitis C virus (HCV) is believed to play an important role in the pathogenesis and/or establishment of persistent infection. We describe here alternative forms of genotype 1b HCV core protein identified after purification of various products of core protein segment 1-169 expressed in Escherichia coli and their analysis by proteolysis, mass spectrometry, and amino acid sequencing. These proteins all result from a +1 frameshift at codon 42 (a different position than that previously reported in genotype 1a) and, for some of them, from a rephasing in the normal open reading frame at the termination codon 144 in the +1 open reading frame. To test the relevance of these recoding events in a eukaryotic translational context, the nucleotide sequences surrounding the two shift sites were cloned in the three reading frames into expression vectors, allowing the production of a C-terminally fused green fluorescent protein, and expressed both in a reticulocyte lysate transcription/translation assay and in culture cells. Both recoding events were confirmed in these expression systems, strengthening the hypothesis that they might occur in HCV-infected cells. Moreover, sera from HCV-positive patients of genotype 1a or 1b were shown to react differently against synthetic peptides encoded in the +1 open reading frame. Together, these results indicate the occurrence of distinct recoding events in genotypes 1a and 1b, pointing out genotype-dependent specific features for F protein.	Univ Lyon 1, Lab Bioinformat & RMN Struct, F-69367 Lyon 07, France; Univ Lyon 1, CNRS,UMR 5086, Inst Biol & Chim Prot, Ctr Commun Sequencage, F-69367 Lyon 07, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Lavergne, JP (corresponding author), Univ Lyon 1, Lab Bioinformat & RMN Struct, 7 Passage Vercors, F-69367 Lyon 07, France.	jp.lavergne@ibcp.fr	PENIN, Francois/A-7315-2008; Boulant, Steeve/W-3754-2019	Boulant, Steeve/0000-0001-8614-4993				BRIERLEY I, 1992, J MOL BIOL, V227, P463, DOI 10.1016/0022-2836(92)90901-U; Choi JA, 2003, MOL CELL BIOL, V23, P1489, DOI 10.1128/MCB.23.5.1489-1497.2003; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CORTAY JC, 1994, J BIOL CHEM, V269, P14885; Draper DE, 1998, COLD SPRING HARBOR M, P415; Farabaugh PJ, 1996, ANNU REV GENET, V30, P507, DOI 10.1146/annurev.genet.30.1.507; Farabaugh PJ, 2000, COLD SPRING HARBOR M, V39, P741; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; GRAMSTAT A, 1994, NUCLEIC ACIDS RES, V22, P3911, DOI 10.1093/nar/22.19.3911; HARADA S, 1991, J VIROL, V65, P3015, DOI 10.1128/JVI.65.6.3015-3021.1991; Hussy P, 1996, VIROLOGY, V224, P93, DOI 10.1006/viro.1996.0510; JACKS T, 1987, P NATL ACAD SCI USA, V84, P4298, DOI 10.1073/pnas.84.12.4298; JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; Jolivet M, 1997, Patent application, Patent No. [1015481, EP 1015481]; Jolivet-Reynaud C, 1998, J MED VIROL, V56, P300, DOI 10.1002/(SICI)1096-9071(199812)56:4&lt;300::AID-JMV3&gt;3.0.CO;2-8; Kato N, 2001, ACTA MED OKAYAMA, V55, P133; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; LO SY, 1994, VIROLOGY, V199, P124, DOI 10.1006/viro.1994.1104; LO SY, 1995, VIROLOGY, V213, P455, DOI 10.1006/viro.1995.0018; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; Penin Francois, 2003, Clin Liver Dis, V7, P1, DOI 10.1016/S1089-3261(02)00066-1; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Rijnbrand RCA, 2000, CURR TOP MICROBIOL, V242, P85; Robertson B, 1998, ARCH VIROL, V143, P2493, DOI 10.1007/s007050050479; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Roussel J, 2003, J GEN VIROL, V84, P1751, DOI 10.1099/vir.0.19065-0; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; Shah AA, 2002, BIOINFORMATICS, V18, P1046, DOI 10.1093/bioinformatics/18.8.1046; Tuplin A, 2002, RNA, V8, P824, DOI 10.1017/S1355838202554066; Varaklioti A, 2002, J BIOL CHEM, V277, P17713, DOI 10.1074/jbc.M201722200; Walewski JL, 2002, RNA, V8, P557, DOI 10.1017/S1355838202029023; Walewski JL, 2001, RNA, V7, P710, DOI 10.1017/S1355838201010111; WEISS R B, 1989, New Biologist, V1, P159; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P65; Xu ZM, 2001, EMBO J, V20, P3840, DOI 10.1093/emboj/20.14.3840; Yeh CT, 2000, J GASTROEN HEPATOL, V15, P182, DOI 10.1046/j.1440-1746.2000.02066.x; YELVERTON E, 1994, MOL MICROBIOL, V11, P303, DOI 10.1111/j.1365-2958.1994.tb00310.x	39	76	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45785	45792		10.1074/jbc.M307174200	http://dx.doi.org/10.1074/jbc.M307174200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952944	hybrid			2022-12-25	WOS:000186452300090
J	Ferguson, HA; Marietta, PM; Van Den Berg, CL				Ferguson, HA; Marietta, PM; Van Den Berg, CL			UV-induced apoptosis is mediated independent of caspase-9 in MCF-7 cells - A model for cytochrome c resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-X-L; ACTIVATION; APAF-1; CLEAVAGE; PROTEASE; MITOCHONDRIA; PATHWAY; INACTIVATION; ACCUMULATION; PROCASPASE-9	The importance of the mitochondria in UV-induced apoptosis has become increasingly apparent. Following DNA damage cytochrome c and other pro-apoptotic factors are released from the mitochondria, allowing for formation of the apoptosome and subsequent cleavage and activation of caspase-9. Active caspase-9 then activates downstream caspases-3 and/or -7, which in turn cleave poly (ADP)-ribose polymerase (PARP) and other downstream targets, resulting in apoptosis. In an effort to understand the mechanisms of Akt-mediated cell survival in breast cancer, we studied the effects of insulin-like growth factor (IGF)-I treatment on UV-treated MCF-7 human breast cancer cells. Apoptosis was induced in MCF-7 cells after UV treatment, as measured by caspase-7 and PARP cleavage, and IGF-I co-treatment protected against this response. Surprisingly caspase-9 cleavage was unchanged with UV and/or IGF-I treatment. Using MCF-7 cells overexpressing caspase-3 we have shown that resistance of caspase-9 to cleavage was not altered by the expression of caspase-3. Furthermore, overexpression of caspase-9 did not enhance PARP or caspase-7 cleavage after UV treatment. Because caspase-8 was activated with UV treatment alone, we believe that UV-induced apoptosis in MCF-7 cells occurs independently of cytochrome c and caspase-9, supporting the existence of a cytoplasmic inhibitor of cytochrome c in MCF-7 cells. We anticipate that such inhibitors may be overexpressed in cancer cells, allowing for treatment resistance.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Van Den Berg, CL (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, 4200 E 9th Ave,Campus Box C238, Denver, CO 80262 USA.	carla.vandenberg@UCHSC.edu			NATIONAL CANCER INSTITUTE [R01CA089288] Funding Source: NIH RePORTER; NCI NIH HHS [CA89288A] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blanc C, 2000, CANCER RES, V60, P4386; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Fang GF, 1998, CANCER RES, V58, P3202; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Niu MY, 2001, ONCOGENE, V20, P3506, DOI 10.1038/sj.onc.1204453; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stegh AH, 2002, J BIOL CHEM, V277, P4351, DOI 10.1074/jbc.M108947200; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XD, 2001, GENE DEV, V15, P2922; Wolf BB, 2001, J BIOL CHEM, V276, P34244, DOI 10.1074/jbc.M011778200; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	42	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45793	45800		10.1074/jbc.M307979200	http://dx.doi.org/10.1074/jbc.M307979200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954616	hybrid			2022-12-25	WOS:000186452300091
J	Hostager, BS; Haxhinasto, SA; Rowland, SL; Bishop, GA				Hostager, BS; Haxhinasto, SA; Rowland, SL; Bishop, GA			Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CLASS-II MOLECULES; LATENT MEMBRANE-PROTEIN-1; MONOCLONAL-ANTIBODIES; CELL DIFFERENTIATION; CUTTING EDGE; MURINE CD40; T-CELLS; ACTIVATION; RESPONSES	CD40 function is initiated by tumor necrosis factor (TNF) receptor-associated factor (TRAF) adapter proteins, which play important roles in signaling by numerous receptors. Characterizing roles of individual TRAFs has been hampered by limitations of available experimental models and the poor viability of most TRAF-deficient mice. Here, B cell lines made deficient in TRAF2 using a novel homologous recombination system reveal new roles for TRAF2. We demonstrate that TRAF2 participates in synergy between CD40 and B cell antigen receptor signals, and in CD40-mediated, TNF-dependent IgM production. We also find that TRAF2 participates in the degradation of TRAF3 associated with CD40 signaling, a role that may limit inhibitory actions of TRAF3. Finally, we show that TRAF2 and TRAF6 have overlapping functions in CD40-mediated NF-kappaB activation and CD80 up-regulation. These findings demonstrate previously unappreciated roles for TRAF2 in signaling by TNF receptor family members, using an approach that facilitates the analysis of genes critical to the viability of whole organisms.	Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Interdisciplinary Program Immunol, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Bishop, GA (corresponding author), Univ Iowa, Dept Microbiol, 3-570 Bowen Sci Bldg,51 Newton Rd, Iowa City, IA 52242 USA.			Bishop, Gail/0000-0002-1291-5078	NIAID NIH HHS [AI49993, AI28847] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028847, R01AI049993, R56AI049993, R29AI028847, R56AI028847] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahonen CL, 2002, NAT IMMUNOL, V3, P451, DOI 10.1038/ni792; BANIYASH M, 1984, EUR J IMMUNOL, V14, P799, DOI 10.1002/eji.1830140907; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; BISHOP GA, 1986, P NATL ACAD SCI USA, V83, P7410, DOI 10.1073/pnas.83.19.7410; BISHOP GA, 1995, EUR J IMMUNOL, V25, P1230, DOI 10.1002/eji.1830250515; BISHOP GA, 1991, J IMMUNOL, V147, P1107; Bishop GA, 2001, ARCH IMMUNOL THER EX, V49, P129; Bourgeois C, 2002, SCIENCE, V297, P2060, DOI 10.1126/science.1072615; Brown KD, 2001, J EXP MED, V193, P943, DOI 10.1084/jem.193.8.943; Brown KD, 2002, J BIOL CHEM, V277, P19433, DOI 10.1074/jbc.M111522200; Busch LK, 1999, J IMMUNOL, V162, P2555; Busch LK, 2001, J IMMUNOL, V167, P5805, DOI 10.4049/jimmunol.167.10.5805; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Catlett IM, 2001, J IMMUNOL, V166, P6019, DOI 10.4049/jimmunol.166.10.6019; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; HAMANO T, 1982, J IMMUNOL, V129, P1403; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; HANSON KD, 1995, MOL CELL BIOL, V15, P45, DOI 10.1128/MCB.15.1.45; Haxhinasto SA, 2002, J IMMUNOL, V169, P1145, DOI 10.4049/jimmunol.169.3.1145; HEATH AW, 1994, EUR J IMMUNOL, V24, P1828, DOI 10.1002/eji.1830240816; Hernan R, 2000, BIOTECHNIQUES, V28, P789, DOI 10.2144/00284pf01; Hostager BS, 2002, J IMMUNOL, V168, P3318, DOI 10.4049/jimmunol.168.7.3318; Hostager BS, 1999, J IMMUNOL, V162, P6307; Hostager BS, 1996, J IMMUNOL, V157, P1047; Hostager BS, 2000, J BIOL CHEM, V275, P15392, DOI 10.1074/jbc.M909520199; Hsing Y, 1999, J IMMUNOL, V162, P2804; Hsing Y, 1997, J IMMUNOL, V159, P4898; HU HM, 1994, J BIOL CHEM, V269, P30069; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Jabara HH, 2002, IMMUNITY, V17, P265, DOI 10.1016/S1074-7613(02)00394-1; Jalukar SV, 2000, J IMMUNOL, V164, P623, DOI 10.4049/jimmunol.164.2.623; KIM KJ, 1979, J IMMUNOL, V122, P549; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; LONG EO, 1991, HUM IMMUNOL, V31, P229, DOI 10.1016/0198-8859(91)90092-N; Manning E, 2002, EUR J IMMUNOL, V32, P39, DOI 10.1002/1521-4141(200201)32:1<39::AID-IMMU39>3.0.CO;2-Y; Nakano H, 1999, P NATL ACAD SCI USA, V96, P9803, DOI 10.1073/pnas.96.17.9803; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SAUER B, 1989, NUCLEIC ACIDS RES, V17, P147, DOI 10.1093/nar/17.1.147; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Sedivy JM, 1999, TRENDS GENET, V15, P88, DOI 10.1016/S0168-9525(98)01689-8; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Stout RD, 1996, IMMUNOL TODAY, V17, P487, DOI 10.1016/0167-5699(96)10060-I; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Wagner DH, 2002, P NATL ACAD SCI USA, V99, P3782, DOI 10.1073/pnas.052247099; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Yanagawa Y, 1999, TRANSGENIC RES, V8, P215, DOI 10.1023/A:1008914020843; Yasui T, 2002, INT IMMUNOL, V14, P319, DOI 10.1093/intimm/14.3.319; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	56	101	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45382	45390		10.1074/jbc.M306708200	http://dx.doi.org/10.1074/jbc.M306708200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12958312	hybrid			2022-12-25	WOS:000186452300042
J	McDonald, WH; Pavlova, Y; Yates, JR; Boddy, MN				McDonald, WH; Pavlova, Y; Yates, JR; Boddy, MN			Novel essential DNA repair proteins Nse1 and Nse2 are subunits of the fission yeast Smc5-Smc6 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHECKPOINT KINASE CDS1; MMS-SENSITIVE MUTANTS; SCHIZOSACCHAROMYCES-POMBE; SMC PROTEINS; SACCHAROMYCES-CEREVISIAE; IDENTIFICATION; CONDENSATION; COHESIN; DAMAGE; RAD18	The structural maintenance of chromosomes (SMC) family of proteins play essential roles in genomic stability. SMC heterodimers are required for sister-chromatid cohesion (Cohesin: Smc1 & Smc3), chromatin condensation (Condensin: Smc2 & Smc4), and DNA repair ( Smc5 & Smc6). The SMC heterodimers do not function alone and must associate with essential non-SMC subunits. To gain further insight into the essential and DNA repair roles of the Smc5-6 complex, we have purified fission yeast Smc5 and identified by mass spectrometry the co-precipitating proteins, Nse1 and Nse2. We show that both Nse1 and Nse2 interact with Smc5 in vivo, as part of the Smc5-6 complex. Nse1 and Nse2 are essential proteins and conserved from yeast to man. Loss of Nse1 and Nse2 function leads to strikingly similar terminal phenotypes to those observed for Smc5-6 inactivation. In addition, cells expressing hypomorphic alleles of Nse1 and Nse2 are, like Smc5-6 mutants, hypersensitive to DNA damage. Epistasis analysis suggests that like Smc5-6, Nse1, and Nse2 function together with Rhp51 in the homologous recombination repair of DNA double strand breaks. The results of this study strongly suggest that Nse1 and Nse2 are novel non-SMC subunits of the fission yeast Smc5-6 DNA repair complex.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Boddy, MN (corresponding author), Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.	nboddy@scripps.edu	Boddy, Michael/A-7214-2009; McDonald, W. Hayes/B-4109-2016	McDonald, W. Hayes/0000-0002-3510-426X	NCI NIH HHS [CA81665] Funding Source: Medline; NCRR NIH HHS [RR11823] Funding Source: Medline; NEI NIH HHS [R01 EY1328801] Funding Source: Medline; NIGMS NIH HHS [GM068608] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA081665] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068608] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; Aono N, 2002, NATURE, V417, P197, DOI 10.1038/417197a; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 2003, MOL CELL BIOL, V23, P5939, DOI 10.1128/MCB.23.16.5939-5946.2003; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; Ciosk R, 2000, MOL CELL, V5, P243, DOI 10.1016/S1097-2765(00)80420-7; Fousteri MI, 2000, EMBO J, V19, P1691, DOI 10.1093/emboj/19.7.1691; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Fujioka Y, 2002, J BIOL CHEM, V277, P21585, DOI 10.1074/jbc.M201523200; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hari KL, 2001, GENE DEV, V15, P1334, DOI 10.1101/gad.877901; Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102; Jessberger R, 2002, NAT REV MOL CELL BIO, V3, P767, DOI 10.1038/nrm930; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kim JS, 2002, J BIOL CHEM, V277, P45149, DOI 10.1074/jbc.M209123200; LEHMANN AR, 1995, MOL CELL BIOL, V15, P7067; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; McDonald WH, 2002, DIS MARKERS, V18, P99, DOI 10.1155/2002/505397; MONTELONE BA, 1995, CURR GENET, V27, P102, DOI 10.1007/BF00313423; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Morishita T, 2002, MOL CELL BIOL, V22, P3537, DOI 10.1128/MCB.22.10.3537-3548.2002; PRAKASH L, 1977, GENETICS, V86, P33; PRAKASH S, 1977, GENETICS, V87, P229; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Sutani T, 1999, GENE DEV, V13, P2271, DOI 10.1101/gad.13.17.2271; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Verkade HM, 1999, MOL BIOL CELL, V10, P2905, DOI 10.1091/mbc.10.9.2905; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4	36	98	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45460	45467		10.1074/jbc.M308828200	http://dx.doi.org/10.1074/jbc.M308828200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12966087	hybrid			2022-12-25	WOS:000186452300051
J	Heckman, CA; Wheeler, MA; Boxer, LM				Heckman, CA; Wheeler, MA; Boxer, LM			Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells	ONCOGENE			English	Article						bcl-2; lymphoma; transcription; C/EBP	NF-KAPPA-B; ACUTE MYELOID-LEUKEMIA; BINDING PROTEIN-BETA; TRANSCRIPTION FACTOR; C-MYB; NEGATIVE REGULATOR; GENE PROMOTER; CREB PROTEINS; ALPHA; DIFFERENTIATION	In follicular lymphomas with the t(14;18) translocation, there is increased expression of the bcl-2 gene, which is dependent upon regulatory elements within the bcl-2 5' flanking region and the immunoglobulin heavy-chain gene enhancers. We found that t(14;18) lymphomas expressed C/EBPalpha, which is not normally expressed in B lymphocytes. Expression of C/EBPalpha increased bcl-2 expression, and two regions of the bcl-2 P2 promoter that mediated this effect were identified. C/EBPbeta was also able to increase bcl-2 promoter activity through these sites. The 5' site was GC-rich and did not contain a C/EBP consensus sequence; however, C/EBP was observed to interact with this site both in vitro by EMSA and in vivo by chromatin immunoprecipitation assay. The 3' region contained the Cdx site, which mediates the effect of A-Myb on the bcl-2 promoter. In vivo binding studies revealed that C/EBP interacted with this region of the bcl-2 promoter as well. Decreased expression of C/EBP factors due to targeting of their transcripts by siRNA molecules resulted in downregulation of Bcl-2 protein. We conclude that C/EBPalpha and C/EBPbeta contribute to the deregulated expression of Bcl-2 in t(14;18) lymphoma cells.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol Med, Palo Alto, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Boxer, LM (corresponding author), Stanford Univ, Sch Med, Dept Med, CCSR 1155,269 Campus Dr, Stanford, CA 94305 USA.			Heckman, Caroline/0000-0002-4324-8706	NATIONAL CANCER INSTITUTE [R56CA056764, R01CA056764] Funding Source: NIH RePORTER; NCI NIH HHS [CA56764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; Chen XN, 1997, BLOOD, V90, P156; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COOPER CL, 1994, J IMMUNOL, V153, P5049; Dearth LR, 2001, J CELL BIOCHEM, V82, P357, DOI 10.1002/jcb.1167; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; Tenen DG, 2001, LEUKEMIA, V15, P688, DOI 10.1038/sj.leu.2402088; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299	32	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7891	7899		10.1038/sj.onc.1206639	http://dx.doi.org/10.1038/sj.onc.1206639			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970736				2022-12-25	WOS:000185388200003
J	Muratovska, A; Zhou, CM; He, SJ; Goodyer, P; Eccles, MR				Muratovska, A; Zhou, CM; He, SJ; Goodyer, P; Eccles, MR			Paired-box genes are frequently expressed in cancer and often required for cancer cell survival	ONCOGENE			English	Article						PAX genes; siRNA; cell survival; tumor	HUMAN FETAL KIDNEY; HUMAN PAX6 GENE; TRANSCRIPTION FACTOR; ALVEOLAR RHABDOMYOSARCOMA; WILMS-TUMOR; APOPTOSIS; MUTATIONS; CARCINOMA; PROTEIN; ONCOGENE	The paired-box (PAX) genes encode a family of nine well-characterized paired-box transcription factors, with important roles in development and disease. Although PAX genes are primarily expressed in the embryo, constitutive expression promotes tissue hyperplasia. Rare tumor-specific mutations of PAX genes implicate an oncogenic role, and persistent PAX expression characterizes several tumors. Yet, a cancer-wide analysis of PAX gene expression to investigate a general role for PAX genes has not been performed. We analysed the pattern and requirement for PAX gene expression in a panel of common cancer cell lines. Very frequent PAX gene expression was identified in tumor cell lines, including lymphoma, breast, ovarian, lung, and colon cancer. In addition, the PAX2 gene was frequently expressed in a panel of 406 common primary tumor tissues. Apoptosis was rapidly induced in ovarian and bladder cancer cell lines following RNA interference to silence PAX2 expression, despite concomitant TP53 and/or HRAS mutations. These data suggest that PAX genes are frequently expressed in cancer, and that endogenous PAX gene expression is required for the growth and survival of cancer cells.	Univ Otago, Dunedin Sch Med, Dept Pathol, Dunedin, New Zealand; McGill Univ, Montreal Childrens Hosp, Res Inst, Dept Pediat, Westmount, PQ H3Z 2Z3, Canada	University of Otago; McGill University	Eccles, MR (corresponding author), Univ Otago, Dunedin Sch Med, Dept Pathol, POB 913, Dunedin, New Zealand.			Filipovska, Aleksandra/0000-0002-6998-8403				BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Bender CM, 1999, MOL CELL BIOL, V19, P6690; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Borycki AG, 1999, DEVELOPMENT, V126, P1665; Bouchard M, 2000, DEVELOPMENT, V127, P3703; Bouchard M, 2002, GENE DEV, V16, P2958, DOI 10.1101/gad.240102; Cazzaniga G, 2001, CANCER RES, V61, P4666; Chi N, 2002, TRENDS GENET, V18, P41, DOI 10.1016/S0168-9525(01)02594-X; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; DAVIS RJ, 1994, CANCER RES, V54, P2869; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; ECCLES MR, 1995, AM J PATHOL, V146, P40; Eccles MR, 1998, PEDIATR NEPHROL, V12, P712, DOI 10.1007/s004670050533; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; FABBRO D, 1994, CANCER RES, V54, P4744; FICKENSCHER HR, 1993, DNA CELL BIOL, V12, P381, DOI 10.1089/dna.1993.12.381; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GNARRA JR, 1995, CANCER RES, V55, P4092; Hettmann T, 2000, DEV BIOL, V222, P110, DOI 10.1006/dbio.2000.9699; Hewitt SM, 1997, ANTICANCER RES, V17, P3211; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; KOZMIK Z, 1993, MOL CELL BIOL, V13, P6024, DOI 10.1128/MCB.13.10.6024; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Lin TK, 2002, J BIOL CHEM, V277, P17048, DOI 10.1074/jbc.M110797200; Mansouri A, 1998, MECH DEVELOP, V78, P171, DOI 10.1016/S0925-4773(98)00168-3; Margue CM, 2000, ONCOGENE, V19, P2921, DOI 10.1038/sj.onc.1203607; Marques AR, 2002, J CLIN ENDOCR METAB, V87, P3947, DOI 10.1210/jc.87.8.3947; Morrison AM, 1998, BLOOD, V92, P3865, DOI 10.1182/blood.V92.10.3865.422k01_3865_3878; Morrison AM, 1998, SEMIN IMMUNOL, V10, P133, DOI 10.1006/smim.1998.0115; Murer L, 2002, NEPHRON, V91, P588, DOI 10.1159/000065017; Ostrom L, 2000, DEV BIOL, V219, P250, DOI 10.1006/dbio.2000.9618; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; Pfeffer PL, 1998, DEVELOPMENT, V125, P3063; Porteous S, 2000, HUM MOL GENET, V9, P1, DOI 10.1093/hmg/9.1.1; Ridgeway AG, 2001, J BIOL CHEM, V276, P19033, DOI 10.1074/jbc.M011491200; RIEGER KM, 1995, BRIT J CANCER, V72, P683, DOI 10.1038/bjc.1995.394; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Salem CE, 2000, INT J CANCER, V87, P179, DOI 10.1002/1097-0215(20000715)87:2<179::AID-IJC4>3.0.CO;2-X; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; Scholl FA, 2001, CANCER RES, V61, P823; Silberstein GB, 2002, ONCOGENE, V21, P1009, DOI 10.1038/sj.onc.1205172; Steinbach JP, 2001, INT J CANCER, V93, P459, DOI 10.1002/ijc.1371; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; STUART ET, 1995, CLIN CANCER RES, V1, P207; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; Torban E, 2000, AM J PATHOL, V157, P833, DOI 10.1016/S0002-9440(10)64597-X; van Raamsdonk CD, 2000, DEVELOPMENT, V127, P5439; Winyard PJD, 1996, J CLIN INVEST, V98, P451, DOI 10.1172/JCI118811	50	194	209	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7989	7997		10.1038/sj.onc.1206766	http://dx.doi.org/10.1038/sj.onc.1206766			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970747				2022-12-25	WOS:000185388200014
J	Iivanainen, E; Nelimarkka, L; Elenius, V; Heikkinen, SM; Junttila, TT; Sihombing, L; Sundvall, M; Maatta, JA; Jukka, V; Laine, O; Yla-Herttuala, S; Higashiyama, S; Alitalo, K; Elenius, K				Iivanainen, E; Nelimarkka, L; Elenius, V; Heikkinen, SM; Junttila, TT; Sihombing, L; Sundvall, M; Maatta, JA; Jukka, V; Laine, O; Yla-Herttuala, S; Higashiyama, S; Alitalo, K; Elenius, K			Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor	FASEB JOURNAL			English	Article						angiogenesis; cancer; ErbB; HB-EGF; Herceptin	DIPHTHERIA-TOXIN RECEPTOR; BLOOD-VESSEL FORMATION; DIFFERENTIAL EXPRESSION; TYROSINE KINASE; TIE2 RECEPTOR; PDGF-B; NEUREGULIN; MEMBER; GENE; ANGIOGENESIS	Recruitment of vascular smooth muscle cells (SMC) by endothelial cells (EC) is essential for angiogenesis. Endothelial-derived heparin binding EGF-like growth factor (HB- EGF) was shown to mediate this process by signaling via ErbB1 and ErbB2 receptors in SMCs. 1) Analysis of ErbB-ligands demonstrated that primary ECs expressed only HB- EGF and neuregulin-1. 2) Primary SMCs expressed ErbB1 and ErbB2, but not ErbB3 or ErbB4. 3) Consistent with their known receptor specificities, recombinant HBEGF, but not neuregulin-1, stimulated tyrosine phosphorylation of ErbB1 and ErbB2 and migration in SMCs. 4) Neutralization of HB- EGF or inhibition of ErbB1 or ErbB2 blocked 70 - 90% of the potential of ECs to stimulate SMC migration. Moreover, 5) angiopoietin-1, an EC effector with a role in recruitment of SMC-like cells to vascular structures in vivo, enhanced EC-stimulated SMC migration by a mechanism involving up-regulation of endothelial HB- EGF. Finally, 6) immunohistochemical analysis of developing human tissues demonstrated that HB- EGF was expressed in vivo in ECs associated with SMCs or pericytes but not in ECs of the hyaloid vessels not associated with SMCs. These results suggest an important role for HB- EGF and ErbB receptors in the recruitment of SMCs by ECs and elaborate on the mechanism by which angiopoietins exert their vascular effects.	Univ Turku, Med Res Labs, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem & Mol Biol, FIN-20520 Turku, Finland; Univ Turku, Turku Grad Sch Biomed Sci, FIN-20520 Turku, Finland; Univ Turku, Dept Pathol, FIN-20520 Turku, Finland; Turku Univ, Cent Hosp, Dept Med, FIN-20520 Turku, Finland; Univ Kuopio, AI Virtanen Inst, Dept Mol Med, FIN-70210 Kuopio, Finland; Ehime Univ, Sch Med, Dept Biochem Med, Shigenobu, Ehime 7910295, Japan; Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; Turku Univ, Cent Hosp, Dept Oncol, FIN-20520 Turku, Finland	University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; Finland National Institute for Health & Welfare; University of Eastern Finland; Ehime University; University of Helsinki; University of Helsinki; University of Turku	Elenius, K (corresponding author), Univ Turku, Med Res Labs, Tykistokatu 6 A, FIN-20520 Turku, Finland.	klaus.elenius@utu.fi	Elenius, Klaus/AAI-7594-2021; Alitalo, Kari K/J-5013-2014	Elenius, Klaus/0000-0001-5700-0827; Alitalo, Kari K/0000-0002-7331-0902; Sundvall, Maria H/0000-0002-0494-2965; Yla-Herttuala, Seppo/0000-0001-7593-2708				Abramovitch R, 1998, FEBS LETT, V425, P441, DOI 10.1016/S0014-5793(98)00283-X; Arkonac BM, 1998, J BIOL CHEM, V273, P4400, DOI 10.1074/jbc.273.8.4400; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Ciardiello F, 2001, CLIN CANCER RES, V7, P1459; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; HIGASHIYAMA S, 1994, HORM RES, V42, P9, DOI 10.1159/000184137; Higashiyama S, 1997, J BIOCHEM-TOKYO, V122, P675; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; IRUELAARISPE ML, 1991, LAB INVEST, V64, P174; Iwamoto R, 2003, P NATL ACAD SCI USA, V100, P3221, DOI 10.1073/pnas.0537588100; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; Junttila TT, 2000, TRENDS CARDIOVAS MED, V10, P304, DOI 10.1016/S1050-1738(01)00065-2; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Laitinen M, 1998, HUM GENE THER, V9, P1481, DOI 10.1089/hum.1998.9.10-1481; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Nykanen AI, 2003, CIRCULATION, V107, P1308, DOI 10.1161/01.CIR.0000054623.35669.3F; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Russell KS, 1999, AM J PHYSIOL-HEART C, V277, pH2205, DOI 10.1152/ajpheart.1999.277.6.H2205; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Strachan L, 2001, J BIOL CHEM, V276, P18265, DOI 10.1074/jbc.M006935200; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467; Zhang K, 1996, J BIOL CHEM, V271, P3884; Zhu MD, 2000, EXP EYE RES, V70, P767, DOI 10.1006/exer.2000.0844	50	94	101	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1609	1621		10.1096/fj.02-0939com	http://dx.doi.org/10.1096/fj.02-0939com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958167				2022-12-25	WOS:000185925100035
J	Joseph, TW; Zaika, A; Moll, UM				Joseph, TW; Zaika, A; Moll, UM			Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage	FASEB JOURNAL			English	Article						p53/HDM2; ubiquitination; proteasomes; degradation; cytoplasm; nucleus	RING-FINGER DOMAIN; SUBCELLULAR-LOCALIZATION; EXPORT SIGNAL; MDM2; UBIQUITINATION; PROTEASOME; CELLS; INHIBITOR; PROTEIN; LIGASE	The principal regulator of p53 stability is HDM2, an E3 ligase mediating p53 degradation via the ubiquitin - 26S proteasome pathway. Until recently, the accepted model held that p53 degradation occurs exclusively on cytoplasmic proteasomes, with an absolute requirement for nuclear export of p53 via the CRM1 pathway. However, 26S proteasomes are abundant in cytosol and nucleus. Using forced overexpression of HDM2 in mutant p53 tumor cells, we previously found that p53 degradation occurs in both the nucleus and the cytoplasm. p53 null cells coexpressing export-defective p53 and HDM2 retained partial competence for p53 degradation, challenging the obligatory export model. Because the ability of local nuclear destruction might add important control in switching off the p53 pathway, we now test this notion for physiological situations in untransfected cells and determine the significance of this regulation. Despite nuclear export blockade by leptomycin B and HTLV1-Rex protein, two potent CRM1 inhibitors, nuclear degradation of endogenous wild-type p53 and HDM2 occurs during down-regulation of the p53 response. This was seen in RKO and U2OS cells recovering from all major forms of DNA damage, including UV, gamma-IR, camptothecin, or cisplatinum. Moreover, significant nuclear degradation of endogenous p53 and HDM2 occurs in isolated nuclear fractions prepared from these recovering cells. Furthermore, nuclear proteasomes efficiently degrade ubiquitinated p53 in vitro. Our data indicate that in nonlethal outcomes of cellular stress, when DNA damage has been successfully repaired and the active p53 response needs to be down-regulated quickly to resume normal homeostasis, both nuclear and cytoplasmic proteasomes are recruited to efficiently degrade the elevated p53 and HDM2 protein levels. The physiological significance of local nuclear destruction lies in the fact that it adds tighter control and speed to switching the p53 pathway off.	SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Moll, UM (corresponding author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.	umoll@notes.cc.sunysb.edu			NCI NIH HHS [T32 CA09176-24] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009176] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hirsch C, 2000, TRENDS CELL BIOL, V10, P268, DOI 10.1016/S0962-8924(00)01768-2; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; KATAHIRA J, 1995, J VIROL, V69, P3125, DOI 10.1128/JVI.69.5.3125-3133.1995; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kumar KS, 2000, WIND STRUCT, V3, P1; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Maki CG, 1996, CANCER RES, V56, P2649; PALMER A, 1994, EUR J CELL BIOL, V64, P163; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Shirangi TR, 2002, FASEB J, V16, P420, DOI 10.1096/fj.01-0617fje; Smart P, 1999, ONCOGENE, V18, P7378, DOI 10.1038/sj.onc.1203260; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Yu ZK, 2000, ONCOGENE, V19, P5892, DOI 10.1038/sj.onc.1203980; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	28	40	40	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1622	1630		10.1096/fj.02-0931com	http://dx.doi.org/10.1096/fj.02-0931com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958168				2022-12-25	WOS:000185925100036
J	Gilham, D; Ho, S; Rasouli, M; Martres, P; Vance, DE; Lehner, R				Gilham, D; Ho, S; Rasouli, M; Martres, P; Vance, DE; Lehner, R			Inhibitors of hepatic microsomal triacylglycerol hydrolase decrease very low density lipoprotein secretion	FASEB JOURNAL			English	Article						VLDL; apoB; hepatocytes; atherosclerosis; lipase	HORMONE-SENSITIVE LIPASE; TRIGLYCERIDE TRANSFER PROTEIN; B-CONTAINING LIPOPROTEINS; APOLIPOPROTEIN-B; RAT HEPATOCYTES; DIACYLGLYCEROL ACYLTRANSFERASE; ENDOPLASMIC-RETICULUM; FATTY-ACIDS; ARYLACETAMIDE DEACETYLASE; ATHEROGENIC DYSLIPIDEMIA	The presence of elevated circulating triacylglycerol (TG)-rich very low density lipoprotein (VLDL) and apolipoprotein B-100 (apoB-100) levels represents an independent risk factor for coronary artery disease. Triacylglycerol hydrolase catalyzes the mobilization of cytoplasmic TG stores. To test the hypothesis that the enzyme plays a role in the provision of core lipids for the assembly of VLDL, we inhibited the lipase activity in primary rat hepatocytes and analyzed lipid and apoB synthesis and secretion. Inhibition of lipolysis resulted in a dramatic decrease in secretion of TGs. In addition, secretion of cholesteryl ester and phosphatidylcholine was substantially decreased. Analysis of secreted apolipoproteins indicated that apoB-100 secretion was much more sensitive to lipase inhibition than was apoB-48 secretion, perhaps because of the ability of apoB-48 to be secreted as a relatively lipid-poor particle. The results agreed with those obtained with hepatoma cells transfected with triacylglycerol hydrolase cDNA, in which preferential lipidation of apoB-100 was observed. Together, our findings provide evidence that inhibition of intracellular TG hydrolysis significantly decreases apoB-100 secretion and suggest that triacylglycerol hydrolase may be a suitable pharmacological target in efforts to lower plasma lipid levels.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, CIHR Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; GlaxoSmithKline Inc, F-91951 Les Ulis, France	University of Alberta; University of Alberta; GlaxoSmithKline	Lehner, R (corresponding author), Univ Alberta, Dept Pediat, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada.	richard.lehner@ualberta.ca	rasouli, mehdi/F-6374-2017	rasouli, mehdi/0000-0002-1842-7198; Lehner, Richard/0000-0002-6008-1805				Aarsland A, 1998, J LIPID RES, V39, P1280; Abo-Hashema KAH, 1999, J BIOL CHEM, V274, P35577, DOI 10.1074/jbc.274.50.35577; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Diczfalusy MA, 1996, ARTERIOSCL THROM VAS, V16, P606, DOI 10.1161/01.ATV.16.4.606; DIXON JL, 1993, J LIPID RES, V34, P167; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GIBBONS GF, 1994, J LIPID RES, V35, P1801; GIBBONS GF, 1992, BIOCHEM J, V287, P749, DOI 10.1042/bj2870749; Gibbons GF, 2000, BBA-MOL CELL BIOL L, V1483, P37, DOI 10.1016/S1388-1981(99)00182-1; Grundy SM, 1998, AM J CARDIOL, V81, p18B, DOI 10.1016/S0002-9149(98)00033-2; Grundy SM, 1997, CIRCULATION, V95, P1, DOI 10.1161/01.CIR.95.1.1; Haemmerle G, 2002, J BIOL CHEM, V277, P12946, DOI 10.1074/jbc.M108640200; Haidara K, 2002, BBA-MOL CELL RES, V1542, P173, DOI 10.1016/S0167-4889(01)00178-1; HODIS HN, 1995, CURR OPIN LIPIDOL, V6, P209, DOI 10.1097/00041433-199508000-00004; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; Lankester DL, 1998, J LIPID RES, V39, P1889; Lehner R, 1999, BIOCHEM J, V343, P1, DOI 10.1042/0264-6021:3430001; Lehner R, 1999, BIOCHEM J, V338, P761, DOI 10.1042/0264-6021:3380761; Lehner R, 1997, BIOCHEMISTRY-US, V36, P1861, DOI 10.1021/bi962186d; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; Moldeus P, 1978, Methods Enzymol, V52, P60; MOREAU H, 1991, BIOCHEMISTRY-US, V30, P1037, DOI 10.1021/bi00218a022; NIKAWA J, 1979, FEBS LETT, V102, P223, DOI 10.1016/0014-5793(79)80005-8; Owen MR, 1997, BIOCHEM J, V323, P17, DOI 10.1042/bj3230017; Pease RJ, 1999, BIOCHEM J, V341, P453, DOI 10.1042/0264-6021:3410453; PROBST MR, 1994, J BIOL CHEM, V269, P21650; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; STRALFORS P, 1987, ENZYMES B, V18, P147; Trickett JI, 2001, J BIOL CHEM, V276, P39522, DOI 10.1074/jbc.M101764200; VANCE DE, 1984, BIOCHIM BIOPHYS ACTA, V792, P39, DOI 10.1016/0005-2760(84)90280-7; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; Wu XJ, 1996, J LIPID RES, V37, P1198; Yang LY, 1996, J LIPID RES, V37, P262; YAO ZM, 1988, J BIOL CHEM, V263, P2998; Yao ZM, 1997, J LIPID RES, V38, P1937	43	101	105	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1685	+		10.1096/fj.02-0728fje	http://dx.doi.org/10.1096/fj.02-0728fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958176				2022-12-25	WOS:000184471600015
J	Dawson, M; Wirtz, D; Hanes, J				Dawson, M; Wirtz, D; Hanes, J			Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN FILAMENT NETWORKS; FIBROSIS SPUTUM; MUCUS; DNA; MICRORHEOLOGY; DIFFUSION	Current biochemical characterizations of cystic fibrosis (CF) sputum do not address the high degree of microheterogeneity in the rheological properties of the mucosal matrix and only provide bulk-average particle diffusion coefficients. The viscoelasticity of CF sputum greatly reduces the diffusion rates of colloidal particles, limiting the effectiveness of gene delivery to underlying lung cells. We determine diffusion coefficients of hundreds of individual amine-modified and carboxylated polystyrene particles ( diameter 100 - 500 nm) embedded in human CF sputum with 5 nm and 33 ms of spatiotemporal resolution. High resolution multiple particle tracking is used to calculate the effective viscoelastic properties of CF sputum at the micron scale, which we relate to its macroscopic viscoelasticity. CF sputum microviscosity, as probed by 100- and 200-nm particles, is an order of magnitude lower than its macroviscosity, suggesting that nanoparticles dispersed in CF sputum are transported primarily through lower viscosity pores within a highly elastic matrix. Multiple particle tracking provides a non-destructive, highly sensitive method to quantify the high heterogeneity of the mucus pore network. The mean diffusion coefficient becomes dominated by relatively few but fast-moving particles as particle size is reduced from 500 to 100 nm. Neutrally charged particles with a diameter < 200 nm undergo more rapid transport in CF sputum than charged particles. Treatment with recombinant human DNase ( Pulmozyme(R)) reduces macroviscoelastic properties of CF sputum by up to 50% and dramatically narrows the distribution of individual particle diffusion rates but surprisingly does not significantly alter the ensemble-average particle diffusion rate.	Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Wirtz, D (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, 3400 N Charles St, Baltimore, MD 21218 USA.	wirtz@jhu.edu; hanes@jhu.edu	Dawson, Michelle R/Q-7217-2019; Wirtz, Denis/A-3257-2010; Jain, Rakesh K/I-1384-2017	Dawson, Michelle R/0000-0002-2122-4711; Jain, Rakesh K/0000-0001-7571-3548				Apgar J, 2000, BIOPHYS J, V79, P1095, DOI 10.1016/S0006-3495(00)76363-6; Banerjee R, 2001, BIOCHEM ENG J, V7, P195, DOI 10.1016/S1369-703X(00)00124-8; Berg, 2018, RANDOM WALKS BIOL; Bhat PG, 1996, J PHARM SCI, V85, P624, DOI 10.1021/js950381s; Cone R., 1999, MUCOSAL IMMUNOLOGY, P43; Ferrari S, 2001, GENE THER, V8, P1380, DOI 10.1038/sj.gt.3301525; Geddes D, 1998, ADV DRUG DELIVER REV, V30, P205, DOI 10.1016/S0169-409X(97)00117-8; Goodman A, 2002, J MOL BIOL, V323, P199, DOI 10.1016/S0022-2836(02)00893-8; HANES J, 2003, PHARM INHALATION AER, P489; Khanvilkar K, 2001, ADV DRUG DELIVER REV, V48, P173, DOI 10.1016/S0169-409X(01)00115-6; Ma LL, 1999, J BIOL CHEM, V274, P19145, DOI 10.1074/jbc.274.27.19145; Mason TG, 1997, PHYS REV LETT, V79, P3282, DOI 10.1103/PhysRevLett.79.3282; Mason TG, 1998, MACROMOLECULES, V31, P3600, DOI 10.1021/ma970564w; Mrsny RJ, 1996, J DRUG TARGET, V4, P233, DOI 10.3109/10611869608995625; Norris DA, 1997, J APPL POLYM SCI, V63, P1481, DOI 10.1002/(SICI)1097-4628(19970314)63:11<1481::AID-APP10>3.0.CO;2-5; Olmsted SS, 2001, BIOPHYS J, V81, P1930, DOI 10.1016/S0006-3495(01)75844-4; Palmer A, 1999, BIOPHYS J, V76, P1063, DOI 10.1016/S0006-3495(99)77271-1; Rubin BK, 1996, J AEROSOL MED, V9, P123, DOI 10.1089/jam.1996.9.123; Sanders NN, 2000, AM J RESP CRIT CARE, V162, P1905, DOI 10.1164/ajrccm.162.5.9909009; Sanders NN, 2002, PHARMACEUT RES, V19, P451, DOI 10.1023/A:1015139527747; Sanders NN, 2000, J PHARM SCI-US, V89, P835, DOI 10.1002/1520-6017(200007)89:7<835::AID-JPS1>3.0.CO;2-6; Suh J, 2003, P NATL ACAD SCI USA, V100, P3878, DOI 10.1073/pnas.0636277100; Tseng Y, 2002, BIOPHYS J, V83, P3162, DOI 10.1016/S0006-3495(02)75319-8; Tseng Y, 2002, J BIOL CHEM, V277, P18143, DOI 10.1074/jbc.M110868200; Tseng Y, 2001, BIOPHYS J, V81, P1643, DOI 10.1016/S0006-3495(01)75818-3; Tseng Y, 2001, J MOL BIOL, V310, P351, DOI 10.1006/jmbi.2001.4716; Xu JY, 2000, J BIOL CHEM, V275, P35886, DOI 10.1074/jbc.M002377200; Zahm JM, 1998, AM J RESP CRIT CARE, V157, P1779, DOI 10.1164/ajrccm.157.6.9706036	28	225	258	0	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50393	50401		10.1074/jbc.M309026200	http://dx.doi.org/10.1074/jbc.M309026200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	13679362	hybrid			2022-12-25	WOS:000187068200090
J	Gorke, B				Gorke, B			Regulation of the Escherichia coli antiterminator protein BglG by phosphorylation at multiple sites and evidence for transfer of phosphoryl groups between monomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; TRANSCRIPTIONAL ANTITERMINATOR; PHOSPHOTRANSFERASE SYSTEM; CATABOLITE REPRESSION; LACTOBACILLUS-CASEI; NEGATIVE REGULATION; RESPONSE REGULATOR; RANDOM MUTAGENESIS; OPERON; DOMAIN	Activity of antiterminator protein BglG regulating the beta-glucoside operon in Escherichia coli is controlled by the phosphoenolpyruvate: carbohydrate phosphotransferase system (PTS) in a dual manner. It requires HPr phosphorylation to be active, whereas phosphorylation by the beta-glucoside-specific transport protein EIIBgl inhibits its activity. BglG and its relatives carry two PTS regulation domains (PRD1 and PRD2), each containing two conserved histidines. For BglG, histidine 208 in PRD2 was reported to be the negative phosphorylation site. In contrast, other antiterminators of this family are negatively regulated by phosphorylation of the first histidine in PRD1, and presumably activated by phosphorylation of the histidines in PRD2. In this work, a screen for mutant BglG proteins that escape repression by EIIBgl yielded exchanges of nine residues within PRD1, including conserved histidines His-101 and His-160, and C-terminally truncated proteins. Genetic and phosphorylation analyses indicate that His-101 in PRD1 is phosphorylated by EIIBgl and that His-160 contributes to negative regulation. His-208 in PRD2 is essential for BglG activity, suggesting that it is phosphorylated by HPr. Surprisingly, phosphorylation by HPr is not fully abolished by exchanges of His-208. However, phosphorylation by HPr is inhibited by exchanges in PRD1 and the phosphorylation of these mutants is restored in the presence of wild-type BglG. These results suggest that the activating phosphoryl group is transiently donated from HPr to PRD1 and subsequently transferred to His-208 of a second BglG monomer. The active His-208-phosphorylated BglG dimer can subsequently be inhibited in its activity by EIIBgl-catalyzed phosphorylation at His-101.	Univ Freiburg, Inst Biol 3, D-79104 Freiburg, Germany	University of Freiburg	Gorke, B (corresponding author), CNRS, Chim Bacterienne Lab, 31 Chemin Joseph Aiguier, F-13402 Marseille, France.			Gorke, Boris/0000-0002-1682-5387				AmsterChoder O, 1997, J BACTERIOL, V179, P5621, DOI 10.1128/jb.179.17.5621-5624.1997; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; Andersen C, 1999, MOL MICROBIOL, V31, P499, DOI 10.1046/j.1365-2958.1999.01191.x; ARNAUD M, 1992, J BACTERIOL, V174, P3161, DOI 10.1128/jb.174.10.3161-3170.1992; Bachem S, 1998, J BACTERIOL, V180, P5319, DOI 10.1128/JB.180.20.5319-5326.1998; Boss A, 1999, J BACTERIOL, V181, P1755, DOI 10.1128/JB.181.6.1755-1766.1999; Chen Q, 1997, J BIOL CHEM, V272, P17263, DOI 10.1074/jbc.272.28.17263; Chen Q, 1997, EMBO J, V16, P4617, DOI 10.1093/emboj/16.15.4617; Declerck N, 2001, J MOL BIOL, V314, P671, DOI 10.1006/jmbi.2001.5185; Declerck N, 1999, J MOL BIOL, V294, P389, DOI 10.1006/jmbi.1999.3256; Dole S, 2002, MOL MICROBIOL, V43, P217, DOI 10.1046/j.1365-2958.2002.02734.x; Gorke B, 1999, EMBO J, V18, P3370, DOI 10.1093/emboj/18.12.3370; Gorke B, 2001, J MOL BIOL, V308, P131, DOI 10.1006/jmbi.2001.4590; GORKE B, 2000, THESIS U FREIBURG BR; Gosalbes MJ, 1999, J BACTERIOL, V181, P3928, DOI 10.1128/JB.181.13.3928-3934.1999; Gosalbes MJ, 2002, MICROBIOL-SGM, V148, P695, DOI 10.1099/00221287-148-3-695; Greenberg DB, 2002, RES MICROBIOL, V153, P519, DOI 10.1016/S0923-2508(02)01362-1; Gunnewijk MGW, 2001, J MOL MICROB BIOTECH, V3, P401; Henstra SA, 2000, J BIOL CHEM, V275, P7037, DOI 10.1074/jbc.275.10.7037; JUNNE T, 1990, J BACTERIOL, V172, P6615, DOI 10.1128/jb.172.12.6615-6616.1990; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LENGELER JW, 1994, PHOSPHATE IN MICROORGANISMS, P182; Lindner C, 1999, MOL MICROBIOL, V31, P995, DOI 10.1046/j.1365-2958.1999.01262.x; LIVNAT L, 2003, P NATL ACAD SCI USA, V100, P7099; MAHADEVAN S, 1987, J BACTERIOL, V169, P2570, DOI 10.1128/jb.169.6.2570-2578.1987; Manival X, 1997, EMBO J, V16, P5019, DOI 10.1093/emboj/16.16.5019; Miller J.H., 1972, EXPT MOL GENETICS; Plumbridge J, 2002, CURR OPIN MICROBIOL, V5, P187, DOI 10.1016/S1369-5274(02)00296-5; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PRASAD I, 1973, J BACTERIOL, V114, P909, DOI 10.1128/JB.114.3.909-915.1973; Rutberg B, 1997, MOL MICROBIOL, V23, P413, DOI 10.1046/j.1365-2958.1997.d01-1867.x; SCHNETZ K, 1990, P NATL ACAD SCI USA, V87, P5074, DOI 10.1073/pnas.87.13.5074; SCHNETZ K, 1987, J BACTERIOL, V169, P2579, DOI 10.1128/jb.169.6.2579-2590.1987; Schnetz K, 1996, J BACTERIOL, V178, P1971, DOI 10.1128/jb.178.7.1971-1979.1996; SPEE JH, 1993, NUCLEIC ACIDS RES, V21, P777, DOI 10.1093/nar/21.3.777; Stulke J, 2002, ARCH MICROBIOL, V177, P433, DOI 10.1007/s00203-002-0407-5; Stulke J, 1998, MOL MICROBIOL, V28, P865, DOI 10.1046/j.1365-2958.1998.00839.x; Tortosa P, 2001, MOL MICROBIOL, V41, P1381, DOI 10.1046/j.1365-2958.2001.02608.x; Tortosa P, 1997, J BIOL CHEM, V272, P17230, DOI 10.1074/jbc.272.27.17230; van Tilbeurgh H, 2001, CURR OPIN STRUC BIOL, V11, P685, DOI 10.1016/S0959-440X(01)00267-6; van Tilbeurgh H, 2001, EMBO J, V20, P3789, DOI 10.1093/emboj/20.14.3789; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	43	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46219	46229		10.1074/jbc.M308002200	http://dx.doi.org/10.1074/jbc.M308002200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963714	hybrid			2022-12-25	WOS:000186569400005
J	Nagababu, E; Ramasamy, S; Abernethy, DR; Rifkind, JM				Nagababu, E; Ramasamy, S; Abernethy, DR; Rifkind, JM			Active nitric oxide produced in the red cell under hypoxic conditions by deoxyhemoglobin-mediated nitrite reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-NITROSOHEMOGLOBIN; PHYSIOLOGICAL CONDITIONS; BLOOD-CELLS; BIOCHEMICAL-CHARACTERIZATION; PLASMA NITRITE; HEMOGLOBIN; NO; OXIDATION; MECHANISM; BINDING	Recent studies have generated a great deal of interest in a possible role for red blood cells in the transport of nitric oxide (NO) to the microcirculation and the vascular effect of this nitric oxide in facilitating the flow of blood through the microcirculation. Many questions have, however, been raised regarding such a mechanism. We have instead identified a completely new mechanism to explain the role of red cells in the delivery of NO to the microcirculation. This new mechanism results in the production of NO in the microcirculation where it is needed. Nitrite produced when NO reacts with oxygen in arterial blood is reutilized in the arterioles when the partial pressure of oxygen decreases and the deoxygenated hemoglobin formed reduces the nitrite regenerating NO. Nitrite reduction by hemoglobin results in a major fraction of the NO generated retained in the intermediate state where NO is bound to Hb(III) and in equilibrium with the nitrosonium cation bound to Hb(II). This pool of NO, unlike Hb(II) NO, is weakly bound and can be released from the heme. The instability of Hb(III) NO in oxygen and its displacement when flushed with argon requires that reliable determinations of red blood cell NO must be performed on freshly lysed samples without permitting the sample to be oxygenated. In fresh blood samples Hb(III) NO accounts for 75% of the red cell NO with appreciably higher values in venous blood than arterial blood. These findings confirm that nitrite reduction at reduced oxygen pressures is a major source for red cell NO. The formation and potential release from the red cell of this NO could have a major impact in regulating the flow of blood through the microcirculation.	NIA, Mol Dynam Sect, NIH, Baltimore, MD 21224 USA; NIA, Clin Invest Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Rifkind, JM (corresponding author), NIA, Mol Dynam Sect, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.				NATIONAL INSTITUTE ON AGING [Z01AG000047, ZIAAG000047] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Benedict FG, 1911, AM J PHYSIOL, V28, P1; Blitzer ML, 1996, AM J PHYSIOL-HEART C, V271, pH1182, DOI 10.1152/ajpheart.1996.271.3.H1182; Butler AR, 1998, BBA-GEN SUBJECTS, V1425, P168, DOI 10.1016/S0304-4165(98)00065-8; DOYLE MP, 1981, J BIOL CHEM, V256, P2393; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; Gladwin MT, 2003, NAT MED, V9, P496, DOI 10.1038/nm0503-496; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P9943, DOI 10.1073/pnas.180155397; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Haas H, 1999, ARZNEIMITTEL-FORSCH, V49, P318; Han TH, 2002, P NATL ACAD SCI USA, V99, P7763, DOI 10.1073/pnas.122118299; Hobbs AJ, 2002, TRENDS PHARMACOL SCI, V23, P406, DOI 10.1016/S0165-6147(02)02067-9; Huang Z, 2001, BBA-GEN SUBJECTS, V1568, P252, DOI 10.1016/S0304-4165(01)00227-6; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Joshi MS, 2002, P NATL ACAD SCI USA, V99, P10341, DOI 10.1073/pnas.152149699; Lancaster JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/niox.1996.0112; Lauer T, 2001, P NATL ACAD SCI USA, V98, P12814, DOI 10.1073/pnas.221381098; Liao JC, 1999, P NATL ACAD SCI USA, V96, P8757, DOI 10.1073/pnas.96.15.8757; Lissi E, 1998, FREE RADICAL BIO MED, V24, P1535, DOI 10.1016/S0891-5849(98)00004-5; Luchsinger BP, 2003, P NATL ACAD SCI USA, V100, P461, DOI 10.1073/pnas.0233287100; May JM, 2000, AM J PHYSIOL-CELL PH, V279, pC1946, DOI 10.1152/ajpcell.2000.279.6.C1946; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; Patel RP, 1999, J BIOL CHEM, V274, P15487, DOI 10.1074/jbc.274.22.15487; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; PreikSteinhoff H, 1996, J CHROMATOGR B, V685, P348, DOI 10.1016/S0378-4347(96)00264-2; Ralevic V, 2002, J PHYSIOL-LONDON, V544, P2, DOI 10.1113/jphysiol.2002.028902; Rassaf T, 2003, NAT MED, V9, P481, DOI 10.1038/nm0503-481; RHODES PM, 1995, BIOCHEM BIOPH RES CO, V209, P590, DOI 10.1006/bbrc.1995.1541; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; SHARMA VS, 1978, J BIOL CHEM, V253, P6467; Spencer NY, 2002, FREE RADICAL BIO MED, V33, pS381; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stepuro II, 1997, BIOCHEMISTRY-MOSCOW+, V62, P960; Vleeming W, 1997, FOOD CHEM TOXICOL, V35, P615, DOI 10.1016/S0278-6915(97)00015-X; Wang YN, 1996, J AM CHEM SOC, V118, P3972, DOI 10.1021/ja9538647; Wolzt M, 1999, J BIOL CHEM, V274, P28983, DOI 10.1074/jbc.274.41.28983	39	291	297	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46349	46356		10.1074/jbc.M307572200	http://dx.doi.org/10.1074/jbc.M307572200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12952953	hybrid			2022-12-25	WOS:000186569400018
J	Hinrichsen, L; Harborth, J; Andrees, L; Weber, K; Ungewickell, EJ				Hinrichsen, L; Harborth, J; Andrees, L; Weber, K; Ungewickell, EJ			Effect of clathrin heavy chain- and alpha-adaptin-specific small inhibitory RNAs on endocytic accessory proteins and receptor trafficking in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; SYNAPTIC VESICLE ENDOCYTOSIS; CULTURED-MAMMALIAN-CELLS; COATED VESICLES; MEDIATED ENDOCYTOSIS; TERMINAL DOMAIN; PLASMA-MEMBRANE; EARLY ENDOSOMES; APPENDAGE DOMAIN; COMPLEX AP-2	To assess the contribution of individual endocytic proteins to the assembly of clathrin coated pits, we depleted the clathrin heavy chain and the alpha-adaptin subunit of AP-2 in HeLa-cells using RNA interference. 48 h after transfection with clathrin heavy chain-specific short interfering RNA both, the heavy and light chains were depleted by more than 80%. Residual clathrin was mainly membrane-associated, and an increase in shallow pits was noted. The membrane-association of adaptors, clathrin assembly lymphoid myeloid leukemia protein (CALM), epsin, dynamin, and Eps15 was only moderately affected by the knockdown and all proteins still displayed a punctate staining distribution. Clathrin depletion inhibited the uptake of transferrin but not that of the epidermal growth factor. However, efficient sorting of the epidermal growth factor into hepatocyte growth factor-regulated tyrosine kinase substrate-positive endosomes was impaired. Depletion of alpha-adaptin abolished almost completely the plasma membrane association of clathrin. Binding of Eps15 to membranes was strongly and that of CALM moderately reduced. Whereas the uptake of transferrin was efficiently blocked in alpha-adaptin knockdown cells, the internalization and sorting of the epidermal growth factor was not significantly impaired. Since neither clathrin nor AP-2 is essential for the internalization of EGF, we conclude that it is taken up by an alternative mechanism.	Hannover Med Sch, Ctr Anat, Dept Cell Biol, D-30623 Hannover, Germany; Max Planck Inst Biophys Chem, Dept Biochem & Cell Biol, D-37070 Gottingen, Germany	Hannover Medical School; Max Planck Society	Ungewickell, EJ (corresponding author), Hannover Med Sch, Ctr Anat, Dept Cell Biol, D-30623 Hannover, Germany.		Gimenez, Luis E Diaz/D-9291-2011					ACTON SL, 1990, J CELL BIOL, V111, P1419, DOI 10.1083/jcb.111.4.1419; AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Bean AJ, 2000, J BIOL CHEM, V275, P15271, DOI 10.1074/jbc.275.20.15271; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Bennett EM, 2001, MOL BIOL CELL, V12, P2790, DOI 10.1091/mbc.12.9.2790; BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; Bretscher MS, 1998, CURR BIOL, V8, P721, DOI 10.1016/S0960-9822(98)70281-7; BRODSKY FM, 1985, J CELL BIOL, V101, P2055, DOI 10.1083/jcb.101.6.2055; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; CHIN DJ, 1989, P NATL ACAD SCI USA, V86, P9289, DOI 10.1073/pnas.86.23.9289; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; De Camilli P, 2002, FEBS LETT, V513, P11, DOI 10.1016/S0014-5793(01)03306-3; Dell'Angelica EC, 2001, TRENDS CELL BIOL, V11, P315, DOI 10.1016/S0962-8924(01)02043-8; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Drake MT, 2001, J BIOL CHEM, V276, P28700, DOI 10.1074/jbc.M104226200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Greener T, 2000, J BIOL CHEM, V275, P1365, DOI 10.1074/jbc.275.2.1365; HANOVER JA, 1984, CELL, V39, P283, DOI 10.1016/0092-8674(84)90006-0; Harborth J, 2001, J CELL SCI, V114, P4557; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Iversen TG, 2003, P NATL ACAD SCI USA, V100, P5175, DOI 10.1073/pnas.0534231100; Kalthoff C, 2002, J BIOL CHEM, V277, P8209, DOI 10.1074/jbc.M111587200; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; LINDNER R, 1992, J BIOL CHEM, V267, P16567; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Morgan JR, 2000, J NEUROSCI, V20, P8667; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; Newmyer SL, 2001, J CELL BIOL, V152, P607, DOI 10.1083/jcb.152.3.607; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; PEARSE BMF, 1976, P NATL ACAD SCI USA, V73, P1255, DOI 10.1073/pnas.73.4.1255; Qualmann B, 2002, INT REV CYTOL, V220, P93; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Raiborg C, 2001, J CELL SCI, V114, P2255; Rosenthal JA, 1999, J BIOL CHEM, V274, P33959, DOI 10.1074/jbc.274.48.33959; Sachse M, 2002, MOL BIOL CELL, V13, P1313, DOI 10.1091/mbc.01-10-0525; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SORKIN A, 1991, J BIOL CHEM, V266, P23453; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; Stahelin RV, 2003, J BIOL CHEM, V278, P28993, DOI 10.1074/jbc.M302865200; STAHL PD, 2002, SCI STKE; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Takei K, 2001, TRENDS CELL BIOL, V11, P385, DOI 10.1016/S0962-8924(01)02082-7; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; Umeda A, 2000, EUR J CELL BIOL, V79, P336, DOI 10.1078/S0171-9335(04)70037-0; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; VALLEE RB, 1993, CIBA F SYMP, V176, P185; van Dam EM, 2002, MOL BIOL CELL, V13, P169, DOI 10.1091/mbc.01-07-0380; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wettey FR, 2002, SCIENCE, V297, P1521, DOI 10.1126/science.1074222; Wu XF, 2001, J CELL BIOL, V155, P291, DOI 10.1083/jcb.200104085; Yamazaki T, 2002, J CELL SCI, V115, P1791; Zhao XH, 2001, J CELL SCI, V114, P353	77	217	220	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45160	45170		10.1074/jbc.M307290200	http://dx.doi.org/10.1074/jbc.M307290200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12960147	hybrid			2022-12-25	WOS:000186452300016
J	Kawai, H; Wiederschain, D; Kitao, H; Stuart, J; Tsai, KKC; Yuan, ZM				Kawai, H; Wiederschain, D; Kitao, H; Stuart, J; Tsai, KKC; Yuan, ZM			DNA damage-induced MDMX degradation is mediated by MDM2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53; PROTEIN; INACTIVATION; GROWTH; DOMAIN; LIGASE; ITSELF	Although genetic studies have demonstrated that MDMX is essential to maintain p53 activity at low levels in non-stressed cells, it is unknown whether MDMX regulates p53 activation by DNA damage. We show here that DNA damage-induced p53 induction is associated with rapid down-regulation of the MDMX protein. Significantly, interference with MDMX down-regulation results in the suppression of p53 activation by genotoxic stress. We also demonstrate that DNA damage-induced MDMX reduction is mediated by MDM2, which targets MDMX for proteasomal degradation by a distinct mechanism that permits preferential MDMX degradation and therefore ensures optimal p53 activation.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Bldg 1,Rm 507,665 Huntington Ave, Boston, MA 02115 USA.		Tsai, Kun-Chih/C-1371-2010	Kawai, Hidehiko/0000-0003-2213-7166; Tsai, Kelvin/0000-0002-1612-2868	NATIONAL CANCER INSTITUTE [R01CA085679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007155] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA85679] Funding Source: Medline; NIEHS NIH HHS [T32ES07155] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Finch RA, 2002, CANCER RES, V62, P3221; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Kawai H, 2002, MOL CELL BIOL, V22, P6079, DOI 10.1128/MCB.22.17.6079-6088.2002; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; MIGLIORINI D, 2001, J BIOL CHEM, V13, P13; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5	16	141	142	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45946	45953		10.1074/jbc.M308295200	http://dx.doi.org/10.1074/jbc.M308295200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12963717	hybrid			2022-12-25	WOS:000186452300108
J	Ludewig, U; Wilken, S; Wu, BH; Jost, W; Obrdlik, P; El Bakkoury, M; Marini, AM; Andre, B; Hamacher, T; Boles, E; von Wiren, N; Frommer, WB				Ludewig, U; Wilken, S; Wu, BH; Jost, W; Obrdlik, P; El Bakkoury, M; Marini, AM; Andre, B; Hamacher, T; Boles, E; von Wiren, N; Frommer, WB			Homo- and hetero-oligomerization of ammonium transporter-1 NH4+ uniporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SACCHAROMYCES-CEREVISIAE; K+ CHANNEL; IN-VIVO; MEMBRANE-PROTEINS; CHLORIDE CHANNEL; PLASMA-MEMBRANE; CELL-MEMBRANE; ROOT HAIRS; POLYPEPTIDES	In most organisms, high affinity ammonium uptake is catalyzed by members of the ammonium transporter family (AMT/MEP/Rh). A single point mutation (G458D) in the cytosolic C terminus of the plasma membrane transporter LeAMT1;1 from tomato leads to loss of function, although mutant and wild type proteins show similar localization when expressed in yeast or plant protoplasts. Co-expression of LeAMT1;1 and mutant in Xenopus oocytes inhibited ammonium transport in a dominant negative manner, suggesting homo-oligomerization. In vivo interaction between LeAMT1;1 proteins was confirmed by the split ubiquitin yeast two-hybrid system. LeAMT1;1 is isolated from root membranes as a high molecular mass oligomer, converted to a similar to35-kDa polypeptide by denaturation. To investigate interactions with the LeAMT1;2 paralog, co-localizing with LeAMT1;1 in root hairs, LeAMT1;2 was characterized as a lower affinity NH4+ uniporter. Co-expression of wild types with the respective G458D/G465D mutants inhibited ammonium transport in a dominant negative manner, supporting the formation of heteromeric complexes in oocytes. Thus, in yeast, oocytes, and plants, ammonium transporters are able to oligomerize, which may be relevant for regulation of ammonium uptake.	Univ Hohenheim, Inst Pflanzenernahrung, D-70599 Stuttgart, Germany; Univ Tubingen, Zentrum Mol Biol Pflanzen, D-72076 Tubingen, Germany; Free Univ Brussels, Inst Biol & Med Mol, Lab Physiol Cellulaire, B-6041 Gosselies, Belgium; Biozentrum, Inst Mikrobiol, D-60054 Frankfurt, Germany; Carnegie Inst Washington, Stanford, CA 94305 USA	University Hohenheim; Eberhard Karls University of Tubingen; Carnegie Institution for Science	von Wiren, N (corresponding author), Univ Hohenheim, Inst Pflanzenernahrung, Fruwirthstr 20, D-70599 Stuttgart, Germany.		Frommer, Wolf B/A-8256-2008; André, Bruno/D-1725-2010; Frommer, Wolf B/K-5042-2017	Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115; Boles, Eckhard/0000-0002-5713-1883; von Wiren, Nicolaus/0000-0002-4966-425X				Baizabal-Aguirre VM, 1999, J MEMBRANE BIOL, V167, P119, DOI 10.1007/s002329900476; Blakey D, 2002, BIOCHEM J, V364, P527, DOI 10.1042/BJ20011761; BRENDON JM, 2002, FUNGAL GENET BIOL, V36, P35; Britto DT, 2001, PLANT PHYSIOL, V125, P523, DOI 10.1104/pp.125.2.523; Burckhardt BC, 1997, PFLUG ARCH EUR J PHY, V434, P306, DOI 10.1007/s004240050401; Cougnon M, 1996, PFLUG ARCH EUR J PHY, V431, P658, DOI 10.1007/BF02191917; Coutts G, 2002, EMBO J, V21, P536, DOI 10.1093/emboj/21.4.536; Daram P, 1997, EMBO J, V16, P3455, DOI 10.1093/emboj/16.12.3455; Dreyer I, 1997, BIOPHYS J, V72, P2143, DOI 10.1016/S0006-3495(97)78857-X; DUBOIS E, 1979, MOL GEN GENET, V175, P67, DOI 10.1007/BF00267857; EYERS SAC, 1994, J BIOL CHEM, V269, P6417; Fischer WN, 2002, PLANT J, V29, P717, DOI 10.1046/j.1365-313X.2002.01248.x; Fusco C, 1999, YEAST, V15, P715, DOI 10.1002/(SICI)1097-0061(19990615)15:8<715::AID-YEA406>3.0.CO;2-K; GOJON A, 1986, PLANT PHYSIOL, V82, P254, DOI 10.1104/pp.82.1.254; HARTELSCHENK S, 1992, J BIOL CHEM, V267, P5569; Howitt SM, 2000, BBA-BIOMEMBRANES, V1465, P152, DOI 10.1016/S0005-2736(00)00136-X; Hsieh MH, 1998, P NATL ACAD SCI USA, V95, P13965, DOI 10.1073/pnas.95.23.13965; Kaiser BN, 2002, PLANT PHYSIOL, V130, P1263, DOI 10.1104/pp.102.010843; Kosolapov A, 2003, J BIOL CHEM, V278, P4305, DOI 10.1074/jbc.M209422200; Lauter FR, 1996, P NATL ACAD SCI USA, V93, P8139, DOI 10.1073/pnas.93.15.8139; Ludewig U, 2002, J BIOL CHEM, V277, P13548, DOI 10.1074/jbc.M200739200; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; Ludewig U, 2001, GENOME BIOL, V2; MADDY AH, 1976, J THEOR BIOL, V62, P315, DOI 10.1016/0022-5193(76)90123-5; Marini AM, 2000, MOL MICROBIOL, V38, P552, DOI 10.1046/j.1365-2958.2000.02151.x; Marini AM, 2000, MOL MICROBIOL, V35, P378, DOI 10.1046/j.1365-2958.2000.01704.x; MARINI AM, 1994, EMBO J, V13, P3456, DOI 10.1002/j.1460-2075.1994.tb06651.x; Marini AM, 1997, TRENDS BIOCHEM SCI, V22, P460, DOI 10.1016/S0968-0004(97)01132-8; Marini AM, 2000, NAT GENET, V26, P341, DOI 10.1038/81656; NINNEMANN O, 1994, EMBO J, V13, P3464, DOI 10.1002/j.1460-2075.1994.tb06652.x; Pilot G, 2001, J BIOL CHEM, V276, P3215, DOI 10.1074/jbc.M007303200; Reinders A, 2002, PLANT CELL, V14, P1567, DOI 10.1105/tpc.002428; SCHULZ EX, 2003, BMC BIOCH, V4, P3; Siewe RM, 1996, J BIOL CHEM, V271, P5398, DOI 10.1074/jbc.271.10.5398; SMART DR, 1988, OECOLOGIA, V76, P336, DOI 10.1007/BF00377026; Soupene E, 2001, MOL CELL BIOL, V21, P5733, DOI 10.1128/MCB.21.17.5733-5741.2001; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; ULLRICH WR, 1984, PHYSIOL PLANTARUM, V61, P369, DOI 10.1111/j.1399-3054.1984.tb06342.x; Veenhoff LM, 2002, TRENDS BIOCHEM SCI, V27, P242, DOI 10.1016/S0968-0004(02)02077-7; von Wiren N, 2000, PLANT J, V21, P167, DOI 10.1046/j.1365-313x.2000.00665.x; von Wiren N, 2000, CURR OPIN PLANT BIOL, V3, P254, DOI 10.1016/S1369-5266(00)00073-X; von Wiren N, 1997, PLANT PHYSIOL BIOCH, V35, P945; WANG MY, 1993, PLANT PHYSIOL, V103, P1259, DOI 10.1104/pp.103.4.1463; Westhoff CM, 2002, J BIOL CHEM, V277, P12499, DOI 10.1074/jbc.C200060200; White PJ, 1996, J MEMBRANE BIOL, V152, P89, DOI 10.1007/s002329900088	47	132	141	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45603	45610		10.1074/jbc.M307424200	http://dx.doi.org/10.1074/jbc.M307424200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952951	hybrid			2022-12-25	WOS:000186452300069
J	O'Toole, PJ; Inoue, T; Emerson, L; Morrison, IEG; Mackie, AR; Cherry, RJ; Norton, JD				O'Toole, PJ; Inoue, T; Emerson, L; Morrison, IEG; Mackie, AR; Cherry, RJ; Norton, JD			Id proteins negatively regulate basic helix-loop-helix transcription factor function by disrupting subnuclear compartmentalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; DNA-BINDING; NUCLEAR COMPARTMENTALIZATION; GLUCOCORTICOID-RECEPTOR; DIFFERENTIATION; EXPRESSION; DOMAIN; ANGIOGENESIS; REPRESSION; DYNAMICS	Id helix-loop-helix (HLH) proteins act as global regulators of metazoan cell fate, cell growth, and differentiation. They heterodimerize with and inhibit the DNA-binding function of members of the basic helix-loop-helix (bHLH) family of transcription factors. Using real time fluorescence microscopy techniques in single living cells, we show here that nuclear pools of chromatin-associated bHLH transcription factor are freely exchangeable and in constant flux. The existence of a dynamic equilibrium between DNA-bound and free bHLH protein is also directly demonstrable in vitro. By contrast, Id protein is not associated with any subcellular, macromolecular structures and displays a more highly mobile, diffuse nuclear-cytoplasmic distribution. When co-expressed with antagonist Id protein, the chromatin-associated sublocalization of bHLH protein is abolished, and there is an accompanying 100-fold increase in its nuclear mobility to a level expected for freely diffusible Id-bHLH heterodimer. These results suggest that nuclear Id protein acts by sequestering pools of transiently diffusing bHLH protein to prevent reassociation with chromatin domains. Such a mechanism would explain how Id proteins are able to overcome the large DNA-binding free energy of bHLH proteins that is necessary to accomplish their inhibitory effect.	Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England; Inst Food Res, Norwich NR4 7UA, Norfolk, England	University of Essex; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Norton, JD (corresponding author), Univ Essex, Dept Biol Sci, Wivenhoe Pk, Colchester CO4 3SQ, Essex, England.	jnorton@essex.ac.uk	Mackie, Alan/N-7780-2018	Mackie, Alan/0000-0002-5681-0593; O'Toole, Peter John/0000-0001-5295-2001				Akiyama TE, 2002, MOL ENDOCRINOL, V16, P707, DOI 10.1210/me.16.4.707; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Atherton GT, 1996, CELL GROWTH DIFFER, V7, P1059; Baumann CT, 2001, J BIOL CHEM, V276, P11237, DOI 10.1074/jbc.M011112200; Becker M, 2002, EMBO REP, V3, P1188, DOI 10.1093/embo-reports/kvf244; Benezra R, 2001, ONCOGENE, V20, P8288, DOI 10.1038/sj.onc.1205161; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bradney C, 2003, J BIOL CHEM, V278, P2370, DOI 10.1074/jbc.M211464200; Carmo-Fonseca M, 2002, CELL, V108, P513, DOI 10.1016/S0092-8674(02)00650-5; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; Chubb JR, 2003, CELL, V112, P403, DOI 10.1016/S0092-8674(03)00078-3; Day RN, 2001, METHODS, V25, P4, DOI 10.1006/meth.2001.1211; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; Elbi C, 2002, MOL BIOL CELL, V13, P2001, DOI 10.1091/mboc.13.6.mk0602002001; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Engel I, 2001, NAT REV IMMUNOL, V1, P193, DOI 10.1038/35105060; FAIRMAN R, 1993, P NATL ACAD SCI USA, V90, P10429, DOI 10.1073/pnas.90.22.10429; Funato N, 2003, J BIOL CHEM, V278, P7486, DOI 10.1074/jbc.M212248200; Grande MA, 1997, J CELL SCI, V110, P1781; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; JACOBS Y, 1994, MOL CELL BIOL, V14, P4087, DOI 10.1128/MCB.14.6.4087; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Ladha S, 1996, BIOPHYS J, V71, P1364, DOI 10.1016/S0006-3495(96)79339-6; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Maleki SJ, 2002, BIOCHEMISTRY-US, V41, P10888, DOI 10.1021/bi025528q; Mancini MG, 1999, J CELL BIOCHEM, V72, P322, DOI 10.1002/(SICI)1097-4644(19990301)72:3<322::AID-JCB2>3.3.CO;2-0; Martinsen BJ, 1998, SCIENCE, V281, P988, DOI 10.1126/science.281.5379.988; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Narumi O, 2000, J BIOL CHEM, V275, P3510, DOI 10.1074/jbc.275.5.3510; Norton JD, 2000, J CELL SCI, V113, P3897; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Schaaf MJM, 2003, MOL CELL BIOL, V23, P1922, DOI 10.1128/MCB.23.6.1922-1934.2003; Spinner DS, 2002, J MOL BIOL, V317, P431, DOI 10.1006/jmbi.2002.5440; Sugai M, 2003, NAT IMMUNOL, V4, P25, DOI 10.1038/ni874; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; Tupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; Wendt H, 1998, J BIOL CHEM, V273, P5735, DOI 10.1074/jbc.273.10.5735; Wilson JW, 2001, CANCER RES, V61, P8803; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968	50	39	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45770	45776		10.1074/jbc.M306056200	http://dx.doi.org/10.1074/jbc.M306056200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952978	hybrid			2022-12-25	WOS:000186452300088
J	Yen, TY; Macher, BA; Bryson, S; Chang, XQ; Tvaroska, I; Tse, R; Takeshita, S; Lew, AM; Datti, A				Yen, TY; Macher, BA; Bryson, S; Chang, XQ; Tvaroska, I; Tse, R; Takeshita, S; Lew, AM; Datti, A			Highly conserved cysteines of mouse core 2 beta 1,6-N-acetylglucosaminyltransferase I form a network of disulfide bonds and include a thiol that affects enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; O-LINKED OLIGOSACCHARIDES; GLYCAN BRANCH FORMATION; P-SELECTIN; N-ACETYLGLUCOSAMINYLTRANSFERASE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; SIALYL LEWIS(X); HUMAN ALPHA-1,3/4-FUCOSYL-TRANSFERASES; DIFFERENTIAL REQUIREMENTS	Core 2 beta1,6-N-acetylglucosaminyltransferase I (C2GnT-I) plays a pivotal role in the biosynthesis of mucin-type O-glycans that serve as ligands in cell adhesion. To elucidate the three-dimensional structure of the enzyme for use in computer-aided design of therapeutically relevant enzyme inhibitors, we investigated the participation of cysteine residues in disulfide linkages in a purified murine recombinant enzyme. The pattern of free and disulfide-bonded Cys residues was determined by liquid chromatography/electrospray ionization tandem mass spectrometry in the absence and presence of dithiothreitol. Of nine highly conserved Cys residues, under both conditions, one (Cys(217)) is a free thiol, and eight are engaged in disulfide bonds, with pairs formed between Cys(59)-Cys(413), Cys(100)-Cys(172), Cys(151)-Cys(199), and Cys(372)-Cys(381). The only non-conserved residue within the beta1,6-N-acetylglucosaminyltransferase family, Cys(235), is also a free thiol in the presence of dithiothreitol; however, in the absence of reductant, Cys(235) forms an intermolecular disulfide linkage. Biochemical studies performed with thiol-reactive agents demonstrated that at least one free cysteine affects enzyme activity and is proximal to the UDP-GlcNAc binding site. A Cys(217)-->Ser mutant enzyme was insensitive to thiol reactants and displayed kinetic properties virtually identical to those of the wild-type enzyme, thereby showing that Cys(217), although not required for activity per se, represents the only thiol that causes enzyme inactivation when modified. Based on the pattern of free and disulfide-linked Cys residues, and a method of fold recognition/threading and homology modeling, we have computed a three-dimensional model for this enzyme that was refined using the T4 bacteriophage beta-glucosyltransferase fold.	GlycoDesign Inc, Toronto, ON M5G 1V2, Canada; San Francisco State Univ, Dept Chem & Biochem, San Francisco, CA 94132 USA; Seikagaku Corp, Cent Res Labs, Tokyo 2070021, Japan	California State University System; San Francisco State University; Seikagaku Corporation	Datti, A (corresponding author), GlycoDesign Inc, 480 Univ Ave,Ste 400, Toronto, ON M5G 1V2, Canada.		Tvaroška, Igor/ABF-2188-2020; Datti, Alessandro/ABA-1108-2021	Tvaroška, Igor/0000-0003-2740-944X; Datti, Alessandro/0000-0001-6824-7382; Bryson, Steve/0000-0001-8924-4201	NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [P20MD000262] Funding Source: NIH RePORTER; NIMHD NIH HHS [1P20 MD 00262] Funding Source: Medline	NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		Angata K, 2001, J BIOL CHEM, V276, P15369, DOI 10.1074/jbc.M100576200; Bernimoulin MP, 2003, J BIOL CHEM, V278, P37, DOI 10.1074/jbc.M204360200; BIERHUIZEN MFA, 1995, GLYCOBIOLOGY, V5, P417, DOI 10.1093/glycob/5.4.417; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Chen C, 2000, J BIOL CHEM, V275, P13819, DOI 10.1074/jbc.275.18.13819; Dan N, 1997, J BIOL CHEM, V272, P14214, DOI 10.1074/jbc.272.22.14214; DATTI A, 1992, ANAL BIOCHEM, V206, P262, DOI 10.1016/0003-2697(92)90364-D; de Vries T, 2001, GLYCOBIOLOGY, V11, P423, DOI 10.1093/glycob/11.5.423; Donovan RS, 1999, GLYCOCONJUGATE J, V16, P607, DOI 10.1023/A:1007024916491; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; FLEISCHER B, 1993, BIOCHEMISTRY-US, V32, P2076, DOI 10.1021/bi00059a027; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Fukuda M, 2002, BBA-GEN SUBJECTS, V1573, P394, DOI 10.1016/S0304-4165(02)00409-9; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Holmes EH, 2000, J BIOL CHEM, V275, P24237, DOI 10.1074/jbc.M000888200; Kaila N, 2002, MED RES REV, V22, P566, DOI 10.1002/med.10018; KITZ R, 1962, J BIOL CHEM, V237, P3245; Koya D, 1999, FASEB J, V13, P2329, DOI 10.1096/fasebj.13.15.2329; Kumar R, 1996, BLOOD, V88, P3872, DOI 10.1182/blood.V88.10.3872.bloodjournal88103872; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Li JH, 2000, J BIOL CHEM, V275, P41476, DOI 10.1074/jbc.M007480200; LOO JA, 1993, ANAL CHEM, V65, P425, DOI 10.1021/ac00052a020; Lowe JB, 2002, IMMUNOL REV, V186, P19, DOI 10.1034/j.1600-065X.2002.18603.x; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; Machida E, 2001, CANCER RES, V61, P2226; Mitoma J, 2003, J BIOL CHEM, V278, P9953, DOI 10.1074/jbc.M212756200; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; Mulligan MS, 1999, J IMMUNOL, V162, P4952; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; Nguyen AT, 1998, J BIOL CHEM, V273, P25244, DOI 10.1074/jbc.273.39.25244; Opat AS, 2000, J BIOL CHEM, V275, P11836, DOI 10.1074/jbc.275.16.11836; Patel KD, 2002, SEMIN IMMUNOL, V14, P73, DOI 10.1006/smim.2001.0344; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; PILLER F, 1988, J BIOL CHEM, V263, P15146; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Rost B, 1996, METHOD ENZYMOL, V266, P525; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; Schwientek T, 2000, J BIOL CHEM, V275, P11106, DOI 10.1074/jbc.275.15.11106; Schwientek T, 1999, J BIOL CHEM, V274, P4504, DOI 10.1074/jbc.274.8.4504; SEKINE M, 1994, J BIOL CHEM, V269, P31143; Senay C, 2002, BBA-PROTEIN STRUCT M, V1597, P90, DOI 10.1016/S0167-4838(02)00266-2; Shimodaira K, 1997, CANCER RES, V57, P5201; Snapp KR, 2001, BLOOD, V97, P3806, DOI 10.1182/blood.V97.12.3806; Sperandio M, 2001, J IMMUNOL, V167, P2268, DOI 10.4049/jimmunol.167.4.2268; Sperandio M, 2001, BLOOD, V97, P3812, DOI 10.1182/blood.V97.12.3812; Tenno M, 2002, EUR J BIOCHEM, V269, P4308, DOI 10.1046/j.1432-1033.2002.03123.x; Thomas S, 2002, GLYCOBIOLOGY, V12, p4G; Toki D, 1997, BIOCHEM J, V325, P63, DOI 10.1042/bj3250063; Tsuboi S, 1998, J BIOL CHEM, V273, P30680, DOI 10.1074/jbc.273.46.30680; Tsuboi S, 2001, BIOESSAYS, V23, P46, DOI 10.1002/1521-1878(200101)23:1<46::AID-BIES1006>3.3.CO;2-V; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; VanderElst IE, 1998, GLYCOBIOLOGY, V8, P731, DOI 10.1093/glycob/8.7.731; Vanderplasschen A, 2000, P NATL ACAD SCI USA, V97, P5756, DOI 10.1073/pnas.100058897; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Vo L, 1998, J BIOL CHEM, V273, P25250, DOI 10.1074/jbc.273.39.25250; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; WILLIAMS D, 1980, J BIOL CHEM, V255, P1247; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yang XJ, 2003, BBA-PROTEINS PROTEOM, V1648, P62, DOI 10.1016/S1570-9639(03)00105-5; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; Yen TY, 2000, J MASS SPECTROM, V35, P990, DOI 10.1002/1096-9888(200008)35:8<990::AID-JMS27>3.0.CO;2-K; Yen TY, 2002, J MASS SPECTROM, V37, P15, DOI 10.1002/jms.241; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	68	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45864	45881		10.1074/jbc.M303851200	http://dx.doi.org/10.1074/jbc.M303851200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954635	hybrid			2022-12-25	WOS:000186452300100
J	Fuentes, L; Perez, R; Nieto, ML; Balsinde, J; Balboa, MA				Fuentes, L; Perez, R; Nieto, ML; Balsinde, J; Balboa, MA			Bromoenol lactone promotes cell death by a mechanism involving phosphatidate phosphohydrolase-1 rather than calcium-independent phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID MOBILIZATION; SIGNAL-TRANSDUCTION; DISTINCT ROLES; INHIBITION; APOPTOSIS; PHOSPHATIDYLCHOLINE; MEMBRANE; CASPASES; PHOSPHATIDYLSERINE; TRIACYLGLYCEROL	Originally described as a serine protease inhibitor, bromoenol lactone ( BEL) has recently been found to potently inhibit Group VI calcium-independent phospholipase A(2) (iPLA(2)). Thus, BEL is widely used to define biological roles of iPLA(2) in cells. However, BEL is also known to inhibit another key enzyme of phospholipid metabolism, namely the magnesium-dependent phosphatidate phosphohydrolase-1 (PAP-1). In this work we report that BEL is able to promote apoptosis in a variety of cell lines, including U937, THP-1, and MonoMac (human phagocyte), RAW264.7 ( murine macrophage), Jurkat ( human T lymphocyte), and GH3 ( human pituitary). In these cells, long term treatment with BEL ( up to 24 h) results in increased annexin-V binding to the cell surface and nuclear DNA damage, as detected by staining with both DAPI and propidium iodide. At earlier times ( 2 h), BEL induces the proteolysis of procaspase-9 and procaspase-3 and increases cleavage of poly(ADP-ribose) polymerase. These changes are preceded by variations in the mitochondrial membrane potential. All these effects of BEL are not mimicked by the iPLA(2) inhibitor methylarachidonyl fluorophosphonate or by treating the cells with a specific iPLA(2) antisense oligonucleotide. However, propranolol, a PAP-1 inhibitor, is able to reproduce these effects, suggesting that it is the inhibition of PAP-1 and not of iPLA(2) that is involved in BEL-induced cell death. In support of this view, BEL-induced apoptosis is accompanied by a very strong inhibition of PAP-1-regulated events, such as incorporation of [H-3] choline into phospholipids and de novo incorporation of [H-3] arachidonic acid into triacylglycerol. Collectively, these results stress the role of PAP-1 as a key enzyme for cell integrity and survival and in turn caution against the use of BEL in studies involving long incubation times, due to the capacity of this drug to induce apoptosis in a variety of cells.	Univ Valladolid, Fac Med, Inst Mol Biol & Genet, IBGM CSIC,Sch Med, E-47005 Valladolid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid	Balsinde, J (corresponding author), Univ Valladolid, Fac Med, Inst Mol Biol & Genet, IBGM CSIC,Sch Med, Ave Ramon & Cajal 7, E-47005 Valladolid, Spain.	jbalsinde@ibgm.uva.es	Pérez, Rebeca/M-5235-2015; Fuentes, Lucia/R-6445-2016; Balboa, María A./V-9493-2018; Balsinde, Jesús/C-7833-2018; Nieto, Maria L/G-7492-2015	Pérez, Rebeca/0000-0002-0445-868X; Balboa, María A./0000-0002-2130-5298; Balsinde, Jesús/0000-0002-4157-6714; Nieto, Maria L/0000-0001-6842-799X				ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Balboa MA, 1998, J BIOL CHEM, V273, P7684, DOI 10.1074/jbc.273.13.7684; Balboa MA, 2003, J IMMUNOL, V170, P5276, DOI 10.4049/jimmunol.170.10.5276; Balboa MA, 2002, J BIOL CHEM, V277, P40384, DOI 10.1074/jbc.M206155200; Balsinde J, 1996, EUR J BIOCHEM, V235, P480, DOI 10.1111/j.1432-1033.1996.00480.x; Balsinde J, 2000, J BIOL CHEM, V275, P22544, DOI 10.1074/jbc.M910163199; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRATTON DL, 1992, J IMMUNOL, V148, P514; Brindley DN, 2002, BBA-MOL CELL BIOL L, V1582, P33, DOI 10.1016/S1388-1981(02)00135-X; Carnevale KA, 2001, J IMMUNOL, V167, P3414, DOI 10.4049/jimmunol.167.6.3414; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Chen M, 2002, APOPTOSIS, V7, P313, DOI 10.1023/A:1016167228059; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Cui Z, 2002, BBA-MOL CELL BIOL L, V1585, P87, DOI 10.1016/S1388-1981(02)00328-1; DANIELS SB, 1983, J BIOL CHEM, V258, P5046; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Gueguen G, 2002, BIOCHEM J, V368, P447, DOI 10.1042/BJ20020273; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MARTIN A, 1994, SIGNAL ACTIVATED PHO, P139; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; PETTUS B, 2003, BIOCHIM BIOPHYS ACTA, V1585, P114; Roshak AK, 2000, J BIOL CHEM, V275, P35692, DOI 10.1074/jbc.M002273200; Sanchez T, 2002, J CELL PHYSIOL, V193, P293, DOI 10.1002/jcp.10162; Siskind LJ, 2002, J BIOL CHEM, V277, P26796, DOI 10.1074/jbc.M200754200; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4; ZHU HJ, 1995, FEBS LETT, V374, P303, DOI 10.1016/0014-5793(95)01116-V; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	43	84	86	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44683	44690		10.1074/jbc.M307209200	http://dx.doi.org/10.1074/jbc.M307209200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12952946	hybrid			2022-12-25	WOS:000186306700101
J	Mitra, RS; Zhang, ZC; Henson, BS; Kurnit, DM; Carey, TE; D'Silva, NJ				Mitra, RS; Zhang, ZC; Henson, BS; Kurnit, DM; Carey, TE; D'Silva, NJ			Rap1A and rap1B ras-family proteins are prominently expressed in the nucleus of squamous carcinomas: nuclear translocation of GTP-bound active form	ONCOGENE			English	Article						rap1; nucleus; regulation; carcinoma	BINDING PROTEINS; HUMAN-PLATELETS; MYOGENIC DIFFERENTIATION; GOLGI-COMPLEX; GROWTH-FACTOR; MAP KINASE; ACTIVATION; TRANSFORMATION; ASSOCIATION; INHIBITION	We recently showed that rap1 regulates growth and proliferation in normal keratinocytes, which provoked us to investigate its expression and regulation in malignant cells. Rap1 is variably expressed in whole cell lysates of squamous cell carcinoma (SCC) cell lines. Immunoblot analysis of nuclear and cytosolic fractions and immunohistochemistry revealed that in addition to cytoplasmic expression, SCC cells also exhibit prominent punctate rap1 expression in the nucleus. This unexpected nuclear distribution was confirmed by the evaluation of human oral cancer specimens by immunohistochemistry, which showed both nuclear and cytoplasmic localization. Cytoplasmic rap1 expression was observed mostly in large differentiated cells, whereas nuclear localization was found in morphologically less differentiated cells. Quantitative reverse transcriptase polymerase chain reaction and Northern blot analysis showed that both rap1A and rap1B are expressed in SCC cell lines although rap1B signals are more prominent. Transfection with enhanced GFP-tagged constitutively active and inactive forms of rap1B demonstrated that the active GTP-bound form translocates to the nucleus whereas inactive rap1B(GDP) is retained in the cytoplasm, much of which is in a perinuclear distribution. Furthermore, growth factors induce nuclear translocation of rap1 in oral cancer cells. This novel discovery that active, GTP-bound rap1 translocates to the nucleus makes it only the second of over 100 small GTP-binding proteins to be identified in the nucleus, and the striking prominence of rap1 expression in the nucleus of SCC cells suggests that activated rap1 plays a role in the malignant process.	Univ Michigan, Sch Dent, Dept Oral Med Pathol & Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Otolaryngol, Lab Head & Neck Canc Biol, Ann Arbor, MI 48109 USA; Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	D'Silva, NJ (corresponding author), Univ Michigan, Sch Dent, Dept Oral Med Pathol & Oncol, Ann Arbor, MI 48109 USA.		D'Silva, Nisha J/B-4734-2013	Carey, Thomas/0000-0002-5202-7518	NCI NIH HHS [1 P50 CA97248] Funding Source: Medline; NIDCR NIH HHS [DE00452-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BERGER G, 1994, BRIT J HAEMATOL, V88, P372, DOI 10.1111/j.1365-2141.1994.tb05033.x; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Carey TE, 1994, ATLAS HUMAN TUMOR CE, P79; CLARK LJ, 1993, BRIT J CANCER, V68, P617, DOI 10.1038/bjc.1993.396; D'Silva NJ, 1998, AM J PHYSIOL-CELL PH, V274, pC1667, DOI 10.1152/ajpcell.1998.274.6.C1667; DSilva NJ, 1997, J HISTOCHEM CYTOCHEM, V45, P965, DOI 10.1177/002215549704500706; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GRUNICKE HH, 1993, CRIT REV ONCOGENESIS, V4, P389; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; JORDAN, 1997, J CAN DENT ASS, V63, P517; Jordan RC, 1997, J CAN DENT ASSOC, V63, P521; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MIRVISH SS, 1995, CANCER LETT, V93, P17, DOI 10.1016/0304-3835(95)03786-V; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Moore JD, 2001, BIOESSAYS, V23, P77, DOI 10.1002/1521-1878(200101)23:1<77::AID-BIES1010>3.3.CO;2-5; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; PIZON V, 1994, J CELL SCI, V107, P1661; Pizon V, 1999, EXP CELL RES, V246, P56, DOI 10.1006/excr.1998.4284; Pizon V, 1996, EUR J CELL BIOL, V69, P224; QIAO J, 2002, J BIOL CHEM, V8, P8; SARANATH D, 1991, BRIT J CANCER, V63, P573, DOI 10.1038/bjc.1991.133; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; SCHNEFEL S, 1992, Cellular Physiology and Biochemistry, V2, P77, DOI 10.1159/000154628; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WAGNER ACC, 1994, AM J PHYSIOL, V266, pG1, DOI 10.1152/ajpgi.1994.266.1.G1; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang YA, 2002, MOL CELL NEUROSCI, V19, P430, DOI 10.1006/mcne.2001.1076; Zou CP, 1999, DIFFERENTIATION, V64, P123, DOI 10.1046/j.1432-0436.1999.6420123.x	39	61	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6243	6256		10.1038/sj.onc.1206534	http://dx.doi.org/10.1038/sj.onc.1206534			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679863				2022-12-25	WOS:000185506200014
J	Zhang, J; Choi, Y; Mavromatis, B; Lichtenstein, A; Li, WQ				Zhang, J; Choi, Y; Mavromatis, B; Lichtenstein, A; Li, WQ			Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway	ONCOGENE			English	Article						Akt/PKB; multiple myeloma; PI3K inhibitors; PTEN; signal transduction	ACTIVATED PROTEIN-KINASE; MULTIPLE-MYELOMA; TUMOR-SUPPRESSOR; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; CELL-LINE; 3-KINASE; INSULIN; APOPTOSIS; RESPONSES	We recently reported that internal deletion of PTEN tumor suppressor gene in OPM2 and Delta47 myeloma lines led to high Akt activation. Re-expression of PTEN induced strong apoptosis and growth inhibition. To understand the biologic importance of the phosphatidylinositol 3 kinase (PI3K)/Akt activation affected by PTEN deletion, we analysed apoptosis and growth inhibition by applying PI3K inhibitors to myeloma lines and by expressing Akt constructs. The PI3K inhibitors preferentially suppressed PTEN-null myeloma growth to those expressing PTEN, indicating that PI3K activation is more critical for growth and survival of those lines with PTEN mutations than others expressing a functional PTEN gene. Since PTEN- null myeloma lines exhibited much stronger Akt activation than PTEN- expressing cells in response to insulin-like growth factor I stimulation, we determined whether Akt could be responsible for PI3K-mediated cell survival and growth of PTEN- null myeloma lines. Expression of an active Akt, but not its kinase dead mutant, reversed wortmannin- and dexamethasone-induced apoptosis and growth inhibition in PTEN- null myeloma lines, suggesting that Akt lies downstream of PI3K for PTEN- null myeloma survival and dexamethasone resistance. In summary, we have provided evidence that PTEN- null myeloma cells are stringently dependent on the PI3K/Akt activation for cell survival. These results may provide a basis to treat myeloma patients with PI3K and Akt inhibitors.	Georgetown Univ, Med Ctr, Sch Med, Lombardi Canc Ctr,Dept Oncol, Washington, DC 20057 USA; W LA VA Med Ctr, Dept Med, Los Angeles, CA USA; Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA	Georgetown University; UCLA Jonsson Comprehensive Cancer Center	Li, WQ (corresponding author), Georgetown Univ, Med Ctr, Sch Med, Lombardi Canc Ctr,Dept Oncol, Box 571469,New Res Bldg,E407,3970 Reservoir Rd NW, Washington, DC 20057 USA.							Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Choi Y, 2002, ONCOGENE, V21, P5289, DOI 10.1038/sj.onc.1205650; Desikan K R, 1999, Curr Opin Hematol, V6, P216, DOI 10.1097/00062752-199907000-00004; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feinman R, 1997, HEMATOL ONCOL CLIN N, V11, P1, DOI 10.1016/S0889-8588(05)70412-3; Gado K, 2001, HAEMATOLOGICA, V86, P227; Ge NL, 2000, ONCOGENE, V19, P4091, DOI 10.1038/sj.onc.1203801; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hsu JH, 2002, ONCOGENE, V21, P1391, DOI 10.1038/sj/onc/1205194; Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Jelinek DF, 1997, J IMMUNOL, V159, P487; Jelinek DF, 1999, HEMATOL ONCOL CLIN N, V13, P1145, DOI 10.1016/S0889-8588(05)70117-9; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kyle RA, 2001, ONCOLOGIST, V6, P119, DOI 10.1634/theoncologist.6-2-119; Li WQ, 2000, CANCER RES, V60, P3909; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; NIESVIZKY R, 1993, BLOOD REV, V7, P24, DOI 10.1016/0268-960X(93)90021-U; Nishimoto N, 1997, HEMATOL ONCOL CLIN N, V11, P159, DOI 10.1016/S0889-8588(05)70421-4; Ogawa M, 2000, CANCER RES, V60, P4262; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Shi YJ, 2002, CANCER RES, V62, P5027; Shi YY, 2002, J BIOL CHEM, V277, P15712, DOI 10.1074/jbc.M200043200; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tu YP, 2000, CANCER RES, V60, P6763; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	36	44	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6289	6295		10.1038/sj.onc.1206718	http://dx.doi.org/10.1038/sj.onc.1206718			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679867				2022-12-25	WOS:000185506200018
J	Quintanilla, M; Ramirez, JR; Perez-Gomez, E; Romero, D; Velasco, B; Letarte, M; Lopez-Novoa, JM; Bernabeu, C				Quintanilla, M; Ramirez, JR; Perez-Gomez, E; Romero, D; Velasco, B; Letarte, M; Lopez-Novoa, JM; Bernabeu, C			Expression of the TGF-beta coreceptor endoglin in epidermal keratinocytes and its dual role in multistage mouse skin carcinogenesis	ONCOGENE			English	Article						endoglin; TGF-beta; keratinocyte; tumor progression	GROWTH-FACTOR-BETA; HEREDITARY HEMORRHAGIC TELANGIECTASIA; VASCULAR ENDOTHELIAL-CELLS; BINDING-PROTEIN ENDOGLIN; TRANSFORMING GROWTH-FACTOR-BETA-1; CHEMICAL CARCINOGENESIS; MONOCLONAL-ANTIBODIES; CELLULAR-RESPONSES; SPINDLE CARCINOMAS; TUMOR PROGRESSION	Endoglin is an integral membrane glycoprotein primarily expressed in the vascular endothelium, but also found on macrophages and stromal cells. It binds several members of the transforming growth factor (TGF)-beta family of growth factors and modulates TGF-beta(1)-dependent cellular responses. However, it lacks cytoplasmic signaling motifs and is considered as an auxiliary receptor for TGF-beta. We show here that endoglin is expressed in mouse and human epidermis and in skin appendages, such as hair follicles and sweat glands, as determined by immunohistochemistry. In normal interfollicular epidermis, endoglin was restricted to basal keratinocytes and absent in differentiating cells of suprabasal layers. Follicular expression of endoglin was high in hair bulb keratinocytes, but decreased in parts distal from the bulb. To address the role of endoglin in skin carcinogenesis in vivo, Endoglin heterozygous mice were subjected to long-term chemical carcinogenesis treatment. Reduction in endoglin had a dual effect during multistage carcinogenesis, by inhibiting the early appearance of benign papillomas, but increasing malignant progression to highly undifferentiated carcinomas. Our results are strikingly similar to those previously reported for transgenic mice overexpressing TGF-beta(1) in the epidermis. These data suggest that endoglin might attenuate TGF-beta(1) signaling in normal epidermis and interfere with progression of skin carcinogenesis.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; Hosp Gomez Ulla, Dept Anat Patol, Madrid 28047, Spain; CSIC, Ctr Invest Biol, Madrid 28040, Spain; Hosp Sick Children, Blood & Canc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 1X8, Canada; Univ Salamanca, Fac Med, Dept Fisiol & Farmacol, Salamanca 37007, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Salamanca	Quintanilla, M (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	mquintanilla@iib.uam.es	Bernabeu, Carmelo/L-3226-2014; Pérez-Gómez, Eduardo/GYA-5856-2022; Perez-gomez, Eduardo/F-5906-2015; Lopez-Novoa, Jose M/A-3672-2008; Quintanilla, Miguel/K-9293-2017; Bernabeu, Carmelo/P-4662-2019	Bernabeu, Carmelo/0000-0002-1563-6162; Pérez-Gómez, Eduardo/0000-0003-0160-5565; Perez-gomez, Eduardo/0000-0003-0160-5565; Bernabeu, Carmelo/0000-0002-1563-6162; Lopez-Novoa, Jose M./0000-0002-6211-7269; Quintanilla, Miguel/0000-0002-2124-7657				AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Altomonte M, 1996, BRIT J CANCER, V74, P1586, DOI 10.1038/bjc.1996.593; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Bodey B, 1998, ANTICANCER RES, V18, P2701; Bolontrade MF, 1998, CARCINOGENESIS, V19, P2107, DOI 10.1093/carcin/19.12.2107; Bourdeau A, 2001, AM J PATHOL, V158, P2011, DOI 10.1016/S0002-9440(10)64673-1; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; BUCHMANN A, 1991, CANCER RES, V51, P4097; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DIAZGUERRA M, 1992, CANCER RES, V52, P680; Diez-Marques L, 2002, BBA-MOL BASIS DIS, V1587, P36, DOI 10.1016/S0925-4439(02)00051-0; Fonsatti E, 2001, J CELL PHYSIOL, V188, P1, DOI 10.1002/jcp.1095; FOWLIS DJ, 1992, CELL GROWTH DIFFER, V3, P81; Frontelo P, 1998, EXP CELL RES, V244, P420, DOI 10.1006/excr.1998.4219; GE AZ, 1994, GENE, V138, P201, DOI 10.1016/0378-1119(94)90808-7; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARUTA Y, 1986, P NATL ACAD SCI USA, V83, P7898, DOI 10.1073/pnas.83.20.7898; JINDAL SK, 1995, BIOL REPROD, V52, P1027, DOI 10.1095/biolreprod52.5.1027; KLEINSZANTO AJP, 1989, CARCINOGENESIS, V10, P2169, DOI 10.1093/carcin/10.11.2169; Kumar S, 1999, CANCER RES, V59, P856; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Letamendia A, 1998, INT J CANCER, V76, P541, DOI 10.1002/(SICI)1097-0215(19980518)76:4<541::AID-IJC16>3.0.CO;2-A; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Li CG, 2001, MICROSC RES TECHNIQ, V52, P437, DOI 10.1002/1097-0029(20010215)52:4<437::AID-JEMT1029>3.0.CO;2-G; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; MARCHUK DA, 2001, METABOLIC MOL BASES, V4, P5419; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; PATAMALAI B, 1994, MOL CARCINOGEN, V9, P220, DOI 10.1002/mc.2940090406; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; Qu R, 1998, CELL TISSUE RES, V292, P333, DOI 10.1007/s004410051064; QUACKENBUSH EJ, 1985, J IMMUNOL, V134, P1276; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REINERS JJ, 1984, CARCINOGENESIS, V5, P301, DOI 10.1093/carcin/5.3.301; Rich JN, 2001, MICROSC RES TECHNIQ, V52, P363, DOI 10.1002/1097-0029(20010215)52:4<363::AID-JEMT1021>3.3.CO;2-6; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; Robledo MM, 1996, BRIT J HAEMATOL, V93, P507, DOI 10.1046/j.1365-2141.1996.d01-1698.x; Rodriguez-Pena A, 2002, HYPERTENSION, V40, P713, DOI 10.1161/01.HYP.0000037429.73954.27; Shovlin CL, 1999, THORAX, V54, P714, DOI 10.1136/thx.54.8.714; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; Takahashi N, 2001, CANCER RES, V61, P7846; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Velasco B, 2001, GENE THER, V8, P897, DOI 10.1038/sj.gt.3301468; Vincent EB, 1998, DEV DYNAM, V213, P237, DOI 10.1002/(SICI)1097-0177(199811)213:3<237::AID-AJA1>3.0.CO;2-M; YUSPA SH, 1986, CARCINOGENESIS, V7, P949, DOI 10.1093/carcin/7.6.949; YUSPA SH, 1994, CANCER RES, V54, P1178; Zhang HW, 1996, J IMMUNOL, V156, P565	70	41	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5976	5985		10.1038/sj.onc.1206841	http://dx.doi.org/10.1038/sj.onc.1206841			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955076	Green Submitted			2022-12-25	WOS:000185137800006
J	Malgrange, B; Knockaert, M; Belachew, S; Nguyen, L; Moonen, G; Meijer, L; Lefebvre, PP				Malgrange, B; Knockaert, M; Belachew, S; Nguyen, L; Moonen, G; Meijer, L; Lefebvre, PP			Inhibition of cyclin-dependent kinases induces differentiation of supernumerary hair cells and Deiters' cells in the developing organ of Corti	FASEB JOURNAL			English	Article						cochlea; MAP kinase; 2,6,9-trisubstituted purines; kinase inhibitor; roscovitine	PHEOCHROMOCYTOMA PC12 CELLS; MAMMALIAN INNER-EAR; NEURONAL DIFFERENTIATION; CDK INHIBITORS; AFFINITY-CHROMATOGRAPHY; INTRACELLULAR TARGETS; SUPPORTING CELLS; ACOUSTIC TRAUMA; NERVOUS-SYSTEM; ADULT ORGAN	In the embryonic day 19 organs of Corti, we showed that roscovitine, a chemical inhibitor of cyclin-dependent kinases (CDKs), significantly increased the number of hair cells (HCs) and corresponding supporting cells (SCs) by triggering differentiation of precursor cells without interacting with cell proliferation. The effect of roscovitine was mimicked by other CDK1, 2, 5, and 7 inhibitors but not by CDK4/6 and mitogen-activated protein kinase pathway antagonists. Immunohistochemical analysis indicated that roscovitine-specific intracellular targets, CDK1, 2, 5, and 7, were expressed in the organ of Corti and especially in Hensen's cells. Affinity chromatography studies showed a tight correlation between the protein levels of CDK1/2 and 5 and the rate of roscovitine-induced supernumerary cells in the organ of Corti. In addition, we demonstrated that basal CDK activity was higher and more roscovitine-sensitive at developmental stages that are selectively permissive for the emergence of supernumerary cells. These results suggest that CDKs are involved in the normal development of the organ of Corti and that, at least in E19 embryos, inhibition of CDKs is sufficient to trigger the differentiation of HCs and corresponding SCs, presumably from the Hensen's cell progenitors and/or from progenitors located in the greater epithelial ridge area.	Univ Liege, Ctr Cellular & Mol Neurobiol, B-4000 Liege, Belgium; Univ Liege, Dept Neurol, B-4000 Liege, Belgium; CNRS, Biol Stn, Roscoff, Bretagne, France	University of Liege; University of Liege; Centre National de la Recherche Scientifique (CNRS)	Malgrange, B (corresponding author), Univ Liege, Ctr Cellular & Mol Neurobiol, 17 Pl Delcour, B-4020 Liege, Belgium.	bmalgrange@ulg.ac.be	Malgrange, Brigitte/F-8384-2010; Belachew, Shibeshih/V-9185-2019; Nguyen, Laurent/E-9882-2016; Malgrange, Brigitte/A-4887-2019	Belachew, Shibeshih/0000-0003-3976-1950; , laurent/0000-0003-3511-4916; Nguyen, Laurent/0000-0002-8560-3008; Malgrange, Brigitte/0000-0002-8957-2528				ABDOUH A, 1993, NEUROREPORT, V5, P33, DOI 10.1097/00001756-199310000-00008; Alessi F, 1998, EXP CELL RES, V245, P8, DOI 10.1006/excr.1998.4216; Bermingham NA, 1999, SCIENCE, V284, P1837, DOI 10.1126/science.284.5421.1837; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Buolamwini JK, 2000, CURR PHARM DESIGN, V6, P379, DOI 10.2174/1381612003400948; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016/S1074-5521(99)80048-9; Chen P, 2003, NAT CELL BIOL, V5, P422, DOI 10.1038/ncb976; Chen P, 1999, DEVELOPMENT, V126, P1581; CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100; CORWIN JT, 1985, P NATL ACAD SCI USA, V82, P3911, DOI 10.1073/pnas.82.11.3911; Dobashi Y, 1996, BIOCHEM BIOPH RES CO, V221, P351, DOI 10.1006/bbrc.1996.0599; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; Dobashi Y, 2000, J BIOL CHEM, V275, P12572, DOI 10.1074/jbc.275.17.12572; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Edamatsu H, 2000, ONCOGENE, V19, P3059, DOI 10.1038/sj.onc.1203625; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fekete DM, 1998, J NEUROSCI, V18, P7811; Flink IL, 1998, J MOL CELL CARDIOL, V30, P563, DOI 10.1006/jmcc.1997.0620; Gao CY, 1999, EXP EYE RES, V69, P695, DOI 10.1006/exer.1999.0749; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; JORGENSEN JM, 1988, NATURWISSENSCHAFTEN, V75, P319, DOI 10.1007/BF00367330; Kawamoto K, 2003, J NEUROSCI, V23, P4395; Keezer SM, 2002, EXP CELL RES, V273, P54, DOI 10.1006/excr.2001.5421; KELLEY MW, 1995, J NEUROSCI, V15, P3013; Kelley MW, 2001, HANDBOOK OF MOUSE AUDITORY RESEARCH: FROM BEHAVIOR TO MOLECULAR BIOLOGY, P137; KELLEY MW, 1993, DEVELOPMENT, V119, P1041; Knockaert M, 2002, BIOCHEM PHARMACOL, V64, P819, DOI 10.1016/S0006-2952(02)01144-9; Knockaert M, 2000, CHEM BIOL, V7, P411, DOI 10.1016/S1074-5521(00)00124-1; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Knockaert M, 2002, ONCOGENE, V21, P6413, DOI 10.1038/sj.onc.1205908; Lanford PJ, 1999, NAT GENET, V21, P289, DOI 10.1038/6804; Lang HN, 2001, DEV BIOL, V234, P120, DOI 10.1006/dbio.2001.0248; Lee HR, 1999, INT J ONCOL, V15, P161; Lefebvre PP, 2000, ACTA OTO-LARYNGOL, V120, P142; Ljungman M, 2001, MOL PHARMACOL, V60, P785; Lowenheim H, 1999, P NATL ACAD SCI USA, V96, P4084, DOI 10.1073/pnas.96.7.4084; Maas JW, 1998, J NEUROCHEM, V70, P1401; Malgrange B, 2002, CELL MOL LIFE SCI, V59, P1744, DOI 10.1007/PL00012502; Malgrange B, 2002, MECH DEVELOP, V112, P79, DOI 10.1016/S0925-4773(01)00642-6; Malgrange B, 2002, HEARING RES, V170, P48, DOI 10.1016/S0378-5955(02)00451-3; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Mgbonyebi OP, 1999, CANCER RES, V59, P1903; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Ohnuma S, 2001, CURR OPIN NEUROBIOL, V11, P66, DOI 10.1016/S0959-4388(00)00175-6; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; PUJO, 1998, DEV AUDITORY SYSTEM, V1436, P146; ROBERSON DF, 1992, HEARING RES, V57, P166, DOI 10.1016/0378-5955(92)90149-H; Rosania GR, 1999, P NATL ACAD SCI USA, V96, P4797, DOI 10.1073/pnas.96.9.4797; Ruben R.J., 1967, ACTA OTO-LARYNGOL, DOI DOI 10.3109/00016486709127790; RYALS BM, 1988, SCIENCE, V240, P1774, DOI 10.1126/science.3381101; Schultz C, 1999, J MED CHEM, V42, P2909, DOI 10.1021/jm9900570; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shou JY, 2003, MOL CELL NEUROSCI, V23, P169, DOI 10.1016/S1044-7431(03)00066-6; Soni R, 2000, BIOCHEM BIOPH RES CO, V275, P877, DOI 10.1006/bbrc.2000.3349; Tang XM, 1998, J CELL BIOCHEM, V68, P128, DOI 10.1002/(SICI)1097-4644(19980101)68:1<128::AID-JCB13>3.0.CO;2-D; TSAI LH, 1993, DEVELOPMENT, V119, P1029; Urashima M, 1997, BLOOD, V90, P4106, DOI 10.1182/blood.V90.10.4106; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Xiong W, 1997, MOL CELL BIOL, V17, P6585, DOI 10.1128/MCB.17.11.6585; Zheng JL, 2000, NAT NEUROSCI, V3, P580, DOI 10.1038/75753; Zheng JL, 2000, DEVELOPMENT, V127, P4551; Zine A, 2000, DEVELOPMENT, V127, P3373; Zine A, 2001, J NEUROSCI, V21, P4712, DOI 10.1523/JNEUROSCI.21-13-04712.2001	65	18	18	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2136	+		10.1096/fj.03-0035fje	http://dx.doi.org/10.1096/fj.03-0035fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958157				2022-12-25	WOS:000185925100030
J	Forbes, JM; Thallas, V; Thomas, MC; Founds, HW; Burns, WC; Jerums, G; Cooper, ME				Forbes, JM; Thallas, V; Thomas, MC; Founds, HW; Burns, WC; Jerums, G; Cooper, ME			The breakdown of pre-existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes	FASEB JOURNAL			English	Article						diabetic nephropathy; advanced glycation; cross-link breaker; extracellular matrix; ALT-711	TISSUE GROWTH-FACTOR; MAILLARD REACTION-PRODUCTS; NONENZYMATIC GLYCATION; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; CROSS-LINKING; IN-VITRO; COLLAGEN; AMINOGUANIDINE; EXPRESSION	Renal accumulation of advanced glycation end products (AGEs) has been linked to the progression of diabetic nephropathy. Cleavage of pre-formed AGEs within the kidney by a cross-link breaker, such as ALT-711, may confer renoprotection in diabetes. STZ diabetic rats were randomized into a) no treatment (D); b) treatment with the AGE cross-link breaker, ALT-711, weeks 16-32 (DALT early); and c) ALT-711, weeks 24-32 (DALT late). Treatment with ALT-711 resulted in a significant reduction in diabetes-induced serum and renal AGE peptide fluorescence, associated with decreases in renal carboxymethyllsine and RAGE immunostaining. Cross-linking of tail tendon collagen seen in diabetic groups was attenuated only by 16 weeks of ALT-711 treatment. ALT-711, independent of treatment duration, retarded albumin excretion rate (AER), reduced blood pressure, and renal hypertrophy. It also reduced diabetes-induced increases in gene expression of transforming growth factor beta1 (TGF-beta1), connective tissue growth factor (CTGF), and collagen IV. However, glomerulosclerotic index, tubulointerstitial area, total renal collagen, nitrotryrosine, protein expression of collagen IV, and TGF-beta1 only showed improvement with early ALT treatment alone. This study demonstrates the utility of a cross-link breaker as a treatment for diabetic nephropathy and describes effects not only on renal AGEs but on putative mediators of renal injury, such as prosclerotic cytokines and oxidative stress.	Baker Med Res Inst, Div Diabet Complicat, Melbourne, Vic, Australia; Alteon Inc, Ramsey, NJ 07446 USA; Austin & Repatriat Med Ctr, Dept Endocrinol, Heidelberg, Germany	Baker Heart and Diabetes Institute	Forbes, JM (corresponding author), Baker Heart Res Inst, Div Diabet Complicat, POB 6492,St Kilda Rd, Cent Melbourne, Vic 8008, Australia.	Josephine.forbes@baker.edu.au	Cooper, Mark E/E-8680-2010; Forbes, Josephine M/A-4569-2012; Cooper, Mark/AAC-5326-2020	Cooper, Mark E/0000-0002-5953-642X; Forbes, Josephine M/0000-0002-5595-8174; Thomas, Merlin/0000-0003-0694-8743				Adler AI, 2000, BMJ-BRIT MED J, V321, P412, DOI 10.1136/bmj.321.7258.412; ALLEN TJ, 1990, DIABETES, V39, P1182, DOI 10.2337/diabetes.39.10.1182; BEISSWENGER PJ, 1995, DIABETES, V44, P824, DOI 10.2337/diabetes.44.7.824; BEISSWENGER PJ, 1993, J CLIN INVEST, V92, P212, DOI 10.1172/JCI116552; BILOUS RW, 1989, DIABETES, V38, P1142, DOI 10.2337/diabetes.38.9.1142; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BUNAG RD, 1973, J APPL PHYSIOL, V34, P279, DOI 10.1152/jappl.1973.34.2.279; CEFALU WT, 1994, CLIN CHEM, V40, P1317; CHARONIS AS, 1990, DIABETES, V39, P807, DOI 10.2337/diabetes.39.7.807; COOPER ME, 1988, J HYPERTENS, V6, P1009, DOI 10.1097/00004872-198812000-00009; Cooper ME, 2000, DIABETOLOGIA, V43, P660, DOI 10.1007/s001250051355; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; EDMONDSON SR, 1995, ENDOCRINOLOGY, V136, P4602, DOI 10.1210/en.136.10.4602; Forbes JM, 1999, KIDNEY INT, V55, P198, DOI 10.1046/j.1523-1755.1999.00253.x; Forbes JM, 2000, KIDNEY INT, V57, P2375, DOI 10.1046/j.1523-1755.2000.00097.x; Forbes JM, 2002, DIABETES, V51, P3274, DOI 10.2337/diabetes.51.11.3274; Forbes JM, 2001, DIABETOLOGIA, V44, P108, DOI 10.1007/s001250051587; GERBER G, 1960, J BIOL CHEM, V235, P2653; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Jandeleit-Dahm K, 2002, CURR OPIN NEPHROL HY, V11, P221, DOI 10.1097/00041552-200203000-00014; Kass DA, 2001, CIRCULATION, V104, P1464, DOI 10.1161/hc3801.097806; Kelly DJ, 2001, J AM SOC NEPHROL, V12, P2098, DOI 10.1681/ASN.V12102098; KILO C, 1972, DIABETES, V21, P881, DOI 10.2337/diab.21.8.881; Kochakian M, 1996, DIABETES, V45, P1694, DOI 10.2337/diabetes.45.12.1694; MAKINO H, 1995, KIDNEY INT, V48, P517, DOI 10.1038/ki.1995.322; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MAKITA Z, 1994, LANCET, V343, P1519, DOI 10.1016/S0140-6736(94)92935-1; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; McLennan SV, 2002, DIABETES, V51, P2612, DOI 10.2337/diabetes.51.8.2612; Mentink CJAL, 2002, CLIN CHIM ACTA, V321, P69, DOI 10.1016/S0009-8981(02)00097-9; MINAKER KL, 1987, AM J MED, V82, P47, DOI 10.1016/0002-9343(87)90271-3; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; Mott JD, 1997, KIDNEY INT, V52, P1302, DOI 10.1038/ki.1997.455; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; Oldfield MD, 2001, J CLIN INVEST, V108, P1853; Onorato JM, 2000, J BIOL CHEM, V275, P21177, DOI 10.1074/jbc.M003263200; PILLSBUR.HC, 1974, AM HEART J, V87, P783, DOI 10.1016/0002-8703(74)90427-X; PRICE RG, 1977, J BIOL CHEM, V252, P8597; REISER KM, 1991, P SOC EXP BIOL MED, V196, P17; Riser BL, 2000, J AM SOC NEPHROL, V11, P25, DOI 10.1681/ASN.V11125; Schwedler SB, 2001, DIABETES OBES METAB, V3, P230, DOI 10.1046/j.1463-1326.2001.00096.x; Soulis T, 1996, KIDNEY INT, V50, P627, DOI 10.1038/ki.1996.358; SOULISLIPAROTA T, 1991, DIABETES, V40, P1328, DOI 10.2337/diabetes.40.10.1328; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; Sun ZL, 2001, CLIN CHIM ACTA, V313, P69, DOI 10.1016/S0009-8981(01)00651-9; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; Twigg SM, 2002, ENDOCRINOLOGY, V143, P4907, DOI 10.1210/en.2002-220619; Twigg SM, 2001, ENDOCRINOLOGY, V142, P1760, DOI 10.1210/endo.142.5.8141; van der Pijl JW, 1998, DIABETOLOGIA, V41, P791, DOI 10.1007/s001250050989; Vasan S, 1996, NATURE, V382, P275, DOI 10.1038/382275a0; Wolffenbuttel BHR, 1998, P NATL ACAD SCI USA, V95, P4630, DOI 10.1073/pnas.95.8.4630; Wrobel K, 1997, CLIN CHEM, V43, P1563; YAGIHASHI S, 1992, DIABETES, V41, P47, DOI 10.2337/diabetes.41.1.47; YAMAMOTO T, 1993, P NATL ACAD SCI USA, V90, P1814, DOI 10.1073/pnas.90.5.1814; Youssef S, 1999, KIDNEY INT, V55, P907, DOI 10.1046/j.1523-1755.1999.055003907.x; ZIYADEH FN, 1991, KIDNEY INT, V39, P464, DOI 10.1038/ki.1991.57	58	211	219	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1762	+		10.1096/fj.02-1102fje	http://dx.doi.org/10.1096/fj.02-1102fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958202				2022-12-25	WOS:000184471600013
J	Foster, PA; Costa, SKP; Poston, R; Hoult, JRS; Brain, SD				Foster, PA; Costa, SKP; Poston, R; Hoult, JRS; Brain, SD			Endothelial cells play an essential role in the thermal hyperalgesia induced by nerve growth factor	FASEB JOURNAL			English	Article						neutrophils; endothelial cells; ICAM-1	RAT HIND PAW; NEUTROPHIL ACCUMULATION; NONNEURONAL CELLS; CUTANEOUS MICROVASCULATURE; MURINE NEUTROPHILS; ADULT-RAT; EXPRESSION; NOCICEPTORS; INVIVO; 5-LIPOXYGENASE	Nerve growth factor (NGF) is a potent mediator of inflammatory hyperalgesia, in addition to roles in the development and maintenance of neurons, We provide evidence for the novel concept that microvascular endothelial cells play a critical primary role in NGF-mediated events that lead to inflammatory hyperalgesia in rat skin. We show that, surprisingly, neutrophils are not directly activated by NGF, although local administration of NGF mediates thermal hyperalgesia via mechanisms involving concomitant neutrophil accumulation. The co-administration of actinomycin D with NGF negated both neutrophil accumulation and thermal hyperalgesia, indicating the dependence of NGF on local de novo protein synthesis. More significantly, an antibody against the endothelial-derived adhesion molecule ICAM-1 also blocked neutrophil accumulation and thermal hyperalgesia. Finally the ability of NGF to stimulate ICAM-1 in human cultured umbilical vein endothelial cells is shown. We propose that NGF acts primarily to activate endothelial cells and that this response is essential for the ensuing neutrophil accumulation and hyperalgesia. The findings reveal a central role of the endothelial cell in initiating NGF-dependent inflammatory hyperalgesia and emphasize the importance of further investigations aimed at examining the feasibility of new therapeutic strategies that target NGF.	Kings Coll London, Ctr Cardiovasc Biol & Med, Sch Biomed Sci, London SE1 1UL, England	University of London; King's College London	Brain, SD (corresponding author), Kings Coll London, Ctr Cardiovasc Biol & Med, Sch Biomed Sci, New Hunts House,Guys Campus, London SE1 1UL, England.	sue.brain@kcl.ac.uk	COSTA, SORAIA K P/X-6388-2019; Costa, Soraia KP/K-7227-2012; Foster, Paul/D-1615-2011; Brain, Susan/L-3681-2013	COSTA, SORAIA K P/0000-0002-2574-4490; Costa, Soraia KP/0000-0002-2574-4490; Foster, Paul/0000-0001-7190-1592; Brain, Susan/0000-0002-9684-8342				ALOE L, 1992, ARTHRITIS RHEUM, V35, P351, DOI 10.1002/art.1780350315; Amann R, 1996, PAIN, V64, P323, DOI 10.1016/0304-3959(95)00120-4; Amann R, 1996, EUR J PHARMACOL, V306, P89, DOI 10.1016/0014-2999(96)00255-5; ANDREEV NY, 1995, PAIN, V63, P109, DOI 10.1016/0304-3959(95)00024-M; Bennett DLH, 2001, NEUROSCIENTIST, V7, P13, DOI 10.1177/107385840100700105; Bennett G, 1998, PAIN, V77, P315, DOI 10.1016/S0304-3959(98)00114-6; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BOYLE MDP, 1985, J IMMUNOL, V134, P564; Cantarella G, 2002, FASEB J, V16, P1307, DOI 10.1096/fj.01-1000fje; Cao T, 2000, J IMMUNOL, V164, P5424, DOI 10.4049/jimmunol.164.10.5424; de Vries A, 1999, AM J RESP CRIT CARE, V159, P1541, DOI 10.1164/ajrccm.159.5.9808058; di Mola FF, 2000, GUT, V46, P670, DOI 10.1136/gut.46.5.670; DONNERER J, 1992, NEUROSCIENCE, V49, P693, DOI 10.1016/0306-4522(92)90237-V; Foster PA, 2002, J PATHOL, V197, P245, DOI 10.1002/path.1111; Friedman WJ, 1999, EXP CELL RES, V253, P131, DOI 10.1006/excr.1999.4705; GEE AP, 1983, P NATL ACAD SCI-BIOL, V80, P7215, DOI 10.1073/pnas.80.23.7215; GRUBER DF, 1990, AM J VET RES, V51, P921; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HATTORI A, 1993, J BIOL CHEM, V268, P2577; Hoglund CO, 2002, PULM PHARMACOL THER, V15, P51, DOI 10.1006/pupt.2001.0314; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Issekutz AC, 1999, J LEUKOCYTE BIOL, V65, P117, DOI 10.1002/jlb.65.1.117; KANNAN Y, 1992, BIOCHEM BIOPH RES CO, V186, P1050, DOI 10.1016/0006-291X(92)90853-D; KANNAN Y, 1991, BLOOD, V77, P1320; Kassel O, 2001, CLIN EXP ALLERGY, V31, P1432, DOI 10.1046/j.1365-2222.2001.01177.x; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEWIN GR, 1993, J NEUROSCI, V13, P2136; LEWIN GR, 1994, EUR J NEUROSCI, V6, P1903, DOI 10.1111/j.1460-9568.1994.tb00581.x; LI AKC, 1980, P NATL ACAD SCI-BIOL, V77, P4379, DOI 10.1073/pnas.77.7.4379; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; Malcangio M, 1997, EUR J NEUROSCI, V9, P1101, DOI 10.1111/j.1460-9568.1997.tb01462.x; MARTIN HA, 1988, J NEUROPHYSIOL, V60, P438, DOI 10.1152/jn.1988.60.2.438; Mendell LM, 1999, MICROSC RES TECHNIQ, V45, P252, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<252::AID-JEMT9>3.0.CO;2-N; MORONEY MA, 1990, BRIT J PHARMACOL, V101, P128, DOI 10.1111/j.1476-5381.1990.tb12101.x; MOVAT HZ, 1987, CAN J PHYSIOL PHARM, V65, P451, DOI 10.1139/y87-077; Pinter E, 1999, EUR J PHARMACOL, V369, P91, DOI 10.1016/S0014-2999(99)00054-0; RAMPART M, 1988, BRIT J PHARMACOL, V94, P1143, DOI 10.1111/j.1476-5381.1988.tb11632.x; Raychaudhuri SK, 2001, ARCH DERMATOL RES, V293, P291, DOI 10.1007/s004030100224; Raychaudhuri SP, 1998, ACTA DERM-VENEREOL, V78, P84; Rueff A, 1996, J NEUROPHYSIOL, V76, P3593, DOI 10.1152/jn.1996.76.5.3593; Rueff A, 1996, PAIN, V66, P359, DOI 10.1016/0304-3959(96)03060-6; SCHIERWAGEN C, 1990, J PHARMACOL METHOD, V23, P179, DOI 10.1016/0160-5402(90)90061-O; Skaper SD, 2001, MOL NEUROBIOL, V24, P183, DOI 10.1385/MN:24:1-3:183; Wagner JG, 2000, PHARMACOL REV, V52, P349; Woodnutt DA, 2000, CELL TISSUE RES, V299, P225, DOI 10.1007/s004419900129; WOOLF CJ, 1994, NEUROSCIENCE, V62, P327, DOI 10.1016/0306-4522(94)90366-2; YOUNG M, 1985, MOL CELL BIOCHEM, V66, P65	47	12	12	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1703	+		10.1096/fj.02-1000fje	http://dx.doi.org/10.1096/fj.02-1000fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958182				2022-12-25	WOS:000184471600006
J	Kong, WM; Stanley, S; Gardiner, J; Abbott, C; Murphy, K; Seth, A; Connoley, I; Ghatei, M; Stephens, D; Bloom, S				Kong, WM; Stanley, S; Gardiner, J; Abbott, C; Murphy, K; Seth, A; Connoley, I; Ghatei, M; Stephens, D; Bloom, S			A role for arcuate cocaine and amphetamine regulated transcript in hyperphagia, thermogenesis, and cold adaptation	FASEB JOURNAL			English	Article						CART; appetite; brown adipose tissue; hypothalamus; gene transfer; cold adaptation	HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; THYROTROPIN-RELEASING-HORMONE; GLUCAGON-LIKE PEPTIDE-1; AGOUTI-RELATED PROTEIN; NEUROPEPTIDE-Y; IN-VIVO; MESSENGER-RNA; CART NEURONS; ENERGY-EXPENDITURE; GENE-EXPRESSION	We have recently shown that injection of the hypothalamic peptide cocaine and amphetamine regulated transcript (CART) into discrete hypothalamic nuclei stimulates food intake. This stimulation was particularly marked in the arcuate nucleus. Here we show that twice daily intra-arcuate injection of 0.2 nmole CART peptide for 7 days was associated with a 60% higher daytime food intake, an 85% higher thermogenic response to the beta3 agonist BRL 35135, and a 60% increase in brown adipose tissue UCP-1 mRNA. In a separate study, using stereotactically targeted gene transfer, a CART transgene was delivered by using polyethylenimine to the arcuate nucleus of adult rats. Food intake was increased significantly during ad libitum feeding and following periods of food withdrawal and food restriction in CART over-expressing animals. CART over-expressing animals lost 12% more weight than controls following a 24-h fast. Brown adipose tissue uncoupling protein-1 (UCP-1) mRNA levels (collected Day 25) were 80% higher in CART over-expressing animals. Finally, by using quantitative in situ hybridization, we found that chronic cold exposure (20 days at 4degreesC) increased arcuate nucleus CART mRNA by 124%. Together with the orexigenic and thermogenic effects of CART, this finding suggests a role for arcuate nucleus CART in cold adaptation.	Univ London Imperial Coll Sci Technol & Med, Dept Metab Med, Div Investigat Sci, Fac Med, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Dept Math, Fac Phys Sci, London W12 0NN, England; Univ London St Georges Hosp, Sch Med, Dept Physiol, London SW17 0RE, England	Imperial College London; Imperial College London; St Georges University London	Bloom, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Metab Med, Div Investigat Sci, Fac Med, Hammersmith Campus, London W12 0NN, England.	s.bloom@imperial.ac.uk		Gardiner, James/0000-0001-9357-1387; Murphy, Kevin/0000-0002-3417-0310				Abbott CR, 2001, ENDOCRINOLOGY, V142, P3457, DOI 10.1210/en.142.8.3457; Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; Aja S, 2001, AM J PHYSIOL-REG I, V281, pR1862, DOI 10.1152/ajpregu.2001.281.6.R1862; Arancibia S, 1996, NEUROENDOCRINOLOGY, V64, P257, DOI 10.1159/000127126; Asnicar MA, 2001, ENDOCRINOLOGY, V142, P4394, DOI 10.1210/en.142.10.4394; Beak SA, 1996, ENDOCRINOLOGY, V137, P4130, DOI 10.1210/en.137.10.4130; BILLINGTON CJ, 1991, AM J PHYSIOL, V260, P321; Bing C, 1998, AM J PHYSIOL-REG I, V274, pR62, DOI 10.1152/ajpregu.1998.274.1.R62; Bing C, 1997, NEUROSCIENCE, V80, P277, DOI 10.1016/S0306-4522(97)00121-8; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Broberger C, 1999, BRAIN RES, V848, P101, DOI 10.1016/S0006-8993(99)01977-0; CATZEFLIS C, 1993, ENDOCRINOLOGY, V132, P224, DOI 10.1210/en.132.1.224; Challis BG, 2000, DIABETES, V49, P872, DOI 10.2337/diabetes.49.5.872; Charnay Y, 1999, J CHEM NEUROANAT, V17, P123, DOI 10.1016/S0891-0618(99)00028-9; Crowder M.J., 1990, ANAL REPEATED MEASUR; del Giudice EM, 2001, DIABETES, V50, P2157, DOI 10.2337/diabetes.50.9.2157; DOUGLASS J, 1995, J NEUROSCI, V15, P2471; Edwards CMB, 2000, BRAIN RES, V866, P128, DOI 10.1016/S0006-8993(00)02257-5; Elias CF, 1998, NEURON, V21, P1375, DOI 10.1016/S0896-6273(00)80656-X; Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R; Elias CF, 2001, J COMP NEUROL, V432, P1, DOI 10.1002/cne.1085; Fekete C, 2000, J NEUROSCI, V20, P9224; Gautvik KM, 1996, P NATL ACAD SCI USA, V93, P8733, DOI 10.1073/pnas.93.16.8733; Guissouma H, 1998, FASEB J, V12, P1755, DOI 10.1096/fasebj.12.15.1755; Haynes WG, 1999, HYPERTENSION, V33, P542, DOI 10.1161/01.HYP.33.1.542; Kim MS, 2000, DIABETES, V49, P177, DOI 10.2337/diabetes.49.2.177; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Lambert PD, 1998, SYNAPSE, V29, P293, DOI 10.1002/(SICI)1098-2396(199808)29:4<293::AID-SYN1>3.0.CO;2-0; Larsen PJ, 2000, OBES RES, V8, P590, DOI 10.1038/oby.2000.76; LIU YL, 1995, BRIT J PHARMACOL, V114, P888, DOI 10.1111/j.1476-5381.1995.tb13287.x; Martres MP, 1998, EUR J NEUROSCI, V10, P3607, DOI 10.1046/j.1460-9568.1998.00366.x; Murphy KG, 2000, J ENDOCRINOL, V166, P659, DOI 10.1677/joe.0.1660659; PAXINOS G, RAT BRAIN; SCHEIDEGGER K, 1984, J CLIN ENDOCR METAB, V58, P895, DOI 10.1210/jcem-58-5-895; Small CJ, 2001, DIABETES, V50, P248, DOI 10.2337/diabetes.50.2.248; Stanley SA, 2001, BRAIN RES, V893, P186, DOI 10.1016/S0006-8993(00)03312-6; STEEL JH, 1988, HISTOCHEMISTRY, V89, P75, DOI 10.1007/BF00496588; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Wang CF, 2000, NEUROREPORT, V11, P3251, DOI 10.1097/00001756-200009280-00040; WEIGLE DS, 1994, FASEB J, V8, P302, DOI 10.1096/fasebj.8.3.8143936; Zhao J, 1998, AM J PHYSIOL-REG I, V275, pR2002, DOI 10.1152/ajpregu.1998.275.6.R2002	41	91	92	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1688	+		10.1096/fj.02-0805fje	http://dx.doi.org/10.1096/fj.02-0805fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958177				2022-12-25	WOS:000184471600014
J	Salnikov, AV; Iversen, VV; Koisti, M; Sundberg, C; Johansson, L; Stuhr, LB; Sjoquist, M; Ahlstrom, H; Reed, RK; Rubin, K				Salnikov, AV; Iversen, VV; Koisti, M; Sundberg, C; Johansson, L; Stuhr, LB; Sjoquist, M; Ahlstrom, H; Reed, RK; Rubin, K			Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy	FASEB JOURNAL			English	Article						5-fluorouracil; prostaglandin E; histopathology; apoptosis; vasculature	IRON-OXIDE NANOPARTICLES; BRADYKININ MODULATION; IN-VITRO; INHIBITION; ANGIOGENESIS; TRANSPORT; DELIVERY; CANCER; AGENTS; MICROENVIRONMENT	Chemotherapy of solid tumors is presently largely ineffective at dosage levels that are compatible with survival of the patient. Here, it is argued that a condition of raised interstitial fluid pressure (IFP) that can be observed in many tumors is a major factor in preventing optimal access of systemically administered chemotherapeutic agents. Using prostaglandin E-1-methyl ester (PGE(1)), which is known transiently to reduce IFP, it was shown that 5-fluorouracil (5-FU) caused significant growth inhibition on two experimental tumors in rats but only after administration of PGE(1). Furthermore, timing experiments showed that only in the period in which IFP is reduced did 5-FU have an antitumor effect. These experiments uniquely demonstrate a clear and, according to the starting hypothesis, logical, synergistic effect of PGE(1) and 5-FU that offers hope for better treatment of many tumors in which raised IFP is likely to be inhibiting optimal results with water-soluble cancer chemotherapeutic agents.	Uppsala Univ, Dept Med Biochem & Microbiol, BMC, SE-75123 Uppsala, Sweden; Univ Bergen, Dept Physiol, N-5009 Bergen, Norway; Univ Hosp, Dept Radiol, SE-75185 Uppsala, Sweden; Uppsala Univ, Dept Med Cell Biol, Physiol Sect, BMC, SE-75123 Uppsala, Sweden	Uppsala University; University of Bergen; Uppsala University; Uppsala University Hospital; Uppsala University	Rubin, K (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, BMC, Box 582, SE-75123 Uppsala, Sweden.	Kristofer.Rubin@imbim.uu.se	Rubin, Kristofer/AAC-1810-2020; Reed, Rolf K./B-9422-2017	Rubin, Kristofer/0000-0003-2789-6276; Reed, Rolf K./0000-0002-2633-6595				AUKLAND K, 1993, PHYSIOL REV, V73, P1, DOI 10.1152/physrev.1993.73.1.1; Bagnato A, 2002, CANCER RES, V62, P6381; Berg A, 1998, AM J PHYSIOL-HEART C, V274, pH663, DOI 10.1152/ajpheart.1998.274.2.H663; Bjornerud A, 2002, MAGNET RESON MED, V47, P461, DOI 10.1002/mrm.10066; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Emerich DF, 2001, J PHARMACOL EXP THER, V296, P632; Emerich DF, 2001, J PHARMACOL EXP THER, V296, P623; Fisher GA, 2002, EUR J CANCER, V38, pS63; Griffon-Etienne G, 1999, CANCER RES, V59, P3776; GULLINO PM, 1995, ACTA ONCOL, V34, P439, DOI 10.3109/02841869509094005; GULLINO PM, 1964, CANCER RES, V24, P780; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Jain RK, 1998, NAT MED, V4, P655, DOI 10.1038/nm0698-655; JAIN RK, 1987, CANCER RES, V47, P3039; Kellar KE, 2000, JMRI-J MAGN RESON IM, V11, P488; Lau C, 2001, TOXICOL SCI, V59, P37, DOI 10.1093/toxsci/59.1.37; Leu AJ, 2000, CANCER RES, V60, P4324; Martin M, 1996, INT J CANCER, V65, P796, DOI 10.1002/(SICI)1097-0215(19960315)65:6<796::AID-IJC16>3.0.CO;2-2; NELSON MJ, 1993, EXP MOL PATHOL, V58, P105, DOI 10.1006/exmp.1993.1009; Netti PA, 2000, CANCER RES, V60, P2497; PHILLIPS RM, 1990, JNCI-J NATL CANCER I, V82, P1457, DOI 10.1093/jnci/82.18.1457; Pietras K, 2002, CANCER RES, V62, P5476; Pietras K, 2001, CANCER RES, V61, P2929; Rubin K, 2000, INT J CANCER, V86, P636, DOI 10.1002/(SICI)1097-0215(20000601)86:5<636::AID-IJC6>3.0.CO;2-R; Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885; Sundberg C, 1996, LAB INVEST, V74, P452; Tannock IF, 1996, J CLIN ONCOL, V14, P3156, DOI 10.1200/JCO.1996.14.12.3156; Tannock IF, 2001, CANCER METAST REV, V20, P123, DOI 10.1023/A:1013125027697; Trifan OC, 2002, CANCER RES, V62, P5778; Turetschek K, 2001, RADIOLOGY, V218, P562, DOI 10.1148/radiology.218.2.r01fe37562; VAUPEL P, 1989, CANCER RES, V49, P6449; Wassberg E, 1999, AM J PATHOL, V154, P395, DOI 10.1016/S0002-9440(10)65286-8; WIIG H, 1982, SCAND J CLIN LAB INV, V42, P159; YAUN I, 1998, SEMIN RADIAT ONCOL, V8, P164	34	91	95	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1756	+		10.1096/fj.02-1201fje	http://dx.doi.org/10.1096/fj.02-1201fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958200				2022-12-25	WOS:000184471600004
J	Cesura, AM; Pinard, E; Schubenel, R; Goetschy, V; Friedlein, A; Langen, H; Polcic, P; Forte, MA; Bernardi, P; Kemp, JA				Cesura, AM; Pinard, E; Schubenel, R; Goetschy, V; Friedlein, A; Langen, H; Polcic, P; Forte, MA; Bernardi, P; Kemp, JA			The voltage-dependent anion channel is the target for a new class of inhibitors of the mitochondrial permeability transition pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; CYTOCHROME-C; INNER MEMBRANE; BM88 ANTIGEN; RAT-BRAIN; YEAST; VDAC; PROTEINS; ISOFORMS; CALCIUM	The relevance of the mitochondrial permeability transition pore (PTP) in Ca2+ homeostasis and cell death has gained wide attention. Yet, despite detailed functional characterization, the structure of this channel remains elusive. Here we report on a new class of inhibitors of the PTP and on the identification of their molecular target. The most potent among the compounds prepared, Ro 68-3400, inhibited PTP with a potency comparable to that of cyclosporin A. Since Ro 68-3400 has a reactive moiety capable of covalent modification of proteins, [H-3] Ro 68-3400 was used as an affinity label for the identification of its protein target. In intact mitochondria isolated from rodent brain and liver and in SH-SY5Y human neuroblastoma cells, [H-3] Ro 68-3400 predominantly labeled a protein of similar to 32 kDa. This protein was identified as the isoform 1 of the voltage-dependent anion channel (VDAC). Both functional and affinity labeling experiments indicated that VDAC might correspond to the site for the PTP inhibitor ubiquinone(0), whereas other known PTP modulators acted at distinct sites. While Ro 68-3400 represents a new useful tool for the study of the structure and function of VDAC and the PTP, the results obtained provide direct evidence that VDAC1 is a component of this mitochondrial pore.	F Hoffmann La Roche & Co Ltd, Drug Discovery Dept, Div Pharmaceut, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Gen Technol, CH-4070 Basel, Switzerland; Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy	Roche Holding; Roche Holding; Oregon Health & Science University; University of Padua	Cesura, AM (corresponding author), F Hoffmann La Roche & Co Ltd, Drug Discovery Dept, Div Pharmaceut, 92-3-76,Grenzacherstr 124, CH-4070 Basel, Switzerland.	andrea.cesura@serono.com; emmanuel.pinard@roche.com	Bernardi, Paolo/C-3656-2008	Bernardi, Paolo/0000-0001-9187-3736; Polcic, Peter/0000-0003-0341-7533	NIGMS NIH HHS [R01-GM35759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anflous K, 2001, J BIOL CHEM, V276, P1954, DOI 10.1074/jbc.M006587200; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; BlachlyDyson E, 1997, MOL CELL BIOL, V17, P5727, DOI 10.1128/MCB.17.10.5727; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Fountoulakis M, 1997, ANAL BIOCHEM, V250, P153, DOI 10.1006/abio.1997.2213; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; HOEK JB, 1980, J BIOL CHEM, V255, P1458; Huizing M, 1998, J BIOENERG BIOMEMBR, V30, P277, DOI 10.1023/A:1020501021222; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Jung DW, 1997, J BIOL CHEM, V272, P21104, DOI 10.1074/jbc.272.34.21104; Khaspekov L, 1999, EUR J NEUROSCI, V11, P3194, DOI 10.1046/j.1460-9568.1999.00743.x; Krapfenbauer K, 2001, EUR J BIOCHEM, V268, P3532, DOI 10.1046/j.1432-1327.2001.02256.x; Linder MD, 2002, J BIOL CHEM, V277, P937, DOI 10.1074/jbc.M107610200; Liu GY, 1996, J BIOL CHEM, V271, P19717, DOI 10.1074/jbc.271.33.19717; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; MAMALAKI A, 1995, J BIOL CHEM, V270, P14201, DOI 10.1074/jbc.270.23.14201; Martinucci S, 2000, FEBS LETT, V480, P89, DOI 10.1016/S0014-5793(00)01911-6; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; PATSAVOUDI E, 1995, J NEUROSCI RES, V40, P506, DOI 10.1002/jnr.490400410; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; Sampson MJ, 1997, J BIOL CHEM, V272, P18966, DOI 10.1074/jbc.272.30.18966; Schinder AF, 1996, J NEUROSCI, V16, P6125; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shinohara Y, 2000, EUR J BIOCHEM, V267, P6067, DOI 10.1046/j.1432-1327.2000.01687.x; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Song JM, 1998, BIOPHYS J, V74, P2926, DOI 10.1016/S0006-3495(98)78000-2; Vergun O, 1999, J PHYSIOL-LONDON, V519, P451, DOI 10.1111/j.1469-7793.1999.0451m.x; Walter L, 2000, J BIOL CHEM, V275, P29521, DOI 10.1074/jbc.M004128200; WARD FE, 1981, J MED CHEM, V24, P1073, DOI 10.1021/jm00141a011; Xu X, 1999, J MEMBRANE BIOL, V170, P89, DOI 10.1007/s002329900540; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; YU WH, 1995, J BIOL CHEM, V270, P13998, DOI 10.1074/jbc.270.23.13998; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	52	88	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49812	49818		10.1074/jbc.M304748200	http://dx.doi.org/10.1074/jbc.M304748200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	12952973	hybrid			2022-12-25	WOS:000187068200022
J	Xu, Y; Wang, L; Buttice, G; Sengupta, PK; Smith, BD				Xu, Y; Wang, L; Buttice, G; Sengupta, PK; Smith, BD			Interferon gamma repression of collagen (COL1A2) transcription is mediated by the RFX5 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II TRANSACTIVATOR; BARE LYMPHOCYTE SYNDROME; CREB BINDING-PROTEIN; REGULATORY FACTOR-X; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-BETA; GENE-EXPRESSION; HUMAN FIBROBLASTS; MOUSE ALPHA-2(I)	Interferon gamma (IFN-gamma) plays an important physiological role during inflammation by down-regulating collagen gene expression and activating major histocompatibility II (MHC-II) complex. The activation of MHC-II by IFN-gamma requires activation of a trimeric DNA binding transcriptional complex, RFX5 complex, containing RFXB (also called RFXANK or Tvl-1), RFXAP, as well as RFX5 protein. Previously, we demonstrated that RFX5 binds to the collagen transcription start site and represses collagen gene expression (Sengupta, P. K., Fargo, J., Smith, B. D. ( 2002) J. Biol. Chem. 277, 24926 24937). In this report, we have examined the role of RFXB and RFXAP proteins within the RFX5 complex to regulate collagen gene expression. The data show that all three RFX5 complex proteins are required for maximum repression. Expression of proteins with mutations known to be important for RFX5 complex formation does not repress collagen promoter activity. Two mutated forms of RFX5 act as dominant negative proteins activating collagen expression and reversing IFN-gamma down-regulation of collagen expression in human lung fibroblasts. IFN-gamma increases expression and nuclear translocation of RFX5. RFXB has a naturally occurring splice variant isoform (RFX SV). Interferon increases expression of the long form of RFXB and decreases expression of RFX SV with the same kinetics as collagen gene expression. Overexpression of the splice variant form reverses the IFN-gamma induced collagen repression in human lung fibroblasts. Finally, all three RFX5 complex proteins increase at the collagen transcription start site with IFN-gamma treatment using chromatin immunoprecipitation analysis. Thus, these studies suggest an important role for RFX5 complex in collagen repression.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Vet Affairs Boston Healthcare Syst, Boston, MA 02118 USA	Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Smith, BD (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.			Smith, Barbara/0000-0002-5375-7627; Buttice', Giovanna/0000-0001-6550-5585	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068094] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL68094] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antoniou KM, 2003, CHEST, V123, P209, DOI 10.1378/chest.123.1.209; Chang CH, 2002, IMMUNOL RES, V25, P131, DOI 10.1385/IR:25:2:131; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; Das S, 2002, J BIOL CHEM, V277, P45172, DOI 10.1074/jbc.M204117200; DeSandro AM, 2000, MOL CELL BIOL, V20, P6587, DOI 10.1128/MCB.20.17.6587-6599.2000; DURAND B, 1994, MOL CELL BIOL, V14, P6839, DOI 10.1128/MCB.14.10.6839; Fontes JD, 1997, NUCLEIC ACIDS RES, V25, P2522, DOI 10.1093/nar/25.12.2522; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; GRANSTEIN RD, 1990, J INVEST DERMATOL, V95, pS75, DOI 10.1111/1523-1747.ep12874789; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; HATAMOCHI A, 1986, J BIOL CHEM, V261, P1310; Higashi K, 1998, MATRIX BIOL, V16, P447, DOI 10.1016/S0945-053X(98)90016-6; Higashi K, 2003, J BIOL CHEM, V278, P5156, DOI 10.1074/jbc.M208724200; Jabrane-Ferrat N, 2003, INT IMMUNOL, V15, P467, DOI 10.1093/intimm/dxg048; Jabrane-Ferrat N, 2002, MOL CELL BIOL, V22, P5616, DOI 10.1128/MCB.22.15.5616-5625.2002; JabraneFerrat N, 1996, MOL CELL BIOL, V16, P4683; JIMENEZ SA, 1984, J CLIN INVEST, V74, P1112, DOI 10.1172/JCI111480; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; Lin JH, 1999, J BIOL CHEM, V274, P14706, DOI 10.1074/jbc.274.21.14706; Mahanta SK, 1997, P NATL ACAD SCI USA, V94, P6324, DOI 10.1073/pnas.94.12.6324; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Masternak K, 2000, GENE DEV, V14, P1156; Masternak K, 2003, NAT IMMUNOL, V4, P132, DOI 10.1038/ni883; Masternak K, 2002, EMBO J, V21, P1379, DOI 10.1093/emboj/21.6.1379; McDevitt H, 2002, IMMUNOL REV, V185, P78, DOI 10.1034/j.1600-065X.2002.18509.x; McDevitt HO, 2000, ANNU REV IMMUNOL, V18, P1, DOI 10.1146/annurev.immunol.18.1.1; Moreno CS, 1997, J IMMUNOL, V158, P5841; Nagarajan UM, 1999, IMMUNITY, V10, P153, DOI 10.1016/S1074-7613(00)80016-3; Nagarajan UM, 2000, J IMMUNOL, V164, P3666, DOI 10.4049/jimmunol.164.7.3666; Nekrep N, 2000, MOL CELL BIOL, V20, P4455, DOI 10.1128/MCB.20.12.4455-4461.2000; Patriotis C, 2001, J CELL PHYSIOL, V187, P176, DOI 10.1002/jcp.1066; Piskurich JF, 1998, J IMMUNOL, V160, P233; Raval A, 2001, MOL CELL, V7, P105, DOI 10.1016/S1097-2765(01)00159-9; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; ROSENBLOOM J, 1984, BIOCHEM BIOPH RES CO, V123, P365, DOI 10.1016/0006-291X(84)90422-4; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sengupta PK, 2002, J BIOL CHEM, V277, P24926, DOI 10.1074/jbc.M111712200; Sengupta PK, 1998, BBA-GENE STRUCT EXPR, V1443, P75, DOI 10.1016/S0167-4781(98)00188-2; Sengupta PK, 1999, J BIOL CHEM, V274, P36649, DOI 10.1074/jbc.274.51.36649; Sisk TJ, 2000, J IMMUNOL, V165, P2511, DOI 10.4049/jimmunol.165.5.2511; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; VARGA J, 1990, EUR J CLIN INVEST, V20, P487, DOI 10.1111/j.1365-2362.1990.tb01915.x; Weissman JDJ, 2000, J BIOL CHEM, V275, P10160, DOI 10.1074/jbc.275.14.10160; Westerheide SD, 1999, NUCLEIC ACIDS RES, V27, P1635, DOI 10.1093/nar/27.7.1635; Yuan WH, 1999, J CELL PHYSIOL, V179, P97, DOI 10.1002/(SICI)1097-4652(199904)179:1<97::AID-JCP12>3.3.CO;2-5; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000; Zhu XS, 2001, MOL CELL BIOL, V21, P7078, DOI 10.1128/MCB.21.20.7078-7088.2001; Zika E, 2003, MOL CELL BIOL, V23, P3091, DOI 10.1128/MCB.23.9.3091-3102.2003	58	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49134	49144		10.1074/jbc.M309003200	http://dx.doi.org/10.1074/jbc.M309003200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12968017				2022-12-25	WOS:000186829000077
J	Blaschke, RJ; Topfer, C; Marchini, A; Steinbeisser, H; Janssen, JWG; Rappold, GA				Blaschke, RJ; Topfer, C; Marchini, A; Steinbeisser, H; Janssen, JWG; Rappold, GA			Transcriptional and translational regulation of the Leri-Weill and Turner syndrome homeobox gene SHOX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME ENTRY SITES; OPEN READING FRAMES; MESSENGER-RNA; SHORT STATURE; INITIATING TRANSLATION; EUKARYOTIC RIBOSOMES; SECONDARY STRUCTURE; EXPRESSION; MUTATIONS; REGION	Regulation of gene expression is particularly important for gene dosage-dependent diseases and the phenomenon of clinical heterogeneity frequently associated with these phenotypes. We here report on the combined transcriptional and translational regulatory mechanisms controlling the expression of the Leri-Weill and Turner syndrome gene SHOX. We define an alternative promotor within exon 2 of the SHOX gene by transient transfections of mono- and bicistronic reporter constructs and demonstrate substantial differences in the translation efficiency of the mRNAs transcribed from these alternative promotors by in vitro translation assays and direct mRNA transfections into different cell lines. Although transcripts generated from the intragenic promotor (P-2) are translated with high efficiencies, mRNA originating from the upstream promotor (P-1) exhibit significant translation inhibitory effects due to seven AUG codons upstream of the main open reading frame (uAUGs). Site-directed mutagenesis of these uAUGs confers full translation efficiency to reporter mRNAs in different cell lines and after injection of Xenopus embryos. In conclusion, our data support a model where functional SHOX protein levels are regulated by a combination of transcriptional and translational control mechanisms.	Univ Heidelberg, Inst Human Genet, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Rappold, GA (corresponding author), Univ Heidelberg, Inst Human Genet, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.		Marchini, Antonio/AAG-7151-2019; Marchini, Antonio/ABD-3328-2020	Marchini, Antonio/0000-0003-3157-4552				Belin V, 1998, NAT GENET, V19, P67, DOI 10.1038/ng0198-67; Blaschke RJ, 2000, TRENDS ENDOCRIN MET, V11, P227, DOI 10.1016/S1043-2760(00)00262-9; Butler JEF, 2001, GENE DEV, V15, P2515, DOI 10.1101/gad.924301; Cai HNN, 2001, DEVELOPMENT, V128, P4339; Calkhoven CF, 2002, TRENDS MOL MED, V8, P577, DOI 10.1016/S1471-4914(02)02424-3; Clement-Jones M, 2000, HUM MOL GENET, V9, P695, DOI 10.1093/hmg/9.5.695; Davuluri RV, 2000, GENOME RES, V10, P1807, DOI 10.1101/gr.GR-1460R; Ellison JW, 1997, HUM MOL GENET, V6, P1341, DOI 10.1093/hmg/6.8.1341; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Han BG, 2002, MOL CELL BIOL, V22, P7372, DOI 10.1128/MCB.22.21.7372-7384.2002; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; JACKSON RJ, 1988, NATURE, V334, P292, DOI 10.1038/334292a0; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Kozak M, 2002, MAMM GENOME, V13, P401, DOI 10.1007/s00335-002-4002-5; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kozak M, 2001, MOL CELL BIOL, V21, P1899, DOI 10.1128/MCB.21.6.1899-1907.2001; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Meijer HA, 2002, BIOCHEM J, V367, P1, DOI 10.1042/BJ20011706; Mendell JT, 2001, CELL, V107, P411, DOI 10.1016/S0092-8674(01)00583-9; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Peri S, 2001, TRENDS GENET, V17, P685, DOI 10.1016/S0168-9525(01)02493-3; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Preiss T, 1999, CURR OPIN GENET DEV, V9, P515, DOI 10.1016/S0959-437X(99)00005-2; Rao E, 1997, NAT GENET, V16, P54, DOI 10.1038/ng0597-54; Rao E, 2001, HUM MOL GENET, V10, P3083, DOI 10.1093/hmg/10.26.3083; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; Schiller S, 2000, EUR J HUM GENET, V8, P54, DOI 10.1038/sj.ejhg.5200402; Schneider R, 2001, MOL CELL BIOL, V21, P8238, DOI 10.1128/MCB.21.23.8238-8246.2001; Shears DJ, 1998, NAT GENET, V19, P70, DOI 10.1038/ng0198-70; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208	40	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47820	47826		10.1074/jbc.M306685200	http://dx.doi.org/10.1074/jbc.M306685200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12960152	hybrid			2022-12-25	WOS:000186731400058
J	Chen, ZH; Stokes, SL; Rice, WJ; Jones, LR				Chen, ZH; Stokes, SL; Rice, WJ; Jones, LR			Spatial and dynamic interactions between phospholamban and the canine cardiac Ca2+ pump revealed with use of heterobifunctional cross-linking agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCO(ENDO)PLASMIC RETICULUM CA2+-ATPASES; BETA-ADRENERGIC STIMULATION; SARCOPLASMIC-RETICULUM; CALCIUM-PUMP; FUNCTIONAL ASSOCIATION; ESCHERICHIA-COLI; ATP-BINDING; THAPSIGARGIN; PHOSPHORYLATION; DOMAIN	Heterobifunctional thiol to amine cross-linking agents were used to gain new insights on the dynamics and conformational factors governing the interaction between the cardiac Ca2+ pump (SERCA2a) and phospholamban (PLB). PLB is a small protein inhibitor of SERCA2a that reduces enzyme affinity for Ca2+ and thereby regulates cardiac contractility. We found that the PLB monomer with Asn(27) or Asn(30) changed to Cys (N27C-PLB or N30C-PLB) cross-linked to lysine of SERCA2a within seconds with greater than or equal to80% efficiency. Optimal cross-linking occurred at spacer chain lengths of 10 and 15 Angstrom for N27C and N30C, respectively. The rapid time course of cross-linking indicated that neither dissociation of PLB pentamers nor binding of PLB monomers to SERCA2a was rate-limiting. Cross-linking occurred only to the E2 (Ca2+-free) conformation of SERCA2a, was strongly favored by nucleotide binding to this state, and was completely inhibited by thapsigargin. Protein sequencing in combination with mutagenesis identified of Lys(328) of SERCA2a as the target of cross-linking. A three-dimensional map of interacting residues indicated that the cross-linking distances were entirely compatible with the 10-Angstrom distance recently determined between N30C of PLB and Cys(318) of SERCA2a. In contrast, Lys(3) of PLB did not cross-link to any Lys (or Cys) of SERCA2a, suggesting that previous three-dimensional models that constrain Lys3 near residues 397 - 400 of thapsigargin-inhibited SERCA2a should be viewed with caution. Furthermore, although earlier models of PLB . SERCA2a are based on thapsigargin-bound SERCA, our results suggest that the nucleotide-bound, E2 conformation is substantially different and represents the key conformational state for interacting with PLB.	Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; New York University; New York University	Jones, LR (corresponding author), Indiana Univ, Sch Med, Krannert Inst Cardiol, 1800 N Capitol Ave, Indianapolis, IN 46202 USA.	lrjones@iupui.edu		Rice, William/0000-0002-5187-255X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL049428, R01HL049428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056960] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49428] Funding Source: Medline; NIGMS NIH HHS [GM56960] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asahi M, 2000, J BIOL CHEM, V275, P15034, DOI 10.1074/jbc.275.20.15034; Asahi M, 2001, P NATL ACAD SCI USA, V98, P10061, DOI 10.1073/pnas.181348298; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; Back JW, 2003, J MOL BIOL, V331, P303, DOI 10.1016/S0022-2836(03)00721-6; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; Guan L, 2002, P NATL ACAD SCI USA, V99, P6613, DOI 10.1073/pnas.102178299; Hermanson G. T., 1996, BIOCONJUGATE TECHNIQ; Hutter MC, 2002, CHEMBIOCHEM, V3, P1200, DOI 10.1002/1439-7633(20021202)3:12<1200::AID-CBIC1200>3.0.CO;2-H; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; Inesi G, 2002, BIOPHYS J, V83, P2327, DOI 10.1016/S0006-3495(02)75247-8; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; Jones LR, 2002, J BIOL CHEM, V277, P28319, DOI 10.1074/jbc.M204085200; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; Lamberth S, 2000, HELV CHIM ACTA, V83, P2141, DOI 10.1002/1522-2675(20000906)83:9<2141::AID-HLCA2141>3.0.CO;2-W; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Mahaney J, 1999, ARCH BIOCHEM BIOPHYS, V372, P408, DOI 10.1006/abbi.1999.1524; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Pollesello P, 1999, BIOPHYS J, V76, P1784, DOI 10.1016/S0006-3495(99)77339-X; Schmidt AG, 2001, CARDIOVASC DRUG THER, V15, P387, DOI 10.1023/A:1013381204658; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Slovic AM, 2003, PROTEIN SCI, V12, P337, DOI 10.1110/ps.0226603; Stokes DL, 2003, ANNU REV BIOPH BIOM, V32, P445, DOI 10.1146/annurev.biophys.32.110601.142433; TATULIAN SA, 1995, BIOCHEMISTRY-US, V34, P4448, DOI 10.1021/bi00013a038; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1994, J BIOL CHEM, V269, P22929; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2003, P NATL ACAD SCI USA, V100, P467, DOI 10.1073/pnas.0237326100; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; van Montfort BA, 2002, J BIOL CHEM, V277, P14717, DOI 10.1074/jbc.M201533200; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; Young HS, 2001, BIOPHYS J, V81, P884, DOI 10.1016/S0006-3495(01)75748-7; Yu MH, 1999, ARCH BIOCHEM BIOPHYS, V362, P225, DOI 10.1006/abbi.1998.1049	43	52	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48348	48356		10.1074/jbc.M309545200	http://dx.doi.org/10.1074/jbc.M309545200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12972413	hybrid			2022-12-25	WOS:000186731400120
J	Lleo, A; Berezovska, O; Ramdya, P; Fukumoto, H; Raju, S; Shah, T; Hyman, BT				Lleo, A; Berezovska, O; Ramdya, P; Fukumoto, H; Raju, S; Shah, T; Hyman, BT			Notch1 competes with the amyloid precursor protein for gamma-secretase and down-regulates presenilin-1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY MAMMALIAN NEURONS; INTRACELLULAR DOMAIN; TERMINAL FRAGMENT; PS1 DEFICIENCY; CELLS; FE65; APP; TRANSLOCATION; PROTEOLYSIS; INHIBITOR	Presenilin 1 (PS1) is a critical component of the gamma-secretase complex, which is involved in the cleavage of several substrates including the amyloid precursor protein (APP) and Notch1. Based on the fact that APP and Notch are processed by the same gamma-secretase, we postulated that APP and Notch compete for the enzyme activity. In this report, we examined the interactions between APP, Notch, and PS1 using the direct gamma-secretase substrates, Notch 1 Deltaextracellular domain (N1DeltaEC) and APP carboxyl-terminal fragment of 99 amino acids, and measured the effects on amyloid-beta protein production and Notch signaling, respectively. Additionally, we tested the hypothesis that downstream effects on PS1 expression may coexist with the competition phenomenon. We observed significant competition between Notch and APP for gamma-secretase activity; transfection with either of two direct substrates of gamma-secretase led to a reduction in the gamma-cleaved products, Notch intracellular domain or amyloid-beta protein. In addition, however, we found that activation of the Notch signaling pathway, by either N1DeltaEC or Notch intracellular domain, induced down-regulation of PS1 gene expression. This finding suggests that Notch activation directly engages gamma-secretase and subsequently leads to diminished PS1 expression, suggesting a complex set of feedback interactions following Notch activation.	Massachusetts Gen Hosp, Alzheimer Res Unit, Charlestown, MA 02114 USA	Harvard University; Massachusetts General Hospital	Hyman, BT (corresponding author), Massachusetts Gen Hosp, Alzheimer Res Unit, Rm 2009,114-16th St, Charlestown, MA 02129 USA.		Lleó, Alberto/K-5783-2019		NIA NIH HHS [AG15379] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG015379] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Berezovska O, 1999, MOL BRAIN RES, V69, P273, DOI 10.1016/S0169-328X(99)00119-9; Berezovska O, 1999, NEUROSCIENCE, V93, P433, DOI 10.1016/S0306-4522(99)00157-8; Berezovska O, 2000, J NEUROCHEM, V75, P583, DOI 10.1046/j.1471-4159.2000.0750583.x; Berezovska O, 1998, J NEUROPATH EXP NEUR, V57, P738, DOI 10.1097/00005072-199808000-00003; Berezovska O, 2001, J BIOL CHEM, V276, P30018, DOI 10.1074/jbc.M008268200; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Jack C, 2001, MOL BRAIN RES, V87, P166, DOI 10.1016/S0169-328X(01)00010-9; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Kinoshita A, 2002, J NEUROCHEM, V82, P839, DOI 10.1046/j.1471-4159.2002.01016.x; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Palacino JJ, 2000, J BIOL CHEM, V275, P215, DOI 10.1074/jbc.275.1.215; Refolo LM, 1999, J NEUROCHEM, V73, P2383, DOI 10.1046/j.1471-4159.1999.0732383.x; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2001, P NATL ACAD SCI USA, V98, P11039, DOI 10.1073/pnas.211352598; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200	33	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47370	47375		10.1074/jbc.M308480200	http://dx.doi.org/10.1074/jbc.M308480200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12960155	hybrid			2022-12-25	WOS:000186731400005
J	Barrera, FN; Poveda, JA; Gonzalez-Ros, JM; Neira, JL				Barrera, FN; Poveda, JA; Gonzalez-Ros, JM; Neira, JL			Binding of the C-terminal sterile alpha motif (SAM) domain of human p73 to lipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-MEMBRANES; ENERGY-TRANSFER; P53 MUTANTS; FLUORESCENCE; PROTEIN; LOCATION; FAMILY; P63; ORGANIZATION; ASSOCIATION	The alpha splice variant of p73 (p73alpha), a homologue of the tumor suppressor p53, has close to its C terminus a sterile alpha motif (SAM), SAMp73, that is thought to be involved in protein-protein interactions. Here, we report the lipid binding properties of this domain. Binding was assayed against zwitterionic (phosphatidylcholine) and anionic (phosphatidic acid) lipids and was studied by different biophysical techniques, namely, circular dichroism and fluorescence spectroscopies and differential scanning calorimetry. These techniques unambiguously indicate that SAMp73 binds to lipids. The binding involves protein surface attachment and partial membrane penetration, accompanied by changes in SAMp73 structure.	Univ Miguel Hernandez, Inst Biol Mol & Celular, Edificio Torregaitan, Alicante 03202, Spain; Univ Zaragoza, Inst Biocomputac & Fis Sistemas Complejos, E-50009 Zaragoza, Spain	Universidad Miguel Hernandez de Elche; University of Zaragoza	Gonzalez-Ros, JM (corresponding author), Univ Miguel Hernandez, Inst Biol Mol & Celular, Edificio Torregaitan, Avda Ferrocarril S-N, Alicante 03202, Spain.	gonzalez.ros@umh.es; jlneira@umh.es	Barrera, Francisco/C-4513-2008; Neira, Jose/ABF-4210-2021; Poveda Larrosa, Jose Antonio/H-5925-2015	Gonzalez Ros, Jose Manuel/0000-0002-4804-6855; Neira, Jose Luis/0000-0002-4933-0428; Barrera, Francisco N./0000-0002-5200-7891; Poveda Larrosa, Jose Antonio/0000-0003-0722-3752				Aviv T, 2003, NAT STRUCT BIOL, V10, P614, DOI 10.1038/nsb956; Barrera FN, 2002, BIOCHEMISTRY-US, V41, P5743, DOI 10.1021/bi0159478; Bork P, 1998, NAT GENET, V18, P313, DOI 10.1038/ng0498-313; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Contreras LM, 2001, BIOPHYS J, V80, P2273, DOI 10.1016/S0006-3495(01)76199-1; COUTINHO A, 1993, J CHEM EDUC, V70, P425, DOI 10.1021/ed070p425; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; DAVENPORT L, 1985, BIOCHEMISTRY-US, V24, P4097, DOI 10.1021/bi00336a044; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; FERRERMONTIEL AV, 1988, BIOCHIM BIOPHYS ACTA, V937, P379, DOI 10.1016/0005-2736(88)90260-X; FORSTER T, 1959, A NATURFORSCH A, V4, P321; Freebern WJ, 2003, J BIOL CHEM, V278, P2249, DOI 10.1074/jbc.M208517200; Garidel P, 1997, BIOPHYS J, V72, P2196, DOI 10.1016/S0006-3495(97)78863-5; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; Ghosh AK, 1997, BIOCHEMISTRY-US, V36, P14291, DOI 10.1021/bi971933j; Green JB, 2003, MOL CELL, V11, P1537, DOI 10.1016/S1097-2765(03)00178-3; Hall TMT, 2003, NAT STRUCT BIOL, V10, P677, DOI 10.1038/nsb0903-677; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kaiser RD, 1998, BIOCHEMISTRY-US, V37, P8180, DOI 10.1021/bi980064a; Kelly SM, 2000, CURR PROTEIN PEPT SC, V1, P349, DOI 10.2174/1389203003381315; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; Kim KR, 2001, INT J GYNECOL PATHOL, V20, P173, DOI 10.1097/00004347-200104000-00010; Kyba M, 1998, DEV GENET, V22, P74, DOI 10.1002/(SICI)1520-6408(1998)22:1<74::AID-DVG8>3.3.CO;2-V; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Marsh D., 1990, CRC HDB LIPID BILAYE; Mateo CR, 2000, BBA-BIOMEMBRANES, V1509, P167, DOI 10.1016/S0005-2736(00)00291-1; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Pace C. N., 1997, PROTEIN STRUCTURE PR, P253; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V401, P317, DOI 10.1016/0005-2736(75)90233-3; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; PRENDERGAST FG, 1981, BIOCHEMISTRY-US, V20, P7333, DOI 10.1021/bi00529a002; Ramachander R, 2002, J BIOL CHEM, V277, P39585, DOI 10.1074/jbc.M207273200; Rankin SE, 1998, BIOCHEMISTRY-US, V37, P12588, DOI 10.1021/bi980408x; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; Santos NC, 1998, BIOCHEMISTRY-US, V37, P8674, DOI 10.1021/bi9803933; Schultz J, 1997, PROTEIN SCI, V6, P249; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; SUREWICZ WK, 1984, BIOCHEMISTRY-US, V23, P6072, DOI 10.1021/bi00320a026; Tabuchi K, 2002, J NEUROSCI, V22, P4264, DOI 10.1523/JNEUROSCI.22-11-04264.2002; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Wang WK, 2000, ACTA CRYSTALLOGR D, V56, P769, DOI 10.1107/S0907444900005059; Wang WK, 2001, ACTA CRYSTALLOGR D, V57, P545, DOI 10.1107/S0907444901002529; White SH, 2001, J BIOL CHEM, V276, P32395, DOI 10.1074/jbc.R100008200; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; WOLBER PK, 1979, BIOPHYS J, V28, P197, DOI 10.1016/S0006-3495(79)85171-1; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zhu JH, 1998, CANCER RES, V58, P5061	61	66	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46878	46885		10.1074/jbc.M307846200	http://dx.doi.org/10.1074/jbc.M307846200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12954612	hybrid			2022-12-25	WOS:000186569400081
J	Rial, DV; Ottado, J; Ceccarelli, EA				Rial, DV; Ottado, J; Ceccarelli, EA			Precursors with altered affinity for Hsp70 in their transit peptides are efficiently imported into chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL PROTEIN TRANSLOCATION; FERREDOXIN-NADP(+) REDUCTASE PRECURSOR; MOLECULAR CHAPERONES; ENVELOPE MEMBRANES; ESCHERICHIA-COLI; BINDING-SITE; IN-VIVO; MITOCHONDRIAL; TRANSPORT; IDENTIFICATION	Protein import into chloroplasts is postulated to occur with the involvement of molecular chaperones. We have determined that the transit peptide of ferredoxin-NADP( H) reductase precursor binds preferentially to an Hsp70 from chloroplast stroma. To investigate the role of Hsp70 molecular chaperones in chloroplast protein import, we analyzed the import into pea chloroplasts of preproteins with decreased Hsp70 binding affinity in their transit peptides. Our results indicate that the precursor with the lowest affinity for Hsp70 molecular chaperones in its transit peptide was imported to chloroplasts with similar apparent K-m as the wild type precursor and a 2- fold increase in V-max. Thus, a strong interaction between chloroplast stromal Hsp70 and the transit peptide seems not to be essential for protein import. These results indicate that in chloroplasts the main unfolding force during protein import may be applied by molecular chaperones other than Hsp70s. Although stromal Hsp70s undoubtedly participate in chloroplast biogenesis, the role of these molecular chaperones in chloroplast protein translocation differs from the one proposed in the mechanisms postulated up to date.	Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, CSIC, Inst Biol Mol & Celular Rosario,Mol Biol Div, RA-2000 Rosario, Santa Fe, Argentina	National University of Rosario	Ceccarelli, EA (corresponding author), Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, CSIC, Inst Biol Mol & Celular Rosario,Mol Biol Div, Suipacha 531,S2002LRK, RA-2000 Rosario, Santa Fe, Argentina.		Ceccarelli, Eduardo A./V-2600-2019; Ceccarelli, Eduardo A./M-8699-2014	Ceccarelli, Eduardo A./0000-0001-5776-3306; Ceccarelli, Eduardo A./0000-0001-5776-3306				Akita M, 1997, J CELL BIOL, V136, P983, DOI 10.1083/jcb.136.5.983; Arakaki AK, 1997, FASEB J, V11, P133, DOI 10.1096/fasebj.11.2.9039955; Artigues A, 1998, J BIOL CHEM, V273, P33130, DOI 10.1074/jbc.273.50.33130; Artigues A, 2002, J BIOL CHEM, V277, P25047, DOI 10.1074/jbc.M203474200; Bruce BD, 2001, BBA-MOL CELL RES, V1541, P2, DOI 10.1016/S0167-4889(01)00149-5; CALCATERRA NB, 1995, BIOCHEMISTRY-US, V34, P12842, DOI 10.1021/bi00039a045; Ceccarelli EA, 1996, EUR J BIOCHEM, V238, P192, DOI 10.1111/j.1432-1033.1996.0192q.x; Chauwin JF, 1998, BIOPHYS J, V74, P1732, DOI 10.1016/S0006-3495(98)77884-1; Chen XJ, 1999, TRENDS CELL BIOL, V9, P222, DOI 10.1016/S0962-8924(99)01554-8; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CREIGHTON TE, 1979, J MOL BIOL, V129, P235, DOI 10.1016/0022-2836(79)90279-1; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Elston TC, 2000, BIOPHYS J, V79, P2235, DOI 10.1016/S0006-3495(00)76471-X; Gaume B, 1998, EMBO J, V17, P6497, DOI 10.1093/emboj/17.22.6497; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GOLDENBERG DP, 1984, ANAL BIOCHEM, V138, P1, DOI 10.1016/0003-2697(84)90761-9; Hinnah SC, 2002, BIOPHYS J, V83, P899, DOI 10.1016/S0006-3495(02)75216-8; Ivey RA, 2000, PLANT PHYSIOL, V122, P1289, DOI 10.1104/pp.122.4.1289; Ivey RA, 2000, CELL STRESS CHAPERON, V5, P62, DOI 10.1379/1466-1268(2000)005<0062:IVAIVI>2.0.CO;2; Jackson-Constan D, 2001, BBA-MOL CELL RES, V1541, P102, DOI 10.1016/S0167-4889(01)00148-3; Jackson-Constan D, 2001, PLANT PHYSIOL, V125, P1567, DOI 10.1104/pp.125.4.1567; Jarvis P, 2001, BBA-MOL CELL RES, V1541, P64, DOI 10.1016/S0167-4889(01)00147-1; KANEMORI M, 1994, J BACTERIOL, V176, P5648, DOI 10.1128/JB.176.18.5648-5653.1994; Keegstra K, 1999, CURR OPIN PLANT BIOL, V2, P471, DOI 10.1016/S1369-5266(99)00021-7; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; KLEMM JD, 1991, BIOCHEMISTRY-US, V30, P589, DOI 10.1021/bi00216a038; Lee KH, 2002, MOL CELLS, V14, P388; Liebermeister W, 2001, J MOL BIOL, V305, P643, DOI 10.1006/jmbi.2000.4302; MARSHALL JS, 1992, PLANT PHYSIOL, V100, P1048, DOI 10.1104/pp.100.2.1048; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Matouschek A, 1997, EMBO J, V16, P6727, DOI 10.1093/emboj/16.22.6727; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; May T, 2000, PLANT CELL, V12, P53, DOI 10.1105/tpc.12.1.53; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; Ottado J, 1998, EUR J BIOCHEM, V253, P132, DOI 10.1046/j.1432-1327.1998.2530132.x; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PFANNER N, 1995, CURR BIOL, V5, P132; PILON M, 1992, FEBS LETT, V302, P65, DOI 10.1016/0014-5793(92)80286-P; Rial DV, 2000, EUR J BIOCHEM, V267, P6239, DOI 10.1046/j.1432-1327.2000.01707.x; Rial DV, 2002, EUR J BIOCHEM, V269, P5431, DOI 10.1046/j.1432-1033.2002.03233.x; Rial DV, 2002, PROTEIN EXPRES PURIF, V25, P503, DOI 10.1016/S1046-5928(02)00024-4; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; Schleiff E, 2002, PLANT MOL BIOL, V50, P177, DOI 10.1023/A:1016027020193; Schleiff E, 2003, P NATL ACAD SCI USA, V100, P4604, DOI 10.1073/pnas.0730860100; SCHREIER PH, 1988, PLANT MOL BIOL MAN B, V5, P1; SERRA EC, 1995, J BIOL CHEM, V270, P19930, DOI 10.1074/jbc.270.34.19930; THEG SM, 1989, J BIOL CHEM, V264, P6730; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; Voos W, 2002, BBA-MOL CELL RES, V1592, P51, DOI 10.1016/S0167-4889(02)00264-1; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; ZANETTI G, 1976, BIOCHIM BIOPHYS ACTA, V445, P14, DOI 10.1016/0005-2744(76)90157-1; Zhang XP, 1999, J MOL BIOL, V288, P177, DOI 10.1006/jmbi.1999.2669; Zhang XP, 2002, TRENDS PLANT SCI, V7, P14, DOI 10.1016/S1360-1385(01)02180-X	59	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46473	46481		10.1074/jbc.M306684200	http://dx.doi.org/10.1074/jbc.M306684200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12970339	hybrid			2022-12-25	WOS:000186569400032
J	Tesco, G; Koh, YH; Tanzi, RE				Tesco, G; Koh, YH; Tanzi, RE			Caspase activation increases beta-amyloid generation independently of caspase cleavage of the beta-amyloid precursor protein (APP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITIES; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; APOPTOSIS; PEPTIDES; INVOLVEMENT; PRESENILIN; PROTEASES; A-BETA-42; PATHWAY	The amyloid precursor protein (APP) undergoes "alternative" proteolysis mediated by caspases. Three major caspase recognition sites have been identified in the APP, i.e. one at the C terminus (Asp(720)) and two at the N terminus (Asp(197) and Asp(219)). Caspase cleavage at Asp(720) has been suggested as leading to increased production of Abeta. Thus, we set out to determine which putative caspase sites in APP, if any, are cleaved in Chinese hamster ovary cell lines concurrently with the increased Abeta production that occurs during apoptosis. We found that cleavage at Asp(720) occurred concurrently with caspase 3 activation and the increased production of total secreted Abeta and Abeta(1-42) in association with staurosporine- and etoposide-induced apoptosis. To investigate the contribution of caspase cleavage of APP to Abeta generation, we expressed an APP mutant truncated at Asp(720) that mimics APP caspase cleavage at the C-terminal site. This did not increase Abeta generation but, in contrast, dramatically decreased Abeta production in Chinese hamster ovary cells. Furthermore, the ablation of caspase-dependent cleavage at Asp(720), Asp(197), and Asp(219) (by site-directed mutagenesis) did not prevent enhanced Abeta production following etoposide-induced apoptosis. These findings indicate that the enhanced Abeta generation associated with apoptosis does not require cleavage of APP at its C-terminal (Asp(720)) and/or N-terminal caspase sites.	Massachusetts Gen Hosp, Ctr Aging Genet & Neurodegenerat, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Tanzi, RE (corresponding author), Massachusetts Gen Hosp, Ctr Aging Genet & Neurodegenerat, Genet & Aging Res Unit, Bldg 114,16th St C3009, Charlestown, MA 02129 USA.		Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454	NIA NIH HHS [5P01 AG15379] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG015379] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barnes NY, 1998, J NEUROSCI, V18, P5869; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; De Strooper B, 2000, J CELL SCI, V113, P1857; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Galli C, 1998, P NATL ACAD SCI USA, V95, P1247, DOI 10.1073/pnas.95.3.1247; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Kalaria RN, 2000, NEUROBIOL AGING, V21, P321, DOI 10.1016/S0197-4580(00)00125-1; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; LeBlanc A, 1995, J NEUROSCI, V15, P7837; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Namura S, 1998, J NEUROSCI, V18, P3659; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; Skovronsky DM, 2000, BIOCHEMISTRY-US, V39, P810, DOI 10.1021/bi991728z; Soriano S, 2001, J BIOL CHEM, V276, P29045, DOI 10.1074/jbc.M102456200; Tesco G, 1998, J BIOL CHEM, V273, P33909, DOI 10.1074/jbc.273.51.33909; Thornberry NA, 1997, BRIT MED BULL, V53, P478; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wilson CA, 2002, NAT NEUROSCI, V5, P849, DOI 10.1038/nn898; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	28	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46074	46080		10.1074/jbc.M307809200	http://dx.doi.org/10.1074/jbc.M307809200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12960154	hybrid			2022-12-25	WOS:000186452300124
J	Wise, EL; Graham, DE; White, RH; Rayment, I				Wise, EL; Graham, DE; White, RH; Rayment, I			The structural determination of phosphosulfolactate synthase from Methanococcus jannaschii at 1.7-angstrom resolution - An enolase that is not an enolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCONATE LACTONIZING ENZYME; ANOMALOUS DIFFRACTION; ANGSTROM RESOLUTION; MANDELATE RACEMASE; PSEUDOMONAS-PUTIDA; ESCHERICHIA-COLI; CARBOXYLIC-ACIDS; ALPHA-PROTONS; ACTIVE-SITE; EVOLUTION	Members of the enolase mechanistically diverse superfamily catalyze a wide variety of chemical reactions that are related by a common mechanistic feature, the abstraction of a proton adjacent to a carboxylate group. Recent investigations into the function and mechanism of the phosphosulfolactate synthase encoded by the ComA gene in Methanococcus jannaschii have suggested that ComA, which catalyzes the stereospecific Michael addition of sulfite to phosphoenolpyruvate to form phosphosulfolactate, may be a member of the enolase superfamily. The ComA-catalyzed reaction, the first step in the coenzyme M biosynthetic pathway, likely proceeds via a Mg2+ ion-stabilized enolate intermediate in a manner similar to that observed for members of the enolase superfamily. ComA, however, has no significant sequence similarity to any known enolase. Here we report the x-ray crystal structure of ComA to 1.7-Angstrom resolution. The overall fold for ComA is an (alpha/beta)(8) barrel that assembles with two other ComA molecules to form a trimer in which three active sites are created at the subunit interfaces. From the positions of two ordered sulfate ions in the active site, a model for the binding of phosphoenolpyruvate and sulfite is proposed. Despite its mechanistic similarity to the enolase superfamily, the overall structure and active site architecture of ComA are unlike any member of the enolase superfamily, which suggests that ComA is not a member of the enolase superfamily but instead acquired an enolase-type mechanism through convergent evolution.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA	University of Wisconsin System; University of Wisconsin Madison; Virginia Polytechnic Institute & State University	Rayment, I (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.		Graham, David E/F-8578-2010; rayment, ivan/A-2720-2008	Graham, David E/0000-0001-8968-7344; rayment, ivan/0000-0001-9279-7835	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065155, R01GM052594] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08293, GM-52594, GM-65155] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABBITT PC, 1995, SCIENCE, V267, P1159, DOI 10.1126/science.7855594; Babbitt PC, 1996, BIOCHEMISTRY-US, V35, P16489, DOI 10.1021/bi9616413; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; FALLER LD, 1977, BIOCHEMISTRY-US, V16, P3864, DOI 10.1021/bi00636a023; Gerlt JA, 2003, CURR OPIN CHEM BIOL, V7, P252, DOI 10.1016/S1367-5931(03)00019-X; Gerlt JA, 2001, ANNU REV BIOCHEM, V70, P209, DOI 10.1146/annurev.biochem.70.1.209; Graham DE, 2002, NAT PROD REP, V19, P133, DOI 10.1039/b103714p; Graham DE, 2002, J BIOL CHEM, V277, P13421, DOI 10.1074/jbc.M201011200; Hasson MS, 1998, P NATL ACAD SCI USA, V95, P10396, DOI 10.1073/pnas.95.18.10396; HELIN S, 1995, J MOL BIOL, V254, P918, DOI 10.1006/jmbi.1995.0666; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; LANDRO JA, 1994, BIOCHEMISTRY-US, V33, P635, DOI 10.1021/bi00169a003; Larsen TM, 1996, BIOCHEMISTRY-US, V35, P4349, DOI 10.1021/bi952859c; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; Roussel A., 1991, SILICON GRAPHICS GEO, V86; Sanda S, 2001, J BIOL CHEM, V276, P3941, DOI 10.1074/jbc.M008200200; Schmidt DMZ, 2001, BIOCHEMISTRY-US, V40, P15707, DOI 10.1021/bi011640x; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thompson TB, 2000, BIOCHEMISTRY-US, V39, P10662, DOI 10.1021/bi000855o	23	12	13	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45858	45863		10.1074/jbc.M307486200	http://dx.doi.org/10.1074/jbc.M307486200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952952	hybrid			2022-12-25	WOS:000186452300099
J	Yang, JH; Nie, YZ; Zhao, QC; Su, YJ; Pypaert, M; Su, HL; Rabinovici, R				Yang, JH; Nie, YZ; Zhao, QC; Su, YJ; Pypaert, M; Su, HL; Rabinovici, R			Intracellular localization of differentially regulated RNA-specific adenosine deaminase isoforms in inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SPLICE-SITE VARIANTS; EDITING ENZYME ADAR1; IN-VITRO; BINDING DOMAINS; LUNG INJURY; HUMAN-CELLS; GLUR-B; INTERFERON; PROTEIN	Adenosine-to-inosine (A-to-I) RNA editing is a post-transcriptional process that amplifies the repertoire of protein production. Recently, the induction of this process through up-regulation of the editing enzyme RNA-specific adenosine deaminase 1 (ADAR1) was documented during acute inflammation. Here we report that the inflammation-induced up-regulation of ADAR1 involves differential production and intracellular localization of several isoforms with distinct RNA-binding domains and localization signals. These include the full-length ADAR1 (p150) and two functionally active short isoforms (p80 and p110). ADAR1 p80 starts at a methionine 519 (M519) due to alternative splicing in exon 2, which deletes the putative nuclear localization signal, the Z-DNA binding domain, and the entire RNA binding domain I. ADAR1 p110 is the mouse homologue of the human ADAR1 110-kDa variant (M246), which retains the second half of the Z-DNA binding domain, all RNA binding domains, and the deaminase domain. Additional variations are found in the third RNA binding domain of ADAR1; they are differentially regulated during inflammation, generating isoforms with different levels of activities. Studies in several cell types transfected with ADAR1-EGFP chimeras demonstrated that the p150 and p80 variants are localized in the cytoplasm and nucleolus, respectively. In agreement with this observation, endogenous ADAR1 was identified in the cytoplasm and nucleolus of mouse splenocytes and HeLa cells. Since the ADAR1 variants are differentially regulated during acute inflammation, it suggests that the localization of these variants and of A-to-I RNA editing in the cytoplasm, nucleus, and nucleolus is intracellularly reorganized in response to inflammatory stimulation.	Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	Yale University; Yale University	Yang, JH (corresponding author), Yale Univ, Sch Med, Dept Surg, 333 Cedar St,LH118, New Haven, CT 06520 USA.	jinghua.yang@yale.edu			NIGMS NIH HHS [GM-60426] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060426] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; Dabiri GA, 1996, EMBO J, V15, P34, DOI 10.1002/j.1460-2075.1996.tb00331.x; Eckmann CR, 1999, J CELL BIOL, V144, P603, DOI 10.1083/jcb.144.4.603; Eckmann CR, 2001, MOL BIOL CELL, V12, P1911, DOI 10.1091/mbc.12.7.1911; Feldmeyer D, 1999, NAT NEUROSCI, V2, P57, DOI 10.1038/4561; George CX, 1999, P NATL ACAD SCI USA, V96, P4621, DOI 10.1073/pnas.96.8.4621; George CX, 1999, GENE, V229, P203, DOI 10.1016/S0378-1119(99)00017-7; Gerber A, 1998, EMBO J, V17, P4780, DOI 10.1093/emboj/17.16.4780; Hanrahan CJ, 2000, GENETICS, V155, P1149; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; Herbert A, 2002, MOL CELL, V10, P1235, DOI 10.1016/S1097-2765(02)00737-2; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; Hudson LD, 1999, CHEST, V116, p74S, DOI 10.1378/chest.116.suppl_1.74S-a; Hurst SR, 1995, RNA, V1, P1051; Kabir K, 2002, SHOCK, V17, P300, DOI 10.1097/00024382-200204000-00010; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; Liu Y, 1999, J BIOL CHEM, V274, P5070, DOI 10.1074/jbc.274.8.5070; Liu Y, 1999, J BIOL CHEM, V274, P18351, DOI 10.1074/jbc.274.26.18351; Liu Y, 1997, J BIOL CHEM, V272, P4419, DOI 10.1074/jbc.272.7.4419; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Longacre A, 2000, CELL, V102, P541, DOI 10.1016/S0092-8674(00)00075-1; Ma E, 2001, J CLIN INVEST, V107, P685, DOI 10.1172/JCI11625; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; Maas S, 1999, P NATL ACAD SCI USA, V96, P8895, DOI 10.1073/pnas.96.16.8895; Maas S, 2000, GENE, V243, P59, DOI 10.1016/S0378-1119(99)00562-4; Martin A, 2002, NATURE, V415, P802, DOI 10.1038/nature714; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Neuberger MS, 2000, SCIENCE, V289, P1705, DOI 10.1126/science.289.5485.1705; Palladino MJ, 2000, CELL, V102, P437, DOI 10.1016/S0092-8674(00)00049-0; Palladino MJ, 2000, RNA, V6, P1004, DOI 10.1017/S1355838200000248; PATTERSON JB, 1995, VIROLOGY, V210, P508, DOI 10.1006/viro.1995.1370; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; Poulsen H, 2001, MOL CELL BIOL, V21, P7862, DOI 10.1128/MCB.21.22.7862-7871.2001; Rabinovici R, 2001, CIRC RES, V88, P1066, DOI 10.1161/hh1001.090877; Raitskin O, 2001, P NATL ACAD SCI USA, V98, P6571, DOI 10.1073/pnas.111153798; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; Samuel CE, 1998, CURR TOP MICROBIOL, V233, P125; Schwab MS, 1997, EUR J CELL BIOL, V73, P287; Slavov D, 2000, GENE, V250, P41, DOI 10.1016/S0378-1119(00)00174-8; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765; WEIER HUG, 1995, GENOMICS, V30, P372, DOI 10.1006/geno.1995.0034; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0; Yang JH, 2003, IMMUNOLOGY, V109, P15, DOI 10.1046/j.1365-2567.2003.01598.x; Yang JH, 1997, P NATL ACAD SCI USA, V94, P4354, DOI 10.1073/pnas.94.9.4354	54	44	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45833	45842		10.1074/jbc.M308612200	http://dx.doi.org/10.1074/jbc.M308612200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954622	hybrid			2022-12-25	WOS:000186452300096
J	Zhang, YW; Kaneda, M; Morita, I				Zhang, YW; Kaneda, M; Morita, I			The gap junction-independent tumor-suppressing effect of connexin 43	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-BOX PROTEIN; UBIQUITIN-DEPENDENT DEGRADATION; INTERCELLULAR COMMUNICATION; GROWTH-CONTROL; CELL-GROWTH; INHIBITOR P27(KIP1); SKP2 EXPRESSION; TYROSINE KINASE; GENES; CANCER	The gap junction gene connexin 43 (Cx43) showed tumor-suppressing effects on various tumor cell lines. We have previously demonstrated that Cx43 inhibited expression of S phase kinase-associated protein 2 (Skp2), the human F-box protein that regulates the ubiquitination of p27. Cx43 did not alter the mRNA level of SKP2, but it promoted the degradation of the Skp2 proteins (Zhang, Y.W., Nakayama, K., Nakayama K. I., and Morita, I. (2003) Cancer Res. 63, 1623-1630). In this study, we showed that the specific gap junction inhibitor 18 beta-glycyrrhetinic acid did not influence the inhibitory effect of Cx43 on Skp2 expression. Further, the deletion mutation analyses demonstrated that the C-terminal domain of Cx43 that did not form gap junctions was sufficient to inhibit expression of Skp2, whereas the N-terminal domain that formed the gap junctions did not show such an effect. Like the full-length Cx43, the C-terminal domain also increased the protein instability of Skp2, whereas the N terminus did not. Moreover, the C-terminal domain was as effective as the full-length Cx43 in inhibiting cell proliferation; however, the N-terminal domain did not show any inhibitory effect on cell proliferation. Therefore, these data revealed a gap junction-independent pathway for Cx43 to inhibit tumor growth by suppressing the Skp2 expression.	Tokyo Med & Dent Univ, Dept Cellular Physiol Chem, Bunkyo Ku, Tokyo 1138549, Japan	Tokyo Medical & Dental University (TMDU)	Zhang, YW (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		高, 雨莉/HGU-8187-2022					Dang XT, 2003, MOL CELL BIOCHEM, V242, P35, DOI 10.1023/A:1021152709313; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H; Huang RP, 1998, CANCER RES, V58, P5089; Koga H, 2003, HEPATOLOGY, V37, P1086, DOI 10.1053/jhep.2003.50186; Kudo Y, 2001, CANCER RES, V61, P7044; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Lin R, 2003, ENDOCRINOLOGY, V144, P749, DOI 10.1210/en.2002-0026; Loewenstein W R, 1992, Semin Cell Biol, V3, P59; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; MESNIL M, 1995, CANCER RES, V55, P629; Moorby C, 2001, EXP CELL RES, V271, P238, DOI 10.1006/excr.2001.5357; Nakamura M, 2003, CELL DEATH DIFFER, V10, P230, DOI 10.1038/sj.cdd.4401125; Omori Y, 1998, INT J CANCER, V78, P446, DOI 10.1002/(SICI)1097-0215(19981109)78:4<446::AID-IJC10>3.3.CO;2-4; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Qin H, 2002, J BIOL CHEM, V277, P29132, DOI 10.1074/jbc.M200797200; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Yamasaki H, 1999, CR ACAD SCI III-VIE, V322, P151, DOI 10.1016/S0764-4469(99)80038-9; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Zhang L, 2003, J BIOL CHEM, V278, P27, DOI 10.1074/jbc.M205424200; Zhang YW, 2000, PLANTA MED, V66, P119, DOI 10.1055/s-2000-11126; Zhang YW, 2001, ONCOGENE, V20, P4138, DOI 10.1038/sj.onc.1204563; Zhang YW, 1999, J CELL PHYSIOL, V180, P305, DOI 10.1002/(SICI)1097-4652(199909)180:3<305::AID-JCP1>3.0.CO;2-Z; Zhang YW, 2003, CANCER RES, V63, P1623; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	31	156	164	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44852	44856		10.1074/jbc.M305072200	http://dx.doi.org/10.1074/jbc.M305072200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12952975	hybrid			2022-12-25	WOS:000186306700120
J	Habraken, Y; Jolois, O; Piette, J				Habraken, Y; Jolois, O; Piette, J			Differential involvement of the hMRE11/hRAD50/NBS1 complex, BRCA1 and MLH1 in NF-kappa B activation by camptothecin and X-ray	ONCOGENE			English	Article						NF-kappa B; double-strand breaks; BRCA1; NBS; ATLD; MMR	NIJMEGEN BREAKAGE SYNDROME; DNA MISMATCH REPAIR; ATM-DEPENDENT PHOSPHORYLATION; ATAXIA-TELANGIECTASIA; TOPOISOMERASE-I; MRE11 COMPLEX; DAMAGE; PROTEIN; KINASE; CANCER	Camptothecin (CPT) and X-ray (XR) generate double-strand breaks (DSB) that can be processed by homologous or nonhomologous recombination. We studied the participation of proteins involved in recombination pathways and cell cycle control in the signal transduction between DNA damage and NF-kappaB. Cells harbouring mutated NBS, hMRE11, BRCA1 or MLH1 were analysed. NBS- and hMRE11-deficient cells present a classical kinetic of NF-kappaB induction after camptothecin treatment. When DSB are generated by XR, NBS-deficient cells exhibit a delayed and strongly reduced level of NF-kappaB induction, whereas the hMRE11 mutated cells do not induce NF-kappaB at all. This indicates an important role of the hMRE11/hRAD50/NBS complex in the signal transduction initiated by XR. In HCC1937 cells that express a truncated version of BRCA1, XR induces a very rapid and transient NF-kappaB activation, whereas CPT leads to a delayed activation suggesting that BRCA1 modulates the transduction pathways in different manners after these two stresses. Finally, we found that a proficient MMR pathway is essential to the NF-kappaB activation after both CPT and XR. These results indicate that DSB originating from XR or CPT do not induce NF-kappaB in a unique way. MMR participates in both cascades, whereas the hMRE11/hRAD50/NBS trimer is specifically involved in the response elicited by XR.	Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium; Univ Liege, Inst Anat L3, Ctr Immunol, Lab Human Histol, B-4020 Liege, Belgium	University of Liege; University of Liege	Habraken, Y (corresponding author), Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium.	Yvette.Habraken@ulg.ac.be						AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Cerosaletti KM, 2000, MUTAGENESIS, V15, P281, DOI 10.1093/mutage/15.3.281; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Habraken Y, 2001, BIOCHEM PHARMACOL, V62, P603, DOI 10.1016/S0006-2952(01)00709-2; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; Jacob S, 2001, CANCER RES, V61, P6555; Jacob S, 2002, BIOCHIMIE, V84, P27, DOI 10.1016/S0300-9084(01)01362-1; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KOI M, 1994, CANCER RES, V54, P4308; KRAAKMANVANDERZ.M, 1999, MUTAT RES, V434, P127; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu CY, 2002, P NATL ACAD SCI USA, V99, P14970, DOI 10.1073/pnas.182557199; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Pichierri P, 2001, CARCINOGENESIS, V22, P1781, DOI 10.1093/carcin/22.11.1781; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Vance JR, 2002, P NATL ACAD SCI USA, V99, P13669, DOI 10.1073/pnas.202242599; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; WU X, 2000, SCIENCE, V289, pA11; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	44	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6090	6099		10.1038/sj.onc.1206893	http://dx.doi.org/10.1038/sj.onc.1206893			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955088				2022-12-25	WOS:000185137800018
J	Marcoux, N; Vuori, K				Marcoux, N; Vuori, K			EGF receptor mediates adhesion-dependent activation of the Rac GTPase: a role for phosphatidylinositol 3-kinase and Vav2	ONCOGENE			English	Article						adhesion; cytoskeleton; integrin; kinase; signaling	GROWTH-FACTOR RECEPTORS; GUANOSINE TRIPHOSPHATASES; PLECKSTRIN HOMOLOGY; SIGNALING PATHWAYS; FAMILY PROTEINS; RHO FAMILY; CELL-CYCLE; INTEGRINS; PHOSPHORYLATION; KINASE	Organization of the actin cytoskeleton in eucaryotic cells is controlled by small GTPases of the Rho family. Rac becomes activated by growth factor stimulation and integrin-mediated cell adhesion to extracellular matrix and is known to have a crucial role in lamellipodia formation, cell spreading and migration. At present, the intracellular pathways that connect cell surface receptors to Rac activation are poorly characterized. It has been reported previously that integrin-mediated cell attachment induces activation of the EGF receptor (EGFR) in the absence of EGF. We demonstrate here that this activation is instrumental for integrin-dependent Rac activation. Thus, we found that cells in which EGFR activity had been inhibited failed to spread and form lamellipodia on fibronectin. Failure to spread coincided with inhibition of adhesion-induced GTP loading of Rac and also with inhibition of the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathway. Subsequent studies demonstrated that an activated form of PI 3-kinase restored Rac GTP loading in the presence of EGFR inhibition, while a dominant-negative form of PI 3-kinase blocked Rac GTP loading in fibronectin-adherent cells. Our further functional studies identified Vav2, a known exchange factor for Rac, as a crucial downstream component in EGFR- and PI 3-kinase-dependent Rac activation upon integrin-mediated cell adhesion. Our results provide a mechanistic insight into integrin-dependent Rac activation, and identify a novel role for EGFR, PI 3-kinase and Vav2 in this pathway.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Vuori, K (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	kvuori@burnham.org						Abassi YA, 2002, EMBO J, V21, P4571, DOI 10.1093/emboj/cdf446; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; Booden MA, 2002, MOL CELL BIOL, V22, P2487, DOI 10.1128/MCB.22.8.2487-2497.2002; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Tamas P, 2003, J BIOL CHEM, V278, P5163, DOI 10.1074/jbc.M207555200; Tamas P, 2001, CELL SIGNAL, V13, P475, DOI 10.1016/S0898-6568(01)00172-3; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6	34	80	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6100	6106		10.1038/sj.onc.1206712	http://dx.doi.org/10.1038/sj.onc.1206712			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955089				2022-12-25	WOS:000185137800019
J	Suen, KC; Yu, MS; So, KF; Chang, RCC; Hugon, J				Suen, KC; Yu, MS; So, KF; Chang, RCC; Hugon, J			Upstream signaling pathways leading to the activation of double-stranded RNA-dependent serine/threonine protein kinase in beta-amyloid peptide neurotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; EUKARYOTIC INITIATION FACTOR-2-ALPHA; CASPASE-MEDIATED CLEAVAGE; NEURONAL DEGENERATION; CALCIUM HOMEOSTASIS; CYSTEINE PROTEASE; FACTOR 2-ALPHA; PC12 CELLS; IN-VITRO; APOPTOSIS	One of the hallmarks of Alzheimer's disease is extracellular accumulation of senile plaques composed primarily of aggregated beta-amyloid (Abeta) peptide. Treatment of cultured neurons with Abeta peptide induces neuronal death in which apoptosis is suggested to be one of the mechanisms. We have demonstrated previously that Abeta peptide induces activation of double-stranded RNA-dependent serine/threonine protein kinase (PKR) and phosphorylation of eukaryotic initiation factor 2alpha (eIF2alpha) in neurons in vitro. Degenerating neurons in brain tissues from Alzheimer's disease patients also displayed high immunoreactivity for phosphorylated PKR and eIF2alpha. Our previous data have also indicated that PKR plays a significant role in mediating Abeta peptide-induced neuronal death, because neurons from PKR knockout mice and neuroblastoma SH-SY5Y cells stably transfected with dominant negative mutant of PKR are less susceptible to Abeta peptide toxicity. Therefore, it is important to understand how PKR is activated by Abeta peptide. We report here that inhibition of caspase-3 activity reduces phosphorylation of PKR and to a certain extent, cleavage of PKR and eIF2alpha in neurons exposed to Abeta peptide. Calcium release from the endoplasmic reticulum and activation of caspase-8 are the upstream signals modulating the caspase-3-mediated activation of PKR by Abeta peptide. Although in other systems HSP90 serves as a repressor for PKR, it is unlikely the candidate for caspase-3 to affect PKR activation in neurons after Abeta peptide exposure. Elucidation of the upstream pathways for PKR activation can help us to understand how this kinase participates in Abeta peptide neurotoxicity and to develop effective neuroprotective strategy.	Univ Hong Kong, Fac Med, Dept Anat, Lab Neurodgenerat Dis, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Cent Lab, Inst Mol Technol Drug Discovery & Synth, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Chang, RCC (corresponding author), Univ Hong Kong, Fac Med, Dept Anat, Lab Neurodgenerat Dis, Lab Block,Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	rccchang@hkucc.hku.hk; j.hugon@chu-poitiers.fr	Suen, Ka Chun/A-2006-2010; Yu, Man Shan/C-4168-2009; Chang, Raymond Chuen-Chung/C-1107-2009	Suen, Ka Chun/0000-0001-6839-8316; Chang, Raymond Chuen-Chung/0000-0001-8538-7993; So, Kwok-Fai/0000-0003-4039-4246				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Allen JW, 2001, J NEUROSCI RES, V65, P45, DOI 10.1002/jnr.1126; BEHL C, 1994, BRAIN RES, V645, P253, DOI 10.1016/0006-8993(94)91659-4; Blanchard BJ, 2002, BIOCHEM BIOPH RES CO, V293, P1197, DOI 10.1016/S0006-291X(02)00346-7; Cantarella G, 2003, CELL DEATH DIFFER, V10, P134, DOI 10.1038/sj.cdd.4401143; Canu N, 1998, J NEUROSCI, V18, P7061; Cardoso SM, 2002, BRAIN RES, V931, P117, DOI 10.1016/S0006-8993(02)02256-4; Chan SL, 2000, J BIOL CHEM, V275, P18195, DOI 10.1074/jbc.M000040200; Chang RCC, 2002, NEUROREPORT, V13, P2429, DOI 10.1097/00001756-200212200-00011; Chang RCC, 2002, J NEUROCHEM, V83, P1215, DOI 10.1046/j.1471-4159.2002.01237.x; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; Deb A, 2001, J IMMUNOL, V166, P6170, DOI 10.4049/jimmunol.166.10.6170; Donze O, 2001, EMBO J, V20, P3771, DOI 10.1093/emboj/20.14.3771; Elyaman W, 2002, MOL BRAIN RES, V109, P233, DOI 10.1016/S0169-328X(02)00582-X; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Gil J, 2002, FEBS LETT, V529, P249, DOI 10.1016/S0014-5793(02)03348-3; Gil J, 2000, ONCOGENE, V19, P3665, DOI 10.1038/sj.onc.1203710; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Harada J, 1999, BRAIN RES, V842, P311, DOI 10.1016/S0006-8993(99)01808-9; He LM, 2002, BRAIN RES, V939, P65, DOI 10.1016/S0006-8993(02)02549-0; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HUESMANN G, 2002, SOC NEUROSCI; Hugon J, 2000, J NEURAL TRANSM-SUPP, P125; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Jhamandas JH, 2003, J NEUROPHYSIOL, V89, P2923, DOI 10.1152/jn.01138.2002; Juin P, 1998, J BIOL CHEM, V273, P17559, DOI 10.1074/jbc.273.28.17559; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; Kruidering M, 2001, J BIOL CHEM, V276, P38417, DOI 10.1074/jbc.M103471200; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Langland JO, 1999, BIOCHEMISTRY-US, V38, P6361, DOI 10.1021/bi982410u; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Marissen WE, 2000, J BIOL CHEM, V275, P9314, DOI 10.1074/jbc.275.13.9314; Mattson MP, 1998, J NEUROCHEM, V70, P1; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Onuki R, 2002, P NATL ACAD SCI USA, V99, P14716, DOI 10.1073/pnas.232177599; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PIKE CJ, 1991, EUR J PHARM-MOLEC PH, V207, P367, DOI 10.1016/0922-4106(91)90014-9; Ray WJ, 1998, MOL MED TODAY, V4, P151, DOI 10.1016/S1357-4310(98)01229-5; Rumora L, 2002, BIOL CHEM, V383, P1751, DOI 10.1515/BC.2002.196; Saelens X, 2001, J BIOL CHEM, V276, P41620, DOI 10.1074/jbc.M103674200; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sastry PS, 2000, J NEUROCHEM, V74, P1, DOI 10.1046/j.1471-4159.2000.0740001.x; Satoh S, 1999, BIOCHEM J, V342, P65, DOI 10.1042/0264-6021:3420065; SHEA TB, 1991, J NEUROCHEM, V56, P842, DOI 10.1111/j.1471-4159.1991.tb02000.x; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Su JH, 2003, NEUROBIOL DIS, V12, P182, DOI 10.1016/S0969-9961(02)00019-0; Su JH, 2001, BRAIN RES, V898, P350, DOI 10.1016/S0006-8993(01)02018-2; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; SUEN KC, 2003, IN PRESS J NEUROCHEM; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Troy CM, 2000, J NEUROSCI, V20, P1386; Vattem KM, 2001, EUR J BIOCHEM, V268, P1143, DOI 10.1046/j.1432-1327.2001.01979.x; Vickers JC, 2000, PROG NEUROBIOL, V60, P139, DOI 10.1016/S0301-0082(99)00023-4; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618	72	79	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49819	49827		10.1074/jbc.M306503200	http://dx.doi.org/10.1074/jbc.M306503200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	12975376	hybrid			2022-12-25	WOS:000187068200023
J	Hiramatsu, T; Sonoda, H; Takanezawa, Y; Morikawa, R; Ishida, M; Kasahara, K; Sanai, Y; Taguchi, R; Aoki, J; Arai, H				Hiramatsu, T; Sonoda, H; Takanezawa, Y; Morikawa, R; Ishida, M; Kasahara, K; Sanai, Y; Taguchi, R; Aoki, J; Arai, H			Biochemical and molecular characterization of two phosphatidic acid-selective phospholipase A(1)s, mPA-PLA(1)alpha and mPA-PLA(1)beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN SEC23P-INTERACTING PROTEIN; SMOOTH-MUSCLE CELLS; LYSOPHOSPHATIDIC ACID; SPHINGOSINE 1-PHOSPHATE; SIGNAL-TRANSDUCTION; SEQUENCE SIMILARITY; COUPLED RECEPTOR; HEPATIC LIPASE; FAMILY; A(2)	We have identified a novel phospholipase A(1), named mPA-PLA(1)beta, which is specifically expressed in human testis and characterized it biochemically together with previously identified mPA-PLA(1)alpha. The sequence of mPA-PLA(1)beta encodes a 460-amino acid protein containing a lipase domain with significant homology to the previously identified phosphatidic acid (PA)-selective PLA(1), mPA-PLA(1)alpha. mPA-PLA(1)beta contains a short lid and deleted beta9 loop, which are characteristics of PLA(1) molecules in the lipase family, and is a member of a subfamily in the lipase family that includes mPA-PLA(1)alpha and phosphatidylserine-specific PLA(1). Both mPA-PLA(1)beta and mPA-PLA(1)alpha recombinant proteins exhibited PA-specific PLA(1) activity and were vanadate-sensitive. When mPA-PLA(1)beta-expressing cells were treated with bacterial phospholipase D, the cells produced lysophosphatidic acid (LPA). In both mPA-PLA(1)alpha and beta-expressing cells, most of the PA generated by the phospholipase D (PLD) treatment was converted to LPA, whereas in control cells it was converted to diacylglycerol. When expressed in HeLa cells most mPA-PLA(1)alpha protein was recovered from the cell supernatant. By contrast, mPA-PLA(1)beta was recovered almost exclusively from cells. Consistent with this observation, we found that mPA-PLA(1)beta has higher affinity to heparin than mPA-PLA(1)alpha. We also found that the membrane-associated mPA-PLA(1)s were insoluble in solubilization by 1% Triton X-100 and were detected in Triton X-100-insoluble buoyant fractions of sucrose gradients. The present study raises the possibility that production of LPA by mPA-PLA(1)alpha and -beta occurs on detergent-resistant membrane domains of the cells where they compete with lipid phosphate phosphatase for PA.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Nagoya City Univ, Fac Pharmaceut Sci, Mizuho Ku, Aichi 4670027, Japan; Univ Tokyo, Grad Sch Med, Dept Metabolome, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Metropolitan Org Med Res, Tokyo Metropolitan Inst Med Sci, Lab Frontier Sci, Bunkyo Ku, Tokyo 1138613, Japan; Japan Sci & Technol Corp, PRESTO, Bunkyo Ku, Tokyo 1138613, Japan; Tokyo Metropolitan Org Med Res, Tokyo Metropolitan Inst Med Sci, Dept Biochem Cell Res, Bunkyo Ku, Tokyo 1138613, Japan	University of Tokyo; Nagoya City University; University of Tokyo; Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST); Tokyo Metropolitan Institute of Medical Science	Aoki, J (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	jaoki@mol.f.u-tokyo.ac.jp		Takanezawa, Yasukazu/0000-0002-9220-5825; Aoki, Junken/0000-0001-9435-1896; Kasahara, Kohji/0000-0001-7010-8365; Sonoda, Hirofumi/0000-0003-3353-1783				ALLAN D, 1976, BIOCHEM J, V156, P225, DOI 10.1042/bj1560225; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Aoki J, 2002, BBA-MOL CELL BIOL L, V1582, P26, DOI 10.1016/S1388-1981(02)00134-8; Baker DL, 2001, ANAL BIOCHEM, V292, P287, DOI 10.1006/abio.2001.5063; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodin S, 2001, BIOCHEMISTRY-US, V40, P15290, DOI 10.1021/bi0109313; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Carriere F, 1998, BBA-REV BIOMEMBRANES, V1376, P417, DOI 10.1016/S0304-4157(98)00016-1; Connelly PW, 1999, CLIN CHIM ACTA, V286, P243, DOI 10.1016/S0009-8981(99)00105-9; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Czarny M, 1999, J BIOL CHEM, V274, P2717, DOI 10.1074/jbc.274.5.2717; Eder AM, 2000, CLIN CANCER RES, V6, P2482; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; GILLETT MPT, 1993, INT J BIOCHEM, V25, P449, DOI 10.1016/0020-711X(93)90639-V; Hayashi K, 2001, CIRC RES, V89, P251, DOI 10.1161/hh1501.094265; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HIGASHI S, 1988, J BIOCHEM-TOKYO, V103, P442, DOI 10.1093/oxfordjournals.jbchem.a122289; Higgs HN, 1998, J BIOL CHEM, V273, P5468, DOI 10.1074/jbc.273.10.5468; Hirata K, 1999, J BIOL CHEM, V274, P14170, DOI 10.1074/jbc.274.20.14170; Hodgkin MN, 1999, BIOCHEM J, V339, P87, DOI 10.1042/0264-6021:3390087; HOFFMAN DR, 1994, INT ARCH ALLERGY IMM, V104, P184, DOI 10.1159/000236728; Hosono H, 2001, J BIOL CHEM, V276, P29664, DOI 10.1074/jbc.M104597200; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Ishii J, 2002, J BIOL CHEM, V277, P39696, DOI 10.1074/jbc.M206140200; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; Kasahara K, 2000, GLYCOCONJUGATE J, V17, P153, DOI 10.1023/A:1026576804247; King TP, 1996, J ALLERGY CLIN IMMUN, V98, P588, DOI 10.1016/S0091-6749(96)70093-3; Lourenssen S, 1998, NEUROSCI LETT, V248, P77, DOI 10.1016/S0304-3940(98)00275-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marheineke K, 1998, FEBS LETT, V441, P49, DOI 10.1016/S0014-5793(98)01523-3; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Nakajima K, 2002, J BIOL CHEM, V277, P11329, DOI 10.1074/jbc.M111092200; NANJUNDAN M, 2001, BIOCHEM J, P637; PAYNE RM, 1994, AM J PHYSIOL, V266, pG914, DOI 10.1152/ajpgi.1994.266.5.G914; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; SANTAMARINAFOJO S, 1994, INT J CLIN LAB RES, V24, P143, DOI 10.1007/BF02592444; Sato T, 1997, J BIOL CHEM, V272, P2192; Scanlan MJ, 2002, INT J CANCER, V98, P485, DOI 10.1002/ijc.10276; Sciorra VA, 1999, MOL BIOL CELL, V10, P3863, DOI 10.1091/mbc.10.11.3863; Shen ZZ, 1998, GYNECOL ONCOL, V71, P364, DOI 10.1006/gyno.1998.5193; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; SOLDATOVA L, 1993, FEBS LETT, V320, P145, DOI 10.1016/0014-5793(93)80080-E; Sonoda H, 2002, J BIOL CHEM, V277, P34254, DOI 10.1074/jbc.M201659200; Tani K, 1999, J BIOL CHEM, V274, P20505, DOI 10.1074/jbc.274.29.20505; TOKUMURA A, 1994, AM J PHYSIOL, V267, pC204, DOI 10.1152/ajpcell.1994.267.1.C204; TOKUMURA A, 1995, PROG LIPID RES, V34, P151, DOI 10.1016/0163-7827(95)00001-G; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Walker AJ, 2001, BIOCHEM J, V353, P129, DOI 10.1042/bj3530129	58	80	85	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49438	49447		10.1074/jbc.M213018200	http://dx.doi.org/10.1074/jbc.M213018200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12963729				2022-12-25	WOS:000186829000112
J	Sato, T; Gotoh, M; Kiyohara, K; Kameyama, A; Kubota, T; Kikuchi, N; Ishizuka, Y; Iwasaki, H; Togayachi, A; Kudo, T; Ohkura, T; Nakanishi, H; Narimatsu, H				Sato, T; Gotoh, M; Kiyohara, K; Kameyama, A; Kubota, T; Kikuchi, N; Ishizuka, Y; Iwasaki, H; Togayachi, A; Kudo, T; Ohkura, T; Nakanishi, H; Narimatsu, H			Molecular cloning and characterization of a novel human beta 1,4-N-acetylgalactosaminyltransferase, beta 4GalNAc-T3, responsible for the synthesis of N,N '-diacetyllactosediamine, GalNAc beta 1-4GlcNAc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; CHONDROITIN N-ACETYLGALACTOSAMINYLTRANSFERASE; BETA-4-GALACTOSYLTRANSFERASE GENE FAMILY; PROTEIN LINKAGE REGION; CHINESE-HAMSTER OVARY; GLYCOPROTEIN HORMONES; UDP-GALACTOSE; CAENORHABDITIS-ELEGANS; GLYCAN STRUCTURES; CRYSTAL-STRUCTURE	We found a novel human glycosyltransferase gene carrying a hypothetical beta1,4-glycosyltransferase motif during a BLAST search, and we cloned its full-length open reading frame by using the 5'-rapid amplification of cDNA ends method. It encodes a type II transmembrane protein of 999 amino acids with homology to chondroitin sulfate synthase in its C-terminal region (GenBank(TM) accession number AB089940). Its putative orthologous gene was also found in mouse (accession number AB114826). The truncated form of the human enzyme was expressed in HEK293T cells as a soluble protein. The recombinant enzyme transferred GalNAc to GlcNAc beta-benzyl. The product was deduced to be GalNAcbeta1-4GlcNAcbeta-benzyl based on mass spectrometry and NMR spectroscopy. We renamed the enzyme beta1,4-N-acetylgalactosaminyltransferase-III (beta4GalNAc-T3). beta4GalNAc-T3 effectively synthesized N,N'-diacetylgalactosediamine, GalNAcbeta1-4GlcNAc, at non-reducing termini of various acceptors derived not only from N-glycans but also from O-glycans. Quantitative real time PCR analysis showed that its transcript was highly expressed in stomach, colon, and testis. As some glycohormones contain N, N'-diacetylgalactosediamine structures in their N-glycans, we examined the ability of beta4GalNAc-T3 to synthesize N, N'-diacetylgalactosediamine structures in N-glycans on a model protein. When fetal calf fetuin treated with neuraminidase and beta1,4-galactosidase was utilized as an acceptor protein, beta4GalNAc-T3 transferred GalNAc to it. Furthermore, the majority of the signal from GalNAc disappeared on treatment with glycopeptidase F. These results suggest that beta4GalNAc-T3 could transfer GalNAc residues, producing N,N'-diacetylgalactosediamine structures at least in N-glycans and probably in both N- and O-glycans.	Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Glycogene Funct Team, Tsukuba, Ibaraki 3058568, Japan; Amersham Biosci KK, Shinjuku Ku, Tokyo 1690073, Japan; Mitsui Knowledge Ind Co Ltd, Nakano Ku, Tokyo 1648721, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tsukuba, Ibaraki 3058568, Japan; New Energy & Ind Technol Dev Org, Toshima Ku, Tokyo 1706028, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST)	Narimatsu, H (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Glycogene Funct Team, OSL Cent 2,1-1-1 Umezono, Tsukuba, Ibaraki 3058568, Japan.		Sato, Takashi/M-2577-2018; Narimatsu, Hisashi/M-4757-2018; Kubota, Tomomi/J-1492-2018	Sato, Takashi/0000-0002-9973-8923; Narimatsu, Hisashi/0000-0002-8402-133X; Togayachi, Akira/0000-0003-3600-9149; Kubota, Tomomi/0000-0002-0723-135X				Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; Do KY, 1997, GLYCOBIOLOGY, V7, P183, DOI 10.1093/glycob/7.2.183; Dohi T, 1996, INT J CANCER, V67, P626, DOI 10.1002/(SICI)1097-0215(19960904)67:5<626::AID-IJC6>3.0.CO;2-W; FEENEY J, 1986, CARBOHYD RES, V152, P63, DOI 10.1016/S0008-6215(00)90287-8; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Gotoh M, 2002, J BIOL CHEM, V277, P38189, DOI 10.1074/jbc.M203619200; Gotoh M, 2002, J BIOL CHEM, V277, P38179, DOI 10.1074/jbc.M202601200; GREEN ED, 1988, J BIOL CHEM, V263, P25; HIYAMA J, 1992, GLYCOBIOLOGY, V2, P401, DOI 10.1093/glycob/2.5.401; Ishizuka Y, 1999, J CARBOHYD CHEM, V18, P523, DOI 10.1080/07328309908544016; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; Karlsson NG, 2002, ANAL BIOCHEM, V305, P173, DOI 10.1006/abio.2002.5657; Kawar ZS, 2002, J BIOL CHEM, V277, P34924, DOI 10.1074/jbc.M206112200; Kitagawa H, 2003, J BIOL CHEM, V278, P23666, DOI 10.1074/jbc.M302493200; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Kutyavin IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/nar/28.2.655; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; Montiel MD, 2003, BIOCHEM J, V373, P369, DOI 10.1042/BJ20021892; Morris HR, 1996, J BIOL CHEM, V271, P32159, DOI 10.1074/jbc.271.50.32159; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; Ohkura T, 2002, J BIOCHEM, V132, P891, DOI 10.1093/oxfordjournals.jbchem.a003302; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Ramakrishnan B, 2002, J BIOL CHEM, V277, P20833, DOI 10.1074/jbc.M111183200; Ramakrishnan B, 2001, J BIOL CHEM, V276, P37665, DOI 10.1074/jbc.M102458200; Ramakrishnan B, 2001, J MOL BIOL, V310, P205, DOI 10.1006/jmbi.2001.4757; Saarinen J, 1999, EUR J BIOCHEM, V259, P829, DOI 10.1046/j.1432-1327.1999.00105.x; Sato T, 2003, J BIOL CHEM, V278, P3063, DOI 10.1074/jbc.M208886200; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1992, J BIOL CHEM, V267, P19140; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; Uyama T, 2003, J BIOL CHEM, V278, P3072, DOI 10.1074/jbc.M209446200; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; Van den Nieuwenhof IM, 2000, EUR J BIOCHEM, V267, P4753, DOI 10.1046/j.1432-1327.2000.01528.x; Woodworth A, 2002, J BIOL CHEM, V277, P50941, DOI 10.1074/jbc.M209876200; Wu A M, 1988, Adv Exp Med Biol, V228, P351; Yada T, 2003, J BIOL CHEM, V278, P39711, DOI 10.1074/jbc.M304421200; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149; YAN SB, 1993, GLYCOBIOLOGY, V3, P597, DOI 10.1093/glycob/3.6.597; YAZAWA S, 1986, CARBOHYD RES, V149, P241, DOI 10.1016/S0008-6215(00)90381-1	49	68	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47534	47544		10.1074/jbc.M308857200	http://dx.doi.org/10.1074/jbc.M308857200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12966086	hybrid			2022-12-25	WOS:000186731400025
J	Siebold, C; Arnold, I; Garcia-Alles, LF; Baumann, U; Erni, B				Siebold, C; Arnold, I; Garcia-Alles, LF; Baumann, U; Erni, B			Crystal structure of the Citrobacter freundii dihydroxyacetone kinase reveals an eight-stranded alpha-helical barrel ATP-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SHEET PROTEINS; ESCHERICHIA-COLI; PHOSPHOTRANSFERASE SYSTEM; KLEBSIELLA-PNEUMONIAE; MANNOSE TRANSPORTER; ANGSTROM RESOLUTION; HUMAN-ERYTHROCYTES; GLYCEROL; PURIFICATION; SEQUENCE	Dihydroxyacetone kinases are a sequence-conserved family of enzymes, which utilize two different phosphoryldonors, ATP in animals, plants and some bacteria, and a multiphosphoprotein of the phosphoenolpyruvate carbohydrate phosphotransferase system in bacteria. Here we report the 2.5-Angstrom crystal structure of the homodimeric Citrobacter freundii dihydroxyacetone kinase complex with an ATP analogue and dihydroxyacetone. The N-terminal domain consists of two alpha/beta-folds with a molecule of dihydroxyacetone covalently bound in hemiaminal linkage to the Nepsilon2 of His-220. The C-terminal domain consists of a regular eight-helix alpha-barrel. The eight helices form a deep pocket, which includes a tightly bound phospholipid. Only the lipid headgroup protrudes from the surface. The nucleotide is bound on the top of the barrel across from the entrance to the lipid pocket. The phosphate groups are coordinated by two Mg(2+) ions to gamma-carboxyl groups of aspartyl residues. The ATP binding site does not contain positively charged or aromatic groups. Paralogues of dihydroxyacetone kinase also occur in association with transcription regulators and proteins of unknown function pointing to biological roles beyond triose metabolism.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland	University of Bern	Baumann, U (corresponding author), Univ Bern, Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.	ulrich.baumann@ibc.unibe.ch; bernhard.erni@ibc.unibe.ch	Baumann, Ulrich/B-1220-2013	Garcia-Alles, Luis/0000-0002-1141-0393				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Asawanonda P, 1999, INT J DERMATOL, V38, P916, DOI 10.1046/j.1365-4362.1999.00779.x; AZZOUT B, 1984, J NUTR, V114, P2167, DOI 10.1093/jn/114.11.2167; Beutler R, 2001, MICROBIOL-SGM, V147, P249, DOI 10.1099/00221287-147-2-249; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Charvolin D, 1999, EUR J BIOCHEM, V264, P562, DOI 10.1046/j.1432-1327.1999.00667.x; COGOLIGREUTER M, 1981, J BIOL CHEM, V256, P5708; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; CORTEZ MY, 1991, AM J CLIN NUTR, V53, P847, DOI 10.1093/ajcn/53.4.847; DANIEL R, 1995, J BACTERIOL, V177, P4392, DOI 10.1128/jb.177.15.4392-4401.1995; DANIEL R, 1995, J BACTERIOL, V177, P2151, DOI 10.1128/jb.177.8.2151-2156.1995; Fesq H, 2001, DERMATOLOGY, V203, P241, DOI 10.1159/000051757; FORAGE RG, 1982, J BACTERIOL, V151, P591, DOI 10.1128/JB.151.2.591-599.1982; Gutknecht R, 1999, J BIOL CHEM, V274, P6091, DOI 10.1074/jbc.274.10.6091; Gutknecht R, 2001, EMBO J, V20, P2480, DOI 10.1093/emboj/20.10.2480; Iushmanov S V, 1988, Mol Gen Mikrobiol Virusol, P9; Ivy JL, 1998, MED SCI SPORT EXER, V30, P837, DOI 10.1097/00005768-199806000-00010; JENKINS BT, 1976, J NEUROCHEM, V26, P377, DOI 10.1111/j.1471-4159.1976.tb04491.x; JIA ZC, 1994, J MOL BIOL, V236, P1341, DOI 10.1016/0022-2836(94)90062-0; JIN RZ, 1984, J GEN MICROBIOL, V130, P83; JOHNSON EA, 1984, J BACTERIOL, V160, P55, DOI 10.1128/JB.160.1.55-60.1984; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kates M., 1972, LAB TECH BIOCH MOL B, V3, P268, DOI [10.1016/S0075-7535(08)70544-8, DOI 10.1016/S0075-7535(08)70544-8]; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kimura T, 1998, BBA-GENE STRUCT EXPR, V1442, P361, DOI 10.1016/S0167-4781(98)00152-3; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Lanz R, 1998, J BIOL CHEM, V273, P12239, DOI 10.1074/jbc.273.20.12239; Lee AG, 2003, BBA-BIOMEMBRANES, V1612, P1, DOI 10.1016/S0005-2736(03)00056-7; Liao DI, 1996, STRUCTURE, V4, P861, DOI 10.1016/S0969-2126(96)00092-5; Luers GH, 1998, YEAST, V14, P759; MAO QC, 1995, J BIOL CHEM, V270, P18295, DOI 10.1074/jbc.270.31.18295; Molin M, 2003, J BIOL CHEM, V278, P1415, DOI 10.1074/jbc.M203030200; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Nguyen BC, 2003, J INVEST DERMATOL, V120, P655, DOI 10.1046/j.1523-1747.2003.12089.x; NONOMURA AM, 1992, P NATL ACAD SCI USA, V89, P9794, DOI 10.1073/pnas.89.20.9794; Nunn RS, 1996, J MOL BIOL, V259, P502, DOI 10.1006/jmbi.1996.0335; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paulsen IT, 2000, MICROBIOL-UK, V146, P2343, DOI 10.1099/00221287-146-10-2343; Richardson JS, 2002, P NATL ACAD SCI USA, V99, P2754, DOI 10.1073/pnas.052706099; RUCH FE, 1974, J BACTERIOL, V119, P50, DOI 10.1128/JB.119.1.50-56.1974; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schulze-Gahmen U, 2003, PROTEINS, V50, P526, DOI 10.1002/prot.10305; Schurmann M, 2001, J BIOL CHEM, V276, P11055, DOI 10.1074/jbc.M008061200; SHELDRICK GM, 1995, ACTA CRYSTALLOGR B, V51, P423, DOI 10.1107/S0108768195003661; Siebold C, 2003, P NATL ACAD SCI USA, V100, P8188, DOI 10.1073/pnas.0932787100; Stewart MQ, 2001, J CELL SCI, V114, P2863; Taguchi T, 2002, CELL BIOCHEM FUNCT, V20, P223, DOI 10.1002/cbf.952; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tessier FJ, 2003, BIOCHEM J, V369, P705, DOI 10.1042/BJ20020668; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Verdino P, 2002, EMBO J, V21, P5007, DOI 10.1093/emboj/cdf526; Voet D, 1999, FUNDAMENTALS BIOCH; WAITES MJ, 1981, J GEN MICROBIOL, V124, P309; Wang WX, 2002, P NATL ACAD SCI USA, V99, P2760, DOI 10.1073/pnas.052706199; WEHMEIER UF, 1994, BBA-PROTEIN STRUCT M, V1208, P348, DOI 10.1016/0167-4838(94)90124-4	57	44	46	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48236	48244		10.1074/jbc.M305942200	http://dx.doi.org/10.1074/jbc.M305942200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12966101	hybrid, Green Published			2022-12-25	WOS:000186731400107
J	Zheng, W; Xie, WR; Zhang, JH; Strong, JA; Wang, L; Yu, L; Xu, M; Lu, L				Zheng, W; Xie, WR; Zhang, JH; Strong, JA; Wang, L; Yu, L; Xu, M; Lu, L			Function of gamma-aminobutyric acid receptor/channel rho(1) subunits in spinal cord	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGER SALAMANDER RETINA; GABA(C) RECEPTOR; RAT RETINA; XENOPUS OOCYTES; RHO-2 SUBUNITS; IN-VITRO; IMMUNOCYTOCHEMICAL LOCALIZATION; SYNAPTIC TRANSMISSION; TACTILE ALLODYNIA; NEUROPATHIC PAIN	gamma-Aminobutyric acid (GABA) receptor/channel rho(1) subunits are important components in inhibitory pathways in the central nervous system. However, the precise locations and roles of these receptors in the central nervous system are unknown. We studied the expression localization of GABA receptor/channel rho(1) subunit in mouse spinal cord and dorsal root ganglia (DRG). The immunohistochemistry results indicated that GABA receptor/ channel rho(1) subunits were expressed in mouse spinal cord superficial dorsal horn ( lamina I and lamina II) and in DRG. To understand the functions of the GABA receptor/ channel rho(1) subunit in these crucial sites of sensory transmission in vivo, we generated GABA receptor/ channel rho(1) subunit mutant mice (rho1(-/-)). GABA receptor/ channel rho(1) subunit expression in the rho1(-/-) mice was eliminated completely, whereas the gross neuroanatomical structures of the rho1(-/-) mice spinal cord and DRG were unchanged. Electrophysiological recording showed that GABA-mediated spinal cord response was altered in the rho1(-/-) mice. A decreased threshold for mechanical pain in the rho1(-/-) mice compared with control mice was observed with the von Frey filament test. These findings indicate that the GABA receptor/ channel rho(1) subunit plays an important role in modulating spinal cord pain transmission functions in vivo.	Univ Calif Los Angeles, David Geffen Sch Med, Harbor UCLA Med Ctr, Div Mol Med, Torrance, CA 90502 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University System of Ohio; University of Cincinnati	Lu, L (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Harbor UCLA Med Ctr, Div Mol Med, 1124 W Carson St,C-2, Torrance, CA 90502 USA.		zhang, jianhua/D-3404-2009	Zhang, Jianhua/0000-0002-2128-9574; Strong, Judith/0000-0001-9363-0551	NATIONAL EYE INSTITUTE [R01EY011653, R01EY015281] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013786, R29DA011284, R01DA009444, R01DA014644, R01DA013471] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY015281, EY11653] Funding Source: Medline; NIDA NIH HHS [DA13786, DA13471, DA14644, DA09444, DA11284] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Basbaum AI, 1999, REGION ANESTH PAIN M, V24, P59, DOI 10.1016/S1098-7339(99)90167-0; Bormann J, 2000, TRENDS PHARMACOL SCI, V21, P16, DOI 10.1016/S0165-6147(99)01413-3; BORMANN J, 1995, TRENDS NEUROSCI, V18, P515, DOI 10.1016/0166-2236(95)98370-E; Boue-Grabot E, 2000, ENDOCRINOLOGY, V141, P1627, DOI 10.1210/en.141.5.1627; Boue-Grabot E, 1998, J NEUROCHEM, V70, P899; BOWERY NG, 1984, NEUROPHARMACOLOGY, V23, P219, DOI 10.1016/0028-3908(84)90063-7; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Craig A D, 2000, Prog Brain Res, V129, P137; CURTIS DR, 1970, NATURE, V226, P1222, DOI 10.1038/2261222a0; CUTTING GR, 1992, GENOMICS, V12, P801, DOI 10.1016/0888-7543(92)90312-G; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Dong CJ, 1998, J NEUROPHYSIOL, V79, P2171, DOI 10.1152/jn.1998.79.4.2171; Ekema GM, 2002, INVEST OPHTH VIS SCI, V43, P2326; Ekema GM, 2001, J MEMBRANE BIOL, V183, P205, DOI 10.1007/s00232-001-0068-3; Enz R, 1999, BRAIN RES, V846, P177, DOI 10.1016/S0006-8993(99)02008-9; Enz R, 2001, BIOL CHEM, V382, P1111, DOI 10.1515/BC.2001.141; Enz R, 1999, EUR J NEUROSCI, V11, P41, DOI 10.1046/j.1460-9568.1999.00423.x; Enz R, 1996, J NEUROSCI, V16, P4479; ENZ R, 1995, EUR J NEUROSCI, V7, P1495, DOI 10.1111/j.1460-9568.1995.tb01144.x; Feigenspan A, 1998, PROG RETIN EYE RES, V17, P99, DOI 10.1016/S1350-9462(97)00008-6; Garret M, 1997, J NEUROCHEM, V68, P1382; Garrett KM, 1997, MOL BRAIN RES, V45, P133, DOI 10.1016/S0169-328X(96)00290-2; Greka A, 2000, EUR J NEUROSCI, V12, P3575, DOI 10.1046/j.1460-9568.2000.00247.x; Greka A, 1998, NEUROREPORT, V9, P229, DOI 10.1097/00001756-199801260-00010; Hackam AS, 1997, J BIOL CHEM, V272, P13750, DOI 10.1074/jbc.272.21.13750; HENRY JL, 1982, NEUROPHARMACOLOGY, V21, P1085, DOI 10.1016/0028-3908(82)90165-4; Hevers W, 1998, MOL NEUROBIOL, V18, P35, DOI 10.1007/BF02741459; HILL DR, 1981, NATURE, V290, P149, DOI 10.1038/290149a0; Hwang JH, 1997, PAIN, V70, P15, DOI 10.1016/S0304-3959(96)03249-6; Johnston GAR, 1996, TRENDS PHARMACOL SCI, V17, P319, DOI 10.1016/S0165-6147(96)10038-9; JOHNSTON GAR, 1994, PROG BRAIN RES, V100, P61; Koulen P, 1997, J COMP NEUROL, V380, P520, DOI 10.1002/(SICI)1096-9861(19970421)380:4<520::AID-CNE8>3.0.CO;2-3; Koulen P, 1998, EUR J NEUROSCI, V10, P115, DOI 10.1046/j.1460-9568.1998.00005.x; Laughlin TM, 1997, PAIN, V72, P253, DOI 10.1016/S0304-3959(97)00046-8; Lu L, 1998, J MEMBRANE BIOL, V164, P115, DOI 10.1007/s002329900398; LUKASIEWICZ PD, 1994, J NEUROSCI, V14, P1213, DOI 10.1523/JNEUROSCI.14-03-01213.1994; Malan TP, 2002, ANESTHESIOLOGY, V96, P1161, DOI 10.1097/00000542-200205000-00020; Malcangio M, 1996, TRENDS PHARMACOL SCI, V17, P457; McCall MA, 2002, J NEUROSCI, V22, P4163, DOI 10.1523/JNEUROSCI.22-10-04163.2002; MENSE S, 1983, AM J MED, V75, P4, DOI 10.1016/0002-9343(83)90226-7; Mohler H, 1996, Ion Channels, V4, P89; OGURUSU T, 1995, J NEUROCHEM, V65, P964; Ogurusu T, 1996, BBA-GENE STRUCT EXPR, V1305, P15, DOI 10.1016/0167-4781(95)00205-7; Pan ZH, 2000, EUR J NEUROSCI, V12, P3137, DOI 10.1046/j.1460-9568.2000.00198.x; POLENZANI L, 1991, P NATL ACAD SCI USA, V88, P4318, DOI 10.1073/pnas.88.10.4318; Qian HH, 1999, P ROY SOC B-BIOL SCI, V266, P2419, DOI 10.1098/rspb.1999.0941; Ragozzino D, 1996, MOL PHARMACOL, V50, P1024; Rozzo A, 2002, EUR J NEUROSCI, V15, P1747, DOI 10.1046/j.1460-9568.2002.02013.x; Rozzo A, 1999, NEUROSCIENCE, V90, P1085, DOI 10.1016/S0306-4522(98)00476-X; Sanes JR, 1999, CURR OPIN NEUROBIOL, V9, P79, DOI 10.1016/S0959-4388(99)80010-5; SAWYNOK J, 1987, PHARMACOL BIOCHEM BE, V26, P463, DOI 10.1016/0091-3057(87)90148-1; Todd AJ, 2002, EXP PHYSIOL, V87, P245, DOI 10.1113/eph8702351; Uusi-Oukari M, 2000, MOL CELL NEUROSCI, V16, P34, DOI 10.1006/mcne.2000.0856; WANG TL, 1994, J NEUROSCI, V14, P6524; Wegelius K, 1998, EUR J NEUROSCI, V10, P350, DOI 10.1046/j.1460-9568.1998.00023.x; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756; Zhang DX, 2001, TRENDS PHARMACOL SCI, V22, P121, DOI 10.1016/S0165-6147(00)01625-4	59	37	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48321	48329		10.1074/jbc.M307930200	http://dx.doi.org/10.1074/jbc.M307930200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12970343	hybrid			2022-12-25	WOS:000186731400117
J	Gomez, MF; Bosc, LVG; Stevenson, AS; Wilkerson, MK; Hill-Eubanks, DC; Nelson, MT				Gomez, MF; Bosc, LVG; Stevenson, AS; Wilkerson, MK; Hill-Eubanks, DC; Nelson, MT			Constitutively elevated nuclear export activity opposes Ca2+-dependent NFATc3 nuclear accumulation in vascular smooth muscle - Role of JNK2 and Crm-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; NF-AT; PHOSPHATASE CALCINEURIN; TRANSCRIPTION FACTORS; CA2+; PROTEIN; DIFFERENTIATION; INHIBITION; PATHWAY; SIGNALS	The transcription factor NFAT ( nuclear factor of activated T-cells) is a cytosolic phosphoprotein that accumulates in the nucleus following dephosphorylation by the calcium (Ca2+)/calmodulin-dependent phosphatase, calcineurin. A defining feature of stimuli that induce NFAT nuclear accumulation/ activation is a sustained increase in global intracellular Ca2+. Contrary to expectations, we have found that a sustained elevation of intracellular Ca2+, induced by membrane potential depolarization and mediated by voltage-dependent Ca2+ channels, does not result in nuclear localization of the NFATc3 isoform in smooth muscle. However, vasoconstrictors (e.g. uridine triphosphate (UTP)) and growth factors, which elevate intracellular Ca2+ and engage multiple intracellular signaling pathways, induce a robust increase in smooth muscle nuclear NFATc3. Here we show that depolarizing stimuli that normally fail to induce NFATc3 nuclear accumulation in arterial smooth muscle effectively induce nuclear accumulation under conditions in which Crm-1-dependent or JNK2-mediated nuclear export processes are disrupted. Consistent with an important regulatory role for JNK, UTP exerts a suppressive effect on JNK activity in smooth muscle. Export of nuclear NFATc3 following UTP-induced nuclear accumulation is dramatically slowed in cerebral arteries from JNK2(-/-) animals. These data indicate that in smooth muscle, stimulation of Ca2+-dependent, calcineurin-mediated nuclear import and suppression of Crm-1/JNK-dependent nuclear export are both required for induction of NFATc3 nuclear accumulation. These results highlight the dynamic interplay between influences that promote and oppose NFAT nuclear accumulation and suggest that in arterial smooth muscle suppression of constitutive nuclear export activity is an important property of NFAT-activating stimuli.	Univ Vermont, Dept Pharmacol, Burlington, VT 05405 USA	University of Vermont	Nelson, MT (corresponding author), Univ Vermont, Dept Pharmacol, 89 Beaumont Ave, Burlington, VT 05405 USA.		Gomez, Maria F/D-3696-2014	Gomez, Maria F/0000-0001-6210-3142; Nelson, Mark/0000-0002-6608-8784	NHLBI NIH HHS [HL 63722, T32 HL/AR 07944, HL 07944, HL 07647-12, HL 44455] Funding Source: Medline; NIDDK NIH HHS [DK 53832] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044455, T32HL007944, R01HL063722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK053832, R01DK053832] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAMBURU J, 1995, J EXP MED, V182, P801, DOI 10.1084/jem.182.3.801; Chow CW, 2000, MOL CELL BIOL, V20, P5227, DOI 10.1128/MCB.20.14.5227-5234.2000; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; Gokina NI, 1999, AM J PHYSIOL-HEART C, V277, pH1178, DOI 10.1152/ajpheart.1999.277.3.H1178; GOMEZ DA, 2000, J BIOL CHEM, V275, P13872; Gomez MF, 2002, J BIOL CHEM, V277, P37756, DOI 10.1074/jbc.M203596200; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Hill-Eubanks DC, 2003, TRENDS CARDIOVAS MED, V13, P56, DOI 10.1016/S1050-1738(02)00212-8; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Knot HJ, 1998, J PHYSIOL-LONDON, V508, P199, DOI 10.1111/j.1469-7793.1998.199br.x; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Paul A, 2000, J BIOL CHEM, V275, P13243, DOI 10.1074/jbc.275.18.13243; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Zhu J, 2000, CELL MOL LIFE SCI, V57, P411, DOI 10.1007/PL00000703; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	28	45	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46847	46853		10.1074/jbc.M304765200	http://dx.doi.org/10.1074/jbc.M304765200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12954637	hybrid			2022-12-25	WOS:000186569400077
J	Qiu, LY; Koenderink, JB; Swarts, HGP; Willems, PHGM; De Pont, JJHHM				Qiu, LY; Koenderink, JB; Swarts, HGP; Willems, PHGM; De Pont, JJHHM			Phe(783), Thr(797), and Asp(804) in transmembrane hairpin M5-M6 of Na+,K+-ATPase play a key role in ouabain binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHIMERIC GASTRIC H+,K+-ATPASE; NA,K-ATPASE ALPHA-SUBUNIT; AMINO-ACID-RESIDUES; RANDOM MUTAGENESIS; RESISTANT ENZYME; ATPASE ACTIVITY; SENSITIVITY; INHIBITION; MECHANISM; AFFINITY	Ouabain is a glycoside that binds to and inhibits the action of Na+, K+-ATPase. Little is known, however, about the specific requirements of the protein surface for glycoside binding. Using chimeras of gastric H+, K+-ATPase and Na+, K+-ATPase, we demonstrated previously that the combined presence of transmembrane hairpins M3-M4 and M5-M6 of Na+, K+-ATPase in a backbone of H+, K+-ATPase (HN34/56) is both required and sufficient for high affinity ouabain binding. Since replacement of transmembrane hairpin M3-M4 by the N terminus up to transmembrane segment 3 (HNN3/56) resulted in a low affinity ouabain binding, hairpin M5-M6 seems to be essential for ouabain binding. To assess which residues of M5-M6 are required for ouabain action, we divided this transmembrane hairpin in seven parts and individually replaced these parts by the corresponding sequences of H+, K+-ATPase in chimera HN34/56. Three of these chimeras failed to bind ouabain following expression in Xenopus laevis oocytes. Altogether, these three chimeras contained 7 amino acids that were specific for Na+, K+-ATPase. Individual replacement of these 7 amino acids by the corresponding amino acids in H+, K+-ATPase revealed a dramatic loss of ouabain binding for F783Y, T797C, and D804E. As a proof of principle, the Na+, K+-ATPase equivalents of these 3 amino acids were introduced in different combinations in chimera HN34. The presence of all 3 amino acids appeared to be required for ouabain action. Docking of ouabain onto a three-dimensional-model of Na+, K+-ATPase suggests that Asp(804), in contrast to Phe(783) and Thr(797), does not actually form part of the ouabain-binding pocket. Most likely, the presence of this amino acid is required for adopting of the proper conformation for ouabain binding.	Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Biochem, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	De Pont, JJHHM (corresponding author), Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Biochem, POB 9101, NL-6500 HB Nijmegen, Netherlands.	J.dePont@ncmls.kun.nl	Willems, P.H.G.M./L-4759-2015; Koenderink, Jan/N-3578-2014	Willems, P.H.G.M./0000-0002-0915-1599; 				Asano S, 1999, J BIOL CHEM, V274, P6848, DOI 10.1074/jbc.274.11.6848; BURNS EL, 1993, J BIOL CHEM, V268, P25632; Burns EL, 1996, J BIOL CHEM, V271, P15879, DOI 10.1074/jbc.271.27.15879; Croyle ML, 1997, EUR J BIOCHEM, V248, P488, DOI 10.1111/j.1432-1033.1997.00488.x; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; Geibel S, 2003, P NATL ACAD SCI USA, V100, P964, DOI 10.1073/pnas.0337336100; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; ISHII T, 1993, P NATL ACAD SCI USA, V90, P8881, DOI 10.1073/pnas.90.19.8881; ISHII T, 1994, P NATL ACAD SCI USA, V91, P6103, DOI 10.1073/pnas.91.13.6103; Koenderink JB, 2000, P NATL ACAD SCI USA, V97, P11209, DOI 10.1073/pnas.200109597; Koenderink JB, 2000, BIOCHEMISTRY-US, V39, P9959, DOI 10.1021/bi0001168; Koenderink JB, 1999, J BIOL CHEM, V274, P11604, DOI 10.1074/jbc.274.17.11604; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; MATSUI H, 1968, BIOCHIM BIOPHYS ACTA, V151, P655, DOI 10.1016/0005-2744(68)90013-2; Middleton DA, 2000, P NATL ACAD SCI USA, V97, P13602, DOI 10.1073/pnas.250471997; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; SCHATZMANN HJ, 1953, HELV PHYSIOL PHARM A, V11, P346; SKOU JC, 1957, BIOCHIM BIOPHYS ACTA, V23, P394, DOI 10.1016/0006-3002(57)90343-8; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944	24	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47240	47244		10.1074/jbc.M308833200	http://dx.doi.org/10.1074/jbc.M308833200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12972417	hybrid, Green Published			2022-12-25	WOS:000186569400124
J	Roelle, S; Grosse, R; Aigner, A; Krell, HW; Czubayko, F; Gudermann, T				Roelle, S; Grosse, R; Aigner, A; Krell, HW; Czubayko, F; Gudermann, T			Matrix metalloproteinases 2 and 9 mediate epidermal growth factor receptor transactivation by gonadotropin-releasing hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAS-BINDING DOMAIN; SIGNALING PATHWAYS; COUPLED RECEPTORS; GNRH RECEPTOR; CELL-LINES; ACTIVATION; CALCIUM; CANCER; SRC	Rapid engagement of the extracellular signal-regulated kinase (ERK) cascade via the G(q/11)-coupled GnRH receptor (GnRHR) is mediated by transactivation of the epidermal growth factor receptor ( EGFR). Here we show that the cross-talk between GnRHR and EGFR in gonadotropic cells is accomplished via gelatinases A and B ( matrix metalloproteinases ( MMPs) 2 and 9), identifying gelatinases as the first distinct members of the MMP family mediating EGFR transactivation by G protein-coupled receptors. Using a specific MMP2 and MMP9 inhibitor, Ro28-2653, GnRH-dependent EGFR transactivation was abrogated. Proving the specificity of the effect, transient transfection of alphaT3-1 cells with ribozymes directed against MMP2 or MMP9 specifically blocked EGFR tyrosine phosphorylation in response to GnRH stimulation. GnRH challenge of alphaT3-1 cells furthered the release of active MMP2 and MMP9 and increased their gelatinolytic activities within 5 min. Rapid release of activated MMP2 or MMP9 was inhibited by ribozyme-targeted down-regulation of MT1-MMP or MMP2, respectively. We found that GnRH-induced Src, Ras, and ERK activation were also gelatinase-dependent. Thus, gelatinase-induced EGFR transactivation was required to engage the extracellular-signal regulated kinase cascade. Activation of c-Jun N-terminal kinase and p38 MAPK by GnRH was unaffected by EGFR or gelatinase inhibition that, however, suppressed GnRH induction of c-Jun and c-Fos. Our findings suggest a novel role for gelatinases in the endocrine regulation of pituitary gonadotropes.	Univ Marburg, Inst Pharmakol & Toxikol, D-35033 Marburg, Germany; Heidelberg Univ, Inst Mol Pharmakol, D-69120 Heidelberg, Germany; Roche Diagnost GmbH, Pharma Res Penzberg, D-82377 Penzberg, Germany	Philipps University Marburg; Ruprecht Karls University Heidelberg; Roche Holding	Gudermann, T (corresponding author), Univ Marburg, Inst Pharmakol & Toxikol, Karl von Frisch Str 1, D-35033 Marburg, Germany.	guderman@staff.uni-marburg.de	Aigner, Achim/R-4429-2017	Aigner, Achim/0000-0002-2778-6256; Grosse, Robert/0000-0002-3380-5273				Aigner A, 2002, GENE THER, V9, P1700, DOI 10.1038/sj.gt.3301839; Arlt M, 2002, CANCER RES, V62, P5543; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Beaulieu E, 1999, NEUROSURGERY, V45, P1432, DOI 10.1097/00006123-199912000-00033; Benard O, 2001, J BIOL CHEM, V276, P4554, DOI 10.1074/jbc.M006995200; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; CARPENTER G, 2000, SCI STKE; CESNJAJ M, 1994, ENDOCRINOLOGY, V135, P692, DOI 10.1210/en.135.2.692; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dhanasekaran N, 2001, ONCOGENE, V20, P1530, DOI 10.1038/sj.onc.1204273; English WR, 2001, J BIOL CHEM, V276, P42018, DOI 10.1074/jbc.M107783200; Grams F, 2001, BIOL CHEM, V382, P1277, DOI 10.1515/BC.2001.159; Grosse R, 2000, J BIOL CHEM, V275, P9193, DOI 10.1074/jbc.275.13.9193; Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Gudermann T, 2000, N-S ARCH PHARMACOL, V361, P345, DOI 10.1007/s002109900208; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kaiser UB, 1997, ENDOCR REV, V18, P46, DOI 10.1210/er.18.1.46; Kawamoto H, 1996, ACTA NEUROCHIR, V138, P1442, DOI 10.1007/BF01411124; Kraus S, 2003, J BIOL CHEM, V278, P32618, DOI 10.1074/jbc.M303886200; Lein M, 2002, ONCOGENE, V21, P2089, DOI 10.1038/sj.onc.1205267; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Liu FJ, 2002, MOL ENDOCRINOL, V16, P419, DOI 10.1210/me.16.3.419; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; Mulvaney JM, 1999, J BIOL CHEM, V274, P29796, DOI 10.1074/jbc.274.42.29796; Mulvaney JM, 2000, J BIOL CHEM, V275, P14182, DOI 10.1074/jbc.275.19.14182; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pereda MP, 2000, J CLIN ENDOCR METAB, V85, P263, DOI 10.1210/jc.85.1.263; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Reiss N, 1997, ENDOCRINOLOGY, V138, P1673, DOI 10.1210/en.138.4.1673; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; Shah BH, 2003, J BIOL CHEM, V278, P19118, DOI 10.1074/jbc.M212932200; Shah BH, 2003, J BIOL CHEM, V278, P2866, DOI 10.1074/jbc.m208783200; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; Turgeon JL, 1996, MOL ENDOCRINOL, V10, P439, DOI 10.1210/me.10.4.439; Turner HE, 2000, J CLIN ENDOCR METAB, V85, P2931, DOI 10.1210/jc.85.8.2931; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; WojtowiczPraga S, 1996, INVEST NEW DRUG, V14, P193	50	112	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47307	47318		10.1074/jbc.M304377200	http://dx.doi.org/10.1074/jbc.M304377200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963732	hybrid			2022-12-25	WOS:000186569400133
J	Trent, JO; Wang, ZX; Murray, JL; Shao, WH; Tamamura, H; Fujii, N; Peiper, SC				Trent, JO; Wang, ZX; Murray, JL; Shao, WH; Tamamura, H; Fujii, N; Peiper, SC			Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CXCR4; PROTEIN-COUPLED RECEPTORS; CORECEPTOR; IDENTIFICATION; INHIBITOR; T140; GLYCOPROTEINS; RHODOPSIN; MOLECULES; RESIDUES	CXCR4 is a G protein- coupled receptor ( GPCR) that has multiple critical functions in normal and pathologic physiology that include regulation of the metastatic behavior of mammary carcinoma, and utilization as a co-receptor for infection by T- tropic strains of human immunodeficiency virus- 1. Molecular dynamic simulations of the rhodopsin- based homology model of CXCR4 were performed in a solvated lipid bilayer to reproduce the microenvironment of this integral membrane protein. The amino acids in CXCR4 necessary for interaction with an inverse agonist, T140, and a weak partial agonist, AMD3100, identified by alanine scanning mutants, were spatially consistent when computationally docked. Whereas T140 binds residues in extracellular domains and regions of the hydrophobic core proximal to the cell surface, amino acids in the central hydrophobic core are critical to binding of AMD3100. The physical localization of T140 binding to CXCR4 by biochemical analyses corroborated the molecular and computational approaches. The structural basis for the interaction of T140 and AMD3100 with CXCR4 confirms that the mechanisms used by these agents are different. This complementary utilization of molecular, physical, and computation analysis provides a powerful approach to elucidate GPCR conformation.	Univ Louisville, Brown Canc Ctr 323, Louisville, KY 40202 USA; Univ Louisville, JG Brown Modeling Facil, Louisville, KY 40202 USA; Univ Louisville, Dept Med, Louisville, KY 40202 USA; Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; Kyoto Univ, Grad Sch Pharmaceut Sci, Kyoto, Japan	University of Louisville; University of Louisville; University of Louisville; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Kyoto University	Trent, JO (corresponding author), Univ Louisville, Brown Canc Ctr 323, 529 S Jackson St, Louisville, KY 40202 USA.		Shao, Wenhai/AAI-3363-2020	trent, John/0000-0002-7346-4231	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041346] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 41346] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Bissantz C, 2003, PROTEINS, V50, P5, DOI 10.1002/prot.10237; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Doranz BJ, 2001, AIDS RES HUM RETROV, V17, P475, DOI 10.1089/08892220151126508; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Gerlach LO, 2001, J BIOL CHEM, V276, P14153, DOI 10.1074/jbc.M010429200; Hendrix CW, 2000, ANTIMICROB AGENTS CH, V44, P1667, DOI 10.1128/AAC.44.6.1667-1673.2000; Huang XQ, 2003, BIOPHYS J, V84, P171, DOI 10.1016/S0006-3495(03)74840-1; Kirkpatrick P, 2003, NAT REV DRUG DISCOV, V2, P171, DOI 10.1038/nrd1030; Knaut H, 2003, NATURE, V421, P279, DOI 10.1038/nature01338; Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Navenot JM, 2001, J MOL BIOL, V313, P1181, DOI 10.1006/jmbi.2001.5086; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Staudinger R, 2000, BIOCHEM BIOPH RES CO, V274, P153, DOI 10.1006/bbrc.2000.3109; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tamamura H, 2000, BIOORG MED CHEM LETT, V10, P2633, DOI 10.1016/S0960-894X(00)00535-7; Tamamura H, 1998, BIOCHEM BIOPH RES CO, V253, P877, DOI 10.1006/bbrc.1998.9871; Vaidehi N, 2002, P NATL ACAD SCI USA, V99, P12622, DOI 10.1073/pnas.122357199; Wang ZX, 1998, J BIOL CHEM, V273, P15007, DOI 10.1074/jbc.273.24.15007; Zhang WB, 2002, J BIOL CHEM, V277, P24515, DOI 10.1074/jbc.M200889200; Zhou NM, 2001, J BIOL CHEM, V276, P42826, DOI 10.1074/jbc.M106582200; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	25	98	104	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47136	47144		10.1074/jbc.M307850200	http://dx.doi.org/10.1074/jbc.M307850200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12958314	hybrid			2022-12-25	WOS:000186569400112
J	Zhi, HJ; Wang, XD; Cabrera, JE; Johnson, RC; Jin, DJ				Zhi, HJ; Wang, XD; Cabrera, JE; Johnson, RC; Jin, DJ			Fis stabilizes the interaction between RNA polymerase and the ribosomal promoter rrnB P1, leading to transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RATE-DEPENDENT REGULATION; PROTEIN H-NS; ESCHERICHIA-COLI; STRINGENT CONTROL; DNA INVERSION; UPSTREAM ACTIVATION; GROWTH-PHASE; RPOB MUTANTS; IN-VIVO; INITIATION	It has been shown that Fis activates transcription of the ribosomal promoter rrnB P1; however, the mechanism by which Fis activates rrnB P1 transcription is not fully understood. Paradoxically, although Fis activates transcription of rrnB P1 in vitro, transcription from the promoter containing Fis sites ( as measured from rrnB P1-lacZ fusions) is not reduced in a fis null mutant strain. In this study, we further investigated the mechanism by which Fis activates transcription of the rrnB P1 promoter and the role of Fis in rRNA synthesis and cell growth in Escherichia coli. Like all other stringent promoters investigated so far, open complex of rrnB P1 has been shown to be intrinsically unstable, making open complex stability a potential regulatory step in transcription of this class of promoters. Our results show that Fis acts at this regulatory step by stabilizing the interaction between RNA polymerase and rrnB P1 in the absence of NTPs. Mutational analysis of the Fis protein demonstrates that there is a complete correlation between Fis-mediated transcriptional activation of rrnB P1 and Fis-mediated stabilization of preinitiation complexes of the promoter. Thus, our study indicates that Fis-mediated stabilization of RNA polymerase-rrnB P1 preinitiation complexes, presumably at the open complex step, contributes prominently to transcriptional activation. Furthermore, our in vivo results show that rRNA synthesis from the P1 promoters of several rRNA operons are reduced 2-fold in a fis null mutant compared with the wild type strain, indicating that Fis plays an important role in the establishment of robust rRNA synthesis when E. coli cells are emerging from a growth-arrested phase to a rapid growth phase. Thus, our results resolve an apparent paradox of the role of Fis in vitro and in vivo in the field.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Jin, DJ (corresponding author), NCI, Mol Biol Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	djjin@helix.nih.gov			NATIONAL CANCER INSTITUTE [Z01BC010632, ZIABC010632] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aiyar SE, 2002, J MOL BIOL, V316, P501, DOI 10.1006/jmbi.2001.5390; Appleman JA, 1998, J BACTERIOL, V180, P1525, DOI 10.1128/JB.180.6.1525-1532.1998; Azam TA, 1999, J BACTERIOL, V181, P6361, DOI 10.1128/JB.181.20.6361-6370.1999; BALKE VL, 1987, J BACTERIOL, V169, P4499, DOI 10.1128/jb.169.10.4499-4506.1987; BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; Barker MM, 2001, J MOL BIOL, V305, P673, DOI 10.1006/jmbi.2000.4327; Bartlett MS, 2000, J BACTERIOL, V182, P1969, DOI 10.1128/JB.182.7.1969-1977.2000; Bartlett MS, 1998, J MOL BIOL, V279, P331, DOI 10.1006/jmbi.1998.1779; BOKAL AJ, 1995, J MOL BIOL, V245, P197, DOI 10.1006/jmbi.1994.0016; Bokal AJ, 1997, EMBO J, V16, P154, DOI 10.1093/emboj/16.1.154; Bordes P, 2003, MOL MICROBIOL, V48, P561, DOI 10.1046/j.1365-2958.2003.03461.x; Cabrera JE, 2001, J BACTERIOL, V183, P6126, DOI 10.1128/JB.183.20.6126-6134.2001; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; Cheng YS, 2000, J MOL BIOL, V302, P1139, DOI 10.1006/jmbi.2000.4123; COLE ST, 1982, MOL GEN GENET, V188, P472, DOI 10.1007/BF00330051; CONDON C, 1992, EMBO J, V11, P4175, DOI 10.1002/j.1460-2075.1992.tb05511.x; Dame RT, 2002, J BIOL CHEM, V277, P2146, DOI 10.1074/jbc.C100603200; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; Goldenberg D, 1996, MOL MICROBIOL, V19, P241, DOI 10.1046/j.1365-2958.1996.363898.x; Gosink KK, 1996, J BACTERIOL, V178, P5182, DOI 10.1128/jb.178.17.5182-5187.1996; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; Gourse RL, 1996, ANNU REV MICROBIOL, V50, P645, DOI 10.1146/annurev.micro.50.1.645; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; Hirvonen CA, 2001, J BACTERIOL, V183, P6305, DOI 10.1128/JB.183.21.6305-6314.2001; Hraiky C, 2000, J BIOL CHEM, V275, P11257, DOI 10.1074/jbc.275.15.11257; Ingraham J. L., 1983, GROWTH BACTERIAL CEL; JIN DJ, 1989, J BACTERIOL, V171, P5229, DOI 10.1128/jb.171.9.5229-5231.1989; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; KOCH C, 1991, NUCLEIC ACIDS RES, V19, P5915, DOI 10.1093/nar/19.21.5915; KOSTREWA D, 1991, NATURE, V349, P178, DOI 10.1038/349178a0; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEIRMO S, 1991, J MOL BIOL, V220, P555, DOI 10.1016/0022-2836(91)90100-K; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; McLeod SM, 1999, J MOL BIOL, V294, P333, DOI 10.1006/jmbi.1999.3262; McLeod SM, 2001, CURR OPIN MICROBIOL, V4, P152, DOI 10.1016/S1369-5274(00)00181-8; Muskhelishvili G, 2003, FRONT BIOSCI-LANDMRK, V8, pD279, DOI 10.2741/969; Muskhelishvili G, 1997, EMBO J, V16, P3655, DOI 10.1093/emboj/16.12.3655; NILSSON L, 1990, EMBO J, V9, P727, DOI 10.1002/j.1460-2075.1990.tb08166.x; NILSSON L, 1992, J BACTERIOL, V174, P921, DOI 10.1128/jb.174.3.921-929.1992; NINNEMANN O, 1992, EMBO J, V11, P1075, DOI 10.1002/j.1460-2075.1992.tb05146.x; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OSUNA R, 1995, J BACTERIOL, V177, P2021, DOI 10.1128/jb.177.8.2021-2032.1995; OSUNA R, 1991, EMBO J, V10, P1593, DOI 10.1002/j.1460-2075.1991.tb07680.x; Pemberton IK, 2000, J MOL BIOL, V299, P859, DOI 10.1006/jmbi.2000.3780; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; Rochman M, 2002, EMBO REP, V3, P355, DOI 10.1093/embo-reports/kvf067; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; Ross W, 1999, J BACTERIOL, V181, P3864, DOI 10.1128/JB.181.12.3864-3868.1999; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; Safo MK, 1997, EMBO J, V16, P6860, DOI 10.1093/emboj/16.22.6860; SANDER P, 1993, J BIOL CHEM, V268, P16907; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; Schneider DA, 2002, P NATL ACAD SCI USA, V99, P8602, DOI 10.1073/pnas.132285199; Schneider R, 1999, MOL MICROBIOL, V34, P953, DOI 10.1046/j.1365-2958.1999.01656.x; Schroder O, 2000, J MOL BIOL, V298, P737, DOI 10.1006/jmbi.2000.3708; SRIVASTAVA AK, 1990, ANNU REV MICROBIOL, V44, P105, DOI 10.1146/annurev.mi.44.100190.000541; TIPPNER D, 1994, MOL MICROBIOL, V11, P589, DOI 10.1111/j.1365-2958.1994.tb00339.x; Travers A, 2001, BIOCHIMIE, V83, P213, DOI 10.1016/S0300-9084(00)01217-7; TRAVERS AA, 1980, J BACTERIOL, V141, P973, DOI 10.1128/JB.141.2.973-976.1980; Walker KA, 1999, J BACTERIOL, V181, P1269, DOI 10.1128/JB.181.4.1269-1280.1999; Wei Y, 2001, J BACTERIOL, V183, P545, DOI 10.1128/JB.183.2.545-556.2001; YUAN HS, 1991, P NATL ACAD SCI USA, V88, P9558, DOI 10.1073/pnas.88.21.9558; Zhang XY, 1996, J MOL BIOL, V259, P27, DOI 10.1006/jmbi.1996.0299; Zhou YN, 1998, P NATL ACAD SCI USA, V95, P2908, DOI 10.1073/pnas.95.6.2908; Zou YN, 1997, J BACTERIOL, V179, P4292, DOI 10.1128/jb.179.13.4292-4298.1997	69	26	26	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47340	47349		10.1074/jbc.M305430200	http://dx.doi.org/10.1074/jbc.M305430200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	13679374	hybrid			2022-12-25	WOS:000186569400136
J	Lu, LF; Cook, WJ; Lin, LL; Noelle, RJ				Lu, LF; Cook, WJ; Lin, LL; Noelle, RJ			CD40 signaling through a newly identified tumor necrosis factor receptor-associated factor 2 (TRAF2) binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CROSS-LINKING CD40; STRUCTURAL BASIS; CUTTING EDGE; ACTIVATION; CELLS; RECOGNITION; KINASE; SPECIFICITY; INDUCTION	Tumor necrosis factor receptor-associated factors (TRAFs) belong to a family of adapter proteins that are involved in tumor necrosis factor receptor superfamily signaling. It has been shown that the recruitment of TRAFs to the CD40 cytoplasmic tail is essential for CD40-mediated B cell responses. However, it has also been shown that some early B cell responses, such as up-regulation of cell surface molecules and B cell proliferation are only marginally impaired by the disruption of previously defined TRAF binding sites (Ahonen, C., Manning, E., Erickson, L.D., O'Connor, B.P., Lind, E.F., Pullen, S.S., Kehry, M.R., and Noelle, R. J. (2002) Nat. Immunol. 3, 451-456; and Manning, E., Pullen, S.S., Souza, D. J., Kehry, M., and Noelle, R. J. (2002) Eur. J. Immunol. 32, 39-49). In this report, we identify a second TRAF2 binding site in the CD40 C terminus. The binding motif "SVQE" fits into the major TRAF2 binding consensus sequence, and its disruption resulted in the loss of remaining CD40 functions. Hence, like CD30, the CD40 cytoplasmic tail contains two distinct and functionally important TRAF2 binding sites.	Dartmouth Coll Sch Med, Dept Microbiol & Immunol, Lebanon, NH 03756 USA	Dartmouth College	Noelle, RJ (corresponding author), Dartmouth Coll Sch Med, Dept Microbiol & Immunol, 640W Borwell,1 Med Ctr Dr, Lebanon, NH 03756 USA.			Lu, Li-Fan/0000-0002-9727-0036	NIAID NIH HHS [AI26996, AI52211] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052211] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahonen CL, 2002, NAT IMMUNOL, V3, P451, DOI 10.1038/ni792; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; Goldstein MD, 1996, J IMMUNOL, V157, P2837; Haxhinasto SA, 2002, J IMMUNOL, V169, P1145, DOI 10.4049/jimmunol.169.3.1145; Hostager BS, 2002, J IMMUNOL, V168, P3318, DOI 10.4049/jimmunol.168.7.3318; Hostager BS, 1999, J IMMUNOL, V162, P6307; Jabara HH, 2002, IMMUNITY, V17, P265, DOI 10.1016/S1074-7613(02)00394-1; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Leo E, 1999, J BIOL CHEM, V274, P22414, DOI 10.1074/jbc.274.32.22414; Li YY, 1996, J IMMUNOL, V157, P1440; Manning E, 2002, EUR J IMMUNOL, V32, P39, DOI 10.1002/1521-4141(200201)32:1<39::AID-IMMU39>3.0.CO;2-Y; McWhirter SM, 1999, P NATL ACAD SCI USA, V96, P8408, DOI 10.1073/pnas.96.15.8408; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Pullen SS, 1999, J BIOL CHEM, V274, P14246, DOI 10.1074/jbc.274.20.14246; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; Werneburg BG, 2001, J BIOL CHEM, V276, P43334, DOI 10.1074/jbc.M104994200; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Zhu N, 2002, J IMMUNOL, V168, P744, DOI 10.4049/jimmunol.168.2.744	21	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45414	45418		10.1074/jbc.M309601200	http://dx.doi.org/10.1074/jbc.M309601200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12960157	hybrid			2022-12-25	WOS:000186452300046
J	Martin, NP; Lefkowitz, RJ; Shenoy, SK				Martin, NP; Lefkowitz, RJ; Shenoy, SK			Regulation of V2 vasopressin receptor degradation by agonist-promoted ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; MEDIATED ENDOCYTOSIS; INTERNALIZATION; PHOSPHORYLATION; MONOUBIQUITIN; TRAFFICKING; PATHWAY	The seven-transmembrane-spanning vasopressin V2 receptor (V2R) is a G(s)-coupled receptor that is rapidly phosphorylated and internalized following stimulation with the agonist, arginine-vasopressin. Herein, we show that the V2R is ubiquitinated following agonist stimulation. V2R-ubiquitination is not observed in a beta-arrestin1,2 deleted mouse fibroblast cell line and is restored following introduction of beta-arrestin2, thus indicating that beta-arrestin2 is required for the ubiquitination of V2R. A mutant V2R (K268R) that is not ubiquitinated still activates G(s) and internalizes with similar kinetics as the wild type receptor. Unstimulated wild type and K268R mutant receptors degrade at similar rates and have comparable half-lives of 217 +/- 17 and 245 +/- 29 min as determined by pulse-chase experiments. However, following agonist stimulation, the rate of receptor degradation for the wild type is enhanced (half-life of 69 +/- 19 min), whereas that of the mutant is only minimally affected (half-life of 188 +/- 11 min). These data suggest that V2R levels are regulated through at least two processes. In the absence of agonist stimulation, a slow degradative pathway operates that is independent of receptor ubiquitination. However, receptor stimulation leads to rapid beta-arrestin2-dependent ubiquitination of the receptor and increased degradation.	Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA.		Shenoy, Sudha/AAN-4075-2021; Lefkowitz, Robert/AAW-2649-2021	Shenoy, Sudha/0000-0002-2565-4663; Martin, Negin/0000-0003-3166-8989	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Birnbaumer M, 2002, RECEPTOR CHANNEL, V8, P51, DOI 10.1080/10606820212134; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Horn F, 2001, NUCLEIC ACIDS RES, V29, P346, DOI 10.1093/nar/29.1.346; Innamorati G, 1999, J RECEPT SIGNAL TR R, V19, P315, DOI 10.3109/10799899909036654; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kojro E, 1999, EUR J BIOCHEM, V266, P538, DOI 10.1046/j.1432-1327.1999.00892.x; LUTZ W, 1990, P NATL ACAD SCI USA, V87, P6507, DOI 10.1073/pnas.87.17.6507; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Piper RC, 2001, TRAFFIC, V2, P612, DOI 10.1034/j.1600-0854.2001.20904.x; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Ponting CP, 2000, BIOCHEM J, V351, P527, DOI 10.1042/0264-6021:3510527; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Zamah AM, 2002, J BIOL CHEM, V277, P31249, DOI 10.1074/jbc.M202753200	23	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45954	45959		10.1074/jbc.M308285200	http://dx.doi.org/10.1074/jbc.M308285200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12960162	hybrid			2022-12-25	WOS:000186452300109
J	Zoltan-Jones, A; Huang, L; Ghatak, S; Toole, BP				Zoltan-Jones, A; Huang, L; Ghatak, S; Toole, BP			Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; MAMMARY-CARCINOMA CELLS; EXTRACELLULAR-MATRIX; CONTACT INHIBITION; RECEPTOR RHAMM; SURFACE CD44; TUMOR-GROWTH; CANCER-CELLS; PERICELLULAR MATRIX; SCATTER-FACTOR	During carcinoma progression, tumor cells often undergo changes similar (but not identical) to epithelial-mesenchymal transitions in embryonic development. In this study, we demonstrate that experimental stimulation of hyaluronan synthesis in normal epithelial cells is sufficient to induce mesenchymal and transformed characteristics. Using recombinant adenoviral expression of hyaluronan synthase-2, we show that increased hyaluronan production promotes anchorage-independent growth and invasiveness, induces gelatinase production, and stimulates phosphoinositide 3-kinase/Akt pathway activity in phenotypically normal Madin-Darby canine kidney and MCF-10A human mammary epithelial cells. Cells infected with hyaluronan synthase-2 adenovirus also acquired mesenchymal characteristics, including up-regulation of vimentin, dispersion of cytokeratin, and loss of organized adhesion proteins at intercellular boundaries. Furthermore, we show that the transforming effects of two well described agents, hepatocyte growth factor (HGF) and beta-catenin, are dependent on hyaluronan-cell interactions. Perturbation of endogenous hyaluronan polymer interactions by treatment with hyaluronan oligomers is shown here to reverse the transforming effects of HGF and beta-catenin in Madin-Darby canine kidney and MCF-10A human mammary epithelial cells. Also, HGF and beta-catenin induced assembly of hyaluronan-dependent pericellular matrices similar to those surrounding mesenchymal cells. Thus, increased expression of hyaluronan is sufficient to induce epithelial-mesenchymal transition and acquisition of transformed properties in phenotypically normal epithelial cells.	Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA	Tufts University	Toole, BP (corresponding author), Med Univ S Carolina, Dept Cell Biol & Anat, 173 Ashley Ave, Charleston, SC 29425 USA.				NATIONAL CANCER INSTITUTE [R01CA073839, R01CA082867] Funding Source: NIH RePORTER; NCI NIH HHS [CA82867, CA73839] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahrens T, 2001, ONCOGENE, V20, P3399, DOI 10.1038/sj.onc.1204435; Anttila MA, 2000, CANCER RES, V60, P150; Auvinen P, 2000, AM J PATHOL, V156, P529, DOI 10.1016/S0002-9440(10)64757-8; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; Gordon LB, 2003, HUM GENET, V113, P178, DOI 10.1007/s00439-003-0958-9; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; Hall CL, 1996, ONCOGENE, V13, P2213; Hay ED, 1995, ACTA ANAT, V154, P8; Hayen W, 1999, J CELL SCI, V112, P2241; HELDIN P, 1993, EXP CELL RES, V208, P422, DOI 10.1006/excr.1993.1264; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Itano N, 1999, CANCER RES, V59, P2499; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Jacobson A, 2002, INT J CANCER, V102, P212, DOI 10.1002/ijc.10683; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; Kermorgant S, 2001, CARCINOGENESIS, V22, P1035, DOI 10.1093/carcin/22.7.1035; Kim KS, 1998, EXP CELL RES, V245, P79, DOI 10.1006/excr.1998.4238; KNUDSON CB, 1985, DEV BIOL, V112, P308, DOI 10.1016/0012-1606(85)90401-4; Knudson W, 1996, AM J PATHOL, V148, P1721; KONGTAWELERT P, 1990, ANAL BIOCHEM, V185, P313, DOI 10.1016/0003-2697(90)90300-X; Kosaki R, 1999, CANCER RES, V59, P1141; Lakka SS, 2002, ONCOGENE, V21, P8011, DOI 10.1038/sj.onc.1205894; Lesley J, 2000, J BIOL CHEM, V275, P26967; Li RS, 2001, J CELL PHYSIOL, V186, P371, DOI 10.1002/1097-4652(2000)9999:999<000::AID-JCP1042>3.0.CO;2-8; Liu NF, 2001, CANCER RES, V61, P5207; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Maleski MP, 1996, EXP CELL RES, V225, P55, DOI 10.1006/excr.1996.0156; MARKWALD RR, 1978, DEV BIOL, V62, P292, DOI 10.1016/0012-1606(78)90218-X; Misra S, 2003, J BIOL CHEM, V278, P25285, DOI 10.1074/jbc.C300173200; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; MORRISWIMAN J, 1992, ANAT RECORD, V234, P575, DOI 10.1002/ar.1092340413; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Park MJ, 2002, CANCER RES, V62, P6318; Peterson RM, 2000, AM J PATHOL, V156, P2159, DOI 10.1016/S0002-9440(10)65086-9; Powell AA, 2001, BIOCHEM J, V356, P481, DOI 10.1042/0264-6021:3560481; Ropponen K, 1998, CANCER RES, V58, P342; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Sherman LS, 2000, J CELL BIOL, V150, P1071, DOI 10.1083/jcb.150.5.1071; Simpson MA, 2002, AM J PATHOL, V161, P849, DOI 10.1016/S0002-9440(10)64245-9; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; Spessotto P, 2002, J CELL BIOL, V158, P1133, DOI 10.1083/jcb.200202120; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Toole BP, 2002, AM J PATHOL, V161, P745, DOI 10.1016/S0002-9440(10)64232-0; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; van Kempen LCL, 2002, DIFFERENTIATION, V70, P610, DOI 10.1046/j.1432-0436.2002.700914.x; Ward JA, 2003, AM J PATHOL, V162, P1403, DOI 10.1016/S0002-9440(10)64273-3; Weston J A, 1977, Prog Clin Biol Res, V15, P217; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163; Zhang SW, 1998, J BIOL CHEM, V273, P11342, DOI 10.1074/jbc.273.18.11342; Zhang YY, 2002, CANCER RES, V62, P3962; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	79	174	175	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45801	45810		10.1074/jbc.M308168200	http://dx.doi.org/10.1074/jbc.M308168200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954618	hybrid			2022-12-25	WOS:000186452300092
J	Alappat, EC; Volkland, J; Peter, ME				Alappat, EC; Volkland, J; Peter, ME			Cell cycle effects by C-FADD depend on its C-terminal phosphorylation site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH DOMAIN PROTEIN; INDUCED APOPTOSIS; T-CELLS; EPITHELIAL-CELLS; FAS; FADD/MORT1; PROLIFERATION; ACTIVATION; SIGNAL; EXPRESSION	Expression of a truncated form of the death receptor adaptor FADD (C-FADD) as a transgene in mice blocks T cell proliferation. Here we provide evidence that the C-terminal phosphorylation site Ser(19)4 in C-FADD affects the cell cycle in nonlymphoid cells as well. High expression of wild type C-FADD but not C-FADD with a S194A point mutation arrested the nontumor cell line MCF10A in G(2)/M but not the tumor cell line MCF7. BJAB as well as MCF10A cells expressing moderate levels of C-FADD with a S194E mutation mimicking phosphorylated C-FADD were more susceptible to a Taxol(R)-induced G(2)/M arrest than cells expressing C-FADD S194A suggesting that C-FADD S194E lowers the threshold for G(2)/M arrest. Our data suggest that C-FADD may affect apoptosis sensitivity of cells by interfering with cell cycle progression and not only by binding to death receptors.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of Chicago	Peter, ME (corresponding author), Univ Chicago, Ben May Inst Canc Res, 924 E 57th St, Chicago, IL 60637 USA.			Peter, Marcus Ernst/0000-0003-3216-036X				Alegre ML, 1998, J IMMUNOL, V161, P3347; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; Bush JA, 2001, EXP CELL RES, V271, P305, DOI 10.1006/excr.2001.5381; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; Gil J, 2000, ONCOGENE, V19, P3665, DOI 10.1038/sj.onc.1203710; Hua ZC, 2003, IMMUNITY, V18, P513, DOI 10.1016/S1074-7613(03)00083-9; Hueber AO, 2000, J BIOL CHEM, V275, P10453, DOI 10.1074/jbc.275.14.10453; JAATTELA M, 1995, ONCOGENE, V10, P2297; Kabra NH, 2001, P NATL ACAD SCI USA, V98, P6307, DOI 10.1073/pnas.111158698; Moran TJ, 2000, CANCER RES, V60, P867; Morgan MJ, 2001, CELL DEATH DIFFER, V8, P696, DOI 10.1038/sj.cdd.4400866; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; Newton K, 2001, CURR BIOL, V11, P273, DOI 10.1016/S0960-9822(01)00067-7; Peter M E, 1999, Results Probl Cell Differ, V23, P25; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Streetz K, 2000, GASTROENTEROLOGY, V119, P446, DOI 10.1053/gast.2000.9364; Wang XZ, 2000, J VIROL, V74, P11296, DOI 10.1128/JVI.74.23.11296-11303.2000; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang J, 2001, J BIOL CHEM, V276, P29815, DOI 10.1074/jbc.M103838200; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	23	47	47	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41585	41588		10.1074/jbc.C300385200	http://dx.doi.org/10.1074/jbc.C300385200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12954630	hybrid			2022-12-25	WOS:000185989500004
J	Suzuki, A; Kusakai, G; Kishimoto, A; Lu, J; Ogura, T; Esumi, H				Suzuki, A; Kusakai, G; Kishimoto, A; Lu, J; Ogura, T; Esumi, H			ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation	ONCOGENE			English	Article						ARK5; Akt; cell survival; caspase 8; HepG2	TRAIL-INDUCED APOPTOSIS; PROTEIN-KINASE; GLUCOSE STARVATION; SIGNALING COMPLEX; TUMOR-CELLS; B-CELLS; AKT; INVOLVEMENT; TOLERANCE; SURVIVAL	AMPK is a serine/threonine protein kinase family and we recently identified a novel member, ARK5. The activation of ARK5 is triggered by Akt, and ARK5 induces tumor cell survival during nutrient starvation. In the current study, we investigated the mechanisms of induction of cell survival by ARK5. Human hepatoma HepG2 cells undergo necrotic cell death within 24 h after the start of glucose starvation, and the cell death signaling has been found to be mediated by death-receptor-independent activation of caspase 8. When HepG2 cells were transfected with ARK5 expression vector and subjected to several cell death stimuli, ARK5 was found to suppress cell death by glucose starvation, TRAIL, and TNF-alpha, but not by ultraviolet irradiation, camptothecin, or doxorubicin. Western blotting analysis revealed that both TRAIL and glucose starvation induced Bid cleavage and FLIP degradation following caspase 8 activation in a time-dependent manner, and ARK5 overexpression clearly delayed Bid cleavage, FLIP degradation, and caspase 8 activation. On the basis of the results of this study, we report that cell survival induced by ARK5 is, at least in part, due to inhibition of caspase 8 activation.	Natl Canc Ctr, Res Inst E, Invest Treatment Div, Chiba 2778577, Japan	National Cancer Center - Japan	Esumi, H (corresponding author), Natl Canc Ctr, Res Inst E, Invest Treatment Div, 6-5-1 Kashiwanoha, Chiba 2778577, Japan.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Esumi H, 2002, J BIOL CHEM, V277, P32791, DOI 10.1074/jbc.M112270200; Folkman J, 2001, P NATL ACAD SCI USA, V98, P398, DOI 10.1073/pnas.98.2.398; Folkman J, 1974, Adv Cancer Res, V19, P331, DOI 10.1016/S0065-230X(08)60058-5; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gupta S., 2001, Current Molecular Medicine (Hilversum), V1, P317, DOI 10.2174/1566524013363780; Hasegawa J, 1996, CANCER RES, V56, P1713; Hashimoto K, 2002, BIOCHEM BIOPH RES CO, V290, P263, DOI 10.1006/bbrc.2001.6193; Heyer BS, 1997, MOL REPROD DEV, V47, P148, DOI 10.1002/(SICI)1098-2795(199706)47:2&lt;148::AID-MRD4&gt;3.0.CO;2-M; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Izuishi K, 2000, CANCER RES, V60, P6201; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kulms D, 2002, J DERMATOL, V29, P189, DOI 10.1111/j.1346-8138.2002.tb00248.x; Lage H, 1999, J CANCER RES CLIN, V125, P156, DOI 10.1007/s004320050258; Lefebvre DL, 2001, BIOCHEM J, V355, P297, DOI 10.1042/0264-6021:3550297; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shimizu S, 1996, ONCOGENE, V12, P2045; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Suzuki A, 2003, J BIOL CHEM, V278, P48, DOI 10.1074/jbc.M206025200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266	45	73	86	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6177	6182		10.1038/sj.onc.1206899	http://dx.doi.org/10.1038/sj.onc.1206899			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679856				2022-12-25	WOS:000185506200007
J	Moreno-Bueno, G; Rodriguez-Perales, S; Sanchez-Estevez, C; Hardisson, D; Sarrio, D; Prat, J; Cigudosa, JC; Matias-Guiu, X; Palacios, J				Moreno-Bueno, G; Rodriguez-Perales, S; Sanchez-Estevez, C; Hardisson, D; Sarrio, D; Prat, J; Cigudosa, JC; Matias-Guiu, X; Palacios, J			Cyclin D1 gene (CCND1) mutations in endometrial cancer	ONCOGENE			English	Article						endometrial carcinoma; cyclin D1 expression; cyclin D1 mutation	BETA-CATENIN; IN-SITU; EXPRESSION; AMPLIFICATION; CARCINOMAS; PHOSPHORYLATION; ABNORMALITIES; PROTEIN; PATHWAY	Cyclin D1 is frequently overexpressed in human neoplasias by gene rearrangement and amplification, but no mutations in the CCND1 gene have so far been reported. However, in vitro mutagenesis of CCND1 has shown that substitutions affecting threonine 286 residue produced cyclin D1 nuclear accumulation, by interfering with protein degradation and induced neoplastic transformation in murine fibroblasts. To test whether similar genetic changes may occur in vivo, we analysed a series of 60 endometrioid endometrial carcinomas (EECs) for cyclin D1 expression and gene amplification by immunohistochemistry and FISH, respectively. Two of 17 carcinomas showing cyclin D1 expression in more than 5% of neoplastic cells, but without gene amplification, were found to harbor single-base substitutions in CCND1 that changed proline 287 into threonine and serine, respectively. Both cases expressed cyclin D1 in more than 50% of neoplastic cells. Additionally, seven tumors with cyclin D1 overexpression of an independent series of 59 EECs were also analysed, and a 12-bp in-frame deletion that eliminated amino acids 289-292 was detected in one case with cylin D1 expression in more than 50% of neoplastic cells. In contrast, no mutations of the CCND1 gene were detected in a set of breast carcinomas with cyclin D1 overexpression without gene amplification. In summary, our data indicate that mutations of CCND1, which probably render the protein insensitive to degradation, represent a previously unreported mechanism of cyclin D1 overexpression in human tumors in vivo.	CNIO, Mol Pathol Programme, Lab Breast & Gynaecol Canc, Melchor Fernandez Almagro 3, Madrid 28029, Spain; CNIO, Biotechnol Programme, Cytogenet Unit, Madrid 28029, Spain; Hosp Univ La Paz, Dept Pathol, Madrid 28029, Spain; Hosp Santa Creu & Sant Pau, Dept Pathol, Barcelona 08025, Spain; Univ Lleida, Hosp Univ Arnau de Vilanova, Dept Pathol & Mol Genet, Lleida 25198, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitario La Paz; Hospital of Santa Creu i Sant Pau; Universitat de Lleida; University Hospital Arnau de Vilanova	Palacios, J (corresponding author), CNIO, Mol Pathol Programme, Lab Breast & Gynaecol Canc, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	jpalacios@cnio.es	Hardisson, David/AAN-3833-2020; Rodriguez-Perales, Sandra/T-7667-2017; SARRIO, DAVID/Y-8903-2019; Hardisson, David/E-2832-2010; Corominas, Joan Prat/C-6420-2011; Cigudosa, Juan C/E-4105-2016; Prat, Jaime/G-4679-2011; Palacios, Jose/AAV-3765-2020; Hardisson, David/A-6259-2011; matias-guiu, xavier/C-3039-2009; Moreno-Bueno, Gema/K-9354-2016	Rodriguez-Perales, Sandra/0000-0001-7221-3636; Hardisson, David/0000-0002-2183-3699; matias-guiu, xavier/0000-0002-7201-6605; Moreno-Bueno, Gema/0000-0002-5030-6687; Sarrio, David/0000-0003-4886-8290				Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Campo E, 1999, SEMIN HEMATOL, V36, P115; Cao QJ, 2002, INT J GYNECOL PATHOL, V21, P147, DOI 10.1097/00004347-200204000-00007; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Hoechtlen-Vollmar W, 2000, BRIT J HAEMATOL, V109, P30, DOI 10.1046/j.1365-2141.2000.02007.x; Kaltz-Wittmer C, 2000, LAB INVEST, V80, P1455, DOI 10.1038/labinvest.3780152; Machin P, 2002, HUM PATHOL, V33, P206, DOI 10.1053/hupa.2002.30723; Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nikaido T, 1996, CANCER, V78, P1248, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1248::AID-CNCR12>3.3.CO;2-U; Quddus MR, 2002, ARCH PATHOL LAB MED, V126, P459; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Schmitz MJ, 2000, GYNECOL ONCOL, V77, P439, DOI 10.1006/gyno.2000.5814; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Simpson JF, 1997, AM J PATHOL, V151, P161; Soslow RA, 2000, INT J GYNECOL PATHOL, V19, P329, DOI 10.1097/00004347-200010000-00006; Steeg PS, 1998, BREAST CANCER RES TR, V52, P17, DOI 10.1023/A:1006102916060; Tsuda H, 2000, BRIT J CANCER, V82, P675; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257	23	87	89	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6115	6118		10.1038/sj.onc.1206868	http://dx.doi.org/10.1038/sj.onc.1206868			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955092				2022-12-25	WOS:000185137800022
J	Valente, RC; Capella, LS; Monteiro, RQ; Rumjanek, VM; Lopes, AG; Capella, MAM				Valente, RC; Capella, LS; Monteiro, RQ; Rumjanek, VM; Lopes, AG; Capella, MAM			Mechanisms of ouabain toxicity	FASEB JOURNAL			English	Article						hypertension; glutathione; reactive oxygen species; apoptosis; necrosis	GROWTH-FACTOR RECEPTOR; SMOOTH-MUSCLE-CELLS; PLASMA-MEMBRANE DEPOLARIZATION; ACTIVATED PROTEIN-KINASES; RATIO BLOCKS APOPTOSIS; SIGNAL-TRANSDUCTION; NA+/K+-ATPASE; ALZHEIMERS-DISEASE; ENDOTHELIAL-CELLS; CARDIAC MYOCYTES	The suggested involvement of ouabain in hypertension raised the need for a better understanding of its cellular action, but the mechanisms of ouabain toxicity are only now being uncovered. In the present study, we show that reduced glutathione (GSH) protected ouabain-sensitive (OS) cells from ouabain-induced toxicity and that the inhibition of GSH synthesis by D, L-buthionine-(S, R)-sulfoximine (BSO) sensitized ouabain-resistant (OR) cells. We could not observe formation of (OH)-O-. or H2O2, but there was an increase in O-2(.-) only in OS cells. Unexpectedly, an increased number of OR cells depolarized after treatment with ouabain, and BSO blocked this depolarization. Moreover, GSH increased ouabain-induced depolarization in OS cells. A sustained increase in tyrosine phosphorylation (P-Tyr) and Ras expression was observed after treatment of OS cells, and GSH prevented it. Conversely, BSO induced P-Tyr and Ras expression in ouabain-treated OR cells. The results obtained have three major implications: There is no direct correlation between membrane depolarization and ouabain-induced cell death; ouabain toxicity is not directly related to its classical action as a Na+, K+-ATPase inhibitor but seems to be associated to signal transduction, and GSH plays a major role in preventing ouabain-induced cell death.	Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, CCS, BR-21949900 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Bioquim Med, Inst Ciencias Biomed, BR-21949900 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Clin Med, BR-21949900 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Capella, MAM (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, CCS, Bloco G, BR-21949900 Rio De Janeiro, Brazil.	capella@bioqmed.ufrj.br	de Queiroz Monteiro, Robson/M-7097-2019; Capella, Marcia/F-1097-2013; Monteiro, Robson/GRX-0672-2022; Rumjanek, Vivian Mary/V-8741-2019; DE QUEIROZ MONTEIRO, ROBSON/B-8007-2014; Valente, Raphael/ABH-7796-2020; Lopes, Anibal/C-4880-2013; FISIOLOGIA, PG/C-5362-2013	Capella, Marcia/0000-0001-8407-9235; Monteiro, Robson/0000-0002-5260-2332; Valente, Raphael/0000-0001-5041-2343; 				Balestrino M, 1999, BRAIN RES, V838, P37, DOI 10.1016/S0006-8993(99)01674-1; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Bhunia AK, 1997, J BIOL CHEM, V272, P15642, DOI 10.1074/jbc.272.25.15642; BOLIVAR JJ, 1987, AM J PHYSIOL, V253, pC151, DOI 10.1152/ajpcell.1987.253.1.C151; Bortner CD, 2001, J BIOL CHEM, V276, P4304, DOI 10.1074/jbc.M005171200; Botella JA, 2003, MOL BIOL CELL, V14, P241, DOI 10.1091/mbc.E02-05-0297; Capella LS, 2002, ARCH BIOCHEM BIOPHYS, V406, P65, DOI 10.1016/S0003-9861(02)00408-3; Capella LS, 2001, BBA-GEN SUBJECTS, V1526, P293, DOI 10.1016/S0304-4165(01)00144-1; Chen CY, 2003, ARCH TOXICOL, V77, P123, DOI 10.1007/s00204-002-0427-6; Chueh SC, 2001, J UROLOGY, V166, P347, DOI 10.1016/S0022-5347(05)66157-5; CLARK S, 1993, BIOCHEM J, V292, P217, DOI 10.1042/bj2920217; Contreras RG, 1999, J CELL SCI, V112, P4223; CONTRERAS RG, 1995, J MEMBRANE BIOL, V145, P305; CONTRERAS RG, 1995, J MEMBRANE BIOL, V145, P295; Emerit I, 1996, P NATL ACAD SCI USA, V93, P12799, DOI 10.1073/pnas.93.23.12799; Filipe P, 1999, MOL MED, V5, P517, DOI 10.1007/BF03401979; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Gartner U, 1999, NEUROSCIENCE, V91, P1, DOI 10.1016/S0306-4522(99)00059-7; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; Haas M, 2000, J BIOL CHEM, V275, P27832; HAGEN TM, 1988, KIDNEY INT, V34, P74, DOI 10.1038/ki.1988.147; Hamlyn JM, 1996, J HYPERTENS, V14, P151, DOI 10.1097/00004872-199602000-00002; Ho CK, 2000, EUR J CELL BIOL, V79, P765, DOI 10.1078/0171-9335-00091; Janaky R, 1999, J NEUROCHEM, V73, P889, DOI 10.1046/j.1471-4159.1999.0730889.x; Kajikawa M, 2002, DIABETES, V51, P2522, DOI 10.2337/diabetes.51.8.2522; Kannan R, 1999, J NEUROCHEM, V73, P390, DOI 10.1046/j.1471-4159.1999.0730390.x; Kannan R, 1996, J BIOL CHEM, V271, P9754, DOI 10.1074/jbc.271.16.9754; KELLY RA, 1993, J AM COLL CARDIOL, V22, pA107, DOI 10.1016/0735-1097(93)90472-D; Kitanaka C, 2002, J NATL CANCER I, V94, P358; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; Kurashina T, 1996, CLIN SCI, V91, P497, DOI 10.1042/cs0910497; Liu J, 2000, J BIOL CHEM, V275, P27838; Luth HJ, 2000, BRAIN RES, V852, P45, DOI 10.1016/S0006-8993(99)02178-2; Mann CL, 2001, ENDOCRINOLOGY, V142, P5059, DOI 10.1210/en.142.12.5059; Manunta P, 1999, HYPERTENSION, V34, P450, DOI 10.1161/01.HYP.34.3.450; Manunta P, 2001, HYPERTENSION, V37, P472, DOI 10.1161/01.HYP.37.2.472; Manunta P, 2000, HYPERTENS RES, V23, pS77, DOI 10.1291/hypres.23.Supplement_S77; Nemeth I, 2001, FREE RADICAL BIO MED, V30, P715, DOI 10.1016/S0891-5849(00)00516-5; Olej B, 1998, BIOSCIENCE REP, V18, P1, DOI 10.1023/A:1022259832207; Orlov SN, 1999, J BIOL CHEM, V274, P16545, DOI 10.1074/jbc.274.23.16545; Orlov SN, 2000, HYPERTENSION, V35, P1062, DOI 10.1161/01.HYP.35.5.1062; Pchejetski D, 2003, BIOCHEM BIOPH RES CO, V301, P735, DOI 10.1016/S0006-291X(02)03002-4; POTAPOVA TV, 1990, FEBS LETT, V262, P69, DOI 10.1016/0014-5793(90)80156-D; POU S, 1993, ANAL BIOCHEM, V212, P85, DOI 10.1006/abio.1993.1295; Rigacci S, 1997, BIOCHEM J, V324, P791, DOI 10.1042/bj3240791; Seres T, 2000, J IMMUNOL, V165, P3333, DOI 10.4049/jimmunol.165.6.3333; Sohn HY, 2000, J BIOL CHEM, V275, P18745, DOI 10.1074/jbc.M000026200; Soler RM, 1998, J NEUROSCI, V18, P1230; Thamilselvan S, 2003, UROL RES, V31, P3, DOI 10.1007/s00240-002-0286-x; Vaziri ND, 2000, HYPERTENSION, V36, P142, DOI 10.1161/01.HYP.36.1.142; Ward SC, 2002, HYPERTENSION, V39, P536, DOI 10.1161/hy0202.103048; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Xiao AY, 2002, J NEUROSCI, V22, P1350, DOI 10.1523/JNEUROSCI.22-04-01350.2002; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323; Yang JQ, 2002, MOL CARCINOGEN, V33, P206, DOI 10.1002/mc.10037; Yang JQ, 2001, FREE RADICAL BIO MED, V31, P520, DOI 10.1016/S0891-5849(01)00613-X; Zhang Z, 2001, ARCH BIOCHEM BIOPHYS, V392, P311, DOI 10.1006/abbi.2001.2464; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	58	32	40	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1700	+		10.1096/fj.02-0937fje	http://dx.doi.org/10.1096/fj.02-0937fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958181				2022-12-25	WOS:000184471600010
J	Hibbert, AP; Morris, SJ; Seidah, NG; Murphy, RA				Hibbert, AP; Morris, SJ; Seidah, NG; Murphy, RA			Neurotrophin-4, alone or heterodimerized with brain-derived neurotrophic factor, is sorted to the constitutive secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; LONG-TERM POTENTIATION; HIPPOCAMPAL-NEURONS; PROPROTEIN CONVERTASES; PROHORMONE CONVERTASES; REGULATED SECRETION; MAMMALIAN-CELLS; TRK RECEPTORS; RELEASE; BIOSYNTHESIS	Nerve growth factor and neurotrophin-3 (NT-3) are processed within the constitutive secretory pathway of neurons and neuroendocrine cells and are released continuously in an activity-independent fashion. In contrast, brain-derived neurotrophic factor (BDNF) is processed in the regulated secretory pathway, stored in vesicles, and released in response to neuronal activity, consistent with its role in modulating synaptic plasticity. In this study, we used vaccinia virus infection and transfection methods to monitor the processing and sorting of neurotrophin-4 (NT-4) in AtT-20 cells, which have been used as a model for the sorting of secretory proteins in neurons. Our data show that NT-4 is processed in the constitutive secretory pathway. The molecule is diffusely distributed within the cells and released, soon after being synthesized, in a manner that is not affected by cell depolarization. We further show that NT-4 and BDNF, when co-expressed, can form heterodimers that are constitutively released. In contrast, heterodimers of NT-3 and BDNF have been shown to be released through the regulated secretory pathway. Thus, NT-4, alone or when co-expressed with BDNF, is processed within and secreted by the constitutive secretory pathway.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada; Hosp Sick Children, Dept Dev Biol, Toronto, ON M5G 1X8, Canada; Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada	McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Murphy, RA (corresponding author), Salk Inst Biol Studies, Off President, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				ALDER M, 1983, P NATL ACAD SCI USA, V80, P2086; ARAKAWA T, 1994, J BIOL CHEM, V269, P27833; Balkowiec A, 2000, J NEUROSCI, V20, P7417, DOI 10.1523/jneurosci.20-19-07417.2000; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; Brechler V, 1996, J BIOL CHEM, V271, P20636, DOI 10.1074/jbc.271.34.20636; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; Chen GQ, 1999, J NEUROSCI, V19, P7983; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; EDWARDS RH, 1988, MOL CELL BIOL, V8, P2456, DOI 10.1128/MCB.8.6.2456; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Eskeland NL, 1996, J CLIN INVEST, V98, P148, DOI 10.1172/JCI118760; Fahnestock M, 2001, MOL CELL NEUROSCI, V18, P210, DOI 10.1006/mcne.2001.1016; Fan G, 2000, NAT NEUROSCI, V3, P350, DOI 10.1038/73921; Farhadi HF, 2000, J NEUROSCI, V20, P4059; Goodman LJ, 1996, MOL CELL NEUROSCI, V7, P222, DOI 10.1006/mcne.1996.0017; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEYMACH JV, 1995, J BIOL CHEM, V270, P12297, DOI 10.1074/jbc.270.20.12297; Heymach JV, 1996, J BIOL CHEM, V271, P25430, DOI 10.1074/jbc.271.41.25430; Hruby D E, 1986, Methods Enzymol, V124, P295; Huang C, 1999, J BIOL CHEM, V274, P36707, DOI 10.1074/jbc.274.51.36707; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JUNG LJ, 1993, J CELL BIOL, V121, P11, DOI 10.1083/jcb.121.1.11; JUNGBLUTH S, 1994, EUR J BIOCHEM, V221, P677, DOI 10.1111/j.1432-1033.1994.tb18780.x; Kohara K, 2001, SCIENCE, V291, P2419, DOI 10.1126/science.1057415; Kruttgen A, 1998, P NATL ACAD SCI USA, V95, P9614, DOI 10.1073/pnas.95.16.9614; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; MOORE HP, 1983, J CELL BIOL, V97, P810, DOI 10.1083/jcb.97.3.810; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; Mowla SJ, 1999, J NEUROSCI, V19, P2069; Mowla SJ, 2001, J BIOL CHEM, V276, P12660, DOI 10.1074/jbc.M008104200; RIDDLE DR, 1995, NATURE, V378, P189, DOI 10.1038/378189a0; Robinson RC, 1999, PROTEIN SCI, V8, P2589; Schober A, 1998, J NEUROSCI, V18, P7272; Seidah NG, 1996, BIOCHEM J, V314, P951, DOI 10.1042/bj3140951; Seidah NG, 1996, FEBS LETT, V379, P247, DOI 10.1016/0014-5793(95)01520-5; Stucky CL, 1998, J NEUROSCI, V18, P7040; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; TREANOR JJS, 1995, J BIOL CHEM, V270, P23104, DOI 10.1074/jbc.270.39.23104; Wang XH, 1998, J NEUROSCI, V18, P4985; Wang XX, 2002, J NEUROSCI, V22, P931, DOI 10.1523/JNEUROSCI.22-03-00931.2002; Xie CW, 2000, P NATL ACAD SCI USA, V97, P8116, DOI 10.1073/pnas.140204597; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000	47	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48129	48136		10.1074/jbc.M300961200	http://dx.doi.org/10.1074/jbc.M300961200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12970359	hybrid			2022-12-25	WOS:000186731400094
J	Marsche, G; Zimmermann, R; Horiuchi, S; Tandon, NN; Sattler, W; Malle, E				Marsche, G; Zimmermann, R; Horiuchi, S; Tandon, NN; Sattler, W; Malle, E			Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; MOUSE PERITONEAL-MACROPHAGES; MODIFIED PROTEINS; LIPID-PEROXIDATION; ENDOTHELIAL-CELLS; AFFINITY LIGAND; MODIFIED LDL; CLASS-A; MYELOPEROXIDASE; OXIDATION	The presence of HOCl-modified epitopes inside and outside monocytes/macrophages and the presence of HOCl-modified apolipoprotein B in atherosclerotic lesions has initiated the present study to identify scavenger receptors that bind and internalize HOCl-low density lipoprotein (LDL). The uptake of HOCl-LDL by THP-1 macrophages was not saturable and led to cholesterol/cholesteryl ester accumulation. HOCl-LDL is not aggregated in culture medium, as measured by dynamic light scattering experiments, but internalization of HOCl-LDL could be inhibited in part by cytochalasin D, a microfilament disrupting agent. This indicates that HOCl-LDL is partially internalized by a pathway resembling phagocytosis-like internalization (in part by fluid-phase endocytosis) as measured with [C-14] sucrose uptake. In contrast to uptake studies, binding of HOCl-LDL to THP-1 cells at 4degreesC was specific and saturable, indicating that binding proteins and/or receptors are involved. Competition studies on THP-1 macrophages showed that HOCl-LDL does not compete for the uptake of acetylated LDL (a ligand to scavenger receptor class A) but strongly inhibits the uptake of copper-oxidized LDL (a ligand to CD36 and SR-BI). The binding specificity of HOCl-LDL to class B scavenger receptors could be demonstrated by Chinese hamster ovary cells overexpressing CD36 and SR-BI and specific blocking antibodies. The lipid moiety isolated from the HOCl-LDL particle did not compete for cell association of labeled HOCl-LDL to CD36 or SR-BI, suggesting that the protein moiety of HOCl-LDL is responsible for receptor recognition. Experiments with Chinese hamster ovary cells overexpressing scavenger receptor class A, type I, confirmed that LDL modified at physiologically relevant HOCl concentrations is not recognized by this receptor.	Karl Franzens Univ Graz, Inst Med Biochem & Mol Biol, A-8010 Graz, Austria; Karl Franzens Univ Graz, Inst Biochem Mol Biol & Microbiol, A-8010 Graz, Austria; Kumamoto Univ, Grad Sch Med Sci, Dept Med Biochem, Komamoto 8600811, Japan; Otsuka Amer Pharmaceut Inc, Maryland Res Labs, Rockville, MD 20850 USA	University of Graz; University of Graz; Kumamoto University	Malle, E (corresponding author), Karl Franzens Univ Graz, Inst Med Biochem & Mol Biol, Harrachgasse 21, A-8010 Graz, Austria.	ernst.malle@kfunigraz.ac.at	Malle, Ernst/D-3071-2013	Marsche, Gunther/0000-0002-2422-5381; Zimmermann, Robert/0000-0002-7354-870X				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; Artl A, 2000, ARTERIOSCL THROM VAS, V20, P763, DOI 10.1161/01.ATV.20.3.763; ASHKENAS J, 1993, J LIPID RES, V34, P983; Baldus S, 2001, J CLIN INVEST, V108, P1759; Brasen JH, 2003, ATHEROSCLEROSIS, V166, P13, DOI 10.1016/S0021-9150(02)00130-2; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; Carr AC, 2001, REDOX REP, V6, P343, DOI 10.1179/135100001101536526; Chisolm GM, 1999, J BIOL CHEM, V274, P25959, DOI 10.1074/jbc.274.37.25959; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; de Winther MPJ, 2000, ARTERIOSCL THROM VAS, V20, P290, DOI 10.1161/01.ATV.20.2.290; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Gillotte-Taylor K, 2001, J LIPID RES, V42, P1474; Gough PJ, 1999, ARTERIOSCL THROM VAS, V19, P461, DOI 10.1161/01.ATV.19.3.461; Grone HJ, 2002, LAB INVEST, V82, P5, DOI 10.1038/labinvest.3780390; HABERLAND ME, 1984, J BIOL CHEM, V259, P1305; Hammer A, 2001, LAB INVEST, V81, P543, DOI 10.1038/labinvest.3780263; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; HAZELL LJ, 1994, BIOCHEM J, V302, P297, DOI 10.1042/bj3020297; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1999, CIRC RES, V85, P950; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Heinecke JW, 2002, TOXICOLOGY, V177, P11, DOI 10.1016/S0300-483X(02)00192-0; Hirano K, 1999, CIRC RES, V85, P108; Jerlich A, 1998, FREE RADICAL BIO MED, V24, P1139, DOI 10.1016/S0891-5849(97)00439-5; Jones NL, 1999, ANAT REC, V255, P57; KATRANTZIS M, 1991, FREE RADICAL BIO MED, V10, P101, DOI 10.1016/0891-5849(91)90003-L; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; Kopprasch S, 1998, ATHEROSCLEROSIS, V136, P315, DOI 10.1016/S0021-9150(97)00233-5; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Kruth HS, 2002, J BIOL CHEM, V277, P34573, DOI 10.1074/jbc.M205059200; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; LIAO LX, 1995, ARTERIOSCL THROM VAS, V15, P2305, DOI 10.1161/01.ATV.15.12.2305; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Malle E, 2000, EUR J BIOCHEM, V267, P4495, DOI 10.1046/j.1432-1327.2000.01498.x; Malle E, 1997, AM J PATHOL, V150, P603; MALLE E, 1995, ARTERIOSCL THROM VAS, V15, P982, DOI 10.1161/01.ATV.15.7.982; MALLE E, 1995, ARTERIOSCL THROM VAS, V15, P377, DOI 10.1161/01.ATV.15.3.377; Malle E, 2003, KIDNEY INT, V64, P1956, DOI 10.1046/j.1523-1755.2003.00336.x; Malle E, 2001, BIOCHEM BIOPH RES CO, V289, P894, DOI 10.1006/bbrc.2001.6074; Marcinkiewicz J, 1997, IMMUNOL TODAY, V18, P577, DOI 10.1016/S0167-5699(97)01161-4; Marsche G, 2001, FASEB J, V15, P1095, DOI 10.1096/fj.00-0532fje; Marsche G, 2002, J BIOL CHEM, V277, P32172, DOI 10.1074/jbc.M200503200; Matveev S, 1999, J LIPID RES, V40, P1647; Nagai R, 2002, J BIOL CHEM, V277, P48905, DOI 10.1074/jbc.M205688200; Nguyen-Khoa T, 1999, BIOCHEM BIOPH RES CO, V263, P804, DOI 10.1006/bbrc.1999.1438; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; Nuszkowski A, 2001, J BIOL CHEM, V276, P14212, DOI 10.1074/jbc.M007659200; Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200; Opper C, 1998, PLATELETS, V9, P339, DOI 10.1080/09537109876582; Panzenboeck U, 1997, J BIOL CHEM, V272, P29711, DOI 10.1074/jbc.272.47.29711; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Poussin C, 1998, J BIOL CHEM, V273, P20285, DOI 10.1074/jbc.273.32.20285; Scheuer H, 2000, AM J PHYSIOL-RENAL, V278, pF63, DOI 10.1152/ajprenal.2000.278.1.F63; Seastone DJ, 2001, J CELL SCI, V114, P2673; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; SUNG SSJ, 1983, J CELL PHYSIOL, V116, P21, DOI 10.1002/jcp.1041160105; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; SWANSON JA, 1989, J CELL SCI, V94, P135; TANDON NN, 1991, BLOOD, V78, P2809; Wang XS, 1999, BIOCHEM J, V343, P347, DOI 10.1042/0264-6021:3430347; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; Woenckhaus C, 1998, CLIN IMMUNOL IMMUNOP, V86, P27, DOI 10.1006/clin.1997.4453; Yan LJ, 1997, J LIPID RES, V38, P992; Zabe M, 1999, CELL CALCIUM, V26, P281, DOI 10.1054/ceca.1999.0081; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136; Zimmermann R, 2000, BBA-MOL CELL BIOL L, V1484, P316, DOI 10.1016/S1388-1981(00)00024-X	74	59	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47562	47570		10.1074/jbc.M308428200	http://dx.doi.org/10.1074/jbc.M308428200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12968020	hybrid			2022-12-25	WOS:000186731400028
J	McQuade, KJ; Rapraeger, AC				McQuade, KJ; Rapraeger, AC			Syndecan-1 transmembrane and extracellular domains have unique and distinct roles in cell spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; BREAST-CARCINOMA CELLS; LIPID RAFTS; MEMBRANE DOMAINS; CORE PROTEIN; GXXXG MOTIF; ASSOCIATION; ADHESION; PROLIFERATION; CYTOSKELETON	Raji cells expressing syndecan- 1 ( Raji- S1) adhere and spread when plated on heparan sulfate- binding extracellular matrix ligands or monoclonal antibody 281.2, an antibody directed against the syndecan- 1 extracellular domain. Cells plated on monoclonal antibody 281.2 initially extend a broad lamellipodium, a response accompanied by membrane ruffling at the cell margin. Membrane ruffling then becomes polarized, leading to an elongated cell morphology. Previous work demonstrated that the syndecan- 1 cytoplasmic domain is not required for these activities, suggesting important roles for the syndecan- 1 transmembrane and/ or extracellular domains in the assembly of a signaling complex necessary for spreading. Work described here demonstrates that truncation of the syndecan- 1 extracellular domain does not affect the initial lamellipodial extension in the Raji- S1 cells but does inhibit the active membrane ruffling that is necessary for cell polarization. Replacement of the entire syndecan- 1 transmembrane domain with leucine residues completely blocks the cell spreading. These data demonstrate that the syndecan- 1 transmembrane and extracellular domains have important but distinct roles in Raji- S1 cell spreading; the extracellular domain mediates an interaction that is necessary for dynamic cytoskeletal rearrangements whereas an interaction of the transmembrane domain is required for the initial spreading response.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Grad Program Cellular & Mol Biol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Rapraeger, AC (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 1300 Univ Ave, Madison, WI 53706 USA.				NCI NIH HHS [R01 CA109010] Funding Source: Medline; NICHD NIH HHS [R01 HD 21881] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021881] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams JC, 2001, J CELL BIOL, V152, P1169, DOI 10.1083/jcb.152.6.1169; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; ARKIN JT, 1998, BIOCHIM BIOPHYS ACTA, V1429, P113; ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; Bass MD, 2002, BIOCHEM J, V368, P1, DOI 10.1042/BJ20021228; Beauvais DM, 2003, EXP CELL RES, V286, P219, DOI 10.1016/S0014-4827(03)00126-5; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Burbach BJ, 2003, MATRIX BIOL, V22, P163, DOI 10.1016/S0945-053X(03)00009-X; Couchman JR, 2001, INT REV CYTOL, V207, P113; Dealy CN, 1997, DEV BIOL, V184, P343, DOI 10.1006/dbio.1997.8525; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Ethell IM, 2001, NEURON, V31, P1001, DOI 10.1016/S0896-6273(01)00440-8; Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607; Granes F, 2000, J CELL SCI, V113, P1267; Kirsch T, 2002, J BIOL CHEM, V277, P42171, DOI 10.1074/jbc.M207209200; Lebakken CS, 2000, EXP CELL RES, V259, P315, DOI 10.1006/excr.2000.4981; Lebakken CS, 1996, J CELL BIOL, V132, P1209, DOI 10.1083/jcb.132.6.1209; LIEBERSBACH BF, 1994, J BIOL CHEM, V269, P20013; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; McFall AJ, 1997, J BIOL CHEM, V272, P12901, DOI 10.1074/jbc.272.20.12901; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Park H, 2002, J BIOL CHEM, V277, P29730, DOI 10.1074/jbc.M202435200; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Reed KA, 1996, FEMS MICROBIOL LETT, V145, P233, DOI 10.1016/S0378-1097(96)00415-6; Reiland J, 1996, BIOCHEM J, V319, P39, DOI 10.1042/bj3190039; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Sambrook J., 2001, MOL CLONING LAB MANU, V2, P81, DOI DOI 10.1093/nar/gku1003; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Tkachenko E, 2002, J BIOL CHEM, V277, P19946, DOI 10.1074/jbc.M200841200; Woods A, 2000, J BIOL CHEM, V275, P24233, DOI 10.1074/jbc.R000001200; Yamashita Y, 1999, J IMMUNOL, V162, P5940	37	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46607	46615		10.1074/jbc.M304775200	http://dx.doi.org/10.1074/jbc.M304775200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12975379	hybrid			2022-12-25	WOS:000186569400048
J	Meng, XW; Chandra, J; Loegering, D; Van Becelaere, K; Kottke, TJ; Gore, SD; Karp, JE; Sebolt-Leopold, J; Kaufmann, SH				Meng, XW; Chandra, J; Loegering, D; Van Becelaere, K; Kottke, TJ; Gore, SD; Karp, JE; Sebolt-Leopold, J; Kaufmann, SH			Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; CASPASE ACTIVATION; CONSTITUTIVE ACTIVATION; HUMAN COLON; PHOSPHORYLATION; PATHWAY; HL-60; ETOPOSIDE; GROWTH; TRANSFORMATION	Because the MAPK pathway plays important roles in cell proliferation and inhibition of apoptosis, this pathway has emerged as a potential therapeutic target for solid tumors and leukemia. At the present time there is little information about activation of this pathway and the consequences of its inhibition in acute lymphocytic leukemia cells (ALL). In the present study, constitutive MAPK pathway activation, as evidenced by phosphorylation of ERK1 and ERK2, was observed in 8 of 8 human lymphoid cell lines and 33% (8: 24) of pretreatment ALL bone marrows. Inhibition of this pathway by the MEK inhibitors CI-1040 and PD098059 induced apoptosis through a unique pathway involving dephosphorylation and aggregation of Fas-associated death domain protein followed by death receptor-independent caspase-8 activation. Jurkat cell variants lacking Fas-associated death domain protein or procaspase-8 were resistant to CI-1040-induced apoptosis, as were Jurkat or Molt3 cells treated with the O-methyl ester of the caspase-8 inhibitor N-(N-alpha-benzyloxycarbonylisoleucylglutamyl) aspartate fluoromethyl ketone. In contrast, CI-1040-induced apoptosis was unaffected by blocking anti-Fas antibody, soluble tumor necrosis factor-alpha-related apoptosis-inducing ligand decoy receptor, or transfection with cDNA encoding the anti-apoptotic Bcl-2 family member Mcl-1 or dominant negative caspase-9. Collectively, these results identify the MAPK pathway as a potential therapeutic target in ALL and delineate a mechanism by which MEK inhibition triggers apoptosis in ALL cells.	Mayo Clin & Mayo Fdn, Div Oncol Res, Rochester, MN 55905 USA; Mayo Grad Sch, Dept Mol Pharmacol, Rochester, MN 55905 USA; Pfizer Inc, Global Res & Dev, Canc Mol Sci Dept, Ann Arbor, MI 48105 USA; Sidney Kimmel Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA	Mayo Clinic; Mayo Clinic; Pfizer; Johns Hopkins University; Johns Hopkins Medicine	Kaufmann, SH (corresponding author), Mayo Clin & Mayo Fdn, Div Oncol Res, Guggenheim 1342 C,200 1st St SW, Rochester, MN 55905 USA.	Kaufmann.Scott@Mayo.edu		Kaufmann, Scott/0000-0002-4900-7145	NATIONAL CANCER INSTITUTE [F32CA093055, R01CA069008] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 69008, F32 CA 93055, R01 CA069008, F32 CA093055] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bible KC, 1997, CANCER RES, V57, P3375; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Condorelli F, 2001, MOL CELL BIOL, V21, P3025, DOI 10.1128/MCB.21.9.3025-3036.2001; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Dent P, 2001, CLIN CANCER RES, V7, P775; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; Huang Y, 2001, CANCER RES, V61, P6918; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Karnes WE, 1998, GASTROENTEROLOGY, V114, P930, DOI 10.1016/S0016-5085(98)70312-9; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kaufmann SH, 1997, BLOOD, V89, P2098, DOI 10.1182/blood.V89.6.2098; Kaufmann SH, 1996, LEUKEMIA LYMPHOMA, V23, P71, DOI 10.3109/10428199609054804; Kaufmann SH, 1998, METH MOL B, V80, P223; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kim SC, 1999, BLOOD, V93, P3893, DOI 10.1182/blood.V93.11.3893.407k14_3893_3899; Kottke TJ, 2002, J BIOL CHEM, V277, P804, DOI 10.1074/jbc.M108419200; LaVallee TM, 2003, CANCER RES, V63, P468; Litzow M R, 2000, Curr Treat Options Oncol, V1, P19, DOI 10.1007/s11864-000-0012-2; LORUSSO PM, 2002, P AN M AM SOC CLIN, V21, P81; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Martin TG, 2001, HEMATOL ONCOL CLIN N, V15, P97, DOI 10.1016/S0889-8588(05)70201-X; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MeighanMantha RL, 1997, EXP CELL RES, V234, P321, DOI 10.1006/excr.1997.3631; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Mesner PW, 1999, J BIOL CHEM, V274, P22635, DOI 10.1074/jbc.274.32.22635; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; OKUDA K, 1992, BLOOD, V79, P2880; Perkins C, 1998, CANCER RES, V58, P4561; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Roos-Mattjus P, 2002, J BIOL CHEM, V277, P43809, DOI 10.1074/jbc.M207272200; Sagata N, 2002, SCIENCE, V298, P1905, DOI 10.1126/science.1079225; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schubert KM, 2001, BIOCHEM J, V356, P473, DOI 10.1042/0264-6021:3560473; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; SETH A, 1991, J BIOL CHEM, V266, P23521; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stahnke K, 2001, BLOOD, V98, P3066, DOI 10.1182/blood.V98.10.3066; Svingen PA, 2000, CLIN CANCER RES, V6, P237; Thorburn J, 2003, CLIN CANCER RES, V9, P861; Tillman DM, 1999, CLIN CANCER RES, V5, P425; Towatari M, 1997, LEUKEMIA, V11, P479, DOI 10.1038/sj.leu.2400617; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Velders MP, 2001, LEUKEMIA, V15, P701, DOI 10.1038/sj.leu.2402103; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; YONEHARA S, 1994, INT IMMUNOL, V6, P1849, DOI 10.1093/intimm/6.12.1849	85	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47326	47339		10.1074/jbc.M304793200	http://dx.doi.org/10.1074/jbc.M304793200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963734	hybrid			2022-12-25	WOS:000186569400135
J	Sullivan, DC; Huminiecki, L; Moore, JW; Boyle, JJ; Poulsom, R; Creamer, D; Barker, J; Bicknell, R				Sullivan, DC; Huminiecki, L; Moore, JW; Boyle, JJ; Poulsom, R; Creamer, D; Barker, J; Bicknell, R			EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT REDUCTASE ERP57; GENE-EXPRESSION; UP-REGULATION; THIOREDOXIN; ADRENOMEDULLIN; IDENTIFICATION; CHAPERONE; DOMAINS; GROWTH; APOPTOSIS	We have identified a novel protein-disulfide isomerase and named it endothelial protein-disulfide isomerase (EndoPDI) because of its high expression in endothelial cells. Isolation of the full-length cDNA showed EndoPDI to be a 48 kDa protein that has three APWCGHC thioredoxin motifs in contrast to the two present in archetypal PDI. Ribonuclease protection and Western analysis has shown that hypoxia induces EndoPDI mRNA and protein expression. In situ hybridization analysis showed that EndoPDI expression is rare in normal tissues, except for keratinocytes of the hair bulb and syncytiotrophoblasts of the placenta, but was present in the endothelium of tumors and in other hypoxic lesions such as atherosclerotic plaques. We have compared the function of EndoPDI to that of PDI in endothelial cells using specific siRNA. PDI was shown to have a protective effect on endothelial cells under both normoxia and hypoxia. In contrast, EndoPDI has a protective effect only in endothelial cells exposed to hypoxia. The loss of EndoPDI expression under hypoxia caused a significant decrease in the secretion of adrenomedullin, endothelin-1, and CD105; molecules that protect endothelial cells from hypoxia-initiated apoptosis. The identification of an endothelial PDI further extends this increasing multigene family and EndoPDI, unlike archetypal PDI, may be a molecule with which to target tumor endothelium.	Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK,Mol Angiogenesis Lab, Oxford OX3 9DS, England; Univ Dublin Trinity Coll, Dept Genet, Mol Evolut Lab, Dublin 2, Ireland; Univ London, Hammersmith Hosp, Imperial Coll Med Sch, Dept Histol, London W12 0NN, England; London Res Inst, Canc Res UK, In Situ Hybridizat Lab, London WC2A 3PX, England; Kings Coll Hosp London, Sch Med & Dent, London SE5 9RS, England; Kings Coll London, St Thomass Hosp, St Johns Inst Dermatol, London SE1 7EH, England	Cancer Research UK; University of Oxford; Trinity College Dublin; Imperial College London; University of London; Cancer Research UK; King's College Hospital NHS Foundation Trust; King's College Hospital; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Bicknell, R (corresponding author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK,Mol Angiogenesis Lab, Oxford OX3 9DS, England.	Roy.Bicknell@cancer.org.uk		Huminiecki, Lukasz/0000-0003-1943-4450; Barker, Jonathan/0000-0002-9030-183X; Bicknell, Roy/0000-0002-0941-8919				ADAMS MD, 1995, NATURE, V377, P3; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bjornheden T, 1999, ARTERIOSCL THROM VAS, V19, P870, DOI 10.1161/01.ATV.19.4.870; Claudio JO, 2002, BLOOD, V100, P2175, DOI 10.1182/blood-2002-01-0008; Clissold PM, 2003, BIOESSAYS, V25, P603, DOI 10.1002/bies.10287; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; DeSilva MG, 1997, DNA CELL BIOL, V16, P269, DOI 10.1089/dna.1997.16.269; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; Freedman RB, 1998, CURR BIOL, V8, pR468, DOI 10.1016/S0960-9822(98)70295-7; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Graven KK, 1998, J LAB CLIN MED, V132, P456, DOI 10.1016/S0022-2143(98)90122-6; Graven KK, 2002, AM J PHYSIOL-LUNG C, V282, pL996, DOI 10.1152/ajplung.00359.2001; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; Ho M, 2003, PHYSIOL GENOMICS, V13, P249, DOI 10.1152/physiolgenomics.00186.2002; Huminiecki L, 2000, GENOME RES, V10, P1796, DOI 10.1101/gr.150700; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; Koivunen P, 1999, EMBO J, V18, P65, DOI 10.1093/emboj/18.1.65; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; Lash AE, 2000, GENOME RES, V10, P1051, DOI 10.1101/gr.10.7.1051; Li CG, 2003, J CELL SCI, V116, P2677, DOI 10.1242/jcs.00470; LYLES MM, 1994, J BIOL CHEM, V269, P30946; McLaughlin SH, 1998, BIOCHEM J, V331, P793, DOI 10.1042/bj3310793; Miller MJ, 1996, J BIOL CHEM, V271, P23345; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Oehler MK, 2001, ONCOGENE, V20, P2937, DOI 10.1038/sj.onc.1204422; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Poulsom R, 1998, EUR J HISTOCHEM, V42, P121; Shichiri M, 1997, HYPERTENSION, V30, P1198, DOI 10.1161/01.HYP.30.5.1198; SUGO S, 1994, BIOCHEM BIOPH RES CO, V201, P1160, DOI 10.1006/bbrc.1994.1827; Tanaka S, 2000, J BIOL CHEM, V275, P10388, DOI 10.1074/jbc.275.14.10388; Tucci M, 1996, AM J PHYSIOL-LUNG C, V271, pL341, DOI 10.1152/ajplung.1996.271.3.L341; VAUPEL P, 1990, ADV EXP MED BIOL, V277, P895; Volkmer J, 1997, FEBS LETT, V406, P291, DOI 10.1016/S0014-5793(97)00288-3; Witte S, 2000, J BIOL CHEM, V275, P1902, DOI 10.1074/jbc.275.3.1902; Yano K, 2001, J CLIN INVEST, V107, P409, DOI 10.1172/JCI11317; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651	40	142	153	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47079	47088		10.1074/jbc.M308124200	http://dx.doi.org/10.1074/jbc.M308124200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963716	hybrid			2022-12-25	WOS:000186569400105
J	French, CA; Tambini, CE; Thacker, J				French, CA; Tambini, CE; Thacker, J			Identification of functional domains in the RAD51L2 (RAD51C) protein and its requirement for gene conversion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION SIGNALS; HOMOLOGY-DIRECTED REPAIR; DNA STRAND EXCHANGE; ATP BINDING-SITE; P-LOOP MOTIF; RECA PROTEIN; SACCHAROMYCES-CEREVISIAE; RECOMBINATIONAL REPAIR; CROSS-SENSITIVITY; COMPLEX-FORMATION	The RAD51 protein plays a key part in the process of homologous recombination through its catalysis of homologous DNA pairing and strand exchange. Additionally five novel mammalian RAD51-like proteins have been identified in mammalian cells, but their roles in homologous recombination are much less well established. These RAD51-like proteins form two different complexes, but only the RAD51L2 (RAD51C) protein is a part of both complexes. By using site-directed mutagenesis of RAD51L2, we show that non-conservative mutation of the putative ATP-binding domain severely reduces its function, whereas a conservative mutation shows partial loss of function. We find that the protein is localized to the nucleus by tagging RAD51L2 with the green fluorescent protein and provisionally identify a C-terminal domain that acts as a nuclear localization signal. Further, a RAD51L2-deficient cell line was found to have significantly reduced homology-directed repair of a DNA double-strand break by gene conversion. This recombination defect could be partially restored by ectopic expression of the human RAD51L2 protein. Therefore we have identified protein domains that are important for the correct functioning of RAD51L2 and have shown that there is a specific requirement for RAD51L2 in gene conversion in mammalian cells.	MRC, Radiat & Genome Stabil Unit, Didcot OX11 0RD, Oxon, England	MRC Harwell	Thacker, J (corresponding author), MRC, Radiat & Genome Stabil Unit, Didcot OX11 0RD, Oxon, England.			French, Catherine/0000-0003-2072-8413				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; Brenneman MA, 2002, MOL CELL, V10, P387, DOI 10.1016/S1097-2765(02)00595-6; CALDECOTT K, 1991, MUTAT RES, V255, P111, DOI 10.1016/0921-8777(91)90046-R; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; French CA, 2002, J BIOL CHEM, V277, P19322, DOI 10.1074/jbc.M201402200; Godthelp BC, 2002, NUCLEIC ACIDS RES, V30, P2172, DOI 10.1093/nar/30.10.2172; Jasin M, 1996, TRENDS GENET, V12, P224, DOI 10.1016/0168-9525(96)10019-6; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Leasure CS, 2001, GENE, V271, P59, DOI 10.1016/S0378-1119(01)00498-X; Lio YC, 2003, J BIOL CHEM, V278, P2469, DOI 10.1074/jbc.M211038200; Liu N, 2002, NUCLEIC ACIDS RES, V30, P1009, DOI 10.1093/nar/30.4.1009; LOGAN KM, 1993, J MOL BIOL, V232, P1048, DOI 10.1006/jmbi.1993.1459; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Masson JY, 2001, P NATL ACAD SCI USA, V98, P8440, DOI 10.1073/pnas.111005698; Miller KA, 2002, J BIOL CHEM, V277, P8406, DOI 10.1074/jbc.M108306200; Morrison C, 1999, MOL CELL BIOL, V19, P6891; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; O'Regan P, 2001, J BIOL CHEM, V276, P22148, DOI 10.1074/jbc.M102396200; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sigurdsson S, 2001, GENE DEV, V15, P3308, DOI 10.1101/gad.935501; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; Sugawara N, 2003, MOL CELL, V12, P209, DOI 10.1016/S1097-2765(03)00269-7; SUGAWARA N, 1995, NATURE, V373, P84, DOI 10.1038/373084a0; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Wiese C, 2002, NUCLEIC ACIDS RES, V30, P1001, DOI 10.1093/nar/30.4.1001; Yokoyama H, 2003, J BIOL CHEM, V278, P2767, DOI 10.1074/jbc.M210899200	41	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45445	45450		10.1074/jbc.M308621200	http://dx.doi.org/10.1074/jbc.M308621200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12966089	hybrid			2022-12-25	WOS:000186452300049
J	Rigas, AC; Ozanne, DM; Neal, DE; Robson, CN				Rigas, AC; Ozanne, DM; Neal, DE; Robson, CN			The scaffolding protein RACK1 interacts with androgen receptor and promotes cross-talk through a protein kinase C signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; LIGAND-INDEPENDENT ACTIVATION; PROSTATE-SPECIFIC ANTIGEN; ADENOCARCINOMA CELL-LINE; ESTROGEN-RECEPTOR; GENE-EXPRESSION; BETA-SUBUNIT; INTRACELLULAR RECEPTOR; PROGESTERONE-RECEPTOR; TRANSDUCTION PATHWAYS	The androgen receptor (AR), a member of the nuclear hormone receptor superfamily, functions as a ligand-dependent transcription factor that regulates genes involved in cell proliferation and differentiation. Using a C-terminal region of the human AR in a yeast two-hybrid screen, we have identified RACK1 (receptor for activated C kinase-1) as an AR-interacting protein. In this report we found that RACK1, which was previously shown to be a protein kinase C (PKC)-anchoring protein that determines the localization of activated PKCbetaII isoform, facilitates ligand-independent AR nuclear translocation upon PKC activation by indolactam V. We also observed RACK1 to suppress ligand-dependent and -independent AR transactivation through PKC activation. In chromatin immunoprecipitation assays, we demonstrate a decrease in AR recruitment to the AR-responsive prostate-specific antigen (PSA) promoter following stimulation of PKC. Furthermore, prolonged exposure to indolactam V, a PKC activator, caused a reduction in PSA mRNA expression in prostate cancer LNCaP cells. Finally, we found PKC activation to have a repressive effect on AR and PSA protein expression in androgen-treated LNCaP cells. Our data suggest that RACK1 may function as a scaffold for the association and modification of AR by PKC enabling translocation of AR to the nucleus but rendering AR unable to activate transcription of its target genes.	Univ Newcastle Upon Tyne, Sch Surg & Reprod Sci, Prostate Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Cambridge, Addenbrookes Hosp, Ctr Oncol, Cambridge CB2 3QQ, England	Newcastle University - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Robson, CN (corresponding author), Univ Newcastle Upon Tyne, Sch Surg & Reprod Sci, Prostate Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Neal, David/0000-0002-6033-5086				ANDREWS PE, 1992, CANCER RES, V52, P1525; ARONICA SM, 1991, ENDOCRINOLOGY, V128, P2045, DOI 10.1210/endo-128-4-2045; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; Baumann M, 2000, EUR J BIOCHEM, V267, P3891, DOI 10.1046/j.1432-1327.2000.01430.x; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; CULIG Z, 1994, CANCER RES, V54, P5474; Darne C, 1998, EUR J BIOCHEM, V256, P541, DOI 10.1046/j.1432-1327.1998.2560541.x; DERUITER PE, 1995, MOL CELL ENDOCRINOL, V110, pR1, DOI 10.1016/0303-7207(95)03534-E; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; Gnanapragasam VJ, 2000, BJU INT, V86, P1001, DOI 10.1046/j.1464-410x.2000.00943.x; Han J, 2002, MOL CELLS, V14, P420; He DY, 2002, MOL PHARMACOL, V62, P272, DOI 10.1124/mol.62.2.272; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; Jenster G, 1999, SEMIN ONCOL, V26, P407; Kiely PA, 2002, J BIOL CHEM, V277, P22581, DOI 10.1074/jbc.M201758200; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Loy CJ, 2003, P NATL ACAD SCI USA, V100, P4562, DOI 10.1073/pnas.0736237100; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; NEWTON CJ, 1994, J STEROID BIOCHEM, V48, P481, DOI 10.1016/0960-0760(94)90197-X; Orio F, 2002, MOL CELL ENDOCRINOL, V198, P105, DOI 10.1016/S0303-7207(02)00374-X; Ozaki T, 2003, ONCOGENE, V22, P3231, DOI 10.1038/sj.onc.1206382; Ozanne DM, 2000, MOL ENDOCRINOL, V14, P1618, DOI 10.1210/me.14.10.1618; Picard D, 1997, BIOCHEM SOC T, V25, P597, DOI 10.1042/bst0250597; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Ron D, 2000, FASEB J, V14, P2303, DOI 10.1096/fj.00-0143com; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Schlegel A, 2001, BIOCHEM J, V359, P203, DOI 10.1042/0264-6021:3590203; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Ting HJ, 2002, P NATL ACAD SCI USA, V99, P661, DOI 10.1073/pnas.022469899; TURGEON JL, 1994, MOL ENDOCRINOL, V8, P860, DOI 10.1210/me.8.7.860; Ueda T, 2002, J BIOL CHEM, V277, P38087, DOI 10.1074/jbc.M203313200; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Usacheva A, 2001, J BIOL CHEM, V276, P22948, DOI 10.1074/jbc.M100087200; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; Wang X, 2002, J BIOL CHEM, V277, P15426, DOI 10.1074/jbc.M111218200; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Wen Y, 2000, CANCER RES, V60, P6841; Wu DQ, 2002, CANCER RES, V62, P2423; Yaka R, 2002, P NATL ACAD SCI USA, V99, P5710, DOI 10.1073/pnas.062046299; Yang L, 2003, J BIOL CHEM, V278, P16820, DOI 10.1074/jbc.M213163200; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; YOUNG CYF, 1994, ONCOL RES, V6, P203	55	42	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46087	46093		10.1074/jbc.M306219200	http://dx.doi.org/10.1074/jbc.M306219200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12958311	hybrid			2022-12-25	WOS:000186452300126
J	Takeuchi, N; Ueda, T				Takeuchi, N; Ueda, T			Down-regulation of the mitochondrial translation system during terminal differentiation of HL-60 cells by 12-O-tetradecanoyl-1-phorbol-13-acetate - Comparison with the cytoplasmic translation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID-LEUKEMIA CELLS; CHICK-EMBRYO CELLS; HUMAN POLYNUCLEOTIDE PHOSPHORYLASE; KINASE C-BETA; PROTEIN-SYNTHESIS; MYOBLAST DIFFERENTIATION; RESPIRATION-DEFICIENT; GENE-EXPRESSION; TRANSCRIPTION FACTOR; ETHIDIUM-BROMIDE	Mitochondrial (mt) biogenesis depends on both the nuclear and mt genomes, and a coordination of these two genetic systems is necessary for proper cell functioning. Little is known about the regulatory mechanisms of mt translation or about the expression of mt translation factors. Here, we studied the expression of mt translation factors during 12-O-tetradecanoyl-1-phorbol-13-acetate (TPA)-induced terminal differentiation of HL-60 cells. For all mt translation factors investigated, mRNA expression was markedly downregulated in a coordinate and specific manner, whereas mRNA levels for the cytoplasmic translation factors showed only a slight reduction. An actinomycin D chase study and nuclear run-on assay revealed that the TPA-induced decrease in mt elongation factor Tu (EF-Tumt) mRNA mainly results from decreased mRNA stability. Polysome analysis showed that there was no significant translational control of mt translation factor (EF-Tumt, ribosomal proteins L7/L12mt and S12mt) mRNA expression during differentiation. Thus, the decreased protein level of one of these mt translation factors (EF-Tumt) simply reflects its decreased mRNA level. It was also demonstrated by pulse labeling of mt translation products that the down-regulation of mt translational activity is actually associated with down-regulated mt translation factor expression during cellular differentiation. Our results illustrate that the regulatory mechanisms of mt translational activity upon terminal differentiation ( in response to the growth arrest) is different to that of the cytoplasmic system, where the control of mRNA translational efficiency of major translation factors is the central mechanism for their down-regulation.	Univ Tokyo, Grad Sch Frontier Sci, Dept Integrat Biosci, Kashiwa, Chiba 2778562, Japan	University of Tokyo	Takeuchi, N (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrat Biosci, Bldg FSB-401,5-1-5 Kashiwanoha, Kashiwa, Chiba 2778562, Japan.		Ueda, Takuya/K-5217-2014	Ueda, Takuya/0000-0002-7760-8271				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BIRNIE GD, 1988, BRIT J CANCER, V58, P41; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; COLLINS SJ, 1980, INT J CANCER, V25, P213, DOI 10.1002/ijc.2910250208; ENGLAND JM, 1978, J MOL BIOL, V119, P455, DOI 10.1016/0022-2836(78)90226-7; GREENBERG ME, 1997, CURRENT PROTOCOLS MO, V1; GREGOIRE M, 1984, EUR J BIOCHEM, V142, P49, DOI 10.1111/j.1432-1033.1984.tb08249.x; Hamai N, 1997, CELL STRUCT FUNCT, V22, P421, DOI 10.1247/csf.22.421; HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584; He HP, 2001, CIRC RES, V89, P461, DOI 10.1161/hh1701.096038; HERZBERG NH, 1993, BIOCHIM BIOPHYS ACTA, V1181, P63, DOI 10.1016/0925-4439(93)90091-E; Herzig RP, 2000, J BIOL CHEM, V275, P13134, DOI 10.1074/jbc.275.17.13134; Ito Y, 2001, CELL DEATH DIFFER, V8, P794, DOI 10.1038/sj.cdd.4400886; Juan HF, 2002, ELECTROPHORESIS, V23, P2490, DOI 10.1002/1522-2683(200208)23:15<2490::AID-ELPS2490>3.0.CO;2-3; KANEKO T, 1988, MOL CELL BIOL, V8, P3311, DOI 10.1128/MCB.8.8.3311; KOROHODA W, 1993, FOLIA HISTOCHEM CYTO, V31, P9; Krichevsky AM, 1999, J BIOL CHEM, V274, P14295, DOI 10.1074/jbc.274.20.14295; LAENG H, 1988, EXP CELL RES, V179, P222, DOI 10.1016/0014-4827(88)90361-8; LANSMAN RA, 1975, J MOL BIOL, V99, P761, DOI 10.1016/S0022-2836(75)80183-5; Laouar A, 2001, MOL CARCINOGEN, V32, P195, DOI 10.1002/mc.10012; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; LEBLONDLAROUCHE L, 1979, J GEN VIROL, V44, P323, DOI 10.1099/0022-1317-44-2-323; Leszczyniecka M, 2002, P NATL ACAD SCI USA, V99, P16636, DOI 10.1073/pnas.252643699; Lin KM, 2002, LEUKEMIA, V16, P1143, DOI 10.1038/sj.leu.2402514; Luciakova K, 2003, J BIOL CHEM, V278, P30624, DOI 10.1074/jbc.M303530200; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; Mariottini P, 1999, J BIOL CHEM, V274, P31853, DOI 10.1074/jbc.274.45.31853; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Marty L, 1996, J BIOL CHEM, V271, P11468, DOI 10.1074/jbc.271.19.11468; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; MORAIS R, 1980, BIOCHEM BIOPH RES CO, V94, P71, DOI 10.1016/S0006-291X(80)80189-6; Orrenius S, 1997, CELL DEATH DIFFER, V4, P427, DOI 10.1038/sj.cdd.4400272; Pandey P, 2000, ONCOGENE, V19, P3941, DOI 10.1038/sj.onc.1203751; Piwowarski J, 2003, J MOL BIOL, V329, P853, DOI 10.1016/S0022-2836(03)00528-X; Rochard P, 2000, J BIOL CHEM, V275, P2733, DOI 10.1074/jbc.275.4.2733; Rochard P, 1996, J CELL PHYSIOL, V168, P239, DOI 10.1002/(SICI)1097-4652(199608)168:2<239::AID-JCP2>3.0.CO;2-Q; Ruan H, 1997, MRNA FORMATION FUNCT, P305, DOI 10.1016/B978-012587545-5/50017-; SAGOH T, 1988, ARCH BIOCHEM BIOPHYS, V262, P599, DOI 10.1016/0003-9861(88)90411-0; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; Scarpulla RC, 2002, GENE, V286, P81, DOI 10.1016/S0378-1119(01)00809-5; Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; TSIFTSOGLOU AS, 1985, INT J CELL CLONING, V3, P349, DOI 10.1002/stem.5530030602; VANDENBOGERT C, 1992, J CELL PHYSIOL, V152, P632, DOI 10.1002/jcp.1041520323; VAYSSIERE JL, 1992, IN VITRO CELL DEV-AN, V28A, P763; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; Xu J, 1999, ONCOL RES, V11, P429; Zheng X, 2002, NUCLEIC ACIDS RES, V30, P4489, DOI 10.1093/nar/gkf580	50	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45318	45324		10.1074/jbc.M307620200	http://dx.doi.org/10.1074/jbc.M307620200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952954	hybrid			2022-12-25	WOS:000186452300034
J	Shindo, K; Takaori-Kondo, A; Kobayashi, M; Abudu, A; Fukunaga, K; Uchiyama, T				Shindo, K; Takaori-Kondo, A; Kobayashi, M; Abudu, A; Fukunaga, K; Uchiyama, T			The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA EDITING ENZYME; HUMAN-IMMUNODEFICIENCY-VIRUS; CYTIDINE DEAMINASE AID; VIRAL VIF PROTEIN; CATALYTIC SUBUNIT; DNA; HYPERMUTATION; CLONING; BINDING; CELLS	Human immunodeficiency virus, type 1 (HIV-1) Vif protein plays an essential role in the regulation of the infectivity of HIV-1 virion. Vif functions to counteract an anti-HIV-1 cellular factor in non-permissive cells, CEM15/Apobec-3G, which shares a cytidine deaminase motif. CEM15/Apobec-3G deaminates dC to dU in the minus strand DNA of HIV-1, resulting in G to A hypermutation in the plus strand DNA. In this study, we have done the mutagenesis analysis on two cytidine deaminase motifs in CEM15/Apobec-3G and examined their antiviral functions as well as the DNA editing activity. Point mutations in the C-terminal active site such as E259Q and C291A almost completely abrogated the antiviral function, while those in the N-terminal active site such as E67Q and C100A retained this activity to a lesser extent as compared with that of the wild type. The DNA editing activities of E67Q and E259Q mutants were both retained but impaired to the same extent. This indicates that the enzymatic activity of this protein is essential but not a sole determinant of the antiviral activity. Furthermore, all the deletion mutants tested in this study lost the antiviral activity because of the loss of the activity for dimerization, suggesting that the entire protein structure is necessary for the antiviral function.	Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Takaori-Kondo, A (corresponding author), Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, 54 Shogoin Kawaracho, Kyoto 6068507, Japan.			Shindo, Keisuke/0000-0001-8793-8189				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; Anant S, 2001, AM J PHYSIOL-CELL PH, V281, pC1904, DOI 10.1152/ajpcell.2001.281.6.C1904; Desrosiers RC, 1998, J VIROL, V72, P1431, DOI 10.1128/JVI.72.2.1431-1437.1998; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1999, J VIROL, V73, P2675, DOI 10.1128/JVI.73.4.2675-2681.1999; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; Simon JHM, 1998, EMBO J, V17, P1259, DOI 10.1093/emboj/17.5.1259; Takaori-Kondo A, 2000, BIOCHEM BIOPH RES CO, V272, P856, DOI 10.1006/bbrc.2000.2860; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	26	158	164	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44412	44416		10.1074/jbc.C300376200	http://dx.doi.org/10.1074/jbc.C300376200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12970355	hybrid, Green Submitted			2022-12-25	WOS:000186306700067
J	Hsiai, TK; Cho, SK; Wong, PK; Ing, M; Salazar, A; Sevanian, A; Navab, M; Demer, LL; Ho, CM				Hsiai, TK; Cho, SK; Wong, PK; Ing, M; Salazar, A; Sevanian, A; Navab, M; Demer, LL; Ho, CM			Monocyte recruitment to endothelial cells in response to oscillatory shear stress	FASEB JOURNAL			English	Article						micro-electromechanical systems (MEMS); cell tracking velocimetry; shear stress sensors; endothelial cells; monocytes	CAROTID BIFURCATION; PULSATILE FLOW; ATHEROSCLEROSIS; HEMODYNAMICS; EXPRESSION; DYNAMICS; ADHESION; ERYTHROCYTES; MECHANISMS; LEUKOCYTES	Leukocyte recruitment to endothelial cells is a critical event in inflammatory responses. The spatial, temporal gradients of shear stress, topology, and outcome of cellular interactions that underlie these responses have so far been inferred from static imaging of tissue sections or studies of statically cultured cells. In this report, we developed micro-electromechanical systems (MEMS) sensors, comparable to a single endothelial cell (EC) in size, to link real-time shear stress with monocyte/EC binding kinetics in a complex flow environment, simulating the moving and unsteady separation point at the arterial bifurcation with high spatial and temporal resolution. In response to oscillatory shear stress (tau) at +/- 2.6 dyn/cm(2) at a time-averaged shear stress (tau(ave)) = 0 and 0.5 Hz, individual monocytes displayed unique to-and-fro trajectories undergoing rolling, binding, and dissociation with other monocyte, followed by solid adhesion on EC. Our study quantified individual monocyte/EC binding kinetics in terms of displacement and velocity profiles. Oscillatory flow induces up-regulation of adhesion molecules and cytokines to mediate monocyte/EC interactions over a dynamic range of shear stress +/- 2.6 dyn/cm(2) (P = 0.50, n = 10).	Univ So Calif, Sch Engn, Dept Biomed Engn, Los Angeles, CA 90089 USA; Univ So Calif, Sch Engn, Div Cardiovasc Med, Los Angeles, CA USA; Keck Sch Med, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Engn & Appl Sci, Dept Mech & Aerosp Engn, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90024 USA; Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California	Hsiai, TK (corresponding author), Univ So Calif, Sch Engn, Dept Biomed Engn, Olin Hall Engn 500, Los Angeles, CA 90089 USA.	hsiai@usc.edu	Wong, Pak Kin/A-7974-2012; Ho, Chih-Ming/I-6537-2012; Demer, Linda L/I-5770-2013	Wong, Pak Kin/0000-0001-7388-2110; Demer, Linda L/0000-0002-9618-6895; Ho, Chih-Ming/0000-0001-7369-5446	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083015, R01HL118650, T32HL007895, K08HL068689] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL068689-01A1, R01 HL118650, T32 HL007895, HL07895, R01 HL083015, K08 HL068689] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P443, DOI 10.1161/hq0302.105593; [Anonymous], 1989, MEASUREMENT WALL SHE; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Chappell DC, 1998, CIRC RES, V82, P532, DOI 10.1161/01.RES.82.5.532; Chen SQ, 2001, P NATL ACAD SCI USA, V98, P950, DOI 10.1073/pnas.98.3.950; Chu Y, 2002, ARTERIOSCL THROM VAS, V22, P611, DOI 10.1161/01.ATV.0000012663.85364.FA; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; DEPAOLA N, 1992, ARTERIOSCLER THROMB, V12, P1254, DOI 10.1161/01.ATV.12.11.1254; FOGELMAN AM, 1988, J LIPID RES, V29, P1243; Frangos JA, 1996, BIOCHEM BIOPH RES CO, V224, P660, DOI 10.1006/bbrc.1996.1081; FUNG YC, 1993, J BIOMECH ENG-T ASME, V115, P1, DOI 10.1115/1.2895465; GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018; HELMLINGER G, 1995, AM J PHYSIOL-CELL PH, V269, pC367, DOI 10.1152/ajpcell.1995.269.2.C367; Hsiai TK, 2002, ANN BIOMED ENG, V30, P646, DOI 10.1114/1.1484222; Hsiai TK, 2001, ARTERIOSCL THROM VAS, V21, P1770, DOI 10.1161/hq1001.097104; HUANG JB, 1995, P IEEE INSTR MEAS C; Jadhav S, 2001, J IMMUNOL, V167, P5986, DOI 10.4049/jimmunol.167.10.5986; Kitayama J, 2000, CELL IMMUNOL, V203, P39, DOI 10.1006/cimm.2000.1671; Ku DN, 1997, ANNU REV FLUID MECH, V29, P399, DOI 10.1146/annurev.fluid.29.1.399; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293; Liu C, 1999, J MICROELECTROMECH S, V8, P90; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035; Marschel P, 2002, ANN BIOMED ENG, V30, P333, DOI 10.1114/1.1475342; Melder RJ, 2000, MICROVASC RES, V59, P316, DOI 10.1006/mvre.1999.2223; MOTOMIYA M, 1984, STROKE, V15, P50, DOI 10.1161/01.STR.15.1.50; PEERSEN E, 1997, EUR J VASC ENDOVASC, V13, P4439; Raffel M., 1998, EXP FLUID MECH; Ravensbergen J, 1998, ARTERIOSCL THROM VAS, V18, P708, DOI 10.1161/01.ATV.18.5.708; Rosenfeld ME, 2002, ARTERIOSCL THROM VAS, V22, P361, DOI 10.1161/hq0302.104847; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SCHMIDSCHONBEIN GW, 1980, MICROVASC RES, V19, P45, DOI 10.1016/0026-2862(80)90083-7; Shanmugan K.S., 1988, RANDOM SIGNALS DETEC; Steinman DA, 2002, MAGN RESON MED, V47, P149, DOI 10.1002/mrm.10025; Taylor AD, 1996, BIOPHYS J, V71, P3488, DOI 10.1016/S0006-3495(96)79544-9; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; Walker NJ, 2002, SCIENCE, V296, P557, DOI 10.1126/science.296.5567.557; ZARINS CK, 1983, CIRC RES, V53, P502, DOI 10.1161/01.RES.53.4.502; Ziegler T, 1998, ARTERIOSCL THROM VAS, V18, P686, DOI 10.1161/01.ATV.18.5.686	39	112	114	1	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1648	1657		10.1096/fj.02-1064com	http://dx.doi.org/10.1096/fj.02-1064com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958171	Green Accepted			2022-12-25	WOS:000185925100039
J	Pai, R; Nakamura, T; Moon, WS; Tarnawski, AS				Pai, R; Nakamura, T; Moon, WS; Tarnawski, AS			Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors	FASEB JOURNAL			English	Article						EGFR; Met-R; beta-catenin; uPAR; PGE(2)	BETA-CATENIN; COLORECTAL-CANCER; CARCINOMA CELLS; PLASMINOGEN-ACTIVATOR; EGF RECEPTOR; EXPRESSION; E-2; METASTASIS; INVASIVENESS; PROGRESSION	Colorectal cancer is the second most frequent cancer in the Western world, often lethal when invasion and/or metastasis occur. In addition to hepatocyte growth factor (HGF), colon cancer invasion may be driven by prostaglandins, especially the E-2 series (PGE(2)), generated by the cyclooxygenase-2 (Cox-2) enzyme. While concentration of PGE2 as well as expression of Cox-2, HGF receptor (c-Met-R), epidermal growth factor receptor (EGFR), and beta-catenin are all dramatically increased in colon cancers and implicated in their growth and invasion, the precise role of PGE2 in the latter process remains unclear. Here we provide evidence that PGE(2) transactivates c-Met-R (contingent upon functional EGFR), increases tyrosine phosphorylation and nuclear accumulation of beta-catenin, and induces urokinase-type plasminogen activator receptor ( uPAR) mRNA expression. This is accompanied by increased beta-catenin association with c-Met-R and enhanced colon cancer cell invasiveness. Inactivation of EGFR and c-Met-R significantly reduced PGE(2)-induced cancer cell invasiveness. Clinical relevance of these findings is confirmed by our immunohistochemical studies demonstrating that cancer cells in the invasive front overexpress Cox-2, c-Met-R, and beta-catenin. Our findings explain a functional relationship between prostaglandins, EGFR, and c-Met-R in colon cancer growth and invasion.	Dept Vet Affairs Med Ctr, Med Serv, Gastroenterol Sect 111G, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; Osaka Univ, Grad Sch Med, Osaka, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; Osaka University	Pai, R (corresponding author), Dept Vet Affairs Med Ctr, Med Serv, Gastroenterol Sect 111G, 5901 E 7th St, Long Beach, CA 90822 USA.	rpai@uci.edu.com						Adam L, 2001, CANCER RES, V61, P81; ALEXANDER N, 2002, AM J PATHOL, V160, P389; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bergstrom JD, 2000, EXP CELL RES, V259, P293, DOI 10.1006/excr.2000.4967; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Chen WS, 2001, INT J CANCER, V91, P894, DOI 10.1002/1097-0215(200102)9999:9999<894::AID-IJC1146>3.3.CO;2-R; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; ELLIS V, 1992, ANN NY ACAD SCI, V667, P13, DOI 10.1111/j.1749-6632.1992.tb51591.x; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; Hao XP, 1997, VIRCHOWS ARCH, V431, P167, DOI 10.1007/s004280050084; Hiscox S, 1999, ANTICANCER RES, V19, P509; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Messa C, 1998, ACTA ONCOL, V37, P285, DOI 10.1080/028418698429595; Ozgul C, 1997, Acta Physiol Hung, V85, P121; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; PYKE C, 1991, AM J PATHOL, V138, P1059; Scheving LA, 2002, BIOCHEM BIOPH RES CO, V290, P197, DOI 10.1006/bbrc.2001.6157; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Tomioka D, 2001, CANCER RES, V61, P7518; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Yang VW, 2000, PROSTAG OTH LIPID M, V60, P83, DOI 10.1016/S0090-6980(99)00054-4	32	154	167	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1640	1647		10.1096/fj.02-1011com	http://dx.doi.org/10.1096/fj.02-1011com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958170				2022-12-25	WOS:000185925100038
J	Berberat, PO; Katori, M; Kaczmarek, E; Anselmo, D; Lassman, C; Ke, B; Shen, X; Busuttil, RW; Yamashita, K; Csizmadia, E; Tyagi, S; Otterbein, LE; Brouard, S; Tobiasch, E; Bach, FH; Kupiec-Weglinski, JW; Soares, MP				Berberat, PO; Katori, M; Kaczmarek, E; Anselmo, D; Lassman, C; Ke, B; Shen, X; Busuttil, RW; Yamashita, K; Csizmadia, E; Tyagi, S; Otterbein, LE; Brouard, S; Tobiasch, E; Bach, FH; Kupiec-Weglinski, JW; Soares, MP			Heavy chain ferritin acts as an anti-apoptotic gene that protects livers from ischemia-reperfusion injury	FASEB JOURNAL			English	Article						heme oxygenase-1; IRI; H-ferritin	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; ADENOVIRUS-MEDIATED EXPRESSION; ENDOTHELIAL-CELL ACTIVATION; HEME OXYGENASE-1; ISCHEMIA/REPERFUSION INJURY; NEUTROPHIL INFILTRATION; LIPID-PEROXIDATION; RAT; PREVENTS	Heme oxygenase-1 (HO-1) is induced under a variety of pro-oxidant conditions such as those associated with ischemia-reperfusion injury (IRI) of transplanted organs. HO-1 cleaves the heme porphyrin ring releasing Fe2+, which induces the expression of the Fe2+ sequestering protein ferritin. By limiting the ability of Fe2+ to participate in the generation of free radicals through the Fenton reaction, ferritin acts as an anti-oxidant. We have previously shown that HO-1 protects transplanted organs from IRI. We have linked this protective effect with the anti-apoptotic action of HO-1. Whether the iron-binding properties of ferritin contributed to the protective effect of HO-1 was not clear. We now report that recombinant adenovirus mediated overexpression of the ferritin heavy chain (H-ferritin) gene protects rat livers from IRI and prevents hepatocellular damage upon transplantation into syngeneic recipients. The protective effect of H-ferritin is associated with the inhibition of endothelial cell and hepatocyte apoptosis in vivo. H-ferritin protects cultured endothelial cells from apoptosis induced by a variety of stimuli. These findings unveil the anti-apoptotic function of H-ferritin and suggest that H-ferritin can be used in a therapeutic manner to prevent liver IRI and thus maximize the organ donor pool used for transplantation.	Harvard Univ, Sch Med,Dept Surg, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, Boston, MA 02215 USA; Univ Calif Los Angeles, Dumont Transplant Ctr, David Geffen Sch Med, Los Angeles, CA USA; Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA; Inst Gulbenkian Ciencias, P-2781901 Oeiras, Portugal	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Instituto Gulbenkian de Ciencia	Soares, MP (corresponding author), Harvard Univ, Sch Med,Dept Surg, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, 99 Brookline Ave, Boston, MA 02215 USA.	msoares@caregroup.harvard.edu	Soares, Miguel P/G-4188-2011; brouard, sophie c/Q-1285-2016	Soares, Miguel/0000-0002-9314-4833; Ke, Bibo/0000-0002-1885-1538				Amersi F, 1999, J CLIN INVEST, V104, P1631, DOI 10.1172/JCI7903; Amersi F, 2002, AM J TRANSPLANT, V2, P600, DOI 10.1034/j.1600-6143.2002.20704.x; Amersi F, 2001, TRANSPLANTATION, V71, P112, DOI 10.1097/00007890-200101150-00018; Anrather J, 1997, J CLIN INVEST, V99, P763, DOI 10.1172/JCI119222; BALLA G, 1992, J BIOL CHEM, V267, P18148; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Blydt-Hansen TD, 2003, J AM SOC NEPHROL, V14, P745, DOI 10.1097/01.ASN.0000050760.87113.25; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; CLAVIEN PA, 1992, TRANSPLANTATION, V53, P957, DOI 10.1097/00007890-199205000-00001; COZZI A, 1990, FEBS LETT, V277, P119, DOI 10.1016/0014-5793(90)80823-2; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; Farmer D. G., 2000, TRANSPLANT REV, V14, P106, DOI DOI 10.1053/TR.2000.4651; FENTON HGH, 1894, J CHEM SOC LOND; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Foxwell B, 1998, P NATL ACAD SCI USA, V95, P8211, DOI 10.1073/pnas.95.14.8211; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Graham F L, 1992, Biotechnology, V20, P363; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; JAESCHKE H, 1990, FASEB J, V4, P3355, DOI 10.1096/fasebj.4.15.2253850; JUCKETT MB, 1995, AM J PATHOL, V147, P782; KAMADA N, 1979, TRANSPLANTATION, V28, P47, DOI 10.1097/00007890-197907000-00011; Katori M, 2002, TRANSPLANTATION, V73, P287, DOI 10.1097/00007890-200201270-00023; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; She HY, 2002, AM J PHYSIOL-GASTR L, V283, pG719, DOI 10.1152/ajpgi.00108.2002; SHIBAHARA S, 1993, J BIOCHEM-TOKYO, V113, P214, DOI 10.1093/oxfordjournals.jbchem.a124028; Soares MP, 2002, ANTIOXID REDOX SIGN, V4, P321, DOI 10.1089/152308602753666370; Soares MP, 1998, J IMMUNOL, V161, P4572; Soares MP, 2001, IMMUNOL REV, V184, P275, DOI 10.1034/j.1600-065x.2001.1840124.x; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; Suttner DM, 1999, AM J PHYSIOL-LUNG C, V276, pL443, DOI 10.1152/ajplung.1999.276.3.L443; SUZUKI S, 1993, TRANSPLANTATION, V55, P1265; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Tenhunen R, 1969, Trans Assoc Am Physicians, V82, P363; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013	42	169	182	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1724	+		10.1096/fj.03-0229fje	http://dx.doi.org/10.1096/fj.03-0229fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958189	Bronze			2022-12-25	WOS:000184471600017
J	Quast, T; Wehner, S; Kirfel, G; Jaeger, K; De Luca, M; Herzog, V				Quast, T; Wehner, S; Kirfel, G; Jaeger, K; De Luca, M; Herzog, V			sAPP as a regulator of dendrite motility and melanin release in epidermal melanocytes and melanoma cells	FASEB JOURNAL			English	Article						beta-amyloid precursor protein; marker protein; whole mount epidermis	AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; MESSENGER-RNA; STIMULATING HORMONE; AXONAL-TRANSPORT; RAT-TISSUES; GROWTH; SKIN; DOMAIN; BINDING	Numerous factorsincludingultraviolet(UV)radiation and growth factors regulate the specific function of epidermal melanocytes. A recently discovered epidermal growth factor is sAPP, the soluble N-terminal ectodomain of the beta-amyloid precursor protein(APP). Using whole mount preparations of isolated human epidermis,we detected a small population of basal cells, which expressed exceptionally highlevelsofAPP.Thesecellswereidentifiedasmelanocytes,which,similar to keratinocytes and neuronal cells, expressed the three APP isoforms 695,751,and 770. They differed in their expression pattern from that of neuronal cells by expressing onlylowlevelsofAPP695.Melanocytesandmelanomacellsinvitroreleased,in addition to keratinocytes,large quantities of sAPP. Because of its growth factor function,we studied possible effects of sAPP on melanocytes. Recombinants APPstronglyincreasedlamellipodiaactivityatdendritictips,an effect that coincided with increased release of melanin particles. Our observations point to the possible use of APP as an immunocytochemical marker for melanocytes. They suggest that sAPP derived from keratinocytes and/or melanocytes belongs to a family of factors operating in the paracrine and/or autocrine regulation of melanocyte function.	Univ Bonn, Inst Cell Biol, D-53121 Bonn, Germany; Univ Bonn, Bonner Forum Biomed, D-53121 Bonn, Germany; Marien Hosp, D-50321 Bruhl, Germany; Fdn Banca Occhi Veneto, I-30171 Venice, Italy	University of Bonn; University of Bonn; St. Marien Hospital	Herzog, V (corresponding author), Univ Bonn, Inst Cell Biol, Ulrich Haberland Str 61A, D-53121 Bonn, Germany.	Herzog@uni-bonn.de	De Luca, Michele/N-5883-2014; Wehner, Sven/X-6326-2019	De Luca, Michele/0000-0002-0850-8445; Wehner, Sven/0000-0002-8632-7631				Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; BOLOGNIA JL, 1988, J AM ACAD DERMATOL, V19, P217, DOI 10.1016/S0190-9622(88)70168-1; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; DELUCA M, 1993, J CELL SCI, V105, P1079; DELUCA M, 1994, KERATINOCYTE HDB, P95; FITZPATRICK T B, 1963, Dermatol Wochenschr, V147, P481; GILCHREST BA, 1979, ANN INTERN MED, V91, P17, DOI 10.7326/0003-4819-91-1-17; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GORDON PR, 1989, J INVEST DERMATOL, V92, P565, DOI 10.1111/1523-1747.ep12709595; GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665; HARA M, 1995, J INVEST DERMATOL, V105, P744, DOI 10.1111/1523-1747.ep12325522; Hara M, 2000, J INVEST DERMATOL, V114, P438, DOI 10.1046/j.1523-1747.2000.00894.x; Hearing VJ, 1999, J INVEST DERM SYMP P, V4, P24, DOI 10.1038/sj.jidsp.5640176; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; Heber S, 2000, J NEUROSCI, V20, P7951; Hinz B, 1999, EXP CELL RES, V251, P234, DOI 10.1006/excr.1999.4541; HIROBE T, 1978, J CELL SCI, V33, P371; Hoffmann J, 2000, EUR J CELL BIOL, V79, P905, DOI 10.1078/0171-9335-00117; HOLBROOK KA, 1989, ANAT EMBRYOL, V180, P443, DOI 10.1007/BF00305119; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; JIMBOW K, 1976, J INVEST DERMATOL, V67, P72, DOI 10.1111/1523-1747.ep12512500; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; KANG J, 1990, BIOCHEM BIOPH RES CO, V166, P1192, DOI 10.1016/0006-291X(90)90992-V; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kirfel G, 2002, EUR J CELL BIOL, V81, P664, DOI 10.1078/0171-9335-00284; Kummer C, 2002, EXP CELL RES, V280, P222, DOI 10.1006/excr.2002.5631; LACOUR JP, 1992, J CELL PHYSIOL, V151, P287, DOI 10.1002/jcp.1041510210; LEVINE N, 1991, JAMA-J AM MED ASSOC, V266, P2730, DOI 10.1001/jama.266.19.2730; Luger TA, 1998, ANN NY ACAD SCI, V840, P381, DOI 10.1111/j.1749-6632.1998.tb09577.x; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; ORTONNE JP, 1990, J INT MED RES, V18, pC8; Perez RG, 1997, J NEUROSCI, V17, P9407; Pietrzik CU, 1998, P NATL ACAD SCI USA, V95, P1770, DOI 10.1073/pnas.95.4.1770; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; Raucher D, 2000, J CELL BIOL, V148, P127, DOI 10.1083/jcb.148.1.127; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; Schmitz A, 2002, HISTOCHEM CELL BIOL, V117, P171, DOI 10.1007/s00418-001-0351-5; Scott GA, 1998, J INVEST DERMATOL, V111, P243, DOI 10.1046/j.1523-1747.1998.00276.x; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SMALL DH, 1994, J NEUROSCI, V14, P2117; SZABO G, 1967, PHILOS T R SOC LONDO, P252; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; Virador VM, 2001, FASEB J, V15, P105, DOI 10.1096/fj.01-0518fje; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Whiteman DC, 1999, ARCH DERMATOL RES, V291, P511, DOI 10.1007/s004030050446; YAMAMOTO O, 1994, PIGM CELL RES, V7, P158, DOI 10.1111/j.1600-0749.1994.tb00044.x; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	54	30	34	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1739	+		10.1096/fj.02-1059fje	http://dx.doi.org/10.1096/fj.02-1059fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958194				2022-12-25	WOS:000184471600028
J	Eschenburg, S; Kabsch, W; Healy, ML; Schonbrunn, E				Eschenburg, S; Kabsch, W; Healy, ML; Schonbrunn, E			A new view of the mechanisms of UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) and 5-enolpyruvylshikimate-3-phosphate synthase (AroA) derived from X-ray structures of their tetrahedral reaction intermediate states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBIOTIC FOSFOMYCIN; STEREOCHEMICAL COURSE; 3-PHOSPHATE SYNTHASE; ACTIVE-SITE; BACTERIAL PEPTIDOGLYCAN; HERBICIDE GLYPHOSATE; SHIKIMATE PATHWAY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DIFFRACTION DATA	UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) and 5-enolpyruvylshikimate-3-phosphate synthase (AroA) constitute the small enzyme family of enolpyruvyl transferases, which catalyze the chemically unusual reaction of enolpyruvyl transfer. MurA catalyzes the first step in the biosynthesis of the bacterial cell wall; AroA is the sixth enzyme of the shikimate pathway leading to the synthesis of aromatic compounds in numerous microorganisms and plants. Because both metabolic pathways are absent from mammals but essential for the growth of microorganisms, MurA and AroA are attractive targets for the development of novel antimicrobial drugs. We have determined the x-ray structures of the D305A mutant of Enterobacter cloacae MurA and the D313A mutant of Escherichia coli AroA, both of which crystallized in the presence of their substrates. The structures depict the tetrahedral reaction intermediate states of the enzymes and prove that, without the aspartate side chain, the overall addition-elimination reaction in both enzymes is halted after the addition step. The presented structures lead to a new view of the catalytic mechanism and, moreover, provide an ideal starting point for the rational design of potent inhibitors of MurA and AroA.	Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA; Max Planck Inst Med Res, Dept Biophys, D-69120 Heidelberg, Germany	University of Kansas; Max Planck Society	Schonbrunn, E (corresponding author), Univ Kansas, Dept Med Chem, 4040A Malott Hall, Lawrence, KS 66045 USA.			Schonbrunn, Ernst/0000-0002-3589-3510				ASANO Y, 1985, J AM CHEM SOC, V107, P4314, DOI 10.1021/ja00300a040; BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615; BOOCOCK MR, 1983, FEBS LETT, V154, P127, DOI 10.1016/0014-5793(83)80888-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; El Zoeiby A, 2003, MOL MICROBIOL, V47, P1, DOI 10.1046/j.1365-2958.2003.03289.x; Eschenburg S, 2002, PLANTA, V216, P129, DOI 10.1007/s00425-002-0908-0; Eschenburg S, 2000, PROTEINS, V40, P290, DOI 10.1002/(SICI)1097-0134(20000801)40:2<290::AID-PROT90>3.0.CO;2-0; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GRIMSHAW CE, 1984, J AM CHEM SOC, V106, P2699, DOI 10.1021/ja00321a037; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KAHAN FM, 1974, ANN NY ACAD SCI, V235, P364, DOI 10.1111/j.1749-6632.1974.tb43277.x; Katz AH, 2003, CURR PHARM DESIGN, V9, P857, DOI 10.2174/1381612033455305; KIM DH, 1995, J AM CHEM SOC, V117, P6380, DOI 10.1021/ja00128a037; Kim DH, 1996, BIOCHEMISTRY-US, V35, P4923, DOI 10.1021/bi952937w; Kim DH, 1996, BIOCHEMISTRY-US, V35, P5435, DOI 10.1021/bi952978s; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEES WJ, 1995, J AM CHEM SOC, V117, P7329, DOI 10.1021/ja00133a006; MARQUARDT JL, 1994, BIOCHEMISTRY-US, V33, P10646, DOI 10.1021/bi00201a011; McDevitt D, 2002, J APPL MICROBIOL, V92, p28S, DOI 10.1046/j.1365-2672.92.5s1.16.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mizyed S, 2003, BIOCHEMISTRY-US, V42, P6986, DOI 10.1021/bi027217l; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roberts F, 1998, NATURE, V393, P801, DOI 10.1038/31723; Robertson B, 2002, COMPUT GRAPH WORLD, V25, P36; Samland AK, 2001, BIOCHEMISTRY-US, V40, P1550, DOI 10.1021/bi001490a; Schonbrunn E, 2001, P NATL ACAD SCI USA, V98, P1376, DOI 10.1073/pnas.98.4.1376; Schonbrunn E, 1996, STRUCTURE, V4, P1065, DOI 10.1016/S0969-2126(96)00113-X; Schonbrunn E, 2000, P NATL ACAD SCI USA, V97, P6345, DOI 10.1073/pnas.120120397; Schonbrunn E, 2000, BIOCHEMISTRY-US, V39, P2164, DOI 10.1021/bi991091j; SHUTTLEWORTH WA, 1994, BIOCHEMISTRY-US, V33, P7062, DOI 10.1021/bi00189a007; Skarzynski T, 1998, BIOCHEMISTRY-US, V37, P2572, DOI 10.1021/bi9722608; Skarzynski T, 1996, STRUCTURE, V4, P1465, DOI 10.1016/S0969-2126(96)00153-0; STALLINGS WC, 1991, P NATL ACAD SCI USA, V88, P5046, DOI 10.1073/pnas.88.11.5046; STEINRUCKEN HC, 1984, EUR J BIOCHEM, V143, P351, DOI 10.1111/j.1432-1033.1984.tb08379.x; STEINRUCKEN HC, 1980, BIOCHEM BIOPH RES CO, V94, P1207, DOI 10.1016/0006-291X(80)90547-1; VANHEIJENOORT J, 1994, N COMP BIOC, V27, P39; Walsh CT, 1996, CHEM BIOL, V3, P83, DOI 10.1016/S1074-5521(96)90282-3	38	71	73	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49215	49222		10.1074/jbc.M309741200	http://dx.doi.org/10.1074/jbc.M309741200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	13129913	hybrid			2022-12-25	WOS:000186829000086
J	Bonnon, C; Goutebroze, L; Denisenko-Nehrbass, N; Girault, JA; Faivre-Sarrailh, C				Bonnon, C; Goutebroze, L; Denisenko-Nehrbass, N; Girault, JA; Faivre-Sarrailh, C			The paranodal complex of F3/Contactin and Caspr/Paranodin traffics to the cell surface via a non-conventional pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE; ENDOPLASMIC-RETICULUM; NEURITE OUTGROWTH; POTASSIUM CHANNEL; MEMBRANE-PROTEINS; DOMAINS; GLYCOSYLATION; GLYCOPROTEIN; JUNCTIONS; IDENTIFICATION	During myelination, membrane-specialized domains are generated by complex interactions between axon and glial cells. The cell adhesion molecules caspr/paranodin and F3/contactin play a crucial role in the generation of functional septate-like junctions at paranodes. We have previously demonstrated that association with the glycosylphosphatidylinositol-linked F3/contactin is required for the recruitment of caspr/paranodin into the lipid rafts and its targeting to the cell surface. When transfected alone in neuroblastoma N2a cells, caspr/ paranodin is retained in the endoplasmic reticulum ( ER). Using chimerical constructs, we show that the cytoplasmic region does not contain any ER retention signal, whereas the ectodomain plays a crucial role in caspr/ paranodin trafficking. A series of truncations encompassing the extracellular region of caspr/ paranodin was unable to abolish ER retention. We show that N-glycosylation and quality control by the lectin-chaperone calnexin are required for the cell surface delivery of caspr/ paranodin. Cell surface transport of F3/contactin and caspr/ paranodin is insensitive to brefeldin A and the two glycoproteins are endoglycosidase H-sensitive when associated in complex, recruited into the lipid rafts, and expressed on the cell surface. Our results indicate a Golgi-independent pathway for the paranodal cell adhesion complex that may be implicated in the segregation of axonal subdomains.	Inst Jean Roche, CNRS, FRE 2533, F-13916 Marseille, France; Inst Fer Moulin, INSERM, U536, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Faivre-Sarrailh, C (corresponding author), Inst Jean Roche, FRE 2533, Blvd Pierre Dramard, F-13916 Marseille 20, France.	sarrailh.c@jean-roche.univ-mrs.fr	Gaiser, Carine/GLT-0142-2022; Faivre-Sarrailh, Catherine/M-6738-2016; Girault, Jean-Antoine/F-7518-2013	Girault, Jean-Antoine/0000-0002-7900-1705; Faivre-Sarrailh, Catherine/0000-0002-1718-0533; Goutebroze, laurence/0000-0002-8712-000X				Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Arroyo EJ, 2000, HISTOCHEM CELL BIOL, V113, P1, DOI 10.1007/s004180050001; Baldwin TA, 2002, J BIOL CHEM, V277, P50333, DOI 10.1074/jbc.M209075200; Bennett V, 2001, CURR OPIN CELL BIOL, V13, P61, DOI 10.1016/S0955-0674(00)00175-7; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Bhat MA, 2001, NEURON, V30, P369, DOI 10.1016/S0896-6273(01)00294-X; Bottomley MJ, 2001, CURR BIOL, V11, P1114, DOI 10.1016/S0960-9822(01)00317-7; Boyle MET, 2001, NEURON, V30, P385, DOI 10.1016/S0896-6273(01)00296-3; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brummendorf T, 1996, CURR OPIN NEUROBIOL, V6, P584, DOI 10.1016/S0959-4388(96)80089-4; Charles P, 2002, CURR BIOL, V12, P217, DOI 10.1016/S0960-9822(01)00680-7; de Souza NF, 2002, BIOCHEMISTRY-US, V41, P11351, DOI 10.1021/bi0258041; Denisenko-Nehrbass N, 2003, J NEUROCHEM, V84, P209, DOI 10.1046/j.1471-4159.2003.01503.x; Denisenko-Nehrbass N, 2003, EUR J NEUROSCI, V17, P411, DOI 10.1046/j.1460-9568.2003.02441.x; DURBEC P, 1994, EUR J NEUROSCI, V6, P461, DOI 10.1111/j.1460-9568.1994.tb00288.x; Einheber S, 1997, J CELL BIOL, V139, P1495, DOI 10.1083/jcb.139.6.1495; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Faivre-Sarrailh C, 2000, J CELL BIOL, V149, P491, DOI 10.1083/jcb.149.2.491; Falk J, 2002, BIOL CELL, V94, P327, DOI 10.1016/S0248-4900(02)00006-0; Garrido JJ, 2001, EMBO J, V20, P5950, DOI 10.1093/emboj/20.21.5950; GENNARINI G, 1991, NEURON, V6, P595, DOI 10.1016/0896-6273(91)90062-5; Girault JA, 2002, CURR OPIN NEUROBIOL, V12, P476, DOI 10.1016/S0959-4388(02)00370-7; Gollan L, 2002, J CELL BIOL, V157, P1247, DOI 10.1083/jcb.200203050; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Isom LL, 2002, FRONT BIOSCI, V7, P12; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; Khanna R, 2001, J BIOL CHEM, V276, P34028, DOI 10.1074/jbc.M105248200; Lambert S, 1997, J NEUROSCI, V17, P7025; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; Menegoz M, 1997, NEURON, V19, P319, DOI 10.1016/S0896-6273(00)80942-3; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Murai KK, 2002, CURR BIOL, V12, P181, DOI 10.1016/S0960-9822(02)00680-2; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; Pedraza L, 2001, NEURON, V30, P335, DOI 10.1016/S0896-6273(01)00306-3; Peles E, 2000, CURR OPIN NEUROBIOL, V10, P558, DOI 10.1016/S0959-4388(00)00122-7; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; Rigato F, 2002, J NEUROSCI, V22, P6596; Rios JC, 2000, J NEUROSCI, V20, P8354, DOI 10.1523/JNEUROSCI.20-22-08354.2000; Roth J, 2002, CHEM REV, V102, P285, DOI 10.1021/cr000423j; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Spacek J, 1997, J NEUROSCI, V17, P190, DOI 10.1523/JNEUROSCI.17-01-00190.1997; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27	43	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48339	48347		10.1074/jbc.M309120200	http://dx.doi.org/10.1074/jbc.M309120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12972410	hybrid			2022-12-25	WOS:000186731400119
J	Dalen, KT; Ulven, SM; Bamberg, K; Gustafsson, JA; Nebb, HI				Dalen, KT; Ulven, SM; Bamberg, K; Gustafsson, JA; Nebb, HI			Expression of the insulin-responsive glucose transporter GLUT4 in adipocytes is dependent on liver X receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; PPAR-GAMMA; FATTY-ACID; PRETRANSLATIONAL SUPPRESSION; CHOLESTEROL-METABOLISM; TISSUE DISTRIBUTION; GENE-EXPRESSION; TRANSGENIC MICE; ADIPOSE-TISSUE; MESSENGER-RNA	The insulin-responsive glucose transporter GLUT4 plays a crucial role in insulin-mediated facilitated glucose uptake into adipose tissue and muscle, and impaired expression of GLUT4 has been linked to obesity and diabetes. In this study, we demonstrate that liver X receptors (LXRs) regulate the expression of GLUT4 through direct interaction with a conserved LXR response element in the GLUT4 promoter. The expression of GLUT4 in WAT is induced by a potent LXR agonist in wild type, LXRalpha(-/-), and LXRbeta(-/-) mice but not in LXRalpha(-/-) beta(-/-) mice, demonstrating that both LXRs are able to mediate ligand activated transcription of the GLUT4 gene. However, basal and insulin stimulated expression of GLUT4 in epididymal WAT is reduced only in mice carrying ablation of the LXRalpha isoform. The expression of GLUT4 is furthermore correlated to the induction of LXRalpha during mouse and human adipocyte differentiation. LXRbeta is thus apparently not able to rescue basal expression of GLUT4 in the absence of LXRalpha. We have previously demonstrated that LXRalpha is downregulated in animal models of obesity and diabetes, thus revealing a striking correlation between GLUT4 and LXRalpha expression in insulin-resistant conditions. This suggests that the LXRalpha isoform has a unique role in adipose expression of GLUT4 and suggests that alteration of adipose tissue expression of LXRalpha might be a novel tool to normalize the expression of a gene that is dysregulated in diabetic and insulin-resistant conditions.	Univ Oslo, Inst Nutr Res, N-0316 Oslo, Norway; AstraZeneca Molndal, Mol Pharmacol Res Area CV & GI, S-43183 Molndal, Sweden; Novum, Dept Biosci & Med Nutr, S-14186 Huddinge, Sweden	University of Oslo; AstraZeneca; Karolinska Institutet	Nebb, HI (corresponding author), Univ Oslo, Inst Nutr Res, POB 1046,Blindern, N-0316 Oslo, Norway.	h.i.nebb@basalmed.uio.no	Dalen, Knut Tomas/C-4719-2016; Ulven, Stine Marie/ABD-7140-2020	Dalen, Knut Tomas/0000-0002-0270-5982; 				Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Alberti S, 2001, J CLIN INVEST, V107, P565, DOI 10.1172/JCI9794; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; Auboeuf D, 1997, DIABETES, V46, P1319, DOI 10.2337/diabetes.46.8.1319; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; Cao GQ, 2003, J BIOL CHEM, V278, P1131, DOI 10.1074/jbc.M210208200; Caruccio L, 1999, J IMMUNOL METHODS, V230, P1, DOI 10.1016/S0022-1759(99)00100-3; Charron MJ, 1999, J BIOL CHEM, V274, P3253, DOI 10.1074/jbc.274.6.3253; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Ciaraldi T, 1997, EUR J ENDOCRINOL, V137, P610, DOI 10.1530/eje.0.1370610; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GARVEY WT, 1992, DIABETES, V41, P465, DOI 10.2337/diabetes.41.4.465; HOFMANN C, 1991, ENDOCRINOLOGY, V129, P1915, DOI 10.1210/endo-129-4-1915; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Juvet LK, 2003, MOL ENDOCRINOL, V17, P172, DOI 10.1210/me.2001-0210; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Rozen S, 2000, Methods Mol Biol, V132, P365; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schuster GU, 2002, CIRCULATION, V106, P1147, DOI 10.1161/01.CIR.0000026802.79202.96; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Simpson F, 2001, TRAFFIC, V2, P2, DOI 10.1034/j.1600-0854.2001.020102.x; Smith U, 2002, INT J OBESITY, V26, P897, DOI 10.1038/sj.ijo.0802028; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; Tobin KAR, 2000, MOL ENDOCRINOL, V14, P741, DOI 10.1210/me.14.5.741; Tobin KAR, 2002, J BIOL CHEM, V277, P10691, DOI 10.1074/jbc.M109771200; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Wabitsch M, 2001, INT J OBESITY, V25, P8, DOI 10.1038/sj.ijo.0801520; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; YOUNG PW, 1995, DIABETES, V44, P1087, DOI 10.2337/diabetes.44.9.1087	51	134	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48283	48291		10.1074/jbc.M302287200	http://dx.doi.org/10.1074/jbc.M302287200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12970362	hybrid			2022-12-25	WOS:000186731400113
J	Nada, S; Shima, T; Yanai, H; Husi, H; Grant, SGN; Okada, M; Akiyama, T				Nada, S; Shima, T; Yanai, H; Husi, H; Grant, SGN; Okada, M; Akiyama, T			Identification of PSD-93 as a substrate for the Src family tyrosine kinase Fyn	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; NMDA RECEPTOR SUBUNITS; POSTSYNAPTIC DENSITY; GUANYLATE KINASES; N-WASP; PROTEIN; DOMAIN; PHOSPHORYLATION; MICE; HIPPOCAMPUS	In order to study the role of tyrosine kinase signaling in the post-synaptic density (PSD), tyrosine-phosphorylated proteins associated with the PSD-95/NMDA receptor complex were analyzed. The NMDA receptor complex from the mouse brain was successfully solubilized with deoxycholate and immunopurified with anti-PSD-95 or anti-phosphotyrosine antibody. Immunoblot analyses revealed that the predominantly tyrosine-phosphorylated proteins in the NMDA receptor complex are the NR2A/B subunits and a novel 120 kDa protein. Purification and microsequencing analysis showed that the 120 kDa protein is mouse PSD-93/Chapsyn-110. Recombinant PSD-93 was phosphorylated by Fyn in vitro, and Tyr-384 was identified as a major phosphorylation site. Tyrosine phosphorylation of PSD-93 was greatly reduced in brain tissue from Fyn-deficient mice compared with wild-type mice. Furthermore, an N-terminal palmitoylation signal of PSD-93 was found to be essential for its anchoring to the membrane, where Fyn is also localized. In COS7 cells, exogenously expressed PSD-93 was phosphorylated, dependent on its membrane localization. In addition, tyrosine-phosphorylated PSD-93 was able to bind to Csk, a negative regulator of Src family kinases, in vitro as well as in a brain lysate. These results suggest that PSD-93 serves as a membrane-anchored substrate of Fyn and plays a role in the regulation of Fyn-mediated modification of NMDA receptor function.	Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, Suita, Osaka 5650871, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Dept Mol & Genet Informat, Tokyo 113, Japan; Univ Edinburgh, Ctr Neurosci, Edinburgh EH9 3JQ, Midlothian, Scotland	Osaka University; University of Tokyo; University of Edinburgh	Nada, S (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.			Grant, Seth/0000-0001-8732-8735				Boeckers TM, 1999, J NEUROSCI, V19, P6506; Bonhoeffer T, 2002, NEURON, V35, P1019, DOI 10.1016/S0896-6273(02)00906-6; Brenman JE, 1996, J NEUROSCI, V16, P7407; Cary LA, 2000, NATURE, V404, P945, DOI 10.1038/35010257; El-Husseini AE, 2000, J BIOL CHEM, V275, P23904, DOI 10.1074/jbc.M909919199; El-Husseini AE, 2000, J CELL BIOL, V148, P159, DOI 10.1083/jcb.148.1.159; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Irie F, 2002, NAT NEUROSCI, V5, P1117, DOI 10.1038/nn964; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; Ogawa A, 2002, J BIOL CHEM, V277, P14351, DOI 10.1074/jbc.C200086200; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Roy BC, 2002, GENES CELLS, V7, P607; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; SUZUKI T, 1995, BIOCHEM BIOPH RES CO, V216, P582, DOI 10.1006/bbrc.1995.2662; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; Wang YT, 1996, P NATL ACAD SCI USA, V93, P1721, DOI 10.1073/pnas.93.4.1721; YAGI T, 1993, ONCOGENE, V8, P3343; Yagi T, 1999, BIOCHEM PHARMACOL, V57, P845; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	34	41	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47610	47621		10.1074/jbc.M303873200	http://dx.doi.org/10.1074/jbc.M303873200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13129934	hybrid			2022-12-25	WOS:000186731400034
J	Saucerman, JJ; Brunton, LL; Michailova, AP; McCulloch, AD				Saucerman, JJ; Brunton, LL; Michailova, AP; McCulloch, AD			Modeling beta-adrenergic control of cardiac myocyte contractility in silico	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; PROTEIN-KINASE-A; SIGNALING PATHWAYS; ADENYLYL-CYCLASE; CYCLIC-AMP; ACTIVATION; HEART; CAMP; PHOSPHOLAMBAN; CHANNELS	The beta-adrenergic signaling pathway regulates cardiac myocyte contractility through a combination of feedforward and feedback mechanisms. We used systems analysis to investigate how the components and topology of this signaling network permit neurohormonal control of excitation-contraction coupling in the rat ventricular myocyte. A kinetic model integrating beta-adrenergic signaling with excitation-contraction coupling was formulated, and each subsystem was validated with independent biochemical and physiological measurements. Model analysis was used to investigate quantitatively the effects of specific molecular perturbations. 3-Fold overexpression of adenylyl cyclase in the model allowed an 85% higher rate of cyclic AMP synthesis than an equivalent overexpression of beta(1)-adrenergic receptor, and manipulating the affinity of G(s)alpha for adenylyl cyclase was a more potent regulator of cyclic AMP production. The model predicted that less than 40% of adenylyl cyclase molecules may be stimulated under maximal receptor activation, and an experimental protocol is suggested for validating this prediction. The model also predicted that the endogenous heat-stable protein kinase inhibitor may enhance basal cyclic AMP buffering by 68% and increasing the apparent Hill coefficient of protein kinase A activation from 1.0 to 2.0. Finally, phosphorylation of the L-type calcium channel and phospholamban were found sufficient to predict the dominant changes in myocyte contractility, including a 2.6 x increase in systolic calcium (inotropy) and a 28% decrease in calcium half-relaxation time (lusitropy). By performing systems analysis, the consequences of molecular perturbations in the beta-adrenergic signaling network may be understood within the context of integrative cellular physiology.	Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Bulgarian Acad Sci, Dept Biophys, BU-1113 Sofia, Bulgaria	University of California System; University of California San Diego; University of California System; University of California San Diego; Bulgarian Academy of Sciences	McCulloch, AD (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Saucerman, Jeffrey/0000-0001-9464-8374	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR008605] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL053773] Funding Source: NIH RePORTER; NCI NIH HHS [CA00216] Funding Source: Medline; NCRR NIH HHS [P41 RR08605] Funding Source: Medline; NHLBI NIH HHS [5 P50 HL53773-09] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAVO JA, 1974, P NATL ACAD SCI USA, V71, P3580, DOI 10.1073/pnas.71.9.3580; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; BERS DM, 2001, EXCITATION CONTRACTI, P42; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; CHUNG MK, 1990, CIRC RES, V67, P753, DOI 10.1161/01.RES.67.3.753; CORBIN JD, 1977, J BIOL CHEM, V252, P3854; DIXON DA, 1989, J BIOL CHEM, V264, P13612; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P6400, DOI 10.1073/pnas.96.11.6400; Feldman AM, 2002, CIRCULATION, V105, P1876, DOI 10.1161/01.CIR.0000016965.24080.12; Ferrell JE, 1999, BIOESSAYS, V21, P866, DOI 10.1002/(SICI)1521-1878(199910)21:10<866::AID-BIES9>3.0.CO;2-1; Frank K, 2000, ANN MED, V32, P572, DOI 10.3109/07853890008998837; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gilman AG, 2002, NATURE, V420, P703, DOI 10.1038/nature01304; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Insel PA, 2003, TRENDS ENDOCRIN MET, V14, P100, DOI 10.1016/S1043-2760(03)00029-8; Jafri MS, 1998, BIOPHYS J, V74, P1149, DOI 10.1016/S0006-3495(98)77832-4; Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095; Katz A.M., 2001, PHYSL HEART, P255; Khalil H.K., 1996, NONLINEAR SYSTEMS, P351; Koch WJ, 2000, ANNU REV PHYSIOL, V62, P237, DOI 10.1146/annurev.physiol.62.1.237; Konhilas JP, 2003, J PHYSIOL-LONDON, V547, P951, DOI 10.1113/jphysiol.2002.038117; KUZNETSOV V, 1995, CIRC RES, V76, P40, DOI 10.1161/01.RES.76.1.40; LUO CH, 1994, CIRC RES, V74, P1071, DOI 10.1161/01.RES.74.6.1071; Marks AR, 2003, CIRCULATION, V107, P1456, DOI 10.1161/01.CIR.0000059745.95643.83; Noble D, 2002, BIOESSAYS, V24, P1155, DOI 10.1002/bies.10186; Pandit SV, 2001, BIOPHYS J, V81, P3029, DOI 10.1016/S0006-3495(01)75943-7; Petroff MGV, 2001, CIRC RES, V89, P445, DOI 10.1161/hh1701.095716; POST SR, 1995, BIOCHEM J, V311, P75, DOI 10.1042/bj3110075; Puglisi JL, 2001, AM J PHYSIOL-CELL PH, V281, pC2049, DOI 10.1152/ajpcell.2001.281.6.C2049; Rich TC, 2001, P NATL ACAD SCI USA, V98, P13049, DOI 10.1073/pnas.221381398; Schmitt JP, 2003, SCIENCE, V299, P1410, DOI 10.1126/science.1081578; Skeberdis VA, 1997, J PHARMACOL EXP THER, V283, P452; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; Tepe NM, 1999, FEBS LETT, V458, P236, DOI 10.1016/S0014-5793(99)01147-3; Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838; Vittone L, 1998, J BIOL CHEM, V273, P9804, DOI 10.1074/jbc.273.16.9804; Xiang Y, 2003, SCIENCE, V300, P1530, DOI 10.1126/science.1079206; XIAO RP, 1993, CIRC RES, V73, P286, DOI 10.1161/01.RES.73.2.286; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982; Zhang J, 2001, P NATL ACAD SCI USA, V98, P14997, DOI 10.1073/pnas.211566798	41	170	172	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47997	48003		10.1074/jbc.M308362200	http://dx.doi.org/10.1074/jbc.M308362200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12972422	hybrid			2022-12-25	WOS:000186731400078
J	Fischer, E; Sauer, U				Fischer, E; Sauer, U			A novel metabolic cycle catalyzes glucose oxidation and anaplerosis in hungry Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL CARBON METABOLISM; ISOCITRATE DEHYDROGENASE; BACILLUS-SUBTILIS/; ENTERIC BACTERIA; FLUX ANALYSIS; ACID CYCLE; RESPONSES; KNOCKOUT; PATHWAYS; PROTEIN	Complete oxidation of carbohydrates to CO2 is considered to be the exclusive property of the ubiquitous tricarboxylic acid cycle, the central process in cellular energy metabolism of aerobic organisms. Based on metabolism- wide in vivo quantification of intracellular carbon fluxes, we describe here complete oxidation of carbohydrates via the novel P- enolpyruvate ( PEP)glyoxylate cycle, in which two PEP molecules are oxidized by means of acetyl coenzyme A, citrate, glyoxylate, and oxaloacetate to CO2, and one PEP is regenerated. Key reactions are the constituents of the glyoxylate shunt and PEP carboxykinase, whose conjoint operation in this bi- functional catabolic and anabolic cycle is in sharp contrast to their generally recognized functions in anaplerosis and gluconeogenesis, respectively. Parallel operation of the PEP- glyoxylate cycle and the tricarboxylic acid cycle was identified in the bacterium Escherichia coli under conditions of glucose hunger in a slow- growing continuous culture. Because the PEP-glyoxylate cycle was also active in glucose excess batch cultures of an NADPH- overproducing phosphoglucose isomerase mutant, one function of this new central pathway may be the decoupling of catabolism from NADPH formation that would otherwise occur in the tricarboxylic acid cycle.	ETH, Inst Biotechnol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Sauer, U (corresponding author), ETH, Inst Biotechnol, CH-8093 Zurich, Switzerland.	sauer@biotech.biol.ethz.ch	Sauer, Uwe/Y-3556-2019; Fischer, Eliane/M-2590-2013	Fischer, Eliane/0000-0002-3399-3737				[Anonymous], 1996, ESCHERICHIA COLI SAL, P1325; Canonaco F, 2001, FEMS MICROBIOL LETT, V204, P247, DOI 10.1111/j.1574-6968.2001.tb10892.x; Canovas L.J., 1969, METHODS ENZYMOLOGY, V13, P288; Chassagnole C, 2002, BIOTECHNOL BIOENG, V79, P53, DOI 10.1002/bit.10288; Cozzone AJ, 1998, ANNU REV MICROBIOL, V52, P127, DOI 10.1146/annurev.micro.52.1.127; Dauner M, 2001, J BACTERIOL, V183, P7308, DOI 10.1128/JB.183.24.7308-7317.2001; Dauner M, 2001, BIOTECHNOL BIOENG, V76, P144, DOI 10.1002/bit.1154; Dauner M, 2001, BIOTECHNOL BIOENG, V76, P132, DOI 10.1002/bit.1153; DIXON GH, 1959, BIOCHEM J, V73, pP3; Emmerling M, 2002, J BACTERIOL, V184, P152, DOI 10.1128/JB.184.1.152-164.2002; Ferenci T, 2001, ENVIRON MICROBIOL, V3, P605, DOI 10.1046/j.1462-2920.2001.00238.x; Fischer E, 2003, EUR J BIOCHEM, V270, P880, DOI 10.1046/j.1432-1033.2003.03448.x; Gottschalk G., 1986, BACTERIAL METABOLISM; Helling RB, 2002, J BACTERIOL, V184, P1041, DOI 10.1128/jb.184.4.1041-1045.2002; HOLMS WH, 1971, J GEN MICROBIOL, V65, P57, DOI 10.1099/00221287-65-1-57; Jiao Z, 2003, FEMS MICROBIOL LETT, V220, P295, DOI 10.1016/S0378-1097(03)00133-2; Konopka A, 2000, CURR OPIN MICROBIOL, V3, P244, DOI 10.1016/S1369-5274(00)00083-7; KORNBERG HL, 1960, NATURE, V185, P153, DOI 10.1038/185153a0; LAPORTE DC, 1984, J BIOL CHEM, V259, P4068; LEE WNP, 1993, J BIOL CHEM, V268, P25522; Marcotte EM, 2001, NAT BIOTECHNOL, V19, P626, DOI 10.1038/90222; MATIN A, 1982, J BACTERIOL, V149, P801, DOI 10.1128/JB.149.3.801-807.1982; NEIJSSEL OM, 1994, MOL MICROBIOL, V13, P179, DOI 10.1111/j.1365-2958.1994.tb00413.x; Noronha SB, 2000, BIOTECHNOL BIOENG, V68, P316, DOI 10.1002/(SICI)1097-0290(20000505)68:3<316::AID-BIT10>3.0.CO;2-2; NotleyMcRobb L, 1997, MICROBIOL-SGM, V143, P1909, DOI 10.1099/00221287-143-6-1909; Papin JA, 2003, TRENDS BIOCHEM SCI, V28, P250, DOI 10.1016/S0968-0004(03)00064-1; Petersen S, 2000, J BIOL CHEM, V275, P35932, DOI 10.1074/jbc.M908728199; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; RAMSEIER TM, 1995, MOL MICROBIOL, V16, P1157, DOI 10.1111/j.1365-2958.1995.tb02339.x; Saier MH, 1996, J BACTERIOL, V178, P3411, DOI 10.1128/jb.178.12.3411-3417.1996; Sauer U, 1999, J BACTERIOL, V181, P6679, DOI 10.1128/JB.181.21.6679-6688.1999; Sauer U, 1997, NAT BIOTECHNOL, V15, P448, DOI 10.1038/nbt0597-448; Stelling J, 2002, NATURE, V420, P190, DOI 10.1038/nature01166; Szyperski T, 1996, TRENDS BIOTECHNOL, V14, P453, DOI 10.1016/S0167-7799(96)10056-1; SZYPERSKI T, 1995, EUR J BIOCHEM, V232, P433, DOI 10.1111/j.1432-1033.1995.433zz.x; WALSH K, 1985, J BIOL CHEM, V260, P8430; Wiechert W, 2001, METAB ENG, V3, P195, DOI 10.1006/mben.2001.0187; Yang C, 2003, BIOTECHNOL BIOENG, V84, P129, DOI 10.1002/bit.10692	38	144	152	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46446	46451		10.1074/jbc.M307968200	http://dx.doi.org/10.1074/jbc.M307968200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963713	hybrid			2022-12-25	WOS:000186569400029
J	Hu, XQ; Zhang, L; Stewart, RR; Weight, FF				Hu, XQ; Zhang, L; Stewart, RR; Weight, FF			Arginine 222 in the pre-transmembrane domain 1 of 5-HT3A receptors links agonist binding to channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; AFFECTS DESENSITIZATION; MAJOR DETERMINANT; STRUCTURAL BASIS; MOLECULAR-BASIS; SUBUNIT; ACTIVATION; RESIDUE; GLUTAMATE; MUTATION	Ligand- gated ion channels are integral membrane proteins that mediate fast synaptic transmission. Molecular biological techniques have been extensively used for determining the structure- function relationships of ligand- gated ion channels. However, the transduction mechanisms that link agonist binding to channel gating remain poorly understood. Arginine 222 ( Arg- 222), located at the distal end of the extracellular N- terminal domain immediately preceding the first transmembrane domain ( TM1), is conserved in all 5- HT3A receptors and alpha7- nicotinic acetylcholine receptors that have been cloned. To elucidate the possible role of Arg- 222 in the function of 5- HT3A receptors, we mutated the arginine residue to alanine ( Ala) and expressed both the wildtype and the mutant receptor in human embryonic kidney 293 cells. Functional studies of expressed wild- type and mutant receptors revealed that the R222A mutation increased the apparent potency of the full agonist, serotonin ( 5- HT), and the partial agonist, 2- Me- 5- HT, 5- and 12- fold, respectively. In addition, the mutation increased the efficacy of 2- Me- 5- HT and converted it from a partial agonist to a full agonist. Furthermore, this mutation also converted the 5- HT3 receptor antagonist/ very weak partial agonist, apomorphine, to a potent agonist. Kinetic analysis revealed that the R222A mutation increased the rate of receptor activation and desensitization but did not affect rate of deactivation. The results suggest that the pre- TM1 amino acid residue Arg- 222 may be involved in the transduction mechanism linking agonist binding to channel gating in 5- HT3A receptors.	NIAAA, Mol & Cellular Neurobiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Hu, XQ (corresponding author), NIAAA, Mol & Cellular Neurobiol Lab, NIH, Pk Bldg,Rm 150, Bethesda, MD 20892 USA.	xhu@mail.nih.gov		Zhang, Lubo/0000-0002-9386-8938	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000479] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Akk G, 1996, J PHYSIOL-LONDON, V496, P185, DOI 10.1113/jphysiol.1996.sp021676; Auerbach A, 1998, J GEN PHYSIOL, V112, P181, DOI 10.1085/jgp.112.2.181; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; Boess FG, 1997, NEUROPHARMACOLOGY, V36, P637, DOI 10.1016/S0028-3908(97)00044-0; CamposCaro A, 1996, P NATL ACAD SCI USA, V93, P6118, DOI 10.1073/pnas.93.12.6118; CELENTANO JJ, 1994, BIOPHYS J, V66, P1039, DOI 10.1016/S0006-3495(94)80885-9; Chang YC, 1999, BIOPHYS J, V77, P2542, DOI 10.1016/S0006-3495(99)77089-X; CHEN J, 1995, BIOPHYS J, V69, P849, DOI 10.1016/S0006-3495(95)79959-3; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Dang H, 2000, MOL PHARMACOL, V57, P1114; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; Grosman C, 2000, J GEN PHYSIOL, V116, P327, DOI 10.1085/jgp.116.3.327; Gunthorpe MJ, 2000, J PHYSIOL-LONDON, V522, P187, DOI 10.1111/j.1469-7793.2000.00187.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HUSSY N, 1994, J PHYSIOL-LONDON, V481, P311, DOI 10.1113/jphysiol.1994.sp020441; Jackson M B, 1999, Adv Neurol, V79, P511; JACKSON MB, 1995, ANNU REV PHYSIOL, V57, P447; Jones MV, 1996, TRENDS NEUROSCI, V19, P96, DOI 10.1016/S0166-2236(96)80037-3; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Krupp JJ, 1998, NEURON, V20, P317, DOI 10.1016/S0896-6273(00)80459-6; LESTER RAJ, 1993, J NEUROSCI, V13, P1088; LESTER RAJ, 1992, J NEUROSCI, V12, P635; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Morales M, 2002, J NEUROSCI, V22, P6732; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; Panicker S, 2002, J NEUROSCI, V22, P1629, DOI 10.1523/JNEUROSCI.22-05-01629.2002; RAJENDRA S, 1995, NEURON, V14, P169, DOI 10.1016/0896-6273(95)90251-1; Reeves DC, 2002, MOL MEMBR BIOL, V19, P11, DOI 10.1080/09687680110110048; Spier AD, 2000, J BIOL CHEM, V275, P5620, DOI 10.1074/jbc.275.8.5620; Steward LJ, 2000, MOL PHARMACOL, V57, P1249; Taverna F, 2000, J BIOL CHEM, V275, P8475, DOI 10.1074/jbc.275.12.8475; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; Unwin N, 2000, PHILOS T R SOC B, V355, P1813, DOI 10.1098/rstb.2000.0737; van Hooft JA, 1998, NEUROPHARMACOLOGY, V37, P259, DOI 10.1016/S0028-3908(98)00044-6; Wang HL, 1999, NAT NEUROSCI, V2, P226, DOI 10.1038/6326; Williams K, 1996, MOL PHARMACOL, V50, P701; YAKEL JL, 1993, P NATL ACAD SCI USA, V90, P5030, DOI 10.1073/pnas.90.11.5030; Zhang L, 2002, J BIOL CHEM, V277, P46256, DOI 10.1074/jbc.M207683200	41	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46583	46589		10.1074/jbc.M308974200	http://dx.doi.org/10.1074/jbc.M308974200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12970351	hybrid			2022-12-25	WOS:000186569400044
J	Yamaguchi, M; Stout, CD				Yamaguchi, M; Stout, CD			Essential glycine in the proton channel of Escherichia coli transhydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; CYTOCHROME-C-OXIDASE; TRANSLOCATING TRANSHYDROGENASE; HYDRIDE TRANSFER; MEMBRANE DOMAIN; NADP(H)-BINDING COMPONENT; TRANSMEMBRANE HELICES; ENERGY TRANSDUCTION; STRUCTURAL-CHANGES; CRYSTAL-STRUCTURES	The nicotinamide nucleotide transhydrogenases of mitochondria and bacteria are proton pumps that couple hydride ion transfer between NAD(H) and NADP(H) bound, respectively, to extramembranous domains I and III, to proton translocation by the membrane-intercalated domain II. Previous experiments have established the involvement of three conserved domain II residues in the proton pumping function of the enzyme: His(91), Ser(139), and Asn(222), located on helices 9, 10, and 13, respectively. Eight highly conserved domain II glycines in helices 9, 10, 13, and 14 were mutated to alanine, and the mutant enzymes were assayed for hydride transfer between domains I and III and for proton translocation by domain II. One of the glycines on helix 14, Gly(252), was further mutated to Cys, Ser, Thr, and Val, expression levels of the mutant enzymes were evaluated, and each was purified and assayed. The results show that Gly(252) is essential for function and support a model for the proton channel composed of helices 9, 10, 13, and 14. Gly(252) would allow spatial proximity of His(91), Ser(139), and Asn(222) for proton conductance within the channel. Gly(252) mutants are distinguished by high levels of cyclic transhydrogenation activity in the absence of added NADP(H) and by complete loss of proton pumping activity. The purified G252A mutant has <1% proton translocation and reverse transhydrogenation activity, retains 0.9 mol of NADP(H) per domain III, and has 96% intrinsic cyclic transhydrogenation activity, which does not exceed 100% upon the addition of NADP(H). These properties imply that Gly(252) mutants exhibit a native-like domain II conformation while blocking proton translocation and coupled exchange of NADP(H) in domain III.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Stout, CD (corresponding author), Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.				NIGMS NIH HHS [GM61545] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061545] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2001, BBA-PROTEIN STRUCT M, V1544, P1, DOI 10.1016/S0167-4838(00)00241-7; Althage M, 2001, BIOCHEMISTRY-US, V40, P9968, DOI 10.1021/bi0103157; Bizouarn T, 2000, BBA-BIOENERGETICS, V1457, P211, DOI 10.1016/S0005-2728(00)00103-1; Bizouarn T, 2002, BBA-BIOENERGETICS, V1555, P122, DOI 10.1016/S0005-2728(02)00266-9; Bizouarn T, 2000, BBA-BIOENERGETICS, V1459, P284, DOI 10.1016/S0005-2728(00)00163-8; Bragg PD, 2000, ARCH BIOCHEM BIOPHYS, V380, P141, DOI 10.1006/abbi.2000.1923; Bragg PD, 2000, BIOCHEM BIOPH RES CO, V273, P955, DOI 10.1006/bbrc.2000.3037; Bragg PD, 1999, ARCH BIOCHEM BIOPHYS, V363, P182, DOI 10.1006/abbi.1998.1062; Bragg PD, 2001, ARCH BIOCHEM BIOPHYS, V388, P299, DOI 10.1006/abbi.2001.2298; Buckley PA, 2000, STRUCTURE, V8, P809, DOI 10.1016/S0969-2126(00)00171-4; CLARKE DM, 1985, EUR J BIOCHEM, V149, P517, DOI 10.1111/j.1432-1033.1985.tb08955.x; Cotton NPJ, 2001, STRUCTURE, V9, P165, DOI 10.1016/S0969-2126(01)00571-8; FISHER R. R., 1982, PYRIDINE NUCLEOTIDE, P279; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; GLAVAS NA, 1995, BBA-BIOENERGETICS, V1231, P297, DOI 10.1016/0005-2728(95)00089-2; GLAVAS NA, 1995, BIOCHEMISTRY-US, V34, P7694, DOI 10.1021/bi00023a016; Hatefi Y, 1996, FASEB J, V10, P444, DOI 10.1096/fasebj.10.4.8647343; HATEFI Y, 1992, MOL MECHANISMS BIOEN, P265; Hou C, 2001, BIOCHEM BIOPH RES CO, V280, P466, DOI 10.1006/bbrc.2000.4142; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; Jackson JB, 1999, FEBS LETT, V464, P1, DOI 10.1016/S0014-5793(99)01644-0; Jackson JB, 2002, BIOCHEMISTRY-US, V41, P4173, DOI 10.1021/bi012078d; Karlsson J, 2003, BIOCHEMISTRY-US, V42, P6575, DOI 10.1021/bi034172v; Klingenberg M., 1974, METHOD ENZYMAT AN, V4, P2045, DOI [10. 1016/B978-0-12-091304-6. 50060-4, DOI 10.1016/B978-0-12-091304-6.50060-4]; Kuhlbrandt W, 2002, SCIENCE, V297, P1692, DOI 10.1126/science.1072574; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanyi JK, 1998, J STRUCT BIOL, V124, P164, DOI 10.1006/jsbi.1998.4044; LEVER TM, 1991, EUR J BIOCHEM, V197, P247, DOI 10.1111/j.1432-1033.1991.tb15905.x; Luecke H, 1999, SCIENCE, V286, P255, DOI 10.1126/science.286.5438.255; Maeda A, 2002, BIOCHEMISTRY-US, V41, P3803, DOI 10.1021/bi011923p; Meuller J, 1999, J BIOL CHEM, V274, P19072, DOI 10.1074/jbc.274.27.19072; Nishimura K, 2002, BIOCHEMISTRY-US, V41, P13170, DOI 10.1021/bi0262799; OLAUSSON T, 1995, BBA-BIOENERGETICS, V1231, P1, DOI 10.1016/0005-2728(95)00058-Q; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P4475, DOI 10.1021/bi00314a037; Pinheiro TJT, 2001, J BIOL CHEM, V276, P44757, DOI 10.1074/jbc.M109227200; Prasad GS, 1999, NAT STRUCT BIOL, V6, P1126; Prasad GS, 2002, BIOCHEMISTRY-US, V41, P12745, DOI 10.1021/bi020251f; Quirk PG, 1999, FEBS LETT, V446, P127, DOI 10.1016/S0014-5793(99)00198-2; Rodrigues DJ, 2002, BBA-BIOENERGETICS, V1555, P8, DOI 10.1016/S0005-2728(02)00247-5; Royant A, 2000, NATURE, V406, P645, DOI 10.1038/35020599; Sass HJ, 2000, NATURE, V406, P649, DOI 10.1038/35020607; Svensson-Ek M, 2002, J MOL BIOL, V321, P329, DOI 10.1016/S0022-2836(02)00619-8; Tajkhorshid E, 2002, SCIENCE, V296, P525, DOI 10.1126/science.1067778; TONG RCW, 1991, BIOCHIM BIOPHYS ACTA, V1080, P19, DOI 10.1016/0167-4838(91)90106-A; Venning JD, 2000, J BIOL CHEM, V275, P19490, DOI 10.1074/jbc.M000577200; Venning JD, 2001, J BIOL CHEM, V276, P30678, DOI 10.1074/jbc.M104429200; White SA, 2000, STRUCT FOLD DES, V8, P1, DOI 10.1016/S0969-2126(00)00075-7; Wikstrom M, 2000, BBA-BIOENERGETICS, V1458, P188, DOI 10.1016/S0005-2728(00)00068-2; YAMAGUCHI M, 1993, J BIOL CHEM, V268, P17871; YAMAGUCHI M, 1991, J BIOL CHEM, V266, P5728; YAMAGUCHI M, 1990, BIOCHEMISTRY-US, V29, P4136, DOI 10.1021/bi00469a017; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P28165; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P16653, DOI 10.1074/jbc.270.28.16653; Yamaguchi M, 1997, BBA-BIOENERGETICS, V1318, P225, DOI 10.1016/S0005-2728(96)00139-9; Yamaguchi M, 2002, J BIOL CHEM, V277, P33670, DOI 10.1074/jbc.M204170200; Yoshikawa S, 2000, J INORG BIOCHEM, V82, P1, DOI 10.1016/S0162-0134(00)00137-9; Zaslavsky D, 2000, BBA-BIOENERGETICS, V1458, P164, DOI 10.1016/S0005-2728(00)00066-9	58	14	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45333	45339		10.1074/jbc.M308236200	http://dx.doi.org/10.1074/jbc.M308236200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952962	hybrid			2022-12-25	WOS:000186452300036
J	Saxena, S; Jonsson, ZO; Dutta, A				Saxena, S; Jonsson, ZO; Dutta, A			Small RNAs with imperfect match to endogenous mRNA repress translation - Implications for off-target activity of small inhibitory RNA in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; DIRECTED INHIBITION; FUNCTIONAL-ANATOMY; GENE; EXPRESSION; INTERFERENCE; MICRORNA; SIRNAS; REPLICATION; DROSOPHILA	A 21-base pair RNA duplex that perfectly matches an endogenous target mRNA selectively degrades the mRNA and suppresses gene expression in mammalian tissue culture cells. A single base mismatch with the target is believed to protect the mRNA from degradation, making this type of interference highly specific to the targeted gene. A short RNA with mismatches to a target sequence present in multiple copies in the 3'-untranslated region of an exogenously expressed gene can, however, silence it by translational repression. Here we report that a mismatched RNA, targeted to a single site in the coding sequence of an endogenous gene, can efficiently silence gene expression by repressing translation. The antisense strand of such a mismatched RNA requires a 5'-phosphate but not a 3'-hydroxyl group. G . U wobble base pairing is tolerated as a match for both RNA degradation and translation repression. Together, these findings suggest that a small inhibitory RNA duplex can suppress expression of off-target cellular proteins by RNA degradation or translation repression. Proper design of experimental small inhibitory RNAs or a search for targets of endogenous microRNAs must therefore take into account that these short RNAs can affect expression of cellular genes with as many as 3 - 4 base mismatches and additional G . U mismatches.	Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of Virginia; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dutta, A (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, 1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Jónsson, Zophonías Oddur/AAO-1354-2020; Jónsson, Zophonías/E-1960-2015; Dutta, Anindya/P-3203-2016	Jónsson, Zophonías Oddur/0000-0001-5798-9647; Dutta, Anindya/0000-0002-4319-0073	NATIONAL CANCER INSTITUTE [R01CA089406] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA89406] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amarzguioui M, 2003, NUCLEIC ACIDS RES, V31, P589, DOI 10.1093/nar/gkg147; Angell SM, 1997, EMBO J, V16, P3675, DOI 10.1093/emboj/16.12.3675; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Boutla A, 2001, CURR BIOL, V11, P1776, DOI 10.1016/S0960-9822(01)00541-3; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Chi JT, 2003, P NATL ACAD SCI USA, V100, P6343, DOI 10.1073/pnas.1037853100; Chiu YL, 2002, MOL CELL, V10, P549, DOI 10.1016/S1097-2765(02)00652-4; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GAUTHERET D, 1995, RNA, V1, P807; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hamasaki K, 2003, FEBS LETT, V543, P51, DOI 10.1016/S0014-5793(03)00400-9; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Holen T, 2002, NUCLEIC ACIDS RES, V30, P1757, DOI 10.1093/nar/30.8.1757; Hu WY, 2002, CURR BIOL, V12, P1301, DOI 10.1016/S0960-9822(02)00975-2; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896; Jorgensen RA, 1996, PLANT MOL BIOL, V31, P957, DOI 10.1007/BF00040715; Kawasaki H, 2003, NATURE, V423, P838, DOI 10.1038/nature01730; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Parrish S, 2000, MOL CELL, V6, P1077, DOI 10.1016/S1097-2765(00)00106-4; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Que QD, 1998, DEV GENET, V22, P100, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;100::AID-DVG10&gt;3.0.CO;2-D; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Schwarz DS, 2002, MOL CELL, V10, P537, DOI 10.1016/S1097-2765(02)00651-2; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yokota T, 2003, EMBO REP, V4, P602, DOI 10.1038/sj.embor.embor840; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zeng Y, 2003, RNA, V9, P112, DOI 10.1261/rna.2780503; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5	43	324	375	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44312	44319		10.1074/jbc.M307089200	http://dx.doi.org/10.1074/jbc.M307089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12952966	hybrid			2022-12-25	WOS:000186306700053
J	Tao, TY; Liu, FL; Klomp, L; Wijmenga, C; Gitlin, JD				Tao, TY; Liu, FL; Klomp, L; Wijmenga, C; Gitlin, JD			The copper toxicosis gene product Murr1 directly interacts with the Wilson disease protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DI-LEUCINE; MENKES PROTEIN; BIOCHEMICAL-CHARACTERIZATION; CHAPERONE; ATOX1; LOCALIZATION; IDENTIFICATION; HOMEOSTASIS; TRAFFICKING; MECHANISM	Copper toxicosis in Bedlington terriers is an autosomal recessive disorder characterized by excessive hepatic copper accumulation in association with a marked decrease in biliary copper excretion. Recent genetic data have revealed that MURR1, a single copy gene on dog chromosome 10q26, is mutated in this disorder. This gene encodes a 190-amino acid open reading frame of unknown function that is highly conserved in vertebrate species. The Wilson disease protein is a copper transporting ATPase shown to play a critical role in biliary copper excretion. Here we demonstrate that the Wilson disease protein directly interacts with the human homologue of Murr1 in vitro and in vivo and that this interaction is mediated via the copper binding, amino terminus of this ATPase. Importantly, this interaction is specific for this copper transporter, a finding consistent with the observation that impaired copper homeostasis in affected terriers is confined to the liver. Our findings reveal involvement of Murr1 in the defined pathway of hepatic biliary copper excretion, suggest a potential mechanism for Murr1 function in this process, and provide biochemical evidence in support of the proposed role of the MURR1 gene in hepatic copper toxicosis.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Univ Med Ctr Utrecht, Dept Med Genet, NL-3583 EA Utrecht, Netherlands	Washington University (WUSTL); Utrecht University; Utrecht University Medical Center	Gitlin, JD (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, McDonnell Pediat Res Bldg,660 S Euclid Ave, St Louis, MO 63110 USA.		Wijmenga, Cisca/AAE-7719-2019; Wijmenga, Cisca/D-2173-2009	Wijmenga, Cisca/0000-0002-5635-1614; 				Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Hamza I, 2003, P NATL ACAD SCI USA, V100, P1215, DOI 10.1073/pnas.0336230100; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; Hamza I, 2001, P NATL ACAD SCI USA, V98, P6848, DOI 10.1073/pnas.111058498; Hellman NE, 2002, J BIOL CHEM, V277, P46632, DOI 10.1074/jbc.M206246200; HULTGREN BD, 1986, AM J VET RES, V47, P365; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Huster D, 2003, GASTROENTEROLOGY, V124, P335, DOI 10.1053/gast.2003.50066; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; Li ZB, 2002, BIOCHEM BIOPH RES CO, V294, P700, DOI 10.1016/S0006-291X(02)00534-X; Loudianos G, 2000, SEMIN LIVER DIS, V20, P353, DOI 10.1055/s-2000-9389; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; Muller T, 1999, Eur J Med Res, V4, P293; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Petris MJ, 1999, HUM MOL GENET, V8, P2107, DOI 10.1093/hmg/8.11.2107; Petris MJ, 1998, HUM MOL GENET, V7, P2063, DOI 10.1093/hmg/7.13.2063; Roelofsen H, 2000, GASTROENTEROLOGY, V119, P782, DOI 10.1053/gast.2000.17834; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG639, DOI 10.1152/ajpgi.1999.276.3.G639; Starcevic M, 2002, SEMIN CELL DEV BIOL, V13, P271, DOI 10.1016/S1084952102000563; Strausak D, 2003, J BIOL CHEM, V278, P20821, DOI 10.1074/jbc.M212437200; Tao TY, 2003, HEPATOLOGY, V37, P1241, DOI 10.1053/jhep.2003.50281; van de Sluis B, 2002, HUM MOL GENET, V11, P165, DOI 10.1093/hmg/11.2.165; Voskoboinik I, 2002, ADV PROTEIN CHEM, V60, P123; Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030	25	140	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41593	41596		10.1074/jbc.C300391200	http://dx.doi.org/10.1074/jbc.C300391200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12968035	hybrid			2022-12-25	WOS:000185989500006
J	Boya, P; Morales, MC; Gonzalez-Polo, RA; Andreau, K; Gourdier, I; Perfettini, JL; Larochette, N; Deniaud, A; Baran-Marszak, F; Fagard, R; Feuillard, J; Asumendi, A; Raphael, M; Pau, B; Brenner, C; Kroemer, G				Boya, P; Morales, MC; Gonzalez-Polo, RA; Andreau, K; Gourdier, I; Perfettini, JL; Larochette, N; Deniaud, A; Baran-Marszak, F; Fagard, R; Feuillard, J; Asumendi, A; Raphael, M; Pau, B; Brenner, C; Kroemer, G			The chemopreventive agent N-(4-hydroxyphenyl) retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family	ONCOGENE			English	Article						4-hydroxyphenylretinamide; Bax; Bcl-2; cell death; chemoprevention; mitochondria	PERMEABILITY TRANSITION PORE; CERAMIDE-INDUCED APOPTOSIS; CELL-DEATH; ENDOPLASMIC-RETICULUM; CANCER-CELLS; CYTOCHROME-C; MEMBRANE PERMEABILIZATION; LOCALIZED INHIBITOR; GD3 GANGLIOSIDE; KAPPA-B	N-(4-hydroxyphenyl) retinamide (4-HPR, fenretinide) is a potent chemopreventive agent whose effect has been suggested to involve apoptosis induction. 4-HPR induces a loss of the mitochondrial transmembrane potential and the mitochondrial release of cytochrome c before caspase activation. Inhibition of mitochondrial membrane permeabilization (MMP) by transfection with Bcl-2 or the Cytomegalovirus UL37 gene product vMIA prevented caspase activation and cell death. In contrast to other retinoid derivatives, 4-HPR has no direct MMP-inducing effects when added to isolated mitochondria or when added to proteoliposomes containing the MMP-regulatory permeability transition pore complex ( PTPC). Moreover, although reactive oxygen species (ROS) overproduction appears to be instrumental for 4-HPR-induced MMP and apoptosis, inhibition of the NF-kappaB or p53-mediated signal transduction pathways failed to modulate 4-HPR-induced apoptosis. 4-HPR was found to cause an antioxidant-inhibitable conformational change of both Bax and Bak, leading to the exposure of their N- termini and to the mitochondrial relocalization of Bax. Cells with a Bax(-/-) Bak(-/-) genotype were resistant against the 4-HPR-induced MMP, overproduction of ROS and cell death. Altogether, these data indicate that 4-HPR induce s MMP through an ROS-mediated pathway that involves the obligatory contribution of the proapopotic Bcl-2 family members Bax and/or Bak.	Inst Gustave Roussy, CNRS, UMR8125, Villejuif, France; Univ Versailles, CNRS, FRE 2445, F-78000 Versailles, France; CHU Kremlin Bicetre, Serv Hematol Biol, U473, Le Kremlin Bicetre, France; Univ Paris 13, APHP, Hop Avicenne, Biochim Lab, Bobigny, France; Univ Paris 13, EA 3406, Bobigny, France; CHU Dupuytren, Hematol Lab, Limoges, France; Univ Basque Country, Sch Med & Dent, Dept Cell Biol & Histol, Leioa 48940, Bizkaia, Spain; CNRS, UMR 5094, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Avicenne - APHP; Universite Paris 13; Universite Paris 13; CHU Limoges; University of Basque Country; Centre National de la Recherche Scientifique (CNRS)	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR1599, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	brenner, catherine/AAE-8632-2020; PERFETTINI, Jean-Luc/N-4699-2017; González-Polo, Rosa A./I-6076-2016; Asumendi, Aintzane/ABF-7001-2021; KROEMER, Guido/B-4263-2013; Boya, Patricia/P-8345-2019; Morales, Maria Celia/AAB-5085-2020; Kroemer, Guido/AAY-9859-2020; LAROCHETTE, Nathanael/R-4298-2017; Boya, Patricia/K-2911-2014; Deniaud, Aurelien/L-5093-2019; Feuillard, Jean/O-8587-2016	PERFETTINI, Jean-Luc/0000-0002-2427-2604; González-Polo, Rosa A./0000-0002-0163-2953; KROEMER, Guido/0000-0002-9334-4405; Boya, Patricia/0000-0003-3045-951X; Morales, Maria Celia/0000-0001-5423-3684; LAROCHETTE, Nathanael/0000-0002-7936-678X; Boya, Patricia/0000-0003-3045-951X; Feuillard, Jean/0000-0001-6223-2454; Asumendi, Aintzane/0000-0002-2156-2323; Andreau, Karine/0000-0002-9773-0733				Appierto V, 2001, BRIT J CANCER, V84, P1528, DOI 10.1054/bjoc.2001.1826; Asumendi A, 2002, BRIT J CANCER, V86, P1951, DOI 10.1038/sj.bjc.6600356; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Brenner C, 2000, METHOD ENZYMOL, V322, P243; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; De Palo G, 2002, GYNECOL ONCOL, V86, P24, DOI 10.1006/gyno.2002.6663; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Erdreich-Epstein A, 2002, J BIOL CHEM, V277, P49531, DOI 10.1074/jbc.M209962200; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Fontana JA, 2002, LEUKEMIA, V16, P463, DOI 10.1038/sj.leu.2402414; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Gourdier I, 2002, FEBS LETT, V529, P232, DOI 10.1016/S0014-5793(02)03347-1; Green A, 1999, CARCINOGENESIS, V20, P1535, DOI 10.1093/carcin/20.8.1535; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Hail N, 2001, J BIOL CHEM, V276, P45614, DOI 10.1074/jbc.M106559200; Hail N, 2000, CANCER EPIDEM BIOMAR, V9, P1293; Hayajneh WA, 2001, VIROLOGY, V279, P233, DOI 10.1006/viro.2000.0726; Holmes WF, 2002, J BIOL CHEM, V277, P45408, DOI 10.1074/jbc.M204600200; Hursting SD, 2002, MOL CARCINOGEN, V33, P16, DOI 10.1002/mc.10020; Hursting SD, 2001, J NUTR, V131, p3092S, DOI 10.1093/jn/131.11.3092S; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Levi MS, 2001, CURR MED CHEM, V8, P1349, DOI 10.2174/0929867013372229; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lim SJ, 2002, INT J CANCER, V101, P243, DOI 10.1002/ijc.10596; Lovat PE, 2002, CANCER RES, V62, P5158; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; Marchetti P, 1999, CANCER RES, V59, P6257; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McCormick AL, 2003, J VIROL, V77, P631, DOI 10.1128/JVI.77.1.631-641.2003; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Notario B, 2003, MOL PHARMACOL, V63, P224, DOI 10.1124/mol.63.1.224; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Prinetti A, 2003, J BIOL CHEM, V278, P5574, DOI 10.1074/jbc.M207269200; Raffaghello L, 2003, INT J CANCER, V104, P559, DOI 10.1002/ijc.10991; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shaker MR, 2001, CLIN EXP METASTAS, V18, P429, DOI 10.1023/A:1010905309570; Shimada K, 2002, MOL CARCINOGEN, V35, P127, DOI 10.1002/mc.10084; Singletary SE, 2002, CLIN CANCER RES, V8, P2835; Susin SA, 2000, METHOD ENZYMOL, V322, P205; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Thomenius MJ, 2003, J BIOL CHEM, V278, P6243, DOI 10.1074/jbc.M208878200; Wang HT, 2001, CANCER RES, V61, P5102; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; You KR, 2002, J BIOL CHEM, V277, P3870, DOI 10.1074/jbc.M109284200; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001; Zou CP, 2002, CANCER LETT, V180, P131, DOI 10.1016/S0304-3835(01)00864-3	65	80	81	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6220	6230		10.1038/sj.onc.1206827	http://dx.doi.org/10.1038/sj.onc.1206827			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679861				2022-12-25	WOS:000185506200012
J	Usami, N; Sekido, Y; Maeda, O; Yamamoto, K; Minna, JD; Hasegawa, Y; Yoshioka, H; Imaizumi, M; Ueda, Y; Takahashi, M; Shimokata, K				Usami, N; Sekido, Y; Maeda, O; Yamamoto, K; Minna, JD; Hasegawa, Y; Yoshioka, H; Imaizumi, M; Ueda, Y; Takahashi, M; Shimokata, K			beta-catenin inhibits cell growth of a malignant mesothelioma cell line, NCI-H28, with a 3p21.3 homozygous deletion	ONCOGENE			English	Article						beta-catenin; malignant mesothelioma; chromosome 3; homozygous deletion	HUMAN LUNG-CANCER; HEPATOCELLULAR CARCINOMAS; EPIGENETIC INACTIVATION; ALLELIC LOSS; GENE; ACTIVATION; MUTATIONS; SITES; APOPTOSIS; MULTIPLE	We have found that a malignant mesothelioma cell line, NCI-H28, had a chromosome 3p21.3 homozygous deletion containing the beta-catenin gene (CTNNB1), which suggested that the deletion of beta-catenin might have a growth advantage in the development of this tumor. To determine whether beta-catenin has a growth-inhibitory activity, we transfected wild-type beta-catenin, Ser37Cys mutant beta-catenin as an activated type, and C-terminus deletion mutant beta-catenin that lacks the transcription activity, into the NCI-H28 cells. A non-small cell lung cancer cell line, NCI-H1299, which expressed endogenous beta-catenin, was also studied. We tested the localization of exogenous beta-catenin in the NCI-H28 cells with immunofluorescence, and found that the wild-type beta-catenin and the C-terminus deletion mutant were more strongly expressed in the plasma membrane and cytoplasm than in the nucleus, while the Ser37Cys mutant was more in the nucleus than in the cytoplasm. By using luciferase-reporter assay, the beta-catenin/T-cell factor 4-mediated transactivity of the Ser37Cys mutant was shown to be higher than that of the wild-type beta-catenin in both cell lines. However, the transactivity of the C-terminus deletion mutant was strongly reduced in both. Colony formation of the NCI-H28 cells was reduced by 50% after transfection with the wild-type beta-catenin, and 60% with the Ser37Cys mutant, but only 20% with the C-terminus deletion mutant compared to the vector control. Inhibition of colony formation in NCI-H28 cells was because of apoptosis, manifested by positive staining of Annexin V and TUNEL assays in transfected cells. In contrast, when transfected with the wild-type beta-catenin, no significant reduction in colony formation was seen in beta-catenin wildtype NCI-H1299 cells. In conclusion, our data indicate that inactivation of beta-catenin by a 3p21.3 homozygous deletion might be a crucial event in the development of the mesothelioma NCI-H28 cells. Thus, while beta-catenin is well known to be a positive growth-stimulating factor for many human cancers, it can also act as a potential growth suppressor in some types of human cancer cells.	Nagoya Univ, Sch Med, Dept Clin Prevent Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Thorac Surg, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Internal Med, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Pathol 2, Nagoya, Aichi 4668550, Japan; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA	Nagoya University; Nagoya University; Nagoya University; Nagoya University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sekido, Y (corresponding author), Nagoya Univ, Sch Med, Dept Clin Prevent Med, Showa Ku, Tsurumai Cho 65, Nagoya, Aichi 4668550, Japan.	ysekido@med.nagoya-u.ac.jp	Hasegawa, Yoshinori/I-1277-2012; Takahashi, Masahide/AAN-4770-2020; Sekido, Yoshitaka/P-9756-2015; Maeda, Osamu/Q-1016-2015; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; Maeda, Osamu/0000-0003-4700-6541; Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [R01CA071618, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71618, P50 CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bell DW, 1997, CANCER RES, V57, P4057; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CHEN JY, 1993, ONCOGENE, V8, P2159; Cheng JQ, 1999, GENE CHROMOSOME CANC, V24, P238, DOI 10.1002/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M; CHENG JQ, 1994, CANCER RES, V54, P5547; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; FLEJTER WL, 1989, GENE CHROMOSOME CANC, V1, P148, DOI 10.1002/gcc.2870010207; Fukuchi T, 1998, CANCER RES, V58, P3526; GIBAS Z, 1986, CANCER GENET CYTOGEN, V20, P191, DOI 10.1016/0165-4608(86)90074-9; HAGEMEIJER A, 1990, CANCER GENET CYTOGEN, V47, P1, DOI 10.1016/0165-4608(90)90258-C; Hasegawa S, 2002, P NATL ACAD SCI USA, V99, P297, DOI 10.1073/pnas.012264999; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Iwao K, 1998, CANCER RES, V58, P1021; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lee WC, 1996, CANCER RES, V56, P4297; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; LU YY, 1994, GENE CHROMOSOME CANC, V9, P76, DOI 10.1002/gcc.2870090114; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Polakis P, 2000, GENE DEV, V14, P1837; POPESCU NC, 1988, CANCER RES, V48, P142; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1999, J BIOL CHEM, V274, P14090, DOI 10.1074/jbc.274.20.14090; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sekido Y, 2002, CANCER GENET CYTOGEN, V137, P33, DOI 10.1016/S0165-4608(02)00536-8; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Shivapurkar N, 1999, CLIN CANCER RES, V5, P17; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9; TAGUCHI T, 1993, CANCER RES, V53, P4349; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TIAINEN M, 1988, CANCER GENET CYTOGEN, V33, P251, DOI 10.1016/0165-4608(88)90035-0; van Gijn ME, 2001, EXP CELL RES, V265, P46, DOI 10.1006/excr.2001.5174; Wistuba II, 2000, CANCER RES, V60, P1949; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	44	24	25	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					7922	7930		10.1038/sj.onc.1206533	http://dx.doi.org/10.1038/sj.onc.1206533			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970740				2022-12-25	WOS:000185388200007
J	Kain, KH; Gooch, S; Klemke, RL				Kain, KH; Gooch, S; Klemke, RL			Cytoplasmic c-Abl provides a molecular 'rheostat' controlling carcinoma cell survival and invasion	ONCOGENE			English	Article						c-Abl kinase; Crk; invasion; survival; metastasis	FOCAL ADHESION KINASE; PROTEIN-TYROSINE KINASE; EPIDERMAL-GROWTH-FACTOR; ADAPTER PROTEIN; DNA-DAMAGE; APOPTOTIC RESPONSE; INDUCED ACTIVATION; FACTOR RECEPTOR; F-ACTIN; IN-VIVO	Tumor cell metastasis involves the coordinated activation of migration and survival mechanisms necessary for cell invasion of foreign tissues. Here, we report that cytoplasmic c-Abl tyrosine kinase determines whether a cell invades the ECM or commits suicide. c-Abl phosphorylates the cytoskeleton-associated adaptor protein, Crk, at tyrosine 221, causing disassociation of Crk from the Crk-associated substrate (CAS) and disassembly of Crk/CAS complexes. c-Abl-induced disruption of Crk/CAS complexes inhibits cell migration and promotes apoptosis in normal cells, and is deregulated in highly invasive carcinoma cells. c-Abl-mediated disassembly of Crk/CAS complexes and induction of death occur via disruption of the cytoskeleton, which is distinct from nuclear c-Abl-induced apoptosis in response to DNA-damaging agents. Inhibition of c-Abl kinase activity or Crk binding to Abl's polyproline region prevents Crk phosphorylation and apoptosis, leading to increased cell survival and invasion of the extracellular matrix. Together, these data illustrate that c-Abl prevents aberrant motility and survival through Crk 221 phosphorylation and modulation of Crk/CAS complexes, and that deregulation of this pathway contributes to cell metastasis.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Klemke, RL (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd,SP 231, La Jolla, CA 92037 USA.	klemke@scripps.edu			NATIONAL CANCER INSTITUTE [R29CA078493, R01CA097022] Funding Source: NIH RePORTER; NCI NIH HHS [CA97022, CA78493] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; Fan PD, 2000, MOL CELL BIOL, V20, P7591, DOI 10.1128/MCB.20.20.7591-7601.2000; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Gong JG, 1999, NATURE, V399, P806; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; MATSUDA M, 1993, J BIOL CHEM, V268, P4441; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Mills JC, 1999, J CELL BIOL, V146, P703, DOI 10.1083/jcb.146.4.703; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Smith JJ, 2002, MOL CELL BIOL, V22, P1412, DOI 10.1128/MCB.22.5.1412-1423.2002; Smith JM, 2002, FRONT BIOSCI, V7, pD31; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Ting AY, 2001, P NATL ACAD SCI USA, V98, P15003, DOI 10.1073/pnas.211564598; Tosello-Trampont AC, 2001, J BIOL CHEM, V276, P13797, DOI 10.1074/jbc.M011238200; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang BL, 1996, ONCOGENE, V13, P1379; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Woodring PJ, 2001, J BIOL CHEM, V276, P27104, DOI 10.1074/jbc.M100559200; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	52	38	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6071	6080		10.1038/sj.onc.1206930	http://dx.doi.org/10.1038/sj.onc.1206930			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955086				2022-12-25	WOS:000185137800016
J	Boelaert, K; Tannahill, LA; Bulmer, JN; Kachilele, S; Chan, SY; Kim, D; Gittoes, NJL; Franklyn, JA; Kilby, MD; Mccabe, CJ				Boelaert, K; Tannahill, LA; Bulmer, JN; Kachilele, S; Chan, SY; Kim, D; Gittoes, NJL; Franklyn, JA; Kilby, MD; Mccabe, CJ			A potential role for PTTG/securin in the developing human fetal brain	FASEB JOURNAL			English	Article						embryonic expression; proliferation; NT-2	TUMOR-TRANSFORMING GENE; FIBROBLAST-GROWTH-FACTOR; NORMAL HUMAN-TISSUES; CHROMATID SEPARATION; HIPPOCAMPAL-NEURONS; PITUITARY-TUMORS; CEREBRAL-CORTEX; THYROID-HORMONE; NERVOUS-SYSTEM; C-MYC	Human securin, known also as PTTG, has established oncogenic and cell cycle regulatory functions. PTTG/securin transforms cells in vitro, inhibits sister chromatid separation, and regulates secretion of fibroblast growth factor-2. FGF-2 is a key regulator of CNS development and PTTG/securin expression has been reported in murine fetal brain. We examined the expression and function of securin and FGF-2 in the developing human fetal brain and in a fetal neuronal cell line (NT 2). Securin expression was significantly reduced in first and second trimester fetal cerebral cortex compared with adult cerebral cortex, where immunocytochemistry revealed intense securin staining in neuronal cell bodies. FGF-2 protein was concordantly lower in fetal cortex, whereas pretranslational expression of PTTG binding factor (PBF) was not significantly altered in fetal brain compared with adult. PCNA expression demonstrated that high securin levels in adult cortex were associated with absent cell proliferation. In NT-2 cells, securin stimulated FGF-2 expression, which could be abrogated by a carboxyl-terminal mutation. Low transient expression of securin resulted in a significant proliferative effect, whereas high levels of securin expression inhibited cell turnover. We propose a potential role for human PTTG/securin in modulating cell proliferation and FGF-2 expression during human neurogenesis.	Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England; Univ Birmingham, Queen Elizabeth Hosp, Div Reprod & Child Hlth, Birmingham B15 2TH, W Midlands, England; Univ Newcastle Upon Tyne, Royal Victoria Infirm, Dept Pathol, Sch Clin & Lab Sci, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	University of Birmingham; University of Birmingham; Newcastle University - UK	Mccabe, CJ (corresponding author), Univ Birmingham, Div Med Sci, Birmingham B15 2TH, W Midlands, England.	mccabcjz@bham.ac.uk	FRCPI, Mark D Kilby MB BS DSc MD FRCOG/AAW-9704-2020; Chan, Shiao/C-8347-2011	FRCPI, Mark D Kilby MB BS DSc MD FRCOG/0000-0001-9987-4223; Chan, Shiao-Yng/0000-0002-3530-3023				Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113; Chan S, 2002, DEV BRAIN RES, V138, P109, DOI 10.1016/S0165-3806(02)00459-5; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; Ciruna BG, 1997, DEVELOPMENT, V124, P2829; CORDONCARDO C, 1990, LAB INVEST, V63, P832; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; ECKENSTEIN FP, 1994, J NEUROBIOL, V25, P1467; FURTH ME, 1987, ONCOGENE, V1, P47; Ghosh MM, 1995, BIOREMED SER, V3, P15; Gittoes NJL, 1997, J CLIN ENDOCR METAB, V82, P1960, DOI 10.1210/jc.82.6.1960; Gonzalez AM, 1996, PEDIATR RES, V39, P375, DOI 10.1203/00006450-199603000-00001; Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275; Heaney AP, 2001, J CLIN ENDOCR METAB, V86, P5025, DOI 10.1210/jc.86.10.5025; HERN WM, 1984, OBSTET GYNECOL, V63, P26; HIRVONEN H, 1990, ONCOGENE, V5, P1787; INGRAHAM CA, 1989, MOL CHEM NEUROPATHOL, V10, P1, DOI 10.1007/BF02969481; Ishikawa H, 2001, J CLIN ENDOCR METAB, V86, P867, DOI 10.1210/jc.86.2.867; Kakar SS, 2001, J HISTOCHEM CYTOCHEM, V49, P1537, DOI 10.1177/002215540104901207; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; McCabe CJ, 2003, CLIN ENDOCRINOL, V58, P141, DOI 10.1046/j.1365-2265.2003.01598.x; McCabe CJ, 2002, J CLIN ENDOCR METAB, V87, P4238, DOI 10.1210/jc.2002-020309; MYERS C, 1991, AM J REPROD IMMUNOL, V25, P133, DOI 10.1111/j.1600-0897.1991.tb01081.x; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; PAVELIC K, 1991, International Journal of Developmental Biology, V35, P209; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; PETROSKI RE, 1991, DEV BIOL, V147, P1, DOI 10.1016/S0012-1606(05)80002-8; *POLK REP, 1998, REV GUID RES US FET; Qian XM, 1997, NEURON, V18, P81, DOI 10.1016/S0896-6273(01)80048-9; Ramos-Morales F, 2000, ONCOGENE, V19, P403, DOI 10.1038/sj.onc.1203320; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; SCHMUTZLER RK, 1992, HUM REPROD, V7, P25, DOI 10.1093/humrep/7.suppl_1.25; Tarabykin V, 2000, MECH DEVELOP, V92, P301, DOI 10.1016/S0925-4773(00)00243-4; VICARIOABEJON C, 1995, NEURON, V15, P105, DOI 10.1016/0896-6273(95)90068-3; Wang ZY, 2001, MOL ENDOCRINOL, V15, P1870, DOI 10.1210/me.15.11.1870; WEISE B, 1993, J NEUROSCI RES, V34, P442, DOI 10.1002/jnr.490340409; Yu R, 2000, MOL ENDOCRINOL, V14, P1137, DOI 10.1210/me.14.8.1137; Yu R, 2001, BRAIN PATHOL, V11, P328; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	44	39	40	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1631	1639		10.1096/fj.02-0948com	http://dx.doi.org/10.1096/fj.02-0948com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958169				2022-12-25	WOS:000185925100037
J	Song, LT; Mandecki, W; Goldman, E				Song, LT; Mandecki, W; Goldman, E			Expression of non-open reading frames isolated from phage display due to translation reinitiation	FASEB JOURNAL			English	Article						E. coli protein synthesis; internal initiation of translation; non-ORF expression; UGA stop codons	REPRESSOR MESSENGER-RNA; ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; PEPTIDE LIBRARY; BINDING-SITE; INITIATION; RIBOSOME; SEQUENCE; BACTERIOPHAGE-T4; ACCURACY	An unusual 38 codon sequence was previously isolated from a random peptide library by binding to growth hormone binding protein in phage display. This sequence, "H10," and several variants did not contain open reading frames, but expressed a beta-galactosidase reporter 10 - 40% as well as control in both the original reading frame from phage display and the frame - 1 to it. Inspection of the sequence suggested that expression in the - 1 frame resulted from initiation at a downstream ATG in that frame, present in H10 and its variants, subsequently confirmed by site-directed mutagenesis. Unexpectedly, mutagenesis of that out-of-frame downstream ATG also increased expression in the original non-open reading frame by two- to threefold, creating a TTG codon adjacent to an existing in-frame TTG codon, suggesting downstream translational reinitiation at a putative TTG start. We undertook an extensive site-directed mutagenesis approach and report that this hypothesis is almost certainly correct. Features required for this reinitiation include an upstream translation start and a stop that can even be a suppressed amber codon 22 nucleotides further downstream from the restart. Replacing the TTG with ATG increases expression only twofold. Reinitiation occurs in either of two reading frames in this sequence.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07101 USA; Pharmaseq Inc, Monmouth Jct, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Goldman, E (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 225 Warren St,POB 1709, Newark, NJ 07101 USA.	egoldman@umdnj.edu	Song, Liting/F-3724-2011	Song, Liting/0000-0001-9789-7616				ADHIN MR, 1990, J MOL BIOL, V213, P811, DOI 10.1016/S0022-2836(05)80265-7; Andre A, 2000, FEBS LETT, V468, P73, DOI 10.1016/S0014-5793(00)01198-4; BARRICK D, 1994, NUCLEIC ACIDS RES, V22, P1287, DOI 10.1093/nar/22.7.1287; BERKHOUT B, 1985, GENE, V37, P171, DOI 10.1016/0378-1119(85)90270-7; Carcamo J, 1998, P NATL ACAD SCI USA, V95, P11146, DOI 10.1073/pnas.95.19.11146; CURRAN JF, 1986, P NATL ACAD SCI USA, V83, P6538, DOI 10.1073/pnas.83.17.6538; CURRAN JF, 1988, J MOL BIOL, V203, P75, DOI 10.1016/0022-2836(88)90092-7; GAO WW, 1995, J MOL BIOL, V251, P210, DOI 10.1006/jmbi.1995.0428; Gesteland RF, 1996, ANNU REV BIOCHEM, V65, P741, DOI 10.1146/annurev.bi.65.070196.003521; Goldman E, 2000, FASEB J, V14, P603, DOI 10.1096/fasebj.14.3.603; Gutkina NI, 2002, BIOCHEM BIOPH RES CO, V298, P37, DOI 10.1016/S0006-291X(02)02392-6; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Jan E, 2002, J MOL BIOL, V324, P889, DOI 10.1016/S0022-2836(02)01099-9; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; MANLEY JL, 1978, J MOL BIOL, V125, P449, DOI 10.1016/0022-2836(78)90310-8; MATTESON RJ, 1991, NUCLEIC ACIDS RES, V19, P3499, DOI 10.1093/nar/19.13.3499; Miller JH., 1972, EXPT MOL GENETICS; NAPOLI C, 1981, J MOL BIOL, V149, P433, DOI 10.1016/0022-2836(81)90480-0; NELSON M, 1992, METHOD ENZYMOL, V216, P279; Ravera MW, 1998, ONCOGENE, V16, P1993, DOI 10.1038/sj.onc.1201717; RINGQUIST S, 1992, MOL MICROBIOL, V6, P1219, DOI 10.1111/j.1365-2958.1992.tb01561.x; Sambrook J., 2002, MOL CLONING LAB MANU; Sasaki J, 2000, P NATL ACAD SCI USA, V97, P1512, DOI 10.1073/pnas.010426997; SHINEDLING S, 1987, J MOL BIOL, V195, P471, DOI 10.1016/0022-2836(87)90176-8; SIPLEY J, 1993, P NATL ACAD SCI USA, V90, P2315, DOI 10.1073/pnas.90.6.2315; SPANJAARD RA, 1989, NUCLEIC ACIDS RES, V17, P5501, DOI 10.1093/nar/17.14.5501; STEEGE DA, 1977, P NATL ACAD SCI USA, V74, P4163, DOI 10.1073/pnas.74.10.4163; Stenstrom CM, 2002, GENE, V288, P1, DOI 10.1016/S0378-1119(02)00501-2; Wilson JE, 2000, CELL, V102, P511, DOI 10.1016/S0092-8674(00)00055-6; Yu JS, 2001, MOL MICROBIOL, V42, P821, DOI 10.1046/j.1365-2958.2001.02681.x; Zemsky J, 2002, GENE EXPRESSION, V10, P109	31	4	4	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1674	1681		10.1096/fj.03-0105com	http://dx.doi.org/10.1096/fj.03-0105com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958174				2022-12-25	WOS:000185925100042
J	Xu, YF; Tuteja, D; Zhang, Z; Xu, DY; Zhang, Y; Rodriguez, J; Nie, LP; Tuxson, HR; Young, JN; Glatter, KA; Vazquez, AE; Yamoah, EN; Chiamvimonvat, N				Xu, YF; Tuteja, D; Zhang, Z; Xu, DY; Zhang, Y; Rodriguez, J; Nie, LP; Tuxson, HR; Young, JN; Glatter, KA; Vazquez, AE; Yamoah, EN; Chiamvimonvat, N			Molecular identification and functional roles of a Ca2+-activated K+ channel in human and mouse hearts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; ACTION-POTENTIAL PROLONGATION; VENTRICULAR MYOCYTES; SMALL-CONDUCTANCE; ATRIAL MYOCYTES; ALPHA-SUBUNIT; CELLS; CURRENTS; APAMIN; EXPRESSION	The repolarization phase of cardiac action potential is prone to aberrant excitation that is common in cardiac patients. Here, we demonstrate that this phase is markedly sensitive to Ca2+ because of the surprising existence of a Ca2+-activated K+ currents in cardiac cells. The current was revealed using recording conditions that preserved endogenous Ca2+ buffers. The Ca2+-activated K+ current is expressed differentially in atria compared with ventricles. Because of the significant contribution of the current toward membrane repolarization in cardiac myocytes, alterations of the current magnitude precipitate abnormal action potential profiles. We confirmed the presence of a small conductance Ca2+-activated K+ channel subtype (SK2) in human and mouse cardiac myocytes using Western blot analysis and reverse transcription-polymerase chain reaction and have cloned SK2 channels from human atria, mouse atria, and ventricles. Because of the marked differential expression of SK2 channels in the heart, specific ligands for Ca2+-activated K+ currents may offer a unique therapeutic opportunity to modify atrial cells without interfering with ventricular myocytes.	Univ Calif Davis, Dept Internal Med, Div Cardiovasc Med, Davis, CA 95616 USA; Univ Calif Davis, Dept Cardiothorac Surg, Davis, CA 95616 USA; Univ Calif Davis, Ctr Neurosci, Dept Otolaryngol, Davis, CA 95616 USA; No Calif Hlth Care Syst, Dept Vet Affairs, Mather, CA 95655 USA; Hebei Med Univ, Dept Pharmacol, Shijiazhuang 050017, Peoples R China	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Hebei Medical University	Chiamvimonvat, N (corresponding author), Univ Calif Davis, Dept Med, Div Cardiovasc Med, 1 Shields Ave,TB 172, Davis, CA 95616 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067737, R01HL085844, R01HL068507] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68507, HL67737, R01 HL085844] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmmed GU, 2001, CIRC RES, V89, P1005, DOI 10.1161/hh2301.100801; Ahmmed GU, 2000, CIRC RES, V86, P558, DOI 10.1161/01.RES.86.5.558; Barry DM, 1996, ANNU REV PHYSIOL, V58, P363, DOI 10.1146/annurev.ph.58.030196.002051; Bertaso F, 2002, BASIC RES CARDIOL, V97, P424, DOI 10.1007/s00395-002-0377-4; Bertil H., 2001, ION CHANNELS EXCITAB; Bou-Abboud E, 2000, J PHYSIOL-LONDON, V529, P345, DOI 10.1111/j.1469-7793.2000.00345.x; Colquhoun David, 1995, P483; Desai R, 2000, J BIOL CHEM, V275, P39954, DOI 10.1074/jbc.M001562200; Gao TY, 2000, J BIOL CHEM, V275, P25436, DOI 10.1074/jbc.M003465200; GILES WR, 1988, J PHYSIOL-LONDON, V405, P123, DOI 10.1113/jphysiol.1988.sp017325; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Kaczorowski GJ, 1999, CURR OPIN CHEM BIOL, V3, P448, DOI 10.1016/S1367-5931(99)80066-0; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Korn SJ., 1991, J NEUROSCI METH, V4, P264; KOUMI S, 1994, EUR J PHARMACOL, V261, P213, DOI 10.1016/0014-2999(94)90322-0; LABBEJULLIE C, 1991, EUR J BIOCHEM, V196, P639, DOI 10.1111/j.1432-1033.1991.tb15860.x; London B, 1998, P NATL ACAD SCI USA, V95, P2926, DOI 10.1073/pnas.95.6.2926; Mitcheson JS, 1997, PFLUG ARCH EUR J PHY, V433, P817, DOI 10.1007/s004240050350; NEHER E, 1992, METHOD ENZYMOL, V207, P123; Oliver D, 2000, NEURON, V26, P595, DOI 10.1016/S0896-6273(00)81197-6; PENNEFATHER P, 1985, P NATL ACAD SCI USA, V82, P3040, DOI 10.1073/pnas.82.9.3040; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; Roden DM, 1997, AM J PHYSIOL-HEART C, V273, pH511, DOI 10.1152/ajpheart.1997.273.2.H511; Stocker M, 2000, MOL CELL NEUROSCI, V15, P476, DOI 10.1006/mcne.2000.0842; VanWagoner DR, 1997, CIRC RES, V80, P772; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Xu HD, 1999, J GEN PHYSIOL, V113, P661, DOI 10.1085/jgp.113.5.661; Xu HD, 1999, J PHYSIOL-LONDON, V519, P11, DOI 10.1111/j.1469-7793.1999.0011o.x; Xu HD, 1999, CIRC RES, V85, P623, DOI 10.1161/01.RES.85.7.623; Xu YF, 2002, AM J PHYSIOL-HEART C, V283, pH302, DOI 10.1152/ajpheart.00044.2002	33	206	218	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49085	49094		10.1074/jbc.M307508200	http://dx.doi.org/10.1074/jbc.M307508200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	13679367	hybrid			2022-12-25	WOS:000186829000071
J	Brandenburg, K; Garidel, P; Andra, J; Jurgens, G; Muller, M; Blume, A; Koch, MHJ; Levin, J				Brandenburg, K; Garidel, P; Andra, J; Jurgens, G; Muller, M; Blume, A; Koch, MHJ; Levin, J			Cross-linked hemoglobin converts endotoxically inactive pentaacyl endotoxins into a physiologically active conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE (LPS)-BINDING PROTEIN; LPS BIOLOGICAL-ACTIVITY; BACTERIAL-ENDOTOXIN; BIOPHYSICAL CHARACTERIZATION; BINDING-PROTEIN; LIPID-A; ENDOTHELIAL-CELLS; PHOSPHOLIPID-MEMBRANES; INFRARED-SPECTROSCOPY; INDUCED ACTIVATION	The interaction of purified alphaalpha cross-linked hemoglobin (alphaalphaHb) with a pentaacylated mutant lipopolysaccharide (pLPS) and the corresponding lipid A (pLA) was studied biophysically and the effects correlated with data from biological assays, i.e. cytokine induction ( tumor necrosis factor-alpha) in human mononuclear cells and the Limulus amebocyte lysate assay. Fourier transform infrared spectroscopic and Zeta-Sizer experiments indicated an electrostatic as well as a non-electrostatic binding of alphaalphaHb to the hydrophilic and to the hydrophobic moieties of the endotoxins with an increase of the inclination angle of the pLA backbone, with respect to the membrane surface, from 25degrees to more than 50degrees. Small angle synchrotron radiation x-ray diffraction measurements indicated a reorientation of the lipid A aggregates from a multilamellar into a cubic structure as a result of alphaalphaHb interaction. Thus, in the absence of alphaalphaHb, the molecular shape of the pentaacyl samples was cylindrical with a moderate inclination of the diglucosamine backbone, whereas, in the presence of the protein, the shape was conical, and the inclination angle was high. The cytokine-inducing capability in human mononuclear cells, negligible for the pure pentaacylated compounds, increased markedly in the presence of alphaalphaHb in a concentration-dependent manner. In the Limulus assay, the pentaacylated samples were active a priori, and their activity was enhanced following binding to alphaalphaHb, at least at the highest protein concentrations. The data can be understood in the light of a reaggregation of the endotoxins because of alphaalphaHb binding, with the endotoxin backbones then readily accessible for serum and membrane proteins. By using fluorescence resonance energy transfer spectroscopy, an uptake of the endotoxin-Hb complex into phospholipid liposomes was observed, which provides a basis for cell activation.	Forschungszentrum Borstel, Div Biophys, D-23845 Borstel, Germany; Univ Halle Wittenberg, Inst Phys Chem, D-06108 Halle An Der Saale, Germany; DESY, European Mol Biol Lab, D-22603 Hamburg, Germany; Univ Calif San Francisco, Sch Med, Dept Lab Med, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA	Forschungszentrum Borstel; Martin Luther University Halle Wittenberg; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Brandenburg, K (corresponding author), Forschungszentrum Borstel, Div Biophys, Pk Allee 10, D-23845 Borstel, Germany.	kbranden@fz-borstel.de						ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Bloom O, 1998, SHOCK, V10, P395, DOI 10.1097/00024382-199812000-00003; BLUME A, 1999, MACROMOLECULES MAN, V4, P109; Blunck R, 2001, J IMMUNOL, V166, P1009, DOI 10.4049/jimmunol.166.2.1009; BOULIN C, 1986, NUCL INSTR METH A, V249; Brandenburg K, 1998, EUR J BIOCHEM, V258, P686, DOI 10.1046/j.1432-1327.1998.2580686.x; Brandenburg K, 2002, BIOPHYS J, V83, P322, DOI 10.1016/S0006-3495(02)75172-2; Brandenburg K, 2002, EUR J BIOCHEM, V269, P5972, DOI 10.1046/j.1432-1033.2002.03333.x; Brandenburg K, 1999, J STRUCT BIOL, V128, P175, DOI 10.1006/jsbi.1999.4186; BRANDENBURG K, 1993, EUR J BIOCHEM, V218, P555, DOI 10.1111/j.1432-1033.1993.tb18409.x; Brandenburg K, 2001, BIOL CHEM, V382, P1215, DOI 10.1515/BC.2001.152; BRANDENBURG K, 2003, IN PRESS CURR TOPICS; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; CHRISTENSEN SM, 1988, J BIOCHEM BIOPH METH, V17, P143, DOI 10.1016/0165-022X(88)90045-0; FRIBERGER P, 1987, DETECTION BACTERIAL, P149; GABRIEL A, 1977, REV SCI INSTRUM, V48, P1303, DOI 10.1063/1.1134870; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GALLATI H, 1982, J CLIN CHEM CLIN BIO, V20, P907; Garidel P, 2000, J LIPOSOME RES, V10, P131, DOI 10.3109/08982100009029383; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Gorbenko GP, 1999, BIOPHYS CHEM, V81, P93, DOI 10.1016/S0301-4622(99)00085-X; Gutsmann T, 2001, INFECT IMMUN, V69, P6942, DOI 10.1128/IAI.69.11.6942-6950.2001; Jurgens G, 2002, J ENDOTOXIN RES, V8, P115, DOI 10.1179/096805102125000263; Jurgens G, 2001, EUR J BIOCHEM, V268, P4233, DOI 10.1046/j.1432-1327.2001.02338.x; KACA W, 1995, BIOCHEMISTRY-US, V34, P11176, DOI 10.1021/bi00035a024; KACA W, 1994, J BIOL CHEM, V269, P25078; KACA W, 1994, J ENDOTOXIN RES, V1, P243; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; KRONER EE, 1981, J BIOL CHEM, V256, P3690; LEVIN J, 1968, THROMB DIATH HAEMOST, V19, P186; LUDERITZ O, 1982, CURR TOP MEMBR TRANS, V17, P79; MARIANI P, 1988, J MOL BIOL, V204, P165, DOI 10.1016/0022-2836(88)90607-9; MARTIN DK, 1995, J MEMBRANE BIOL, V147, P305; Muller M, 2003, J ENDOTOXIN RES, V9, P181, DOI 10.1179/096805103125001595; Rietschel ET, 1996, CURR TOP MICROBIOL, V216, P39; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Roth R I, 1994, Prog Clin Biol Res, V388, P161; ROTH RI, 1994, BLOOD, V83, P2860, DOI 10.1182/blood.V83.10.2860.2860; ROTH RI, 1994, ARTIF CELL BLOOD SUB, V22, P387, DOI 10.3109/10731199409117869; Roth RI, 1996, J ENDOTOXIN RES, V3, P361, DOI 10.1177/096805199600300412; ROTH RI, 1993, TRANSFUSION, V33, P919, DOI 10.1046/j.1537-2995.1993.331194082383.x; Roth RI, 1996, THROMB HAEMOSTASIS, V76, P258; Schromm AB, 2000, EUR J BIOCHEM, V267, P2008, DOI 10.1046/j.1432-1327.2000.01204.x; Schromm AB, 1998, J IMMUNOL, V161, P5464; Schromm AB, 1996, FEBS LETT, V399, P267, DOI 10.1016/S0014-5793(96)01338-5; Seydel U, 2000, EUR J BIOCHEM, V267, P3032; Seydel U, 2001, J ENDOTOXIN RES, V7, P243, DOI 10.1177/09680519010070030901; Stowell CP, 2001, TRANSFUSION, V41, P287, DOI 10.1046/j.1537-2995.2001.41020287.x; Su DH, 1999, CRIT CARE MED, V27, P771, DOI 10.1097/00003246-199904000-00034; Su DH, 1997, INFECT IMMUN, V65, P1258, DOI 10.1128/IAI.65.4.1258-1266.1997; Thieblemont N, 1999, J EXP MED, V190, P523, DOI 10.1084/jem.190.4.523; TOBIAS PS, 1994, CHEST, V105, pS48, DOI 10.1378/chest.105.3.48S; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93	56	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47660	47669		10.1074/jbc.M304743200	http://dx.doi.org/10.1074/jbc.M304743200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13679376	hybrid			2022-12-25	WOS:000186731400040
J	Flemming, D; Schlitt, A; Spehr, V; Bischof, T; Friedrich, T				Flemming, D; Schlitt, A; Spehr, V; Bischof, T; Friedrich, T			Iron-sulfur cluster N2 of the Escherichia coli NADH : ubiquinone oxidoreductase (Complex I) is located on subunit NuoB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING NADH; SITE-DIRECTED MUTAGENESIS; NUCLEAR-ENCODED SUBUNITS; QUINONE OXIDOREDUCTASE; RESPIRATORY-CHAIN; PARACOCCUS-DENITRIFICANS; MITOCHONDRIAL NADH; RHODOBACTER-CAPSULATUS; ELECTRON-TRANSPORT; 49-KDA SUBUNIT	The proton-pumping NADH: ubiquinone oxidoreductase, also called respiratory complex I, couples the transfer of electrons from NADH to ubiquinone with the translocation of protons across the membrane. One FMN and up to 9 iron-sulfur (Fe/S) clusters participate in the redox reaction. There is discussion that the EPR-detectable Fe/S cluster N2 is involved in proton pumping. However, the assignment of this cluster to a distinct subunit of the complex as well as the number of Fe/S clusters giving rise to the EPR signal are still under debate. Complex I from Escherichia coli consists of 13 polypetides called NuoA to N. Either subunit NuoB or NuoI could harbor Fe/S cluster N2. Whereas NuoB contains a unique motif for the binding of one Fe/S cluster, NuoI contains a typical ferredoxin motif for the binding of two Fe/S clusters. Individual mutation of all four conserved cysteine residues in NuoB resulted in a loss of complex I activity and of the EPR signal of N2 in the cytoplasmic membrane as well as in the isolated complex. Individual mutations of all eight conserved cysteine residues of NuoI revealed a variable phenotype. Whereas cluster N2 was lost in most NuoI mutants, it was still present in the cytoplasmic membranes of the mutants NuoI C63A and NuoI C102A. N2 was also detected in the complex isolated from the mutant NuoI C102A. From this we conclude that the Fe/S cluster N2 is located on subunit NuoB.	Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany; Univ Dusseldorf, Inst Biochem, D-40225 Dusseldorf, Germany	University of Freiburg; Heinrich Heine University Dusseldorf	Friedrich, T (corresponding author), Univ Freiburg, Inst Organ Chem & Biochem, Albertstr 21, D-79104 Freiburg, Germany.	tfriedri@uni-freiburg.de	Flemming, Dirk/AAP-3274-2021					Ahlers PM, 2000, J BIOL CHEM, V275, P23577, DOI 10.1074/jbc.M002074200; ALBRACHT SPJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P221, DOI 10.1016/0005-2728(93)90176-G; Albracht SPJ, 2000, FEBS LETT, V485, P1, DOI 10.1016/S0014-5793(00)02172-4; Brandt U, 1997, BBA-BIOENERGETICS, V1318, P79, DOI 10.1016/S0005-2728(96)00141-7; Braun M, 1998, BIOCHEMISTRY-US, V37, P1861, DOI 10.1021/bi971176p; CHEN WP, 1993, NUCLEIC ACIDS RES, V21, P2260, DOI 10.1093/nar/21.9.2260; Chevallet M, 1997, EUR J BIOCHEM, V250, P451, DOI 10.1111/j.1432-1033.1997.0451a.x; Chevallet M, 2003, BBA-BIOENERGETICS, V1557, P51, DOI 10.1016/S0005-2728(02)00398-5; CONDON C, 1985, J BIOL CHEM, V260, P9427; DEJONG AMP, 1994, BBA-BIOENERGETICS, V1186, P163, DOI 10.1016/0005-2728(94)90175-9; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVAULT D, 1976, J THEOR BIOL, V62, P115, DOI 10.1016/0022-5193(76)90054-0; DOOIJEWAARD G, 1976, BIOCHIM BIOPHYS ACTA, V440, P1, DOI 10.1016/0005-2728(76)90109-2; Duarte M, 2000, GENETICS, V156, P607; Duarte M, 2002, BIOCHEM J, V364, P833, DOI 10.1042/BJ20011750; Esposti MD, 1998, BBA-BIOENERGETICS, V1364, P222, DOI 10.1016/S0005-2728(98)00029-2; Flemming D, 2003, J BIOL CHEM, V278, P3055, DOI 10.1074/jbc.M208849200; Friedrich T, 1998, BBA-BIOENERGETICS, V1365, P215, DOI 10.1016/S0005-2728(98)00070-X; FRIEDRICH T, 1989, EUR J BIOCHEM, V180, P173, DOI 10.1111/j.1432-1033.1989.tb14629.x; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; FRIEDRICH T, 1995, FEBS LETT, V367, P107, DOI 10.1016/0014-5793(95)00548-N; Friedrich T, 2001, J BIOENERG BIOMEMBR, V33, P169, DOI 10.1023/A:1010722717257; FRIEDRICH T, 1994, EUR J BIOCHEM, V219, P691, DOI 10.1111/j.1432-1033.1994.tb19985.x; Friedrich T, 2000, FEBS LETT, V479, P1, DOI 10.1016/S0014-5793(00)01867-6; Golinelli MP, 1998, BIOCHEMISTRY-US, V37, P10429, DOI 10.1021/bi9806394; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; INGLEDEW WJ, 1980, BIOCHEM J, V186, P111, DOI 10.1042/bj1860111; Kashani-Poor N, 2001, J BIOL CHEM, V276, P24082, DOI 10.1074/jbc.M102296200; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KUSHNER SR, 1971, P NATL ACAD SCI USA, V68, P824, DOI 10.1073/pnas.68.4.824; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; MARTIN AE, 1990, P NATL ACAD SCI USA, V87, P598, DOI 10.1073/pnas.87.2.598; MATSUSHITA K, 1987, BIOCHEMISTRY-US, V26, P7732, DOI 10.1021/bi00398a029; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Moulis JM, 1996, J BIOL INORG CHEM, V1, P2, DOI 10.1007/s007750050017; ODEN KL, 1990, GENE, V96, P29, DOI 10.1016/0378-1119(90)90337-Q; Ohnishi T, 1999, BIOCHEM SOC T, V27, P586, DOI 10.1042/bst0270586; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; OHNISHI T, 1973, BIOCHIM BIOPHYS ACTA, V301, P105, DOI 10.1016/0304-4173(73)90001-3; OHNISHI T, 1981, J BIOL CHEM, V256, P9216; RAGAN CI, 1978, BIOCHEM J, V172, P539, DOI 10.1042/bj1720539; Rasmussen T, 2001, BIOCHEMISTRY-US, V40, P6124, DOI 10.1021/bi0026977; RIED JL, 1987, GENE, V57, P239, DOI 10.1016/0378-1119(87)90127-2; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schuler F, 1999, P NATL ACAD SCI USA, V96, P4149, DOI 10.1073/pnas.96.7.4149; Schulte U, 1999, J MOL BIOL, V292, P569, DOI 10.1006/jmbi.1999.3096; Schulte U, 1998, BIOFACTORS, V8, P177, DOI 10.1002/biof.5520080303; SLED VD, 1993, J BIOENERG BIOMEMBR, V25, P347, DOI 10.1007/BF00762460; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Spehr V, 1999, BIOCHEMISTRY-US, V38, P16261, DOI 10.1021/bi9919605; TOWBIN H, 1979, P NATL ACAD SCI USA, V1320, P217; VANBELZEN R, 1992, EUR J BIOCHEM, V209, P1019, DOI 10.1111/j.1432-1033.1992.tb17377.x; VANBELZEN R, 1989, BIOCHIM BIOPHYS ACTA, V974, P311, DOI 10.1016/S0005-2728(89)80249-X; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Yano T, 1996, J BIOL CHEM, V271, P5907, DOI 10.1074/jbc.271.10.5907; YANO T, 1995, J BIOL CHEM, V270, P18264, DOI 10.1074/jbc.270.31.18264; YANO T, 1994, FEBS LETT, V354, P160, DOI 10.1016/0014-5793(94)01107-9; Yano T, 1999, J BIOL CHEM, V274, P28598, DOI 10.1074/jbc.274.40.28598; Yano T, 2003, J BIOL CHEM, V278, P15514, DOI 10.1074/jbc.M212275200; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x; Zickermann V, 2003, J BIOL CHEM, V278, P29072, DOI 10.1074/jbc.M302713200; Zu YB, 2002, BIOCHEMISTRY-US, V41, P10056, DOI 10.1021/bi026026f	71	49	50	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47602	47609		10.1074/jbc.M308967200	http://dx.doi.org/10.1074/jbc.M308967200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12975362	hybrid			2022-12-25	WOS:000186731400033
J	Lu, L; Lamm, ME; Li, HM; Corthesy, B; Zhang, JR				Lu, L; Lamm, ME; Li, HM; Corthesy, B; Zhang, JR			The human polymeric immunoglobulin receptor binds to Streptococcus pneumoniae via domains 3 and 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PNEUMOCOCCAL SURFACE PROTEIN; FREE SECRETORY COMPONENT; NASOPHARYNGEAL EPITHELIAL-CELLS; HUMAN-MILK; IG RECEPTOR; FACTOR-H; VIRULENCE FACTORS; HUMAN-COMPLEMENT; E-CADHERIN; PSPC	Streptococcus pneumoniae ( the pneumococcus) is a major cause of bacterial pneumonia, middle ear infection ( otitis media), sepsis, and meningitis. Our previous study demonstrated that the choline-binding protein A ( CbpA) of S. pneumoniae binds to the human polymeric immunoglobulin receptor (pIgR) and enhances pneumococcal adhesion to and invasion of cultured epithelial cells. In this study, we sought to determine the CbpA-binding motif on pIgR by deletional analysis. The extracellular portion of pIgR consists of five Ig-like domains (D1 - D5), each of which contains 104 - 114 amino acids and two disulfide bonds. Deletional analysis of human pIgR revealed that the lack of either D3 or D4 resulted in the loss of CbpA binding, whereas complete deletions of domains D1, D2, and D5 had undetectable impacts. Subsequent analysis showed that domains D3 and D4 together were necessary and sufficient for the ligand-binding activity. Furthermore, CbpA binding of pIgR did not appear to require Ca2+ or Mg2+. Finally, treating pIgR with a reducing agent abolished CbpA binding, suggesting that disulfide bonding is required for the formation of CbpA-binding motif(s). These results strongly suggest a conformational CbpA-binding motif( s) in the D3/D4 region of human pIgR, which is functionally separated from the IgA-binding site(s).	Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA; Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; CHU Vaudois, Div Immunol & Allergy, R&D Lab, CH-1005 Lausanne, Switzerland	Albany Medical College; Case Western Reserve University; State University of New York (SUNY) System; Wadsworth Center; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Zhang, JR (corresponding author), Albany Med Coll, Ctr Immunol & Microbial Dis, M-C 151, Albany, NY 12208 USA.		Li, Hongmin/ABI-2439-2020	Li, Hongmin/0000-0002-8684-5308	NIAID NIH HHS [AI26449, AI36359] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026449, P01AI036359] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alcantara RB, 2001, INFECT IMMUN, V69, P3569, DOI 10.1128/IAI.69.6.3569-3575.2001; ALONSODEVELASCO E, 1995, MICROBIOL REV, V59, P591, DOI 10.1128/MMBR.59.4.591-603.1995; BAKOS MA, 1991, J IMMUNOL, V147, P3419; Balachandran P, 2002, INFECT IMMUN, V70, P2526, DOI 10.1128/IAI.70.5.2526-2534.2002; Berry AM, 1996, INFECT IMMUN, V64, P5255, DOI 10.1128/IAI.64.12.5255-5262.1996; Briles DE, 1997, MICROB DRUG RESIST, V3, P401, DOI 10.1089/mdr.1997.3.401; Brooks-Walter A, 1999, INFECT IMMUN, V67, P6533; Cheng Q, 2000, BIOCHEMISTRY-US, V39, P5450, DOI 10.1021/bi992157d; Chintalacharuvu KR, 2003, INFECT IMMUN, V71, P2563, DOI 10.1128/IAI.71.5.2563-2570.2003; COYNE RS, 1994, J BIOL CHEM, V269, P31620; Crottet P, 1999, BIOCHEM J, V341, P299, DOI 10.1042/0264-6021:3410299; Crottet P, 1999, J BIOL CHEM, V274, P31456, DOI 10.1074/jbc.274.44.31456; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; CUNNINGHAMRUNDLES C, 1975, J BIOL CHEM, V250, P1987; Dallas SD, 1998, J MED MICROBIOL, V47, P879, DOI 10.1099/00222615-47-10-879; Dave S, 2001, INFECT IMMUN, V69, P3435, DOI 10.1128/IAI.69.5.3435-3437.2001; Dintilhac A, 1997, MOL MICROBIOL, V25, P727, DOI 10.1046/j.1365-2958.1997.5111879.x; Duthy TG, 2002, INFECT IMMUN, V70, P5604, DOI 10.1128/IAI.70.10.5604-5611.2002; EIFFERT H, 1984, H-S Z PHYSIOL CHEM, V365, P1489, DOI 10.1515/bchm2.1984.365.2.1489; Fleury D, 1999, NAT STRUCT BIOL, V6, P530, DOI 10.1038/9299; GIUGLIANO LG, 1995, J MED MICROBIOL, V42, P3, DOI 10.1099/00222615-42-1-3; Hammerschmidt S, 1997, MOL MICROBIOL, V25, P1113, DOI 10.1046/j.1365-2958.1997.5391899.x; Hammerschmidt S, 2000, MOL MICROBIOL, V36, P726, DOI 10.1046/j.1365-2958.2000.01897.x; Hava D, 2002, MOL MICROBIOL, V45, P1389, DOI 10.1046/j.1365-2958.2002.t01-1-03106.x; Hexham JM, 1999, J EXP MED, V189, P747, DOI 10.1084/jem.189.4.747; Holmes AR, 2001, MOL MICROBIOL, V41, P1395, DOI 10.1046/j.1365-2958.2001.02610.x; Iannelli F, 2002, GENE, V284, P63, DOI 10.1016/S0378-1119(01)00896-4; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; Janulczyk R, 2000, J BIOL CHEM, V275, P37257, DOI 10.1074/jbc.M004572200; Jarva H, 2002, J IMMUNOL, V168, P1886, DOI 10.4049/jimmunol.168.4.1886; Johansen FE, 2001, J IMMUNOL, V167, P5185, DOI 10.4049/jimmunol.167.9.5185; Keitel T, 1997, CELL, V91, P811, DOI 10.1016/S0092-8674(00)80469-9; KOBAYASHI K, 1971, IMMUNOCHEMISTRY, V8, P785, DOI 10.1016/0019-2791(71)90446-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMKHIOUED B, 1995, EUR J IMMUNOL, V25, P117, DOI 10.1002/eji.1830250121; Lau GW, 2001, MOL MICROBIOL, V40, P555, DOI 10.1046/j.1365-2958.2001.02335.x; Lecuit M, 2001, SCIENCE, V292, P1722, DOI 10.1126/science.1059852; Lecuit M, 1999, EMBO J, V18, P3956, DOI 10.1093/emboj/18.14.3956; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Madsen M, 2000, J INFECT DIS, V181, P1330, DOI 10.1086/315388; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mestecky J., 1999, MUCOSAL IMMUNOLOGY, P133; MIZOGUCHI A, 1982, J BIOL CHEM, V257, P9612; MOSTOV K, 1999, MUCOSAL IMMUNOLOGY, P181; Murdoch C, 2002, J INFECT DIS, V186, P1253, DOI 10.1086/344527; MUSHER DM, 2000, PRINCIPLES PRACTICE, V2, P2128; NIKOLOVA EB, 1994, IMMUNOLOGY, V82, P321; Norderhaug IN, 1999, CRIT REV IMMUNOL, V19, P481; Novak R, 1998, MOL MICROBIOL, V29, P1285, DOI 10.1046/j.1365-2958.1998.01016.x; PATON JC, 1984, INFECT IMMUN, V43, P1085, DOI 10.1128/IAI.43.3.1085-1087.1984; PATON JC, 1983, INFECT IMMUN, V41, P1212, DOI 10.1128/IAI.41.3.1212-1216.1983; Paton JC, 2000, GRAM-POSITIVE PATHOGENS, P201; Phalipon A, 2002, IMMUNITY, V17, P107, DOI 10.1016/S1074-7613(02)00341-2; PISKURICH JF, 1995, J IMMUNOL, V154, P1735; PURKAYASTHA S, 1979, J BIOL CHEM, V254, P6583; Romero-Steiner S, 2003, CLIN DIAGN LAB IMMUN, V10, P246, DOI 10.1128/CDLI.10.2.246-251.2003; Rosenow C, 1997, MOL MICROBIOL, V25, P819, DOI 10.1111/j.1365-2958.1997.mmi494.x; Sambrook J., 2002, MOL CLONING LAB MANU; Smith BL, 2000, J INFECT DIS, V182, P497, DOI 10.1086/315722; Smith J.A., 2000, CURRENT PROTOCOLS MO; TOMANA M, 1978, ANAL BIOCHEM, V89, P110, DOI 10.1016/0003-2697(78)90731-5; Tu AHT, 1999, INFECT IMMUN, V67, P4720, DOI 10.1128/IAI.67.9.4720-4724.1999; Wurzner R, 1999, MOL IMMUNOL, V36, P249, DOI 10.1016/S0161-5890(99)00049-8; YOTHER J, 1994, J BACTERIOL, V176, P2976, DOI 10.1128/JB.176.10.2976-2985.1994; Zhang JR, 2000, CELL, V102, P827, DOI 10.1016/S0092-8674(00)00071-4; Zhang JR, 1997, CELL, V89, P275, DOI 10.1016/S0092-8674(00)80206-8	67	51	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48178	48187		10.1074/jbc.M306906200	http://dx.doi.org/10.1074/jbc.M306906200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13679368	hybrid			2022-12-25	WOS:000186731400100
J	Channavajhala, PL; Wu, LY; Cuozzo, JW; Hall, JP; Liu, W; Lin, LL; Zhang, YH				Channavajhala, PL; Wu, LY; Cuozzo, JW; Hall, JP; Liu, W; Lin, LL; Zhang, YH			Identification of a novel human kinase supporter of Ras (hKSR-2) that functions as a negative regulator of Cot (Tpl2) signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; KSR-1 GENE ENCODES; EPITHELIAL-CELLS; NUCLEAR-FACTOR; T-CELLS; INTERLEUKIN-8 EXPRESSION; NF-KAPPA-B1 P105; C-ELEGANS; SUPPRESSOR	Kinase suppressor of Ras ( KSR) is an integral and conserved component of the Ras signaling pathway. Although KSR is a positive regulator of the Ras/ mitogen-activated protein ( MAP) kinase pathway, the role of KSR in Cot- mediated MAPK activation has not been identified. The serine/ threonine kinase Cot ( also known as Tp12) is a member of the MAP kinase kinase kinase ( MAP3K) family that is known to regulate oncogenic and inflammatory pathways; however, the mechanism( s) of its regulation are not precisely known. In this report, we identify an 830- amino acid novel human KSR, designated hKSR- 2, using predictions from genomic data base mining based on the structural profile of the KSR kinase domain. We show that, similar to the known human KSR, hKSR- 2 co- immunoprecipitates with many signaling components of the Ras/ MAPK pathway, including Ras, Raf, MEK- 1, and ERK- 1/ 2. In addition, we demonstrate that hKSR- 2 co- immunoprecipitates with Cot and that co- expression of hKSR- 2 with Cot significantly reduces Cot- mediated MAPK and NF-kappaB activation. This inhibition is specific to Cot, because Ras- induced ERK and IkappaB kinase- induced NF-kappaB activation are not significantly affected by hKSR- 2 co- expression. Moreover, Cot- induced interleukin- 8 production in HeLa cells is almost completely inhibited by the concurrent expression of hKSR- 2, whereas transforming growth factor beta- activated kinase 1 ( TAK1)/ TAK1- binding protein 1 ( TAB1)- induced interleukin- 8 production is not affected by hKSR- 2 co- expression. Taken together, these results indicate that hKSR- 2, a new member of the KSR family, negatively regulates Cot- mediated MAP kinase and NF-kappaB pathway signaling.	Wyeth Res, Dept Inflammat, Cambridge, MA 02140 USA; Wyeth Res, Dept Genom, Cambridge, MA 02140 USA	Pfizer; Pfizer	Channavajhala, PL (corresponding author), Wyeth Res, Dept Inflammat, 200 Cambridge Pk Dr, Cambridge, MA 02140 USA.			Cuozzo, John/0000-0002-6229-0395				Ballester A, 1997, J IMMUNOL, V159, P1613; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Bhattacharyya A, 2002, BIOCHEM J, V368, P121, DOI 10.1042/BJ20020555; Bian ZM, 2001, EXP EYE RES, V73, P111, DOI 10.1006/exer.2001.1019; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; de Gregorio R, 2001, J BIOL CHEM, V276, P27003, DOI 10.1074/jbc.M100885200; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Liu R, 2000, ARTHRITIS RHEUM, V43, P1145, DOI 10.1002/1529-0131(200005)43:5<1145::AID-ANR25>3.0.CO;2-T; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Marie C, 1999, INFECT IMMUN, V67, P688, DOI 10.1128/IAI.67.2.688-693.1999; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; Morrison DK, 2001, J CELL SCI, V114, P1609; Neff L, 2001, CELL MICROBIOL, V3, P703, DOI 10.1046/j.1462-5822.2001.00148.x; Nguyen A, 2002, MOL CELL BIOL, V22, P3035, DOI 10.1128/MCB.22.9.3035-3045.2002; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Ono K, 2001, J BIOL CHEM, V276, P24396, DOI 10.1074/jbc.M102631200; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Roy F, 2002, CURR BIOL, V12, pR325, DOI 10.1016/S0960-9822(02)00831-X; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; Sanchez-Gongora E, 2000, J BIOL CHEM, V275, P31379, DOI 10.1074/jbc.M000382200; SASAI H, 1993, BRIT J CANCER, V67, P262, DOI 10.1038/bjc.1993.50; Schlesinger Thomas K., 1998, Frontiers in Bioscience, V3, pD1181; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Stewart S, 1999, MOL CELL BIOL, V19, P5523; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Xing HR, 2001, J BIOL CHEM, V276, P9733, DOI 10.1074/jbc.M008096200; Yan F, 2001, CANCER RES, V61, P963; Zetoune FS, 2001, CYTOKINE, V15, P282, DOI 10.1006/cyto.2001.0921; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zhou M, 2002, J MOL BIOL, V315, P435, DOI 10.1006/jmbi.2001.5263	43	38	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47089	47097		10.1074/jbc.M306002200	http://dx.doi.org/10.1074/jbc.M306002200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12975377	hybrid			2022-12-25	WOS:000186569400106
J	Chiba, T; Hagihara, Y; Higurashi, T; Hasegawa, K; Naiki, H; Goto, Y				Chiba, T; Hagihara, Y; Higurashi, T; Hasegawa, K; Naiki, H; Goto, Y			Amyloid fibril formation in the context of full-length protein - Effects of proline mutations on the amyloid fibril formation of beta(2)-microglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-MICROGLOBULIN REVEALS; EXTENSION IN-VITRO; DISULFIDE BOND; ALTERNATIVE CONFORMATIONS; MAJOR DETERMINANT; PRION PROTEIN; KINETIC-MODEL; DISEASE; TRANSTHYRETIN; AGGREGATION	beta(2)-Microglobulin (beta2-m), a typical immunoglobulin domain made of seven beta-strands, is a major component of amyloid fibrils formed in dialysis-related amyloidosis. To understand the mechanism of amyloid fibril formation in the context of full-length protein, we prepared various mutants in which proline (Pro) was introduced to each of the seven beta-strands of beta2-m. The mutations affected the amyloidogenic potential of beta2-m to various degrees. In particular, the L23P, H51P, and V82P mutations significantly retarded fibril extension at pH 2.5. Among these, only L23P is included in the known "minimal" peptide sequence, which can form amyloid fibrils when isolated as a short peptide. This indicates that the residues in regions other than the minimal sequence, such as H51P and V82P, determine the amyloidogenic potential in the full-length protein. To further clarify the mutational effects, we measured their stability against guanidine hydrochloride of the native state at pH 8.0 and the amyloid fibrils at pH 2.5. The amyloidogenicity of mutants showed a significant correlation with the stability of the amyloid fibrils, and little correlation was observed with that of the native state. It has been proposed that the stability of the native state and the unfolding rate to the amyloidogenic precursor as well as the conformational preference of the denatured state determine the amyloidogenicity of the proteins. The present results reveal that, in addition, stability of the amyloid fibrils is a key factor determining the amyloidogenic potential of the proteins.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan; Natl Inst Adv Ind Sci & Technol, Special Div Human Life Technol, Osaka 5638577, Japan; Japan Sci & Technol Corp, CREST, Fukui 9101193, Japan; Fukui Med Univ, Dept Pathol, Fukui 9101193, Japan	Osaka University; Japan Science & Technology Agency (JST); National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST); University of Fukui	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.		HAGIHARA, Yoshihisa/K-4996-2016; Naiki, Hironobu/G-5599-2014	HAGIHARA, Yoshihisa/0000-0002-5980-1764; 				BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Brett M, 1999, BRAIN, V122, P183, DOI 10.1093/brain/122.2.183; CASEY TT, 1986, HUM PATHOL, V17, P731, DOI 10.1016/S0046-8177(86)80183-6; Chiti F, 2002, P NATL ACAD SCI USA, V99, P16419, DOI 10.1073/pnas.212527999; Chiti F, 2002, NAT STRUCT BIOL, V9, P137, DOI 10.1038/nsb752; Doering DS, 1996, BIOCHEMISTRY-US, V35, P12677, DOI 10.1021/bi9615699; DOHURA K, 1989, BIOCHEM BIOPH RES CO, V163, P974, DOI 10.1016/0006-291X(89)92317-6; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUSTAVSSON A, 1991, BIOCHEM BIOPH RES CO, V175, P1159, DOI 10.1016/0006-291X(91)91687-8; Hagihara Y, 2002, J BIOL CHEM, V277, P51043, DOI 10.1074/jbc.M208893200; Hagihara Y, 2002, P NATL ACAD SCI USA, V99, P6619, DOI 10.1073/pnas.102172099; Hammarstrom P, 2002, P NATL ACAD SCI USA, V99, P16427, DOI 10.1073/pnas.202495199; Hasegawa K, 2003, BIOCHEM BIOPH RES CO, V304, P101, DOI 10.1016/S0006-291X(03)00543-6; Hong DP, 2002, J BIOL CHEM, V277, P21554, DOI 10.1074/jbc.M200188200; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; Jones S, 2003, J MOL BIOL, V325, P249, DOI 10.1016/S0022-2836(02)01227-5; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; Katou H, 2002, PROTEIN SCI, V11, P2218, DOI 10.1110/ps.0213202; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; KOCH KM, 1992, KIDNEY INT, V41, P1416, DOI 10.1038/ki.1992.207; Kozhukh GV, 2002, J BIOL CHEM, V277, P1310, DOI 10.1074/jbc.M108753200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; MCCUTCHEN SL, 1993, BIOCHEMISTRY-US, V32, P12119, DOI 10.1021/bi00096a024; McParland VJ, 2002, NAT STRUCT BIOL, V9, P326, DOI 10.1038/nsb791; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; Monti M, 2002, PROTEIN SCI, V11, P2362, DOI 10.1110/ps.0206902; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Naiki H, 1996, LAB INVEST, V74, P374; NAIKI H, 1991, LAB INVEST, V65, P104; Ohhashi Y, 2002, J BIOCHEM, V131, P45, DOI 10.1093/oxfordjournals.jbchem.a003076; Richardson JS, 2002, P NATL ACAD SCI USA, V99, P2754, DOI 10.1073/pnas.052706099; SELVAGGINI C, 1993, BIOCHEM BIOPH RES CO, V194, P1380, DOI 10.1006/bbrc.1993.1977; Sigurdsson EM, 2002, TRENDS MOL MED, V8, P411, DOI 10.1016/S1471-4914(02)02403-6; Souillac PO, 2002, J BIOL CHEM, V277, P12657, DOI 10.1074/jbc.M109230200; Trinh CH, 2002, P NATL ACAD SCI USA, V99, P9771, DOI 10.1073/pnas.152337399; Verdone G, 2002, PROTEIN SCI, V11, P487, DOI 10.1110/ps.29002; Yamada M, 1999, NEUROLOGY, V53, P181, DOI 10.1212/WNL.53.1.181	47	111	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47016	47024		10.1074/jbc.M304473200	http://dx.doi.org/10.1074/jbc.M304473200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12958308	Green Published, hybrid			2022-12-25	WOS:000186569400097
J	Ikeda, T; Kasai, M; Suzuki, J; Kuroyama, H; Seki, S; Utsuyama, M; Hirokawa, K				Ikeda, T; Kasai, M; Suzuki, J; Kuroyama, H; Seki, S; Utsuyama, M; Hirokawa, K			Multimerization of the receptor activator of nuclear factor-kappa B ligand (RANKL) isoforms and regulation of osteoclastogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DIFFERENTIATION FACTOR; OSTEOPROTEGERIN LIGAND; CRYSTAL-STRUCTURE; EXTRACELLULAR DOMAIN; INHIBITORY FACTOR; BONE-RESORPTION; IN-VITRO; TRANCE/RANKL; EXPRESSION	The receptor activator of nuclear factor-kappaB ligand ( RANKL), a member of the tumor necrosis factor family, is a transmembrane protein, which is known as an essential initiation factor of osteoclastogenesis. Previously, we identified three RANKL isoforms. RANKL1 was identical to the originally reported RANKL. RANKL2 had a shorter intracellular domain. RANKL3 did not have the intracellular or transmembrane domains and was suggested to act as a soluble form protein. Here, we show that RANKL forms homo- or heteromultimers. NIH3T3 cells transfected with RANKL1 or RANKL2 form mononuclear tartrate- resistant acid phosphatase- positive preosteoclasts in an in vitro osteoclastogenesis assay system. Coexpression of RANKL1 and RANKL2 induces multinucleated osteoclasts. RANKL3 has no effect on the formation of preosteoclasts or osteoclasts but significantly inhibits fusion of preosteoclasts when coexpressed with RANKL1 and RANKL2. These findings imply the presence of multiple multimeric structures of RANKL, which may regulate bone metabolism.	Tokyo Med & Dent Univ, Grad Sch, Dept Pathol & Immunol, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Geriatr Dent, Bunkyo Ku, Tokyo 1138519, Japan; Natl Inst Infect Dis, Dept Safety Res Blood & Biol Prod, Shinjuku Ku, Tokyo 1628640, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); National Institute of Infectious Diseases (NIID)	Ikeda, T (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Dept Pathol & Immunol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.							BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997; Hachiya A, 2001, ANTIMICROB AGENTS CH, V45, P495, DOI 10.1128/AAC.45.2.495-501.2001; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Ikeda T, 2001, ENDOCRINOLOGY, V142, P1419, DOI 10.1210/en.142.4.1419; Inoue M, 1998, MOL ENDOCRINOL, V12, P1955, DOI 10.1210/me.12.12.1955; Ito S, 2002, J BIOL CHEM, V277, P6631, DOI 10.1074/jbc.M106525200; Jimi E, 1999, J IMMUNOL, V163, P434; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002-9440(10)64556-7; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788; SHIOI A, 1994, CALCIFIED TISSUE INT, V55, P387, DOI 10.1007/BF00299320; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITH RA, 1987, J BIOL CHEM, V262, P6951; Tsukii K, 1998, BIOCHEM BIOPH RES CO, V246, P337, DOI 10.1006/bbrc.1998.8610; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; Willard D, 2000, PROTEIN EXPRES PURIF, V20, P48, DOI 10.1006/prep.2000.1278; YAMATO H, 1993, CALCIFIED TISSUE INT, V52, P255, DOI 10.1007/BF00298729; Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	27	44	46	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47217	47222		10.1074/jbc.M304636200	http://dx.doi.org/10.1074/jbc.M304636200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	13679377	hybrid			2022-12-25	WOS:000186569400121
J	Kumar, MJ; Nicholls, DG; Andersen, JK				Kumar, MJ; Nicholls, DG; Andersen, JK			Oxidative alpha-ketoglutarate dehydrogenase inhibition via subtle elevations in monoamine oxidase B levels results in loss of spare respiratory capacity - Implications for Parkinson's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL COMPLEX-I; HYDROGEN-PEROXIDE; HUMAN-BRAIN; NERVE-TERMINALS; FRONTAL-CORTEX; NEURONS; GLUTATHIONE; STRESS; CELLS; METABOLITES	Age-related increases in brain monoamine oxidase B (MAO-B) and its ability to produce reactive oxygen species as a by-product of catalysis could contribute to neurodegeneration associated with Parkinson's disease. This may be via increased oxidative stress and/or mitochondrial dysfunction either on its own or through its interaction with endogenous or exogenous neurotoxic species. We have created genetically engineered dopaminergic PC12 cell lines with subtly increased levels of MAO-B mimicking those observed during normal aging. In our cells, increased MAO-B activity was found to result in increased H2O2 production. This was found to correlate with a decrease in mitochondrial complex I activity which may involve both direct oxidative damage to the complex itself as well as oxidative effects on the tricarboxylic acid cycle enzyme alpha-ketoglutarate dehydrogenase (KGDH) which provides substrate for the complex. Both complex I and KGDH activities have been reported to be decreased in the Parkinsonian brain. These in vitro events are reversible by catalase addition. Importantly, MAO-B elevation was found to abolish the spare KGDH threshold capacity, which can normally be significantly inhibited before it affects maximal mitochondrial oxygen consumption rates. Our data suggest that H2O2 production via subtle elevations in MAO-B levels can result in oxidative effects on KGDH that can compromise the ability of dopaminergic neurons to cope with increased energetic stress.	Buck Inst Age Res, Novato, CA 94945 USA	Buck Institute for Research on Aging	Kumar, MJ (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	jkumar@buckinstitute.org	NICHOLLS, DAVID G/K-4300-2012	Andersen, Julie/0000-0003-1324-4875	NIA NIH HHS [R01 AG 15980] Funding Source: Medline; NINDS NIH HHS [R01 NS 41908] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015980] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARBEAU A, 1973, J AM GERIATR SOC, V21, P145, DOI 10.1111/j.1532-5415.1973.tb00865.x; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BENCH CJ, 1993, PSYCHOPHARMACOLOGY, V112, P308, DOI 10.1007/BF02244926; BENEDETTI MS, 1989, BIOCHEM PHARMACOL, V38, P555, DOI 10.1016/0006-2952(89)90198-6; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bignami Amico, 1995, P843; BUCKMAN TD, 1993, J NEUROCHEM, V60, P2046, DOI 10.1111/j.1471-4159.1993.tb03489.x; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CALNE DB, 1983, LANCET, V2, P1457, DOI 10.1016/S0140-6736(83)90802-4; Chinopoulos C, 2001, J NEUROCHEM, V76, P302, DOI 10.1046/j.1471-4159.2001.00060.x; Chinopoulos C, 1999, ANN NY ACAD SCI, V893, P269, DOI 10.1111/j.1749-6632.1999.tb07834.x; Cohen G, 1990, J Neural Transm Suppl, V32, P229; Cohen G, 1983, J Neural Transm Suppl, V19, P89; Cohen G, 1999, J NEUROCHEM, V73, P2310, DOI 10.1046/j.1471-4159.1999.0732310.x; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; EKBLOM J, 1993, GLIA, V8, P122, DOI 10.1002/glia.440080208; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; FOWLER CJ, 1980, J NEURAL TRANSM, V49, P1, DOI 10.1007/BF01249185; Fowler JS, 1997, NEUROBIOL AGING, V18, P431, DOI 10.1016/S0197-4580(97)00037-7; GALVA MD, 1995, J NEURAL TRANSM-GEN, V101, P83, DOI 10.1007/BF01271547; Gibson GE, 2003, NEUROCHEM INT, V43, P129, DOI 10.1016/S0197-0186(02)00225-5; Glover V, 1980, J Neural Transm Suppl, P163; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAAS RH, 1995, ANN NEUROL, V37, P714, DOI 10.1002/ana.410370604; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hauptmann N, 1996, ARCH BIOCHEM BIOPHYS, V335, P295, DOI 10.1006/abbi.1996.0510; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P552, DOI 10.1021/bi971958i; Irwin I, 1997, NEUROBIOL AGING, V18, P235, DOI 10.1016/S0197-4580(97)00003-1; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Jha N, 2000, J BIOL CHEM, V275, P26096, DOI 10.1074/jbc.M000120200; Kang YS, 1997, NEUROREPORT, V8, P2053, DOI 10.1097/00001756-199705260-00049; KNOLL J, 1986, ADV NEUROL, V45, P107; KORNHUBER J, 1989, BRAIN RES, V499, P81, DOI 10.1016/0006-8993(89)91136-0; LANGSTON JW, 1986, CLIN NEUROPHARMACOL, V9, P485, DOI 10.1097/00002826-198612000-00001; Lenaz G, 1997, MOL CELL BIOCHEM, V174, P329, DOI 10.1023/A:1006854619336; Li H, 2001, J NEURAL TRANSM, V108, P1363, DOI 10.1007/s007020100013; MAKAR TK, 1994, J NEUROCHEM, V62, P45; MANN JJ, 1985, CLIN PHARM STUDIES P, P37; MIZUNO Y, 1990, J NEUROL SCI, V96, P49, DOI 10.1016/0022-510X(90)90056-S; MIZUNO Y, 1994, ANN NEUROL, V35, P204, DOI 10.1002/ana.410350212; MIZUNO Y, 1988, J NEUROL SCI, V86, P97, DOI 10.1016/0022-510X(88)90010-X; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nulton-Persson AC, 2001, J BIOL CHEM, V276, P23357, DOI 10.1074/jbc.M100320200; RAPS SP, 1989, BRAIN RES, V493, P398, DOI 10.1016/0006-8993(89)91178-5; RICAURTE GA, 1986, BRAIN RES, V376, P117, DOI 10.1016/0006-8993(86)90905-4; ROBINSON DS, 1971, ARCH GEN PSYCHIAT, V24, P536; SAGARA J, 1993, J NEUROCHEM, V61, P1672, DOI 10.1111/j.1471-4159.1993.tb09802.x; SASTRE M, 1993, J NEUROCHEM, V61, P881, DOI 10.1111/j.1471-4159.1993.tb03599.x; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; SCHAPIRA AHV, 1990, J NEUROCHEM, V55, P2142, DOI 10.1111/j.1471-4159.1990.tb05809.x; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Sheehan JP, 1997, J NEUROCHEM, V68, P1221; Shih JC, 1979, MONOAMINE OXIDASE ST, P413; Sims NR, 2000, MOL BRAIN RES, V77, P176, DOI 10.1016/S0169-328X(00)00049-8; SOONG NW, 1992, NAT GENET, V2, P318; SZUTOWICZ A, 1989, J BIOL CHEM, V264, P17660; TERRY RD, 1987, ANN NEUROL, V21, P530, DOI 10.1002/ana.410210603; Tretter L, 1997, J NEUROCHEM, V69, P2529; Tretter L, 2000, J NEUROSCI, V20, P8972; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Ward MW, 2000, J NEUROSCI, V20, P7208; WESTLUND KN, 1988, NEUROSCIENCE, V25, P439, DOI 10.1016/0306-4522(88)90250-3; WESTLUND KN, 1985, SCIENCE, V230, P181, DOI 10.1126/science.3875898; WHITTEMORE ER, 1994, NEUROREPORT, V5, P1485, DOI 10.1097/00001756-199407000-00019; Xin WK, 2000, CHEM RES TOXICOL, V13, P749, DOI 10.1021/tx990170t; Zhou MJ, 1997, ANAL BIOCHEM, V253, P169, DOI 10.1006/abio.1997.2392	67	104	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46432	46439		10.1074/jbc.M306378200	http://dx.doi.org/10.1074/jbc.M306378200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963742	hybrid			2022-12-25	WOS:000186569400027
J	Mancini, R; Aebi, M; Helenius, A				Mancini, R; Aebi, M; Helenius, A			Multiple endoplasmic reticulum-associated pathways degrade mutant yeast carboxypeptidase Y in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; MANNOSIDASE-LIKE PROTEIN; ER-ASSOCIATED DEGRADATION; QUALITY-CONTROL; SECRETORY PATHWAY; MISFOLDED GLYCOPROTEINS; MOLECULAR CHAPERONES; SACCHAROMYCES-CEREVISIAE; RETRO-TRANSLOCATION; IN-VIVO	The degradation of misfolded and unassembled proteins by the endoplasmic reticulum (ER)-associated degradation (ERAD) has been shown to occur mainly through the ubiquitin-proteasome pathway after transport of the protein to the cytosol. Recent work has revealed a role for N-linked glycans in targeting aberrant glycoproteins to ERAD. To further characterize the molecular basis of substrate recognition and sorting during ERAD in mammalian cells, we expressed a mutant yeast carboxypeptidase Y (CPY*) in CHO cells. CPY* was retained in the ER in un-aggregated form, and degraded after a 45-min lag period. Degradation was predominantly by a proteasome-independent, non-lysosomal pathway. The inhibitor of ER mannosidase I, kifunensine, blocked the degradation by the alternate pathway but did not affect the proteasomal fraction of degradation. Upon inhibition of glucose trimming, the initial lag period was eliminated and degradation thus accelerated. Our results indicated that, although the proteasome is a major player in ERAD, alternative routes are present in mammalian cells and can play an important role in the disposal of both glycoproteins and non-glycoproteins.	Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland; Swiss Fed Inst Technol, Inst Microbiol, CH-8092 Zurich, Switzerland	ETH Zurich; ETH Zurich	Helenius, A (corresponding author), Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland.							Amshoff C, 1999, BIOL CHEM, V380, P669, DOI 10.1515/BC.1999.083; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; Bodendorf U, 2001, J BIOL CHEM, V276, P12019, DOI 10.1074/jbc.M008861200; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; Braakman I, 2001, EMBO REP, V2, P666, DOI 10.1093/embo-reports/kve162; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Cabral CM, 2000, J BIOL CHEM, V275, P25015, DOI 10.1074/jbc.M910172199; Cannon KS, 1999, J BIOL CHEM, V274, P7537, DOI 10.1074/jbc.274.11.7537; Chillaron J, 2000, BIOL CHEM, V381, P1155, DOI 10.1515/BC.2000.143; Chung DH, 2000, J BIOL CHEM, V275, P4981, DOI 10.1074/jbc.275.7.4981; de Virgilio M, 1999, MOL BIOL CELL, V10, P4059, DOI 10.1091/mbc.10.12.4059; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; ENDRIZZI JA, 1994, BIOCHEMISTRY-US, V33, P11106, DOI 10.1021/bi00203a007; Fagioli C, 2001, J BIOL CHEM, V276, P12885, DOI 10.1074/jbc.M009603200; Fayadat L, 2000, J BIOL CHEM, V275, P15948, DOI 10.1074/jbc.M905763199; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Frigerio L, 2000, CURR BIOL, V10, pR674, DOI 10.1016/S0960-9822(00)00680-1; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Heinemann FS, 1998, MOL BIOL CELL, V9, P3445, DOI 10.1091/mbc.9.12.3445; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Holst B, 1996, EMBO J, V15, P3538, DOI 10.1002/j.1460-2075.1996.tb00723.x; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Jakob CA, 2001, EMBO REP, V2, P423; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Jung GM, 1999, J BIOCHEM-TOKYO, V126, P1; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Loo TW, 1998, J BIOL CHEM, V273, P32373, DOI 10.1074/jbc.273.49.32373; Miller SC, 1998, J BIOL CHEM, V273, P32618, DOI 10.1074/jbc.273.49.32618; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; Nakatsukasa K, 2001, J BIOL CHEM, V276, P8635, DOI 10.1074/jbc.C100023200; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Parodi AJ, 1999, BBA-GEN SUBJECTS, V1426, P287, DOI 10.1016/S0304-4165(98)00130-5; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; SU K, 1993, J BIOL CHEM, V268, P14301; Tokunaga F, 2000, J BIOL CHEM, V275, P40757, DOI 10.1074/jbc.M001073200; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; URADE R, 1993, J BIOL CHEM, V268, P22004; Wang EW, 2000, P NATL ACAD SCI USA, V97, P9990, DOI 10.1073/pnas.180328897; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wilson CM, 2000, J BIOL CHEM, V275, P21224, DOI 10.1074/jbc.M000567200; WINTHER JR, 1991, EUR J BIOCHEM, V197, P681, DOI 10.1111/j.1432-1033.1991.tb15959.x; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	63	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46895	46905		10.1074/jbc.M302979200	http://dx.doi.org/10.1074/jbc.M302979200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12954632	hybrid			2022-12-25	WOS:000186569400083
J	Rahmani, M; Yu, CR; Reese, E; Ahmed, W; Hirsch, K; Dent, P; Grant, S				Rahmani, M; Yu, CR; Reese, E; Ahmed, W; Hirsch, K; Dent, P; Grant, S			Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition	ONCOGENE			English	Article						sodium butyrate; LY294002; apoptosis; AKT; MEK/ERK; p21(CIP1/WAF1)	GLYCOGEN-SYNTHASE KINASE-3; BREAST-CANCER CELLS; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; SODIUM-BUTYRATE; SIGNALING PATHWAY; GRANULOCYTIC DIFFERENTIATION; DEPSIPEPTIDE FR901228; RECEPTOR-GAMMA; UP-REGULATION	Effects of the PI-3 kinase inhibitor LY294002 (LY) have been examined in relation to responses of human leukemia cells to histone deacetylase inhibitors (HDIs). Coexposure of U937 cells for 24 h to marginally toxic concentrations of LY294002 (e.g., 30 mum) and sodium butyrate (SB; 1 mM) resulted in a marked increase in mitochondrial damage (e.g., cytochrome c and Smac/DIABLO release, loss of DeltaPsi(m)), caspase activation, and apoptosis. Similar results were observed in Jurkat, HL-60, and K562 leukemic cells and with other HDIs (e.g., SAHA, MS-275). Exposure of cells to SB/LY was associated with Bcl-2 and Bid cleavage, XIAP and Mcl-1 downregulation, and diminished CD11b expression. While LY blocked SB-mediated Akt activation, enforced expression of a constitutively active (myristolated) Akt failed to attenuate SB/LY-mediated lethality. Unexpectedly, treatment of cells with SB+/-LY resulted in a marked reduction in phosphorylation ( activation) of p44/42 mitogen-activated protein ( MAP) kinase. Moreover, enforced expression of a constitutively active MEK1 construct partially but significantly attenuated SB/LY-induced apoptosis. Lastly, cotreatment with LY blocked SB-mediated induction of p21(CIP1/WAF1); moreover, enforced expression of p21(CIP1/WAF1) significantly reduced SB/LY-mediated apoptosis. Together, these findings indicate that LY promotes SB-mediated apoptosis through an AKT-independent process that involves MEK/MAP kinase inactivation and interference with p21(CIP1/WAF1) induction.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Div Hematol Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Grant, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Div Hematol Oncol, MCV Stn Box 230, Richmond, VA 23298 USA.			Hirsch, Karen/0000-0002-5474-3243; Rahmani, Mohamed/0000-0002-3992-8039	NATIONAL CANCER INSTITUTE [R55CA093798, R01CA093798, R01CA063753] Funding Source: NIH RePORTER; NCI NIH HHS [CA 93798, CA 63753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Asada M, 1998, LEUKEMIA, V12, P1944, DOI 10.1038/sj.leu.2401228; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Byrd JC, 1999, BLOOD, V94, P1401, DOI 10.1182/blood.V94.4.1401.416k30_1401_1408; Cartee L, 2001, CANCER RES, V61, P2583; Cataldi A, 2000, CELL SIGNAL, V12, P667, DOI 10.1016/S0898-6568(00)00109-1; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Das D, 2000, FEBS LETT, V472, P50, DOI 10.1016/S0014-5793(00)01416-2; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GUM JR, 1987, J BIOL CHEM, V262, P1092; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Kubota Y, 1998, CELL GROWTH DIFFER, V9, P247; Kubota Y, 2001, EMBO J, V20, P5666, DOI 10.1093/emboj/20.20.5666; Lee BI, 2001, CANCER RES, V61, P931; Lewandowski D, 2002, BRIT J HAEMATOL, V118, P535, DOI 10.1046/j.1365-2141.2002.03601.x; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; Miranda MB, 2002, LEUKEMIA, V16, P683, DOI 10.1038/sj.leu.2402400; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036; Nakashio A, 2000, CANCER RES, V60, P5303; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Page C, 2000, ANTICANCER RES, V20, P407; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Park SJ, 2002, IMMUNOPHARM IMMUNOT, V24, P211, DOI 10.1081/IPH-120003751; Rahmani M, 2002, EXP CELL RES, V277, P31, DOI 10.1006/excr.2002.5548; Rane SG, 2002, BLOOD, V100, P2753, DOI 10.1182/blood.V100.8.2753; Rosato RR, 2002, MOL CANCER THER, V1, P253; Rosato RR, 2001, INT J ONCOL, V19, P181; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Sidhu JS, 2001, MOL PHARMACOL, V59, P1138, DOI 10.1124/mol.59.5.1138; Sowa Y, 2000, BIOFACTORS, V12, P283, DOI 10.1002/biof.5520120142; Stein RC, 2001, ENDOCR-RELAT CANCER, V8, P237, DOI 10.1677/erc.0.0080237; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176; Wang QD, 2002, CLIN CANCER RES, V8, P1940; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yu CR, 2003, CANCER RES, V63, P1822; Yu XD, 2002, J NATL CANCER I, V94, P504; Yusta B, 2002, J BIOL CHEM, V277, P24896, DOI 10.1074/jbc.M201358200	61	89	96	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6231	6242		10.1038/sj.onc.1206646	http://dx.doi.org/10.1038/sj.onc.1206646			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679862				2022-12-25	WOS:000185506200013
J	Butz, K; Ristriani, T; Hengstermann, A; Denk, C; Scheffner, M; Hoppe-Seyler, F				Butz, K; Ristriani, T; Hengstermann, A; Denk, C; Scheffner, M; Hoppe-Seyler, F			siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells	ONCOGENE			English	Article						RNA interference; human papillomavirus; apoptosis; tumour virus; tumour therapy	INDUCED APOPTOSIS; RNA INTERFERENCE; MAMMALIAN-CELLS; GENE-EXPRESSION; MESSENGER-RNA; P53 PROTEIN; E7; INHIBITION; PEPTIDES; TYPE-16	The targeted inhibition of antiapoptotic factors in tumour cells may provide a rational approach towards the development of novel anticancer therapies. Using human papillomavirus (HPV)-transformed cells as a model system, we investigated if RNA interference (RNAi)-mediated gene silencing can be employed in order to overcome the apoptosis resistance of cancer cells. We found that both vector-borne and synthetic small interfering (si)RNAs, specifically directed against the antiapoptotic HPV E6 oncogene, restored dormant tumour suppressor pathways in HPV-positive cancer cells that are otherwise inactive in the presence of E6. This ultimately resulted in massive apoptotic cell death, selectively in HPV-positive tumour cells. These findings show that RNAi provides a powerful molecular strategy to inactivate intracellular E6 function efficiently. Moreover, they define E6 as a most promising therapeutic target to eliminate HPV-positive tumour cells specifically by RNAi. Thus, by sequence-specific targeting of antiapoptotic genes, siRNAs may be developed into novel therapeutics that can efficiently correct the apoptosis deficiency of cancer cells.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Univ Cologne, Fak Med, Zentrum Biochem, D-50931 Cologne, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Cologne	Hoppe-Seyler, F (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	hoppe-seyler@dkfz.de	Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128; Hoppe-Seyler, Felix/0000-0002-1864-300X				Agami R, 2002, CURR OPIN CHEM BIOL, V6, P829, DOI 10.1016/S1367-5931(02)00378-2; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Butz K, 1998, ONCOGENE, V17, P781, DOI 10.1038/sj.onc.1201995; BUTZ K, 1995, ONCOGENE, V10, P927; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Hoppe-Seyler F, 1999, ANTICANCER RES, V19, P4747; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523; Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SMOTKIN D, 1989, J VIROL, V63, P1441, DOI 10.1128/JVI.63.3.1441-1447.1989; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Venturini F, 1999, NUCLEIC ACIDS RES, V27, P1585, DOI 10.1093/nar/27.7.1585; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	46	267	303	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5938	5945		10.1038/sj.onc.1206894	http://dx.doi.org/10.1038/sj.onc.1206894			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955072				2022-12-25	WOS:000185137800002
J	Andriamampandry, C; Taleb, O; Viry, S; Muller, C; Humbert, JP; Gobaille, S; Aunis, D; Maitre, M				Andriamampandry, C; Taleb, O; Viry, S; Muller, C; Humbert, JP; Gobaille, S; Aunis, D; Maitre, M			Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate	FASEB JOURNAL			English	Article						receptor for neuromodulator; drug of abuse; GHB; sleep regulation	SUCCINIC SEMI-ALDEHYDE; REGIONAL-DISTRIBUTION; HYDROXYCROTONIC ACID; GUINEA-PIG; SUPERFAMILY; SITES; SLEEP; LOCALIZATION; EXPRESSION; NARCOLEPSY	gamma-Hydroxybutyrate (GHB) is an endogenous neuromodulator with therapeutical applications in anesthesia, sleep disorders, and drug addiction. We report the cloning of a GHB receptor from a rat hippocampal cDNA library. This receptor has a molecular mass of 56 kDa and belongs to the seven-transmembrane receptor family. The peptidic sequence has no significant homology with any known receptor, including GABA(B) receptors. Its mRNA is restricted to the brain and is particularly abundant in the hippocampus, cortex, striatum, thalamus, olfactory bulbs, and cerebellum, matching the distribution of GHB binding sites in rat brain. Southern blot revealed the presence of homologous sequences in several species including the human. Binding assays on transfected CHO cells showed a dissociation constant (K-d) of 426 nM for GHB and no affinity for GABA, baclofen, or glutamate. In patch-clamp experiments, transfected CHO cells revealed a functional G-protein-coupled receptor as demonstrated by GTP-gamma-S-induced irreversible activation. Application of 0.1-15 muM GHB specifically induced an inward current at negative membrane potentials that was not reproduced by application of baclofen (10 muM). CGP-55845, a GABAB receptor antagonist, did not inhibit the GHB-induced response nor did the GHB receptor antagonist NCS-382, suggesting that the GHB receptor system includes several subtypes.	Fac Med Strasbourg, Inst Chim Biol, F-67085 Strasbourg, France; Fac Med Strasbourg, INSERM, U575, F-67085 Strasbourg, France	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Maitre, M (corresponding author), Fac Med Strasbourg, Inst Chim Biol, 11 Rue Humann, F-67085 Strasbourg, France.	maitre@neurochem.u-strasbg.fr	Maitre, Michel/J-9974-2016; Dominique, Aunis/W-1419-2019; Taleb, Omar/K-1457-2016	Maitre, Michel/0000-0003-1478-4806; Taleb, Omar/0000-0003-2407-0380				Andriamampandry C, 1998, BIOCHEM J, V334, P43, DOI 10.1042/bj3340043; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BENAVIDES J, 1982, LIFE SCI, V30, P953, DOI 10.1016/0024-3205(82)90624-5; Bourguignon JJ, 2000, ALCOHOL, V20, P227, DOI 10.1016/S0741-8329(99)00086-5; BRUGGER F, 1993, EUR J PHARMACOL, V235, P153, DOI 10.1016/0014-2999(93)90836-7; CASH CD, 1979, J NEUROCHEM, V33, P1169, DOI 10.1111/j.1471-4159.1979.tb05261.x; Cash CD, 1996, NEUROSCI LETT, V209, P25, DOI 10.1016/0304-3940(96)12589-1; CHIN MY, 1992, WESTERN J MED, V156, P380; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colombo G, 2002, GAMMA-HYDROXYBUTYRATE: MOLECULAR, FUNCTIONAL, AND CLINICAL ASPECTS, P150, DOI 10.4324/9780203300992_chapter_9; Crunelli V, 2002, GAMMA-HYDROXYBUTYRATE: MOLECULAR, FUNCTIONAL, AND CLINICAL ASPECTS, P75, DOI 10.4324/9780203300992_chapter_5; DOHERTY JD, 1978, J PHARMACOL EXP THER, V207, P130; Friedman J, 1996, NEUROLOGY, V46, P469, DOI 10.1212/WNL.46.2.469; GALLIMBERTI L, 1989, LANCET, V2, P787; Galloway GP, 1997, ADDICTION, V92, P89, DOI 10.1111/j.1360-0443.1997.tb03640.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRIS NC, 1989, NEUROSCIENCE, V31, P363, DOI 10.1016/0306-4522(89)90380-1; HECHLER V, 1992, BRAIN RES, V572, P345, DOI 10.1016/0006-8993(92)90498-X; HECHLER V, 1990, NEUROSCI LETT, V110, P204, DOI 10.1016/0304-3940(90)90812-N; HECHLER V, 1993, J PHARMACOL EXP THER, V264, P1406; KALINYAK JE, 1987, J BIOL CHEM, V262, P460; Kemmel V, 1998, NEUROSCIENCE, V86, P989, DOI 10.1016/S0306-4522(98)00085-2; LABORIT G, 1980, AGRESSOLOGIE, V21, P189; LABORIT H, 1964, INT J NEUROPHARMACOL, V3, P433; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MAITRE M, 1990, J PHARMACOL EXP THER, V255, P657; Maitre M, 1997, PROG NEUROBIOL, V51, P337, DOI 10.1016/S0301-0082(96)00064-0; MAITRE M, 1994, EUR J PHARMACOL, V256, P211, DOI 10.1016/0014-2999(94)90248-8; MAMELAK M, 1986, SLEEP, V9, P285, DOI 10.1093/sleep/9.1.285; Maniatis T., 1982, MOL CLONING LAB MANU; OLPE HR, 1979, EUR J PHARMACOL, V53, P359, DOI 10.1016/0014-2999(79)90460-6; PRITCHETT DB, 1988, EMBO J, V7, P4135, DOI 10.1002/j.1460-2075.1988.tb03308.x; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROTH RH, 1970, BIOCHEM PHARMACOL, V19, P3013, DOI 10.1016/0006-2952(70)90087-0; RUMIGNY JF, 1981, J NEUROCHEM, V36, P1433, DOI 10.1111/j.1471-4159.1981.tb00583.x; RUMIGNY JF, 1981, FEBS LETT, V134, P96, DOI 10.1016/0014-5793(81)80559-5; SCHARF MB, 1985, J CLIN PSYCHIAT, V46, P222; Scharf MB, 1998, J RHEUMATOL, V25, P1986; SCRIMA L, 1990, SLEEP, V13, P479, DOI 10.1093/sleep/13.6.479; Sincock PM, 1997, J HISTOCHEM CYTOCHEM, V45, P515, DOI 10.1177/002215549704500404; SNEAD OC, 1994, BRAIN RES, V659, P147, DOI 10.1016/0006-8993(94)90874-5; Snead OC, 2000, J NEUROCHEM, V75, P1986, DOI 10.1046/j.1471-4159.2000.0751986.x; SNEAD OC, 1991, NEUROPHARMACOLOGY, V30, P161, DOI 10.1016/0028-3908(91)90199-L; SNEAD OC, 1981, DEV BRAIN RES, V1, P579; SNEAD OC, 1984, BIOCHEM PHARMACOL, V33, P2587; Stell IM, 1996, BRIT MED J, V313, P424; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; VAYER P, 1988, NEUROSCI LETT, V87, P99, DOI 10.1016/0304-3940(88)90152-8; VAYER P, 1988, NEUROCHEM INT, V12, P53, DOI 10.1016/0197-0186(88)90148-9; VAYER P, 1985, BIOCHEM PHARMACOL, V34, P2401, DOI 10.1016/0006-2952(85)90804-4	51	92	100	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1691	+		10.1096/fj.02-0846fje	http://dx.doi.org/10.1096/fj.02-0846fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958178				2022-12-25	WOS:000184471600011
J	Laurine, E; Gregoire, C; Fandrich, M; Engemann, S; Marchal, S; Thion, L; Mohr, M; Monsarrat, B; Michel, B; Dobson, CM; Wanker, E; Erard, M; Verdier, JM				Laurine, E; Gregoire, C; Fandrich, M; Engemann, S; Marchal, S; Thion, L; Mohr, M; Monsarrat, B; Michel, B; Dobson, CM; Wanker, E; Erard, M; Verdier, JM			Lithostathine quadruple-helical filaments form proteinase K-resistant deposits in Creutzfeldt-Jakob disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERIVATIVE UV-SPECTROSCOPY; ALZHEIMERS-DISEASE; CRYSTAL-STRUCTURE; FIBRIL FORMATION; BINDING PROTEIN; HIGH-PRESSURE; IN-VITRO; AGGREGATION; AMYLOIDOSIS; EXPRESSION	Autocatalytic cleavage of lithostathine leads to the formation of quadruple-helical fibrils (QHF-litho) that are present in Alzheimer's disease. Here we show that such fibrils also occur in Creutzfeldt-Jakob and Gerstmann-Straussler-Scheinker diseases, where they form protease-K-resistant deposits and co-localize with amyloid plaques formed from prion protein. Lithostathine does not appear to change its native-like, globular structure during fibril formation. However, we obtained evidence that a cluster of six conserved tryptophans, positioned around a surface loop, could act as a mobile structural element that can be swapped between adjacent protein molecules, thereby enabling the formation of higher order fibril bundles. Despite their association with these clinical amyloid deposits, QHF-litho differ from typical amyloid fibrils in several ways, for example they produce a different infrared spectrum and cannot bind Congo Red, suggesting that they may not represent amyloid structures themselves. Instead, we suggest that lithostathine constitutes a novel component decorating disease-associated amyloid fibrils. Interestingly, [6,6']bibenzothiazolyl-,2'diamine, an agent found previously to disrupt aggregates of huntingtin associated with Huntington's disease, can dissociate lithostathine bundles into individual protofilaments. Disrupting QHF-litho fibrils could therefore represent a novel therapeutic strategy to combat clinical amyloidoses.	Ecole Prat Hautes Etud, F-34095 Montpellier 05, France; Inst Mol Biotechnol, D-07708 Jena, Germany; Max Delbruck Ctr Mol Med, Neuroproteom Sect, D-13125 Berlin, Germany; INSERM, U128, F-34095 Montpellier 05, France; Inst Pharmacol & Biol Struct, F-31077 Toulouse 04, France; Hop Hautepierre, Serv Anat Pathol Gen, F-67100 Strasbourg, France; Hop St Marguerite, Unite Neurogeriat, F-13385 Marseille 05, France; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universite de Montpellier; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Cambridge	Verdier, JM (corresponding author), Univ Montpellier 2, EPHE, 11 Pl Eugene Bataillon,CC94, F-34095 Montpellier 05, France.	verdier@univ-montp2.fr	MARCHAL, stéphane/M-4324-2017	MARCHAL, stéphane/0000-0002-1101-7890; VERDIER, Jean-Michel/0000-0002-7252-1556; Wanker, Erich/0000-0001-8072-1630				BALDWIN MA, 1994, PHILOS T ROY SOC B, V343, P435, DOI 10.1098/rstb.1994.0041; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; Bergdoll M, 1997, STRUCTURE, V5, P391, DOI 10.1016/S0969-2126(97)00196-2; Bertrand JA, 1996, EMBO J, V15, P2678, DOI 10.1002/j.1460-2075.1996.tb00628.x; Bons N, 2002, CR BIOL, V325, P67, DOI 10.1016/S1631-0691(02)01390-2; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; BROWN P, 1990, NEUROLOGY, V40, P226, DOI 10.1212/WNL.40.2.226; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Cerini C, 1999, J BIOL CHEM, V274, P22266, DOI 10.1074/jbc.274.32.22266; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; DECARO A, 1984, BIOCHEM J, V222, P669, DOI 10.1042/bj2220669; DELAMONTE SM, 1990, J CLIN INVEST, V86, P1004, DOI 10.1172/JCI114762; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; DONG AC, 1995, J PHARM SCI-US, V84, P415, DOI 10.1002/jps.2600840407; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; Duplan L, 2001, NEUROBIOL AGING, V22, P79, DOI 10.1016/S0197-4580(00)00182-2; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; Fandrich M, 2002, EMBO J, V21, P5682, DOI 10.1093/emboj/cdf573; Ferrer I, 2001, ACTA NEUROPATHOL, V101, P49; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Fukuda K, 2000, BIOCHEMISTRY-US, V39, P1915, DOI 10.1021/bi992134z; GLENNER GG, 1974, J HISTOCHEM CYTOCHEM, V22, P1141, DOI 10.1177/22.12.1141; GREER J, 1991, METHOD ENZYMOL, V202, P239; Gregoire C, 2001, EMBO J, V20, P3313, DOI 10.1093/emboj/20.13.3313; Hakansson M, 2002, CURR PROTEIN PEPT SC, V3, P629, DOI 10.2174/1389203023380459; HARIS PI, 1992, TRENDS BIOCHEM SCI, V17, P328, DOI 10.1016/0968-0004(92)90305-S; Heiser V, 2002, P NATL ACAD SCI USA, V99, P16400, DOI 10.1073/pnas.182426599; Iida T, 2001, NEUROPATHOLOGY, V21, P294, DOI 10.1046/j.1440-1789.2001.00407.x; Lange R, 1996, EUR BIOPHYS J BIOPHY, V24, P284; Lange R, 1996, EUR BIOPHYS J BIOPHY, V24, P277; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; LAURINE E, 2003, J BIOL CHEM; Linhananta A, 2002, PROTEIN SCI, V11, P1695, DOI 10.1110/ps.0205002; Lomas DA, 2002, NAT REV GENET, V3, P759, DOI 10.1038/nrg907; Newcomer ME, 2002, CURR OPIN STRUC BIOL, V12, P48, DOI 10.1016/S0959-440X(02)00288-9; OZTURK M, 1989, P NATL ACAD SCI USA, V86, P419, DOI 10.1073/pnas.86.2.419; Pepys MB, 2002, NATURE, V417, P254, DOI 10.1038/417254a; Pepys MB, 2001, PHILOS T R SOC B, V356, P203, DOI 10.1098/rstb.2000.0766; Ramoni R, 2002, BIOCHEM J, V365, P739, DOI 10.1042/BJ20011631; Rousseau F, 2001, P NATL ACAD SCI USA, V98, P5596, DOI 10.1073/pnas.101542098; Sandilands A, 2002, EMBO J, V21, P6005, DOI 10.1093/emboj/cdf609; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Westermark P, 2002, AMYLOID, V9, P197; Zerovnik E, 2002, EUR J BIOCHEM, V269, P3362, DOI 10.1046/j.1432-1033.2002.03024.x	47	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51770	51778		10.1074/jbc.M306767200	http://dx.doi.org/10.1074/jbc.M306767200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	13129929	hybrid			2022-12-25	WOS:000187206300112
J	Chen, QF; Behar, KL; Xu, T; Fan, CH; Haddad, GG				Chen, QF; Behar, KL; Xu, T; Fan, CH; Haddad, GG			Expression of Drosophila trehalose-phosphate synthase in HEK-293 cells increases hypoxia tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; UBIQUITIN; THERMOTOLERANCE; MECHANISMS; APOPTOSIS; SURVIVAL; YEAST	Increasing hypoxia tolerance in mammalian cells is potentially of major importance, but it has not been feasible thus far. The disaccharide trehalose, which accumulates dramatically during heat shock, enhances thermotolerance and reduces aggregation of denatured proteins. Previous studies from our laboratory showed that over-expression of Drosophila trehalose-phosphate synthase (dtps1) increases the trehalose level and anoxia tolerance in flies. To determine whether trehalose can protect against anoxic injury in mammalian cells, we transfected the dtps1 gene into human HEK-293 cells using the recombinant plasmid pcDNA3.1(-)-dtps1 and obtained more than 20 stable cell strains. Glucose starvation in culture showed that HEK-293 cells transfected with pcDNA3.1(-)-dtps1 (HEK-dtps1) do not metabolize intracellular trehalose, and, interestingly, these cells accumulated intracellular trehalose during hypoxic exposure. In contrast to HEK-293 cells transfected with pcDNA3.1(-) (HEK-v), cells with trehalose were more resistant to low oxygen stress (1% O-2). To elucidate how trehalose protects cells from anoxic injury, we assayed protein solubility and the amount of ubiquitinated proteins. There was three times more insoluble protein in HEK-v than in HEK-dtps1 after 3 days of exposure to low O-2. The amount of Na+-K+ ATPase present in the insoluble proteins dramatically increased in HEK-v cells after 2 and 3 days of exposure, whereas there was no significant change in HEK-dtps1 cells. Ubiquitinated proteins increased dramatically in HEK-v cells after 2 and 3 days of exposure but not in HEK-dtps1 cells over the same period. Our results indicate that increased trehalose in mammalian cells following transfection by the Drosophila tps1 gene protects cells from hypoxic injury. The mechanism of this protection is likely related to a decrease in protein denaturation, through protein-trehalose interactions, resulting in enhanced cellular recovery from hypoxic stress.	Yeshiva Univ Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, New Haven, CT 06520 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yale University; Yale University; Yale University	Haddad, GG (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Pediat, 1410 Pelham Pkwy, Bronx, NY 10461 USA.	Ghaddad@aecom.yu.edu		Behar, Kevin/0000-0003-1467-0446	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD032573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037754] Funding Source: NIH RePORTER; NICHD NIH HHS [P01 HD032573, P01-HD32573-09] Funding Source: Medline; NINDS NIH HHS [R01-NS37754] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arguelles JC, 2000, ARCH MICROBIOL, V174, P217, DOI 10.1007/s002030000192; AUFRICHT C, 1998, J PHYSL, V274, pF215; Banasiak KJ, 2000, PROG NEUROBIOL, V62, P215, DOI 10.1016/S0301-0082(00)00011-3; BARTON JK, 1982, J BACTERIOL, V151, P177, DOI 10.1128/JB.151.1.177-185.1982; Beattie GM, 1997, DIABETES, V46, P519, DOI 10.2337/diabetes.46.3.519; Bell W, 1998, J BIOL CHEM, V273, P33311, DOI 10.1074/jbc.273.50.33311; Boutilier RG, 2001, J EXP BIOL, V204, P3171; CARPENTER JF, 1989, BIOCHEMISTRY-US, V28, P3916, DOI 10.1021/bi00435a044; Chen QF, 2002, J BIOL CHEM, V277, P3274, DOI 10.1074/jbc.M109479200; Crowe JH, 1990, WATER SCI REV, V5, P1; DEVIRGILIO C, 1994, EUR J BIOCHEM, V219, P179; Elbein AD, 2003, GLYCOBIOLOGY, V13, p17R, DOI 10.1093/glycob/cwg047; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Klimaschewski L, 2003, NEWS PHYSIOL SCI, V18, P29, DOI 10.1152/nips.01408.2002; Pasquini LA, 2002, NEUROCHEM RES, V27, P1401, DOI 10.1023/A:1021631901827; Puhlev I, 2001, CRYOBIOLOGY, V42, P207, DOI 10.1006/cryo.2001.2324; RUDOLPH BR, 1990, CHEM PHYS LIPIDS, V53, P243, DOI 10.1016/0009-3084(90)90050-2; Singer MA, 1998, TRENDS BIOTECHNOL, V16, P460, DOI 10.1016/S0167-7799(98)01251-7; Soldatenkov VA, 1997, CANCER RES, V57, P3881; Suzuki K, 2000, CIRCULATION, V102, P216; THEVELEIN JM, 1998, P NATL ACAD SCI USA, V79, P3503; Winderickx J, 1996, MOL GEN GENET, V252, P470, DOI 10.1007/s004380050252; Zhong N, 2000, ACTA PHARMACOL SIN, V21, P467	24	49	60	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49113	49118		10.1074/jbc.M308652200	http://dx.doi.org/10.1074/jbc.M308652200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	13129920	hybrid			2022-12-25	WOS:000186829000074
J	Rauch, J; Gumperz, J; Robinson, C; Skold, M; Roy, C; Young, DC; Lafleur, M; Moody, DB; Brenner, MB; Costello, CE; Behar, SM				Rauch, J; Gumperz, J; Robinson, C; Skold, M; Roy, C; Young, DC; Lafleur, M; Moody, DB; Brenner, MB; Costello, CE; Behar, SM			Structural features of the acyl chain determine self-phospholipid antigen recognition by a CD1d-restricted invariant NKT (iNKT) cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-GALACTOSYLCERAMIDE; T-CELLS; MOUSE CD1; CRYSTAL-STRUCTURE; LIPID ANTIGEN; ACTIVATION; BINDING; LIGAND; REQUIREMENTS; GLYCOLIPIDS	Little is known about the antigen specificity of CD1d-restricted T cells, except that they frequently recognize CD1d-expressing antigen-presenting cells in the absence of exogenous antigen. We previously demonstrated that the 24.8.A iNKT cell hybridoma was broadly reactive with CD1d-transfected cell lines and recognized the polar lipid fraction of a tumor cell extract. In the present study, the antigen recognized by the 24.8.A iNKT cell hybridoma was purified to homogeneity and identified as palmitoyl-oleoyl-sn-glycero-3-phosphoethanolamine (16: 0 - 18: 1 PE). The 24.8. A iNKT cell hybridoma recognized synthetic 16: 0-18: 1[cis] PE, confirming that this phospholipid is antigenic. Recognition correlated with the degree of unsaturation of the acyl chains. Using a panel of synthetic PEs, the 24.8. A iNKT cell hybridoma was shown to be activated by PEs that contained at least one unsaturated acyl chain. The configuration of the double bonds was important, as the 24.8. A iNKT cell hybridoma recognized unsaturated acyl chains in the cis, but not the trans, configuration. PEs with multiple double bonds were recognized better than those with a single double bond, and increasing acyl chain unsaturation correlated with increased binding of PE to CD1d. These data illustrate the potential importance of the acyl chain structure for phospholipid antigen binding to CD1d.	Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; McGill Univ, Ctr Hlth, Res Inst, Div Rheumatol, Montreal, PQ H3G 1A4, Canada; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Univ Montreal, Dept Chem, Montreal, PQ H3C 3J7, Canada	Harvard University; Brigham & Women's Hospital; McGill University; Boston University; Universite de Montreal	Behar, SM (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Smith Bldg,Rm 516,1 Jimmy Fund Way, Boston, MA 02115 USA.	sbehar@rics.bwh.harvard.edu	Behar, Samuel M/C-3541-2009	Costello, Catherine/0000-0003-1594-5122; Behar, Samuel/0000-0002-3374-6699	Canadian Institutes of Health Research [42391] Funding Source: Medline; NHLBI NIH HHS [R01 HL071590] Funding Source: Medline; NIAID NIH HHS [R01 AI049313, R01-AI49313] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049313] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; Behar SM, 1999, J IMMUNOL, V162, P161; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; Burdin N, 1998, J IMMUNOL, V161, P3271; Cantu C, 2003, J IMMUNOL, V170, P4673, DOI 10.4049/jimmunol.170.9.4673; CARDELL S, 1995, J EXP MED, V182, P993, DOI 10.1084/jem.182.4.993; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; Cronan JE, 2002, CURR OPIN MICROBIOL, V5, P202, DOI 10.1016/S1369-5274(02)00297-7; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; Cullis P.R., 1985, PHOSPHOLIPIDS CELLUL, P1; D'Andrea A, 2000, EUR J IMMUNOL, V30, P1544, DOI 10.1002/1521-4141(200006)30:6<1544::AID-IMMU1544>3.0.CO;2-I; De Silva AD, 2002, J IMMUNOL, V168, P723, DOI 10.4049/jimmunol.168.2.723; Exley M, 1997, J EXP MED, V186, P109, DOI 10.1084/jem.186.1.109; Exley MA, 2001, J LEUKOCYTE BIOL, V69, P713; Gadola SD, 2002, J IMMUNOL, V168, P5514, DOI 10.4049/jimmunol.168.11.5514; Gonzalez-Aseguinolaza G, 2000, P NATL ACAD SCI USA, V97, P8461, DOI 10.1073/pnas.97.15.8461; Grant EP, 2002, J IMMUNOL, V168, P3933, DOI 10.4049/jimmunol.168.8.3933; Gumperz JE, 2000, IMMUNITY, V12, P211, DOI 10.1016/S1074-7613(00)80174-0; Joyce S, 1998, SCIENCE, V279, P1541, DOI 10.1126/science.279.5356.1541; Kakimi K, 2000, J EXP MED, V192, P921, DOI 10.1084/jem.192.7.921; Kawano T, 1999, CANCER RES, V59, P5102; Kawano T, 1998, P NATL ACAD SCI USA, V95, P5690, DOI 10.1073/pnas.95.10.5690; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; LJUNGGREN HG, 1991, INT J CANCER, P38; Miyamoto K, 2001, NATURE, V413, P531, DOI 10.1038/35097097; Moody DB, 2000, J EXP MED, V192, P965, DOI 10.1084/jem.192.7.965; Moody DB, 2002, NAT IMMUNOL, V3, P435, DOI 10.1038/ni780; Moody DB, 1997, SCIENCE, V278, P283, DOI 10.1126/science.278.5336.283; Naidenko OV, 1999, J EXP MED, V190, P1069, DOI 10.1084/jem.190.8.1069; Niazi KR, 2001, J IMMUNOL, V166, P2562, DOI 10.4049/jimmunol.166.4.2562; Park SH, 1998, J IMMUNOL, V160, P3128; Park SH, 2001, J EXP MED, V193, P893, DOI 10.1084/jem.193.8.893; Porcelli SA, 1997, CURR BIOL, V7, pR508, DOI 10.1016/S0960-9822(06)00250-8; Schofield L, 1999, SCIENCE, V283, P225, DOI 10.1126/science.283.5399.225; SMITH PBW, 1995, ANAL CHEM, V67, P1824, DOI 10.1021/ac00107a011; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; Taniguchi M, 2003, ANNU REV IMMUNOL, V21, P483, DOI 10.1146/annurev.immunol.21.120601.141057; TILCOCK CPS, 1982, BIOCHIM BIOPHYS ACTA, V684, P212, DOI 10.1016/0005-2736(82)90008-6; van der Vliet HJJ, 2000, BLOOD, V95, P2440, DOI 10.1182/blood.V95.7.2440.007k35_2440_2442; Wang B, 2001, J EXP MED, V194, P313, DOI 10.1084/jem.194.3.313; Wilson SB, 1998, NATURE, V391, P177, DOI 10.1038/34419; Zajonc DM, 2003, NAT IMMUNOL, V4, P808, DOI 10.1038/ni948; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	44	116	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47508	47515		10.1074/jbc.M308089200	http://dx.doi.org/10.1074/jbc.M308089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12963715	hybrid, Green Accepted			2022-12-25	WOS:000186731400022
J	Guo, C; Piacentini, L				Guo, C; Piacentini, L			Type I collagen-induced MMP-2 activation coincides with up-regulation of membrane type 1-matrix metalloproteinase and TIMP-2 in cardiac fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1 MATRIX-METALLOPROTEINASE; INTEGRIN ALPHA(V) SUBUNIT; GELATINASE-A; ENDOTHELIAL-CELLS; TISSUE INHIBITOR; PROGELATINASE-A; CARCINOMA-CELLS; ANGIOTENSIN-II; TUMOR-CELLS; EXPRESSION	Migration of cardiac fibroblasts is implicated in infarct healing and ventricular remodeling. Activation of matrix metalloproteinases induced by three-dimensional type I collagen, the principal component of the myocardial interstitium, is hypothesized to be essential for this migration. By utilizing primary cultures of cardiac fibroblasts and collagen lattice models, we demonstrated that type I collagen induced MMP-2 activation, and cells undergoing a change from isometric tension to mechanical unloading were associated with increased levels of total and active MMP-2 species. The collagen-induced MMP-2 activation coincided with up-regulated cellular levels of both membrane type 1-matrix metalloproteinase (MT1-MMP) and TIMP-2. A fraction of cellular membrane prepared from cells embedded in the collagen lattice containing active MT1-MMP and TIMP-2 was capable of activating pro-MMP-2, and exogenous TIMP-2 had a biphasic effect on this membrane-mediated MMP-2 activation. Interestingly, the presence of 43-kDa MT1-MMP species in a fraction of intracellular soluble proteins prepared from monolayer cells but not cells embedded in the lattices indicates that MT1-MMP metabolizes differently under the two different culture conditions. Treatment of cells embedded in the lattice with furin inhibitor attenuated pro-MT1-MMP processing and MMP-2 activation and impeded cell migration and invasion. These results suggest that the migration and invasion of cardiac fibroblasts is furin-dependent and that the active species of MT1-MMP and MMP-2 may be involved in both events.	De Montfort Univ, Sch Pharm & Pharmaceut Sci, Leicester LE1 9BH, Leics, England	De Montfort University	Guo, C (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Guo, Chun/AAM-5894-2020	Guo, Chun/0000-0002-1540-3166				AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; ALBINI A, 1987, CANCER RES, V47, P3239; Arora PD, 1999, AM J PATHOL, V154, P871, DOI 10.1016/S0002-9440(10)65334-5; Aznavoorian S, 2001, CANCER RES, V61, P6264; Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; Bassi DE, 2001, P NATL ACAD SCI USA, V98, P10326, DOI 10.1073/pnas.191199198; Borg KT, 1997, CARDIOVASC PATHOL, V6, P261, DOI 10.1016/S1054-8807(96)00138-X; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deryugina EI, 1997, J CELL SCI, V110, P2473; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Graf K, 2000, HYPERTENSION, V35, P978, DOI 10.1161/01.HYP.35.4.978; Grinnell F, 1999, EXP CELL RES, V248, P608, DOI 10.1006/excr.1999.4440; Grinnell F, 1999, J BIOL CHEM, V274, P918, DOI 10.1074/jbc.274.2.918; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kanekar S, 2000, CELL ADHES COMMUN, V7, P513, DOI 10.3109/15419060009040308; Kurschat P, 1999, J BIOL CHEM, V274, P21056, DOI 10.1074/jbc.274.30.21056; Lee AY, 1997, P NATL ACAD SCI USA, V94, P4424, DOI 10.1073/pnas.94.9.4424; Li L, 1997, EXP CELL RES, V232, P322, DOI 10.1006/excr.1997.3510; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; MAYER U, 1993, EUR J BIOCHEM, V217, P877, DOI 10.1111/j.1432-1033.1993.tb18316.x; MONSKY WL, 1993, CANCER RES, V53, P3159; MURPHY G, 1981, BIOCHEM J, V199, P807, DOI 10.1042/bj1990807; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Nakamura H, 1999, CANCER RES, V59, P467; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nguyen M, 2000, INT J BIOCHEM CELL B, V32, P621, DOI 10.1016/S1357-2725(00)00013-3; NOMURA H, 1995, CANCER RES, V55, P3263; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; PAULY RR, 1994, CIRC RES, V75, P41, DOI 10.1161/01.RES.75.1.41; Pei DQ, 2000, J BIOL CHEM, V275, P33988, DOI 10.1074/jbc.M006493200; Piacentini L, 2000, J MOL CELL CARDIOL, V32, P565, DOI 10.1006/jmcc.2000.1109; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; Rosenfeldt H, 2000, J BIOL CHEM, V275, P3088, DOI 10.1074/jbc.275.5.3088; Ruangpanit N, 2001, MATRIX BIOL, V20, P193, DOI 10.1016/S0945-053X(01)00135-4; Sato T, 1997, J CELL SCI, V110, P589; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; Shofuda KI, 2001, ANN NY ACAD SCI, V947, P337; STETLERSTEVENSON WG, 1994, INVAS METAST, V14, P259; Theret N, 1999, HEPATOLOGY, V30, P462, DOI 10.1002/hep.510300236; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; VRACKO R, 1988, LAB INVEST, V58, P77; Weber KT, 1997, CIRCULATION, V96, P4065; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zigrino P, 2001, EUR J CELL BIOL, V80, P68, DOI 10.1078/0171-9335-00134; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730	53	46	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46699	46708		10.1074/jbc.M307238200	http://dx.doi.org/10.1074/jbc.M307238200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12970340	hybrid			2022-12-25	WOS:000186569400060
J	Igarashi, N; Okada, T; Hayashi, S; Fujita, T; Jahangeer, S; Nakamura, S				Igarashi, N; Okada, T; Hayashi, S; Fujita, T; Jahangeer, S; Nakamura, S			Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; IMPORTIN-BETA; KINASE; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE; RECEPTORS; GROWTH; PHOSPHATE; INTERACTS	Sphingosine kinase-1 (SPHK1) is a key enzyme catalyzing the formation of an important bioactive lipid messenger, sphingosine 1-phosphate, and is implicated in the regulation of cell proliferation and antiapoptotic processes. Biological features of another isozyme SPHK2, however, remain unclear. The present studies were undertaken to characterize SPHK2 by comparison with SPHK1. When SPHK2 was transiently expressed in various cell lines, it was localized in the nuclei as well as in the cytosol, whereas SPHK1 was distributed in the cytosol but not in the nucleus. We have mapped a functional nuclear localization signal (NLS) to the N-terminal region of SPHK2. We have observed that the expression of SPHK2 in various cell types causes inhibition of DNA synthesis, resulting in the cell cycle arrest at G(1)/S phase. We have also demonstrated that an NLS mutant of SPHK2, SPHK2R93E/R94E, failed to enter the nucleus and to inhibit DNA synthesis. Moreover, a fusion protein, NLS-SPHK1, where SPHK1 was fused to the NLS sequence of SPHK2 acquired the ability to enter nuclei and inhibited DNA synthesis. These results indicate that SPHK2 localizes in the nuclei and causes inhibition of DNA synthesis, and this may affect subsequent cellular events.	Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Biochem, Kobe, Hyogo 6500017, Japan	Kobe University	Nakamura, S (corresponding author), Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Biochem, Kobe, Hyogo 6500017, Japan.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUNCE CM, 1988, ANAL BIOCHEM, V175, P67, DOI 10.1016/0003-2697(88)90362-4; CHAUVEAU J, 1956, EXP CELL RES, V11, P317, DOI 10.1016/0014-4827(56)90107-0; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Hayashi S, 2002, J BIOL CHEM, V277, P33319, DOI 10.1074/jbc.M201442200; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Kleuser B, 2001, FEBS LETT, V503, P85, DOI 10.1016/S0014-5793(01)02697-7; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; KREK W, 1995, METHOD ENZYMOL, V254, P114; Lacana E, 2002, J BIOL CHEM, V277, P32947, DOI 10.1074/jbc.M202841200; Le Stunff H, 2002, BBA-MOL CELL BIOL L, V1582, P8, DOI 10.1016/S1388-1981(02)00132-4; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Perander M, 2001, J BIOL CHEM, V276, P13015, DOI 10.1074/jbc.M010356200; Pyne S, 2002, BBA-MOL CELL BIOL L, V1582, P121, DOI 10.1016/S1388-1981(02)00146-4; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Truant R, 1999, MOL CELL BIOL, V19, P1210; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200	21	327	336	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46832	46839		10.1074/jbc.M306577200	http://dx.doi.org/10.1074/jbc.M306577200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12954646	hybrid			2022-12-25	WOS:000186569400075
J	Lee, SG; Fischetti, VA				Lee, SG; Fischetti, VA			Presence of D-alanine in an endopeptidase from Streptococcus pyogenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS; GENES	D- Amino acids are commonly found in peptide antibiotics and the cell wall peptidoglycan of bacterial cell walls but have not been identified in proteins or enzymes. Here we report the presence of 6 - 7 D- alanine residues in an endopeptidase of Streptococcus pyogenes, a unique enzyme involved in surface protein attachment that we term LPXTGase. Using D- amino acid oxidase coupled with catalase for the deamination of D- alanine to pyruvic acid ( a conversion unique to D- alanine), we were able to identify [C-14] pyruvic acid in a [C-14] alanine-labeled preparation of purified LPXTGase, which represents 27% of the amino acid composition. Because D-amino acids are not accommodated in ribosomal peptide synthesis, these results suggest that the same process used in assembling peptide antibiotics or a yet unidentified mechanism may synthesize the core protein of this endopeptidase.	Rockefeller Univ, Lab Bacterial Pathogenesis, New York, NY 10021 USA	Rockefeller University	Fischetti, VA (corresponding author), Rockefeller Univ, Lab Bacterial Pathogenesis, 1230 York Ave, New York, NY 10021 USA.	vaf@rockefeller.edu			NIAID NIH HHS [AI 11822] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011822, R37AI011822] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKER H, 1977, BIOCHEMISTRY-US, V16, P5727; Brace CL, 2001, P NATL ACAD SCI USA, V98, P10017, DOI 10.1073/pnas.171305898; Holtzel A, 2001, J ANTIBIOT, V54, P434; JOLLES P, 1998, D AMINO ACIDS SEQUEN; KLEINKAUF H, 1991, BIOMED BIOCHIM ACTA, V50, pS219; Lee S G, 1975, Methods Enzymol, V43, P585; Lee SG, 2002, J BIOL CHEM, V277, P46912, DOI 10.1074/jbc.M208660200; Meister A., 1963, ENZYMES, V7, P609; Paulus H, 1975, Methods Enzymol, V43, P579; Pelter S, 1997, J BIOTECHNOL, V56, P115, DOI 10.1016/S0168-1656(97)00082-5; PFLEGEL P, 1977, PHARMAZIE, V32, P92; Rieder H, 1975, Methods Enzymol, V43, P548; SCIACOVELLI O, 1976, Z NATURFORSCH C, V31, P5; Takita T., 1990, BIOCH PEPTIDE ANTIBI, P289; Thibaut D, 1997, J BACTERIOL, V179, P697, DOI 10.1128/jb.179.3.697-704.1997; van Wageningen AMA, 1998, CHEM BIOL, V5, P155, DOI 10.1016/S1074-5521(98)90060-6; ZHANG JH, 1995, J BACTERIOL, V177, P4009, DOI 10.1128/jb.177.14.4009-4020.1995	17	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46649	46653		10.1074/jbc.M307378200	http://dx.doi.org/10.1074/jbc.M307378200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	13129927	hybrid			2022-12-25	WOS:000186569400053
J	Majerus, EM; Zheng, XL; Tuley, EA; Sadler, JE				Majerus, EM; Zheng, XL; Tuley, EA; Sadler, JE			Cleavage of the ADAMTS13 propeptide is not required for protease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; FACTOR-CLEAVING PROTEASE; ALPHA-CONVERTING-ENZYME; INTRACELLULAR MATURATION; FACTOR-VIII; VONWILLEBRAND-FACTOR; CYSTEINE SWITCH; GENE FAMILY; ACTIVATION	ADAMTS13 belongs to the " a disintegrin and metalloprotease with thrombospondin repeats" family, and cleaves von Willebrand factor multimers into smaller forms. For several related proteases, normal folding and enzymatic latency depend on an NH2- terminal propeptide that is removed by proteolytic processing during biosynthesis. However, the ADAMTS13 propeptide is unusually short and poorly conserved, suggesting it may not perform these functions. ADAMTS13 was secreted from transfected HeLa cells with a half- time of 7 h and the rate- limiting step was exported from the endoplasmic reticulum. Deletion of the propeptide did not impair the secretion of active ADAMTS13, indicating that the propeptide is dispensable for folding. Furin was shown to be sufficient for ADAMTS13 propeptide processing in two ways. First, mutation of the furin consensus recognition site prevented propeptide cleavage in HeLa cells and resulted in secretion of pro- ADAMTS13. Second, furin- deficient LoVo cells secreted ADAMTS13 with the propeptide intact, and cotransfection with furin restored propeptide cleavage. In both cell lines, secreted pro- ADAMTS13 had normal proteolytic activity toward von Willebrand factor. In cells coexpressing both ADAMTS13 and von Willebrand factor, pro- ADAMTS13 cleaved pro- von Willebrand factor intracellularly. Therefore, the ADAMTS13 propeptide is not required for folding or secretion, and does not perform the common function of maintaining enzyme latency.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Sadler, JE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, 660 S Euclid Ave,Box 8022, St Louis, MO 63110 USA.	esadler@im.wustl.edu	Zheng, X. Long/ABD-7362-2021; Sadler, Evan/D-8556-2011	Zheng, X. Long/0000-0003-1680-5295; Sadler, J. Evan/0000-0001-5705-469X				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; ASADA Y, 1985, THROMB RES, V38, P469, DOI 10.1016/0049-3848(85)90180-X; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Cal S, 2001, J BIOL CHEM, V276, P17932, DOI 10.1074/jbc.M100534200; Cao J, 2000, J BIOL CHEM, V275, P29648, DOI 10.1074/jbc.M001920200; Fujikawa K, 2001, BLOOD, V98, P1662, DOI 10.1182/blood.V98.6.1662; Furian M, 1999, THROMB HAEMOSTASIS, V82, P592; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Furlan M, 1998, BAILLIERE CLIN HAEM, V11, P509, DOI 10.1016/S0950-3536(98)80064-4; Gerritsen HE, 2001, BLOOD, V98, P1654, DOI 10.1182/blood.V98.6.1654; Hallenberger S, 1997, J VIROL, V71, P1036, DOI 10.1128/JVI.71.2.1036-1045.1997; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; Kang TB, 2002, J BIOL CHEM, V277, P25583, DOI 10.1074/jbc.M203532200; Kang TB, 2002, CANCER RES, V62, P675; Kokame K, 2002, P NATL ACAD SCI USA, V99, P11902, DOI 10.1073/pnas.172277399; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; Lee TP, 2002, BLOOD, V100, p497A; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; MATSUSHITA T, 1995, J BIOL CHEM, V270, P13406, DOI 10.1074/jbc.270.22.13406; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Miranda L, 1996, P NATL ACAD SCI USA, V93, P7695, DOI 10.1073/pnas.93.15.7695; MOAKE JL, 1982, NEW ENGL J MED, V307, P1432, DOI 10.1056/NEJM198212023072306; NACHMAN R, 1977, J CLIN INVEST, V60, P914, DOI 10.1172/JCI108846; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pei DQ, 2000, J BIOL CHEM, V275, P33988, DOI 10.1074/jbc.M006493200; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Peiretti F, 2003, EXP CELL RES, V285, P278, DOI 10.1016/S0014-4827(03)00052-1; REHEMTULLA A, 1992, BLOOD, V79, P2349; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SODETZ JM, 1977, J BIOL CHEM, V252, P5538; Soejima K, 2001, J BIOCHEM-TOKYO, V130, P475, DOI 10.1093/oxfordjournals.jbchem.a003009; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; STOCKER W, 1995, PROTEIN SCI, V4, P823; Stone AL, 1999, J PROTEIN CHEM, V18, P447, DOI 10.1023/A:1020692710029; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; Wang WM, 2003, J BIOL CHEM, V278, P19549, DOI 10.1074/jbc.M300767200; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Yeh RF, 2001, GENOME RES, V11, P803, DOI 10.1101/gr.175701; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200; Zheng XL, 2003, J BIOL CHEM, V278, P30136, DOI 10.1074/jbc.M305331200	61	88	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46643	46648		10.1074/jbc.M309872200	http://dx.doi.org/10.1074/jbc.M309872200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12975358	hybrid			2022-12-25	WOS:000186569400052
J	Nguyen, QGV; Buskin, JN; Himeda, CL; Shield, MA; Haushka, SD				Nguyen, QGV; Buskin, JN; Himeda, CL; Shield, MA; Haushka, SD			Differences in the function of three conserved E-boxes of the muscle creatine kinase gene in cultured myocytes and in transgenic mouse skeletal and cardiac muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAS DOMAIN PROTEIN-1; LOOP-HELIX PROTEINS; TRANSCRIPTION FACTORS; REGULATORY ELEMENTS; DNA-BINDING; CHLORAMPHENICOL ACETYLTRANSFERASE; DEVELOPMENTAL REGULATION; EXPRESSION; ENHANCER; MYOD	The 1256-base pair enhancer-promoter of the mouse muscle creatine kinase gene includes three CAnnTG E-boxes that are conserved among mammals and have flanking and middle sequences conforming to consensus muscle regulatory factor binding sites. This study seeks to determine whether these E-boxes are critical for muscle creatine kinase expression in physiologically distinct muscles. Mutations of the "right" and "left" E-boxes in the enhancer decreased expression in cultured skeletal myocytes similar to 10- and 2-fold, respectively, whereas a "promoter" E-box mutation had little effect. In neonatal myocardiocytes, the left E-box mutation decreased expression similar to 3-fold, whereas right or promoter E-box mutations had no effect. Very different effects were seen in transgenic mice, where the promoter E-box mutation decreased expression in quadriceps, extensor digitorum longus, and soleus similar to 10-fold, and similar to 100-fold in distal tongue, diaphragm, and ventricle. The right E-box mutation, tested in the presence of the other two mutations, caused a significant decrease in distal tongue, but not in quadriceps, extensor digitorum longus, soleus, or ventricle. Mutation of the left E-box actually raised expression in soleus, suggesting a possible repressor role for this control element. The discrepancies between mutation effects in differentiating skeletal muscle cultures, neonatal myocardiocytes, and adult mice suggested that the E-boxes might play different roles during muscle development and adult steady-state function. However, transgenic analysis of embryonic and early postnatal mice indicated no positive role for these three E-boxes in early development, implying that differences in E-box function between adult muscle and cultured cells are the result of physiological signals.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Haushka, SD (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.	haus@u.washington.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R24HL064387, R01HL064387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018860, R37AR018860] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 64387] Funding Source: Medline; NIAMS NIH HHS [AR 18860] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aickin M, 1996, AM J PUBLIC HEALTH, V86, P726, DOI 10.2105/AJPH.86.5.726; AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; APONE S, 1995, J BIOL CHEM, V270, P21420, DOI 10.1074/jbc.270.36.21420; Arnold HH, 1996, INT J DEV BIOL, V40, P345; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BURKHOLDER TJ, 1994, J MORPHOL, V221, P177, DOI 10.1002/jmor.1052210207; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; Calvo S, 1999, MOL CELL BIOL, V19, P515; Calvo S, 2001, MOL CELL BIOL, V21, P8490, DOI 10.1128/MCB.21.24.8490-8503.2001; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; Chu K, 2001, RECENT PROG HORM RES, V56, P23, DOI 10.1210/rp.56.1.23; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; Dai YS, 2002, J BIOL CHEM, V277, P24390, DOI 10.1074/jbc.M202490200; Dambly-Chaudiere C, 1998, INT J DEV BIOL, V42, P269; Dean J, 2002, J REPROD IMMUNOL, V53, P171, DOI 10.1016/S0165-0378(01)00100-0; Donovan J, 2002, CURR BIOL, V12, P1605, DOI 10.1016/S0960-9822(02)01149-1; Donoviel DB, 1996, MOL CELL BIOL, V16, P1649; FabreSuver C, 1996, J BIOL CHEM, V271, P4646, DOI 10.1074/jbc.271.9.4646; Freitas EMS, 2002, TOXICON, V40, P1471, DOI 10.1016/S0041-0101(02)00165-4; Garami M, 1996, HYPERTENSION, V28, P315, DOI 10.1161/01.HYP.28.2.315; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Grange RW, 2001, AM J PHYSIOL-CELL PH, V281, pC1487, DOI 10.1152/ajpcell.2001.281.5.C1487; Hauser MA, 2000, MOL THER, V2, P16, DOI 10.1006/mthe.2000.0089; Hilfiker-Kleiner D, 2002, CARDIOVASC RES, V53, P460, DOI 10.1016/S0008-6363(01)00463-1; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; Hughes SM, 1997, MECH DEVELOP, V61, P151, DOI 10.1016/S0925-4773(96)00631-4; HUGHES SM, 1993, DEVELOPMENT, V118, P1137; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JAYNES JB, 1986, MOL CELL BIOL, V6, P2855, DOI 10.1128/MCB.6.8.2855; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; JOHNSON JE, 1989, DEV BIOL, V134, P258, DOI 10.1016/0012-1606(89)90095-X; Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0; Kaufman M.H., 1992, ATLAS MOUSE DEV; Kiefer JC, 2001, DEV BIOL, V232, P77, DOI 10.1006/dbio.2000.0114; Kophengnavong T, 2000, MOL CELL BIOL, V20, P261, DOI 10.1128/MCB.20.1.261-272.2000; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEDENT V, 2002, GENOME BIOL, V3; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; Lowrey PL, 2000, ANNU REV GENET, V34, P533, DOI 10.1146/annurev.genet.34.1.533; LYONS GE, 1991, DEVELOPMENT, V113, P1017; Maemura K, 2002, J MOL CELL CARDIOL, V34, P703, DOI 10.1006/jmcc.2002.2043; Maxwell PH, 2001, ADV EXP MED BIOL, V502, P365; MILLER J, 1981, P NATL ACAD SCI-BIOL, V78, P3829, DOI 10.1073/pnas.78.6.3829; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Muroya S, 2002, ZOOL SCI, V19, P755, DOI 10.2108/zsj.19.755; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nguyen QGV, 2003, TRANSGENIC RES, V12, P337, DOI 10.1023/A:1023369225799; Norton JD, 2000, J CELL SCI, V113, P3897; Pin CL, 2002, BIOCHEM BIOPH RES CO, V299, P7, DOI 10.1016/S0006-291X(02)02571-8; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Ritter O, 1999, J CELL BIOCHEM, V74, P551, DOI 10.1002/(SICI)1097-4644(19990915)74:4<551::AID-JCB5>3.3.CO;2-0; Rowitch DH, 2002, TRENDS NEUROSCI, V25, P417, DOI 10.1016/S0166-2236(02)02201-4; Schwitzgebel VM, 2001, MOL CELL ENDOCRINOL, V185, P99, DOI 10.1016/S0303-7207(01)00628-1; Seward DJ, 2001, AM J PHYSIOL-CELL PH, V280, pC408, DOI 10.1152/ajpcell.2001.280.2.C408; SHAW WV, 1968, J BACTERIOL, V95, P28, DOI 10.1128/JB.95.1.28-36.1968; Shield MA, 1996, MOL CELL BIOL, V16, P5058; SKERJANC IS, 1994, DEV BIOL, V163, P125, DOI 10.1006/dbio.1994.1128; Spits H, 1998, IMMUNOL REV, V165, P75, DOI 10.1111/j.1600-065X.1998.tb01231.x; Srivastava D, 1999, TRENDS CARDIOVAS MED, V9, P11, DOI 10.1016/S1050-1738(98)00033-4; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Tanaka T, 2002, J MOL CELL CARDIOL, V34, P739, DOI 10.1006/jmcc.2002.2012; Thattaliyath BD, 2002, BIOCHEM BIOPH RES CO, V297, P870, DOI 10.1016/S0006-291X(02)02297-0; Thomas T, 1998, DEV BIOL, V196, P228, DOI 10.1006/dbio.1998.8849; TRASK RV, 1988, J BIOL CHEM, V263, P17142; Vetter ML, 2001, SEMIN CELL DEV BIOL, V12, P491, DOI 10.1006/scdb.2001.0273; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Walters EH, 2000, J MUSCLE RES CELL M, V21, P647, DOI 10.1023/A:1005683825960; Walters EH, 2000, AM J PHYSIOL-REG I, V278, pR1381, DOI 10.1152/ajpregu.2000.278.5.R1381; Wang G L, 1996, Curr Opin Hematol, V3, P156; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; WIGSTON DJ, 1992, J NEUROBIOL, V23, P61, DOI 10.1002/neu.480230107; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; Xiao QX, 2002, AM J PHYSIOL-HEART C, V283, pH213, DOI 10.1152/ajpheart.01085.2001; Yamagishi H, 2000, J CLIN INVEST, V105, P261, DOI 10.1172/JCI8856; Yamagishi H, 2001, DEV BIOL, V239, P190, DOI 10.1006/dbio.2001.0417; YAMASHITA K, 1991, J MUSCLE RES CELL M, V12, P37, DOI 10.1007/BF01781172; Yan Z, 2001, J BIOL CHEM, V276, P17361, DOI 10.1074/jbc.M101251200; YI JM, 1991, NUCLEIC ACIDS RES, V19, P3027	87	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46494	46505		10.1074/jbc.M308194200	http://dx.doi.org/10.1074/jbc.M308194200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12968024	hybrid			2022-12-25	WOS:000186569400138
J	Olivera, A; Rosenfeldt, HM; Bektas, M; Wang, F; Ishii, I; Chun, J; Milstien, S; Spiegel, S				Olivera, A; Rosenfeldt, HM; Bektas, M; Wang, F; Ishii, I; Chun, J; Milstien, S; Spiegel, S			Sphingosine kinase type 1 induces G(12/13)-mediated stress fiber formation, yet promotes growth and survival independent of G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; HETEROTRIMERIC G-PROTEINS; BREAST-CANCER CELLS; DEPENDENT ACTIVATION; SIGNAL-TRANSDUCTION; INTRACELLULAR SPHINGOSINE-1-PHOSPHATE; TYROSINE PHOSPHORYLATION; LYSOPHOSPHATIDIC ACID; EXTRACELLULAR-MATRIX; RHO GTPASES	Sphingosine 1- phosphate ( S1P) is the ligand for a family of specific G protein- coupled receptors ( GPCRs) that regulate a wide variety of important cellular functions, including growth, survival, cytoskeletal rearrangements, and cell motility. However, whether it also has an intracellular function is still a matter of great debate. Overexpression of sphingosine kinase type 1, which generated S1P, induced extensive stress fibers and impaired formation of the Src- focal adhesion kinase signaling complex, with consequent aberrant focal adhesion turnover, leading to inhibition of cell locomotion. We have dissected biological responses dependent on intracellular S1P from those that are receptor- mediated by specifically blocking signaling of Galpha(q), Galpha(i), Galpha(12/13), and Gbetagamma subunits, the G proteins that S1P receptors ( S1PRs) couple to and signal through. We found that intracellular S1P signaled " inside out" through its cell- surface receptors linked to G(12/ 13) -mediated stress fiber formation, important for cell motility. Remarkably, cell growth stimulation and suppression of apoptosis by endogenous S1P were independent of GPCRs and inside- out signaling. Using fibroblasts from embryonic mice devoid of functional S1PRs, we also demonstrated that, in contrast to exogenous S1P, intracellular S1P formed by overexpression of sphingosine kinase type 1 promoted growth and survival independent of its GPCRs. Hence, exogenous and intracellularly generated S1Ps affect cell growth and survival by divergent pathways. Our results demonstrate a receptor- independent intracellular function of S1P, reminiscent of its action in yeast cells that lack S1PRs.	Virginia Commonwealth Univ, Sch Med, Dept Biochem, Richmond, VA 23298 USA; NIAMS, Mol Immunol & Inflammat Branch, NIH, Bethesda, MD 20892 USA; NIMH, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA; Natl Inst Neurosci, Dept Mol Genet, Tokyo 1878502, Japan; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Center for Neurology & Psychiatry - Japan; Scripps Research Institute	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.	sspiegel@vcu.edu		Ishii, Isao/0000-0002-5367-205X; Bektas, Meryem/0000-0001-8080-7557	NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH001039, K02MH001723] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61774] Funding Source: Medline; NIMH NIH HHS [MH 01723] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Boujaoude LC, 2001, J BIOL CHEM, V276, P35258, DOI 10.1074/jbc.M105442200; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; Heringdorf DMZ, 2001, EUR J PHARMACOL, V414, P145, DOI 10.1016/S0014-2999(01)00789-0; Hisano N, 1999, BLOOD, V93, P4293, DOI 10.1182/blood.V93.12.4293.412k26_4293_4299; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; ILLC D, 1995, NATURE, V377, P539; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kleuser B, 2001, FEBS LETT, V503, P85, DOI 10.1016/S0014-5793(01)02697-7; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Ohmori T, 2001, J BIOL CHEM, V276, P5274, DOI 10.1074/jbc.M005405200; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Paris F, 2002, NAT MED, V8, P901, DOI 10.1038/nm0902-901; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Rani CSS, 1997, J BIOL CHEM, V272, P10777; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ronnstrand L, 2001, INT J CANCER, V91, P757, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1136>3.0.CO;2-J; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Scheschonka A, 2000, MOL PHARMACOL, V58, P719, DOI 10.1124/mol.58.4.719; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Spiegel S, 2002, TRENDS CELL BIOL, V12, P236, DOI 10.1016/S0962-8924(02)02277-8; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; van Koppen CJ, 2001, LIFE SCI, V68, P2535, DOI 10.1016/S0024-3205(01)01049-9; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wang F, 1999, CANCER RES, V59, P6185; Wang F, 1999, EXP CELL RES, V247, P17, DOI 10.1006/excr.1998.4327; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; Watterson KR, 2002, J BIOL CHEM, V277, P5767, DOI 10.1074/jbc.M110647200; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499	75	134	142	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46452	46460		10.1074/jbc.M308749200	http://dx.doi.org/10.1074/jbc.M308749200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963721	hybrid			2022-12-25	WOS:000186569400030
J	Collet, JF; D'Souza, JC; Jakob, U; Bardwell, JCA				Collet, JF; D'Souza, JC; Jakob, U; Bardwell, JCA			Thioredoxin 2, an oxidative stress-induced protein, contains a high affinity zinc binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; ESCHERICHIA-COLI; REDOX SWITCH; REDUCTION; ACTIVATION; MECHANISM; HSP33; ROLES	Two thioredoxins have been described in Escherichia coli, TrxA and Trx2. Both thioredoxins are capable of reducing disulfide bonds using a conserved pair of cysteine residues present in a WCGPC motif. A number of unique structural and regulatory features distinguish the Trx2 subfamily from the much larger TrxA family. The Trx2 subfamily has an additional N-terminal domain of +/-30 residues, which contains two additional conserved CXXC motifs. Moreover, the gene coding for Trx2 is under control of the oxidative stress transcription factor OxyR in E. coli. This suggests that Trx2 may play a role in the cellular defense against oxidative stress. We show here that Trx2 contains zinc in a 1:1 stoichiometry, making it the first identified zinc-binding thioredoxin. The zinc atom is coordinated by the four cysteines of the two N-terminal CXXC motifs. The zinc center of Trx2 binds zinc with a very high affinity (K-a of > 10(18) M-1). We show that in vitro oxidation of the zinc binding cysteines by H2O2 releases the zinc and induces a conformational change. The zinc-free protein conserves its reductase activity. Altogether, our results suggest that the zinc center might play the role of a redox switch, changing a yet to be identified activity.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Catholique Louvain, Chim Physiol Lab, B-1200 Brussels, Belgium	University of Michigan System; University of Michigan; Universite Catholique Louvain	Bardwell, JCA (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.		Collet, Jean Francois/F-2105-2010	Collet, Jean-Francois/0000-0001-8069-7036	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065318, R01GM064662] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM065318, GM064662] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; GALANG CK, 1993, MOL CELL BIOL, V13, P4609, DOI 10.1128/MCB.13.8.4609; Graf PCF, 2002, CELL MOL LIFE SCI, V59, P1624, DOI 10.1007/PL00012489; Graumann J, 2001, STRUCTURE, V9, P377, DOI 10.1016/S0969-2126(01)00599-8; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Hunt JA, 1997, J BIOL CHEM, V272, P20364, DOI 10.1074/jbc.272.33.20364; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Jakob U, 2000, J BIOL CHEM, V275, P38302, DOI 10.1074/jbc.M005957200; KOH YS, 1995, J BACTERIOL, V177, P2673, DOI 10.1128/jb.177.10.2673-2678.1995; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; Pomposiello PJ, 2001, TRENDS BIOTECHNOL, V19, P109, DOI 10.1016/S0167-7799(00)01542-0; Ren B, 1998, NAT STRUCT BIOL, V5, P602, DOI 10.1038/862; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Ritz D, 2000, J BIOL CHEM, V275, P2505, DOI 10.1074/jbc.275.4.2505; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; Romero-Isart N, 2002, J INORG BIOCHEM, V88, P388, DOI 10.1016/S0162-0134(01)00347-6; RUSSEL M, 1995, METHOD ENZYMOL, V252, P264; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; Vlamis-Gardikas A, 2002, METHOD ENZYMOL, V347, P286; Wisz MS, 1998, BIOCHEMISTRY-US, V37, P8269, DOI 10.1021/bi980718f; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zhou ZHS, 1999, BIOCHEMISTRY-US, V38, P15915, DOI 10.1021/bi992062b	28	71	73	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45325	45332		10.1074/jbc.M307818200	http://dx.doi.org/10.1074/jbc.M307818200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952960	hybrid			2022-12-25	WOS:000186452300035
J	Eghbali, M; Toro, L; Stefani, E				Eghbali, M; Toro, L; Stefani, E			Diminished surface clustering and increased perinuclear accumulation of large conductance Ca(2+-)activated K+ channel in mouse myometrium with pregnancy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; EXPRESSION; CURRENTS; MYOCYTES; SUBUNIT; POTENT	Large conductance Ca2+-activated K+ channels play a critical role in regulating myometrium contractility. Their current density, mRNA, and total protein are greatly diminished in myometrium of late pregnant rats versus nonpregnant animals. Opposite to rats, in mice, channel mRNA and total protein increase in late pregnancy, but current density decreases as in rats. Here, we investigated the mechanism of these differences. Real time PCR and Western blots demonstrate that, in late pregnancy, channel transcript quantities and total protein were diminished in rats but up-regulated in mice. High resolution confocal microscopy of single myocytes showed that, in nonpregnant mice, channels were expressed in clusters at the surface membrane. In late pregnancy, although there was an overall increase in channel protein, its majority was accumulated in perinuclear organelles, and channel clustering practically disappeared from the surface membrane. This contrasts with rat myometrium, where there is a reduction of channel transcripts and overall protein levels including the surface membrane. We conclude that large conductance Ca2+-activated K+ channel surface expression is reduced in both rat and mouse late pregnant myometrium. However, in rats, the main mechanism for the reduced channel expression at the cell surface is a diminished transcription, whereas in mice, it is an altered traffic to the surface.	Univ Calif Los Angeles, Sch Med, Dept Anesthesiol, Div Mol Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Stefani, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Anesthesiol, Div Mol Med, BH-520A CHS,Box 957115, Los Angeles, CA 90095 USA.	estefani@ucla.edu			NHLBI NIH HHS [HL47382, HL54970] Funding Source: Medline; NICHD NIH HHS [HD38983] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038983] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047382, R01HL054970, R29HL047382] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrews PD, 2002, TRAFFIC, V3, P29, DOI 10.1034/j.1600-0854.2002.30105.x; Antonucci DE, 2001, NEUROSCIENCE, V108, P69, DOI 10.1016/S0306-4522(01)00476-6; ANWER K, 1993, AM J PHYSIOL, V265, pC976, DOI 10.1152/ajpcell.1993.265.4.C976; Benkusky NA, 2002, FEBS LETT, V524, P97, DOI 10.1016/S0014-5793(02)03011-9; Benkusky NA, 2000, J BIOL CHEM, V275, P27712; CANDIA S, 1992, BIOPHYS J, V63, P583, DOI 10.1016/S0006-3495(92)81630-2; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; Holdiman AJ, 2002, MOL CELL ENDOCRINOL, V192, P1, DOI 10.1016/S0303-7207(02)00136-3; Holmes TJ, 2000, J MICROSC-OXFORD, V200, P114, DOI 10.1046/j.1365-2818.2000.00751.x; McNally JG, 1999, METHODS, V19, P373, DOI 10.1006/meth.1999.0873; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; PEREZ GJ, 1993, AM J OBSTET GYNECOL, V168, P652, DOI 10.1016/0002-9378(93)90513-I; Scriven DRL, 2000, BIOPHYS J, V79, P2682, DOI 10.1016/S0006-3495(00)76506-4; Shaw Peter J., 1995, P373; Song M, 1999, FEBS LETT, V460, P427, DOI 10.1016/S0014-5793(99)01394-0; Song M, 2001, J BIOL CHEM, V276, P31883, DOI 10.1074/jbc.M101058200; Wang SY, 1998, J GEN PHYSIOL, V112, P737, DOI 10.1085/jgp.112.6.737; ZhuGe R, 2002, J GEN PHYSIOL, V120, P15, DOI 10.1085/jgp.20028571	20	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45311	45317		10.1074/jbc.M306564200	http://dx.doi.org/10.1074/jbc.M306564200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952984	hybrid			2022-12-25	WOS:000186452300033
J	Harding, A; Hsu, V; Kornfeld, K; Hancock, JF				Harding, A; Hsu, V; Kornfeld, K; Hancock, JF			Identification of residues and domains of Raf important for function in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP-KINASE; PLASMA-MEMBRANE; CAENORHABDITIS-ELEGANS; SIGNAL-TRANSDUCTION; POSITIVE REGULATOR; SCAFFOLD PROTEINS; LET-60 RAS; MEK KINASE; CELL FATES	Random mutagenesis and genetic screens for impaired Raf function in Caenorhabditis elegans were used to identify six loss-of-function alleles of lin-45 raf that result in a substitution of a single amino acid. The mutations were classified as weak, intermediate, and strong based on phenotypic severity. We engineered these mutations into the homologous residues of vertebrate Raf-1 and analyzed the mutant proteins for their underlying biochemical defects. Surprisingly, phenotype strength did not correlate with the catalytic activity of the mutant proteins. Amino acid substitutions Val-589 and Ser-619 severely compromised Raf kinase activity, yet these mutants displayed weak phenotypes in the genetic screen. Interestingly, this is because these mutant Raf proteins efficiently activate the MAPK (mitogen-activated protein kinase) cascade in living cells, a result that may inform the analysis of knockout mice. Equally intriguing was the observation that mutant proteins with non-functional Ras-binding domains, and thereby deficient in Ras-mediated membrane recruitment, displayed only intermediate strength phenotypes. This confirms that secondary mechanisms exist to couple Ras to Raf in vivo. The strongest phenotype in the genetic screens was displayed by a S508N mutation that again did not correlate with a significant loss of kinase activity or membrane recruitment by oncogenic Ras in biochemical assays. Ser-508 lies within the Raf-1 activation loop, and mutation of this residue in Raf-1 and the equivalent Ser-615 in B-Raf revealed that this residue regulates Raf binding to MEK. Further characterization revealed that in response to activation by epidermal growth factor, the Raf-S508N mutant protein displayed both reduced catalytic activity and aberrant activation kinetics: characteristics that may explain the C. elegans phenotype.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Mol & Cellular Pathol, Brisbane, Qld 4072, Australia; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	University of Queensland; University of Queensland; Washington University (WUSTL)	Hancock, JF (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	j.hancock@imb.uq.edu.au	Harding, Angus/B-4120-2012	Hancock, John/0000-0003-0542-4710				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Adams JA, 2003, BIOCHEMISTRY-US, V42, P601, DOI 10.1021/bi020617o; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; CHURCH DL, 1995, DEVELOPMENT, V121, P2525; Cissel DS, 2000, J BIOL CHEM, V275, P7066, DOI 10.1074/jbc.275.10.7066; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FINNEY R, 1995, METHOD ENZYMOL, V255, P310; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; Hsu V, 2002, GENETICS, V160, P481; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Li WQ, 2000, GENE DEV, V14, P895; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; McPherson RA, 1999, ONCOGENE, V18, P3862, DOI 10.1038/sj.onc.1202730; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Mitsuhashi S, 2003, J BIOL CHEM, V278, P82, DOI 10.1074/jbc.M208888200; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Selfors LM, 1998, P NATL ACAD SCI USA, V95, P6903, DOI 10.1073/pnas.95.12.6903; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; Wojnowski L, 1998, MECH DEVELOP, V76, P141, DOI 10.1016/S0925-4773(98)00111-7; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Yochem J, 1997, MOL CELL BIOL, V17, P2716, DOI 10.1128/MCB.17.5.2716; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	57	12	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45519	45527		10.1074/jbc.M303106200	http://dx.doi.org/10.1074/jbc.M303106200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954633	hybrid			2022-12-25	WOS:000186452300059
J	Mills, JC; Andersson, N; Stappenbeck, TS; Chen, CCM; Gordon, JI				Mills, JC; Andersson, N; Stappenbeck, TS; Chen, CCM; Gordon, JI			Molecular characterization of mouse gastric zymogenic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PROTEIN; EPITHELIAL-CELLS; PARIETAL-CELLS; STOMACH; GROWTH; CORPUS; DYNAMICS; MIGRATION; FURIN; INHIBITION	Zymogenic cells (ZCs), acid-producing parietal cells (PCs), and mucus-secreting pit cells are the principal epithelial lineages in the stomachs of adult mice and humans. Each lineage is derived from the multipotent gastric stem cell and undergoes perpetual renewal within discrete mucosal invaginations (gastric units). In this report, we analyze the molecular features of ZCs and their contributions to gastric epithelial homeostasis. GeneChip analysis yielded a dataset of 57 mRNAs encoding known proteins and 14 ESTs enriched in adult mouse ZCs. This dataset, obtained from comparisons of cellular populations purified by counterflow elutriation and lectin panning, was validated by real-time quantitative reverse transcription-PCR studies of the in vivo expression of selected genes using cells harvested from different regions of gastric units by laser capture microdissection. ZC-enriched mRNAs include regulators of angiogenesis (e.g. platelet-derived growth factors A and B). Because PCs are enriched in transcripts encoding other angiogenic factors (e.g. Vegfb), the contributions of these two lineages to vascular development was examined by performing quantitative three-dimensional imaging of the capillary networks that surround gastric units in two types of mice. In normal adult gnotobiotic FVB/N animals, network density is on average 2-fold higher in ZC- and PC-containing units located in the proximal (corpus) region of the stomach compared with units positioned in the distal (antral) region that lack these lineages (p < 0.01). Gnotobiotic transgenic mice with an engineered ablation of all ZCs and PCs have a 2-fold reduction in capillary network density in their corpus region gastric units compared with the corpus units of normal littermates (p < 0.01). These results support an emerging theme that angiogenesis in the adult mouse gut is modulated by cross-talk between its epithelial lineages and the underlying mesenchyme.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, 660 S Euclid Ave, St Louis, MO 63110 USA.	jgordon@molecool.wustl.edu	Mills, Jason/AAA-6688-2021	Mills, Jason/0000-0002-0402-4662; Andersson, Niklas/0000-0002-3493-7358	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058529, K08DK002954] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02954, DK58529] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersson N, 1999, BBA-MOL CELL RES, V1451, P297, DOI 10.1016/S0167-4889(99)00101-9; Arceiz E, 1997, EUR J GASTROEN HEPAT, V9, P1179; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; Bjerknes M, 2002, AM J PHYSIOL-GASTR L, V283, pG767, DOI 10.1152/ajpgi.00415.2001; Blandizzi C, 1999, EUR J PHARMACOL, V373, P71, DOI 10.1016/S0014-2999(99)00212-5; CORREA P, 1992, CANCER RES, V52, P6735; CROFT DN, 1966, GUT, V7, P333, DOI 10.1136/gut.7.4.333; DEMPSEY PJ, 1992, GASTROENTEROLOGY, V103, P1950, DOI 10.1016/0016-5085(92)91455-D; DONALDSON RM, 1987, PHYSL GASTROINTESTIN, P957; Dougherty KM, 1999, CANCER RES, V59, P6015; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; GORVEL JP, 1985, CELL TISSUE RES, V239, P241, DOI 10.1007/BF00214925; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hooper LV, 2002, METHOD MICROBIOL, V31, P559, DOI 10.1016/S0580-9517(02)31030-4; Kamimura H, 1999, AM J PHYSIOL-GASTR L, V277, pG183, DOI 10.1152/ajpgi.1999.277.1.G183; KARAM SM, 1993, ANAT RECORD, V236, P280, DOI 10.1002/ar.1092360203; KARAM SM, 1993, ANAT REC, V236, P314, DOI 10.1002/ar.1092360205; KARAM SM, 1993, ANAT REC, V236, P333, DOI 10.1002/ar.1092360206; KARAM SM, 1993, ANAT REC, V236, P297, DOI 10.1002/ar.1092360204; KARAM SM, 1992, ANAT RECORD, V232, P231, DOI 10.1002/ar.1092320208; KARAM SM, 1993, ANAT REC, V236, P259, DOI 10.1002/ar.1092360202; Karam SM, 1997, AM J PHYSIOL-GASTR L, V272, pG1209, DOI 10.1152/ajpgi.1997.272.5.G1209; Karlsson L, 2000, DEVELOPMENT, V127, P3457; Kawano J, 2001, HISTOCHEM CELL BIOL, V115, P421; Khatib AM, 2001, J BIOL CHEM, V276, P30686, DOI 10.1074/jbc.M101725200; KOELZ HR, 1992, SCAND J GASTROENTERO, V27, P2, DOI 10.3109/00365529209095998; Lazure C, 1998, J BIOL CHEM, V273, P8572, DOI 10.1074/jbc.273.15.8572; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Li L, 2002, GASTROENTEROLOGY, V123, P764, DOI 10.1053/gast.2002.35386; Li QT, 1996, J BIOL CHEM, V271, P3671, DOI 10.1074/jbc.271.7.3671; Mills JC, 2002, P NATL ACAD SCI USA, V99, P14819, DOI 10.1073/pnas.192574799; Mills JC, 2001, P NATL ACAD SCI USA, V98, P13687, DOI 10.1073/pnas.231332398; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Nakajima T, 2002, DIGEST DIS SCI, V47, P2729, DOI 10.1023/A:1021005221934; Patel AR, 1999, AM J PHYSIOL-GASTR L, V276, pG441, DOI 10.1152/ajpgi.1999.276.2.G441; Pommier Gilbert J., 1995, Progress in Growth Factor Research, V6, P197, DOI 10.1016/0955-2235(95)00022-4; PRINZ C, 1993, GASTROENTEROLOGY, V105, P449, DOI 10.1016/0016-5085(93)90719-S; QuHong, 1997, J HISTOCHEM CYTOCHEM, V45, P21; Stappenbeck TS, 2003, P NATL ACAD SCI USA, V100, P1004, DOI 10.1073/pnas.242735899; Stappenbeck TS, 2002, P NATL ACAD SCI USA, V99, P15451, DOI 10.1073/pnas.202604299; Stappenbeck TS, 2002, METHOD ENZYMOL, V356, P167; Syder AJ, 2003, P NATL ACAD SCI USA, V100, P3467, DOI 10.1073/pnas.0230380100; Syder AJ, 1999, MOL CELL, V3, P263, DOI 10.1016/S1097-2765(00)80454-2; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Weiss TS, 2001, P NATL ACAD SCI USA, V98, P14961, DOI 10.1073/pnas.261572098; Westwood M, 2001, J BIOL CHEM, V276, P41668, DOI 10.1074/jbc.M102793200; Wysolmerski JJ, 1998, ANNU REV PHYSIOL, V60, P431, DOI 10.1146/annurev.physiol.60.1.431; Zirngibl R, 2001, EXP CELL RES, V266, P87, DOI 10.1006/excr.2001.5217	49	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46138	46145		10.1074/jbc.M308385200	http://dx.doi.org/10.1074/jbc.M308385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12963718	hybrid			2022-12-25	WOS:000186452300131
J	Chauhan, D; Li, GL; Sattler, M; Podar, K; Mitsiades, C; Mitsiades, N; Munshi, N; Hideshima, T; Anderson, KC				Chauhan, D; Li, GL; Sattler, M; Podar, K; Mitsiades, C; Mitsiades, N; Munshi, N; Hideshima, T; Anderson, KC			Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells	ONCOGENE			English	Article						multiple myeloma; apoptosis; superoxide; cytochrome c; Smac (second mitochondrial activator of caspases); 2-methoxyestradiol; dexamethasone	MEDIATED APOPTOSIS; CANCER-CELLS; CYTOCHROME-C; ACTIVATION; RESISTANCE; INDUCTION; MECHANISM; PROTEIN; SMAC	Superoxide (O-2(-)) radicals have been linked to apoptosis. Here, we show that 2-methoxyestradiol (2ME2)-induced apoptosis in multiple myeloma ( MM) cells is associated with O-2(-) generation, whereas dexamethasone (Dex)induced apoptosis occurs without concurrent increase in O-2(-). In contrast, both these agents decrease mitochondrial transmembrane potential (Deltapsi(m)). Treatment of MM cells with an antioxidant N-acetyl-L-cysteine blocks 2ME2, but not Dex-induced apoptosis as well as release of mitochondrial proteins cytochrome c (cyto c) and Smac. Taken together, these results demonstrate that there are at least two distinct apoptotic pathways: one dependent on O-2(-), which is induced by 2ME2 and is associated with release of cyto c and Smac; and the other an independent of O-2(-), which is triggered by Dex and associated with Smac release.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02215 USA.		Podar, Klaus/ABD-1112-2020; Munshi, Nikhil/ABE-2338-2021	Podar, Klaus/0000-0002-7414-3632; 	NCI NIH HHS [CA 78373] Funding Source: Medline; PHS HHS [50947] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bossy-Wetzel E, 1999, MUTAT RES-DNA REPAIR, V434, P243, DOI 10.1016/S0921-8777(99)00032-4; Chauhan D, 2002, BLOOD, V100, P2187, DOI 10.1182/blood-2002-02-0376; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; Ding M, 2002, MOL CELL BIOCHEM, V234, P81, DOI 10.1023/A:1015901232124; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Du J, 2001, FREE RADICAL BIO MED, V31, P469, DOI 10.1016/S0891-5849(01)00611-6; Dussmann H, 2003, J BIOL CHEM, V278, P12645, DOI 10.1074/jbc.M210826200; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Li NY, 2003, FREE RADICAL BIO MED, V34, P465, DOI 10.1016/S0891-5849(02)01325-4; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Matsuyama S, 2000, CELL DEATH DIFFER, V7, P1155, DOI 10.1038/sj.cdd.4400779; Ng CP, 2002, PROSTATE, V53, P286, DOI 10.1002/pros.10155; Poot M, 1999, CYTOMETRY, V35, P311, DOI 10.1002/(SICI)1097-0320(19990401)35:4<311::AID-CYTO3>3.3.CO;2-5; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang ZL, 1999, CANCER RES, V59, P1259; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	23	49	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6296	6300		10.1038/sj.onc.1206734	http://dx.doi.org/10.1038/sj.onc.1206734			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679868				2022-12-25	WOS:000185506200019
J	Aasen, T; Hodgins, MB; Edward, M; Graham, SV				Aasen, T; Hodgins, MB; Edward, M; Graham, SV			The relationship between connexins, gap junctions, tissue architecture and tumour invasion, as studied in a novel in vitro model of HPV-16-associated cervical cancer progression	ONCOGENE			English	Article						gap junctions; connexins; cell-cell communication; papillomavirus; tumourigenesis; organotypic culture	HUMAN-PAPILLOMAVIRUS TYPE-16; CELL-CELL COMMUNICATION; INTERCELLULAR COMMUNICATION; GROWTH-CONTROL; HUMAN KERATINOCYTES; CARCINOMA CELLS; DOWN-REGULATION; HUMAN BREAST; E-CADHERIN; EXPRESSION	Disruption of gap junctional intercellular communication (GJIC) and/or connexins (gap junction proteins) is frequently reported in malignant cell lines and tumours. Certain human papillomaviruses (HPV) associated with the development of cancers, especially of the cervix, have previously been reported to downregulate GJIC in vitro. There is also evidence for reduced gap junctions in cervical dysplasia. However, many squamous hyperproliferative conditions, including HPV-induced warts, often show extensive upregulation of certain connexins. The association between HPV and GJIC, and the mechanism and consequence of deregulated GJIC in cervical tumour progression, remains unclear. Therefore, using a variety of nonmalignant and malignant cell lines and an organotypic raft-culture system, we investigated the relationship between HPV, gap junctions and tumour progression. Established cervical tumour cell lines carrying HPV were unable to communicate via gap junctions (when assayed by dye-transfer techniques). This correlated with lack of connexin protein expression, while transfection with connexins 26 or 43 led to functional gap junction membrane plaques. On the other hand, immortal but nonmalignant cell lines that contained episomal or integrated HPV-16, but required feeder-layer and growth-factor support, were consistently well coupled, and expressed multiple connexins at membrane junctions. In vitro selection of feeder-layer and growth-factor-independent variants eventually lead to loss of GJIC, which correlated with loss of membrane and increased cytoplasmic connexin 43 localization. However, this was preceded by loss of differentiation and stromal invasion, as assayed on the organotypic raft-culture model. Using this model, a comparison between noncoupled, well-coupled and connexin-transfected cell lines revealed no firm correlation between GJIC and dysplasia, but GJIC appeared to favour increased stratification. These findings demonstrate that loss of GJIC is frequent, but appears to occur more as a consequence of, rather than being the cause of, epithelial dysplasia, and may be influenced by, but is not directly attributable to, HPV.	Univ Glasgow, Div Canc Sci & Mol Pathol, Sect Squamous Cell Biol & Dermatol, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Div Virol, IBLS, Glasgow G11 5JR, Lanark, Scotland	University of Glasgow; University of Glasgow	Hodgins, MB (corresponding author), Univ Glasgow, Div Canc Sci & Mol Pathol, Sect Squamous Cell Biol & Dermatol, Robertson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	m.b.hodgins@clinmed.gla.ac.uk	Aasen, Trond/B-5279-2013	Aasen, Trond/0000-0003-0763-2695; Graham, Sheila/0000-0002-7140-8279	Wellcome Trust [064140] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; ASAMOTO M, 1994, CARCINOGENESIS, V15, P2163, DOI 10.1093/carcin/15.10.2163; Ashrafi GH, 2000, J GEN VIROL, V81, P689, DOI 10.1099/0022-1317-81-3-689; Bhattacharyya T, 1998, MED MYCOL, V36, P15, DOI 10.1080/02681219880000031; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; BUDUNOVA IV, 1995, CARCINOGENESIS, V16, P2717, DOI 10.1093/carcin/16.11.2717; Budunova IV, 1996, MOL CARCINOGEN, V15, P202; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; Dubina MV, 2002, ONCOGENE, V21, P4992, DOI 10.1038/sj.onc.1205630; DuflotDancer A, 1997, ONCOGENE, V15, P2151, DOI 10.1038/sj.onc.1201393; Eiberger J, 2001, CELL COMMUN ADHES, V8, P163, DOI 10.3109/15419060109080717; ENNAJI MM, 1995, CELL MOL BIOL, V41, P481; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FINBOW ME, 1993, J CELL SCI, V106, P463; FITZGERALD DJ, 1994, CARCINOGENESIS, V15, P1859, DOI 10.1093/carcin/15.9.1859; FRIEDL F, 1970, P SOC EXP BIOL MED, V135, P543; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; Graeber SHM, 1998, EXP CELL RES, V243, P142, DOI 10.1006/excr.1998.4130; Habermann H, 2002, J UROLOGY, V167, P655, DOI 10.1016/S0022-5347(01)69118-3; Hernandez-Blazquez FJ, 2001, EXP CELL RES, V270, P235, DOI 10.1006/excr.2001.5342; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Holden PR, 1997, CARCINOGENESIS, V18, P15, DOI 10.1093/carcin/18.1.15; Huang RP, 1998, CANCER RES, V58, P5089; Ito A, 2000, J CLIN INVEST, V105, P1189, DOI 10.1172/JCI8257; Jamieson S, 1998, J PATHOL, V184, P37, DOI 10.1002/(SICI)1096-9896(199801)184:1<37::AID-PATH966>3.0.CO;2-D; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Kelsell DP, 2001, TRENDS CELL BIOL, V11, P2, DOI 10.1016/S0962-8924(00)01866-3; King TJ, 2000, CARCINOGENESIS, V21, P1097, DOI 10.1093/carcin/21.6.1097; King TJ, 2000, CARCINOGENESIS, V21, P311; Krutovskikh VA, 2000, ONCOGENE, V19, P505, DOI 10.1038/sj.onc.1203340; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Laird DW, 1999, CANCER RES, V59, P4104; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Lesueur F, 2002, BIOCHEM BIOPH RES CO, V294, P108, DOI 10.1016/S0006-291X(02)00451-5; Lin JHC, 2003, J NEUROSCI, V23, P430, DOI 10.1523/JNEUROSCI.23-02-00430.2003; Lucke T, 1999, J INVEST DERMATOL, V112, P354, DOI 10.1046/j.1523-1747.1999.00512.x; Manthey D, 2001, J MEMBRANE BIOL, V181, P137, DOI 10.1007/s00232-001-0017-1; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Martin PEM, 2001, J CELL SCI, V114, P3845; Martyn KD, 1997, CELL GROWTH DIFFER, V8, P1015; MCNUTT NS, 1971, J CELL BIOL, V51, P805, DOI 10.1083/jcb.51.3.805; MCNUTT NS, 1969, SCIENCE, V165, P597, DOI 10.1126/science.165.3893.597; MESNIL M, 1995, CANCER RES, V55, P629; Moorby C, 2001, EXP CELL RES, V271, P238, DOI 10.1006/excr.2001.5357; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Naus CCG, 1999, ADV EXP MED BIOL, V468, P373; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; Omori Y, 1998, INT J CANCER, V78, P446, DOI 10.1002/(SICI)1097-0215(19981109)78:4<446::AID-IJC10>3.3.CO;2-4; Omori Y, 2001, MUTAT RES-FUND MOL M, V477, P191, DOI 10.1016/S0027-5107(01)00120-8; PATTILLO R A, 1977, Science (Washington D C), V196, P1456, DOI 10.1126/science.867042; Piechocki MP, 1999, CARCINOGENESIS, V20, P401, DOI 10.1093/carcin/20.3.401; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; Qin H, 2002, J BIOL CHEM, V277, P29132, DOI 10.1074/jbc.M200797200; Richard G, 2002, AM J HUM GENET, V70, P1341, DOI 10.1086/339986; Risek B, 1998, J CELL SCI, V111, P1395; Saito T, 1998, ONCOGENE, V17, P1673, DOI 10.1038/sj.onc.1202092; Saito T, 2001, INT J CANCER, V93, P317, DOI 10.1002/ijc.1350; Saitoh M, 1997, CARCINOGENESIS, V18, P1319, DOI 10.1093/carcin/18.7.1319; Saunders MM, 2001, CANCER RES, V61, P1765; Sawey MJ, 1996, MOL CARCINOGEN, V17, P49, DOI 10.1002/(SICI)1098-2744(199610)17:2<49::AID-MC1>3.3.CO;2-8; Shore L, 2001, BIOCHEM J, V357, P489, DOI 10.1042/0264-6021:3570489; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STERLING J, 1990, J VIROL, V64, P6305, DOI 10.1128/JVI.64.12.6305-6307.1990; Tan LW, 2002, CARCINOGENESIS, V23, P231, DOI 10.1093/carcin/23.2.231; Temme A, 1997, CURR BIOL, V7, P713, DOI 10.1016/S0960-9822(06)00302-2; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; Tomakidi P, 2000, CELL TISSUE RES, V301, P323, DOI 10.1007/s004410000231; Trosko James E., 1998, Frontiers in Bioscience, V3, pD208; Van Geel M, 2002, BRIT J DERMATOL, V146, P938, DOI 10.1046/j.1365-2133.2002.04893.x; VESSEY CJ, 1995, J PATHOL, V176, P151, DOI 10.1002/path.1711760208; Wiszniewski L, 2001, CELL COMMUN ADHES, V8, P409, DOI 10.3109/15419060109080762; Yamakage K, 1998, MOL CARCINOGEN, V23, P121, DOI 10.1002/(SICI)1098-2744(199810)23:2<121::AID-MC9>3.0.CO;2-P; Yamakage K, 2000, J INVEST DERMATOL, V114, P289, DOI 10.1046/j.1523-1747.2000.00873.x; Yamasaki H, 1999, CR ACAD SCI III-VIE, V322, P151, DOI 10.1016/S0764-4469(99)80038-9; Yano T, 2001, CARCINOGENESIS, V22, P1593, DOI 10.1093/carcin/22.10.1593; Yeager M, 1998, CURR OPIN STRUC BIOL, V8, P517, DOI 10.1016/S0959-440X(98)80131-0; Zhai Y, 2002, AM J PATHOL, V160, P1229, DOI 10.1016/S0002-9440(10)62550-3; Zhang ZQ, 1998, CARCINOGENESIS, V19, P1889, DOI 10.1093/carcin/19.11.1889; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	81	51	56	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					7969	7980		10.1038/sj.onc.1206709	http://dx.doi.org/10.1038/sj.onc.1206709			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970745				2022-12-25	WOS:000185388200012
J	Fagman, H; Larsson, F; Arvidsson, Y; Meuller, J; Nordling, M; Martinson, T; Helmbrecht, K; Brabant, G; Nilsson, M				Fagman, H; Larsson, F; Arvidsson, Y; Meuller, J; Nordling, M; Martinson, T; Helmbrecht, K; Brabant, G; Nilsson, M			Nuclear accumulation of full-length and truncated adenomatous polyposis coli protein in tumor cells depends on proliferation	ONCOGENE			English	Article						APQ beta-catenin; cell-cell adhesion; proliferation; nuclear transport	APC GENE-PRODUCT; BETA-CATENIN; SUPPRESSOR PROTEIN; SUBCELLULAR-LOCALIZATION; CYCLE PROGRESSION; COLORECTAL-CANCER; EPITHELIAL-CELLS; PHOSPHATASE 2A; S-PHASE; MUTATIONS	The adenomatous polyposis coli (APC) tumor suppressor is a nucleocytoplasmic protein. The nuclear accumulation of APC was recently found to vary depending on cell density, suggesting that putative APC function(s) in the nucleus is controlled by the establishment of cell contacts. We report here that the density-dependent redistribution of APC between nucleus and cytoplasm prevails in 6/6 thyroid and colorectal carcinoma cell lines. Moreover, mutated APC lacking known nuclear localization sequences had the similar distribution pattern as the full-length protein. APC invariably accumulated in the nuclei of Ki-67 expressing cells, but was largely cytoplasmic when cell cycle exit was induced by serum starvation or at high cell density. APC colocalized with beta-catenin in the nucleus only in one cell line (SW480). Also, APC maintained a predominantly nuclear position in early confluent states when cytoplasmic beta-catenin was recruited to newly formed adherens-like junctions. The results indicate that nuclear targeting of APC is driven by cell cycle entry rather than altered cell-cell contact. The ability of C-terminally truncated APC to accumulate in the nucleus suggests that nuclear import signals other than NLS1(APC) and NLS2(APC) are functionally important. Residual function(s) of N-terminal APC fragments in tumor cells carrying APC mutations might be beneficial to tumor growth and survival.	Univ Gothenburg, Inst Anat & Cell Biol, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Sahlgrenska Univ Hosp E, Dept Clin Genet, SE-41685 Gothenburg, Sweden; Hannover Med Sch, Dept Clin Endocrinol, D-30625 Hannover, Germany	University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg; Hannover Medical School	Fagman, H (corresponding author), Univ Gothenburg, Inst Anat & Cell Biol, Box 420, SE-40530 Gothenburg, Sweden.	henrik.fagman@anatcell.gu.se	Martinsson, Tommy/J-4140-2013	Martinsson, Tommy/0000-0002-9403-3123; Fagman, Henrik/0000-0001-5853-6295; Nordling, Margareta/0000-0002-4047-4994; Larsson, Fredrik/0000-0002-7888-6863				Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Brocardo MG, 2001, BIOCHEM BIOPH RES CO, V284, P982, DOI 10.1006/bbrc.2001.5066; Cetta F, 1998, WORLD J SURG, V22, P1231, DOI 10.1007/s002689900550; Deka J, 1999, ONCOGENE, V18, P5654, DOI 10.1038/sj.onc.1202944; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Galea MA, 2001, J BIOL CHEM, V276, P45833, DOI 10.1074/jbc.M107149200; GERDES J, 1984, J IMMUNOL, V133, P1710; Hamada F, 2002, NAT CELL BIOL, V4, P208, DOI 10.1038/ncb755; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Homma MK, 2002, P NATL ACAD SCI USA, V99, P5959, DOI 10.1073/pnas.092143199; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Mogensen MM, 2002, J CELL BIOL, V157, P1041, DOI 10.1083/jcb.200203001; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Neufeld KL, 2000, EMBO REP, V1, P519; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PROSSER J, 1994, BRIT J CANCER, V70, P841, DOI 10.1038/bjc.1994.408; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Senda T, 1996, BIOCHEM BIOPH RES CO, V223, P329, DOI 10.1006/bbrc.1996.0894; Sieber OM, 2000, MOL MED TODAY, V6, P462; SMITH KJ, 1994, CANCER RES, V54, P3672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972; vanderLuijt RB, 1997, HUM MUTAT, V9, P7, DOI 10.1002/(SICI)1098-1004(1997)9:1<7::AID-HUMU2>3.0.CO;2-8; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	52	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6013	6022		10.1038/sj.onc.1206731	http://dx.doi.org/10.1038/sj.onc.1206731			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955080				2022-12-25	WOS:000185137800010
J	Guo, Z; Shao, LF; Feng, XS; Reid, K; Marderstein, E; Nakao, A; Geller, DA				Guo, Z; Shao, LF; Feng, XS; Reid, K; Marderstein, E; Nakao, A; Geller, DA			A critical role for C/EBP beta binding to the AABS promoter response element in the human iNOS gene	FASEB JOURNAL			English	Article						iNOS; nitric oxide; cytokines; AABS; C/EBP beta	NITRIC-OXIDE SYNTHASE; FACTOR-KAPPA-B; INTERFERON-GAMMA; TRANSCRIPTIONAL REGULATION; NUCLEAR-FACTOR; CYTOKINE INDUCTION; MOLECULAR-CLONING; PROTEIN-BETA; EXPRESSION; CELLS	The human iNOS (hiNOS) gene is expressed in a tissue-specific manner, but the molecular basis for this regulation has not been elucidated. Here, we show that liver cell-specific hiNOS gene activation involves protein-DNA binding to an A-activator binding site (AABS) located at -192 nucleotides in the hiNOS promoter region. Mutation of this site in the -7.2 kb hiNOS promoter construct inhibited basal hiNOS promoter activity in primary rat hepatocytes (77%), and two human liver cell lines, AKN-1 (63%) and HepG2 (60%), but had no significant effect on basal hiNOS activity in three non-hepatic human cell types. Interestingly, mutation of AABS significantly abrogated cytokine-induced promoter activity in all cell types. C/EBPbeta transcription factor bound to AABS by gel shift assay. Overexpression of C/EBPbeta active form (LAP) increased hiNOS basal promoter activity similar to sixfold in liver cells, but had minimal effect in non-hepatic cells. In contrast, overexpression of the transcriptional inhibitor (LIP) strongly suppressed both basal and cytokine-inducible promoter activity. These data show that the cis-acting AABS DNA element mediates liver-specific basal hiNOS promoter activity through binding of the trans-acting C/EBPbeta factor. Further, C/EBPbeta binding to AABS functions as a "switchpoint" that is necessary for cytokine-inducible hiNOS gene expression in all cell types examined.	Univ Pittsburgh, Starzl Transplant Inst, Dept Surg, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Geller, DA (corresponding author), Univ Pittsburgh, Starzl Transplant Inst, Dept Surg, 3459 5th Ave,UPMC Montefiore,7 South, Pittsburgh, PA 15213 USA.	gellerda@msx.upmc.edu						AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; DREWES T, 1991, NUCLEIC ACIDS RES, V19, P6383, DOI 10.1093/nar/19.23.6383; Eberhardt W, 1996, BIOCHEM BIOPH RES CO, V223, P752, DOI 10.1006/bbrc.1996.0968; Feng XS, 2002, P NATL ACAD SCI USA, V99, P14212, DOI 10.1073/pnas.212306199; Ganster RW, 2001, P NATL ACAD SCI USA, V98, P8638, DOI 10.1073/pnas.151239498; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; GELLER DA, 1995, J IMMUNOL, V155, P4890; Guo FH, 1997, J CLIN INVEST, V100, P829, DOI 10.1172/JCI119598; KALING M, 1991, MOL CELL BIOL, V11, P93, DOI 10.1128/MCB.11.1.93; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; Kolyada AY, 1996, BIOCHEM BIOPH RES CO, V220, P600, DOI 10.1006/bbrc.1996.0449; Kolyada AY, 2001, MOL MED, V7, P329, DOI 10.1007/BF03402216; Kroncke KD, 1998, CLIN EXP IMMUNOL, V113, P147; Kunz D, 1996, P NATL ACAD SCI USA, V93, P255, DOI 10.1073/pnas.93.1.255; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MANCHADO C, 1994, BIOCHEM J, V302, P695, DOI 10.1042/bj3020695; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Mellott JK, 2001, AM J PHYSIOL-LUNG C, V280, pL390, DOI 10.1152/ajplung.2001.280.3.L390; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Nussler AK, 1999, IN VITRO CELL DEV-AN, V35, P190, DOI 10.1007/s11626-999-0026-4; NUSSLER AK, 1992, J EXP MED, V176, P261, DOI 10.1084/jem.176.1.261; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Ratovitski EA, 1999, J BIOL CHEM, V274, P30250, DOI 10.1074/jbc.274.42.30250; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Sakitani K, 1998, GENES CELLS, V3, P321, DOI 10.1046/j.1365-2443.1998.00193.x; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Welm AL, 1999, MOL CELL BIOL, V19, P1695; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	38	30	32	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1718	+		10.1096/fj.02-1172fje	http://dx.doi.org/10.1096/fj.02-1172fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958187				2022-12-25	WOS:000184471600029
J	Do Lee, S; Colla, E; Sheen, MR; Na, KY; Kwon, HM				Do Lee, S; Colla, E; Sheen, MR; Na, KY; Kwon, HM			Multiple domains of TonEBP cooperate to stimulate transcription in response to hypertonicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; NF-KAPPA-B; GENE-TRANSCRIPTION; DNA-BINDING; TONICITY; ACTIVATION; CELLS; PHOSPHORYLATION; DROSOPHILA; SCREEN	Tonicity-responsive enhancer binding protein (TonEBP), also known as NFAT5, belongs to the Rel family of transcriptional activators. In the kidney medulla and thymus, TonEBP plays a major role in protecting renal cells and T cells from the deleterious effects of ambient hypertonicity. TonEBP is stimulated by hypertonicity via several pathways: increased expression of protein, nuclear translocation, and increased transactivation. In this study, we identified five domains of TonEBP involved in transactivation. The two conserved glutamine repeats were not involved in transactivation. There were three activation domains that could stimulate transcription independently. In addition, there were two modulation domains that potentiated the activity of the activation domains. One of the activation domains is unique to a splice isoform that is more active than others, indicating that alternative splicing can affect the activity of TonEBP. Another activation domain and one of the modulation domains were stimulated by hypertonicity. All the five domains acted in synergy in every combination. Although overall phosphorylation of TonEBP increased in response to hypertonicity, phosphorylation of the activation and modulation domains did not increase in isolation. In sum, TonEBP possesses far more elaborate domains involved in transactivation compared with other Rel proteins.	Univ Maryland, Dept Med, Baltimore, MD 21201 USA; Univ Parma, Grad Program Mol Biol & Pathol, I-43100 Parma, Italy	University System of Maryland; University of Maryland Baltimore; University of Parma	Kwon, HM (corresponding author), N3W143,22 S Greene St, Baltimore, MD 21201 USA.		Colla, Emanuela/H-2483-2013; Lee-Kwon, Whaseon/D-6021-2011	Colla, Emanuela/0000-0002-4755-7450; lee, sang do/0000-0003-1778-6575	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061677] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK61677] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bourbon HM, 2002, MECH DEVELOP, V110, P71, DOI 10.1016/S0925-4773(01)00566-4; Cha JH, 2001, J AM SOC NEPHROL, V12, P2221, DOI 10.1681/ASN.V12112221; Dahl SC, 2001, AM J PHYSIOL-CELL PH, V280, pC248, DOI 10.1152/ajpcell.2001.280.2.C248; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P16800, DOI 10.1073/pnas.222659799; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P739, DOI 10.1073/pnas.241637298; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; Graef IA, 2001, P NATL ACAD SCI USA, V98, P5740, DOI 10.1073/pnas.101602398; Huang AM, 2000, GENETICS, V156, P1219; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Ko BCB, 2002, J BIOL CHEM, V277, P46085, DOI 10.1074/jbc.M208138200; Kraut R, 2001, CURR BIOL, V11, P417, DOI 10.1016/S0960-9822(01)00124-5; Kultz D, 2001, P NATL ACAD SCI USA, V98, P1999, DOI 10.1073/pnas.98.4.1999; Lee SD, 2002, BIOCHEM BIOPH RES CO, V294, P968, DOI 10.1016/S0006-291X(02)00572-7; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lopez-Rodriguez C, 2001, IMMUNITY, V15, P47, DOI 10.1016/S1074-7613(01)00165-0; Luo C, 1996, MOL CELL BIOL, V16, P3955; LUO C, 1996, J EXP MED, V184, P8907; Maouyo D, 2002, AM J PHYSIOL-RENAL, V282, pF802, DOI 10.1152/ajprenal.00123.2001; Michea L, 2000, AM J PHYSIOL-RENAL, V278, pF209, DOI 10.1152/ajprenal.2000.278.2.F209; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Nahm O, 2002, AM J PHYSIOL-CELL PH, V282, pC49, DOI 10.1152/ajpcell.00267.2001; Nakayama Y, 2000, J BIOL CHEM, V275, P38275, DOI 10.1074/jbc.M004678200; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Sands J.M., 2000, KIDNEY PHYSL PATHOPH, V3, P1175; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; Stroud JC, 2002, NAT STRUCT BIOL, V9, P90, DOI 10.1038/nsb749; Trama J, 2000, J IMMUNOL, V165, P4884, DOI 10.4049/jimmunol.165.9.4884; Trama J, 2002, J IMMUNOL, V169, P5477, DOI 10.4049/jimmunol.169.10.5477; Woo SK, 2000, AM J PHYSIOL-RENAL, V278, pF1006; Woo SK, 2000, AM J PHYSIOL-CELL PH, V278, pC323, DOI 10.1152/ajpcell.2000.278.2.C323; Woo SK, 2002, PFLUG ARCH EUR J PHY, V444, P579, DOI 10.1007/s00424-002-0849-2; Woo SK, 2002, MOL CELL BIOL, V22, P5753, DOI 10.1128/MCB.22.16.5753-5760.2002; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	35	10	10	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47571	47577		10.1074/jbc.M308795200	http://dx.doi.org/10.1074/jbc.M308795200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12970349	hybrid			2022-12-25	WOS:000186731400029
J	Hodder, AN; Drew, DR; Epa, VC; Delorenzi, M; Bourgon, R; Miller, SK; Moritz, RL; Frecklington, DF; Simpson, RJ; Speed, TP; Pike, RN; Crabb, BS				Hodder, AN; Drew, DR; Epa, VC; Delorenzi, M; Bourgon, R; Miller, SK; Moritz, RL; Frecklington, DF; Simpson, RJ; Speed, TP; Pike, RN; Crabb, BS			Enzymic, phylogenetic, and structural characterization of the unusual papain-like protease domain of Plasmodium falciparum SERA5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL MEMBRANE ANTIGEN-1; HUMAN MALARIA PARASITE; BLOOD STAGE ANTIGEN; GENOME SEQUENCE; SERINE-STRETCH; PROCATHEPSIN B; LOCALIZATION; RECOGNITION; INHIBITION; MEROZOITES	Serine repeat antigen 5 (SERA5) is an abundant antigen of the human malaria parasite Plasmodium falciparum and is the most strongly expressed member of the nine-gene SERA family. It appears to be essential for the maintenance of the erythrocytic cycle, unlike a number of other members of this family, and has been implicated in parasite egress and/or erythrocyte invasion. All SERA proteins possess a central domain that has homology to papain except in the case of SERA5 ( and some other SERAs), where the active site cysteine has been replaced with a serine. To investigate if this domain retains catalytic activity, we expressed, purified, and refolded a recombinant form of the SERA5 enzyme domain. This protein possessed chymotrypsin-like proteolytic activity as it processed substrates downstream of aromatic residues, and its activity was reversed by the serine protease inhibitor 3,4-diisocoumarin. Although all Plasmodium SERA enzyme domain sequences share considerable homology, phylogenetic studies revealed two distinct clusters across the genus, separated according to whether they possess an active site serine or cysteine. All Plasmodia appear to have at least one member of each group. Consistent with separate biological roles for members of these two clusters, molecular modeling studies revealed that SERA5 and SERA6 enzyme domains have dramatically different surface properties, although both have a characteristic papain-like fold, catalytic cleft, and an appropriately positioned catalytic triad. This study provides impetus for the examination of SERA5 as a target for antimalarial drug design.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Commonwealth Sci & Ind Res Org, Div Hlth Sci & Nutr, Melbourne, Vic 3052, Australia; Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA; Ludwig Inst Canc Res, Joint Prote Lab, Melbourne, Vic 3052, Australia; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3052, Australia; Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of California System; University of California Berkeley; Ludwig Institute for Cancer Research; Walter & Eliza Hall Institute; Monash University	Hodder, AN (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3050, Australia.	hodder@wehi.edu.au; crabb@wehi.edu.au	Crabb, Brendan/F-5287-2013; Speed, Terence P/B-8085-2009; Moritz, Robert L/B-9222-2011; Epa, Vidana C./D-2320-2013	Speed, Terence P/0000-0002-5403-7998; Pike, Robert/0000-0002-2083-0269; Bourgon, Richard/0000-0002-5890-4374; Simpson, Richard/0000-0002-9834-0796				Aoki S, 2002, J BIOL CHEM, V277, P47533, DOI 10.1074/jbc.M207145200; BZIK DJ, 1988, MOL BIOCHEM PARASIT, V30, P279, DOI 10.1016/0166-6851(88)90097-7; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; COLL M, 1991, EMBO J, V10, P1; Cygler M, 1996, STRUCTURE, V4, P405, DOI 10.1016/S0969-2126(96)00046-9; DEBRABANT A, 1992, MOL BIOCHEM PARASIT, V53, P89, DOI 10.1016/0166-6851(92)90010-H; DELPLACE P, 1987, MOL BIOCHEM PARASIT, V23, P193, DOI 10.1016/0166-6851(87)90026-0; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; FLOCKNER H, 1995, PROTEINS, V23, P376, DOI 10.1002/prot.340230311; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gor DO, 1998, VACCINE, V16, P1193, DOI 10.1016/S0264-410X(98)80119-9; Greenbaum DC, 2002, SCIENCE, V298, P2002, DOI 10.1126/science.1077426; HADLEY T, 1983, EXP PARASITOL, V55, P306, DOI 10.1016/0014-4894(83)90027-9; Hodder AN, 1996, J BIOL CHEM, V271, P29446, DOI 10.1074/jbc.271.46.29446; Hodder AN, 2001, INFECT IMMUN, V69, P3286, DOI 10.1128/IAI.69.5.3286-3294.2001; HOWELL S, 2003, J BIOL CHEM, V278, P28572; Kiefer MC, 1996, MOL BIOCHEM PARASIT, V78, P55, DOI 10.1016/S0166-6851(96)02607-2; KNAPP B, 1989, MOL BIOCHEM PARASIT, V32, P73, DOI 10.1016/0166-6851(89)90131-X; KNAPP B, 1991, MOL BIOCHEM PARASIT, V44, P1, DOI 10.1016/0166-6851(91)90215-R; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li H, 2002, PARASITOL INT, V51, P343, DOI 10.1016/S1383-5769(02)00042-9; Li J, 2002, MOL BIOCHEM PARASIT, V120, P177, DOI 10.1016/S0166-6851(01)00452-2; LUETHY R, 1992, Nature (London), V356, P83; LYON JA, 1986, J IMMUNOL, V136, P2245; Miller SK, 2002, J BIOL CHEM, V277, P47524, DOI 10.1074/jbc.M206974200; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pang XL, 1999, INFECT IMMUN, V67, P1821; Podobnik M, 1997, J MOL BIOL, V271, P774, DOI 10.1006/jmbi.1997.1218; Rathore D, 2001, MOL BIOCHEM PARASIT, V114, P89, DOI 10.1016/S0166-6851(01)00241-9; Rich SM, 2000, P NATL ACAD SCI USA, V97, P6994, DOI 10.1073/pnas.97.13.6994; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salmon BL, 2001, P NATL ACAD SCI USA, V98, P271, DOI 10.1073/pnas.011413198; Sarkany Z, 2003, BIOCHEMISTRY-US, V42, P516, DOI 10.1021/bi027004w; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wu YM, 2003, GENOME RES, V13, P601, DOI 10.1101/gr.913403	38	74	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48169	48177		10.1074/jbc.M306755200	http://dx.doi.org/10.1074/jbc.M306755200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13679369	hybrid			2022-12-25	WOS:000186731400099
J	Kim, YK; Kim, SJ; Yatani, A; Huang, YH; Castelli, G; Vatner, DE; Liu, J; Zhang, QZ; Diaz, G; Zieba, R; Thaisz, J; Drusco, A; Croce, C; Sadoshima, J; Condorelli, G; Vatner, SF				Kim, YK; Kim, SJ; Yatani, A; Huang, YH; Castelli, G; Vatner, DE; Liu, J; Zhang, QZ; Diaz, G; Zieba, R; Thaisz, J; Drusco, A; Croce, C; Sadoshima, J; Condorelli, G; Vatner, SF			Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-REPERFUSION INJURY; CARDIOMYOCYTES IN-VITRO; PRESSURE-OVERLOAD; TRANSGENIC MICE; MYOCARDIAL-CONTRACTILITY; HEART-FAILURE; GENE-TRANSFER; CELL-SIZE; ACTIVATION; MYOCYTES	Transgenic mice with cardiac-specific overexpression of active Akt (TG) not only exhibit hypertrophy but also show enhanced left ventricular (LV) function. In 3-4-month-old TG, heart/body weight was increased by 60% and LV ejection fraction was elevated (84 +/- 2%, p < 0.01) compared with nontransgenic littermates ( wild type (WT)) (73 &PLUSMN; 1%). An increase in isolated ventricular myocyte contractile function (% contraction) in TG compared with WT (6.1 &PLUSMN; 0.2 versus 3.5 &PLUSMN; 0.2%, p < 0.01) was associated with increased Fura-2 Ca2+ transients (396 +/- 50 versus 250 +/- 24 nmol/liter, p < 0.05). The rate of relaxation (+dL/dt) was also enhanced in TG (214 &PLUSMN; 15 versus 98 &PLUSMN; 18 &mu;m/s, p < 0.01). L-type Ca2+ current (I-Ca) density was increased in TG compared with WT (-9.0 +/- 0.3 versus 7.2 +/- 0.3 pA/pF, p < 0.01). Sarcoplasmic reticulum Ca2+ ATPase 2a (SERCA2a) protein levels were increased (p < 0.05) by 6.6-fold in TG, which could be recapitulated in vitro by adenovirus-mediated overexpression of Akt in cultured adult ventricular myocytes. Conversely, inhibiting SERCA with either ryanodine or thapsigargin affected myocyte contraction and relaxation and Ca2+ channel kinetics more in TG than in WT. Thus, myocytes from mice with overexpressed Akt demonstrated enhanced contractility and relaxation, Fura-2 Ca2+ transients, and Ca2+ channel currents. Furthermore, increased protein expression of SERCA2a plays an important role in mediating enhanced LV function by Akt. Up-regulation of SERCA2a expression and enhanced LV myocyte contraction and relaxation in Akt-induced hypertrophy is opposite to the down-regulation of SERCA2a and reduced contractile function observed in many other forms of LV hypertrophy.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Cell Biol & Mol Med, Cardiovasc Res Inst, Newark, NJ 07103 USA; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Jefferson University	Condorelli, G (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Cell Biol & Mol Med, Cardiovasc Res Inst, 185 S Orange Ave,MSB G-609, Newark, NJ 07103 USA.		Condorelli, Gerolama/AAC-3472-2022; Young, Richard A/F-6495-2012; castelli, germana/J-7244-2016; Condorelli, Gianluigi/Q-6736-2017	Condorelli, Gerolama/0000-0003-0177-8829; Young, Richard A/0000-0001-8855-8647; castelli, germana/0000-0002-3593-1230; Condorelli, Gianluigi/0000-0003-0481-6843; Sadoshima, Junichi/0000-0003-3724-4132	NHLBI NIH HHS [HL33065, HL67724, HL65183, HL69020, HL61476, HL62442, HL65182, HL59139, HL33107] Funding Source: Medline; NIA NIH HHS [AG14121] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059139, R01HL061476, R01HL033107, R01HL065183, P01HL069020, R01HL067724, R01HL033065, R01HL062442, R37HL033107, R01HL065182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014121] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Asai K, 1999, J CLIN INVEST, V104, P551, DOI 10.1172/JCI7418; Baker DL, 1998, CIRC RES, V83, P1205, DOI 10.1161/01.RES.83.12.1205; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bers DM, 2000, CIRC RES, V87, P275, DOI 10.1161/01.RES.87.4.275; Blair LAC, 1999, J NEUROSCI, V19, P1940; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Coffer PJ, 1998, BIOCHEM J, V335, P1; Condorelli G, 2002, P NATL ACAD SCI USA, V99, P12333, DOI 10.1073/pnas.172376399; Cook SA, 2002, J BIOL CHEM, V277, P22528, DOI 10.1074/jbc.M201462200; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Franklin IK, 2001, BIOCHEM J, V358, P217, DOI 10.1042/0264-6021:3580217; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Kim SJ, 1999, J CLIN INVEST, V103, P1089, DOI 10.1172/JCI4848; Kim SJ, 2001, CIRC RES, V89, P831, DOI 10.1161/hh2101.098547; KISS E, 1995, CIRC RES, V77, P759, DOI 10.1161/01.RES.77.4.759; Masaki H, 1997, AM J PHYSIOL-HEART C, V272, pH606, DOI 10.1152/ajpheart.1997.272.2.H606; MATSUI H, 1995, AM J PHYSIOL-CELL PH, V268, pC252, DOI 10.1152/ajpcell.1995.268.1.C252; Matsui T, 2001, CIRCULATION, V104, P330; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; Miao WF, 2000, J MOL CELL CARDIOL, V32, P2397, DOI 10.1006/jmcc.2000.1283; Mockridge JW, 2000, BIOCHEM BIOPH RES CO, V270, P947, DOI 10.1006/bbrc.2000.2522; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; *NAT RES COUNC, 1996, GUID CAR US LAB; Sadoshima J, 2002, J CLIN INVEST, V110, P271, DOI 10.1172/JCI200214938; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; VATNER DE, 1994, CIRCULATION, V90, P1423, DOI 10.1161/01.CIR.90.3.1423; Yatani A, 1999, J MOL CELL CARDIOL, V31, P1327, DOI 10.1006/jmcc.1999.0966	37	93	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47622	47628		10.1074/jbc.M305909200	http://dx.doi.org/10.1074/jbc.M305909200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13129932	hybrid			2022-12-25	WOS:000186731400035
J	Liu, Y; Sinha, S; Owens, G				Liu, Y; Sinha, S; Owens, G			A transforming growth factor-beta control element required for SM alpha-actin expression in vivo also partially mediates GKLF-dependent transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; SMOOTH-MUSCLE CELLS; TGF-BETA; GENE-EXPRESSION; CARG ELEMENTS; GROWTH-FACTOR-BETA-1; PROMOTER; DIFFERENTIATION; MICE; INHIBITION	We previously demonstrated that a conserved transforming growth factor-beta control element (TCE) within the 5'-region of the smooth muscle cell (SMC) differentiation marker gene SM alpha-actin could mediate both transcriptional activation and repression in cultured SMCs through interaction with members of the zinc finger Kruppel-like transcription factor (KLF) family. The aims of the present studies were to: 1) determine the role of the SM alpha-actin TCE in vivo through mutagenesis studies in transgenic mice and 2) further characterize the possible role and mechanisms by which the TCE-binding factor GKLF/KLF4 induces repression of SMC marker genes in various SMC model systems in vitro. Our results showed that the TCE was required for SM alpha-actin promoter activity in transgenic mice in vivo. Results of transient transfection studies showed that GKLF-induced repression of a SM alpha-actin promoter/luciferase reporter gene partially depended on the TCE. Furthermore, a GKLF overexpressing adenovirus inhibited whereas GKLF morpholino antisense oligos increased expression of endogenous SMC marker genes. Results of chromatin immunoprecipitation assays showed GKLF binding to TCE containing regions of various SMC marker gene promoters within intact chromatin. Finally, results of co-transfection studies showed that overexpression of IKLF/KLF5 reversed GKLF-dependent repression thus supporting a model of reciprocal activation-repression of SMC gene expression by different members of the KLF gene family.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	University of Virginia	Owens, G (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, 415 Lane Rd,MR 5,Rm 1220,POB 801394, Charlottesville, VA 22908 USA.		Sinha, Sanjay/AAF-1692-2021	Sinha, Sanjay/0000-0001-5900-1209	NHLBI NIH HHS [R37HL57353, P01HL19242, P01HL38854] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL057353, P01HL019242, R01HL057353, R01HL038854] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; Foster KW, 2000, CANCER RES, V60, P6488; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Hautmann MB, 1999, ARTERIOSCL THROM VAS, V19, P2049, DOI 10.1161/01.ATV.19.9.2049; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Hudziak RM, 1996, ANTISENSE NUCLEIC A, V6, P267, DOI 10.1089/oli.1.1996.6.267; Hungerford JE, 1999, J VASC RES, V36, P2, DOI 10.1159/000025622; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; LAWLER S, 1994, DEVELOPMENT, V120, P165; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; Mack CP, 1999, CIRC RES, V84, P852; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; Mallat Z, 2001, CIRC RES, V89, P930, DOI 10.1161/hh2201.099415; Manabe I, 2001, J CLIN INVEST, V107, P823, DOI 10.1172/JCI11385; NIKOL S, 1992, J CLIN INVEST, V90, P1582, DOI 10.1172/JCI116027; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; OWENS GK, 1995, PHYSIOL REV, V75, P487; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; OWENS GK, 1996, ATHEROSCLEROSIS CORO, P401; Regan CP, 2000, J CLIN INVEST, V106, P1139, DOI 10.1172/JCI10522; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P63, DOI 10.1089/oli.1.1997.7.63; VERBEEK MM, 1994, AM J PATHOL, V144, P372; WOLF YG, 1994, J CLIN INVEST, V93, P1172, DOI 10.1172/JCI117070; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	45	89	92	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48004	48011		10.1074/jbc.M301902200	http://dx.doi.org/10.1074/jbc.M301902200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12970361	hybrid			2022-12-25	WOS:000186731400079
J	Soldano, KL; Jivan, A; Nicchitta, CV; Gewirth, DT				Soldano, KL; Jivan, A; Nicchitta, CV; Gewirth, DT			Structure of the N-terminal domain of GRP94 - Basis for ligand specificity and regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; HSP90 MOLECULAR CHAPERONE; NUCLEOTIDE-BINDING DOMAIN; ATP BINDING; CRYSTAL-STRUCTURE; PEPTIDE BINDING; GELDANAMYCIN; ACTIVATION; HYDROLYSIS; RADICICOL	GRP94, the endoplasmic reticulum (ER) paralog of the chaperone Hsp90, plays an essential role in the structural maturation or secretion of a subset of proteins destined for transport to the cell surface, such as the Toll-like receptors 2 and 4, and IgG, respectively. GRP94 differs from cytoplasmic Hsp90 by exhibiting very weak ATP binding and hydrolysis activity. GRP94 also binds selectively to a series of substituted adenosine analogs. The high resolution crystal structures at 1.75-2.1 Angstrom of the N-terminal and adjacent charged domains of GRP94 in complex with N-ethylcarboxamidoadenosine, radicicol, and 2-chlorodideoxyadenosine reveals a structural mechanism for ligand discrimination among hsp90 family members. The structures also identify a putative subdomain that may act as a ligand-responsive switch. The residues of the charged region fold into a disordered loop whose termini are ordered and continue the twisted beta sheet that forms the structural core of the N-domain. This continuation of the beta sheet past the charged domain suggests a structural basis for the association of the N-terminal and middle domains of the full-length chaperone.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University; Duke University	Gewirth, DT (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	gewirth@duke.edu						Baker-LePain JC, 2002, J EXP MED, V196, P1447, DOI 10.1084/jem.20020436; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hartson SD, 1996, BIOCHEMISTRY-US, V35, P13451, DOI 10.1021/bi961332c; HUTCHISON KA, 1989, J BIOL CHEM, V264, P19898; HUTCHISON KA, 1990, BIOCHEMISTRY-US, V29, P5138, DOI 10.1021/bi00473a020; IANNOTTI AM, 1988, ARCH BIOCHEM BIOPHYS, V264, P54, DOI 10.1016/0003-9861(88)90569-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lusty CJ, 1999, J APPL CRYSTALLOGR, V32, P106, DOI 10.1107/S002188989801053X; Maruya M, 1999, J MOL BIOL, V285, P903, DOI 10.1006/jmbi.1998.2349; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; Meyer P, 2003, MOL CELL, V11, P647, DOI 10.1016/S1097-2765(03)00065-0; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Nganga A, 2000, BIOCHEM J, V352, P865, DOI 10.1042/0264-6021:3520865; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Owen BAL, 2002, J BIOL CHEM, V277, P7086, DOI 10.1074/jbc.M111450200; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Randow F, 2001, NAT CELL BIOL, V3, P891, DOI 10.1038/ncb1001-891; RICHARDS FM, 1988, PROTEINS, V3, P71, DOI 10.1002/prot.340030202; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Rosser MFN, 2000, J BIOL CHEM, V275, P22798, DOI 10.1074/jbc.M001477200; Sastry S, 1999, J BIOL CHEM, V274, P12023, DOI 10.1074/jbc.274.17.12023; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Supino-Rosin L, 2000, J BIOL CHEM, V275, P21850, DOI 10.1074/jbc.M001834200; Vega VL, 2003, MOL BIOL CELL, V14, P764, DOI 10.1091/mbc.E02-08-0498; Wassenberg JJ, 2000, J BIOL CHEM, V275, P22806, DOI 10.1074/jbc.M001476200; Wearsch PA, 1998, BIOCHEMISTRY-US, V37, P5709, DOI 10.1021/bi9801006; Wearsch PA, 1996, BIOCHEMISTRY-US, V35, P16760, DOI 10.1021/bi962068q; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; Word JM, 1999, J MOL BIOL, V285, P1711, DOI 10.1006/jmbi.1998.2400	53	107	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48330	48338		10.1074/jbc.M308661200	http://dx.doi.org/10.1074/jbc.M308661200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12970348	hybrid			2022-12-25	WOS:000186731400118
J	Coulet, F; Nadaud, S; Agrapart, M; Soubrier, F				Coulet, F; Nadaud, S; Agrapart, M; Soubrier, F			Identification of hypoxia-response element in the human endothelial nitric-oxide synthase gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; PAS DOMAIN PROTEIN-1; DNA-BINDING ACTIVITY; ADULT-RAT LUNG; POSTTRANSCRIPTIONAL REGULATION; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; DOWN-REGULATION; MESSENGER-RNA; UP-REGULATION	The human endothelial nitric-oxide synthase gene (heNOS) is constitutively expressed in endothelial cells, and its expression is induced under hypoxia. The goal of this study was to search for regulatory elements of the endothelial nitric-oxide synthase (eNOS) gene responsive to hypoxia. Levels of eNOS mRNA, measured by real time reverse transcriptase-PCR analysis, were increased, and heNOS promoter activity was enhanced by hypoxia as compared with normoxia control experiments. Promoter truncation followed by footprint analysis allowed the mapping and identification of the hypoxia-responsive elements at position -5375 to -5366, closely related to hypoxia-inducible factor (HIF)-responsive element (HRE). To test whether known HIF-1 and HIF-2 are involved in hypoxia-induced heNOS promoter activation, HMEC-1 and HUVEC were transiently transfected with HIF-1alpha and HIF-1beta or HIF-2alpha and HIF-1beta expression vectors. Exogenous HIF-2 markedly increased luciferase reporter activity driven by the heNOS promoter in its native location. The induction of luciferase was conserved with the antisense construct and was increased in cotransfection experiments when this fragment was cloned 5' to the proximal 785-bp fragment of the eNOS promoter. Deletion analysis and site-directed mutagenesis demonstrated that the two contiguous HIF consensus binding sites spanning bp -5375 to -5366 relative to the transcription start site were both functional for heNOS promoter activity induction by hypoxia and by HIF-2 overexpression. In conclusion, we demonstrate that heNOS is a hypoxia-inducible gene, whose transcription is stimulated through HIF-2 interaction with two contiguous HRE sites located at -5375 to -5366 of the heNOS promoter.	Univ Paris 06, Fac Med Pitie Salpetriere, INSERM, U525, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Soubrier, F (corresponding author), Univ Paris 06, Fac Med Pitie Salpetriere, INSERM, U525, 91 Bd Hop, F-75013 Paris, France.	florent.soubrier@chups.jussieu.fr	Nadaud, Sophie/A-7063-2013; Nadaud, Sophie/GXV-0505-2022	Nadaud, Sophie/0000-0002-1452-6009; 				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Arnet UA, 1996, J BIOL CHEM, V271, P15069, DOI 10.1074/jbc.271.25.15069; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Damert A, 1997, BIOCHEM J, V327, P419, DOI 10.1042/bj3270419; Dhar AK, 2001, J CLIN MICROBIOL, V39, P2835, DOI 10.1128/JCM.39.8.2835-2845.2001; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Fink T, 2002, BLOOD, V99, P2077, DOI 10.1182/blood.V99.6.2077; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Graven KK, 2003, BBA-GENE STRUCT EXPR, V1626, P10, DOI 10.1016/S0167-4781(03)00049-6; GREENBERG B, 1993, AM J PHYSIOL, V265, pH1712, DOI 10.1152/ajpheart.1993.265.5.H1712; Hoffmann A, 2001, J CELL PHYSIOL, V188, P33, DOI 10.1002/jcp.1092; Isozumi Kazuo, 1994, Keio Journal of Medicine, V43, P31; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kappel A, 1999, BLOOD, V93, P4284, DOI 10.1182/blood.V93.12.4284.412k25_4284_4292; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Laumonnier Y, 2000, J BIOL CHEM, V275, P40732, DOI 10.1074/jbc.M004696200; Le Cras TD, 1998, J CLIN INVEST, V101, P795, DOI 10.1172/JCI786; Leach RM, 2002, RESP PHYSIOL NEUROBI, V132, P55, DOI 10.1016/S1569-9048(02)00049-6; Li HG, 2002, NITRIC OXIDE-BIOL CH, V7, P132, DOI 10.1016/S1089-8603(02)00127-1; Li YX, 2003, J BIOL CHEM, V278, P16899, DOI 10.1074/jbc.M300596200; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MCPHERSON RW, 1994, AM J PHYSIOL, V266, pH476, DOI 10.1152/ajpheart.1994.266.2.H476; McQuillan Lynda P., 1994, American Journal of Physiology, V267, pH1921; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Murata T, 2001, EUR J PHARMACOL, V421, P45, DOI 10.1016/S0014-2999(01)01015-9; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Navarro-Antolin J, 2000, J BIOL CHEM, V275, P3075, DOI 10.1074/jbc.275.5.3075; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; POHL U, 1989, AM J PHYSIOL, V256, pH1595, DOI 10.1152/ajpheart.1989.256.6.H1595; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Searles CD, 1999, CIRC RES, V85, P588, DOI 10.1161/01.RES.85.7.588; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; SHAUL PW, 1995, AM J RESP CELL MOL, V13, P167, DOI 10.1165/ajrcmb.13.2.7542896; St-Pierre B, 2002, J BIOL CHEM, V277, P46544, DOI 10.1074/jbc.M111652200; Takemoto M, 2002, CIRCULATION, V106, P57, DOI 10.1161/01.CIR.0000020682.73694.AB; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Templeton DM, 2003, BBA-GEN SUBJECTS, V1619, P113, DOI 10.1016/S0304-4165(02)00497-X; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Toporsian M, 2000, CIRC RES, V86, P671, DOI 10.1161/01.RES.86.6.671; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Xiao DL, 2001, AM J PHYSIOL-HEART C, V280, pH812, DOI 10.1152/ajpheart.2001.280.2.H812; Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205; Ziegler T, 1998, HYPERTENSION, V32, P351, DOI 10.1161/01.HYP.32.2.351	57	156	165	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46230	46240		10.1074/jbc.M305420200	http://dx.doi.org/10.1074/jbc.M305420200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963737	hybrid			2022-12-25	WOS:000186569400006
J	Nishi, T; Nishi, SK; Forgac, M				Nishi, T; Nishi, SK; Forgac, M			Expression and function of the mouse V-ATPase d subunit isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; RENAL TUBULAR-ACIDOSIS; IN-VIVO DISSOCIATION; MUTATIONAL ANALYSIS; GENE ENCODES; LUMINAL ACIDIFICATION; MOLECULAR-CLONING; CATALYTIC SUBUNIT; NEUROSPORA-CRASSA	We have identified a cDNA encoding a novel isoform of the mouse V-ATPase d subunit (d2). The protein encoded is 350 amino acids in length and shows 42 and 67% identity to the yeast d subunit (Vma6p) and the mouse d1 isoform, respectively. Reverse transcriptase-PCR analysis using isoform-specific primers demonstrate that d2 is expressed mainly in kidney and at lower levels in heart, spleen, skeletal muscle, and testis. Although d1 and d2 show similar levels of sequence homology to Vma6p, only the d1 isoform can complement the phenotype of a yeast strain in which VMA6 has been disrupted when cells are grown at 30degreesC. The d2 isoform, however, can complement the vma6Delta phenotype when cells are grown at 25degreesC. Moreover, partial assembly of the V-ATPase complex on the vacuolar membrane can be detected under these conditions, although assembly is significantly lower than that observed for the strain expressing Vma6p. This reduced assembly is also reflected in a reduced level of concanamycin-sensitive ATPase activity and proton transport in isolated vacuoles. Comparison of the kinetic properties of V-ATPase complexes containing Vma6p and d1 demonstrate that although the K-m for ATP hydrolysis is similar (0.26 and 0.31 mM, respectively), the coupling ratio (proton transport/ATP hydrolysis) is similar to3-6-fold higher for d1-containing complexes than for Vma6p-containing complexes. These results suggest that subunit d may play a role in coupling of proton transport and ATP hydrolysis.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA.	michael.forgac@tufts.edu			NIDDK NIH HHS [DK 34928] Funding Source: Medline; NIGMS NIH HHS [R01 GM034478, R37 GM034478, GM 34478] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; ADACHI I, 1990, J BIOL CHEM, V265, P960; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; Bauerle C, 1998, PLANT PHYSIOL, V117, P859, DOI 10.1104/pp.117.3.859; Bowman EJ, 2000, J EXP BIOL, V203, P97; Brown D, 2000, J EXP BIOL, V203, P137; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Futai M, 2000, J EXP BIOL, V203, P107; Graham LA, 1998, J CELL BIOL, V142, P39, DOI 10.1083/jcb.142.1.39; Graham LA, 2000, J EXP BIOL, V203, P61; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Kawasaki-Nishi S, 2001, P NATL ACAD SCI USA, V98, P12397, DOI 10.1073/pnas.221291798; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1995, J BIOL CHEM, V270, P7320, DOI 10.1074/jbc.270.13.7320; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; MacLeod KJ, 1998, J BIOL CHEM, V273, P150, DOI 10.1074/jbc.273.1.150; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; Melnik VI, 1996, BBA-BIOENERGETICS, V1273, P77, DOI 10.1016/0005-2728(95)00144-1; Merzendorfer H, 1997, J EXP BIOL, V200, P225; Murata Y, 2002, J BIOL CHEM, V277, P36296, DOI 10.1074/jbc.M200586200; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; Nelson N, 2000, J EXP BIOL, V203, P89; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishi T, 1997, J BIOCHEM, V121, P922; Nishi T, 2001, J BIOL CHEM, V276, P34122, DOI 10.1074/jbc.M104682200; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; Shao E, 2003, J BIOL CHEM, V278, P12985, DOI 10.1074/jbc.M212096200; Smith AN, 2002, GENE, V297, P169, DOI 10.1016/S0378-1119(02)00884-3; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; Sun-Wada GH, 2003, GENE, V302, P147, DOI 10.1016/S0378-1119(02)01099-5; Sun-Wada GH, 2002, J BIOL CHEM, V277, P18098, DOI 10.1074/jbc.M111567200; Sze H, 2002, TRENDS PLANT SCI, V7, P157, DOI 10.1016/S1360-1385(02)02240-9; Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677; TEMESVARI L, 1994, J BIOL CHEM, V269, P25719; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; VANHILLE B, 1993, BIOCHEM BIOPH RES CO, V197, P15, DOI 10.1006/bbrc.1993.2434; WANG SY, 1988, J BIOL CHEM, V263, P17638; Wieczorek H, 2000, J EXP BIOL, V203, P127; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; Xu T, 2000, J BIOL CHEM, V275, P22075, DOI 10.1074/jbc.M002983200	53	42	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46396	46402		10.1074/jbc.M303924200	http://dx.doi.org/10.1074/jbc.M303924200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963731	hybrid			2022-12-25	WOS:000186569400023
J	Anyatonwu, GI; Buck, ED; Ehrlich, BE				Anyatonwu, GI; Buck, ED; Ehrlich, BE			Methanethiosulfonate ethylammonium block of amine currents through the ryanodine receptor reveals single pore architecture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; CARDIAC SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; CYSTEINE-SUBSTITUTION; POTASSIUM CHANNELS; ORGANIC CATIONS; K+ CHANNEL; CONDUCTION; RECONSTITUTION; STABILIZATION	The homotetrameric structure of the ryanodine-sensitive intracellular calcium (Ca2+) release channel (ryanodine receptor (RyR)) suggests that the four RyR subunits either combine to form a single pore or that each RyR subunit is an independently conducting pathway. Previously we showed that methanethiosulfonate ethylammonium (MTSEA(+)) covalently modifies the RyR to reduce current amplitudes in a time-dependent and stepwise manner. To ascertain the number of functionally conducting pores in the RyR, two approaches were combined: modification of the receptor by MTSEA(+) and the use of different sized current carriers. Previous reports (Tinker, A., and Williams, A.J. (1993) J. Gen. Physiol. 102, 1107-1129) have shown that the organic cations methylamine, dimethylamine, ethylamine, and trimethylamine are permeant through the RyR but with reduced current amplitude depending upon the diameter of the respective amine. Experiments using the thiol reagent MTSEA(+) to modify the channel protein showed that the current amplitudes decrease in steps leading to complete block of the channel when cesium (Cs+) is the current carrier. MTSEA(+) modification decreased the number of channel substates as the diameter of the current carrier increased. Comparison of the degree of inhibition of MTSEA(+)-modified currents allows for differentiation between the two models for channel architecture. These results demonstrate that the conduction pathway for the RyR is comprised of a single central pore.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Warner Instruments Inc, Hamden, CT 06514 USA	Yale University; Yale University	Ehrlich, BE (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	barbara.ehrlich@yale.edu	/AAX-8408-2021	/0000-0001-9657-9704				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Betanzos M, 2002, NAT STRUCT BIOL, V9, P704, DOI 10.1038/nsb828; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Buck ED, 1999, J PHARMACOL EXP THER, V289, P477; DANI JA, 1991, J THEOR BIOL, V153, P401, DOI 10.1016/S0022-5193(05)80578-8; Ding SH, 2002, J GEN PHYSIOL, V120, P87, DOI 10.1085/jgp.20028611; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dulhunty A, 2000, ANTIOXID REDOX SIGN, V2, P27, DOI 10.1089/ars.2000.2.1-27; FEHER JJ, 1991, J MOL CELL CARDIOL, V23, P249, DOI 10.1016/0022-2828(91)90061-P; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kaftan E, 1996, CIRC RES, V78, P990, DOI 10.1161/01.RES.78.6.990; KURZ LL, 1995, BIOPHYS J, V68, P900, DOI 10.1016/S0006-3495(95)80266-3; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Liu J, 2000, NEURON, V28, P899, DOI 10.1016/S0896-6273(00)00162-8; Manjunatha B, 1997, J GEN PHYSIOL, V110, P749, DOI 10.1085/jgp.110.6.749; Marks AR, 1997, AM J PHYSIOL-HEART C, V272, pH597, DOI 10.1152/ajpheart.1997.272.2.H597; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; Quinn KE, 1997, J GEN PHYSIOL, V109, P255, DOI 10.1085/jgp.109.2.255; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; Roux B, 1999, SCIENCE, V285, P100, DOI 10.1126/science.285.5424.100; Serysheva II, 1999, BIOPHYS J, V77, P1936, DOI 10.1016/S0006-3495(99)77035-9; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; Shah PK, 2001, PROTEIN ENG, V14, P867, DOI 10.1093/protein/14.11.867; Sitsapesan R, 1998, STRUCTURE FUNCTION R; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TINKER A, 1992, J GEN PHYSIOL, V100, P479, DOI 10.1085/jgp.100.3.479; TINKER A, 1993, J GEN PHYSIOL, V102, P1107, DOI 10.1085/jgp.102.6.1107; TINKER A, 1993, BIOPHYS J, V65, P1678, DOI 10.1016/S0006-3495(93)81201-3; TINKER A, 1995, BIOPHYS J, V68, P111, DOI 10.1016/S0006-3495(95)80165-7; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; Wagenknecht T, 1997, CURR OPIN STRUC BIOL, V7, P258, DOI 10.1016/S0959-440X(97)80034-6; Williams AJ, 2001, Q REV BIOPHYS, V34, P61, DOI 10.1017/S0033583501003675; XU M, 1993, J BIOL CHEM, V268, P21505; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	36	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45528	45538		10.1074/jbc.M307863200	http://dx.doi.org/10.1074/jbc.M307863200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12963712	hybrid			2022-12-25	WOS:000186452300060
J	Nakayamada, S; Okada, Y; Saito, K; Tamura, M; Tanaka, Y				Nakayamada, S; Okada, Y; Saito, K; Tamura, M; Tanaka, Y			beta(1) integrin/focal adhesion kinase-mediated signaling induces intercellular adhesion molecule 1 and receptor activator of nuclear factor kappa B ligand on Osteoblasts and osteoclast maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-CELLS; DOWN-REGULATION; GROWTH-FACTOR; EXPRESSION; DIFFERENTIATION; TRANSCRIPTION; OSTEOPOROSIS; MECHANISMS; APOPTOSIS; MIGRATION	We have assessed characteristics of primary human osteoblasts, shedding light on signaling mediated by beta(1) integrin. beta(1) integrins are major receptors for these matrix glycoproteins. 1) Integrins beta(1), alpha(2), alpha(3), alpha(4), alpha(5), alpha(6), and alpha(v) were highly expressed on primary osteoblasts. 2) Engagement of beta(1) integrins on osteoblasts by cross-linking with specific antibody or ligand matrices, such as fibronectin or collagen, augmented expression of intercellular adhesion molecule 1 (ICAM-1) and receptor activator of nuclear factor kappaB ligand (RANKL) on the surface. 3) Up-regulation of ICAM-1 and RANKL on osteoblasts by beta(1) stimulation was completely abrogated by pretreatment with herbimycin A and genistein, tyrosine kinase inhibitors, or transfection of dominant negative truncations of focal adhesion kinase (FAK). 4) Engagement of beta(1) integrins on osteoblasts induced tartrate-resistant acid phosphatase-positive multinuclear cell formation in the coculture system of osteoblasts and peripheral monocytes. 5) Up-regulation of tartrate-resistant acid phosphatase-positive multinuclear cell formation by beta(1) stimulation was completely abrogated by transfection of dominant negative truncations of FAK. Our results indicate that beta(1) integrin-dependent adhesion of osteoblasts to bone matrices induces ICAM-1 and RANKL expression and osteoclast formation via tyrosine kinase, especially FAK. We here propose that beta(1) integrin/FAK-mediated signaling on osteoblasts could be involved in ICAM-1- and RANKL-dependent osteoclast maturation.	Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 2, Kitakyushu, Fukuoka 8078555, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan	Tanaka, Y (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, Kitakyushu, Fukuoka 8078555, Japan.	tanaka@med.uoeh-u.ac.jp	Okada, Yosuke/AAT-3173-2020					Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Bennett JH, 2001, HISTOL HISTOPATHOL, V16, P603, DOI 10.14670/HH-16.603; Bennett JH, 2001, ARCH ORAL BIOL, V46, P229, DOI 10.1016/S0003-9969(00)00114-X; BERESFORD JN, 1984, METAB BONE DIS RELAT, V5, P229, DOI 10.1016/0221-8747(84)90064-X; Brakebusch C, 2002, J CLIN INVEST, V109, P999, DOI 10.1172/JCI200215468; CLOVER J, 1992, J CELL SCI, V103, P267; Damsky CH, 1999, BONE, V25, P95, DOI 10.1016/S8756-3282(99)00106-4; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Duong L T, 2001, Rev Endocr Metab Disord, V2, P95, DOI 10.1023/A:1010063225902; Fujimoto H, 2001, GENES CELLS, V6, P337, DOI 10.1046/j.1365-2443.2001.00428.x; Globus RK, 1998, J CELL SCI, V111, P1385; GRZESIK WJ, 1994, J BONE MINER RES, V9, P487, DOI 10.1002/jbmr.5650090408; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; HUGHES DE, 1993, J BONE MINER RES, V8, P527; Kotake S, 1996, J BONE MINER RES, V11, P88; Koyama Y, 1996, J IMMUNOL, V157, P5097; Liu SC, 2000, J CELL SCI, V113, P3563; Liu ZJ, 1999, J IMMUNOL, V163, P4901; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Martin KH, 2002, SCIENCE, V296, P1652, DOI 10.1126/science.296.5573.1652; Mundy G R, 2001, Rev Endocr Metab Disord, V2, P105, DOI 10.1023/A:1010015309973; Nakayamada S, 2003, ARTHRITIS RHEUM, V48, P1239, DOI 10.1002/art.10941; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Raisz LG, 1999, CLIN CHEM, V45, P1353; Raisz LG, 2001, J BONE MINER RES, V16, P1948, DOI 10.1359/jbmr.2001.16.11.1948; Rodan GA, 1998, J CELL BIOCHEM, P55; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 2003, KIDNEY INT, V63, P722, DOI 10.1046/j.1523-1755.2003.00772.x; Tanaka Y, 1999, J IMMUNOL, V163, P6209; Tanaka Y, 1998, BLOOD, V91, P3909; TANAKA Y, 1995, J BONE MINER RES, V10, P1462; Tanaka Y, 2002, J BIOL CHEM, V277, P21446, DOI 10.1074/jbc.M202238200; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; Tanaka Y, 2000, J BONE MINER RES, V15, P1912, DOI 10.1359/jbmr.2000.15.10.1912; Tanaka Yoshiya, 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P443; Vassiliou G, 1998, J IMMUNOL METHODS, V215, P9, DOI 10.1016/S0022-1759(98)00030-1; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zimmerman D, 2000, DEV BIOL, V220, P2, DOI 10.1006/dbio.2000.9633	46	59	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45368	45374		10.1074/jbc.M308786200	http://dx.doi.org/10.1074/jbc.M308786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954625	hybrid			2022-12-25	WOS:000186452300040
J	Wang, HQ; Quan, TH; He, TY; Franke, TF; Voorhees, JJ; Fisher, GJ				Wang, HQ; Quan, TH; He, TY; Franke, TF; Voorhees, JJ; Fisher, GJ			Epidermal growth factor receptor-dependent, NF-kappa B-independent activation of the phosphatidylinositol 3-kinase/Akt pathway inhibits ultraviolet irradiation-induced caspases-3,-8, and-9 in human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; UV-INDUCED APOPTOSIS; SERINE-THREONINE KINASE; PROMOTES CELL-SURVIVAL; CYTOCHROME-C; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; SKIN-CANCER; AKT	Both phosphatidylinositol 3-kinase (PI3K)/Akt and NF-kappaB pathways function to promote cellular survival following stress. Recent evidence indicates that the antiapoptotic activity of these two pathways may be functionally dependent. Ultraviolet (UV) irradiation causes oxidative stress, which can lead to apoptotic cell death. Human skin cells (keratinocytes) are commonly exposed to UV irradiation from the sun. We have investigated activation of the PI3K/Akt and NF-kappaB pathways and their roles in protecting human keratinocytes (KCs) from UV irradiation-induced apoptosis. This activation of PI3K preceded increased levels (3-fold) of active/phosphorylated Akt. UV (50 mJ/cm(2) from UVB source) irradiation caused rapid recruitment of PI3K to the epidermal growth factor receptor ( EGFR). Pretreatment of KCs with EGFR inhibitor PD169540 abolished UV-induced Akt activation/phosphorylation, as did the PI3K inhibitors LY294002 or wortmannin. This inhibition of Akt activation was associated with a 3-4-fold increase of UV-induced apoptosis, as measured by flow cytometry and DNA fragmentation ELISA. In contrast to Akt, UV irradiation did not detectably increase nuclear localization of NF-kappaB, indicating that it was not strongly activated. Consistent with this observation, interference with NF-kappaB activation by adenovirus-mediated overexpression of dominant negative IKK-beta or IkappaB-alpha did not increase UV-induced apoptosis. However, adenovirus-mediated overexpression of constitutively active Akt completely blocked UV-induced apoptosis observed with PI3K inhibition by LY294002, whereas adenovirus mediated overexpression of dominant negative Akt increased UV-induced apoptosis by 2-fold. Inhibition of UV-induced activation of Akt increased release of mitochondrial cytochrome c 3.5-fold, and caused appearance of active forms of caspase-9, caspase-8, and caspase-3. Constitutively active Akt abolished UV-induced cytochrome c release and activation of caspases-9, -8, and -3. These data demonstrate that PI3K/Akt is essential for protecting human KCs against UV-induced apoptosis, whereas NF-kappaB pathway provides little, if any, protective role.	Univ Michigan, Dept Dermatol, Sch Med, Ann Arbor, MI 48109 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	University of Michigan System; University of Michigan; Columbia University	Fisher, GJ (corresponding author), Univ Michigan, Dept Dermatol, Sch Med, Med Sci 1,Room 6447,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.			Quan, Taihao/0000-0002-0954-5109				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Caricchio R, 1998, J IMMUNOL, V161, P241; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Delhase M, 1999, COLD SPRING HARB SYM, V64, P491, DOI 10.1101/sqb.1999.64.491; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; FISHER GJ, 1993, J INVEST DERMATOL, V101, P553, DOI 10.1111/1523-1747.ep12365967; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; GERARD R, 1995, DNA CLONING PRACTICA, P300; Goswami R, 1999, J NEUROSCI RES, V57, P884, DOI 10.1002/(SICI)1097-4547(19990915)57:6<884::AID-JNR14>3.3.CO;2-1; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; HATANO E, 2001, AM J PHYSIOL-GASTR L, V1, pG1357; Hermann C, 2000, ARTERIOSCL THROM VAS, V20, P402, DOI 10.1161/01.ATV.20.2.402; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kulms D, 2000, PHOTODERMATOL PHOTO, V16, P195, DOI 10.1034/j.1600-0781.2000.160501.x; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li LW, 1999, MOL CELL BIOL, V19, P8547; Lin JQ, 1999, CANCER RES, V59, P2891; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Meng FY, 2002, J BIOL CHEM, V277, P29674, DOI 10.1074/jbc.M112464200; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; MIYASHITA T, 1995, CELL, V80, P293; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Ozes ON, 1999, NATURE, V401, P82; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Peus D, 2000, PHOTOCHEM PHOTOBIOL, V72, P135, DOI 10.1562/0031-8655(2000)072<0135:UIEGFR>2.0.CO;2; Piette J, 1997, BIOL CHEM, V378, P1237; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; Shea CR, 1991, PHYSL BIOCH MOL BIOL, V2, P910; Sitailo LA, 2002, J BIOL CHEM, V277, P19346, DOI 10.1074/jbc.M200401200; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; STOVER D, 1995, J BIOL CHEM, V26, P15591; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Wang HQ, 1999, J CELL SCI, V112, P3497; Weedon D, 1979, Am J Dermatopathol, V1, P133; Yang CH, 2001, J BIOL CHEM, V276, P13756, DOI 10.1074/jbc.M011006200; Yuan ZQ, 2002, J BIOL CHEM, V277, P29973, DOI 10.1074/jbc.M203636200; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	68	90	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45737	45745		10.1074/jbc.M300574200	http://dx.doi.org/10.1074/jbc.M300574200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952968	hybrid			2022-12-25	WOS:000186452300084
J	Totzke, G; Schulze-Osthoff, K; Janicke, RU				Totzke, G; Schulze-Osthoff, K; Janicke, RU			Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition	ONCOGENE			English	Article						NS-398; nimesulide; COX-2; death receptor; apoptosis	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CANCER CELLS; ANTICANCER AGENTS; HUMAN COLON; KAPPA-B; EXPRESSION; CELECOXIB; GROWTH; SUPPRESSION; INDUCTION	Cyclooxygenase-2 (COX-2) is involved in diverse processes such as inflammation, carcinogenesis and apoptosis. As COX-2 inhibitors interfere with these processes, inhibition of COX-2 has been suggested as a promising anticancer treatment. However, the role of COX-2 in modulation of apoptosis as well as the death pathways affected by COX-2 inhibitors are poorly characterized. Here we demonstrate that the selective COX-2 inhibitors NS-398 and nimesulide increased TNF sensitivity of TNF-resistant HeLa H21 and TNF-sensitive HeLa D98 cells, although this cytokine induced significant COX-2 activity, as judged by prostaglandin E-2 (PGE(2)) production, only in H21 cells. TNF did also not induce PGE(2) production in MCF-7/casp-3 cells stably expressing COX-2; however, nimesulide strongly enhanced TNF-induced apoptosis in these cells. Furthermore, COX-2 activity in HeLa H21 cells could be inhibited by NS-398 concentrations that were 10000-fold lower compared to those required for the induction of cell death. Most intriguingly, sensibilization to apoptosis was specifically observed in response to activation of death receptors. Not only TNF-induced cell death but also apoptosis triggered by the CD95 and TRAIL receptors was enhanced by nimesulide. In contrast, apoptosis induced by the anticancer drugs doxorubicine and etoposide that target the mitochondrial death pathway remained unaffected. Together, our data suggest that COX-2 inhibitors overcome apoptosis resistance and selectively sensitize tumor cells to the extrinsic death receptor-induced apoptotic pathway independently of COX-2.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Schulze-Osthoff, K (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1,Bldg 23-12, D-40225 Dusseldorf, Germany.	kso@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Callejas NA, 2002, HEPATOLOGY, V35, P341, DOI 10.1053/jhep.2002.31163; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chang YWE, 2000, MOL CELL BIOL, V20, P8571, DOI 10.1128/MCB.20.22.8571-8579.2000; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Dannenberg AJ, 2001, LANCET ONCOL, V2, P544, DOI 10.1016/S1470-2045(01)00488-0; Davies NM, 2000, CLIN PHARMACOKINET, V38, P225, DOI 10.2165/00003088-200038030-00003; Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Elder DJE, 2002, INT J CANCER, V99, P323, DOI 10.1002/ijc.10330; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; GUPTA RA, 2000, ANN NY ACAD SCI, V10, P196; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; Held J, 2001, DRUG RESIST UPDATE, V4, P243, DOI 10.1054/drup.2001.0208; Hida T, 1998, CANCER RES, V58, P3761; Hida T, 2000, CLIN CANCER RES, V6, P2006; Hsi LC, 2000, EXP CELL RES, V256, P563, DOI 10.1006/excr.2000.4863; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Huang Y, 2001, CANCER RES, V61, P6918; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; JENDROSSEK V, 2003, IN PRESS FASSEB J; Jiang XH, 2002, ONCOGENE, V21, P6113, DOI 10.1038/sj.onc.1205778; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; KO Y, 1995, MOL CELL PROBE, V9, P215, DOI 10.1016/S0890-8508(95)90070-5; Lin MT, 2001, J BIOL CHEM, V276, P48997, DOI 10.1074/jbc.M107829200; Liu XH, 1998, CANCER RES, V58, P4245; Masferrer JL, 2000, CANCER RES, V60, P1306; McGinty A, 2000, J BIOL CHEM, V275, P12095, DOI 10.1074/jbc.275.16.12095; Nzeako UC, 2002, HEPATOLOGY, V35, P552, DOI 10.1053/jhep.2002.31774; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Ravi R, 2002, CANCER RES, V62, P4180; Ricchi P, 2002, BRIT J CANCER, V86, P1501, DOI 10.1038/sj.bjc.6600289; Ristimaki A, 1997, CANCER RES, V57, P1276; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shureiqi I, 2000, CANCER RES, V60, P6846; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Song XQ, 2002, J NATL CANCER I, V94, P585; Souza RF, 2000, CANCER RES, V60, P5767; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stier S, 2000, FEBS LETT, V467, P299, DOI 10.1016/S0014-5793(00)01177-7; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Tang XM, 2002, CANCER RES, V62, P4903; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Tucker ON, 1999, CANCER RES, V59, P987; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Waskewich C, 2002, CANCER RES, V62, P2029; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wong BCY, 2003, ONCOGENE, V22, P1189, DOI 10.1038/sj.onc.1206234; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451; Zimmermann KC, 1999, CANCER RES, V59, P198	58	73	77	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					8021	8030		10.1038/sj.onc.1206837	http://dx.doi.org/10.1038/sj.onc.1206837			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970750				2022-12-25	WOS:000185388200017
J	Breuil, V; Schmid-Antomarchi, H; Schmid-Alliana, A; Rezzonico, R; Euller-Ziegler, L; Rossi, B				Breuil, V; Schmid-Antomarchi, H; Schmid-Alliana, A; Rezzonico, R; Euller-Ziegler, L; Rossi, B			The receptor activator of nuclear factor (NF)kappa B ligand (RANKL) is a new chemotactic factor for human monocytes	FASEB JOURNAL			English	Article						migration; CD14+; MonoMac6 cell line; osteoprotegerin	TUMOR-NECROSIS-FACTOR; OSTEOPROTEGERIN LIGAND; T-CELLS; OSTEOCLAST DIFFERENTIATION; RHEUMATOID-ARTHRITIS; BONE LOSS; KAPPA-B; FAMILY; EXPRESSION; CYTOKINE	Bone resorption is regulated by the immune system, where receptor activator of nuclear factor (NF)kappaB ligand (RANKL), a new member of the tumor-necrosis factor family, may contribute to pathological conditions. Due to the role of RANKL in the maturation of monocyte-derived osteoclasts, we hypothesized that RANKL could exert chemotactic properties toward monocytic cells. Our results demonstrate that RANKL induces the migration of MonoMac-6 monocytic cells as well as human freshly isolated total peripheral blood mononuclear cells (PBMC) and CD14(+) purified PBMC. RANKL induces the migration of MonoMac-6 cells in a dose-dependent manner and with an efficacy similar to MCP-1. After an 8-h incubation, the soluble form of RANKL (sRANKL) started to exhibit a chemoattractive effect on MonoMac-6 cells, with an increased effect observed up to 24 h. RANKL elicits an additive chemotactic effect to MCP-1. Furthermore, addition of the RANKL decoy receptor osteoprotegerin in the lower well or RANKL in the upper well abrogates the RANKL-induced migration of MonoMac-6 cells, hallmarking a true specific activity. RNase protection assay experiments indicate that exposure of MonoMac-6 cells to RANKL had no significant effect on the expression of a variety of chemokines, known to attract monocytes. This study provides evidence that RANKL behaves as a chemotactic factor for monocytic cells, emphazing the cross-talk between bone and immune systems.	Fac Med Pasteur, INSERM, Unit 364, IFR 50, F-06107 Nice 2, France; Archet Hosp, Dept Rheumatol, F-06200 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Rossi, B (corresponding author), Fac Med Pasteur, INSERM, Unit 364, IFR 50, Ave Valombrose, F-06107 Nice 2, France.	rossi@unice.fr	SCHMID-ALLIANA, Annie/P-4366-2016; REZZONICO, Roger/N-9626-2016	SCHMID-ALLIANA, Annie/0000-0003-2321-7408; REZZONICO, Roger/0000-0002-8460-1641				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Cambien B, 2001, BLOOD, V97, P359, DOI 10.1182/blood.V97.2.359; Collin-Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Goldring SR, 2000, ARTHRITIS RES, V2, P33, DOI 10.1186/ar67; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Haynes DR, 2003, RHEUMATOLOGY, V42, P123, DOI 10.1093/rheumatology/keg047; Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; JIANG YL, 1992, J IMMUNOL, V148, P2423; Kim D, 2000, J EXP MED, V192, P1467, DOI 10.1084/jem.192.10.1467; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lader CS, 2001, BRIT J HAEMATOL, V112, P430, DOI 10.1046/j.1365-2141.2001.02437.x; Lorenzo J, 2000, J CLIN INVEST, V106, P749, DOI 10.1172/JCI11089; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; McGowan NWA, 2001, ENDOCRINOLOGY, V142, P1678, DOI 10.1210/en.142.4.1678; MING WJ, 1987, J IMMUNOL, V138, P1469; Muller WA, 2001, J EXP MED, V194, pF47, DOI 10.1084/jem.194.9.f47; Nosaka K, 2002, BLOOD, V99, P634, DOI 10.1182/blood.V99.2.634; Parfitt AM, 1998, BONE, V23, P491, DOI 10.1016/S8756-3282(98)00140-9; Parfitt AM, 2000, BONE, V26, P319, DOI 10.1016/S8756-3282(00)80937-0; Speden DJ, 2002, J RHEUMATOL, V29, P516; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Takami M, 1999, CELL TISSUE RES, V298, P327, DOI 10.1007/s004419900092; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	35	49	50	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1751	+		10.1096/fj.02-1188fje	http://dx.doi.org/10.1096/fj.02-1188fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958198				2022-12-25	WOS:000184471600003
J	Herrmann, J; Gulati, R; Napoli, C; Woodrum, JE; Lerman, LO; Rodriguez-Porcel, M; Sica, V; Simari, RD; Ciechanover, A; Lerman, A				Herrmann, J; Gulati, R; Napoli, C; Woodrum, JE; Lerman, LO; Rodriguez-Porcel, M; Sica, V; Simari, RD; Ciechanover, A; Lerman, A			Oxidative stress-related increase in ubiquitination in early coronary atherogenesis	FASEB JOURNAL			English	Article						coronary artery disease; proteasome; ubiquitin	FACTOR-KAPPA-B; OXIDIZED PROTEINS; ENDOTHELIAL FUNCTION; PROTEASOME PATHWAY; DEGRADATION; 20S; ACTIVATION; HYPERCHOLESTEROLEMIA; IMMUNOREACTIVITY; ACCUMULATION	The ubiquitin-proteasome system (UPS) is involved in the removal of damaged proteins and the activation of transcription factors, such as nuclear-factor-kappaB. Recent reports, however, questioned the functional activity of the UPS under conditions of increased oxidative stress, such as experimental hypercholesterolemia, which was the objective of our study. Pigs were placed on a normal chow diet (N) or on a hypercholesterolemic diet without (HC) or with vitamin C and E supplementation (HC+VIT) for 12 weeks. Compared with N, plasma concentration of total cholesterol increased in both HC and HC+VIT [76 +/- 21 vs. 400 +/- 148 (P<0.05) and 329 +/- 102 (P<0.05) mg/dL], whereas increase in lipid peroxidation, as assessed by LDL-malondialdehyde plasma concentration, was found in HC but not in HC+VIT [6.6 +/- 0.7 vs. 8.5 +/- 0.3 (P<0.05) and 6.8 +/- 0.7 nmol/mg protein]. In comparison with N, the level of ubiquitin conjugates in the coronary artery, as assessed by immunoblotting, increased by 42% in HC but not in HC+VIT and was localized predominantly to media vascular smooth muscle cells by immunostaining. There was no difference in proteasome proteolytic activity among the study groups. These results demonstrate that the UPS is functionally active in early atherogenesis despite increase in oxidative stress with important repercussions in the pathophysiology and therapy of cardiovascular diseases.	Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA; Mayo Clin, Div Hypertens, Rochester, MN USA; Univ Naples Federico II, Dept Med & Clin Pathol, Naples, Italy; Technion Israel Inst Technol, Rappaport Inst Res Med Sci, Haifa, Israel	Mayo Clinic; Mayo Clinic; University of Naples Federico II; Technion Israel Institute of Technology	Lerman, A (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.	lerman.amir@mayo.edu	Ciechanover, Aaron J/C-9166-2017; Lerman, Lilach/M-4962-2017	Napoli, Claudio/0000-0002-5455-555X				Adam PJ, 1997, CARDIOVASC RES, V33, P416, DOI 10.1016/S0008-6363(96)00220-9; Adamo AM, 1999, J NEUROSCI RES, V55, P523, DOI 10.1002/(SICI)1097-4547(19990215)55:4<523::AID-JNR12>3.0.CO;2-Q; AEBI H, 1984, METHOD ENZYMOL, V105, P121; ALLAIN CC, 1974, CLIN CHEM, V20, P470; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bulteau AL, 2001, J BIOL CHEM, V276, P30057, DOI 10.1074/jbc.M100142200; Ciechanover A, 2000, J CELL BIOCHEM, P40; Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; Davies SS, 2002, FASEB J, V16, P715, DOI 10.1096/fj.01-0696fje; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; De Nigris F, 2001, ANTIOXID REDOX SIGN, V3, P1119, DOI 10.1089/152308601317203620; de Nigris F, 2001, BIOCHEM BIOPH RES CO, V281, P945, DOI 10.1006/bbrc.2001.4431; FigueiredoPereira ME, 1997, MOL BIOL REP, V24, P35, DOI 10.1023/A:1006848405975; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; Friguet B, 2002, METHOD ENZYMOL, V353, P253; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Herrmann J, 2002, J AM COLL CARDIOL, V40, P1919, DOI 10.1016/S0735-1097(02)02564-0; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3; Igarashi Masahiko, 1994, Artery, V21, P256; Ishii T, 1999, FREE RADICAL RES, V31, P351, DOI 10.1080/10715769900300921; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Kikuchi J, 2000, ARTERIOSCL THROM VAS, V20, P128, DOI 10.1161/01.ATV.20.1.128; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; LOWE J, 1993, BRAIN PATHOL, V3, P55, DOI 10.1111/j.1750-3639.1993.tb00726.x; Meiners S, 2002, CIRCULATION, V105, P483, DOI 10.1161/hc0402.102951; Napoli C, 2001, MAYO CLIN PROC, V76, P619; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Peterson TE, 1999, BIOCHEM BIOPH RES CO, V265, P722, DOI 10.1006/bbrc.1999.1738; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; Ritchie NE, 1998, CIRCULATION, V98, P1707, DOI 10.1161/01.CIR.98.17.1707; Rodriguez-Porcel M, 2002, CARDIOVASC RES, V53, P1010, DOI 10.1016/S0008-6363(01)00535-1; Rodriguez-Porcel M, 2001, J AM COLL CARDIOL, V37, P608, DOI 10.1016/S0735-1097(00)01139-6; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200; Wilson SH, 2002, ATHEROSCLEROSIS, V160, P147, DOI 10.1016/S0021-9150(01)00546-9; Wilson SH, 2000, ATHEROSCLEROSIS, V148, P23, DOI 10.1016/S0021-9150(99)00211-7; Wilson SH, 2001, ARTERIOSCL THROM VAS, V21, P122, DOI 10.1161/01.ATV.21.1.122	42	47	52	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1730	+		10.1096/fj.02-0841fje	http://dx.doi.org/10.1096/fj.02-0841fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958191				2022-12-25	WOS:000184471600001
J	Titos, E; Claria, J; Planaguma, A; Lopez-Parra, M; Villamor, N; Parrizas, M; Carrio, A; Miquel, R; Jimenez, W; Arroyo, V; Rivera, F; Rodes, J				Titos, E; Claria, J; Planaguma, A; Lopez-Parra, M; Villamor, N; Parrizas, M; Carrio, A; Miquel, R; Jimenez, W; Arroyo, V; Rivera, F; Rodes, J			Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis	FASEB JOURNAL			English	Article						hepatic inflammation; sinusoidal liver cells; arachidonic acid metabolites	LEUKOTRIENE-SYNTHESIS; CANCER CELLS; CYSTEINYL LEUKOTRIENES; HL-60 CELLS; LUNG-CANCER; IN-VITRO; PROLIFERATION; INJURY; SURVIVAL; MACROPHAGES	The existence of an increased number of Kupffer cells is recognized as critical in the initiation of the inflammatory cascade leading to liver fibrosis. Because 5-lipoxygenase(5-LO) is a key regulator of cell growth and survival, in the current investigation we assessed whether inhibition of the 5-LO pathway would reduce the excessive number of Kupffer cells and attenuate inflammation and fibrosis in experimental liver disease. Kupffer cells were the only liver cell type endowed with a metabolically active 5-LO pathway(i.e., expressed mRNAs for 5-LO,5-LO-activating protein[FLAP], and leukotriene [LT] C-4 synthase and generated LnTB(4) and cysteinyl-LTs). Both the selective 5-LO inhibitor AA861 and the FLAP inhibitor BAY-X-1005 markedly reduced the number of Kupffer cells in culture. The antiproliferative properties of AA861 and BAY-X-1005 were associated with the occurrence of condensed nuclei, fragmented DNA,and changes in DNA content and cell cycle frequency distribution consistent with anapoptotic process. In vivo, in carbon tetrachloride-treated rats,BAY-X-1005 had a significant antifibrotic effect and reduced liver damage and the hepatic content of hydroxyproline. Together,these findings indicate a novel mechanism by which inactivation of the 5-LO pathway could disrupt the sequence of events leading to liver inflammation and fibrosis.	Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, DNA Unit, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Hormonal Lab, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Hematopathol Lab, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Pathol Lab, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Genet Lab, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Liver Unit, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Claria, J (corresponding author), Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, DNA Unit, 170 Barcelona, E-08036 Barcelona, Spain.	jclaria@clinic.ub.es	Parrizas, Marcelina/AAS-3629-2021; Arroyo, Vicente/F-9189-2015; Titos, Esther/AAA-5394-2019; Claria, Joan/M-7772-2019	Arroyo, Vicente/0000-0002-2728-1848; Titos, Esther/0000-0002-2543-2243; Claria, Joan/0000-0003-4333-7749; Jimenez, Wladimiro/0000-0002-9376-0214; Parrizas, Marcelina/0000-0003-1296-8302; Carrio, Ana/0000-0002-8394-2321				Alric L, 2000, INFLAMM RES, V49, P700, DOI 10.1007/s000110050649; Anderson KM, 1998, ANTICANCER RES, V18, P791; Avis I, 2001, FASEB J, V15, P2007, DOI 10.1096/fj.00-0866fje; Avis IM, 1996, J CLIN INVEST, V97, P806, DOI 10.1172/JCI118480; BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; BAUD L, 1987, J IMMUNOL, V138, P1190; BAUD L, 1985, J CLIN INVEST, V76, P374, DOI 10.1172/JCI111972; BOUWENS L, 1984, HEPATOLOGY, V4, P213, DOI 10.1002/hep.1840040208; BOUWENS L, 1986, HEPATOLOGY, V6, P718, DOI 10.1002/hep.1840060430; Brown SB, 1996, J CELL BIOCHEM, V60, P246, DOI 10.1002/(SICI)1097-4644(19960201)60:2<246::AID-JCB9>3.0.CO;2-X; Canaider S, 2000, LIFE SCI, V66, pPL265, DOI 10.1016/S0024-3205(00)00500-2; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Claria J, 1999, ASCITES AND RENAL DYSFUNCTION IN LIVER DISEASE, P379; CROFTON RW, 1978, J EXP MED, V148, P1, DOI 10.1084/jem.148.1.1; Datta K, 1999, BIOCHEM J, V340, P371, DOI 10.1042/0264-6021:3400371; DECKER K, 1990, EUR J BIOCHEM, V192, P245, DOI 10.1111/j.1432-1033.1990.tb19222.x; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; Ding XZ, 1999, BIOCHEM BIOPH RES CO, V261, P218, DOI 10.1006/bbrc.1999.1012; Dittmann KH, 1998, LEUKEMIA RES, V22, P49, DOI 10.1016/S0145-2126(97)00132-X; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Frey T, 1997, CYTOMETRY, V28, P253, DOI 10.1002/(SICI)1097-0320(19970701)28:3<253::AID-CYTO10>3.0.CO;2-O; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Fukai F, 1996, CELL BIOL INT, V20, P423, DOI 10.1006/cbir.1996.0053; FUKAI F, 1993, ARCH BIOCHEM BIOPHYS, V305, P378, DOI 10.1006/abbi.1993.1435; GEERTS A, 1988, J HEPATOL, V6, P50, DOI 10.1016/S0168-8278(88)80461-6; Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182; Ghosh J, 1997, BIOCHEM BIOPH RES CO, V235, P418, DOI 10.1006/bbrc.1997.6799; GRESSNER AM, 1994, ANN BIOL CLIN-PARIS, V52, P205; HOEDEMAKERS RMJ, 1994, HEPATOLOGY, V19, P666, DOI 10.1002/hep.1840190318; KEPPLER D, 1988, SEMIN LIVER DIS, V8, P357, DOI 10.1055/s-2008-1040557; King MA, 2000, CYTOMETRY, V40, P10, DOI 10.1002/(SICI)1097-0320(20000501)40:1<10::AID-CYTO2>3.0.CO;2-F; Kondo K, 1998, THROMB HAEMOSTASIS, V79, P635; Lee E, 1999, AM J RESP CRIT CARE, V160, P2079, DOI 10.1164/ajrccm.160.6.9903136; Lee E, 2000, AM J RESP CRIT CARE, V161, P1881, DOI 10.1164/ajrccm.161.6.9907054; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; Luckey SW, 2001, EXP MOL PATHOL, V71, P226, DOI 10.1006/exmp.2001.2399; MULLERPEDDINGHAUS R, 1993, J PHARMACOL EXP THER, V267, P51; Ou D, 2001, CANCER LETT, V166, P223, DOI 10.1016/S0304-3835(01)00411-6; PASQUALE D, 1993, EXP HEMATOL, V21, P1361; Peters-Golden M, 2002, AM J RESP CRIT CARE, V165, P229, DOI 10.1164/ajrccm.165.2.2104050; Planaguma A, 2002, FASEB J, V16, P1937, DOI 10.1096/fj.02-0224fje; Provost P, 1999, P NATL ACAD SCI USA, V96, P1881, DOI 10.1073/pnas.96.5.1881; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; Shimada K, 1998, HEPATOLOGY, V28, P1275, DOI 10.1002/hep.510280516; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; THOMPSON WD, 1980, J PATHOL, V130, P65, DOI 10.1002/path.1711300202; Titos E, 2000, GASTROENTEROLOGY, V119, P794, DOI 10.1053/gast.2000.17831; TSUKUI T, 1992, J LEUKOCYTE BIOL, V52, P383, DOI 10.1002/jlb.52.4.383; Uz T, 2001, EUR J PHARMACOL, V418, P15, DOI 10.1016/S0014-2999(01)00924-4; Walker JL, 2002, AM J PHYSIOL-HEART C, V282, pH585, DOI 10.1152/ajpheart.00003.2001; WINWOOD PJ, 1993, SEMIN LIVER DIS, V13, P50, DOI 10.1055/s-2007-1007337; YOSHIMOTO T, 1982, BIOCHIM BIOPHYS ACTA, V713, P470	54	63	66	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1745	+		10.1096/fj.02-1157fje	http://dx.doi.org/10.1096/fj.02-1157fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958196				2022-12-25	WOS:000184471600025
J	Perbandt, M; Burmeister, C; Walter, RD; Betzel, C; Liebau, E				Perbandt, M; Burmeister, C; Walter, RD; Betzel, C; Liebau, E			Native and inhibited structure of a Mu class-related glutathione S-transferase from Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; COMPLEX; ENZYME; CRYSTALLIZATION; DETOXIFICATION; REFINEMENT; MALARIA; DRUG	The parasite Plasmodium falciparum causes malaria tropica, the most prevailing parasitic disease worldwide, with 300 - 500 million infections and 1.5 - 2.7 million deaths/year. The emergence of strains resistant to drugs used for prophylaxis and treatment and no vaccine available makes the structural analysis of potential drug targets essential. For that reason, we analyzed the three-dimensional structure of the glutathione S-transferase from P. falciparum (Pf-GST1) in the apoform and in complex with its inhibitor S-hexyl-glutathione. The structures have been analyzed to 2.6 and 2.2 Angstrom, respectively. Pf-GST1 shares several structural features with the Mu-type GSTs and is therefore closely related to this class, even though alignments with its members display low sequence identities in the range of 20 - 33%. Upon S-hexyl-glutathione binding, the overall structure and the glutathione-binding site (G-site) remain almost unchanged with the exception of the flexible C terminus. The detailed comparison of the parasitic enzyme with the human host Mu-class enzyme reveals that, although the overall structure is homologue, the shape of the hydrophobic binding pocket ( H-site) differs substantially. In the human enzyme, it is shielded from one side by the large Mu-loop, whereas in Pf-GST1 the Mu-loop is truncated and the space to recognize and bind voluminous substrates is extended. This structural feature can be exploited to support the design of specific and parasite-selective inhibitors.	Univ Hamburg, Dept Biochem & Mol Biol, D-20146 Hamburg, Germany; Univ Hosp Eppendorf, Inst Biochem & Mol Biol 1, Ctr Med Expt, DESY, D-22603 Hamburg, Germany; Bernhard Nocht Inst Trop Med, Dept Biochem, D-20359 Hamburg, Germany	University of Hamburg; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Hamburg; University Medical Center Hamburg-Eppendorf; Bernhard Nocht Institut fur Tropenmedizin	Perbandt, M (corresponding author), Univ Hamburg, Dept Biochem & Mol Biol, Martin Luther King Pl 6, D-20146 Hamburg, Germany.	markus.perbandt@desy.de	Betzel, Christian/G-8105-2018; Perbandt, Markus/K-7603-2018	Betzel, Christian/0000-0002-3879-5019; 				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Burmeister C, 2003, ACTA CRYSTALLOGR D, V59, P1469, DOI 10.1107/S0907444903011090; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; Cardoso RMF, 2003, PROTEINS, V51, P137, DOI 10.1002/prot.10345; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; DUBOIS VL, 1995, EXP PARASITOL, V81, P117, DOI 10.1006/expr.1995.1099; Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a; Harwaldt P, 2002, BIOL CHEM, V383, P821, DOI 10.1515/BC.2002.086; Hemingway J, 2000, INSECT BIOCHEM MOLEC, V30, P1009, DOI 10.1016/S0965-1748(00)00079-5; HOLMGREN A, 1975, P NATL ACAD SCI USA, V72, P2305, DOI 10.1073/pnas.72.6.2305; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liebau E, 2002, MOL BIOCHEM PARASIT, V124, P85, DOI 10.1016/S0166-6851(02)00160-3; LISTOWSKI I, 1994, HEPATIC TRANSPORT BI, P1; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCTIGUE MA, 1995, J MOL BIOL, V246, P21, DOI 10.1006/jmbi.1994.0061; Muller S, 2003, TRENDS PARASITOL, V19, P320, DOI 10.1016/S1471-4922(03)00141-7; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Neuefeind T, 1997, BIOL CHEM, V378, P199; Neuefeind T, 1997, J MOL BIOL, V274, P577, DOI 10.1006/jmbi.1997.1401; Neuefeind T, 1997, J MOL BIOL, V274, P446, DOI 10.1006/jmbi.1997.1402; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patskovsky YV, 2000, J BIOL CHEM, V275, P3296, DOI 10.1074/jbc.275.5.3296; Platel DFN, 1999, MOL BIOCHEM PARASIT, V98, P215, DOI 10.1016/S0166-6851(98)00170-4; RAGHUNATHAN S, 1994, J MOL BIOL, V238, P815, DOI 10.1006/jmbi.1994.1336; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; ROUSSELL A, 1991, SILICON GRAPHICS DIR; Salinas AE, 1999, CURR MED CHEM, V6, P279; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; SODERBERG BO, 1978, P NATL ACAD SCI USA, V75, P5827, DOI 10.1073/pnas.75.12.5827; Srivastava P, 1999, TROP MED INT HEALTH, V4, P251, DOI 10.1046/j.1365-3156.1999.00387.x; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Townsend Danyelle, 2003, Am J Pharmacogenomics, V3, P157, DOI 10.2165/00129785-200303030-00002; VORE M, 1994, ENVIRON HEALTH PERSP, V102, P422, DOI 10.2307/3432028	42	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1336	1342		10.1074/jbc.M309663200	http://dx.doi.org/10.1074/jbc.M309663200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	12972411	hybrid			2022-12-25	WOS:000187722800061
J	Kaplan, DL; Davey, MJ; O'Donnell, M				Kaplan, DL; Davey, MJ; O'Donnell, M			Mcm4,6,7 uses a "pump in ring" mechanism to unwind DNA by steric exclusion and actively translocate along a duplex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; REPLICATIVE HELICASE; MCM PROTEINS; COMPLEXES; PRIMASE; DOMAIN; COMPONENTS; INITIATION; G1-PHASE; SITE	Mcm4,6,7 is a ring-shaped heterohexamer and the putative eukaryotic replication fork helicase. In this study, we examine the mechanism of Mcm4,6,7. Mcm4,6,7 binds to only one strand of a duplex during unwinding, corresponding to the leading strand of a replication fork. Mcm4,6,7 unwinding stops at a nick in either strand. The Mcm4,6,7 ring also actively translocates along duplex DNA, enabling the protein to drive branch migration of Holliday junctions. The Mcm4,6,7 mechanism is very similar to DnaB, except the proteins translocate with opposite polarity along DNA. Mcm4,6,7 and DnaB have different structural folds and evolved independently; thus, the similarity in mechanism is surprising. We propose a "pump in ring" mechanism for both Mcm4,6,7 and DnaB, wherein a single-stranded DNA pump is situated within the central channel of the ring-shaped helicase, and unwinding is the result of steric exclusion. In this example of convergent evolution, the "pump in ring" mechanism was probably selected by eukaryotic and bacterial replication fork helicases in order to restrict unwinding to replication fork structures, stop unwinding when the replication fork encounters a nick, and actively translocate along duplex DNA to accomplish additional activities such as DNA branch migration.	Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, Lab DNA Replicat, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute	Kaplan, DL (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	dkaplan@mod.rockefeller.edu	Davey, Megan/B-4066-2012	Kaplan, Daniel/0000-0003-2760-7745; O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [GM 38839, GM 62540] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839, R01GM062540] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Davey MJ, 2003, J BIOL CHEM, V278, P4491, DOI 10.1074/jbc.M210511200; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Gomez EB, 2002, GENETICS, V160, P1305; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hacker KJ, 1997, BIOCHEMISTRY-US, V36, P14080, DOI 10.1021/bi971644v; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Kaplan DL, 1999, J BIOL CHEM, V274, P6889, DOI 10.1074/jbc.274.11.6889; Kaplan DL, 2002, MOL CELL, V10, P647, DOI 10.1016/S1097-2765(02)00642-1; Kelman Z, 2003, NAT STRUCT BIOL, V10, P148, DOI 10.1038/nsb0303-148; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; KORNBERG A, 1992, DNA REPLICATION, P275; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; LASKEY RA, 2003, EMBO REP, V22, P704; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Leipe DD, 2000, GENOME RES, V10, P5; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; Lindner K, 2002, MOL BIOL CELL, V13, P435, DOI 10.1091/mbc.01-11-0537; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; Sato M, 2000, J MOL BIOL, V300, P421, DOI 10.1006/jmbi.2000.3865; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; VanLoock MS, 2002, CURR BIOL, V12, P472, DOI 10.1016/S0960-9822(02)00696-6; Vanloock MS, 2001, J MOL BIOL, V311, P951, DOI 10.1006/jmbi.2001.4932; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Yabuta N, 2003, GENES CELLS, V8, P413, DOI 10.1046/j.1365-2443.2003.00645.x; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; Yang SX, 2002, J MOL BIOL, V321, P839, DOI 10.1016/S0022-2836(02)00711-8; You ZY, 1999, MOL CELL BIOL, V19, P8003; Yu X, 2002, EMBO REP, V3, P792, DOI 10.1093/embo-reports/kvf160; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	50	136	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49171	49182		10.1074/jbc.M308074200	http://dx.doi.org/10.1074/jbc.M308074200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	13679365	hybrid			2022-12-25	WOS:000186829000081
J	Chang, TS; Kim, MJ; Ryoo, K; Park, J; Eom, SJ; Shim, J; Nakayama, KI; Nakayama, K; Tomita, M; Takahashi, K; Lee, MJ; Choi, EJ				Chang, TS; Kim, MJ; Ryoo, K; Park, J; Eom, SJ; Shim, J; Nakayama, KI; Nakayama, K; Tomita, M; Takahashi, K; Lee, MJ; Choi, EJ			P57(KIP2) modulates stress-activated signaling by inhibiting c-Jun NH2-terminal kinase/stress-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BECKWITH-WIEDEMANN-SYNDROME; N-TERMINAL KINASE; CDK INHIBITOR; CELL-DIFFERENTIATION; MICE LACKING; MAP KINASES; APOPTOSIS; JNK; TRANSDUCTION; PROLIFERATION	p57(KIP2), a member of the Cip/Kip family of enzymes that inhibit several cyclin-dependent kinases, plays a role in many biological events including cell proliferation, differentiation, apoptosis, tumorigenesis and developmental changes. The human p57(KIP2) gene is located in chromosome 11p15.5, a region implicated in sporadic cancers and Beckwith-Wiedemann syndrome. We here report that p57(KIP2) physically interacts with and inhibits c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK). The carboxyl-terminal QT domain of p57(KIP2) is crucial for the inhibition of JNK/ SAPK. Overexpressed p57(KIP2) also suppressed UV- and MEKK1-induced apoptotic cell death. p57(KIP2) expression during C2C12 myoblast differentiation resulted in repression of the JNK activity stimulated by UV light. Furthermore, UV- stimulated JNK1 activity was higher in mouse embryonic fibroblasts derived from p57(-/-) mice than in the cells from wild-type mice. Taken together, these findings suggest that p57(KIP2) modulates stress-activated signaling by functioning as an endogenous inhibitor of JNK/ SAPK.	Korea Univ, Sch Life Sci & Biotechnol, Natl Creat Res Initiat Ctr Cell Death, Seoul 136701, South Korea; Kyushu Univ, Dept Cellular & Mol Biol, Div Cell Biol, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Lab Embryon & Genet Engn, Higashi Ku, Fukuoka 8128582, Japan; Showa Univ, Sch Pharmaceut Sci, Dept Physiol Chem, Shinagawa Ku, Tokyo 1428555, Japan; Samsung Biomed Res Inst, Dept Lab Anim Res, Seoul 135710, South Korea; Sejong Univ, Coll Nat Sci, Dept Mol Biol, Seoul 143747, South Korea	Korea University; Kyushu University; Kyushu University; Showa University; Sungkyunkwan University (SKKU); Samsung Medical Center; Sejong University	Choi, EJ (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Natl Creat Res Initiat Ctr Cell Death, Seoul 136701, South Korea.							Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; Hatada I, 1997, HUM GENET, V100, P681, DOI 10.1007/s004390050573; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shim J, 2000, J BIOL CHEM, V275, P14107, DOI 10.1074/jbc.275.19.14107; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Takahashi K, 2000, J BIOCHEM-TOKYO, V127, P73, DOI 10.1093/oxfordjournals.jbchem.a022586; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	26	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48092	48098		10.1074/jbc.M309421200	http://dx.doi.org/10.1074/jbc.M309421200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12963725	hybrid			2022-12-25	WOS:000186731400089
J	Salmona, M; Morbin, M; Massignan, T; Colombo, L; Mazzoleni, G; Capobianco, R; Diomede, L; Thaler, F; Mollica, L; Musco, G; Kourie, JJ; Bugiani, O; Sharma, D; Inouye, H; Kirschner, DA; Forloni, G; Tagliavini, F				Salmona, M; Morbin, M; Massignan, T; Colombo, L; Mazzoleni, G; Capobianco, R; Diomede, L; Thaler, F; Mollica, L; Musco, G; Kourie, JJ; Bugiani, O; Sharma, D; Inouye, H; Kirschner, DA; Forloni, G; Tagliavini, F			Structural properties of Gerstmann-Straussler-Scheinker disease amyloid protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; HUMAN PRION PROTEIN; SCRAPIE PRION; ALPHA-HELICES; PRP PEPTIDES; IN-VITRO; FRAGMENT; INDIANA; RESIDUES-106-126; FIBRILS	Prion protein (PrP) amyloid formation is a central feature of genetic and acquired forms of prion disease such as Gerstmann-Straussler-Scheinker disease (GSS) and variant Creutzfeldt-Jakob disease. The major component of GSS amyloid is a PrP fragment spanning residues similar to 82 - 146. To investigate the determinants of the physicochemical properties of this fragment, we synthesized PrP-(82 - 146) and variants thereof, including entirely and partially scrambled peptides. PrP-( 82 - 146) readily formed aggregates that were partially resistant to protease digestion. Peptide assemblies consisted of 9.8-nm-diameter fibrils having a parallel cross-beta-structure. Second derivative of infrared spectra indicated that PrP-( 82 - 146) aggregates are primarily composed of beta-sheet (54%) and turn (24%) which is consistent with their amyloid-like properties. The peptide induced a remarkable increase in plasma membrane microviscosity of primary neurons. Modification of the amino acid sequence 106 - 126 caused a striking increase in aggregation rate, with formation of large amount of protease-resistant amorphous material and relatively few amyloid fibrils. Alteration of the 127 - 146 region had even more profound effects, with the inability to generate amyloid fibrils. These data indicate that the intrinsic properties of PrP-( 82 - 146) are dependent upon the integrity of the C-terminal region and account for the massive deposition of PrP amyloid in GSS.	Ist Ric Farmacol Mario Negri, I-20157 Milan, Italy; Ist Nazl Neurol Carlo Besta, I-20133 Milan, Italy; DIBIT, Dulbecco Telethon Inst, I-20132 Milan, Italy; Australian Natl Univ, Dept Chem, Membrane Transport Grp, Canberra, ACT 0200, Australia; Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; IRCCS Istituto Neurologico Besta; Fondazione Telethon; Dulbecco Telethon Institute (DTI); Australian National University; Boston College	Salmona, M (corresponding author), Ist Ric Farmacol Mario Negri, Via Eritrea 62, I-20157 Milan, Italy.	salmona@marionegri.it	salmona, mario/ABI-4066-2020; Diomede, Luisa/P-3417-2014; Musco, Giovanna/Q-2756-2019; salmona, mario/AAA-7116-2020; musco, giovanna/I-7122-2012; Tagliavini, Fabrizio/AAO-7891-2021; colombo, laura/AAA-6716-2020; Forloni, Gianluigi/AAB-2115-2020	Diomede, Luisa/0000-0002-2258-0531; salmona, mario/0000-0002-9098-9873; musco, giovanna/0000-0002-0469-2994; Tagliavini, Fabrizio/0000-0003-1039-7315; colombo, laura/0000-0002-3243-0270; Forloni, Gianluigi/0000-0001-5374-3914; Sharma, Deepak/0000-0001-8436-1759; massignan, tania/0000-0002-6176-2696; Morbin, Michela/0000-0001-8034-3123; Kirschner, Daniel/0000-0003-3498-1452; MOLLICA, LUCA/0000-0001-8164-7663	Telethon [TCP99035] Funding Source: Medline	Telethon(Fondazione Telethon)		Balbirnie M, 2001, P NATL ACAD SCI USA, V98, P2375, DOI 10.1073/pnas.041617698; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P468; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; DEGIOIA L, 1994, J BIOL CHEM, V269, P7859; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Ghetti B, 1996, BRAIN PATHOL, V6, P127, DOI 10.1111/j.1750-3639.1996.tb00796.x; Ghetti B, 1996, P NATL ACAD SCI USA, V93, P744, DOI 10.1073/pnas.93.2.744; GIACCONE G, 1992, P NATL ACAD SCI USA, V89, P9349, DOI 10.1073/pnas.89.19.9349; Inouye H, 1998, J STRUCT BIOL, V122, P247, DOI 10.1006/jsbi.1998.3998; Inouye H, 2000, J MOL BIOL, V300, P1283, DOI 10.1006/jmbi.2000.3926; INOUYE H, 1993, BIOPHYS J, V64, P502, DOI 10.1016/S0006-3495(93)81393-6; Inouye H, 1997, J MOL BIOL, V268, P375, DOI 10.1006/jmbi.1997.0949; KRISTENSSON K, 1993, NEUROLOGY, V43, P2335, DOI 10.1212/WNL.43.11.2335; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MAKOWSKI L, 1989, BROOKH S SYNCHR RAD, P341; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; Nilsson MR, 2003, BIOCHEMISTRY-US, V42, P375, DOI 10.1021/bi0204746; OLDENBOURG R, 1986, REV SCI INSTRUM, V57, P2362, DOI 10.1063/1.1138680; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 2000, P NATL ACAD SCI USA, V97, P10168, DOI 10.1073/pnas.97.18.10168; Parchi P, 1998, P NATL ACAD SCI USA, V95, P8322, DOI 10.1073/pnas.95.14.8322; Piccardo P, 1998, J NEUROPATH EXP NEUR, V57, P979, DOI 10.1097/00005072-199810000-00010; Piccardo P, 1996, J NEUROPATH EXP NEUR, V55, P1157, DOI 10.1097/00005072-199611000-00007; Pillot T, 1997, J MOL BIOL, V274, P381, DOI 10.1006/jmbi.1997.1382; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Salmona M, 1999, BIOCHEM J, V342, P207, DOI 10.1042/0264-6021:3420207; Salmona M, 1997, NEUROBIOL DIS, V4, P47, DOI 10.1006/nbdi.1997.0133; SELVAGGINI C, 1993, BIOCHEM BIOPH RES CO, V194, P1380, DOI 10.1006/bbrc.1993.1977; Supattapone S, 1999, CELL, V96, P869, DOI 10.1016/S0092-8674(00)80596-6; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; TAGLIAVINI F, 1994, CELL, V79, P695, DOI 10.1016/0092-8674(94)90554-1; TAGLIAVINI F, 1991, EMBO J, V10, P513, DOI 10.1002/j.1460-2075.1991.tb07977.x; Tagliavini F, 2001, ADV PROTEIN CHEM, V57, P171; Tagliavini F, 2001, J BIOL CHEM, V276, P6009, DOI 10.1074/jbc.M007062200; Tagliavini F, 2000, J MOL BIOL, V300, P1309, DOI 10.1006/jmbi.2000.3840; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145	43	65	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48146	48153		10.1074/jbc.M307295200	http://dx.doi.org/10.1074/jbc.M307295200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12970341	hybrid, Green Published			2022-12-25	WOS:000186731400096
J	Xiong, GM; Martin, HJ; Maser, E				Xiong, GM; Martin, HJ; Maser, E			Identification and characterization of a novel translational repressor of the steroid-inducible 3 alpha-hydroxysteroid dehydrogenase/carbonyl reductase gene in Comamonas testosteroni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ESCHERICHIA-COLI; 3-ALPHA,20-BETA-HYDROXYSTEROID DEHYDROGENASE; 3-DIMENSIONAL STRUCTURE; ANTIBIOTIC-RESISTANCE; EXPRESSION; DEGRADATION; CATABOLISM; INDUCTION; KINASE	Comamonas testosteroni 3alpha-hydroxysteroid dehydrogenase/ carbonyl reductase (3alpha-HSD/CR) is a key enzyme in the degradation of steroid compounds in soil and may therefore play a significant role in the bioremediation of hormonally active compounds in the environment. The enzyme is also involved in the degradation of the steroid antibiotic fusidic acid. In addition, 3alpha-HSD/CR mediates the carbonyl reduction of non-steroidal aldehydes and ketones. Because the gene of 3alpha-HSD/CR (hsdA) is inducible by steroids, we were interested in the mode of its molecular regulation. Recently, we could identify the first molecular determinant in procaryotic steroid signaling, i.e. a repressor protein (RepA), which acts as a negative regulator by binding to upstream operator sequences of hsdA, thereby blocking hsdA transcription. In this work, we identified and cloned a second novel regulator gene that we named repB. The gene locates 932 bp downstream from hsdA on the C. testosteroni chromosome with an orientation opposite to that of hsdA. The open reading frame of repB consists of 237 bp and translates into a protein of 78 amino acids that was found to act as a repressor that regulates hsdA expression on the translational level. Northern blot analysis, UV-cross linking, gel-shift assays, and competition experiments proved that RepB binds to a 16-nucleotide sequence downstream of AUG at the 5' end of the 3alpha-HSD/ CR mRNA, thereby blocking hsdA translation. Testosterone, on the other hand, was shown to specifically bind to RepB, thereby yielding the release of RepB from the 3alpha-HSD/CR mRNA such that hsdA translation could proceed. Data bank searches with the RepB primary structure yielded a 46.2% identity to the regulator of nucleoside diphosphate kinase, a formerly unknown protein from Escherichia coli that can restore a growth defect in alginate production in Pseudomonas aeruginosa. In conclusion, the induction of hsdA by steroids in fact is a derepression where steroidal inducers bind to two repressor proteins, RepA and RepB, thereby preventing blocking of hsdA transcription and translation, respectively.	Univ Marburg, Dept Pharmacol & Toxicol, D-30533 Marburg, Germany; Univ Klinikum Schleswig Holstein, Inst Expt Toxicol, D-24105 Kiel, Germany	Philipps University Marburg; University of Kiel; Schleswig Holstein University Hospital	Maser, E (corresponding author), Univ Marburg, Dept Pharmacol & Toxicol, Karl Von Frisch Str 1, D-30533 Marburg, Germany.	maser@toxi.uni-kiel.de	Maser, Edmund/B-1728-2010					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARAI H, 1991, AGR BIOL CHEM TOKYO, V55, P2431; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERG P, 1953, NATURE, V172, P1008, DOI 10.1038/1721008a0; Cabrera JE, 2000, J STEROID BIOCHEM, V73, P147, DOI 10.1016/S0960-0760(00)00066-2; COULTER AW, 1968, J BIOL CHEM, V243, P3238; Florin C, 1996, J BACTERIOL, V178, P3322, DOI 10.1128/jb.178.11.3322-3330.1996; GARCIAVALDES E, 1988, APPL ENVIRON MICROB, V54, P2478; GENTIRAIMONDI S, 1991, GENE, V105, P43, DOI 10.1016/0378-1119(91)90512-A; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; Grimm C, 2000, J BIOL CHEM, V275, P41333, DOI 10.1074/jbc.M007559200; Harder J, 1997, ARCH MICROBIOL, V167, P269, DOI 10.1007/s002030050442; KIESLICH K, 1985, J BASIC MICROB, V25, P461, DOI 10.1002/jobm.3620250713; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; KROOK M, 1993, FEBS LETT, V322, P139, DOI 10.1016/0014-5793(93)81554-D; LEPPIK RA, 1987, BIOCHEM J, V243, P15, DOI 10.1042/bj2430015; Levit MN, 2002, J BIOL CHEM, V277, P5163, DOI 10.1074/jbc.M111170200; LEVY HR, 1959, J BIOL CHEM, V234, P2009; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahato SB, 1997, STEROIDS, V62, P332, DOI 10.1016/S0039-128X(96)00251-6; MAHATO SB, 1993, PHYTOCHEMISTRY, V34, P883, DOI 10.1016/S0031-9422(00)90685-X; MARCUS PI, 1956, J BIOL CHEM, V218, P661; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Mobus E, 1998, J BIOL CHEM, V273, P30888, DOI 10.1074/jbc.273.47.30888; Mobus E, 1997, J BACTERIOL, V179, P5951; MOLNAR I, 1995, MOL MICROBIOL, V15, P895, DOI 10.1111/j.1365-2958.1995.tb02359.x; OHTSUKI K, 1984, BIOCHEM INT, V8, P715; OPPERMANN UCT, 1993, ADV EXP MED BIOL, V328, P379; Oppermann UCT, 1996, J STEROID BIOCHEM, V58, P217, DOI 10.1016/0960-0760(96)00021-0; Oppermann UCT, 1996, EUR J BIOCHEM, V241, P744, DOI 10.1111/j.1432-1033.1996.00744.x; Parkhill J, 2003, NAT GENET, V35, P32, DOI 10.1038/ng1227; PLESIAT P, 1991, J BACTERIOL, V173, P7219, DOI 10.1128/jb.173.22.7219-7227.1991; POSTEL EH, 2003, INT J BIOCHEM CELL B, V30, P1291; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schlax PJ, 2003, MOL MICROBIOL, V48, P1157, DOI 10.1046/j.1365-2958.2003.03517.x; SCHLICTMAN D, 1995, MOL MICROBIOL, V16, P309, DOI 10.1111/j.1365-2958.1995.tb02303.x; SHANKAR S, 1995, MOL MICROBIOL, V17, P935, DOI 10.1111/j.1365-2958.1995.mmi_17050935.x; Skowasch D, 2002, BIOCHEM BIOPH RES CO, V294, P560, DOI 10.1016/S0006-291X(02)00516-8; TALALAY P, 1952, NATURE, V170, P620, DOI 10.1038/170620a0; Xiong GM, 2001, J BIOL CHEM, V276, P9961, DOI 10.1074/jbc.M010962200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	42	32	36	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47400	47407		10.1074/jbc.M309210200	http://dx.doi.org/10.1074/jbc.M309210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12975360	hybrid			2022-12-25	WOS:000186731400009
J	Zhou, H; Cadigan, KM; Thiele, DJ				Zhou, H; Cadigan, KM; Thiele, DJ			A copper-regulated transporter required for copper acquisition, pigmentation, and specific stages of development in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BIOCHEMICAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; PLASMA-MEMBRANE; FACTOR MTF-1; YEAST; EXPRESSION; TRANSCRIPTION; MECHANISM; GENES	The trace element copper is required for normal growth and development, serving as an essential catalytic co-factor for enzymes involved in energy generation, oxidative stress protection, neuropeptide maturation, and other fundamental processes. In yeast and mammals copper acquisition occurs through the action of the Ctr1 family of high affinity copper transporters. Here we describe studies using Drosophila melanogaster to investigate the role of copper acquisition through Ctr1 in normal growth and development. Three distinct Drosophila Ctr1 genes (Ctr1A, Ctr1B, and Ctr1C) have been identified, which have unique expression patterns over the course of development. Interestingly, Ctr1B, which is expressed exclusively during the late embryonic and larval stages of development, is transcriptionally activated in response to nutritionally induced copper deprivation and down-regulated in response to copper adequacy. The generation of Ctr1B mutant flies results in decreased larval copper accumulation, marked body pigmentation defects that parallel defects in tyrosinase activity, and specific developmental arrest under conditions of both nutritional copper limitation and excess. These studies establish that copper acquisition through the Drosophila Ctr1B transporter is crucial for normal growth and in early and specific stages of metazoan development.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Cadigan, KM (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	cadigan@umich.edu; dennis.thiele@duke.edu		Cadigan, Ken/0000-0003-2431-1703	NIGMS NIH HHS [GM62555] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062555] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashburner M., 1989, DROSOPHILA LAB HDB; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Culotta VC, 1999, ADV EXP MED BIOL, V448, P247; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Egli D, 2003, EMBO J, V22, P100, DOI 10.1093/emboj/cdg012; Eide DJ, 2000, ADV MICROB PHYSIOL, V43, P1, DOI 10.1016/S0065-2911(00)43001-8; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; Eisses JF, 2002, J BIOL CHEM, V277, P29162, DOI 10.1074/jbc.M203652200; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FILSHIE BK, 1971, TISSUE CELL, V3, P77, DOI 10.1016/S0040-8166(71)80033-2; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; HALLIWELL B, 1985, MOL ASPECTS MED, V8, P89, DOI 10.1016/0098-2997(85)90001-9; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Jiang N, 2000, DEV BIOL, V226, P118, DOI 10.1006/dbio.2000.9832; KAMPFENKEL K, 1995, J BIOL CHEM, V270, P28479, DOI 10.1074/jbc.270.47.28479; Klomp AEM, 2002, BIOCHEM J, V364, P497, DOI 10.1042/BJ20011803; Kolhekar AS, 1997, J NEUROSCI, V17, P1363, DOI 10.1523/jneurosci.17-04-01363.1997; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; LASTOWSKIPERRY D, 1985, J BIOL CHEM, V260, P1527; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lee J, 2002, J BIOL CHEM, V277, P40253, DOI 10.1074/jbc.M208002200; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; MARCHALSEGAULT D, 1990, BIOL CELL, V70, P129, DOI 10.1016/0248-4900(90)90368-D; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2003, J BIOL CHEM, V278, P9639, DOI 10.1074/jbc.M209455200; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; PROHASKA JR, 1990, ADV EXP MED BIOL, V262, P123; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sancenon V, 2003, PLANT MOL BIOL, V51, P577, DOI 10.1023/A:1022345507112; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SOLIOZ M, 1995, J BIOL CHEM, V270, P9217, DOI 10.1074/jbc.270.16.9217; Suzuki M, 1999, PEDIATR INT, V41, P436; Szczypka MS, 1997, YEAST, V13, P1423, DOI 10.1002/(SICI)1097-0061(199712)13:15<1423::AID-YEA190>3.3.CO;2-3; TAPP RL, 1975, J CELL SCI, V17, P449; Waggoner DJ, 1999, NEUROBIOL DIS, V6, P221, DOI 10.1006/nbdi.1999.0250; Woodhouse LR, 2001, CRC MOD NUT, P1; WRIGHT TRF, 1987, ADV GENET, V24, P127, DOI 10.1016/s0065-2660(08)60008-5; Zhang B, 2001, MOL CELL BIOL, V21, P4505, DOI 10.1128/MCB.21.14.4505-4514.2001; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481; Zhou H, 2001, J BIOL CHEM, V276, P20529, DOI 10.1074/jbc.M102004200	52	92	94	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48210	48218		10.1074/jbc.M309820200	http://dx.doi.org/10.1074/jbc.M309820200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12966081	hybrid			2022-12-25	WOS:000186731400104
J	Hao, N; Yildirim, N; Wang, YQ; Elston, TC; Dohlman, HG				Hao, N; Yildirim, N; Wang, YQ; Elston, TC; Dohlman, HG			Regulators of G protein signaling and transient activation of signaling - Experimental and computational analysis reveals negative and positive feedback controls on G protein activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; ALPHA-FACTOR PHEROMONES; END RULE PATHWAY; A-FACTOR; N-MYRISTOYLATION; FACTOR RECEPTOR; UBIQUITINATION; SUBUNIT; PHOSPHORYLATION; GPA1	Cellular responses to hormones and neurotransmitters are necessarily transient. The mating pheromone signal in yeast is typical. Signal initiation requires cell surface receptors, a G protein heterotrimer, and downstream effectors. Signal inactivation requires Sst2, a regulator of G protein signaling ( RGS) protein that accelerates GTPase activity. We conducted a quantitative analysis of RGS and G protein expression and devised computational models that describe their activity in vivo. These results indicated that pheromone- dependent transcriptional induction of the RGS protein constitutes a negative feedback loop that leads to desensitization. Modeling also suggested the presence of a positive feedback loop leading to resensitization of the pathway. In confirmation of the model, we found that the RGS protein is ubiquitinated and degraded in response to pheromone stimulation. We identified and quantitated these positive and negative feedback loops, which account for the transient response to external signals observed in vivo.	Univ N Carolina, Dept Math, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Elston, TC (corresponding author), Univ N Carolina, Dept Math, Chapel Hill, NC 27599 USA.	telston@amath.unc.edu; hdohlman@med.unc.edu	Hao, Nan/O-3462-2016	Hao, Nan/0000-0003-2857-4789; Dohlman, Henrik/0000-0003-2443-0729	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055316, R01GM055316, R01GM059167] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM055316, GM 59167, R01 GM059167, GM 55316] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; Davydov IV, 2000, J BIOL CHEM, V275, P22931, DOI 10.1074/jbc.M001605200; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Dohlman HG, 2002, ANNU REV PHYSIOL, V64, P129, DOI 10.1146/annurev.physiol.64.081701.133448; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; DOHLMAN HG, 1993, P NATL ACAD SCI USA, V90, P9688, DOI 10.1073/pnas.90.20.9688; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Guo M, 2003, MOL CELL, V12, P517, DOI 10.1016/S1097-2765(03)00307-1; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Hoffman GA, 2002, METHOD ENZYMOL, V344, P617; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; JENNESS DD, 1986, MOL CELL BIOL, V6, P318, DOI 10.1128/MCB.6.1.318; Kallal L, 2000, YEAST, V16, P387, DOI 10.1002/(SICI)1097-0061(20000330)16:5<387::AID-YEA525>3.0.CO;2-U; Kepler TB, 2001, BIOPHYS J, V81, P3116, DOI 10.1016/S0006-3495(01)75949-8; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; Marotti LA, 2002, BIOCHEMISTRY-US, V41, P5067, DOI 10.1021/bi015940q; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Portiz MA, 2001, YEAST, V18, P1331, DOI 10.1002/yea.777; Riccobene TA, 1999, J THEOR BIOL, V200, P207, DOI 10.1006/jtbi.1999.0988; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; Shea L, 1997, BIOCHEM PHARMACOL, V53, P519, DOI 10.1016/S0006-2952(96)00768-X; Shea LD, 2000, LIFE SCI, V68, P647, DOI 10.1016/S0024-3205(00)00977-2; Siekhaus DE, 2003, NAT CELL BIOL, V5, P231, DOI 10.1038/ncb941; SIKORSKI RS, 1989, GENETICS, V122, P19; Song JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/jbc.271.34.20273; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; Tyson JJ, 2003, CURR OPIN CELL BIOL, V15, P221, DOI 10.1016/S0955-0674(03)00017-6; Versele M, 1999, EMBO J, V18, P5577, DOI 10.1093/emboj/18.20.5577; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang YQ, 2003, J BIOL CHEM, V278, P22284, DOI 10.1074/jbc.M301272200; Wang YQ, 2002, J BIOL CHEM, V277, P15766, DOI 10.1074/jbc.M111733200; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217	44	72	72	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46506	46515		10.1074/jbc.M308432200	http://dx.doi.org/10.1074/jbc.M308432200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12968019	hybrid			2022-12-25	WOS:000186569400035
J	Orelle, C; Dalmas, O; Gros, P; Di Pietro, A; Jault, JM				Orelle, C; Dalmas, O; Gros, P; Di Pietro, A; Jault, JM			The conserved glutamate residue adjacent to the Walker-B motif is the catalytic base for ATP hydrolysis in the ATP-binding cassette transporter BmrA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; RESISTANCE PROTEIN MRP1; NUCLEOTIDE-BINDING; ABC TRANSPORTER; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MECHANISM; CYCLE; DOMAIN	ATP-binding cassette (ABC) proteins constitute one of the widest families in all organisms, whose P-glycoprotein involved in resistance of cancer cells to chemotherapy is an archetype member. Although three-dimensional structures of several nucleotide-binding domains of ABC proteins are now available, the catalytic mechanism triggering the functioning of these proteins still remains elusive. In particular, it has been postulated that ATP hydrolysis proceeds via an acid-base mechanism catalyzed by the Glu residue adjacent to the Walker-B motif (Geourjon, C., Orelle, C., Steinfels, E., Blanchet, C., Deleage, G., Di Pietro, A., and Jault, J.M. (2001) Trends Biochem. Sci. 26, 539-544), but the involvement of such residue as the catalytic base in ABC transporters was recently questioned (Sauna, Z.E., Muller, M., Peng, X. H., and Ambudkar, S. V. (2002) Biochemistry, 41, 13989-14000). The equivalent glutamate residue (Glu(504)) of a half-ABC transporter involved in multidrug resistance in Bacillus subtilis, BmrA ( formerly known as YvcC), was therefore mutated to Asp, Ala, Gln, Ser, and Cys residues. All these mutants were fully devoid of ATPase activity, yet they showed a high level of vanadate-independent trapping of 8-N-3-alpha-P-32-labeled nucleotide(s), following preincubation with 8-N-3-[alpha-P-32]ATP. However, and in contrast to the wild-type enzyme, the use of 8-N-3-[gamma-P-32]ATP unequivocally showed that all the mutants trapped exclusively the triphosphate form of the analogue, suggesting that they were not able to perform even a single hydrolytic turnover. These results demonstrate that Glu(504) is the catalytic base for ATP hydrolysis in BmrA, and it is proposed that equivalent glutamate residues in other ABC transporters play the same role.	UJF, CEA, CNRS,UMR 5090, Lab Biophys Mol & Cellulaire, F-38054 Grenoble 9, France; UCBL1, CNRS, UMR 5086, Inst Biol & Chim Prot, F-69367 Lyon 07, France; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); McGill University	Jault, JM (corresponding author), UJF, CEA, CNRS,UMR 5090, Lab Biophys Mol & Cellulaire, CEA 17 Rue Martyrs,Batiment K, F-38054 Grenoble 9, France.	jault@dsvsud.cea.fr	jault, jean-michel/G-2086-2012; Orelle, Cédric/AAI-1495-2020	jault, jean-michel/0000-0003-1743-2777; Orelle, Cédric/0000-0003-3418-3290				Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Chami M, 2002, J MOL BIOL, V315, P1075, DOI 10.1006/jmbi.2001.5309; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Dassa E, 2001, RES MICROBIOL, V152, P211, DOI 10.1016/S0923-2508(01)01194-9; Daumke O, 2001, EUR J BIOCHEM, V268, P4776, DOI 10.1046/j.1432-1327.2001.02406.x; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Geourjon C, 2001, TRENDS BIOCHEM SCI, V26, P539, DOI 10.1016/S0968-0004(01)01907-7; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; Gottesman MM, 2001, J BIOENERG BIOMEMBR, V33, P453, DOI 10.1023/A:1012866803188; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Karttunen JT, 2001, P NATL ACAD SCI USA, V98, P7431, DOI 10.1073/pnas.121180198; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Muneyuki E, 2000, BBA-BIOENERGETICS, V1458, P467, DOI 10.1016/S0005-2728(00)00095-5; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; Peracchi A, 2001, TRENDS BIOCHEM SCI, V26, P497, DOI 10.1016/S0968-0004(01)01911-9; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1170, DOI 10.1021/bi026555j; Sauna ZE, 2001, J BIOENERG BIOMEMBR, V33, P481, DOI 10.1023/A:1012875105006; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Steinfels E, 2002, BBA-BIOMEMBRANES, V1565, P1, DOI 10.1016/S0005-2736(02)00515-1; Todd AE, 2002, TRENDS BIOCHEM SCI, V27, P419, DOI 10.1016/S0968-0004(02)02158-8; Ueda K, 1999, BBA-BIOMEMBRANES, V1461, P305, DOI 10.1016/S0005-2736(99)00157-1; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; Urbatsch IL, 2003, J BIOL CHEM, V278, P23171, DOI 10.1074/jbc.M301957200; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; Van Bambeke F, 2000, BIOCHEM PHARMACOL, V60, P457, DOI 10.1016/S0006-2952(00)00291-4; van Endert PM, 2002, TRENDS BIOCHEM SCI, V27, P454, DOI 10.1016/S0968-0004(02)02090-X; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	49	139	141	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47002	47008		10.1074/jbc.M308268200	http://dx.doi.org/10.1074/jbc.M308268200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12968023	hybrid			2022-12-25	WOS:000186569400095
J	Wang, MS; Liu, YLE; Goldberg, ID; Shi, YE				Wang, MS; Liu, YLE; Goldberg, ID; Shi, YE			Induction of mammary gland differentiation in transgenic mice by the fatty acid-binding protein MRG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH INHIBITOR EXPRESSION; TUMOR-SUPPRESSOR GENE; BREAST-CANCER GROWTH; HEART-TYPE; CELLS; PROLACTIN; IDENTIFICATION; PROLIFERATION; MORPHOGENESIS; ACTIVATION	A mammary-derived growth inhibitor-related gene (MRG) was previously identified and characterized. MRG induces differentiation of mammary epithelial cells in vitro and its expression is associated with mammary differentiation. To further define the role of MRG on mammary gland differentiation, a MRG transgenic mice model under the control of mouse mammary tumor virus promoter was established and the effect of MRG on mammary gland differentiation was investigated at histological and molecular levels. Expression of endogenous mouse MRG gene was significantly increased from the non-differentiated gland of control virgin mice to the functionally differentiated gland of pregnant control mice. Whole mount analyses demonstrated that ductal development was not affected by MRG transgene expression. While there was no lobuloalveolar structure in control virgin mice, expression of MRG transgene in the mammary gland resulted in the development of lobuloalveolar-like structure, which mimics the gland from early pregnancy. Consistent with the morphological change, expression of MRG also increased milk protein beta-casein expression in the gland. To study the mechanism of MRG-induced mammary differentiation, we investigated the Stat5 activation in the glands from the transgenic mouse versus virgin control mouse. While activated Stat5 was expressed at the minimal level in the non-differentiated control virgin gland, a significant Stat5 phosphorylation was observed in the virgin transgenic gland. Our data indicate that MRG is a mediator of the differentiating effects of pregnancy on breast epithelium, and overexpression of MRG in young nulliparous mice can induce differentiation.	Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Pk, NY 11040 USA	Northwell Health; Yeshiva University	Shi, YE (corresponding author), Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, Long Isl Campus, New Hyde Pk, NY 11040 USA.	shi@lij.edu			NCI NIH HHS [CA 93542-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093542] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anton ES, 1997, DEVELOPMENT, V124, P3501; BASS NM, 1986, BIOCHEM BIOPH RES CO, V137, P929, DOI 10.1016/0006-291X(86)90314-1; BIECHE I, 1994, CANCER RES, V54, P4274; BIELKA H, 1986, BIOMED BIOCHIM ACTA, V45, P441; BILLICH S, 1988, EUR J BIOCHEM, V175, P549, DOI 10.1111/j.1432-1033.1988.tb14227.x; BINAS B, 1995, DEV GENET, V17, P167, DOI 10.1002/dvg.1020170208; BINAS B, 1992, IN VITRO CELL DEV-AN, V28A, P625; BOHMER FD, 1988, J CELL BIOCHEM, V38, P199, DOI 10.1002/jcb.240380307; Borchers T, 1997, PROSTAG LEUKOTR ESS, V57, P77, DOI 10.1016/S0952-3278(97)90496-8; BRANDT R, 1988, BIOCHEMISTRY-US, V27, P1420, DOI 10.1021/bi00405a005; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; Chapman RS, 2000, ADV EXP MED BIOL, V480, P129; Chodosh LA, 1999, CANCER RES, V59, p1765S; Clark AJ, 2000, TRANSGENIC RES, V9, P439, DOI 10.1023/A:1026552629493; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; Enger SM, 1998, CANCER EPIDEM BIOMAR, V7, P365; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; Gallahan D, 1996, CANCER RES, V56, P1775; Hennighausen L, 1997, J MAMMARY GLAND BIOL, V2, P365, DOI 10.1023/A:1026347313096; HOHOFF C, 1998, CANCER RES, V57, P3084; Huynh H, 1996, CANCER RES, V56, P4865; HUYNH HT, 1995, CANCER RES, V55, P2225; Ji HJ, 1997, CANCER RES, V57, P759; KURTZ A, 1990, J CELL BIOL, V110, P1779, DOI 10.1083/jcb.110.5.1779; LI ML, 1995, J CELL PHYSIOL, V164, P1, DOI 10.1002/jcp.1041640102; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Love R R, 1997, Oncology (Williston Park), V11, P161; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; Russo I H, 1993, Eur J Cancer Prev, V2 Suppl 3, P101; RUSSO IH, 1991, BRIT J CANCER, V64, P481, DOI 10.1038/bjc.1991.335; RUSSO J, 1995, J CELL BIOCHEM, P58; Shi YE, 1997, CANCER RES, V57, P3084; Shi YE, 1998, CANCER RES, V58, P4016; Shimizu F, 1997, BBA-GENE STRUCT EXPR, V1354, P24, DOI 10.1016/S0167-4781(97)00115-2; Smith GH, 1996, BREAST CANCER RES TR, V39, P21, DOI 10.1007/BF01806075; Specht B, 1996, J BIOL CHEM, V271, P19943, DOI 10.1074/jbc.271.33.19943; Theile M, 1996, ONCOGENE, V13, P677; TREUNER M, 1994, GENE, V147, P237, DOI 10.1016/0378-1119(94)90073-6; UNTERBERG C, 1990, J BIOL CHEM, V265, P16255; Wang MS, 2000, CANCER RES, V60, P6482; WITTY EP, 1995, MOL BIOL CELL, V6, P1287, DOI 10.1091/mbc.6.10.1287; Xiao GW, 1999, P NATL ACAD SCI USA, V96, P3700, DOI 10.1073/pnas.96.7.3700; YANG YM, 1994, J CELL BIOL, V127, P1097, DOI 10.1083/jcb.127.4.1097; ZSCHIESCHE W, 1995, HISTOCHEM CELL BIOL, V103, P147, DOI 10.1007/BF01454012	46	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47319	47325		10.1074/jbc.M308131200	http://dx.doi.org/10.1074/jbc.M308131200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12975368	hybrid			2022-12-25	WOS:000186569400134
J	Chavakis, T; Santoso, S; Clemetson, KJ; Sachs, UJH; Isordia-Salas, I; Pixley, RA; Nawroth, PP; Colman, RW; Preissner, KT				Chavakis, T; Santoso, S; Clemetson, KJ; Sachs, UJH; Isordia-Salas, I; Pixley, RA; Nawroth, PP; Colman, RW; Preissner, KT			High molecular weight kininogen regulates platelet-leukocyte interactions by bridging Mac-1 and glycoprotein Ib	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-ADHERENT PLATELETS; BINDING-PROTEIN; UROKINASE RECEPTOR; ENDOTHELIAL-CELLS; VESSEL WALL; P-SELECTIN; INTEGRIN; ADHESION; IDENTIFICATION; MECHANISMS	Leukocyte-platelet interaction is important in mediating leukocyte adhesion to a thrombus and leukocyte recruitment to a site of vascular injury. This interaction is mediated at least in part by the beta(2)-integrin Mac-1 (CD11b/CD18) and its counter-receptor on platelets, glycoprotein Ibalpha (GPIbalpha). High molecular weight kininogen (HK) was previously shown to interact with both GPIbalpha and Mac-1 through its domains 3 and 5, respectively. In this study we investigated the ability of HK to interfere with the leukocyte-platelet interaction. In a purified system, HK binding to GPIbalpha was inhibited by HK domain 3 and the monoclonal antibody (mAb) SZ2, directed against the epitope 269-282 of GPIbalpha, whereas mAb AP1, directed to the region 201-268 of GPIbalpha had no effect. In contrast, mAb AP1 inhibited the Mac-1-GPIbalpha interaction. Binding of GPIbalpha to Mac-1 was enhanced 2-fold by HK. This effect of HK was abrogated in the presence of HK domains 3 or 5 or peptides from the 475-497 region of the carboxyl terminus of domain 5 as well as in the presence of mAb SZ2 but not mAb AP1. Whereas no difference in the affinity of the Mac-1-GPIbalpha interaction was observed in the absence or presence of HK, maximal binding of GPIbalpha to Mac-1 doubled in the presence of HK. Moreover, HK/HKa increased the Mac-1-dependent adhesion of myelomonocytic U937 cells and K562 cells transfected with Mac-1 to immobilized GPIbalpha or to GPIbalpha-transfected Chinese hamster ovary cells. Finally, Mac-1-dependent adhesion of neutrophils to surface-adherent platelets was enhanced by HK. Thus, HK can bridge leukocytes with platelets by interacting via its domain 3 with GPIbalpha and via its domain 5 with Mac-1 thereby augmenting the Mac-1-GPIbalpha interaction. These distinct molecular interactions of HK with leukocytes and platelets contribute to the regulation of the adhesive behavior of vascular cells and provide novel molecular targets for reducing atherothrombotic pathologies.	Heidelberg Univ, Dept Internal Med 1, D-69115 Heidelberg, Germany; Univ Giessen, Inst Clin Immunol & Transfus Med, D-35392 Giessen, Germany; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Univ Bern, Theodor Kocher Inst, CH-3012 Bern, Switzerland; Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA	Ruprecht Karls University Heidelberg; Justus Liebig University Giessen; Justus Liebig University Giessen; University of Bern; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Chavakis, T (corresponding author), Univ Klinikum Heidelberg, Med Klin 1, Bergheimer Str 58, D-69115 Heidelberg, Germany.	triantafyllos.chavakis@med.uni-heidelberg.de	Sachs, Ulrich/GSI-7824-2022; Chavakis, Triantafyllos/ABE-8845-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056914] Funding Source: NIH RePORTER; NCI NIH HHS [CA63938] Funding Source: Medline; NHLBI NIH HHS [HL56914] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bradford HN, 1997, BLOOD, V90, P1508, DOI 10.1182/blood.V90.4.1508.1508_1508_1515; CARLOS TM, 1994, BLOOD, V84, P2068; Chavakis T, 2000, BLOOD, V96, P514; Chavakis T, 1999, BLOOD, V93, P2976; Chavakis T, 2002, J BIOL CHEM, V277, P23157, DOI 10.1074/jbc.M202529200; Chavakis T, 2002, J BIOL CHEM, V277, P32677, DOI 10.1074/jbc.M204010200; Chavakis T, 2002, NAT MED, V8, P687, DOI 10.1038/nm728; Chavakis T, 2001, FASEB J, V15, P2365, DOI 10.1096/fj.01-0201com; Chavakis Triantafyllos, 2003, Current Vascular Pharmacology, V1, P59, DOI 10.2174/1570161033386790; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; Colman RW, 2000, BLOOD, V95, P543, DOI 10.1182/blood.V95.2.543; DELACADENA RA, 1994, THROMB HAEMOSTASIS, V72, P125; Diacovo TG, 1996, BLOOD, V88, P146; DIACOVO TG, 1994, J CLIN INVEST, V94, P1243, DOI 10.1172/JCI117442; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; Evangelista V, 1996, BLOOD, V88, P4183, DOI 10.1182/blood.V88.11.4183.bloodjournal88114183; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; JANDROTPERRUS M, 1992, BLOOD, V80, P2781; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; Kuijper PHM, 1997, BLOOD, V89, P166, DOI 10.1182/blood.V89.1.166.166_166_175; KUNAPULI SP, 1993, J BIOL CHEM, V268, P2486; Kunapuli SP, 1996, J BIOL CHEM, V271, P11228, DOI 10.1074/jbc.271.19.11228; LANGUINO LR, 1995, P NATL ACAD SCI USA, V92, P1505, DOI 10.1073/pnas.92.5.1505; MARCUS AJ, 1994, SEMIN HEMATOL, V31, P261; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Renne T, 2000, J BIOL CHEM, V275, P33688, DOI 10.1074/jbc.M000313200; RINDER CS, 1992, BLOOD, V79, P1201; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Santoso S, 1999, BLOOD, V94, P4103, DOI 10.1182/blood.V94.12.4103.424k27_4103_4111; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; Simon DI, 2000, J EXP MED, V192, P193, DOI 10.1084/jem.192.2.193; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Weber C, 1997, J CLIN INVEST, V100, P2085, DOI 10.1172/JCI119742; XIE JL, 1995, J IMMUNOL, V155, P3619	40	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45375	45381		10.1074/jbc.M304344200	http://dx.doi.org/10.1074/jbc.M304344200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952972	hybrid			2022-12-25	WOS:000186452300041
J	Fedorov, R; Hartmann, E; Ghosh, DK; Schlichting, I				Fedorov, R; Hartmann, E; Ghosh, DK; Schlichting, I			Structural basis for the specificity of the nitric-oxide synthase inhibitors W1400 and N-omega-propyl-L-Arg for the inducible and neuronal isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE INHIBITORS; OXYGENASE DOMAIN; HEME DOMAIN; L-ARGININE; CRYSTAL-STRUCTURES; BINDING MODE; IN-VIVO; CYTOCHROME-P-450; MECHANISM; PTERIN	The high level of amino acid conservation and structural similarity in the immediate vicinity of the substrate binding sites of the oxygenase domains of the nitric-oxide synthase (NOS) isoforms (eNOSoxy, iNOSoxy, and nNOSoxy) make the interpretation of the structural basis of inhibitor isoform specificity a challenge and provide few clues for the design of new selective compounds. Crystal structures of iNOSoxy and nNOSoxy complexed with the inhibitors W1400 and N-omega-propyl-L-arginine provide a rationale for their isoform specificity. It involves differences outside the immediate active site as well as a conformational flexibility in the active site that allows the adoption of distinct conformations in response to interactions with the inhibitors. This flexibility is determined by isoform-specific residues outside the active site.	Max Planck Inst Med Res, Abt Biomol Mech, D-69120 Heidelberg, Germany; Max Planck Inst Mol Physiol, Abt Biophys Chem, D-44227 Dortmund, Germany; Duke Univ, Durham, NC 27713 USA; Vet Adm Med Ctr, Durham, NC 27713 USA	Max Planck Society; Max Planck Society; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Schlichting, I (corresponding author), Max Planck Inst Med Res, Abt Biomol Mech, Jahnstr 29, D-69120 Heidelberg, Germany.		Schlichting, Ilme/I-1339-2013	Fedorov, Roman/0000-0002-5240-4205				ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Babu BR, 1998, CURR OPIN CHEM BIOL, V2, P491, DOI 10.1016/S1367-5931(98)80125-7; Babu BR, 1999, J BIOL CHEM, V274, P25218, DOI 10.1074/jbc.274.36.25218; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collins JL, 1998, J MED CHEM, V41, P2858, DOI 10.1021/jm980072p; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; DEMONTELLANO PRO, 1981, BIOCHEMISTRY-US, V20, P7266, DOI 10.1021/bi00528a033; DEMONTELLANO PRO, 1906, CYTOCHROME P 450; Fast W, 1997, BIOORGAN MED CHEM, V5, P1601, DOI 10.1016/S0968-0896(97)00109-0; Fedorov R, 2003, ARCH BIOCHEM BIOPHYS, V409, P25, DOI 10.1016/S0003-9861(02)00555-6; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; GERBER NC, 1995, J BIOL CHEM, V270, P17791, DOI 10.1074/jbc.270.30.17791; Ghosh DK, 2001, P NATL ACAD SCI USA, V98, P10392, DOI 10.1073/pnas.181251298; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GROVES JT, 1988, J AM CHEM SOC, V110, P8443, DOI 10.1021/ja00233a021; Huang H, 1999, J MED CHEM, V42, P3147, DOI 10.1021/jm990111c; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KNOWLES RG, 1990, BIOCHEM J, V270, P833, DOI 10.1042/bj2700833; Kotsonis P, 2001, J BIOL CHEM, V276, P49133, DOI 10.1074/jbc.M011469200; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; Li HY, 2002, BIOCHEMISTRY-US, V41, P13868, DOI 10.1021/bi020417c; Li HY, 2001, BIOCHEMISTRY-US, V40, P5399, DOI 10.1021/bi002658v; Li HY, 2000, J INORG BIOCHEM, V81, P133, DOI 10.1016/S0162-0134(00)00099-4; MANSUY D, 1987, PURE APPL CHEM, V59, P759, DOI 10.1351/pac198759060759; Raman CS, 2001, J BIOL CHEM, V276, P26486, DOI 10.1074/jbc.M102255200; Raman CS, 2001, BIOCHEMISTRY-US, V40, P13448, DOI 10.1021/bi010957u; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Reif DW, 2000, FREE RADICAL BIO MED, V28, P1470, DOI 10.1016/S0891-5849(00)00250-1; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; TAYLOR WR, 1989, J MOL BIOL, V208, P1, DOI 10.1016/0022-2836(89)90084-3; Zhang HQ, 1997, J MED CHEM, V40, P3869, DOI 10.1021/jm970550g	35	66	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45818	45825		10.1074/jbc.M306030200	http://dx.doi.org/10.1074/jbc.M306030200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954642	hybrid			2022-12-25	WOS:000186452300094
J	Omi, R; Goto, M; Miyahara, I; Mizuguchi, H; Hayashi, H; Kagamiyama, H; Hirotsu, K				Omi, R; Goto, M; Miyahara, I; Mizuguchi, H; Hayashi, H; Kagamiyama, H; Hirotsu, K			Crystal structures of threonine synthase from Thermus thermophilus HB8 - Conformational change, substrate recognition, and mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-ACETYLSERINE SULFHYDRYLASE; AMINO-ACID AMINOTRANSFERASE; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; ASPARTATE; EVOLUTION; MOLSCRIPT; GLUTAMATE; PROGRAM; COMPLEX	Threonine synthase, which is a PLP-dependent enzyme, catalyzes the beta,gamma-replacement reaction of L-homoserine phosphate to yield threonine and inorganic phosphate. The three-dimensional structures of the enzyme from Thermus thermophilus HB8 in its unliganded form and complexed with the substrate analogue 2-amino-5-phosphonopentanoic acid have been determined at 2.15 and 2.0 Angstrom resolution, respectively. The complexed form, assigned as an enamine, uncovered the interactions of the cofactor-analogue conjugate with the active site residues. The binding of the substrate analogue induces a large conformational change at the domain level. The small domain rotates by about 25degrees and approaches the large domain to close the active site. The complicated catalytic process of the enzyme has been elucidated based on the complex structure to reveal the stereochemistry of the reaction and to present the released inorganic phosphate as a possible catalyst to carry a proton to the Cgamma atom of the substrate.	Osaka City Univ, Grad Sch Sci, Dept Chem, Osaka 5588585, Japan; RIKEN, Inst Phys & Chem Res, Sayo, Hyogo 6795148, Japan; Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan; Osaka Med Coll, Dept Biochem, Osaka 5698686, Japan	Osaka Metropolitan University; RIKEN; Osaka University; Osaka Medical College	Hirotsu, K (corresponding author), Osaka City Univ, Grad Sch Sci, Dept Chem, Osaka 5588585, Japan.	hirotsu@sci.osaka-cu.ac.jp	Mizuguchi, Hiroyuki/B-5676-2013	Mizuguchi, Hiroyuki/0000-0001-7055-316X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burkhard P, 1999, J MOL BIOL, V291, P941, DOI 10.1006/jmbi.1999.3002; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; COOK PF, 2003, BIOCHIM BIOPHYS ACTA, V1647, P321; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FLAVIN M, 1960, J BIOL CHEM, V235, P1112; Fromme JC, 2003, NAT STRUCT BIOL, V10, P204, DOI 10.1038/nsb902; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; Garrido-Franco M, 2002, J BIOL CHEM, V277, P12396, DOI 10.1074/jbc.M108734200; Goto M, 2003, BIOCHEMISTRY-US, V42, P3725, DOI 10.1021/bi026722f; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Jansonius JN, 1998, CURR OPIN STRUC BIOL, V8, P759, DOI 10.1016/S0959-440X(98)80096-1; JANSONIUS JN, 1987, STRUCTURAL BASIS CAT, P187; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laber B, 1999, EUR J BIOCHEM, V263, P212, DOI 10.1046/j.1432-1327.1999.00487.x; LABER B, 1994, BIOCHEMISTRY-US, V33, P3413, DOI 10.1021/bi00177a035; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4 ESRF EESF; MALASHKEVICH VN, 1993, BIOCHEMISTRY-US, V32, P13451, DOI 10.1021/bi00212a010; Mehta PK, 2000, ADV ENZYMOL RAMB, V74, P129; Meier M, 2001, EMBO J, V20, P3910, DOI 10.1093/emboj/20.15.3910; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; METZLER DE, 1954, J AM CHEM SOC, V76, P648, DOI 10.1021/ja01632a004; MITCHELL JBO, 1992, J MOL BIOL, V226, P251, DOI 10.1016/0022-2836(92)90137-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Okada K, 2001, BIOCHEMISTRY-US, V40, P7453, DOI 10.1021/bi010384l; OKAMOTO A, 1994, J BIOCHEM, V116, P95, DOI 10.1093/oxfordjournals.jbchem.a124509; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Schneider G, 2000, STRUCT FOLD DES, V8, pR1, DOI 10.1016/S0969-2126(00)00085-X; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thomazeau K, 2001, PROTEIN SCI, V10, P638, DOI 10.1110/ps.44301; Yao M, 2000, J BIOL CHEM, V275, P34557, DOI 10.1074/jbc.M004681200	44	29	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46035	46045		10.1074/jbc.M308065200	http://dx.doi.org/10.1074/jbc.M308065200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952961	hybrid			2022-12-25	WOS:000186452300120
J	Song, SW; Wheeler, LJ; Mathews, CK				Song, SW; Wheeler, LJ; Mathews, CK			Deoxyribonucleotide pool imbalance stimulates deletions in HeLa cell mitochondrial DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDINE PHOSPHORYLASE-DEFICIENCY; MOUSE L-CELLS; DEOXYNUCLEOTIDE CARRIER; REPLICATION; MAINTENANCE; MUTATIONS; FIDELITY; GENE; VERTEBRATES; ASYMMETRY	Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder associated with multiple mutations in mitochondrial DNA, both deletions and point mutations, and mutations in the nuclear gene for thymidine phosphorylase. Spinazzola et al. (Spinazzola, A., Marti, R., Nishino, I., Andreu, A., Naini, A., Tadesse, S., Pela, I., Zammarchi, E., Donati, M., Oliver, J., and Hirano, M. (2001) J. Biol. Chem. 277, 4128-4133) showed that MNGIE patients have elevated circulating thymidine levels and they hypothesized that this generates imbalanced mitochondrial deoxyribonucleoside triphosphate (dNTP) pools, which in turn are responsible for mitochondrial (mt) DNA mutagenesis. We tested this hypothesis by culturing HeLa cells in medium supplemented with 50 muM thymidine. After 8-month growth, mtDNA in the thymidine-treated culture, but not the control, showed multiple deletions, as detected both by Southern blotting and by long extension polymerase chain reaction. After 4-h growth in thymidine-supplemented medium, we found the mitochondrial dTTP and dGTP pools to expand significantly, the dCTP pool to drop significantly, and the dATP pool to drop slightly. In whole-cell extracts, dTTP and dGTP pools also expanded, but somewhat less than in mitochondria. The dCTP pool shrank by about 50%, and the dATP pool was essentially unchanged. These results are discussed in terms of the recent report by Nishigaki et al. (Nishigaki, Y., Marti, R., Copeland, W.C., and Hirano, M. (2003) J. Clin. Invest. 111, 1913-1921) that most mitochondrial point mutations in MNGIE patients involve T 3 C transitions in sequences containing two As to the 5' side of a T residue. Our finding of dTTP and dGTP elevations and dATP depletion in mitochondrial dNTP pools are consistent with a mutagenic mechanism involving T-G mispairing followed by a next-nucleotide effect involving T insertion opposite A.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Mathews, CK (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES000040] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES-00040] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BESTWICK RK, 1982, J BIOL CHEM, V257, P9305; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938; BOGENHAGEN D, 1977, CELL, V11, P719, DOI 10.1016/0092-8674(77)90286-0; Bogenhagen DF, 1999, AM J HUM GENET, V64, P1276, DOI 10.1086/302392; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bridges EG, 1999, J BIOL CHEM, V274, P4620, DOI 10.1074/jbc.274.8.4620; BUROKER NE, 1990, GENETICS, V124, P157; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998; Goodman MF, 1998, GENETICS, V148, P1475; Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279; HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721; Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; Marcelino LA, 1999, MUTAT RES-DNA REPAIR, V434, P177, DOI 10.1016/S0921-8777(99)00028-2; Marti R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8; Martomo SA, 2002, MUTAT RES-FUND MOL M, V499, P197, DOI 10.1016/S0027-5107(01)00283-4; Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Rosenberg MJ, 2002, NAT GENET, V32, P175, DOI 10.1038/ng948; SAMBROOK J, 1989, MOL CLONING, V2, P9; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Wang JH, 1999, NUCLEOS NUCLEOT, V18, P807, DOI 10.1080/15257779908041567; YOUNG P, 1994, BIOCHEM BIOPH RES CO, V203, P46, DOI 10.1006/bbrc.1994.2146; ZHANG XL, 1995, J BIOL CHEM, V270, P8401, DOI 10.1074/jbc.270.15.8401	36	92	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					43893	43896		10.1074/jbc.C300401200	http://dx.doi.org/10.1074/jbc.C300401200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	13679382	hybrid			2022-12-25	WOS:000186306700003
J	Melnikova, VO; Santamaria, AB; Bolshakov, SV; Ananthaswamy, HN				Melnikova, VO; Santamaria, AB; Bolshakov, SV; Ananthaswamy, HN			Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase	ONCOGENE			English	Article						mutant p53; phosphorylation; serine 15; stabilization; ERK; skin tumor; UV	WILD-TYPE P53; DAMAGE-INDUCED PHOSPHORYLATION; NUCLEAR EXPORT SIGNAL; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; ENHANCED PHOSPHORYLATION; P38 KINASE; PROTEIN; MUTATIONS; GROWTH	Upon DNA damage, phosphorylation and nuclear translocation of wild-type p53 tumor suppressor protein signals its functional activation. However, very little is known about phosphorylation and localization of mutant p53. We found that mutant p53 protein in UV-induced murine primary skin tumors and cultured cell tines was constitutively phosphorylated at serine 15 residue and localized in the cell's nuclei. To investigate the mechanism of constitutive phosphorylation of mutant p53, we tested the involvement of a wide range of protein kinases and found that ERK1/2 mitogen-activated protein kinase was physically associated with mutant p53 in the nucleus. Addition of active recombinant ERK2 kinase protein in vitro to immunoprecipitated mutant p53 resulted in increased phosphorylation at serine 15. Furthermore, ERK1/2 activity was higher in tumor cells than normal cells, suggesting that phosphorylation of mutant p53 at serine 15 depends on the level of ERK1/2 activation. Interestingly, accumulation of mutant p53 in tumor cells was paralleled by low levels of Murine Double Minute 2 protein (MDM2) expression. However, when MDM2 was overexpressed, the fraction of mutant p53 that was phosphorylated at serine 15 resisted degradation, whereas the level of total p53 decreased, suggesting that phosphorylation at serine 15 and downregulation of MDM2 protein may both contribute to stabilization of mutant p53 in tumor cells.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Ananthaswamy, HN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, 1515 Holcombe Blvd,Box 178, Houston, TX 77030 USA.	hanantha@mdanderson.org			NCI NIH HHS [CA 16672, CA 46523] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA046523] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; Ananthaswamy HN, 1998, PHOTOCHEM PHOTOBIOL, V67, P227, DOI 10.1562/0031-8655(1998)067<0227:MIHSHM>2.3.CO;2; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Araki R, 1999, CANCER RES, V59, P3543; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Brown DR, 2001, INT J ONCOL, V18, P449; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Buschmann T, 2000, J MOL BIOL, V295, P1009, DOI 10.1006/jmbi.1999.3387; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; De Guzman RN, 2000, J MOL BIOL, V303, P243, DOI 10.1006/jmbi.2000.4141; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; KANJILAL S, 1993, CANCER RES, V53, P2961; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; KIESER A, 1994, ONCOGENE, V9, P963; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koga H, 2000, ONCOGENE, V19, P4178, DOI 10.1038/sj.onc.1203745; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1995, ONCOGENE, V10, P2387; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Minamoto T, 2001, ONCOGENE, V20, P3341, DOI 10.1038/sj.onc.1204458; Nagata Y, 1999, ONCOGENE, V18, P6037, DOI 10.1038/sj.onc.1202978; Ouhtit A, 2000, AM J PATHOL, V156, P201, DOI 10.1016/S0002-9440(10)64720-7; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; PIERCEALL WE, 1992, CANCER RES, V52, P3946; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1999, GENE DEV, V13, P152; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; She QB, 2002, ONCOGENE, V21, P1580, DOI 10.1038/sj.onc.1205239; She QB, 2001, CANCER RES, V61, P1604; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sigal A, 2000, CANCER RES, V60, P6788; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	54	42	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5958	5966		10.1038/sj.onc.1206595	http://dx.doi.org/10.1038/sj.onc.1206595			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955074				2022-12-25	WOS:000185137800004
J	Rouzaud, F; Annereau, JP; Valencia, JC; Costin, GE; Hearing, VJ				Rouzaud, F; Annereau, JP; Valencia, JC; Costin, GE; Hearing, VJ			Regulation of melanocortin 1 receptor expression at the mRNA and protein levels by its natural agonist and antagonist	FASEB JOURNAL			English	Article						promoter; 5 ' untranslated region (5 ' UTR); melanocyte; translation	MELANOCYTE-STIMULATING-HORMONE; AGOUTI SIGNALING PROTEIN; TRANSLATIONAL CONTROL; POINT MUTATIONS; MSH RECEPTORS; IN-VITRO; GENES; INITIATION; CELLS; HYPOTHALAMUS	Five melanocortin receptors, which form a subfamily of G protein-coupled receptors, are expressed in mammalian tissues and regulate such diverse physiological processes as pigmentation, adrenal function, energy homeostasis, feeding efficiency, and sebaceous gland lipid production, as well as immune and sexual function. Pigmentation in mammals is stimulated by alpha-melanocyte stimulating hormone (MSH), which binds to the melanocortin 1 receptor (Mclr) and induces an activation of melanogenic enzymes through stimulation of adenylate cyclase and protein kinase A. The antagonist agouti signal protein (ASP) interacts with the Mclr and blocks its stimulation by MSH. We examined the influence of ASP or MSH on Mclr gene expression, and we report that both ligands influence the Mclr 5' promoter structure in distinct manners. Our study further shows that MSH regulates Mclr function at both the mRNA and protein levels, whereas ASP acts only on its translation.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Room 1B25, Bethesda, MD 20892 USA.	hearingv@nih.gov			DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Malek ZA, 2001, J CELL SCI, V114, P1019; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Bray GA, 2000, NATURE, V404, P672, DOI 10.1038/35007544; Broberger C, 1998, J COMP NEUROL, V402, P460; Broberger C, 1998, P NATL ACAD SCI USA, V95, P15043, DOI 10.1073/pnas.95.25.15043; CHAKRABORTY A, 1995, J INVEST DERMATOL, V105, P655, DOI 10.1111/1523-1747.ep12324134; CHAKRABORTY AK, 1992, BIOCHEM BIOPH RES CO, V188, P1325, DOI 10.1016/0006-291X(92)91376-2; CONE RD, 1993, MELANOTROPIC PEPTIDE, P342; COSTIN GE, 2003, IN PRESS J CELL SCI; Curry JD, 2001, BRIT J HAEMATOL, V115, P826, DOI 10.1046/j.1365-2141.2001.03190.x; Davuluri RV, 2000, GENOME RES, V10, P1807, DOI 10.1101/gr.GR-1460R; Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R; Furumura M, 1998, P NATL ACAD SCI USA, V95, P7374, DOI 10.1073/pnas.95.13.7374; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GESCHWIND II, 1966, ENDOCRINOLOGY, V79, P1165, DOI 10.1210/endo-79-6-1165; Haskell-Luevano C, 1999, ENDOCRINOLOGY, V140, P1408, DOI 10.1210/en.140.3.1408; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; Huang QH, 1999, AM J PHYSIOL-REG I, V276, pR864, DOI 10.1152/ajpregu.1999.276.3.R864; HUNT G, 1995, J ENDOCRINOL, V147, pR1, DOI 10.1677/joe.0.147R001; JACKSON IJ, 1993, NATURE, V362, P587, DOI 10.1038/362587a0; Jean S, 2001, BBA-GENE STRUCT EXPR, V1522, P89, DOI 10.1016/S0167-4781(01)00326-8; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; KAMEYAMA K, 1988, J CELL PHYSIOL, V137, P35, DOI 10.1002/jcp.1041370105; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MacNeil DJ, 2002, EUR J PHARMACOL, V450, P91, DOI 10.1016/S0014-2999(02)01989-1; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Preiss T, 1999, CURR OPIN GENET DEV, V9, P515, DOI 10.1016/S0959-437X(99)00005-2; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Sakai C, 1997, EMBO J, V16, P3544, DOI 10.1093/emboj/16.12.3544; Scott MC, 2002, PIGM CELL RES, V15, P433, DOI 10.1034/j.1600-0749.2002.02051.x; Searle A.G., 1968, COMP GENETICS COAT C; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Siegrist W, 1997, J RECEPT SIGNAL TR R, V17, P75, DOI 10.3109/10799899709036595; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; SMITH AI, 1988, ENDOCR REV, V9, P159, DOI 10.1210/edrv-9-1-159; Suzuki I, 1997, J INVEST DERMATOL, V108, P838, DOI 10.1111/1523-1747.ep12292572; TAMURA A, 1987, IN VITRO CELL DEV B, V23, P519; Toyofuku K, 2001, FASEB J, V15, P2149, DOI 10.1096/fj.01-0216com; Valencia JC, 2001, J INVEST MED, V49, P421, DOI 10.2310/6650.2001.33787; Vergoni AV, 1999, EUR J PHARMACOL, V369, P11, DOI 10.1016/S0014-2999(99)00045-X; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Yang YK, 1999, MOL ENDOCRINOL, V13, P148, DOI 10.1210/me.13.1.148; ZUCKER M, 1999, ALGORITHMS THERMODYN	52	36	37	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2154	+		10.1096/fj.03-0206fje	http://dx.doi.org/10.1096/fj.03-0206fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500544				2022-12-25	WOS:000185925100010
J	Fanning, PJ; Emkey, G; Smith, RJ; Grodzinsky, AJ; Szasz, N; Trippel, SB				Fanning, PJ; Emkey, G; Smith, RJ; Grodzinsky, AJ; Szasz, N; Trippel, SB			Mechanical regulation of mitogen-activated protein kinase signaling in articular cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; MATRIX SYNTHESIS; DYNAMIC COMPRESSION; INTERSTITIAL FLUID; GENE-EXPRESSION; CHONDROCYTES; AGGRECAN; EXPLANTS; CELLS; INTERLEUKIN-1	Articular chondrocytes respond to mechanical forces by alterations in gene expression, proliferative status, and metabolic functions. Little is known concerning the cell signaling systems that receive, transduce, and convey mechanical information to the chondrocyte interior. Here, we show that ex vivo cartilage compression stimulates the phosphorylation of ERK1/ 2, p38 MAPK, and SAPK/ ERK kinase- 1 ( SEK1) of the JNK pathway. Mechanical compression induced a phased phosphorylation of ERK consisting of a rapid induction of ERK1/ 2 phosphorylation at 10 min, a rapid decay, and a sustained level of ERK2 phosphorylation that persisted for at least 24 h. Mechanical compression also induced the phosphorylation of p38 MAPK in strictly a transient fashion, with maximal phosphorylation occurring at 10 min. Mechanical compression stimulated SEK1 phosphorylation, with a maximum at the relatively delayed time point of 1 h and with a higher amplitude than ERK1/ 2 and p38 MAPK phosphorylation. These data demonstrate that mechanical compression alone activates MAPK signaling in intact cartilage. In addition, these data demonstrate distinct temporal patterns of MAPK signaling in response to mechanical loading and to the anabolic insulin- like growth factor- I. Finally, the data indicate that compression coactivates distinct signaling pathways that may help define the nature of mechanotransduction in cartilage.	Massachusetts Gen Hosp, Orthopaed Res Labs, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Joslin Diabet Ctr, Boston, MA 02215 USA; MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Joslin Diabetes Center, Inc.; Massachusetts Institute of Technology (MIT)	Trippel, SB (corresponding author), Indiana Univ, Sch Med, Dept Orthoped Surg, 541 Clin Dr, Indianapolis, IN 46202 USA.	strippel@iupui.edu			NIAMS NIH HHS [AR45749, AR33236] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045749, R37AR033236, R01AR033236] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bonassar LJ, 2000, ARCH BIOCHEM BIOPHYS, V379, P57, DOI 10.1006/abbi.2000.1820; Bonassar LJ, 2001, J ORTHOP RES, V19, P11, DOI 10.1016/S0736-0266(00)00004-8; BOUSTANY NN, 1995, J ORTHOPAED RES, V13, P733, DOI 10.1002/jor.1100130513; BOUSTANY NN, 1995, J ORTHOPAED RES, V13, P740, DOI 10.1002/jor.1100130514; Buschmann MD, 1999, ARCH BIOCHEM BIOPHYS, V366, P1, DOI 10.1006/abbi.1999.1197; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; FREEMAN PM, 1994, J ORTHOPAED RES, V12, P311, DOI 10.1002/jor.1100120303; Garcia AM, 2003, ARCH BIOCHEM BIOPHYS, V415, P69, DOI 10.1016/S0003-9861(03)00215-7; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823; GRITZKA TL, 1973, J BONE JOINT SURG AM, VA 55, P1698, DOI 10.2106/00004623-197355080-00015; Grodzinsky AJ, 2000, ANNU REV BIOMED ENG, V2, P691, DOI 10.1146/annurev.bioeng.2.1.691; Guilak F, 1994, Osteoarthritis Cartilage, V2, P91, DOI 10.1016/S1063-4584(05)80059-7; HALL AC, 1991, J ORTHOPAED RES, V9, P1, DOI 10.1002/jor.1100090102; Herberhold C, 1999, J BIOMECH, V32, P1287, DOI 10.1016/S0021-9290(99)00130-X; HODGE WA, 1986, P NATL ACAD SCI USA, V83, P2879, DOI 10.1073/pnas.83.9.2879; Huber M, 2000, INVEST RADIOL, V35, P573, DOI 10.1097/00004424-200010000-00003; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; Hung CT, 2000, J BIOMECH, V33, P73, DOI 10.1016/S0021-9290(99)00176-1; Jin G, 2000, J ORTHOPAED RES, V18, P899, DOI 10.1002/jor.1100180608; Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092-8674(00)00112-4; Kim YJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P331, DOI 10.1006/abbi.1996.0181; KIM YJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P1, DOI 10.1006/abbi.1994.1201; Lee DA, 1998, BIOCHEM BIOPH RES CO, V251, P580, DOI 10.1006/bbrc.1998.9520; Loening AM, 2000, ARCH BIOCHEM BIOPHYS, V381, P205, DOI 10.1006/abbi.2000.1988; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Millward-Sadler SJ, 1999, J CELL BIOL, V145, P183, DOI 10.1083/jcb.145.1.183; MORALES TI, 1989, CONNECT TISSUE RES, V19, P255, DOI 10.3109/03008208909043900; Mow VC, 1999, OSTEOARTHR CARTILAGE, V7, P41, DOI 10.1053/joca.1998.0161; MUIR H, 1995, BIOESSAYS, V17, P1039, DOI 10.1002/bies.950171208; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Quinn TM, 1999, ANN NY ACAD SCI, V878, P420, DOI 10.1111/j.1749-6632.1999.tb07700.x; Quinn TM, 1998, J CELL SCI, V111, P573; Ragan PM, 1999, J ORTHOPAED RES, V17, P836, DOI 10.1002/jor.1100170608; REPO RU, 1977, J BONE JOINT SURG AM, V59, P1068, DOI 10.2106/00004623-197759080-00012; SAH RLY, 1989, J ORTHOPAED RES, V7, P619, DOI 10.1002/jor.1100070502; SCHALKWIJK J, 1989, ARTHRITIS RHEUM, V32, P66, DOI 10.1002/anr.1780320111; Scherle PA, 1997, BIOCHEM BIOPH RES CO, V230, P573, DOI 10.1006/bbrc.1996.5985; Talts JF, 1998, ANN NY ACAD SCI, V857, P74, DOI 10.1111/j.1749-6632.1998.tb10108.x; THOMPSON RC, 1991, J BONE JOINT SURG AM, V73A, P990, DOI 10.2106/00004623-199173070-00005; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TRIPPEL SB, 1989, PEDIATR RES, V25, P76, DOI 10.1203/00006450-198901000-00017; Trippel ST, 1992, BIOL REGULATION CHON, P161; TYLER JA, 1985, BIOCHEM J, V227, P869, DOI 10.1042/bj2270869; URBAN JPG, 1993, J CELL PHYSIOL, V154, P262, DOI 10.1002/jcp.1041540208; Urban JPG, 2000, BIORHEOLOGY, V37, P185; Valhmu WB, 1998, ARCH BIOCHEM BIOPHYS, V353, P29, DOI 10.1006/abbi.1998.0633; WILKINS RJ, 1995, J CELL PHYSIOL, V164, P474, DOI 10.1002/jcp.1041640305; Wu QQ, 2000, EXP CELL RES, V256, P383, DOI 10.1006/excr.2000.4847	52	112	116	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50940	50948		10.1074/jbc.M305107200	http://dx.doi.org/10.1074/jbc.M305107200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	12952976	hybrid			2022-12-25	WOS:000187206300015
J	Min, TP; Kasahara, H; Bedgar, DL; Youn, BY; Lawrence, PK; Gang, DR; Halls, SC; Park, HJ; Hilsenbeck, JL; Davin, LB; Lewis, NG; Kang, C				Min, TP; Kasahara, H; Bedgar, DL; Youn, BY; Lawrence, PK; Gang, DR; Halls, SC; Park, HJ; Hilsenbeck, JL; Davin, LB; Lewis, NG; Kang, C			Crystal structures of pinoresinol-lariciresinol and phenylcoumaran benzylic ether reductases and their relationship to isoflavone reductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOSE 4-EPIMERASE; ESCHERICHIA-COLI; FORSYTHIA-INTERMEDIA; MOLECULAR-CLONING; EXPRESSION; BIOSYNTHESIS; PROTEIN; BINDING; CANCER; ENZYME	Despite the importance of plant lignans and isoflavonoids in human health protection (e. g. for both treatment and prevention of onset of various cancers) as well as in plant biology (e. g. in defense functions and in heartwood development), systematic studies on the enzymes involved in their biosynthesis have only recently begun. In this investigation, three NADPH-dependent aromatic alcohol reductases were comprehensively studied, namely pinoresinol-lariciresinol reductase (PLR), phenylcoumaran benzylic ether reductase (PCBER), and isoflavone reductase (IFR), which are involved in central steps to the various important bioactive lignans and isoflavonoids. Of particular interest was in determining how differing regio- and enantio-specificities are achieved with the different enzymes, despite each apparently going through similar enone intermediates. Initially, the three-dimensional x-ray crystal structures of both PLR_Tp1 and PCBER_Pt1 were solved and refined to 2.5 and 2.2 Angstrom resolutions, respectively. Not only do they share high gene sequence similarity, but their structures are similar, having a continuous alpha/beta NADPH-binding domain and a smaller substrate-binding domain. IFR (whose crystal structure is not yet obtained) was also compared (modeled) with PLR and PCBER and was deduced to have the same overall basic structure. The basis for the distinct enantio-specific and regio- specific reactions of PCBER, PLR, and IFR, as well as the reaction mechanism and participating residues involved (as identified by site-directed mutagenesis), are discussed.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA	Washington State University; Washington State University	Kang, C (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.		Kasahara, Hiroyuki/F-6445-2012; Gang, David/B-1001-2013	Kasahara, Hiroyuki/0000-0002-4858-0978; Davin, Laurence/0000-0002-3248-6485; Lewis, Norman/0000-0001-5742-032X				ADLERCREUTZ H, 1993, J STEROID BIOCHEM, V44, P147, DOI 10.1016/0960-0760(93)90022-O; ADLERCREUTZ H, 1992, J STEROID BIOCHEM, V41, P331, DOI 10.1016/0960-0760(92)90359-Q; ADLERCREUTZ H, 1988, PROGR CANC RES THERA, V35, P409; BORRIELLO SP, 1985, J APPL BACTERIOL, V58, P37, DOI 10.1111/j.1365-2672.1985.tb01427.x; BRENEMAN CM, 1990, J COMPUT CHEM, V11, P361, DOI 10.1002/jcc.540110311; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Canel C, 2000, PHYTOCHEMISTRY, V54, P115, DOI 10.1016/S0031-9422(00)00094-7; CHEN RD, 1995, P NATL ACAD SCI USA, V92, P11666, DOI 10.1073/pnas.92.25.11666; CHU A, 1993, J BIOL CHEM, V268, P27026; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Davin LB, 1997, SCIENCE, V275, P362, DOI 10.1126/science.275.5298.362; Didierjean C, 1997, J MOL BIOL, V268, P739, DOI 10.1006/jmbi.1997.0998; DinkovaKostova AT, 1996, J BIOL CHEM, V271, P29473, DOI 10.1074/jbc.271.46.29473; DIXON RA, 1999, COMPREHENSIVE NATURA, V1, P774; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; Ford JD, 2001, J NAT PROD, V64, P1388, DOI 10.1021/np010367x; FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690; Frisch M. J., 1998, GAUSSIAN 98; Fujita M, 1999, J BIOL CHEM, V274, P618, DOI 10.1074/jbc.274.2.618; Gang DR, 1999, J BIOL CHEM, V274, P7516, DOI 10.1074/jbc.274.11.7516; Gang DR, 1998, ACS SYM SER, V697, P389, DOI DOI 10.1021/BK-1998-0697.CH025; Griffiths K, 1996, NUTR CANC; Hehre W. J., 1986, AB INITIO MOL ORBITA; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Karamloo F, 2001, EUR J BIOCHEM, V268, P5310, DOI 10.1046/j.0014-2956.2001.02463.x; Lewis N. G., 1999, COMPREHENSIVE NATURA, V1, P639, DOI DOI 10.1016/B978-0-08-091283-7.00027-8; LWANDE W, 1985, INSECT SCI APPL, V6, P537, DOI 10.1017/S1742758400004379; MARTIN PM, 1978, ENDOCRINOLOGY, V103, P1860, DOI 10.1210/endo-103-5-1860; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OSAWA T, 1985, AGR BIOL CHEM TOKYO, V49, P3351, DOI 10.1080/00021369.1985.10867272; PAIVA NL, 1994, ARCH BIOCHEM BIOPHYS, V312, P501, DOI 10.1006/abbi.1994.1338; PAIVA NL, 1991, PLANT MOL BIOL, V17, P653, DOI 10.1007/BF00037051; Pereira PJB, 2001, NAT STRUCT BIOL, V8, P215, DOI 10.1038/84948; Petrucco S, 1996, PLANT CELL, V8, P69, DOI 10.1105/tpc.8.1.69; Phillips R., 1992, J AM MATH SOC, V5, P1, DOI 10.1090/S0894-0347-1992-1127079-X; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SCHENK PM, 1995, BIOTECHNIQUES, V19, P196; SCHLIEPER D, 1990, PHYTOCHEMISTRY, V29, P1519, DOI 10.1016/0031-9422(90)80112-T; SETCHELL KDR, 1982, FALK S, V31, P93; Teoh K. H., 2003, Flaxseed in human nutrition, P41; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6294, DOI 10.1021/bi970025j; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Thompson LU, 1996, NUTR CANCER, V26, P159, DOI 10.1080/01635589609514472; WATERS AP, 1982, J REPROD FERTIL, V66, P379; Xia ZQ, 2000, PHYTOCHEMISTRY, V55, P537, DOI 10.1016/S0031-9422(00)00242-9; Xia ZQ, 2001, J BIOL CHEM, V276, P12614, DOI 10.1074/jbc.M008622200	49	72	86	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50714	50723		10.1074/jbc.M308493200	http://dx.doi.org/10.1074/jbc.M308493200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	13129921	hybrid			2022-12-25	WOS:000187068200127
J	Yamagami, T; Tsuchisaka, A; Yamada, K; Haddon, WF; Harden, LA; Theologis, A				Yamagami, T; Tsuchisaka, A; Yamada, K; Haddon, WF; Harden, LA; Theologis, A			Biochemical diversity among the 1-amino-cyclopropane-1-carboxylate synthase isozymes encoded by the Arabidopsis gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID SYNTHASE; ETHYLENE BIOSYNTHESIS; ESCHERICHIA-COLI; KEY ENZYME; ASPARTATE-AMINOTRANSFERASE; DIFFERENTIAL EXPRESSION; MULTIGENE FAMILY; ACTIVE-SITE; WILD-TYPE; TOMATO	1-Amino-cyclopropane-1-carboxylate synthase (ACS, EC 4.4.1.14) is the key enzyme in the ethylene biosynthetic pathway in plants. The completion of the Arabidopsis genome sequence revealed the presence of twelve putative ACS genes, ACS1-12, dispersed among five chromosomes. ACS1-5 have been previously characterized. However, ACS1 is enzymatically inactive whereas ACS3 is a pseudogene. Complementation analysis with the Escherichia coli aminotransferase mutant DL39 shows that ACS10 and 12 encode aminotransferases. The remaining eight genes are authentic ACS genes and together with ACS1 constitute the Arabidopsis ACS gene family. All genes, except ACS3, are transcriptionally active and differentially expressed during Arabidopsis growth and development. IAA induces all ACS genes, except ACS7 and ACS9; CHX enhances the expression of all functional ACS genes. The ACS genes were expressed in E. coli, purified to homogeneity by affinity chromatography, and biochemically characterized. The quality of the recombinant proteins was verified by N-terminal amino acid sequence and MALDI-TOF mass spectrometry. The analysis shows that all ACS isozymes function as dimers and have an optimum pH, ranging between 7.3 and 8.2. Their K-m values for AdoMet range from 8.3 to 45 muM, whereas their k(cat) values vary from 0.19 to 4.82 s(-1) per monomer. Their K-i values for AVG and sinefungin vary from 0.019 to 0.80 muM and 0.15 to 12 muM, respectively. The results indicate that the Arabidopsis ACS isozymes are biochemically distinct. It is proposed that biochemically diverse ACS isozymes function in unique cellular environments for the biosynthesis of C2H4, permitting the signaling molecule to exert its unique effects in a tissue- or cell-specific fashion.	USDA, Ctr Plant Gene Express, Albany, CA 94710 USA; USDA, Food Safety & Hlth Res Unit, Western Reg Res Ctr, Albany, CA 94710 USA	United States Department of Agriculture (USDA); United States Department of Agriculture (USDA)	Theologis, A (corresponding author), USDA, Ctr Plant Gene Express, Albany, CA 94710 USA.	theo@nature.berkeley.edu						Abeles F, 1992, ETHYLENE PLANT BIOL; An YQ, 1996, PLANT J, V10, P107, DOI 10.1046/j.1365-313X.1996.10010107.x; Arabidopsis Genome Initiative, 2000, Nature (London), V408, P796, DOI 10.1038/35048692; Arteca JM, 1999, PLANT MOL BIOL, V39, P209, DOI 10.1023/A:1006177902093; Barry CS, 1996, PLANT J, V9, P525, DOI 10.1046/j.1365-313X.1996.09040525.x; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; Bazzanella A, 1998, J CHROMATOGR A, V809, P231, DOI 10.1016/S0021-9673(98)00144-7; Beh CT, 2001, GENETICS, V157, P1117; BERG CM, 1988, GENE, V65, P195, DOI 10.1016/0378-1119(88)90456-8; Bleecker AB, 2000, ANNU REV CELL DEV BI, V16, P1, DOI 10.1146/annurev.cellbio.16.1.1; BLEECKER AB, 1986, P NATL ACAD SCI USA, V83, P7755, DOI 10.1073/pnas.83.20.7755; BOLLER T, 1979, PLANTA, V145, P293, DOI 10.1007/BF00454455; BOLLER T, 1984, ETHYLENE BIOCH PHYSL, P87; BOTELLA JR, 1993, GENE, V123, P249, DOI 10.1016/0378-1119(93)90132-M; BURNS JK, 1986, PHYSIOL PLANTARUM, V66, P609, DOI 10.1111/j.1399-3054.1986.tb05588.x; Capitani G, 1999, J MOL BIOL, V294, P745, DOI 10.1006/jmbi.1999.3255; Carninci P, 1999, METHOD ENZYMOL, V303, P19; Chae HS, 2003, PLANT CELL, V15, P545, DOI 10.1105/tpc.006882; DESTEFANOBELTRAN LJC, 1995, MOL GEN GENET, V246, P496, DOI 10.1007/BF00290453; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; GRAUR D, 2000, FUNDAMENTALS MOL EVO, P249; GREGERSON RG, 1994, PLANT MOL BIOL, V25, P387, DOI 10.1007/BF00043868; Gu ZL, 2002, TRENDS GENET, V18, P609, DOI 10.1016/S0168-9525(02)02837-8; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HARRIS H, 1979, CIBA F SYMP, V27, P187; Huai Q, 2001, J BIOL CHEM, V276, P38210; HUANG PL, 1991, P NATL ACAD SCI USA, V88, P7021, DOI 10.1073/pnas.88.16.7021; HYODO H, 1985, PLANT CELL PHYSIOL, V26, P161; ICEKSON I, 1983, BIOCHEM BIOPH RES CO, V113, P586, DOI 10.1016/0006-291X(83)91766-7; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI N, 1994, J BIOL CHEM, V269, P6908; Li YS, 1997, BIOCHEMISTRY-US, V36, P15477, DOI 10.1021/bi971625l; Liang XW, 1995, GENE, V167, P17, DOI 10.1016/0378-1119(95)00694-X; LIANG XW, 1992, P NATL ACAD SCI USA, V89, P11046, DOI 10.1073/pnas.89.22.11046; Liang XW, 1996, PLANT J, V10, P1027, DOI 10.1046/j.1365-313X.1996.10061027.x; LINCOLN JE, 1993, J BIOL CHEM, V268, P19422; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; LIZADA MCC, 1979, ANAL BIOCHEM, V100, P140, DOI 10.1016/0003-2697(79)90123-4; Lochmann H, 1998, J CHROMATOGR A, V817, P337, DOI 10.1016/S0021-9673(98)00383-5; McCarthy DL, 2001, BIOCHEMISTRY-US, V40, P12276, DOI 10.1021/bi011050z; MEHTA PK, 1994, BIOCHEM BIOPH RES CO, V198, P138, DOI 10.1006/bbrc.1994.1020; MEHTA PK, 1989, EUR J BIOCHEM, V186, P249, DOI 10.1111/j.1432-1033.1989.tb15202.x; MIURA GA, 1985, ANAL BIOCHEM, V147, P217, DOI 10.1016/0003-2697(85)90030-2; MIYAZAKI JH, 1987, PHYTOCHEMISTRY, V26, P2655, DOI 10.1016/S0031-9422(00)83566-9; NAKAGAWA N, 1988, PLANT CELL PHYSIOL, V29, P1255; NAKAJIMA N, 1990, PLANT CELL PHYSIOL, V31, P1021; NAKAJIMA N, 1986, PLANT CELL PHYSIOL, V27, P969; Nowak MA, 1997, NATURE, V388, P167, DOI 10.1038/40618; OELLER PW, 1991, SCIENCE, V254, P437, DOI 10.1126/science.1925603; OLSON DC, 1991, P NATL ACAD SCI USA, V88, P5340, DOI 10.1073/pnas.88.12.5340; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; ROTTMANN WH, 1991, J MOL BIOL, V222, P937, DOI 10.1016/0022-2836(91)90587-V; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO T, 1991, J BIOL CHEM, V266, P3752; SATO T, 1989, P NATL ACAD SCI USA, V86, P6621, DOI 10.1073/pnas.86.17.6621; SATOH S, 1993, CURR PLANT SCI BIOT, V16, P7; SATOH S, 1988, PLANT PHYSIOL, V88, P109, DOI 10.1104/pp.88.1.109; SCHUNCK B, 1995, J VIROL METHODS, V55, P427, DOI 10.1016/0166-0934(95)00069-3; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Tarun AS, 1998, J BIOL CHEM, V273, P12509, DOI 10.1074/jbc.273.20.12509; Tarun AS, 1998, P NATL ACAD SCI USA, V95, P9796, DOI 10.1073/pnas.95.17.9796; Tatsuki M, 2001, J BIOL CHEM, V276, P28051, DOI 10.1074/jbc.M101543200; THEOLOGIS A, 1993, DEV GENET, V14, P282, DOI 10.1002/dvg.1020140406; Thomma BPHJ, 2001, CURR OPIN IMMUNOL, V13, P63, DOI 10.1016/S0952-7915(00)00183-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vogel JP, 1998, P NATL ACAD SCI USA, V95, P4766, DOI 10.1073/pnas.95.8.4766; Wang KLC, 2002, PLANT CELL, V14, pS131, DOI 10.1105/tpc.001768; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; WHITE MF, 1994, P NATL ACAD SCI USA, V91, P12428, DOI 10.1073/pnas.91.26.12428; Woeste KE, 1999, PLANT PHYSIOL, V119, P521, DOI 10.1104/pp.119.2.521; YANG SF, 1993, BOT BULL ACAD SINICA, V34, P89; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; YIP WK, 1990, P NATL ACAD SCI USA, V87, P7930, DOI 10.1073/pnas.87.20.7930; YIP WK, 1992, P NATL ACAD SCI USA, V89, P2475, DOI 10.1073/pnas.89.6.2475; YOSHII H, 1981, PLANT CELL PHYSIOL, V22, P369; YU YB, 1979, ARCH BIOCHEM BIOPHYS, V198, P280, DOI 10.1016/0003-9861(79)90420-X; ZAREMBINSKI TI, 1994, PLANT MOL BIOL, V26, P1579, DOI 10.1007/BF00016491	79	249	279	3	50	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49102	49112		10.1074/jbc.M308297200	http://dx.doi.org/10.1074/jbc.M308297200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12968022	hybrid			2022-12-25	WOS:000186829000073
J	Chowdhury, S; Ragaz, C; Kreuger, E; Narberhaus, F				Chowdhury, S; Ragaz, C; Kreuger, E; Narberhaus, F			Temperature-controlled structural alterations of an RNA thermometer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOSENSOR CONTROLS EXPRESSION; MESSENGER-RNA; BRADYRHIZOBIUM-JAPONICUM; SMALL MOLECULES; GENE; PROTEIN; TRANSCRIPTION; TRANSLATION; SIGMA(32); HOMOLOGS	Thermoresponsive structures in the 5'-untranslated region of mRNA are known to control translation of heat shock and virulence genes. Expression of many rhizobial heat shock genes is regulated by a conserved sequence element called ROSE for repression of heat shock gene expression. This cis-acting, untranslated mRNA is thought to prevent ribosome access at low temperature through an extended secondary structure, which partially melts when the temperature rises. We show here by a series of in vivo and in vitro approaches that ROSE is a sensitive thermometer responding in the physiologically relevant temperature range between 30 and 40 degreesC. Point mutations predicted to disrupt base pairing enhanced expression at 30 degreesC. Compensatory mutations restored repression, emphasizing the importance of secondary structures in the sensory RNA. Only moderate inducibility of a 5'-truncated ROSE variant suggests that interactions between individual stem loops coordinate temperature sensing. In the presence of a complementary oligonucleotide, the functionally important stem loop of ROSE was rendered susceptible to RNase H treatment at heat shock temperatures. Since major structural rearrangements were not observed during UV and CD spectroscopy, subtle structural changes involving the Shine-Dalgarno sequence are proposed to mediate translational control. Temperature perception by the sensory RNA is an ordered process that most likely occurs without the aid of accessory factors.	ETH, Inst Microbiol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Narberhaus, F (corresponding author), ETH, Inst Microbiol, Schmelzbergstr 7, CH-8092 Zurich, Switzerland.	fnarber@micro.biol.ethz.ch	Taylor, Graham/A-4027-2012	Narberhaus, Franz/0000-0002-8552-5310; Kreuger, Emma/0000-0002-7797-8854				ALTUVIA S, 1989, J MOL BIOL, V210, P265, DOI 10.1016/0022-2836(89)90329-X; Epshtein V, 2003, P NATL ACAD SCI USA, V100, P5052, DOI 10.1073/pnas.0531307100; Gross CA, 1996, ESCHERICHIA COLI SAL, P1382; HOE NP, 1993, J BACTERIOL, V175, P7901, DOI 10.1128/JB.175.24.7901-7909.1993; Johansson J, 2002, CELL, V110, P551, DOI 10.1016/S0092-8674(02)00905-4; Konkel ME, 2000, MICROBES INFECT, V2, P157, DOI 10.1016/S1286-4579(00)00272-0; KULLIK I, 1991, J BACTERIOL, V173, P1125, DOI 10.1128/jb.173.3.1125-1138.1991; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lai EC, 2003, CURR BIOL, V13, pR285, DOI 10.1016/S0960-9822(03)00203-3; McDaniel BAM, 2003, P NATL ACAD SCI USA, V100, P3083, DOI 10.1073/pnas.0630422100; Minder AC, 2000, J BACTERIOL, V182, P14, DOI 10.1128/JB.182.1.14-22.2000; Mironov AS, 2002, CELL, V111, P747, DOI 10.1016/S0092-8674(02)01134-0; Morita M, 1999, J BACTERIOL, V181, P401, DOI 10.1128/JB.181.2.401-410.1999; Morita MT, 1999, GENE DEV, V13, P655, DOI 10.1101/gad.13.6.655; Munchbach M, 1999, J BACTERIOL, V181, P83; NAKAHIGASHI K, 1995, NUCLEIC ACIDS RES, V23, P4383; Narberhaus F, 1996, J BACTERIOL, V178, P5337, DOI 10.1128/jb.178.18.5337-5346.1996; Narberhaus F, 2002, ARCH MICROBIOL, V178, P404, DOI 10.1007/s00203-002-0481-8; Narberhaus F, 1998, ARCH MICROBIOL, V169, P89, DOI 10.1007/s002030050547; Narberhaus F, 1998, MOL MICROBIOL, V28, P315, DOI 10.1046/j.1365-2958.1998.00794.x; Nocker A, 2001, NUCLEIC ACIDS RES, V29, P4800, DOI 10.1093/nar/29.23.4800; Nocker A, 2001, ARCH MICROBIOL, V176, P44, DOI 10.1007/s002030100294; Nou XW, 1998, J BACTERIOL, V180, P6719, DOI 10.1128/JB.180.24.6719-6728.1998; Nou XW, 2000, P NATL ACAD SCI USA, V97, P7190, DOI 10.1073/pnas.130013897; Ravnum S, 2001, MOL MICROBIOL, V39, P1585, DOI 10.1046/j.1365-2958.2001.02346.x; REGENSBURGER B, 1983, ARCH MICROBIOL, V135, P103, DOI 10.1007/BF00408017; Repoila F, 2001, J BACTERIOL, V183, P4012, DOI 10.1128/JB.183.13.4012-4023.2001; Sambrook J, 2001, MOL CLONING LAB MANU; Serganov A, 2003, EMBO J, V22, P1898, DOI 10.1093/emboj/cdg170; Stormo GD, 2001, P NATL ACAD SCI USA, V98, P9465, DOI 10.1073/pnas.181334498; Storz G, 1999, GENE DEV, V13, P633, DOI 10.1101/gad.13.6.633; Weisberg RA, 2002, MOL CELL, V10, P1266, DOI 10.1016/S1097-2765(02)00788-8; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145; Winkler WC, 2002, P NATL ACAD SCI USA, V99, P15908, DOI 10.1073/pnas.212628899; Yamanaka K, 1999, J BACTERIOL, V181, P6284, DOI 10.1128/JB.181.20.6284-6291.1999; Yura T, 2000, BACTERIAL STRESS RESPONSES, P3; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	37	76	78	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47915	47921		10.1074/jbc.M306874200	http://dx.doi.org/10.1074/jbc.M306874200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12963744	hybrid			2022-12-25	WOS:000186731400069
J	Sohn, J; Youn, HS; Jeoung, MK; Koo, YB; Yi, CS; Ji, I; Ji, TH				Sohn, J; Youn, HS; Jeoung, MK; Koo, YB; Yi, CS; Ji, I; Ji, TH			Orientation of follicle-stimulating hormone (FSH) subunits complexed with the FSH receptor - beta subunit toward the N terminus of exodomain and alpha subunit to exoloop 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; CHORIONIC-GONADOTROPIN RECEPTOR; LEUCINE-RICH REPEATS; EXTRACELLULAR DOMAIN; LIGAND INTERACTIONS; HIGH-AFFINITY; HINGE REGION; LH RECEPTOR; BINDING; PROTEIN	Follicle-stimulating hormone (FSH) comprises an alpha subunit and a beta subunit, whereas the FSH receptor consists of two halves with distinct functions: the N-terminal extracellular exodomain and C-terminal membrane-associated endodomain. FSH initially binds to exodomain, and the resulting FSH/exodomain complex modulates the endodomain and generates signal. However, it has been difficult to determine which subunit of FSH contacts the exodomain or endodomain and in what orientation FSH interacts with them. To address these crucial issues, the receptor was Ala-scanned and the hormone subunits were probed with photoaffinity labeling with receptor peptides corresponding to the N-terminal region of the exodomain and exoloop 3 of the endodomain. Our results show that both regions of the receptors are important for hormone binding and signal generation. In addition, the FSH beta subunit is specifically labeled with the N-terminal peptide, whereas the alpha subunit is labeled with the exoloop 3 peptide. These contrasting results show that the FSH beta subunit is close to the N-terminal region and that the alpha subunit is projected toward exoloop 3 in the endodomain. The results raise the fundamental question whether the alpha subunit, common among the glycoprotein hormones, plays a major role in generating the hormone signal common to all glycoprotein hormones.	Univ Kentucky, Dept Chem, Lexington, KY 40506 USA; Univ Kentucky, Dept Biol, Lexington, KY 40506 USA	University of Kentucky; University of Kentucky	Ji, TH (corresponding author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.				NICHD NIH HHS [HD-18702] Funding Source: Medline; NIDDK NIH HHS [DK-51469] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGELOVA K, 2002, J BIOL CHEM, V17, P17; Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; Babu P S, 1999, Mol Cell Biol Res Commun, V2, P21, DOI 10.1006/mcbr.1999.0139; Bayley H, 1983, PHOTOGENERATED REAGE; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Bradbury FA, 1997, J BIOL CHEM, V272, P5921, DOI 10.1074/jbc.272.9.5921; Couture L, 1996, J MOL ENDOCRINOL, V16, P15, DOI 10.1677/jme.0.0160015; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; Dias JA, 1998, BIOL REPROD, V58, P1331, DOI 10.1095/biolreprod58.6.1331; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; Fox KM, 2001, MOL ENDOCRINOL, V15, P378, DOI 10.1210/me.15.3.378; Garcia-Campayo V, 2002, ENDOCRINOLOGY, V143, P3773, DOI 10.1210/en.2002-220336; Hong SH, 1998, J BIOL CHEM, V273, P13835, DOI 10.1074/jbc.273.22.13835; Hong SH, 1997, J BIOL CHEM, V272, P4166, DOI 10.1074/jbc.272.7.4166; Jackson AM, 1999, MOL ENDOCRINOL, V13, P2175, DOI 10.1210/me.13.12.2175; JI I, 1993, J BIOL CHEM, V268, P20851; JI I, 1980, P NATL ACAD SCI-BIOL, V77, P7167, DOI 10.1073/pnas.77.12.7167; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; Ji IH, 1995, ENDOCRINE, V3, P907, DOI 10.1007/BF02738896; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KAUER JC, 1986, J BIOL CHEM, V261, P695; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; Nakabayashi K, 2000, J BIOL CHEM, V275, P30264, DOI 10.1074/jbc.M005568200; Narayan P, 2002, MOL ENDOCRINOL, V16, P2733, DOI 10.1210/me.2002-0208; Nechamen CA, 2003, MOL CELL ENDOCRINOL, V201, P123, DOI 10.1016/S0303-7207(02)00424-0; Nechamen CA, 2000, MOL CELL ENDOCRINOL, V166, P101, DOI 10.1016/S0303-7207(00)00281-1; Nishi S, 2002, J BIOL CHEM, V277, P3958, DOI 10.1074/jbc.M109617200; Osuga Y, 1997, MOL ENDOCRINOL, V11, P1659, DOI 10.1210/me.11.11.1659; Phang T, 1998, J BIOL CHEM, V273, P13841, DOI 10.1074/jbc.273.22.13841; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; ROCHE PC, 1985, LUTEINIZING HORMONE, P17; ROZELL T, 1995, MOL ENDOCRINOL, P1727; Schmidt A, 2001, J BIOL CHEM, V276, P23373, DOI 10.1074/jbc.M100057200; SEETHARAMAIAH GS, 1994, ENDOCRINOLOGY, V134, P549, DOI 10.1210/en.134.2.549; Sohn J, 2002, J BIOL CHEM, V277, P50165, DOI 10.1074/jbc.M207646200; Song YS, 2001, J BIOL CHEM, V276, P3426, DOI 10.1074/jbc.M003772200; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; Tao YX, 2002, MOL ENDOCRINOL, V16, P1881, DOI 10.1210/me.2001-0199; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; Vischer HF, 2003, J BIOL CHEM, V278, P15505, DOI 10.1074/jbc.M300634200; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; XIE YB, 1990, J BIOL CHEM, V265, P21411; Zeng HW, 2001, J BIOL CHEM, V276, P3451, DOI 10.1074/jbc.M007488200	52	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47868	47876		10.1074/jbc.M307751200	http://dx.doi.org/10.1074/jbc.M307751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12963710	hybrid			2022-12-25	WOS:000186731400064
J	Hwang, J; Saha, A; Boo, YC; Sorescu, GP; McNally, JS; Holland, SM; Dikalov, S; Giddens, DP; Griendling, KK; Harrison, DG; Jo, H				Hwang, J; Saha, A; Boo, YC; Sorescu, GP; McNally, JS; Holland, SM; Dikalov, S; Giddens, DP; Griendling, KK; Harrison, DG; Jo, H			Oscillatory shear stress stimulates endothelial production of O2- from p47(phox)-dependent NAD(P)H oxidases, leading to monocyte adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; HUMAN CAROTID BIFURCATION; PROTEIN-KINASE-A; NADPH OXIDASE; SUPEROXIDE-DISMUTASE; UP-REGULATION; CELLS; ATHEROSCLEROSIS; EXPRESSION; FLOW	Arterial regions exposed to oscillatory shear (OS) in branched arteries are lesion-prone sites of atherosclerosis, whereas those of laminar shear (LS) are relatively well protected. Here, we examined the hypothesis that OS and LS differentially regulate production of O-2(-) from the endothelial NAD(P)H oxidase, which, in turn, is responsible for their opposite effects on a critical atherogenic event, monocyte adhesion. We used aortic endothelial cells obtained from C57BL/6 (MAE-C57) and p47(phox-/-) (MAE- p47(-/-)) mice, which lack a component of NAD(P)H oxidase. O-2(-) production was determined by dihydroethidium staining and an electron spin resonance using an electron spin trap methoxycarbonyl-2,2,5,5- tetramethyl-pyrrolidine. Chronic exposure (18 h) to an arterial level of OS (+/- 5 dynes/cm(2)) increased O-2(-) (2-fold) and monocyte adhesion (3-fold) in MAE-C57 cells, whereas chronic LS (15 dynes/cm(2), 18 h) significantly decreased both monocyte adhesion and O-2(-) compared with static conditions. In contrast, neither LS nor OS were able to induce O-2(-) production and monocyte adhesion to MAE- p47(-/-). Treating MAE-C57 with a cell-permeable superoxide dismutase compound, polyethylene glycol-superoxide dismutase, also inhibited OS-induced monocyte adhesion. In addition, over-expressing p47(phox) in MAE-p47(-/-) restored OS-induced O-2(-) production and monocyte adhesion. These results suggest that chronic exposure of endothelial cells to OS stimulates O-2(-) and/or its derivatives produced from p47(phox)-dependent NAD(P) H oxidase, which, in turn, leads to monocyte adhesion, an early and critical atherogenic event.	Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30322 USA; Emory Univ, Div Cardiol, Atlanta, GA 30322 USA; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA	University System of Georgia; Georgia Institute of Technology; Emory University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jo, H (corresponding author), Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30322 USA.		Jo, Hanjoong/L-6216-2019; Giddens, Don P/AAD-5531-2019	Jo, Hanjoong/0000-0003-1833-372X; Boo, Yong Chool/0000-0001-9895-2066; Dikalov, Sergey/0000-0003-2976-6184; Griendling, Kathy/0000-0002-9456-8582	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071014, R01HL067413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 71014, HL 67413] Funding Source: Medline; NIGMS NIH HHS [T32 GM008169] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babior BM, 2002, ISRAEL MED ASSOC J, V4, P1023; Berk BC, 2001, ANN NY ACAD SCI, V947, P93; Boo YC, 2002, AM J PHYSIOL-HEART C, V283, pH1819, DOI 10.1152/ajpheart.00214.2002; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; Chappell DC, 1998, CIRC RES, V82, P532, DOI 10.1161/01.RES.82.5.532; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; Dimmeler S, 1999, ARTERIOSCL THROM VAS, V19, P656, DOI 10.1161/01.ATV.19.3.656; Endres M, 1997, STROKE, V28, P77, DOI 10.1161/01.STR.28.1.77; Garcia-Cardena G, 2001, P NATL ACAD SCI USA, V98, P4478, DOI 10.1073/pnas.071052598; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; Go YM, 1998, AM J PHYSIOL-HEART C, V275, pH1898, DOI 10.1152/ajpheart.1998.275.5.H1898; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Holland JA, 2000, ENDOTHELIUM-J ENDOTH, V7, P109, DOI 10.3109/10623320009072206; JACKSON SH, 1995, J EXP MED, V182, P751, DOI 10.1084/jem.182.3.751; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293; Kuzkaya N, 2003, J BIOL CHEM, V278, P22546, DOI 10.1074/jbc.M302227200; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Landmesser U, 2002, HYPERTENSION, V40, P511, DOI 10.1161/01.HYP.0000032100.23772.98; Li JM, 2002, J BIOL CHEM, V277, P19952, DOI 10.1074/jbc.M110073200; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Patel RP, 2000, FREE RADICAL BIO MED, V28, P1780, DOI 10.1016/S0891-5849(00)00235-5; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sorescu D, 2002, CIRCULATION, V105, P1429, DOI 10.1161/01.CIR.0000012917.74432.66; Sorescu GP, 2003, J BIOL CHEM, V278, P31128, DOI 10.1074/jbc.M300703200; Suh SH, 1999, PFLUG ARCH EUR J PHY, V438, P612, DOI 10.1007/s004240051084; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Szocs K, 2002, ARTERIOSCL THROM VAS, V22, P21, DOI 10.1161/hq0102.102189; Takeshita S, 2000, BIOCHEM BIOPH RES CO, V273, P66, DOI 10.1006/bbrc.2000.2898; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Tsao PS, 1996, CIRCULATION, V94, P1682, DOI 10.1161/01.CIR.94.7.1682; ZARINS CK, 1983, CIRC RES, V53, P502, DOI 10.1161/01.RES.53.4.502; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4; Ziegler T, 1998, HYPERTENSION, V32, P351, DOI 10.1161/01.HYP.32.2.351	36	229	234	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47291	47298		10.1074/jbc.M305150200	http://dx.doi.org/10.1074/jbc.M305150200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12958309	hybrid, Green Submitted			2022-12-25	WOS:000186569400131
J	Keizer, DW; West, PJ; Lee, EF; Yoshikami, D; Olivera, BM; Bulaj, G; Norton, RS				Keizer, DW; West, PJ; Lee, EF; Yoshikami, D; Olivera, BM; Bulaj, G; Norton, RS			Structural basis for tetrodotoxin-resistant sodium channel binding by mu-conotoxin SmIIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SKELETAL-MUSCLE; SYMPATHETIC-GANGLIA; POTASSIUM CHANNELS; AQUEOUS-SOLUTIONS; POTENT INHIBITOR; H-3 SAXITOXIN; SHK TOXIN; GIIIA; NMR	SmIIIA is a new mu-conotoxin isolated recently from Conus stercusmuscarum. Although it shares several biochemical characteristics with other mu-conotoxins ( the arrangement of cysteine residues and a conserved arginine believed to interact with residues near the channel pore), it has several distinctive features, including the absence of hydroxyproline, and is the first specific antagonist of tetrodotoxin-resistant voltage-gated sodium channels to be characterized. It therefore represents a potentially useful tool to investigate the functional roles of these channels. We have determined the three-dimensional structure of SmIIIA in aqueous solution. Consistent with the absence of hydroxyprolines, SmIIIA adopts a single conformation with all peptide bonds in the trans configuration. The spatial orientations of several conserved Arg and Lys side chains, including Arg(14) ( using a consensus numbering system), which plays a key role in sodium channel binding, are similar to those in other mu-conotoxins but the N-terminal regions differ, reflecting the trans conformation for the peptide bond preceding residue 8 in SmIIIA, as opposed to the cis conformation in mu-conotoxins GIIIA and GIIIB. Comparison of the surfaces of SmIIIA with other mu-conotoxins suggests that the affinity of SmIIIA for TTX-resistant channels is influenced by the Trp(15) side chain, which is unique to SmIIIA. Arg(17), which replaces Lys in the other mu-conotoxins, may also be important. Consistent with these inferences from the structure, assays of two chimeras of SmIIIA and PIIIA in which their N- and C-terminal halves were recombined, indicated that residues in the C-terminal half of SmIIIA confer affinity for tetrodotoxin-resistant sodium channels in the cell bodies of frog sympathetic neurons. SmIIIA and the chimera possessing the C-terminal half of SmIIIA also inhibit tetrodotoxin-resistant sodium channels in the postganglionic axons of sympathetic neurons, as indicated by their inhibition of C-neuron compound action potentials that persist in the presence of tetrodotoxin.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Univ Utah, Interdepartmental Program Neurosci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Cognetix Inc, Salt Lake City, UT 84108 USA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Norton, RS (corresponding author), Walter & Eliza Hall Inst Med Res, NMR Lab, 381 Royal Parade, Parkville, Vic 3052, Australia.		Keizer, David/P-9196-2014; Lee, Erinna/N-1523-2015	Keizer, David/0000-0002-0442-0999; Lee, Erinna/0000-0003-1255-9808; Norton, Raymond/0000-0001-8893-0584	NIGMS NIH HHS [GM 48677] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Baxter NJ, 1997, J BIOMOL NMR, V9, P359, DOI 10.1023/A:1018334207887; BECKER S, 1992, BIOCHEMISTRY-US, V31, P8229, DOI 10.1021/bi00150a016; Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; Case DA, 1995, J BIOMOL NMR, V6, P341; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chahine M, 1995, RECEPTOR CHANNEL, V3, P161; CHEN LQ, 1992, FEBS LETT, V309, P253, DOI 10.1016/0014-5793(92)80783-D; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; Dudley SC, 1995, BIOPHYS J, V69, P1657, DOI 10.1016/S0006-3495(95)80045-7; French RJ, 1996, NEURON, V16, P407, DOI 10.1016/S0896-6273(00)80058-6; Goldin AL, 2001, ANNU REV PHYSIOL, V63, P871, DOI 10.1146/annurev.physiol.63.1.871; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hill JM, 1996, BIOCHEMISTRY-US, V35, P8824, DOI 10.1021/bi960073o; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hui Chen, 1996, Life Sciences, V58, P359; Hui KY, 2002, J GEN PHYSIOL, V119, P45, DOI 10.1085/jgp.119.1.45; Jones RM, 2000, CURR PHARM DESIGN, V6, P1249, DOI 10.2174/1381612003399653; JONES SW, 1987, J PHYSIOL-LONDON, V389, P605, DOI 10.1113/jphysiol.1987.sp016674; Kalman K, 1998, J BIOL CHEM, V273, P32697, DOI 10.1074/jbc.273.49.32697; KEIM P, 1973, J BIOL CHEM, V248, P7811; Koradi R, 1996, J MOL GRAPHICS, V14, P29; LANCELIN JM, 1991, BIOCHEMISTRY-US, V30, P6908, DOI 10.1021/bi00242a014; Lanigan MD, 2002, BIOCHEMISTRY-US, V41, P11963, DOI 10.1021/bi026400b; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li RA, 2003, J BIOL CHEM, V278, P8717, DOI 10.1074/jbc.M210882200; Li RA, 2002, FEBS LETT, V511, P159, DOI 10.1016/S0014-5793(01)03316-6; LUDVIGSEN S, 1992, J BIOMOL NMR, V2, P227, DOI 10.1007/BF01875318; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Miles LA, 2002, J BIOL CHEM, V277, P43033, DOI 10.1074/jbc.M206690200; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; MOCZYDLOWSKI E, 1986, P NATL ACAD SCI USA, V83, P5321, DOI 10.1073/pnas.83.14.5321; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nielsen KJ, 2002, J BIOL CHEM, V277, P27247, DOI 10.1074/jbc.M201611200; OHIZUMI Y, 1986, J BIOL CHEM, V261, P6149; OLIVERA BM, 1995, TRENDS BIOTECHNOL, V13, P422, DOI 10.1016/S0167-7799(00)88996-9; OTT KH, 1991, FEBS LETT, V278, P160, DOI 10.1016/0014-5793(91)80107-E; Pennington MW, 1996, BIOCHEM BIOPH RES CO, V219, P696, DOI 10.1006/bbrc.1996.0297; PERUTZ MF, 1985, J MOL BIOL, V183, P491, DOI 10.1016/0022-2836(85)90016-6; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Safo P, 2000, J NEUROSCI, V20, P76, DOI 10.1523/JNEUROSCI.20-01-00076.2000; SATO K, 1991, J BIOL CHEM, V266, P16989; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SEAVEY B R, 1991, Journal of Biomolecular NMR, V1, P217, DOI 10.1007/BF01875516; SELYANKO AA, 1990, J PHYSIOL-LONDON, V425, P471, DOI 10.1113/jphysiol.1990.sp018114; SHIRE SJ, 1974, BIOCHEMISTRY-US, V13, P2967, DOI 10.1021/bi00711a028; Shon KJ, 1998, J NEUROSCI, V18, P4473; SMITH PA, 1994, PROG NEUROBIOL, V43, P439, DOI 10.1016/0301-0082(94)90062-0; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TANOKURA M, 1976, BIOPOLYMERS, V15, P393, DOI 10.1002/bip.1976.360150215; Tavazoie SF, 1997, BRIT J PHARMACOL, V120, P995, DOI 10.1038/sj.bjp.0700993; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P12577, DOI 10.1021/bi00165a006; West PJ, 2002, BIOCHEMISTRY-US, V41, P15388, DOI 10.1021/bi0265628	55	50	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46805	46813		10.1074/jbc.M309222200	http://dx.doi.org/10.1074/jbc.M309222200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12970353	hybrid			2022-12-25	WOS:000186569400072
J	Robbe, C; Capon, C; Maes, E; Rousset, M; Zweibaum, A; Zanetta, JP; Michalski, JC				Robbe, C; Capon, C; Maes, E; Rousset, M; Zweibaum, A; Zanetta, JP; Michalski, JC			Evidence of regio-specific glycosylation in human intestinal mucins - Presence of an acidic gradient along the intestinal tract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP-A; BRONCHIAL-MUCUS GLYCOPROTEINS; HOST-MICROBIAL INTERACTIONS; WEIGHT SALIVARY MUCIN; HUMAN COLONIC MUCIN; OLIGOSACCHARIDE-ALDITOLS; H-1-NMR SPECTROSCOPY; MAMMALIAN INTESTINE; ANTIGEN EXPRESSION; CYSTIC-FIBROSIS	Mucin glycans were isolated from different regions of the normal human intestine (ileum, cecum, transverse and sigmoid colon, and rectum) of two individuals with ALe(b) blood group. A systematic study of the monosaccharides and oligosaccharide alditols released by reductive beta-elimination from mucins was performed using gas chromatography, matrix-assisted laser desorption ionization time-of-flight mass spectrometry, and nuclear magnetic resonance spectroscopy techniques. Important variations were observed in the mucin-associated oligosaccharide content with an increasing gradient of sialic acid from the ileum to the colon associated with a reverse gradient of fucose. Moreover, a comparative study of the Sda/Cad and ABH blood group determinants along the gastrointestinal tract showed the same reverse distribution in the two kinds of antigens. In addition, besides their heterogeneity, sialic acids presented considerable variations in the degree of O-acetylation in relation to glycan sialylation level. These data are discussed in view of recent concepts suggesting that the oligosaccharide composition of the gut constitutes a varied ecosystem for microorganisms that are susceptible to adapt there and possess the specific adhesion system and specific enzymes able to provide a carbohydrate nutrient.	Univ Sci & Technol Lille, Unite Glycobiol Struct & Fonct, Unite Mixte Rech CNRS USTL 8576, IFR 118, F-59655 Villeneuve Dascq, France; Fac Sci Pharmaceut & Biol Lille 2, Biochim Lab, F-59006 Lille, France; Inst Biomed Cordeliers, UMR INSERM UPMC U505, F-75006 Paris, France	Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Michalski, JC (corresponding author), Univ Sci & Technol Lille, Unite Glycobiol Struct & Fonct, Unite Mixte Rech CNRS USTL 8576, IFR 118, F-59655 Villeneuve Dascq, France.			Robbe Masselot, Catherine/0000-0001-6266-6033				AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; Bansil R, 1996, MACROMOL SYMP, V109, P105, DOI 10.1002/masy.19961090110; BREG J, 1987, EUR J BIOCHEM, V168, P57, DOI 10.1111/j.1432-1033.1987.tb13387.x; Bresalier RS, 1996, GASTROENTEROLOGY, V110, P1354, DOI 10.1053/gast.1996.v110.pm8613039; Bulai T, 2003, FEBS LETT, V534, P185, DOI 10.1016/S0014-5793(02)03838-3; Capon C, 2001, BIOCHEM J, V358, P657, DOI 10.1042/bj3580657; Capon C, 1997, J BIOL CHEM, V272, P31957, DOI 10.1074/jbc.272.51.31957; CAPON C, 1989, EUR J BIOCHEM, V182, P39; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; CORFIELD AP, 1992, INFECT IMMUN, V60, P3971, DOI 10.1128/IAI.60.10.3971-3978.1992; Corfield AP, 1999, GLYCOCONJUGATE J, V16, P307, DOI 10.1023/A:1007026314792; DEBOLOS C, 1995, GASTROENTEROLOGY, V109, P723, DOI 10.1016/0016-5085(95)90379-8; Dohi T, 1996, INT J CANCER, V67, P626, DOI 10.1002/(SICI)1097-0215(19960904)67:5<626::AID-IJC6>3.0.CO;2-W; DUA VK, 1986, J BIOL CHEM, V261, P1599; Falk PG, 1998, MICROBIOL MOL BIOL R, V62, P1157, DOI 10.1128/MMBR.62.4.1157-1170.1998; FEENEY J, 1986, CARBOHYD RES, V152, P63, DOI 10.1016/S0008-6215(00)90287-8; Forstner G., 1994, PHYSL GASTROINTESTIN, P1245; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Gordon JI, 1997, AM J PHYSIOL, V273, P565; Groenink J, 1996, ANTON LEEUW INT J G, V70, P79, DOI 10.1007/BF00393572; HOLGERSSON J, 1990, J BIOL CHEM, V265, P20790; Hooper LV, 1998, BIOESSAYS, V20, P336, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;336::AID-BIES10&gt;3.0.CO;2-3; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; Hooper LV, 2002, ANNU REV NUTR, V22, P283, DOI 10.1146/annurev.nutr.22.011602.092259; Hooper LV, 2001, GLYCOBIOLOGY, V11, p1R, DOI 10.1093/glycob/11.2.1R; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KAMERLING JP, 1992, BIOL MAGN RESON, V10, P1; KARLSSON KA, 1995, CURR OPIN STRUC BIOL, V5, P622, DOI 10.1016/0959-440X(95)80054-9; Karlsson NG, 1997, J BIOL CHEM, V272, P27025, DOI 10.1074/jbc.272.43.27025; Kim Young S., 1998, Keio Journal of Medicine, V47, P10; LAMBLIN G, 1984, EUR J BIOCHEM, V143, P227, DOI 10.1111/j.1432-1033.1984.tb08363.x; LAMBLIN G, 1991, AM REV RESPIR DIS, V144, P519; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13655; LEVINE MJ, 1978, INFECT IMMUN, V19, P107, DOI 10.1128/IAI.19.1.107-115.1978; Maes E, 1997, GLYCOCONJUGATE J, V14, P127, DOI 10.1023/A:1018577302255; MALAGOLINI N, 1989, CANCER RES, V49, P6466; MALAGOLINI N, 1991, BIOCHEM BIOPH RES CO, V180, P681, DOI 10.1016/S0006-291X(05)81119-2; Montreuil J, 1986, CARBOHYDRATE ANAL PR, P143; MORTON JA, 1988, IMMUNOL INVEST, V17, P217, DOI 10.3109/08820138809052961; NASIRUDDIN, 1986, J BIOL CHEM, V261, P1992; PILLER F, 1986, CARBOHYD RES, V149, P171, DOI 10.1016/S0008-6215(00)90376-8; PODOLSKY DK, 1985, J BIOL CHEM, V260, P5510; PODOLSKY DK, 1985, J BIOL CHEM, V260, P8262; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; Prakobphol A, 1998, BIOCHEMISTRY-US, V37, P4916, DOI 10.1021/bi972612a; Prakobphol A, 1999, BIOCHEMISTRY-US, V38, P6817, DOI 10.1021/bi990145m; Reddy MS, 1996, INFECT IMMUN, V64, P1477, DOI 10.1128/IAI.64.4.1477-1479.1996; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; SCHAUER R, 1997, GLYCOPROTEINS 2 B, V29, P243; SLOMIANY BL, 1980, J BIOL CHEM, V255, P9719; STRECKER G, 1992, BIOCHIMIE, V74, P39, DOI 10.1016/0300-9084(92)90182-E; STRECKER G, 1989, GLYCOCONJUGATE J, V6, P271, DOI 10.1007/BF01047847; VANDERREIJDEN WA, 1993, BIORHEOLOGY, V30, P141; VANHALBEEK H, 1982, EUR J BIOCHEM, V127, P7; VANHALBEEK H, 1988, EUR J BIOCHEM, V177, P443; VANKLINKEN BJ, 1995, AM J PHYSIOL, V269, P613; WIERUSZESKI JM, 1990, GLYCOCONJUGATE J, V7, P13, DOI 10.1007/BF01050400; WU AM, 1994, MOL CELL BIOCHEM, V137, P39, DOI 10.1007/BF00926038; Zanetta JP, 2001, GLYCOBIOLOGY, V11, P663, DOI 10.1093/glycob/11.8.663; ZWEIBAUM A, 1975, TISSUE ANTIGENS, V6, P121	63	144	147	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46337	46348		10.1074/jbc.M302529200	http://dx.doi.org/10.1074/jbc.M302529200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12952970	hybrid			2022-12-25	WOS:000186569400017
J	Zhang, Q; Chieu, HK; Low, CP; Zhang, SC; Heng, CK; Yang, HY				Zhang, Q; Chieu, HK; Low, CP; Zhang, SC; Heng, CK; Yang, HY			Schizosaccharomyces pombe cells deficient in triacylglycerols synthesis undergo apoptosis upon entry into the stationary phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DIACYLGLYCEROL ACYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; ACYL-COENZYME; PATHWAY; DEATH; IDENTIFICATION; CLONING; ESTERIFICATION	Triacylglycerols ( TAG) are important energy storage molecules for nearly all eukaryotic organisms. In this study, we found that two gene products ( Plh1p and Dga1p) are responsible for the terminal step of TAG synthesis in the fission yeast Schizosaccharomyces pombe through two different mechanisms: Plh1p is a phospholipid diacylglycerol acyltransferase, whereas Dga1p is an acyl- CoA: diacylglycerol acyltransferase. Cells with both dga1(+) and plh1(+) deleted ( DKO cells) lost viability upon entry into the stationary phase and demonstrated prominent apoptotic markers. Exponentially growing DKO cells also underwent dramatic apoptosis when briefly treated with diacylglycerols ( DAGs) or free fatty acids. We provide strong evidence suggesting that DAG, not sphingolipids, mediates fatty acids- induced lipoapoptosis in yeast. Lastly, we show that generation of reactive oxygen species is essential to lipoapoptosis.	Natl Univ Singapore, Fac Med, Dept Biochem, Singapore 119260, Singapore; Natl Univ Singapore, Fac Med, Dept Pediat, Singapore 119260, Singapore	National University of Singapore; National University of Singapore	Yang, HY (corresponding author), Natl Univ Singapore, Fac Med, Dept Biochem, Singapore 119260, Singapore.	bchyangr@nus.edu.sg	Heng, Chew-Kiat/A-5530-2009; Yang, Hongyuan/AAR-1326-2020	Heng, Chew-Kiat/0000-0002-7309-9473; Yang, Hongyuan/0000-0002-8482-6031				Alvarez ME, 1998, CELL, V92, P773, DOI 10.1016/S0092-8674(00)81405-1; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; Bergman RN, 2000, TRENDS ENDOCRIN MET, V11, P351, DOI 10.1016/S1043-2760(00)00323-4; Buszczak M, 2002, GENETICS, V160, P1511; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Cheng JJ, 2003, MOL CELL BIOL, V23, P163, DOI 10.1128/MCB.23.1.163-177.2003; Craven RA, 1998, GENE, V221, P59, DOI 10.1016/S0378-1119(98)00434-X; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Dahlqvist A, 2000, P NATL ACAD SCI USA, V97, P6487, DOI 10.1073/pnas.120067297; Farese RV, 2000, CURR OPIN LIPIDOL, V11, P229, DOI 10.1097/00041433-200006000-00002; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; Forsburg SL, 1999, TRENDS GENET, V15, P340, DOI 10.1016/S0168-9525(99)01798-9; Gangar A, 2002, BIOCHEM J, V365, P577, DOI 10.1042/bj20011654; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P110; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Lardizabal KD, 2001, J BIOL CHEM, V276, P38862, DOI 10.1074/jbc.M106168200; LEHNER R, 1993, J BIOL CHEM, V268, P8781; Li TW, 2000, BIOCHEM BIOPH RES CO, V272, P270, DOI 10.1006/bbrc.2000.2767; LIGHTNER VA, 1983, J BIOL CHEM, V258, P856; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Listenberger LL, 2001, J BIOL CHEM, V276, P14890, DOI 10.1074/jbc.M010286200; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Madeo F, 2002, CURR GENET, V41, P208, DOI 10.1007/s00294-002-0310-2; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Mazzoni C, 2003, MOL BIOL CELL, V14, P721, DOI 10.1091/mbc.E02-05-0258; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Oelkers P, 2000, J BIOL CHEM, V275, P15609, DOI 10.1074/jbc.C000144200; Oelkers P, 2002, J BIOL CHEM, V277, P8877, DOI 10.1074/jbc.M111646200; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; Perez P, 2002, J BIOCHEM, V132, P513, DOI 10.1093/oxfordjournals.jbchem.a003250; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; Sandager L, 2002, J BIOL CHEM, V277, P6478, DOI 10.1074/jbc.M109109200; Severin FF, 2002, CURR BIOL, V12, pR233, DOI 10.1016/S0960-9822(02)00776-5; Song Y, 1999, MOL BIOL CELL, V10, P1609, DOI 10.1091/mbc.10.5.1609; Toone WM, 1998, GENES CELLS, V3, P485, DOI 10.1046/j.1365-2443.1998.00211.x; Unger RH, 2002, BBA-MOL CELL BIOL L, V1585, P202, DOI 10.1016/S1388-1981(02)00342-6; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WernerWashburne M, 1996, MOL MICROBIOL, V19, P1159, DOI 10.1111/j.1365-2958.1996.tb02461.x; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Zheng ZF, 2001, J BIOL CHEM, V276, P41710, DOI 10.1074/jbc.M104749200; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	52	105	109	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47145	47155		10.1074/jbc.M306998200	http://dx.doi.org/10.1074/jbc.M306998200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12963726	hybrid			2022-12-25	WOS:000186569400113
J	Zhang, ZY; Charsky, C; Kane, PM; Wilkens, S				Zhang, ZY; Charsky, C; Kane, PM; Wilkens, S			Yeast V1-ATPase - Affinity purification and structural features by electron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; V-TYPE ATPASE; CROSS-LINKING; 3-DIMENSIONAL STRUCTURE; PERIPHERAL STALK; DELTA-SUBUNIT; PROTON PUMP; RESOLUTION; F-1-ATPASE; INTERACTS	V-1-ATPase from the yeast Saccharomyces cerevisiae was purified via a FLAG affinity tag introduced into the N terminus of the G subunit. The preparation migrated as a single band in native gel electrophoresis and contained subunits ABCDEFGH ( with subunit C present at substoichiometric amounts) as determined by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. The initial specific Ca-ATPase activity was similar to6 mumol/min/mg. The structure of the yeast V-1-ATPase was studied by electron microscopy of negatively stained and frozen hydrated samples. A 25-Angstrom resolution three-dimensional model of the complex was calculated from two-dimensional projections by the angular reconstitution technique. The model shows six elongated densities arranged in pseudo-3-fold symmetry around a large central cavity. At the top of the molecule, various protrusions can be seen. At the bottom of the complex, two large masses are visible that are connected to the main body of the molecule. Comparison of the yeast V-1 structure with the structure of the intact V1V0-ATPase from bovine brain clathrin-coated vesicles (Wilkens, S., Vasilyeva, E., and Forgac, M. (1999) J. Biol. Chem. 274, 31804 - 31810) indicates that the structure of the isolated V1 from yeast is very similar to the structure of the V-1 domain in the intact V-ATPase complex.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	University of California System; University of California Riverside; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Wilkens, S (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	stephan.wilkens@ucr.edu			NIGMS NIH HHS [GM 58600, R01 GM050322, GM 50322] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322, R01GM058600] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1988, J BIOL CHEM, V263, P8796; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; Charsky CMH, 2000, J BIOL CHEM, V275, P37232, DOI 10.1074/jbc.M006640200; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; Domgall I, 2002, J BIOL CHEM, V277, P13115, DOI 10.1074/jbc.M112011200; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; DUBE P, 1993, EMBO J, V12, P1303, DOI 10.1002/j.1460-2075.1993.tb05775.x; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; Gruber G, 2000, BIOCHEMISTRY-US, V39, P8609, DOI 10.1021/bi000103u; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; KANE PM, 1995, J BIOL CHEM, V270, P17025; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Lu M, 2002, J BIOL CHEM, V277, P38409, DOI 10.1074/jbc.M203521200; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Radermacher M, 2001, J STRUCT BIOL, V135, P26, DOI 10.1006/jsbi.2001.4395; Sagermann M, 2001, P NATL ACAD SCI USA, V98, P7134, DOI 10.1073/pnas.131192798; SCHATZ M, 1995, J STRUCT BIOL, V114, P28, DOI 10.1006/jsbi.1995.1003; SIKORSKI RS, 1989, GENETICS, V122, P19; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Weber J, 2003, J BIOL CHEM, V278, P13623, DOI 10.1074/jbc.C300061200; Wieczorek H, 2000, J EXP BIOL, V203, P127; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 2001, CELL BIOCHEM BIOPHYS, V34, P191, DOI 10.1385/CBB:34:2:191; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; Xie XS, 1996, J BIOL CHEM, V271, P30980; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; Xu T, 2000, J BIOL CHEM, V275, P22075, DOI 10.1074/jbc.M002983200; ZHANG X, 2000, J BIOL CHEM, V275, P35592	47	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47299	47306		10.1074/jbc.M309445200	http://dx.doi.org/10.1074/jbc.M309445200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12960158	hybrid			2022-12-25	WOS:000186569400132
J	Chandrasekharan, MB; Li, GG; Bishop, KJ; Hall, TC				Chandrasekharan, MB; Li, GG; Bishop, KJ; Hall, TC			S phase progression is required for transcriptional activation of the beta-phaseolin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID; CHROMATIN-STRUCTURE; DNA-REPLICATION; GENE-EXPRESSION; KINASE INHIBITOR; TOBACCO; ARREST; ABI3; EMBRYOGENESIS; INDUCTION	Elucidating the mechanisms by which the transcription machinery accesses promoters in their chromatin environment is a fundamental aspect of understanding gene regulation. The phas promoter is normally constrained by a rotationally and translationally positioned nucleosome over its TATA region except during embryogenesis when it is potentiated by the presence of Phaseolus vulgaris ABI3-like factor (PvALF), a plant-specific transcription factor, and activated by an abscisic acid (ABA)-induced signal transduction cascade. Ectopic expression of PvALF and the supply of ABA in transgenic tobacco or Arabidopsis leaves can activate expression from phas. We confirmed by [H-3] thymidine incorporation that active DNA replication occurred concomitant with the presence of PvALF and ABA. Arrest of DNA synthesis or S phase progression by infiltration of the leaves with replication inhibitors (hydroxyurea, roscovitine, mimosine) strongly inhibited transcriptional activation, especially the ABA-mediated activation step. Similarly, activation of endogenous Arabidopsis MAT and LEA genes in leaf tissue by the presence of ABA and ectopically expressed PvALF was inhibited by DNA replication arrest. No change in transcript levels on the arrest of replication was detected for abi1, abi2, and era1, negative regulators of the ABA signal transduction cascade or for cell cycle components ick1 and aip3. However, a reduction in transcript accumulation for the crucial ABA signaling effector, abi5, occurred upon DNA replication arrest (probably reflected in the decrease in MAT and LEA gene expression). Contrary to the conventional view that ABA inhibits DNA replication, our findings show that ABA acts in concert with S phase progression to activate gene expression.	Texas A&M Univ, Inst Dev & Mol Biol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Hall, TC (corresponding author), Texas A&M Univ, Inst Dev & Mol Biol, College Stn, TX 77843 USA.	tim@idmb.tamu.edu	Chandrasekharan, Mahesh/AAF-4793-2020	Chandrasekharan, Mahesh/0000-0002-9956-8354				Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; Bechtold N, 1998, METH MOL B, V82, P259; BINO RJ, 1993, ANN BOT-LONDON, V72, P181, DOI 10.1006/anbo.1993.1097; BOBB AJ, 1995, PLANT J, V8, P331, DOI 10.1046/j.1365-313X.1995.08030331.x; Busk PK, 1998, PLANT MOL BIOL, V37, P425, DOI 10.1023/A:1006058700720; Bustos MM, 1998, PLANT MOL BIOL, V37, P265, DOI 10.1023/A:1005999725715; Chandrasekharan MB, 2003, PLANT J, V33, P853, DOI 10.1046/j.1365-313X.2003.01678.x; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Combettes Bruno, 1999, Methods in Cell Science, V21, P109, DOI 10.1023/A:1009880705257; Cutler S, 1996, SCIENCE, V273, P1239, DOI 10.1126/science.273.5279.1239; DAVIES JW, 1969, ANAL BIOCHEM, V27, P77, DOI 10.1016/0003-2697(69)90221-8; Dewitte W, 2003, ANNU REV PLANT BIOL, V54, P235, DOI 10.1146/annurev.arplant.54.031902.134836; FEDOROFF NV, 2002, SCI STKE; Finkelstein RR, 2002, PLANT CELL, V14, pS15, DOI 10.1105/tpc.010441; Finkelstein RR, 2000, PLANT CELL, V12, P599, DOI 10.1105/tpc.12.4.599; GAMBLE PE, 1986, EUR J BIOCHEM, V160, P117, DOI 10.1111/j.1432-1033.1986.tb09947.x; Gampala SSL, 2002, J BIOL CHEM, V277, P1689, DOI 10.1074/jbc.M109980200; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; Hall TC, 1999, SEED PROTEINS, P209; JACQMARD A, 1995, J EXP BOT, V46, P663, DOI 10.1093/jxb/46.6.663; JEFFERSON RA, 1987, EMBO J, V6, P3901; Jones HD, 2000, PLANT J, V21, P133, DOI 10.1046/j.1365-313x.2000.00662.x; Kirchmaier AL, 2001, SCIENCE, V291, P646, DOI 10.1126/science.291.5504.646; KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x; Kurup S, 2000, PLANT J, V21, P143, DOI 10.1046/j.1365-313x.2000.00663.x; Li GF, 1998, P NATL ACAD SCI USA, V95, P4772, DOI 10.1073/pnas.95.8.4772; Li GF, 1999, P NATL ACAD SCI USA, V96, P7104, DOI 10.1073/pnas.96.12.7104; Li GF, 2001, PLANT MOL BIOL, V46, P121, DOI 10.1023/A:1010693703421; Li GF, 2001, J BIOL CHEM, V276, P2062, DOI 10.1074/jbc.M007504200; LIU YQ, 1994, PLANTA, V194, P368, DOI 10.1007/BF00197537; Lopez-Molina L, 2002, PLANT J, V32, P317, DOI 10.1046/j.1365-313X.2002.01430.x; Lu C, 2002, P NATL ACAD SCI USA, V99, P15812, DOI 10.1073/pnas.242607499; Merlot S, 2001, PLANT J, V25, P295, DOI 10.1046/j.1365-313x.2001.00965.x; Nakamura S, 2001, PLANT J, V26, P627, DOI 10.1046/j.1365-313x.2001.01069.x; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; Planchais S, 1997, PLANT J, V12, P191, DOI 10.1046/j.1365-313X.1997.12010191.x; Planchais S, 2000, FEBS LETT, V476, P78, DOI 10.1016/S0014-5793(00)01675-6; Raz V, 2001, DEVELOPMENT, V128, P243; Rock CD, 2000, NEW PHYTOL, V148, P357, DOI 10.1046/j.1469-8137.2000.00769.x; Siddiqui NU, 1998, PLANT PHYSIOL, V118, P1181, DOI 10.1104/pp.118.4.1181; Sussex I. M., 1979, The plant seed: development, preservation, and germination [Rubinstein, I.; Phillips, R.L.; Green, C.E.; Gengenbach, B.G. (Editors)]., P129; Suzuki M, 2001, PLANT J, V28, P409, DOI 10.1046/j.1365-313X.2001.01165.x; Suzuki M, 1997, PLANT CELL, V9, P799, DOI 10.1105/tpc.9.5.799; Swiatek A, 2002, PLANT PHYSIOL, V128, P201, DOI 10.1104/pp.010592; VANDERGEEST AHM, 1995, PLANT PHYSIOL, V109, P1151, DOI 10.1104/pp.109.4.1151; VANDERGEEST AHM, 1994, PLANT J, V6, P413, DOI 10.1046/j.1365-313X.1994.06030413.x; Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332; Venturi CB, 2000, MOL CELL BIOL, V20, P6435, DOI 10.1128/MCB.20.17.6435-6448.2000; Wang H, 1998, PLANT J, V15, P501, DOI 10.1046/j.1365-313X.1998.00231.x; WOLFFE AP, 1994, J CELL SCI, V107, P2055; YOUNG CW, 1967, CANCER RES, V27, P535; Zuo JR, 2000, PLANT J, V24, P265, DOI 10.1046/j.1365-313x.2000.00868.x	53	13	13	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45397	45405		10.1074/jbc.M307787200	http://dx.doi.org/10.1074/jbc.M307787200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12960166	hybrid			2022-12-25	WOS:000186452300044
J	Lehtimaki, KK; Valonen, PK; Griffin, JL; Vaisanen, TH; Grohn, OHJ; Kettunen, MI; Vepsalainen, J; Yla-Herttuala, S; Nicholson, J; Kauppinen, RA				Lehtimaki, KK; Valonen, PK; Griffin, JL; Vaisanen, TH; Grohn, OHJ; Kettunen, MI; Vepsalainen, J; Yla-Herttuala, S; Nicholson, J; Kauppinen, RA			Metabolite changes in BT4C rat gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death as studied by H-1 NMR spectroscopy in vivo, ex vivo, and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVERSE CORRELATION; H-1 MRS; BRAIN; APOPTOSIS; CHOLINE; ACCUMULATION; INHIBITION; RELAXATION; INDUCTION; PULSES	Programmed cell death was induced by HSV-tk gene therapy in rat BT4C glioma cells, and metabolite changes associated with cell damage were monitored in vivo by H-1 NMR spectroscopy and ex vivo by high resolution magic angle spinning (HRMAS) H-1 NMR, and in vitro in perchloric acid extracts of tumors. Metabolite concentrations, as quantified in vivo using water as an internal reference and in vitro in extracts, were correlated with cell density. The results showed that both in vivo and in vitro glycine and creatine concentrations followed volume-averaged cell density, whereas that of total choline-containing compounds was unaffected by a cell loss approaching 60%. Meanwhile, both saturated and unsaturated 1H NMR visible lipids increased. HRMAS H-1 NMR spectroscopy of the tumor samples at 14.1 tesla demonstrated the presence of nucleotide peaks from adenosine and uridine nucleotides in glioma samples ex vivo. The assignment of a doublet at 7.95 ppm to UDP was confirmed by spiking experiments of tumor extracts in conjunction with H-1 and P-31 NMR spectroscopy. HRMAS also resolved the choline-containing peak at 3.2 ppm in vivo into resonances from choline (3.20 ppm), phosphocholine (3.22 ppm), glycerophosphocholine (3.24 ppm), and taurine (3.26 ppm). These resonances were uncorrelated with temporal progression through programmed cell death. Our results show that H-1 NMR-detected lipids and some of the small molecular weight metabolites respond to gene therapy. However, the choline-containing compounds are unaffected by severe decline in cell density. The latter observation supports the idea that triacylglycerols, rather than membrane phospholipids, are the key components of H-1 NMR visible lipids, and it also casts doubt on the validity of resonance of choline-containing compounds as a diagnostic marker of programmed cell death in vivo.	Univ Kuopio, Dept Biomed NMR, FIN-70211 Kuopio, Finland; Univ Kuopio, Natl BioNMR Facil, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Chem, FIN-70211 Kuopio, Finland; Univ Kuopio, AI Virtanen Inst mol SCi, Dept Biotechnol & Mol Med, FIN-70211 Kuopio, Finland; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Biol Chem, London, England	University of Eastern Finland; University of Eastern Finland; University of Eastern Finland; University of Eastern Finland; Imperial College London	Kauppinen, RA (corresponding author), Univ Manchester, Sch Biol Sci, 1-33 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	risto.kauppinen@man.ac.uk	Nicholson, Jeremy K/B-3395-2012; Kettunen, Mikko I/K-2299-2012; Lehtimäki, Kimmo K/A-6018-2009; Kauppinen, Risto A/F-3274-2011	Nicholson, Jeremy K/0000-0002-8123-8349; Kettunen, Mikko I/0000-0002-2004-660X; Lehtimäki, Kimmo K/0000-0003-2750-8229; Yla-Herttuala, Seppo/0000-0001-7593-2708				ALSAFFAR MMS, 2001, BRIT J CANCER, V86, P963; Anthony ML, 1999, J BIOL CHEM, V274, P19686, DOI 10.1074/jbc.274.28.19686; Beckwith-Hall BM, 1998, CHEM RES TOXICOL, V11, P260, DOI 10.1021/tx9700679; Bhakoo KK, 1997, CELL MOL BIOL, V43, P621; Blankenberg FG, 1996, BLOOD, V87, P1951; CUMMINS CJ, 1983, J NEUROCHEM, V40, P128, DOI 10.1111/j.1471-4159.1983.tb12662.x; Garwood M, 2001, J MAGN RESON, V153, P155, DOI 10.1006/jmre.2001.2340; GARWOOD M, 1991, J MAGN RESON, V94, P511, DOI 10.1016/0022-2364(91)90137-I; Grand S, 1999, RADIOLOGY, V213, P785, DOI 10.1148/radiology.213.3.r99dc10785; Griffin JL, 2003, CANCER RES, V63, P3195; Griffin JL, 2003, BBA-GEN SUBJECTS, V1619, P151, DOI 10.1016/S0304-4165(02)00475-0; Griffin JL, 2001, FEBS LETT, V509, P263, DOI 10.1016/S0014-5793(01)03175-1; Griffin JL, 2001, CHEM RES TOXICOL, V14, P1428, DOI 10.1021/tx015521u; Grohn OHJ, 1999, MAGNET RESON MED, V42, P268, DOI 10.1002/(SICI)1522-2594(199908)42:2<268::AID-MRM8>3.0.CO;2-A; GRUETTER R, 1993, MAGNET RESON MED, V29, P804, DOI 10.1002/mrm.1910290613; Gupta RK, 1999, MAGNET RESON MED, V41, P2, DOI 10.1002/(SICI)1522-2594(199901)41:1<2::AID-MRM2>3.0.CO;2-Y; Hakumaki JM, 1999, NAT MED, V5, P1323, DOI 10.1038/15279; Hakumaki JM, 1998, CANCER RES, V58, P3791; Hakumaki JM, 2002, CANCER GENE THER, V9, P338, DOI 10.1038/sj.cgt.7700450; Hakumaki JM, 2000, TRENDS BIOCHEM SCI, V25, P357, DOI 10.1016/S0968-0004(00)01614-5; KAUPPINEN RA, 1991, J NEUROCHEM, V57, P1136, DOI 10.1111/j.1471-4159.1991.tb08271.x; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kizu O, 1998, MAGN RESON IMAGING, V16, P197, DOI 10.1016/S0730-725X(97)00255-5; KUESEL AC, 1994, NMR BIOMED, V7, P149, DOI 10.1002/nbm.1940070308; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179; MORI S, 1995, MAGNET RESON MED, V33, P41, DOI 10.1002/mrm.1910330107; Nelson SJ, 1999, NMR BIOMED, V12, P123, DOI 10.1002/(SICI)1099-1492(199905)12:3<123::AID-NBM541>3.0.CO;2-Y; Paxinos G., 1996, RAT BRAIN STEREOTAXI; PONTEN U, 1973, J NEUROCHEM, V21, P1127, DOI 10.1111/j.1471-4159.1973.tb07567.x; Poptani H, 1998, CANCER GENE THER, V5, P101; Ronen SM, 1999, BRIT J CANCER, V80, P1035, DOI 10.1038/sj.bjc.6690459; Sandmair AM, 2000, CANCER GENE THER, V7, P413, DOI 10.1038/sj.cgt.7700132; Sijens PE, 1995, INVEST RADIOL, V30, P738, DOI 10.1097/00004424-199512000-00008; SIMINOVITCH DJ, 1988, BIOPHYS J, V54, P373, DOI 10.1016/S0006-3495(88)82970-9; Sze D Y, 1994, Immunomethods, V4, P113, DOI 10.1006/immu.1994.1013; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tkac I, 1999, MAGNET RESON MED, V41, P649, DOI 10.1002/(SICI)1522-2594(199904)41:4<649::AID-MRM2>3.0.CO;2-G; Tugnoli V, 2001, BIOPOLYMERS, V62, P297, DOI 10.1002/bip.10005; Williams SNO, 1998, MAGNET RESON MED, V40, P411, DOI 10.1002/mrm.1910400311	40	70	76	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45915	45923		10.1074/jbc.M306209200	http://dx.doi.org/10.1074/jbc.M306209200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12954643	hybrid			2022-12-25	WOS:000186452300104
J	Zhong, ZP; Helinski, D; Toukdarian, A				Zhong, ZP; Helinski, D; Toukdarian, A			A specific region in the N terminus of a replication initiation protein of plasmid RK2 is required for recruitment of Pseudomonas aeruginosa DnaB helicase to the plasmid origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; DISTANTLY RELATED BACTERIA; NUCLEOPROTEIN STRUCTURES; TRFA; PRIMASE; FORK; COMPLEX; GENES	Broad host range plasmid RK2 encodes two versions of its essential replication initiation protein, TrfA, using in-frame translational starts spaced 97 amino acids apart. The smaller protein, TrfA-33, is sufficient for plasmid replication in many bacterial hosts. Efficient replication in Pseudomonas aeruginosa, however, specifically requires the larger TrfA-44 protein. With the aim of identifying sequences of TrfA-44 required for stable replication of RK2 in P. aeruginosa, specific deletions and a substitution mutant within the N terminus sequence unique to TrfA-44 were constructed, and the mutant proteins were tested for activity. Deletion mutants were targeted to three of the four predicted helical regions in the first 97 amino acids of TrfA-44. Deletion of TrfA-44 amino acids 21-32 yielded a mutant protein, TrfA-44Delta2, that had lost the ability to bind and load the DnaB helicase of P. aeruginosa or Pseudomonas putida onto the RK2 origin in vitro and did not support stable replication of an RK2 mini-replicon in P. aeruginosa in vivo. A substitution of amino acid 22 within this essential region resulted in a protein, TrfA-44E22A, with reduced activity in vitro, particularly with the P. putida helicase. Deletion of amino acids 37-55 (TrfA-44Delta3) slightly affected protein activity in vitro with the P. aeruginosa helicase and significantly with the P. putida helicase, whereas deletion of amino acids 71-88 (TrfA-44Delta4) had no effect on TrfA activity in vitro with either helicase. These results identify regions of the TrfA-44 protein that are required for recruitment of the Pseudomonas DnaB helicases in the initiation of RK2 replication.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Toukdarian, A (corresponding author), Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA.				NIAID NIH HHS [AI-07194] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; Blasina A, 1996, P NATL ACAD SCI USA, V93, P3559, DOI 10.1073/pnas.93.8.3559; Caspi R, 2000, J BIOL CHEM, V275, P18454, DOI 10.1074/jbc.M000552200; Caspi R, 2001, EMBO J, V20, P3262, DOI 10.1093/emboj/20.12.3262; Datta HJ, 1999, P NATL ACAD SCI USA, V96, P73, DOI 10.1073/pnas.96.1.73; Dennis J J, 1995, Methods Mol Biol, V47, P125; Doran KS, 1998, J BIOL CHEM, V273, P8447, DOI 10.1074/jbc.273.14.8447; Doran KS, 1999, MOL MICROBIOL, V33, P490, DOI 10.1046/j.1365-2958.1999.01491.x; DURLAND RH, 1987, PLASMID, V18, P164, DOI 10.1016/0147-619X(87)90044-8; FANG FC, 1991, J BACTERIOL, V173, P5861, DOI 10.1128/jb.173.18.5861-5868.1991; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; Hiasa H, 1999, J BIOL CHEM, V274, P27244, DOI 10.1074/jbc.274.38.27244; Jiang Y, 2003, P NATL ACAD SCI USA, V100, P8692, DOI 10.1073/pnas.1532393100; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; Konieczny I, 1997, J BIOL CHEM, V272, P33312, DOI 10.1074/jbc.272.52.33312; Lu YB, 1998, EMBO J, V17, P5192, DOI 10.1093/emboj/17.17.5192; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; Marszalek J, 1996, J BIOL CHEM, V271, P18535, DOI 10.1074/jbc.271.31.18535; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; Messer W, 1999, BIOCHIMIE, V81, P819, DOI 10.1016/S0300-9084(00)87165-5; Odegrip R, 2000, J VIROL, V74, P4057, DOI 10.1128/JVI.74.9.4057-4063.2000; Ratnakar PVAL, 1996, P NATL ACAD SCI USA, V93, P5522, DOI 10.1073/pnas.93.11.5522; ROBERTS RC, 1990, J BACTERIOL, V172, P6204, DOI 10.1128/jb.172.11.6204-6216.1990; Rost B, 1996, METHOD ENZYMOL, V266, P525; SCHMIDHAUSER TJ, 1983, PLASMID, V9, P325, DOI 10.1016/0147-619X(83)90010-0; SHINGLER V, 1989, BIOCHIM BIOPHYS ACTA, V1007, P301, DOI 10.1016/0167-4781(89)90152-8; Sutton MD, 1998, J BIOL CHEM, V273, P34255, DOI 10.1074/jbc.273.51.34255; THOMAS CM, 1981, MOL GEN GENET, V181, P1, DOI 10.1007/BF00338996; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thorsted PB, 1996, PLASMID, V36, P95, DOI 10.1006/plas.1996.0037; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; Tougu K, 1996, J BIOL CHEM, V271, P21391, DOI 10.1074/jbc.271.35.21391; Toukdarian AE, 1996, J BIOL CHEM, V271, P7072, DOI 10.1074/jbc.271.12.7072; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	38	18	18	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45305	45310		10.1074/jbc.M306058200	http://dx.doi.org/10.1074/jbc.M306058200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12952979	hybrid			2022-12-25	WOS:000186452300032
J	Zhou, M; Zhang, YH; Ardans, JA; Wahl, LM				Zhou, M; Zhang, YH; Ardans, JA; Wahl, LM			Interferon-gamma differentially regulates monocyte matrix metalloproteinase-1 and -9 through tumor necrosis factor-alpha and caspase 8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-H SYNTHASE-2; IFN-GAMMA; INTERSTITIAL COLLAGENASE; HUMAN MACROPHAGES; INDUCED APOPTOSIS; TIMP-1 PRODUCTION; TNF-ALPHA; IN-VITRO; ACTIVATION; SUPPRESSION	Tumor necrosis factor-alpha (TNFalpha) and granulocyte macrophage colony-stimulating factor (GM-CSF) individually enhance monocyte matrix metalloproteinase-9 (MMP-9) but induce MMP-1 only when added in combination. Because interferon-gamma (IFNgamma) is also found at inflammatory sites, we determined its effect on monocyte MMPs in the presence or absence of TNFalpha and GM-CSF. IFNgamma alone did not stimulate monocyte MMP-9 or MMP-1; however, in the presence of GM-CSF it induced MMP-1 and enhanced MMP-1 stimulated by GM-CSF and TNFalpha. IFNgamma induced MMP-1 in the presence of GM-CSF through the stimulation of TNFalpha production through a mechanism involving both p38 and ERK1/2 MAPKs, in which GM-CSF stimulated ERK1/2 whereas IFNgamma activated p38. In support of this conclusion TNFalpha neutralizing antibody and antibodies against TNF receptor I and -II blocked the induction of MMP-1 by GM-CSF and IFNgamma. In contrast to its effects on MMP-1, IFNgamma inhibited TNFalpha-induced MMP-9 through a caspase 8-dependent pathway as demonstrated by the restoration of MMP-9 with caspase 8 inhibitors. Moreover, the phosphorylation of STAT1 by IFNgamma was blocked by an inhibitor of caspase 8, indicating that STAT1 had a suppressive effect on MMP-9. Caspase 8-mediated phosphorylation of STAT1 through p38 MAPK as shown by the inhibition of IFNgamma-induced phosphorylation of p38 by caspase 8 inhibitors. Activation of caspase 8 by IFNgamma did not result in increased apoptosis. Thus IFNgamma in the presence of GM-CSF and/or TNFalpha differentially regulates monocyte MMPs through induction of TNFalpha and a novel mechanism involving caspase 8 that is independent of apoptosis.	NIDCR, Immunopathol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Wahl, LM (corresponding author), NIDCR, Immunopathol Sect, NIH, 30 Convent Dr,Bldg 30,Rm 325, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000456] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; HAYES MP, 1995, CYTOKINE, V7, P427, DOI 10.1006/cyto.1995.0058; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Huang SY, 2002, ONCOGENE, V21, P2504, DOI 10.1038/sj.onc.1205341; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; LACRAZ S, 1992, J CLIN INVEST, V90, P382, DOI 10.1172/JCI115872; LACRAZ S, 1995, J CLIN INVEST, V96, P2304, DOI 10.1172/JCI118286; Mertz PM, 1996, CELL IMMUNOL, V173, P252, DOI 10.1006/cimm.1996.0275; MERTZ PM, 1994, J BIOL CHEM, V269, P21322; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Quiding-Jarbrink M, 2001, INFECT IMMUN, V69, P5661, DOI 10.1128/IAI.69.9.5661-5670.2001; Randow F, 1997, J IMMUNOL, V158, P2911; Rathbun RK, 2000, BLOOD, V96, P4204; Rokhlin OW, 1998, CANCER RES, V58, P5870; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Sanceau J, 2002, J BIOL CHEM, V277, P35766, DOI 10.1074/jbc.M202959200; Saren P, 1996, J IMMUNOL, V157, P4159; SHAPIRO SD, 1990, J CLIN INVEST, V86, P1204, DOI 10.1172/JCI114826; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WAHL LM, 1990, J IMMUNOL, V144, P3518; WAHL LM, 1991, CURRENT PROTOCOLS IM; WAHL SM, 1987, J IMMUNOL, V139, P1342; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Zhang YH, 1998, J IMMUNOL, V161, P3071	29	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45406	45413		10.1074/jbc.M309075200	http://dx.doi.org/10.1074/jbc.M309075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12960156	hybrid			2022-12-25	WOS:000186452300045
J	Soung, YH; Lee, JW; Kim, HS; Park, WS; Kim, SY; Lee, JH; Park, JY; Cho, YG; Kim, CJ; Park, YG; Nam, SW; Jeong, SW; Kim, SH; Lee, JY; Yoo, NJ; Lee, SH				Soung, YH; Lee, JW; Kim, HS; Park, WS; Kim, SY; Lee, JH; Park, JY; Cho, YG; Kim, CJ; Park, YG; Nam, SW; Jeong, SW; Kim, SH; Lee, JY; Yoo, NJ; Lee, SH			Inactivating mutations of CASPASE-7 gene in human cancers	ONCOGENE			English	Article						CASPASE-7; mutation; solid cancer; apoptosis; caspases	FAS APO-1/CD95 GENE; INDUCED APOPTOSIS; CELL-DEATH; MAMMALIAN HOMOLOG; CYSTEINE PROTEASE; CARCINOMA; DISTINCT; CLEAVES; CASCADE; CED-3	Caspase-7 is a caspase involved in the execution phase of apoptosis. To explore the possibility that the genetic alterations of CASPASE-7 might be involved in the development of human cancers, we analysed the entire coding region and all splice sites of human CASPASE-7 gene for the detection of somatic mutations in a series of human solid cancers, including carcinomas from stomach, colon, head/neck, esophagus, urinary bladder and lung. Overall, we detected CASPASE-7 mutations in two of 98 colon carcinomas (2.0%), one of 50 esophageal carcinomas (2.0%) and one of 33 head/neck carcinomas (3.0%). We expressed the tumor-derived caspase-7 mutants in 293 T cells and found that the apoptosis was reduced compared to the wild-type caspase-7. This is the first report on the CASPASE-7 gene, mutations in human malignancies, and our data suggest that the inactivating mutations of the CASPASE-7 gene might lead to the loss of its apoptotic function and contribute to the pathogenesis of some human solid cancers.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Biostat, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Biochem, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Lee, SH (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.		kim, Hong Sug/G-2731-2014; Yoo, Nam Jin/GNM-9060-2022					Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; KRAWCZAK M, 1992, HUM GENET, V90, P41; Kurokawa H, 1999, ONCOL REP, V6, P33; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Mollenhauer J, 2001, CANCER RES, V61, P8880; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; Palmerini F, 2001, HUM PATHOL, V32, P461, DOI 10.1053/hupa.2001.24328; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Schwartz S, 1999, CANCER RES, V59, P2995; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; ZORNIG M, 1995, ONCOGENE, V10, P2397	26	75	76	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					8048	8052		10.1038/sj.onc.1206727	http://dx.doi.org/10.1038/sj.onc.1206727			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970753				2022-12-25	WOS:000185388200020
J	Wersinger, C; Prou, D; Vernier, P; Sidhu, A				Wersinger, C; Prou, D; Vernier, P; Sidhu, A			Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress	FASEB JOURNAL			English	Article						Parkinson's disease; synucleinopathies; MPP+; neurodegeneration; Lewy bodies	MULTIPLE-SYSTEM ATROPHY; CORTICAL LEWY BODIES; PARKINSONS-DISEASE; WILD-TYPE; NACP/ALPHA-SYNUCLEIN; NEURONAL CELLS; PROTEIN; PATHOGENESIS; MUTATIONS; INCLUSIONS	Human alpha-synuclein accumulates in dopaminergic neurons as intraneuronal inclusions, Lewy bodies, which are characteristic of idiopathic Parkinson's disease (PD). Here, we suggest that modulation of the functional activity of the dopamine transporter (DAT) by alpha-synuclein may be a key factor in the preferential degeneration of mesencephalic dopamine (DA)- synthesizing neurons in PD. In cotransfected Ltk-, HEK 293, and SK-N-MC cells, alpha-synuclein induced a 35% decrease in [H-3] DA uptake. Biotinylated DAT levels were decreased by 40% in cotransfected cells relative to cells expressing only DAT. DAT was colocalized with alpha-synuclein in mesencephalic neurons and cotransfected Ltk- cells. Coimmunoprecipitation studies showed the existence of a complex between alpha-synuclein and DAT, in specific rat brain regions and cotransfected cells, through specific amino acid motifs of both proteins. The attenuation of DAT function by alpha-synuclein was cytoprotective, because DA-mediated oxidative stress and cell death were reduced in cotransfected cells. The neurotoxin MPP+ (1-methyl-4-phenylpyridinium), oxidative stress, or impairment of cell adhesion ablated the alpha-synuclein-mediated inhibition of DAT activity, which caused increased uptake of DA and increased biotinylated DAT levels, in both mesencephalic neurons and cotransfected cells. These studies suggest a novel normative role for alpha-synuclein in regulating DA synaptic availability and homeostasis, which is relevant to the pathophysiology of PD.	Georgetown Univ, Dept Pediat, Washington, DC 20007 USA; CNRS, Inst Neurobiol Alfred Fessard, F-91198 Gif Sur Yvette, France	Georgetown University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Sidhu, A (corresponding author), Lab Mol Neurochem, Res Bldg,Room W222,3970 Reservoir Rd NW, Washington, DC 20007 USA.	sidhua@georgetown.edu	Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Alim MA, 2002, J BIOL CHEM, V277, P2112, DOI 10.1074/jbc.M102981200; Baba M, 1998, AM J PATHOL, V152, P879; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Chan P, 1998, NEUROLOGY, V50, P1136, DOI 10.1212/WNL.50.4.1136; Chen NH, 2000, EUR J PHARMACOL, V405, P329, DOI 10.1016/S0014-2999(00)00563-X; Ciliax BJ, 1999, J COMP NEUROL, V409, P38, DOI 10.1002/(SICI)1096-9861(19990621)409:1<38::AID-CNE4>3.0.CO;2-1; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; D'Andrea MR, 2001, NEUROSCI LETT, V306, P137, DOI 10.1016/S0304-3940(01)01811-0; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; Ebadi M, 2001, BIOL SIGNAL RECEPT, V10, P224; Eells JB, 2003, CURR MED CHEM, V10, P857, DOI 10.2174/0929867033457700; El-Agnaf OMA, 2000, J STRUCT BIOL, V130, P300, DOI 10.1006/jsbi.2000.4262; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Gai WP, 1998, LANCET, V352, P547, DOI 10.1016/S0140-6736(05)79256-4; Goedert M, 1998, MOL PSYCHIATR, V3, P462, DOI 10.1038/sj.mp.4000458; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Gosavi N, 2002, J BIOL CHEM, V277, P48984, DOI 10.1074/jbc.M208194200; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Jensen PH, 2000, J BIOL CHEM, V275, P21500, DOI 10.1074/jbc.M000099200; Kahle PJ, 2000, ANN NY ACAD SCI, V920, P33; Kawamata H, 2001, J NEUROCHEM, V77, P929, DOI 10.1046/j.1471-4159.2001.00301.x; Kholodilov NG, 1999, NEUROSCI LETT, V275, P105, DOI 10.1016/S0304-3940(99)00740-5; Kholodilov NG, 1999, J NEUROCHEM, V73, P2586, DOI 10.1046/j.1471-4159.1999.0732586.x; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Lippa CF, 1999, ANN NEUROL, V45, P353, DOI 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4; LODER MK, 2003, IN PRESS J BIOL CHEM; Lotharius J, 2002, HUM MOL GENET, V11, P2395, DOI 10.1093/hmg/11.20.2395; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Lotharius J, 2002, J BIOL CHEM, V277, P38884, DOI 10.1074/jbc.M205518200; Lucking CB, 2000, CELL MOL LIFE SCI, V57, P1894, DOI 10.1007/PL00000671; Mori F, 2002, BRAIN RES, V941, P118, DOI 10.1016/S0006-8993(02)02643-4; Mouradian MM, 2002, NEUROLOGY, V58, P179, DOI 10.1212/WNL.58.2.179; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Nelson N, 1998, J NEUROCHEM, V71, P1785; Payton JE, 2001, MOL BRAIN RES, V95, P138, DOI 10.1016/S0169-328X(01)00257-1; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; Prou D, 2001, J CELL SCI, V114, P3517; Przedborski S, 2001, J NEUROCHEM, V76, P637, DOI 10.1046/j.1471-4159.2001.00174.x; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; Sharma N, 2001, AM J PATHOL, V159, P339, DOI 10.1016/S0002-9440(10)61700-2; Sidhu A, 1998, J NEUROCHEM, V70, P2459; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Stephan A, 2002, HIPPOCAMPUS, V12, P55, DOI 10.1002/hipo.10006; Takeda A, 1998, AM J PATHOL, V152, P367; Trojanowski JQ, 1998, ARCH NEUROL-CHICAGO, V55, P151, DOI 10.1001/archneur.55.2.151; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Wersinger C, 2003, NEUROSCI LETT, V340, P189, DOI 10.1016/S0304-3940(03)00097-1; Wersinger C, 2003, NEUROSCI LETT, V342, P124, DOI 10.1016/S0304-3940(03)00212-X; WERSINGER C, 2003, IN PRESS MOL CELL NE; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9; Zourlidou A, 2003, NEUROSCI LETT, V340, P234, DOI 10.1016/S0304-3940(03)00081-8	72	116	117	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2151	+		10.1096/fj.03-0152fje	http://dx.doi.org/10.1096/fj.03-0152fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958153				2022-12-25	WOS:000185925100029
J	Grether-Beck, S; Felsner, I; Brenden, H; Krutmann, J				Grether-Beck, S; Felsner, I; Brenden, H; Krutmann, J			Mitochondrial cytochrome c release mediates ceramide-induced activator protein 2 activation and gene expression in keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; INDUCED APOPTOSIS; CARCINOMA-CELLS; ADP/ATP CARRIER; SPHINGOMYELIN PATHWAY; HYDROGEN-PEROXIDE; EPITHELIAL-CELLS; UVA RADIATION; REDOX STATE	The intracellular signaling pathway(s) through which second messenger ceramides induce gene expression in human cells has not yet been characterized. In the present study, ceramide-induced expression of intercellular adhesion molecule-1 (ICAM-1), which requires activation of transcription factor activator protein 2 (AP-2), was found to be mediated through a mitochondrial pathway. Inhibitors of mitochondrial electron transport chain (e.g. rotenone, thenoyltrifluoroacetone, and antimycin A) reduced ceramide-induced ICAM-1 expression. Stimulation of human keratinocytes with cell-permeant ceramides at concentrations that did not induce apoptosis ( no activation of caspases 3, 8, and 9 and no nucleosomal fragmentation) but caused AP-2 activation and ICAM-1 induction released cytochrome c (cyt c) from mitochondria into the cytoplasm of cells. This cyt c release was an indispensable prerequisite for effective ceramide signaling, because its inhibition by modulating the mitochondrial megachannel with bonkrekic acid or carboxyatractyloside prevented ceramide-induced AP-2 activation and ICAM-1 expression. Analysis of the interaction between cyt c and AP-2 revealed that cyt c oxidized AP-2 and that this redox regulation greatly enhanced the DNA binding capacity of AP-2. Mitochondria thus have a previously unrecognized function in signaling ceramide-induced transcription factor activation and gene regulation.	Univ Dusseldorf gGmBH, Inst Umweltmed Forsch, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Krutmann, J (corresponding author), Univ Dusseldorf gGmBH, Inst Umweltmed Forsch, Hennekamp 50, D-40225 Dusseldorf, Germany.							Ahrens C, 1997, P NATL ACAD SCI USA, V94, P6837, DOI 10.1073/pnas.94.13.6837; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Asakuma J, 2003, CANCER RES, V63, P1365; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; Bello RI, 2001, J BIOL CHEM, V276, P44379, DOI 10.1074/jbc.M107168200; Berneburg M, 1999, J BIOL CHEM, V274, P15345, DOI 10.1074/jbc.274.22.15345; BONIFACINO JS, 2001, CURRENT PROTOCOLS IM; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Bossy-Wetzel E, 2000, METHOD ENZYMOL, V322, P235; Brustovetsky N, 1996, P NATL ACAD SCI USA, V93, P664, DOI 10.1073/pnas.93.2.664; Burek C, 2001, ONCOGENE, V20, P6493, DOI 10.1038/sj.onc.1204841; Capaldi RA, 1995, METHOD ENZYMOL, V260, P117, DOI 10.1016/0076-6879(95)60134-1; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; Corsini E, 1996, J INVEST DERMATOL, V107, P720, DOI 10.1111/1523-1747.ep12365608; Cutler RG, 2001, MECH AGEING DEV, V122, P895, DOI 10.1016/S0047-6374(01)00246-9; Di Nardo A, 2000, BRIT J DERMATOL, V143, P491, DOI 10.1111/j.1365-2133.2000.03700.x; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Driscoll KE, 1998, ENVIRON HEALTH PERSP, V106, P1171, DOI 10.2307/3433981; DUTTON PL, 1975, BIOCHIM BIOPHYS ACTA, V387, P536, DOI 10.1016/0005-2728(75)90092-4; FISHER WR, 1973, J BIOL CHEM, V248, P3188; Gallagher S. R., 2001, CURRENT PROTOCOLS IM; Gaubin Y, 2000, BBA-MOL CELL RES, V1495, P4, DOI 10.1016/S0167-4889(99)00149-4; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; Gropp T, 1999, BIOPHYS J, V77, P714, DOI 10.1016/S0006-3495(99)76926-2; Hampton MB, 1998, BIOCHEM J, V329, P95; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HANNUN YA, 2002, J BIOL CHEM, V277, P25447; HENNINGER HP, 1993, BIOL CHEM H-S, V374, P625, DOI 10.1515/bchm3.1993.374.7-12.625; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Huber T, 1999, BIOCHEMISTRY-US, V38, P762, DOI 10.1021/bi981431l; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JOSEPH P, 1994, ONCOL RES, V6, P525; Knaapen AM, 2002, CARCINOGENESIS, V23, P1111, DOI 10.1093/carcin/23.7.1111; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; KRUTMANN J, 1992, SPRINGER SEMIN IMMUN, V13, P333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEENDERS HJ, 1972, J CELL BIOL, V55, P257, DOI 10.1083/jcb.55.2.257; LIAO XS, 1991, MOL CELL BIOL, V11, P38, DOI 10.1128/MCB.11.1.38; Listenberger LL, 2001, J BIOL CHEM, V276, P14890, DOI 10.1074/jbc.M010286200; Martinou JC, 1999, NATURE, V399, P411, DOI 10.1038/20804; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; Matroule JY, 1999, J BIOL CHEM, V274, P2988, DOI 10.1074/jbc.274.5.2988; Miguet C, 2001, CELL DEATH DIFFER, V8, P83, DOI 10.1038/sj.cdd.4400792; Morita A, 1997, PHOTOCHEM PHOTOBIOL, V65, P630, DOI 10.1111/j.1751-1097.1997.tb01904.x; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P517; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; Piette J, 1997, BIOL CHEM, V378, P1237; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; SACCHETTA P, 1986, ANAL BIOCHEM, V154, P205, DOI 10.1016/0003-2697(86)90516-6; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Siskind LJ, 2002, J BIOL CHEM, V277, P26796, DOI 10.1074/jbc.M200754200; Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200; STADE BG, 1990, IMMUNOBIOLOGY, V182, P79, DOI 10.1016/S0171-2985(11)80585-1; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Taanman JW, 1996, BBA-MOL BASIS DIS, V1315, P199, DOI 10.1016/0925-4439(95)00127-1; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497	67	28	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47498	47507		10.1074/jbc.M309511200	http://dx.doi.org/10.1074/jbc.M309511200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12952965	hybrid			2022-12-25	WOS:000186731400021
J	Hwang, M; Morasso, MI				Hwang, M; Morasso, MI			The novel murine Ca2+-binding protein, scarf, is differentially expressed during epidermal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-LIKE PROTEIN; BINDING; FAMILY; S100; IDENTIFICATION; LOCALIZATION; SENSORS; MARKER; TISSUE	Calcium (Ca2+) signaling-dependent systems, such as the epidermal differentiation process, must effectively respond to variations in Ca2+ concentration. Members of the Ca2+-binding proteins play a central function in the transduction of Ca2+ signals, exerting their roles through a Ca2+-dependent interaction with their target proteins, spatially and temporally. By performing a suppression subtractive hybridization screen we identified a novel mouse gene, Scarf (skin calmodulin-related factor), which has homology to calmodulin (CaM)- like Ca2+-binding protein genes and is exclusively expressed in differentiating keratinocytes in the epidermis. The Scarf open reading frame encodes a 148-amino acid protein that contains four conserved EF-hand motifs ( predicted to be Ca2+-binding domains) and has homology to mouse CaM, human CaM-like protein, hClp, and human CaM-like skin protein, hClsp. The functionality of Scarf EF-hand domains was assayed with a radioactive Ca2+-binding method. By Southern blot and computational genome sequence analysis, a highly related gene, Scarf2, was found 15 kb downstream of Scarf on mouse chromosome 13. The functional Scarf Ca2+-binding domains suggest a role in the regulation of epidermal differentiation through the control of Ca2+-mediated signaling.	NIAMS, Dev Skin Biol Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Morasso, MI (corresponding author), NIAMS, Dev Skin Biol Unit, NIH, Bldg 50,Rm 1525, Bethesda, MD 20892 USA.	morasso@nih.gov			NIAMS NIH HHS [Z01 AR041124-06] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041124] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Broome AM, 2003, J HISTOCHEM CYTOCHEM, V51, P675, DOI 10.1177/002215540305100513; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Durussel I, 2002, BIOCHEMISTRY-US, V41, P5439, DOI 10.1021/bi016062z; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAO ZH, 1993, J BIOL CHEM, V268, P20096; Haeseleer F, 2000, J BIOL CHEM, V275, P1247, DOI 10.1074/jbc.275.2.1247; Haeseleer F, 2002, BIOCHEM BIOPH RES CO, V290, P615, DOI 10.1006/bbrc.2001.6228; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Kalinin AE, 2002, BIOESSAYS, V24, P789, DOI 10.1002/bies.10144; KAWASAKI H, 1985, ANAL BIOCHEM, V148, P297, DOI 10.1016/0003-2697(85)90232-5; Krieg P, 1997, GENOMICS, V43, P339, DOI 10.1006/geno.1997.4818; LICHTI U, 1988, CANCER RES, V48, P74; MACKEM S, 1991, DEVELOPMENT, V112, P791; Mehul B, 2000, J BIOL CHEM, V275, P12841, DOI 10.1074/jbc.275.17.12841; Mehul B, 2001, J INVEST DERMATOL, V116, P905, DOI 10.1046/j.0022-202x.2001.01376.x; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; Nelson MR, 1998, CALMODULIN AND SIGNAL TRANSDUCTION, P17; Park GT, 2002, J BIOL CHEM, V277, P45195, DOI 10.1074/jbc.M205380200; PRESLAND RB, 1995, J INVEST DERMATOL, V104, P218, DOI 10.1111/1523-1747.ep12612770; Rogers MS, 2001, EXP CELL RES, V267, P216, DOI 10.1006/excr.2001.5254; Rogers MS, 2001, J BIOL CHEM, V276, P12182, DOI 10.1074/jbc.M010056200; Ruse M, 2001, BIOCHEMISTRY-US, V40, P3167, DOI 10.1021/bi0019747; Yang J, 2002, P NATL ACAD SCI USA, V99, P7711, DOI 10.1073/pnas.102006299; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	29	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47827	47833		10.1074/jbc.M306561200	http://dx.doi.org/10.1074/jbc.M306561200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12970338	hybrid, Green Accepted			2022-12-25	WOS:000186731400059
J	Drew, ME; Morris, JC; Wang, ZF; Wells, L; Sanchez, M; Landfear, SM; Englund, PT				Drew, ME; Morris, JC; Wang, ZF; Wells, L; Sanchez, M; Landfear, SM; Englund, PT			The adenosine analog tubercidin inhibits glycolysis in Trypanosoma brucei as revealed by an RNA interference library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; PHOSPHOGLYCERATE KINASE; FUNCTIONAL EXPRESSION; ESCHERICHIA-COLI; TRANSPORTER; COMPARTMENTATION; PURIFICATION; MICROBODY; ENZYMES; CLONING	We used an RNA interference ( RNAi) library in a forward genetic selection to study the mechanism of toxicity of tubercidin ( 7- deazaadenosine) to procyclic Trypanosoma brucei. Following transfection of cells with an RNAi-based genomic library, we used 5 muM tubercidin to select a drug- resistant cell line. Surprisingly, we found in these resistant cells that the hexose transporters had been silenced. We subsequently found that silencing of hexokinase, a glycolytic enzyme, also yielded tubercidin-resistant parasites. These observations suggested that glycolysis could be a target of tubercidin action and that RNAi silencing of glycolytic enzymes was gradual enough to allow the parasites to adapt to alternative sources of energy. Indeed, adaptation of procyclic trypanosomes to a glucose- independent metabolism by reduction of glucose in the culture medium caused tubercidin resistance. High pressure liquid chromatography analysis of glycolytic intermediates from parasites treated with tubercidin showed a dose- dependent increase in concentration of 1,3- bisphosphoglycerate, a substrate of phosphoglycerate kinase. Furthermore, tubercidin triphosphate inhibited recombinant T. brucei phosphoglycerate kinase activity in vitro with an IC50 of 7.5 muM. We conclude that 5 muM tubercidin kills trypanosomes by targeting glycolysis, especially by inhibition of phosphoglycerate kinase.	Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA	Johns Hopkins University; Johns Hopkins Medicine; Oregon Health & Science University	Englund, PT (corresponding author), Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.		Drew, Mark/E-2993-2011; Wells, Lance/H-3118-2013	Wang, Zefeng/0000-0002-6605-3637; Morris, James/0000-0003-2515-5714; Wells, Lance/0000-0003-4956-5363; Landfear, Scott/0000-0002-1643-6664	NIAID NIH HHS [R01 AI044138, AI 21334, AI 44138] Funding Source: Medline; NIGMS NIH HHS [GM 27605] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021334, R01AI044138] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACS G, 1964, P NATL ACAD SCI USA, V52, P493, DOI 10.1073/pnas.52.2.493; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; Barrett MP, 1998, MOL BIOCHEM PARASIT, V91, P195, DOI 10.1016/S0166-6851(97)00192-8; BHATTACHARYA M, 1995, ANAL BIOCHEM, V232, P98, DOI 10.1006/abio.1995.9954; Blattner J, 1998, P NATL ACAD SCI USA, V95, P11596, DOI 10.1073/pnas.95.20.11596; Clayton CE, 1996, PARASITOL TODAY, V12, P465, DOI 10.1016/S0169-4758(96)10073-9; IOVANNISCI DM, 1984, MOL BIOCHEM PARASIT, V12, P139, DOI 10.1016/0166-6851(84)90131-2; LANGFORD CK, 1994, J BIOL CHEM, V269, P17939; Morris JC, 2002, EMBO J, V21, P4429, DOI 10.1093/emboj/cdf474; OPPERDOES FR, 1977, FEBS LETT, V80, P360, DOI 10.1016/0014-5793(77)80476-6; OSINGA KA, 1985, EMBO J, V4, P3811, DOI 10.1002/j.1460-2075.1985.tb04152.x; PARSONS M, 1990, MOL BIOCHEM PARASIT, V42, P197, DOI 10.1016/0166-6851(90)90162-F; Sanchez MA, 1999, J BIOL CHEM, V274, P30244, DOI 10.1074/jbc.274.42.30244; Sanchez MA, 2002, J BIOL CHEM, V277, P21499, DOI 10.1074/jbc.M202319200; SCHOBERT B, 1995, ANAL BIOCHEM, V226, P288, DOI 10.1006/abio.1995.1227; terKuile BH, 1997, J BACTERIOL, V179, P4699, DOI 10.1128/jb.179.15.4699-4705.1997; Verlinde CLM, 2001, DRUG RESIST UPDATE, V4, P50, DOI 10.1054/drup.2000.0177; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Zomer AWM, 1998, BBA-PROTEIN STRUCT M, V1386, P179, DOI 10.1016/S0167-4838(98)00095-8	20	53	53	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46596	46600		10.1074/jbc.M309320200	http://dx.doi.org/10.1074/jbc.M309320200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12972414	hybrid			2022-12-25	WOS:000186569400046
J	Jeppesen, MG; Ortiz, P; Shepard, W; Kinzy, TG; Nyborg, J; Andersen, GR				Jeppesen, MG; Ortiz, P; Shepard, W; Kinzy, TG; Nyborg, J; Andersen, GR			The crystal structure of the glutathione S-transferase-like domain of elongation factor 1B gamma from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-I; 3-DIMENSIONAL STRUCTURE; NUCLEOTIDE-EXCHANGE; ARABIDOPSIS-THALIANA; ESCHERICHIA-COLI; MAJOR SUBSTRATE; TRANSFER-RNA; ACTIVE-SITE; PROTEIN; COMPLEX	The crystal structure of the N- terminal 219 residues ( domain 1) of the conserved eukaryotic translation elongation factor 1Bgamma ( eEF1Bgamma), encoded by the TEF3 gene in Saccharomyces cerevisiae, has been determined at 3.0 Angstrom resolution by the single wavelength anomalous dispersion technique. The structure is overall very similar to the glutathione S- transferase proteins and contains a pocket with architecture highly homologous to what is observed in glutathione S- transferase enzymes. The TEF3- encoded form of eEF1Bgamma has no obvious catalytic residue. However, the second form of eEF1Bgamma encoded by the TEF4 gene contains serine 11, which may act catalytically. Based on the x- ray structure and gel filtration studies, we suggest that the yeast eEF1 complex is organized as an [ eEF1A . eEF1B alpha. eEF1Bgamma](2) complex. A 23-residue sequence in the middle of eEF1Bgamma is essential for the stable dimerization of eEF1Bgamma and the quaternary structure of the eEF1 complex.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, Piscataway, NJ 08854 USA; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Aarhus University; Rutgers State University New Brunswick; Rutgers State University Medical Center; European Synchrotron Radiation Facility (ESRF)	Andersen, GR (corresponding author), Aarhus Univ, Dept Mol Biol, Gustav Wieds Vej 10 C, DK-8000 Aarhus C, Denmark.	grand@imsb.au.dk		Andersen, Gregers Rom/0000-0001-6292-3319; Kinzy, Terri/0000-0003-1394-9226; Shepard, William/0000-0002-5724-1193	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062789] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062789, GM 62789] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1999, ACTA CRYSTALLOGR D, V55, P181, DOI 10.1107/S0907444998006635; Al-Maghrebi M, 2002, NUCLEIC ACIDS RES, V30, P5017, DOI 10.1093/nar/gkf656; Andersen GR, 2000, MOL CELL, V6, P1261, DOI 10.1016/S1097-2765(00)00122-2; BEC G, 1994, J BIOL CHEM, V269, P2086; BJORNESTEDT R, 1995, J MOL BIOL, V247, P765; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choi JH, 1998, J BIOL CHEM, V273, P29915, DOI 10.1074/jbc.273.45.29915; DeLano WL, 2002, PYMOL USERS MANUAL; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Guerreiro P, 1996, YEAST, V12, P273, DOI 10.1002/(SICI)1097-0061(19960315)12:3<273::AID-YEA898>3.0.CO;2-1; Hanbauer I, 2003, P NATL ACAD SCI USA, V100, P8199, DOI 10.1073/pnas.1432898100; HIRAGA K, 1993, FEBS LETT, V316, P165, DOI 10.1016/0014-5793(93)81208-H; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; JANSSEN GMC, 1991, J BIOL CHEM, V266, P14885; JANSSEN GMC, 1988, EUR J BIOCHEM, V171, P119, DOI 10.1111/j.1432-1033.1988.tb13766.x; JANSSEN GMC, 1994, J BIOL CHEM, V269, P31410; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAMBOURIS NG, 1993, YEAST, V9, P151, DOI 10.1002/yea.320090206; Kamiie K, 2002, BIOSCI BIOTECH BIOCH, V66, P558, DOI 10.1271/bbb.66.558; KINZY TG, 1994, NUCLEIC ACIDS RES, V22, P2703, DOI 10.1093/nar/22.13.2703; Kleywegt GJ, 2000, ACTA CRYSTALLOGR D, V56, P249, DOI 10.1107/S0907444999016364; Kobayashi S, 2001, BIOCHEM BIOPH RES CO, V288, P509, DOI 10.1006/bbrc.2001.5799; KOONIN EV, 1994, PROTEIN SCI, V3, P2045, DOI 10.1002/pro.5560031117; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Mansilla F, 2002, BIOCHEM J, V365, P669, DOI 10.1042/BJ20011681; Merrick WC, 2000, COLD SPRING HARBOR M, V39, P89; Minella O, 1998, BIOSCIENCE REP, V18, P119, DOI 10.1023/A:1020140527930; MORALES J, 1992, NUCLEIC ACIDS RES, V20, P4091, DOI 10.1093/nar/20.15.4091; Neuefeind T, 1997, J MOL BIOL, V274, P446, DOI 10.1006/jmbi.1997.1402; Oakley AJ, 2001, PROTEIN SCI, V10, P2176, DOI 10.1110/ps.21201; PEMBLE SE, 1992, BIOCHEM J, V287, P957, DOI 10.1042/bj2870957; Polekhina G, 2001, BIOCHEMISTRY-US, V40, P1567, DOI 10.1021/bi002249z; Prade L, 1997, BIOL CHEM, V378, P317; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; Reinemer P, 1996, J MOL BIOL, V255, P289, DOI 10.1006/jmbi.1996.0024; RIPMASTER TL, 1993, MOL CELL BIOL, V13, P7901, DOI 10.1128/MCB.13.12.7901; Rossjohn J, 1998, STRUCT FOLD DES, V6, P721, DOI 10.1016/S0969-2126(98)00074-4; Rossjohn J, 1998, STRUCTURE, V6, P309, DOI 10.1016/S0969-2126(98)00034-3; Rossjohn J, 1996, PROTEIN ENG, V9, P327, DOI 10.1093/protein/9.4.327; SAHA SK, 1986, J BIOL CHEM, V261, P2599; Sanders J, 1996, J CELL SCI, V109, P1113; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Sheu GT, 1999, MOL CELL BIOCHEM, V191, P181, DOI 10.1023/A:1006802125856; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stenberg G, 2000, J BIOL CHEM, V275, P10421, DOI 10.1074/jbc.275.14.10421; Tokumoto M, 2002, DNA SEQUENCE, V13, P27, DOI 10.1080/10425170290019865; VANDAMME H, 1991, EUR J BIOCHEM, V197, P505, DOI 10.1111/j.1432-1033.1991.tb15938.x; Vanwetswinkel S, 2003, J BIOL CHEM, V278, P43443, DOI 10.1074/jbc.M306031200; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; XIA CL, 1993, BIOCHEM J, V293, P357, DOI 10.1042/bj2930357	58	42	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47190	47198		10.1074/jbc.M306630200	http://dx.doi.org/10.1074/jbc.M306630200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12972429	hybrid			2022-12-25	WOS:000186569400118
J	Jones, LH; Liu, AM; Davidson, VL				Jones, LH; Liu, AM; Davidson, VL			An engineered Cu-A amicyanin capable of intermolecular electron transfer reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROUS-OXIDE REDUCTASE; SITE-DIRECTED MUTAGENESIS; BLUE COPPER PROTEIN; PARACOCCUS-DENITRIFICANS; METHYLAMINE DEHYDROGENASE; CYTOCHROME C-551I; SPECTROSCOPIC CHARACTERIZATION; THIOBACILLUS-VERSUTUS; PSEUDOMONAS-STUTZERI; TRANSFER COMPLEX	The type I copper center of amicyanin was replaced with a binuclear Cu-A center. To create this model Cu-A protein, a portion of the amino acid sequence that contains three of the ligands to the native type I copper center of Paracoccus denitrificans amicyanin was replaced with the corresponding portion of sequence that provides five ligands for the Cu-A center of cytochrome c oxidase from P. denitrificans. UV-visible and electron paramagnetic resonance spectroscopy confirm that the engineered protein as isolated possesses the mixed-valence (CuCu1.5)-Cu-1.5 (purple) Cu-A center. Comparison of the spectroscopic properties of this Cu-A amicyanin with those of the Cu-A centers of other natural and engineered Cu-A proteins suggests that the spectroscopic features may be dictated more by the protein host than the sequence of the Cu-A loop. Novel reactions for a simple Cu-A model protein are also described. In contrast to other natural and engineered Cu-A proteins, the fully reduced Cu-A amicyanin may be reoxidized by molecular oxygen to the mixed-valence state. It is also shown that Cu-A amicyanin can serve as an electron donor and an electron acceptor for other redox proteins. The mixed-valence form accepts electrons from cytochromes c-551i and c-550 from P. denitrificans. The fully reduced form donates electrons to native and P94F amicyanin. The function as either an electron donor or acceptor is consistent with the measured redox potential of Cu-A amicyanin of + 273 mV. These data indicate that this Cu-A amicyanin will be a particularly useful model protein for structure-function studies of reactivity and the electron transfer properties of the Cu-A redox center.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center	Davidson, VL (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, 2500 N State St, Jackson, MS 39216 USA.		Liu, Aimin/C-1572-2017	Liu, Aimin/0000-0002-4182-8176; Davidson, Victor/0000-0002-1966-7302	NIGMS NIH HHS [GM 41574] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041574, R01GM041574] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; ANTHOLINE WE, 1992, EUR J BIOCHEM, V209, P875, DOI 10.1111/j.1432-1033.1992.tb17360.x; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BISHOP GR, 1995, BIOCHEMISTRY-US, V34, P12082, DOI 10.1021/bi00037a052; Bishop GR, 1998, BIOCHEMISTRY-US, V37, P11026, DOI 10.1021/bi980265e; Bishop GR, 1996, BIOCHEMISTRY-US, V35, P8948, DOI 10.1021/bi960404x; Bishop GR, 1997, BIOCHEMISTRY-US, V36, P13586, DOI 10.1021/bi970586a; BROOKS HB, 1994, BIOCHEMISTRY-US, V33, P5696, DOI 10.1021/bi00185a005; Brown K, 2000, NAT STRUCT BIOL, V7, P191; Charnock JM, 2000, EUR J BIOCHEM, V267, P1368, DOI 10.1046/j.1432-1327.2000.01131.x; CHEN LY, 1992, BIOCHEMISTRY-US, V31, P4959, DOI 10.1021/bi00136a006; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; Cooper C. E., 1995, BIOENERGETICS PRACTI, P85; Cunane LM, 1996, ACTA CRYSTALLOGR D, V52, P676, DOI 10.1107/S0907444996001072; DAVIDSON VL, 1990, METHOD ENZYMOL, V188, P241; Davidson VL, 2002, METHOD ENZYMOL, V353, P121; Davidson VL, 1997, BIOCHEMISTRY-US, V36, P12733, DOI 10.1021/bi971353m; DAVIDSON VL, 1995, J BIOL CHEM, V270, P23941, DOI 10.1074/jbc.270.41.23941; Davidson VL, 2001, ADV PROTEIN CHEM, V58, P95; Davidson VL, 2000, BBA-BIOENERGETICS, V1457, P27, DOI 10.1016/S0005-2728(00)00052-9; Davidson VL, 1996, BIOCHEMISTRY-US, V35, P8120, DOI 10.1021/bi952854f; DEGIER JWL, 1995, EUR J BIOCHEM, V229, P148; Dennison C, 1996, FEBS LETT, V394, P340, DOI 10.1016/0014-5793(96)00981-7; DENNISON C, 1995, FEBS LETT, V365, P92, DOI 10.1016/0014-5793(95)00429-D; Epel B, 2002, J AM CHEM SOC, V124, P8152, DOI 10.1021/ja012514j; FARRAR JA, 1995, EUR J BIOCHEM, V232, P294, DOI 10.1111/j.1432-1033.1995.tb20811.x; Farver O, 1999, P NATL ACAD SCI USA, V96, P899, DOI 10.1073/pnas.96.3.899; Gamelin DR, 1998, J AM CHEM SOC, V120, P5246, DOI 10.1021/ja973161k; GRAY KA, 1986, FEBS LETT, V207, P239, DOI 10.1016/0014-5793(86)81496-X; Hay M, 1996, P NATL ACAD SCI USA, V93, P461, DOI 10.1073/pnas.93.1.461; Hay MT, 2000, J BIOL INORG CHEM, V5, P699, DOI 10.1007/s007750000158; Hay MT, 1998, INORG CHEM, V37, P191, DOI 10.1021/ic971232a; HUSAIN M, 1986, J BIOL CHEM, V261, P8577; HUSAIN M, 1985, J BIOL CHEM, V260, P4626; HUSAIN M, 1987, J BACTERIOL, V169, P1712, DOI 10.1128/jb.169.4.1712-1717.1987; HUSAIN M, 1986, BIOCHEMISTRY-US, V25, P2431, DOI 10.1021/bi00357a020; KRONECK PMH, 1989, FEBS LETT, V248, P212, DOI 10.1016/0014-5793(89)80464-8; KRONECK PMH, 1990, FEBS LETT, V268, P274, DOI 10.1016/0014-5793(90)81026-K; LAPPALAINEN P, 1993, J BIOL CHEM, V268, P26416; LOMMEN A, 1990, J BIOL CHEM, V265, P2768; LOMMEN A, 1988, EUR J BIOCHEM, V176, P213, DOI 10.1111/j.1432-1033.1988.tb14271.x; Lukoyanov D, 2002, BIOPHYS J, V82, P2758, DOI 10.1016/S0006-3495(02)75616-6; Machczynski MC, 2002, J INORG BIOCHEM, V88, P375, DOI 10.1016/S0162-0134(02)00364-1; Neese F, 1996, J AM CHEM SOC, V118, P8692, DOI 10.1021/ja960125x; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; RAITIO M, 1987, EMBO J, V6, P2825, DOI 10.1002/j.1460-2075.1987.tb02579.x; RIESTER J, 1989, EUR J BIOCHEM, V178, P751, DOI 10.1111/j.1432-1033.1989.tb14506.x; Robinson H, 1999, BIOCHEMISTRY-US, V38, P5677, DOI 10.1021/bi9901634; Salgado J, 1998, BIOCHEMISTRY-US, V37, P7378, DOI 10.1021/bi9728598; Slutter CE, 1996, BIOCHEMISTRY-US, V35, P3387, DOI 10.1021/bi9525839; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VANSPANNING RJM, 1990, FEBS LETT, V275, P217, DOI 10.1016/0014-5793(90)81475-4; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Zhen YJ, 2002, BIOCHEMISTRY-US, V41, P2288, DOI 10.1021/bi0114628; Zhu ZY, 1998, BIOCHEMISTRY-US, V37, P17128, DOI 10.1021/bi9817919; ZUMFT WG, 1996, ADV INORG BIOCHEM, V11, P193	56	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47269	47274		10.1074/jbc.M308863200	http://dx.doi.org/10.1074/jbc.M308863200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12970350	hybrid			2022-12-25	WOS:000186569400128
J	Maynes, JT; Garen, C; Cherney, MM; Newton, G; Arad, D; Av-Gay, Y; Fahey, RC; James, MNG				Maynes, JT; Garen, C; Cherney, MM; Newton, G; Arad, D; Av-Gay, Y; Fahey, RC; James, MNG			The crystal structure of 1-D-myo-inosityl-2-acetamido-2-deoxy-alpha-D-glucopyranoside deacetylase (MshB) from Mycobacterium tuberculosis reveals a zinc hydrolase with a lactate dehydrogenase fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT FORMALDEHYDE DEHYDROGENASE; MYCOTHIOL BIOSYNTHESIS; SMEGMATIS MUTANTS; ENZYME; MODEL; IDENTIFICATION; ANTIBIOTICS; REFINEMENT; PROGRAM; DENSITY	Mycothiol ( 1- D- myo- inosityl 2-( N- acetyl- L- cysteinyl)amido- 2- deoxy- alpha- D- glucopyranoside, MSH or AcCys-GlcN- inositol ( Ins)) is the major reducing agent in actinomycetes, including Mycobacterium tuberculosis. The biosynthesis of MSH involves a deacetylase that removes the acetyl group from the precursor GlcNAc- Ins to yield GlcN- Ins. The deacetylase ( MshB) corresponds to Rv1170 of M. tuberculosis with a molecular mass of 33,400 Da. MshB is a Zn2+ metalloprotein, and the deacetylase activity is completely dependent on the presence of a divalent metal cation. We have determined the x- ray crystallographic structure of MshB, which reveals a protein that folds in a manner resembling lactate dehydrogenase in the N- terminal domain and a C-terminal domain consisting of two beta- sheets and two alpha- helices. The zinc binding site is in the N- terminal domain occupying a position equivalent to that of the NAD(+) co- factor of lactate dehydrogenase. The Zn2+ is 5 coordinate with 3 residues from MshB ( His- 13, Asp- 16, His- 147) and two water molecules. One water would be displaced upon binding of substrate ( GlcNAc- Ins); the other is proposed as the nucleophilic water assisted by the general base carboxylate of Asp- 15. In addition to the Zn2+ providing electrophilic assistance in the hydrolysis, His- 144 imidazole could form a hydrogen bond to the oxyanion of the tetrahedral intermediate. The extensive sequence identity of MshB, the deacetylase, with mycothiol S- conjugate amidase, an amide hydrolase that mediates detoxification of mycothiol S-conjugate xenobiotics, has allowed us to construct a faithful model of the catalytic domain of mycothiol S-conjugate amidase based on the structure of MshB.	Univ Alberta, Fac Med, Dept Biochem, Canadian Inst Hlth Res,Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ British Columbia, Dept Med, Vancouver, BC V5Z 2J5, Canada	Institute for Work & Health; University of Alberta; University of California System; University of California San Diego; University of British Columbia	James, MNG (corresponding author), Univ Alberta, Fac Med, Dept Biochem, Canadian Inst Hlth Res,Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada.		Av-Gay, Yossef/H-5128-2019; Maynes, Jason/AAE-4344-2020; Av-Gay, Yossef/H-2311-2014	Av-Gay, Yossef/0000-0002-9547-0237; Garen, Craig/0000-0002-7772-9890				Amaral L, 2001, TROP MED INT HEALTH, V6, P1016, DOI 10.1046/j.1365-3156.2001.00804.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brown ID, 1996, J APPL CRYSTALLOGR, V29, P479, DOI 10.1107/S002188989600163X; Buchmeier NA, 2003, MOL MICROBIOL, V47, P1723, DOI 10.1046/j.1365-2958.2003.03416.x; Chang TH, 2002, J BIOL CHEM, V277, P50176, DOI 10.1074/jbc.M208374200; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Handa N, 2003, PROTEIN SCI, V12, P1621, DOI 10.1110/gad.03104003; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Koledin T, 2002, ARCH MICROBIOL, V178, P331, DOI 10.1007/s00203-002-0462-y; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MissetSmits M, 1997, FEBS LETT, V409, P221, DOI 10.1016/S0014-5793(97)00510-3; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Newton GL, 2003, J BACTERIOL, V185, P3476, DOI 10.1128/JB.185.11.3476-3479.2003; Newton GL, 2002, ARCH MICROBIOL, V178, P388, DOI 10.1007/s00203-002-0469-4; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; Newton GL, 2000, J BACTERIOL, V182, P6958, DOI 10.1128/JB.182.24.6958-6963.2000; Newton GL, 1999, BIOCHEM BIOPH RES CO, V255, P239, DOI 10.1006/bbrc.1999.0156; Newton GL, 2000, BIOCHEMISTRY-US, V39, P10739, DOI 10.1021/bi000356n; Norin A, 1997, EUR J BIOCHEM, V248, P282, DOI 10.1111/j.1432-1033.1997.00282.x; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; QUIOCHO FA, 1993, BIOCHEM SOC T, V21, P442, DOI 10.1042/bst0210442; Rawat M, 2002, ANTIMICROB AGENTS CH, V46, P3348, DOI 10.1128/AAC.46.11.3348-3355.2002; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; Roe RR, 1999, J MOL MODEL, V5, P134, DOI 10.1007/s008940050113; Sareen D, 2002, BIOCHEMISTRY-US, V41, P6885, DOI 10.1021/bi012212u; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1763, DOI 10.1107/S0907444901013749; Vogt RN, 2003, BIOCHEM J, V374, P657, DOI 10.1042/BJ20030642; WHITE JL, 1976, J MOL BIOL, V102, P759, DOI 10.1016/0022-2836(76)90290-4; WHO, 1998, GLOB SURV DIAGN THER, V2, P1, DOI DOI 10.1016/J.KJMS	34	63	67	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47166	47170		10.1074/jbc.M308914200	http://dx.doi.org/10.1074/jbc.M308914200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12958317	hybrid			2022-12-25	WOS:000186569400115
J	Guaragnella, N; Butow, RA				Guaragnella, N; Butow, RA			ATO3 encoding a putative outward ammonium transporter is an RTG-independent retrograde responsive gene regulated by GCN4 and the Ssy1-Ptr3-Ssy5 amino acid sensor system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SACCHAROMYCES-CEREVISIAE; GENOME-WIDE; YEAST; EXPRESSION; MITOCHONDRIA; COMMUNICATION; NUCLEUS; COMPLEX; TARGET	Respiratory deficient yeast cells such as rho(o) petites activate an inter-organelle signaling pathway called retrograde regulation. This results in changes in the expression of a subset of nuclear genes leading to major reconfigurations of metabolism that enable cells to adapt to the respiratory deficient state. Previous studies have focused on the role of three positive regulatory factors in the retrograde pathway, Rtg1p, Rtg2p, and Rtg3p, which are essential for both basal and elevated expressions of some, but not all, retrograde responsive genes. Here we characterize the retrograde regulation of one of those genes, ATO3, whose elevated expression in rho(o) petites is largely independent of RTG gene function. ATO3 encodes a member of the YaaH family of proteins that is a putative outward ammonium transporter. We show that Ato3p-green fluorescent protein is preferentially localized to the plasma membrane of mother cells. rho(o) petites express more Ato3p-green fluorescent protein in their plasma membrane than do rho(+) cells, consistent with the elevated level of ATO3 transcripts in rho(o) cells. We find that ATO3 expression has two levels of control, both of which are connected to amino acid sensing and regulation. The first involves GCN4, which is required for the bulk of ATO3 expression. The second involves the Ssy1-Ptr3-Ssy5 amino acid sensor system, which is preferentially required for elevated ATO3 expression in rho(o) cells. We propose that ATO3 is induced in rho(o) cells to eliminate the excess ammonia that arises because of a potential defect in ammonia assimilation in those cells.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Butow, RA (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	ronald.butow@utsouthwestern.edu			NIGMS NIH HHS [GM 22525] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022525, R37GM022525] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; Bateman JM, 2002, J BIOL CHEM, V277, P47946, DOI 10.1074/jbc.M209071200; CHELSTOWSKA A, 1995, J BIOL CHEM, V270, P18141, DOI 10.1074/jbc.270.30.18141; Chelstowska A, 1999, YEAST, V15, P1377, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1377::AID-YEA473>3.0.CO;2-0; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Devaux F, 2002, FEBS LETT, V515, P25, DOI 10.1016/S0014-5793(02)02387-6; Dilova I, 2002, CURR BIOL, V12, P389, DOI 10.1016/S0960-9822(02)00677-2; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; Forsberg H, 2001, MOL MICROBIOL, V42, P215, DOI 10.1046/j.1365-2958.2001.02627.x; Forsberg H, 2001, MOL CELL BIOL, V21, P814, DOI 10.1128/MCB.21.3.814-826.2001; Hallstrom TC, 2000, J BIOL CHEM, V275, P37347, DOI 10.1074/jbc.M007338200; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; Jia YK, 1997, MOL CELL BIOL, V17, P1110, DOI 10.1128/MCB.17.3.1110; Kermorgant M, 1997, CURR GENET, V31, P302, DOI 10.1007/s002940050209; Klasson H, 1999, MOL CELL BIOL, V19, P5405; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; Liu ZC, 2003, MOL CELL, V12, P401, DOI 10.1016/S1097-2765(03)00285-5; Liu ZC, 1999, MOL CELL BIOL, V19, P6720; Liu ZC, 2001, EMBO J, V20, P7209, DOI 10.1093/emboj/20.24.7209; Palkova Z, 2002, MOL BIOL CELL, V13, P3901, DOI 10.1091/mbc.E01-12-0149; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; Riego L, 2002, BIOCHEM BIOPH RES CO, V293, P79, DOI 10.1016/S0006-291X(02)00174-2; Rose MD., 1990, METHODS YEAST GENETI; Sekito T, 2000, MOL BIOL CELL, V11, P2103, DOI 10.1091/mbc.11.6.2103; Sekito T, 2002, MOL BIOL CELL, V13, P795, DOI 10.1091/mbc.01-10-0473; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; Traven A, 2001, J BIOL CHEM, V276, P4020, DOI 10.1074/jbc.M006807200; Zikanova B, 2002, BIOCHEM BIOPH RES CO, V294, P962, DOI 10.1016/S0006-291X(02)00589-2	30	41	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45882	45887		10.1074/jbc.M309301200	http://dx.doi.org/10.1074/jbc.M309301200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12966084	hybrid			2022-12-25	WOS:000186452300101
J	Gondi, CS; Lakka, SS; Yanamandra, N; Siddique, K; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS				Gondi, CS; Lakka, SS; Yanamandra, N; Siddique, K; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS			Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis	ONCOGENE			English	Article						adenovirus; antisense; glioma; invasion; uPA and uPAR	PLASMINOGEN-ACTIVATOR RECEPTOR; HUMAN GLIOBLASTOMA CELLS; UROKINASE RECEPTOR; MEDIATED DELIVERY; MONOCLONAL-ANTIBODY; ACTIN CYTOSKELETON; SURFACE UROKINASE; IN-VITRO; CANCER; MICE	Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) play an important role in the invasiveness of gliomas and other infiltrative tumors. In glioma cell lines and tumors, high grade correlates with increased expression of uPAR and uPA. We report here the downregulation of uPAR and uPA by delivery of antisense sequences of uPAR and uPA in a single adenoviral vector, Ad-uPAR-uPA (Ad, adenovirus). The bicistronic construct (Ad-uPAR-uPA) infected glioblastoma cell line had significantly reduced levels of uPAR, uPA enzymatic activity and immunoreactivity for these proteins when compared to controls. The Ad-uPAR-uPA infected cells showed a markedly lower level of invasion in the Matrigel invasion assays, and their spheroids failed to invade the fetal rat brain aggregates in the coculture system. Intracranial injection of SNB19 cells with the Ad-uPAR-uPA antisense bicistronic construct showed inhibited invasiveness and tumorigenicity. Subcutaneous injections of bicistronic antisense constructs into established tumors (U87 MG) caused regression of those tumors. Our results support the therapeutic potential of targeting the individual components of the uPAR-uPA system by using a single adenovirus construct for the treatment of glioma and other invasive cancers.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Dept Neurosurg, Peoria, IL USA; Univ Illinois, Dept Pathol, Peoria, IL USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA.	jsrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NCI NIH HHS [CA 75557] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075557] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi Y, 2001, J BIOL CHEM, V276, P47171, DOI 10.1074/jbc.M104334200; Adachi Y, 2002, ONCOGENE, V21, P87, DOI 10.1038/sj.onc.1204999; Blasi F, 1999, APMIS, V107, P96, DOI 10.1111/j.1699-0463.1999.tb01531.x; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Chang AW, 1998, ARTERIOSCL THROM VAS, V18, P1855, DOI 10.1161/01.ATV.18.12.1855; Chintala SK, 1998, J BIOL CHEM, V273, P13545, DOI 10.1074/jbc.273.22.13545; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; ELLIS V, 1993, J BIOL CHEM, V268, P4806; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; Fibbi G, 1998, LAB INVEST, V78, P1109; FOEKENS JA, 1995, J NATL CANCER I, V87, P751, DOI 10.1093/jnci/87.10.751; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Gutierrez LS, 2000, CANCER RES, V60, P5839; Kjoller L, 2002, BIOL CHEM, V383, P5, DOI 10.1515/BC.2002.002; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KOBAYASHI H, 1993, JPN J CANCER RES, V84, P633, DOI 10.1111/j.1349-7006.1993.tb02023.x; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; LAFRENIE RM, 1992, CANCER RES, V52, P2202; Li H, 1998, GENE THER, V5, P1105, DOI 10.1038/sj.gt.3300742; Min HY, 1996, CANCER RES, V56, P2428; Mohan PM, 1999, CANCER RES, V59, P3369; MOHANAM S, 1993, CANCER RES, V53, P4143; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; Park IK, 1997, INT J CANCER, V71, P867, DOI 10.1002/(SICI)1097-0215(19970529)71:5<867::AID-IJC27>3.0.CO;2-3; SAPPINO AP, 1987, CANCER RES, V47, P4043; SCHMITT M, 1992, BIOL CHEM H-S, V373, P611, DOI 10.1515/bchm3.1992.373.2.611; Sieuwerts AM, 2002, THROMB HAEMOSTASIS, V87, P674; Sturge J, 2002, J CELL SCI, V115, P699; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; YAMAMOTO M, 1994, CANCER RES, V54, P5016; YAMAMOTO M, 1994, CANCER RES, V54, P3656; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767	37	82	93	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5967	5975		10.1038/sj.onc.1206535	http://dx.doi.org/10.1038/sj.onc.1206535			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955075				2022-12-25	WOS:000185137800005
J	Yu, WM; Hawley, TS; Hawley, RG; Qu, CK				Yu, WM; Hawley, TS; Hawley, RG; Qu, CK			Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling	ONCOGENE			English	Article						SHP-2; tyrosine phosphatase; IL-3; hematopoietic cell proliferation and differentiation	COLONY-STIMULATING FACTOR; HEMATOPOIETIC-CELL DEVELOPMENT; GROWTH-FACTOR RECEPTOR; PHOSPHOTYROSINE PHOSPHATASE; BETA-SUBUNIT; SHC-PTB; T-CELL; PROTEIN; ACTIVATION; KINASE	SHP-2 tyrosine phosphatase is highly expressed in hematopoietic cells, however, the function of SHP-2 in hematopoietic cell signaling is not well understood. Here we focus on the role of SHP-2 phosphatase in the signal transduction of interleukin (IL)-3, a cytokine involved in hematopoietic cell survival, proliferation, and differentiation. We established immortalized SHP-2(-/-) hematopoietic cell pools and showed that IL-3-induced proliferative response was diminished in SHP-2(-/-) cells. Moreover, inhibition of the catalytic activity of SHP-2 in wild-type (WT) bone marrow hematopoietic progenitor cells and Ba/F3 cells by overexpression of catalytically inactive SHP-2 mutant suppressed their differentiative and proliferative responses to IL-3, demonstrating an important positive role for SHP-2 in IL-3 signal transduction. Further biochemical analyses revealed that IL-3-induced Jak/Stat, Erk, and PI3 kinase pathways in SHP-2(-/-) cells were impaired and reintroduction of WT SHP-2 into mutant cells partially restored IL-3 signaling. Interestingly, in catalytically inactive SHP-2-overexpressing Ba/F3 cells, although IL-3-induced activation of Jak2 and Erk kinases was reduced and shortened, PI3 kinase activation remained unaltered. Taken together, these results suggest that SHP-2 tyrosine phosphatase plays multiple roles in IL-3 signal transduction, functioning in both catalytic-dependent and -independent manners in the Jak/Stat, Erk, and PI3 kinase pathways.	Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Hematopoiesis, Rockville, MD 20855 USA; Amer Red Cross, Jerome H Holland Lab Biomed Sci, Flow Cytometry Facil, Rockville, MD 20855 USA; George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA	American Red Cross; American Red Cross; George Washington University	Qu, CK (corresponding author), Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Hematopoiesis, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	quc@usa.redcross.org		Hawley, Robert/0000-0003-3512-5818	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066305, R01HL068212] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL66305, R01HL68212] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Bone H, 2000, CELL SIGNAL, V12, P183, DOI 10.1016/S0898-6568(99)00088-1; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; HAWLEY RG, 1994, ONCOGENE, V9, P1; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Maegawa H, 1999, J BIOL CHEM, V274, P30236, DOI 10.1074/jbc.274.42.30236; Manes S, 1999, MOL CELL BIOL, V19, P3125; Miyakawa Y, 2001, J BIOL CHEM, V276, P2494, DOI 10.1074/jbc.M002633200; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Okuda K, 1999, ANN NY ACAD SCI, V872, P305, DOI 10.1111/j.1749-6632.1999.tb08474.x; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; Qu CK, 2001, BLOOD, V97, P911, DOI 10.1182/blood.V97.4.911; Qu CK, 1998, MOL CELL BIOL, V18, P6075, DOI 10.1128/MCB.18.10.6075; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; Yu WM, 2002, BLOOD, V100, P3828, DOI 10.1182/blood-2002-03-0937; Yu WM, 2002, BLOOD, V99, P2351, DOI 10.1182/blood.V99.7.2351; Yuan LP, 2003, J BIOL CHEM, V278, P15208, DOI 10.1074/jbc.M211327200; Zhang SL, 1999, BIOCHEM BIOPH RES CO, V254, P440, DOI 10.1006/bbrc.1998.9959; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	43	57	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5995	6004		10.1038/sj.onc.1206846	http://dx.doi.org/10.1038/sj.onc.1206846			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955078				2022-12-25	WOS:000185137800008
J	Fuchs, M; Hilfiker, A; Kaminski, K; Hilfiker-Kleiner, D; Guener, Z; Klein, G; Podewski, E; Schieffer, B; Rose-John, S; Drexler, H				Fuchs, M; Hilfiker, A; Kaminski, K; Hilfiker-Kleiner, D; Guener, Z; Klein, G; Podewski, E; Schieffer, B; Rose-John, S; Drexler, H			Role of interleukin-6 for left ventricular remodeling and survival after experimental myocardial infarction	FASEB JOURNAL			English	Article						interleukins; mice, knock out; Jak Stat; heart; infarct size	LEUKEMIA-INHIBITORY FACTOR; CARDIAC MYOCYTES; HEART-FAILURE; JAK/STAT PATHWAY; ANGIOTENSIN-II; CYTOKINE EXPRESSION; ACTIVATION; RAT; RECEPTOR; GP130	Circulating levels of interleukin (IL)-6 are elevated after myocardial infarction (MI) and associated with increased morbidity and mortality. Its myocardial expression post-MI suggests a pathophysiological role in this condition. To explore the role of endogenous IL-6, we analyzed MI size, left ventricular (LV) remodeling, and mortality after permanent coronary ligation in IL-6 knockout mice (IL-6(-/-)) and wild-type controls (WT). Six weeks after MI, IL-6(-/-) and WT had similar mortality rates, MI sizes, LV remodeling, and LV dysfunction in vivo, determined by catheterization. Infarct size 24 h post-MI, shown by 2,3,5-triphenyltetrazolium chloride (TTC) staining, was similar at 24 h. Treatment with exogenous IL-6 did not alter MI size in WT. Infarction resulted in marked phosphorylation of STAT3, without differences between genotypes. Leukemia inhibitory factor (LIF) protein was increased 48 h post-MI in IL-6(-/-), and angiotensin II and AT(1) receptor (AT(1)R) protein were strongly increased in IL-6(-/-\) baseline and post-MI, suggesting compensatory up- regulation. Lack of IL-6 does not affect long-term MI size or LV function, remodeling, and survival. In mice lacking IL-6, other members of the IL-6 family such as LIF and other factors signaling via JAK/STAT such as angiotensin may act in a compensatory manner to activate the JAK/STAT pathway, thereby maintaining STAT3 phosphorylation, which is crucial for the cellular effects of IL-6 cytokines.	Hannover Med Sch, D-30625 Hannover, Germany; Univ Kiel, Dept Biochem, Kiel, Germany	Hannover Medical School; University of Kiel	Drexler, H (corresponding author), Hannover Med Sch, Carl Neuberg Str 1, D-30625 Hannover, Germany.	drexler.helmut@mh-hannover.de	Kaminski, Karol A./J-4515-2014; Rose-John, Stefan/A-7998-2010	Kaminski, Karol A./0000-0002-9465-2581; Rose-John, Stefan/0000-0002-7519-3279				Clark WM, 2000, STROKE, V31, P1715, DOI 10.1161/01.STR.31.7.1715; Deten A, 2002, CARDIOVASC RES, V55, P329, DOI 10.1016/S0008-6363(02)00413-3; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; Gwechenberger M, 1999, CIRCULATION, V99, P546, DOI 10.1161/01.CIR.99.4.546; Hilfiker A, 2002, CIRCULATION, V106, P254, DOI 10.1161/01.CIR.0000021426.87274.62; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; Jones KD, 2001, GYNAECOL ENDOSC, V10, P281, DOI 10.1046/j.1365-2508.2001.00461.x; Korte T, 2002, J INTERV CARD ELECTR, V6, P121, DOI 10.1023/A:1015359332161; KUKIELKA GL, 1995, CIRCULATION, V92, P1866, DOI 10.1161/01.CIR.92.7.1866; KUKIELKA GL, 1993, J CLIN INVEST, V92, P1504, DOI 10.1172/JCI116729; Li BS, 1997, AM J PHYSIOL-HEART C, V273, pH2508, DOI 10.1152/ajpheart.1997.273.5.H2508; Lutgens E, 1999, CARDIOVASC RES, V41, P586, DOI 10.1016/S0008-6363(98)00216-8; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Matsui H, 1996, RES COMMUN MOL PATH, V93, P149; Negoro S, 2000, CARDIOVASC RES, V47, P797, DOI 10.1016/S0008-6363(00)00138-3; Nemoto S, 2002, AM J PHYSIOL-HEART C, V282, pH2316, DOI 10.1152/ajpheart.00763.2001; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Ono K, 1998, CIRCULATION, V98, P149, DOI 10.1161/01.CIR.98.2.149; Pan J, 1997, CIRC RES, V81, P611, DOI 10.1161/01.RES.81.4.611; PFEFFER MA, 1979, CIRC RES, V44, P503, DOI 10.1161/01.RES.44.4.503; TorreAmione G, 1996, J AM COLL CARDIOL, V27, P1201, DOI 10.1016/0735-1097(95)00589-7; Tsutamoto T, 1998, J AM COLL CARDIOL, V31, P391, DOI 10.1016/S0735-1097(97)00494-4; VANDAM M, 1993, J BIOL CHEM, V268, P15285; Wang F, 2001, CIRCULATION, V103, P1296; Wollert KC, 1999, CARDIOVASC RES, V43, P838, DOI 10.1016/S0008-6363(99)00145-5; Wollert KC, 1997, CIRCULATION, V95, P1910; YAMAWAKI S, 1995, ELS APPL ELECT MAT, V6, P91; YOUKER K, 1992, J CLIN INVEST, V89, P602, DOI 10.1172/JCI115626; Yue P, 1998, AM J PHYSIOL-HEART C, V275, pH250, DOI 10.1152/ajpheart.1998.275.1.H250	30	110	117	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2118	+		10.1096/fj.03-0331fje	http://dx.doi.org/10.1096/fj.03-0331fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958147				2022-12-25	WOS:000185925100028
J	Rogers, MS; Rohan, RM; Birsner, AE; D'Amato, RJ				Rogers, MS; Rohan, RM; Birsner, AE; D'Amato, RJ			Genetic loci that control vascular endothelial growth factor-induced angiogenesis	FASEB JOURNAL			English	Article						quantitative trait locus; QTL; corneal neovascularization recombinant inbred; BXD	QUANTITATIVE TRAIT LOCI; TUMOR ANGIOGENESIS; PERMEABILITY FACTOR; IN-VITRO; MOUSE; CELLS; MICE; NEOVASCULARIZATION; EXPRESSION; GENOME	Angiogenesis is regulated by the balance between angiogenic stimulators and inhibitors. Numerous reports have demonstrated that tumors induce aggressive angiogenesis by upregulating the production of angiogenesis stimulating growth factors to overcome the baseline levels of endogenous inhibitors. However, the possibility of large differences in the host's responsiveness to angiogenic factors has been largely overlooked. Using the corneal micropocket neovascularization assay, we have observed >10-fold differences in responsiveness to either basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF) among various mouse strains. The inheritance pattern observed for these traits supported a QTL (quantitative trait locus) approach to mapping the genes responsible for the differences in angiogenic responsiveness. To overcome variability in the assay, we used recombinant inbred lines to map this phenotype. In the BXD series of recombinant inbred mouse strains, we have mapped the regions responsible for regulating VEGF-induced angiogenesis using both composite interval mapping and multiple interval mapping. Both approaches link VEGF responsiveness to regions on chromosomes 2 (near D2Mit6) and 10 (near D10Mit20). Candidate angiogenesis-related genes in these regions include those for collagen XVIII/endostatin, matrix metalloproteinase 11, integrin beta(2), prostaglandin D2 synthase, and interleukin-1 receptor antagonist.	Childrens Hosp, Dept Surg, Div Surg Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	D'Amato, RJ (corresponding author), Childrens Hosp, Dept Surg, Div Surg Res, 300 Longwood Ave, Boston, MA 02115 USA.	robert.damato@tch.harvard.edu	Rogers, Michael S/A-9814-2009; Rogers, Michael/AAE-2217-2019	Rogers, Michael S/0000-0002-5250-8434; Rogers, Michael/0000-0002-5250-8434				Balasubramanian SP, 2002, BRIT J CANCER, V87, P1057, DOI 10.1038/sj.bjc.6600625; Blake JA, 2002, NUCLEIC ACIDS RES, V30, P113, DOI 10.1093/nar/30.1.113; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Brockmann GA, 2001, FASEB J, V15, P978, DOI 10.1096/fj.00-0391com; Brockmann GA, 2000, GENOME RES, V10, P1941, DOI 10.1101/gr.GR1499R; Cherrington JM, 2000, ADV CANCER RES, V79, P1, DOI 10.1016/S0065-230X(00)79001-4; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; Coxon A, 2002, ARTHRITIS RHEUM, V46, P2604, DOI 10.1002/art.10546; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Erb MH, 2002, CURR EYE RES, V24, P245, DOI 10.1076/ceyr.24.4.245.8412; Gao YL, 2000, CIRC RES, V87, P739, DOI 10.1161/01.RES.87.9.739; Gupta AR, 2001, J GENE MED, V3, P252, DOI 10.1002/1521-2254(200105/06)3:3<252::AID-JGM185>3.0.CO;2-S; Iughetti P, 2001, CANCER RES, V61, P7375; Jackson AU, 2002, J GERONTOL A-BIOL, V57, pB9, DOI 10.1093/gerona/57.1.B9; Jansen RC, 1996, TRENDS PLANT SCI, V1, P89, DOI 10.1016/S1360-1385(96)80040-9; Kao CH, 1999, GENETICS, V152, P1203; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; LANDER ES, 1989, GENETICS, V121, P185; Lee WH, 1999, ENDOCRINE, V11, P181, DOI 10.1385/ENDO:11:2:181; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lin L, 1998, EXP LUNG RES, V24, P481, DOI 10.3109/01902149809087382; Loughnan MS, 1996, AUST NZ J OPHTHALMOL, V24, P289, DOI 10.1111/j.1442-9071.1996.tb01596.x; Mariotti M, 2000, J BIOL CHEM, V275, P24047, DOI 10.1074/jbc.M001928200; McLaren J, 2000, HUM REPROD UPDATE, V6, P45, DOI 10.1093/humupd/6.1.45; Miller RA, 2002, J GERONTOL A-BIOL, V57, pB3, DOI 10.1093/gerona/57.1.B3; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871; Rowse GJ, 1998, CANCER RES, V58, P2675; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Smith SK, 2001, BRIT J OBSTET GYNAEC, V108, P777, DOI 10.1111/j.1471-0528.2001.00211.x; Taba Y, 2000, CIRC RES, V86, P967, DOI 10.1161/01.RES.86.9.967; Taomoto M, 2000, INVEST OPHTH VIS SCI, V41, P230; Tripodis N, 2001, J NATL CANCER I, V93, P1484, DOI 10.1093/jnci/93.19.1484; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Watson CJ, 2000, CYTOKINE, V12, P1232, DOI 10.1006/cyto.2000.0692; ZENG ZB, 1994, GENETICS, V136, P1457; ZENG ZB, 1993, P NATL ACAD SCI USA, V90, P10972, DOI 10.1073/pnas.90.23.10972; ZENG ZB, 1994, P 5 WORLD C GEN APPL, V22, P65; Zorick TS, 2001, EUR J HUM GENET, V9, P811, DOI 10.1038/sj.ejhg.5200721	43	48	48	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2112	+		10.1096/fj.03-0246fje	http://dx.doi.org/10.1096/fj.03-0246fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958152				2022-12-25	WOS:000185925100019
J	Greco, M; Villani, G; Mazzucchelli, F; Bresolin, N; Papa, S; Attardi, G				Greco, M; Villani, G; Mazzucchelli, F; Bresolin, N; Papa, S; Attardi, G			Marked aging-related decline in efficiency of oxidative phosphorylation in human skin fibroblasts	FASEB JOURNAL			English	Article						fetal fibroblasts; mitochondrial respiration; cytochrome c oxidase	CYTOCHROME-C-OXIDASE; MITOCHONDRIAL-DNA; RESPIRATORY-CHAIN; SKELETAL-MUSCLE; HUMAN-CELLS; IN-VIVO; WILD-TYPE; AGE; MUTATION; LIVER	An extensive analysis has been carried out of mitochondrial biochemical and bioenergetic properties of fibroblasts, mostly skin-derived, from a large group of subjects ranging in age between 20 wk fetal and 103 yr. A striking age-related change observed in a fundamental process underlying mitochondrial biogenesis and function was the very significant decrease in rate of mitochondrial protein synthesis in individuals above 40 yr. The analysis of endogenous respiration rate revealed a significant decrease in the age range from 40 to 90 yr and a tendency to uncoupling in the samples from subjects above 60 year. A surprising finding was the occurrence of a subgroup of individuals greater than or equal to90 yr old whose skin fibroblasts exhibited an exceptionally high respiration rate. This high rate was not due to respiration uncoupling, rather pointing to a compensatory phenomenon, not involving an increase in mtDNA content, in the corresponding skin fibroblast populations, or, possibly, to a selection of a different cell type secondary to more extensive dermal atrophy. The most important aging-related phenotypic effects observed were those that affected the cell oxidative phosphorylation (OX-PHOS) capacity. These were, in particular, the very significant reduction in the ratio of uncoupled to oligomycin-inhibited endogenous respiration observed in intact fibroblasts, which pointed to a decrease with donor's age in the control of respiration by the mitochondrial membrane potential, the very significant decrease in efficiency of OX-PHOS, as determined by novel in situ measurements of P:O ratios, and, consistent with these results, the very significant reduction in the respiratory control ratios. These findings clearly pointed to a dramatic mitochondrial dysfunction, which would lead to a decrease in ATP synthesis rate, with the observed decline in mitochondrial protein synthesis rate being a likely contributing factor. These observations have important implications for understanding the biology of aging, as well as the pathogenesis of aging-related degenerative diseases.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Milan, Inst Clin Neurol, Osped Maggiore Policlin, I-20122 Milan, Italy; Univ Bari, Dept Med Biochem & Biol, I-70124 Bari, Italy	California Institute of Technology; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Universita degli Studi di Bari Aldo Moro	Attardi, G (corresponding author), CALTECH, Div Biol, 156-29, Pasadena, CA 91125 USA.	attardi@caltech.edu		Bresolin, Nereo/0000-0001-6694-3595; Papa, Sergio/0000-0002-4417-1763				Allen RG, 1997, J BIOL CHEM, V272, P24805, DOI 10.1074/jbc.272.40.24805; Attardi G, 2002, MITOCHONDRION, V2, P27, DOI 10.1016/S1567-7249(02)00032-6; Barazzoni R, 2000, J BIOL CHEM, V275, P3343, DOI 10.1074/jbc.275.5.3343; BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2; Boffoli D, 1996, BBA-MOL BASIS DIS, V1315, P66, DOI 10.1016/0925-4439(95)00107-7; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMYN A, 1994, AM J HUM GENET, V54, P966; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; Cuezva JM, 1997, J BIOENERG BIOMEMBR, V29, P365, DOI 10.1023/A:1022450831360; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GONZALEZ IL, 1985, P NATL ACAD SCI USA, V82, P7666, DOI 10.1073/pnas.82.22.7666; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; HAYASHI JI, 1994, J BIOL CHEM, V269, P6878; Isobe K, 1998, J BIOL CHEM, V273, P4601, DOI 10.1074/jbc.273.8.4601; KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0; KUNTZ WS, 2000, J BIOL CHEM, V275, P27741; KUNZ D, 1995, BIOCHEM MOL MED, V54, P105, DOI 10.1006/bmme.1995.1015; Laderman KA, 1996, J BIOL CHEM, V271, P15891, DOI 10.1074/jbc.271.27.15891; Lenaz G, 2000, BBA-BIOENERGETICS, V1459, P397, DOI 10.1016/S0005-2728(00)00177-8; Michikawa Y, 1999, Somat Cell Mol Genet, V25, P333, DOI 10.1023/A:1019972500785; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9; MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167; MULLERHOCKER J, 1993, VIRCHOWS ARCH A, V422, P7, DOI 10.1007/BF01605127; Papa S, 1996, BBA-BIOENERGETICS, V1276, P87, DOI 10.1016/0005-2728(96)00077-1; REIS RJS, 1983, J BIOL CHEM, V258, P9078; TORII K, 1992, AM J RESP CELL MOL, V6, P88, DOI 10.1165/ajrcmb/6.1.88; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; Ventura B, 2002, BBA-BIOENERGETICS, V1553, P249, DOI 10.1016/S0005-2728(01)00246-8; Villani G, 1998, J BIOL CHEM, V273, P31829, DOI 10.1074/jbc.273.48.31829; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; Villani G, 2001, METHOD CELL BIOL, V65, P119, DOI 10.1016/S0091-679X(01)65007-6; Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com; Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499; YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0; YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164; YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699	38	82	84	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1706	+		10.1096/fj.02-1009fje	http://dx.doi.org/10.1096/fj.02-1009fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958183				2022-12-25	WOS:000184471600007
J	Yang, CW; Li, C; Jung, JY; Shin, SJ; Choi, BS; Lim, SW; Sun, BK; Kim, YS; Kim, J; Chang, YS; Bang, BK				Yang, CW; Li, C; Jung, JY; Shin, SJ; Choi, BS; Lim, SW; Sun, BK; Kim, YS; Kim, J; Chang, YS; Bang, BK			Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney	FASEB JOURNAL			English	Article						renal ischemia-reperfusion; erythropoietin; apoptosis; stress kinase; heat shock protein 70	DELAYED GRAFT FUNCTION; HEAT-SHOCK; KINASE ACTIVATION; ACUTE REJECTION; CYCLOSPORINE-A; MAP KINASES; APOPTOSIS; ISCHEMIA/REPERFUSION; HEAT-SHOCK-PROTEIN-70; EXPRESSION	Improving the ability of the kidney to tolerate ischemic injury has important implications. We investigated the effect of recombinant human erythropoietin (rHuEPO) treatment on subsequent ischemia/reperfusion (I/R) injury and evaluated the role of heat shock protein (HSP) 70 in rHuEPO-induced renal protection. rHuEPO (3000 U/kg) was administered 24 h before I/R injury, and rats were killed at 24, 48, and 72 h after I/R injury. Pretreatment of rHuEPO resulted in the following: i) decreased serum creatinine level; ii) decreased tubular cell apoptosis and necrosis, measured by DNA fragmentation analysis and TUNEL staining and histomorphological criteria; iii) decreased tubular cell proliferation as determined by proliferating cell nuclear antigen expression; iv) increased bcl-2 protein and decreased caspase 3 activity; and v) decreased JNK expression. rHuEPO treatment increased HSP70 expression in a dose-dependent manner in normal rat kidneys, and inhibition of HSP70 expression by quercetin eliminated the renoprotective effect of rHuEPO in ischemic kidneys. Our study demonstrates that rHuEPO has a protective effect on subsequent I/R injury and that this effect is associated with induction of HSP70. Our study provides a new avenue for therapy to prevent renal damage after I/R injury.	Catholic Univ Korea, Dept Anat, Cell Death Dis Res Ctr, Seoul 137040, South Korea; Catholic Univ Korea, Cell Death Dis Res Ctr, Dept Internal Med, Coll Med, Seoul, South Korea; YanBian Univ, Coll Med, Affiliated Hosp, Nephrol & Dialysis Unit, JiLan 133000, Peoples R China	Catholic University of Korea; Catholic University of Korea; Yanbian University	Kim, J (corresponding author), Catholic Univ Korea, Dept Anat, Cell Death Dis Res Ctr, 505 Banpo Dong, Seoul 137040, South Korea.	jinkim@catholic.ac.kr		JUNG, JU YOUNG/0000-0002-6355-5738				Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Blondeau N, 2002, NEUROSCIENCE, V109, P231, DOI 10.1016/S0306-4522(01)00473-0; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Chong ZZ, 2002, J CEREBR BLOOD F MET, V22, P503, DOI 10.1097/00004647-200205000-00001; Di Mari JF, 1999, AM J PHYSIOL-RENAL, V277, pF195, DOI 10.1152/ajprenal.1999.277.2.F195; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Hayashi Y, 2002, CIRCULATION, V106, P2601, DOI 10.1161/01.CIR.0000035651.72240.07; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Ikeyama S, 2001, J HEPATOL, V35, P53, DOI 10.1016/S0168-8278(01)00053-8; Ishizaka N, 2002, HYPERTENSION, V39, P122, DOI 10.1161/hy1201.096818; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jacobs-Helber SM, 2000, BLOOD, V96, P933, DOI 10.1182/blood.V96.3.933.015k52_933_940; Kaushal GP, 1998, AM J PHYSIOL-RENAL, V274, pF587, DOI 10.1152/ajprenal.1998.274.3.F587; Kelly KJ, 2001, KIDNEY INT, V59, P1798, DOI 10.1046/j.1523-1755.2001.0590051798.x; Kim J, 1999, J AM SOC NEPHROL, V10, P1; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Madamanchi NR, 2001, ARTERIOSCL THROM VAS, V21, P321, DOI 10.1161/01.ATV.21.3.321; McLaren AJ, 1999, CLIN TRANSPLANT, V13, P266, DOI 10.1034/j.1399-0012.1999.130308.x; Mehta A, 2002, MOL CELL BIOCHEM, V240, P19, DOI 10.1023/A:1020675721351; MESTRIL R, 1994, J CLIN INVEST, V93, P759, DOI 10.1172/JCI117030; MIYAKE T, 1977, J BIOL CHEM, V252, P5558; MORIN R L, 1990, P1; Nemoto T, 2001, KIDNEY INT, V59, P246, DOI 10.1046/j.1523-1755.2001.00485.x; Nogae S, 1998, J AM SOC NEPHROL, V9, P620; Oberbauer R, 2001, J LAB CLIN MED, V138, P343, DOI 10.1067/mlc.2001.118926; Park KM, 2001, J BIOL CHEM, V276, P11870, DOI 10.1074/jbc.M007518200; PETERSEN NS, 1981, P NATL ACAD SCI-BIOL, V78, P1708, DOI 10.1073/pnas.78.3.1708; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; SANFILIPPO F, 1984, TRANSPLANTATION, V38, P643, DOI 10.1097/00007890-198412000-00019; Sesti F, 2002, GYNECOL OBSTET INVES, V54, P1, DOI 10.1159/000064688; TROPPMANN C, 1995, TRANSPLANTATION, V59, P962, DOI 10.1097/00007890-199504150-00007; Uddin S, 2000, BIOCHEM BIOPH RES CO, V275, P16, DOI 10.1006/bbrc.2000.3266; Vairano M, 2002, EUR J NEUROSCI, V16, P584, DOI 10.1046/j.1460-9568.2002.02125.x; VANES A, 1983, TRANSPLANTATION, V36, P255; VAZIRI ND, 1994, AM J PHYSIOL, V266, pF360, DOI 10.1152/ajprenal.1994.266.3.F360; VENKATACHALAM MA, 1978, KIDNEY INT, V14, P31, DOI 10.1038/ki.1978.87; Wang JG, 2002, MULTIBODY SYST DYN, V7, P145, DOI 10.1023/A:1014491204982; Wang XX, 2002, J NEUROCHEM, V83, P1094, DOI 10.1046/j.1471-4159.2002.01224.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAMOTO K, 1984, AM J PATHOL, V116, P253; Yang CW, 2003, TRANSPLANTATION, V75, P20, DOI 10.1097/01.TP.0000040002.12912.65; Yang CW, 2001, TRANSPLANTATION, V72, P1753; Yang CW, 2001, EXP NEPHROL, V9, P284; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Ysebaert DK, 1997, TRANSPLANT P, V29, P2348, DOI 10.1016/S0041-1345(97)00396-5	52	202	229	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1754	+		10.1096/fj.02-1191fje	http://dx.doi.org/10.1096/fj.02-1191fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958199				2022-12-25	WOS:000184471600018
J	Voigt, P; Knapp, EW				Voigt, P; Knapp, EW			Tuning heme redox Potentials in the cytochrome c subunit of photosynthetic reaction centers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSEUDOMONAS-VIRIDIS; ELECTRON-TRANSFER; PROTONATION; OXIDASE; SITE; RESOLUTION; PROTEINS; DYNAMICS; PROGRAM; CHARGES	The photosynthetic reaction center ( RC) from Rhodopseudomonas viridis contains four cytochrome c hemes. They establish the initial part of the electron transfer ( ET) chain through the RC. Despite their chemical identity, their midpoint potentials cover an interval of 440 mV. The individual heme midpoint potentials determine the ET kinetics and are therefore tuned by specific interactions with the protein environment. Here, we use an electrostatic approach based on the solution of the linearized Poisson-Boltzmann equation to evaluate the determinants of individual heme redox potentials. Our calculated redox potentials agree within 25 meV with the experimentally measured values. The heme redox potentials are mainly governed by solvent accessibility of the hemes and propionic acids, by neutralization of the negative charges at the propionates through either protonation or formation of salt bridges, by interactions with other hemes, and to a lesser extent, with other titratable protein side chains. In contrast to earlier computations on this system, we used quantum chemically derived atomic charges, considered an equilibrium-distributed protonation pattern, and accounted for interdependencies of site-site interactions. We provide values for the working potentials of all hemes as a function of the solution redox potential, which are crucial for calculations of ET rates. We identify residues whose site-directed mutation might significantly influence ET processes in the cytochrome c part of the RC. Redox potentials measured on a previously generated mutant could be reproduced by calculations based on a model structure of the mutant generated from the wild type RC.	Free Univ Berlin, Inst Chem, Dept Biol Chem & Pharm, D-14195 Berlin, Germany	Free University of Berlin	Knapp, EW (corresponding author), Free Univ Berlin, Inst Chem, Dept Biol Chem & Pharm, Takustr 6, D-14195 Berlin, Germany.	knapp@chemie.fu-berlin.de	Knapp, Ernst-Walter/AAH-6720-2021; Knapp, Ernst-Walter/E-4493-2010	Knapp, Ernst-Walter/0000-0002-2858-0460; Knapp, Ernst-Walter/0000-0002-2858-0460; Voigt, Philipp/0000-0003-4366-0490				ALEGRIA G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P258, DOI 10.1016/S0005-2728(05)80108-2; Baptista AM, 1999, BIOPHYS J, V76, P2978, DOI 10.1016/S0006-3495(99)77452-7; BASHFORD D, 1992, J MOL BIOL, V224, P473, DOI 10.1016/0022-2836(92)91009-E; BASHFORD D, 1991, J PHYS CHEM-US, V95, P9556, DOI 10.1021/j100176a093; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1988, PROTEINS, V4, P148, DOI 10.1002/prot.340040208; Chen IP, 2000, BIOCHEMISTRY-US, V39, P3592, DOI 10.1021/bi992443p; CORNELL WD, 1993, J AM CHEM SOC, V115, P9620, DOI 10.1021/ja00074a030; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; DRACHEVA SM, 1988, EUR J BIOCHEM, V171, P253, DOI 10.1111/j.1432-1033.1988.tb13784.x; Frisch G.W., 2016, GAUSSIAN 16 REVISION; FRITZSCH G, 1989, BIOCHIM BIOPHYS ACTA, V977, P157, DOI 10.1016/S0005-2728(89)80066-0; GUNNER MR, 1991, P NATL ACAD SCI USA, V88, P9151, DOI 10.1073/pnas.88.20.9151; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lancaster CRD, 1997, STRUCTURE, V5, P1339, DOI 10.1016/S0969-2126(97)00285-2; LANCASTER CRD, 2001, HDB METALLOPROTEINS, P119; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Michel H, 1999, BIOCHEMISTRY-US, V38, P15129, DOI 10.1021/bi9910934; MULLIKEN RS, 1955, J CHEM PHYS, V23, P1833, DOI 10.1063/1.1740588; NITSCHKE W, 1989, BIOCHEMISTRY-US, V28, P3161, DOI 10.1021/bi00434a008; Osyczka A, 1998, BIOCHEMISTRY-US, V37, P11732, DOI 10.1021/bi980910h; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Popovic DM, 2001, J AM CHEM SOC, V123, P6040, DOI 10.1021/ja003878z; Rabenstein B, 1998, BIOCHEMISTRY-US, V37, P2488, DOI 10.1021/bi971921y; Rabenstein B, 1998, EUR BIOPHYS J BIOPHY, V27, P626, DOI 10.1007/s002490050174; *SCHROD INC, 2000, JAG 4 2; St-Amant A, 1996, REV COMPUTATIONAL CH, V7, P217; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Ullmann GM, 2000, J PHYS CHEM B, V104, P6293, DOI 10.1021/jp000711j; Ullmann GM, 1999, EUR BIOPHYS J BIOPHY, V28, P533, DOI 10.1007/s002490050236; Warshel A, 1998, CURR OPIN STRUC BIOL, V8, P211, DOI 10.1016/S0959-440X(98)80041-9; Wilson GS, 1983, BIOELECTROCH BIOENER, V1, P172	37	55	56	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					51993	52001		10.1074/jbc.M307560200	http://dx.doi.org/10.1074/jbc.M307560200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	12975370	hybrid			2022-12-25	WOS:000187480700005
J	Alphey, MS; Williams, RAM; Mottram, JC; Coombs, GH; Hunter, WN				Alphey, MS; Williams, RAM; Mottram, JC; Coombs, GH; Hunter, WN			The crystal structure of Leishmania major 3-mercaptopyruvate sulfurtransferase - A three-domain architecture with a serine protease-like triad at the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LIVER RHODANESE; ESCHERICHIA-COLI; MERCAPTOPYRUVATE SULFURTRANSFERASE; MITOCHONDRIAL RHODANESE; SUBSTITUTED RHODANESE; CATALYTIC DOMAIN; SULFUR; SEQUENCE; THIOREDOXIN; PHOSPHATASE	Leishmania major 3-mercaptopyruvate sulfurtransferase is a crescent-shaped molecule comprising three domains. The N-terminal and central domains are similar to the thiosulfate sulfurtransferase rhodanese and create the active site containing a persulfurated catalytic cysteine (Cys-253) and an inhibitory sulfite coordinated by Arg-74 and Arg-185. A serine protease-like triad, comprising Asp-61, His-75, and Ser-255, is near Cys-253 and represents a conserved feature that distinguishes 3-mercaptopyruvate sulfurtransferases from thiosulfate sulfurtransferases. During catalysis, Ser-255 may polarize the carbonyl group of 3- mercaptopyruvate to assist thiophilic attack, whereas Arg-74 and Arg-185 bind the carboxylate group. The enzyme hydrolyzes benzoyl-Arg-p-nitroanilide, an activity that is sensitive to the presence of the serine protease inhibitor N-alpha-p-tosyl-L- lysine chloromethyl ketone, which also lowers 3- mercaptopyruvate sulfurtransferase activity, presumably by interference with the contribution of Ser-255. The L. major 3- mercaptopyruvate sulfurtransferase is unusual with an 80-amino acid C-terminal domain, bearing remarkable structural similarity to the FK506-binding protein class of peptidylprolyl cis/trans-isomerase. This domain may be involved in mediating protein folding and sulfurtransferase-protein interactions.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland	University of Dundee; University of Glasgow; University of Glasgow	Hunter, WN (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.	w.n.hunter@dundee.ac.uk	Williams, Roderick/V-4317-2019; Hunter, William/AAE-3947-2019	Williams, Roderick/0000-0001-5065-9768; Mottram, Jeremy/0000-0001-5574-3766				Adams H, 2002, FEBS LETT, V518, P173, DOI 10.1016/S0014-5793(02)02695-9; Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bordo D, 2002, EMBO REP, V3, P741, DOI 10.1093/embo-reports/kvf150; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Colnaghi R, 2001, FEBS LETT, V500, P153, DOI 10.1016/S0014-5793(01)02610-2; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; Gliubich F, 1996, J BIOL CHEM, V271, P21054, DOI 10.1074/jbc.271.35.21054; Gliubich F, 1998, ACTA CRYSTALLOGR D, V54, P481, DOI 10.1107/S090744499701216X; HANNESTAD U, 1981, BIOCHEM MED METAB B, V26, P106, DOI 10.1016/0006-2944(81)90035-1; Hofmann K, 1998, J MOL BIOL, V282, P195, DOI 10.1006/jmbi.1998.1998; HOL WGJ, 1983, FUND APPL TOXICOL, V3, P370, DOI 10.1016/S0272-0590(83)80007-4; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamphausen T, 2002, PLANT J, V32, P263, DOI 10.1046/j.1365-313X.2002.01420.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krauth-Siegel RL, 1999, PARASITOL TODAY, V15, P404, DOI 10.1016/S0169-4758(99)01516-1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; LIKJ LJ, 1983, BIOCHEMISTRY-US, V22, P2952; Meister A., 1953, FED PROC, V12, P245; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; Mueller EG, 2001, J BIOL CHEM, V276, P33588, DOI 10.1074/jbc.M104067200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAGAHARA N, 1995, J BIOL CHEM, V270, P16230, DOI 10.1074/jbc.270.27.16230; Nagahara N, 1996, J BIOL CHEM, V271, P27395, DOI 10.1074/jbc.271.44.27395; Nagahara N, 1999, HISTOL HISTOPATHOL, V14, P1277, DOI 10.14670/HH-14.1277; Nakamura T, 2000, EUR J BIOCHEM, V267, P5621, DOI 10.1046/j.1432-1327.2000.01633.x; Nandi DL, 2000, INT J BIOCHEM CELL B, V32, P465, DOI 10.1016/S1357-2725(99)00035-7; Nandi DL, 1998, INT J BIOCHEM CELL B, V30, P973, DOI 10.1016/S1357-2725(98)00050-8; NICHOLLS A, 1993, GRASP MANUAL VERSION; NISHINO T, 1983, P NATL ACAD SCI-BIOL, V80, P1826, DOI 10.1073/pnas.80.7.1826; Ogasawara Y, 2001, P NATL ACAD SCI USA, V98, P9494, DOI 10.1073/pnas.171320998; OGATA K, 1990, J BIOL CHEM, V265, P8087; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PAGANI S, 1984, EUR J BIOCHEM, V142, P361, DOI 10.1111/j.1432-1033.1984.tb08295.x; Palenchar PM, 2000, J BIOL CHEM, V275, P8283, DOI 10.1074/jbc.275.12.8283; Papenbrock J, 2000, EUR J BIOCHEM, V267, P145, DOI 10.1046/j.1432-1327.2000.00980.x; Pereira PJB, 2002, EMBO REP, V3, P88, DOI 10.1093/embo-reports/kvf009; PERRAKIS A, 1997, ACTA CRYSTALLOGR D, V30, P551; PLOEGMAN JH, 1978, J MOL BIOL, V123, P557, DOI 10.1016/0022-2836(78)90207-3; PLOEGMAN JH, 1979, J MOL BIOL, V127, P149, DOI 10.1016/0022-2836(79)90236-5; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; Quigley PM, 2003, P NATL ACAD SCI USA, V100, P3137, DOI 10.1073/pnas.0530312100; Ray WK, 2000, J BACTERIOL, V182, P2277, DOI 10.1128/JB.182.8.2277-2284.2000; Riboldi-Tunnicliffe A, 2001, NAT STRUCT BIOL, V8, P779, DOI 10.1038/nsb0901-779; SCHLESINGER P, 1974, J BIOL CHEM, V249, P780; Sinars CR, 2003, P NATL ACAD SCI USA, V100, P868, DOI 10.1073/pnas.0231020100; SORBO B, 1957, BIOCHIM BIOPHYS ACTA, V24, P324, DOI 10.1016/0006-3002(57)90201-9; Spallarossa A, 2001, STRUCTURE, V9, P1117, DOI 10.1016/S0969-2126(01)00666-9; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Williams RAM, 2003, J BIOL CHEM, V278, P1480, DOI 10.1074/jbc.M209395200; WILSON KP, 1995, ACTA CRYSTALLOGR D, V51, P511, DOI 10.1107/S0907444994014514	63	32	33	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48219	48227		10.1074/jbc.M307187200	http://dx.doi.org/10.1074/jbc.M307187200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12952945	hybrid			2022-12-25	WOS:000186731400105
J	Goransson, U; Craik, DJ				Goransson, U; Craik, DJ			Disulfide mapping of the cyclotide kalata B1 - Chemical proof of the cyclic cystine knot motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROCYCLIC PEPTIDES; PLANT CYCLOTIDES; 3-DIMENSIONAL STRUCTURE; SELECTIVE REDUCTION; STRUCTURAL MOTIF; PROTEINS; POLYPEPTIDES; CIRCULIN; TRYPSIN; ELUCIDATION	The cyclotides are a recently discovered family of plant proteins that have the fascinating structural feature of a continuous cyclic backbone and, putatively, a knotted arrangement of their three conserved disulfide bonds. We here show definite chemical proof of the I-IV, II-V, III-VI knotted disulfide connectivity of the prototypic cyclotide kalata B1. This has been achieved by a new approach for disulfide analysis, involving partial reduction and stepwise alkylation including introduction of charges and enzymatic cleavage sites by aminoethylation of cysteines. The approach overcomes the intrinsic difficulties for disulfide mapping of cyclotides, i.e. the cyclic amide backbone, lack of cleavage sites between cysteines, and a low or clustered content of basic amino acids, and allowed a direct determination of the disulfide bonds in kalata B1 using analysis by mass spectrometry. The established disulfide connectivity is unequivocally shown to be cystine knotted by a topological analysis. This is the first direct chemical determination of disulfides in native cyclotides and unambiguously confirms the unique cyclic cystine knot motif.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Uppsala Univ, Ctr Biomed, Dept Med Chem, Div Pharmacognosy, S-75123 Uppsala, Sweden	University of Queensland; Uppsala University		d.craik@imb.uq.edu.au	Craik, David/B-1695-2010	Craik, David/0000-0003-0007-6796; Goransson, Ulf/0000-0002-5005-9612				Bokesch HR, 2001, J NAT PROD, V64, P249, DOI 10.1021/np000372l; Broussalis AM, 2001, PHYTOCHEMISTRY, V58, P47, DOI 10.1016/S0031-9422(01)00173-X; BURNS JA, 1991, J ORG CHEM, V56, P2648, DOI 10.1021/jo00008a014; Claeson P, 1998, J NAT PROD, V61, P77, DOI 10.1021/np970342r; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2001, TOXICON, V39, P1809, DOI 10.1016/S0041-0101(01)00129-5; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; Craik DJ, 2002, CURR OPIN DRUG DI DE, V5, P251; Daly NL, 2003, J BIOL CHEM, V278, P6314, DOI 10.1074/jbc.M210492200; Derua R, 1996, BIOCHEM BIOPH RES CO, V228, P632, DOI 10.1006/bbrc.1996.1708; Felizmenio-Quimio ME, 2001, J BIOL CHEM, V276, P22875, DOI 10.1074/jbc.M101666200; Goransson U, 2003, ANAL BIOCHEM, V318, P107, DOI 10.1016/S0003-2697(03)00114-3; Goransson U, 1999, J NAT PROD, V62, P283, DOI 10.1021/np9803878; GRAN L, 1973, ACTA PHARMACOL TOX, V33, P400; GRAN L, 1973, LLOYDIA, V36, P174; GRAY W. R., 1997, PROTEIN STRUCTURE PR, P165; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GRAY WR, 1993, PROTEIN SCI, V2, P1749, DOI 10.1002/pro.5560021018; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; Gustafson KR, 2000, J NAT PROD, V63, P176, DOI 10.1021/np990432r; Hallock YF, 2000, J ORG CHEM, V65, P124, DOI 10.1021/jo990952r; Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756; ISHII Y, 1986, BIOPHYS J, V50, P75, DOI 10.1016/S0006-3495(86)83440-3; Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898; LIANG CZ, 1995, J AM CHEM SOC, V117, P4201, DOI 10.1021/ja00120a001; Lindholm P, 2002, MOL CANCER THER, V1, P365; LINDLEY H, 1956, NATURE, V178, P647, DOI 10.1038/178647a0; Mislow K, 1996, CROAT CHEM ACTA, V69, P1385; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; Rosengren KJ, 2003, J BIOL CHEM, V278, P8606, DOI 10.1074/jbc.M211147200; Rucker C, 2002, MATCH-COMMUN MATH CO, P153; SAETHER O, 1995, BIOCHEMISTRY-US, V34, P4147, DOI 10.1021/bi00013a002; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; SHON KJ, 1994, BIOCHEMISTRY-US, V33, P11420, DOI 10.1021/bi00204a003; Skjeldal L, 2002, ARCH BIOCHEM BIOPHYS, V399, P142, DOI 10.1006/abbi.2002.2769; Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; Trabi M, 2001, BIOCHEMISTRY-US, V40, P4211, DOI 10.1021/bi002028t; van den Hooven HW, 2001, BIOCHEMISTRY-US, V40, P3458, DOI 10.1021/bi0023089; WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002; Wu J, 1998, ANAL BIOCHEM, V258, P268, DOI 10.1006/abio.1998.2596; Wu J, 1998, PROTEIN SCI, V7, P1017; Wu J, 1997, PROTEIN SCI, V6, P391; Wu J, 1996, ANAL BIOCHEM, V235, P161, DOI 10.1006/abio.1996.0108	44	122	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48188	48196		10.1074/jbc.M308771200	http://dx.doi.org/10.1074/jbc.M308771200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12960160	hybrid			2022-12-25	WOS:000186731400101
J	Huang, JH; Asawa, T; Takato, T; Sakai, R				Huang, JH; Asawa, T; Takato, T; Sakai, R			Cooperative roles of Fyn and cortactin in cell migration of metastatic murine melanoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; CARCINOMA-CELLS; C-SRC; INTEGRIN; ACTIN; OVEREXPRESSION; ASSOCIATION; ACTIVATION; SUBSTRATE	Src family kinases are major regulators of various integrin-mediated biological processes, although their functional roles and substrates in cancer metastasis are unknown. We explored the roles of Src family tyrosine kinases in cell migration and the spread of K-1735 murine melanoma cell lines with low or high metastatic potential. Corresponding to elevated cell motility and spreading ability, Fyn was selectively activated among Src family kinases, and the cell motility was blocked by an inhibitor of Src family kinases. Significant tyrosine phosphorylation of cortactin, stable complex formation between activated Fyn and cortactin, and co-localization of cortactin with Fyn at cell membranes were all observed only in cells with high metastatic potential. Both integrin-mediated Fyn activation and hyperphosphorylation of cortactin were observed 2 - 5 h after stimulation in highly metastatic cells, and they required de novo protein synthesis. We demonstrate that cortactin is a specific substrate and cooperative effector of Fyn in integrin-mediated signaling processes regulating metastatic potential.	Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, Tokyo 1040045, Japan; Univ Tokyo, Dept Oral & Maxillofacial Surg, Bunkyo Ku, Tokyo 1138655, Japan; RIKEN, Brain Sci Inst, Lab Mol Neurogenesis, Wako, Saitama 3510198, Japan	National Cancer Center - Japan; University of Tokyo; RIKEN	Sakai, R (corresponding author), Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.			Sakai, Ryuichi/0000-0001-6833-1103				BASARA ML, 1985, CANCER RES, V45, P2487; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; Boyer B, 2002, ONCOGENE, V21, P2347, DOI 10.1038/sj.onc.1205298; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; FIDLER IJ, 1981, J NATL CANCER I, V67, P947; FIDLER IJ, 1990, CANCER RES, V50, P6130; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang JH, 2002, J BIOL CHEM, V277, P27265, DOI 10.1074/jbc.M203063200; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Kaksonen M, 2000, J CELL SCI, V113, P4421; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Li YS, 2001, CANCER RES, V61, P6906; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Sakai R, 1997, ONCOGENE, V14, P1419, DOI 10.1038/sj.onc.1200954; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; TAKAYAMA T, 1993, INT J CANCER, V54, P875, DOI 10.1002/ijc.2910540525; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; ZHAN X, 1993, J BIOL CHEM, V268, P24427	38	58	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48367	48376		10.1074/jbc.M308213200	http://dx.doi.org/10.1074/jbc.M308213200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	13129922	hybrid			2022-12-25	WOS:000186731400122
J	Im, YJ; Lee, JH; Park, SH; Park, SJ; Rho, SH; Kang, GB; Kim, E; Eom, SH				Im, YJ; Lee, JH; Park, SH; Park, SJ; Rho, SH; Kang, GB; Kim, E; Eom, SH			Crystal structure of the Shank PDZ-ligand complex reveals a class IPDZ interaction and a novel PDZ-PDZ dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEINS; SYNAPTIC PROTEINS; CARBOXYL-TERMINI; BETA-PIX; FAMILY; DOMAIN; RECOGNITION; MULTIMERIZATION; ASSOCIATION; REGULATOR	The Shank/proline-rich synapse-associated protein family of multidomain proteins is known to play an important role in the organization of synaptic multiprotein complexes. For instance, the Shank PDZ domain binds to the C termini of guanylate kinase-associated proteins, which in turn interact with the guanylate kinase domain of postsynaptic density-95 scaffolding proteins. Here we describe the crystal structures of Shank1 PDZ in its peptide free form and in complex with the C-terminal hexapeptide (EAQTRL) of guanylate kinase-associated protein (GKAP1a) determined at 1.8- and 2.25-Angstrom resolutions, respectively. The structure shows the typical class I PDZ interaction of PDZ-peptide complex with the consensus sequence -X-(Thr/Ser)-X-Leu. In addition, Asp-634 within the Shank1 PDZ domain recognizes the positively charged Arg at - 1 position and hydrogen bonds, and salt bridges between Arg-607 and the side chains of the ligand at - 3 and - 5 positions contribute further to the recognition of the peptide ligand. Remarkably, whether free or complexed, Shank1 PDZ domains form dimers with a conserved betaB/betaC loop and N-terminal betaA strands, suggesting a novel model of PDZ-PDZ homodimerization. This implies that antiparallel dimerization through the N-terminal betaA strands could be a common configuration among PDZ dimers. Within the dimeric structure, the two-peptide binding sites are arranged so that the N termini of the bound peptide ligands are in close proximity and oriented toward the 2-fold axis of the dimer. This configuration may provide a means of facilitating dimeric organization of PDZ-target assemblies.	Kwangju Inst Sci & Technol, Dept Life Sci, Gwangju 500712, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Natl Creat Res Initiat Ctr Synaptogenesis, Taejon 305701, South Korea	Gwangju Institute of Science & Technology (GIST); Korea Advanced Institute of Science & Technology (KAIST)	Eom, SH (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Gwangju 500712, South Korea.		Kim, Eunjoon/C-1566-2011	Rho, Seong-Hwan/0000-0002-8650-8205; Park, Soo Jeong/0000-0002-9224-9932				Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Birrane G, 2003, J BIOL CHEM, V278, P1399, DOI 10.1074/jbc.C200571200; Boeckers TM, 1999, J NEUROSCI, V19, P6506; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dauter Z, 2000, ACTA CRYSTALLOGR D, V56, P232, DOI 10.1107/S0907444999016352; Dong HL, 1999, J NEUROSCI, V19, P6930, DOI 10.1523/JNEUROSCI.19-16-06930.1999; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Im YJ, 2003, J BIOL CHEM, V278, P8501, DOI 10.1074/jbc.M212263200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; Kimple ME, 2001, EMBO J, V20, P4414, DOI 10.1093/emboj/20.16.4414; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Laura RP, 2002, J BIOL CHEM, V277, P12906, DOI 10.1074/jbc.M200818200; Lim S, 2001, MOL CELL NEUROSCI, V17, P385, DOI 10.1006/mcne.2000.0940; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; Park E, 2003, J BIOL CHEM, V278, P19220, DOI 10.1074/jbc.M301052200; Park SH, 2002, ACTA CRYSTALLOGR D, V58, P1353, DOI 10.1107/S0907444902009162; Sheng M, 2000, J CELL SCI, V113, P1851; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Yao I, 1999, J BIOL CHEM, V274, P27463, DOI 10.1074/jbc.274.39.27463	38	85	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48099	48104		10.1074/jbc.M306919200	http://dx.doi.org/10.1074/jbc.M306919200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12954649	hybrid			2022-12-25	WOS:000186731400090
J	Numao, S; Kuntz, DA; Withers, SG; Rose, DR				Numao, S; Kuntz, DA; Withers, SG; Rose, DR			Insights into the mechanism of Drosophila melanogaster Golgi alpha-mannosidase II through the structural analysis of covalent reaction intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SEQUENCE SIMILARITIES; GLYCOSIDASE MECHANISMS; CATALYTIC NUCLEOPHILE; IDENTIFICATION; CRYSTALLOGRAPHY; CLASSIFICATION; METASTASIS; DISTORTION; FLUORIDES; FAMILIES	The family 38 golgi alpha-mannosidase II, thought to cleave mannosidic bonds through a double displacement mechanism involving a reaction intermediate, is a clinically important enzyme involved in glycoprotein processing. The structure of three different covalent glycosyl-enzyme intermediates have been determined to 1.2-Angstrom resolution for the Golgi alpha-mannosidase II from Drosophila melanogaster by use of fluorinated sugar analogues, both with the wild-type enzyme and a mutant enzyme in which the acid/base catalyst has been removed. All these structures reveal sugar intermediates bound in a distorted S-1(5) skew boat conformation. The similarity of this conformation with that of the substrate in the recently determined structure of the Michaelis complex of a beta-mannanase (Ducros, V. M. A., Zechel, D. L., Murshudov, G. N., Gilbert, H. J., Szabo, L., Stoll, D., Withers, S. G., and Davies, G. J. (2002) Angew. Chem. Int. Ed. Engl. 41, 2824 - 2827) suggests that these disparate enzymes have recruited common stereoelectronic features in evolving their catalytic mechanisms.	Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; Princess Margaret Hosp, Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of British Columbia; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Rose, DR (corresponding author), Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Numao, Shin/0000-0002-6204-7117				Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brunger AT, 2002, ACCOUNTS CHEM RES, V35, P404, DOI 10.1021/ar010034r; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURDA P, 1999, IOCH BIOPHYS ACTA, V1426, P239; Couldrey C, 2000, BREAST CANCER RES, V2, P321, DOI 10.1186/bcr75; Davies GJ, 2003, BIOCHEM SOC T, V31, P523, DOI 10.1042/BST0310523; DeLano W, 2002, PYMOL 0 99; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Deslongchamps P., 1983, ORGANIC CHEM SERIES, V1; Ducros VMA, 2002, ANGEW CHEM INT EDIT, V41, P2824, DOI 10.1002/1521-3773(20020802)41:15<2824::AID-ANIE2824>3.0.CO;2-G; Goss PE, 1997, CLIN CANCER RES, V3, P1077; Goss PE, 1995, CLIN CANCER RES, V1, P935; Granovsky M, 2000, NAT MED, V6, P306; HALL LD, 1971, CAN J CHEMISTRY, V49, P118, DOI 10.1139/v71-017; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Henrissat B, 1998, BIOCHEM SOC T, V26, P153, DOI 10.1042/bst0260153; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; Howard S, 1997, BIOCHEM BIOPH RES CO, V238, P896, DOI 10.1006/bbrc.1997.7148; Howard S, 1998, J BIOL CHEM, V273, P2067, DOI 10.1074/jbc.273.4.2067; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; LEATHERBARROW RJ, 2001, GRAFIT VERSION 4 0 1; Lowry T. H., 1987, MECH THEORY ORGANIC; McCarter JD, 1996, J BIOL CHEM, V271, P6889, DOI 10.1074/jbc.271.12.6889; Numao S, 2000, FEBS LETT, V484, P175, DOI 10.1016/S0014-5793(00)02148-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SHARMA SK, 1995, TETRAHEDRON LETT, V36, P5627; Sidhu G, 1999, BIOCHEMISTRY-US, V38, P5346, DOI 10.1021/bi982946f; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STODDART JF, 1971, STEREOCHEMISTRY CARB, P49; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; van den Elsen JMH, 2001, EMBO J, V20, P3008, DOI 10.1093/emboj/20.12.3008; Vasella A, 2002, CURR OPIN CHEM BIOL, V6, P619, DOI 10.1016/S1367-5931(02)00380-0; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+	36	86	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48074	48083		10.1074/jbc.M309249200	http://dx.doi.org/10.1074/jbc.M309249200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12960159	hybrid			2022-12-25	WOS:000186731400087
J	Crimeen-Irwin, B; Ellis, S; Christiansen, D; Ludford-Menting, MJ; Milland, J; Lanteri, M; Loveland, BE; Gerlier, D; Russell, SM				Crimeen-Irwin, B; Ellis, S; Christiansen, D; Ludford-Menting, MJ; Milland, J; Lanteri, M; Loveland, BE; Gerlier, D; Russell, SM			Ligand binding determines whether CD46 is internalized by clathrin-coated pits or macropinocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE COFACTOR PROTEIN; II-RESTRICTED PRESENTATION; MEASLES-VIRUS INFECTION; MHC CLASS-II; DIFFERENTIAL DOWN-REGULATION; COMPLEMENT-MEDIATED LYSIS; CELLULAR PILUS RECEPTOR; T-CELLS; NEISSERIA-GONORRHOEAE; CYTOPLASMIC DOMAINS	CD46 is a ubiquitous human cell surface receptor for the complement components C3b and C4b and for various pathogens, including the measles virus and human herpes virus 6. Ligand binding to CD46 affects (i) protection of autologous cells from complement attack by breakdown of complement components, (ii) intracellular signals that affect the regulation of immune cell function, (iii) antigen presentation, and (iv) down-regulation of cell surface CD46. Recent evidence indicates that CD46 signaling can link innate and acquired immune function. The molecular mechanisms for these processes and the importance of intracellular trafficking of the receptor have not yet been elucidated. We demonstrate here that, in nonlymphoid cells, CD46 is constitutively internalized via clathrin-coated pits, traffics to multivesicular bodies, and is recycled to the cell surface. However, cross-linking of CD46 at the cell surface, by either multivalent antibody or by measles virus, induces pseudopodia that engulf the ligand in a process similar to macropinocytosis, and leads to the degradation of cell surface CD46. Thus, we have elucidated two pathways for CD46 internalization, which are regulated by the valence of cross-linking of CD46 and which utilize either clathrin-coated pits or pseudopodial extension. This has important implications for CD46 signaling, antigen presentation, CD46 down-regulation, and engulfment of pathogens.	Peter MacCallum Canc Ctr, Trescowthick Res Labs, Melbourne, Vic 3002, Australia; Austin Hlth, Austin Res Inst, Heidelberg, Vic 3084, Australia; UCBL, CNRS, UMR 5537, Inst Federatif Laennec, F-69372 Lyon, France	Peter Maccallum Cancer Center; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Russell, SM (corresponding author), Peter MacCallum Canc Ctr, Trescowthick Res Labs, St Andrews Pl, Melbourne, Vic 3002, Australia.		Gerlier, Denis/L-6094-2014; Russell, Sarah M/B-9341-2009	Gerlier, Denis/0000-0001-5539-456X; Russell, Sarah M/0000-0001-5826-9641; Milland, Julie/0000-0003-1368-220X; Ellis, Sarah/0000-0002-5772-6051				Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Astier A, 2000, J IMMUNOL, V164, P6091, DOI 10.4049/jimmunol.164.12.6091; BACALLAO R, 1995, SEMIN NEPHROL, V15, P285; Bansal P, 1999, J IMMUNOL, V162, P4430; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; Brown BK, 1999, J BIOL CHEM, V274, P11439, DOI 10.1074/jbc.274.16.11439; Cardoso AI, 1996, J GEN VIROL, V77, P2695, DOI 10.1099/0022-1317-77-11-2695; CARDOSO AI, 1995, VIROLOGY, V212, P255, DOI 10.1006/viro.1995.1479; Christiansen D, 2000, J GEN VIROL, V81, P911, DOI 10.1099/0022-1317-81-4-911; Clague MJ, 2001, J CELL SCI, V114, P3075; COYNE KE, 1992, J IMMUNOL, V149, P2906; Dharmawardhane S, 2000, MOL BIOL CELL, V11, P3341, DOI 10.1091/mbc.11.10.3341; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Eugene E, 2002, J CELL SCI, V115, P1231; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FENICHEL P, 1989, J REPROD FERTIL, V87, P699; Firsching R, 1999, J VIROL, V73, P5265, DOI 10.1128/JVI.73.7.5265-5273.1999; GERLIER D, 1994, CELL BIOL INT, V18, P315, DOI 10.1006/cbir.1994.1080; GERLIER D, 1994, J EXP MED, V179, P353, DOI 10.1084/jem.179.1.353; Gromme M, 1999, P NATL ACAD SCI USA, V96, P10326, DOI 10.1073/pnas.96.18.10326; Hirano A, 1996, J VIROL, V70, P6929, DOI 10.1128/JVI.70.10.6929-6936.1996; Hirano A, 1999, J VIROL, V73, P4776, DOI 10.1128/JVI.73.6.4776-4785.1999; Hoffmann I, 2001, J CELL BIOL, V155, P133, DOI 10.1083/jcb.200106148; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; Inverardi L, 1997, TRANSPLANTATION, V63, P1318, DOI 10.1097/00007890-199705150-00021; Johansson L, 2003, SCIENCE, V301, P373, DOI 10.1126/science.1086476; Kallstrom H, 1997, MOL MICROBIOL, V25, P639, DOI 10.1046/j.1365-2958.1997.4841857.x; Kallstrom H, 2001, CELL MICROBIOL, V3, P133, DOI 10.1046/j.1462-5822.2001.00095.x; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; Katayama Y, 2000, J VIROL, V74, P1252, DOI 10.1128/JVI.74.3.1252-1257.2000; Kemper C, 2003, NATURE, V421, P388, DOI 10.1038/nature01315; Kleijmeer MJ, 2001, TRAFFIC, V2, P124, DOI 10.1034/j.1600-0854.2001.020207.x; KRANTIC S, 1995, J GEN VIROL, V76, P2793, DOI 10.1099/0022-1317-76-11-2793; Kurita-Taniguchi M, 2000, J IMMUNOL, V165, P5143, DOI 10.4049/jimmunol.165.9.5143; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; Lecouturier V, 1996, J VIROL, V70, P4200, DOI 10.1128/JVI.70.7.4200-4204.1996; Lee SW, 2002, J CELL BIOL, V156, P951, DOI 10.1083/jcb.200109005; Ludford-Menting MJ, 2002, J BIOL CHEM, V277, P4477, DOI 10.1074/jbc.M108479200; Maisner A, 1997, J BIOL CHEM, V272, P20793, DOI 10.1074/jbc.272.33.20793; MALVOISIN E, 1993, J GEN VIROL, V74, P2365, DOI 10.1099/0022-1317-74-11-2365; Marie JC, 2001, IMMUNITY, V14, P69, DOI 10.1016/S1074-7613(01)00090-5; Marie JC, 2002, NAT IMMUNOL, V3, P659, DOI 10.1038/ni810; Milland J, 2002, J BIOL CHEM, V277, P10374, DOI 10.1074/jbc.M111799200; Milland J, 1996, EUR J BIOCHEM, V238, P221, DOI 10.1111/j.1432-1033.1996.0221q.x; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; NANICHE D, 1993, J GEN VIROL, V74, P1073, DOI 10.1099/0022-1317-74-6-1073; Nobes C, 2000, CURR BIOL, V10, pR739, DOI 10.1016/S0960-9822(00)00736-3; OGLESBY TJ, 1992, J EXP MED, V175, P1547, DOI 10.1084/jem.175.6.1547; OKADA N, 1995, P NATL ACAD SCI USA, V92, P2489, DOI 10.1073/pnas.92.7.2489; Pelchen-Matthews A, 1998, EUR J IMMUNOL, V28, P3639, DOI 10.1002/(SICI)1521-4141(199811)28:11<3639::AID-IMMU3639>3.0.CO;2-Q; PELCHENMATTHEWS A, 1993, J EXP MED, V178, P1209, DOI 10.1084/jem.178.4.1209; Peppelenbosch MP, 2000, J IMMUNOL, V165, P1984, DOI 10.4049/jimmunol.165.4.1984; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; PURCELL DFJ, 1990, IMMUNOLOGY, V70, P155; PURCELL DFJ, 1991, IMMUNOGENETICS, V33, P335, DOI 10.1007/BF00216692; Rivailler P, 1998, EUR J IMMUNOL, V28, P1301, DOI 10.1002/(SICI)1521-4141(199804)28:04<1301::AID-IMMU1301>3.0.CO;2-S; RUSSELL SM, 1992, EUR J IMMUNOL, V22, P1513, DOI 10.1002/eji.1830220625; SANDRIN MS, 1987, IMMUNOGENETICS, V25, P279, DOI 10.1007/BF00404419; Santoro F, 1999, CELL, V99, P817, DOI 10.1016/S0092-8674(00)81678-5; SchneiderSchaulies J, 1996, J VIROL, V70, P255, DOI 10.1128/JVI.70.1.255-263.1996; SCHNEIDERSCHAULIES J, 1995, J VIROL, V69, P7257, DOI 10.1128/JVI.69.11.7257-7259.1995; SCHNEIDERSCHAULIES J, 1995, P NATL ACAD SCI USA, V92, P3943, DOI 10.1073/pnas.92.9.3943; SCHNORR JJ, 1995, EUR J IMMUNOL, V25, P976, DOI 10.1002/eji.1830250418; SEYA T, 1990, J EXP MED, V172, P1673, DOI 10.1084/jem.172.6.1673; SPARROW RL, 1983, HUM IMMUNOL, V7, P1, DOI 10.1016/0198-8859(83)90002-2; Teuchert M, 1999, J BIOL CHEM, V274, P19979, DOI 10.1074/jbc.274.28.19979; VARIORKRISHNAN G, 1994, J VIROL, V68, P7891, DOI 10.1128/JVI.68.12.7891-7899.1994; Wang GX, 2000, J IMMUNOL, V164, P1839, DOI 10.4049/jimmunol.164.4.1839; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Yamazaki T, 2002, J CELL SCI, V115, P1791; Yant S, 1997, J VIROL, V71, P766, DOI 10.1128/JVI.71.1.766-770.1997; Zaffran Y, 2001, J IMMUNOL, V167, P6780, DOI 10.4049/jimmunol.167.12.6780	75	66	67	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46927	46937		10.1074/jbc.M308261200	http://dx.doi.org/10.1074/jbc.M308261200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12958316	hybrid			2022-12-25	WOS:000186569400087
J	Benderdour, M; Charron, G; deBlois, D; Comte, B; Des Rosiers, C				Benderdour, M; Charron, G; deBlois, D; Comte, B; Des Rosiers, C			Cardiac mitochondrial NADP(+)-isocitrate dehydrogenase is inactivated through 4-hydroxynonenal adduct formation - An event that precedes hypertrophy development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ISOCITRATE DEHYDROGENASE; ALPHA-KETOGLUTARATE DEHYDROGENASE; SPONTANEOUSLY HYPERTENSIVE RATS; OXIDATIVE STRESS; LIPID-PEROXIDATION; CARDIOVASCULAR-DISEASES; SELECTIVE INACTIVATION; FAILING MYOCARDIUM; SUPEROXIDE ANION; HEART-FAILURE	Mitochondrial NADP(+)-isocitrate dehydrogenase activity is crucial for cardiomyocyte energy and redox status, but much remains to be learned about its role and regulation. We obtained data in spontaneously hypertensive rat hearts that indicated a partial inactivation of this enzyme before hypertrophy development. We tested the hypothesis that cardiac mitochondrial NADP(+)-isocitrate dehydrogenase is a target for modification by the lipid peroxidation product 4-hydroxynonenal, an aldehyde that reacts readily with protein sulfhydryl and amino groups. This hypothesis is supported by the following in vitro and in vivo evidence. In isolated rat heart mitochondria, enzyme inactivation occurred within a few minutes upon incubation with 4-hydroxynonenal and was paralleled by 4-hydroxynonenal/NADP(+)-isocitrate dehydrogenase adduct formation. Enzyme inactivation was prevented by the addition of its substrate isocitrate or a thiol, cysteine or glutathione, suggesting that 4-hydroxynonenal binds to a cysteine residue near the substrate's binding site. Using an immunoprecipitation approach, we demonstrated the formation of 4-hydroxynonenal/NADP(+)-isocitrate dehydrogenase adducts in the heart and their increased level (210%) in 7-week-old spontaneously hypertensive rats compared with control Wistar Kyoto rats. To the best of our knowledge, this is the first study to demonstrate that mitochondrial NADP(+)-isocitrate dehydrogenase is a target for inactivation by 4-hydroxynonenal binding. Furthermore, the pathophysiological significance of our finding is supported by in vivo evidence. Taken altogether, our results have implications that extend beyond mitochondrial NADP(+)-isocitrate dehydrogenase. Indeed, they emphasize the implication of post-translational modifications of mitochondrial metabolic enzymes by 4-hydroxynonenal in the early oxidative stress-related pathophysiological events linked to cardiac hypertrophy development.	Univ Montreal, Dept Nutr, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Des Rosiers, C (corresponding author), Ctr Hosp Univ Montreal, Hop Notre Dame Y3616, Lab Metab Intermediaire, 1560 Rue Sherbrooke E, Montreal, PQ H2L 4M1, Canada.		Rosiers, Christine Des/O-6285-2014					Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; BLASIG IE, 1995, AM J PHYSIOL-HEART C, V269, pH14, DOI 10.1152/ajpheart.1995.269.1.H14; Borutaite V, 2003, FEBS LETT, V541, P1, DOI 10.1016/S0014-5793(03)00278-3; Burcham PC, 2002, TOXICOLOGY, V181, P229, DOI 10.1016/S0300-483X(02)00287-1; Chen JJ, 2001, J MOL CELL CARDIOL, V33, P1919, DOI 10.1006/jmcc.2001.1454; Cheung PY, 1998, ARCH BIOCHEM BIOPHYS, V350, P104, DOI 10.1006/abbi.1997.0496; Comte B, 2002, AM J PHYSIOL-HEART C, V283, pH1505, DOI 10.1152/ajpheart.00287.2002; Cosentino F, 1998, J CLIN INVEST, V101, P1530, DOI 10.1172/JCI650; Dai LJ, 2001, AM J PHYSIOL-HEART C, V281, pH2261, DOI 10.1152/ajpheart.2001.281.6.H2261; Dhalla NS, 2000, J HYPERTENS, V18, P655, DOI 10.1097/00004872-200018060-00002; Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x; Eaton P, 1999, AM J PHYSIOL-HEART C, V276, pH935, DOI 10.1152/ajpheart.1999.276.3.H935; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; GRUNE T, 1994, CELL BIOCHEM FUNCT, V12, P143, DOI 10.1002/cbf.290120210; HALLIWELL B, 1993, AM J CLIN NUTR, V57, P715; Haraguchi CM, 2003, J HISTOCHEM CYTOCHEM, V51, P215, DOI 10.1177/002215540305100210; HUH TL, 1993, BIOCHEM J, V292, P705, DOI 10.1042/bj2920705; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P552, DOI 10.1021/bi971958i; Ide T, 1999, CIRC RES, V85, P357, DOI 10.1161/01.RES.85.4.357; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; Korotchkina LG, 2001, FREE RADICAL BIO MED, V30, P992, DOI 10.1016/S0891-5849(01)00491-9; Leonarduzzi G, 2000, FREE RADICAL BIO MED, V28, P1370, DOI 10.1016/S0891-5849(00)00216-1; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P1065, DOI 10.1006/jmcc.2001.1378; Lucas DT, 1998, P NATL ACAD SCI USA, V95, P510, DOI 10.1073/pnas.95.2.510; Lucas DT, 1999, P NATL ACAD SCI USA, V96, P6689, DOI 10.1073/pnas.96.12.6689; Mak S, 2001, CHEST, V120, P2035, DOI 10.1378/chest.120.6.2035; McIntyre M, 1999, HYPERTENSION, V34, P539, DOI 10.1161/01.HYP.34.4.539; Nakagami H, 2003, J MOL CELL CARDIOL, V35, P851, DOI 10.1016/S0022-2828(03)00145-7; Nakamura K, 2002, CIRCULATION, V105, P2867, DOI 10.1161/01.CIR.0000018605.14470.DD; Nulton-Persson AC, 2003, BIOCHEMISTRY-US, V42, P4235, DOI 10.1021/bi027370f; Nulton-Persson AC, 2001, J BIOL CHEM, V276, P23357, DOI 10.1074/jbc.M100320200; Poli G, 2000, IUBMB LIFE, V50, P315, DOI 10.1080/15216540051081092; Reckelhoff JF, 2003, AM J PHYSIOL-REG I, V284, pR893, DOI 10.1152/ajpregu.00491.2002; Sadek HA, 2002, ARCH BIOCHEM BIOPHYS, V406, P222, DOI 10.1016/S0003-9861(02)00446-0; Sawyer DB, 2002, J MOL CELL CARDIOL, V34, P379, DOI 10.1006/jmcc.2002.1526; SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X; SHIMAMOTO N, 1982, BASIC RES CARDIOL, V77, P359, DOI 10.1007/BF02005337; SMYTH GE, 1991, J BIOL CHEM, V266, P14918; Srivastava S, 1998, J BIOL CHEM, V273, P10893, DOI 10.1074/jbc.273.18.10893; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Toyokuni S, 2000, ANTIOXID REDOX SIGN, V2, P681, DOI 10.1089/ars.2000.2.4-681; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Veronneau M, 2002, FREE RADICAL BIO MED, V33, P1380; Yang ES, 2002, FREE RADICAL BIO MED, V33, P927, DOI 10.1016/S0891-5849(02)00981-4; Yang LP, 1996, J CELL BIOCHEM, V60, P400, DOI 10.1002/(SICI)1097-4644(19960301)60:3<400::AID-JCB11>3.3.CO;2-2; Yang YS, 2003, ACTA BIOCHIM POL, V50, P319; Zalba G, 2001, HYPERTENSION, V38, P1395, DOI 10.1161/hy1201.099611	50	105	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45154	45159		10.1074/jbc.M306285200	http://dx.doi.org/10.1074/jbc.M306285200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12960146	hybrid			2022-12-25	WOS:000186452300015
J	Lee, JH; Ghirlando, R; Bhaskara, V; Hoffmeyer, MR; Gu, J; Paull, TT				Lee, JH; Ghirlando, R; Bhaskara, V; Hoffmeyer, MR; Gu, J; Paull, TT			Regulation of Mre11/Rad50 by Nbs1 - Effects on nucleotide-dependent DNA binding and association with ataxia-telangiectasia-like disorder mutant complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN BREAKAGE SYNDROME; DOUBLE-STRAND BREAKS; FORKHEAD-ASSOCIATED DOMAIN; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; HUMAN RAD50/MRE11; DAMAGE RESPONSE; PROTEIN COMPLEX; FOCUS FORMATION; REPAIR COMPLEX	The Mre11/Rad50 complex is a critical component of the cellular response to DNA double-strand breaks, in organisms ranging from archaebacteria to humans. In mammalian cells, Mre11/Rad50 (M/R) associates with a third component, Nbs1, that regulates its activities and is targeted by signaling pathways that initiate DNA damage-induced checkpoint responses. Mutations in the genes that encode Nbs1 and Mre11 are responsible for the human radiation sensitivity disorders Nijmegen breakage syndrome (NBS) and ataxia-telangiectasia-like disorder (ATLD), respectively, which are characterized by defective checkpoint responses and high levels of chromosomal abnormalities. Here we demonstrate nucleotide-dependent DNA binding by the human M/R complex that requires the Nbs1 protein and is specific for double-strand DNA duplexes. Efficient DNA binding is only observed with non-hydrolyzable analogs of ATP, suggesting that ATP hydrolysis normally effects DNA release. The alleles of MRE11 associated with ATLD and the C-terminal Nbs1 polypeptide associated with NBS were expressed with the other components and found to form triple complexes except in the case of ATLD 3/4, which exhibits variability in Nbs1 association. The ATLD 1/2, ATLD 3/4, and p70 M/R/N complexes exhibit nucleotide-dependent DNA binding and exonuclease activity equivalent to the wild-type enzyme, although the ATLD complexes both show reduced activity in endonuclease assays. Sedimentation equilibrium analysis of the recombinant human complexes indicates that Mre11 is a stable dimer, Mre11 and Nbs1 form a 1: 1 complex, and both M/R and M/R/N form large multimeric assemblies of similar to1.2 MDa. Models of M/R/N stoichiometry in light of this and previous data are discussed.	Univ Texas, Dept Mol Genet & Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; NIDDK, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Paull, TT (corresponding author), Univ Texas, Dept Mol Genet & Microbiol, 1 Univ Stn,A4800, Austin, TX 78712 USA.		Ghirlando, Rodolfo/A-8880-2009; Lee, Jihoon/AAK-3497-2021	Lee, Jihoon/0000-0001-7387-935X; Paull, Tanya/0000-0002-2991-651X; Bhaskara, Venugopal/0000-0002-8807-3292	NATIONAL CANCER INSTITUTE [P01CA094000] Funding Source: NIH RePORTER; NCI NIH HHS [CA94000-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJIMURA M, 1993, GENETICS, V133, P51; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Anderson DE, 2001, J BIOL CHEM, V276, P37027, DOI 10.1074/jbc.M106179200; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Cerosaletti KM, 2003, J BIOL CHEM, V278, P21944, DOI 10.1074/jbc.M211689200; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; Connelly JC, 1998, P NATL ACAD SCI USA, V95, P7969, DOI 10.1073/pnas.95.14.7969; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; de Jager M, 2002, NUCLEIC ACIDS RES, V30, P4425, DOI 10.1093/nar/gkf574; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0027-5107(74)90176-6; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; GHIRLANDO R, 1995, BIOCHEMISTRY-US, V34, P13320, DOI 10.1021/bi00041a007; Gonzalez-Barrera S, 2003, MOL CELL, V11, P1661, DOI 10.1016/S1097-2765(03)00183-7; Grenon M, 2001, NAT CELL BIOL, V3, P844, DOI 10.1038/ncb0901-844; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hirano M, 2002, EMBO J, V21, P5733, DOI 10.1093/emboj/cdf575; Hopfner KP, 2000, J BACTERIOL, V182, P6036, DOI 10.1128/JB.182.21.6036-6041.2000; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; IVANOV EL, 1992, GENETICS, V132, P651; JOHZUKA K, 1995, GENETICS, V139, P1521; Kironmai KM, 1997, GENES CELLS, V2, P443; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lobachev KS, 2002, CELL, V108, P183, DOI 10.1016/S0092-8674(02)00614-1; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Paull TT, 2000, P NATL ACAD SCI USA, V97, P6409, DOI 10.1073/pnas.110144297; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Tauchi H, 2001, J BIOL CHEM, V276, P12, DOI 10.1074/jbc.C000578200; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhao S, 2002, NUCLEIC ACIDS RES, V30, P4815, DOI 10.1093/nar/gkf612	50	80	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45171	45181		10.1074/jbc.M308705200	http://dx.doi.org/10.1074/jbc.M308705200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12966088	hybrid			2022-12-25	WOS:000186452300017
J	De Falco, G; Bellan, C; Lazzi, S; Claudio, P; La Sala, D; Cinti, C; Tosi, P; Giordano, A; Leoncini, L				De Falco, G; Bellan, C; Lazzi, S; Claudio, P; La Sala, D; Cinti, C; Tosi, P; Giordano, A; Leoncini, L			Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms	ONCOGENE			English	Article						pRb2/p130; Tat; HIV; lymphoma; cell cycle	HUMAN-IMMUNODEFICIENCY-VIRUS; KAPOSIS-SARCOMA PATHOGENESIS; LARGE T-ANTIGEN; TRANSGENIC MICE; CELL-CYCLE; GENE-EXPRESSION; GROWTH-FACTOR; IN-VIVO; PROTEIN; TYPE-1	Tat protein is an early nonstructural protein necessary for virus replication, which is secreted by infected cells and taken up by uninfected cells. Extensive evidence indicates that Tat may be a cofactor in the development of AIDS-related neoplasms. The molecular mechanism underlying Tat's oncogenic activity may include deregulation of cellular genes. Among these genes, it has recently been shown that pRb2/p130 oncosuppressor protein is one of the targets in the interaction between HIV gene product Tat and host proteins. However, whether the HIV-1 gene product Tat may inactivate the oncosuppressive function of pRb2/p130 has not yet been elucidated. Here, we show that mRNA levels of pRb2/p130 increase in the presence of Tat, whereas no change in the phosphorylation status of pRb2/p130 is observed. In addition, Tat can inhibit the growth control activity exerted by pRb2/p130 in the T98G cell line. Finally, Tat does not compete with E2F-4 in binding to pRb2/p130. The interaction between Tat and pRb2/p130 seems to result in the deregulation of the control exerted by pRb2/p130 on the cell cycle. Taken together, these results open a window on the role of pRb2/ p130 in AIDS-related oncogenesis.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; CNR, ITOI, Bologna Unit, I-40126 Bologna, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena; Consiglio Nazionale delle Ricerche (CNR)	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, BioLife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	giordano@temple.edu	leoncini, lorenzo/P-8361-2018; BELLAN, CRISTIANA/L-3903-2013; Giordano, Antonio/F-1927-2010; Lazzi, Stefano/P-8265-2018; BELLAN, CRISTIANA/ABG-4750-2021; Claudio, Pier Paolo/AAW-7282-2021; LEONCINI, Lorenzo/U-4413-2019	leoncini, lorenzo/0000-0002-7457-300X; BELLAN, CRISTIANA/0000-0001-6119-9007; Giordano, Antonio/0000-0002-5959-016X; Lazzi, Stefano/0000-0002-2218-3771; BELLAN, CRISTIANA/0000-0001-6119-9007; Claudio, Pier Paolo/0000-0001-7790-1622; LEONCINI, Lorenzo/0000-0002-7457-300X; Cinti, Caterina/0000-0001-8049-0369	NCI NIH HHS [R21-CA099955] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA099955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; Altavilla G, 1999, AM J PATHOL, V154, P1231, DOI 10.1016/S0002-9440(10)65375-8; Ambrosino C, 2002, J BIOL CHEM, V277, P31448, DOI 10.1074/jbc.M112398200; BARILLARI G, 1992, J IMMUNOL, V149, P3727; Barillari G, 2002, CLIN MICROBIOL REV, V15, P310, DOI 10.1128/CMR.15.2.310-326.2002; Boshoff C, 2002, NAT REV CANCER, V2, P373, DOI 10.1038/nrc797; Chang Hsiao-Kuey, 1995, Journal of Biomedical Science, V2, P189, DOI 10.1007/BF02253380; Cinti C, 2000, CANCER RES, V60, P383; Cinti C, 2000, AM J PATHOL, V156, P751, DOI 10.1016/S0002-9440(10)64941-3; Clark E, 2000, J VIROL, V74, P5040, DOI 10.1128/JVI.74.11.5040-5052.2000; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CANCER RES, V60, P8; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Claudio PP, 2001, CANCER RES, V61, P462; CORALLINI A, 1993, CANCER RES, V53, P5569; Corallini A, 1996, AIDS, V10, P701, DOI 10.1097/00002030-199606001-00003; Dalgleish AG, 2002, ADV CANCER RES, V84, P231, DOI 10.1016/S0065-230X(02)84008-8; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; de la Fuente C, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-14; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; Fiorelli V, 1999, J IMMUNOL, V162, P1165; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gaidano G, 1998, AM J PATHOL, V152, P623; Gatignol A, 2000, Adv Pharmacol, V48, P209; Kashanchi F, 2000, J VIROL, V74, P652, DOI 10.1128/JVI.74.2.652-660.2000; KIM CM, 1992, ONCOGENE, V7, P1525; Knowles DM, 1999, MODERN PATHOL, V12, P200; Kundu M, 1997, J BIOL CHEM, V272, P29468, DOI 10.1074/jbc.272.47.29468; Kundu M, 1998, J BIOL CHEM, V273, P8130, DOI 10.1074/jbc.273.14.8130; Kundu RK, 1999, BLOOD, V94, P275, DOI 10.1182/blood.V94.1.275.413a30_275_282; Lazzi S, 2002, HUM PATHOL, V33, P723, DOI 10.1053/hupa.2002.125372; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; Mahieux R, 2001, J VIROL, V75, P1736, DOI 10.1128/JVI.75.4.1736-1743.2001; Noonan D, 2000, Adv Pharmacol, V48, P229; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Rubartelli A, 1998, IMMUNOL TODAY, V19, P543, DOI 10.1016/S0167-5699(98)01351-6; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STEIN GS, 1999, MOL BASIS CELL CYCLE; Stiegler P, 1998, J CELL BIOCHEM, P30; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; Vene R, 2001, CLIN EXP METASTAS, V18, P533, DOI 10.1023/A:1011991906685; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; Wu A, 1999, CANCER, V86, P2038, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2038::AID-CNCR22>3.0.CO;2-A; ZAULI G, 1995, BLOOD, V86, P3823, DOI 10.1182/blood.V86.10.3823.bloodjournal86103823	48	33	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6214	6219		10.1038/sj.onc.1206637	http://dx.doi.org/10.1038/sj.onc.1206637			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679860				2022-12-25	WOS:000185506200011
J	Stoica, GE; Franke, TF; Moroni, M; Mueller, S; Morgan, E; Iann, MC; Winder, AD; Reiter, R; Wellstein, A; Martin, MB; Stoica, A				Stoica, GE; Franke, TF; Moroni, M; Mueller, S; Morgan, E; Iann, MC; Winder, AD; Reiter, R; Wellstein, A; Martin, MB; Stoica, A			Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway	ONCOGENE			English	Article						estradiol; estrogen receptor-alpha; ErbB2; Akt	EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER-CELLS; SIGNAL-TRANSDUCTION PATHWAYS; STEROID-HORMONE RECEPTORS; ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MCF-7 CELLS; TYROSINE KINASE; BINDING-SITES; TAMOXIFEN RESISTANCE	Epidermal growth factor (EGF), insulin-like growth factor-I (IGF-I), and heregulin-beta1 (HRG-beta1), can modulate the expression and activity of the estrogen receptor-alpha (ER-alpha) via the phosphatidylinositol 3-kinase (PI 3-K)/Akt pathway in the ER-alpha-positive breast cancer cell line, MCF-7. Estradiol can also rapidly activate PI 3-K/Akt in these cells (nongenomic effect). The recent study examines whether Akt is involved in the ER-alpha regulation by estradiol (genomic effect). Stable transfection of parental MCF-7 cells with a dominant-negative Akt mutant, as well as the PI 3-K inhibitors wortmannin and LY 294,002, blocked the effect of estradiol on ER-alpha expression and activity by 70-80 and 55-63%, respectively. Stable transfection of MCF-7 cells with a constitutively active Akt mimicked the effect of estradiol. The changes in ER-alpha expression and activity were abrogated in response to estradiol by an arginine to cysteine mutation in the pleckstrin homology (PH) domain of Akt (R25C), suggesting the involvement of this amino acid in the interaction between Akt and ER-alpha. Experiments employing selective ErbB inhibitors demonstrate that the effect of estradiol on ER-a expression and activity is mediated by ErbB2 and not by EGFR. Moreover, anchorage-dependent and -independent growth assays, cell cycle and membrane ruffling analyses showed that Akt exerts estrogen-like activity on cell growth and membrane ruffling and that a selective ErbB2 inhibitor, but not anti-ErbB2 antibodies directed to the extracellular domain, can block these effects. In the presence of constitutively active Akt, tamoxifen only partially inhibits cell growth. In contrast, in cells stably transfected with either a dominant-negative Akt or with R25C-Akt, as well as in parental cells in the presence of a selective ErbB2 inhibitor, the effect of estradiol on anchorage-dependent and -independent cell growth was inhibited by 50-75 and 100%, respectively. Dominant-negative Akt inhibited membrane ruffling by 54%; however, R25C-Akt did not have any effect, suggesting that kinase activity plays an important role in this process. Scatchard analysis demonstrated a 67% reduction in estrogen-binding capacity in cells transfected with constitutively active Akt. No change in binding affinity of estradiol to the receptor was observed upon transfection with either Akt mutant. Taken together, our results suggest that estradiol treatment results in binding to membrane ER-alpha and interaction with a heterodimer containing ErbB2, leading to tyrosine phosphorylation. This results in the activation of PI 3-K and Akt. Akt, in turn, may interact with nuclear ER-alpha, altering its expression and activity.	Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20057 USA; Georgetown Univ, Sch Nursing & Hlth Studies, Washington, DC 20057 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	Georgetown University; Georgetown University; Columbia University	Stoica, A (corresponding author), E411 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.			Wellstein, Anton/0000-0002-0570-4950	NATIONAL CANCER INSTITUTE [P30CA051008, P50CA058185] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-51008, P50-CA-58185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ARTEAGA CL, 1988, MOL ENDOCRINOL, V2, P1064, DOI 10.1210/mend-2-11-1064; AURICCHIO F, 1995, CELL GROWTH DIFFER, V6, P105; Bacus SS, 1996, AM J PATHOL, V148, P549; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896; GUIOCHONMANTEL A, 1996, J STEROID BIOCHEM, V56, P1; HEATH JP, 1991, CELL MOTIL CYTOSKEL, V18, P245, DOI 10.1002/cm.970180402; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; Honda K, 2000, J NEUROSCI RES, V60, P321, DOI 10.1002/(SICI)1097-4547(20000501)60:3<321::AID-JNR6>3.3.CO;2-K; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; Kato S, 1998, ONCOLOGY-BASEL, V55, P5, DOI 10.1159/000055253; Kato  S, 2001, Breast Cancer, V8, P3, DOI 10.1007/BF02967472; Katzenellenbogen BS, 1997, BREAST CANCER RES TR, V44, P23, DOI 10.1023/A:1005835428423; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; KIM HH, 1994, J BIOL CHEM, V269, P24747; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; LEITZEL K, 1995, J CLIN ONCOL, V13, P1129, DOI 10.1200/JCO.1995.13.5.1129; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; Lobenhofer EK, 2000, CELL GROWTH DIFFER, V11, P99; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729; Martin MB, 2000, ENDOCRINOLOGY, V141, P4503, DOI 10.1210/en.141.12.4503; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MCLESKEY SW, 1993, CANCER RES, V53, P2168; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Nemere I, 1998, BIOCHEM BIOPH RES CO, V248, P443, DOI 10.1006/bbrc.1998.8492; NICHOLSON S, 1990, J STEROID BIOCHEM, V37, P811, DOI 10.1016/0960-0760(90)90424-J; Normanno N, 1997, J MAMMARY GLAND BIOL, V2, P143, DOI 10.1023/A:1026351730785; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REDDY KB, 1994, CELL GROWTH DIFFER, V5, P1275; REDDY KB, 1992, CANCER RES, V52, P3636; SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157, DOI 10.1210/mend-2-12-1157; Salomon D S, 1988, Cancer Treat Res, V40, P363; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SALOMON DS, 1995, BREAST CANCER RES TR, V33, P103, DOI 10.1007/BF00682718; SAPINO A, 1986, CANCER RES, V46, P2526; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P209; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; Stoica A, 2000, J CELL BIOCHEM, V76, P605, DOI 10.1002/(SICI)1097-4644(20000315)76:4<605::AID-JCB9>3.0.CO;2-T; Stoica A, 2000, MOL ENDOCRINOL, V14, P545, DOI 10.1210/me.14.4.545; Stoica A, 2000, J ENDOCRINOL, V165, P371, DOI 10.1677/joe.0.1650371; Stoica GE, 2003, MOL ENDOCRINOL, V17, P818, DOI 10.1210/me.2002-0330; Stoica GE, 2003, ONCOGENE, V22, P2073, DOI 10.1038/sj.onc.1206311; Sweeney CJ, 2001, CANCER, V92, P2639, DOI 10.1002/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vasudevan N, 2001, P NATL ACAD SCI USA, V98, P12267, DOI 10.1073/pnas.221449798; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; Wen Y, 2000, CANCER RES, V60, P6841; Wosikowski K, 1997, CLIN CANCER RES, V3, P2405; WRIGHT C, 1992, J CLIN PATHOL, V45, P459, DOI 10.1136/jcp.45.5.459-b; ZEILLINGER R, 1989, ONCOGENE, V4, P109; Zhang K, 1996, J BIOL CHEM, V271, P3884	91	131	140	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7998	8011		10.1038/sj.onc.1206769	http://dx.doi.org/10.1038/sj.onc.1206769			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970748				2022-12-25	WOS:000185388200015
J	Iwahara, T; Akagi, T; Shishido, T; Hanafusa, H				Iwahara, T; Akagi, T; Shishido, T; Hanafusa, H			CrkII induces serum response factor activation and cellular transformation through its function in Rho activation	ONCOGENE			English	Article						CrkII; Rho; transformation	BINDING PROTEIN-RHO; HETEROTRIMERIC G-PROTEINS; GROWTH-FACTOR RECEPTOR; C-FOS PROMOTER; HTLV-I TAX; ADAPTER PROTEIN; V-CRK; LYSOPHOSPHATIDIC ACID; SIGNALING PATHWAY; TYROSINE PHOSPHORYLATION	CrkII belongs to the adaptor protein family that plays a crucial role in signal transduction. In order to better understand the biological functions of CrkII, we focused on the regulation of gene expression by CrkII. Various transcriptional control elements were examined for their activation by CrkII-expression, and we found that CrkII selectively activates the serum response element (SRE), a transcriptional control element of immediate-early genes. This SRE activation induced by CrkII-overexpression was mediated by the serum response factor (SRF) via Rho. Indeed, we confirmed that the amount of activated Rho was increased in the CrkII-expressing cells. Moreover, we showed that when overexpressed, CrkII induces the cellular transformation of NIH 3T3 cells and that a dominant negative mutant of Rho suppresses this transformation, strongly suggesting that activation of Rho is essential for the transforming activity by CrkII. Furthermore, we also found that CrkII and Galpha12, a member of the heterotrimeric G proteins, synergistically activates Rho as well as the SRF, and that an SH3 mutant of CrkII can inhibit the Galpha12-induced activation of SRF. These results strongly suggest that CrkII is involved in the activation of Rho and SRF by Galpha12. Our study provides strong evidence that Rho activation plays a crucial role in CrkII-mediated signals to induce gene expression and cellular transformation.	Osaka Biosci Inst, Mol Oncol Lab, Osaka 5650874, Japan		Hanafusa, H (corresponding author), Osaka Biosci Inst, Mol Oncol Lab, 6-2-4 Furuedai, Osaka 5650874, Japan.	saburo@obisun1.obi.or.jp						Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; ALLEY MC, 1991, CANCER RES, V51, P1247; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; FUJII M, 1995, ONCOGENE, V11, P7; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Haskell MD, 2001, J CELL SCI, V114, P1699; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lowry WE, 2002, DEV CELL, V2, P733, DOI 10.1016/S1534-5807(02)00175-2; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Meijne AML, 1997, EXP CELL RES, V234, P477, DOI 10.1006/excr.1997.3637; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Nakashima N, 1999, J BIOL CHEM, V274, P3001, DOI 10.1074/jbc.274.5.3001; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Posern G, 2000, ONCOGENE, V19, P6361, DOI 10.1038/sj.onc.1204027; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Smith JJ, 2002, MOL CELL BIOL, V22, P1412, DOI 10.1128/MCB.22.5.1412-1423.2002; Stam JC, 2001, J BIOL CHEM, V276, P25176, DOI 10.1074/jbc.M009825200; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tsuda M, 2002, CELL GROWTH DIFFER, V13, P131; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731	82	15	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5946	5957		10.1038/sj.onc.1206633	http://dx.doi.org/10.1038/sj.onc.1206633			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955073				2022-12-25	WOS:000185137800003
J	Varani, K; Abbracchio, MP; Cannella, M; Cislaghi, G; Giallonardo, P; Mariotti, C; Cattabriga, E; Cattabeni, F; Borea, PA; Squitieri, F; Cattaneo, E				Varani, K; Abbracchio, MP; Cannella, M; Cislaghi, G; Giallonardo, P; Mariotti, C; Cattabriga, E; Cattabeni, F; Borea, PA; Squitieri, F; Cattaneo, E			Aberrant A(2A) receptor function in peripheral blood cells in Huntington's disease	FASEB JOURNAL			English	Article						A(2A) adenosine receptor; blood circulating cells; Huntington's disease; biomarker	ADENOSINE RECEPTORS; LIGAND-BINDING; BIOCHEMICAL-CHARACTERIZATION; NEURODEGENERATIVE DISEASE; MEMBRANES; LYMPHOCYTES; MECHANISM; STRIATUM; SYSTEMS; MODELS	A(2A) adenosine receptors specifically found on striatal medium spiny neurons play a major role in sensory motor function and may also be involved in neuropsychiatric and neurodegenerative disorders. One hypothesis concerning Huntington's disease (HD) proposes that an imbalance of the cortico-striatal pathway, due to the mutation in the HD gene, leads to striatal vulnerability. An A(2A) receptor dysfunction has been previously demonstrated in striatal cells engineered to express mutant huntingtin. Here we tested whether a similar dysfunction (i.e., the binding and functional parameters of A(2A) adenosine receptors) is present in peripheral blood cells (platelets, lymphocytes, and neutrophils) of subjects carrying the mutant gene. This study involved 48 heterozygous and three homozygous patients compared with 58 healthy subjects. Moreover, we selected seven at-risk mutation carriers. A(2A) receptor density and function are substantially increased in peripheral blood cells from both patients and subjects at the presymptomatic stage. In the neutrophils of the three homozygous HD subjects receptor dysfunction was higher than in heterozygotes. These data indicate the existence of an aberrant A(2A) receptor phenotype in the peripheral blood cells of subjects carrying the HD mutation. Future studies will assess whether this parameter can be exploited as a peripheral biomarker of Huntington's disease.	IRCCS Neuromed, Neurogenet Unit, I-86077 Pozzilli, IS, Italy; Univ Ferrara, Dept Clin & Expt Med, Pharmacol Unit, I-44100 Ferrara, Italy; Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy; Fornaroli Hosp, Neurol Sect, Magenta, MI, Italy; IRCCS C Besta, Neurogenet Sect, Milan, Italy	IRCCS Neuromed; University of Ferrara; University of Milan; University of Milan	Squitieri, F (corresponding author), IRCCS Neuromed, Neurogenet Unit, Local Camerelle, I-86077 Pozzilli, IS, Italy.	neurogen@neuromed.it; elena.cattaneo@unimi.it	Squitieri, Ferdinando/N-1852-2019; Cannella, Milena/G-8291-2011; Mariotti, Caterina/AAP-9425-2021; Abbracchio, Maria Pia/B-9342-2014	Squitieri, Ferdinando/0000-0002-7397-1727; Mariotti, Caterina/0000-0003-2405-3564; Abbracchio, Maria Pia/0000-0002-7833-3388; CANNELLA, Milena/0000-0001-6284-9374; CATTANEO, ELENA/0000-0002-0755-4917	Telethon [GGP02185] Funding Source: Medline	Telethon(Fondazione Telethon)		Abbracchio MP, 1999, ANN NY ACAD SCI, V890, P79, DOI 10.1111/j.1749-6632.1999.tb07983.x; Barbanti P, 2000, CEPHALALGIA, V20, P15, DOI 10.1046/j.1468-2982.2000.00001.x; BENJAMIN CM, 1994, AM J HUM GENET, V55, P606; BLUM D, 2003, LANCET, V362, P366; Cannella M, 2001, NEUROL SCI, V22, P55, DOI 10.1007/s100720170044; Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; Cha JHJ, 1999, PHILOS T R SOC B, V354, P981, DOI 10.1098/rstb.1999.0449; Di Luca M, 1998, ARCH NEUROL-CHICAGO, V55, P1195, DOI 10.1001/archneur.55.9.1195; Draper N.R., 1998, APPL REGRESSION ANAL, P79; FERRE S, 1993, J NEUROSCI, V13, P5402, DOI 10.1523/JNEUROSCI.13-12-05402.1993; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; Gusella JF, 2000, NAT REV NEUROSCI, V1, P109, DOI 10.1038/35039051; Ilani T, 2001, P NATL ACAD SCI USA, V98, P625, DOI 10.1073/pnas.021535398; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; Kieburtz K, 1996, MOVEMENT DISORD, V11, P136, DOI 10.1002/mds.870110204; Lawrence AD, 1998, BRAIN, V121, P1343, DOI 10.1093/brain/121.7.1343; Lin CH, 2001, HUM MOL GENET, V10, P137, DOI 10.1093/hmg/10.2.137; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MAGGI R, 1993, PHARMACOL RES, V28, P351, DOI 10.1006/phrs.1993.1137; MARTINEZMIR MI, 1991, NEUROSCIENCE, V42, P697, DOI 10.1016/0306-4522(91)90038-P; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PARSONS B, 1995, J NEUROCHEM, V65, P2057; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Rovati GE, 1998, TRENDS PHARMACOL SCI, V19, P365; Rubinsztein DC, 2002, TRENDS GENET, V18, P202, DOI 10.1016/S0168-9525(01)02625-7; Seubert CN, 2000, ANESTHESIOLOGY, V92, P567, DOI 10.1097/00000542-200002000-00041; Sipione S, 2001, MOL NEUROBIOL, V23, P21; Squitieri F, 2001, BRAIN RES BULL, V56, P233, DOI 10.1016/S0361-9230(01)00648-7; SQUITIERI F, 1994, HUM MOL GENET, V3, P2103, DOI 10.1093/hmg/3.12.2103; Squitieri F, 2003, BRAIN, V126, P946, DOI 10.1093/brain/awg077; Ujfalusi A, 1998, LIFE SCI, V64, pPL19, DOI 10.1016/S0024-3205(98)00547-5; Varani K, 2000, MOL PHARMACOL, V57, P968; Varani K, 1998, BRIT J PHARMACOL, V123, P1723, DOI 10.1038/sj.bjp.0701758; Varani K, 1996, BRIT J PHARMACOL, V117, P1693, DOI 10.1111/j.1476-5381.1996.tb15341.x; Varani K, 1999, BRIT J CLIN PHARMACO, V47, P167, DOI 10.1046/j.1365-2125.1999.00866.x; Varani K, 2003, FASEB J, V17, P2148, DOI 10.1096/fj.03-0079fje; Varani K, 2001, FASEB J, V15, P1245, DOI 10.1096/fj.00-0730fje; Varani K, 1997, BRIT J PHARMACOL, V122, P386, DOI 10.1038/sj.bjp.0701378; Vonsattel JPG, 1998, J NEUROPATH EXP NEUR, V57, P369	39	122	126	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2148	+		10.1096/fj.03-0079fje	http://dx.doi.org/10.1096/fj.03-0079fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958155				2022-12-25	WOS:000185925100018
J	Xu, P; Yoshioka, K; Yoshimura, D; Tominaga, Y; Nishioka, T; Ito, M; Nakabeppu, Y				Xu, P; Yoshioka, K; Yoshimura, D; Tominaga, Y; Nishioka, T; Ito, M; Nakabeppu, Y			In vitro development of mouse embryonic stem cells lacking JNK/stress-activated protein kinase-associated protein 1 (JSAP1) scaffold protein revealed its requirement during early embryonic neurogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; C-JUN; TRANSCRIPTION FACTOR; MICE LACKING; EXPRESSION; GENE; JNK; DIFFERENTIATION; WNT; PHOSPHORYLATION	The Jsap1 gene encodes a scaffold protein for c-Jun N-terminal kinase cascades. We established c-Jun N-terminal kinase (JNK)/stress-activated protein kinase-associated protein 1 (JSAP1)-null mouse embryonic stem cell lines by homologous recombination. The JSAP1-null embryonic stem cells were viable, however, exhibited hyperplasia of the ectoderm during embryoid body formation, and spontaneously differentiated into neurons more efficiently than did wild type. The expression of components of c-Jun N-terminal kinase cascades and a subset of marker mRNAs during early embryogenesis was altered in the JSAP1-null mutants. Retinoic acid dramatically increased the expression of JSAP1 and JNK3, which were co-precipitated with anti-JNK3 in the neuroectoderm of wild type but not JSAP1-null embryoid bodies. In the neurons differentiated from the wild type embryoid bodies, JSAP1 was localized in the soma, neurites, and growth cone-like structure of the neurites, and neurite outgrowth from the JSAP1-null embryoid bodies was apparently less efficient than from wild type. JSAP1 and c-Jun N-terminal kinase 3 were coexpressed in the embryonic ectoderm of E7.5 mouse embryo, whereas Wnt1 and Pax2 were coexpressed with JSAP1 at the midbrain-hindbrain junction in E12.5 mouse embryo, thus suggesting that JSAP1 is required for early embryonic neurogenesis.	Kyushu Univ, Med Inst Bioregulat, Div Neurofunct Genom, Dept Immunobiol & Neurosci, Fukuoka 8128582, Japan; CREST, Japan Sci & Technol Corp, Fukuoka 8128582, Japan; Kanazawa Univ, Canc Res Inst, Dept Mol & Cellular Biol, Div Cell Cycle Regulat, Kanazawa, Ishikawa 9200934, Japan; Kitasato Univ, Dept Biosci, Sch Sci, Kanagawa 2288555, Japan	Kyushu University; Japan Science & Technology Agency (JST); Kanazawa University; Kitasato University	Nakabeppu, Y (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Neurofunct Genom, Dept Immunobiol & Neurosci, Fukuoka 8128582, Japan.	yusaku@bioreg.kyushu-u.ac.jp	Nakabeppu, Yusaku/A-8902-2011; Sakai, Yasunari/S-7965-2018	Nakabeppu, Yusaku/0000-0002-6739-242X; Sakai, Yasunari/0000-0002-5747-8692				BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Bain G., 1998, CULTURING NERVE CELL, P189; BEDDINGTON R, 2002, PRINCIPLES DEV, P109; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Byrd DT, 2001, NEURON, V32, P787, DOI 10.1016/S0896-6273(01)00532-3; Cassia R, 1997, J NEUROSCI RES, V50, P421, DOI 10.1002/(SICI)1097-4547(19971101)50:3<421::AID-JNR8>3.0.CO;2-K; CEREGHINI S, 1992, DEVELOPMENT, V116, P783; Cipelletti B, 2002, NEUROSCIENCE, V115, P657, DOI 10.1016/S0306-4522(02)00531-6; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Elion EA, 2001, J CELL SCI, V114, P3967; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Funahashi J, 1999, DEV GROWTH DIFFER, V41, P59; HERRMANN BG, 1994, TRENDS GENET, V10, P280, DOI 10.1016/0168-9525(90)90011-T; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Ide Y, 2003, GENOMICS, V81, P47, DOI 10.1016/S0888-7543(02)00009-5; Ito M, 1999, MOL CELL BIOL, V19, P7539; Ito M, 2000, GENE, V255, P229, DOI 10.1016/S0378-1119(00)00335-8; JOYNER AL, 1993, GENE TARGETING PRACT, P1; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P17; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kiecker C, 2001, DEVELOPMENT, V128, P4189; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kuboki Y, 2000, J BIOL CHEM, V275, P39815, DOI 10.1074/jbc.C000403200; Kudoh T, 2002, DEVELOPMENT, V129, P4335; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lagutin OV, 2003, GENE DEV, V17, P368, DOI 10.1101/gad.1059403; Mallamaci A, 2000, J NEUROSCI, V20, P1109, DOI 10.1523/JNEUROSCI.20-03-01109.2000; Martinez S, 2001, INT J DEV BIOL, V45, P367; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MURPHY TH, 1991, J NEUROCHEM, V57, P1862, DOI 10.1111/j.1471-4159.1991.tb06396.x; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nakata T, 1998, J CELL BIOL, V140, P659, DOI 10.1083/jcb.140.3.659; Niehrs C, 1999, TRENDS GENET, V15, P314, DOI 10.1016/S0168-9525(99)01767-9; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; O'Shea KS, 1999, ANAT RECORD, V257, P32, DOI 10.1002/(SICI)1097-0185(19990215)257:1<32::AID-AR6>3.0.CO;2-2; Sano Y, 2001, GENOME RES, V11, P1833, DOI 10.1101/gr.194301; Schimenti J, 2000, TRENDS GENET, V16, P240, DOI 10.1016/S0168-9525(00)02020-5; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; SOUDAIS C, 1995, DEVELOPMENT, V121, P3877; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Tsuchimoto D, 2001, NUCLEIC ACIDS RES, V29, P2349, DOI 10.1093/nar/29.11.2349; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; WILSON V, 1995, DEVELOPMENT, V121, P877; Wurst W, 2001, NAT REV NEUROSCI, V2, P99, DOI 10.1038/35053516; Xu P, 1998, VIRCHOWS ARCH, V432, P17, DOI 10.1007/s004280050129; Yamaguchi TP, 2001, CURR BIOL, V11, pR713, DOI 10.1016/S0960-9822(01)00417-1; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zandstra PW, 2000, BIOTECHNOL BIOENG, V69, P607, DOI 10.1002/1097-0290(20000920)69:6<607::AID-BIT4>3.3.CO;2-6	59	143	149	3	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48422	48433		10.1074/jbc.M307888200	http://dx.doi.org/10.1074/jbc.M307888200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12857738	hybrid			2022-12-25	WOS:000186731400128
J	Shin, JH; Jiang, Y; Grabowski, B; Hurwitz, J; Kelman, Z				Shin, JH; Jiang, Y; Grabowski, B; Hurwitz, J; Kelman, Z			Substrate requirements for duplex DNA translocation by the eukaryal and archaeal minichromosome maintenance helicases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; SINGLE-STRANDED-DNA; LARGE TUMOR-ANTIGEN; REPLICATION-FORK; HEXAMERIC HELICASES; BIND CHROMATIN; ATP HYDROLYSIS; MCM PROTEINS; 3RD DOMAIN; COMPLEX	Replicative DNA helicases are ring-shaped hexamers that play an essential role in DNA synthesis by separating the two strands of chromosomal DNA to provide the single-stranded ( ss) substrate for replicative polymerases. Biochemical and structural studies suggest that these helicases translocate along one strand of the duplex, which passes through and interacts with the central channel of these ring-shaped hexamers, and displace the complementary strand. A number of these helicases were shown to also encircle both strands simultaneously and then translocate along double-stranded (ds) DNA. In this report it is shown that the Schizosaccharomyces pombe Mcm4,6,7 complex and archaeal minichromosome maintenance (MCM) helicase from Methanothermobacter thermautotrophicus move along duplex DNA. These two helicases, however, differ in the substrate required to support dsDNA translocation. Although the S. pombe Mcm4,6,7 complex required a 3'-overhang ssDNA region to initiate its association with the duplex, the archaeal protein initiated its transit along dsDNA in the absence of a 3'-overhang region, as well. Furthermore, DNA substrates containing a streptavidinbiotin steric block inhibited the movement of the eukaryotic helicase along ss and dsDNAs but not of the archaeal enzyme. The M. thermautotrophicus MCM helicase, however, was shown to displace a streptavidinbiotin complex from ss, as well as dsDNAs. The possible roles of dsDNA translocation by the MCM proteins during the initiation and elongation phases of chromosomal replication are discussed.	Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	University System of Maryland; University of Maryland Baltimore; Memorial Sloan Kettering Cancer Center	Kelman, Z (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	kelman@umbi.umd.edu	Kasiviswanathan, Rajesh/D-2744-2012	Bell, Stephen/0000-0002-8474-6592	NIGMS NIH HHS [GM 38559] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5253; Carpentieri F, 2002, J BIOL CHEM, V277, P12118, DOI 10.1074/jbc.M200091200; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Davey MJ, 2003, J BIOL CHEM, V278, P4491, DOI 10.1074/jbc.M210511200; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Enemark EJ, 2000, MOL CELL, V6, P149, DOI 10.1016/S1097-2765(00)00016-2; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Fouts ET, 1999, J BIOL CHEM, V274, P4447, DOI 10.1074/jbc.274.7.4447; GOETZ GS, 1988, J BIOL CHEM, V263, P383; Grabowski B, 2003, ANNU REV MICROBIOL, V57, P487, DOI 10.1146/annurev.micro.57.030502.090709; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jezewska MJ, 1998, BIOCHEMISTRY-US, V37, P3116, DOI 10.1021/bi972564u; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Kaplan DL, 2002, MOL CELL, V10, P647, DOI 10.1016/S1097-2765(02)00642-1; Kelman LM, 2003, MOL MICROBIOL, V48, P605, DOI 10.1046/j.1365-2958.2003.03369.x; Kelman Z, 2003, NAT STRUCT BIOL, V10, P148, DOI 10.1038/nsb0303-148; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Krude T, 1996, J CELL SCI, V109, P309; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Laskey RA, 2003, EMBO REP, V4, P26, DOI 10.1038/sj.embor.embor706; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; Morris PD, 1999, BIOCHEMISTRY-US, V38, P5164, DOI 10.1021/bi9822269; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Poplawski A, 2001, J BIOL CHEM, V276, P49371, DOI 10.1074/jbc.M108519200; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; Shechter DF, 2000, J BIOL CHEM, V275, P15049, DOI 10.1074/jbc.M000398200; Shin JH, 2003, J BIOL CHEM, V278, P49053, DOI 10.1074/jbc.M308599200; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Tye BK, 2000, P NATL ACAD SCI USA, V97, P2399, DOI 10.1073/pnas.97.6.2399; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; You ZY, 1999, MOL CELL BIOL, V19, P8003; Yu X, 2002, EMBO REP, V3, P792, DOI 10.1093/embo-reports/kvf160	44	103	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49053	49062		10.1074/jbc.M308599200	http://dx.doi.org/10.1074/jbc.M308599200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12975364	hybrid			2022-12-25	WOS:000186829000067
